<SEC-DOCUMENT>0001035267-23-000019.txt : 20230210
<SEC-HEADER>0001035267-23-000019.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210171119
ACCESSION NUMBER:		0001035267-23-000019
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTUITIVE SURGICAL INC
		CENTRAL INDEX KEY:			0001035267
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				770416458
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30713
		FILM NUMBER:		23613334

	BUSINESS ADDRESS:	
		STREET 1:		1020 KIFER ROAD
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94086
		BUSINESS PHONE:		4085232100

	MAIL ADDRESS:	
		STREET 1:		1020 KIFER ROAD
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94086
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>isrg-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780,d:025de1eec32044f5a30c5872569f0e8d--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:isrg="http://www.intuitivesurgical.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>isrg-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV8zLTEtMS0xLTE1MDAzNA_5fd8745a-f38d-4644-89c1-f7f947c8159e">0001035267</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV80LTEtMS0xLTE1MDAzNA_3295c6db-1f48-47b9-ae04-c180a0e26dd6">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV81LTEtMS0xLTE1MDAzNA_5f1122d7-cdb0-410b-9a55-66440133eded">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV82LTEtMS0xLTE1MDAzNA_b50cbba7-f638-4c64-af03-cff2b0c60ddf">FY</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV83LTEtMS0xLTE1MDAzNA_85fd4fe8-d5cc-46e5-8bff-6abf589e2f4a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" name="us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" name="us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" name="us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" name="us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38">http://www.intuitivesurgical.com/20221231#IntangibleAndOtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">http://www.intuitivesurgical.com/20221231#IntangibleAndOtherAssets</ix:nonNumeric><ix:nonNumeric contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37">http://fasb.org/us-gaap/2022#LiabilitiesOtherThanLongtermDebtNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">http://fasb.org/us-gaap/2022#LiabilitiesOtherThanLongtermDebtNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1">http://fasb.org/us-gaap/2022#Liabilities</ix:nonNumeric><ix:nonNumeric contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">http://fasb.org/us-gaap/2022#Liabilities</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i20cd9153845f4947a182196df818b48b_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8zLTEtMS0xLTIwMDYzMw_0c3fc56b-485d-4ab2-a444-a28fa13ab863">12.5000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i20cd9153845f4947a182196df818b48b_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl80LTEtMS0xLTIwMDYzMw_609169c6-fc23-4587-8660-ef9383058480">2.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl81LTEtMS0xLTIwMDYzMw_a6009330-cc7e-4003-b423-ce1851d40b25">12.5000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl82LTEtMS0xLTIwMDYzMw_1136244d-2ddb-4cb1-becd-bdc0d2d85185">2.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic52d8d269cc94237acc26da529069828_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl83LTEtMS0xLTIwMDYzMw_bca98a61-98ed-4709-836f-f6078c937d7a">14.5833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic52d8d269cc94237acc26da529069828_D20220101-20221231" decimals="6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl84LTEtMS0xLTIwMDYzMw_423ab172-3605-49bb-acfc-572cef5734c8">2.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl85LTEtMS0xLTIwMDYzMw_459f2e7d-799b-4875-90c3-4fc0b8d7d770">25.0000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMC0xLTEtMS0yMDA2MzM_d24fb0b4-2cf4-4bf3-bb00-4ba80c29a959">2.0833</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMi0xLTEtMS0yMDA2MzM_76ba640e-2e82-4b23-9564-ae7125616bd3">33.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231" decimals="6" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMy0xLTEtMS0yMDA2MzM_b30db74b-a7cf-42a7-a68c-5724ab677b11">2.7778</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xNy0xLTEtMS0yMDA2MzM_d6747ed2-2268-409e-b27a-5b6e229bd73e">25.0000</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i78daf21ac2234a819cab8768cbb59e61_D20210101-20211231" decimals="6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xOS0xLTEtMS0yMDA2MzM_f359bcbd-4456-43fb-b10e-2769ffc9936a">33.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="isrg-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205ff87813544221905e1bacbc0e834a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib0ed59a4d8384c88a2ad8e007a293a45_I20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb57e4322a5a41099da8c576ba2c235e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5abb42db044edb933f0bac478561e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3fdd4cfad61458ba3bd1f961574b7c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e1406152504c24becb2d14ea3aba96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea73322238bf4952ba8f6f56b4843fd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86284f29e88649f98a3081d2acc55f59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28b90c84ec44021a92cdcdb2c25b28a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b59bb58abc7479d89bc7d2b74d70544_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f52079425724fd694aa42f7b37a71e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ac86aca2b842e9883ccef967301ae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae840c0106e4c1996ae436a312416d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a090d2385f44532aa7e60497f976b8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c801b2cffa477fb54e06f63ca156ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6e09d2840745a2be9bd85eeaaa8a92_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5043d7c11ba745e8a27d34923ccd110f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c08937764b145139a93a060599d3467_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7c7907f86d4cce9957516da107670e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdde0a5261214008b1be258b805ec820_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad839dce5564f57a74be0b40182551f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a4a986595294305b5ea409ad41fcfc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2ad8e3ddd245609178c33ddcac1011_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ab8f76e64a46d58941675cc8783c2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5ce2953a28440b89e7ee68bba323d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8054044227734087aef06647c25d127e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03428188c1ee49ef8ce9c5b683046ed8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb108484a5da4e338d0d4751f13dd73a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f263d8dd40419bb80418ab7843bf76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf372d2348047f5953ac29d0036d748_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01169c36a4df47e8985588f97df426ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae3572c7a714189861826346d019725_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8c36ddf45540d2be8a68a9375992f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5549eca14af04f2faba84d86c3277878_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf66fd192a04254983a4b04fde0c089_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff5abbcecdbf42949927127eac25660e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf1941ab4cf4eaa9051a8d048ff8396_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1b51b8c04f48c796dbafa733a218ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-27</xbrli:startDate><xbrli:endDate>2021-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iecd854fcb4004bbcbf41e8c107112eee_I20210927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a274d8413eb4abe939b46c4859e5585_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21289ee699604ccda2bbe939f4826b3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3a2ff2c2da4f4385ae63c2bcc6c672_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26454d7ae8c44d190970894b06cf238_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea9298fff88462ca644d8893e65377d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f6d6fb99c046d289fc7290155d8526_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14855bc25d64407e9c3e34a6c5aa703b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6108e23d4714957986c26ca264b5fe8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4c591526ea478bb99b449397dd0039_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23950580a4342bd9a17e543bc89fa46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f714fd0e404cf8b81228344910a645_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibac2a4c8f53d40f38da16d18c79f554b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00eade1132384910a1edcc4602cd7f03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672bca309a9e49d7b8514f35e4e5676e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212dee94b35b42048df23efbc2d406d9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:EnterpriseWideSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1fd94d996648b992458725d1c804c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:PurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia195f6ae1083417ea6ba55e0f754b575_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>isrg:segment</xbrli:measure></xbrli:unit><xbrli:context id="i18ca052badd544ec96dacbdeb71e006a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af42d049a95445eb385849c884a645d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0778c030794ba48d3da31c3443b61c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:HighCreditRatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:ModerateCreditRatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib606f0cd45974794b541dc9482583db5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:LowCreditRatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dba95d10fbc41fc971720e2efa2c528_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46268e7a8003454a8651b908542fda66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id177033e3c704b16966079b0d35b30a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaaec3561f8241d9906a1ef96fca02df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564a11c205e348b89bbea004fd0d0881_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7bf33483de84677a014730d8912b575_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id997ca722e2f4788a65a9e8536746348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394f7efea4cd4225a8986de3d68e8579_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59583221ff1b4c91878682716a636bb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2587a04e00144b698e16da96b21f34a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8308ebf06c1c41218705b5b531829bcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08bf20bd9fe482f996a73a760e92a96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9444962effa548219751ad1adbb4d73f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0705226857e341b09873d9b24560e21a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i357d64746ac9439288fd1ba185b246c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1b5039fc4342148b973bb59e8d775f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702b19a2b8bb41359e443d04869386fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae9291dcd4e4adf9b84f4736b3bebec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">isrg:IntangibleAndOtherAssetsNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc10b5ae76314ee18fd591fd9b32d6ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5134dae76a5341b9aaabb6667f245625_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">isrg:IntangibleAndOtherAssetsNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71314a12af6b429986b5c9a4271f446a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">isrg:BroncusHoldingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079b7ef7442a42a7840e702b882a1012_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7280a7103fee4e258e2f35b51eff9ab1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i910cb2fb179a407d8a5c75fc680d2303_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c8e03657644033b868750e96ab9643_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46df387e6efe4ff08b0f664717fc0831_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21fdc4fc554441f08d904ff171695e33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided6c6550364405b97c4d34389c5ffff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964a856360ad4285ade38db2e34a431b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i231b0f91933940b08ff7af08baa651f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf83fed589c5486b9792c680888aeea0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0cbc403979c45828117eb065cab8fa2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i804002ab970d48a5a57bbae1404bf198_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a74a66492084258931e13b5981fa79f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22a8bae9b2c48eebe8b50b3819f8d70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edae5cd8cd2410183098ef4010c1892_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246f937640f04aaca1e106cbdf7b1a32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0cc5eca2d9942c3921b4aba2cde8e4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b35002f4f84795b5c367b377727c09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1c067c42d24d09b83f44eb0b71ce2b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae156a408ef48c79d517473c3535ecd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0a839f694a4a25a79f064404e8b099_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0b0eb6066646e28b5f0ecd47f541fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8144e739c7bc4ec28218fb43ce081ed4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3831ecf897f94e55ade9139765dde100_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55328c6d3ad9447fb62f387c720a2058_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1626e0eb7e514e2fb0c7df23826a6fec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b2f32382954088b7a0390205e6b628_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8304025c63864a2aa1a6a11f46d0864b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6837fa9980f8427899e6791fa305524d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36d1a1db0674a418d5a7f72e7b54de5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950b136a19ae40d9b9d11a4c60b1f0a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe17b049a1e34a548921b45ddee7b35f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib380a2c52e2d42409c0b1646842faf2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5df141ea8e40509cb916df8b2ff26f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c243171572a42cea628d49efffe8709_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda45a3621c84f1b9aef4071b842c2b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c746302eaf44e986f9840477b463de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9c7f30e288439fb419bcf27013ae6f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb59dcfb65644da9a3e23bb2aeea13c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1962e48f84bd458fb0b88daa39518d23_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bf5f4d5aed4a8b8454b48cd962b54e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b449d3de1df438a8825ceebf4e43693_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea54ffe275324b9381bef67e6b9ae4a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46c00d9c67d4ce9b8f5e8bbcc799cad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9ee599e0834c439f28abe74bf98547_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0333e95f85d48cf88145bfeb59afc5d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6107b94bba54498d96a497fbaf65d4cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf73792053ae49508767ca0ac0d77523_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990140e98ac543b0a1e3275119938c07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22cdd1443bcf48778c9fb236cb3f5a7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic357251bdc6148b78354861f8ff47859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1917b42017a44a168cb0fcb89a52d9bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0815014e2048d88e0fbadfebe22ea8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a3a8ceed2f49e880418977490f5d20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f06663da7d74354b3bd5efcad839096_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e20be5b265d48b181f0ff33e8f0c656_D20221019-20221019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">isrg:RexMedicalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-19</xbrli:startDate><xbrli:endDate>2022-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454d4ac87d7a4c0cabb826bc3c10cbcd_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d83242175d438fb29d5d804eea01f7_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i839d2a9749664c4bab3d1bdaacba0520_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife86c560869f4c39bf37fbe4692b9019_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78018ef69be42c396e169846e05b20b_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea6d8fa775a4209b8ce714c8dc3009a_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c368f15dd6943a5a4c230f46529d97e_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36cb3acbf52841e3bc3c63820c01fa42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c13220ef9824187bfc2e616446c4a3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181617f6fdb54de7954b15a38947b6bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473c6bb0442144b58cb06ae162b7e6a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b37d08e5a44af0beaf8cc7bb58696d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006259a527c0455b9e5463d5168ec708_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999a1d9653924dbe965c17ddd3a03def_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3150d3865845838cf5476e0ce21fc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0051b5c888cd406ea6c081c905d7c0bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70dfa53208644c0c9c0a6ec85264d603_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f1669e3b2446aca797556ff1d0ccd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d140b2190d4fc9ae1e1dc1d5ddb6c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15316780633245bbb91889b5d7ee1820_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17bfdaa573143ba98966885510cdde7_D20100401-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-04-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59158a68bbb4286aa90fa8eb06c7834_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b469324ce32446fb9def5b7b3c5cfbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9145bce4606d4940ad42ef487d849840_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i410198a3903441b68830e22a66897156_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia179814817fd4ff9878baee2be535b17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89170b9133ed4804b600e82c78c15cd5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409a1f3ac0ee4fcd9e608f4ff5c23e1b_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfae84224074580bb7bb01e54a43b99_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:AwardedtoAxis">isrg:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3241e96d8cae42fd893bed581e6753b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:AugustGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13aa27cc6a90415195d355246bcee08b_I20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8bc21a2592240cda306d477679d44f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65114e3030914e0a8cb520556e6fff7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9334eee01684436a51c2d0f31644073_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fe342469174f21b1e6e465beeaa26e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>isrg:period</xbrli:measure></xbrli:unit><xbrli:context id="if8fa15cbbe464ea8b44d4cc396aa1978_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c51c4092a524901b1803e5ce38a9526_I20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727584465aae4a70bf59561fe029a223_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a94340d69fc401d83c0ba90f1f24db2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3066fccc99431ea0149fec8907d401_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cb93da736742b282702b76ba91dfee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b8da69b805467d85bab92c30ac5b9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea0eb37deed46c3a1671bb3033ffa09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994c9aabae284d2ea354cdf5d3af175d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0740ebe40d864b4da35c3b393f1777dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ec653142c748c98233a20d2e6fab4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174231a7f81b42edb1f0569a32f0f3d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic497a710b79f4cfbadc4cbf7577e4244_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59e1332f83f433bafce8ca9eb07b593_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc843d98e1341af9834acde67e83d17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f463df323b94b2ca79195cb77ae86c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a32dfb6574f44df8ff7344da9391dc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee7d626dd6442c084221823215a5e3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c2ead6914ce4c29ad6ab0ea4e54ec31_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d9f668182e4bce91778830a95c13c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5570cfc269954912b1db7819ee5a7b87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1765d5cde54c3a8c9535c06750c11d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fed7f0046594d5e9b7d0285eebe8dbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa21ecf135f4e53ae80c53876c575de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8730f5559847e5a2a128e0dc663cac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703c917c11ba41f5bc3d9e8c4fa82c6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd22f87fb8ad43d2af45c67cf1ea9e08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31db10c6d6c45489ada87073252b5c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e05145f69544e49958c2c699ac2e14a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c76b4eb5b2d43bdbd83af671ec30557_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483a5421245644e8b7c29c4dd81da287_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37f0a23420d421f959a8c22e7707a05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3634dbe2d578411bbbc75e8831903c17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NonvestedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cf962b95e84dc7891ff65923990d77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NonvestedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20cd9153845f4947a182196df818b48b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:FebruaryGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52d8d269cc94237acc26da529069828_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:AugustGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NewHireOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialGrantOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2000-03-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78daf21ac2234a819cab8768cbb59e61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialRSUgrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="isrg:AwardedtoAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749d4dedba014c68aa5c7acf3007a4d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">isrg:DomesticAndForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c4df323b92487582860c45f1709563_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552384583d88412ebd23eaaff77ee647_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a0a29ffcad84c7ba35a79003fcce055_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54e38a6bc054a1bb5bcc9ff5b0db69b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745afcb5136f43d88582feee765c64c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001035267</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3 id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4 id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i025de1eec32044f5a30c5872569f0e8d_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk2_13cd1b3f-d45f-404b-b50d-2fc8cbe74aad">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(MARK ONE)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MWE0MWY3N2RmY2MzNGIxM2FkNTg4MWNhNTc1ZmZlMmIvdGFibGVyYW5nZToxYTQxZjc3ZGZjYzM0YjEzYWQ1ODgxY2E1NzVmZmUyYl8wLTAtMS0xLTE1MDAzNA_5dae84f4-81e0-42d2-8325-2ee40d6f5d48">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY180OTQ3ODAyMzI5MjQ0_9bf61e1e-5015-4c45-8279-93df2cb88a8d">December 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjMzYTU1YmU5NWM1NDY2Mzk5NGVhZjhjM2U5NjM0YjUvdGFibGVyYW5nZToyMzNhNTViZTk1YzU0NjYzOTk0ZWFmOGMzZTk2MzRiNV8wLTAtMS0xLTE1MDAzNA_7f66bcbc-9d3d-47ac-a048-0c38fea755b7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA1_47af1b48-4813-431b-8c88-0b02045f9731">000-30713</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><img src="isrg-20221231_g1.jpg" alt="isrg-20221231_g1.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:197px"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTEw_f344f141-4d8a-419e-84d6-e94b428d48bf">Intuitive Surgical, Inc.</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6ZmM5MTMwYTdiYjEzNGJlM2JiZTQ3MWI1MDE0ODVhNmQvdGFibGVyYW5nZTpmYzkxMzBhN2JiMTM0YmUzYmJlNDcxYjUwMTQ4NWE2ZF8wLTAtMS0xLTE1MDAzNA_d39f2d39-5e5e-4f1d-95f1-991c3e67b31d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6ZmM5MTMwYTdiYjEzNGJlM2JiZTQ3MWI1MDE0ODVhNmQvdGFibGVyYW5nZTpmYzkxMzBhN2JiMTM0YmUzYmJlNDcxYjUwMTQ4NWE2ZF8wLTItMS0xLTE1MDAzNA_040c1602-b06e-4185-ae15-95b2439e4ef3">77-0416458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAy_0b0fe70d-d0bd-4a96-8d60-0fc2234e8d2e">1020 Kifer Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDkx_72dd7499-019b-43d4-857d-ecda2a6907ae"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAz_7e2c27f9-724e-4c58-a6cf-9fbdca7c817a">Sunnyvale</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk3_6d385f5c-7c87-44d5-a82e-183df30d7c18">California</ix:nonNumeric> <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDky_6bf77f03-5793-4c76-b8cc-3a16f707bec8">94086</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA2_e88b9330-0fd4-4eff-ab4b-2db89ac64f36">(408)</ix:nonNumeric> <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk4_96d58491-e7ff-415e-9bfb-a0ddc8bd1f05">523-2100</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:39.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTAtMS0xLTE1MDAzNA_592a4775-eca4-44ff-abfb-b81204859d69">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTEtMS0xLTE1MDAzNA_e746df3d-0f09-4ba0-b210-eed39e2ef36c">ISRG</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTItMS0xLTE1MDAzNA_4df290c8-c0b2-4d6e-8a8c-2964ba6153e3">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA3_af650071-7176-43e0-9d56-9ef14c53b5f8">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA0_7ddde211-2f8b-4381-9c79-b007f0e7f960">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA4_23cfa67e-6bac-44a3-878b-78ba913f8bef">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk0_e8a1ce28-bba4-46d2-9a1a-4400d9797927">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:31.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8wLTAtMS0xLTE1MDAzNA_4216c67e-d2fe-463e-b963-fa57d42e175b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8xLTQtMS0xLTE1MDAzNA_9aa86f27-876c-4d42-bc94-c67da4d39f9f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8yLTQtMS0xLTE1MDAzNA_0553ab35-145e-4e1a-b170-d4d8e36fd3e4">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;   &#9744;&#160;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk5_3e07f5ca-07dd-496f-9a60-ec6b64bd8e18">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.    &#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).    &#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk1_be996500-1e09-4181-8c35-ebdb8d4103b6">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates on June&#160;30, 2022, based upon the closing price of Common Stock on such date as reported on The Nasdaq Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="i205ff87813544221905e1bacbc0e834a_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18yOTAx_e96d6034-da85-442a-acda-740522302ac8">71.4</ix:nonFraction>&#160;billion. Shares of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock as of February&#160;7, 2023, was <ix:nonFraction unitRef="shares" contextRef="ib0ed59a4d8384c88a2ad8e007a293a45_I20230207" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zMjIz_8ea59648-0083-4c9b-befb-fbbd763a2a68">350,389,679</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAw_69f649d4-9021-4e61-810a-3d1a7e166c6b" escape="true">Part III incorporates information by reference to the definitive proxy statement for the Company&#8217;s Annual Meeting of Stockholders to be held on or about April&#160;27, 2023, to be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_19">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_61">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_61">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_61">26</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_76">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_76">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_76">54</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_79">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_79">54</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_82">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_82">55</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_85">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_85">55</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_88">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91">Market for</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91"> Registrant&#8217;s Common Equity, Related Stockholder Matters</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91">Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_91">56</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_94">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">[RESERVED]</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_94">57</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_97">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_97">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_97">58</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_199">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_199">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_199">82</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_202">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_202">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_202">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_280">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_280">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_280">122</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_283">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_283">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_283">122</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_286">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_286">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_286">122</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_289">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_289">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_289">123</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_292">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_295">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_295">Directors, Executive Officers</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_295">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_295"> and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_295">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_298">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_298">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_298">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_301">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_301">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_301">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_304">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_304">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_304">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_307">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_307">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_307">124</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_310">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_313">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_313">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_313">125</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_319">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_319">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_319">126</a></span></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_322">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_322">127</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;targeted,&#8221; and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements related to the expected impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, future results of operations, future financial condition, our financing plans and future capital requirements, our potential tax assets or liabilities, and statements based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and our beliefs and assumptions regarding these economies and markets. These forward-looking statements are necessarily estimates reflecting the judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which impacts customer spending and our costs, including increased inflation and interest rates; the conflict in Ukraine; disruption to our supply chain, including increased difficulties in obtaining a sufficient supply of materials in the semiconductor and other markets; the risk that the COVID-19 pandemic could lead to material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by hospitals; closures of our facilities; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals, clearances, or certifications from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), comparable regulatory authorities, or notified bodies; diversion of resources to respond to COVID-19 outbreaks; the impact of global and regional economic and credit market conditions on healthcare spending; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedure counts; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; risks associated with our operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party, including, but not limited to, product liability claims; adverse publicity regarding us and the safety of our products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221; Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results may differ materially and adversely from those expressed in any forward-looking statement, and we undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law. Additional risks are described throughout this report, particularly in Part&#160;I, &#8220;Item&#160;1A. Risk Factors,&#8221; and include, but are not limited to, those summarized on the following pages.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR BUSINESS</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Macroeconomic conditions could have a materially adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on sole and single source suppliers and ability to purchase at acceptable prices a sufficient supply of materials, parts, and components could harm our ability to meet product demand in a timely manner or within budget.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public health crises or epidemic diseases, or the perception of their effects, could materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to litigation, investigations, and other legal proceedings relating to our products, our customers, our competitors, and government regulators that could materially adversely affect our financial condition, divert management&#8217;s attention, and harm our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our markets are highly competitive, customers may choose to purchase our competitors&#8217; products or services or may not accept robotic-assisted medical procedures, which could result in reduced revenue and loss of market share.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our products do not achieve and maintain market acceptance, we will not be able to generate the revenue necessary to support our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If hospitals are unable to obtain coverage and reimbursement for procedures using our products, if reimbursement is insufficient to cover the costs of purchasing our products, or if limitations are imposed by governments on the amount hospitals can charge for certain procedures, we may be unable to generate sufficient sales to support our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our products contain defects or encounter performance problems, we may have to recall our products and, as a result, incur additional unforeseen costs, and our reputation may suffer.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We could be subject to significant, uninsured losses, which may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose key personnel or are unable to attract and retain other personnel, our ability to compete will be harmed, and increases in labor costs could materially adversely impact our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative publicity, whether accurate or inaccurate, concerning our products or our company could reduce market acceptance of our products and could result in decreased product demand and reduced revenues.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We experience long and variable capital sales cycles and seasonality in our business, which may cause fluctuations in our financial results.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New product developments and introductions may adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to a variety of risks due to our operations outside of the U.S.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur losses associated with currency fluctuations and may not be able to effectively hedge our exposure.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers may use remanufactured and/or unauthorized third-party instruments and accessories, which could result in reduced revenue and negatively impact our reputation.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information technology system failures, cyberattacks, or deficiencies in our cybersecurity could harm our business, customer relations, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to complex and evolving laws and regulations regarding privacy, data protection, and other matters relating to information collection.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to successfully acquire or integrate new businesses, products, and technology, we may not realize expected benefits, or our business may be harmed.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully manage our collaboration arrangements, licensing arrangements, joint ventures, strategic alliances, or partnerships with third parties, we may not realize the expected benefits from such alliances, which may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect gross profit margins to vary over time, and changes in our gross profit margins could adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We utilize distributors for a portion of our sales and service of our products in certain countries, which subjects us to a number of risks that could harm our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We offer alternative capital acquisition approaches and, as a result, we are exposed to the credit risk of some of our customers and the risk of losses of revenue, which could result in material losses.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are exposed to credit risk and fluctuations in the market value of our investments.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing armed conflict between Russia and Ukraine could adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter manufacturing problems or delays that could result in lost revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions at the FDA and other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent products from being developed, cleared, certified, approved, or commercialized in a timely manner or at all, which may adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to risks associated with real estate construction and development.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued consolidation in the healthcare industry could have an adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Climate change and natural disasters or other events beyond our control could disrupt our business and result in loss of revenue or higher expenses.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in our effective tax rate may adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use estimates, make judgments, and apply certain methods in determining our financial results and in measuring the progress of our business. As these estimates, judgments, and methods change, our results of operations and our assessment of the progress of our business could vary.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR REGULATORY ENVIRONMENT</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Complying with FDA and foreign regulations is a complex process, and our failure to fully comply could subject us to significant enforcement actions.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products are subject to a lengthy and uncertain domestic regulatory review process. If we do not obtain and maintain the necessary domestic regulatory authorizations, we will not be able to sell our products in the U.S.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and foreign regulatory authorities and, if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our manufacturing facilities do not continue to meet federal, state, or other manufacturing standards, we may be required to temporarily cease all or part of our manufacturing operations, import/export of our products, and/or recall some products, which would result in significant product delivery delays and lost revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products are subject to international regulatory processes and approval or certification requirements. If we do not obtain and maintain the necessary international regulatory approvals or certifications, we will not be able to sell our products in other countries.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in healthcare legislation and policy may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to federal, state, and foreign laws governing our business practices, which, if violated, could result in substantial penalties. Additionally, challenges to, or investigation into, our practices could cause adverse publicity and be costly to respond to and, thus, could harm our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If hospitals and other surgery facilities do not continue to meet federal, state, or other regulatory standards, they may be required to temporarily cease all or part of their system utilization.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to fully protect and successfully defend our intellectual property from use by third parties, our ability to compete in the market may be harmed.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may be successful in asserting that our products infringe their intellectual property rights, which may cause us to pay substantial damages and/or enjoin us from commercializing our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products rely on licenses from third parties, which may not be available to us on commercially reasonable terms or at all. If we lose access to these technologies, our revenues could decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL RISK FACTORS</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future operating results may be below securities analysts&#8217; or investors&#8217; expectations, which could cause our stock price to decline.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price has been, and will likely continue to be, volatile.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to financial accounting standards may affect our reported results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of material risk factors described above should be read together with the text of the full risk factors below in the section entitled &#8220;Item&#160;1A. Risk Factors&#8221; and the other information set forth in this Annual Report on Form 10-K, including our Consolidated Financial Statements and the related notes, as well as other documents that we file with the U.S. Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_19"></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, &#8220;Intuitive Surgical,&#8221; &#8220;Intuitive,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries. Intuitive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Intuitive Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci Si</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci X</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci Xi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, da Vinci SP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoWrist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Firefly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Iris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OnSite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SimNow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SureForm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and SynchroSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks or registered trademarks of the Company.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_22"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Background</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Intuitive&#8217;s mission, we believe minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints. We envision a future of care that is less invasive and profoundly better, where diseases are identified earlier and treated quickly so patients can get back to what matters most.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive is committed to advancing minimally invasive care through a comprehensive ecosystem of products and services. This connected ecosystem includes systems, instruments and accessories, learning, and services connected by a digital portfolio that enables actionable digital insights across the care continuum and provides enhanced capabilities, intraoperative guidance, decision support, and a personalized learning journey, all with the goal to help improve outcomes and efficiency.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive brings nearly three decades of experience and technical innovation to our robotic-assisted surgical solutions. While surgery and acute interventions have improved significantly in the past decades, there remains a significant need for better outcomes and decreased variability of these outcomes across care teams. The current healthcare environment continues to stress critical resources, including the professionals who staff care teams: surgeons, anesthesiologists, nurses, and other staff. At the same time, governments strain to cover the healthcare needs of their populations and demand lower total costs per patient to treat disease. In the face of these challenges, we believe scientific and technological advances in biology, computing, imaging, algorithms, and robotics may offer new methods to solve continued and difficult problems.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address our customers&#8217; needs by sharing their goals reflected in the quadruple aim. First, we focus on improving patient outcomes through an ecosystem of advanced robotic systems, instruments and accessories, progressive technology learning pathways, and comprehensive support and program assistance services. Second, we seek to improve the patient experience by minimizing disruption to lives and creating greater predictability for the treatment experience. Third, we seek to improve care team satisfaction by creating products and services that are dependable, smart, and optimized for the care environment in which they are used. Finally, we seek to lower the total cost to treat per patient episode when compared with existing treatment alternatives, providing a return on investment for hospitals and healthcare systems and value for payers.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_25"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systems</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced robotic systems provide precise, powerful systems with high-performance vision, extending the care team&#8217;s capabilities to enhance minimally invasive care. These systems include the da Vinci Surgical System, which was designed to enable complex surgery using a minimally invasive approach, and the Ion endoluminal system, which extends our commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Surgical Systems</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By striving to find less invasive ways to enter the body, provide clearer views of anatomy and more precise tissue interactions, and help hone surgical skills, Intuitive launched its first da Vinci Surgical System in 1999. In 2000, the FDA cleared da Vinci for general laparoscopic surgery.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several models of the da Vinci Surgical System: our fourth generation da Vinci X, da Vinci Xi, and da Vinci SP Surgical Systems, our third generation da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Si Surgical System, our second generation da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S Surgical System, and our first generation da Vinci standard Surgical System. The da Vinci surgical systems are designed to enable surgeons to perform a wide range of surgical procedures within our targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties. To date, surgeons have used the da Vinci Surgical System to perform dozens of different types of surgical procedures. Da Vinci systems offer surgeons three-dimensional, high definition (&#8220;3DHD&#8221;) vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera (endoscope) and wristed instruments (e.g., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our da Vinci surgical systems are comprised of the following components:</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Surgeon&#8217;s Console</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The da Vinci Surgical System allows surgeons to operate while comfortably seated at an ergonomic console viewing a 3DHD image of the surgical field. The surgeon&#8217;s fingers grasp instrument controls below the display </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the surgeon&#8217;s hands naturally positioned relative to his or her eyes. Using electronic hardware, software, algorithms, and mechanics, our technology translates the surgeon&#8217;s hand movements into precise and corresponding real-time micro movements of the da Vinci instruments positioned inside the patient. On most of our current systems (da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi, da Vinci SP, and da Vinci Si), a second surgeon&#8217;s console may be used in two ways: to provide assistance to the primary surgeon during surgery or to act as an active aid during surgeon-proctor training sessions. With the da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi, da Vinci SP, and da Vinci Si, a surgeon sitting at a second console can view the same surgery as the primary surgeon and can be passed control of some or all of the da Vinci instruments during the surgery. In addition, surgeons can control 3D virtual pointers to augment the dual-surgeon experience. The da Vinci Surgical System is designed to allow surgeons to operate while seated, which may be clinically&#160;advantageous because of reduced surgeon fatigue. The da Vinci Surgical System&#8217;s design provides natural hand-eye alignment at the surgeon&#8217;s console. Because the da Vinci Surgical System&#8217;s robotic arms hold the camera and instruments steady, there is less surgeon and assistant fatigue.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient-Side Cart</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The patient-side cart holds electromechanical arms that manipulate the instruments inside the patient. Up to four arms attached to the cart can be positioned, as appropriate, and then locked into place. At least two arms hold surgical instruments, one representing the surgeon&#8217;s left hand and one representing the surgeon&#8217;s right hand. A third arm positions the endoscope, allowing the surgeon to easily move, zoom, and rotate the field of vision. A fourth instrument arm extends surgical capabilities by enabling the surgeon to add a third instrument to perform additional tasks. The fourth instrument arm is a standard, integrated feature on the da Vinci X, da Vinci Xi, and da Vinci Si Surgical Systems. Our da Vinci SP Surgical System includes a single arm with three multi-jointed, wristed instruments and the first da Vinci fully wristed, 3DHD camera. The instruments and the camera all emerge through a single cannula and are triangulated around the target anatomy to avoid external instrument collisions that can occur in narrow surgical workspaces.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3DHD Vision System.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our vision system includes a 3DHD endoscope with two independent vision channels linked to two separate color monitors through sophisticated image processing electronics and software. The resulting 3DHD image has high resolution, high contrast, low flicker, and low cross fading. A digital zoom feature in the 3DHD vision system allows surgeons to magnify the surgical field of view without adjusting the endoscope position and, thereby, reduces interference between the endoscope and instruments. The 3DHD vision system is a standard, integrated feature on the da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> da Vinci SP,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Si</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and da Vinci S Surgical Systems.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Firefly Fluorescence Imaging (&#8220;Firefly&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Firefly is a standard feature of the da Vinci X, da Vinci Xi, and da Vinci SP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical Systems and is available as an upgrade on our da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Si Surgical System. This imaging capability combines an injectable fluorescent dye with a specialized da Vinci camera head, endoscope, and laser-based illuminator to allow surgeons to identify vasculature, tissue perfusion, or biliary ducts in three dimensions beneath tissue surfaces in real-time. The most common procedural categories for the use of Firefly are urology, gynecology, and general surgery.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Xi Integrated Table Motion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Integrated Table Motion coordinates the movements of the da Vinci robotic arms with an advanced operating room (&#8220;OR&#8221;) table, the TS 7000dV OR Table sold by Hillrom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to enable managing the patient&#8217;s position in real-time while the da Vinci robotic arms remain docked.&#160;This gives OR teams the capability to improve the positioning of the operating table during da Vinci Surgical System procedures. Integrated Table Motion enables the patient to be dynamically positioned during the procedure. It enables surgeons to extend reach, facilitate access, and choose the angle of approach to target anatomy, as well as reposition the table during the procedure to enhance anesthesiologists&#8217; management of the patient.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ion Endoluminal System</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the FDA cleared our Ion endoluminal system, which is a flexible, robotic-assisted, catheter-based platform that utilizes instruments and accessories for which the first cleared indication is minimally invasive biopsies in the lung. Our Ion system extends our commercial offering beyond surgery into diagnostic, endoluminal procedures. The system features an ultra-thin, ultra-maneuverable catheter that can articulate 180 degrees in all directions and allows navigation far into the peripheral lung and provides the stability necessary for precision in a biopsy. Many suspicious lesions found in the lung may be small and difficult to access, which can make diagnosis challenging, and Ion helps physicians obtain tissue samples from deep within the lung, which could help enable earlier diagnosis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments and Accessories</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a comprehensive suite of stapling, energy, and core instrumentation for our surgical systems. Our technology is designed to transform the surgeon&#8217;s natural hand movements outside of the body into corresponding micro-movements inside the patient&#8217;s body and suture with precision, just as they can in open surgery. With our technology, a surgeon can also use &#8220;motion scaling,&#8221; a feature that translates, for example, a three-millimeter hand movement outside the patient&#8217;s body into a one-millimeter instrument movement in the surgical field inside the patient&#8217;s body. Motion scaling is designed to allow precision and control for delicate tasks. In addition, our technology filters the tremor inherent in a surgeon&#8217;s hands.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Most of the various instruments that we manufacture incorporate EndoWrist technology with wristed joints for natural dexterity and tips customized for various surgical procedures. Da Vinci instruments are offered in a variety of diameters, of which 8mm and 12mm diameter sizes are the most commonly sold. Various da Vinci instrument tips include forceps, scissors, electrocautery tools, scalpels, and other surgical tools that are familiar to the surgeon from open surgery and conventional minimally invasive surgery (&#8220;MIS&#8221;). A variety of instruments may be selected and used interchangeably during a surgery. Most instruments are sterilizable at the hospital, while others are provided sterile, and most are reusable for a defined number of procedures. A programmed memory chip inside each instrument performs several functions that help determine how the da Vinci system and instruments work together. In addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures to help ensure that its performance meets specifications during each procedure.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we announced our &#8220;Extended Use Program,&#8221; which consists of select da Vinci Xi and da Vinci X instruments possessing 12 to 18 uses (&#8220;Extended Use Instruments&#8221;) compared to the previously 10 uses. These Extended Use Instruments represent some of our higher volume instruments but exclude stapling, monopolar, and advanced energy instruments. Instruments included in the program are used across a number of da Vinci surgeries. Their increased uses are the result of continuous, significant investments in the design and production capabilities of our instruments, resulting in improved quality and durability. Extended Use Instruments were introduced in the U.S. and Europe in the fourth quarter of 2020 and were launched in most other countries around the world during the first half of 2021, except China due to regulatory timelines. We believe that, as of the end of 2021, in the U.S. and Europe, full cutover to Extended Use Instruments had occurred, as customers had substantially utilized all of their remaining 10 use instruments.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Stapling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The EndoWrist and SureForm Staplers are wristed, stapling instruments intended for resection, transection, and creation of anastomoses. These instruments enable operators to precisely position and fire the stapler. We have various clearances for five staplers that can be used with the da Vinci X and da Vinci Xi Surgical Systems: the EndoWrist Stapler 30 and 45 and the SureForm Stapler 30, 45, and 60, where the numeric designation indicates the length of the staple line. The&#160;EndoWrist&#160;Stapler 30 is intended to deliver particular utility with fine tissue interaction in lobectomy and other thoracic procedures. The&#160;EndoWrist&#160;Stapler 45 is used in general surgery, gynecologic, thoracic, and urologic procedures. The SureForm Staplers 30, 45, and 60 are single-use, fully wristed, stapling instruments intended</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be used in general surgery, thoracic, gynecologic, urologic, and pediatric surgery procedures. The SureForm Stapler 30 may deliver particular utility in thoracic procedures. The SureForm 45 may deliver particular utility in thoracic and colorectal procedures where maneuverability and visualization are limited. The SureForm Stapler 60 is intended to deliver particular utility in bariatric procedures. We also have various clearances for five stapler reloads: gray (2.0 mm), white (2.5 mm), blue (3.5 mm), green (4.3 mm), and black (4.6 mm). Not all reloads are available for use on all staplers. Not all staplers or reloads are available in all countries.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The EndoWrist One Vessel Sealer is a wristed, single-use instrument intended for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument. This instrument enables surgeons to fully control vessel sealing, while providing the benefits of robotic-assisted surgery. This instrument is designed to enhance surgical efficiency and autonomy in a variety of general surgery and gynecologic procedures. The da Vinci Vessel Sealer Extend is our newest instrument in the Vessel Sealing family of products. The da Vinci Vessel Sealer Extend is a single-use, fully wristed bipolar electrosurgical instrument compatible with our fourth-generation multiport systems. It is intended for grasping and blunt dissection of tissue and for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The E-100 generator is Intuitive&#8217;s first generator and is offered as an upgrade to power our da Vinci Vessel Sealer Extend and SynchroSeal instruments. SynchroSeal enables a surgeon to perform rapid, one-step sealing and transection with a single pedal press. SynchroSeal uses advanced bipolar energy from its raised cut electrode to transect tissue and then cool down quickly.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accessory Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We sell various accessory products, which are used in conjunction with the da Vinci Surgical Systems as surgical procedures are performed. Accessory products include sterile drapes used to help ensure a sterile field during surgery, vision products, such as replacement 3D stereo endoscopes, camera heads, and light guides, and other items that facilitate use of the da Vinci Surgical Systems.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Learning</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive provides progressive learning pathways to support the safe and effective use of our technology. They are structured and measured training pathways for surgeons, physicians, and care teams. These pathways leverage both learning engagements and learning technologies. Learning engagement touchpoints vary by specific pathway, skill level, and interest, while learning technologies enable and provide training directly to the customer. The portfolio of learning offerings includes role-specific Training Pathways, Learning Engagements, and Learning Technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Training Pathways.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Intuitive Training Pathways are progressive learning journeys that help our customers achieve proficiency using Intuitive technology. There are pathways for surgeons and physicians, residents and fellows, OR care teams, patient side assists, and robotic coordinators, as well as recommendations for executives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Learning Engagements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Intuitive Learning Engagements are touchpoints that support customers throughout their learning journeys. They vary by pathway, skill level, and focus area. Engagements include case observations, online education, in-service training, simulation/skills training, OR care team training, technology training, reprocessing training, proctoring, advanced training, and curriculum development support. Many of these programs take place at established Intuitive training centers and include instruction by expert surgeons and physicians.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Learning Technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Learning Technologies include solutions that provide education and training directly to the customer as well as the enabling technologies that make provision possible. Intuitive&#8217;s enabling technologies include Telepresence and the Procedure Analytics Platform. Specific technology solutions include Intuitive Learning, SimNow, customized training models, remote case observations, and remote proctoring. Two of the technology solutions most heavily utilized by customers are Intuitive Learning and SimNow.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intuitive Learning.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Intuitive Learning provides our customers with access to the technology, procedure, and simulation materials essential to their specific learning journeys. Both assignment of learning materials and tracking of learning progress occur seamlessly within the platform. While Intuitive Learning plans guide learners through each step in their pathways, customers are also able to search the platform independently for additional materials that may be relevant to their area of focus. This platform also provides customers with immediate access to their various training certificates.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SimNow. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cloud-enabled SimNow simulation platform is a practice tool that gives a user the opportunity to practice their skills and gain familiarity with the surgeon console controls and supports the user&#8217;s progressive learning pathway. SimNow incorporates 3D, physics-based computer simulation technology to immerse the user within a virtual environment and provides training capabilities that have been used extensively by surgeons. The user navigates through the environment and completes exercises by controlling virtual instruments from the surgeon console. Upon completion of a skills exercise, the skills simulator provides a quantitative assessment of user performance based on a variety of task-specific metrics. The SimNow online connection drives real-time simulation performance tracking for surgeons and administrators through an online dashboard and supports remote updates of the VR content and 3DHD videos to drive a more interactive and engaging customer experience. SimNow is intended to augment, not replace, existing training programs for the da Vinci X, da Vinci Xi, and da Vinci SP Surgical Systems.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Services</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a network of field service engineers across the U.S., Europe, and Asia and maintain relationships with various distributors around the globe. This infrastructure of service and support specialists offers a full complement of services for our customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive support and program assistance helps ensure customers and care teams maximize program performance and protect their investment. Services include readiness support, maintenance support, perioperative consulting, Custom Hospital Analytics, and market consulting optimization.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Readiness and Maintenance Support.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Readiness support is operational support to ensure smooth onboarding and adoption of new systems and technology. Maintenance support helps to maximize operational efficiency and reduce unplanned equipment downtime. It includes services care plans, support teams, OnSite monitoring, software upgrades and updates, as well as a customer portal. The service plan portfolio offers flexible service plans to ensure reliability of the systems and instruments and help optimize the robotics program. The support team of expert field service, remote technical support, and customer care agents resolve and prevent any technology issues that could inhibit optimal utilization. OnSite monitoring offers remote service in real-time for pre-operative and intraoperative troubleshooting, as well as proactive monitoring of system performance. Software upgrades and updates enable the latest product innovations, enhancements, and reliability improvements. The customer portal is an online tool that enables customers to access system utilization and program analytics, view orders and maintenance history, and initiate product returns and exchanges to help achieve the operational and financial goals of a robotics program.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Perioperative Consulting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Perioperative consulting is a suite of customized solutions to improve a hospital&#8217;s efficiency and performance with Intuitive technologies. New system integration support is available to streamline the start-up process and expedite increased procedure volumes. Overall program assessments help to support efficiency improvements, cost reductions, and system access optimization.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Program Analytics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Custom Hospital Analytics program enables the integration of data sources so that individual health institutions can analyze their data in their own environment. Using this data, executives, administrators, care teams, and surgeons can gain alignment around their programs based on their KPIs, determine best practices, assess gaps, and take actionable steps to address any gaps.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Digital Solutions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrated digital capabilities provide connected offerings, streamlining performance for hospitals with program-enhancing insights. Secure-by-design, cloud-enabled products analyze and simplify essential data to continuously optimize the use of time, tools, and techniques.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intuitive Hosted &amp; Managed Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The vast majority of our systems are network connected and directly communicate with Intuitive to enable proactive monitoring as well as provide software updates and data insights to Intuitive customers.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3D Modeling Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Iris is our augmented reality imaging product for use in kidney procedures. The service extracts CT scans, runs them through machine-learning algorithms and, after technicians&#8217; revision and radiologists&#8217; review, returns a 3D segmented model of the kidney for use in planning for a procedure and for intraoperative visualization of the area. The tool uses augmented reality to give surgeons an image with details of the kidney anatomy &#8211; blood vessels, tumor shape, and size &#8211; that they may not be able to see well with other imaging. Intuitive designed this to help with pre-operative planning and intraoperative guidance as well as to be shared as a teaching tool for other physicians and patients. It can also be part of the viewing experience inside of the da Vinci surgeon console to enhance information and let surgeons know where critical anatomy sits as they work through a procedure. We have completed several pilot studies with Iris to obtain customer feedback, which is currently being incorporated to support a future product launch.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">My Intuitive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This mobile and web application was developed to be the single point for Intuitive customers to access individual or program-level data from Intuitive. The application also offers comparisons of those insights with anonymized national benchmarks to help drive operational efficiencies and decreased costs. The most recent version enables mobile access to Intuitive&#8217;s Learning platform, case reports generated automatically for the surgeon, and an ability for surgeons to publish their practice information online for patients seeking local physicians.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intuitive Hub</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Intuitive Hub is part of our OR informatics platform that integrates multiple applications and data sets to help orchestrate medical procedure workflows. For the care team, Intuitive Hub acts as a point-of-care device that automates tasks, such as video recording and bookmarking, and can be used to facilitate peer-to-peer collaboration utilizing our Telepresence offering. For physicians, Intuitive Hub connects video and other data that can be accessed after a medical procedure to help facilitate personalized learning and increased efficiency.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_28"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We align our goals to those of our customers, often called the Quadruple Aim: enabling physicians and hospitals to improve outcomes for their patients, improve their patient&#8217;s and the care team&#8217;s experience, and lower the total cost to treat per patient episode. Through the use of smart, connected systems, robotic technologies, advanced imaging, and informatics, our objective is to create value for patients, surgeons, and hospitals, as summarized below.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We believe that the value of a medical procedure to a patient can be defined: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Value = Procedure Efficacy / Invasiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We define </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">procedure efficacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a measure of the success of the procedure in helping resolve the underlying disease and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">invasiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a measure of patient pain and disruption of regular activities. When the patient value of a procedure using an Intuitive product is greater than that of alternative treatment options, patients may benefit from seeking out surgeons and hospitals that offer those products, which could potentially result in a local market share shift. Adoption of Intuitive technology occurs procedure by procedure and market by market and is driven by the relative patient value and the total treatment costs of da Vinci procedures as compared to alternative treatment options for the same disease state or condition. We believe that most patients will place a higher value on procedures that are not only more efficacious but also less invasive than alternative treatments. Our goal is to provide products to surgeons who, in turn, provide patients with procedure options that are both highly effective and less invasive than others.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Surgeon Value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We offer physicians and their operating room staff training on the technical use of our products. We provide an ergonomic platform through our da Vinci surgical system for surgeons to perform their procedures. We seek to provide surgeons with reliable and easy-to-use products. For example, the change to cloud-based analytics and routine use of local analytics may help surgeons track their procedures and processes and, with a network-connected smartphone and the My Intuitive app, surgeons can access and explore their procedure data, such as console time and instrument usage, to gain insights into their program.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We assist hospitals in building value by offering patient value using da Vinci products, thereby increasing surgical revenue and reducing costs through lower complication rates and reduced lengths of patient stay. For example, we believe robotic-assisted surgery with the da Vinci Surgical System is a cost-effective approach to many surgeries as compared to alternative treatment options, as recognized in many published studies. We also offer our Custom Hospital Analytics program, which enables the integration of data sources so that individual health institutions can analyze their data in their own environment. Using this data, administrators, chiefs of surgery, and surgeons can gain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alignment around their programs based on their KPIs, determine best practices, assess gaps, and take actionable steps to address any gaps.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_31"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Applications</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the beneficiaries of productive collaborations with leading surgeons in exploring and developing new techniques and applications for robotic-assisted surgery with the da Vinci Surgical System and minimally invasive biopsies with the Ion endoluminal system&#8212;an important part of our creative process. We primarily focus our development efforts on those procedures in which we believe our products bring the highest patient value, surgeon value, and hospital value. We currently focus on five surgical specialties: general surgery, urologic surgery, gynecologic surgery, cardiothoracic surgery, and head and neck surgery. Key procedures that we are focused on include hernia repair, colon and rectal procedures, cholecystectomy, bariatric surgery, prostatectomy, partial nephrectomy, hysterectomy, sacrocolpopexy, lobectomy, and transoral robotic surgery. We also focus on minimally invasive biopsies in the lung. Representative surgical applications are described below.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Surgery</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hernia Repair.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A hernia occurs when an organ or other tissue squeezes through a weak spot in a surrounding muscle or connective tissue. During a hernia repair surgery, the weakened tissue is secured, and defects are repaired. Common types of hernias are ventral and inguinal.&#160;Ventral, or abdominal hernia, may occur through a scar after surgery in the abdomen.&#160;Inguinal hernia is a bulge in the groin and is more common in men.&#160;Hernia repair can be performed using traditional open surgery or MIS. There is a wide range of complexity in hernia repair surgeries and varying surgeon opinions regarding optimal surgical approach. The benefits of minimally invasive and robotic-assisted hernia repair surgery vary by patient.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorectal Surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  These procedures typically involve benign or cancerous conditions of the lower digestive system, in particular the rectum or colon. Common procedures in this area include hemicolectomy, sigmoidectomy, low anterior resection, and abdominoperineal resection. Surgeons have reported that the use of robotic-assisted surgery with a da Vinci Surgical System and our latest technologies, such as the EndoWrist Stapler and da Vinci Energy, has enabled them to offer MIS approaches to a broader range of colorectal surgery patients.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cholecystectomy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Cholecystectomy, or the surgical removal of the gall bladder, is a commonly performed general surgery procedure.&#160;Cholecystectomy is the primary method for the treatment of gallstones and other gall bladder diseases.&#160;Most cholecystectomies are performed using multi-port MIS techniques, although some surgeons choose to perform cholecystectomy using manual single-port instrumentation.&#160;Firefly technology can be used to visualize biliary anatomy in three dimensions beneath the tissue surfaces during multi-port da Vinci cholecystectomies.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bariatric Surgery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; A body of literature points to the benefit of surgery to treat patients with morbid obesity and its secondary effects, such as diabetes. Sleeve gastrectomy and Roux-en-Y gastric bypass (&#8220;RYGB&#8221;) are commonly performed surgical procedures for morbid obesity in the U.S. The body habitus of morbidly obese patients can make laparoscopic surgery physically challenging for the surgeon, and certain surgeons have found value in using the da Vinci Surgical System to improve upon the ergonomics when performing MIS in morbidly obese patients.&#160;In addition, RYGB can be a technically challenging procedure due to the suturing, stapling, and tissue (bowel) manipulation that is required.&#160;Surgeons using the da Vinci Surgical System have reported a reduction in a critical complication (anastomotic leaks) relative to laparoscopic RYGB. Also, we believe SureForm 60 may have particular utility in bariatric procedures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Urologic Surgery</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prostatectomy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Radical prostatectomy is the removal of the prostate gland in patients diagnosed with clinically localized prostate cancer. The standard approach to the removal of the prostate was via an open surgical procedure. The conventional laparoscopic approach is an option, but it is difficult and poses challenges to even the most skilled urologist. The da Vinci Surgical System has enabled a large number of surgeons to convert from using an open surgical technique to a minimally invasive technique.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partial Nephrectomy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Partial nephrectomy is the removal of a small portion of a kidney (typically, an area of the kidney containing a tumor). Partial nephrectomies are most commonly performed in patients diagnosed with clinically localized renal cancer. Excluding robotic-assisted surgery with a da Vinci Surgical System, there are three common surgical approaches to performing partial nephrectomies: open surgical technique, laparoscopy, and hand-assisted laparoscopy, which is a hybrid of the open and laparoscopic techniques. Surgeons have reported that the da Vinci Surgical System&#8217;s capabilities may enable a large number of these procedures to be performed through a minimally invasive technique, conferring the benefits of MIS to a broader range of partial nephrectomy patients. Treatment guidelines for patients with localized renal cancer recommend partial nephrectomy due to the benefits that nephron-sparing surgery has in long-term patient outcomes. Published clinical literature has shown that the presence of a da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical System is associated with a higher-proportion of patients receiving a guideline-recommended partial nephrectomy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gynecologic Surgery</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hysterectomy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Removal of the uterus is one of the most commonly performed surgeries in gynecology and is performed for a variety of underlying benign and cancerous conditions. Hysterectomies can be performed using open surgery (laparotomy) or MIS techniques, which include vaginal, laparoscopic, and robotic-assisted approaches. Prior to the clearance of the da Vinci Surgical System for use in gynecological procedures in 2005, the majority of hysterectomies performed were open surgeries. We believe that robotic-assisted surgery with the da Vinci Surgical System provides patients the opportunity to receive a minimally invasive treatment as an alternative to an open hysterectomy.</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sacrocolpopexy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The abdominal (open) sacrocolpopexy is one of the operations performed to treat vaginal vault prolapse. Sacrocolpopexy involves suturing a synthetic mesh that connects and supports the vagina to the sacrum (tailbone). A sacrocolpopexy can be performed using a conventional laparoscopic technique; however, it is generally described as difficult and cumbersome to perform. Surgeons have reported that the da Vinci Surgical System&#8217;s capabilities may enable a larger number of these procedures to be performed through a minimally invasive technique, conferring the benefits of MIS to a broader range of sacrocolpopexy patients.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cardiothoracic Surgery</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thoracic Surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Conventional approaches to surgical procedures in the thorax include both open and video-assisted thoracoscopic approaches. Procedures performed via these methods include pulmonary wedge resection, pulmonary lobectomy, thymectomy, mediastinal mass excision, and esophagectomy. Many thoracic procedures remain open procedures. Surgeons have reported that the use of robotic-assisted surgery with a da Vinci Surgical System in thoracic surgery has enabled them to offer MIS approaches to a broader range of thoracic surgery patients and improved clinical outcomes compared to open and video-assisted thoracic surgery in published single-center, multi-center, and national database clinical studies. Also, we believe the EndoWrist&#160;Stapler 30 and the SureForm Stapler 30 may have particular utility in thoracic procedures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Head and Neck Surgery</span></div><div style="margin-bottom:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transoral Surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Head and neck cancers are typically treated by either surgical resection or chemo-radiation, or a combination of both. Surgical resection performed by an open approach may require a &#8220;jaw-splitting&#8221; mandibulotomy. This procedure, while effective in treating cancer, is potentially traumatic and disfiguring to the patient. MIS approaches via the mouth (transoral surgery) are challenged by line-of-sight limitations dictated by conventional endoscopic tools. Chemo-radiation as a primary therapy does allow patients to avoid traumatic surgical incisions; however, the literature suggests that this modality diminishes patients&#8217; ability to speak and swallow normally. Surgeons have reported that da Vinci transoral surgery allows them to operate on tumors occurring in the oropharynx (i.e., tonsil and base of tongue) and larynx via the mouth and to overcome some of the line-of-sight limitations of conventional transoral surgery.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Da Vinci Procedure Mix</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our da Vinci procedure business is broadly split into two categories:&#160;(1) cancer procedures and (2) procedures for benign conditions. Cancer and other highly complex procedures tend to be reimbursed at higher rates than less complex procedures for benign conditions. Thus, hospitals are more sensitive to the costs associated with treating less complex, benign conditions. Our strategy is to provide hospitals with attractive clinical and economical solutions across the spectrum of procedure complexity. Our fully featured da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical System with advanced instruments, including the da Vinci Energy and EndoWrist and SureForm Stapler products, and our Integrated Table Motion product, targets the more complex procedure segment.&#160;Our da Vinci X Surgical System is targeted toward price-sensitive markets and procedures.&#160;Our da Vinci SP Surgical System complements the da Vinci Xi and X Surgical Systems by enabling surgeons to access narrow workspaces.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Summary</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are over 70 representative clinical uses for da Vinci Surgical Systems. We believe that there are numerous additional applications that can be addressed with the da Vinci Surgical System, and we work closely with our surgeon customers to refine and explore new techniques in which a da Vinci Surgical System may bring value. As of December&#160;31, 2022, we had an installed base of 7,544 da Vinci Surgical Systems, including 4,563 in the U.S., 1,388 in Europe, 1,234 in Asia, and 359 in the rest of the world. We estimate that surgeons using our technology completed approximately 1,875,000 surgical procedures of various types in hospitals throughout the world during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, over time, we believe that there are numerous additional applications that can be addressed with the Ion endoluminal system. As of December&#160;31, 2022, we had an installed base of 321 Ion systems, 320 of which are located in the U.S. We plan to seek additional clearances for Ion in markets outside of the U.S. (&#8220;OUS&#8221;) over time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Customer Support</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Model</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our products through direct sales organizations in the U.S., Europe (excluding Spain, Portugal, Italy, Greece, and most Eastern European countries), China, Japan, South Korea, India, Taiwan and, as of June 2022, Canada. We provide products and services in China through our majority-owned joint venture (&#8220;Joint Venture&#8221;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;) and its affiliates. See &#8220;Item 7. Management&#8217;s Discussion and Analysis </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details on the Joint Venture. In the remainder of our markets outside of the U.S., we provide our products through distributors. During the years ended December&#160;31, 2022, 2021, and 2020, domestic revenue accounted for 67%, 67%, and 68%, respectively, of total revenue, while revenue from our OUS markets accounted for 33%, 33%, and 32%, respectively, of total revenue.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct sales organization is composed of a capital sales team, responsible for selling systems, and a clinical sales team, responsible for supporting the systems used in procedures performed at our hospital accounts. Our hospital accounts include both individual hospitals and healthcare facilities as well as hospitals and healthcare facilities that are part of an integrated delivery network (&#8220;IDN groups&#8221;). The initial system sale into an account is a major capital equipment purchase by our customers and typically has a lengthy sales cycle that can be affected by macroeconomic factors, capital spending prioritization, the timing of budgeting cycles, and competitive bidding processes. Capital sales activities include educating surgeons or physicians and hospital staff across multiple specialties on the benefits of robotic-assisted surgery with a da Vinci Surgical System or robotic-assisted bronchoscopy with an Ion endoluminal system, total treatment costs, and the clinical applications that our technology enables. We also train our sales organization to educate hospital management on the potential benefits of adopting our technology, including the clinical benefits of robotic-assisted surgery with a da Vinci Surgical System or robotic-assisted bronchoscopy with an Ion endoluminal system, in support of their quadruple aim objectives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical sales team works on site at hospitals, interacting with surgeons or physicians, operating room staff, and hospital administrators to develop and sustain successful robotic-assisted surgery or bronchoscopy programs. They assist the hospital in identifying surgeons or physicians who have an interest in robotic-assisted surgery or bronchoscopy and the potential</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits provided by the da Vinci Surgical System and the Ion endoluminal system. Our clinical sales team provides current clinical information on robotic-assisted surgery or bronchoscopy practices and new product applications to the hospital teams. Our clinical sales team has grown with the expanded installed bases of da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems and Ion endoluminal systems as well as the total number of procedures performed. We expect this organization to continue to grow as our business expands.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers place orders to replenish their supplies of instruments and accessories on a regular basis. Orders received are typically shipped within one business day. New direct customers who purchase a system typically place an initial stocking order of instruments and accessories soon after they receive their system.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to seasonal fluctuations. Historically, our sales of da Vinci Surgical Systems have tended to be heavier in the fourth quarter and lighter in the first quarter, as hospital budgets are reset. In addition, we have historically experienced lower procedure volume in the first and third quarters and higher procedure volume in the second and fourth quarters. More than half of da Vinci procedures performed are for benign conditions. These benign procedures and other short-term elective procedures tend to be more seasonal than cancer procedures and surgeries for other life-threatening conditions. In the U.S., volumes for procedures associated with benign conditions are typically seasonally higher in the fourth quarter when more patients have met annual deductibles and lower in the first quarter when deductibles are reset. Seasonality outside of the U.S. varies and is more pronounced around local holidays and vacation periods. The timing of procedures and changes in procedure volume impact the timing of instruments and accessories and capital purchases. As a result of factors outlined in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Pandemic&#8221; below, including the past and potential future recommendations of authorities to defer elective procedures, historical procedure patterns have been and may continue to be disrupted.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer Support</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a network of field service and technical support engineers across the U.S., Europe, and Asia and maintain relationships with various distributors around the globe. This infrastructure of service and support specialists, along with advanced service tools and solutions, offers a full complement of services for our customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring. We generate service revenue by providing these services to our customers through comprehensive service contracts and time and material programs.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_37"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our research and development efforts on innovation and improvement for products and services that align with our mission: We believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe that we can expand the potential of physicians to heal without constraints. We employ engineering and research and development staff to focus on delivering future innovations and sustaining improvements that advance our mission. In certain instances, we complement our research and development effort through collaborations with other companies, such as Baxter International Inc.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_40"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our systems at our facilities in Sunnyvale, California, Durham, North Carolina and, as of 2022, Peachtree Corners, Georgia. We manufacture our instruments at our facilities in Sunnyvale, California and Mexicali, Mexico. We also have manufacturing at multiple sites in Germany.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase both custom and off-the-shelf components from a large number of suppliers and subject them to stringent quality specifications and processes. Some of the components necessary for the assembly of our products are currently provided to us by sole-sourced suppliers (the only recognized supply source available to us) or single-sourced suppliers (the only approved supply source for us among other sources). We purchase the majority of our components and major assemblies through purchase orders rather than long-term supply agreements and generally do not maintain large volumes of finished goods relative to our anticipated demand.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_43"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition in the forms of existing open surgery, conventional MIS, drug therapies, radiation treatment, and other emerging diagnostic and interventional surgical approaches. Our success depends on continued clinical and technical innovation, quality, and reliability, as well as educating hospitals, surgeons, and patients on the demonstrated results associated with robotic-assisted medical procedures using da Vinci Surgical Systems or Ion endoluminal systems and their value relative to other techniques. We also face competition from several companies that have introduced or are developing new approaches and products for the MIS market. We believe that the entrance or emergence of competition validates MIS and robotic-assisted surgery or robotic-assisted bronchoscopy.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, as we add new robotically controlled products (e.g., da Vinci Stapling and da Vinci Energy) that compete with product offerings traditionally within the domains of open surgery and/or conventional MIS, we face greater competition from larger and well-established companies, such as Johnson &amp; Johnson and Medtronic plc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The companies that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field include, but are not limited to, the following companies: Asensus Surgical, Inc.; avateramedical GmbH; CMR Surgical Ltd.; Johnson &amp; Johnson; Medicaroid Corporation; Medrobotics Corporation; Medtronic plc; meerecompany Inc.; Olympus Corporation; Samsung Electronics Co., Ltd; Shandong Weigao Group Medical Polymer Company Ltd.; Shanghai Microport Medbot (Group) Co., Ltd.; and Titan Medical Inc. Other companies with substantial experience in industrial robotics could potentially expand into the field of medical robotics and become a competitor. In addition, research efforts utilizing computers and robotics for medical procedures are underway at various companies and research institutions. Our revenues may be adversely impacted as our competitors announce their intent to enter our markets and as our customers anticipate the availability of competing products.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_46"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We place considerable importance on obtaining and maintaining patent, copyright, trademark, and trade secret protection for significant new technologies, products, and processes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally rely upon a combination of intellectual property laws, confidentiality procedures, and contractual provisions to protect our proprietary technology. For example, we have trademarks, both registered and unregistered, that provide distinctive identification of our products in the marketplace. We also have exclusive and non-exclusive patent licenses with various third parties to supplement our own robust patent portfolio.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we owned more than 4,300 patents granted and still in force and more than 2,100 patents pending worldwide. We intend to continue filing new patent applications in the U.S. and foreign jurisdictions to seek protection for our technology.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are granted for finite terms. Upon expiration, the inventions claimed in a patent enter the public domain.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_49"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are subject to regulation in the U.S. by the FDA and the State of California as well as by other countries and regions in which we market and promote our products. In addition, our products must meet the requirements of a large and growing body of international standards, which govern the design, manufacture, materials content and sourcing, testing, certification, packaging, installation, use, and disposal of our products. We must continually keep abreast of these regulations, standards, and requirements and integrate our compliance into the development and regulatory documentation for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our products. Failure to meet these standards could limit our ability to market our products in those regions that require compliance with such standards. Examples of standards to which we are subject include electrical safety standards, such as those of the International Electrotechnical Commission (e.g., IEC 60601-ss series of standards), and composition standards, such as the Reduction of Hazardous Substances (&#8220;RoHS&#8221;) and the Waste Electrical and Electronic Equipment (&#8220;WEEE&#8221;) Directives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;), as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, recordkeeping, complaint and adverse event reporting, clearance, approval, certification, promotion, marketing, export, import distribution, and service of medical devices in the U.S. to ensure that medical devices distributed domestically are safe and effective for their intended uses.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FFDCA, medical devices are classified into one of three classes&#8212;Class I, Class II, or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. Our current products are Class II medical devices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II medical devices are those that are subject to general controls, and most require premarket demonstration of adherence to certain performance standards or other special controls, as specified by the FDA, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries, and FDA guidance documents.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FFDCA requesting authorization to commercially distribute the device. The FDA&#8217;s authorization to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Our current products are subject to premarket notification and clearance under section 510(k) of the FFDCA. To obtain 510(k) clearance, we must submit to the FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA agrees that the device is substantially equivalent to a predicate device, it will grant clearance to commercially market the device in the U.S. The FDA has a statutory 90-day period to respond to a 510(k) submission; however, as a practical matter, clearance often takes longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. If the FDA determines that the device, or its intended use, is not &#8220;substantially equivalent,&#8221; the device may be designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the de novo classification pathway, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PMA process is more demanding than the 510(k) premarket notification process. In a PMA application, the manufacturer must demonstrate that the device is safe and effective, and the PMA application must be supported by extensive data, including data from preclinical studies and human clinical trials. The FDA, by statute and regulation, has 180 days to review a PMA application, although the review more often occurs over a significantly longer period of time and can take up to several years. In approving a PMA application or clearing a 510(k) submission, the FDA may also require some additional manufacturing controls, design control activities and approvals, as well as specific post-market surveillance requirements when necessary to protect the public health or to provide additional safety and effectiveness data for the device. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and make periodic reports to the FDA on the clinical status of those patients.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations designed to determine the safety and effectiveness of a medical device must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;) regulations, which govern investigational device labeling, prohibit the promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site. During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to the FDA&#8217;s regulations and must obtain patient informed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA, or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period and make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in September 2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the recommended testing methods, where feasible.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), de novo classification, or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance, approval of a PMA, or issuance of a de novo classification. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may place significant limitations upon the intended use of our products as a condition of granting marketing authorization. Moreover, after a device is placed on the market, numerous FDA and other regulatory requirements continue to apply. These requirements include establishment registration and device listing with the FDA; compliance with medical device reporting regulations, which require that manufacturers report to the FDA if their device caused or contributed, or may have caused or contributed, to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; compliance with corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FFDCA that may present a risk to health; the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device. In addition, the FDA and the Federal Trade Commission also regulate the advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that there is scientific data to substantiate the claims, and that our advertising is neither false nor misleading. In general, we may not promote or advertise our products for uses not within the scope of our intended use statement in our clearances or make unsupported safety and effectiveness claims. </span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing processes are required to comply with the Quality System Regulation (&#8220;QSR&#8221;). The QSR covers, among other things, the methods used in, and the facilities and controls used for, the design, testing, controlling, documenting, manufacture, packaging, labeling, storage, installation, and servicing of all medical devices intended for human use. The QSR also requires maintenance of extensive records, which demonstrate compliance with the FDA regulation, the manufacturer&#8217;s own procedures, specifications, and testing, as well as distribution and post-market experience. Compliance with the QSR is necessary for a manufacturer to be able to continue to market cleared or approved product offerings in the U.S. A company&#8217;s facilities, records, and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with applicable QSR requirements could result in the shut-down of, or restrictions on, manufacturing operations and the recall or seizure of marketed products. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters, untitled letters, fines, injunctions, consent decrees, administrative penalties, and civil or criminal penalties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recalls, withdrawals, or administrative detention or seizure of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approvals for our products; or</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the discovery of previously unknown problems with any marketed products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products manufactured outside of the U.S. by or for us are subject to U.S. Customs and FDA inspection upon entry into the U.S. We must demonstrate compliance of such products with U.S. regulations and carefully document the eventual distribution or re-exportation of such products. Failure to comply with all applicable regulations could prevent us from having access to products or components critical to the manufacture of finished products and lead to shortages and delays.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal, and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality, and security of health-related and other personal information and could apply now or in the future to our operations or the operations of our partners. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect, process, share, disclose, transfer, and otherwise use data, some of which contains personal information about identifiable individuals including, but not limited to, our employees, clinical trial participants, partners, and vendors. Therefore, we are subject to U.S. (federal, state, local) and international laws and regulations, including those in the European Economic Area (&#8220;EEA&#8221;) and the UK regarding data privacy and security and our use of such data.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the European Union General Data Protection Regulation 2016/679 and applicable national supplementing laws (collectively, the &#8220;EU GDPR&#8221;) and to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the &#8220;UK GDPR&#8221;) (the EU GDPR and UK GDPR together referred to as the &#8220;GDPR&#8221;). The GDPR imposes comprehensive data privacy compliance obligations in relation to our collection, processing, sharing, disclosure, transfer, and other use of data relating to an identifiable living individual or &#8220;personal data,&#8221; including a principle of accountability and the obligation to demonstrate compliance through policies, procedures, training, and audit.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR and UK GDPR also regulate cross-border transfers of personal data out of the EEA and the UK. Recent legal developments in Europe have created complexity and uncertainty regarding such transfers, in particular in relation to transfers to the United States.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we may collect and store personal information and other sensitive information, including proprietary and confidential business information, trade secrets, intellectual property, patient information, sensitive third-party information, and employee information. To protect this information, our existing cybersecurity policies require continuous monitoring and detection programs, network security precautions, encryption of critical data, and in-depth security assessments of vendors. We maintain various protections designed to safeguard against cyberattacks, including firewalls and virus detection software. We have established and regularly test our disaster recovery plan, and we protect against business interruption by backing up our major systems. In addition, we periodically scan our environment for any vulnerabilities, perform penetration testing, and engage third parties to assess the effectiveness of our data security practices. In addition, we maintain insurance that includes cybersecurity coverage.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity program is executed by a team of highly skilled cybersecurity professionals, including, but not limited to, risk and threat analysts, penetration testers, security operations center analysts, cyber regulatory analysts, and risk/threat modelers. Team members maintain certification(s) and practical application of skills through organizations, such as ISC2 (Certified Information Security Systems Professional or CISSP), Global Information Assurance (GIAC), EC-Council, the Committee on National Security Systems (CNSS), and the National Security Agency (NSA). The program incorporates industry-standard frameworks, policies, and practices designed to protect the privacy and security of our sensitive information. Our cybersecurity team reports to the Board of Directors on a quarterly basis on information security and cybersecurity matters or more frequently as needed. Our Audit Committee, which is comprised of several members of our Board of Directors, has oversight responsibility for our data security practices, and we believe that the committee has the requisite skills and visibility into the design and operation of our data security practices to fulfill this responsibility effectively. Five members of our Board </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Directors have enhanced information security expertise, including Gary S. Guthart, Ph.D., Joseph C. Beery, Amal M. Johnson, Keith R. Leonard Jr., and Mark J. Rubash.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of our cybersecurity program, our security measures cannot guarantee that a significant cyberattack will not occur. A successful attack on our information technology systems could have significant consequences for the business. While we devote resources to our security measures to protect our systems and information, these measures cannot provide absolute security. See &#8220;Risk Factors &#8211; Information technology system failures, cyberattacks, or deficiencies in our cybersecurity could harm our business, customer relations, financial condition, or results of operations&#8221; for additional information about the risks to our business associated with a breach or compromise to our information technology systems.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the FDA issued draft guidance on cybersecurity related to quality systems and premarket submission content for medical devices. The 2022 draft guidance for premarket cybersecurity in medical devices would increase the expectations that the FDA has for manufacturers. We are diligently pursuing compliance with this new guidance.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for us to market our products in countries outside the United States, we must obtain regulatory approvals or certifications and comply with extensive product and quality system regulations in other countries. These regulations, including the requirements for approvals, clearance, or certifications and the time required for regulatory review, vary from country to country. Some countries have regulatory review processes that are substantially longer than U.S. processes. Failure to obtain regulatory approval or certification in a timely manner and meet all of the local requirements, including language and specific safety standards, in any foreign country in which we plan to market our products could prevent us from marketing products in such countries or subject us to sanctions and fines.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">China</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China has its own regulatory agency. They require regulatory approvals and compliance with extensive safety and quality system regulations. Failure to obtain regulatory approval or failure to comply with any regulation may negatively impact our ability to generate revenue and harm our business. In addition to product registration approvals, our system sales into China are also dependent on obtaining importation authorizations and provincial approvals, as well as hospitals completing a tender and hospital listing process under the authorization. In October 2018, the China National Health Commission published on its official website the quota for major medical equipment to be imported and sold in China through 2020. After an adjustment notice was published in the third quarter of 2020 (ref. NHC Financial Notice [2020] 315), the government will allow for the total sale of 225 new Endoscopic Surgical Instrument Control Systems (surgical robots) into China, which could include da Vinci Surgical Systems as well as surgical systems introduced by others. Sales of da Vinci Surgical Systems under the quota are uncertain, as they are dependent on hospitals completing a tender process and receiving associated approvals.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most medical devices must undergo thorough safety examinations and demonstrate medical efficacy before they receive regulatory approval to be sold in Japan. We obtained approval from the Japanese Ministry of Health, Labor, and Welfare (&#8220;MHLW&#8221;) for our da Vinci Si Surgical System in October 2012, for our da Vinci Xi Surgical System in March 2015, and for our da Vinci X Surgical System in April 2018. National reimbursement status in Japan was received for prostatectomy procedures in April 2012 and for da Vinci partial nephrectomy procedures in April 2016. An additional 12 da Vinci procedures were granted reimbursement effective April 1, 2018, including gastrectomy, low anterior resection, lobectomy, and hysterectomy, for both malignant and benign conditions. An additional seven da Vinci procedures were granted reimbursement effective April 1, 2020. An additional eight da Vinci procedures were granted reimbursement effective April 1, 2022, including colon resection. In addition, we received higher reimbursement for da Vinci gastrectomy procedures, as compared to open and conventional laparoscopic procedure reimbursements. The additional reimbursed procedures have varying levels of conventional laparoscopic penetration and will generally be reimbursed at rates equal to the conventional laparoscopic procedures. Given the reimbursement level and laparoscopic penetration for these additional procedures, there can be no assurance that the adoption pace for these procedures will be similar to prostatectomy or partial nephrectomy, given their higher reimbursement, or any other da Vinci procedure. If these procedures are not adopted and we are not successful in obtaining adequate procedure reimbursements for additional procedures, then the demand for our products in Japan could be limited. The process of reimbursement for new da Vinci surgical procedures in Japan is led by the surgical societies. The societies submit for reimbursement or incremental reimbursement to the MHLW for their evaluation. The decision to reimburse requires in-country clinical data and is fixed in April of even-numbered years. In September 2022, we received regulatory clearance for the da Vinci SP Surgical System in Japan for the same set of procedures as can be performed on the da Vinci Xi Surgical System in Japan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (&#8220;EU&#8221;), all medical devices placed on the EU market must meet the essential requirements, including the requirement that a medical device must be designed and manufactured in such a way that it will not compromise </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performance intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until and including May 25, 2021, medical devices were regulated by Council Directive 93/42/EEC (the &#8220;EU Medical Devices Directive&#8221; or &#8220;MDD&#8221;), which has been repealed and replaced by Regulation (EU) No 2017/745 (the &#8220;EU Medical Devices Regulation&#8221; or &#8220;MDR&#8221;). Our current certificates have been granted under the MDD. However, as of May 26, 2021, some of the MDR requirements apply in place of the corresponding requirements of the MDD with regard to the registration of economic operators and of devices, post-market surveillance, and vigilance. Pursuing marketing of medical devices in the EU requires that our devices be certified under the new regime set forth in the MDR, and we are diligently pursuing our plan to be fully compliant by May 26, 2024. Under recently proposed draft legislation issued by the European Commission, this date would be extended to December 2027 for higher classification devices (Class III and certain Class C IIb implantable devices) and to December 2028 for medium- and lower-risk devices (for the other Class IIb devices, Class IIa, and some Class I devices). We may adjust our transition plans to take this transitional period into account, if said legislative proposal is adopted by the European Parliament and Council.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices Directive</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EU Medical Devices Directive, all medical devices placed on the market in the EU must meet the essential requirements laid down in Annex I to the EU Medical Devices Directive, including the requirement that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients or the safety and health of users and others. In addition, the device must achieve the performance intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as the sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter, as it creates a rebuttable presumption that the device satisfies the essential requirements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-assess the conformity of its products with the essential requirements (except for any parts that relate to sterility or metrology), a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. A notified body would typically audit and examine a product&#8217;s technical dossiers and the manufacturer&#8217;s quality system (the notified body must presume that quality systems that implement the relevant harmonized standards, which is ISO 13485:2016 for Medical Devices Quality Management Systems, conform to these requirements). If satisfied that the relevant product conforms to the relevant essential requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the Conformit&#233; Europ&#233;enne mark (&#8220;CE mark&#8221;) to the device, which allows the device to be placed on the market throughout the EU.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the term of the certificate of conformity, the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In particular, there will be a new audit by the notified body before it will renew the relevant certificate(s).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices Regulation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, the MDR was adopted with the aim of ensuring better protection of public health and patient safety. The MDR establishes a uniform, transparent, predictable, and sustainable regulatory framework across the EU for medical devices and ensures a high level of safety and health while supporting innovation. Unlike directives, regulations are directly applicable in EU member states without the need for member states to implement into national law. This aims at increasing harmonization across the EU.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR became effective on May 26, 2021. Devices lawfully placed on the market pursuant to the MDD prior to May 26, 2021, may generally continue to be made available on the market or put into service until and including May 26, 2025, provided that the requirements of the transitional provisions are fulfilled (referred to as the &#8220;sell-off&#8221; provision). In particular, the certificate in question must still be valid. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the MDR, in particular the obligations described below. If it is adopted by the European Parliament and Council, under draft legislation proposed by the European Commission, the sell-off provision would be removed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR requires that, before placing a device on the market, other than a custom-made device, manufacturers (as well as other economic operators, such as authorized representatives and importers) must register by submitting identification information to the electronic system (EUDAMED), unless they have already registered. The information to be submitted by manufacturers (and authorized representatives) also includes the name, address, and contact details of the person or persons </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for regulatory compliance. The new Regulation also requires that, before placing a device on the market, other than a custom-made device, manufacturers must assign a unique identifier to the device and provide it along with other core data to the unique device identifier (&#8220;UDI&#8221;) database. These new requirements aim at ensuring better identification and traceability of the devices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All manufacturers placing medical devices on the market in the EU must comply with the EU medical device vigilance system, which has been reinforced by the MDR. Under this system, serious incidents and Field Safety Corrective Actions (&#8220;FSCAs&#8221;) must be reported to the relevant authorities of the EU member states. These reports will have to be submitted through Eudamed (once functional) and aim to ensure that, in addition to reporting to the relevant authorities of the EU member states, other actors, such as the economic operators in the supply chain, will also be informed. Until Eudamed is fully functional, the corresponding provisions of the MDD continue to apply. Manufacturers are required to take FSCAs, which are defined as any corrective action for technical or medical reasons to prevent or reduce a risk of a serious incident associated with the use of a medical device that is made available on the market.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of medical devices are subject to some general principles set forth in EU legislation. According to the MDR, only devices that are CE marked may be marketed and advertised in the EU in accordance with their intended purpose. Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, while not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example, requiring that advertisements are evidenced, balanced, and not misleading. Specific requirements are defined at a national level. EU member states&#8217; laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts,&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, regulatory authorities have the power to carry out announced and, if necessary, unannounced inspections of companies, as well as suppliers and/or sub-contractors and, where necessary, the facilities of professional users. Failure to comply with regulatory requirements (as applicable) could require time and resources to respond to the regulatory authorities&#8217; observations and to implement corrective and preventive actions, as appropriate. Regulatory authorities have broad compliance and enforcement powers and, if such issues cannot be resolved to their satisfaction, can take a variety of actions, including untitled or warning letters, fines, consent decrees, injunctions, or civil or criminal penalties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned EU rules are generally applicable in the EEA, which consists of the 27 EU Member States as well as Iceland, Liechtenstein, and Norway.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) has become the sovereign regulatory authority responsible for the Great Britain (i.e., England, Wales, and Scotland) medical device market. Following the end of the Brexit transitional period on January 1, 2021, new regulations require all medical devices to be registered with the MHRA before being placed on the Great Britain market. From January 1, 2022, non-UK manufacturers were required to appoint a UK Responsible Person for the purposes of registering devices placed on the Great Britain market. Under the terms of the Protocol on Ireland/Northern Ireland, the MDR applies to medical devices placed on the Northern Ireland market in the same way as it applies to medical devices marketed in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2022, the MHRA published its response to a 10-week consultation on the future regulation of medical devices in the UK. Regulations implementing the new regime were originally scheduled to come into force in July 2023 but have recently been postponed to July 2024. Devices bearing CE marks issued by EU notified bodies under the MDR or MDD are now subject to transitional arrangements. In its consultation response, the MHRA indicated that the future UK regulations will allow devices certified under the MDR to be placed on the market in Great Britain under the CE mark until either the certificate expires or for five years after the new regulations take effect, whichever is sooner. Following these transitional periods, all medical devices will require a UK Conformity Assessed (&#8220;UKCA&#8221;) mark in order to be placed on the market in Great Britain. Manufacturers may choose to use the UKCA mark on a voluntary basis prior to entry of the new regulations on July 1, 2024. However, from July 2024, products that do not have existing and valid certification under the EU Medical Devices Directive or EU MDR and, therefore, are not subject to the transitional arrangements will be required to carry the UKCA mark if they are to be sold into the market in Great Britain. For products to be sold into the market in Northern Ireland, CE marking will continue to be recognized as a result of the Northern Ireland Protocol implemented following the UK&#8217;s exit from the EU. UKCA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marking will not be recognized in the EU. Following the transitional period, compliance with the UK regulations will be a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Trade Deal between the UK and the EU generally provides for cooperation and exchange of information between the parties in the areas of product safety and compliance, including market surveillance, enforcement activities and measures, standardization-related activities, exchanges of officials, and coordinated product recalls. As such, processes for compliance and reporting should reflect requirements from regulatory authorities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other countries</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations in other countries, including the requirements for approvals, certification, or clearance and the time required for regulatory review, vary from country to country. Certain countries, such as South Korea, Brazil, Australia, India, and Canada, have their own regulatory agencies. These countries typically require regulatory approvals and compliance with extensive safety and quality system regulations included in the MDSAP (Medical Device Single Audit Program) that we comply with every year as part of our annual audit program. Failure to obtain regulatory approval in any foreign country in which we plan to market our products, or failure to comply with any regulation in any foreign country in which we market our products may negatively impact our ability to generate revenue and harm our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, local regulations may apply, which govern the use of our products and which could have an adverse effect on our product utilization if they are unfavorable. All such regulations are revised from time to time and, in general, are increasing in complexity and in the scope and degree of documentation and testing required. There can be no assurance that the outcomes from such documentation and testing will be acceptable to any particular regulatory agency or will continue to be acceptable over time. There are further regulations governing the importation, marketing, sale, distribution, use, and service as well as the removal and disposal of medical devices in the regions in which we operate and market our products. Failure to comply with any of these regulations could result in sanctions or fines and could prevent us from marketing our products in these regions.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_52"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third-Party Coverage and Payment</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers, including physicians, hospitals, and outpatient facilities, typically bill third-party payors for the costs and fees associated with the procedures in which our products are used. In the U.S., in order to receive payment for the procedures performed using our products, our customers must report codes that describe the services or products furnished and determine the medical necessity of the service or whether the service is included in the payors&#8217; policy. In the U.S. and most markets globally where we sell our products, payment for medical services and surgical procedures to hospitals, outpatient facilities, and surgeons (collectively &#8220;providers&#8221;) is determined by the government, commercial payors (insurers), or a combination of both.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and its fiscal intermediaries (Medicare Administrative Contractors) and state Medicaid programs establish reimbursement policies for medical and surgical services at the state and federal level for the Medicare and Medicaid programs. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and payment policies but also have their own methods and approval processes. Commercial payors in non-capitated contracts commonly establish payment to providers based on a percentage of the Medicare payment rate.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians and outpatient facilities bill for medical and surgical services by reporting a combination of billing codes. Current Procedural Terminology (&#8220;CPT&#8221;) codes are created by the American Medical Association (&#8220;AMA&#8221;) with input from CMS and commercial payors to describe medical and surgical procedures. CPT codes currently exist for minimally invasive surgical procedures, which may involve the da Vinci surgical system, as well as for robotic-assisted bronchoscopy, which may involve the Ion endoluminal system. In general, the majority of payors, including Medicare, consider robotic assistance as a tool used to perform the procedure and do not pay providers more for a procedure that involves robotic assistance using the da Vinci, Ion, or any other robotic system. Because there is often no separate payment for the use of our products, the additional cost associated with the use of our products can affect the profit margin of the hospital or surgery center where the procedure is performed. If hospitals do not obtain sufficient payment from third-party payors for procedures performed with our products, or if governmental and private payors&#8217; policies do not cover surgical procedures performed using our products, we may not be able to generate the revenue necessary to support our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals bill for inpatient services by reporting ICD-10-PCS codes. CMS is primarily responsible for overseeing changes and modifications to ICD-10-PCS codes. Medicare payments to hospitals for services provided during an inpatient stay are based on the Inpatient Prospective Payment System (&#8220;IPPS&#8221;). Under the IPPS, each patient discharge is categorized into a Medicare Severity Adjusted Diagnosis-Related Group (&#8220;MS-DRG&#8221; or &#8220;DRG&#8221;). Each DRG has an assigned payment weight based on the average resources used for Medicare patients in that DRG, taking into account the patient&#8217;s principal diagnosis, surgical procedures, age, discharge status, and additional or secondary diagnoses, among other things. The DRG is a single, bundled payment intended to cover all costs associated with the inpatient admission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of robotic technology does not influence the MS-DRG assignment or payment for an inpatient admission related to a surgical procedure. CMS annually updates hospital inpatient and outpatient payments based on hospitals&#8217; charge data. Hospital inpatient and outpatient payments are also adjusted based on whether the hospital is a teaching hospital, its geographic location, and any failures to meet certain quality metrics, among other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial payors commonly establish inpatient facility payment for providers using published Medicare DRG rates as a benchmark. Commercial payment to providers varies depending on the procedure performed, geographic location, contractual allowances, and other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and commercial payor payments to facilities for medical and surgical services may not always fully reimburse providers for all costs associated with furnishing these procedures. If payment is insufficient for procedures involving our technology, hospitals and physicians may decide not to use our products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries outside of the U.S., payment for surgical services to physicians and facilities differs considerably and varies by country. In some markets, there is a single public payor who provides a global annual budget to hospitals to provide all care to the population served in a designated geographic area. In other markets, private insurance can be purchased or is provided by employers to supplement public health insurance. In some countries, patients may be permitted to pay directly for surgical services; however, such &#8220;co-pay&#8221; practices are not common (or allowed) in many countries. Further, in many global markets, access to procedures and technology is governed or heavily influenced by Health Technology Assessment (&#8220;HTA&#8221;) organizations, which conduct periodic and extensive evidence-based reviews of the clinical value and cost effectiveness of a new technology. To effectively conduct our business, we may need to seek OUS reimbursement approvals, and we do not know if these required approvals will be obtained in a timely manner or at all. In addition, in some markets, HTA organizations may publish reports with mixed conclusions about the clinical and economic value of our products to the population. Such reviews could negatively impact hospital adoption of our technology.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_549755816252"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), was enacted. The ACA made changes that have significantly impacted healthcare providers, insurers, pharmaceutical companies, and medical device manufacturers. The ACA contained a number of provisions designed to generate the revenues necessary to fund health insurance coverage expansion and appropriated funding to research the comparative effectiveness of healthcare treatments and strategies. To date, this research has had a negligible effect on Medicare coverage and reimbursement decisions as well as influence on other third-party payor coverage and reimbursement policies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA remained in effect in its current form.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included an aggregate reduction in Medicare payments, which went into effect on April 1, 2013, and will remain in effect through 2031, unless additional Congressional action is taken, with the exception of a temporary suspension due to the COVID-19 pandemic from May 1, 2020, through March 31, 2022. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers. The Medicare Access and CHIP Reauthorization Act of 2015, enacted on April 16, 2015 (&#8220;MACRA&#8221;), repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 and are based on various performance measures and physicians&#8217; participation in alternative payment models, such as accountable care organizations. Individual states in the U.S. have also become increasingly aggressive in passing legislation and implementing regulations designed to control product pricing, including price or patient reimbursement constraints and discounts, and require marketing cost disclosure and transparency measures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and abroad, reimbursement is dynamic and subject to change annually by public and private payors. Congress and government agencies may also intervene and pass legislation that is intended to reduce healthcare spending, which could impact market access. Such legislative interventions can vacillate significantly based on government leadership. Other federal or state healthcare reform measures that may be adopted in the future could have a material adverse effect on our business. Any regulatory or legislative developments in domestic or foreign markets that eliminate or reduce reimbursement rates for procedures performed with our products could harm our ability to sell our products or cause downward pressure on the prices of our products, either of which would adversely affect our business, financial condition, and results of business operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in December 2021, the EU Regulation No 2021/2282 on HTA, amending Directive 2011/24/EU, was adopted. This regulation, which entered into force in January 2022, intends to boost cooperation among EU member states in assessing health technologies, including certain medical devices, and provides the basis for cooperation at the EU level for joint </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical, etc.) aspects of health technology and making decisions on pricing and reimbursement.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_55"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of our company depends on our ability to attract, retain, and further develop top talent. We enable this by continuously striving to make Intuitive an inclusive, diverse, and safe workplace with opportunities for our employees to grow and develop in their careers. These objectives are supported through strong compensation, benefits, programs that encourage employee health and wellness, and connections between our employees and the communities in which they live and work.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,120</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> full-time employees, 1,651 of whom were engaged directly in research and development, 4,843 in manufacturing operations, 3,834 in commercial and service operations, and 1,792 in administrative activities. During 2022, the number of employees increased by approximately 2,327. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur employees are based in 29 different countries around the world. Our global workforce consists of diverse, highly skilled talent at all levels. During 2022, our turnover rate was approximately 10.9%.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inclusion and Diversity</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive&#8217;s inclusion and diversity (&#8220;I&amp;D&#8221;) vision is to empower our employees and customers from every background to fully contribute toward our mission to expand the potential of physicians to heal without constraints. We want to build an environment where every individual can belong and flourish &#8211; in our company and the communities we serve.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that everyone should feel included and fairly treated, and we embrace the unique qualities that make people who they are. This includes all genders and gender identities, races, ethnicities, ages, national origins, native languages, disabilities, sexual orientations, body sizes, military backgrounds, socioeconomic backgrounds, religions, and family structures. We believe in seeking the different to propel innovation and creativity forward.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a four-part strategy to guide our I&amp;D progress: ensuring an inclusive experience, where employees from all backgrounds feel welcome, supported, and valued; building a diverse workforce to fuel innovation and better mirror the patients we serve; continuously investing in and enhancing the fairness of our people practices and sharing progress; and strengthening industry engagement through collaboration with the healthcare community, diversity-focused organizations, and shareholders to drive positive change. Employee Resource Groups (&#8220;ERGs&#8221;) have been one key area of I&amp;D focus and growth, providing support and community for traditionally marginalized groups, including women, people of color, members of the lesbian, gay, bisexual, transgender, queer, and/or questioning (&#8220;LGBTQ+&#8221;) community, military veterans, and employees with disabilities. Details of our employee workforce composition, including a link to our Employer Information Report (&#8220;EEO-1&#8221;) submission to the U.S. Equal Employment Opportunity Commission (&#8220;EEOC&#8221;), are available on our website. Although we reference the availability of our EEO-1 on our website in this Annual Report on Form 10-K, our EEO-1 and any other materials on our website are not incorporated by reference into this Annual Report on Form 10-K or any of our other filings under the Securities Act of 1933, as amended, or the Exchange Act. While matters discussed in such EEO-1 and other website materials may be significant, any significance should not be read as necessarily rising to the level of materiality used for the purposes of our compliance with the U.S. federal securities laws, even if we use the word &#8220;material&#8221; or &#8220;materiality&#8221; in such materials.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From a governance perspective, maintaining a mix of backgrounds and experience in our Board composition is essential to understanding and reflecting the needs of our diverse stakeholders. Currently, four of our 11 Board members self-identify as women, and three of our 11 board members self-identify as individuals from underrepresented communities (defined as an individual who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, or Alaska Native, or who self-identifies as LGBTQ+).</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety, and Wellness</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we continue to invest and expand. We provide our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection, peace of mind, and security, including workplace health and safety best practices integrated into everyday activities and programs that support employee time away from work, family care, mental health, or financial well-being.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evolve our programs to respond to the best interest of our changing workforce, as well as the communities in which we operate, in compliance with government regulations. Each Intuitive location manages overall safety with guidance based on regional, country, and local regulations and best practices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we focused on collecting internal and external insights to inform decision-making on work models that would align with how employees will work in the current environment, which has evolved as a result of the COVID-19 pandemic. These efforts will allow for an improved employee experience, regardless of whether an employee is working from home, fully on-site, or in a hybrid fashion. As we move into 2023, our focus will be on the implementation and sustained success of these new work models, including on-site engagement activities that reinforce our differentiating culture and facilitate cross-team networking, collaboration, and innovation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide compensation and benefits programs to help meet the needs of our employees. In addition to base compensation, these programs, which vary by country and region, include annual bonuses, stock awards, an Employee Stock Purchase Plan, retirement savings plans, healthcare, income protection benefits, paid time off, family leave, family care resources, and flexible work schedules, among many others.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring fair and equitable pay is integral to our commitment to our employees. Our executive team and Board of Directors strongly support this commitment. We regularly review pay for internal equity and ensure our compensation structure is appropriate, including with regard to race/ethnicity and gender. We also engage outside counsel to ensure compliance with pay equity laws. When we identify any potential differences in pay for whatever reason, we research those differences and act if appropriate. Employees are encouraged to share any pay equity concerns with management, Human Resources, or confidentially through our reporting hotline, including anonymously. Intuitive has a non-retaliation policy for raising any workplace concerns, including around pay.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our employees and the passion, commitment, and expertise they contribute to Intuitive. To enhance employee retention and engagement, we offer ongoing learning and leadership training opportunities that support growth.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With a commitment to building strong, inclusive leaders, in 2022, we rolled out an enhancement to our existing manager development program designed to equip our people leaders with fundamental management skills to accelerate leadership success. This program is delivered over a twelve-month period through a mix of in-person, virtual, and on-demand learning. For our individual contributor employee population, we offer a variety of general and targeted development opportunities, including technical skills training, career learning journeys, and networking opportunities. We also provide extra support for Employee Resource Group leaders via a 1:1 coaching program.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have robust annual global performance and compensation planning processes for reviewing all employees&#8217; performance and pay. As part of this process, Intuitive supports career development and growth through our Talent Action Planning program, which encourages employees to work on targeted talent development actions to enhance on-the-job performance and prepare for future career opportunities with the support of their leaders. To support our people leaders in managing the performance of their teams, we train them on conducting effective career conversations and performance reviews and making fair and equitable compensation recommendations. Compensation guidelines are provided to leaders, which take into consideration market pay data and performance, as well as job experience. In 2022, we added a new focus on clarity and consistency in our internal promotion processes.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Programs</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that building connections between our employees, their families, and our communities creates a more meaningful, fulfilling, and enjoyable workplace. Through our engagement programs, our employees can pursue their interests and hobbies, connect to volunteering and giving opportunities, and enjoy unique recreational experiences with family members.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Intuitive Foundation is a nonprofit organization established in 2018 and funded by Intuitive. Since its founding, the Intuitive Foundation has been dedicated to promoting health, advancing education, and reducing human suffering. The Foundation supports outreach programs financially while we provide the volunteers and mentors from within our company. Since its inception, we have contributed $85&#160;million to the Intuitive Foundation to fulfill its mission.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage you to review the &#8220;Employee health and safety&#8221; and &#8220;Global access and engagement outreach initiatives&#8221; sections of our 2022 ESG Annual Report (to be made available on our website) for more detailed information regarding our Human Capital programs and initiatives. Although we reference our ESG Annual Report available on our website in this report, this report and any other materials on our corporate website are not incorporated by reference into this Annual Report or any other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. While matters discussed in such ESG Annual Report and website materials may be significant, any significance should not be read as necessarily rising to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the level of materiality used for the purposes of our compliance with the U.S. federal securities laws, even if we use the word &#8220;material&#8221; or &#8220;materiality&#8221; in such materials.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_58"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our periodic and current reports, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, available free of charge on our website as soon as practicable after such material is electronically filed or furnished with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.intuitive.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the reports are filed under &#8220;SEC Filings&#8221; on the Company &#8212; Investor Relations portion of our website. Periodically, we webcast Company announcements, product launch events, and executive presentations, which can be viewed via our Investor Relations page on our website. In addition, we provide notifications of our material news, including SEC filings, investor events, and press releases as part of our Investor Relations page on our website. The contents of our website are not intended to be incorporated by reference into this report or in any other report or document we file, and any references to our website are intended to be inactive textual references only. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The contents of these websites are not incorporated into this filing. Further, references to the URLs for these websites are intended to be inactive textual references only.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business as one segment, as defined by U.S. generally accepted accounting principles. Our financial results for the years ended December&#160;31, 2022, 2021, and 2020 are discussed in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive Surgical, Inc. was founded in 1995. We are a Delaware corporation with our principal executive offices located at 1020 Kifer Road, Sunnyvale, California 94086. Our telephone number is (408)&#160;523-2100, and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.intuitive.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should consider each of the following risk factors, which could materially affect our business, financial condition, or future results of operations. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results of operations. In addition, the global economic environment and additional or unforeseen effects from the COVID-19 pandemic amplify many of these risks.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_64"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR BUSINESS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROECONOMIC CONDITIONS COULD HAVE A MATERIALLY ADVERSE IMPACT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic conditions, such as high inflation, changes to monetary policy, increasing interest rates, volatile currency exchange rates, credit and sovereign debt concerns in certain European countries, concerns about slowed growth in China and other OUS markets, decreasing consumer confidence and spending, including capital spending, and global or local recessions can adversely impact demand for our products, which could negatively impact our business, financial condition, or results of operations. Recent macroeconomic conditions have been adversely impacted by political instability and military hostilities in multiple geographies (including the conflict between Ukraine and Russia), monetary and financial uncertainties, and the ongoing COVID-19 pandemic. The results of these macroeconomic conditions, and the actions taken by governments, central banks, companies, and consumers in response, have and may continue to result in higher inflation in the U.S. and globally, which is likely, in turn, to lead to an increase in costs and may cause changes in fiscal and monetary policy, including increased interest rates. Other adverse impacts of recent macroeconomic conditions have been and may continue to be supply chain constraints, logistics challenges, and fluctuations in labor availability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a higher inflationary environment, we may be unable to raise the prices of our products and services sufficiently to keep up with the rate of inflation. Impacts from inflationary pressures could be more pronounced and materially adversely impact aspects of our business where revenue streams and cost commitments are linked to contractual agreements that extend further into the future, as we may not be able to quickly or easily adjust pricing, reduce costs, or implement countermeasures. A higher inflationary environment can also negatively impact raw material, component, and logistics costs that, in turn, may increase the costs of producing and distributing our products. Recently, the costs of raw materials, transportation, construction, services, and energy necessary for the production and distribution of our products have increased significantly.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, hospitals and distributors may choose to postpone or reduce spending due to financial difficulties or difficulties in obtaining credit to finance purchases of our products due to increased interest rates and restraints on credit. Hospitals, in particular, are experiencing and may continue to experience financial and operational pressures as a result of staffing shortages, the supply chain environment, and increased inflation, which could impact their ability to access capital markets and other funding sources, increase the cost of funding, or impede their ability to comply with debt covenants, all of which could impede their ability to provide patient care, defer elective surgeries, and impact their profitability. To the extent that hospitals face financial pressures, reductions in government spending, or higher interest rates, hospitals&#8217; ability or willingness to spend on capital equipment may be adversely impacted, all of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the impact of efforts by central banks and federal, state, and local governments to combat elevated levels of inflation. If their efforts to create downward pressure on inflation are too aggressive, they may lead to a recession. Alternatively, if they are insufficient or are not sustained long enough to bring inflation to lower, more acceptable levels, hospitals&#8217; ability or willingness to spend on capital equipment may be impacted for a prolonged period of time. If a recession occurs, economies weaken, or inflationary trends continue, our business and operating results could be materially adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in early 2023, the U.S. Government reached its existing statutory limit on the amount of permissible federal debt, and this limit must be raised in order for the U.S. Government to continue to pay its obligations on a timely basis. If the debt ceiling is not raised, it is unclear how the U.S. Government would prioritize its payments towards its various programs, which could have a significant impact on the overall economy as well as on medical procedures performed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we have and may continue to experience supply chain constraints due to the current supply chain environment and logistic challenges, including difficulties obtaining a sufficient supply of component materials used in our products. If interest rates continue to rise, access to credit may become more difficult, which may result in the insolvency of key suppliers, including single-source suppliers, which would exacerbate supply chain challenges. Such supply chain constraints could cause us to fail to meet product demand, which could result in deferred or canceled procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR RELIANCE ON SOLE AND SINGLE SOURCE SUPPLIERS AND ABILITY TO PURCHASE AT ACCEPTABLE PRICES A SUFFICIENT SUPPLY OF MATERIALS, PARTS, AND COMPONENTS COULD HARM OUR ABILITY TO MEET PRODUCT DEMAND IN A TIMELY MANNER OR WITHIN BUDGET.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the components necessary for the assembly of our products are currently provided to us by sole-sourced suppliers or single-sourced suppliers. We generally purchase components through purchase orders rather than long-term supply agreements and generally do not maintain large volumes of inventory. While alternative suppliers exist and could be identified for single-sourced components, the disruption or termination of the supply of components, or inflationary pressure in our supply chain, could cause a significant increase in the costs of these components, which could affect our operating results. A disruption or termination in the supply of components could also result in our inability to meet demand for our products, which could harm our ability to generate revenues, lead to customer dissatisfaction, and damage our reputation and our brand. Furthermore, if we are required to change the manufacturer of a key component of our products, we may be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The time and processes associated with the verification of a new manufacturer could delay our ability to manufacture our products on schedule or within budget, which may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to meet customers&#8217; demands depends, in part, on our ability to timely obtain an adequate delivery of quality materials, parts, and components from our suppliers. An information technology systems interruption, including cyberattacks, could adversely affect the ordering, distribution, and manufacturing processes of our suppliers. Difficulties remain in obtaining a sufficient supply of semiconductor and other component materials, and we expect such difficulties to persist in the foreseeable future. Prices of such materials have also increased, and global supply has become significantly constrained due to the increased demand for materials, including semiconductors, to support expansion of server and cloud networks as a greater proportion of the global population worked remotely, the introduction of 5G, and the continued electrification of vehicles. We engage in activities to seek to mitigate such supply disruptions by, for example, increasing our communications with our suppliers and modifying our purchase order coverage and inventory levels. Such global shortages in important components have resulted in, and will continue to cause, inflationary pressure in our supply chain, which would impact our profits and profit margin. If shortages and price increases in important supply-chain materials in the semiconductor or other markets continue, we could also fail to meet product demand, which would adversely impact our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PUBLIC HEALTH CRISES OR EPIDEMIC DISEASES, OR THE PERCEPTION OF THEIR EFFECTS, COULD MATERIALLY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations expose us to risks associated with public health crises and outbreaks of epidemic, pandemic, or contagious diseases, such as the current outbreak of a novel strain of coronavirus (COVID-19). To date, COVID-19 has had, and may continue to have, an adverse impact on our operations, our supply chains and distribution systems, and our expenses, including as a result of preventive and precautionary measures that we, other businesses, and governments have taken and may continue to take. In addition, hospitals are experiencing staffing shortages and supply chain issues that could impact their ability to provide patient care. Due to these impacts and measures, we have experienced and may continue to experience significant and unpredictable reductions in the demand for our products as healthcare customers divert medical resources and priorities towards the treatment of that disease. Also, our customers have delayed, cancelled, or redirected and, in the future, may delay, cancel, or redirect, planned capital expenditures in order to focus resources on COVID-19 or in response to economic disruption related to COVID-19. For example, as a result of the global COVID-19 pandemic, in the first half of 2020, we experienced a significant decline in procedure volume in the U.S. and Western Europe, as healthcare systems diverted resources to meet the increasing demands of managing COVID-19. In addition, U.S. and global public health bodies have, at times, recommended delaying elective surgeries during the COVID-19 pandemic, which may continue to negatively impact the usage of our products and the number of da Vinci procedures performed. Also, as we are conducting IDE studies to support 510(k) submission for da Vinci platforms and for seeking new indications, we may experience delays in obtaining new product approvals, or clearances from the FDA or foreign approvals or certifications from foreign authorities or notified bodies or delays in recruiting patients in our ongoing and planned clinical studies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 outbreak, we experienced significant business disruptions, including restrictions on our ability to travel as well as distribute and service our products, temporary closures of our facilities and the facilities of our suppliers and their contract manufacturers, and a reduction in access to our customers due to diverted resources and priorities and the business hours of hospitals, as governments institute prolonged shelter-in-place and/or self-quarantine mandates. For example, our corporate headquarters and many of our operations, including certain of our manufacturing facilities, are located in California, which previously instituted risk reduction orders applicable to our employees in that region, significantly impacting the ability of our employees to get to their places of work to produce products and hampering our products from moving through the supply chain. These unprecedented measures to slow the spread of the virus taken by local governments and healthcare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities globally, including the deferral of elective medical procedures and social distancing measures, had, and may continue to have, a negative impact on our operations and financial results. Furthermore, our future ways of working changes, including working from home, fully on-site, or in a hybrid fashion, may present additional risks, uncertainties, and costs that could affect our performance, including increased operational risk, uncertainty regarding office space needs, heightened vulnerability to cyberattacks due to remote work, potential reduced productivity, changes to our company culture, and increased costs to ensure our offices are safe and functional as hybrid offices that enable effective collaboration of both remote and in-person colleagues.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic adversely affected and may continue to adversely affect the economies and financial markets of many countries, which may result in a period of regional, national, and global economic slowdown or regional, national, or global recessions that could curtail or delay spending by hospitals and affect demand for our products as well as increased risk of customer defaults or delays in payments. Our customers may terminate or amend their agreements for the purchase, lease, or service of our products due to bankruptcy, lack of liquidity, lack of funding, operational failures, or other reasons. COVID-19 and the current financial, economic, and capital markets environment, and future developments in these and other areas present material uncertainty and risk with respect to our performance, financial condition, volume of business, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of other epidemic, pandemic, or contagious diseases, such as, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome, or the H1N1 virus, could also divert medical resources and priorities towards the treatment of that disease. An outbreak of other contagious diseases could negatively affect hospital admission rates or disrupt our business similar to the impact of the COVID-19 pandemic highlighted above. Any of these outbreaks could negatively impact the number of procedures performed and have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE SUBJECT TO LITIGATION, INVESTIGATIONS, AND OTHER LEGAL PROCEEDINGS RELATING TO OUR PRODUCTS, OUR CUSTOMERS, OUR COMPETITORS, AND GOVERNMENT REGULATORS THAT COULD MATERIALLY ADVERSELY AFFECT OUR FINANCIAL CONDITION, DIVERT MANAGEMENT&#8217;S ATTENTION, AND HARM OUR BUSINESS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may become, subject to various legal proceedings and claims that arise in or outside the ordinary course of business. Certain current lawsuits and pending proceedings to which we are party, including purported class actions, product liability litigation, and patent litigation, are described in Note 8 to the Consolidated Financial Statements included in Part II, Item&#160;8.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our business exposes us to significant risks of patent claims, product liability claims, and competition claims (including antitrust claims), many of which are common in the medical device industry. For example, product liability claims have been brought against us by, or on behalf of, individuals alleging that they have sustained personal injuries and/or death as a result of purported product defects, the alleged failure to warn, and/or the alleged inadequate training by us of physicians regarding the use of the da Vinci Surgical System. The individuals who have brought the product liability claims seek recovery for their alleged personal injuries and, in many cases, punitive damages. Current product liability claims have resulted in negative publicity regarding our Company, and these and any other product liability or negligence claims or product recalls also could harm our reputation. Refer to our risk factor titled &#8220;Negative Publicity, Whether Accurate or Inaccurate, Concerning Our Products or Our Company Could Reduce Market Acceptance of Our Products and Could Result in Decreased Product Demand and Reduced Revenues&#8221; for additional risks related to the potential effects of negative publicity on our business. Also, antitrust claims have been brought against us by third parties looking to compete in the instruments or servicing space and by certain customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of these product liability claims and other legal proceedings cannot be predicted with certainty. We purchase and maintain business insurance for certain liabilities and self-insure our product liability claims through a fronting policy. We cannot determine whether our existing business insurance program would be sufficient to cover the costs or potential losses related to these lawsuits and proceedings or otherwise be excluded under the terms of any insurance policy. Regardless of merit, litigation may be time-consuming and disruptive to our operations and cause significant legal costs (including settlements, judgments, legal fees, and other related defense costs) and diversion of management attention. If we do not prevail in these legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that could have a material adverse effect on our business, financial condition, or results of operations. We could also be subject to governmental investigations in connection with many of these claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BECAUSE OUR MARKETS ARE HIGHLY COMPETITIVE, CUSTOMERS MAY CHOOSE TO PURCHASE OUR COMPETITORS&#8217; PRODUCTS OR SERVICES OR MAY NOT ACCEPT ROBOTIC-ASSISTED MEDICAL PROCEDURES, WHICH COULD RESULT IN REDUCED REVENUE AND LOSS OF MARKET SHARE.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robotic-assisted surgery with a da Vinci Surgical System or robotic-assisted bronchoscopy using an Ion endoluminal system are technologies that compete with established and emerging treatment options in reconstructive medical procedures or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease management. These competitive treatment options include open surgery, conventional MIS, drug therapies, radiation treatment, and other emerging diagnostic and interventional surgical approaches. Some of these procedures are widely accepted in the medical community and, in many cases, have a long history of use. Technological advances could make such treatments more effective or less expensive than using our products, which could render our products obsolete or unmarketable. Studies could be published that show that other treatment options are more beneficial and/or cost-effective than robotic-assisted medical procedures. We cannot be certain that physicians will use our products to replace or supplement established treatments or that our products will continue to be competitive with current or future technologies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we face or expect to face competition from companies that develop or have developed wristed, robotic-assisted, or computer-assisted medical systems and products. Companies have introduced products in the field of robotic medical procedures or have made explicit statements about their efforts to enter the field including, but not limited to, the following companies: Asensus Surgical, Inc.; avateramedical GmbH; CMR Surgical Ltd.; Johnson &amp; Johnson; Medicaroid Corporation; Medrobotics Corporation; Medtronic plc; meerecompany Inc.; Olympus Corporation; Samsung Electronics Co., Ltd; Shandong Weigao Group Medical Polymer Company Ltd.; Shanghai Microport Medbot (Group) Co., Ltd.; and Titan Medical Inc. Other companies with substantial experience in industrial robotics could potentially expand into the field of medical robotics and become competitors. Our revenues may be reduced due to pricing pressure or eliminated if our competitors develop and market products that are more effective or less expensive than our products. If we are unable to compete successfully, our revenues will suffer, which could have a material adverse effect on our business, financial condition, or result of operations. We may not be able to maintain or improve our competitive position against current or potential competitors, especially those with greater resources.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third-party service providers that provide services to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci Surgical System and Ion endoluminal system operators may emerge and compete with us on price or offerings. To date, substantially all of our customers have sourced services on their systems from us through service contract commitments or time and materials contracts. Furthermore, there are third-party service providers offering consulting services targeted at analyzing the cost-effectiveness of hospitals&#8217; robotic-assisted medical programs, including procedures performed, placement of systems, and consumption of instruments and accessories. We currently provide similar services and analysis to our customers, but it is difficult to assess the impact that this may have on our business. If we are unable to compete successfully with any third-party service providers, our revenues may suffer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF OUR PRODUCTS DO NOT ACHIEVE AND MAINTAIN MARKET ACCEPTANCE, WE WILL NOT BE ABLE TO GENERATE THE REVENUE NECESSARY TO SUPPORT OUR BUSINESS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The da Vinci Surgical System and our other products represent a fundamentally new way of performing medical procedures. Achieving and maintaining physician, patient, and third-party payor acceptance of robotic-assisted medical procedures as a preferred method of performing these procedures is crucial to our success. If our products fail to achieve or maintain market acceptance, customers will not purchase our products, and we will not be able to generate the revenue necessary to support our business. We believe that physicians&#8217; and third-party payors&#8217; acceptance of the benefits of procedures performed using our products will be essential for acceptance of our products by patients. Physicians will not recommend the use of our products unless we can demonstrate that they produce results comparable or superior to existing techniques. Even if we can prove the effectiveness of our products through clinical studies, physicians may elect not to use our products for any number of other reasons. For example, cardiologists may continue to recommend conventional heart surgery simply because such surgery is already widely accepted. In addition, physicians may be slow to adopt our products because of the perceived liability risks arising from the use of new products and the uncertainty of reimbursement from third-party payors, particularly in light of ongoing healthcare reform initiatives and the evolving U.S. healthcare environment.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that there will continue to be a learning process involved for patient care teams to become proficient in the use of our products. Broad use of our products requires training of patient care teams. Market acceptance could be delayed by the time required to complete this training. We may not be able to rapidly train patient care teams in numbers sufficient to generate adequate demand for our products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF HOSPITALS ARE UNABLE TO OBTAIN COVERAGE AND REIMBURSEMENT FOR PROCEDURES USING OUR PRODUCTS, IF REIMBURSEMENT IS INSUFFICIENT TO COVER THE COSTS OF PURCHASING OUR PRODUCTS, OR IF LIMITATIONS ARE IMPOSED BY GOVERNMENTS ON THE AMOUNT HOSPITALS CAN CHARGE FOR CERTAIN PROCEDURES, WE MAY BE UNABLE TO GENERATE SUFFICIENT SALES TO SUPPORT OUR BUSINESS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., hospitals generally bill for the services performed with our products to various third-party payors, such as Medicare, Medicaid, other government programs, and private insurance plans. If hospitals do not obtain sufficient reimbursement from third-party payors for procedures performed with our products, or if government and private payors&#8217; policies do not cover surgical procedures performed using our products, we may not be able to generate the revenues necessary to support our business. In addition, to the extent that there is a shift from an inpatient setting to outpatient settings, we may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience pricing pressure and a reduction in the number of procedures performed. Our success in OUS markets also depends on the eligibility of our products for coverage and reimbursement through government-sponsored healthcare payment systems and third-party payors. Reimbursement practices vary significantly by country. Many OUS markets have government-managed healthcare systems that control reimbursement for new products and procedures. Other foreign markets have both private insurance systems and government-managed systems that control reimbursement for new products and procedures. Market acceptance of our products may depend on the availability and level of coverage and reimbursement in a country within a particular time. In addition, healthcare cost containment efforts similar to those in the U.S. are prevalent in many of the other countries in which we sell, and intend to sell, our products, and these efforts are expected to continue. Refer to our risk factor titled &#8220;Changes in Healthcare Legislation and Policy May Have a Material Adverse Effect on Our Business, Financial Condition, or Results of Operations&#8221; for additional risks related to the ability of hospitals to obtain reimbursements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the Hunan Provincial Healthcare Security Administration implemented significant limits on what hospitals can charge patients for surgeries using robotic surgical technology, including soft tissue surgery and orthopedics. This rule has had and may continue to have a material negative impact on our procedures performed in the Hunan province. In addition to the Hunan province, the Hainan province (an island province of China) recently announced a policy to implement almost identical limits on what hospitals can charge patients for surgeries using robotic surgical technology. We cannot assure you that other provincial healthcare administrations will not impose similar limits.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF OUR PRODUCTS CONTAIN DEFECTS OR ENCOUNTER PERFORMANCE PROBLEMS, WE MAY HAVE TO RECALL OUR PRODUCTS AND, AS A RESULT, INCUR ADDITIONAL UNFORESEEN COSTS, AND OUR REPUTATION MAY SUFFER.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the quality and reliability of our products. While we subject components sourced and products manufactured to stringent quality specifications and processes, our products incorporate mechanical parts, electrical components, optical components, and computer software, any of which may contain errors or exhibit failures, especially when products are first introduced. Component failures, manufacturing flaws, design defects, or inadequate disclosure of product-related risks with respect to our products could result in an unsafe condition or injury to, or death of, the patient. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after commercial shipment. Because our products are designed to be used to perform complex surgical procedures, due to the serious and costly consequences of product failure, we and our customers have an increased sensitivity to such defects. In the past, we have voluntarily recalled certain products. Although our products are subject to stringent quality processes and controls, we cannot provide assurance that our products will not experience component aging, errors, or performance problems. If we experience product flaws or performance problems, any or all of the following could occur:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in product shipments;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in market acceptance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of our resources;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, which can include, but not be limited to, product withdrawals from the market, labeling changes, design changes, customer notifications, and notifications to global regulatory bodies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased service or warranty costs; or</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product liability claims.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with defects or performance problems of our products could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE COULD BE SUBJECT TO SIGNIFICANT, UNINSURED LOSSES, WHICH MAY HAVE A MATERIAL ADVERSE IMPACT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain risks, we do not maintain insurance coverage due to cost and/or availability.&#160;For example, we self-insure our product liability risks, and we indemnify our directors and officers for third-party claims and do not carry insurance to cover that indemnity or the related underlying potential losses. Also, we do not carry, among other types of coverage, earthquake insurance. In addition, in the future, we may not continue to maintain certain existing insurance coverage or adequate levels of coverage. Premiums for many types of insurance have increased significantly in recent years and, depending on market conditions and our circumstances, certain types of insurance, such as directors&#8217; and officers&#8217; insurance, may not be available in the future on acceptable terms or at all. Because we retain some portion of our insurable risks and, in some cases, we are entirely self-insured, unforeseen or catastrophic losses in excess of insurance coverage could require us to pay substantial amounts, which may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF WE LOSE KEY PERSONNEL OR ARE UNABLE TO ATTRACT AND RETAIN OTHER PERSONNEL, OUR ABILITY TO COMPETE WILL BE HARMED, AND INCREASES IN LABOR COSTS COULD MATERIALLY ADVERSELY IMPACT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific staff. For example, our product development plans depend, in part, on our ability to attract and retain software, mechanical, electrical, and robotics engineers. Attracting and retaining qualified personnel will be critical to our success, and competition for qualified personnel is intense. We may not be able to attract and retain personnel on acceptable terms given the constrained labor market and competition for such personnel among technology and healthcare companies. Additionally, as a result of recent declines in our stock price, certain long-term incentive benefits, such as recently issued stock options, may be viewed as having less value and, accordingly, could lead to higher attrition. Moreover, we may encounter higher recruiting expenses, wage rates, and retention benefits, which may result from higher inflationary environments. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in labor availability globally, including labor shortages and staff burnout and attrition, may also impact our ability to hire and retain personnel critical to our manufacturing, logistics, and commercial operations. The extent and duration of the impact of labor market challenges are subject to numerous factors, including the continuing impact of the COVID-19 pandemic, availability of qualified and highly skilled persons in the markets where we operate and unemployment levels within these markets, behavioral changes, such as fully engaging employees and earning loyalty, prevailing wage rates, health and other insurance and benefit costs, inflation, adoption of new or revised employment and labor laws and regulations or government programs, safety levels of our operations, and our reputation within the labor market. The loss of any of our qualified personnel or our inability to attract and retain qualified personnel could harm our business and our ability to compete, and related expenses could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if we fail to attract, motivate, or retain personnel, or relax our standards in order to meet the demands of our growth, our corporate culture, our ability to achieve our strategic objectives, and our compliance with obligations under our internal controls and other requirements may be harmed. We believe that a critical contributor to our success has been our corporate culture, which we believe fosters innovation, teamwork, and a focus on execution, as well as facilitates critical knowledge transfer and knowledge sharing. Many of our employees have worked remotely during the COVID-19 pandemic, which makes it challenging to maintain or enhance our culture. While we are exploring ways to improve the employee experience, regardless of whether an employee is working from home, fully on-site, or in a hybrid fashion, the impact this will have on our corporate culture, innovation, collaboration, and ability to attract and retain talent is uncertain.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEGATIVE PUBLICITY, WHETHER ACCURATE OR INACCURATE, CONCERNING OUR PRODUCTS OR OUR COMPANY COULD REDUCE MARKET ACCEPTANCE OF OUR PRODUCTS AND COULD RESULT IN DECREASED PRODUCT DEMAND AND REDUCED REVENUES.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been reports and articles published questioning patient safety and efficacy associated with robotic-assisted surgery with the da Vinci Surgical System, its cost relative to other disease management methods, and the adequacy of surgeon training. Negative publicity, including statements made by public officials, whether accurate or inaccurate, concerning our products or our Company could reduce market acceptance of our products and could result in decreased product demand and a decline in revenues. In addition, significant negative publicity could result in an increased number of product liability claims, regardless of whether these claims are meritorious. The number of claims could be further increased by plaintiffs&#8217; law firms that use a wide variety of media to advertise their services and solicit clients for product liability cases against us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE EXPERIENCE LONG AND VARIABLE CAPITAL SALES CYCLES&#160;AND SEASONALITY IN OUR BUSINESS, WHICH MAY CAUSE FLUCTUATIONS IN OUR FINANCIAL RESULTS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales and purchase order cycle of our systems is lengthy, because the systems are major capital items and their purchase generally requires the approval of senior management of hospitals, their parent organizations, purchasing groups, and government bodies, as applicable. In addition, sales to some of our customers are subject to competitive bidding or public tender processes. These approval and bidding processes can be lengthy.&#160;As a result, hospitals may delay or accelerate system purchases in conjunction with the timing of their capital budget timelines.&#160;Further, IDN groups are creating larger networks of system users with increasing purchasing power and are increasingly evaluating their robotic-assisted surgery programs to optimize the efficiency of surgeries using da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surgical Systems. Further, the introduction of new products could adversely impact our sales cycle as customers take additional time to assess the benefits and costs of such products. As a result, it is difficult for us to predict the length of capital sales cycles and, therefore, the exact timing of capital sales. Historically, our sales of da Vinci Surgical Systems have tended to be heavier in the fourth quarter and lighter in the first quarter, as hospital budgets are reset.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced procedure growth for a number of benign conditions, including hysterectomies, sacrocolpopexies, hernia repairs, cholecystectomies, bariatrics, and certain other surgeries. Many of these types of surgeries may be postponed in the short term by patients to avoid vacation periods and for other personal scheduling reasons. Patients may also accelerate procedures to take advantage of&#160;insurance funding cut-off dates. Historically, we have experienced lower procedure volume in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the first and third quarters of the year and higher procedure volume in the second and fourth quarters of the year. The timing of procedures and changes in procedure growth directly affect the timing of instruments and accessories and capital purchases by customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above factors may contribute to substantial fluctuations in our quarterly operating results. Because of these fluctuations, it is possible that, in future periods, our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW PRODUCT DEVELOPMENTS AND INTRODUCTIONS MAY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop and introduce new products with enhanced features and extended capabilities from time to time. We may introduce new products that target different markets than what our existing products target. The success of new product introductions depends on a number of factors including, but not limited to, timely and successful research and development, regulatory clearances, approvals, or certifications, pricing, competition, market and consumer acceptance, the effective forecasting and management of product demand, inventory levels, the management of manufacturing and supply costs, and the risk that new products may have quality or other defects in the early stages of introduction.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest substantially in various research and development projects to expand our product offerings. Our research and development efforts are critical to our success, and our research and development projects may not be successful. We may be unable to develop and market new products successfully, and the products we invest in and develop may not be well-received by customers or meet our expectations. Our research and development investments may not generate significant operating income or contribute to our future operating results for several years, and such contributions may not meet our expectations or even cover the costs of such investments. In addition, the introduction or announcement of new products or product enhancements may shorten the life cycle of our existing products or reduce demand for our current products, thereby offsetting any benefits of successful product introductions and potentially leading to challenges in managing inventory of existing products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to various regulatory processes, and we must obtain and maintain regulatory approvals and certifications in order to sell our new products. If a potential purchaser believes that we plan to introduce a new product in the near future or is located in a country where a new product that we have introduced has not yet received regulatory clearance or certification, planned purchases may be deferred or delayed. In the past, we have experienced a slowdown in demand for existing products in advance of new product introductions, and we may experience a slowdown in demand in the future as well. It is also possible that a new product introduction could cause downward pressure on the prices of our existing products or require us to change how we sell our products, either of which could have material adverse effects on our revenues.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to effectively develop new products and manage new product introductions in the future, our business, financial condition, or results of operations could be adversely impacted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE SUBJECT TO A VARIETY OF RISKS DUE TO OUR OPERATIONS OUTSIDE OF THE U.S.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture, perform research and development activities, and distribute our products in OUS markets. Revenue from OUS markets accounted for approximately 33%, 33%, and 32% of our revenue for the years ended December&#160;31, 2022, 2021, and 2020, respectively. Our OUS operations are, and will continue to be, subject to a number of risks including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to obtain or maintain the same degree of protection against infringement of our intellectual property rights due to differing intellectual property protection laws in OUS countries from those in the U.S.;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple OUS regulatory requirements that are subject to change and that could impact our ability to manufacture and sell our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tariffs, trade barriers, and regulatory requirements;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protectionist laws, policies, and business practices that favor local competitors or lead to non-U.S. customers favoring domestic technology solutions, which could slow our growth in OUS markets;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">local or national regulations that make it difficult or impractical to market or use our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. relations with the governments of the other countries in which we operate;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability or regulatory limitations on our ability to move goods across borders;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with foreign currency exchange rate fluctuations;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in establishing, staffing, and managing OUS operations, including differing labor relations;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense of establishing facilities and operations in new foreign markets;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the building and maintenance of an organization capable of supporting geographically dispersed operations, including appropriate business procedures and controls;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anti-corruption&#160;laws, such as the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), and other local laws prohibiting corrupt payments to governmental officials;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and anti-competition laws;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets, including exposure to a higher degree of financial risk if we extend credit to customers in these economies; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions due to natural disasters, outbreak of disease, climate change, and other events beyond our control.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have increased, and will continue to increase, our operations in China. There is inherent risk, based on the complex relationships between China and the U.S., that political, diplomatic, military, or other events could result in business disruptions, including increased regulatory enforcement against companies, tariffs, trade embargoes, or export restrictions. Tariffs increase the cost of our products and the components and raw materials that go into making them. These increased costs adversely impact the gross margin that we earn on our products. Tariffs can also make our products more expensive for customers, which could make our products less competitive and reduce consumer demand. Countries may also adopt other measures, such as controls on imports or exports of goods, technology, or data, which could adversely impact our operations and supply chain and limit our ability to offer our products and services as designed. These measures can require us to take various actions, including changing suppliers and restructuring business relationships. Changing our operations in accordance with new or changed trade restrictions can be expensive, time-consuming, disruptive to our operations and distracting to management. Such restrictions can be announced with little or no advance notice, and we may not be able to effectively mitigate all adverse impacts from such measures. Political uncertainty surrounding trade and other international disputes could also have a negative effect on consumer confidence and spending. Any of these events could reduce customer demand, increase the cost of our products and services, or otherwise have a materially adverse impact on our customers&#8217; and suppliers&#8217; businesses or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2020, the U.S. government amended the Entity List rules to expand the requirement to obtain a license prior to the export of certain technologies. In addition, in 2020, a new U.S. regulation seeks to prohibit the U.S. government from contracting with companies who use the products or services of certain Chinese companies. We believe that these regulations do not materially adversely impact our business at this time but cannot predict the impact that additional regulatory changes may have on our business in the future. These actions or similar actions may result in policies and regulations in response that could adversely affect our business operations in China or may otherwise limit our ability to offer our products and services in China and other parts of the world.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and enactment of legislation by the government of the UK, the UK formally withdrew from the EU and ratified a trade and cooperation agreement governing its relationship with the EU. The EU&#8211;UK Trade and Cooperation Agreement (the &#8220;TCA&#8221;) was applied provisionally as of January 1, 2021, and entered into force on May 1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the EU Medical Devices Regulation will not be implemented in the UK, and previous legislation that sought to mirror the EU Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in Great Britain continues to be based on the requirements derived from previous EU legislation, and the UK may choose to retain regulatory flexibility or align with the EU Medical Devices Regulation going forward. On June 26, 2022, the MHRA published its response to a 10-week consultation on the future regulation of medical devices in the UK. Regulations implementing the new regime were originally scheduled to come into force in July 2023 but have recently been postponed to July 2024. Devices issued by EU notified bodies are now subject to transitional arrangements. Following these transitional periods, it is expected that all medical devices will require a UKCA mark, but CE marks issued by EU notified bodies will remain valid until this time. Manufacturers may choose to use the UKCA mark on a voluntary basis until June 30, 2023. However, UKCA marking will not be recognized in the EU. Following the transitional period, compliance with the UK legislation will be a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization-related activities, exchanges of officials, and coordinated product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries, the &#8220;rules of origin&#8221; criteria will need to be reviewed. Depending on which countries products will ultimately be sold in, manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for placing medical devices on the Northern Ireland market will differ from those in Great Britain. These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and our business would likely be impacted and the demand for our products could be depressed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. federal government has made changes to the U.S. trade policy, including entering into a successor to the North American Free Trade Agreement (&#8220;NAFTA&#8221;), known as the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;), effective as of July 1, 2020. In addition, the U.S. federal government has implemented, or is considering the imposition of, tariffs on certain foreign goods. Such tariffs and, if enacted, any further legislation or actions taken by the U.S. federal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government that restrict trade, such as additional tariffs, trade barriers, and other protectionist or retaliatory measures taken by governments in Europe, Asia, and other countries, could adversely impact our ability to sell products and services in our OUS markets. Tariffs could increase the cost of our products and the components and raw materials that go into making them. These increased costs could adversely impact the gross margin that we earn on our products, which could make our products less competitive and reduce consumer demand. Countries may also adopt other protectionist measures that could limit our ability to offer our products and services.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, a large portion of our OUS sales are denominated in U.S. dollars. As a result, an increase in the value of the U.S. dollar relative to foreign currencies could make our products less competitive and/or less affordable in OUS markets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to meet and manage these risks, our OUS operations may not be successful, which would limit the growth of our business and could have a material adverse effect on our business, financial condition, or result of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE MAY INCUR LOSSES ASSOCIATED WITH CURRENCY FLUCTUATIONS AND MAY NOT BE ABLE TO EFFECTIVELY HEDGE OUR EXPOSURE.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results are subject to volatility due to fluctuations in foreign currency exchange rates. Our primary exposure to fluctuations in foreign currency exchange rates relates to revenue and operating expenses denominated in currencies other than the U.S. dollar. The weakening of foreign currencies relative to the U.S. dollar adversely affects our foreign currency-denominated revenue. Margins on OUS revenue could also be materially adversely affected by foreign currency exchange rate fluctuations, as we may not be able to raise local prices to fully offset the strengthening of the U.S. dollar. Conversely, the strengthening of foreign currencies relative to the U.S. dollar, while generally beneficial to our foreign currency-denominated revenue and earnings, may cause us to reduce pricing on our products in our OUS markets and may cause us to incur losses on our foreign currency hedging instruments, thereby limiting the benefit that strengthened foreign currencies could have on our results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attempt to mitigate a portion of these risks through foreign currency hedging, based on our judgment of the appropriate trade-offs among risk, opportunity, and expense. Although we have established a hedging program to partially hedge our exposure to foreign currency exchange rate fluctuations, primarily related to transactions denominated in the Euro, the British Pound, the Japanese Yen, the Korean Won, the New Taiwan Dollar, and the Swiss Franc, and we regularly review our hedging program and make adjustments as necessary, our hedging activities may not offset more than a portion of the adverse financial impact caused by unfavorable movement in foreign currency exchange rates, which could materially adversely affect our financial condition or results of operations. See &#8220;Item 7A. Quantitative and Qualitative Disclosures About Market Risk&#8221; for additional discussion on the impact of foreign exchange risk.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR CUSTOMERS MAY USE REMANUFACTURED AND/OR UNAUTHORIZED THIRD-PARTY INSTRUMENTS AND ACCESSORIES, WHICH COULD RESULT IN REDUCED REVENUE AND NEGATIVELY IMPACT OUR REPUTATION.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue is generated through our sales of instruments and accessories. Third parties have offered and may continue to offer customers counterfeit instruments and accessories and/or instruments and accessories that have been remanufactured and/or are unauthorized, including instruments that have been remanufactured to support the use of some of our limited-use instruments beyond their labeled useful life. As of the filing date, we are unaware that the FDA or any other regulatory agency has granted 510(k) or equivalent clearance for the remanufacturing of any instruments for use with a da Vinci X or da Vinci Xi Surgical System, but we understand that the FDA has granted 510(k) clearance to one company for the remanufacturing of an EndoWrist instrument used with our da Vinci S and da Vinci Si Surgical Systems. While our sales arrangements with customers generally prohibit the use of unauthorized and unapproved instruments and accessories that lack FDA clearance or other applicable regulatory approval or certification with our systems, such activities could potentially result in reduced revenue, increased patient safety risks, and negative publicity for us if these products cause injuries and/or do not function as intended when used with our systems, any of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION TECHNOLOGY SYSTEM FAILURES, CYBERATTACKS, OR DEFICIENCIES IN OUR CYBERSECURITY COULD HARM OUR BUSINESS, CUSTOMER RELATIONS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems are critical to the success of our products, help us operate effectively and efficiently, interface with customers, maintain our supply chain and manufacturing operations, maintain financial accuracy and efficiency, and help us produce our Consolidated Financial Statements. If we do not allocate and effectively manage the resources necessary to build and sustain the proper information technology infrastructure, we could be subject to transaction errors, processing inefficiencies, the loss of existing customers, difficulty attracting new customers, business operation disruptions, diversion of the attention of management and key information technology resources, security breaches, or the unauthorized access to, loss of, or damage to intellectual property, confidential information, or personal information. Our information </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology systems and those of our third-party service providers, strategic partners, and other contractors or consultants are vulnerable to attack, damage, or interruption from a variety of sources. These sources include computer viruses and malware (e.g., ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors, or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. If our information technology systems do not effectively and securely collect, store, process, and report relevant data for the operation of our business, our ability to effectively plan, forecast, and execute our business plan and comply with applicable laws and regulations could be impaired. Any such impairment could materially and adversely affect our financial condition, results of operations, and the timeliness with which we report our internal and external operating results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires us to use and store customer, employee, and business partner personal information. This may include names, addresses, phone numbers, email addresses, contact preferences, tax identification numbers, and payment account information. We require usernames and passwords in order to access our information technology systems. We also use encryption and authentication technologies to secure the transmission and storage of data. These security measures may be compromised as a result of security breaches by unauthorized persons, employee error, malfeasance, faulty password management, or other irregularity and result in persons obtaining unauthorized access to our data or accounts. Third parties may attempt to fraudulently induce employees or customers into disclosing usernames, passwords, or other sensitive information, which may, in turn, be used to access our information technology systems. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unauthorized persons may attempt to hack into our products or systems to obtain personal data relating to patients or employees, our confidential or proprietary information, or confidential information we hold on behalf of third parties. If the unauthorized persons successfully hack into or interfere with our connected products or services, they may create issues with product functionality that could pose a risk of the loss of data, a risk to patient safety, and a risk of product recall or field action, which could adversely impact our business and reputation. We have programs in place to detect, contain, and respond to data security incidents, and we make ongoing improvements to our information-sharing products in order to minimize vulnerabilities, in accordance with industry and regulatory standards. However, because the techniques used to obtain unauthorized access to or steal personal information or intellectual property, or sabotage systems containing personal information or intellectual property, change frequently and may originate from less regulated and remote areas of the world and be difficult to detect, we may not be able to anticipate and prevent these intrusions or mitigate them when and if they occur. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, avoid detection, and remove or obfuscate forensic evidence.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on external vendors to supply and/or support certain aspects of our information technology systems. The systems of these external vendors may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our own information technology systems, and we are dependent on these third parties to deploy appropriate security programs to protect their systems. In addition to potential exposure to data breaches, security and cybersecurity incidents, or other actions that may compromise the security of or interfere with the function of our systems, defects or vulnerabilities in the software or systems of our external vendors may expose failures in our internal controls and risk management processes, which may adversely impact our business, financial condition, or results of operations and may also harm our reputation, brand, and customer relationships.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we devote significant resources to network security, data encryption, and other security measures to protect our systems and data, these security measures cannot provide absolute security. We and certain of our service providers are, from time to time, subject to cyberattacks and security breaches and incidents. We consider such cyberattacks or security breaches and incidents to be in the ordinary course of business for a company of our size in our industry. While we do not believe that we have experienced any significant system failure, accident, or security breach to date, if such an event were to occur, it could impair our ability to attract and retain customers for our products, impact the price of our stock, materially damage commercial relationships, and expose us to litigation or government investigations, which could result in penalties, fines, or judgments against us. The costs to us to eliminate or alleviate network security problems, bugs, viruses, worms, ransomware and other malicious software programs, and security vulnerabilities could be significant. Our efforts to address these problems may not be successful and could result in unexpected interruptions, delays, cessation of service, and harm to our business operations. Moreover, if a security breach affects our systems or results in the unauthorized release of personal information, our reputation and brand could be materially damaged, and use of our products and services could decrease. We would also be exposed to a risk of loss, litigation and potential liability, and regulatory scrutiny, which could have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, attacks are expected to continue accelerating in both frequency and sophistication with increasing use of tools and techniques that are designed to circumvent controls, avoid detection, and remove or obfuscate forensic evidence, all of which hinders our ability to identify, investigate, and recover from incidents.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, due to the political uncertainty involving Russia and Ukraine, there is also an increased likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly impact our operations. Any attempts by cyber-attackers to disrupt our services or information technology systems or the services or information technology systems of our third-party service providers, strategic partners, and other contractors or consultants, if successful, could harm our business, result in the misappropriation of funds, be expensive to remedy, and damage our reputation or brand.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain cyber insurance coverage that is intended to address data security risks, such insurance coverage may be insufficient to cover all losses or claims that may arise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR BUSINESS IS SUBJECT TO COMPLEX AND EVOLVING LAWS AND REGULATIONS REGARDING PRIVACY, DATA PROTECTION, AND OTHER MATTERS RELATING TO INFORMATION COLLECTION.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous state, federal, and foreign laws, regulations, decisions, and directives regarding privacy and the collection, storage, transmission, use, processing, disclosure, and protection of different types of personal data and personal information and other customer or other data, the scope of which is continually evolving and subject to differing interpretations. We may be subject to significant consequences, including penalties and fines, for any failure to comply with such laws, regulations, and directives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the GDPR, which is in effect across the EEA, imposes several stringent requirements for controllers and processors of personal data including, for example, imposing strict standards when obtaining consent from individuals to process their personal data, requiring robust disclosures to individuals, providing individual data rights, imposing short timelines for data breach notifications, limiting retention periods and secondary use of information, imposing certain requirements pertaining to health data as well as pseudonymized (i.e., key-coded) data, regulating cross-border transfers of personal data out of the EEA, as well as additional obligations when we contract third-party processors in connection with the processing of personal data. The GDPR provides that EEA member states may make their own further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EEA member states may result in fines of up to 4% of the total worldwide annual turnover of the preceding financial year and other administrative penalties. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/change our data processing activities, enforcement notices, assessment notices (for a compulsory audit), and/or civil claims (including class actions). Compliance with new data protection rules imposed by GDPR may be onerous and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, since 2021, we have been subject to the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g., fines up to 4% of worldwide annual turnover of the preceding financial year. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term and how data transfers to and from the UK will be regulated in the long term. These changes may lead to additional costs and increase our overall risk exposure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, &#8220;HIPAA&#8221;), imposes privacy, security, and breach notification obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining, or transmitting individually identifiable health information for or on behalf of such covered entities and their covered subcontractors. Entities that are found to be in violation of HIPAA, as the result of a breach of unsecured personal information, a complaint about privacy practices, or an audit by the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if they are required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the Federal Trade Commission (the &#8220;FTC&#8221;), violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair and/or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the California Consumer Privacy Act (the &#8220;CCPA&#8221;) went into effect in 2020 and gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information and how their personal information is used. The CCPA imposes compliance burdens on many organizations doing business in California that collect personal information about California residents. The CCPA&#8217;s definition of personal information is very broad and specifically includes biometric information. The CCPA allows for significant fines by the state attorney general, as well as a private right of action from individuals in relation to certain security breaches. The enactment of the CCPA is prompting a wave of similar legislative developments in other U.S. states and creating the potential for a patchwork of overlapping but different state laws. These developments are increasing our compliance burden and our risk, including risks of regulatory fines, litigation, and associated reputational harm. Additionally, a new California ballot initiative, the California Privacy Rights Act (the &#8220;CPRA&#8221;) recently passed in California. The CPRA will substantially expand the requirements of the CCPA and will impose additional data protection obligations on companies doing business in California. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Colorado, Connecticut, and Utah and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA or UK to the United States. For example, on July 16, 2020, the Court of Justice of the European Union (the &#8220;CJEU&#8221;) invalidated the EU-U.S. Privacy Shield Framework (&#8220;Privacy Shield&#8221;) under which personal data could be transferred from the EU to U.S. entities who had self-certified under the Privacy Shield scheme. The CJEU further noted that reliance on the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism and potential alternative to the Privacy Shield) alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. European court and regulatory decisions subsequent to the CJEU decision of July 16, 2020, have taken a restrictive approach to international data transfers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a mixture of mechanisms to transfer personal data from our EU business to the U.S. (including having previously relied on Privacy Shield) and are evaluating whether additional mechanisms will be required to establish adequate safeguards for personal data. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used and/or start taking enforcement action, we could suffer additional costs, complaints, and/or regulatory investigations or fines. Moreover, if we are unable to transfer Personal Information between and among countries and regions in which we operate, it could affect the manner in which we provide our services and could adversely affect our financial results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Israel, The Protection of Privacy Law, 5741-1981 (the &#8220;Israeli Privacy Law&#8221;) regulates the protection of privacy and personal data, along with several other specific regulations enacted thereunder and, in particular, the Privacy Protection Regulations (Data Security), 5777-2017 (together with Israeli Privacy Law, the &#8220;Israeli Privacy Law and Regulations&#8221;). Under the Israeli Privacy Law and Regulations, organizations are subject to various privacy and data protection requirements, including mandatory registration of databases with the Israeli Registrar of Databases (if certain conditions are met), executing data processing agreements with data recipients, safeguarding the collection and processing of personal data, safeguarding the transfer of personal data (which is specifically subject to the requirements of the Privacy Protection Regulations), personal data breach notification obligations, and other requirements. The Privacy Protection Authority (the &#8220;PPA&#8221;) is responsible for enforcement of the Israeli Privacy Law and Regulations and periodically publishes opinions and guidelines on privacy matters. In terms of enforcement, failure to comply with the Israeli Privacy Law and Regulations can result in PPA investigations, administrative fines or sanctions, and civil or criminal actions (civil proceedings may include statutory damages without the need to prove actual damages).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any failure, or perceived failure, by us to comply with or make effective modifications to our policies or to comply with any federal, state, or international privacy, data-retention, or data-protection-related laws, regulations, orders, or industry self-regulatory principles could result in proceedings or actions against us by governmental entities or others, a loss of customer confidence, damage to our brand and reputation, and a loss of customers, any of which could have an adverse effect on our business. In addition, various federal, state, and foreign legislative or regulatory bodies may enact new or additional laws and regulations concerning privacy, data-retention, and data-protection issues, including laws or regulations mandating disclosure to domestic or international law enforcement bodies, which could adversely impact our business or our reputation with customers. For example, some countries have adopted laws mandating that some personal information regarding customers in their country be maintained solely in their country. Having to maintain local data centers and redesign product, service, and business operations to limit personal information processing to within individual countries could increase our operating costs significantly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF WE FAIL TO SUCCESSFULLY ACQUIRE OR INTEGRATE NEW BUSINESSES, PRODUCTS, AND TECHNOLOGY, WE MAY NOT REALIZE EXPECTED BENEFITS, OR OUR BUSINESS MAY BE HARMED.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need to grow our businesses in response to changing technologies, customer demands, and competitive pressures. In some circumstances, we may decide to grow our business through the acquisition of complementary businesses, products, or technologies rather than through internal development.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying suitable acquisition candidates can be difficult, time-consuming, and costly, and we may not be able to identify suitable candidates or successfully complete identified acquisitions. In addition, completing an acquisition can divert our management and key personnel from our business operations, which could harm our business and affect our financial results. Even if we complete an acquisition, we may not be able to successfully integrate newly acquired organizations, products, technologies, or employees into our operations or may not fully realize some of the expected synergies. An acquired company may have deficiencies in product quality, regulatory marketing authorizations or certifications, or intellectual property protections, which are not detected during due diligence activities or which are unasserted at the time of acquisition. It may be difficult, expensive, and time-consuming for us to re-establish market access, regulatory compliance, or cure such deficiencies in product quality or intellectual property protection in such cases, which may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrating an acquisition can also be expensive and time-consuming and may strain our resources. In many instances, integrating a new business will also involve implementing or improving internal controls appropriate for a public company at a business that lacks them. In addition, we may be unable to retain the employees of acquired companies or the acquired company&#8217;s customers, suppliers, distributors, or other partners for a variety of reasons, including that these entities may be our competitors or may have close relationships with our competitors. Furthermore, acquired companies may have less mature or less sophisticated information systems, securities practices, or training, which may result in an increased risk of security and cybersecurity incidents when such companies are integrated. In 2020, we acquired Orpheus Medical Ltd. and its wholly owned subsidiaries (&#8220;Orpheus Medical&#8221;) to deepen and expand our integrated informatics platform. The integration of this acquisition involves complex operations across different geographic locations and new products, distribution networks, and legal jurisdictions. Therefore, we cannot assure you that we can successfully integrate this acquisition or realize the expected benefits from this acquisition. Failure to successfully integrate our acquisitions may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF WE DO NOT SUCCESSFULLY MANAGE OUR COLLABORATION ARRANGEMENTS, LICENSING ARRANGEMENTS, JOINT VENTURES, STRATEGIC ALLIANCES, OR PARTNERSHIPS WITH THIRD PARTIES, WE MAY NOT REALIZE THE EXPECTED BENEFITS FROM SUCH ALLIANCES, WHICH MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships to complement or augment our research and development, product development, training, procedure development, and marketing efforts. For example, in 2016, we entered into an agreement to form the Joint Venture. In January 2019, the Joint Venture acquired certain assets related to the da Vinci distribution business of Chindex, a subsidiary of Fosun Pharma, following which the Joint Venture began direct distribution operations for da Vinci products and services in China. There can be no assurance that we and the Joint Venture can successfully complete development of robotic-assisted, catheter-based medical devices, or that we and the Joint Venture will successfully commercialize such products. There can also be no assurance that the Joint Venture will not require additional contributions to fund its business, that the Joint Venture will become profitable, or that the expected benefits of the acquisition of certain assets of Chindex will be realized. Proposing, negotiating, and implementing collaborations, in-licensing agreements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. In addition, other companies, including those with substantially greater financial, marketing, sales, technology, or other business resources, may compete with us for these opportunities or arrangements. As a result, we may not identify, secure, or complete any such arrangements in a timely manner, on a cost-effective basis, or on otherwise favorable terms, if it all.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will realize the expected benefits from these alliances. In addition, we may not be in a position to exercise sole decision-making authority regarding any collaboration or other arrangement, which could create the potential risk of creating impasses on decisions, and our alliances may have economic or business interests that are, or that may become, inconsistent with our interests. It is possible that conflicts may arise in these relationships, such as conflicts concerning the achievement of performance milestones or the interpretation of significant terms under any agreement, such as those related to financial obligations, termination rights, or the ownership or control of intellectual property developed during the collaboration. These alliances can be difficult to manage, given the potentially different interests of the parties involved, and we could suffer delays in product development or other operational difficulties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will realize a return on our strategic investments. Further, if we acquire privately held companies, valuations of such companies are inherently complex due to the lack of readily available market data. If we determine that our investments in privately held companies have experienced a decline in value, we may be required to record impairments, which could be material and have an adverse effect on our results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These alliances may also involve significant costs and divert the focus and attention of our management and other key personnel. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, or disrupt our ordinary business activities. Such arrangements may also expose us to numerous known and unknown risks, including unique risks with respect to the economic, political, and regulatory environment of any foreign entities with whom we partner, including Fosun Pharma. Any of the foregoing may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE EXPECT GROSS PROFIT MARGINS TO VARY OVER TIME, AND CHANGES IN OUR GROSS PROFIT MARGINS COULD ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margins have fluctuated from period to period, and we expect that they will continue to fluctuate in the future. Our gross profit margins may be adversely affected by numerous factors, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in customer, geographic, or product mix, including the mix of system models sold or leased;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the portion of sales involving a trade-in of another system and the amount of trade-in credits given;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our introduction of new products, which may have lower margins than our existing products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to maintain or reduce production costs;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to our pricing strategy;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in production volume driven by demand for our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in material, labor, or other manufacturing-related costs, including the impact of foreign exchange rate fluctuations for foreign currency-denominated costs;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to U.S. and foreign trade policies, such as the enactment of tariffs on goods imported into the U.S. including, but not limited to, goods imported from Mexico where we manufacture a majority of our instruments that we sell;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inventory obsolescence, which may result from maintaining significant inventories of raw materials, components, and finished goods;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recall charges; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to offset the unfavorable impact of the factors noted above by increasing the volume of products shipped, reducing product manufacturing costs, or otherwise, our business, financial condition, or results of operations may be adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE UTILIZE DISTRIBUTORS FOR A PORTION OF OUR SALES AND SERVICE OF OUR PRODUCTS IN CERTAIN COUNTRIES, WHICH SUBJECTS US TO A NUMBER OF RISKS THAT COULD HARM OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strategic relationships with a number of key distributors for the sale and service of our products in certain countries. If these strategic relationships are terminated and not replaced, our revenues and/or ability to sell or service our products in the markets serviced by these distributors could be adversely affected. In addition, we may be named as a defendant in lawsuits against our distributors related to sales or service of our products performed by them. Refer to our risk factor titled &#8220;We are subject to litigation, investigations, and other legal proceedings relating to our products, our customers, our competitors, and government regulators that could materially adversely affect our financial condition, divert management&#8217;s attention, and harm our business.&#8221; Our distributors may affect our ability to effectively market our products in certain countries or regulatory jurisdictions if a distributor holds the regulatory authorization or certification in such countries or within such regions and causes, by action or inaction, the suspension of such marketing authorization or certification or sanctions for non-compliance. It may be difficult, expensive, and time-consuming for us to re-establish market access or regulatory compliance in such cases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE OFFER ALTERNATIVE CAPITAL ACQUISITION APPROACHES AND, AS A RESULT, WE ARE EXPOSED TO THE CREDIT RISK OF SOME OF OUR CUSTOMERS AND THE RISK OF LOSSES OF REVENUE, WHICH COULD RESULT IN MATERIAL LOSSES.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe customer financing through leasing is an important consideration for some of our customers and have experienced an increase in demand for customer financing. Lease financing arrangements have the effect of reducing cash flows at lease commencement and, instead, spread them over the life of the lease term, which increases the time taken to recover our product costs and can impact our liquidity. We may experience losses from a customer&#8217;s failure to make payments according to the contractual lease terms. Our exposure to the credit risks relating to our lease financing arrangements may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty, or other customer-specific factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have programs in place that are designed to monitor and mitigate the associated risks, there can be no assurance that such programs will be effective in reducing credit risks relating to these lease financing arrangements. If the level of credit losses we experience in the future exceeds our expectations, such losses could have a material adverse effect on our financial condition or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our leasing arrangements allow customers to cancel, return, or upgrade the systems leased prior to the end of the lease term without incurring a financial penalty. We also lease our systems to certain qualified customers where the lease payments are based on their usage of the systems. While leases and usage-based arrangements enable our customers to upgrade and get access to new technologies faster, it may also enable competitors to more easily induce customers to switch to a competitor&#8217;s system. Furthermore, depending on the timing and terms of the upgrade transaction, the amount of revenue generated on the initial and upgraded lease arrangements may not, in the aggregate, generate the same amount of revenue that a traditional sale and trade-in transaction would. Also, if customers do not perform a sufficient number of procedures on systems leased under usage-based arrangements, or return or terminate leases prematurely, it could have a material adverse effect on our business, financial condition, or result of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE EXPOSED TO CREDIT RISK AND FLUCTUATIONS IN THE MARKET VALUE OF OUR INVESTMENTS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes both domestic and international investments. The credit ratings and pricing of our investments can be negatively affected by liquidity concerns, credit deterioration, financial results, economic risk, political risk, or other factors. As a result, the value and liquidity of our cash equivalents and marketable securities could fluctuate substantially. Our other income and&#160;expense could also vary materially from expectations depending on gains or losses&#160;realized on the sale or exchange of investments, impairment charges resulting from revaluations of debt and equity&#160;securities and other investments, changes in interest rates,&#160;increases or decreases in cash balances, volatility in foreign exchange rates, and changes in the fair value of derivative instruments.&#160;Increased volatility in the financial markets and overall economic&#160;uncertainty could increase the risk that actual amounts realized on our investments may differ significantly&#160;from the fair values currently assigned to them.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Intuitive Ventures fund plans to invest in early-stage companies, which involve substantial risks and uncertainties. These risks and uncertainties include, among other things, uncertainties inherent in research and development; uncertainties regarding the ability of Intuitive Ventures to identify investment candidates; uncertainties regarding the success of Intuitive Ventures&#8217; investments; uncertainties and variables inherent in the operating and financial performance in investments made, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; future exchange and interest rates; and changes in tax and other laws, regulations, rates and policies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not realized any significant losses on our cash equivalents, marketable securities, or other investments, future fluctuations in their value could have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE ONGOING ARMED CONFLICT BETWEEN RUSSIA AND UKRAINE COULD ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russian military forces launched a military action in Ukraine, and sustained conflict and disruption in the region has continued. The length, impact, and outcome of this ongoing military conflict is highly unpredictable and could lead to significant market and other disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, supply chain interruptions, political and social instability, trade disputes or trade barriers, changes in consumer or purchaser preferences, as well as an increase in cyberattacks and espionage.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia&#8217;s military actions against Ukraine have led to substantial expansion of sanction programs imposed by the United States, the European Union, the United Kingdom, Canada, Switzerland, Japan, and other countries against Russia, Belarus, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crimea Region of Ukraine, the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic, including, among others:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">blocking sanctions against some of the largest state-owned and private Russian financial institutions (and their subsequent removal from the Society for Worldwide Interbank Financial Telecommunication payment system) and certain Russian businesses, some of which have significant financial and trade ties to the European Union;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">blocking sanctions against Russian and Belarusian individuals, including the Russian President, other politicians, and those with government connections or involved in Russian military activities; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">blocking of Russia&#8217;s foreign currency reserves as well as expansion of sectoral sanctions and export and trade restrictions, limitations on investments and access to capital markets, and bans on various Russian imports.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In retaliation against new international sanctions and as part of measures to stabilize and support the volatile Russian financial and currency markets, the Russian authorities also imposed significant currency control measures aimed at restricting the outflow of foreign currency and capital from Russia, imposed various restrictions on transacting with non-Russian parties, banned exports of various products, and imposed other economic and financial restrictions. The situation is rapidly evolving, and additional sanctions by Russia on the one hand, and by the other countries on the other hand, could adversely affect the global economy, financial markets, energy supply and prices, certain critical materials and metals, supply chains, and global logistics and could adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively monitoring the situation in Ukraine and Russia and assessing its impact on our business, including our business partners and customers. To date, we have not experienced any material interruptions in our infrastructure, supplies, technology systems, or networks needed to support our operations. We have no way to predict the progress or outcome of the military conflict in Ukraine or its impacts in Ukraine, Russia, Belarus, Europe, or the U.S. The extent and duration of the military action, sanctions, other consequences, such as Russia imposing restrictions on transactions or banning the export of energy products, including natural gas, and the resulting market disruptions could be significant and could potentially have substantial impact on the global economy and our business for an unknown period of time. Impacts to our business may include, but are not limited to, procedures performed, demand for our products, and ability to spend on capital equipment and healthcare in general. Any such disruption may also magnify the impact of other risks described.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE MAY ENCOUNTER MANUFACTURING PROBLEMS OR DELAYS THAT COULD RESULT IN LOST REVENUE.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing our products is a complex process. We (or our critical suppliers) may encounter difficulties in scaling up or maintaining production of our products, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems involving production yields;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control and assurance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">component supply shortages;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import or export restrictions on components, materials, or technology;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages of qualified personnel; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with state, federal, and foreign regulations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If demand for our products exceeds our manufacturing capacity, we could develop a substantial backlog of customer orders. If we are unable to develop or maintain larger-scale manufacturing capabilities or build new manufacturing capabilities or facilities on schedule or within budget, our ability to generate revenue and maintain profit margins as expected will be limited and our reputation in the marketplace could be damaged, all of which may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISRUPTIONS AT THE FDA AND OTHER GOVERNMENT AGENCIES OR NOTIFIED BODIES CAUSED BY FUNDING SHORTAGES OR GLOBAL HEALTH CONCERNS COULD HINDER THEIR ABILITY TO HIRE, RETAIN, OR DEPLOY KEY LEADERSHIP AND OTHER PERSONNEL, OR OTHERWISE PREVENT PRODUCTS FROM BEING DEVELOPED, CLEARED, CERTIFIED, APPROVED, OR COMMERCIALIZED IN A TIMELY MANNER OR AT ALL, WHICH MAY ADVERSELY AFFECT OUR BUSINESS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals, health systems, and physicians depend on a number of government agencies and services to effectively deliver healthcare to their patients. A prolonged government shutdown could impact inspections, regulatory review and certifications, grants, or approvals or could cause other situations that could impede their ability to effectively deliver healthcare, including attempts to reduce payments and other reimbursements to hospitals by federal healthcare programs. These situations could adversely affect our customers&#8217; ability to perform procedures with our devices and/or their decisions to purchase additional products from us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the ability of the FDA, foreign authorities, and notified bodies to review and clear, approve, or certify new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies or notified bodies, including a prolonged government shutdown, may cause significant regulatory delays and, therefore, delay our efforts to seek clearances, approvals, or certifications from the FDA, foreign authorities, and notified bodies and adversely affect business travel and import and export of products, all of which could have a material adverse effect on our business, financial condition, or results of operations. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA, other regulatory authorities, or notified bodies from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA, other regulatory authorities, or notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in the EU, notified bodies must be officially designated to certify products and services in accordance with the EU Medical Devices Regulation. While several notified bodies have been designated, the COVID-19 pandemic has significantly slowed down their designation process, and the current designated notified bodies are facing a large number of requests with the new regulation, as a consequence of which review times have lengthened. Unless additional transitional measures are implemented, this situation could impact our ability to grow our business in the EU and EEA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE SUBJECT TO RISKS ASSOCIATED WITH REAL ESTATE CONSTRUCTION AND DEVELOPMENT.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our facilities is subject to risks relating to our ability to complete our projects on schedule or within budget. Factors that may result in a development project being prevented or delayed from completion or exceeding budget include, but are not limited to (i) construction delays due to labor challenges, poor weather, defects, or cost overruns, which may increase project development costs; (ii) cost escalations associated with materials, including changes in availability, proximity, and cost of materials, such as steel, cement, concrete, aggregates, oil, fuel, and other construction materials, including changes in U.S. trade policies and retaliatory responses from other countries, changes in foreign exchange rates, as well as cost escalations associated with subcontractors and labor; (iii) the discovery of hazardous or toxic substances, or other environmental, culturally-sensitive, or related issues; (iv) an inability to obtain, or a significant delay in obtaining, zoning, construction, occupancy, and other required governmental permits and authorizations; (v) difficulty in complying with local, city, county, and state rules and regulations regarding permitting, zoning, subdivision, utilities, and water quality, as well as federal rules and regulations regarding air and water quality and protection of endangered species and their habitats; (vi) insufficient infrastructure capacity or availability (e.g., water, sewer, and roads) to serve the needs of our projects; (vii) failure to achieve or sustain anticipated occupancy levels; (viii) condemnation of all or parts of development or operating properties, which could adversely affect the value or viability of such projects; and (ix) natural disasters and other extreme weather conditions, including, but not limited to, hurricanes, tornadoes, earthquakes, wildfires, or flooding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTINUED CONSOLIDATION IN THE HEALTHCARE INDUSTRY COULD HAVE AN ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry has been consolidating, and organizations continue to consolidate purchasing decisions for many of our healthcare provider customers. Numerous initiatives and reforms by legislators, regulators, and third-party payers to curb the rising cost of healthcare have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products. As the healthcare industry consolidates, competition to provide products and services is expected to continue to intensify, resulting in pricing pressures and decreased average selling prices. We expect that market demand, government regulation, third-party payor coverage and reimbursement policies, government contracting requirements, and societal pressures will continue to change the worldwide healthcare industry, resulting in further consolidation, which may exert further downward pressure on prices of our products and services and may have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLIMATE CHANGE AND NATURAL DISASTERS OR OTHER EVENTS BEYOND OUR CONTROL COULD DISRUPT OUR BUSINESS AND RESULT IN LOSS OF REVENUE OR HIGHER EXPENSES.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters, terrorist activities, and other events beyond our control including, but not limited to, internet security threats and violence motivated by political or social causes, could adversely affect our business, financial condition, or results of operations. Moreover, global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. The impacts of climate change may include physical risks (such as frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs, transition risks, shifts in market trends, and other adverse effects. Such impacts may disrupt parties in our supply chain, our customers, and our operations. For example, the March 2011 earthquake and tsunami in Japan, and their aftermath, created economic uncertainty and disrupted economic activities in Japan, including a reduction in hospital spending.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physical risks associated with climate change are subject to increasing societal, regulatory, and political focus in the U.S. and globally. Shifts in weather patterns caused by climate change are expected to increase the frequency, severity, or duration of certain adverse weather conditions and natural disasters, such as hurricanes, tornadoes, earthquakes, wildfires, droughts, extreme temperatures, or flooding, which could cause more significant business and supply chain interruptions, damage to our products and facilities as well as the infrastructure of hospitals, medical care facilities, and other customers, reduced workforce availability, increased costs of raw materials and components, increased liabilities, and decreased revenues than what we have experienced in the past from such events. The geographic location of our California headquarters and many of our manufacturing facilities, as well as the facilities of certain of our key suppliers and service providers, subject them to earthquake, drought, and wildfire risks. If a major earthquake, wildfire, or other natural disaster were to damage our facilities or the facilities of our suppliers and service providers, or impact the ability of our employees or the employees of our suppliers and service providers to travel to their workplace, we may experience potential impacts ranging from production and shipping delays to lost revenues and increased costs, which could harm our business. Moreover, periods with increased drought and annual periods of wildfire danger may increase the probability of planned power outages in the communities where we work and live. For example, in October 2019, Pacific Gas and Electric, the public electric utility in the Northern California region, used planned power outages to avoid and contain wildfires sparked during strong wind events by downed power lines or equipment failure. If prolonged or frequent, such planned blackouts could impact our operations and the operations of our suppliers and service providers located in the Northern California region. While this danger has a low assessed risk of disrupting normal business operations, it has a potential impact on our employees&#8217; abilities to commute to work or to work from home and stay connected effectively. We do not have multiple-site capacity for all of our operations in the event of a business disruption, and we are predominantly self-insured and may not be able to sufficiently cover losses or additional expenses that we may sustain. Furthermore, the impacts of global climate change on water resources may result in water scarcity, which could impact our ability to access sufficient quantities of water in certain locations and result in increased costs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the increasing concern over climate change has resulted and may continue to result in more legal and regulatory requirements designed to mitigate the effects of climate change on the environment, including regulating greenhouse gas emissions, alternative energy policies, and sustainability initiatives. If such laws or regulations are more stringent than current legal or regulatory requirements, we may experience increased compliance burdens and costs to meet the regulatory obligations. Changes in requirements may adversely affect raw material sourcing from suppliers, our manufacturing operations and those of our suppliers, and the distribution of our products. Further, there may be increasing scrutiny and changing expectations from the market and other stakeholders with respect to Environmental, Social, and Governance (ESG) practices. Any such regulatory changes or increased market expectations could also have a significant effect on our operating and financial decisions, including those involving capital expenditures to reduce emissions and comply with other regulatory requirements or stakeholder expectations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN OUR EFFECTIVE TAX RATE MAY ADVERSELY AFFECT OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxes in the U.S. and other jurisdictions around the world. Tax rates in these jurisdictions may be subject to significant change due to economic and/or political conditions. A number of other factors may also impact our future effective tax rate, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the jurisdictions in which profits are determined to be earned and taxed;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resolution of issues arising from tax audits with various tax authorities;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the valuation of our deferred tax assets and liabilities;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in expenses not deductible for tax purposes, including write-offs of acquired intangibles and impairment of goodwill in connection with acquisitions;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the availability of tax credits, tax holidays, and tax deductions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in share-based compensation; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax laws or the interpretation of such tax laws and changes in generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict what changes to the tax laws of the U.S. and other jurisdictions may be proposed or enacted in the future or what effect such changes would have on our business. Any significant increase in our future effective tax rate could have a material adverse impact on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE USE ESTIMATES, MAKE JUDGMENTS, AND APPLY CERTAIN METHODS IN DETERMINING OUR FINANCIAL RESULTS AND IN MEASURING THE PROGRESS OF OUR BUSINESS. AS THESE ESTIMATES, JUDGMENTS, AND METHODS CHANGE, OUR RESULTS OF OPERATIONS AND OUR ASSESSMENT OF THE PROGRESS OF OUR BUSINESS COULD VARY.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods, estimates, and judgments we use in applying our accounting policies have a significant impact on our results of operations. Such methods, estimates, and judgments are, by their nature, subject to substantial risks, uncertainties, and assumptions, and factors may arise over time that may lead us to change our methods, estimates, and judgments. Changes in any of our assumptions may adversely affect our reported financial results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize methods for determining surgical market sizes, the number and type (cancerous or benign) of certain procedures performed, and the installed base of our systems that involve estimates and judgments, which are, by their nature, subject to substantial risks, uncertainties, and assumptions. Our estimates of surgical market sizes, the number and type of procedures performed, or the installed base of our systems do not have an impact on our results of operations but are used to estimate the progress of our business. Estimates and judgments for determining surgical market sizes, the number and type of procedures, and the installed base of our systems and the accuracy of these estimates may be impacted over time with changes in treatment modalities, hospital reporting behavior, system internet connectivity, distributor reporting behavior, increases in procedures per field employee, and other factors. In addition, from time to time, we may change the method for determining market sizes, the number and type of procedures, and the installed base of our systems, causing variation in our reporting.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_67"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR REGULATORY ENVIRONMENT</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPLYING WITH FDA AND FOREIGN REGULATIONS IS A COMPLEX PROCESS, AND OUR FAILURE TO FULLY COMPLY COULD SUBJECT US TO SIGNIFICANT ENFORCEMENT ACTIONS.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products are commercially distributed, numerous quality and post-market regulatory requirements apply, including the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued compliance with the FDA&#8217;s QSR, which requires manufacturers to follow design, testing, control, documentation, and other quality assurance procedures during the development and manufacturing process;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s general prohibition against false or misleading statements in the labeling or promotion of products for unapproved or &#8220;off-label&#8221; uses;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stringent complaint reporting and Medical Device Reporting regulations, which require that manufacturers keep detailed records of investigations or complaints against their devices and report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate use of the corrective and preventive actions process to identify and correct or prevent significant, systemic failures of products or processes or in trends which suggest the same; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reporting of corrections and removals, which requires that manufacturers report to the FDA recalls and field corrective actions taken to reduce a risk to health or to remedy a violation of the FFDCA that may pose a risk to health.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to inspection and marketing surveillance by the FDA to determine our compliance with regulatory requirements. If the FDA finds that we have failed to comply, it can institute a wide variety of enforcement actions, ranging from inspectional observations (as set forth on FDA Form 483) to a public Warning Letter to more severe civil and criminal sanctions, including the seizure of our products and equipment or ban on the import or export of our products. The FDA has, in the past, issued and could, in the future, issue Warning Letters or other adverse communications to us. If we fail to satisfy or remediate the matters discussed in any such Warning Letters or communications, the FDA could take further enforcement actions, including prohibiting the sale or marketing of the affected product. Our failure to comply with applicable requirements could lead to an enforcement action that may have an adverse effect on our financial condition or results of operations. The receipt of a Warning Letter could place certain limits on the ability to obtain FDA-issued Certificates to Foreign Government (&#8220;CFGs&#8221;) used for new and re-registration of products in certain other countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also strictly regulates labeling, advertising, promotion, and other activities relating to the marketing of our products. Medical devices may be promoted only for their cleared or approved indications and in accordance with the provisions of the cleared or approved label. It is possible that federal or state enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under a variety of statutory authorities, including under the FFDCA, as well as laws prohibiting false claims for reimbursement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any modification or change of medical devices cleared for the market requires the manufacturer to make a determination whether the change is significant enough to require new 510(k) clearance. We have created labeling, advertising, and user training for the da Vinci Surgical System to describe specific surgical procedures that we believe are fully within the scope of our existing 510(k) indications for use stated in our 510(k) clearances. Although we have relied on expert in-house and external staff, consultants, and advisors, some of whom were formerly employed by the FDA and are familiar with the FDA perspective, we cannot provide assurance that the FDA would agree that all such specific procedures are within the scope of the existing general clearance or that we have compiled adequate information to support the safety and efficacy of using the da Vinci Surgical System for all such specific procedures. From time to time, we modify our products, including the hardware and software in the da Vinci Surgical System, after we obtain 510(k) clearance from the FDA for the devices in ways that we do not believe require new 510(k) clearance. We cannot provide assurance that the FDA would agree in all cases with our determinations not to seek new 510(k) clearance for any of these changes. If the FDA disagrees with our assessments that a new 510(k) clearance was not required prior to commercializing the devices with these changes or modifications, then the FDA could impose enforcement sanctions and/or require us to obtain 510(k) clearance or other FDA marketing authorization for any modification to our products. We may be prohibited from marketing the modified device until such marketing authorization is granted.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a wholly owned manufacturing facility located in Mexicali, Mexico, which manufactures reusable and disposable surgical instruments. This facility is registered with the FDA as well as with Mexican authorities. The facility is operated under U.S. and international quality system regulations, including those applicable to Canada, the EU, and Japan, among others. Our wholly owned manufacturing facility in Mexicali, Mexico has an FDA Establishment Registration but has not been inspected by the FDA to date. If the FDA were to identify non-conformances in our product documentation or quality system compliance, it could hold indefinitely the importation of instruments at the border, which would deprive us of the ability to sell and supply the majority of our customers until the FDA requirements have been satisfied. Similar supply disruptions could occur if key suppliers outside of the U.S. were to encounter non-conformances with their documentation or quality system compliance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCTS ARE SUBJECT TO A LENGTHY AND UNCERTAIN DOMESTIC REGULATORY REVIEW PROCESS. IF WE DO NOT OBTAIN AND MAINTAIN THE NECESSARY DOMESTIC REGULATORY AUTHORIZATIONS, WE WILL NOT BE ABLE TO SELL OUR PRODUCTS IN THE U.S.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are subject to extensive regulation in the U.S. by the FDA. The FDA regulates the development and clinical testing, manufacturing, labeling, storage, record keeping, promotion, sales, distribution, and post-market support and medical device reporting in the U.S. to ensure that&#160;medical products distributed domestically are safe and effective for their intended uses. In order for us to market products for use in the U.S., we generally must first obtain clearance from the FDA pursuant to Section&#160;510(k) of the FFDCA or approval of the product through the premarket approval (&#8220;PMA&#8221;) pathway. Clearance under Section&#160;510(k) requires demonstration that a new device is substantially equivalent to another device with 510(k) clearance or grandfathered (&#8220;pre-amendment&#8221;) status and for which a PMA is not required. If we develop products in the future that are not considered to be substantially equivalent to a device with 510(k) clearance or grandfathered status, we may be required to obtain marketing authorization through the more burdensome PMA process or alternatively through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification process, which is a path to market for novel devices that are low to moderate risk and for which a predicate device is not available. A PMA is typically a much more complex, lengthy, and burdensome application than a 510(k) or a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification request. To support a PMA, the FDA would likely require that we conduct one or more clinical studies to demonstrate that the device is safe and effective for its intended uses. In some cases, such studies may also be required to support a 510(k) application or a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification request. The FDA may not act favorably or quickly in its review of any marketing application submissions, or we may encounter significant difficulties and costs in our efforts to obtain marketing authorization from the FDA, either of which could delay or preclude the sale of new products in the U.S. In addition, the FDA may place significant limitations upon the intended use of our products as a condition of granting marketing authorization. Product applications can also be denied or withdrawn due to failure to comply with regulatory requirements or the occurrence of unforeseen problems following marketing authorization. Any delays or failure to obtain FDA marketing authorization for new or modified products that we develop, any limitations imposed by the FDA on new product use, or the costs of obtaining FDA clearance or approvals could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA or other regulatory agencies may change their policies, adopt additional regulations, revise existing regulations, or take other actions that may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently approved or cleared products on a timely basis. We may be found non-compliant as a result </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of future changes in, or interpretations of, regulations by the FDA or other regulatory agencies. For example, on February 23, 2022, the FDA issued a proposed rule to amend the QSR, which establishes current good manufacturing practice requirements for medical device manufacturers, to align more closely with the International Organization for Standardization (&#8220;ISO&#8221;) standards. This proposal has not yet been finalized or adopted. Accordingly, it is unclear the extent to which this or any other proposals, if adopted, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise create competition that may negatively affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in September 2019, the FDA issued revised guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical device, a company must, among other things, apply for and obtain IRB approval of the proposed investigation. In addition, if the clinical study involves a &#8220;significant risk&#8221; (as defined by the FDA) to human health, the sponsor of the investigation must also submit and obtain FDA approval of an IDE application. Many of our products to date have been or would be considered significant risk devices requiring IDE approval prior to investigational use. We may not be able to obtain FDA and/or IRB approval to undertake clinical trials in the U.S. for any new devices that we intend to market in the U.S. in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain such approvals, we may not be able to conduct studies that comply with the IDE and other regulations governing clinical investigations or the data from any such trials may not support clearance or approval of the investigational device. Clinical testing is difficult to design and implement, can take many years, can be expensive, and carries uncertain outcomes and, if we fail to complete our planned or ongoing clinical trials or if such clinical trials produce negative or inconclusive results, we may be delayed or prevented from obtaining regulatory clearances or approvals to commercialize our products for new or expanded indications. Additionally, we may experience delays in our ongoing clinical trials for any number of reasons, which could adversely affect the costs, timing, or successful completion of our clinical trials. Moreover, the disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting, or completing our planned and ongoing clinical trials. If we fail to complete our planned and ongoing clinical trials or if such clinical trials produce negative or inconclusive results, we may be delayed or prevented from obtaining regulatory clearances or approvals to commercialize our products for new or expanded indications, which may limit the market for our products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain such approvals or to comply with such regulations could have a material adverse effect on our business, financial condition, or results of operations. Certainty that clinical trials will meet desired endpoints, produce meaningful or useful data, and be free of unexpected adverse effects or that the FDA will accept the validity of foreign clinical study data cannot be assured, and such uncertainty could preclude or delay market clearance or authorizations resulting in significant financial costs and reduced revenue.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCTS MAY CAUSE OR CONTRIBUTE TO ADVERSE MEDICAL EVENTS OR BE SUBJECT TO FAILURES OR MALFUNCTIONS THAT WE ARE REQUIRED TO REPORT TO THE FDA AND FOREIGN REGULATORY AUTHORITIES AND, IF WE FAIL TO DO SO, WE WOULD BE SUBJECT TO SANCTIONS THAT COULD HARM OUR REPUTATION, BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA and foreign regulatory authorities when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or foreign regulatory authorities could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, approval, or certification, seizure of our products or delay in clearance, approval, or certification of future products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in the design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government&#8209;mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects, or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA or foreign regulatory authorities may require, or we may decide, that we will need to obtain new clearances, approvals, or certifications for the device before we may market or distribute the corrected device. Seeking such clearances, approvals, or certifications may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement actions, including FDA or foreign regulatory authorities warning letters, product seizure, injunctions, administrative penalties, or civil or criminal fines.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA or foreign regulatory authorities. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA or foreign regulatory authorities. If the FDA or foreign regulatory authorities disagree with our determinations, it could require us to report those actions as recalls, and we may be subject to enforcement actions. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us, and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF OUR MANUFACTURING FACILITIES DO NOT CONTINUE TO MEET FEDERAL, STATE, OR OTHER MANUFACTURING STANDARDS, WE MAY BE REQUIRED TO TEMPORARILY CEASE ALL OR PART OF OUR MANUFACTURING OPERATIONS, IMPORT/EXPORT OF OUR PRODUCTS, AND/OR RECALL SOME PRODUCTS, WHICH WOULD RESULT IN SIGNIFICANT PRODUCT DELIVERY DELAYS AND LOST REVENUE.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities are subject to periodic inspection by regulatory authorities and notified bodies, and our operations will continue to be regulated and inspected by the FDA and other regulatory agencies and notified bodies for compliance with Good Manufacturing Practice requirements contained in the QSR and other regulatory requirements. We are also required to comply with ISO quality system standards as well as EU legislation and norms in order to produce products for sale in the EU. In addition, many countries, such as Canada and Japan, have very specific additional regulatory requirements for quality assurance and manufacturing. If we fail to continue to comply with Good Manufacturing Practice requirements, as well as ISO or other regulatory standards, we may be required to cease all or part of our operations until we comply with these regulations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to be subject to FDA and certain other inspections by other regulatory authorities and notified bodies at any time. Maintaining such compliance is difficult and costly. We cannot be certain that our facilities will be found to comply with Good Manufacturing Practice requirements or ISO standards and other regulatory requirements in future inspections and audits by regulatory authorities and notified bodies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently participating in the Medical Device Single Audit Program (&#8220;MDSAP&#8221;), which allows an MDSAP-recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that evaluates our quality system to assess compliance with the requirements of multiple regulatory jurisdictions, including the U.S., Japan, Brazil, Australia, and Canada. The information collected in an MDSAP audit is shared and reviewed amongst all the regulatory authorities participating in the MDSAP, who may or may not determine that additional information or auditing is required.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Sunnyvale, California facility is licensed by the State of California to manufacture medical devices. We have been subject to periodic inspections by the California Department of Health Services Food and Drug Branch and, if we are unable to maintain this license following any future inspections, we will be unable to manufacture or ship some products, which would have a material adverse effect on our results of operations. In addition, both our Sunnyvale, California and Mexicali, Mexico facilities are subject to periodic inspections by other regulatory bodies, including third-party auditors on behalf of national regulatory authorities. Compliance with multiple regulatory standards is complex, difficult, and costly to maintain, and material deficiencies could result in significant limitations on our ability to manufacture, transport, and sell our products in one or more countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCTS ARE SUBJECT TO INTERNATIONAL REGULATORY PROCESSES AND APPROVAL OR CERTIFICATION REQUIREMENTS. IF WE DO NOT OBTAIN AND MAINTAIN THE NECESSARY INTERNATIONAL REGULATORY APPROVALS OR CERTIFICATIONS, WE WILL NOT BE ABLE TO SELL OUR PRODUCTS IN OTHER COUNTRIES.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be able to sell our products in other countries, we must obtain regulatory approvals or certifications and comply with the regulations of those countries, which may differ substantially from those of the U.S. These regulations, including the requirements for approvals or certifications and the time required for regulatory review, vary from country to country. Obtaining and maintaining foreign regulatory approvals or certifications is complex, and the time to obtain clearances or certifications in other countries varies; therefore, we cannot be certain that we will receive regulatory approvals or certifications in any other country in which we plan to market our products or obtain such approvals or certifications on a favorable schedule. If we fail to obtain or maintain regulatory approval or certification in any other country in which we plan to market our products, our ability to generate revenue will be harmed. In particular, if the FDA refuses to provide CFGs, our ability to register products or renew such registrations may be delayed or denied.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, one of the most significant moving targets related to the regulatory landscape is in the EU; more specifically, the regulation of medical devices has recently evolved. The EU Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive, became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to the EU Medical Devices Directive prior to May 26, 2021, may generally continue to be made available on the market or put into service until May 26, 2025, provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. However, since May 26, 2021, manufacturers must already comply with a number of new, or reinforced, requirements set forth in the EU Medical Devices Regulation, including registration of economic operators and of devices, post-market surveillance, market surveillance, and vigilance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the transitional provisions, in order to sell our products in EU member states, our products must comply with the general safety and performance requirements of the EU Medical Devices Regulation. Compliance with these requirements is a prerequisite to be able to affix the CE mark to our products, without which they cannot be sold or marketed in the EU. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation, including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. It is the responsibility of the Person Responsible for Regulatory Compliance (&#8220;PRRC&#8221;) to ensure such requirements are fulfilled and in place in the company. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients or the safety and health of users and, where applicable, other persons, provided that any risks that may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance requirements, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification and may include a technical documentation assessment and an onsite audit. Except for low-risk medical devices (Class I), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts that relate to sterility, metrology, or reuse aspects), a conformity assessment procedure requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design, and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements and we have the organizational structure to support it (i.e., PRRC), the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU or any countries recognizing the CE mark. The aforementioned EU rules are generally applicable in the EEA.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 1999, further to their certification by our notified body, Presafe, we affixed the CE mark to our da Vinci Surgical System and EndoWrist instruments, attesting compliance with the former EU Medical Devices Directive, and we have maintained these certifications continuously since that time. Subsequent products and accessories have also received certifications by our notified body in accordance with the former EU Medical Devices Directive. Where required, we are maintaining our certificates granted under the former EU Medical Devices Directive and have either gained, or are working towards, certification under the EU Medical Devices Regulation for all medical devices that we intend to continue to market in the EU and EEA. Should we not gain such certification by the end of the validity of our certificates granted under the former EU Medical Devices Directive, which may not exceed the transitional period currently set forth in the EU Medical Devices Regulation of May 26, 2024, this would prevent us from selling our products in the EU and EEA. However, under recently proposed draft legislation issued by the European Commission, this date could be extended to December 2027 for higher classification devices (Class III and certain Class IIb implantable devices) and to December 2028 for medium- and lower-risk devices (for the other Class IIb devices, Class IIa devices, and some Class I devices).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Switzerland, which is the country from which we import our products into the EU and where our EU regulatory team is based, has not yet entered into a Mutual Recognition Agreement with the EU that covers the EU Medical Device Regulation and allows medical devices to move freely between Switzerland and the EU. Therefore, for future needs, we will adjust the manner in which we bring our products into the EU market. Any such adjustments could cause temporary disruptions in and have adverse financial implications to our business in Europe.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we received approvals from the Japanese Ministry of Health, Labor and Welfare for&#160;our da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S, Si, Xi, X, and SP Surgical Systems and various associated instruments and accessories for use in certain da Vinci procedures.&#160;We may seek additional approvals for other products and/or indications; however, there can be no assurance that such approvals will be granted. In addition, because not all of our instruments have received product approvals and reimbursement is an additional process to generate market acceptance, it is possible that procedures will be adopted slowly or not at all. Sales of our products depend, in part, on the extent to which the costs of our products are reimbursed by governmental health administration authorities. There are multiple pathways to obtain reimbursement for procedures including those that require in-country clinical data and which are considered for reimbursed status in April of even-numbered years. If we are not successful in obtaining the necessary reimbursement approvals or obtaining approvals for future products and procedures, then the demand for our products could be limited. These limitations could eliminate a significant market opportunity for our products in Japan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital sales in China are subject to importation authorizations and purchasing tender processes. In October 2018, the China National Health Commission published on its official website the quota for major medical equipment to be imported and sold in China through 2020. After an adjustment notice was published in the third quarter of 2020 (ref. NHC Financial Notice [2020] 315), the government will allow for the total sale of 225 new Endoscopic Surgical Instrument Control Systems (surgical robots) into China, which could include da Vinci Surgical Systems as well as surgical systems introduced by others. Future system sales and our ability to grow future procedure volumes are dependent on the completion of these purchasing tender authorizations. The timing and magnitude of these future authorizations, which may determine our system placements in future years, is not certain, and we expect to continue to experience variability in the timing of capital sales in China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN HEALTHCARE LEGISLATION AND POLICY MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the ACA was enacted, which made changes that have impacted and are expected to significantly impact the pharmaceutical and medical device industries.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA contained a number of provisions designed to generate the revenues necessary to fund health insurance coverage expansions among other things. This included a number of Medicare payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare services through bundled payment models and appropriated funding for comparative effectiveness research.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive branch, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included an aggregate reduction in Medicare payments, which went into effect on April 1, 2013, and will remain in effect through 2031, unless additional Congressional action is taken, with the exception of a temporary suspension due to the COVID-19 pandemic from May 1, 2020, through March 31, 2022. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers. MACRA repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 and are based on various performance measures and physicians&#8217; participation in alternative payment models, such as accountable care organizations. Individual states in the U.S. have also become increasingly aggressive in passing legislation and implementing regulations designed to control product pricing, including price or patient reimbursement constraints and discounts, and require marketing cost disclosure and transparency measures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect additional state and federal healthcare reform measures to be adopted in the future that could have a material adverse effect on our industry generally and on our customers. Any changes to, or uncertainty with respect to, future reimbursement rates or changes in hospital admission rates could impact our customers&#8217; demand for our products and services, which, in turn, could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the federal, state, and local governments, Medicare, Medicaid, managed-care organizations, and foreign governments have, in the past, considered, are currently considering, and may, in the future, consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect both private and public </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement for healthcare services. Future significant changes in the healthcare systems in the U.S. or other countries, including retroactive and prospective rate and coverage criteria changes, competitive bidding or tender processes for certain products and services, and other changes intended to reduce expenditures along with uncertainty about whether and how changes may be implemented, could have a negative impact on the demand for our products. We are unable to predict whether other healthcare policies, including policies stemming from legislation or regulations affecting our business may be proposed or enacted in the future, what effect such policies would have on our business, or what effect ongoing uncertainty about these matters will have on the purchasing decisions of our customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in December 2021, the EU Regulation No. 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;), amending Directive 2011/24/EU, was adopted. This regulation, which entered into force in January 2022, intends to boost cooperation among EU member states in assessing health technologies, including certain high-risk medical devices, and provides the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical, etc.) aspects of health technology and making decisions on pricing and reimbursement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WE ARE SUBJECT TO FEDERAL, STATE, AND FOREIGN LAWS GOVERNING OUR BUSINESS PRACTICES, WHICH, IF VIOLATED, COULD RESULT IN SUBSTANTIAL PENALTIES. ADDITIONALLY, CHALLENGES TO, OR INVESTIGATION INTO, OUR PRACTICES COULD CAUSE ADVERSE PUBLICITY AND BE COSTLY TO RESPOND TO AND, THUS, COULD HARM OUR BUSINESS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dodd-Frank Wall Street Reform and Consumer Protection Act requires us to track and disclose the source of any tantalum, tin, gold, and tungsten used in manufacturing that may originate in the Democratic Republic of the Congo or adjoining regions (so called &#8220;conflict minerals&#8221;). These metals are central to the technology industry and are present in some of our products as component parts. In most cases, no acceptable alternative material exists that has the necessary properties that our products require. Because it is not possible to determine the source of the metals by analysis, we must obtain a good faith description of the source of the intermediate components and raw materials from parties in our supply chain. The components that incorporate those metals may originate from many sources, and we purchase fabricated products from manufacturers who may have a long and difficult-to-trace supply chain. As the spot price of these materials varies, producers of the metal intermediates can be expected to change the mix of sources used. Accordingly, components and assemblies we buy may have a mix of sources as their origin. We are required to carry out a diligent effort to determine and disclose the source of these materials. There can be no assurance that we can obtain this information accurately or reliably, or at all, from intermediate producers who may be unwilling or unable to provide this information or further identify their sources of supply or to notify us if these sources change. In addition, these metals are subject to price fluctuations and shortages that can affect our ability to obtain the manufactured materials that we rely on at favorable terms or from consistent sources. These changes could have an adverse impact on our ability to manufacture and market our devices and products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we conduct our business. The healthcare laws and regulations that may affect our ability to operate include the federal Anti-Kickback Statute, which prohibits, among other things, payments or other remuneration that could be considered to induce hospitals, physicians, or other potential purchasers of our products either to refer patients or to purchase, lease, order, or arrange for or recommend the purchase, lease, or order of healthcare products or services for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid and any other third-party payor programs. Further, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Similar laws must be complied with in foreign jurisdiction.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other federal healthcare programs that are false or fraudulent. Although we do not submit claims directly to government payors, manufacturers can be held liable under the federal false claim act if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, which created additional federal criminal statutes prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws may affect our sales, marketing, and other promotional activities by limiting the kinds of financial arrangements that we may have with hospitals, physicians, or other potential purchasers of our products. They particularly impact how we structure our sales offerings, including discount practices, customer support, speaker, education, and training programs, physician consulting, and other service arrangements. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances. Violating anti-kickback laws and false claims laws can result in civil and criminal fines and penalties, which can be substantial and include monetary damages and penalties, imprisonment, and exclusion from government healthcare programs for non-compliance. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to defend and, thus, could harm our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physicians Payments Sunshine Act imposes reporting and disclosure requirements on certain device manufacturers for any &#8220;transfer of value&#8221; made or distributed to physicians (including family members), as defined by statute, certain non-physician practitioners, including physician assistants and nurse practitioners, and teaching hospitals. Such information must be made publicly available in a searchable format. In addition, device manufacturers are required to report and disclose any ownership or investment interests held by physicians and their immediate family members, as well as any transfers of value made to such physician owners and investors, during the preceding calendar year. Similar requirements apply in foreign jurisdictions. Failure to submit required information may result in civil monetary penalties for all payments, transfers of value, or ownership or investment interests not reported in an annual submission. Device manufacturers are required to submit reports to CMS by the 90th day of each calendar year.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have similar laws and regulations, such as anti-kickback and false claims laws, which may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Certain states mandate implementation of commercial compliance programs to ensure compliance with these laws, impose restrictions on device manufacturer marketing practices, and/or require the tracking and reporting of gifts, compensation, and other remuneration to physicians or marketing expenditures and pricing information. The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may be found out of compliance with one or more of the requirements, subjecting us to significant civil monetary penalties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with complex foreign and U.S. laws and regulations that apply to our OUS operations increases our cost of doing business in foreign jurisdictions and could expose us or our employees to fines and penalties in the U.S. and/or abroad. These numerous, and sometimes conflicting, laws and regulations include U.S. laws, such as the FCPA, and similar laws in other countries, such as the U.K. Bribery Act of 2010. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business, and damage to our reputation. Although we have implemented policies and procedures designed to ensure compliance with these laws, there can be no assurance that our employees, contractors, or agents will not violate our policies.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to certain antitrust and competition laws in the jurisdictions in which we conduct our business, in particular the U.S. and the EU. These laws prohibit, among other things, anticompetitive agreements and practices. If any of our commercial agreements or practices are found to violate or infringe such laws, we may be subject to civil and other penalties. We may also be subject to third-party claims for damages. Further, agreements that infringe upon these antitrust and competition laws may be void and unenforceable, in whole or in part, or require modification in order to be lawful and enforceable. If we are unable to enforce our commercial agreements, whether at all or in material part, our business, financial condition, or results of operations could be adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to claims, lawsuits, and government investigations involving labor and employment. Such claims, lawsuits, and government investigations are inherently uncertain. Regardless of the outcome, any of these types of legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to the risk that our employees, independent contractors, consultants, manufacturers, suppliers, and any other third parties that we may engage in connection with the development and commercialization of our products may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless, and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the laws of the FDA and other similar regulatory authorities, including those laws requiring the reporting of true, complete, and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, fraud, and abuse laws and regulations; or (iv) laws that require the true, complete, and accurate reporting of financial information or data. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or the creation of fraudulent data in clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to the risk that a person or government could allege fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business or results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs, or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF HOSPITALS AND OTHER SURGERY FACILITIES DO NOT CONTINUE TO MEET FEDERAL, STATE, OR OTHER REGULATORY STANDARDS, THEY MAY BE REQUIRED TO TEMPORARILY CEASE ALL OR PART OF THEIR SYSTEM UTILIZATION.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global customers are subject to periodic inspection by regulatory authorities. Our customers are required to comply with applicable local and international regulations, including with respect to the reprocessing of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments and accessories. Hospitals may not follow cleaning and sterilization instructions properly, or equipment used for cleaning and sterilization may malfunction or be used improperly. If our customers deviate from cleaning and sterilization instructions, regulatory authorities may require them to suspend the use of our systems.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_70"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATING TO OUR INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IF WE ARE UNABLE TO FULLY PROTECT AND SUCCESSFULLY DEFEND OUR INTELLECTUAL PROPERTY FROM USE BY THIRD PARTIES, OUR ABILITY TO COMPETE IN THE MARKET MAY BE HARMED.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on obtaining patent protection for the proprietary technologies contained in our products and on successfully defending our patents against infringing products and/or services in litigation or administrative proceedings, including patent oppositions, reviews, or reexaminations. We incur substantial costs in obtaining patents and, if necessary, defending our patent rights. We do not know whether we will be successful in obtaining the desired patent protection for our new proprietary technologies or that the protection we do obtain will be found valid and enforceable when challenged. The success of defending our proprietary rights can be highly uncertain, because it involves complex and often evolving legal issues and procedures that are dependent on the particular facts of each case.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely on other intellectual property rights, such as trade secret, copyright, and trademark laws to protect proprietary technologies. We further utilize nondisclosure agreements and other contractual provisions as well as technical measures to protect our proprietary technologies. Nevertheless, these measures may be inadequate in protecting our technologies. If these measures prove to be inadequate in protecting our technologies, our competitive advantages may be reduced. Moreover, we may not have adequate remedies for potential breaches by employees, consultants, and others who participate in developing our proprietary technologies against their agreements with us regarding intellectual property. As a result, our trade secrets may be lost. Notwithstanding our efforts to protect our intellectual property, our competitors may independently develop similar or alternative technologies or products that are equal to or superior to our technologies without infringing any of our intellectual property, which would harm our ability to compete in the market.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As foreign markets become more significant in revenue for us, our foreign operations and strategic alliances with foreign entities will likely increase. Our exposure to risks associated with these operations requires us to increase our reliance on protecting our intellectual property against infringing products and/or services in markets outside of the U.S. The laws and judicial systems in these countries may introduce yet another level of uncertainty in our effort to obtain the desired protection as well as defending our rights.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHERS MAY BE SUCCESSFUL IN ASSERTING THAT OUR PRODUCTS INFRINGE THEIR INTELLECTUAL PROPERTY RIGHTS, WHICH MAY CAUSE US TO PAY SUBSTANTIAL DAMAGES AND/OR ENJOIN US FROM COMMERCIALIZING OUR PRODUCTS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to introduce and commercialize new products and technologies, there may be U.S. and foreign patents issued to third parties that relate to our products. Some of these patents may be broad enough to cover one or more aspects of our products. We do not know whether any of these patents, if challenged, would be held valid, enforceable, and infringed. From time to time, we receive, and likely will continue to receive, letters from third parties accusing us of infringing and/or inviting us to license their patents. We may be sued by, or become involved in an administrative proceeding with, one or more of these third parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that a court or administrative body would agree with any arguments or defenses that we may have concerning invalidity, unenforceability, or non-infringement of any third-party patent. In addition, other parties may have filed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or will file patent applications covering products that are similar to or identical to ours. We cannot be certain that patents issuing from our own patent applications covering our products will have a priority date over any patents issuing from applications filed by a third party.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry has experienced extensive intellectual property litigation and administrative proceedings. If third parties assert infringement claims or institute administrative proceedings against us, our technical and management personnel will need to spend significant time and effort, and we will incur large expenses in defending against these attacks. We cannot be certain that we will prevail in defending against infringement, validity, or enforceability claims against us. If plaintiffs in patent administrative proceedings are successful, our patent portfolio may be adversely affected. If plaintiffs in any patent action are successful, we may be enjoined from selling or importing our products, we may have to pay substantial damages, including treble damages, or we may be required to obtain a license that requires us to pay substantial royalties or relocate our manufacturing facilities. In addition, any public announcements related to litigation or administrative proceedings initiated or threatened against us could cause our stock price to decline.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCTS RELY ON LICENSES FROM THIRD PARTIES, WHICH MAY NOT BE AVAILABLE TO US ON COMMERCIALLY REASONABLE TERMS OR AT ALL. IF WE LOSE ACCESS TO THESE TECHNOLOGIES, OUR REVENUES COULD DECLINE.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on technology that we license from others, including technology that is integral to our products. There is no assurance that we can obtain or retain licenses on acceptable terms or at all. The license agreements we have entered into with several industry partners may be terminated for breach. If any of these agreements are terminated, we may be unable to reacquire the necessary license on satisfactory terms or at all. The failure to obtain, retain, or maintain licenses could prevent or delay further development or commercialization of our products, which may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_73"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL RISK FACTORS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR FUTURE OPERATING RESULTS MAY BE BELOW SECURITIES ANALYSTS&#8217; OR INVESTORS&#8217; EXPECTATIONS, WHICH COULD CAUSE OUR STOCK PRICE TO DECLINE.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nascent nature of our industry, we have limited insight into trends that may emerge in our market and affect our business. The revenue and income potential of our market are unproven, and we may be unable to maintain or grow our revenue. Our products typically have lengthy sales cycles. In addition, our costs may be higher than we anticipated. If we fail to generate sufficient revenues or our costs are higher than we expect, our results of operations may be materially adversely affected. Further, future revenue from sales of our products is difficult to forecast, because the market for new surgical technologies is still evolving. Our results of operations could be impacted by numerous factors, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products achieve and maintain market acceptance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions relating to regulatory matters;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product quality and supply problems;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inflationary pressures on the cost of producing and distributing our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our timing and ability to develop our manufacturing and sales and marketing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demand for our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and timing of particular sales and any collection delays related to those sales;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of surgical training in the use of our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop, introduce, and market new or enhanced versions of our products on a timely basis;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party payor reimbursement policies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our proprietary rights and defend against third-party challenges;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to license additional intellectual property rights; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress and results of any clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results in any particular period will not be a reliable indication of our future performance. It is possible that, in future periods, our operating results will be below the expectations of securities analysts or investors. If this occurs, the price of our common stock and the value of your investment will likely decline.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STOCK PRICE HAS BEEN, AND WILL LIKELY CONTINUE TO BE, VOLATILE.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has experienced fluctuations and may fluctuate significantly in the future. For example, during 2020, the adjusted closing price of our common stock reached a high of $272.70 and a low of $122.58; during </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, it reached a high of $365.42 and a low of $228.30; and, during 2022, it reached a high of $360.00 and a low of $183.06. Our stock price can fluctuate for a number of reasons, including:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements about us or our competitors;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our operating results and financial guidance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our introduction or abandonment of new technologies or products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory approvals and enforcement actions;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our product pricing policies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in earnings estimates or recommendations by analysts;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting policies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic changes and overall market volatility;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to product quality and the supply chain for our products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">media coverage, whether accurate or inaccurate, fair or misleading;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political uncertainties;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short sales on shares of our common stock or other activities by short sellers; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our stock repurchase program.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future stock repurchase programs will be contingent on a variety of factors, including our financial condition, results of operations, and business requirements. There can be no assurance that we will continue repurchasing our common stock in the future, consistent with historical levels or at all, or that our stock repurchase programs will have a beneficial impact on our stock price.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, stock markets generally have experienced, and in the future may experience, significant price and volume volatility. This volatility has a substantial effect on the market prices of securities of many public companies for reasons frequently unrelated or disproportionate to the operating performance of the specific companies. Further, the securities of many medical device companies, including us, have historically been subject to extensive price and volume fluctuations that may affect the market price of their common stock. If these broad market fluctuations continue, it may have a material adverse impact on the market price of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES TO FINANCIAL ACCOUNTING STANDARDS MAY AFFECT OUR REPORTED RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in accounting standards can have a significant effect on our reported results and may retroactively affect previously reported results. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing standards or the reevaluation of current practices may adversely affect our reported financial results or the way we conduct our business.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_76"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_79"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we own approximately 2.0&#160;million square feet of space on 112 acres of land in Sunnyvale, California, where we house our principal headquarters, research and development, service, and support functions, as well as certain of our manufacturing operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of Sunnyvale, California, we own facilities in other U.S. locations that are used for sales, training, manufacturing, engineering, and administrative functions, including approximately 530,000 square feet of space on 60 acres of land in Peachtree Corners, Georgia. We also lease approximately 750,000 square feet of space for certain engineering, warehousing, and support functions at various locations in the U.S. Outside of the U.S., we own properties in Mexicali, Mexico, primarily for manufacturing operations, and Aubonne, Switzerland, primarily for our international headquarters. In China, our Joint Venture leases facilities for research and development, manufacturing, and sales operations. In Germany, we own and lease facilities for manufacturing operations, as we build out operations of our acquisition of certain assets and operations from Sch&#246;lly Fiberoptic GmbH. In Israel, we lease facilities, including space for the operations of our subsidiary, Orpheus Medical. In addition, we lease various international facilities for sales and other operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_250">Note 8 to the Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Part II, Item 8 of this report is incorporated herein by reference.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_85"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_91"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per-share information presented have been retroactively adjusted to reflect the three-for-one stock split of our issued and outstanding common stock in October 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMON STOCK</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;ISRG.&#8221;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;7, 2023, there were 130 stockholders of record of our common stock, although there are a significantly larger number of beneficial owners of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIVIDENDS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings for use in the operation and expansion of our business. In addition, we may use a portion of our retained earnings to repurchase shares of our common stock, if appropriate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Item 12. "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" under Part III of this Annual Report on Form 10-K for information on where to find information required by Item 201(d) of Regulation S-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT SALES OF UNREGISTERED SECURITIES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the quarter ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares<br/>Repurchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>Price&#160;Paid<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares&#160;Purchased&#160;As<br/>Part of a Publicly<br/>Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar<br/>Amount&#160;of&#160;Shares&#160;That<br/>May Yet be Purchased<br/>Under the Program (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 to October 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 to November 30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;billion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 to December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;billion</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total during quarter ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,933,491&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,933,491&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Since March 2009, we have had an active stock repurchase program (the &#8220;Repurchase Program&#8221;). As of&#160;December&#160;31, 2022, our Board of Directors (our &#8220;Board&#8221;) had authorized an aggregate amount of up to&#160;$10.0&#160;billion&#160;for stock repurchases, of which the most recent authorization occurred in July 2022, when our Board increased the authorized amount available under our Repurchase Program to&#160;$3.5&#160;billion. The remaining amount available to repurchase shares under the authorized Repurchase Program as of&#160;December&#160;31, 2022, is $1.5 billion. The authorized Repurchase Program does not have an expiration date.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK PERFORMANCE GRAPH</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This graph is not &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filings of Intuitive Surgical, Inc. under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph set forth below compares the cumulative total stockholder return on our common stock between December&#160;31, 2017, and December&#160;31, 2022, with the cumulative total return of (i)&#160;the Nasdaq Composite Index, (ii)&#160;the S&amp;P 500 Healthcare Index, and (iii)&#160;the S&amp;P 500 Index over the same period. This graph assumes an investment of $100.00 on December&#160;31, 2017, in our common stock, the Nasdaq Composite Index, the S&amp;P Healthcare Index, and the S&amp;P 500 Index and assumes the re-investment of dividends, if any.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the graph below are based on historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPARISON OF CUMULATIVE TOTAL RETURN AMONG INTUITIVE, NASDAQ COMPOSITE, S&amp;P HEALTHCARE INDEX, AND S&amp;P 500 INDEX</span></td></tr></table></div><div style="text-align:center"><img src="isrg-20221231_g2.jpg" alt="isrg-20221231_g2.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Healthcare Index</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i025de1eec32044f5a30c5872569f0e8d_94"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[RESERVED]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Open surgery remains the predominant form of surgery and is used in almost every area of the body. However, the large incisions required for open surgery create trauma to patients, typically resulting in longer hospitalization and recovery times, increased hospitalization costs, and additional pain and suffering relative to minimally invasive surgery, where MIS is available. For over three decades, MIS has reduced trauma to patients by allowing selected surgeries to be performed through small ports rather than large incisions. MIS has been widely adopted for certain surgical procedures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Da Vinci Surgical Systems enable surgeons to extend the benefits of MIS to many patients who would otherwise undergo a more invasive surgery by using computational, robotic, and imaging technologies to overcome many of the limitations of traditional open surgery or conventional MIS. Surgeons using a da Vinci Surgical System operate while seated comfortably at a console viewing a 3D, high-definition image of the surgical field. This immersive console connects surgeons to the surgical field and their instruments. While seated at the console, the surgeon manipulates instrument controls in a natural manner, similar to open surgical technique. Our technology is designed to provide surgeons with a range of articulation of the surgical instruments used in the surgical field analogous to the motions of a human wrist, while filtering out the tremor inherent in a surgeon&#8217;s hand. In designing our products, we focus on making our technology easy and safe to use.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our da Vinci products fall into five broad categories: da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. We also provide a comprehensive suite of systems, learning, and services offerings. Digitally-enabled for nearly three decades, these three offerings aim to decrease variability by providing dependable, consistent functionality and an integrated user experience. Our systems category includes robotic platforms, software, vision, energy, and instruments and accessories. Our learning category includes educational technology, such as simulation and telepresence, as well as technical training programs and personalized peer-to-peer learning opportunities. Our services category assists and optimizes minimally invasive programs through readiness, on-demand support, consultation for minimally invasive program optimization, and hospitals customized analytics. Within our integrated ecosystem, our focus is to decrease variability in surgery by offering actionable insights, with digital solutions, to take action with the potential to improve outcomes, personalize learning, and optimize efficiency. We take a holistic approach, offering intelligent technology and systems designed to work together to make MIS intervention more available and applicable.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercialized the following da Vinci Surgical Systems: the da Vinci standard Surgical System in 1999, the da Vinci S Surgical System in 2006, the da Vinci Si Surgical System in 2009, and the fourth generation da Vinci Xi Surgical System in 2014. We extended our fourth-generation platform by adding the da Vinci X Surgical System, commercialized in 2017, and the da Vinci SP Surgical System, commercialized in 2018. The da Vinci SP Surgical System accesses the body through a single incision, while the other da Vinci Surgical Systems access the body through multiple incisions. All da Vinci systems include a surgeon&#8217;s console (or consoles), imaging electronics, a patient-side cart, and computational hardware and software. We are in the early stages of launching our da Vinci SP Surgical System, and we have an installed base of 121 da Vinci SP Surgical Systems as of December 31, 2022. We have received FDA clearance for the da Vinci SP Surgical System for urologic and certain transoral procedures, and we have received regulatory clearance in South Korea, where the da Vinci SP Surgical System may be used for a broad set of procedures. In September 2022, we also received regulatory clearance for the da Vinci SP Surgical System in Japan for the same set of procedures as can be performed on the da Vinci Xi Surgical System in Japan. We plan to seek FDA clearances for additional indications for da Vinci SP over time. We also plan to seek clearances in other OUS markets over time. The success of the da Vinci SP Surgical System is dependent on positive experiences and improved clinical outcomes for the procedures for which it has been cleared as well as securing additional clinical clearances.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer approximately 70 different multi-port da Vinci instruments to provide surgeons with flexibility in choosing the types of tools needed to perform a particular surgery. These multi-port instruments are generally robotically controlled and provide end effectors (tips) that are similar to those used in either open or laparoscopic surgery. We offer advanced instrumentation for the da Vinci X and da Vinci Xi platforms, including da Vinci Energy and da Vinci Stapler products, to provide surgeons with sophisticated, computer-aided tools to precisely and efficiently interact with tissue. Da Vinci X and da Vinci Xi Surgical Systems share the same instruments, whereas the da Vinci Si Surgical System uses instruments that are not compatible with da Vinci X or da Vinci Xi systems. We currently offer nine core instruments on our da Vinci SP Surgical System. We plan to expand the SP instrument offering over time.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Training technologies include our Intuitive Simulation products, our Intuitive Telepresence remote case observation and telementoring tools, and our dual console for use in surgeon proctoring and collaborative surgery.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the FDA cleared our Ion endoluminal system to enable minimally invasive biopsies in the lung. Our Ion system extends our commercial offering beyond surgery into diagnostic procedures with this first application. Our rollout of the Ion </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">system is progressing well, and we are continuing to gather additional clinical evidence. We plan to seek additional clearances for the Ion system in OUS markets over time.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of new product introductions depends on a number of factors including, but not limited to, pricing, competition, market and consumer acceptance, the effective forecasting and management of product demand, inventory levels, the management of manufacturing and supply costs, and the risk that new products may have quality or other defects in the early stages of introduction.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic Environment</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty surrounding macroeconomic factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, rising interest rates, labor shortages, and significant disruption in the commodities&#8217; markets as a result of the Russia and Ukraine conflict may result in a recession, which could have a material adverse effect on our long-term business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced increased difficulties in obtaining a sufficient supply of a number of component materials used in our products, such as semiconductor components as well as a range of other materials, including, but not limited to, metals and polymers, as global supply has become significantly constrained due to increased demand for certain materials. Additionally, prices of such materials have increased due to the increased demand and supply shortage. With rising interest rates, access to credit may become more difficult, and any insolvency of key suppliers, including sole-source and single-source suppliers, may exacerbate current supply chain challenges. We are engaged in activities to seek to mitigate supply disruptions, but the global supply chain shortages will remain a challenge for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such global shortages in important components as well as certain logistics challenges have resulted in, and will continue to cause, inflationary cost pressure in our supply chain. To date, these supply chain challenges have not materially impacted our results of operations or ability to deliver products and services to our customers. However, if shortages in important supply chain materials in the semiconductor or other markets or logistics challenges continue, we could fail to meet product demand, which could result in deferred or canceled procedures. If inflationary pressures in logistics or component costs persist, we may not be able to adjust pricing, reduce costs, or implement countermeasures. Additionally, there is uncertainty surrounding the impact of any monetary policy changes taken by the U.S. Federal Reserve and other central banks to address the structural risks associated with inflation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in labor availability globally, including labor shortages and staff burnout and attrition, could also impact our ability to hire and retain personnel critical to our manufacturing, logistics, and commercial operations. We are also highly dependent on the principal members of our management and scientific staff. The loss of critical members of our team, or our inability to attract and retain qualified personnel, could significantly harm our operations, business, and ability to compete.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current macroeconomic environment is impacting our customers financially and operationally as well. Hospitals are experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, rising interest rates make access to credit more expensive, unrealized losses decrease available cash reserves, and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. As a consequence of the financial pressures and decreased profitability, some hospitals have indicated that they are lowering their capital investment plans and tightening their operational budgets. We believe that these factors have contributed to a softening in our U.S. capital pipeline, and we expect that demand for capital, particularly in the U.S., will continue to be impacted while macroeconomic conditions remain challenging. In addition, as competition progresses in various markets, we will likely experience longer selling cycles and pricing pressures. Any or all of these factors could negatively impact the number of da Vinci procedures performed or the number of system placements and have a material adverse effect on our business, financial condition, or results of operations resulting in failure to achieve our anticipated financial results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, as a result of the outbreak of a novel strain of coronavirus (COVID-19), we saw a substantial reduction in da Vinci procedures. The initial decline in procedures in the first quarter of 2020 was significant, most notably in China and then later in Western Europe and the U.S. as the pandemic spread. The second quarter of 2020 saw a further significant decline in procedures, followed by a period of recovery and new resurgences. In the U.S., procedures initially continued to decline, before starting a recovery as COVID-19 cases dropped and elective procedures were permitted. In China, procedure volumes recovered strongly, while the impact on procedure volumes of other countries varied. The third and fourth quarters of 2020 were characterized by the continued recovery of procedure volumes in the U.S. and China, while the procedure volumes of other countries, such as Japan, continued to vary depending on the spread and/or resurgence of COVID-19.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, COVID-19 resurgences affected da Vinci procedure volumes at various times throughout the year in most of the markets that we operate in. After each resurgence, as COVID-19 cases and hospitalizations subsided, we saw procedure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volumes recover. In the U.S., the impact of high COVID-related hospitalization rates on procedure volumes was exacerbated by staffing shortages. Although hospitals were better equipped to handle COVID patients as compared to the outset of the pandemic, COVID-19 resurgences challenged hospital resources and negatively impacted da Vinci procedure volumes. In addition, delays in diagnosis and treatment of underlying conditions had a negative impact on da Vinci procedure volumes. Volumes associated with benign procedures were generally impacted to a higher degree when COVID-19 cases and hospitalizations increased, reflecting the deferability of certain elective surgeries.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, a resurgence of COVID-19 resulted in a significant increase in infections and hospitalization rates in the U.S. and certain countries in Europe, which, in turn, negatively impacted procedure volumes in January and February. As infections and hospitalizations started to decrease in February in the U.S. and Europe, we saw a recovery of procedure volumes. In March and during the second quarter of 2022, we also saw a resurgence in COVID-19 cases and increased hospitalizations and government interventions impacting parts of Asia, particularly China, which negatively impacted procedure volumes. During the third quarter of 2022, we did not experience significant disruptions from COVID-19. In the fourth quarter of 2022, we saw a resurgence in COVID-19 cases in China, which had a significant negative impact on our procedure volumes in the region.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depth and extent to which the COVID-19 pandemic will impact individual markets will vary based on the availability of vaccinations, personal protective equipment, intensive care units and operating rooms, and medical staff, as well as government interventions. The impact of COVID-19 on our procedure volumes varies widely by country, region, and type. When COVID-19 infection rates spike in a particular region, procedure volumes have been negatively impacted and the diagnoses of new conditions and their related treatments have been deferred. While there is a backlog of patients, it is unpredictable when those patients will ultimately seek diagnosis and treatment and whether they will be treated through surgery. Based on our experience during the last three years, we do not expect all markets, regions, and procedure types to recover at the same time or at the same pace.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">System Demand</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the impact of the COVID-19 pandemic progressed throughout 2020, customers in affected regions deferred decisions to purchase or lease systems into future quarters and, in some cases, indefinitely. In addition, the year-over-year stagnation in procedures during 2020 and, in turn, reduced utilization of our systems had resulted in unused capacity in the existing installed base. On the other hand, throughout 2021, we experienced strong system demand, as utilization levels recovered. In general, we believe that the COVID-19 pandemic had less of an impact on hospital spending capacity and that customers recognize that surgery meets their quadruple aim objectives better than other surgical approaches. This system demand continued during 2022; however, in 2022, our system demand was also impacted by macroeconomic challenges impacting our customers, primarily in the U.S. Refer to the factors outlined in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section above.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Relief Program</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced a program to provide financial relief to our customers. The program consisted of three main elements. The first element provided credits against service fees otherwise due in the six-month period from April 1 through September 30, 2020, which generally reflected the underutilization of the system during that period. Those credits were offered to most customers worldwide. The second element of the program deferred certain lease payments, and the third element extended certain payment terms. Service fee credits resulted in an $80&#160;million decrease in service revenue in 2020. While the short-term payment relief offered did not have a material impact on the results of operations, we deferred $15&#160;million of lease billings and extended payment terms associated with $181&#160;million of trade receivables during the program, of which $19&#160;million remained outstanding as of December 31, 2020. All of the trade receivables with extended payment terms were collected as of December 31, 2021. We may be subject to increased credit risks resulting in collection delinquencies and defaults, which could materially impact our bad debt write-offs and provisions for credit losses. Although we have programs in place that are designed to monitor and mitigate the associated risks, there can be no assurance that such programs will be effective in reducing credit risks relating to these lease financing arrangements and extended payment terms. There was no similar customer relief program offered in 2021 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Increase in Risks</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and local actions, such as &#8220;shelter-in-place&#8221; orders and restrictions on our ability to travel and access our customers or temporary closures of our facilities, including our training and manufacturing operations, or the facilities of our suppliers and their contract manufacturers, could further significantly impact our sales and our ability to produce and ship our products and supply our customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 has contributed to the staffing shortages experienced by hospitals, which impacts hospitals&#8217; ability to provide patient care and, in some cases, results in the deferral of elective surgeries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Response</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our priorities and actions during the COVID-19 pandemic have been and remain as follows. First, we are focused on the health and safety of all those we serve&#8212;patients, customers, our communities, and our employees&#8212;implementing continuous updates to our health and safety policies and processes. Second, we are supporting our customers according to their priorities&#8212;clinical, operational, and economic&#8212;and ensuring continuity of supply by working with our suppliers and our distributors. Third, we are securing our workforce economically. We have built a valuable team over the years, and we believe they will be important in a recovery that follows the pandemic. Finally, we will continue to invest in our priority development programs while eliminating avoidable spend.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As COVID-19 vaccination rates increase and the severity of cases declines, we are implementing our return-to-office strategy. We collected internal and external insights to inform decision-making on work models that would align with how employees will work in the current environment, which has evolved as a result of the COVID-19 pandemic. These efforts will allow for an improved employee experience, regardless of whether an employee is working from home, fully on-site, or in a hybrid fashion. Our top priority in this process continues to be the health and safety of our employees.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_103"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Model</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue from the placement of da Vinci Surgical Systems, in sales or sales-type lease arrangements where revenue is recognized up-front or in operating lease and usage-based arrangements where revenue is recognized over time. We earn recurring revenue from the sales of instruments, accessories, and services, as well as the revenue from operating leases. The da Vinci Surgical System generally sells for between $0.5&#160;million and $2.5&#160;million, depending upon the model, configuration, and geography, and represents a significant capital equipment investment for our customers when purchased. Our instruments and accessories have limited lives and will either expire or wear out as they are used in surgery, at which point they need to be replaced. We generally earn between $600 and $3,500 of instruments and accessories revenue per surgical procedure performed, depending on the type and complexity of the specific procedures performed and the number and type of instruments used. In late 2020, we launched our Extended Use Program (refer to further discussion in the section below) in the U.S. and Europe, with the intention to reduce the cost for customers to treat patients, which in turn will reduce our overall instruments and accessories revenue per procedure. We typically enter into service contracts at the time systems are sold or leased at an annual fee between $80,000 and $190,000, depending upon the configuration of the underlying system and the composition of the services offered under the contract. These service contracts have generally been renewed at the end of the initial contractual service periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue from our Ion endoluminal system in a business model consistent with the da Vinci Surgical System model described above. We generate revenue from the placement of Ion systems, in sales or sales-type lease arrangements where revenue is recognized up-front or in operating lease and usage-based arrangements where revenue is recognized over time. We earn recurring revenue from the sales of instruments, accessories, and services, as well as revenue from operating leases. The average selling price of an Ion system is generally significantly lower than the average selling price of a da Vinci Surgical System. For the years ended December 31, 2022, 2021, and 2020, Ion&#8217;s contribution to revenue and gross margin was not significant.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as part of our ecosystem of products and services, we provide a portfolio of learning offerings and digital solutions. We do not currently generate material revenue from these offerings.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Extended Use Program</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we introduced our Extended Use Program in the U.S. and Europe, which consists of select da Vinci Xi and da Vinci X instruments possessing 12 to 18 uses compared to the previously 10 uses. These Extended Use Instruments represent some of our higher volume instruments but exclude stapling, monopolar, and advanced energy instruments. Instruments included in the program are used across a number of da Vinci surgeries. Their increased uses are the result of continuous, significant investments in the design and production capabilities of our instruments, resulting in improved quality and durability. Extended Use Instruments were then launched in most other countries around the world in the first half of 2021, except China due to regulatory timelines. In addition, simultaneous with the regional launches of Extended Use Instruments, we have lowered the price of certain instruments that are most commonly used in lower acuity procedures and/or lower reimbursed procedures within the region. These actions have reduced the cost for customers to treat patients, which in turn has reduced our revenue per procedure. In the U.S. and Europe, during 2021, we saw customers adjust their instrument buying patterns to reduce their inventory levels to reflect the additional uses per instrument. We believe that, as of the end of 2021, in the U.S. and Europe, full cutover to Extended Use Instruments has occurred, as customers have substantially utilized all of their remaining 10 use instruments. The precise impact of these actions on future revenue will be dependent on the future volume and mix of procedures and whether cost elasticity will enable greater penetration into available markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recurring revenue consists of instruments and accessories revenue, service revenue, and operating lease revenue. Recurring revenue increased to $4.9 billion, or 79% of total revenue in 2022, compared to $4.3 billion, or 75% of total revenue in 2021, and $3.4 billion, or 77% of total revenue in 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments and accessories revenue has grown at a faster rate than systems revenue over time. Instruments and accessories revenue increased to $3.52 billion in 2022, compared to $3.10 billion in 2021 and $2.46 billion in 2020. The increase in instruments and accessories revenue largely reflects continued procedure adoption.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue was $1.02 billion in 2022, compared to $0.92 billion in 2021 and $0.72 billion in 2020. The increase in service revenue was primarily driven by the growth of the base of installed da Vinci Surgical Systems producing service revenue, as well as the effects of the Customer Relief Program in 2020, which resulted in an $80&#160;million decrease in service revenue. The installed base of da Vinci Surgical Systems grew 12% to approximately 7,544 as of December&#160;31, 2022; 12% to approximately 6,730 as of December&#160;31, 2021; and 7% to approximately 5,989 as of December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the installed base, number of placements, and utilization of systems as metrics for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Management believes that the installed base, number of placements, and utilization of systems provide meaningful supplemental information regarding our performance, as management believes that the installed base, number of placements, and utilization of systems are an indicator of the rate of adoption of robotic-assisted surgery or bronchoscopy as well as an indicator of future recurring revenue. Management believes that both it and investors benefit from referring to the installed base, number of placements, and utilization of systems in assessing our performance and when planning, forecasting, and analyzing future periods. The installed base, number of placements, and utilization of systems also facilitate management&#8217;s internal comparisons of our historical performance. We believe that the installed base, number of placements, and utilization of systems are useful to investors as metrics because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of our business. The vast majority of installed systems are connected via the internet. System logs can also be accessed by field engineers for systems that are not connected to the internet. We utilize this information as well as other information from agreements and discussions with our customers that involve estimates and judgments, which are, by their nature, subject to substantial uncertainties and assumptions. Estimates and judgments for determining the installed base, number of placements, and utilization of systems may be impacted over time by various factors, including system internet connectivity, hospital and distributor reporting behavior, and inherent complexities in new agreements. Such estimates and judgments are also susceptible to technical errors. In addition, the relationship between the installed base, number of placements, and utilization of systems and our revenues may fluctuate from period to period, and growth in the installed base, number of placements, and utilization of systems may not correspond to an increase in revenue. The installed base, number of placements, and utilization of systems are not intended to be considered in isolation or as a substitute for, or superior to, revenue or other financial information prepared and presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2013, we have entered into sales-type and operating lease arrangements directly with certain qualified customers as a way to offer customers flexibility in how they acquire systems and expand their robotic-assisted programs while leveraging our balance sheet. These leases generally have commercially competitive terms as compared to other third-party entities that offer equipment leasing. We have also entered into usage-based arrangements with qualified customers that have committed da Vinci programs where we charge for the system and service as the systems are utilized. We believe that these alternative financing structures have been effective and well-received, and we are willing to expand the proportion of these structures based on customer demand. We include operating and sales-type leases, and systems placed under usage-based arrangements, in our system placement and installed base disclosures. We exclude operating lease-related revenue, usage-based revenue, and Ion system revenue from our da Vinci Surgical System average selling price (&#8220;ASP&#8221;) computations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the years ended December 31, 2022, 2021, and 2020, we placed 591, 668, and 432 da Vinci Surgical Systems, respectively, under lease and usage-based arrangements, of which 492, 517, and 317 systems, respectively, were operating lease and usage-based arrangements. In the years ended December 31, 2022, 2021, and 2020, we placed 112, 57, and 9 Ion systems, respectively, under lease and usage-based arrangements, of which 101, 50, and 9 systems, respectively, were operating lease and usage-based arrangements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from operating lease arrangements is generally recognized on a straight-line basis over the lease term or, in the case of usage-based arrangements, as the systems are used. We generally set operating lease and usage-based pricing at a modest premium relative to purchased systems reflecting the time value of money and, in the case of usage-based arrangements, the risk that system utilization may fall short of anticipated levels. Variable lease revenue recognized from usage-based arrangements has been included in our operating lease metrics herein. Operating lease revenue has grown at a faster rate than overall systems revenue and was $377 million, $277 million, and $177 million for the years ended December 31, 2022, 2021, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2020, respectively, of which $133 million, $78 million, and $28 million, respectively, was variable lease revenue. As revenue for operating leases and usage-based systems is recognized over time, total systems revenue growth is reduced in a period when the number of operating lease and usage-based placements increases as a proportion of total system placements. Generally, lease transactions generate similar gross margins as our sale transactions. A total of 1,683, 1,294, and 901 da Vinci Surgical Systems were installed at customers under operating lease or usage-based arrangements as of December 31, 2022, 2021, and 2020, respectively. A total of 132, 61, and 11 Ion systems were installed at customers under operating lease or usage-based arrangements as of December 31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to the credit risks relating to our lease financing arrangements may increase if our customers are adversely affected by changes in healthcare laws, coverage and reimbursement, economic pressures or uncertainty, or other customer-specific factors. As a result of these macroeconomic factors impacting our customers, we may be exposed to defaults under our lease financing arrangements. Moreover, usage-based arrangements generally contain no minimum payments; therefore, customers may exit such arrangements without paying a financial penalty to us.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some operating lease arrangements, our customers are provided with the right to purchase the leased system at certain points during and/or at the end of the lease term. Revenue generated from customer purchases of systems under operating lease arrangements (&#8220;Lease Buyouts&#8221;) was $72 million, $96 million, and $52 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. We expect that revenue recognized from customer exercises of the buyout options will fluctuate based on the timing of when, and if, customers choose to exercise their buyout options.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systems Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System placements are driven by procedure growth in most markets. In some markets, system placements are constrained by regulation. In geographies where da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adoption is in an early stage or system placements are constrained by regulation, system sales will precede procedure growth. System placements also vary due to seasonality largely aligned with hospital budgeting cycles. We typically place a higher proportion of annual system placements in the fourth quarter and a lower proportion in the first quarter as customer budgets are reset. Systems revenue is also affected by the proportion of system placements under operating lease and usage-based arrangements, recurring operating lease and usage-based revenue, operating lease buyouts, product mix, ASPs, trade-in activities, and customer mix. Systems revenue declined 1% to $1.68 billion in 2022. Systems revenue grew 44% to $1.69 billion in 2021. Systems revenue declined 12% to $1.18 billion in 2020. Based on the factors outlined in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, we believe that historical system placement trends may not be a good indicator of future system placements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Procedure Mix / Products</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our da Vinci Surgical Systems are generally used for soft tissue surgery for areas of the body between the pelvis and the neck, primarily in general surgery, gynecologic surgery, urologic surgery, cardiothoracic surgery, and head and neck surgery. Within these categories, procedures range in complexity from cancer and other highly complex procedures to less complex procedures for benign conditions. Cancer and other highly complex procedures tend to be reimbursed at higher rates than less complex procedures for benign conditions. Thus, hospitals are more sensitive to the costs associated with treating less complex, benign conditions. Our strategy is to provide hospitals with attractive clinical and economical solutions across the spectrum of procedure complexity. Our fully featured&#160;da Vinci Xi&#160;Surgical System with advanced instruments (including da Vinci Energy&#160;and EndoWrist&#160;and SureForm Stapler products) and our Integrated Table Motion product targets the more complex procedure segment. Our da Vinci X Surgical System is targeted toward price-sensitive markets and procedures. Our da Vinci SP Surgical System complements the da Vinci Xi and X Surgical Systems by enabling surgeons to access narrow workspaces.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Procedure Seasonality</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More than half of da Vinci procedures performed are for benign conditions, most notably hernia repairs, hysterectomies, and cholecystectomies. These benign procedures and other short-term elective procedures tend to be more seasonal than cancer operations and surgeries for other life-threatening conditions. Seasonality in the U.S. for procedures for benign conditions typically results in higher fourth quarter procedure volume when more patients have met annual deductibles and lower first quarter procedure volume when deductibles are reset. Seasonality outside of the U.S. varies and is more pronounced around local holidays and vacation periods. As a result of the factors outlined in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, including past and potentially future recommendations of authorities to defer elective procedures, historical procedure patterns may be disrupted.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Channels</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our products through direct sales organizations in the U.S., Europe (excluding Spain, Portugal, Italy, Greece, and most Eastern European countries), China (through our Intuitive-Fosun Pharma joint venture), Japan, South Korea, India, Taiwan and, as of June 2022, Canada. In the remainder of our OUS markets, we provide our products through distributors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products must meet the requirements of a large and growing body of international standards that govern the product safety, efficacy, advertising, labeling, safety reporting design, manufacture, materials content and sourcing, testing, certification, packaging, installation, use, and disposal of our products. Examples of such standards include electrical safety standards, such as those of the International Electrotechnical Commission, and composition standards, such as the Reduction of Hazardous Substances and the Waste Electrical and Electronic Equipment Directives. Failure to meet these standards could limit our ability to market our products in those regions that require compliance with such standards.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and operations are also subject to increasingly stringent medical device, privacy, and other regulations by regional, federal, state, and local authorities. After a device is placed on the market, numerous FDA and other regulatory requirements continue to apply. These requirements include establishment registration and device listing with the FDA and compliance with medical device reporting regulations, which require that manufacturers report to the FDA if their device caused or contributed, or may have caused or contributed, to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently revised our medical device reporting policies, which had been developed based on previous feedback from the FDA. These revisions have been made in consultation with the FDA to better align with existing regulations. There has been an increase in medical device reporting filings due to changes in our reportability criteria. In addition, we have been investing in resources and utilizing external experts to strengthen our quality system. These efforts are ongoing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate that timelines for the introduction of new products and/or indications may be extended relative to past experience as a result of these regulations. For example, we have seen elongated regulatory approval timelines in the U.S. and Europe.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clearances, Approvals, and Certifications</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generally obtained the regulatory clearances, approvals, and certifications required to market our products associated with our da Vinci Surgical Multiport Systems (Standard, S, Si, Xi, and X systems) for our targeted surgical specialties within the U.S., South Korea, Japan, and the European markets in which we operate. Since 2020, we have obtained regulatory clearances, approvals, and certifications for the following products:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, we obtained regulatory clearance for the da Vinci SP Surgical System in Japan for use in general surgeries, thoracic surgeries (excluding cardiac procedures and intercostal approaches), urologic surgeries, gynecological surgeries, and trans-oral head and neck surgeries. We obtained the initial FDA clearance for our da Vinci SP Surgical System in April 2014 and have since invested in important platform refinements. We also received regulatory clearance in South Korea for our da Vinci SP Surgical System in May 2018.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2022, we received regulatory clearance in China to market both our 12 mm SureForm 45 Stapler and SureForm 60 Stapler and corresponding reloads.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2022, we received regulatory clearance in China to market our da Vinci Vessel Sealer Extend with up to 7 mm vascular indications.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2021, we obtained FDA clearance for our 8 mm SureForm 30 Curved-Tip Stapler and reloads for use in general, thoracic, gynecologic, urologic, and pediatric surgery. The 8 mm SureForm 30 Curved-Tip Stapler is expected to launch in the U.S. in 2023, with other countries to follow. In October 2022, we received regulatory clearance in Japan to market our 8 mm SureForm 30 Curved-Tip and Straight-Tip Stapler instruments and reloads for use in general, thoracic (except for cardiac), gynecologic, and urologic surgery.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In late 2020 and early 2021, we obtained FDA clearance, European certification, and other regulatory clearances in most of our significant markets to market our Extended Use Instruments.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2019, we obtained FDA clearance for our SynchroSeal instrument and E-100 generator. Following the FDA clearance, in February 2020, we obtained European certification for both products. In March 2020, we received regulatory clearance in Japan to market both our SynchroSeal instrument and E-100 generator. We received regulatory clearance in South Korea to market our SynchroSeal instrument and E-100 generator in January 2020 and August 2020, respectively.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2019, we obtained FDA clearance for our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload, which round out our SureForm 45 portfolio. We have also obtained European certification for our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload. In September 2019, we received regulatory clearance in Japan to market both our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload. We received regulatory clearance in South Korea to market our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload in June 2021 and July 2021, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2019, we obtained European certification for our da Vinci Endoscope Plus for the da Vinci Xi and da Vinci X Surgical Systems in Europe. Following the European certification, in July 2019, we obtained FDA clearance for our da Vinci Endoscope Plus. We have also received regulatory clearances in South Korea and Japan to market our da Vinci Endoscope Plus in December 2019 and May 2020, respectively. In March 2022, we received regulatory clearance in China to market our da Vinci Endoscope Plus.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2019, we obtained FDA clearance for our da Vinci Handheld Camera and, in February 2020, we obtained European certification.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the descriptions of our new products that received regulatory clearances, approvals, or certifications in 2022, 2021, and 2020 in the Recent Product Introductions section below.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the China National Health Commission published on its official website the quota for major medical equipment to be sold in China through 2020. After an adjustment notice was published in the third quarter of 2020, the government will now allow for the total sale of 225 new surgical robots into China, which could include da Vinci Surgical Systems as well as surgical systems introduced by others. As of December 31, 2022, we have sold 187 da Vinci Surgical Systems under this quota, and we believe that four system quotas are no longer available; therefore, 34 surgical robots should still be available for sale under this quota. Future sales of da Vinci Surgical Systems under the quota are uncertain, as they are dependent on hospitals completing a tender process and receiving associated approvals. Additionally, any delays in the granting of a new quota in China will constrain our ability to further grow our installed base in China as well as limit our capacity for procedure growth in China.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Hunan Provincial Healthcare Security Administration implemented significant limits on what hospitals can charge patients for surgeries using robotic surgical technology, including soft tissue surgery and orthopedics. This rule has had a material negative impact on our procedures performed in the Hunan province. In addition to the Hunan province, the Hainan province (an island province of China) recently announced a policy to implement almost identical limits on what hospitals can charge patients for surgeries using robotic surgical technology. However, currently, only a small portion of our installed base in China is located in the Hunan and Hainan provinces. Companies providing robotic surgical technology, including our joint venture in China, are meeting with Chinese government healthcare agencies to discuss this development and provide feedback. We cannot assure you that other provincial healthcare administrations will not impose similar limits.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Japanese Ministry of Health, Labor, and Welfare considers reimbursement for procedures in April of even-numbered years. The process for obtaining reimbursement requires Japanese university hospitals and surgical societies, with our support, to seek reimbursement. There are multiple pathways to obtain reimbursement for procedures, including those that require in-country clinical data/economic data. In April 2012 and April 2016, the MHLW granted reimbursement status for prostatectomy and partial nephrectomy, respectively. Most prostatectomies and partial nephrectomies were open procedures prior to da Vinci reimbursement. Da Vinci procedure reimbursement for prostatectomy and partial nephrectomy procedures are higher than open and conventional laparoscopic procedure reimbursements. An additional 12 da Vinci procedures were granted reimbursement effective April 1, 2018, including gastrectomy, low anterior resection, lobectomy, and hysterectomy, for both malignant and benign conditions, and an additional seven da Vinci procedures were granted reimbursement effective April 1, 2020. An additional eight da Vinci procedures were granted reimbursement effective April 1, 2022, including colon resection. In addition, we received higher reimbursement for da Vinci gastrectomy procedures, as compared to open and conventional laparoscopic procedure reimbursements. The additional reimbursed procedures have varying levels of conventional laparoscopic penetration and will generally be reimbursed at rates equal to the conventional laparoscopic procedures. Given the reimbursement level and laparoscopic penetration for these additional procedures, there can be no assurance that the adoption pace for these procedures will be similar to prostatectomy or partial nephrectomy, given their higher reimbursement, or any other da Vinci procedure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recalls and Corrections</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical device companies have regulatory obligations to correct or remove medical devices in the field that could pose a risk to health. The definition of &#8220;recalls and corrections&#8221; is expansive and includes repair, replacement, inspections, relabeling, and issuance of new or additional instructions for use or reinforcement of existing instructions for use and training when such actions are taken for specific reasons of safety or compliance. These field actions require stringent documentation, reporting, and monitoring worldwide. There are other actions that a medical device manufacturer may take in the field without reporting including, but not limited to, routine servicing and stock rotations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we determine whether a field action is reportable in any regulatory jurisdiction, we prepare and submit notifications to the appropriate regulatory agency for the particular jurisdiction. Regulators can require the expansion, reclassification, or change in scope and language of the field action. In general, upon submitting required notifications to regulators regarding a field action that is a recall or correction, we will notify customers regarding the field action, provide any additional documentation required in their national language, and arrange, as required, the return or replacement of the affected product or a field service visit to perform the correction.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Field actions, as well as certain outcomes from regulatory activities, can result in adverse effects on our business, including damage to our reputation, delays by customers of purchase decisions, reduction or stoppage of the use of installed systems, and reduced revenue as well as increased expenses.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to an internally-discovered defect in a component manufactured by a third party and used in certain da Vinci arms, we will be issuing a voluntary field action on or about February 10, 2023. As agreed with the FDA, the field action recommends that customers stop using approximately 109 da Vinci X and Xi systems until we can replace the affected arms, which we anticipate completing during February 2023. The affected part does not have patient contact, and there have been no adverse events reported related to this issue. We do not expect this field action to have a material impact on our business, financial condition, or results of operations.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_109"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We model patient value as equal to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">procedure efficacy / invasiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In this equation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">procedure efficacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is defined as a measure of the success of the surgery in resolving the underlying disease, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">invasiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is defined as a measure of patient pain and disruption of regular activities. When the patient value of a da Vinci procedure is greater than that of alternative treatment options, patients may benefit from seeking out surgeons and hospitals that offer da Vinci Surgery, which could potentially result in a local market share shift. Adoption of da Vinci procedures occurs procedure by procedure and market by market and is driven by the relative patient value and total treatment costs of da Vinci procedures as compared to alternative treatment options for the same disease state or condition.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the number and type of procedures as metrics for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Management believes that the number and type of procedures provide meaningful supplemental information regarding our performance, as management believes procedure volume is an indicator of the rate of adoption of robotic-assisted surgery or bronchoscopy as well as an indicator of future revenue (including revenue from usage-based arrangements). Management believes that both it and investors benefit from referring to the number and type of procedures in assessing our performance and when planning, forecasting, and analyzing future periods. The number and type of procedures also facilitate management&#8217;s internal comparisons of our historical performance. We believe that the number and type of procedures are useful to investors as metrics, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of our business. The vast majority of our installed systems are connected via the internet. System logs can also be accessed by field engineers for systems that are not connected to the internet. We utilize certain methods that rely on information collected from the installed systems for determining the number and type of procedures performed that involve estimates and judgments, which are, by their nature, subject to substantial uncertainties and assumptions. Estimates and judgments for determining the number and type of procedures may be impacted over time by various factors, including changes in treatment modalities, hospital and distributor reporting behavior, and system internet connectivity. Such estimates and judgments are also susceptible to algorithmic or other technical errors. In addition, the relationship between the number and type of procedures and our revenues may fluctuate from period to period, and procedure volume growth may not correspond to an increase in revenue. The number and type of procedures are not intended to be considered in isolation or as a substitute for, or superior to, revenue or other financial information prepared and presented in accordance with GAAP.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Worldwide Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems and instruments are regulated independently in various countries and regions of the world. The discussion of indications for use and representative or target procedures is intended solely to provide an understanding of the market for our products and is not intended to promote for sale or use any Intuitive product outside of its licensed or cleared labeling and indications for use.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of robotic-assisted surgery using the da Vinci Surgical System has the potential to grow for those procedures that offer greater patient value than to non-da Vinci alternatives and competitive total economics for healthcare providers. Our da Vinci Surgical Systems are used primarily in general surgery, urologic surgery, gynecologic surgery, cardiothoracic surgery, and head and neck surgery. We focus our organization and investments on developing, marketing, and training products and services for procedures in which da Vinci can bring patient value relative to alternative treatment options and/or economic benefit to healthcare providers. Target procedures in general surgery include hernia repair (both ventral and inguinal), colorectal, cholecystectomy, and bariatric procedures. Target procedures in urology include prostatectomy and partial nephrectomy. Target procedures in gynecology include hysterectomy for both cancer and benign conditions and sacrocolpopexy. In cardiothoracic surgery, target procedures include lobectomy. In head and neck surgery, target procedures include transoral surgery. Not all indications, procedures, or products described may be available in a given country or region or on all generations of da Vinci Surgical Systems. Surgeons and their patients need to consult the product labeling in their specific country and for each product in order to determine the cleared uses, as well as important limitations, restrictions, or contraindications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the adoption of robotic-assisted bronchoscopy using the Ion system has the potential to grow if it can offer greater patient value than non-Ion alternatives and competitive total economics for healthcare providers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, approximately 1,875,000 surgical procedures were performed with da Vinci Surgical Systems, compared to approximately 1,594,000 and 1,243,000 surgical procedures performed with da Vinci Surgical Systems in 2021 and 2020, respectively. The increase in our overall procedure volume in 2022 reflects the disruption caused by the COVID-19 pandemic in 2022 and 2021, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, and was driven by growth in U.S. general surgery, OUS urology, and OUS general surgery (particularly cancer) procedures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, approximately 23,500 biopsy procedures were performed with Ion systems, compared to approximately 7,400 and 1,700 biopsy procedures performed with Ion systems in 2021 and 2020, respectively. The increase in our overall procedure volume in 2022 reflects a larger installed base of approximately 321 systems, an increase of 149% compared to the installed base of approximately 129 systems as of 2021. Currently, the vast majority of Ion biopsy procedures are performed in the U.S.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. da Vinci Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall U.S. procedure volume with da Vinci Surgical Systems grew to approximately 1,282,000 in 2022, compared to approximately 1,109,000 in 2021 and approximately 876,000 in 2020. General surgery was our largest and fastest growing U.S. specialty in 2022 with procedure volume that grew to approximately 720,000 in 2022, compared to approximately 588,000 in 2021 and approximately 434,000 in 2020. Gynecology was our second largest U.S. surgical specialty in 2022 with procedure volume that grew to approximately 341,000 in 2022, compared to approximately 316,000 in 2021 and approximately 267,000 in 2020. Urology was our third largest U.S. surgical specialty in 2022 with procedure volume that grew to approximately 162,000 in 2022, compared to approximately 153,000 in 2021 and approximately 134,000 in 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OUS da Vinci Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall OUS procedure volume with da Vinci Surgical Systems grew to approximately 593,000 in 2022, compared to approximately 485,000 in 2021 and approximately 367,000 in 2020. Urology was our largest OUS specialty in 2022 with procedure volume that grew to approximately 316,000 in 2022, compared to approximately 264,000 in 2021 and approximately 215,000 in 2020. General surgery was our second largest OUS specialty in 2022 with procedure volume that grew to approximately 133,000 in 2022, compared to approximately 101,000 in 2021 and approximately 68,000 in 2020. Gynecology procedures also contributed to OUS procedure growth.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_112"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Events and Trends</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_115"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overall.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total da Vinci procedures performed by our customers grew approximately 18% for the year ended December 31, 2022, compared to approximately 28% for the year ended December 31, 2021. The 2022 and 2021 procedure results (and comparative 2020 procedures results) reflected disruption caused by the COVID-19 pandemic, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, which significantly impacted our procedures in certain periods in geographies and markets where there was a resurgence of the virus. The 2022 procedure growth was largely attributable to growth in U.S. general surgery, OUS urology, and OUS general surgery (particularly cancer) procedures. Delays in both the diagnosis and treatments of diseases reflecting disruptions caused by COVID-19 have previously and may continue to impact the number of procedures performed by our customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. da Vinci procedures grew approximately 16% for the year ended December 31, 2022, compared to approximately 27% for the year ended December 31, 2021. The 2022 and 2021 procedure results (and comparative 2020 procedures results) reflected disruption caused by the COVID-19 pandemic, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, which significantly impacted our procedures. The 2022 U.S. procedure growth was largely attributable to growth in general surgery procedures, most notably hernia repair, cholecystectomy, and bariatric procedures. Growth in the more mature gynecologic and urologic procedure categories was more moderate.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. General Surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;General surgery procedures in the U.S. grew to approximately 720,000 in 2022, compared to approximately 588,000 in 2021 and approximately 434,000 in 2020. Inguinal and ventral hernia repairs, cholecystectomies, and bariatric procedures contributed the most incremental procedures in 2022 and 2021, while cholecystectomies and bariatric procedures contributed the most incremental procedures in 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that growth in hernia repair using da Vinci reflects improved clinical outcomes within certain patient populations, as well as potential cost benefits relative to certain alternative treatments. We believe that hernia repair procedures represent a significant opportunity with the potential to drive growth in future periods. However, given the differences in surgical complexity associated with the treatment of various hernia patient populations and varying surgeon opinions regarding optimal surgical technique, it is difficult to estimate the timing of and to what extent hernia repair procedure volume will grow in the future. We expect a large portion of hernia repairs will continue to be performed via different modalities of surgery.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the already very high level of laparoscopic techniques used in cholecystectomy, it is unclear whether our growth is sustainable and to what extent da Vinci may be adopted.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bariatric procedures have grown significantly over the last three years. These procedures have been an increased area of focus and may also have benefited from certain patients prioritizing weight loss, as obesity is a significant COVID-19 risk factor. In addition, our SureForm 60mm Stapler provides surgeons with a more optimized robotic tool set for bariatric procedures. However, the diagnoses and treatment pathways for bariatric patients are long, and we cannot provide any assurance that we will continue to see significant growth in bariatric procedures in future periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of da Vinci for colorectal procedures, which includes several underlying procedures, including low anterior resections for rectal cancers and certain colon procedures for benign and cancerous conditions, has been ongoing for several years and is supported by certain technologies, such as the EndoWrist and SureForm Staplers, energy devices, and Integrated Table Motion.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OUS Procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OUS da Vinci procedures grew approximately 22% for the year ended December 31, 2022, compared to approximately 32% for the year ended December 31, 2021. The 2022 and 2021 procedure results (and comparative 2020 procedures results) reflected disruption caused by the COVID-19 pandemic, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above, which significantly impacted our procedures. The 2022 OUS procedure growth was driven by continued growth in urologic procedures, including prostatectomies and partial nephrectomies, and earlier stage growth in general surgery (particularly colorectal), gynecologic, and thoracic procedures. The 2022 OUS procedure growth rate reflects continued da Vinci adoption in European and Asian markets. We saw strong procedure growth in Japan, Germany, and the UK during 2022. Procedure growth in China was negatively impacted by COVID-19 restrictions in effect during 2022, particularly during Q2, and the subsequent effect of lifting those restrictions in Q4, which resulted in a surge of COVID-19 cases. We believe that growth in these global markets is being driven by increased acceptance among surgeons and health systems, supported by expanded global evidence validating the clinical and economic value of da Vinci procedures as well as increased surgeon training.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OUS Urology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Along with general surgery, OUS urology procedures have been a strong contributor to our overall procedure growth. OUS urology procedures grew to approximately 316,000 in 2022, compared to approximately 264,000 in 2021 and approximately 215,000 in 2020. In the U.S., da Vinci is the standard of care for the surgical treatment of prostate cancer, and we believe that the growth is largely aligned with surgical volumes of prostate cancer. For OUS, prostatectomy is at varying states of adoption in different areas of the world but is the largest overall da Vinci procedure. In 2022, we saw more moderate growth in OUS prostatectomy procedures compared to higher growth in 2021, as we are further up the adoption curve.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kidney cancer procedures have also been a strong contributor to our recent global urology procedure growth. Clinical publications have demonstrated that the use of a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci system increases the likelihood that a patient will receive nephron sparing surgery through a partial nephrectomy, which is typically the surgical society guideline recommended therapy.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OUS General Surgery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;OUS general surgery procedures grew to approximately 133,000 in 2022, compared to approximately 101,000 in 2021 and approximately 68,000 in 2020. Colorectal procedures contributed the most incremental procedures in 2022, 2021, and 2020, aided by improved clinical outcomes relative to open and laparoscopic techniques within certain patient populations, along with enabling technologies, such as EndoWrist and SureForm staplers, energy devices, and Integrated Table Motion.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_118"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">System Demand</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We placed 1,264 da Vinci Surgical Systems in 2022, compared to 1,347 systems in 2021. The decrease in systems placed reflects a smaller number of third generation da Vinci systems available for trade-in along with the macroeconomic challenges impacting our customers, primarily in the U.S. As a consequence of the macroeconomic challenges, some hospitals have indicated that they are lowering their capital investment plans and tightening operational budgets. We expect that demand for capital will be impacted while macroeconomic conditions remain challenging.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 da Vinci placements declined 6% compared with 2021, and we expect that future placements of da Vinci Surgical Systems will be impacted by a number of factors: supply chain risks; economic and geopolitical factors; inflationary pressures; rising interest rates; hospital staffing shortages; the impact of the current COVID-19 pandemic, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above; hospital response to the evolving healthcare environment; procedure growth rates; hospital consolidation trends; evolving system utilization and point of care dynamics; capital replacement trends, including a declining number of older generation systems available for trade-in transactions; additional reimbursements in various global markets, including Japan; the timing around governmental tenders and authorizations, including China; the timing of when we receive regulatory clearance in our other OUS markets for our da Vinci Xi Surgical System, da Vinci X Surgical System, and da Vinci SP Surgical System, and related instruments; and market response. Market acceptance of our da Vinci SP Surgical System and the nature and timing of additional da Vinci SP regulatory indications may also impact future system placements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Demand may also be impacted by competition, including from companies that have introduced products in the field of robotic-assisted medical procedures or have made explicit statements about their efforts to enter the field including, but not limited to, the following companies: Asensus Surgical, Inc.; avateramedical GmbH; CMR Surgical Ltd.; Johnson &amp; Johnson; Medicaroid Corporation; Medrobotics Corporation; Medtronic plc; meerecompany Inc.; Olympus Corporation; Samsung Electronics Co., Ltd; Shandong Weigao Group Medical Polymer Company Ltd.; Shanghai Microport Medbot (Group) Co., Ltd.; and Titan Medical Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the above factors will also impact future demand for our Ion system, as we extend our commercial offering into diagnostics, along with additional factors associated with a new product introduction, including, but not limited to, our ability to optimize manufacturing and our supply chain, competition, clinical data to demonstrate value, and market acceptance.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_124"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Product Introductions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SureForm 30 Curved-Tip Stapler and Reloads.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2021, we obtained FDA clearance for our 8 mm SureForm 30 Curved-Tip Stapler and reloads (gray, white, and blue) for use in general, thoracic, gynecologic, urologic, and pediatric surgery. We designed this instrument to help surgeons better visualize and reach anatomy through a combination of the 8 mm diameter instrument shaft and jaws, 120-degree cone of wristed articulation, and the curved tip. As it fits through the 8 mm da Vinci surgical system instrument cannula, the stapler allows different angles for surgeons to approach patient anatomy. Consistent with our other SureForm staplers, the 8 mm SureForm 30 Curved-Tip Stapler integrates SmartFire technology, which makes automatic adjustments to the firing process as staples are formed and the transection is made. The technology makes more than 1,000 measurements per second, helping achieve a consistent staple line. We completed initial evaluations of the 8 mm SureForm 30 stapler with certain customers in the U.S. in 2022. The full U.S. product launch will occur in late 2023, with other countries to follow. In October 2022, we received regulatory clearance in Japan to market our 8 mm SureForm 30 Curved-Tip and Straight-Tip Stapler instruments and reloads for use in general, thoracic (except for cardiac), gynecologic, and urologic surgery. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SynchroSeal and E-100 Generator.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2019, we obtained FDA clearance for our SynchroSeal instrument and E-100 generator. Following the FDA clearance, in February 2020, we received European certification for both products. In March 2020, we received regulatory clearance in Japan to market both our SynchroSeal instrument and E-100 generator. In August 2020, we received regulatory clearance in South Korea to market our E-100 generator. SynchroSeal is a single-use, bipolar, electrosurgical instrument intended for grasping, dissection, sealing, and transection of tissue. With its wristed articulation, rapid sealing cycle, and refined curved jaw, SynchroSeal offers enhanced versatility to the da Vinci Energy portfolio. The E-100 generator is an electrosurgical generator developed to power two key instruments&#8211;Vessel Sealer Extend and SynchroSeal&#8211;on the da Vinci X and da Vinci Xi Surgical Systems. The generator delivers high frequency energy for cutting, coagulation, and vessel sealing of tissues.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SureForm 45 Curved-Tip Stapler and Gray Reload.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2019, we obtained FDA clearance for the SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload. We have also obtained European certification for our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload. In September 2019, we received regulatory clearance in Japan to market both our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload. We received regulatory clearance in South Korea to market our SureForm 45 Curved-Tip Stapler and SureForm 45 Gray reload in June 2021 and July 2021, respectively. SureForm 45 Curved-Tip Stapler is a single-use, fully wristed stapling instrument with a curved tip intended for resection, transection, and/or creation of anastomoses. SureForm 45 Gray reload is a new, single-use cartridge that contains multiple staggered rows of implantable staples and a stainless steel knife. The SureForm 45 Curved-Tip Stapler and Gray reload have particular utility in thoracic procedures and round out our SureForm 45 portfolio. Not all reloads or staplers are available for use on all systems or in all countries.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Endoscope Plus. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we obtained European certification for our da Vinci Endoscope Plus, an enhanced 3D endoscope for use with our da Vinci X and Xi Surgical Systems. Following the European certification, in July 2019, we obtained FDA clearance for our da Vinci Endoscope Plus. We have also received regulatory clearances in South Korea and Japan to market our da Vinci Endoscope Plus in December 2019 and May 2020, respectively. In March 2022, we received regulatory clearance in China to market our da Vinci Endoscope Plus. The da Vinci Endoscope Plus leverages new sensor technology to allow for increased sharpness and color accuracy.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Da Vinci Handheld Camera.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2019, we obtained FDA clearance for our da Vinci Handheld Camera, a lightweight, 2D camera head, which can be connected to third-party laparoscopes. This allows the laparoscopic image to be displayed on the da Vinci X/Xi vision cart to address aspects of da Vinci procedures that may require the use of a laparoscope, thus eliminating the need for redundant equipment in the operating room and increasing procedure efficiency. In February 2020, we obtained European certification for our da Vinci Handheld Camera. We broadly launched the da Vinci Handheld Camera in our European direct markets and in the U.S. in May 2020 and June 2020, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Orpheus Medical</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired Orpheus Medical Ltd. and its wholly owned subsidiaries to deepen and expand our integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical videos. Orpheus Medical is a wholly owned subsidiary of Intuitive.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_130"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intuitive Ventures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we launched Intuitive Ventures, an inaugural $100&#160;million fund focused on investment opportunities in companies that share Intuitive&#8217;s commitment to advancing positive outcomes in healthcare. As of December&#160;31, 2022, we have invested $33&#160;million of the $100&#160;million.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_133"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Operational and Financial Highlights</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenue increased by 9% to $6.2 billion for the year ended December&#160;31, 2022, compared to $5.7 billion for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 1,875,000 da Vinci procedures were performed during the year ended December&#160;31, 2022, an increase of 18% compared to approximately 1,594,000 da Vinci procedures for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approximately 23,500 Ion procedures were performed during the year ended December 31, 2022, an increase of 218% compared to approximately 7,400 Ion procedures for the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Instruments and accessories revenue increased by 13% to $3.52 billion for the year ended December&#160;31, 2022, compared to $3.10 billion for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Systems revenue decreased by 1% to $1.68 billion for the year ended December&#160;31, 2022, compared to $1.69 billion for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">da Vinci Surgical Systems were placed during the year ended December&#160;31, 2022, a decrease of 6% compared to 1,347 systems during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31, 2022, we had a da Vinci Surgical System installed base of approximately 7,544 systems, an increase of 12% compared to the installed base of approximately 6,730 systems as of December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Utilization of da Vinci Surgical Systems, measured in terms of procedures per system per year, increased 4% relative to 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">192 Ion systems were placed during the year ended December&#160;31, 2022, an increase of 106% compared to 93 systems during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December 31, 2022, we had an Ion system installed base of approximately 321 systems, an increase of 149% compared to the installed base of approximately 129 systems as of December 31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross profit as a percentage of revenue was 67.4% for the year ended December&#160;31, 2022, compared to 69.3% for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating income decreased by 13% to $1.58&#160;billion for the year ended December&#160;31, 2022, compared to $1.82&#160;billion for the year ended December&#160;31, 2021. Operating income included $517 million and $457 million of share-based compensation expense related to employee stock plans and $45.4 million and $37.0 million of intangible asset-related charges for the years ended December&#160;31, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31, 2022, we had $6.74 billion in cash, cash equivalents, and investments. Cash, cash equivalents, and investments decreased by $1.88 billion, compared to $8.62 billion as of December&#160;31, 2021, primarily as a result of cash used for share repurchases of $2.61 billion, capital expenditures, and taxes paid related to net share settlements of equity awards, as well as unrealized losses on interest-bearing debt securities classified as available for sale, partially offset by cash provided by operating activities and proceeds from stock options exercises and employee stock purchases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our Consolidated Financial Statements and Notes thereto. This section of the Annual Report on Form 10-K generally discusses 2022 and 2021 items and year-to-year comparisons between 2022 and 2021. Discussions of 2020 items and year-to-year comparisons between 2021 and 2020 that are not included in this report on Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the years indicated, certain Consolidated Statements of Income information (in millions, except percentages):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of total Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of total Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of total Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,710.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,329.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,196.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,958.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interest in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i025de1eec32044f5a30c5872569f0e8d_142"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by 9% to $6.2 billion for the year ended December&#160;31, 2022, compared to $5.7 billion for the year ended December 31, 2021. Total revenue for the year ended December&#160;31, 2021, increased by 31% compared to $4.4 billion for the year ended December 31, 2020. The increase in total revenue for the year ended December 31, 2022, resulted from 13% higher instruments and accessories revenue, driven by approximately 18% higher da Vinci procedure volume, partially offset by foreign currency impacts and customer buying patterns, and 12% higher service revenue, partially offset by 1% lower systems revenue, driven by 6% lower da Vinci system placements, partially offset by higher operating lease revenue. In conjunction with our 2020 COVID-19 Customer Relief Program implemented in the second quarter of 2020, service revenue in 2020 was reduced by $80&#160;million as a result of service fee credits provided to customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue denominated in foreign currencies as a percentage of total revenue was approximately 24%, 23%, and 23% for the years ended December&#160;31, 2022, 2021, and 2020, respectively. We generally sell our products and services in local currencies where we have direct distribution channels. Foreign currency rate fluctuations, as determined by comparing current period revenue in USD to current period revenue in local currency using the same foreign exchange rates as the prior year same period, net of the impacts from foreign currency hedging, had an unfavorable impact on OUS total revenue of $138 million for the year </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2022, as compared to 2021. Foreign currency rate fluctuations, net of the impacts from foreign currency hedging, had a favorable impact on OUS total revenue of $35 million for the year ended December 31, 2021, as compared to 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue generated in the U.S. accounted for 67%, 67%, and 68% of total revenue for the years ended December&#160;31, 2022, 2021, and 2020, respectively. We believe that U.S. revenue has accounted for the large majority of total revenue due to U.S. patients&#8217; ability to choose their provider and method of treatment, reimbursement structures supportive of innovation and MIS, and our initial investments focused on U.S. infrastructure. We have been investing in our business in OUS markets, and our OUS procedures have grown faster in proportion to U.S. procedures. We expect that our OUS procedures and revenue will make up a greater portion of our business in the long term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue and system unit placements for the years ended December 31, 2022, 2021, and 2020, respectively (in millions, except percentages and unit placements):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,710.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OUS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,710.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of Revenue &#8212; U.S.</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of Revenue &#8212; OUS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recurring revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,293.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of Total revenue </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Da Vinci Surgical System Placements by Region</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. unit placements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OUS unit placements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unit placements*</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Systems placed under operating leases (included in total unit placements)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Da Vinci Surgical System Placements involving System Trade-ins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unit placements involving trade-ins</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unit placements not involving trade-ins</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Ion System Placements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">**</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**Systems placed under operating leases (included in total unit placements)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i025de1eec32044f5a30c5872569f0e8d_145"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue increased by 8% to $5.20 billion for the year ended December&#160;31, 2022, compared to $4.79 billion for the year ended December&#160;31, 2021. Product revenue for the year ended December&#160;31, 2021, increased by 32% compared to $3.63 billion for the year ended December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments and accessories revenue increased by 13% to $3.52 billion for the year ended December&#160;31, 2022, compared to $3.10 billion for the year ended December&#160;31, 2021. The increase in instruments and accessories revenue was primarily driven by da Vinci procedure growth of approximately 18% and incremental sales of our advanced instruments. The increase was partially offset by foreign currency impacts, customer buying patterns, and hospitals normalizing their purchasing of new Extended Use Instruments as a result of the recent launch of our Extended Use Program. The 2022 U.S. da Vinci procedure growth was approximately 16%, driven by strong growth in general surgery procedures, most notably hernia repair, cholecystectomy, and bariatric procedures, as well as moderate growth in the more mature gynecologic and urologic procedure categories. The 2022 OUS da Vinci procedure growth was approximately 22%, driven by continued growth in urologic procedures, including prostatectomies and partial nephrectomies, and earlier stage growth in general surgery (particularly colorectal), gynecologic, and thoracic procedures. Both growth rates were impacted by the disruption caused by the COVID-19 pandemic, as noted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above. Geographically, the 2022 OUS da Vinci procedure growth was driven by procedure expansion in a number of markets with particular strength in Japan, Germany, and the UK. We also saw procedure growth in China, despite the procedure growth rate being lower than the prior year as a result of an increase in COVID-19 cases, particularly in the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems revenue decreased by 1% to $1.68 billion for the year ended December&#160;31, 2022, compared to $1.69 billion for the year ended December&#160;31, 2021. The decrease in systems revenue was primarily driven by lower sales-type lease revenue, fewer da Vinci system placements, lower 2022 da Vinci ASPs, lower lease buyout revenue, and a higher proportion of da Vinci system placements under operating leases, partially offset by higher operating lease revenue and more Ion system placements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 1,264 da Vinci Surgical Systems were placed compared to 1,347 systems during 2021. By geography, 692 systems were placed in the U.S., 280 in Europe, 244 in Asia, and 48 in other markets during 2022, compared to 865 systems placed in the U.S., 232 in Europe, 203 in Asia, and 47 in other markets during 2021. The decrease in system placements was primarily driven by a smaller number of third generation da Vinci systems available for trade-in along with the macroeconomic challenges impacting our customers, primarily in the U.S. Nevertheless, the incremental system placements reflect continued procedure growth and further customer validation that robotic-assisted surgery addresses their quadruple aim objectives. As of December 31, 2022, we had a da Vinci Surgical System installed base of approximately 7,544 systems, compared to an installed base of approximately 6,730 systems as of December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We placed 591 and 668 da Vinci Surgical Systems under lease or usage-based arrangements, of which 492 and 517 systems were classified as operating leases for the years ended December 31, 2022, and 2021, respectively. Operating lease revenue, including the contribution from Ion systems, was $377 million for the year ended December 31, 2022, compared to $277 million for the year ended December 31, 2021. Da Vinci Surgical Systems placed as operating leases represented 39% of total placements during 2022,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. 1,683 da Vinci Surgical Systems were installed at customers under operating lease or usage-based arrangements as of December 31, 2022, compared to 1,294 systems as of December&#160;31, 2021. Revenue from Lease Buyouts was $72 million for the year ended December 31, 2022, compared to $96 million for the year ended December 31, 2021. We expect revenue from Lease Buyouts to fluctuate from period to period depending on the timing of when, and if, customers choose to exercise the buyout options embedded in their leases.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The da Vinci Surgical System ASP, excluding systems placed under operating lease or usage-based arrangements and Ion systems, was approximately $1.49 million for the year ended December 31, 2022, compared to approximately $1.55 million for the year ended December 31, 2021. The lower 2022 ASP was largely driven by unfavorable foreign currency impacts, unfavorable geographic mix, and higher pricing discounts, partially offset by favorable product mix and fewer trade-ins. ASP fluctuates from period to period based on geographic and product mix, product pricing, systems placed involving trade-ins, and changes in foreign exchange rates.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 192 Ion systems were placed compared to 93 systems during 2021. We placed 112 and 57 Ion systems under lease or usage-based arrangements, of which 101 and 50 systems were classified as operating leases for the years ended December 31, 2022, and 2021, respectively. Ion systems placed as operating leases represented 53% of total placements during 2022, compared to 54% during 2021.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_148"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue increased by 12% to $1.02 billion for the year ended December&#160;31, 2022, compared to $0.92 billion for the year ended December&#160;31, 2021. Service revenue increased by 27% for the year ended December&#160;31, 2021, compared to $0.72 billion for the year ended December&#160;31, 2020. The increase in service revenue in 2022 was primarily driven by a larger installed base of da Vinci Surgical Systems producing service revenue, partially offset by foreign currency impacts. The increase in service revenue in 2021 was primarily driven by a larger installed base of da Vinci Surgical Systems producing service revenue, as well as the effects of the Customer Relief Program in the prior year, which resulted in an $80&#160;million decrease in service revenue in 2020 as a result of service fee credits provided to customers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit for the year ended December&#160;31, 2022, increased by 5% to $3.50 billion, representing 67.3% of product revenue, compared to $3.33 billion, representing 69.5% of product revenue, for the year ended December&#160;31, 2021. The higher product gross profit for the year ended December&#160;31, 2022, was primarily driven by higher product revenue, partially offset by lower product gross profit margin. The lower product gross profit margin for the year ended December&#160;31, 2022, was primarily driven by higher fixed overhead costs from investments to drive the growth of the business and strengthen our operating capabilities, higher freight and materials costs, unfavorable foreign currency impacts, and lower 2022 da Vinci system ASPs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit for the years ended December&#160;31, 2022, and 2021, included share-based compensation expense of $67.6 million and $68.9 million, respectively, and intangible assets amortization expense of $17.3 million and $17.6 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service gross profit for the year ended December&#160;31, 2022, increased by 11% to $0.70 billion, representing 68.2% of service revenue, compared to $0.63 billion, representing 68.6% of service revenue, for the year ended December&#160;31, 2021. The higher service gross profit for the year ended December&#160;31, 2022, was primarily driven by higher service revenue, reflecting a larger installed base of da Vinci Surgical Systems, partially offset by a lower service gross profit margin. The lower service gross profit margin for the year ended December&#160;31, 2022, was primarily driven by higher freight and overhead costs, as well as unfavorable foreign currency impacts, partially offset by lower materials costs for repairs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service gross profit for the years ended December&#160;31, 2022, and 2021, included share-based compensation expense of $23.6 million and $22.2 million, respectively, and intangible assets amortization expense of $1.9 million and $1.0 million, respectively.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_154"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses include costs for sales, marketing and administrative personnel, sales and marketing activities, trade show expenses, legal expenses, regulatory fees, and general corporate expenses.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the year ended December&#160;31, 2022, increased by 19% to $1.74 billion, compared to $1.47 billion for the year ended December&#160;31, 2021. The increase in selling, general and administrative expenses for the year ended December&#160;31, 2022, was primarily driven by higher headcount, resulting in increased fixed and share-based compensation expense, higher variable compensation, increased infrastructure costs to support our growth, and higher litigation charges, partially offset by favorable foreign currency impacts. In addition, there were higher travel, training, and marketing expenses for the year ended December&#160;31, 2022, as compared with the prior year. In the fourth quarter of 2021, we made a charitable contribution of $30&#160;million to the Intuitive Foundation, a not-for-profit organization whose mission is to reduce the global burden of disease and suffering through research, education, and philanthropy aimed at better outcomes for patients around the globe.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the years ended December 31, 2022, and 2021, included share-based compensation expense of $261 million and $232 million, respectively, and intangible assets amortization expense of $5.9 million and $7.3 million, respectively.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_157"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include costs associated with the design, development, testing, and significant enhancement of our products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December&#160;31, 2022, increased by 31% to $0.88 billion, compared to $0.67 billion for the year ended December&#160;31, 2021. The increase in research and development expenses for the year ended December&#160;31, 2022, was primarily driven by higher personnel-related expenses, including share-based compensation expense, project costs incurred to support a broader set of product development initiatives, including future generations of robotics, Ion and SP platform investments, and digital investments, and intangible asset-related charges.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the years ended December 31, 2022, and 2021, included share-based compensation expense of $164 million and $134 million, respectively, and intangible asset-related charges of $20.3 million and $11.1 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses fluctuate with project timing. Based upon our broader set of product development initiatives and the stage of the underlying projects, we expect to continue to make substantial investments in research and development and anticipate that research and development expenses will continue to increase in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net, for the year ended December&#160;31, 2022, decreased by 57% to $30 million, compared to $69 million for the year ended December 31, 2021. Interest and other income, net decreased by 56% for the year ended December&#160;31, 2021, compared to $157 million for the year ended December&#160;31, 2020. The decrease in interest and other income, net, for the year ended December&#160;31, 2022, was primarily driven by unrealized losses on investments resulting from strategic arrangements (compared to unrealized gains on investments resulting from strategic arrangements in 2021) and higher foreign exchange losses, partially offset by higher interest income earned, despite lower cash and investment balances, due to an increase in average interest rates.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held an equity investment in preferred shares of Broncus Holding Corporation (&#8220;Broncus&#8221;), which was reflected in our Consolidated Financial Statements on a cost basis. In the first quarter of 2021, we recorded an unrealized gain on our investment in Broncus of approximately $14&#160;million. In September 2021, Broncus completed an initial public offering (&#8220;IPO&#8221;) of common shares on the Stock Exchange of Hong Kong. Upon completion of the IPO, the preferred shares were converted to common shares in Broncus, and we recognized a net gain on this investment in the third quarter of 2021 of approximately $8&#160;million. We were restricted from selling these shares for a period of six months. For the year ended December&#160;31, 2022, we recognized a loss on this investment of approximately $21&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held an equity investment in common shares of Bolder Surgical Holdings, Inc. (&#8220;Bolder&#8221;), which was reflected in our Consolidated Financial Statements on a cost basis. During the fourth quarter of 2021, Hologic, Inc., a publicly traded company, completed its acquisition of Bolder. Under the terms of the acquisition agreement, we received cash on the date of closing and recognized a gain on this investment of approximately $10&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held an equity investment in preferred shares of InTouch Technologies, Inc. (&#8220;InTouch&#8221;), which was reflected in our Consolidated Financial Statements on a cost basis. On July 1, 2020, Teladoc Health, Inc. (&#8220;Teladoc&#8221;), a publicly traded company, completed its acquisition of InTouch. Based on the terms of the agreement, we received Teladoc shares on the date of closing and recognized a gain on our investment of approximately $45&#160;million. We were restricted from selling these shares for a period of six months. In January 2021, we sold all of our shares in Teladoc and recognized a gain on this investment of approximately $11&#160;million. This gain was offset by a $7.5&#160;million loss recognized upon the settlement of a corresponding derivative collar contract in January 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recorded unrealized gains on other strategic investments in 2020 of approximately $22&#160;million.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_163"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $262 million and $162 million for the years ended December&#160;31, 2022, and 2021, respectively. Our effective tax rate for 2022 was approximately 16.3% compared to 8.6% for 2021. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rates for 2022 and 2021 differed from the U.S. federal statutory rate of 21% primarily due to the excess tax benefits associated with employee equity plans, the effect of income earned by certain overseas entities being taxed at rates lower than the federal statutory rate, and the federal research and development credit benefit, partially offset by U.S. tax on foreign earnings and state income taxes (net of federal benefit).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the year ended December&#160;31, 2022, reflected the impact of a change in U.S. tax law effective January 1, 2022, which requires the capitalization and amortization of research and development expenditures incurred after December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in income tax expense for the year ended December&#160;31, 2022, was primarily due to the impact of the capitalization of research and development and lower excess tax benefits, as discussed below, as well as the fact that income tax expense for the year ended December&#160;31, 2021, included a one-time benefit of $66.4&#160;million from the re-measurement of our Swiss deferred tax assets resulting from the extension of the economic useful life of certain intangible assets. The increase was partially offset by a one-time charge of $13.6&#160;million in 2021, which related to intercompany charges for share-based compensation for relevant periods prior to 2020, triggered by additional Internal Revenue Service (&#8220;IRS&#8221;) guidance issued in July 2021 associated with a Ninth Circuit Court of Appeals opinion involving an independent third party.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes for 2022 and 2021 included excess tax benefits associated with employee equity plans of $99&#160;million and $186 million, respectively, which reduced our effective tax rate by 6.1 and 9.8 percentage points, respectively. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of our stock, the volume of share-based awards settled or vested, and the value assigned to employee equity awards under GAAP, which results in increased income tax expense volatility.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act (&#8220;IRA&#8221;) was enacted in the United States. The IRA introduces a 15% alternative minimum tax based on the financial statement income of certain large corporations, effective for tax years beginning after December 31, 2022. The IRA also includes a 1% excise tax on the net fair market value of stock repurchases made after </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022. We have considered the applicable tax law changes, and there is no impact on our tax provision for the year ended December&#160;31, 2022. We will continue to evaluate the impact of these tax law changes on future periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state, and foreign income tax returns in many jurisdictions in the U.S. and abroad. Years prior to 2016 are considered closed for most significant jurisdictions. Certain of our unrecognized tax benefits could change due to activities of various tax authorities, including evolving interpretations of existing tax laws in the jurisdictions we operate, potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect our effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, we cannot estimate the range of reasonably possible changes in unrecognized tax benefits that may occur in the next 12 months.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the examination of our income tax returns by the IRS and other tax authorities. The outcome of these audits cannot be predicted with certainty. Management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. If any issues addressed in our tax audits are resolved in a manner not consistent with management&#8217;s expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_166"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income Attributable to Noncontrolling Interest in Joint Venture</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Joint Venture with Fosun Pharma was established to research, develop, manufacture, and sell robotic-assisted, catheter-based medical devices. The Joint Venture is owned 60% by us and 40% by Fosun Pharma and is located in China. The catheter-based technology will initially target early diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world. Distribution of catheter-based medical devices in China will be conducted by the Joint Venture, while distribution outside of China will be conducted by us.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, the Joint Venture acquired certain assets, including distribution rights, customer relationships, and certain personnel, from Chindex and its affiliates, a subsidiary of Fosun Pharma, and began direct operations for da Vinci products and services in China. As of December 31, 2022, the companies have contributed $55&#160;million of up to $100&#160;million required by the joint venture agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest in Joint Venture for the year ended December 31, 2022, was $22.1&#160;million, compared to $23.5&#160;million for the year ended December 31, 2021, and $6.2&#160;million for the year ended December 31, 2020. The decrease in net income attributable to noncontrolling interest in Joint Venture for the year ended December&#160;31, 2022, was primarily due to a decrease in sales and an increase in selling, general and administrative expenses in China, partially offset by a decrease in income tax expense in China.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_169"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_172"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal source of liquidity is cash provided by operations and by the issuance of common stock through the exercise of stock options and our employee stock purchase program. Cash and cash equivalents plus short- and long-term investments decreased by $1.88 billion to $6.74 billion as of December&#160;31, 2022, from $8.62 billion as of December&#160;31, 2021, primarily from cash used in share repurchases, capital expenditures, and taxes paid related to net share settlements of equity awards, as well as unrealized losses on interest-bearing debt securities classified as available for sale, offset by cash provided by our operations and proceeds from stock option exercises and employee stock purchases. Cash and cash equivalents plus short- and long-term investments increased by $1.75&#160;billion to $8.62 billion as of December&#160;31, 2021, from $6.87&#160;billion as of December&#160;31, 2020, primarily from cash provided by our operations and proceeds from stock option exercises and employee stock purchases, partially offset by capital expenditures and taxes paid related to net share settlements of equity awards.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash requirements depend on numerous factors, including market acceptance of our products, the resources we devote to developing and supporting our products, and other factors. We expect to continue to devote substantial resources to expand procedure adoption and acceptance of our products. We have made substantial investments in our commercial operations, product development activities, facilities, and intellectual property. Based on our business model, we anticipate that we will continue to be able to fund future growth through cash provided by our operations. We believe that our current cash, cash equivalents, and investment balances, together with income to be derived from the sale of our products, will be sufficient to meet our liquidity requirements for the foreseeable future. However, we may experience reduced cash flow from operations as a result of the increasing risk of a recession along with other macroeconomic and geopolitical headwinds.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $396 million of our cash, cash equivalents, and investments was held by foreign subsidiaries. We intend to repatriate earnings from our Swiss subsidiary and our joint venture in Hong Kong, as needed, since the U.S. and foreign tax implications of such repatriations are not expected to be significant. We will continue to indefinitely reinvest earnings from the rest of our foreign subsidiaries, which are not significant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk&#8221; for discussion on the impact of interest rate risk and market risk on our investment portfolio.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_175"></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Cash Flow Data</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the years ended December&#160;31, 2022, 2021, and 2020 (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,572.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i025de1eec32044f5a30c5872569f0e8d_178"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, net cash provided by operating activities of $1.49 billion exceeded our net income of $1.34 billion, primarily due to the following factors:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Our net income included non-cash charges of $766 million, consisting primarily of the following significant items: share-based compensation of $513 million; depreciation expense and losses on the disposal of property, plant, and equipment of $338 million; changes in deferred income taxes of $(185) million; and net losses on investments, accretion, and amortization of $49 million.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The non-cash charges outlined above were partially offset by changes in operating assets and liabilities that resulted in $619 million of cash used in operating activities during the year ended December&#160;31, 2022. Inventory, including the transfer of equipment from inventory to property, plant, and equipment, increased by $547 million, primarily to address the growth in the business as well as to mitigate risks of disruption that could arise from trade, supply, or other matters. Refer to further details in the supplemental cash flow information in Note 4 to the Consolidated Financial Statements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable increased by $159 million, primarily due to the timing of billings and collections. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets increased by $129 million, primarily due to an increase in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investments in sales-type leases and an increase in recoverable VAT related to growth in our OUS activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unfavorable impact of these items on cash provided by operating activities was partially offset by a $122 million increase in other liabilities, primarily due to additional accruals related to capital expenditures and timing of income tax payments, a $52 million increase in accrued compensation and employee benefits, primarily due to higher headcount and variable compensation, and a $21 million increase in accounts payable, primarily due to the timing of billing and payments.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, net cash provided by operating activities of&#160;$2.09 billion&#160;exceeded our net income of&#160;$1.73 billion,&#160;primarily due to the following factors:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Our net income included non-cash charges of $729 million, consisting primarily of the following significant items: share-based compensation of $449 million; depreciation expense and losses on the disposal of property, plant, and equipment of $283 million; changes in deferred income taxes of $(63) million; and amortization of intangible assets of $27 million.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The non-cash charges outlined above were partially offset by changes in operating assets and liabilities that resulted in&#160;$368 million&#160;of cash used in operating activities during the year ended December&#160;31, 2021. Inventory, including the transfer of equipment from inventory to property, plant, and equipment, increased by $256 million, primarily to address the growth in the business as well as to mitigate risks of disruption that could arise from trade, supply, or other matters. Refer to further details in the supplemental cash flow information in Note 4 to the Consolidated Financial Statements. Prepaid expenses and other assets increased by $205 million, primarily due to an increase in net investments in sales-type leases, and accounts receivable increased by $142 million, primarily due to the timing of billings and collections. The unfavorable impact of these items on cash used in operating activities was partially offset by a $115 million increase in accrued compensation and employee benefits, primarily due to higher headcount and variable compensation, a $51 million increase in other liabilities, primarily due to additional accruals related to capital expenditures and timing of income tax payments, a $36&#160;million increase in accounts payable, primarily due to the timing of payments and vendor billings, and a $33 million increase in deferred revenue, primarily due to increased volume of sales contracts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2022, consisted primarily of proceeds from maturities and sales of investments, net of purchases, of $1.92 billion, partially offset by $532 million paid for the acquisition of property, plant, and equipment.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2021, consisted primarily of purchases of investments, net of proceeds from maturities and sales, of&#160;$2.10 billion&#160;and $340 million paid for the acquisition of property, plant, and equipment.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2020, consisted of purchases of investments, net of proceeds from maturities and sales, of $561 million, $342 million paid for the acquisition of property, plant, and equipment, and $38&#160;million paid for the Orpheus Medical acquisition, net of cash acquired.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest predominantly in high quality, fixed income securities. Our investment portfolio may, at any time, contain investments in U.S. treasury and U.S. government agency securities, taxable and tax-exempt municipal notes, corporate notes and bonds, commercial paper, non-U.S. government agency securities, cash deposits, and money market funds.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_184"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December 31, 2022, consisted primarily of cash used in the repurchase of approximately 11.2 million shares of our common stock for $2.61 billion, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of which related to accelerated share buyback programs executed and settled during 2022 and further described in Note 9 to the Consolidated Financial Statements, and taxes paid on behalf of employees related to net share settlements of vested employee equity awards of $194 million, partially offset by proceeds from stock option exercises and employee stock purchases of $234 million.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2021, consisted primarily of proceeds from stock option exercises and employee stock purchases of $277 million, partially offset by taxes paid on behalf of employees related to net share settlements of vested employee equity awards of $212 million, and the payment of deferred purchase consideration of $22 million.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December 31,&#160;2020, consisted&#160;primarily of taxes paid on behalf of employees related to net share settlements of vested employee equity awards of&#160;$175 million, cash used in the repurchase of approximately 0.7 million shares of our common stock in the open market for $134 million, and the payment of deferred purchase consideration of $85&#160;million, partially offset by proceeds from stock option exercises and employee stock purchases of $309 million.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures are increasing as we continue to build the Company to supply our customers with highly differentiated products manufactured in highly automated factories that facilitate outstanding performance in product quality, availability, and cost. A significant portion of this investment involves the construction of facilities to expand our manufacturing and commercial capabilities. We have also been vertically integrating key technologies to develop a more robust supply chain and bring important products to market at attractive price points. These investments include increased ownership of our imaging pipelines, investments in strategic instruments and accessories technologies, as well as the development of software and digital products that allow us to serve our customers better. We expect these capital investments to increase significantly in 2023 to a range between $800&#160;million and $1&#160;billion, over half of which will be facilities-related investments. We intend to fund these capital investments with cash generated from operations.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_187"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commercial Commitments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We lease spaces for our operations in the U.S. as well as in Japan, China, Israel, Mexico, Germany, South Korea, the United Kingdom, and other countries. We also lease automobiles for certain sales and field service employees. These leases have varying terms of up to 20 years. Operating lease amounts include future minimum lease payments under all of our non-cancellable operating leases with an initial term in excess of one year. Refer to Note 6 to the Consolidated Financial Statements included in Part II, Item 8 for further details.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase commitments and obligations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Total purchase commitments and obligations as of December 31, 2022, are estimated to be $2.14&#160;billion, of which $1.79&#160;billion is expected to be due within a year. These amounts include an estimate of all open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers for which we have not received the goods or services, commitments for capital expenditures, including construction-related activities, for which we have not received the goods or services, and commitments for the acquisition and licensing of intellectual property. More than one third of our estimated purchase commitments and obligations are facilities-related. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule, or adjust our requirements based on our business needs prior to the delivery of goods or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance of services. In addition to the above, we have committed to making potential future milestone payments to third parties as part of licensing, collaboration, and development arrangements. Payments under these agreements generally become due and payable only upon achievement of certain developmental, regulatory, and/or commercial milestones. For instances in which the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on our Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Tax Act deemed repatriation tax.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  As of December&#160;31, 2022, our obligation associated with the deemed repatriation tax is $161&#160;million, of which $40&#160;million is due within a year. Amounts due are expected to be paid in installments in accordance with the 2017 Tax Act.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to make a reasonably reliable estimate as to when payments may occur for our unrecognized tax benefits.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_190"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we did not have any significant off-balance sheet arrangements, as defined in Item&#160;303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_193"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements are prepared in conformity with GAAP, which requires us to make judgments, estimates, and assumptions. See &#8220;Note 2. Summary of Significant Accounting Policies,&#8221; in Notes to the Consolidated Financial Statements, which is included in &#8220;Item&#160;8. Financial Statements and Supplementary Data,&#8221; for a description of our significant accounting policies and methods used in the preparation of our Consolidated Financial Statements. The methods, estimates, and judgments that we use in applying our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. Our most critical accounting estimates include:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation and recognition of investments, which impacts our investment portfolio balance when we assess fair value and interest and other income, net, when we record impairments;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the standalone selling prices used to allocate the contract consideration to the individual performance obligations, which impacts revenue recognition;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of inventory, which impacts gross profit margins;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of and assessment of the recoverability of intangible assets and goodwill and the estimated useful lives of intangible assets, which primarily impacts gross profit margin or operating expenses when we record asset impairments or accelerate their amortization;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recognition and measurement of current and deferred income taxes (including the measurement of uncertain tax positions), which impact our provision for taxes; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the estimate of probable loss associated with legal contingencies, which impacts accrued liabilities and operating expenses.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments Valuation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments may include, at any time, a diversified portfolio of cash equivalents and short- and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes, as well as equity investments with and without readily determinable value. The assessment of the fair value of investments can be difficult and subjective. GAAP establishes three levels of inputs that may be used to measure fair value. Each level of input has different levels of subjectivity and difficulty involved in determining fair value. Valuation of Level 1 and 2 instruments generally do not require significant management judgment, and the estimation is not difficult. Level 3 instruments include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&#160;The determination of fair value for Level 3 instruments requires the most management judgment and subjectivity. There were no Level 3 securities for the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After determining the fair value of our available-for-sale instruments, we identify instruments with an amortized cost basis in excess of their estimated fair value. Available-for-sale instruments in an unrealized loss position are written down to fair value through a charge to interest and other income, net in the Consolidated Statements of Income, if we intend to sell the security or it is more likely than not we will be required to sell the security before recovery of its amortized cost basis. For the remaining securities, we assess what amount of the excess, if any, is caused by expected credit losses. Factors considered in determining whether a credit-related loss exists include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. These judgments could prove to be wrong, and companies with relatively high credit ratings and solid financial conditions may not be able to fulfill their obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant impairment charges were recorded during the years ended December 31, 2022, 2021, and 2020. As of December&#160;31, 2022, and 2021, net unrealized losses on investments of $154.2 million and $16.0 million, net of tax, respectively, were included in accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Our system sale arrangements contain multiple products and services, including system(s), system components, system accessories, instruments, accessories, and services. Other than services, we generally deliver all of the products upfront. Each of these products and services is a distinct performance obligation. System accessories, instruments, accessories, and services are also sold on a standalone basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling prices considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. We regularly review standalone selling prices and maintain internal controls over establishing and updating these estimates.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our system sales arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are billed at a stated service price. Revenue that is allocated to the service obligation is deferred and recognized ratably over the service period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory valuation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. The cost basis of our inventory is reduced for any products that are considered excess or obsolete based on assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which could have a material adverse effect on the results of our operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of intangible assets and goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We allocate the fair value of purchase consideration, including contingent consideration, to assets acquired and liabilities assumed in a business combination based on their estimated fair values at the acquisition date. The excess of the fair value of the purchase consideration over the fair value of assets acquired, liabilities assumed, and any noncontrolling interest is recorded as goodwill. When determining the fair value of assets acquired, liabilities assumed, and any noncontrolling interest, management is required to make certain estimates and assumptions, especially with respect to intangible assets. The estimates and assumptions used in valuing intangible assets include, but are not limited to, the amount and timing of projected future cash flows, the discount rate used to determine the present value of these cash flows, and the determination of the assets&#8217; life cycle. These estimates are inherently uncertain and, therefore, actual results may differ from the estimates made.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets include identifiable intangible assets and goodwill. Identifiable intangible assets include developed technology, patents, distribution rights, customer relationships, licenses, and non-competition arrangements. Currently, all of our identifiable intangible assets have finite lives. Goodwill and intangible assets with indefinite lives are subject to an annual impairment review (or more frequent if impairment indicators arise) by applying a fair value-based test. There have been no such impairments.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets with finite lives are subject to impairment testing and are reviewed for impairment when events or circumstances indicate that the carrying value of an asset is not recoverable and its carrying amount exceeds its fair value. We evaluate the recoverability of the carrying value of these identifiable intangible assets based on estimated undiscounted cash flows to be generated from such assets. If the cash flow estimates or the significant operating assumptions upon which they are based change in the future, we may be required to record additional impairment charges.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation and classification of intangible assets and goodwill and the assignment of useful lives for purposes of amortization involves judgments and the use of estimates. The evaluation of these intangible assets and goodwill for impairment under established accounting principles is required on a recurring basis. Changes in business conditions could potentially require future adjustments to the assumptions made. When we determine that the useful lives of assets are shorter than we had originally estimated, we accelerate the rate of amortization over the assets&#8217; new, shorter useful lives. No impairment charges or accelerated amortization were recorded for the years ended December&#160;31, 2022, 2021, and 2020. A considerable amount of judgment is required in assessing impairment, which includes financial forecasts. If conditions are different from management&#8217;s current estimates, material write-downs of long-lived assets may be required, which would adversely affect our operating results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets in accordance with GAAP. These estimates and judgments occur in the calculation of tax credits, benefits, and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statement purposes, as well as the interest and penalties related to uncertain tax positions. Significant changes to these estimates may result in an increase or decrease in our tax provision in the current period or subsequent periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we must assess the likelihood that we will be able to recover our deferred tax assets. In the event that all or part of our deferred tax assets are not recoverable in the future, we must increase our provision for taxes by recording a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be recoverable. In order for our deferred tax assets to be recoverable, we must be able to generate sufficient taxable income in those jurisdictions where the deferred tax assets are located. We consider forecasted income, including income that may be generated as a result of certain tax planning strategies, together with future reversals of existing taxable temporary differences, in determining the need for a valuation allowance. As of December&#160;31, 2022, we believe that it is more likely than not that our deferred tax assets will ultimately be recovered, with the exception of our California deferred tax assets. We believe that, due to the computation of California taxes under the single sales factor, it is more likely than not that our California deferred tax assets will not be realized. Should there be a change in our ability to recover our deferred tax assets, our tax provision would be affected in the period in which such change takes place.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. If we determine that a tax position will more likely than not be sustained on audit, then the second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as we have to determine the probability of various possible outcomes. We re-evaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effective settlement of audit issues, and new audit activity. Such a change in the recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for legal contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, insurance, employee-related, and other matters. We record a liability and related charge to earnings in our Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. Our assessment is re-evaluated each accounting period and is based on all available information, including discussion with any outside legal counsel that represents us. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a loss is reasonably possible, but not probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the Notes to the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables and is difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on our business, financial condition, and results of operations or cash flows.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_196"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 2. Summary of Significant Accounting Policies&#8221; of the Notes to Consolidated Financial Statements in &#8220;Item&#160;8. Financial Statements and Supplementary Data&#8221; for additional information regarding recent accounting pronouncements, including the respective expected dates of adoption and estimated effects, if any, on our Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve principal while supporting our liquidity requirements. To achieve this objective, we maintain a diversified portfolio of cash equivalents and short- and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. The securities are classified as available-for-sale and consequently are recorded at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive loss. The weighted average duration of our portfolio as of December&#160;31, 2022, was approximately 0.8 years. If interest rates rise, the market value of our investments may decline, which could result in a realized loss if we are forced to sell an investment before its scheduled maturity. A hypothetical increase or decrease in interest rates by 25 basis points would have resulted in a decrease or increase in the fair value of our net investment position of approximately $12 million, respectively, as of December&#160;31, 2022. We do not utilize derivative financial instruments to manage our interest rate risks.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertain financial markets could result in a tightening in the credit markets, a reduced level of liquidity in many financial markets, and extreme volatility in fixed income and credit markets. The credit ratings of the securities we have invested in could deteriorate and may have an adverse impact on the carrying value of these investments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Risk</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue, expense, and capital purchasing activities are transacted in U.S. dollars. However, we generally sell our products and services in local currencies where we have direct distribution channels. We operate in a number of markets on a direct sales basis and incur operating expenses in local currencies. We also purchase certain product components from non-U.S. suppliers in local currency. As a result, because a portion of our operations consists of sales activities outside of the U.S., we have foreign exchange exposures to non-U.S. dollar revenues, operating expenses, accounts receivable, accounts payable, and foreign currency bank balances.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, sales denominated in foreign currencies were approximately 24% of total revenue. The objective of our hedging program is to mitigate the impact of changes in currency exchange rates on our net cash flow from foreign currency-denominated sales and expenses. For the year ended December&#160;31, 2022, our revenue would have decreased by approximately $100 million if the U.S. dollar exchange rate strengthened by 10%. We also hedge the net recognized non-functional currency balance sheet exposures with foreign exchange forward contracts to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. A 10% strengthening of the U.S. dollar exchange rate against all currencies to which we have exposure, after considering foreign currency hedges and offsetting positions as of December&#160;31, 2022, would have resulted in an approximately $2.7 million increase in the carrying amounts of those net assets. Actual gains and losses in the future may differ materially from the hypothetical gains and losses discussed above based on changes in the timing and amount of foreign currency exchange rate movements and our actual exposure and hedging transactions. Bank counterparties to foreign exchange forward contracts expose us to credit-related losses in the event of their nonperformance. To mitigate that risk, we only contract with counterparties that meet certain minimum requirements under our counterparty risk assessment process. We monitor credit ratings and potential downgrades on at least a quarterly basis. Based on our ongoing assessment of counterparty risk, we will adjust our exposure to various counterparties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we sell to distributors outside of the U.S. in U.S. dollars, strengthening of the dollar can impact our distributors&#8217; margins and could impact the end customers&#8217; ability to purchase our products if our distributors seek to recover the impact of the change in the dollar by increasing product and service prices. Less than 10% of our revenue is conducted through distributors outside of the U.S. Strengthening of the dollar relative to non-U.S. currencies could have an adverse impact on our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations outside of the U.S. are subject to risks typical of operations outside of the U.S. including, but not limited to, differing economic conditions, changes in the political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7"> of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index To Consolidated Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_205">Report of Independent Registered Public Accounting Firm</a> &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PCAOB ID:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDIvZnJhZzphYWJlMWFhZDA3NGU0NDU3OTMzOTQ1MjFiZTgyYjAwOS90YWJsZTowM2NiMzhjMjUzOTM0ODk4OWUzY2QyZjkwNTZhM2I2Ny90YWJsZXJhbmdlOjAzY2IzOGMyNTM5MzQ4OTg5ZTNjZDJmOTA1NmEzYjY3XzItMi0xLTEtMTUwMDM0_5fa8aebd-0418-4bcd-b261-f7efb7ac69a0">238</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_205">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_208">Consolidated Balance Sheets as of December&#160;31, </a>2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_208">, and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_208">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_211">Consolidated Statements of Income for the years ended December&#160;31, </a>2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_211">, </a>2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_211">, and </a>2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_211">86</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_214">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, </a>2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_214">, </a>2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_214">, and </a>2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_214">87</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_217">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, </a>2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_217">, </a>2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_217">, and </a>2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_217">88</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_220">Consolidated Statements of Cash Flows for the years ended December&#160;31, </a>2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_220">, </a>2021<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_220">, and </a>2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_220">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_223">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_223">90</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_277">Schedule II&#8212;Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_277">121</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted, because they are not applicable or the required information is shown in the Consolidated Financial Statements or the Notes thereto.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Intuitive Surgical, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Intuitive Surgical, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of stockholders&#8217; equity and of cash flows for each of the three years in the period ended December&#160;31, 2022, including the related notes and financial statement schedule listed in the index appearing under Item 15(a)(2) (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the COSO.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of Standalone Selling Prices Related to System Sale Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 5 to the consolidated financial statements, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4XzM4NDgyOTA3MDk1OTc_bf79d33b-3ac7-4393-bd8a-06fb2a69f9b8">1,680.1</ix:nonFraction> million of systems revenue, during the year ended December&#160;31, 2022. The Company&#8217;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then management estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the determination of standalone selling prices related to system sale arrangements is a critical audit matter are the significant judgment by management when determining estimates of standalone selling prices, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence relating to the estimates of standalone selling prices used to allocate the transaction price of an arrangement to each distinct performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls over the revenue recognition process, including controls over the determination of the estimates of standalone selling prices. These procedures also included, among others, (i) testing management&#8217;s process for determining the estimates of standalone selling prices; (ii) evaluating the appropriateness of the overall methodology used by management to develop the estimates, including the appropriateness of the data inputs related to the products and services, geographies, and type of customer used in the methodology; (iii) testing the completeness and accuracy of the data used in the methodology; and (iv) testing the accuracy of management&#8217;s calculations of estimated selling prices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4Xzg4MTk_66b7b82a-2106-4e4c-add6-50c62cec70f5">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4Xzg4MjA_256246b9-7891-4035-a6bc-9d922fafb4cb">San Jose, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;10, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents </a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS, EXCEPT PAR VALUE AMOUNTS)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzQtMS0xLTEtMTUwMDM0_643b5ec3-01f2-4926-a4a7-3c2191917b3b">1,581.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzQtMy0xLTEtMTUwMDM0_964e2cdb-8dd8-4231-8fc0-14d7b8d6f063">1,290.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzUtMS0xLTEtMTUwMDM0_3e5c9b39-eac3-40e2-aadd-0ba1781aff5a">2,536.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzUtMy0xLTEtMTUwMDM0_7e3885ee-29a8-41f2-9989-e30fe5ec301e">2,913.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzljMjk3YjVjZTg2NDAzZDk5NGI2M2EwYjJjODAxN2RfNTQ5NzU1ODE0MDA1_537e3aa1-8d56-432b-82de-9300581bfabd">22.4</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzljMjk3YjVjZTg2NDAzZDk5NGI2M2EwYjJjODAxN2RfNTQ5NzU1ODE0MDEx_c334ef8a-ceab-4ad3-8ecf-123b1d274bd4">20.2</ix:nonFraction> as of December 31, 2022, and 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMS0xLTEtMTUwMDM0_8e313121-698e-4e19-8269-06c99cdb351c">942.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMy0xLTEtMTUwMDM0_485947cd-860f-451e-a7cb-e073c2a6e5f5">782.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMS0xLTEtMTUwMDM0_3860936d-1cb1-4384-833c-2d6938cd9a74">893.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMy0xLTEtMTUwMDM0_3652dc36-52d2-4090-93f7-26528b8cca89"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMy0xLTEtMTUwMDM0_addf0141-b03a-4eaf-8740-6fbbb9166f11">587.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzgtMS0xLTEtMTUwMDM0_524744bd-d0fd-4519-af4a-0162650682be">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzgtMy0xLTEtMTUwMDM0_e150eb76-94b6-457a-b550-b6c54ef476e5">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzktMS0xLTEtMTUwMDM0_699cfa6c-2e80-4851-9d6a-08afedf74083">6,253.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzktMy0xLTEtMTUwMDM0_1e7f853b-67cc-4f07-87ee-d852132427e6">5,844.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEwLTEtMS0xLTE1MDAzNA_7b15a6c4-aa33-4bf8-a329-db22d9846ddc">2,374.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEwLTMtMS0xLTE1MDAzNA_9abb740d-f8ef-481a-91e4-dea275063fcd">1,876.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzExLTEtMS0xLTE1MDAzNA_2906a3c0-29b6-4108-955a-56abb107c327">2,623.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzExLTMtMS0xLTE1MDAzNA_1d7bc8c4-c336-46a8-afe0-86fdb1f0a186">4,415.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEyLTEtMS0xLTE1MDAzNA_2b84c010-f2f0-4e8d-aa4e-cafa89ca300c">664.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEyLTMtMS0xLTE1MDAzNA_7c6a6415-1d62-40cd-ae70-7c5511b3c78e">441.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:IntangibleAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEzLTEtMS0xLTE1MDAzNA_13283c97-9d76-41fd-9616-70f53bf89988">710.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:IntangibleAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEzLTMtMS0xLTE1MDAzNA_8a4e9e4e-843d-4b5f-bc35-94ad2179d759">633.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE0LTEtMS0xLTE1MDAzNA_439399c3-618b-42f8-a90f-cb75340f30ff">348.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE0LTMtMS0xLTE1MDAzNA_5b3ab911-45d5-47d2-a70f-253bf29d5672">343.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE1LTEtMS0xLTE1MDAzNA_9d371bde-d4bb-4866-9bbe-ecd88ed7985f">12,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE1LTMtMS0xLTE1MDAzNA_8490ddf3-bacb-45bd-aa19-e2b7c085009e">13,555.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE4LTEtMS0xLTE1MDAzNA_53b1d833-ab2e-489f-9d38-7e8e4d66864f">147.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE4LTMtMS0xLTE1MDAzNA_d9b3596f-648d-4422-abba-2ccf6aa7c32e">121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE5LTEtMS0xLTE1MDAzNA_c28b9e81-0480-4690-a3c7-c937436fe4ac">401.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE5LTMtMS0xLTE1MDAzNA_8832486d-4298-416b-bcb9-025faa2f574c">350.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIwLTEtMS0xLTE1MDAzNA_590cf096-93ed-4df0-a449-d5650189aec7">397.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIwLTMtMS0xLTE1MDAzNA_3dcbcdf3-79fe-4468-8f3f-33afd5b4f25d">377.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIxLTEtMS0xLTE1MDAzNA_f7f53990-9f7e-4356-a4be-7257ec2207e4">476.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIxLTMtMS0xLTE1MDAzNA_f22370ef-56be-4516-8f0b-c825ed7d19ab">301.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIyLTEtMS0xLTE1MDAzNA_50fb12a0-63d9-4166-b4e4-fc54e884a991">1,422.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIyLTMtMS0xLTE1MDAzNA_f06927a3-84fb-4283-8a8b-3f0dfd99de72">1,149.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIzLTEtMS0xLTE1MDAzNA_bfb4f65c-6f3c-407a-b827-37719718b5f2">439.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIzLTMtMS0xLTE1MDAzNA_2cca96a0-b326-42d8-93aa-c3ba6aac1f20">453.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI0LTEtMS0xLTE1MDAzNA_9b1699ee-f25e-4c71-8a5a-290bd4937f87">1,861.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI0LTMtMS0xLTE1MDAzNA_f6f44908-724a-4c37-8e83-714363e7602f">1,603.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI1LTEtMS0xLTE1MDAzNA_c1f85c7c-58de-43e4-937c-cb593c7248b0"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI1LTMtMS0xLTE1MDAzNA_804b7f63-6b30-4f7f-91ab-e57a0d85037a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzA_7dfafc80-b4c3-475e-b897-87b6b4ce5535"><ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzA_e7c57feb-3e26-4183-b822-5880ea4c5412">2.5</ix:nonFraction></ix:nonFraction> shares authorized, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzc_789e8d29-60f4-4ef1-b07a-3bcbb37b6e05"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzc_8ab57b40-6b81-4c5b-98b4-d76c5f034c95">0.001</ix:nonFraction></ix:nonFraction> par value, issuable in series; <ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_07ac1355-9ec6-45cb-84f7-45c2a64bb471"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_0b16cebd-f01d-4763-b1e7-a76d03e0e4a2"><ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_2224cd64-d0b2-4900-b46a-978d7f1165a5"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_b6c7f64f-1747-4697-a76b-824f9b831c61">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022, and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTEtMS0xLTE1MDAzNA_c6b534db-4b8a-476e-9630-acadb632e20c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTMtMS0xLTE1MDAzNA_7f13d2f0-c628-4705-8baa-7fa3d5c5aa4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA4NQ_8dda9d1c-27dc-41ed-85d8-c567b784e7f4"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA4NQ_c97d6899-41ff-4394-818e-8ad90215a549">600.0</ix:nonFraction></ix:nonFraction> shares authorized, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA5NA_59f61142-26eb-431e-9095-a3583dbd0d0a"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA5NA_d0d887bb-ac54-41ef-8dc1-73a08151b395">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODM_371725e1-554d-4a0f-a3c1-71b45b09d9fa"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODM_c33b686b-bc07-4cf4-bcad-cf8b8d2c20dd">350.0</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODc_5a0b2a5c-b82f-46d3-89b7-4d1a1b2ea9b3"><ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODc_ca69dd3b-970e-40f4-9330-ae0301ddc41b">357.7</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022, and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTEtMS0xLTE1MDAzNA_66762e78-e148-423f-9316-030420fbcf59">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTMtMS0xLTE1MDAzNA_808e0db6-9a26-4949-8a48-470e854b9d5e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI5LTEtMS0xLTE1MDAzNA_4f94f633-eb95-41b6-886b-846b9425a83d">7,703.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI5LTMtMS0xLTE1MDAzNA_68931001-ead2-4aae-8a57-ad50473e467f">7,164.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMwLTEtMS0xLTE1MDAzNA_9e8ec45f-1479-43e9-9210-cee057a8e314">3,500.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMwLTMtMS0xLTE1MDAzNA_4bdc4d9b-ec9a-418c-a8ff-28e3526851f3">4,760.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMxLTEtMS0xLTE1MDAzNA_7bb5fbd3-d5d5-438b-8021-6a61b87bb195">162.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMxLTMtMS0xLTE1MDAzNA_9b9aa056-1d07-408e-8d48-a29d4375834d">24.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intuitive Surgical, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMyLTEtMS0xLTE1MDAzNA_ecf35b68-b219-428b-bc03-af5c3d1cbfc2">11,041.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMyLTMtMS0xLTE1MDAzNA_1d8cc6d1-64bd-40c8-a629-4eb2ffebbf35">11,901.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMzLTEtMS0xLTE1MDAzNA_04c32df9-0456-412c-b992-88b8cf3bc532">70.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMzLTMtMS0xLTE1MDAzNA_0d0ee1c5-c9fa-4361-92dc-3aeebb4c0491">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM0LTEtMS0xLTE1MDAzNA_c22dffa9-8859-4852-9dfb-92ab77c51b4b">11,112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM0LTMtMS0xLTE1MDAzNA_a4d7b1e3-f2da-4ef6-823d-078b289398ba">11,951.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM1LTEtMS0xLTE1MDAzNA_3f5222c4-c76a-4f72-8217-1781c5a49084">12,974.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM1LTMtMS0xLTE1MDAzNA_d1c41a9d-3b72-454b-a708-c8d4c7457f88">13,555.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtMS0xLTEtMTUwMDM0_9e9e3a8a-f50b-49be-8d59-5986fd7d593e">5,198.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtMy0xLTEtMTUwMDM0_227c20e9-1f04-4f2e-901a-99e0faf2c0fc">4,793.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtNS0xLTEtMTUwMDM0_17ccb50e-fa19-45e4-a7bc-78fe48e8783e">3,634.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtMS0xLTEtMTUwMDM0_f15e0215-d394-4000-bfd4-abe733044f02">1,024.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtMy0xLTEtMTUwMDM0_9b1b3ea9-f8f7-4610-be46-c1e1bb018f15">916.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtNS0xLTEtMTUwMDM0_892e8c5a-27c7-475a-8895-a0daa694de0c">723.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtMS0xLTEtMTUwMDM0_7655ced4-e5db-47bf-8633-6a249b9d4892">6,222.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtMy0xLTEtMTUwMDM0_8bab8ad0-eb83-418a-a2a4-572aef862c19">5,710.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtNS0xLTEtMTUwMDM0_4772a152-1877-442b-b9f8-077a3450209e">4,358.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctMS0xLTEtMTUwMDM0_701771b3-e58a-41be-b4b2-1c168f904fb0">1,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctMy0xLTEtMTUwMDM0_543f5654-9277-4c04-9793-dbb688535f86">1,464.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctNS0xLTEtMTUwMDM0_21c81804-f291-418e-bd3c-98add2c30578">1,230.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtMS0xLTEtMTUwMDM0_ad4fed1e-edba-48cd-81ba-0b0a7516c0aa">325.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtMy0xLTEtMTUwMDM0_80fc069d-1965-427f-821a-8b253553240e">287.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtNS0xLTEtMTUwMDM0_e5f07190-d997-4a98-94e2-350289b7b828">266.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktMS0xLTEtMTUwMDM0_efcb8841-61d7-4499-957f-3b861ce11823">2,026.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktMy0xLTEtMTUwMDM0_61ac86d4-b07d-47b7-9275-caac6582b0f9">1,751.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktNS0xLTEtMTUwMDM0_c6526c7b-3fef-468f-b4b3-c9911428ae8d">1,497.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTEtMS0xLTE1MDAzNA_d1bf4e72-05cf-4e79-9843-7450d81f0733">4,196.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTMtMS0xLTE1MDAzNA_36667086-4b16-4f07-8376-ae7a1c7e1949">3,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTUtMS0xLTE1MDAzNA_0af32090-0e42-4003-8c7f-be162ff18550">2,861.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTEtMS0xLTE1MDAzNA_73e68223-27a8-45ae-90c8-bfb3d51256d4">1,739.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTMtMS0xLTE1MDAzNA_84a09df8-d74c-46d7-8207-6043fb552e77">1,466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTUtMS0xLTE1MDAzNA_1f119c61-0320-4f65-8850-c0042cae3a66">1,216.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTEtMS0xLTE1MDAzNA_d56af6d3-5953-4c5a-9488-255483a36b10">879.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTMtMS0xLTE1MDAzNA_f6d7d0e6-ccd5-4e89-a7ee-f18e580796a4">671.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTUtMS0xLTE1MDAzNA_f28c6b4d-2905-4af6-a53d-4b37cf41842d">595.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTEtMS0xLTE1MDAzNA_5e82df7c-f321-4395-8f28-be6ee61e00ef">2,618.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTMtMS0xLTE1MDAzNA_159c576b-d3a9-45f2-91b7-d5c56b5990bc">2,137.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTUtMS0xLTE1MDAzNA_a93807ec-a913-4274-9491-f30ae4bf3485">1,811.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTEtMS0xLTE1MDAzNA_69b7a43c-b769-44ea-a6c0-f94d81b3f253">1,577.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTMtMS0xLTE1MDAzNA_e5872caa-cd67-418a-8782-f936b50939b9">1,821.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTUtMS0xLTE1MDAzNA_a97e6353-741b-471f-8685-00adc53b44a4">1,049.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTEtMS0xLTE1MDAzNA_54e3dea5-c4fd-45d1-8df4-c9144683e027">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTMtMS0xLTE1MDAzNA_56178df5-580b-450a-b54f-1c4861f83531">69.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTUtMS0xLTE1MDAzNA_59caac93-3eb4-4f30-bdfa-0686de19ca03">157.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTEtMS0xLTE1MDAzNA_c5607227-60ba-4282-a4df-4187b07aa27c">1,606.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTMtMS0xLTE1MDAzNA_69db53e9-b675-4d3a-b7ab-27d04536cc81">1,890.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTUtMS0xLTE1MDAzNA_4490df86-074d-48de-985b-82a4b71cdcec">1,207.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTEtMS0xLTE1MDAzNA_4e120866-97e7-4ffa-a67a-6bf42d5cf00b">262.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTMtMS0xLTE1MDAzNA_240bf1d0-8fac-4ae2-bd40-433a82367af7">162.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTUtMS0xLTE1MDAzNA_ccf6c9ae-b378-4178-8112-719d5866c0b6">140.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTEtMS0xLTE1MDAzNA_9e002019-582f-4706-8aba-388f1f3aa1a0">1,344.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTMtMS0xLTE1MDAzNA_6a595b57-7d9f-4438-9d53-ee370a5db7e6">1,728.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTUtMS0xLTE1MDAzNA_81d247c2-6dbb-45e1-bbab-57ecd9a5d0de">1,066.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interest in joint venture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3fdd4cfad61458ba3bd1f961574b7c4_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTEtMS0xLTE1MDAzNA_0289b190-d9a4-4582-b866-24ac4e503def">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8e1406152504c24becb2d14ea3aba96_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTMtMS0xLTE1MDAzNA_fdd1ad5e-0dbf-41de-b790-b2554dbe0a04">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea73322238bf4952ba8f6f56b4843fd8_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTUtMS0xLTE1MDAzNA_7f49251c-a806-4aca-ab70-925895173495">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTEtMS0xLTE1MDAzNA_07a1fe66-4ae4-41a3-9936-4fe7cb052638">1,322.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTMtMS0xLTE1MDAzNA_4be92bc6-bb88-4ea1-805e-b36c7be3a093">1,704.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTUtMS0xLTE1MDAzNA_b9411dcf-af09-43c7-814d-65a2937f0846">1,060.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Intuitive Surgical, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTEtMS0xLTE1MDAzNA_4e3efbb9-6cbe-4e8a-a467-024272ef5491">3.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTMtMS0xLTE1MDAzNA_1dfddc96-6bd0-479d-8b3e-3244cefd7e98">4.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTUtMS0xLTE1MDAzNA_db98fcc4-1fbf-47e5-9f58-58305e2f674e">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTEtMS0xLTE1MDAzNA_996e6097-4b8f-47ca-b549-b9549e64f1d3">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTMtMS0xLTE1MDAzNA_da505f47-04b5-46d2-81fb-09fb3f6def80">4.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTUtMS0xLTE1MDAzNA_989706a0-c354-42e9-88d8-6a9031a4ce2b">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTEtMS0xLTE1MDAzNA_fc02180a-7b8f-4697-8a56-1eda28408b65">355.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTMtMS0xLTE1MDAzNA_a75b91a8-e4f6-4efe-a3d9-52a0f253cd8e">356.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTUtMS0xLTE1MDAzNA_8167bffc-78dc-4892-b280-9ced69980008">351.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTEtMS0xLTE1MDAzNA_584332e7-fc11-4538-a62c-cdb978097e79">362.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTMtMS0xLTE1MDAzNA_dc33f3e0-e33e-45f1-af15-4cd5111983b0">365.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTUtMS0xLTE1MDAzNA_17a42421-661e-48d7-9d84-511389322a99">361.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS)</span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItMS0xLTEtMTUwMDM0_9e002019-582f-4706-8aba-388f1f3aa1a0">1,344.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItMy0xLTEtMTUwMDM0_6a595b57-7d9f-4438-9d53-ee370a5db7e6">1,728.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItNS0xLTEtMTUwMDM0_81d247c2-6dbb-45e1-bbab-57ecd9a5d0de">1,066.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtMS0xLTEtMTUwMDM0_e56d5ef5-b8ba-4d70-a99b-5477c3e5dd8e">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtMy0xLTEtMTUwMDM0_e8ceb305-cc32-4e0f-a12f-8e54bb2d4e8b">13.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtNS0xLTEtMTUwMDM0_2890a8e6-5eb3-4fbf-864a-1bd78ddf9035">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities (net of tax):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtMS0xLTEtMTUwMDM0_916da407-fa8c-4642-a7bd-43aa752e6a57">138.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtMy0xLTEtMTUwMDM0_d8c7a2f8-4e48-43fd-8295-34f199eeaa6e">45.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtNS0xLTEtMTUwMDM0_229f16d0-f529-417d-a4f2-a2866b8cbd34">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reclassification adjustment for gains on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctMS0xLTEtMTUwMDM0_8ee3c73e-8069-4cec-837e-fdcb03867ba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctMy0xLTEtMTUwMDM0_bde8ea6d-9bb6-4b2e-b7ba-06ea9644cbc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctNS0xLTEtMTUwMDM0_f3c7ac68-537a-4a5f-95d7-612be8d19a18">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtMS0xLTEtMTUwMDM0_e93bfdfe-2878-4f42-b5c6-3da6e7029802">138.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtMy0xLTEtMTUwMDM0_4611fa6c-5a73-4186-b925-3b79aadc1cef">45.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtNS0xLTEtMTUwMDM0_5b6bd3a5-a7db-413f-81a1-d833d7137fa5">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge instruments (net of tax):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTEtMS0xLTE1MDAzNA_eb1a66c1-1636-437f-81f9-b3c91eae61fa">35.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTMtMS0xLTE1MDAzNA_e2615d75-2e4a-44c0-b6a1-80a059f608c8">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTUtMS0xLTE1MDAzNA_9dcbb88b-0621-4dff-9346-84a6f25584b2">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reclassification adjustment for (gains) losses on hedge instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTEtMS0xLTE1MDAzNA_9f6c29b5-d79e-4497-9726-7e7f39dc6eba">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTMtMS0xLTE1MDAzNA_7327aa39-354d-4690-b729-14e495be4d71">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTUtMS0xLTE1MDAzNA_0d9a6aec-b8fe-4a2c-b0e2-5670e733b76e">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTEtMS0xLTE1MDAzNA_5310e191-191e-4691-9543-af163246dbaf">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTMtMS0xLTE1MDAzNA_2b70b316-f38c-4401-9504-12058ce96322">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTUtMS0xLTE1MDAzNA_ff477435-6e75-4266-b07b-c2acb0e595c9">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans (net of tax):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTEtMS0xLTE1MDAzNA_73fdb280-1b1d-43c1-bc66-95f393eb7eb7">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTMtMS0xLTE1MDAzNA_6e0be272-8059-4942-930d-ac5ffddc44f5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTUtMS0xLTE1MDAzNA_8fa6dc52-35b4-4280-82ba-2de47ddf4493">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reclassification adjustment for losses on employee benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTEtMS0xLTE1MDAzNA_cc7ac09f-4aa8-42db-9583-ac83813ed444">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTMtMS0xLTE1MDAzNA_359cf55d-8b19-49b4-8b1c-f8c0d9ebd987">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTUtMS0xLTE1MDAzNA_0e3f720e-1bd3-4136-8919-954320a4824d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTEtMS0xLTE1MDAzNA_ee086e90-1330-4e1d-bbdf-b504e19a763b">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTMtMS0xLTE1MDAzNA_ed2d1e5c-fb76-40ee-b189-6d918be3cc7d">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTUtMS0xLTE1MDAzNA_f44b1893-839f-4ae2-a6fb-49bb3e110f01">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTEtMS0xLTE1MDAzNA_84d41f31-bd4e-4450-93dc-1fb97e2492fb">140.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTMtMS0xLTE1MDAzNA_bc4b750a-0246-406e-ae59-9df58a8eba55">49.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTUtMS0xLTE1MDAzNA_30b55ff9-4bed-4dec-86d2-67211cd06646">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTEtMS0xLTE5MjE0Ng_57ebb485-4d41-471e-bc01-3ae132e1a78e">1,204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTMtMS0xLTE5MjE0Nw_db39543c-bd2d-422e-8410-7213292e1c48">1,678.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTUtMS0xLTE5MjE1Ng_e8df8af4-1a65-4e87-b62b-f2327833f5f6">1,079.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTEtMS0xLTE5MjE2NQ_1e90f05f-5789-4cee-94bc-bd41f5692ecb">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTMtMS0xLTE5MjE3Mg_9ba9e43b-d51e-4b77-8bcd-8576a47f52d7">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTUtMS0xLTE5MjE3OQ_f8b6427f-c6d4-469f-bdb4-b2b80453a0a0">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTEtMS0xLTE1MDAzNA_f46b61a2-ec17-4bcc-897d-0f0c76510240">1,184.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTMtMS0xLTE1MDAzNA_62794673-6141-4c2b-b51c-828a338b6508">1,655.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTUtMS0xLTE1MDAzNA_afa4332e-ac6e-4812-bd6f-5d881bdc622b">1,073.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.267%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Intuitive Surgical, Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest<br/>in <br/>Joint<br/>Venture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86284f29e88649f98a3081d2acc55f59_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMS0xLTEtMTUwMDM0_746a87fe-59ca-4230-8603-24a78cbb09d6">347.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86284f29e88649f98a3081d2acc55f59_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMy0xLTEtMTUwMDM0_7f699a9f-3acc-41f9-8446-4312490201c4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28b90c84ec44021a92cdcdb2c25b28a_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItNS0xLTEtMTUwMDM0_138be367-b00c-4763-9f46-711aff3fd429">5,756.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b59bb58abc7479d89bc7d2b74d70544_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItNy0xLTEtMTUwMDM0_a4d190fe-92b0-4074-8168-5b7c36a9173c">2,494.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f52079425724fd694aa42f7b37a71e5_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItOS0xLTEtMTUwMDM0_0e271428-1a47-4385-88b9-6ed4625c4b7d">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac86aca2b842e9883ccef967301ae5_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTEtMS0xLTE1MDAzNA_5622fcd2-1491-4458-8680-24fc1df44eaf">8,263.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae840c0106e4c1996ae436a312416d9_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTMtMS0xLTE1MDAzNA_33bf26fb-3855-4744-8d80-16cb464c145d">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTUtMS0xLTE1MDAzNA_b480c6c5-c66d-4cb2-b9fb-39f2d8a39e6d">8,284.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of new accounting standards (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2c801b2cffa477fb54e06f63ca156ce_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f6e09d2840745a2be9bd85eeaaa8a92_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5043d7c11ba745e8a27d34923ccd110f_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through employee stock plans </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMS0xLTEtMTUwMDM0_9c21bb62-e8c8-4232-a8fd-01aa27f812e4">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMy0xLTEtMTY0Mzk1_af3beef7-1839-4b01-a165-e8ae08240b48">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtNS0xLTEtMTUwMDM0_ec6bb413-fbf8-43f0-9772-d7a01ef25ab8">308.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMTEtMS0xLTE1MDAzNA_e10e9d9d-20e1-45cf-a376-2156a0824cfb">308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMTUtMS0xLTE1MDAzNA_735c83ef-e773-43e6-b42b-5df4418e1559">308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMS0xLTEtMTUwMDM0_d66b1567-3037-4f29-a147-a20282df31f4">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtNS0xLTEtMTUwMDM0_ae797397-a82f-4d3c-a1a3-a04bac04cd41">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtNy0xLTEtMTUwMDM0_77200ff5-6afb-4a2d-b8e7-0284b28bfe54">167.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMTEtMS0xLTE1MDAzNA_70f4f6bf-70df-44e6-a264-b0c42a16ceb6">175.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMTUtMS0xLTE1MDAzNA_125ca316-ff14-4ec9-bc7e-99c28efe69f8">175.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense related to employee stock plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtNS0xLTEtMTUwMDM0_ea9417dc-ea9a-48e5-9c1f-b479c212f144">395.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtMTEtMS0xLTE1MDAzNA_03f03da7-68e7-49e6-95d9-1536841fd4af">395.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtMTUtMS0xLTE1MDAzNA_5d085da5-0b6f-4ff2-87eb-842b953a165f">395.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMS0xLTEtMTUwMDM0_9468ccfa-c5df-46d4-866b-91a696222604">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctNS0xLTEtMTUwMDM0_fcfd7646-3cf3-4fa5-a921-bf376406a16e">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctNy0xLTEtMTUwMDM0_5afb02d8-760a-46ff-80d7-63a94ea02122">126.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMTEtMS0xLTE1MDAzNA_d9f40e3c-8595-4d07-b8ee-eca8fefdedcb">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMTUtMS0xLTE1MDAzNA_78d4d4f6-8b2b-412b-b674-f277a1dcdd16">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtNy0xLTEtMTUwMDM0_61b55b27-3301-4152-94c3-eb7415274e23">1,060.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtMTEtMS0xLTE1MDAzNA_bec60047-2b8d-4ae1-a014-8d526f3e419f">1,060.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtMTUtMS0xLTE1MDAzNA_89aa1228-da49-446e-8fd3-43ee951a8df8">1,060.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c08937764b145139a93a060599d3467_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktOS0xLTEtMTUwMDM0_171a5c63-0c8d-489d-acbb-f45a80948060">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTEtMS0xLTE1MDAzNA_e671439a-a86b-4c34-8de4-fb5b2ab56cdc">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTMtMS0xLTE1MDAzNA_c920a636-e9a2-414e-b837-dbedaf0d995b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTUtMS0xLTE1MDAzNA_93d999c3-99ea-4e0c-acc9-fa068c543c82">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest in joint venture</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzExLTEzLTEtMS0xNTAwMzQ_abc0d722-1bb1-4f20-a352-1744da50ef18">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzExLTE1LTEtMS0xNTAwMzQ_23306aa0-3a78-4384-86ae-47b6ceac5322">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d7c7907f86d4cce9957516da107670e_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTEtMS0xLTE1MDAzNA_c95af0ee-2ca6-4f16-88a1-5a3d4b34e0c2">353.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7c7907f86d4cce9957516da107670e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTMtMS0xLTE1MDAzNA_420514ea-8a95-44c2-a17d-0db6d8310ed0">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdde0a5261214008b1be258b805ec820_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTUtMS0xLTE1MDAzNA_2ddd6e58-8484-493d-818b-9cd654605ed9">6,444.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad839dce5564f57a74be0b40182551f_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTctMS0xLTE1MDAzNA_3d6b2174-9507-4d61-8d64-4660daa5b736">3,261.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTktMS0xLTE1MDAzNA_86466a72-93b7-4d9d-a449-014068385925">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4a986595294305b5ea409ad41fcfc9_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTExLTEtMS0xNTAwMzQ_2a710673-d64f-46df-97ec-a11fbeef0e33">9,731.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2ad8e3ddd245609178c33ddcac1011_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTEzLTEtMS0xNTAwMzQ_6f723e1d-7d6e-4738-8736-ad99a14d3f54">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTE1LTEtMS0xNTAwMzQ_58e7e3fc-7c07-48b4-a5a2-06d4eb1a09f8">9,759.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through employee stock plans </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTEtMS0xLTE1MDAzNA_d9942d93-951e-4c82-9959-c02536057f99">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTUtMS0xLTE1MDAzNA_351460c3-ffc3-4f6e-b20f-0596812ee942">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTExLTEtMS0xNTAwMzQ_e494160e-184b-4177-9026-4b9b568d3d0a">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTE1LTEtMS0xNTAwMzQ_ec7ed3a1-ab88-43aa-8ae0-1200d1135e5d">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTEtMS0xLTE1MDAzNA_4c700a00-6035-46c4-80b8-ba42354779d4">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTUtMS0xLTE1MDAzNA_7aa7dba3-39f1-479a-a1d8-fce838dab6b0">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTctMS0xLTE1MDAzNA_8dc20b50-858a-40a9-b91d-7863c5715758">205.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTExLTEtMS0xNTAwMzQ_e010746f-fb44-46f3-a97f-e5d480faa41a">211.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTE1LTEtMS0xNTAwMzQ_7e78d8e7-558d-49c1-8cd5-d3b35e98dff1">211.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense related to employee stock plans</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTUtMS0xLTE1MDAzNA_5ff6cdc2-5b6b-4329-8d29-137649e165b8">449.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTExLTEtMS0xNTAwMzQ_7aa19049-e776-4bb5-8f72-ff2179790062">449.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTE1LTEtMS0xNTAwMzQ_4545a87b-fcac-4d61-9758-81eb13f7dffd">449.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTctMS0xLTE1MDAzNA_9ee39f62-8c1b-4ac6-9ac3-90993e7d590d">1,704.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTExLTEtMS0xNTAwMzQ_f5e71b57-ccca-4954-a499-0cd486229f36">1,704.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTE1LTEtMS0xNTAwMzQ_4f9a23f0-b919-48bb-b7ae-1c31e2ba3049">1,704.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTktMS0xLTE1MDAzNA_6dac4637-82cb-4f15-837d-486e630b9737">49.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTExLTEtMS0xNTAwMzQ_96a66ac2-a9a1-409e-91f1-25b3da57022a">49.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTEzLTEtMS0xNTAwMzQ_c4b1b68f-e194-4cc4-be75-97ce59c77f23">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTE1LTEtMS0xNTAwMzQ_74596d05-6921-4b39-b6b9-98b43e32aef3">49.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest in joint venture</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIxLTEzLTEtMS0xNTAwMzQ_701abab4-a8ff-494b-a995-d6e40d71a9ad">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIxLTE1LTEtMS0xNTAwMzQ_ed4e7d37-235b-4d3c-a6a2-db2896f4cb86">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c5ce2953a28440b89e7ee68bba323d9_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTEtMS0xLTE1MDAzNA_a828b1a8-0cc5-426c-bd1a-e56492fbdc85">357.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5ce2953a28440b89e7ee68bba323d9_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTMtMS0xLTE1MDAzNA_fe5ce8b2-727b-44e7-9c53-cbcb438211c3">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8054044227734087aef06647c25d127e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTUtMS0xLTE1MDAzNA_67604fcb-291a-4f10-9a51-8cc586270269">7,164.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03428188c1ee49ef8ce9c5b683046ed8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTctMS0xLTE1MDAzNA_696544f2-2f8b-4c62-8d93-a88a93e4c6f7">4,760.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTktMS0xLTE1MDAzNA_88240cd7-0816-4b13-883b-70e9a86e747d">24.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f263d8dd40419bb80418ab7843bf76_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTExLTEtMS0xNTAwMzQ_27931f16-950d-459a-93f6-e6c20365c44f">11,901.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf372d2348047f5953ac29d0036d748_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTEzLTEtMS0xNTAwMzQ_9ba863d1-6ea6-4c64-ad9e-68de02d60c39">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTE1LTEtMS0xNTAwMzQ_6fcd0b69-1411-4295-bd18-6b8c8ad9ba84">11,951.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through employee stock plans </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTEtMS0xLTE1MDAzNA_63ef1823-ce89-49f5-898e-7c55fa8111ff">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTUtMS0xLTE1MDAzNA_eb7a4a63-bd92-42a6-b06d-1f14477b5f46">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTExLTEtMS0xNTAwMzQ_ddac22fd-7de1-4876-bd2c-0c007787e191">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTE1LTEtMS0xNTAwMzQ_83e0aa09-dd86-45ae-8fd6-7544b71db7c0">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTEtMS0xLTE1MDAzNA_f4b43073-dcce-4f88-909b-cbe40936d35a">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTUtMS0xLTE1MDAzNA_efae2cbe-5275-4a1c-acaa-9124165aba64">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTctMS0xLTE1MDAzNA_faa660d3-f9ab-4ffe-8490-41c5de2dcd6d">186.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTExLTEtMS0xNTAwMzQ_424076f2-0028-498a-b054-9e58bdeb23da">194.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTE1LTEtMS0xNTAwMzQ_88c11096-b773-49de-8521-5683333db975">194.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense related to employee stock plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTUtMS0xLTE1MDAzNA_0bc36431-3bf7-46ee-8152-96660168209e">524.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTExLTEtMS0xNTAwMzQ_83ce37ac-bdd9-4717-8674-e37317bc6452">524.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTE1LTEtMS0xNTAwMzQ_29793f47-53bc-42bd-b24c-e53f22c658fa">524.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTEtMS0xLTE1MDAzNA_de9b58db-5caa-4c8d-a534-611368609510">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTUtMS0xLTE1MDAzNA_15efe486-1193-4790-84d8-0375f22602dc">211.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTctMS0xLTE1MDAzNA_4043947d-657c-46e1-956b-95e262170ad5">2,396.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTExLTEtMS0xNTAwMzQ_8bdefd7e-d3c6-42e0-9dfa-93d4045027e0">2,607.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTE1LTEtMS0xNTAwMzQ_1cd48e2a-8501-44aa-8c5e-706969cb4cb2">2,607.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTctMS0xLTE1MDAzNA_46ba181b-268c-4620-a24b-75fba4a144ef">1,322.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTExLTEtMS0xNTAwMzQ_a1b06559-0016-43cc-b8e9-ac245f83a743">1,322.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTE1LTEtMS0xNTAwMzQ_850ce3c8-ef71-4e81-933f-9215201d8ca2">1,322.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTktMS0xLTE1MDAzNA_a208308d-8b8d-424d-b246-fd0326a69b87">138.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTExLTEtMS0xNTAwMzQ_7be52eb4-2007-4d2d-b3e0-90c7daf26a14">138.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTEzLTEtMS0xNTAwMzQ_7fb3fafc-a8ef-4b60-b591-321aff0890a0">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTE1LTEtMS0xNTAwMzQ_9cbfc619-6281-4768-b107-7b9c196953b0">140.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest in joint venture</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMwLTEzLTEtMS0xNTAwMzQ_14c9f101-5074-4e14-bd0c-903fc1dddd2f">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMwLTE1LTEtMS0xNTAwMzQ_042364ff-393f-42c1-9b5c-2e0ece01ea0f">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTEtMS0xLTE1MDAzNA_21b081f8-0f85-454f-9e9f-babcdafe5787">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTMtMS0xLTE1MDAzNA_f115d8ff-b30c-4212-971c-07764d95d7d9">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5549eca14af04f2faba84d86c3277878_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTUtMS0xLTE1MDAzNA_5a40f5e6-36bb-4787-a34b-cdbf0041af64">7,703.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf66fd192a04254983a4b04fde0c089_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTctMS0xLTE1MDAzNA_3c418c63-8d7b-44c6-85b0-8bb8e1e598ae">3,500.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5abbcecdbf42949927127eac25660e_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTktMS0xLTE1MDAzNA_4ce516ce-ca18-4d72-8674-4947e197fcbf">162.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf1941ab4cf4eaa9051a8d048ff8396_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTExLTEtMS0xNTAwMzQ_514df5b7-479e-433b-9d40-94330de00e12">11,041.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1b51b8c04f48c796dbafa733a218ea_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTEzLTEtMS0xNTAwMzQ_e8689100-634b-4c64-a2d6-f229b5ad254b">70.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTE1LTEtMS0xNTAwMzQ_012f94f7-85cb-4c0f-a134-9da5d261cc2f">11,112.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="48" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Represents the adjustment related to the adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">redit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</span></ix:footnote></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS)</span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtMS0xLTEtMTUwMDM0_80542779-be0c-4c4e-aa8d-41029d8d29e3">1,344.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtMy0xLTEtMTUwMDM0_dac94ad2-3124-4e59-92e2-5f76540a50c6">1,728.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtNS0xLTEtMTUwMDM0_37b7876b-34a6-4da7-8e4a-d481142b26bc">1,066.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and loss on disposal of property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtMS0xLTEtMTUwMDM0_e14831fa-bdff-4f8a-be7b-a602bfdb6e1a">338.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtMy0xLTEtMTUwMDM0_e75b23fa-83cc-479e-9d82-513fbfec5c5f">282.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtNS0xLTEtMTUwMDM0_4d2f164c-1329-492e-85cb-49f9d287d245">226.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtMS0xLTEtMTUwMDM0_f5061c7f-1573-4a48-bb06-635691ba32c2">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtMy0xLTEtMTUwMDM0_401b0309-fad0-46ae-8305-078e5262fa7d">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtNS0xLTEtMTUwMDM0_7ad1b847-fd28-4bd9-ba5f-75580ef4008c">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMS0xLTEtMTk1ODk5_4058dcf7-15ff-489d-b0f1-2b4f2edaf51b">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMy0xLTEtMTk1OTEw_a7cc135e-af9e-4aa2-b723-d62b2a11122e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctNS0xLTEtMTk1OTIx_22bd60bd-ef4a-4f18-ae4d-dd4200cfc6ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on investments, accretion of discounts, and amortization of premiums on investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMS0xLTEtMTUwMDM0_7d81e88a-b481-4a37-9cf5-ef24167034fe">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMy0xLTEtMTUwMDM0_c080b36e-3fd5-4ad9-a72b-2b15ec0fec13">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctNS0xLTEtMTUwMDM0_fd5503a5-2ff3-4db0-bad5-2ae68e40b78b">55.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtMS0xLTEtMTUwMDM0_2d20f6e0-5644-46a5-b7aa-7d0be9c698f0">185.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtMy0xLTEtMTUwMDM0_8c5c760a-e4e7-47bf-9dc7-1fd249ba7416">62.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtNS0xLTEtMTUwMDM0_381ffc75-76d7-4a22-9513-faea771dc0c1">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktMS0xLTEtMTUwMDM0_3cdc4ef2-7e7d-4f98-8617-e6e7cfc63ecf">513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktMy0xLTEtMTUwMDM0_339667a2-5dc1-426c-98a0-c9f7917057b0">449.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktNS0xLTEtMTUwMDM0_dd79a5f1-2e15-488c-879c-e6f77ad34b3e">395.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract acquisition assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTEtMS0xLTE1MDAzNA_50df3d59-279b-40d3-b8e2-56d22407ae52">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTMtMS0xLTE1MDAzNA_85dce361-10cf-4dc1-b6ed-02f44bd2f9ae">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTUtMS0xLTE1MDAzNA_5753b6f6-e024-4312-aae0-0455f65e6b92">17.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTEtMS0xLTE1MDAzNA_b61259be-efa7-475b-9cf7-af1a2d4601f7">159.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTMtMS0xLTE1MDAzNA_571181e0-8f32-4d79-b718-d6fd00a7a3f3">142.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTUtMS0xLTE1MDAzNA_ee46a415-2441-447d-aa9a-982199cda2db">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTEtMS0xLTE1MDAzNA_12d9e6b7-ea91-4036-8748-6443285decea">546.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTMtMS0xLTE1MDAzNA_95c33e98-378a-4241-8086-54b6dfdd801c">256.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTUtMS0xLTE1MDAzNA_e0860824-efd0-4ebd-b0cf-29bb7f35b3c2">170.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTEtMS0xLTE1MDAzNA_a359b6fe-016a-4077-a891-34794d350798">129.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTMtMS0xLTE1MDAzNA_691499f2-07f7-4c37-9e18-f097c833dcc8">204.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTUtMS0xLTE1MDAzNA_2936ed61-f531-42c9-8ebd-cb32b174d133">111.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTEtMS0xLTE1MDAzNA_a8a18ac9-c83a-44b3-87dc-70e2ebeaec8f">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTMtMS0xLTE1MDAzNA_aedd583b-fb5a-4cfb-85e1-79abba49c54e">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTUtMS0xLTE1MDAzNA_526c741c-b5fe-4095-bad8-4f0d183ac9f5">32.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTEtMS0xLTE1MDAzNA_1ae3d763-bb80-4d0a-99b9-74630d15e1ba">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTMtMS0xLTE1MDAzNA_83ba632d-4c92-4481-8f1c-13bf7a250a1e">115.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTUtMS0xLTE1MDAzNA_23033637-7f3f-4617-9999-d88b9e47e91c">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTEtMS0xLTE1MDAzNA_228516a0-b565-4f79-b08a-b145fae12149">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTMtMS0xLTE1MDAzNA_74dcaad2-0d15-46ab-9e45-9341736075e8">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTUtMS0xLTE1MDAzNA_92bc3ba6-f972-4f78-9ba3-996163155713">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTEtMS0xLTE1MDAzNA_11973df1-4a0b-4ec7-943b-cf1ea3808b84">121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTMtMS0xLTE1MDAzNA_e2740b4f-214f-4a2a-8ff2-0c5804183b22">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTUtMS0xLTE1MDAzNA_b8229b0b-186c-4e39-b824-72b5c8336886">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTEtMS0xLTE1MDAzNA_1401d4ba-fd94-45c1-ad29-c763c9a40637">1,490.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTMtMS0xLTE1MDAzNA_d5899b34-b373-4338-ba04-ba0564664ed9">2,089.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTUtMS0xLTE1MDAzNA_70ad9bb8-67ca-4940-ba3d-0c83981304e1">1,484.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTEtMS0xLTE1MDAzNA_fde7d5d3-a0e3-4600-a73d-b07807b0a150">1,399.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTMtMS0xLTE1MDAzNA_b352ccbc-a7ef-41cb-9887-faed82bba964">6,452.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTUtMS0xLTE1MDAzNA_d53b53db-61a9-49f1-b19f-6af04c8ef955">4,292.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTEtMS0xLTE1MDAzNA_0674d8a4-e423-45be-8e5e-b4b3dde432cd">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTMtMS0xLTE1MDAzNA_7163d831-468b-46cd-b95b-d89c1830de44">84.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTUtMS0xLTE1MDAzNA_363ed874-629b-436d-9d14-b47df8eafb24">800.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTEtMS0xLTE1MDAzNA_6b3c0e1b-f7e0-42f7-9aea-07dbb0c96eab">3,254.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTMtMS0xLTE1MDAzNA_629fe9ac-df88-4c62-aaee-64c20bd5ece3">4,267.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTUtMS0xLTE1MDAzNA_c929f5de-4091-46a8-b392-38ae0bc96e6c">2,930.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property, plant, and equipment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTEtMS0xLTE1MDAzNA_440ac132-660b-4182-9db6-550720027490">532.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTMtMS0xLTE1MDAzNA_9914874f-2ff0-4a14-ac50-7f22a4b415af">339.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTUtMS0xLTE1MDAzNA_59cb16ad-8b9f-4cbc-990f-45a9780e128f">341.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash, and intellectual property and other investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTEtMS0xLTE1MDAzNA_d04eff56-cceb-49a3-b97c-bd25a358e984">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTMtMS0xLTE1MDAzNA_6b6f0353-e78e-4a4f-bbef-ab9198b94d46">22.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTUtMS0xLTE1MDAzNA_d55298ff-097f-4c55-bd71-9804f291caf4">37.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTEtMS0xLTE1MDAzNA_b968fb7f-3e74-4cf4-bbf4-5cccfe8a11fd">1,370.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTMtMS0xLTE1MDAzNA_a2559416-08c0-4dea-bd3e-c3c4890dbbdf">2,461.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTUtMS0xLTE1MDAzNA_022ca980-0fdf-48dc-b3cd-4803f996b1e9">940.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock relating to employee stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTEtMS0xLTE1MDAzNA_0257178b-de61-4495-b11a-ce999f6df80b">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTMtMS0xLTE1MDAzNA_bb0858d6-4fe3-4391-a2bf-3ce671ed316c">276.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTUtMS0xLTE1MDAzNA_1c63352f-bae9-431f-bbd1-0e6a48585293">308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTEtMS0xLTE1MDAzNA_6617c12b-fbbf-47e9-adb5-9062636c16ea">194.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTMtMS0xLTE1MDAzNA_e2cdf1b5-9063-488a-b307-811715c13366">211.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTUtMS0xLTE1MDAzNA_c9164dbe-d83b-4012-9748-3451e0dd7ae5">175.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTEtMS0xLTE1MDAzNA_c87146a2-bbe6-40f9-94e9-d81c2b2b9d1f">2,607.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTMtMS0xLTE1MDAzNA_08b2c246-be88-4690-9653-8f48224f69b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTUtMS0xLTE1MDAzNA_6dc30719-82f3-48fb-a2ec-d5fbb576661b">134.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of deferred purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTEtMS0xLTE1MDAzNA_92094aac-7cb0-40a2-9c8b-bf10c0564c7b">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTMtMS0xLTE1MDAzNA_91b7c347-5a40-46a0-8c67-e54d8423ca1f">21.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTUtMS0xLTE1MDAzNA_600e7755-a670-4640-9a34-c82399f585e7">85.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTEtMS0xLTE1MDAzNA_b12fd948-b546-4d41-b6b3-df796e305df7">2,572.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTMtMS0xLTE1MDAzNA_08461c7f-d121-495a-a07e-65f0effb93b8">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTUtMS0xLTE1MDAzNA_cacd7bf7-ddf4-4e8c-917a-54e793f3a4db">85.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTEtMS0xLTE1MDAzNA_d2a65d67-b85e-4e4b-9b5b-4cf35c70e414">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTMtMS0xLTE1MDAzNA_44630733-2f17-4ae2-a4c7-52f646105ba4">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTUtMS0xLTE1MDAzNA_f6702c4f-c4bc-4648-87eb-94bc778e6cf0">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTEtMS0xLTE1MDAzNA_bbc581b3-b036-4c76-8417-4844d5f2be49">294.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTMtMS0xLTE1MDAzNA_0624f7a7-b6fc-4fd4-a7c0-eecd2d41c32b">332.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTUtMS0xLTE1MDAzNA_a712066d-6189-437b-820c-e1307eb6ec33">455.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTEtMS0xLTE1MDAzNA_56650930-8dfa-40fc-bb71-2b22d47914a9">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTMtMS0xLTE1MDAzNA_cc4e7a06-6d34-414e-bdfb-8759b6236fe0">1,638.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTUtMS0xLTE1MDAzNA_366a57c6-6718-4c7f-b4a5-696b09c90e43">1,182.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTEtMS0xLTE1MDAzNA_1c2d42c8-1c4d-43e2-b68a-48349d011fab">1,600.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTMtMS0xLTE1MDAzNA_56c85709-4f07-4b9f-95dd-baa5620cfccd">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTUtMS0xLTE1MDAzNA_3b15a38f-3e81-4c93-9ed0-aa2b3eeab77e">1,638.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i025de1eec32044f5a30c5872569f0e8d_226"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjYvZnJhZzpmYjgyY2UxYzI1NjE0YTc1YmQwYThjNWViMGU5NzQ2Ny90ZXh0cmVnaW9uOmZiODJjZTFjMjU2MTRhNzViZDBhOGM1ZWIwZTk3NDY3XzUwMw_806ba099-f232-4aae-982c-f2c70433c10a" continuedAt="ia04d4dc5d58b4a9c8824df5e8b57780a" escape="true">DESCRIPTION OF THE BUSINESS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><ix:continuation id="ia04d4dc5d58b4a9c8824df5e8b57780a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive Surgical, Inc. (&#8220;Intuitive&#8221; or the &#8220;Company&#8221;) develops, manufactures, and markets the da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Surgical System and the Ion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> endoluminal system.&#160;The Company&#8217;s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, and a high-performance vision system and use proprietary instruments and accessories.</span></ix:continuation></div><div id="i025de1eec32044f5a30c5872569f0e8d_229"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjEx_a031e126-ffde-46a9-aaeb-4e713633921f" continuedAt="ifca40978e42744d899f9d88dde241af4" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ifca40978e42744d899f9d88dde241af4" continuedAt="i8be32b990b384794b9d62b219b9902db"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDc3_7870f756-5298-4706-8c90-265058833aea" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of the Company and its wholly and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTA1_5107a601-d9ce-423f-9053-8226cd6422d0" escape="true">The Consolidated Financial Statements include the results and balances of the Company&#8217;s majority-owned joint venture (&#8220;Joint Venture&#8221;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;). Chindex Medical Limited (&#8220;Chindex&#8221;), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders&#8217; equity. The noncontrolling interest&#8217;s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Split</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued pursuant to the <ix:nonFraction unitRef="number" contextRef="i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjQ4NjU_ca2ae150-d9ab-413b-8177-4e5705f2086a">three</ix:nonFraction>-for-one stock split (the &#8220;Stock Split&#8221;) of the Company&#8217;s issued and outstanding common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iecd854fcb4004bbcbf41e8c107112eee_I20210927" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjQ4NTg_c902a585-19e8-4dee-b7e9-7363a534281d">0.001</ix:nonFraction> per share, were distributed on October 4, 2021, to stockholders of record as of September 27, 2021. All share and per-share information presented in the Consolidated Financial Statements have been retroactively adjusted to reflect the Stock Split.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTYx_779cb9aa-264c-4ee9-a00f-468bfe152072" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management&#8217;s most significant, complex, and subjective judgments include the valuation and recognition of investments, the standalone selling prices used to allocate the contract consideration to the individual performance obligations, the valuation of inventory, the valuation of and assessment of the recoverability of intangible assets and goodwill, the recognition and measurement of current and deferred income taxes, including the measurement of uncertain tax positions, and the estimates for legal contingencies. Actual results could differ materially from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjA3_4b9a845e-1179-4187-b83f-0756f7d9b8e5" continuedAt="i73b3fc1c055741168b32a17d826e5364" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company&#8217;s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73b3fc1c055741168b32a17d826e5364">The Company&#8217;s accounts receivable are primarily derived from billings related to revenue arrangements with customers and distributors located throughout the world. The Company performs credit evaluations of its customers&#8217; financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date.</ix:continuation> As of December&#160;31, 2022, and 2021, <ix:nonFraction unitRef="number" contextRef="i9a274d8413eb4abe939b46c4859e5585_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MjI_2483d917-1837-40bf-b47a-2a0049dc36a1">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i21289ee699604ccda2bbe939f4826b3c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0Mjk_3aec60a9-8daa-47e8-a3db-c80868fa5abd">67</ix:nonFraction>%, respectively, of accounts receivable were from domestic customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, domestic revenue accounted for <ix:nonFraction unitRef="number" contextRef="i9e3a2ff2c2da4f4385ae63c2bcc6c672_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MzI_d30ebb15-1ee3-4c83-81c3-3285678a4b69">67</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ie26454d7ae8c44d190970894b06cf238_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MzU_ed15fde3-4be3-4bde-8a80-71056747f6b3">67</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i3ea9298fff88462ca644d8893e65377d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0Mzg_c7854e68-a8ad-4ea5-9f4b-c7efc2ace227">68</ix:nonFraction>% of total revenue, respectively, while outside of the U.S. (&#8220;OUS&#8221;) revenue accounted for <ix:nonFraction unitRef="number" contextRef="i87f6d6fb99c046d289fc7290155d8526_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTM_40635487-e11b-4186-946f-78f29ebbb908">33</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i14855bc25d64407e9c3e34a6c5aa703b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTY_807f783d-d189-4931-8105-640be6c5c5a1">33</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="id6108e23d4714957986c26ca264b5fe8_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTk_e8ee04de-b7ed-4978-b5ed-8c3c64718f93">32</ix:nonFraction>%, respectively, of total revenue for each of the years then ended.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions, including materials shortages and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i8be32b990b384794b9d62b219b9902db" continuedAt="i0cfbbb59f9524b4da7c776992aaa0007"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the Company has experienced increased difficulties in obtaining a sufficient supply of a number of component materials used in its products, such as semiconductor components as well as a range of other materials including, but not limited to, metals and polymers, as global supply has become significantly constrained due to increased demand for certain materials. Additionally, prices of such materials have increased due to the increased demand and supply shortage. With rising interest rates, access to credit may become more difficult, and any insolvency of the Company&#8217;s key suppliers, including sole-source and single-source suppliers, may exacerbate current supply chain challenges. The Company is engaged in activities to seek to mitigate supply disruptions by, for example, increasing its communications with its suppliers and modifying its purchase order coverage and inventory levels. However, the global supply chain shortages will remain a challenge for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such global shortages in important components as well as certain logistics challenges have resulted in, and will continue to cause, inflationary cost pressure in the Company&#8217;s supply chain. To date, the inflationary cost pressure has been more pronounced in the Company&#8217;s logistics costs, but these supply chain challenges have not materially impacted the Company&#8217;s results of operations or ability to deliver products and services to its customers. However, if shortages in important supply chain materials in the semiconductor or other markets or logistics challenges continue, the Company could fail to meet product demand, which could result in deferred or canceled procedures. Additionally, if inflationary pressures in logistics or component costs persist, the Company may not be able to quickly or easily adjust pricing, reduce costs, or implement countermeasures. Additionally, there is uncertainty surrounding the impact of any monetary policy changes taken by the U.S. Federal Reserve and other central banks to address the structural risks associated with inflation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in labor availability globally, including labor shortages and staff burnout and attrition, could also impact the Company&#8217;s ability to hire and retain personnel critical to its manufacturing, logistics, and commercial operations. The Company is also highly dependent on the principal members of its management and scientific staff. The loss of critical members of the Company&#8217;s team, or its inability to attract and retain qualified personnel, could significantly harm its operations, business, and ability to compete.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals are also experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, rising interest rates make access to credit more expensive, unrealized losses decrease available cash reserves, and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. To the extent macroeconomic conditions remain challenging, it is likely that hospitals&#8217; spend on capital equipment will be adversely impacted. In addition, as competition progresses in various markets, longer selling cycles and pricing pressures are likely to result. As of the date of issuance of these Consolidated Financial Statements, the extent to which these macroeconomic factors may materially adversely affect the Company&#8217;s financial condition, liquidity, or results of operations is uncertain.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to additional risks and uncertainties due to the ongoing COVID-19 pandemic. The extent of the impact on the Company&#8217;s business is highly uncertain and difficult to predict. The Company&#8217;s customers may divert resources to treat COVID-19 patients and defer some elective surgical procedures, both of which may impact the Company&#8217;s customers&#8217; ability to meet their obligations, including to the Company. The severity of the impact of the COVID-19 pandemic on the Company&#8217;s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company&#8217;s customers, all of which are uncertain and cannot be predicted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer Relief Program</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, the Company introduced a series of programs to provide financial relief to customers (the &#8220;Customer Relief Program&#8221;). As part of the Customer Relief Program, the Company provided its customers service fee credits, extended payment terms, and deferred payments related to Intuitive System Leasing arrangements. The Customer Relief Program ended at the end of the third quarter of 2020. There was no similar customer relief program offered in 2021 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service fee credits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As part of the Customer Relief Program, the Company provided service fee credits to customers based on the reduction in the utilization of their systems during the second and third quarters of 2020 relative to a pre-COVID-19 level baseline. The Company reflected the service fee credits as a reduction of service revenue and accounts receivable in the quarter they were earned by its customers. The service fee credit program resulted in an $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-6" name="isrg:ServiceFeeCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzkwMTk_9fbc62ad-b02a-407c-bb59-55e551d6b84c">80</ix:nonFraction>&#160;million decrease in service revenue in 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term payment relief</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In response to the COVID-19 pandemic, the Company introduced a payment deferral program to provide financial relief to qualified customers. This relief extended payment terms up to 180 days for qualified and creditworthy customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also introduced a lease payment deferral program in which creditworthy customers with active Intuitive system leasing arrangements could elect to defer lease payments up to five months that are payable at the end of the lease by extending the lease term. This program did not result in substantial increases in the rights of the lessor or the obligations of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i0cfbbb59f9524b4da7c776992aaa0007" continuedAt="i8cb2cede0cdc4569bbc2fdc4034dc0fe"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessee, and the Company elected to apply the relief provided by the Financial Accounting Standards Board (&#8220;FASB&#8221;) FAQ on accounting for COVID-19 and market volatility by not applying the lease modification guidance in ASC 842 to the lease arrangements affected by the deferrals and lease extensions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating lease arrangements where the lease term was extended by adding the deferred period to the end of the contract, the Company recalculated the straight-line revenue based on the revised terms, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. For its sales-type lease arrangements impacted, the Company accounted for the deferral in the timing of lease payments as if there were no changes in the lease contract, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. While the short-term payment relief offered did not have a material impact on the results of operations, the Company deferred $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-6" name="isrg:SalesTypeLeaseLeaseReceivableExtendedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNjU4_4c2254c8-0a6f-4e7d-a104-ce265f79a475">15</ix:nonFraction>&#160;million of lease billings and extended payment terms associated with $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-6" name="isrg:AccountsReceivableExtendedPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNzIy_0405a803-e631-42ba-8bfc-1604bbb1c6bd">181</ix:nonFraction>&#160;million of billings during the program, of which $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNzY2_96589ce1-30d6-4c67-aec0-75ba9c0948f1">19</ix:nonFraction>&#160;million remained outstanding as of December 31, 2020. All of the trade receivables with extended payment terms have been collected as of December 31, 2021.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDgz_85b86815-1b58-449b-9877-d05aa5c768f5" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity from the date of purchase of 90&#160;days or less to be cash equivalents.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NzQ_18258391-1eb1-4526-9d1f-2b8530e71d1d">19.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE2NDkyNjc1MTE1NTI_ef4f4612-ebb0-4658-83cb-dad1dcf29bac">17.9</ix:nonFraction> million, respectively, of restricted cash primarily associated with its insurance programs. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjEy_31e7af8c-8ad3-4501-89f9-e10f74140ff3" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company&#8217;s investments may consist of money market funds, U.S. treasury and U.S. government agency securities, high-quality corporate notes and bonds, commercial paper, non-U.S. government agency securities, and taxable and tax-exempt municipal notes. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest and other income, net, if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to interest and other income, net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at the date of purchase greater than 90 days and remaining maturities as of the reporting period of less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company recognizes equity investments with readily determinable fair values at the quoted market price with changes in value recorded in interest and other income, net. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIy_de163e98-ef3c-4c0e-9ca0-a9905ad27097" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, municipal notes, and equity investments without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjE2_5f38d6c1-72f5-4d3e-850d-9024f0feea2d" continuedAt="i8c987f94b4644233ab84c5012e3adcd2" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company&#8217;s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i8cb2cede0cdc4569bbc2fdc4034dc0fe" continuedAt="i2a12d697d4cb49f2bfc63feab2e5597c"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c987f94b4644233ab84c5012e3adcd2">Additionally, the cost basis of the Company&#8217;s inventory does not include any unallocated fixed overhead costs associated with abnormally low utilization of its factories.</ix:continuation></span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIz_10ded282-70d7-430f-97f5-e5fd77b4a8a6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant, and Equipment</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc0_495bfa69-a730-4ebf-8145-1707bf777ac1" continuedAt="ibc1ec496d03f47d583ef6b5bc137e8d2" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="ief4c591526ea478bb99b449397dd0039_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzEtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NzNkMjQ2NTExNGMwNDljYTkyYWExOWM2MTdiYmZiZjNfMTA_ed9fba4d-bdca-41a5-9826-fc2084c48b12">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="if23950580a4342bd9a17e543bc89fa46_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzItMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MDc0N2FhNDQ3NmI4NGVhOWFlNzVlMTUyOWMxYjZjYmJfMTA_41a8fe8a-8779-4a3b-96d0-326d3d1b1291">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27f714fd0e404cf8b81228344910a645_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzQtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MjY1ZGZmYzFmYzg0NDhjMmE0YTQ0ZGFjNzg5MjVlN2NfNA_51ff2024-98f6-426c-8272-57a08cfdf46b">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater of lease term or <ix:nonNumeric contextRef="ibac2a4c8f53d40f38da16d18c79f554b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzUtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NWUyNjQ2YzQxMGE1NDhhMGFlZmE2Y2M2YjYxNTEzNjNfMjk_46cc85af-8524-416f-8104-ea405a9d598f">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i00eade1132384910a1edcc4602cd7f03_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzUtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NWUyNjQ2YzQxMGE1NDhhMGFlZmE2Y2M2YjYxNTEzNjNfMzU_6ff3c7f3-eeec-4ae3-911b-10f74158e32d">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i672bca309a9e49d7b8514f35e4e5676e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzYtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MWUwZTdiNDc5ZjQ4NGI4OGIyOGIzNWZlMzE0ZjFiMTJfNA_ffd21252-d2cf-42d3-89d4-90aec17c64d2">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise-wide software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i212dee94b35b42048df23efbc2d406d9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzctMS0xLTEtMTUwMDM0L3RleHRyZWdpb246ZmRlZDY1MGM5MDZkNGUyMGJkOGJlNDZlMzMzYzc0MmNfNA_c9550aca-fbd3-4b07-b034-65c0aca02516">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of <ix:nonNumeric contextRef="ibd1fd94d996648b992458725d1c804c3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzgtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246ZjgyNDFmN2IzZThkNDdiODg0M2NiNmFhMzM2Yjg2ZThfMTQ_7121821c-eeaf-4d2e-85f4-91ca1205b6dc">3</ix:nonNumeric> years or life of license</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2022, 2021, and 2020, was $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0ODc_77832287-f169-42e3-83c1-34b87f429212">326</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0OTA_a5afd404-b2af-45d4-842a-e117835a8da5">280</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0OTM_e50167f2-f7e8-4d58-beef-cb9ad2195339">221</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTcx_3c481019-8596-46cd-a4be-169570d10e03" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Software Costs for Internal Use</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, which are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Once the software is ready for its intended use, amounts capitalized are amortized over an estimated useful life of up to <ix:nonNumeric contextRef="ia195f6ae1083417ea6ba55e0f754b575_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE2MjY1_d9d8a291-76c9-4f4b-9edb-87f3ec5fd592">5</ix:nonNumeric> years, generally on a straight-line basis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Implementation Costs in a Cloud Computing Arrangement </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract for which it is the customer in accordance with the requirements for capitalizing costs incurred to develop internal-use software. These capitalized implementation costs are recorded within intangible and other assets, net, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc1_0ccc0ce5-6f61-46ec-b8be-8d86ed5f7f64" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business acquisitions in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires the acquiring entity in a business combination to recognize the assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree using acquisition-date fair values. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjE3_9d0f3fcb-71d9-4151-9d7e-a08f978f81f5" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in <ix:nonFraction unitRef="segment" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4MTUz_d96b2ceb-bd44-4143-819a-6ec0061c5faa">one</ix:nonFraction> segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets&#8217; useful lives, which range from approximately <ix:nonNumeric contextRef="i18ca052badd544ec96dacbdeb71e006a_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4NTgw_679d353b-37fa-4a9a-9bdc-9ab96b2c71ce">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4NTg2_29588960-7008-4494-a1f3-4a311bee4aef">9</ix:nonNumeric> years.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc2_30d69c8e-a799-430f-9189-62506d31449e" continuedAt="i4556b780465649918a348a5deef925e6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-lived Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets, which include finite-lived intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i2a12d697d4cb49f2bfc63feab2e5597c" continuedAt="ica20af963ea24518a9f4d8bb7466043c"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4556b780465649918a348a5deef925e6">Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.</ix:continuation></span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTU1_97add4b2-c5dd-40f6-8ba9-526444926ac1" continuedAt="i24277528face4cceb466ead65148e1ee" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue consists of product revenue, resulting from the sale of systems, system components, and instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and the collectability of the contract consideration is probable. The Company&#8217;s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer.&#160;The Company&#8217;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDg3_26936ab5-c01f-43a5-94b7-f9338253f97d">The Company&#8217;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price.</ix:nonNumeric> The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations at a point in time. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations in the following manner:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">System sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:SystemSalesArrangementWarrantyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMDQ_17167ee9-20b7-4ef1-bc71-25422767b147">one-year</ix:nonNumeric> warranty. Warranty costs were not material for the periods presented.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and accessories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also could occur at the time of delivery, depending on the customer arrangement. The Company generally allows its customers in the normal course of business to return unused products for a limited period of time subsequent to the initial purchase and records an allowance against revenue for estimated returns.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then-fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems can be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. The assigned value of the traded-in units is reported as a component of inventory until resold or otherwise disposed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer&#8217;s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="ica20af963ea24518a9f4d8bb7466043c" continuedAt="ie9fb97041165438288164d5179576620"><ix:continuation id="i24277528face4cceb466ead65148e1ee"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Recognized from the Costs to Obtain a Contract with a Customer</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain sales incentives provided to the Company&#8217;s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial system sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1MDk_441929c6-5fd6-49f7-b0de-ed1e3f2b4f1d">72.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1MTI_88781998-b768-4729-b8fa-13811057f544">71.8</ix:nonFraction> million as of December&#160;31, 2022, and 2021, respectively. The Company did not incur any impairment losses during the periods presented.</span></div></ix:continuation><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LessorLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTE5_1e31887a-1d09-4da7-a673-2844f6d86654" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements with certain qualified customers. Leases have terms that generally range from <ix:nonNumeric contextRef="i0af42d049a95445eb385849c884a645d_I20221231" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2MjEw_6aee562a-5de9-4957-99e7-cdb0ed9199a9">24</ix:nonNumeric> to <ix:nonNumeric contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2MjE2_f821315f-eac0-42b1-90f8-8423756f0ed4">84</ix:nonNumeric> months and are usually collateralized by a security interest in the underlying assets. The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to <ix:nonNumeric contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2NDIy_7839768c-3a4f-4a6a-8be8-9c0c44c70c1a">84</ix:nonNumeric> months. For these usage-based lease arrangements, the lease fee is generally billed monthly in arrears based on a contractual per-use fee, and usage is generally defined as the number of procedures performed with the system.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company&#8217;s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service. For some lease arrangements, customers are provided with the right to purchase the leased system at some point during and/or at the end of the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. Certain lease arrangements may also include upgrade rights that allow customers to upgrade the leased system to newer technology at some point during the lease term. Generally, these upgrade rights do not specify the terms, including the price or structure of the future upgrade transactions, as those terms are negotiated based on the circumstances at the time of the upgrade, including the then-fair value of the system as well as other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term and is presented as product revenue. Revenue related to lease elements from usage-based arrangements is recognized as the customers utilize the systems and is presented as product revenue.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTU3_f9a58b38-a346-44ef-beb3-35b4ab352b78" continuedAt="i9ef0e771bda24b8fbd938520031c68f8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Leasing Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December&#160;31, 2022. The Company currently does not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company does not have insight into the inputs necessary to calculate the implicit rate of the leases. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s real estate and automobile leases. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="ie9fb97041165438288164d5179576620" continuedAt="ibc6cb2de1cb342d383fe3d82e4c2ae87"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ef0e771bda24b8fbd938520031c68f8">Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company&#8217;s automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</ix:continuation></span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTQ0_ff625690-fa20-4070-8fcc-6b6dde7a1a55" escape="true"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. For the years ended December 31, 2022, and 2021, bad debt expense was not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment in sales-type leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from <ix:nonNumeric contextRef="i0af42d049a95445eb385849c884a645d_I20221231" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzU0OTc1NTg3OTA1MQ_6aee562a-5de9-4957-99e7-cdb0ed9199a9">24</ix:nonNumeric> to <ix:nonNumeric contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231" name="us-gaap:LessorSalesTypeLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzU0OTc1NTg3OTA1NQ_f821315f-eac0-42b1-90f8-8423756f0ed4">84</ix:nonNumeric> months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company&#8217;s assessment of the current expected lifetime loss on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Lease receivables are considered past due 90 days after invoice.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the credit risk of the net investment in sales-type leases using a number of factors, including, but not limited to, the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTI5_9bb324ab-6cf8-45cd-8553-024d9b3b5c04" continuedAt="ie8fbebbb15c6455c906b5ee3500c4180" escape="true">The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="ie8fbebbb15c6455c906b5ee3500c4180"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Investment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Rating:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMS0xLTEtMTUwMDM0_4053a75a-e5cf-4c94-9f98-310e06caa3e0">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMy0xLTEtMTUwMDM0_ca9e0202-287f-4d43-a3af-81c8ccecea44">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItNS0xLTEtMTUwMDM0_d98ad3fa-914b-4422-a2e3-5a5be39ff82b">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItNy0xLTEtMTUwMDM0_42a66b8c-b3d8-44ea-8544-288c46a8306d">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItOS0xLTEtMTUwMDM0_1bee2c1e-7d43-4d03-a859-b59d7a7b94cc">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMTItMS0xLTE1MDAzNA_66a0a052-7e5c-487a-bd56-64dca62e99a6">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMTQtMS0xLTE1MDAzNA_a79b330c-a361-4844-8e49-af3c360b0b83">213.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMS0xLTEtMTUwMDM0_89defa71-1123-4c9b-8bae-cf4c69bdb1d6">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMy0xLTEtMTUwMDM0_6e4eb352-ff78-45d4-a628-4c54986b13fb">69.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtNS0xLTEtMTUwMDM0_24fed6b8-b7c9-42f0-b04f-fccc204fc495">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtNy0xLTEtMTUwMDM0_15f584c8-1ebf-4bcd-9f6f-d02df89d4502">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtOS0xLTEtMTUwMDM0_4d46ba94-4270-4ea2-a8f3-7ffda90a7efb">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMTItMS0xLTE1MDAzNA_4afb66d2-e6e7-4b45-8172-f8dd34b0d50c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMTQtMS0xLTE1MDAzNA_ee3f8f10-d8f6-4cfd-9d16-122c7791f9f7">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMS0xLTEtMTUwMDM0_00a0fee4-0fa9-421d-abef-3909eae199fc">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMy0xLTEtMTUwMDM0_6b66e7a0-110a-4b27-9918-30e50d4a771f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtNS0xLTEtMTUwMDM0_c6dc6d7f-eaf7-4943-a0fb-504fe0f9f2b3">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtNy0xLTEtMTUwMDM0_634c9c66-e739-410b-9dda-677183039136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtOS0xLTEtMTUwMDM0_2e2b9d2e-4225-4ab2-a4ba-ec93a019969d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMTItMS0xLTE1MDAzNA_5922161b-25ff-4a09-bedd-29767edacfba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib606f0cd45974794b541dc9482583db5_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMTQtMS0xLTE1MDAzNA_6518ee15-73a5-47b0-bbbf-25a739d59576">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMS0xLTEtMTUwMDM0_385cc3ae-5256-437b-a581-9ed9e3970aec">168.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMy0xLTEtMTUwMDM0_4d9174d4-6ea5-4942-bdc9-c88d6cea205e">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtNS0xLTEtMTUwMDM0_60efd4c6-d31e-4f9e-a62d-78deb8167b5c">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtNy0xLTEtMTUwMDM0_85247086-c12c-41ed-bb65-9b749147241f">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtOS0xLTEtMTUwMDM0_f8435cd7-f3e6-4f44-85ac-ad0dec4a75e6">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMTItMS0xLTE1MDAzNA_0ed07132-724e-493b-a819-0c33a3c5550e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMTQtMS0xLTE1MDAzNA_f2241d24-d32f-477a-9ce6-90efe5f0e593">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, and 2021, credit losses related to the net investment in sales-type leases were not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, procedure coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade and lease receivables as hospital cash flows are impacted by their response to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and are denominated in a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. Additionally, all of the Company&#8217;s investments in corporate debt securities are in securities with high-quality credit ratings, which have historically experienced low rates of default. For the years ended December 31, 2022, and 2021, credit losses related to available-for-sale debt securities were not material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIw_64c2a6cc-32be-4869-a42d-7e07ffb738b4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for sales returns is based on the Company&#8217;s estimates of potential future returns of certain products related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company&#8217;s products.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="ibc6cb2de1cb342d383fe3d82e4c2ae87" continuedAt="i17db507c42e7478ab347d7457c11616d"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDkw_e8921ca8-f555-499e-af24-7842410713f9" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants long-term equity awards under its stock-based compensation plans to certain employees of the Company. These awards include restricted stock units, stock options, and performance stock units. The Company accounts for share-based compensation plans using the fair value recognition and measurement provisions under GAAP. The Company&#8217;s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of restricted stock units (&#8220;RSUs&#8221;) is determined based on the closing quoted price of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock options granted and utilizes the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the date of grant; (2) expected term; (3) expected volatility; and (4) risk-free interest rate.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjY1MTU_7c9e27c0-a100-480c-8fb0-6c634e4f95d8" continuedAt="i5ea56e831d114d8bbaf4ffecd9eceec3">one</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ea56e831d114d8bbaf4ffecd9eceec3"> year</ix:continuation> on the Company&#8217;s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company&#8217;s stock and the term of such options. Due to the sufficient volume of the traded options, the Company used <ix:nonFraction unitRef="number" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzM2Mzg2_741cbba5-7f8e-4071-92d6-9eab3e6e7d7d">100</ix:nonFraction>% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Performance stock units (&#8220;PSUs&#8221;) include predefined performance and market conditions. The fair value of performance stock units with performance conditions is based on the closing quoted price of the Company&#8217;s common stock on the date of the grant and is recognized on a straight-line basis over the requisite service period. The Company estimates the number of awards with performance conditions that will ultimately vest based on the probability of achievement each quarter to determine the amount of compensation expense to recognize each reporting period. The fair value of performance stock units that include a market condition is determined using a Monte Carlo valuation model and is recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of shares to be issued under the Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) is computed using the Black-Scholes-Merton model at the commencement of an offering period in February and August of each year utilizing the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the initial date of the offering period; (2) expected term; (3) expected volatility; and (4) risk-free interest rate. Share-based compensation for the ESPP is expensed straight-line over the two-year offering period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 10. Share-Based Compensation&#8221; for a detailed discussion of the Company&#8217;s stock plans and share-based compensation expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjAz_8ed2fc93-7675-482e-80bc-4a99c4714fa4" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Computation of Net Income per Share</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company&#8217;s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company&#8217;s employee stock purchase plan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i17db507c42e7478ab347d7457c11616d" continuedAt="idd603f3755fc4045890b404520132bf4"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTM5_3db45bc0-f681-429f-9460-4195ac14ee41" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTgx_dcd74038-a3b8-4d14-bf7f-13c3c6fec7ee" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Other Hedging Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders&#8217; equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company&#8217;s derivative contracts are generally <ix:nonNumeric contextRef="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMTI_85f617de-3b2a-4333-83c4-9613701ca70c">twelve months</ix:nonNumeric> or shorter.&#160;The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (&#8220;OCI&#8221;) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMzA_21c899a8-8488-49d8-b4f9-60528e53e1dd">two-month</ix:nonNumeric> time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in the fair value of such derivative instruments also are reflected in current earnings. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTE2_4caac9e1-6155-4ecb-b98e-afe3e9d5adfd" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Consolidated Financial Statements from such positions are then measured based on the largest benefit that has a greater than <ix:nonFraction unitRef="number" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="isrg:IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQyMjIx_ec719470-15b5-45fa-a4c9-f4dfff7fe8f6">50</ix:nonFraction>% likelihood of being realized upon ultimate settlement. The Company includes interest and penalty on unrecognized tax benefits as a component of its income tax expense.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for&#160;Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) as period costs when incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTEw_35599d0f-7d8b-44af-861a-4fb842f711fe" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in <ix:nonFraction unitRef="segment" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQyNjkz_eceb446c-55f4-4043-8dcc-c7e34b3d107f">one</ix:nonFraction> segment. The chief operating decision maker regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. As of both December&#160;31, 2022, and 2021, <ix:nonFraction unitRef="number" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="isrg:LongLivedAssetsMaintainedInTheUnitedStatesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1NTk_3be796f3-447d-4c58-8518-f6a37ff16ffb">84</ix:nonFraction>% of long-lived assets were in the United States. Revenue from external customers is attributed to individual countries based on customer location.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTY2_d1616c4b-515b-4b10-93da-444cdbabb3d4" continuedAt="i584507c0f27440cba8790289a8c0f56d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company&#8217;s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="idd603f3755fc4045890b404520132bf4"><ix:continuation id="i584507c0f27440cba8790289a8c0f56d"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the Consolidated Financial Statements. The Company expenses legal fees as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company&#8217;s business, financial condition, and results of operations or cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTg5_e28ea984-58eb-45f6-b9b9-7546d2099d96" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2022-03&#8221;), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The Company early adopted ASU 2022-03 as of July 1, 2022, on a prospective basis. There was no impact of the adoption of ASU 2022-03 on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings and Vintage Disclosures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2022-02&#8221;), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses-Measured at Amortized Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company&#8217;s future Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MDg_dae7b941-1d8c-44ec-a219-5c4b876a7192" continuedAt="if43d01689c454dfbad22140ca52c66d3" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="if43d01689c454dfbad22140ca52c66d3" continuedAt="id85d375222d34106993302664efb3270"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MjA_1d470285-93e6-4fe4-bc3e-b24ea7cda8d6" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash and available-for-sale debt securities&#8217; amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtMS0xLTEtMTUwMDM0_3b14c7fe-25e1-4d5f-98be-a6d7d95fc06c">497.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtOS0xLTEtMTUwMDM0_6a60e3cc-a494-4f1c-a9e6-296ebea0b3c7">497.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtMTEtMS0xLTE1MDAzNA_24ccfdc5-6910-411f-98b0-b9b7bdcfe93f">497.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46268e7a8003454a8651b908542fda66_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMS0xLTEtMTUwMDM0_82c5699b-645b-40b1-85f4-806a1d7c19c8">1,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46268e7a8003454a8651b908542fda66_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtOS0xLTEtMTUwMDM0_3a022b3a-86eb-4d6e-aa83-e2ca192239f9">1,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46268e7a8003454a8651b908542fda66_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTEtMS0xLTE1MDAzNA_f03b8ea1-a09b-47a4-9a9f-7bad12623721">1,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46268e7a8003454a8651b908542fda66_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTMtMS0xLTE1MDAzNA_b7241464-4630-4eae-9d99-4862dc09fd5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46268e7a8003454a8651b908542fda66_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTUtMS0xLTE1MDAzNA_dbcd8d5b-cb12-46ad-a24a-2caa012d869d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMS0xLTEtMTUwMDM0_8961267d-d11f-4875-90be-ef9d7d59e9e5">2,715.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMy0xLTEtMTUwMDM0_332c79eb-056a-442a-95fb-b1a8ae4c0be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtNS0xLTEtMTUwMDM0_9afa850e-e78a-4dfe-924f-d2a4cca76eb2">96.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtNy0xLTEtMTUwMDM0_4cf7f145-ef6d-40b3-ad7f-65df163a1a28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtOS0xLTEtMTUwMDM0_497272c0-fd7d-48cd-9d75-f83f62d2a123">2,618.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTEtMS0xLTE1MDAzNA_d71106d7-6bd4-488d-bd51-cd15963ec70e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTMtMS0xLTE1MDAzNA_dfa43fe3-5353-4892-85fa-587e189d02b3">1,542.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id177033e3c704b16966079b0d35b30a6_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTUtMS0xLTE1MDAzNA_9ad29d34-6270-4357-a2a5-d179df4b74c7">1,076.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMS0xLTEtMTUwMDM0_875087db-ef9e-4bca-8d1f-8b90bc2b08cd">3,799.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMy0xLTEtMTUwMDM0_24e9669e-be67-4c0e-a30a-60c46ed19354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctNS0xLTEtMTUwMDM0_aa6adadc-5c5a-47a2-83f7-f92cf5456366">96.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctNy0xLTEtMTUwMDM0_7a537eaf-e7c1-4dbe-8d83-1d39ad677559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctOS0xLTEtMTUwMDM0_cc4ec8cf-d869-4445-85a1-eb3e73f31381">3,702.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTEtMS0xLTE1MDAzNA_b7a26339-e484-4179-a85c-67e82c32ffec">1,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTMtMS0xLTE1MDAzNA_c8f3ad0e-f458-4575-b1a3-a4824e2ddbc4">1,542.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTUtMS0xLTE1MDAzNA_27620c14-203a-4f66-87f8-dd8a7cb13002">1,076.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMS0xLTEtMTUwMDM0_856b3aea-36b0-47c1-97e6-248f7d7f8cf3">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMy0xLTEtMTUwMDM0_1c2bfea3-46e3-4283-b939-a18a442a0091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktNS0xLTEtMTUwMDM0_96b0ee6d-1c44-4aa9-ac0d-a8674d71a772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktNy0xLTEtMTUwMDM0_214ad963-a6ff-4eb5-b93b-cf657f6bda88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktOS0xLTEtMTUwMDM0_f05444ec-5384-4bec-aa92-989fe7e6f912">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTEtMS0xLTE1MDAzNA_63eb1f37-fdba-41b6-ae67-83c5b8c91eb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTMtMS0xLTE1MDAzNA_d6303de6-9a03-4cc1-b58a-c9f06d084019">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTUtMS0xLTE1MDAzNA_d41a82b5-3fd5-42e5-9ac9-b7b02e4e8e84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTEtMS0xLTE1MDAzNA_dacaf44e-a23c-40e2-b744-c02593769ad4">2,022.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTMtMS0xLTE1MDAzNA_e9910c37-0915-4d0d-af6a-e58906ae3f8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTUtMS0xLTE1MDAzNA_0d11bf5b-9df5-4766-9ed5-d1afcb67bf5b">76.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTctMS0xLTE1MDAzNA_c903eb3a-f1f7-499c-8d30-00d1e4e791d8">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTktMS0xLTE1MDAzNA_b64c1a37-b0a1-4036-909c-a5c2b501cf67">1,944.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTExLTEtMS0xNTAwMzQ_8ff8fa9d-fa68-4c48-b513-3940e5097791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTEzLTEtMS0xNTAwMzQ_29c6dafa-9ed5-4e24-92ee-3f2562977be2">651.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTE1LTEtMS0xNTAwMzQ_c51e3aad-f4b7-498c-b9fd-afcea4a6d056">1,293.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTEtMS0xLTE1MDAzNA_14e9c407-8c5b-4237-b3cd-c70869c524f7">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTMtMS0xLTE1MDAzNA_20bd1c33-a14f-47fc-90a8-b0bd12f9ba33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTUtMS0xLTE1MDAzNA_1ef1cbcc-c220-466c-bda6-ecb3558bdd57">19.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTctMS0xLTE1MDAzNA_5ea748b7-d2b7-492b-a670-b2f42ba103a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTktMS0xLTE1MDAzNA_33ec3ee6-64f0-40ca-b486-2393c8cf9e04">427.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTExLTEtMS0xNTAwMzQ_0c081252-4057-487d-8ec9-ba36721f611c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTEzLTEtMS0xNTAwMzQ_8cd324dd-f171-4b45-aea9-5eb1da04ead1">247.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTE1LTEtMS0xNTAwMzQ_81ccfece-f90c-44f2-a58b-3f9af2aeba37">179.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTEtMS0xLTE1MDAzNA_893c698f-424b-4f8f-b175-fd0fe9d105dd">155.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTMtMS0xLTE1MDAzNA_3c960dce-9b51-40ac-895a-8cd68ddda289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTUtMS0xLTE1MDAzNA_e8a8b48d-5db5-465e-b416-929213d9e4fd">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTctMS0xLTE1MDAzNA_8766e85f-61dc-4a4f-8717-1673224dca73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTktMS0xLTE1MDAzNA_ba49f4f5-c2d9-42f5-8089-57c0f6a7f6d1">149.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTExLTEtMS0xNTAwMzQ_d337662c-774c-4146-af0e-1f363351074e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTEzLTEtMS0xNTAwMzQ_92914f8a-3ae9-4ad9-ae9d-172da88be777">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTE1LTEtMS0xNTAwMzQ_34d0bf4b-81c8-4278-be31-29940f57f4c8">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTEtMS0xLTE1MDAzNA_b6430abf-e0a4-4c69-92f9-11f29c952e5e">2,644.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTMtMS0xLTE1MDAzNA_e86f5c79-e1e6-4d12-8e5e-ec6d9a16c7f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTUtMS0xLTE1MDAzNA_dcc8410c-c7eb-4b8b-b966-cdc30993f765">101.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTctMS0xLTE1MDAzNA_e25019f4-8598-4dc3-997d-61049e845615">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTktMS0xLTE1MDAzNA_1dbb8a30-9e33-4afe-b5f1-ddb6bb2fb4bf">2,541.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTExLTEtMS0xNTAwMzQ_8d1b99af-941d-4bc8-a59c-a13c44b7360f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTEzLTEtMS0xNTAwMzQ_565ff203-3305-4262-a3b0-cf6bff0e1d19">994.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTE1LTEtMS0xNTAwMzQ_de7b28f0-7752-452e-a012-e677c2668029">1,547.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTEtMS0xLTE1MDAzNA_f9dd326e-e483-4cb6-bdf8-a1c8b0308a87">6,941.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTMtMS0xLTE1MDAzNA_cdcb3be5-8872-4abf-9fe5-53785b1ce7c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTUtMS0xLTE1MDAzNA_02967932-db81-4316-bd7b-d4a68b131287">198.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTctMS0xLTE1MDAzNA_f12beae0-013b-490f-8f04-7e3ebf43883d">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTktMS0xLTE1MDAzNA_dca71708-3ecd-40d0-a1a6-da927074f8ba">6,741.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTExLTEtMS0xNTAwMzQ_8bf8e2e9-791e-4e1f-93ca-75ced003a1a7">1,581.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTEzLTEtMS0xNTAwMzQ_016ad47e-f2ae-4f7f-bb5a-0d1e7f8a1c8a">2,536.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTE1LTEtMS0xNTAwMzQ_88e8336d-ca94-4789-9cbe-546d9b6193db">2,623.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bf33483de84677a014730d8912b575_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtMS0xLTEtMTUwMDM0_b4577ee4-9491-49a8-8b34-d7856d26b883">572.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bf33483de84677a014730d8912b575_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtOS0xLTEtMTUwMDM0_e0f0e227-8943-4704-971e-a231e1840d93">572.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7bf33483de84677a014730d8912b575_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtMTEtMS0xLTE1MDAzNA_cba85637-e838-475b-900b-09d97d0dd823">572.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997ca722e2f4788a65a9e8536746348_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMS0xLTEtMTUwMDM0_67d4ec66-707a-44e2-a016-d0dd1f8a188f">696.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997ca722e2f4788a65a9e8536746348_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtOS0xLTEtMTUwMDM0_a22fbc27-5f29-4963-a5dd-c6166ad78868">696.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997ca722e2f4788a65a9e8536746348_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTEtMS0xLTE1MDAzNA_7d1824cd-4604-4817-bd0e-78e9f1753c55">696.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997ca722e2f4788a65a9e8536746348_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTMtMS0xLTE1MDAzNA_b7e59b3f-5895-4f79-b3eb-ef2959add87d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997ca722e2f4788a65a9e8536746348_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTUtMS0xLTE1MDAzNA_96a1632e-8f10-4bba-9569-a5f4810836ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMS0xLTEtMTUwMDM0_5082a9d5-91b0-47af-b96c-05bd4a305c10">3,429.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMy0xLTEtMTUwMDM0_af986b6a-541a-404a-bb5b-bbbd80b8290a">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtNS0xLTEtMTUwMDM0_3fcccdca-b088-4d14-9aa2-11c631ccd4dc">15.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtNy0xLTEtMTUwMDM0_f8fcc3df-8600-43be-9b59-85d091a8cda8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtOS0xLTEtMTUwMDM0_14c36501-f2f6-4701-a122-6965cd1ff806">3,420.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTEtMS0xLTE1MDAzNA_875048a0-5f67-413a-a09a-8dc6a2841776">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTMtMS0xLTE1MDAzNA_955bc79d-c0c3-4544-b9e3-3748c2ccd6f9">1,100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTUtMS0xLTE1MDAzNA_08422426-c399-4edc-a9a6-dae1596fd852">2,302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMS0xLTEtMTUwMDM0_e2fcd450-01b0-45b4-ae5a-be7dad66b060">4,125.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMy0xLTEtMTUwMDM0_fc19f3d4-b7b3-4395-858f-b42afbf45ae7">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctNS0xLTEtMTUwMDM0_fe1b1068-4ff1-4a25-ab75-fed985d38d44">15.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctNy0xLTEtMTY4NTUz_9a602735-2f6c-4933-81de-6861d1b64997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctOS0xLTEtMTUwMDM0_f6177320-51b0-436f-ac47-1919013a91c0">4,116.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTEtMS0xLTE1MDAzNA_9785ae91-4e4f-4687-a60c-d8ea137b113d">713.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTMtMS0xLTE1MDAzNA_707e8cb9-b6f8-4f71-8b6a-0de99cc9934a">1,100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTUtMS0xLTE1MDAzNA_d22504e3-9920-43eb-ad3f-abd6f21e230c">2,302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMS0xLTEtMTUwMDM0_5925e52e-0dd4-48fe-a3b8-4f8895545204">717.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMy0xLTEtMTUwMDM0_6bef1a4e-26a0-4865-89d6-2db99a6bc64f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktNS0xLTEtMTUwMDM0_ec8da079-4f5b-4743-b969-bae59eca2d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktNy0xLTEtMTUwMDM0_01873727-a704-4493-b981-2563b80328fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktOS0xLTEtMTUwMDM0_bdaa5c6b-30d9-4fce-828b-733a73fc8f9f">717.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTEtMS0xLTE1MDAzNA_74c3b3a6-1e22-45fc-8684-cffdf0b6f013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTMtMS0xLTE1MDAzNA_162bf471-4cab-45d0-b760-0571d69d9821">717.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59583221ff1b4c91878682716a636bb3_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTUtMS0xLTE1MDAzNA_b6ee0b6c-b094-4276-8808-b1eaf64e5d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTEtMS0xLTE1MDAzNA_cea72d1c-5750-406d-b985-1f224da9f54a">2,485.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTMtMS0xLTE1MDAzNA_35f238bf-f692-415d-a6f7-e61f67dd7fd2">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTUtMS0xLTE1MDAzNA_5bc607b5-be4a-4a80-aca5-be85b599b60e">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTctMS0xLTE1MDAzNA_a21837a7-5545-4de6-99e9-27b022263a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTktMS0xLTE1MDAzNA_a7b9159c-9225-46cf-8d93-893513319295">2,476.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTExLTEtMS0xNTAwMzQ_93a4e024-f3ac-40fb-a863-e7a7a0ec838d">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTEzLTEtMS0xNTAwMzQ_809dabdf-3b1b-43a7-806b-4ff004953938">886.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTE1LTEtMS0xNTAwMzQ_745d6786-39ef-4ebc-b10c-70cae4671b11">1,584.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTEtMS0xLTE1MDAzNA_5713f5a6-6dd6-4808-8dd2-60b9910b52a0">526.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTMtMS0xLTE1MDAzNA_17df62e4-ffd1-4950-bb9c-2c15a698f5da">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTUtMS0xLTE1MDAzNA_4fd1983d-b866-4b8e-a9c4-cc776f9331f5">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTctMS0xLTE1MDAzNA_ad62765d-5ef1-47fa-b834-fc17a050a4b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTktMS0xLTE1MDAzNA_52768a2d-903f-48ba-84ce-7489d9f8f4d2">523.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTExLTEtMS0xNTAwMzQ_5ddb93e4-3f10-4a20-8dc2-0abf0f71c91c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTEzLTEtMS0xNTAwMzQ_ffeb0fd5-6a8a-4104-9fb4-0c7cb070e9b8">137.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTE1LTEtMS0xNTAwMzQ_ea52b99d-518a-4d72-81e9-cb9091ad1db6">385.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTEtMS0xLTE1MDAzNA_274eccf0-fed7-4d85-8354-6d558eed08e5">213.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTMtMS0xLTE1MDAzNA_945a912a-fde2-498e-8cf6-7df68a25e3cc">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTUtMS0xLTE1MDAzNA_6cff5f5d-a826-4aa0-a794-12d58840079c">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTctMS0xLTE1MDAzNA_62bb05be-41ef-4712-97a0-e65e154ed454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTktMS0xLTE1MDAzNA_880083fc-8674-46a7-86f0-adb31ae3654f">213.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTExLTEtMS0xNTAwMzQ_ca7ebcad-02b6-4f6c-bf22-f1354ee5d5fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTEzLTEtMS0xNTAwMzQ_3171e9fc-4827-4c02-a26d-ad6edba11ead">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTE1LTEtMS0xNTAwMzQ_6b935e4c-d4cb-4003-ad15-a2533bd46b49">142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTEtMS0xLTE1MDAzNA_7318f580-ad7c-48c4-be1f-7b661e3b083b">3,942.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTMtMS0xLTE1MDAzNA_1f98316b-6485-4d7c-a690-dceae2f73035">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTUtMS0xLTE1MDAzNA_bc5a5ace-99b8-49e8-9d5b-dff005c0230f">15.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTctMS0xLTE2ODU5OQ_8d30da34-7720-4030-923b-f7d0b88ae413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTktMS0xLTE1MDAzNA_7579b938-166e-4eff-8433-2e7ff9e6ce62">3,930.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTExLTEtMS0xNTAwMzQ_a4dcdd00-19b0-4e07-b937-2ce6db90a0f0">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTEzLTEtMS0xNTAwMzQ_21959f4e-7bf4-4fe1-a942-0c8e362b737f">1,812.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTE1LTEtMS0xNTAwMzQ_f1647066-adf6-4f16-9931-84af733280b7">2,112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTEtMS0xLTE1MDAzNA_fae4db4d-9483-4fa2-8ac4-f73f39b9291e">8,640.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTMtMS0xLTE1MDAzNA_941403b1-1049-45e5-be65-f1edd7dbd587">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTUtMS0xLTE1MDAzNA_b8bc9b58-5edc-4e99-81a6-e6b2f56c86b0">31.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTctMS0xLTE2ODYyNA_83f50db8-95ca-434b-9f4c-26b4aac4a17b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTktMS0xLTE1MDAzNA_8fa6b3c4-8335-4cbf-8ca7-fe705ccc6514">8,619.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTExLTEtMS0xNTAwMzQ_30ff124f-a588-4a74-a062-f0c25db5be16">1,290.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTEzLTEtMS0xNTAwMzQ_daff1109-c49f-4227-b23d-0a4014977229">2,913.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTE1LTEtMS0xNTAwMzQ_dc56f5c0-438b-44fd-8c01-133e2b70a06b">4,415.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="id85d375222d34106993302664efb3270" continuedAt="i2e6f37edf71d4789b1cfdc7e1d7a67ae"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYzOTE_98a4f8b0-28ed-486f-9fc1-292c990734d1" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s cash equivalents and available-for-sale debt securities (excluding money market funds) as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzEtMS0xLTEtMTUwMDM0_86cb73a8-6008-44a2-9134-048183977d09">2,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzEtMy0xLTEtMTUwMDM0_2ef7c8ec-d71b-421a-a3fd-033ff3536017">2,536.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzItMS0xLTEtMTUwMDM0_3f27f439-ecf6-4a93-80f9-137dabb3e133">2,773.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzItMy0xLTEtMTUwMDM0_0e584d7b-a4f0-428b-b778-2b141bb1c9cf">2,623.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzMtMS0xLTEtMTUwMDM0_ee79a124-0220-48d4-a39e-bd8d325ad835">5,359.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzMtMy0xLTEtMTUwMDM0_326ea012-e1b3-42fc-9caf-363005f188c2">5,160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities, because certain borrowers have the right to call or prepay certain obligations. Gross realized gains and losses recognized on the sale of investments were <ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NTkxOTQ_4eb3d1bc-0e3b-4f66-a2c9-5b450be8c970">immaterial</ix:nonFraction> for the years ended December&#160;31, 2022, and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, net unrealized losses on available-for-sale debt securities, net of tax, of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NjgyNDc_7e312d6c-7c7b-4047-bbb3-fd5ceae10fb4">154.2</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NjgyMzU_24f8a585-3521-4afb-8d5e-899086ae5f54">16.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, were included in accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MTk_aeb52a80-0c7c-43c9-bbfe-707ae1f62815" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized&#160;losses&#160;less<br/>than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized losses&#160;12<br/>months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMS0xLTEtMTY5MjQ4_9fb42b93-ea60-4a49-8907-05592082bd8d">731.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMy0xLTEtMTY5MjQ4_2c6a4b19-f8ef-4e80-bf94-aa4ae0a07b56">26.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItNS0xLTEtMTY5MjQ4_b090c6aa-191d-4797-a481-43d9b35cc4cd">1,886.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItNy0xLTEtMTY5MjQ4_d0af0ecd-d100-4d74-92f1-af5acdd4ddac">70.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItOS0xLTEtMTY5MjQ4_7acfda41-af74-40e0-a744-06cdf8bfe928">2,618.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9444962effa548219751ad1adbb4d73f_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMTEtMS0xLTE2OTI0OA_882394b6-7f95-4584-a2bd-b4f686ab89cb">96.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMS0xLTEtMTUwMDM0_b887d226-10f8-45c7-97f2-5812f238103f">631.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMy0xLTEtMTUwMDM0_c643cdb1-fc05-4875-ab7c-4e3950e3c12c">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtNS0xLTEtMTUwMDM0_17eb76e8-e712-4651-9e0c-ec9d2ffbab3a">1,221.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtNy0xLTEtMTUwMDM0_6e8cd9fd-8516-4165-80b2-ea3203bce566">58.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtOS0xLTEtMTUwMDM0_91cf2799-dd13-4ea7-950e-abc7a0fc6f67">1,853.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMTEtMS0xLTE1MDAzNA_8b156b3a-f316-4aae-afbb-610140fde778">76.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMS0xLTEtMTUwMDM0_cd8c5721-3302-4619-bdf4-f1b56912578f">102.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMy0xLTEtMTUwMDM0_bac97a55-7c6f-47c9-8db9-8f74e3de4671">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtNS0xLTEtMTUwMDM0_9d622a6a-a9c0-4833-a098-3e929426e17e">324.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtNy0xLTEtMTUwMDM0_a619e105-a00f-44d6-b47d-62d5e45787b9">15.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtOS0xLTEtMTUwMDM0_2352eead-f291-44ff-9807-0e1d4104e374">427.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMTEtMS0xLTE1MDAzNA_d3a611fb-1385-49b4-94c0-8611f68fc924">19.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMS0xLTEtMTUwMDM0_be93491e-a583-4016-81d9-6fd47161f7dc">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMy0xLTEtMTUwMDM0_a33c0099-0a9a-447d-89f5-9e0d038d80eb">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtNS0xLTEtMTUwMDM0_621a8d00-5477-4f36-8e1f-8f3585d3a7e2">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtNy0xLTEtMTUwMDM0_48c0f4cc-7794-419b-90ce-55bc711cc513">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtOS0xLTEtMTUwMDM0_4d64c05c-44c1-42bf-928a-fe25d8f302d7">149.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0705226857e341b09873d9b24560e21a_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMTEtMS0xLTE1MDAzNA_869f6662-2600-4b75-8bf3-b23c9415303c">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMS0xLTEtMTUwMDM0_207217ce-a5eb-4bea-ae44-44262cf9a3cc">1,510.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMy0xLTEtMTUwMDM0_aacddd23-971f-46ad-8d64-6bedffe1f7d6">49.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctNS0xLTEtMTUwMDM0_2e574b6a-b977-4ded-b49a-db880d0472f5">3,538.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctNy0xLTEtMTUwMDM0_5f7b3275-8c14-48b4-bdd3-dad2a64306af">149.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctOS0xLTEtMTUwMDM0_424735d6-d7db-4d12-a81a-eea680b09c0f">5,048.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMTEtMS0xLTE1MDAzNA_864f13a4-a5f3-402c-9510-a3e05b2db1e1">198.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTEtMS0xLTE2OTI2Ng_88e94007-3c7d-4a74-8c8f-98d312a66795">2,596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTMtMS0xLTE2OTI2Ng_fbeee95a-fc93-4b1e-a59e-88fa620fe64d">15.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTUtMS0xLTE2OTI2Ng_0c56414f-e1f3-4834-bd5e-a759a3656d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTctMS0xLTE2OTI2Ng_a600db84-206a-444c-af5a-0e57be27f2ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTktMS0xLTE2OTI2Ng_307537e6-fb2d-4118-b07f-a81e5d4d85bc">2,596.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTExLTEtMS0xNjkyNjY_86c113ad-6961-4c7a-92bd-e00e7bfa75bc">15.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTEtMS0xLTE2OTY5NA_c74e91ba-cf9c-4828-89a9-013304c700a9">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTMtMS0xLTE2OTczNw_2afc9053-8d79-45b1-9ad5-fdc0747029b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTUtMS0xLTE2OTc3OQ_71cd3a16-3d34-4964-988e-854cd7ecf29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTctMS0xLTE2OTgyMQ_fd998b91-8f8b-4551-b741-d813f2fe2a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTktMS0xLTE2OTg2OA_71ae1076-17e4-48ee-985a-445b7f43cb51">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTExLTEtMS0xNjk5MzA_6b31093d-38e6-4d9d-aff5-b5dab12996ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTEtMS0xLTE1MDAzNA_961107dc-7b57-4e35-82e2-84ba1a200130">1,687.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTMtMS0xLTE1MDAzNA_3096cbb3-6a82-4c6c-ba7f-9412c33f0704">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTUtMS0xLTE1MDAzNA_8ac8951d-073e-4b67-917f-a9458b3f1e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTctMS0xLTE1MDAzNA_45409aed-8e47-41e1-b668-a7a9c2a56221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTktMS0xLTE1MDAzNA_92e30303-2991-457f-bb27-43ff93e60043">1,687.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTExLTEtMS0xNTAwMzQ_91df5d7c-99b4-45de-88ad-dbb7da73180c">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTEtMS0xLTE1MDAzNA_05624c3a-e6c2-4d52-89ce-7301ab44bb82">412.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTMtMS0xLTE1MDAzNA_3f6558b0-7b8d-4c21-90e0-57526803162f">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTUtMS0xLTE1MDAzNA_31adb959-be0d-461e-93e3-6b88aa977be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTctMS0xLTE1MDAzNA_a55eaf0c-b002-47b3-9dff-1a194b45824e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTktMS0xLTE1MDAzNA_f680c572-31f4-47af-b393-558232056dee">412.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTExLTEtMS0xNTAwMzQ_a88387f5-2944-4bea-93e3-136332e78612">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTEtMS0xLTE1MDAzNA_6725b5ca-1895-4528-a4bd-0f0fe5c228a3">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTMtMS0xLTE1MDAzNA_bea19c0a-5be8-4f25-8141-b544a01d5c3b">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTUtMS0xLTE1MDAzNA_5e8cc14b-5673-4771-b670-ef95f8f82da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTctMS0xLTE1MDAzNA_2e3f495e-d425-463d-8281-7051d91ae44e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTktMS0xLTE1MDAzNA_8599a4ae-36ec-4380-91b9-f9c0c2c38786">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTExLTEtMS0xNTAwMzQ_fe3fdbc1-96ac-40ca-8701-2dd935c07b53">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTEtMS0xLTE1MDAzNA_eab88ebc-f3bd-4c8c-9dc9-7e3b7816faa6">4,856.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTMtMS0xLTE1MDAzNA_3014432d-b16c-4247-a939-46fdb7c8e105">31.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTUtMS0xLTE1MDAzNA_bdc2c5d8-2c02-401c-830b-b8e72f8fef71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTctMS0xLTE1MDAzNA_59d38597-66fb-4b62-ae15-08bc17a25098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTktMS0xLTE1MDAzNA_f6fc34d1-cd19-49cd-a11a-474a52a5908f">4,856.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTExLTEtMS0xNTAwMzQ_ebf71dbe-83d6-4bca-b796-f6c9ecf87721">31.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on the Company&#8217;s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of December&#160;31, 2022, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i2e6f37edf71d4789b1cfdc7e1d7a67ae" continuedAt="i40b0dbfe70f8407a81fc5514e154153a"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYzOTQ_6f4865ed-e87f-457d-ab03-044d203ae6fb" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Changes in Fair Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchases / Sales / Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaids and other current assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments with readily determinable value (Level 1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMS0xLTEtMTUwMDM0_072b22d7-11de-4063-bdb2-2f1b343ab5db">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMy0xLTEtMTUwMDM0_4196c251-3806-4264-965c-0c08a74dfe90">21.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231" decimals="-5" sign="-" name="isrg:EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItNS0xLTEtMTUwMDM0_db1fed9d-5fae-4fc7-9455-3a32512e3dcc">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItNy0xLTEtMTUwMDM0_393d07a7-f31c-45e8-ade2-ad3e49617c97">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702b19a2b8bb41359e443d04869386fd_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItOS0xLTEtMTUwMDM0_c7c07d90-22ff-451f-8f09-33d2ba30e7c8">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae9291dcd4e4adf9b84f4736b3bebec_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMTEtMS0xLTE1MDAzNA_3b79ecd2-cfd1-4490-8771-fb1a52f20886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments without readily determinable value (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMS0xLTEtMTUwMDM0_e4645773-c105-4fc2-b416-f3aa4471f3df">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231" decimals="-5" name="isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMy0xLTEtMTUwMDM0_e707de29-d493-4b4b-9a51-b394ce282577">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231" decimals="-5" name="isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtNS0xLTEtMTUwMDM0_c7f1025b-5abd-44f4-bb2a-9bdc68e8568b">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtNy0xLTEtMTUwMDM0_2fe394af-be09-40f5-837c-6ff5a8e77ad9">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc10b5ae76314ee18fd591fd9b32d6ac_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtOS0xLTEtMTUwMDM0_13242378-3699-4179-b4e4-d004fa0a862b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5134dae76a5341b9aaabb6667f245625_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMTEtMS0xLTE1MDAzNA_a61fbc90-4393-4111-af0c-fac3e66c0709">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Recorded in interest and other income, net.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other includes foreign currency translation gains/(losses).</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Broncus Holding Corporation (&#8220;Broncus&#8221;) completed an initial public offering (&#8220;IPO&#8221;) of common shares on the Stock Exchange of Hong Kong. Upon completion of its IPO, the Company&#8217;s preferred shares of Broncus were converted into common shares, which have a readily determinable value (Level 1). The Company was restricted from selling these shares for a period of six months. In 2022, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i71314a12af6b429986b5c9a4271f446a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzM4NDgyOTA3MTg3MjU_e1e0f3b7-5109-4dab-99d8-0e1852c23064">21.2</ix:nonFraction> million loss on this investment reflected in changes in fair value for Level 1 equity investments, which was reflected in Interest and other income, net.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a $<ix:nonFraction unitRef="usd" contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231" decimals="-5" name="isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzM4NDgyOTA3MTg5ODA_c78e4085-0288-4506-8231-c57424ea67d6">0.2</ix:nonFraction>&#160;million increase in fair value, which was reflected in interest and other income, net, due to changes in observable prices for certain equity investments that lack readily determinable market values (Level 2). There were no decreases in fair value reflected in net income due to impairments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivatives</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the Company&#8217;s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, intercompany balances, and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (&#8220;USD&#8221;). The terms of the Company&#8217;s derivative contracts are generally twelve months or shorter. The derivative assets and liabilities are measured using Level 2 fair value inputs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (&#8220;EUR&#8221;), the British Pound (&#8220;GBP&#8221;), the Japanese Yen (&#8220;JPY&#8221;), the Korean Won (&#8220;KRW&#8221;), and the New Taiwan Dollar (&#8220;TWD&#8221;). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and the Swiss Franc (&#8220;CHF&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive loss in stockholders&#8217; equity and reclassifies the amount into earnings in the same period in which the hedged transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Derivatives Not Designated as Hedging Instruments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, TWD, Indian Rupee (&#8220;INR&#8221;), Mexican Peso (&#8220;MXN&#8221;), Chinese Yuan (&#8220;CNY&#8221;), and Canadian Dollar (&#8220;CAD&#8221;).</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MTI_7ac69aec-8af6-4db1-bb22-873dbcf5fd61" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:59.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb">Recognized gains (losses) in interest and other income, net</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079b7ef7442a42a7840e702b882a1012_D20220101-20221231" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMS0xLTEtMTUwMDM0_a5db0764-bcfe-4195-adb0-4df0bacf9016">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7280a7103fee4e258e2f35b51eff9ab1_D20210101-20211231" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMy0xLTEtMTUwMDM0_0dca9176-c84a-4a75-b771-daa62c37e932">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i910cb2fb179a407d8a5c75fc680d2303_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItNS0xLTEtMTUwMDM0_d9165c82-3635-4c46-9c4a-5c46eb1f2116">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) related to balance sheet re-measurement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtMS0xLTEtMTUwMDM0_01ab912b-dc93-4b25-91c1-e6aee0187d01">54.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtMy0xLTEtMTUwMDM0_0f63ea55-562a-406b-9f9c-3f741954ec34">16.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtNS0xLTEtMTUwMDM0_297da13f-6b30-4c80-9c17-8e800cd1068d">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i40b0dbfe70f8407a81fc5514e154153a"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts for derivative instruments provide one measure of the transaction volume. <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MjM_2b5eab2a-81db-475e-b096-93f8dc06aa90" continuedAt="i38fc8a2052ee43e0b34c6201f19e27e7" escape="true">Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i38fc8a2052ee43e0b34c6201f19e27e7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c8e03657644033b868750e96ab9643_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtMS0xLTEtMTUwMDM0_5859f889-3e14-4362-a5a2-c4f603292c99">188.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46df387e6efe4ff08b0f664717fc0831_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtMy0xLTEtMTUwMDM0_298c4435-3b73-48ea-8a53-98076a7536c1">181.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fdc4fc554441f08d904ff171695e33_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtNS0xLTEtMTUwMDM0_369e1d6c-0600-4fea-be13-5e95ada6af63">496.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided6c6550364405b97c4d34389c5ffff_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtNy0xLTEtMTUwMDM0_1b1df814-de72-4a46-b777-bcc9ba03cc36">318.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross fair value recorded in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964a856360ad4285ade38db2e34a431b_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtMS0xLTEtMTUwMDM0_08b03b05-3b58-4abd-9841-9a0bf0cbea73">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231b0f91933940b08ff7af08baa651f4_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtMy0xLTEtMTUwMDM0_d01b4ad3-a17e-4812-8a87-7c62d003e4aa">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf83fed589c5486b9792c680888aeea0_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtNS0xLTEtMTUwMDM0_6e74df07-4c4c-4177-a6bb-be5853bb2d7a">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0cbc403979c45828117eb065cab8fa2_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtNy0xLTEtMTUwMDM0_d1c32cc6-de9b-4719-9aa4-ab28e2f4d972">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804002ab970d48a5a57bbae1404bf198_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtMS0xLTEtMTUwMDM0_68058710-ef43-4042-9c34-71ae50dc859b">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a74a66492084258931e13b5981fa79f_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtMy0xLTEtMTUwMDM0_dea11e45-c974-40ab-a8dc-2b3f8920a692">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22a8bae9b2c48eebe8b50b3819f8d70_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtNS0xLTEtMTUwMDM0_9a1b9163-2605-4c20-b7c4-66410f0778af">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3edae5cd8cd2410183098ef4010c1892_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtNy0xLTEtMTUwMDM0_79f2febe-9aae-477f-aa55-9fd793f99fe1">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_238"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5NQ_132483e7-cbeb-4005-b07d-252d92f4f815" continuedAt="i50d99e6cbb1e492793682deb769372ef" escape="true">CONSOLIDATED FINANCIAL STATEMENT DETAILS</ix:nonNumeric></span></div><ix:continuation id="i50d99e6cbb1e492793682deb769372ef" continuedAt="ibc8d1928ec8a411798265427b15ede06"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzQ5NDc4MDIzMjU0NzY_081a68f9-8733-44a6-8226-9f456c49ce5d" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide details of selected consolidated financial statement items (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:TradeAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzMtMS0xLTEtMTg4MDE3_fafe9027-65e8-43a0-bdd2-3ac8a7d62235">864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:TradeAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzMtMy0xLTEtMTg4MDMx_ecdfb4a9-658a-4393-8990-7588574e20e6">731.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled accounts receivable and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:UnbilledReceivablesAndOtherReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzYtMS0xLTEtMjAwNTQw_2a5943b7-4bea-4568-8978-17ad05bb3e85">91.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:UnbilledReceivablesAndOtherReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzYtMy0xLTEtMjAwNTQ2_4e850eec-e879-435f-92a6-ba3cef83aee7">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:SalesReturnsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMS0xLTEtMTk5NjUz_7aafae6f-5139-4d59-b8ca-39c155cc806d">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:SalesReturnsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMy0xLTEtMTk5NjUz_86201808-f143-4d53-96f3-4d8e1704f906">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMS0xLTEtMTk5NDk3_728f1436-7b72-4bb9-8309-dd7ae94caf39">942.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMy0xLTEtMTk5NDk4_b9c4b52e-e6be-43fd-aeeb-5a6edea73184">782.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5MA_4118ea90-e5be-49be-8d64-a15930aeb562" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Inventory</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzMtMS0xLTEtMTUwMDM0_f201327b-b755-4f93-b62c-572325923890">382.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzMtMy0xLTEtMTUwMDM0_a218998a-e6ab-4259-9e7f-95694edbf43b">214.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzQtMS0xLTEtMTUwMDM0_b4346cfc-425a-41a0-8666-2f486938b62e">159.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzQtMy0xLTEtMTUwMDM0_b2b53bb6-ca0c-4eff-b678-bbdc676ad804">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzUtMS0xLTEtMTUwMDM0_0ab0a979-be23-48df-8f67-89c00928f490">350.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzUtMy0xLTEtMTUwMDM0_8e105e44-744a-4c70-817e-9219138ed827">276.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMS0xLTEtMTUwMDM0_3860936d-1cb1-4384-833c-2d6938cd9a74">893.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMy0xLTEtMTUwMDM0_3652dc36-52d2-4090-93f7-26528b8cca89"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMy0xLTEtMTUwMDM0_addf0141-b03a-4eaf-8740-6fbbb9166f11">587.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5MQ_39a6088f-ad6e-4174-86c3-eed843c5dadd" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Prepaids and other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases &#8211; short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzMtMS0xLTEtMjAwMDgw_422401d0-08d1-49e2-8708-86e5147b8541">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzMtMy0xLTEtMjAwMDgw_327a0efe-3129-4824-96ae-39da25e0b8c5">110.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzQtMS0xLTEtMTUwMDM0_b33e7a1e-914d-4b3b-999e-1243d6cddbf5">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzQtMy0xLTEtMTUwMDM0_85b06ed6-6e41-4d89-bccb-27fa0d772a07">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaids and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzYtMS0xLTEtMTUwMDM0_6b8f9d82-22cf-4e79-b82e-f0aa657b7ef8">164.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzYtMy0xLTEtMTUwMDM0_06738238-6f71-4f30-baeb-b1254fc5a37c">133.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaids and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzctMS0xLTEtMTUwMDM0_53a03294-9ae7-448a-8e39-9b7f4fd425e6">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzctMy0xLTEtMTUwMDM0_3f7a36a4-5247-4e04-930b-64f1077c2fdf">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="ibc8d1928ec8a411798265427b15ede06"><div style="margin-bottom:6pt"><ix:continuation id="ibc1ec496d03f47d583ef6b5bc137e8d2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzMtMS0xLTEtMTUwMDM0_1a271571-c54e-4eab-bfd2-925b0cac9b98">388.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzMtMy0xLTEtMTUwMDM0_db7138ea-6e60-4beb-a6db-063f119c85ef">367.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building/leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzQtMS0xLTEtMTUwMDM0_5bd573e9-3e83-4d8d-9469-b4eee1e78a1a">866.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzQtMy0xLTEtMTUwMDM0_4af9cd8d-bbe1-4460-bf02-986523da9b21">812.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzUtMS0xLTEtMTUwMDM0_caba2ca3-a76b-4bd6-bf45-e041a58802e8">566.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzUtMy0xLTEtMTUwMDM0_e8014aa4-8821-489d-a4c6-9fd6ca14913b">497.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets &#8211; Intuitive System Leasing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzYtMS0xLTEtMTUwMDM0_376ea8ea-2b39-45a2-b248-8eaaeabd7c3c">806.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzYtMy0xLTEtMTUwMDM0_ed0ca1c5-f75f-447d-8d17-6a4dccc36136">616.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:ComputerAndOfficeEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzctMS0xLTEtMTUwMDM0_c6738176-ba22-49ea-85fb-f897bfc060c7">134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:ComputerAndOfficeEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzctMy0xLTEtMTUwMDM0_7bad37c2-d4c1-424b-af87-67b7adcf5380">123.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzgtMS0xLTEtMTUwMDM0_9e02eb8b-05d8-41f7-afb2-83eb88d72adc">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzgtMy0xLTEtMTUwMDM0_a5fc29e8-55f2-4abf-bef5-b719fcf90dc1">217.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzktMS0xLTEtMTUwMDM0_19273857-b566-4aa8-a75c-ebaf42079528">608.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzktMy0xLTEtMTUwMDM0_34df97db-59a9-4af9-a4c4-26acfa57d0c3">209.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEwLTEtMS0xLTE1MDAzNA_bff5b258-f856-41c4-bde4-16c7e5f7cfc3">3,612.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEwLTMtMS0xLTE1MDAzNA_f57de2df-fec7-4aed-abd7-a62df77ae22d">2,845.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzExLTEtMS0xLTE1MDAzNA_b0582b16-9488-45aa-b4f1-ac8591e57846">1,237.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzExLTMtMS0xLTE1MDAzNA_9c72e732-f215-4ed3-ad39-6b5383a40acd">968.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEyLTEtMS0xLTE1MDAzNA_7b15a6c4-aa33-4bf8-a329-db22d9846ddc">2,374.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEyLTMtMS0xLTE1MDAzNA_9abb740d-f8ef-481a-91e4-dea275063fcd">1,876.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Accumulated depreciation associated with operating lease assets &#8211; Intuitive System Leasing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzE0LTEtMS0xLTE1MDAzNA_2643f9ef-ed09-4895-a7ab-45369c74ca44">285.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzE0LTMtMS0xLTE1MDAzNA_66856a09-7c55-4dc1-8059-56ca27937507">182.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI4MQ_ed49d9fa-e678-4c43-b3ba-60aadd5aa0ba" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other accrued liabilities &#8211; short-term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzMtMS0xLTEtMTUwMDM0_0ed14567-8229-4ee0-9346-9542706f6c21">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzMtMy0xLTEtMTUwMDM0_c3e05edd-dc9c-4d45-b4a9-4d99689766be">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction-related capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMS0xLTEtMjAwMTIy_888e12de-d772-45f9-8de2-64cd9c4cdfd8">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMy0xLTEtMjAwMTIy_90a1351e-165f-4c2a-85e8-c10d04156df7">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMS0xLTEtMTUwMDM0_92a91ccf-74fb-4d5c-9757-f1cd58142fe8">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMy0xLTEtMTUwMDM0_9660e4e7-2bed-4e72-976d-3cab7946a162">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred and contingent purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:DeferredPurchaseConsiderationPaymentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzUtMS0xLTEtMTUwMDM0_0ed6d646-f963-41c3-be2b-986111804310">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:DeferredPurchaseConsiderationPaymentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzUtMy0xLTEtMTUwMDM0_876b7af0-ad6a-47ff-ba64-c56594d3f1c4">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzctMS0xLTEtMTUwMDM0_62ad7cdf-8ab0-428d-bccf-73588483480f">299.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzctMy0xLTEtMTUwMDM0_b90cab4d-d4a7-46bb-a2c6-d349c47266bd">209.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities &#8211; short-term</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzgtMS0xLTEtMTUwMDM0_f7f53990-9f7e-4356-a4be-7257ec2207e4">476.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzgtMy0xLTEtMTUwMDM0_f22370ef-56be-4516-8f0b-c825ed7d19ab">301.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI4Nw_772c8716-f703-4848-80d4-7045d6e3ed60" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes &#8211; long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzMtMS0xLTEtMTUwMDM0_902b0078-c4df-47ad-9ef1-edb216027b3c">288.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzMtMy0xLTEtMTUwMDM0_8ee9095f-deb6-4ecc-84c9-bc97ada03e52">316.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredRevenueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzQtMS0xLTEtMTUwMDM0_55d80ce8-c65e-410f-9117-1afd172ccf40">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredRevenueNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzQtMy0xLTEtMTUwMDM0_2959e074-10a7-4e99-921d-bb7725a6c77f">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzUtMS0xLTEtMTUwMDM0_bc5ab1fd-ca66-4cfa-bd7f-e6bebb68b0c8">110.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzUtMy0xLTEtMTUwMDM0_bc1e2cea-91ca-4523-9252-e8230b18ec82">100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzYtMS0xLTEtMTUwMDM0_bfb4f65c-6f3c-407a-b827-37719718b5f2">439.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzYtMy0xLTEtMTUwMDM0_2cca96a0-b326-42d8-93aa-c3ba6aac1f20">453.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzMwMA_f279c91c-72e8-481b-82cf-b45e4f515713" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItMS0xLTEtMTUwMDM0_11f23f96-9dbc-489f-8d51-ffa3d0f81074">444.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItMy0xLTEtMTUwMDM0_661681a8-1651-43a3-8c40-80e51df79c64">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItNS0xLTEtMTUwMDM0_17cef421-b4dd-41a5-a04a-862954877483">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment transfers from inventory to property, plant, and equipment </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtMS0xLTEtMTUwMDM0_0ad3c017-696d-4922-8e13-ffb643bf5ce1">279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtMy0xLTEtMTUwMDM0_f5fe9d88-18c5-45f7-ad01-febb9826829d">302.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtNS0xLTEtMTUwMDM0_2d7ce8b3-6d89-4335-aa53-50df16d6771a">186.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property, plant, and equipment in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtMS0xLTEtMTUwMDM0_cf281295-502f-425c-8ee8-3137807d678c">73.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtMy0xLTEtMTUwMDM0_140918be-5bbd-48ce-a095-b36720d4659b">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtNS0xLTEtMTUwMDM0_e591779f-90f4-478b-9321-e05c0655a58d">47.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTQ_f32ab9a6-118f-4310-95f0-3f32a0cf5a07" continuedAt="i8035c95d08bf46cd8ecf380b8e07f637" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="i8035c95d08bf46cd8ecf380b8e07f637" continuedAt="idb5447a50c37422083ce4e0c6b40398e"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTU_9e725566-cd92-468b-ac42-a60cbe1f4f64" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by types and geography (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246f937640f04aaca1e106cbdf7b1a32_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItNS0xLTEtMTUwMDM0_a59150c2-472e-4634-8e04-154e1bcddb6e">2,507.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cc5eca2d9942c3921b4aba2cde8e4f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItNy0xLTEtMTUwMDM0_ba44b71e-fe67-4f74-b538-441cfd2dfd7d">2,225.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b35002f4f84795b5c367b377727c09_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItOS0xLTEtMTUwMDM0_9fc65b32-2bfd-4994-a3f4-496584619254">1,785.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1c067c42d24d09b83f44eb0b71ce2b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtNS0xLTEtMTUwMDM0_7b0581fb-0cd4-4563-bd51-6c63b0887fee">966.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae156a408ef48c79d517473c3535ecd_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtNy0xLTEtMTUwMDM0_e4dc9885-b206-46b7-b547-924c05fa12d3">1,024.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0a839f694a4a25a79f064404e8b099_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtOS0xLTEtMTUwMDM0_a91527a3-1c12-4bbc-a6c0-34369fb84b1c">695.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0b0eb6066646e28b5f0ecd47f541fd_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtNS0xLTEtMTUwMDM0_3851b3c6-f239-4146-9d6f-ff57a26a5d73">684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144e739c7bc4ec28218fb43ce081ed4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtNy0xLTEtMTUwMDM0_716b2f8b-a867-464c-9b1b-87facbcc2f6f">603.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3831ecf897f94e55ade9139765dde100_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtOS0xLTEtMTUwMDM0_d8a0d7a9-762f-410d-8e5a-454b6e4a8e6f">482.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55328c6d3ad9447fb62f387c720a2058_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtNS0xLTEtMTUwMDM0_a70c00b1-6a32-4186-b6bc-f082c5f6a336">4,157.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1626e0eb7e514e2fb0c7df23826a6fec_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtNy0xLTEtMTUwMDM0_1f7ea0e1-33e9-4681-b6bc-59fb5533e6cc">3,853.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b2f32382954088b7a0390205e6b628_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtOS0xLTEtMTUwMDM0_c6c967b7-4bd6-4715-96ac-38168eb0bebd">2,962.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">OUS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8304025c63864a2aa1a6a11f46d0864b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtNS0xLTEtMTUwMDM0_c5489ccc-09a2-4c32-b297-d04621b2f6a9">1,010.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6837fa9980f8427899e6791fa305524d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtNy0xLTEtMTUwMDM0_4253c141-f413-4e49-9567-595ce9e8054c">875.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36d1a1db0674a418d5a7f72e7b54de5_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtOS0xLTEtMTUwMDM0_72bfe070-d344-4d50-8ad4-ffa8e809cc0e">670.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950b136a19ae40d9b9d11a4c60b1f0a6_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktNS0xLTEtMTUwMDM0_4b3c73b4-dcf7-494a-9698-c1370cb25a00">714.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe17b049a1e34a548921b45ddee7b35f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktNy0xLTEtMTUwMDM0_b8f6e5e8-0f15-4b5b-adf7-2aeb14fc398b">668.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib380a2c52e2d42409c0b1646842faf2a_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktOS0xLTEtMTUwMDM0_7373c4c5-72cc-4c56-9051-9cbb40f347ef">483.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5df141ea8e40509cb916df8b2ff26f_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTUtMS0xLTE1MDAzNA_3976bc4c-5c9a-4588-9516-33b8595f3950">339.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c243171572a42cea628d49efffe8709_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTctMS0xLTE1MDAzNA_e0de00f9-3f89-4d05-956c-9ea3972ffcc8">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda45a3621c84f1b9aef4071b842c2b2_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTktMS0xLTE1MDAzNA_3eac7fc6-160f-46b7-8a36-2e40fe81d8bf">241.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total OUS revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c746302eaf44e986f9840477b463de_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTUtMS0xLTE1MDAzNA_1bc00665-f0d8-4b93-a9d4-71d46b8bdc51">2,064.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9c7f30e288439fb419bcf27013ae6f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTctMS0xLTE1MDAzNA_ac7b6b67-b6ec-4302-8feb-e1458e5d3ae6">1,856.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb59dcfb65644da9a3e23bb2aeea13c1_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTktMS0xLTE1MDAzNA_cb74f3bd-ede1-40b6-adb8-d4e0fc72c626">1,395.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1962e48f84bd458fb0b88daa39518d23_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTUtMS0xLTE1MDAzNA_c0d5677a-513a-406d-92ed-47bb720776b9">3,517.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69bf5f4d5aed4a8b8454b48cd962b54e_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTctMS0xLTE1MDAzNA_f6b888c8-7f73-4a91-869e-51c75471cf53">3,100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b449d3de1df438a8825ceebf4e43693_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTktMS0xLTE1MDAzNA_d5e6059c-282b-409e-9508-01601755b53d">2,455.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTUtMS0xLTE1MDAzNA_bf79d33b-3ac7-4393-bd8a-06fb2a69f9b8">1,680.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea54ffe275324b9381bef67e6b9ae4a8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTctMS0xLTE1MDAzNA_1e49f5ee-7341-4b8b-9ad7-8cc986dc1592">1,693.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46c00d9c67d4ce9b8f5e8bbcc799cad_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTktMS0xLTE1MDAzNA_b62cc9d0-430c-49f5-b703-d069759c2354">1,178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTUtMS0xLTE1MDAzNA_f15e0215-d394-4000-bfd4-abe733044f02">1,024.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTctMS0xLTE1MDAzNA_9b1b3ea9-f8f7-4610-be46-c1e1bb018f15">916.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTktMS0xLTE1MDAzNA_892e8c5a-27c7-475a-8895-a0daa694de0c">723.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTUtMS0xLTE1MDAzNA_7655ced4-e5db-47bf-8633-6a249b9d4892">6,222.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTctMS0xLTE1MDAzNA_8bab8ad0-eb83-418a-a2a4-572aef862c19">5,710.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTktMS0xLTE1MDAzNA_4772a152-1877-442b-b9f8-077a3450209e">4,358.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which revenue has not yet been recognized. A significant portion of these performance obligations relate to service obligations in the Company&#8217;s system sale and lease arrangements that will be satisfied and recognized as revenue in future periods. The transaction price allocated to the remaining performance obligations was $<ix:nonFraction unitRef="usd" contextRef="i2f9ee599e0834c439f28abe74bf98547_I20221231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ4OTE_248bce0d-9559-4c2f-9137-cdb8034f98e8">1.86</ix:nonFraction>&#160;billion as of December&#160;31, 2022. The remaining performance obligations are expected to be satisfied over the term of the system sale, lease, and service arrangements, which are generally up to <ix:nonNumeric contextRef="i2f9ee599e0834c439f28abe74bf98547_I20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2Xzc3MQ_e8ddb442-2df7-440f-86a1-7a7970851cd1">5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTY_49ce3ee3-056f-4153-bb8a-89127641813f" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information summarizes the Company&#8217;s contract assets and liabilities (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzItMS0xLTEtMTUwMDM0_514dd2e0-f0b8-4796-849e-58699334db57">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzItMy0xLTEtMTUwMDM0_5ee32f33-b388-493b-b727-0667d8d75eb5">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzMtMS0xLTEtMTUwMDM0_1eb04e6a-c7d9-4912-9705-a44ad8b7c879">438.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzMtMy0xLTEtMTUwMDM0_0350438d-fde9-4373-8440-30c05565a363">414.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ5MTA_17199cd2-2ba0-4b10-a493-e69c72c57a19">380</ix:nonFraction>&#160;million of revenue that was included in the deferred revenue balance as of December&#160;31, 2021. During the year ended December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ5MTM_376884ee-ad08-4b17-8d27-299bbeae0e80">351</ix:nonFraction> million of revenue that was included in the deferred revenue balance as of December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="idb5447a50c37422083ce4e0c6b40398e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTc_7edbbf0b-4689-4385-b3dd-b46d473d11ab" escape="true"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMjA_4af30d2b-ea02-4e54-b181-467b56013da8" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents product revenue from Intuitive System Leasing arrangements (in millions):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">Sales-type lease revenue</span></span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMi0xLTEtMTUwMDM0_acdb6fef-49db-4261-9f1f-998ae70d4b5f">156.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItNC0xLTEtMTUwMDM0_2ab1b46f-e1b1-488e-b0ad-13d1d2a0f41f">220.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItNi0xLTEtMTUwMDM0_3fccc052-ccce-4612-bc95-41a147ea77cd">154.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">Operating lease revenue*</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMi0xLTEtMTUwMDM0_0e94606d-acc4-4415-b373-e8e2bcf4514d">376.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtNC0xLTEtMTUwMDM0_2dc54ef3-6311-4d57-b1d0-f38b69adcd09">276.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtNi0xLTEtMTUwMDM0_c1f0891d-3b94-487b-b681-907945b5f950">176.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Variable lease revenue relating to usage-based arrangements included within operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0333e95f85d48cf88145bfeb59afc5d_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtMi0xLTEtMTcxOTM5_46922741-beda-4715-8467-c4406f224e53">133.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6107b94bba54498d96a497fbaf65d4cf_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtNC0xLTEtMTcxOTQ2_69c26a7c-145c-4e45-90a3-e10b649347df">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf73792053ae49508767ca0ac0d77523_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtNi0xLTEtMTcxOTUz_2512cf0b-4e7d-47a0-aca4-cafe6da925ae">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_244"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzU_f4427358-142b-4371-9a59-28af13327e87" continuedAt="ied027a26a3384d4199b44b5bbf3a4713" escape="true"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODQ_85c19d28-e0f2-4bc0-a000-a48095dc551a" continuedAt="ief50a460219e4a179b14fea27514aacf" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ied027a26a3384d4199b44b5bbf3a4713" continuedAt="iefee9c5bf7054dd8a6c8c480eb44586b"><ix:continuation id="ief50a460219e4a179b14fea27514aacf" continuedAt="i56168af06c36433793f184d928aa1f7b"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Lessor Information related to Intuitive System Leasing</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-type Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:LessorSalesTypeLeaseLeaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0OTA_81c8cbe9-a532-4576-ade7-0193d0c51ea8" continuedAt="id1782e38146446b7afb1d804c39de32b" escape="true">Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="id1782e38146446b7afb1d804c39de32b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:SalesTypeLeaseGrossInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzItMS0xLTEtMTUwMDM0_2972a212-c64e-43af-adf7-2c842a444345">449.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:SalesTypeLeaseGrossInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzItMy0xLTEtMTUwMDM0_7297d37e-57c3-4f33-8a09-da3472b7bd81">404.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:SalestypeLeaseDeferredSellingProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzMtMS0xLTEtMTUwMDM0_937c6d9b-b1f8-4c2f-8031-3f1db7f207f8">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:SalestypeLeaseDeferredSellingProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzMtMy0xLTEtMTUwMDM0_801a0023-d9dc-435b-95e6-2b6879a974c2">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzQtMS0xLTEtMTUwMDM0_ac929fd0-8d97-424e-a5d9-d26dd80f88cf">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzQtMy0xLTEtMTUwMDM0_a734a633-2b6c-408a-b0e0-ae11bed6c507">392.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzUtMS0xLTEtMTUwMDM0_436b5c3d-d88e-4921-adc1-38897d1657df">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzUtMy0xLTEtMTUwMDM0_f4ef94a1-cb21-462b-aa06-8d778952b732">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzYtMS0xLTEtMTUwMDM0_a6b24d5d-6a85-434d-bcbc-4607be425439">432.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzYtMy0xLTEtMTUwMDM0_da64e772-21dc-4a8e-a10a-4505a286b0d2">389.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i990140e98ac543b0a1e3275119938c07_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzgtMS0xLTEtMTUwMDM0_dbffea85-ef0b-44ff-b2b4-ea3c92d76a3a">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cdd1443bcf48778c9fb236cb3f5a7c_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzgtMy0xLTEtMTUwMDM0_ccc80feb-fe38-46b2-8858-765d9dbf5a06">110.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic357251bdc6148b78354861f8ff47859_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzktMS0xLTEtMTUwMDM0_2afd5665-4f77-421b-ad6b-72a1ed4e419e">300.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1917b42017a44a168cb0fcb89a52d9bf_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzktMy0xLTEtMTUwMDM0_e952291a-f905-4ad8-81a2-a96637000982">278.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzEwLTEtMS0xLTE1MDAzNA_c6de5fcd-fbc5-4576-8aac-56f14bd4f3e1">432.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:SalesTypeLeaseLeaseReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzEwLTMtMS0xLTE1MDAzNA_e6472363-b68c-4a1f-a07f-7a248adfb875">389.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0Nzc_486f29a2-8119-43ad-bbb3-605e2b5f476e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzEtMS0xLTEtMTUwMDM0_f3ff5c69-8d5f-4ef1-8f9f-193d1a210ffb">137.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzItMS0xLTEtMTUwMDM0_765cf328-3a4b-4f5b-af17-0c1ff0baf1e2">126.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzMtMS0xLTEtMTUwMDM0_7786c4d9-3b42-491d-acda-834e067eb839">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzQtMS0xLTEtMTUwMDM0_2ab93d9d-c971-4457-9483-c2c3cc1a1292">60.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzUtMS0xLTEtMTUwMDM0_8a887cbb-92f6-4251-a221-5262c1d208b6">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzYtMS0xLTEtMTUwMDM0_e99b7b15-d150-4d68-b77e-10dcecfcaa61">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzctMS0xLTEtMTUwMDM0_5eca383c-8049-4c71-b1c5-1baa491a6c89">449.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating lease terms are generally less than seven years. <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODA_292ba069-8147-4d3a-80cc-4429dfc64d31" continuedAt="i0ccfa3a12b9f42ad85575353e74bb7cd" escape="true">Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i0ccfa3a12b9f42ad85575353e74bb7cd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:86.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzEtMS0xLTEtMTUwMDM0_36b4b67a-59f6-4f66-8d78-4b42a5ff620b">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzItMS0xLTEtMTUwMDM0_5c41abf2-c7fa-4244-a039-c1c1f8d8f1ea">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzMtMS0xLTEtMTUwMDM0_9ba8a401-0186-4496-a3d8-22d54fedef35">194.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzQtMS0xLTEtMTUwMDM0_fe4bf054-b780-4fcf-a356-ffcd3d1ebff1">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzUtMS0xLTEtMTUwMDM0_e6dfa401-23fe-4d8d-9d3c-89d5fdd1eb4e">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzYtMS0xLTEtMTUwMDM0_cd1d448e-7aa4-46cd-8c2d-0514ac5a21b8">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzctMS0xLTEtMTUwMDM0_5d1b556e-c563-40a9-9669-62116614bc7e">954.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="iefee9c5bf7054dd8a6c8c480eb44586b"><ix:continuation id="i56168af06c36433793f184d928aa1f7b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee Information</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjM_a8c9c997-9b76-4a49-acc0-142c65a70443">25.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjY_7dc9524f-b3aa-44f0-a039-103fe9992706">20.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjk_56fa2c13-d516-4713-a3e0-7902d39ca4d1">21.0</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. For leases with terms of 12 months or less, the related expense was immaterial for each of the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODE_51c1eb8b-88c8-422a-8d8e-a689d0f53ad1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases that were included within operating cash outflows</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItMS0xLTEtMTUwMDM0_aedfdce2-363e-40f1-a6ad-82e540ec415a">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItMy0xLTEtMTUwMDM0_eee7c97d-9401-4273-8fdb-319dd2246f15">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItNS0xLTEtMTUwMDM0_8ac4f730-12db-4ab3-8f18-ceefc225093b">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recognized related to new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtMS0xLTEtMTUwMDM0_efa3a6c1-9dce-417c-ad6c-4e453f2e028e">34.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtMy0xLTEtMTUwMDM0_0ce4f84b-6159-4117-9d4c-5f7f62b28cf2">30.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtNS0xLTEtMTUwMDM0_9bd773e2-45b0-4a4f-9049-dff32bcfed06">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzA_064090b2-3668-4f5e-8a85-4f474161786d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">Intangible and other assets, net (Right-of-use assets)</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMS0xLTEtMTUwMDM0_e860ac68-515f-413b-bde6-b870d3b24948">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMy0xLTEtMTUwMDM0_ddb76383-192c-4dd7-a023-8b7d7f4ac5fb">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">Other accrued liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMS0xLTEtMTUwMDM0_2d5ad1a1-d7fe-4c35-8313-dbd1140191e4">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMy0xLTEtMTUwMDM0_8d91d3af-9a75-4d0c-87ec-a58dbc82ce44">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMS0xLTEtMTUwMDM0_3d2a6b3f-dc4d-41f0-b359-4f8465a9974d">69.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMy0xLTEtMTUwMDM0_7b3bef69-5ccd-41a9-b87a-9747b9964663">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">Total lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMS0xLTEtMTUwMDM0_bffd96c6-3432-4d4f-a3ea-8a90ea4972b2">93.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMy0xLTEtMTUwMDM0_28395a5a-7535-4c74-a87f-ab4f356a5c00">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzgtMS0xLTEtMTUwMDM0_65b719ec-0d68-4afd-bee5-39bdf84a5af5">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzgtMy0xLTEtMTUwMDM0_1d877332-3c8d-4f7e-9e10-097560e3025b">4.9</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzktMS0xLTEtMTUwMDM0_881eab94-c70d-4d11-80fb-fe56793da4ea">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzktMy0xLTEtMTUwMDM0_942518bf-19a8-4026-8518-14621cdc06f0">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-indent:18pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzQ_a9103bf7-97f4-421e-aeb3-4633a82e552b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the future payments related to the Company&#8217;s operating lease liabilities are scheduled as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzEtMS0xLTEtMTUwMDM0_5b6cdea3-8258-4236-95e2-1f9c3ac5e691">26.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzItMS0xLTEtMTUwMDM0_f5f5afde-7038-4dbd-a242-ad3e5d325f53">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzMtMS0xLTEtMTUwMDM0_34802449-3a52-496a-8795-2d4ecc2b235a">19.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzQtMS0xLTEtMTUwMDM0_db8658b8-693f-465c-bbe7-59f741f73334">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzUtMS0xLTEtMTUwMDM0_81863d43-dae6-47ed-a40e-7be12880b88a">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzYtMS0xLTEtMTUwMDM0_21332c79-dacb-4f1c-b374-938958fe08df">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzctMS0xLTEtMTUwMDM0_23e5ecc2-7e09-4c1e-a2d6-70bdec83dad0">101.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzgtMS0xLTEtMTUwMDM0_5af04ff2-5d19-4206-bd8b-b6742debfc70">7.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzktMS0xLTEtMTUwMDM0_3af68577-4424-4c0e-b06a-21d77d560fe9">93.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_247"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU5MDU_3ba873bb-cc38-4ce6-ad35-f7e4887e0bcb" continuedAt="i2c9a89fad8514da386fccc224c77e239" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i2c9a89fad8514da386fccc224c77e239" continuedAt="idd06ad3b57e740f6b209776a1014682b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material acquisitions in 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company acquired Orpheus Medical Ltd. and its wholly owned subsidiaries (&#8220;Orpheus Medical&#8221;) to deepen and expand the Company&#8217;s integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical videos.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="idd06ad3b57e740f6b209776a1014682b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU5MDI_90e46f6f-2a04-4b4c-a063-b637f728757b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzEtMi0xLTEtMTUwMDM0_ab1b30da-3e04-425c-8a85-4f6f4c5980af">336.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzItMi0xLTEtMTUwMDM0_3520a4fc-04e1-4e2a-913a-e61d500ec6c8">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzMtMi0xLTEtMTUwMDM0_caa5ea9c-008c-454c-aa58-606e24059b58">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzQtMi0xLTEtMTUwMDM0_39ac3c16-3eaf-4ab4-a6f3-560c92afe123">343.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzUtMi0xLTEtMTUwMDM0_0bb5f347-4ce1-4158-b59e-f4f41d3e0ea7">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzYtMi0xLTEtMTUwMDM0_0a4e0ab8-74c4-4da7-a5df-ec826d2b85e4">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzctMi0xLTEtMTUwMDM0_f30ac57b-03c8-4581-ae8d-257e60ddc5e3">348.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its annual goodwill impairment test and determined that no impairment existed. As of December&#160;31, 2022, there has been no impairment of goodwill.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU4OTc_90e3acc2-319f-4a79-a469-4ca9834183e0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:34.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMi0xLTEtMTUwMDM0_2e064eb6-a274-46ca-b083-b68ec6cfc573">199.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItNC0xLTEtMTUwMDM0_2d5c06a4-9a74-4184-8206-f37a5a2dadbf">167.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItNi0xLTEtMTUwMDM0_b550ba97-ac30-4615-ad0b-d75a534bcac2">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItOC0xLTEtMTUwMDM0_33473b2a-c799-4d5d-ae83-6a0bf896748c">219.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMTAtMS0xLTE1MDAzNA_bf2a1eff-727a-44d7-a5b6-77100946c3d9">173.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMTItMS0xLTE1MDAzNA_b09ea1d3-ae4e-41a0-974c-40b837b1d667">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights and others</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMi0xLTEtMTUwMDM0_8a661b77-294d-4be0-85a5-19f1cc840abf">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtNC0xLTEtMTUwMDM0_1cb71db7-3a59-4bf5-8b5e-8a879fcbe0f0">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtNi0xLTEtMTUwMDM0_8ee901d9-b4cc-4178-b2f7-3f6d23179908">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtOC0xLTEtMTUwMDM0_1d59687e-122d-40a7-b1d7-a4d089d44e36">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMTAtMS0xLTE1MDAzNA_5a7a23c3-4dbf-47e6-b564-b7fc09d8bd7f">19.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMTItMS0xLTE1MDAzNA_e2e220bb-d93e-4d0d-9a1d-79ec7e412a1c">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMi0xLTEtMTUwMDM0_e1fd5e2b-60b5-4e5d-aa09-2d5847b74647">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtNC0xLTEtMTUwMDM0_dee7af3e-85f7-46a9-8779-d18f824ed9c1">18.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtNi0xLTEtMTUwMDM0_30f9a535-712c-477f-a0f8-bede1c61cc81">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtOC0xLTEtMTUwMDM0_99327ce4-d92a-4d98-9e87-81ab6fc896b2">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMTAtMS0xLTE1MDAzNA_ccafbc4e-8b98-413a-96e5-950297e04405">14.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMTItMS0xLTE1MDAzNA_d84546bf-ad87-439c-94d3-da1878daaac8">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMi0xLTEtMTUwMDM0_e8ae5895-858b-4c27-a4ca-e4b520875244">242.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtNC0xLTEtMTUwMDM0_0e113013-9d41-4087-8e90-94f5c8d9c026">192.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtNi0xLTEtMTUwMDM0_8dbc63d6-d20c-4108-812f-2169d26f11a8">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtOC0xLTEtMTUwMDM0_de900ab5-f17a-4a65-8998-dc9e1d30616e">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMTAtMS0xLTE1MDAzNA_4e54c1bf-a9c6-400b-90fb-6e7e9ebe8778">206.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMTItMS0xLTE1MDAzNA_e45f0e27-430b-4b6c-bce7-c32aac342e6c">70.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMTk_19331248-dd81-4380-9b62-0fbd115ec46b">27.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMjI_6a8756f2-ae66-442b-b7ca-cec8d1cab3cd">27.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMjU_a73ebff2-c4e2-4362-a6fa-8ebd97aaf852">49.8</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU4OTI_02099bd6-afe0-4628-92e2-63534e637396" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense related to intangible assets as of December&#160;31, 2022, is as follows (in&#160;millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzEtMS0xLTEtMTUwMDM0_5a0f2f89-d597-48dc-a526-68d94254f039">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzItMS0xLTEtMTUwMDM0_a9203f4b-e03d-459d-aed4-61f5c0347f9c">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzMtMS0xLTEtMTUwMDM0_f20593fa-2a30-424a-8961-f9cccabbbc5c">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzQtMS0xLTEtMTUwMDM0_90805827-3043-4229-a9d8-4a2b2de95327">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzUtMS0xLTEtMTUwMDM0_13eb7628-d2f7-4e97-b889-ce02ed67fcf6">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzYtMS0xLTEtMTUwMDM0_ea9937b1-c42b-497d-aef2-0a9f33292072">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzctMS0xLTEtMTUwMDM0_a6c34b89-1125-45e0-b9b1-c95c42f9080c">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, measurement period adjustments to intangible assets, changes in foreign currency exchange rates, impairment of intangible assets, accelerated amortization of intangible assets, and other events.</span></div></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_250"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzEzODA3_28466580-2030-488f-af0d-11ba11dd7ca0" continuedAt="i7923a55304ad4125b21dbbf0773c8660" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i7923a55304ad4125b21dbbf0773c8660" continuedAt="i704070ccb6e14e9f9eb9f819c896eab9"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s commitments include an estimated amount of approximately $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-6" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzYwNDczMTM5NjY1ODM_1228c7f6-0f0f-4737-a31b-6a6793356ad0">2.14</ix:nonFraction>&#160;billion relating to the Company&#8217;s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures and construction-related activities for which the Company has not received the services, and acquisition and licensing of intellectual property. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i704070ccb6e14e9f9eb9f819c896eab9" continuedAt="i75b26fb3b90b432ab3688d52f7ecbcce"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its business needs prior to the delivery of goods or performance of services. Additionally, the Company has committed to making certain future milestone payments to third parties as part of licensing, collaboration, and development arrangements. Payments under these arrangements generally become due and payable only upon the achievement of certain specified developmental, regulatory, and/or commercial milestones. For instances in which the achievement of these milestones is neither probable nor reasonably estimable, such contingencies are not included in the estimated amount.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, commercial, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be, and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liability and related charge to earnings are recorded in the Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company&#8217;s business, financial condition, or future results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzE2NDkyNjc0NjY2NjE_8eb3e7ca-05a4-4933-9d15-981d07852ae9">28.1</ix:nonFraction>&#160;million of pre-tax litigation charges in 2022. During the years ended 2021 and 2020, pre-tax litigation charges were insignificant.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts. The plaintiffs generally allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. Several of the filed cases have trial dates in the next 12 months.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cases raise a variety of allegations including, to varying degrees, that plaintiffs&#8217; injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company&#8217;s part to provide adequate training resources to the healthcare professionals who performed plaintiffs&#8217; surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including, for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. The Company disputes these allegations and is defending against these claims.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimate of the anticipated cost of resolving the pending cases is based on negotiations with attorneys for the claimants.&#160;The final outcome of the pending lawsuits and claims, and others that might arise, is dependent on many variables that are difficult to predict, and the ultimate cost associated with these product liability lawsuits and claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company&#8217;s business, financial condition, or future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, &#8220;Ethicon&#8221;) filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company&#8217;s EndoWrist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stapler instruments infringe several of Ethicon&#8217;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,585,658; 8,479,969; 9,113,874; 8,998,058; 8,991,677; 9,084,601; and 8,616,431. A claim construction hearing occurred on October 1, 2018, and the Court issued a scheduling order on December 28, 2018. On March 20, 2019, the Court granted the Company&#8217;s Motion to Stay pending an Inter Partes Review to be held at the Patent Trademark and Appeals Board to review patentability of six of the seven patents noted above and vacated the trial date. On August 1, 2019, the Court granted the parties&#8217; joint stipulation to modify the stay in light of Ethicon&#8217;s U.S. International Trade Commission (&#8220;USITC&#8221;) complaint against Intuitive involving U.S. Patent Nos. 8,479,969 and 9,113,874, discussed below. There is currently no trial date scheduled for this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2018, Ethicon filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that the Company&#8217;s SureForm 60 Staplers infringe five of Ethicon&#8217;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,884,369; 7,490,749; 8,602,288; 8,602,287; and 9,326,770. The Company filed an answer denying all claims. On March 19, 2019, Ethicon filed a Motion for Leave to File a First Amended </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i75b26fb3b90b432ab3688d52f7ecbcce" continuedAt="i752bbb9bd1754995b927a6250b132216"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complaint, removing allegations related to U.S. Patent No. 9,326,770 and adding allegations related to U.S. Patent Nos. 9,844,379 and 8,479,969. On July 17, 2019, the Court entered an order denying the amendment, without prejudice, and granting the parties&#8217; joint stipulation to stay the case in its entirety in light of the USITC investigation involving U.S. Patent Nos. 9,844,369 and 7,490,749, discussed below. There is currently no trial date scheduled for this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2019, Ethicon filed a complaint with the USITC, asserting infringement of U.S. Patent Nos. 9,884,369 (&#8220;&#8217;369&#8221;); 7,490,749 (&#8220;&#8217;749&#8221;); 9,844,379 (&#8220;&#8217;379&#8221;); 9,113,874 (&#8220;&#8217;874&#8221;); and 8,479,969 (&#8220;&#8217;969&#8221;). On June 28, 2019, the USITC voted to institute an investigation (No. 337-TA-1167) with respect to the claims in this complaint. The accused products include the Company&#8217;s EndoWrist 30, EndoWrist 45, SureForm 45, and SureForm 60 Staplers, as well as the stapler reload cartridges. In March 2020, Ethicon dismissed its claims concerning the &#8217;749 patent. The evidentiary hearing took place in February 2021. On March 26, 2021, the U.S. Patent Trial and Appeal Board (&#8220;PTAB&#8221;) issued a Final Written Decision in which it found the claims in the &#8217;379 patent asserted against the Company in this USITC proceeding to be invalid. On June 8, 2021, the Chief Administrative Law Judge issued an Initial Determination concluding that (1) the accused products do not infringe the asserted claims in the &#8217;874 or &#8217;969 patents; (2) the asserted claims in the &#8217;874 and &#8217;969 patents are invalid; (3) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#8217;369 patent; (4) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#8217;379 patent; and (5) the Company was estopped from contending that the asserted claims in the &#8217;379 patent are invalid. Ethicon has not challenged the Initial Determination with regard to the findings that absolve Intuitive of any liability regarding the accused EndoWrist staplers and associated reload cartridges. On October 14, 2021, the USITC issued its Opinion in which it made the following rulings: (1) the USITC absolved Intuitive from any liability regarding the &#8217;874, &#8217;969, and &#8217;369 patents; and (2) the USITC found that, while the SureForm staplers and their associated reload cartridges infringe the asserted claims in the &#8217;379 patent, it has suspended the imposition of any remedial order pending an opinion from the U.S. Court of Appeal for the Federal Circuit of whether the Patent and Trademark Office correctly found the asserted claims in this patent to be invalid. On May 23, 2022, the U.S. Court of Appeal for the Federal Circuit affirmed the earlier PTAB Final Written Decision invalidating the asserted claims in the &#8217;379 patent. A hearing before the U.S. Court of Appeal for the Federal Circuit has been scheduled for March 8, 2023, on Ethicon&#8217;s appeal of the USITC&#8217;s Opinion. An adverse ruling on Ethicon&#8217;s appeal of the USITC&#8217;s Opinion could result in a prohibition on importing the accused SureForm products into the U.S. or necessitating workarounds. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, a jury rendered a verdict against the Company awarding $<ix:nonFraction unitRef="usd" contextRef="i9e20be5b265d48b181f0ff33e8f0c656_D20221019-20221019" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzE2NDkyNjc0NjA4Mjg_d7090fcb-7a8e-4e21-b55a-f548ca21da0a">10</ix:nonFraction>&#160;million in damages to Rex Medical, L.P. in a patent infringement lawsuit. The Company intends to appeal the decision and vigorously defend its position. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2019, Restore Robotics LLC and Restore Repair LLC (&#8220;Restore&#8221;) filed a complaint in the Northern District of Florida alleging anti-trust claims against the Company. On May 13, 2019, Restore filed an amended complaint alleging anti-trust claims relating to the da Vinci Surgical System and EndoWrist service, maintenance, and repair processes. On September 16, 2019, the Court partially granted and partially denied the Company&#8217;s Motion to Dismiss the amended complaint.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, the Company filed an answer denying the anti-trust allegations and filed a counterclaim against Restore. The Company filed amended counterclaims after the Court partially granted and partially denied Restore&#8217;s Motion to Dismiss the counterclaim. The amended counterclaims allege that Restore violated the Federal Lanham Act, the Federal Computer Fraud and Abuse Act, and Florida&#8217;s Deceptive and Unfair Trade Practices Act and that Restore is also liable to the Company for Unfair Competition and Tortious Interference with Contract. On January 7, 2020, the Court denied Restore&#8217;s Motion to Dismiss the amended counterclaims.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, the Court granted in part and denied in part the parties&#8217; Motions for Summary Judgment. Shortly thereafter, Restore&#8217;s licensor, Rebotix Repair LLC (&#8220;Rebotix&#8221;) filed a notice in a separate legal action that it had received an email from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) confirming that &#8220;extending the number of uses and modifying [EndoWrist] instrument[s] with a new chip&#8221; constitutes &#8220;remanufacturing&#8221; and required 510(k) clearance, which neither Restore nor Rebotix has obtained. In light of this communication with the FDA, on April 13, 2022, the Company filed a Motion for Reconsideration to the Court&#8217;s Summary Judgment Order, which the Court denied on May 31, 2022. This case was scheduled for trial in February 2023. On January 23, 2023, the parties resolved all of their claims against each other and, on January 27, 2023, the case was dismissed with prejudice. The settlement had an immaterial impact on the Company&#8217;s Consolidated Financial Statements for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the claims asserted in the Restore case, on May 10, 2021, Surgical Instrument Service Company, Inc. (&#8220;SIS&#8221;) filed a complaint in the Northern District of California Court alleging anti-trust claims against the Company relating to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i752bbb9bd1754995b927a6250b132216"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoWrist service, maintenance, and repair processes. The Court granted in part and denied in part the Company&#8217;s Motion to Dismiss, and discovery has commenced. The Company filed an answer denying the anti-trust allegations and filed counterclaims against SIS. The counterclaims allege that SIS violated the Federal Lanham Act, California&#8217;s Unfair Competition Law, and California&#8217;s False Advertising Law and that SIS is also liable to the Company for Unfair Competition and Tortious Interference with Contract. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three class action complaints were filed against the Company in the Northern District of California Court alleging anti-trust allegations relating to the service and repair of certain instruments manufactured by the Company. A complaint by Larkin Community Hospital was filed on May 20, 2021, a complaint by Franciscan Alliance, Inc. and King County Public Hospital District No. 1 was filed on July 6, 2021, and a complaint by Kaleida Health was filed on July 8, 2021. The Court has consolidated the Franciscan Alliance, Inc. and King County Public Hospital District No. 1 and Kaleida Health cases with the Larkin Community Hospital case, which is now captioned on the Larkin docket as &#8220;In Re: da Vinci Surgical Robot Antitrust Litigation.&#8221; A Consolidated Amended Class Action Complaint has been filed on behalf of each plaintiff named in the earlier-filed cases. On January 14, 2022, Kaleida Health voluntarily dismissed itself as a party to this case. On January 18, 2022, the Company filed an answer against the plaintiffs in this matter, and discovery has commenced. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.</span></div></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_253"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMzU_7ab064d8-519f-4409-94f6-6b5a26cecd40" continuedAt="i5973fbc628b240e494ba413a549ba70d" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i5973fbc628b240e494ba413a549ba70d" continuedAt="i16bd1e5cb954466f87066ecbf702b3e5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has authorized an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMTY_5b349df9-ee41-4be9-8340-e390242214a3">10.0</ix:nonFraction>&#160;billion of funding for the Company&#8217;s common stock repurchase program (the &#8220;Repurchase Program&#8221;) since its establishment in March 2009. The most recent authorization occurred in July 2022 when the Board increased the authorized amount available under the Repurchase Program to $<ix:nonFraction unitRef="usd" contextRef="i454d4ac87d7a4c0cabb826bc3c10cbcd_I20220701" decimals="-8" name="isrg:StockRepurchaseProgramincreasedtoauthorizedamount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMjA_f7aa35f7-60c5-4a18-89bb-32aab05aa350">3.5</ix:nonFraction>&#160;billion, including amounts remaining under previous authorization. As of December&#160;31, 2022, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMzc_12fbb739-f5fc-4269-a4fa-f504189c0e0a">1.5</ix:nonFraction> billion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an accelerated share repurchase program (the &#8220;August ASR Program&#8221;) with Goldman, Sachs &amp; Co. (&#8220;Goldman&#8221;) to repurchase $<ix:nonFraction unitRef="usd" contextRef="i97d83242175d438fb29d5d804eea01f7_I20220831" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzU4OA_79b6653c-2a36-4a11-8727-73d9ef1a70bb">1.0</ix:nonFraction>&#160;billion of the Company&#8217;s common stock. The Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="i97d83242175d438fb29d5d804eea01f7_I20220831" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY0MA_79666088-ec6c-49d0-a661-5908d4da0507">1.0</ix:nonFraction>&#160;billion to Goldman and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="i839d2a9749664c4bab3d1bdaacba0520_D20220801-20220831" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzYxNA_8a7175a6-d522-435b-ae90-27960a24533d">3.5</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, which were subsequently retired. In September 2022, the August ASR Program was completed, and an additional <ix:nonFraction unitRef="shares" contextRef="ife86c560869f4c39bf37fbe4692b9019_D20220901-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY5MQ_3c3b0c0e-bb65-4e58-b0d6-a23b4abc61ec">1.1</ix:nonFraction>&#160;million shares of common stock were received and retired. In total, <ix:nonFraction unitRef="shares" contextRef="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY2Ng_69f39c50-0281-41d7-af64-a4ef50dfff8e">4.6</ix:nonFraction>&#160;million shares were repurchased at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzcxMg_a1baee87-dba0-4b76-a2b8-f11fe0a02049">217.52</ix:nonFraction>. The total cost of the August ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into an accelerated share repurchase program (the &#8220;October ASR Program&#8221;) with Citibank, N.A. (&#8220;Citibank&#8221;) to repurchase $<ix:nonFraction unitRef="usd" contextRef="id78018ef69be42c396e169846e05b20b_I20221031" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODI1NQ_32c4a19e-b3f4-4f0f-8229-cdecc9dc7c2a">1.0</ix:nonFraction>&#160;billion of the Company&#8217;s common stock. The Company made an initial payment of $<ix:nonFraction unitRef="usd" contextRef="id78018ef69be42c396e169846e05b20b_I20221031" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODMzMA_5cdf96c5-9cc2-472d-8f7c-9eba164ce594">1.0</ix:nonFraction>&#160;billion to Citibank and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="i5ea6d8fa775a4209b8ce714c8dc3009a_D20221001-20221031" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODM4MA_fa56a119-e57a-4d81-8b1f-7773677d7425">3.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, which were subsequently retired. In December 2022, the October ASR Program was completed, and an additional <ix:nonFraction unitRef="shares" contextRef="i6c368f15dd6943a5a4c230f46529d97e_D20221201-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODg4MQ_8baae79c-3bfa-4027-b2d8-a433e08bd589">0.3</ix:nonFraction>&#160;million shares of common stock were received and retired. In total, <ix:nonFraction unitRef="shares" contextRef="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODkwOQ_6c5c32dd-93fb-4bee-a93e-785c2d74d7e2">3.9</ix:nonFraction>&#160;million shares were repurchased at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODkzMg_c04e70e7-8188-4b59-b70c-6aa544f85b4e">254.48</ix:nonFraction>. The total cost of the October ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="isrg:ScheduleofCommonStockRepurchasedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMjI_d0ffde0b-8af3-4ace-afaf-673019c46011" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock repurchase activities (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItMS0xLTEtMTUwMDM0_05d2964d-5f9f-4988-91a3-a51bf838d7de">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItMy0xLTEtMTUwMDM0_f99ed2ea-42a2-4c8d-9ab8-5cbc62405571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItNS0xLTEtMTUwMDM0_61295feb-6458-43e4-8e50-86b339fb1b19">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtMS0xLTEtMTUwMDM0_9128ce74-488d-4c01-a8bb-ec7431d8e6d4">233.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtMy0xLTEtMTUwMDM0_2b563c8c-951b-4f51-a2b9-b9aa3947de55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtNS0xLTEtMTUwMDM0_a7ea38d2-eba6-4159-9700-e45ea0e1e03c">183.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of shares repurchased</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtMS0xLTEtMTUwMDM0_6b5479e6-5bfb-4300-a3eb-96d1574f589a">2,607.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtMy0xLTEtMTUwMDM0_755ce8ae-a6c3-4633-af04-b5ec4749760f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtNS0xLTEtMTUwMDM0_29f5220b-9a1c-4e2a-ba51-f15c9d7bafff">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the par value method of accounting for its stock repurchases. As a result of share repurchase activities during the years ended December&#160;31, 2022, 2021, and 2020, the Company reduced common stock and additional paid-in capital by an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-6" sign="-" name="isrg:AggregateReductionInCommonStockDuringStockRepurchases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjg5Mg_66736c4b-4b32-4ea4-b2c1-87373137a68e">211</ix:nonFraction> million, <ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-6" name="isrg:AggregateReductionInCommonStockDuringStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkwMA_b04764e4-d090-43e8-8d4c-30a477bfafb7">zero</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-6" sign="-" name="isrg:AggregateReductionInCommonStockDuringStockRepurchases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkwNw_8ae3f034-9f2a-4ddc-9146-e69638a32161">8</ix:nonFraction> million, respectively, and charged $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-6" sign="-" name="isrg:AmountChargedToRetainedEarningsDuringStockRepurchases" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkxNA_a8465360-540f-4d43-bdb5-de3787627e20">2.396</ix:nonFraction> billion, <ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-6" name="isrg:AmountChargedToRetainedEarningsDuringStockRepurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkyMQ_546460ce-da7e-465a-9c3a-a58c1c08e2c0">zero</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-6" sign="-" name="isrg:AmountChargedToRetainedEarningsDuringStockRepurchases" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkyOQ_8c59a29c-9010-41fc-87c4-943426d817a3">126</ix:nonFraction> million, respectively, to retained earnings.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i16bd1e5cb954466f87066ecbf702b3e5"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss), Net of Tax, Attributable to Intuitive Surgical, Inc.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMjQ_69e208a7-d0a2-4212-a283-49bd61c67c6a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized&#160;<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36cb3acbf52841e3bc3c63820c01fa42_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItMS0xLTEtMTUwMDM0_e06213a5-b18f-479b-90a7-1407a3e25bb9">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c13220ef9824187bfc2e616446c4a3c_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItMy0xLTEtMTUwMDM0_afc4e2cc-c0b0-4f28-b0c9-f5f18be7124c">16.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i181617f6fdb54de7954b15a38947b6bd_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItNS0xLTEtMTUwMDM0_7d006f06-651f-4722-9f5e-395d08bc432e">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i473c6bb0442144b58cb06ae162b7e6a4_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItNy0xLTEtMTUwMDM0_f5bfb8c9-9ed7-4a72-a820-01333ae10304">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItOS0xLTEtMTUwMDM0_9251b21d-2e23-45aa-aad3-e3799f68055b">24.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtMS0xLTEtMTUwMDM0_f7d0d707-dc1a-45b4-8bad-786f2bdb90eb">35.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtMy0xLTEtMTUwMDM0_6977ffed-1121-4ac2-9051-2860a1eb1c5f">138.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtNS0xLTEtMTUwMDM0_71c96262-1b5a-427a-a600-724e833db164">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtNy0xLTEtMTUwMDM0_ddfd6f9f-bcec-4b9e-9aac-c741a21c8f60">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtOS0xLTEtMTUwMDM0_0f2ede49-576c-4fdc-907b-0f58835df6dd">166.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtMS0xLTEtMTUwMDM0_d92ee3a0-6526-4b97-bf4a-fa2d22b8b657">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtMy0xLTEtMTUwMDM0_0ddec7ee-4c87-49fc-9836-813304367805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtNS0xLTEtMTUwMDM0_a0897811-e9f7-4529-bf1f-1178475e8479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtNy0xLTEtMTUwMDM0_186b15d9-9ec4-4de8-bad4-35973b80cb6d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtOS0xLTEtMTUwMDM0_9d0d1be3-11f0-4654-942d-5234968ac56d">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtMS0xLTEtMTUwMDM0_5f3316d3-071d-43af-b7af-9569ca4091d6">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtMy0xLTEtMTUwMDM0_6ef1aec9-7cdf-4f44-9c81-b6d4b359bf26">138.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtNS0xLTEtMTUwMDM0_20499aba-f121-4967-8b8b-ddcb17388f4d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtNy0xLTEtMTUwMDM0_1a7e4c5f-f762-478e-8f0f-25539cc3ace7">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtOS0xLTEtMTUwMDM0_8cffa60e-6afc-4308-a2e3-2f35e179a241">138.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32b37d08e5a44af0beaf8cc7bb58696d_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtMS0xLTEtMTUwMDM0_cc4dd2c2-e1b8-4b2b-8d6b-925eaa238ad3">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i006259a527c0455b9e5463d5168ec708_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtMy0xLTEtMTUwMDM0_0d7d30bf-aa2d-41b2-a697-0f221c1af7c1">154.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i999a1d9653924dbe965c17ddd3a03def_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtNS0xLTEtMTUwMDM0_9097d568-9a18-416b-b40b-75a8f9e55a59">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3150d3865845838cf5476e0ce21fc6_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtNy0xLTEtMTUwMDM0_bf7a961a-2109-4ad1-9e28-f10e422c512d">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff5abbcecdbf42949927127eac25660e_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtOS0xLTEtMTUwMDM0_3e109c8e-adf4-40af-87cf-a3af462983df">162.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0051b5c888cd406ea6c081c905d7c0bd_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTEtMS0xLTE1MDAzNA_504eafbd-7bf3-4b4e-9f51-f274e84e7375">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70dfa53208644c0c9c0a6ec85264d603_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTMtMS0xLTE1MDAzNA_f12b6ca2-866e-47aa-a6a7-9165629aeb24">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f1669e3b2446aca797556ff1d0ccd1_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTUtMS0xLTE1MDAzNA_600fa397-f73f-4b18-83dd-a57ec540bf5c">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94d140b2190d4fc9ae1e1dc1d5ddb6c1_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTctMS0xLTE1MDAzNA_3c3d914c-1c7c-4489-affd-cb19d8ce2e32">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTktMS0xLTE1MDAzNA_12ba2995-bce8-4a92-b3a7-3659ee630539">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTEtMS0xLTE1MDAzNA_542644f6-88c0-4940-825e-f1d1b1849627">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTMtMS0xLTE1MDAzNA_b24f6da7-5fb3-468b-95c2-0970758da3cb">45.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTUtMS0xLTE1MDAzNA_beeb8938-415f-4f42-914c-22c7c955cd27">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTctMS0xLTE1MDAzNA_027781e3-001a-4390-a542-93d4819b8e07">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTktMS0xLTE1MDAzNA_981e746f-8a9d-4478-9a36-c584783bda94">45.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTEtMS0xLTE1MDAzNA_fcf28a9e-2a86-4fda-a8b0-c3f2c332e712">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTMtMS0xLTE1MDAzNA_4ee1806a-84ca-48d3-8286-bab94e8aac94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTUtMS0xLTE1MDAzNA_fce704b0-52a7-40d1-bc4f-6bcb6a8db897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTctMS0xLTE1MDAzNA_c2a8f54d-d146-40e2-ba15-3778359c1fe1">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTktMS0xLTE1MDAzNA_d332db38-93e5-4f8d-8deb-2faaf2b02bbc">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTEtMS0xLTE1MDAzNA_ae172be8-5655-42ca-9162-30168a0d3c96">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTMtMS0xLTE1MDAzNA_6aad0182-b6e3-45d9-94b7-05ae8cfc85f5">45.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTUtMS0xLTE1MDAzNA_93438aed-b62e-4bb9-b9cf-90489358b975">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTctMS0xLTE1MDAzNA_4f56e9ad-8be7-40de-9832-a778d13fb160">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTktMS0xLTE1MDAzNA_ddaf3ab9-678a-4751-b51a-7f69798d90bc">49.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36cb3acbf52841e3bc3c63820c01fa42_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTEtMS0xLTE1MDAzNA_f060a254-d647-4f38-ac40-bc9db22d8b9d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c13220ef9824187bfc2e616446c4a3c_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTMtMS0xLTE1MDAzNA_c06c1ba2-d8bb-4c67-a488-8bf52855913f">16.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i181617f6fdb54de7954b15a38947b6bd_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTUtMS0xLTE1MDAzNA_58f424a7-69ef-407d-b525-955a7fd7656e">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i473c6bb0442144b58cb06ae162b7e6a4_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTctMS0xLTE1MDAzNA_e3dac752-2103-4cbf-9a06-0cbd7e9ed0e0">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTktMS0xLTE1MDAzNA_07013b22-562b-4eb5-90d0-eb4eb2052425">24.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzQ5NDc4MDIzMzM5Nzg_0addc9e8-7ace-4851-900d-dd6ddb0c9098" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit for net losses recorded in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTplZjc3MmU3ZGE2Mzk0OTQ1YmY2MDFlZWMzY2E4Yzc3ZC90YWJsZXJhbmdlOmVmNzcyZTdkYTYzOTQ5NDViZjYwMWVlYzNjYThjNzdkXzMtMS0xLTEtMTk2MTgz_833e3d9c-46cf-4f2d-900a-e5e38b56c0b4">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTplZjc3MmU3ZGE2Mzk0OTQ1YmY2MDFlZWMzY2E4Yzc3ZC90YWJsZXJhbmdlOmVmNzcyZTdkYTYzOTQ5NDViZjYwMWVlYzNjYThjNzdkXzMtMy0xLTEtMjAwNjA5_1f8d6395-09eb-47b8-a562-fb3fb8f6cb86">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications for hedge instruments, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#8217;s Consolidated Financial Statements. The tax impacts for amounts reclassified from accumulated other comprehensive loss relating to hedge instruments, available-for-sale securities, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#8217;s Consolidated Financial Statements.</span></div></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_256"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MzQ_e3014888-8b90-4227-a10a-942338a9555d" continuedAt="i543b2bca31204282892c67796664ef20" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i543b2bca31204282892c67796664ef20" continuedAt="i8c26f7ab82284ef9939e333494bfd52b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2010 Incentive Award Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2010, the Company&#8217;s stockholders approved the 2010 Incentive Award Plan (&#8220;2010 Plan&#8221;). Under this plan, the Company can issue RSUs, nonqualified stock options (&#8220;NSOs&#8221;), and PSUs to employees, non-employee directors, and consultants. Equity awards granted to employees and non-employee directors include a mix of RSUs, stock options, and, as applicable, PSUs. The 2010 Plan generally permits NSOs to be granted at no less than the fair market value of the common stock on the date of grant. Prior to 2022, NSOs were granted with terms of <ix:nonNumeric contextRef="ia17bfdaa573143ba98966885510cdde7_D20100401-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ2Ng_28a3c058-3a48-42c3-a592-b4f5794cf1cb">10</ix:nonNumeric> years from the date of the grant. Beginning in 2022, the Company changed the term of its new NSO grants to <ix:nonNumeric contextRef="ia59158a68bbb4286aa90fa8eb06c7834_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTkyMjg_ee11ad39-91df-430a-acee-6704715dfeb9">7</ix:nonNumeric> years from the date of the grant. The 2010 Plan expires in 2032. In April 2022, the Company&#8217;s shareholders approved an amended and restated 2010 Plan to provide for an increase in the number of shares of common stock reserved for issuance thereunder from&#160;<ix:nonFraction unitRef="shares" contextRef="i3b469324ce32446fb9def5b7b3c5cfbb_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzcyMA_03000bd8-d9a9-4a5c-b76d-f3f5dc020fd2">103,350,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction unitRef="shares" contextRef="i9145bce4606d4940ad42ef487d849840_I20190430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzcyNg_6bc01d0e-d1ab-4bfb-9531-6302ffcf24f0">110,350,000</ix:nonFraction>. As of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i8c26f7ab82284ef9939e333494bfd52b" continuedAt="i6684fadd83094a10b340e9280ba9a7b1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="i410198a3903441b68830e22a66897156_I20221231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzc1NA_83491837-d5ff-4b40-a76a-88674c8e9b3b">27.2</ix:nonFraction> million shares were reserved for future issuance under the 2010 Plan. A maximum of approximately <ix:nonFraction unitRef="shares" contextRef="ia179814817fd4ff9878baee2be535b17_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzgzMg_1e107ec9-e21b-4030-8392-52ca84aa3a7d">11.8</ix:nonFraction> million of these shares can be awarded as RSUs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2009 Employment Commencement Incentive Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2009, the Board adopted the 2009 Employment Commencement Incentive Plan (&#8220;New Hire Plan&#8221;). The New Hire Plan provides for the shares to be used exclusively for the grant of RSUs and NSOs to new employees (&#8220;New Hire Options&#8221;), who were not previously employees or non-employee directors of the Company. The Compensation Committee approves all equity awards under the New Hire Plan, which are granted to newly-hired employees once a month on the fifth business day of each month after their hire. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed <ix:nonNumeric contextRef="i89170b9133ed4804b600e82c78c15cd5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE1Njg_3dd8aa96-91a7-421d-b68d-c938f530199a">10</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2015, the Board of Directors amended and restated the New Hire Plan to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the New Hire Plan from <ix:nonFraction unitRef="shares" contextRef="i409a1f3ac0ee4fcd9e608f4ff5c23e1b_I20180331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE4MDI_35c56342-b4e8-43bb-99d6-b76f1c3bb967">10,395,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="idcfae84224074580bb7bb01e54a43b99_I20150430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE4MDg_e7994367-5b0e-461f-abe2-74c0deba0965">13,095,000</ix:nonFraction>. The New Hire Plan expired in October 2019 and, therefore, there are no shares reserved for future grants under the New Hire Plan. However, awards granted prior to the plan&#8217;s expiration continue to remain outstanding until their original expiration date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted to employees vest in one-fourth increments annually over a <ix:nonNumeric contextRef="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTM_30b7230f-6590-475d-943c-4478ae797bf2">four-year</ix:nonNumeric> period. The RSUs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated RSU grants that vest on the same term as the annual RSU grants. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are paid in cash to the appropriate taxing authorities on behalf of the Company&#8217;s employees.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonqualified Stock Options.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, annual NSO grants were made to employees on February&#160;15 (or the next business day if the date is not a business day) and on August&#160;15 (or the next business day if the date is not a business day). Beginning in 2020, the Company changed the timing of its annual equity award grants to the last trading day of February and on the same date in August or, if that date is not a trading day, the next trading day. The February NSO grants vest 1/8 upon completion of 6 months of service and 1/48&#160;per month thereafter. The August&#160;NSO grants vest 7/48 at the end of one month and 1/48&#160;per month thereafter through a <ix:nonNumeric contextRef="i3241e96d8cae42fd893bed581e6753b6_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzI3MjA_589a2c75-1f54-47ee-8b3e-f2096e8a987c">3.5</ix:nonNumeric>-year vesting period. NSOs granted to new hires generally vest 1/4 upon completion of one year of service and 1/48&#160;per month thereafter. NSOs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated NSO grants that vest on the same term as the annual NSO grants. Option vesting terms are determined by the Board and, in the future, may vary from past practices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company granted PSUs to officers and other key employees, which are designed to provide further incentives for the achievement of the Company&#8217;s long-term objectives. The PSUs are subject to three-year cliff vesting and pre-established, quantitative goals. Whether any PSUs vest, and the amount that does vest, is tied to completion of service over three years and the achievement of three equally-weighted, quantitative metrics that directly align with or help drive the Company&#8217;s strategy and long-term total shareholder return.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2000 Non-Employee Directors&#8217; Stock Option Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2000, the Board of Directors adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;Directors&#8217; Plan&#8221;). In October 2009, the automatic evergreen increase provisions were eliminated so that no further automatic increases would be made to the number of shares reserved for issuance under the Directors&#8217; Plan. In addition, the common stock authorized for issuance under the Directors&#8217; Plan was reduced to <ix:nonFraction unitRef="shares" contextRef="i13aa27cc6a90415195d355246bcee08b_I20091031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzM0MTk_a0ce42ff-6a86-4c6d-9ad0-bef79e882432">1,350,000</ix:nonFraction>. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed <ix:nonNumeric contextRef="ie8bc21a2592240cda306d477679d44f7_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc5MDA_9d441ef2-978c-44b7-acfa-0a98e43a8304">10</ix:nonNumeric> years. Prior to 2016, initial stock option grants to new non-employee directors vested over a <ix:nonNumeric contextRef="i65114e3030914e0a8cb520556e6fff7b_D20190101-20191231" name="isrg:StockOptionsGrantedInitialVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTU_d2871d26-c067-46e1-b718-a80d1ef03834">three-year</ix:nonNumeric> period with 1/3 of the shares vesting after one year from the date of grant and 1/36 of the shares vesting monthly thereafter. Annual stock option grants vested <ix:nonNumeric contextRef="id9334eee01684436a51c2d0f31644073_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzM4MzI_a9a3b1e4-0856-4d9a-9609-5969b8793a6a">one year</ix:nonNumeric> from the date of the grant. Since 2016, new non-employee directors received pro-rated stock option grants that vest on the same term as the annual stock option grants. The Directors&#8217; Plan was terminated in November 2020 and, therefore, there are no shares reserved for future grants under the Directors&#8217; Plan. However, options granted prior to the plan&#8217;s termination continue to remain outstanding until their original expiration date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2000 Employee Stock Purchase Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2000, the Board adopted the ESPP. Employees are generally eligible to participate in the ESPP if they are customarily employed by the Company for more than <ix:nonNumeric contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" name="isrg:MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" format="ixt-sec:durhour" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1MTM_95b74ad3-7d8f-40bb-8523-8c0ef788ba5a">20</ix:nonNumeric> hours per week and more than <ix:nonNumeric contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" name="isrg:MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1NDU_c908d568-aefe-4fc6-839f-277280363f5a">5</ix:nonNumeric> months in a calendar year and are not <ix:nonFraction unitRef="number" contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" decimals="INF" name="isrg:MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1ODY_892c017b-2deb-48df-a34c-141127ba6688">5</ix:nonFraction>% stockholders of the Company. Under the ESPP, eligible employees may select a rate of payroll deduction up to <ix:nonFraction unitRef="number" contextRef="i20fe342469174f21b1e6e465beeaa26e_I20221231" decimals="INF" name="isrg:MaximumPercentageOfPayrollDeductionUnderEspp" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ2OTg_40128523-47f2-4d1f-a0e2-e040d38f39b0">15</ix:nonFraction>% of their eligible compensation subject to certain maximum purchase limitations. The duration for each offering period is <ix:nonNumeric contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" name="isrg:OfferingPeriodEmployeeStockPurchasePlans" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4MjI_5b68a130-83b9-4ce9-987e-fa7dea1cf4c2">24</ix:nonNumeric> months and is divided into <ix:nonFraction unitRef="period" contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" decimals="INF" name="isrg:OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4NTI_ae9147de-6dc5-4715-a917-1451fd6a2c76">four</ix:nonFraction> purchase periods of approximately <ix:nonNumeric contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" name="isrg:OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4ODk_413c01fb-9d9d-4500-a0d6-e50412fa7bd0">six months</ix:nonNumeric> in length. Offerings are concurrent. The purchase price of the shares under the offering is the lesser of <ix:nonFraction unitRef="number" contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5OTg_80309d6c-a9ed-4bb1-a6f1-66689753820a">85</ix:nonFraction>% of the fair market value of the shares on the offering date or <ix:nonFraction unitRef="number" contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzUwNjQ_5ffc88c3-3287-47b6-a7aa-534355f4cae7">85</ix:nonFraction>% of the fair market value of the shares on the purchase date. A <ix:nonNumeric contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231" name="isrg:PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTQ_0233b01e-41d3-41a0-86ce-de1c9d6c20f2">two-year</ix:nonNumeric> look-back feature in the ESPP causes the offering period to reset if the fair value of the Company&#8217;s common stock on the first or last day of the purchase period is less than that on the original offering date. ESPP purchases by employees are settled with newly-issued common stock from the ESPP&#8217;s previously authorized and available pool of shares. In April&#160;2017, the Company&#8217;s stockholders approved an amended and restated ESPP to provide for an increase in the number of shares of common stock reserved for issuance </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i6684fadd83094a10b340e9280ba9a7b1" continuedAt="iac6af9ae4141437dba87c21908206113"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from&#160;<ix:nonFraction unitRef="shares" contextRef="if8fa15cbbe464ea8b44d4cc396aa1978_I20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzU2NjI_0dcd9310-8ffb-433e-a0d4-5e7300ef4b09">18,270,945</ix:nonFraction>&#160;to&#160;<ix:nonFraction unitRef="shares" contextRef="i5c51c4092a524901b1803e5ce38a9526_I20170430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzU2Njg_796c61fa-d4a9-4877-8eae-4c6947e277d7">22,770,945</ix:nonFraction>. As of December&#160;31, 2022, there were approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i727584465aae4a70bf59561fe029a223_I20221231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA2ODM_8f8c9404-f6d1-401f-ae34-e03761d0fdbc">2.4</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTY4MzQ_404bbd6a-5537-4a78-9a4a-a066677b9850" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December&#160;31, 2022, was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a94340d69fc401d83c0ba90f1f24db2_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzEtMS0xLTEtMTg4OTE1_3b8b39c6-e821-427c-b830-43ce969a657f">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a94340d69fc401d83c0ba90f1f24db2_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzEtMy0xLTEtMTg4OTE1_b1e6d855-2e78-426a-b02f-e1803730bc0c">207.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzItMS0xLTEtMTg4OTE1_32ddf5d2-5367-4e84-aed0-5b0722a0a3a6">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzItMy0xLTEtMTg4OTE1_5def3130-a471-4ecd-8c3a-a3994a57d462">272.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzMtMS0xLTEtMTg4OTE1_d453b132-7517-456c-a0f5-81c3d610f241">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzMtMy0xLTEtMTg4OTE1_2ead39e6-9ae2-4788-8434-2437b64361ab">191.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzQtMS0xLTEtMTg4OTE1_ecbcf094-0556-4d27-b041-78a10843a065">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzQtMy0xLTEtMTg4OTE1_9d04726a-e995-41c2-a7ba-506163539e13">235.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzUtMS0xLTEtMjAwNjU1_4127d7e3-d164-41a7-a574-baf07ea45bb4">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzUtMy0xLTEtMTg4OTE1_a94611a1-cc78-4ee9-a343-4711512ac9e3">241.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231" decimals="-5" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE3MjY_be34a7d9-a91d-43a2-b461-e1d9e5274108">4.2</ix:nonFraction> million shares of RSUs were expected to vest with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4MDQ_5afdf288-3985-4966-a891-cb41f0428429">1.12</ix:nonFraction> billion. The aggregate vesting date fair value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4NjY_afbdb5d7-9a2e-4e54-ad4b-b5927b52f48d">536</ix:nonFraction> million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i65cb93da736742b282702b76ba91dfee_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4NzE_2e08ee85-d757-4efe-bbb1-c87786b59cbf">578</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4ODA_3b7dea65-623e-4208-8222-c202dcdc6cb9">478</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1Mjg_510bbf69-c514-417d-a4bd-aa397a1ea926" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSO activity during 2022 under all of the stock plans was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise&#160;Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzItMS0xLTEtMTUwMDM0_db703442-34bb-43f5-a919-8deb1e65272c">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzItMy0xLTEtMTUwMDM0_c11ca4d7-f560-4d2d-82d8-7b9361db77da">125.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzMtMS0xLTEtMTUwMDM0_9f80395e-ca0a-4029-81ae-128f8c44b683">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzMtMy0xLTEtMTUwMDM0_1c7f09d0-e125-4201-a447-79fb6e3f2039">249.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzQtMS0xLTEtMTUwMDM0_8028f469-d333-4f73-b7ac-7e34b6e95124">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzQtMy0xLTEtMTUwMDM0_ec20ca55-17c4-45f8-b1ce-83f14862607f">77.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzUtMS0xLTEtMTUwMDM0_65704896-ad8c-4a82-9e63-46b95a683afc">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzUtMy0xLTEtMTUwMDM0_5e8abcb6-ef7d-4b15-81b4-b99154b89f07">240.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzYtMS0xLTEtMTUwMDM0_c8391a0b-d2b5-4748-ac4d-2565ce818126">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzYtMy0xLTEtMTUwMDM0_adcfd2f8-6020-4e17-a62f-5b07cdc24e1a">144.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised under the Company&#8217;s stock plans determined as of the date of option exercise was $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3Mjk_bd01c5da-9653-4e3f-8729-b9831654a514">315</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3MzM_48c7cf99-2b53-4af8-9578-bd788b0f8b08">613</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3MzY_3e6a5605-eb45-489d-bc5e-d524315868ae">598</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Cash received from option exercises and employee stock purchase plans for the years ended December&#160;31, 2022, 2021, and 2020, was $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTI_779766bb-af88-43a3-91e1-34ec9155daf3">234</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTU_45a8c540-1f5d-4d4c-b08d-47f452a24587">276</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTg_ebc3466d-95fc-4e94-90e0-1115a80fd55c">309</ix:nonFraction> million, respectively. The income tax benefit from stock options exercised was&#160;$<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3Nzg_c51d1e74-2ffd-407c-a6b3-b5339fd3cd3b">70</ix:nonFraction> million&#160;for the year ended&#160;December&#160;31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="iac6af9ae4141437dba87c21908206113" continuedAt="i801edde3d583439aba904c7d6dec90c0"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1Mzg_5ef90c72-e474-4d0d-bc6f-a3e35c3e1aa5" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes significant ranges of outstanding and exercisable options as of December&#160;31, 2022 (number of shares and aggregate intrinsic value in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMC0xLTEtMTUwMDM0L3RleHRyZWdpb246ZWJiOTNkMmYxYTk4NDBjNTllMTA2OGZjNmZjZTUyOGJfNDM5ODA0NjUxMTExMw_08a6d7e0-aeae-45da-8aac-a9c8d0b89de4">29.91</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMC0xLTEtMTUwMDM0L3RleHRyZWdpb246ZWJiOTNkMmYxYTk4NDBjNTllMTA2OGZjNmZjZTUyOGJfNDM5ODA0NjUxMTExOQ_3b401969-470f-4082-86bb-7deb73b55c61">49.34</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMi0xLTEtMTUwMDM0_5361ad04-1881-48bc-b4ee-0f5a705752ed">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItNC0xLTEtMTUwMDM0_636dad09-7239-4d34-bf62-5586de123d8f">0.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItNi0xLTEtMTUwMDM0_707784af-fa3e-4d0d-83de-d5551581d7d9">45.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMTAtMS0xLTE1MDAzNA_815a85c3-aa63-45fd-b3fb-c18262a3eec8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMTQtMS0xLTE1MDAzNA_f3fd005f-fc60-46ab-82d6-b42dbe232363">45.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NGNjZDgyMzBlMmIwNGQ3ZGEyZmEwOGVkZTY2Mzk5NjJfNDM5ODA0NjUxMTExMw_02c08c84-697c-41d9-80bc-98691020193c">51.02</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NGNjZDgyMzBlMmIwNGQ3ZGEyZmEwOGVkZTY2Mzk5NjJfNDM5ODA0NjUxMTExNw_6a156de6-2f00-4675-991c-7ac78c96480a">59.23</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMi0xLTEtMTUwMDM0_6938ff36-c6b7-4ce1-9c39-caf11bf22e5f">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtNC0xLTEtMTUwMDM0_7bfc7a2e-3e38-4af7-98b8-f46151a499e8">2.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtNi0xLTEtMTUwMDM0_f720454c-af8c-4b36-81b5-cdff9c46fd2b">55.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMTAtMS0xLTE1MDAzNA_daa77748-74ba-4014-8661-6eb56106d4f1">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMTQtMS0xLTE1MDAzNA_b830e7ed-fa0d-4395-85fd-b6a802907fad">55.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NmRiNDgzNjkzZGU0NDM4NTk1MDA5Yjk5MDgzOTRiMzBfNDM5ODA0NjUxMTExMw_f1d6fe9c-3c01-4625-b728-2c51e7c81f71">59.46</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NmRiNDgzNjkzZGU0NDM4NTk1MDA5Yjk5MDgzOTRiMzBfNDM5ODA0NjUxMTExNw_85e6a667-6ba4-4e59-b0b9-87ee7de8577c">77.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMi0xLTEtMTUwMDM0_20156992-4200-4836-ab29-c8a3ccb872a0">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtNC0xLTEtMTUwMDM0_db8e2a7b-67e6-40cd-982c-0ed8af0914f4">2.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtNi0xLTEtMTUwMDM0_a96d3062-e11b-47b7-bc0d-83784181b3db">67.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMTAtMS0xLTE1MDAzNA_d9b8c0d3-3d0e-42e4-a15f-2470d28fbf6a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMTQtMS0xLTE1MDAzNA_5b2b42f4-4641-4606-a5ba-8ed3c010eed1">67.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MGQ4Mjg0OGI1N2RmNDNmZDk5ZWM1N2ZhZGIwYjJlNGNfNDM5ODA0NjUxMTExMw_7c596a29-aee6-450c-9d8a-087a535c03a7">77.04</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MGQ4Mjg0OGI1N2RmNDNmZDk5ZWM1N2ZhZGIwYjJlNGNfNDM5ODA0NjUxMTExNw_2ba3c153-308e-4ac2-86de-2d4c1ccef88f">139.52</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMi0xLTEtMTUwMDM0_eb207e2a-6e89-4ce7-ab56-d4c1d1469110">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtNC0xLTEtMTUwMDM0_c7ea2174-4c35-4bff-88fe-d7b8f3414cf5">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtNi0xLTEtMTUwMDM0_bf43f0d4-ed47-4b89-8da6-bcac1b0ea3de">108.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMTAtMS0xLTE1MDAzNA_763715d0-384b-4370-a860-50956f4c2df7">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMTQtMS0xLTE1MDAzNA_2e5bff75-5ca7-4f55-a46e-e0066d8bdaa4">108.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NzZlOGE4YzdjODYwNGY3MDk2ZGUwYmNmOWFiMWFlZTFfNDM5ODA0NjUxMTExMw_1d4b2f21-4df5-4678-b272-c2cda0fc09dd">143.49</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NzZlOGE4YzdjODYwNGY3MDk2ZGUwYmNmOWFiMWFlZTFfNDM5ODA0NjUxMTExNw_6344051f-2f27-49c6-bde3-6a9b8fc72ceb">174.26</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMi0xLTEtMTUwMDM0_d8466897-34eb-48fb-a2e6-1cd063136e07">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtNC0xLTEtMTUwMDM0_fb92f01a-db39-4f40-8997-a47d93108554">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtNi0xLTEtMTUwMDM0_64ec62ed-90b9-4daf-831c-39d6219f5fff">168.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMTAtMS0xLTE1MDAzNA_971158f1-e7d7-4d03-bb72-a3104921c373">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMTQtMS0xLTE1MDAzNA_71ff49d3-019e-443a-8334-a4c5e82130b4">168.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzkxNDU3MmUxZmEyNGZlMmJjY2Q0ZmQ4NGUzYjZlOTFfNDM5ODA0NjUxMTExMw_dd31020a-2a56-4a27-8631-1d72839ead27">175.53</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzkxNDU3MmUxZmEyNGZlMmJjY2Q0ZmQ4NGUzYjZlOTFfNDM5ODA0NjUxMTExNw_efb5b20d-4be5-4643-817e-fa298f7fe752">182.83</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMi0xLTEtMTUwMDM0_1da4bc61-4600-4c57-8c4a-32fba0dd0612">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctNC0xLTEtMTUwMDM0_47da6d27-5e87-4ce1-839b-6fbb6e8dd6e3">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctNi0xLTEtMTUwMDM0_b33e2d98-6cac-46a3-93bd-cd09dec057fb">179.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMTAtMS0xLTE1MDAzNA_25c8d7d1-01ac-4025-87f9-32e97b809efd">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMTQtMS0xLTE1MDAzNA_40fd96dd-daa0-4338-8e41-185c05abd503">180.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YTc2MGYxNDk2NTUyNDVmNWExNjdkMmNmYzIwYjY2MWRfNDM5ODA0NjUxMTExMw_15645b2c-50fd-4640-a83d-d8af28197a19">182.90</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YTc2MGYxNDk2NTUyNDVmNWExNjdkMmNmYzIwYjY2MWRfNDM5ODA0NjUxMTExNw_94f1a643-7ce6-4182-a7f6-275ff31485d9">242.34</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMi0xLTEtMTUwMDM0_b8763fd7-8e17-47a3-a0de-08b1d7af1728">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtNC0xLTEtMTUwMDM0_1f3ef1f5-1586-4763-96f3-bff22429f6bd">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtNi0xLTEtMTUwMDM0_5ba72ed1-5ac5-46aa-bf72-a5f708248df2">219.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMTAtMS0xLTE1MDAzNA_1f190d74-9cca-4437-8ef3-e2479bc9f7a0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMTQtMS0xLTE1MDAzNA_08980b2e-b972-470d-8963-6c318907d82c">224.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YzFlY2Q2YzRiMjcxNDNmZTlmZWI1YjY5Zjg5Nzk2MTdfNDM5ODA0NjUxMTExMw_f2aaa464-7b9a-487c-93ec-05948dff71ea">243.26</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YzFlY2Q2YzRiMjcxNDNmZTlmZWI1YjY5Zjg5Nzk2MTdfNDM5ODA0NjUxMTExNw_8fb10c7e-f11f-4e3e-9434-7abfeaadced4">290.33</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMi0xLTEtMTUwMDM0_147586a4-8a44-4289-9a70-1bb1ba81c7c8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktNC0xLTEtMTUwMDM0_d29534ed-15d0-4a07-a6a8-93a7aaf88249">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktNi0xLTEtMTUwMDM0_c8d6ebba-cd38-46a2-9c47-6ee559b19300">268.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMTAtMS0xLTE1MDAzNA_4ba19a2d-b7da-4dd9-8464-7765dc4ccc28">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMTQtMS0xLTE1MDAzNA_8994f023-9607-469f-ae04-d72fdbab823e">261.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmZkMmI2MGY4OGMzNTQzMzU4Y2Q3MjZlNWRjOWQzOGUzXzQzOTgwNDY1MTExMTM_82d4dc5d-1a3e-4aac-b500-f1c3f069ce52">292.49</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmZkMmI2MGY4OGMzNTQzMzU4Y2Q3MjZlNWRjOWQzOGUzXzQzOTgwNDY1MTExMTc_a9df7283-3374-48c2-8aaf-9f9294e70630">341.16</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTItMS0xLTE1MDAzNA_a14e8972-002f-4ba2-bedd-f65288000347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTQtMS0xLTE1MDAzNA_3310c8de-7d15-4066-af95-b627ae91fbd2">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTYtMS0xLTE1MDAzNA_051feae8-5225-4c97-9755-9c410672fe59">311.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTEwLTEtMS0xNTAwMzQ_9e8c965a-9276-4450-869c-f700c9f2451c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTE0LTEtMS0xNTAwMzQ_91c6724a-01ba-42a7-88d1-5656f447521f">330.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjc1Yjk4M2EyYTBjOTQ3MzhiNDVhZGYxMjQwN2YwMGRjXzQzOTgwNDY1MTExMTM_367a2701-6447-4c2f-a2b5-8119034458b7">347.42</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjc1Yjk4M2EyYTBjOTQ3MzhiNDVhZGYxMjQwN2YwMGRjXzQzOTgwNDY1MTExMTc_0b722dc3-db66-409a-9a6e-803efc858a83">347.42</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTItMS0xLTE1MDAzNA_c0451e79-d656-4f3c-bbac-d1eee619c51c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTQtMS0xLTE1MDAzNA_b31795e1-9f6d-4029-a26a-2c82dfa428a2">8.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTYtMS0xLTE1MDAzNA_21c1d23d-818e-45b4-b616-3c9a9a2423a4">347.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTEwLTEtMS0xNTAwMzQ_e293f77e-fb77-4136-bab6-f02f3fb8b3f8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTE0LTEtMS0xNTAwMzQ_2e9a1f9b-d91a-4031-8b22-8e906133bd8e">347.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTItMS0xLTE1MDAzNA_9437593d-0585-4768-9712-bc7678b9652c">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTQtMS0xLTE1MDAzNA_180c8ba4-110f-4c2a-9d30-772e3fa193d8">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTYtMS0xLTE1MDAzNA_cd3f6e05-6650-47e8-9024-ca786030399e">144.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTgtMS0xLTE1MDAzNA_b0a3d9d0-452d-4335-82dd-3e0d505d3389">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTEwLTEtMS0xNTAwMzQ_956a0feb-c948-422b-9e4a-9ccc1d69b66d">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTEyLTEtMS0xNTAwMzQ_6b365d5c-7016-4f7f-bf31-68cbf44bd249">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTE0LTEtMS0xNTAwMzQ_9045919e-a1f2-4f78-ac54-51b03716cbc5">121.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTE2LTEtMS0xNTAwMzQ_18e03467-5a17-4f00-9666-60ee6d39144a">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#8217;s closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3ODY_41a05be9-d7ef-484c-9b1d-d4355907e347">265.35</ix:nonFraction> as of December&#160;31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MDU_9c9f1654-22d7-488c-b9a6-cfab9b71dae0">10.6</ix:nonFraction> million shares of stock options vested and expected to vest had a weighted-average remaining contractual life of <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MDg_a8bc0fda-5142-4f4f-8cdb-ad801b0273d8">4.7</ix:nonNumeric> years, an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MTE_4ceb76ac-7450-4ee7-a787-3bcacd392f92">1.35</ix:nonFraction> billion, and a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MTQ_7d79a3b2-46af-4ab1-ba29-362adee04b8c">143.06</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 PSU grant metrics are focused on relative total shareholder return (&#8220;TSR&#8221;), year-over-year da Vinci procedure growth for 2023, and two-year compound annual da Vinci procedure growth for 2024. TSR is considered a market condition, and the expense is determined at the grant date. The two procedure growth goals are considered performance conditions, and the expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the two performance conditions. The number of shares earned at the end of the three-year period will vary, based on actual performance, from 0% to 125% of the target number of PSUs granted. PSUs are subject to forfeiture if employment terminates prior to the vesting date. PSUs are not considered issued or outstanding shares of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value for each component of the PSUs individually. The fair value for the component with the TSR metric was determined using Monte Carlo simulation. The fair value per share for the components with the procedure growth metrics is equal to the closing stock price on the grant date.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTY4MzU_115847d5-d836-4cc7-b8e9-b982a392105d" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU activity during 2022 was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib59e1332f83f433bafce8ca9eb07b593_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzEtMS0xLTEtMjAwNjc0_d707414a-020c-4a79-b434-f11a7c64d3ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib59e1332f83f433bafce8ca9eb07b593_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzEtMy0xLTEtMjAwNjc0_8a2880e5-c98a-476a-b09a-e0f1bb736050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="-5" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzItMS0xLTEtMjAwNjU4_8249ef7c-3147-417e-9b98-bfa89f2d545a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzItMy0xLTEtMTk0NjQz_08a05a53-9883-4c5a-8a35-7958789a823f">299.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzMtMS0xLTEtMjAwNjc0_30263517-a8b9-48a0-a4fd-e7f5e4549050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzMtMy0xLTEtMjAwNjc0_fb5c90f3-ec84-435b-9c37-0951a8f7f5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="-5" name="isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzQtMS0xLTEtMjAwNjc0_bc1ea200-31b1-41f5-b62d-6fee4c877d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="2" name="isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzQtMy0xLTEtMjAwNjc0_7b78ae42-d6f7-4398-9d69-4b2ac989c3d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzUtMS0xLTEtMjAwNjc0_425f3ca0-b5f6-4643-968d-1b6f90ea475c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzUtMy0xLTEtMjAwNjc0_287b84d5-77e0-4de5-97b9-629f8db20a05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="-5" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzYtMS0xLTEtMjAwNjc0_5c8e1e6e-4b81-490f-ada5-383f7fd164ee">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzYtMy0xLTEtMjAwNjc0_6e571f6c-ff3b-4977-9b29-bc3f14a2cced">299.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="-5" name="isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyODg3Njc_38e6af60-c677-484b-ac3a-167722cbe712">0.1</ix:nonFraction>&#160;million shares of PSUs were expected to vest with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyODg3NTk_188b8b65-b690-4669-b28a-2a74b5523968">18</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i801edde3d583439aba904c7d6dec90c0"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, employees purchased approximately <ix:nonFraction unitRef="shares" contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MTA_51c108bc-b61b-4904-b181-39910f2b3a2e">0.4</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MTU_79421da5-b730-4447-88a5-980070375422">0.5</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MjQ_ee706baa-3096-4e7d-8af7-1a676784c9cf">0.5</ix:nonFraction> million shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pproximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5Nzg_6eec5012-deb1-4ec9-b788-c65bff7d0618">87.9</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5ODM_0dbad8e9-4a14-4281-92b8-098e68635b5d">75.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5OTI_da7c6401-ea02-417e-b17d-6311a59de2dc">71.2</ix:nonFraction> million in employee contributions for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MzE_abb33784-8882-421d-8d28-65ec55f0247f" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;product</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f463df323b94b2ca79195cb77ae86c6_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItMS0xLTEtMTUwMDM0_b0a9ff90-4f73-4d04-914d-64507966d2f9">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32dfb6574f44df8ff7344da9391dc0_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItMy0xLTEtMTUwMDM0_eb7a1c71-e4cb-485c-8b8b-4b300d1745dd">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee7d626dd6442c084221823215a5e3d_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItNS0xLTEtMTUwMDM0_1584d1bb-33d7-4e1a-8e2b-2445fd27d322">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2ead6914ce4c29ad6ab0ea4e54ec31_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtMS0xLTEtMTUwMDM0_57897346-d0a6-42d5-9b8c-3d184e5fa3e2">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d9f668182e4bce91778830a95c13c2_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtMy0xLTEtMTUwMDM0_26fb3c1f-9de4-4b2b-a0d2-1fe5ef95d744">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5570cfc269954912b1db7819ee5a7b87_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtNS0xLTEtMTUwMDM0_05c0c696-5ce9-42e7-ba1b-4a297130500e">24.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1765d5cde54c3a8c9535c06750c11d_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtMS0xLTEtMTUwMDM0_6f6864f9-6eb1-4a16-ac56-0dea6ea576c2">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fed7f0046594d5e9b7d0285eebe8dbd_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtMy0xLTEtMTUwMDM0_63426451-d774-4b35-9ee7-f827c8148990">91.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa21ecf135f4e53ae80c53876c575de_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtNS0xLTEtMTUwMDM0_b32c36cd-dd3e-4d90-87ab-93d8bdb9909d">82.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8730f5559847e5a2a128e0dc663cac_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtMS0xLTEtMTUwMDM0_84acc132-b6ec-463b-8e79-09ff0a2e75a8">261.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703c917c11ba41f5bc3d9e8c4fa82c6e_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtMy0xLTEtMTUwMDM0_4ba616cf-1409-4c0f-83b0-b1785faa376b">231.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd22f87fb8ad43d2af45c67cf1ea9e08_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtNS0xLTEtMTUwMDM0_bd4bc45d-99d9-4506-92c1-f00ad89015a6">202.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31db10c6d6c45489ada87073252b5c5_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtMS0xLTEtMTUwMDM0_6d91e827-642d-4244-a3b4-4e1da9d6ace4">164.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e05145f69544e49958c2c699ac2e14a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtMy0xLTEtMTUwMDM0_20c205c7-4b7b-42d1-b490-c2098e338c37">134.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c76b4eb5b2d43bdbd83af671ec30557_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtNS0xLTEtMTUwMDM0_791dc971-d078-4e7c-a28e-db9c071a3d93">113.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctMS0xLTEtMTUwMDM0_ec69d94b-9aa6-4472-948e-23d748ac2cc6">516.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctMy0xLTEtMTUwMDM0_9a4ecb84-d912-4d7f-8de8-9b3e2df6d9c2">456.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctNS0xLTEtMTUwMDM0_6fe90eee-d968-42b8-b37b-266a48b3e02c">398.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtMS0xLTEtMTUwMDM0_a064ef68-914d-46e0-b9e0-0e83c2224df5">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtMy0xLTEtMTUwMDM0_5073d03a-3c73-4a20-9a35-267c83b4539f">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtNS0xLTEtMTUwMDM0_61a168cc-ae04-4b77-8dc2-9183922c8d1e">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense after income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktMS0xLTEtMTUwMDM0_c35edcb4-6c5c-4309-aeda-d47effc3716a">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktMy0xLTEtMTUwMDM0_a8a001e6-a51b-418d-b8c5-07a2d5ff9fad">363.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktNS0xLTEtMTUwMDM0_6d17f5aa-7bd9-402f-a68e-79af54b662a4">317.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans and rights to acquire stock granted under the ESPP. <ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MTk_41ab0611-25a3-4852-b6eb-f872f351530c" continuedAt="i0467a15de6aa4ed99abf54f1370d775e" escape="true">The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted-average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December&#160;31, 2022, 2021, and 2020, were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="i0467a15de6aa4ed99abf54f1370d775e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMS0xLTEtMTkyMjM4_d8444615-e8c4-4b1b-8858-9783f7946c38">272.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i65cb93da736742b282702b76ba91dfee_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMy0xLTEtMTkyMjM4_d2ae5399-1345-475c-a23a-b284d07d2451">256.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtNS0xLTEtMTkyMjM4_53551a18-9364-4045-8204-553842034213">181.89</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK OPTIONS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItMS0xLTEtMTUwMDM0_99614939-b62f-4d42-9e0d-1ac4dec540e3">2.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItMy0xLTEtMTUwMDM0_0cb52698-5d18-4582-8676-acea5776379a">0.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItNS0xLTEtMTUwMDM0_276839cc-ccd6-4bf0-8b48-6d91d1bb3828">0.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMS0xLTEtMTUwMDM0_b0de6eab-d322-40cd-b8bb-794748cbf169">3.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMy0xLTEtMTUwMDM0_7f29bc9b-9ece-4c99-9422-72df9453a8f6">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtNS0xLTEtMTUwMDM0_1b7c666f-51f9-412a-a85a-17ad91183401">4.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtMS0xLTEtMTUwMDM0_ea0402ee-4e34-4f69-bb84-62cb26e54bf4">38</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtMy0xLTEtMTUwMDM0_a1c4090f-ccf6-472c-a7d6-42d78a1e9eb0">32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtNS0xLTEtMTUwMDM0_a4359e54-9aac-4ed7-bae0-20b62d504140">32</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtMS0xLTEtMTUwMDM0_8f668f6c-92bc-4e90-b038-efb9fb322231">73.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtMy0xLTEtMTUwMDM0_d33be621-9d6e-45f0-a36c-6b8fe4de4cdf">78.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtNS0xLTEtMTUwMDM0_54178ea7-89fe-4746-a1e2-1ad0e9bb2122">54.34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTEtMS0xLTE5MjI0OA_7f4066a5-6963-44e9-bc90-112ea7516f67">299.32</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i483a5421245644e8b7c29c4dd81da287_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTMtMS0xLTIwMDY4Mw_4210d565-f411-4d48-967a-072304e6cbbe">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie37f0a23420d421f959a8c22e7707a05_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTUtMS0xLTIwMDY4Mw_f021f00d-9016-4d1c-b45a-923d0b6fac19">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctMS0xLTEtMTUwMDM0_4984b390-28f0-46d4-8473-56410c07eb72">2.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctMy0xLTEtMTUwMDM0_be016512-76c0-461e-ab6f-7110f0e02535">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctNS0xLTEtMTUwMDM0_857b7530-e995-42de-aace-48131bbb627b">0.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtMS0xLTEtMTUwMDM0_953b52a2-2b91-47b7-a46a-717cfdfe751e">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtMy0xLTEtMTUwMDM0_843a47b9-5e40-47d3-9963-451df84d43f7">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtNS0xLTEtMTUwMDM0_bfd60ec3-28c2-4dd4-88ec-e0cb0b60e96b">1.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktMS0xLTEtMTUwMDM0_12c3083a-b7b3-4d0a-801f-8aea4210a4c8">39</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktMy0xLTEtMTUwMDM0_cf8d309c-a978-498d-be89-465d04e92f98">29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktNS0xLTEtMTUwMDM0_9caf335d-81c7-43f1-a4ef-be8c6c9e3045">30</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTEtMS0xLTE1MDAzNA_405480ee-75e7-4b40-a6f8-ebc4bb1ff428">80.61</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTMtMS0xLTE1MDAzNA_a1fff7dd-2a08-4212-941c-a4708812b889">89.98</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTUtMS0xLTE1MDAzNA_a835587e-885d-459c-8c77-4c1f31c9c7e7">57.29</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As share-based compensation expense recognized in the Consolidated Statements of Income during the years ended December&#160;31, 2022, 2021, and 2020, is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MTg_fb261116-b580-42f7-bf3f-916d5fbda18b">700</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3634dbe2d578411bbbc75e8831903c17_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxNDU_91438b2c-76ef-4b53-8341-cee1c02c98c7">121</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxMDY_1da1268c-0ffe-4a8e-a327-ca21c4e4479a">15</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i727584465aae4a70bf59561fe029a223_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MjE_2c29357a-123a-4251-88b4-1b07a9a5e417">65</ix:nonFraction> million of total unrecognized compensation expense related to unvested restricted stock units, unvested stock options, unvested performance stock units, and rights granted to acquire common stock under the ESPP, respectively. The unrecognized compensation expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NjA5NjU_afc87fc2-44f1-4507-b6e7-92b2466d20ec">2.3</ix:nonNumeric> years for unvested restricted stock units, <ix:nonNumeric contextRef="ib4cf962b95e84dc7891ff65923990d77_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MDU_91c310de-ced5-4000-b1be-defa1c865039">2.4</ix:nonNumeric> years for unvested stock options, <ix:nonNumeric contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxNTM_b99e481e-dded-445a-9ff8-0430d8e991ba">2.2</ix:nonNumeric> years for unvested performance stock units, and <ix:nonNumeric contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5Mjc_6b42614a-8a28-4e97-8d0e-4acf060b272d">1.5</ix:nonNumeric> years for rights granted to acquire common stock under the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzQ_e3ecaeba-2de7-4e15-8588-a07fda890cb4" continuedAt="i94dc07dccb7b4eceab38432dcd450e51" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i94dc07dccb7b4eceab38432dcd450e51" continuedAt="i59ce3b112ded4a16a92029b4b79fdb83"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1Njg_bee3fe9e-ebd2-4c54-9818-cfcd147b4554" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItMS0xLTEtMTUwMDM0_1b68f68b-7fa5-46ff-8c42-6c8c60dd6915">956.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItMy0xLTEtMTUwMDM0_0c935ea0-a4fe-4b7d-8802-546d4065cdec">1,298.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItNS0xLTEtMTUwMDM0_824a6ce0-3ea7-49c9-96e8-88a55a173a8c">926.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtMS0xLTEtMTUwMDM0_b170dd2c-63f3-4ffa-ab36-d51b24e31b4c">650.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtMy0xLTEtMTUwMDM0_077e30ae-9517-4e4d-842d-51f4294dc697">591.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtNS0xLTEtMTUwMDM0_bbef1469-75e0-407b-8934-7bec4ae3c9ed">280.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtMS0xLTEtMTUwMDM0_04486abb-9de6-4388-ba17-a6e1348ba12b">1,606.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtMy0xLTEtMTUwMDM0_f07fc8a3-b06d-43ca-9b16-ee31a5336a1b">1,890.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtNS0xLTEtMTUwMDM0_fbecd462-17d5-40ce-8140-19994f1485ab">1,207.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzY_53ab56f3-3c3e-4702-b24a-98d861fd9288" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtMS0xLTEtMTUwMDM0_d974997a-bb80-4d9d-acf9-bb007142da2a">350.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtMy0xLTEtMTUwMDM0_598a3130-1d1b-4240-9ab6-d9678935818f">158.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtNS0xLTEtMTUwMDM0_de3d19ac-f6be-4e5d-82ee-b10c27add452">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtMS0xLTEtMTUwMDM0_202fb54b-30c2-45ce-b9d1-d21dcdfb0be9">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtMy0xLTEtMTUwMDM0_a5bdee64-eb2f-4bcf-a3e2-4d66fa7f6f52">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtNS0xLTEtMTUwMDM0_741dcfa9-6e1f-4066-8314-9a421d65cd7f">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtMS0xLTEtMTUwMDM0_fc03542e-241a-4e93-8935-bf9b2405ab5b">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtMy0xLTEtMTUwMDM0_f3fb40a8-2fc8-4f2c-abb2-20f8e2a6f478">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtNS0xLTEtMTUwMDM0_a8ae5ccc-02c3-483a-93e5-5977ce714bfd">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtMS0xLTEtMTUwMDM0_1f175032-c114-46c8-9a1e-738d83e5fe4a">447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtMy0xLTEtMTUwMDM0_ae5fce93-90ff-4fa9-908e-bcfca073a8b3">226.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtNS0xLTEtMTUwMDM0_0f30833b-17e1-4712-95bd-3f8fc21c2c9d">82.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtMS0xLTEtMTUwMDM0_37c4d01f-cbdd-4af8-9d46-5b026b2b81bb">188.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtMy0xLTEtMTUwMDM0_04065928-8997-4f89-9873-f00109cfe204">21.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtNS0xLTEtMTUwMDM0_ee851f0a-32e1-4ded-8013-eda6c8b78770">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktMS0xLTEtMTUwMDM0_6de0288a-8bc7-471e-841f-019cffbb7c13">16.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktMy0xLTEtMTUwMDM0_495323f4-e31b-486b-866a-ecf9565300fb">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktNS0xLTEtMTUwMDM0_9f47aa15-56fa-43e3-9c4e-45276eba9a37">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTEtMS0xLTE1MDAzNA_6bff05c5-6638-4e9f-ade8-db30356c2072">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTMtMS0xLTE1MDAzNA_a4d56ce3-084c-40a6-80c5-c47134d42cae">43.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTUtMS0xLTE1MDAzNA_6167fc7c-2690-4aa3-8a7d-64eabe89cb63">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTEtMS0xLTE1MDAzNA_4be2284d-b936-4259-b9d9-06eda9186dd3">185.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTMtMS0xLTE1MDAzNA_f160a3c2-f8dc-4810-87f4-ee9694d1dc2e">64.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTUtMS0xLTE1MDAzNA_517c597e-4ed3-4d39-8b2a-20913bf46aef">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTEtMS0xLTE1MDAzNA_1b69a2dc-42e4-437f-b4a3-edc38e42379c">262.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTMtMS0xLTE1MDAzNA_68a5b860-c401-4541-999e-012aeaaf6f86">162.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTUtMS0xLTE1MDAzNA_893c299d-647b-4879-bbe8-bc11f02241a9">140.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the year ended December&#160;31, 2022, reflected the impact of a change in U.S. tax law effective January 1, 2022, which requires the capitalization and amortization of research and development expenditures incurred after December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was enacted in the United States. The IRA introduces a 15% alternative minimum tax based on the financial statement income of certain large corporations, effective for tax years beginning after December 31, 2022. The IRA also includes a 1% excise tax on the net fair market value of stock repurchases made after December 31, 2022. The Company considered the applicable tax law changes, and there is no impact to the Company&#8217;s tax provision for the twelve months ended December&#160;31, 2022. The Company will continue to evaluate the impact of these tax law changes on future periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2021 income tax expense included a one-time benefit of $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM4NDgyOTA3MDYyMjI_040c89e2-dcc7-4e28-9274-69862f168f38">66.4</ix:nonFraction>&#160;million from re-measurement of its Swiss deferred tax assets resulting from the extension of the economic useful life of certain intangible assets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i59ce3b112ded4a16a92029b4b79fdb83" continuedAt="i34097fac625c43099d9384a5ddbe7f81"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1OTU_cca47592-a68a-423b-89a3-dff2b28b6506" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December&#160;31, 2022, 2021, and 2020, as a result of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItMS0xLTEtMTUwMDM0_6a5c3a2e-b492-4493-9e98-afc68fb8b125">337.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItMy0xLTEtMTUwMDM0_0aace0c6-15b0-482e-9932-ea81a4fbcc29">397.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItNS0xLTEtMTUwMDM0_1d597fcc-bfdf-4c4a-ace7-8eff251af7b0">253.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in tax resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtMS0xLTEtMTUwMDM0_36e5c1e1-846b-4bef-a94c-91ea513b32f0">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtMy0xLTEtMTUwMDM0_f42c7f0c-1c0a-41a3-9fc2-18a4c9d5bd7d">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtNS0xLTEtMTUwMDM0_d457428c-2190-48c9-a048-75632ab39556">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtMS0xLTEtMTUwMDM0_8b5158f6-982d-4f1c-84b4-6b957c7e0b37">64.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtMy0xLTEtMTUwMDM0_f7689700-aee3-4eee-8771-1c4e6dd7fddf">54.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtNS0xLTEtMTUwMDM0_62619dac-44c0-482e-8140-341c156cd2b6">19.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtMS0xLTEtMTUwMDM0_43b6e20f-015b-4bd5-a203-679080fbe265">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtMy0xLTEtMTUwMDM0_df979993-77ca-47c1-b6ea-1fe86d18f26b">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtNS0xLTEtMTUwMDM0_53932dd4-d817-4967-9fab-7da8b5b48a6b">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctMS0xLTEtMTUwMDM0_2f6d2af6-edfe-42c0-b90c-e97bc0f65189">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctMy0xLTEtMTUwMDM0_2a51c82f-1118-43b5-a5bc-0145afd9c5b9">30.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctNS0xLTEtMTUwMDM0_00142887-cc3b-4507-a0bb-c669c6d17d11">37.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation not benefited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtMS0xLTEtMTUwMDM0_327db923-7162-4fa8-a32f-4d1a8db71f5c">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtMy0xLTEtMTUwMDM0_d2e4a92d-2027-4ec4-9201-7ea6c6956031">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtNS0xLTEtMTUwMDM0_d9e6d350-58e3-40e1-ab64-e1fdef2ea7a9">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit related to share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktMS0xLTEtMTUwMDM0_c66aa5eb-b7b9-4f45-a0b1-0f7780803319">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktMy0xLTEtMTUwMDM0_1135498e-81f8-4131-b023-865390686da0">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktNS0xLTEtMTUwMDM0_1ba75176-7eb6-4845-b3ee-345d9c94016f">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTEtMS0xLTE1MDAzNA_884589be-0a4a-4709-82f7-914814821d88">11.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTMtMS0xLTE1MDAzNA_1dc2ce05-a8e8-4957-b8f0-9f51ece96426">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTUtMS0xLTE1MDAzNA_7f635892-193e-4232-8cc5-61ea746164aa">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits related to share-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTEtMS0xLTE1MDAzNA_a3a46116-f453-456b-b9c9-746e4d237d45">98.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTMtMS0xLTE1MDAzNA_19eaa03c-8b7c-4a84-8777-c16ec0651af5">185.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTUtMS0xLTE1MDAzNA_4efdf000-225d-4b3f-9381-82f533c514f7">166.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax re-measurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTEtMS0xLTE1MDAzNA_866c6f32-c980-4435-86f8-18f73a46f51c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" sign="-" name="isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTMtMS0xLTE1MDAzNA_57bd8c16-3554-4771-8a4d-4f043547e6c4">66.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTUtMS0xLTE1MDAzNA_f780d5c0-ec5c-433c-a2b4-df50496380e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTEtMS0xLTE1MDAzNA_be53a5d9-5898-488f-9241-32928d7cad5f">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTMtMS0xLTE1MDAzNA_a10a5982-b9c0-4bdf-9e07-9a8eeb5f112f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTUtMS0xLTE1MDAzNA_477ff11b-75b1-46d7-8dc3-476766e9af9f">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTEtMS0xLTE1MDAzNA_9a40a20a-80f5-4af8-b62d-55eef4c75a80">262.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTMtMS0xLTE1MDAzNA_495b7499-1226-40e1-95c5-c2198b7b6994">162.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTUtMS0xLTE1MDAzNA_2d23999a-1123-45f2-8a1e-5782e71801b6">140.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzE_571239d7-7f30-4ae5-bf74-f2b45c36c00a" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect tax carryforwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMS0xLTEtMTk3NDc3_c060d86f-64c6-477a-9a49-240490c928b7">342.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMy0xLTEtMTk3NDc3_ac488ddd-6d8e-4136-88f0-91e236801b64">369.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMS0xLTEtMTk3NTA1_866c2a4c-4c25-4e4c-843d-54a92bfac103">172.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMy0xLTEtMTk3NTA1_96bf57b5-4ca1-4704-a5d4-7838bafbd5ea">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMS0xLTEtMTUwMDM0_b7061e8a-300c-4a47-8b04-35faa62f48af">156.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMy0xLTEtMTUwMDM0_67d26442-f896-40fe-91d0-e6584d92d6d3">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMS0xLTEtMTUwMDM0_ee3b9358-f39f-4637-8cfe-de4bfff0bea5">121.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMy0xLTEtMTUwMDM0_82767df8-f900-4c62-bded-71d59f72ead7">110.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses deducted in later years for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzUtMS0xLTEtMTUwMDM0_fd40f4a2-3b73-47ee-bcf7-859b4978440e">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzUtMy0xLTEtMTUwMDM0_45cea204-75b0-4513-bae7-f8e382c4e749">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzgtMS0xLTEtMTUwMDM0_9eda91b8-f5f0-4e35-9624-87f9645317b1">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzgtMy0xLTEtMTUwMDM0_eba64c00-1e4b-410b-b17a-72c936424831">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzktMS0xLTEtMTk1MDEy_a517d6b6-3288-48a3-8bca-33a811205d84">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzktMy0xLTEtMTk1MDUw_ec2ad3e5-42a2-4bc6-950b-17fe6baf3022">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTEtMS0xLTE5NzkwMg_75b31ee1-386b-4585-bd3e-82e130e32f81">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTMtMS0xLTE5NzkwMg_b524d2db-02c4-4af3-b54c-a516a6d32f44">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEwLTEtMS0xLTE1MDAzNA_6681f7ca-b7e3-4cd4-afd2-7609ce746073">919.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEwLTMtMS0xLTE1MDAzNA_79fcd2f7-8ee0-422d-b851-988e9b85f320">651.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTEtMS0xLTE1MDAzNA_0672df2d-8022-49f3-9ab5-4d3b196de5aa">168.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTMtMS0xLTE1MDAzNA_c7200490-dc66-4bba-ba7d-b5ba803f5783">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEyLTEtMS0xLTE1MDAzNA_09267fed-eba0-4e8f-b09c-ef9e9ef29334">750.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEyLTMtMS0xLTE1MDAzNA_7fbb8416-88f8-4020-9e5e-528973c39462">547.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE0LTEtMS0xLTE1MDAzNA_4a925c93-44bc-4e31-b113-f79b52f3f8a1">64.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE0LTMtMS0xLTE1MDAzNA_146b8172-f713-4ce9-a42f-bf54a89a69a4">79.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="isrg:DeferredTaxLiabilitiesRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE1LTEtMS0xLTE1MDAzNA_2b2d8c7d-2992-4f63-8469-7d2306a3011f">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="isrg:DeferredTaxLiabilitiesRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE1LTMtMS0xLTE1MDAzNA_33988a37-0dbf-4f1a-a781-c280f2f1ab4b">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE2LTEtMS0xLTE1MDAzNA_57a85cdb-8ae3-401a-a403-2dd905e66506">9.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE2LTMtMS0xLTE1MDAzNA_3da06853-0418-4c0c-83e0-5e5670c99ebc">9.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE3LTEtMS0xLTE1MDAzNA_93cdb5e6-412e-4ddd-bd16-2af998cf5e4d">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE3LTMtMS0xLTE1MDAzNA_4cc161b7-7c5e-45a5-8ad5-f71d4951caaa">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE4LTEtMS0xLTE1MDAzNA_56eb3d69-d895-4fc7-901f-f586d55b02d8">86.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE4LTMtMS0xLTE1MDAzNA_c0c71cb3-c9a9-4c65-b2e0-6faeade7de18">106.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE5LTEtMS0xLTE1MDAzNA_8bb47f07-a432-40f5-aba0-a13f12bc0038">664.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE5LTMtMS0xLTE1MDAzNA_6e4158fb-25e6-415c-82a5-73584f76bba5">440.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i749d4dedba014c68aa5c7acf3007a4d0_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzE2MjMz_6ee028c5-b505-4296-8443-a305045d93ae">27.4</ix:nonFraction> million of U.S. and foreign federal net operating loss carryforwards, certain of which will expire starting in 2028 if not utilized. Utilization of these net operating loss carryforwards may be subject to certain limitations. The Company does not expect the limitations to result in any permanent loss of these tax benefits. As of December 31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i01c4df323b92487582860c45f1709563_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzE2MjM3_72fa53dc-c00a-4521-9563-dcbf07bd7a92">221.9</ix:nonFraction>&#160;million in California research and development credit carryforwards, which do not expire.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><ix:continuation id="i34097fac625c43099d9384a5ddbe7f81"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, the Company had valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTQ4OA_0672df2d-8022-49f3-9ab5-4d3b196de5aa">168.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTQ5MQ_c7200490-dc66-4bba-ba7d-b5ba803f5783">104.6</ix:nonFraction> million, respectively, primarily related to California deferred tax assets, for which the Company does not believe a tax benefit is more likely than not to be realized.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to repatriate earnings from its Swiss subsidiary and joint venture in Hong Kong, as needed, and the U.S. and foreign tax implications of such repatriations are not expected to be significant. The Company will continue to indefinitely reinvest earnings from the rest of its foreign subsidiaries, which are not significant.</span></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1OTI_64099933-4b9b-4517-b028-ab59676bcbdb" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December&#160;31, 2022, 2021, and 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItMS0xLTEtMTUwMDM0_65b2e7a0-2cc5-4a38-8ce2-d0490c3148a5">222.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItMy0xLTEtMTUwMDM0_f1a5c65e-4f47-45bb-9d87-ee74e06fd8d3">176.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItNS0xLTEtMTUwMDM0_67e28780-b26e-44c0-b1c5-ec0b36f84ee2">96.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtMS0xLTEtMTUwMDM0_9ad624c4-6871-4cfb-bb24-bc78912237cd">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtMy0xLTEtMTUwMDM0_03914d35-43b2-459b-8051-36f416943934">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtNS0xLTEtMTUwMDM0_caa32803-2a45-43bd-89f1-d9d09ed7af8d">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtMS0xLTEtMTUwMDM0_5c48069f-64c8-47c1-9c70-7386173a3b5f">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtMy0xLTEtMTUwMDM0_b61f2798-9290-486b-aed9-f3bda8c20bc7">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtNS0xLTEtMTUwMDM0_c4987ebb-7db9-46cf-927f-c670c1c2ec97">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtMS0xLTEtMTUwMDM0_ab162f86-e145-4e80-9da5-1169e7cc4e89">16.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtMy0xLTEtMTUwMDM0_b1ca3c70-31a4-46bc-b596-d51aa76b4c89">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtNS0xLTEtMTUwMDM0_2a060db7-f781-4a83-b56d-20d33acfa691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to settlements with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtMS0xLTEtMTUwMDM0_fea92d7e-f80c-417a-b033-afd91f82ef6a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtMy0xLTEtMTUwMDM0_5ce7410b-b873-4621-9452-619118fdc208">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtNS0xLTEtMTUwMDM0_6ac3dc8b-dce8-45bb-bae2-f847dff7d485">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctMS0xLTEtMTUwMDM0_88523332-8c55-49a1-8d33-629864bc5db6">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctMy0xLTEtMTUwMDM0_fddc5b42-3ccf-4a18-9836-bca010813683">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctNS0xLTEtMTUwMDM0_aaf5fb10-c446-45dd-8f8d-0408b91059fe">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtMS0xLTEtMTUwMDM0_8efdf962-3b05-4f45-ad2f-940cf4ba71e8">252.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtMy0xLTEtMTUwMDM0_87eef1b9-43b1-4de1-82af-e486209d2842">222.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtNS0xLTEtMTUwMDM0_b28e1940-0253-429a-8a01-edbc5fcd95a8">176.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 2021, and 2020, gross interest related to unrecognized tax benefits accrued was $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTczNA_ffefd8d3-a261-4d0e-b8cd-6b10b4f7c164">21.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTczNw_415b1401-e065-4a03-a5f1-543f570b2bd4">14.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTc0MA_2d4bff63-7405-4c3c-81fc-b47d09854173">11.0</ix:nonFraction> million, respectively. The Company&#8217;s net unrecognized tax benefits and related interest are presented in other long-term liabilities and long-term deferred tax assets on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross unrecognized tax benefits as of December&#160;31, 2022, were $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTc1Nw_05c28c05-3125-49b0-ac72-d37d8f22441d">252.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzI3NDg3NzkwODQzODI_052de69e-f245-48d0-8ec4-3c2d8516a343">187.4</ix:nonFraction>&#160;million, if recognized, would have an impact on the Company&#8217;s effective tax rate.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an increase in the income tax provision of $<ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM2ODA_ce58aa70-e743-4c9a-b82e-a48771e2d909">39.3</ix:nonFraction>&#160;million during the year ended December 31, 2020, as a result of a Ninth Circuit Court of Appeals opinion involving an independent third party related to charging foreign subsidiaries for share-based compensation. An additional charge of $<ix:nonFraction unitRef="usd" contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM3NDg_708e9d39-b279-4354-be33-5fb9a7aaa689">13.6</ix:nonFraction>&#160;million related to this matter was recorded to income tax expense in 2021, after additional IRS guidance was issued in July 2021. The Company will continue to monitor future IRS actions or other developments regarding this matter and will assess the impact of any such developments on its income tax provision in the quarter that they occur.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files federal, state, and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2016 are closed for the significant jurisdictions. Certain of the Company&#8217;s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company&#8217;s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of&#160;reasonably possible&#160;changes in unrecognized tax benefits that may occur in the next 12 months.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company&#8217;s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company&#8217;s provision for income taxes. If any issues addressed in the Company&#8217;s tax audits are resolved in a manner not consistent with management&#8217;s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU4NQ_93fc6bde-4795-44c3-ab59-8836eb828897" continuedAt="i9875612290cc4db08c4f05f0044f023c" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i9875612290cc4db08c4f05f0044f023c"><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU4Mg_493ecb20-5a80-4bea-b777-c150925194c6" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net income per share&#160;attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtMS0xLTEtMTUwMDM0_fd92bffa-51c2-447b-9aee-629aa77101a3">1,322.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtMy0xLTEtMTUwMDM0_3b559059-2e88-4655-92c9-35a4af570fa4">1,704.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtNS0xLTEtMTUwMDM0_8fe8ec60-3473-4a5e-bba9-e68a403c3a44">1,060.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in basic calculation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtMS0xLTEtMTUwMDM0_fc02180a-7b8f-4697-8a56-1eda28408b65">355.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtMy0xLTEtMTUwMDM0_a75b91a8-e4f6-4efe-a3d9-52a0f253cd8e">356.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtNS0xLTEtMTUwMDM0_8167bffc-78dc-4892-b280-9ced69980008">351.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: dilutive effect of potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtMS0xLTEtMTUwMDM0_5d4ef6c6-976c-4f9d-aefb-2dc1d8b3c4a7">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtMy0xLTEtMTUwMDM0_f8847d75-2a10-46dd-bb1a-ed12db7714a8">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtNS0xLTEtMTUwMDM0_419a75ed-5745-40fb-ad7b-68722e75cb1a">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in diluted calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctMS0xLTEtMTUwMDM0_74edf9cd-33d4-44dc-88b4-33eb8a2f9144">362.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctMy0xLTEtMTUwMDM0_9ba1188c-fa1e-49d0-b634-35b605fa849f">365.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctNS0xLTEtMTUwMDM0_dd147251-e152-425e-b0ba-a837937eb260">361.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Intuitive Surgical, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktMS0xLTEtMTUwMDM0_3adc52a8-e740-400d-9343-a29fef098dc2">3.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktMy0xLTEtMTUwMDM0_f51d5be3-7c08-4c0d-a81d-a265f160406b">4.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktNS0xLTEtMTUwMDM0_8e68c3a9-d925-48a6-be5f-88818f0d7289">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTEtMS0xLTE1MDAzNA_bab5c7e4-1d5b-4a68-acc5-4b69a1d80f42">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTMtMS0xLTE1MDAzNA_3df8a433-151e-40c5-9753-2b8ba9df881b">4.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTUtMS0xLTE1MDAzNA_5fe83b8c-fdce-4cd2-9619-251dd1665d92">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation awards of approximately <ix:nonFraction unitRef="shares" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ3OA_df56beff-9712-4d9d-8027-370e78373ba9">3.4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ4MQ_537a6f50-5018-4e9e-94d6-34fe9eb838d1">0.8</ix:nonFraction> million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ4NA_3659b44f-5c3a-4807-83f9-80c320b3be4e">1.9</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares for the years ended December&#160;31, 2022, 2021, and 2020, respectively, were outstanding but were not included in the computation of diluted net income per share attributable to Intuitive Surgical, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.</span></div></ix:continuation><div id="i025de1eec32044f5a30c5872569f0e8d_268"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzc1NA_8131a1b8-5ba8-4308-a6b8-4acbdcacad7b" continuedAt="i129cf792e9ab41e080fa354b20e303b4" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i129cf792e9ab41e080fa354b20e303b4">The Company sponsors various retirement plans for its eligible U.S. and non-U.S. employees. For employees in the U.S., the Company maintains the Intuitive Surgical, Inc. 401(k) Plan (the &#8220;Plan&#8221;). As allowed under Section&#160;401(k) of the Internal Revenue Code, the Plan provides tax-deferred salary contributions for eligible U.S. employees. The Plan allows employees to contribute up to <ix:nonFraction unitRef="number" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzQyMw_52b5450d-f390-4870-9901-7cf190d0cb64">100</ix:nonFraction>% of their annual compensation to the Plan on a pre-tax and/or after-tax basis. Employee contributions are limited to a maximum annual amount as set periodically by the Internal Revenue Code. The Company matches <ix:nonFraction unitRef="number" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzYzMw_8c0e4c64-f0cb-4c11-9287-5099d6fb88cf">200</ix:nonFraction>% of employee contributions up to $<ix:nonFraction unitRef="usd" contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzY2OA_f6afe341-1140-456c-82fa-d243af559f7d">1,500</ix:nonFraction> per calendar year per person.&#160;All matching employer contributions vest immediately.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_277"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN MILLIONS)</span></div></div><ix:nonNumeric contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90ZXh0cmVnaW9uOjA1NGJiYjRjYjQyNTQxZDBiNjczM2QxMTc2ZTdkZTEwXzQ4_0703574d-3613-49b8-be90-b7f6b7241a24" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning&#160;of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance&#160;at<br/>End&#160;of&#160;Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItMS0xLTEtMTUwMDM0_ec8b51c4-2cae-4b9d-8b0e-59127dee2526">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItMy0xLTEtMTUwMDM0_65ef812c-db85-48c5-b6f8-1ab8e6d1318b">44.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItNS0xLTEtMTUwMDM0_ead13879-2f9a-4d33-b232-19c94edaf165">43.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552384583d88412ebd23eaaff77ee647_I20221231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItNy0xLTEtMTUwMDM0_ce27f16c-9169-4f81-bb18-bda2b759228f">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0a29ffcad84c7ba35a79003fcce055_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtMS0xLTEtMTUwMDM0_3f4ab0ce-3a67-473d-8df3-5e08786cd239">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtMy0xLTEtMTUwMDM0_890f01d4-e587-4c34-acd6-f94f9503b193">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtNS0xLTEtMTUwMDM0_e7b25174-9d05-44af-870c-eedcc9e234b0">44.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtNy0xLTEtMTUwMDM0_2d1d63a3-82b6-4e2e-820a-19e50ef17420">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2020</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54e38a6bc054a1bb5bcc9ff5b0db69b_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtMS0xLTEtMTUwMDM0_9fd3c72d-1cd2-496e-bc9b-f761194b51be">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745afcb5136f43d88582feee765c64c4_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtMy0xLTEtMTUwMDM0_075ae097-296b-4060-8210-910eb06336b0">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i745afcb5136f43d88582feee765c64c4_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtNS0xLTEtMTUwMDM0_6808c178-cbee-4060-8f8b-583d9ee90796">35.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0a29ffcad84c7ba35a79003fcce055_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtNy0xLTEtMTUwMDM0_a3491d52-2e2a-4968-a288-7f2fdd8ddc34">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Primarily represents products returned.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_280"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_283"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations Over Internal Controls</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Consolidated Financial Statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of the Consolidated Financial Statements in accordance with GAAP and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including our principal executive officer and principal financial officer, does not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of our assessment under the framework in the Internal Control&#8212;Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2022, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included under &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_286"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_292"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part III is omitted from this report on Form 10-K and is incorporated herein by reference to our definitive Proxy Statement for our next Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which we intend to file pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, within 120 days after December&#160;31, 2022.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_295"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item concerning our directors and corporate governance is incorporated by reference to the information set forth in the section titled &#8220;Directors and Corporate Governance&#8221; in our Proxy Statement. Information required by this item concerning our executive officers is incorporated by reference to the information set forth in the section entitled &#8220;Executive Officers of the Company&#8221; in our Proxy Statement. Information regarding our Section&#160;16 reporting compliance and code of business conduct and ethics is incorporated by reference to the information set forth in the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; in our Proxy Statement.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_298"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; and &#8220;Compensation for Directors&#8221; in our Proxy Statement.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_301"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; in our Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2022.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_304"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding certain relationships and related transactions and director independence is incorporated by reference to the information set forth in the sections titled &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Directors and Corporate Governance&#8221; in our Proxy Statement.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_307"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_310"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_313"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULE</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Financial Statements&#8212;See Index to Consolidated Financial Statements at Item&#160;8 of this report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The following financial statement schedule of Intuitive Surgical, Inc. for 2022, 2021, and 2020 is filed as part of this report and should be read in conjunction with the Consolidated Financial Statements of Intuitive Surgical, Inc.:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.380%"><tr><td style="width:1.0%"></td><td style="width:78.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_277">Schedule II - Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_277">121</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted, because they are not applicable, not required under the instructions, or the information requested is set forth in the Consolidated Financial Statements or related notes thereto.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Exhibits</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this report are listed under &#8220;Exhibits&#8221; at subsection (b)&#160;of this Item&#160;15.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_316"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526720000166/ex-31xamendedandrestat.htm">Amended and Restated Certificate of Incorporation of the Company, as Amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526721000178/exhibit31-arcertificateofi.htm">Amendment to Amended and Restated Certificate of Incorporation of the Company. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526721000021/exhibit31-amendedandrestat.htm">Amended and Restated Bylaws of the Company.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000089161800002457/0000891618-00-002457.txt">Specimen Stock Certificate.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526722000014/isrg-20211231xex42q42021xf.htm">Description of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526722000014/isrg-20211231xex42q42021xf.htm">s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000089161800001640/0000891618-00-001640.txt">2000 Non-Employee Directors&#8217; Stock Option Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000103526715000087/ex101intuitivesurgicalincf.htm">Form of Indemnity Agreement.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3(8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000103526715000051/ex422009employmentcommence.htm">2009 Employment Commencement Incentive Plan, as amended and restated.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000103526717000079/ex1012000employeestockpurc.htm">2000 Employee Stock Purchase Plan, as amended and restated.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(10)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1035267/000103526722000115/ex-101xamendedandrestated2.htm">2010 Incentive Award Plan, as amended and restated.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000119312508246630/dex101.htm">Severance Plan.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7(12)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000103526716000130/isrg-20151231xex109.htm">Form of Amended and Restated Intuitive Surgical, Inc. 2009 Employment Commencement Incentive Plan Stock Option Grant Notice.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8(13)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1035267/000103526716000130/isrg-20151231xex1010.htm">Form of Amended and Restated Intuitive Surgical, Inc. 2009 Employment Commencement Incentive Plan Restricted Stock Unit Grant Notice.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-109xfy23optionagree.htm">Form of Amended and Restated Intuitive Surgical, Inc. 2010 Incentive Award Plan Global Stock Option Grant Notice.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-1010xfy23rsuagreeme.htm">Form of Amended and Restated Intuitive Surgical, Inc. 2010 Incentive Award Plan Global Restricted Stock Unit Grant Notice.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-1011xfy23psuagreeme.htm">Form of Amended and Restated Intuitive Surgical, Inc. 2010 Incentive Award Plan Global Performance Stock Unit Grant Notice</a>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-211xsubsidiariesq4o.htm">Intuitive Surgical, Inc. Subsidiaries.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-231xauditorconsentq.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-311xceocertofsoxsec.htm">Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-312xcfocertofsoxsec.htm">Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q422ex-3212xceoandcfocerto.htm">Certification of Chief Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Intuitive Surgical, Inc.&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Stockholders&#8217; Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged at Level I through IV.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Intuitive Surgical, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 3.1 filed with the Company&#8217;s Quarterly Report on Form 10-Q filed on July 23, 2020 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 3.1 filed with the Company&#8217;s Quarterly Report on Form 10-Q filed on October 20, 2021 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 3.1 filed with the Company&#8217;s Current Report on Form 8-K filed on February 1, 2021 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 4.2 filed with the Company&#8217;s Registration Statement Amendment on Form S-1/A filed on May&#160;2, 2000 (File No.&#160;333-33016).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 4.2 filed with the Company&#8217;s Annual Report on Form 10-K filed on February 3, 2022 (File No. 333-33016).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to exhibits filed with the Company&#8217;s Registration Statement on Form S-1 filed on March&#160;22, 2000 (File No.&#160;333-33016).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed on August 3, 2015 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 4.2 filed with the Company&#8217;s Registration Statement on Form S-8 filed on May 1, 2015 (File No. 333-203793).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed on April&#160;26, 2017 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed on May 3, 2022 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed on December&#160;2, 2008 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Incorporated by reference to Exhibit 10.9 filed with the Company&#8217;s 2015 Annual Report on Form 10-K filed on February&#160;2, 2016 (File No. 000-30713).</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">Incorporated by reference to Exhibit 10.10 filed with the Company&#8217;s 2015 Annual Report on Form 10-K filed on February&#160;2, 2016 (File No. 000-30713).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> *      Management contract or compensatory plan or arrangement.</span></div><div id="i025de1eec32044f5a30c5872569f0e8d_319"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:63pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i025de1eec32044f5a30c5872569f0e8d_322"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i025de1eec32044f5a30c5872569f0e8d_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.327%"><tr><td style="width:1.0%"></td><td style="width:10.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INTUITIVE SURGICAL, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UTHART&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gary S. Guthart, Ph.D.<br/>President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  February&#160;10, 2023</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Gary Guthart, Ph.D., and Jamie Samath, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place, and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10&#8209;K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UTHART</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer, and Director <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gary S. Guthart, Ph.D.</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMIE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMATH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer <br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jamie E. Samath</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160; F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REDRIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IDMAN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Corporate Controller <br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fredrik C. Widman</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RAIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARRATT</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Craig H. Barratt, Ph.D.</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSEPH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EERY</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Joseph C. Beery</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHNSON</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amal M. Johnson</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ON </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANIA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Don R. Kania, Ph.D.</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amy L. Ladd, Ph.D.</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EITH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EONARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Keith R. Leonard Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EVY</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alan J. Levy, Ph.D.</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OVER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACHTSHEIM</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jami Dover Nachtsheim</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ONICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EED</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Monica P. Reed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UBASH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mark J. Rubash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>q422ex-109xfy23optionagree.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i196beda6d10f4b58be61b2e8d4a17a7f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC. 2010 INCENTIVE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL STOCK OPTION GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intuitive Surgical, Inc., a Delaware corporation (the &#8220;Company&#8221;), pursuant to its Amended and Restated 2010 Incentive Award Plan (the &#8220;Plan&#8221;), hereby grants to the holder listed below (&#8220;Participant&#8221;) an option to purchase the number of shares of the Company&#8217;s Common Stock (the &#8220;Option&#8221;) set forth below.  This Option is subject to all of the terms and conditions as set forth in this Global Stock Option Grant Notice (the &#8220;Grant Notice&#8221;), the Global Stock Option Agreement (including any additional terms and conditions for Participant&#8217;s country included in the appendix attached thereto) (the &#8220;Agreement&#8221;), the Plan and the Grant Notice, all of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting Commencement Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Shares Subject to Option&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise Price (Per Share)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Exercise Price&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:93.6pt;text-align:justify;text-indent:-93.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Grant&#58;&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:14pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Incentive Stock Option&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:14pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Nonstatutory Stock Option</font></div><div style="margin-bottom:6pt;padding-left:93.6pt;text-align:justify;text-indent:-93.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;Early Exercise Is Not Permitted</font></div><div style="padding-left:93.6pt;text-align:justify;text-indent:-93.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; &#160;&#160;&#160;&#160;Option will vest as shown in the Vest Schedule on the corporate broker&#8217;s website, subject to the Participant&#8217;s continued service with the Company through each applicable vesting date.</font></div><div style="margin-bottom:6pt;padding-left:93.6pt;text-align:justify;text-indent:-93.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;By one or a combination of the following items (described in the Global Stock Option Agreement)&#58;</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">By cash or check&#59;</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">By delivery of already-owned shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Shares are publicly traded for participants in the United States only&#59; or</font></div><div style="padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">Through the delivery of a notice that Participant has placed a market sell order with a broker with respect to Shares then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the Option exercise price&#59; provided that payment of such proceeds is then made to the Company at such time as may be required by the Company, but in any event not later than the settlement of such sale.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By Participant&#8217;s signature below, or by indicating acceptance of this award through the Company&#8217;s online acceptance procedure (including online acceptance through a third-party website authorized by the Company), Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice.  Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing or accepting the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Grant Notice or the Agreement.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC.</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">via Online Electronic Acceptance</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:85.5pt;text-align:justify;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Attachments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  Global Stock Option Agreement and Amended and Restated 2010 Incentive Award Plan</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC. 2010 INCENTIVE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to your Global Stock Option Grant Notice (&#8220;Grant Notice&#8221;) and this Global Stock Option Agreement, including any additional terms and conditions for your country set forth in the appendix attached hereto (the &#8220;Appendix&#8221; and, together with the Global Stock Option Agreement, this &#8220;Agreement&#8221;), Intuitive Surgical, Inc. (the &#8220;Company&#8221;) has granted you an option under its Amended and Restated 2010 Incentive Award Plan (the &#8220;Plan&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The details of your option are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon your Termination of Service, except as otherwise provided by the Administrator or as set forth in a written agreement between you and the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">For purposes of your option, a Termination of Service will be deemed to have occurred as of the date you are no longer actively providing services to the Company or any Affiliate (regardless of the reason for such Termination of Service and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where you are employed or otherwise rendering services, or the terms of your employment or other service agreement, if any).  Your employment or service relationship will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> your period of service will not be extended by any contractual notice period or period of &#8220;garden leave&#8221; or similar period mandated under applicable laws in the jurisdiction where you are employed or otherwise rendering services, or the terms of your employment or service agreement, if any). Unless otherwise expressly provided in the Plan or determined by the Company (i) your right to vest in the option, if any, will terminate as of the date of Termination of Service, and (ii) the period (if any) during which you may exercise this option after a Termination of Service will commence on such date. Notwithstanding the forgoing, the Administrator shall have exclusive discretion to determine when a Termination of Service has occurred for purposes of the option (including when you are no longer considered to be providing services while on a leave of absence). In the event of your leave of absence, vesting of the option shall be governed by the Company&#8217;s leave of absence policies, as may be amended from time to time, and in accordance will applicable laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding the foregoing, vesting of your option is also subject to acceleration under certain circumstances following a Change of Control (as defined in the Intuitive Surgical, Inc. Severance Plan (the &#8220;Severance Plan&#8221;)), in accordance with the terms of the Severance Plan, as may be amended from time to time.  The Severance Plan can be found on the Company&#8217;s Infoweb.  The terms of the Severance Plan include that the Board has the discretionary authority to amend or terminate the Severance Plan in any respect by resolution adopted by a two-thirds or greater majority of the Board, unless a Change of Control has previously occurred.  Any changes to the terms of the Severance Plan properly approved by the Board shall be binding on the option being granted in the Grant Notice.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Number Of Shares And Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time pursuant to Section&#160;13 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Method Of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Payment of the exercise price is due in full upon exercise of all or any part of your option.  You may elect to make payment of the exercise price in cash or by check or in any other manner permitted by your Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Whole Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You may exercise your option only for whole shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision in the Plan or this Agreement, unless there is an available exemption from registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company shall not be required to permit the exercise of the option and&#47;or delivery of shares of Common Stock prior to the completion of any registration or qualification of the shares of Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) or of any governmental body, or prior to obtaining any approval or other clearance from any U.S. or non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable.  You understand that the Company is under no obligation to register or qualify the shares of Common Stock with the SEC or any state or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares of Common Stock.  Further, you agree that the Company shall have unilateral authority to amend this Agreement without your consent, to the extent necessary to comply with securities or other laws applicable to the issuance of shares of Common Stock. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of your option commences on the Date of Grant and expires upon the earliest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">three (3) months after your Termination of Service (as described in Section&#160;1(b)) for any reason other than your Disability or death, provided that if during any part of such three- (3-) month period your option is not exercisable solely because of the condition set forth in the preceding paragraph relating to &#8220;Securities Law Compliance,&#8221; your option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) months after your Termination of Service&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">twelve (12) months after your Termination of Service due to your Disability&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">eighteen (18) months after your Termination of Service due to your death if you die either during your employment or within three (3) months after your Termination of Service&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">the Expiration Date indicated in your Grant Notice&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the day before the seventh (7th) anniversary of the Date of Grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For U.S. taxpayers, if your option is an incentive stock option, note that, to obtain the federal income tax advantages associated with an &#8220;incentive stock option,&#8221; the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an &#8220;incentive stock option&#8221; if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment terminates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;Disability&#8221; means the permanent and total disability of a person within the meaning of Section&#160;22(e)(3) of the Code, as determined by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">You may exercise the vested portion of your option during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, together with such additional documents as the Company may then require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any Tax-Related Items (as defined in Section&#160;10 below) arising from the option or the underlying shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">For U.S. taxpayers, if your option is an incentive stock option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Option shall be subject to the restrictions on transferability set forth in Section 11.3 of the Plan, subject to the Intuitive Surgical, Inc. Equity Domestic Relations Order Policy, effective July 1, 2014, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Option Not A Service Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or service of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment or service relationship.  In addition, nothing in your option shall obligate the Company or an Affiliate, their respective shareholders, Boards of Directors, officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Withholding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Regardless of any action the Company and&#47;or the Affiliate employing or otherwise retaining you (the &#8220;Employer&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company and&#47;or the Employer.  You further acknowledge that neither the Company nor the Employer (i) make any representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of your option, including, but not limited to, the grant, vesting or exercise of your option, the subsequent sale of shares of Common Stock acquired pursuant to such exercise and the receipt of any dividends&#59; and (ii) do not commit or are under any obligation to structure </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms of the grant or any aspect of your option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  Further, if you are subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items.  In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or an Affiliate&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at exercise of your option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization).  In addition, upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the applicable amount of tax required to be withheld by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding rates or other withholding rates, including maximum withholding rates in your jurisdiction(s), in which case, you may receive a refund of any over-withheld amount in cash and will have no entitlement to the equivalent in shares of Common Stock. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you are deemed to have been issued the full number of shares of Common Stock subject to your exercised option, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items due.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">You agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to permit your exercise of this option or to issue or deliver shares of Common Stock or proceeds from the sale of shares of Common Stock if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Nature Of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting your option, you acknowledge, understand and agree that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended or terminated by the Company at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">the grant of your option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future option grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">your participation in the Plan is voluntary&#59;</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">your option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">your option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not part of normal or expected compensation for purposes of, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the shares of Common Stock underlying your option is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">if the underlying shares of Common Stock do not increase in value after the date of grant, your option will have no value&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">if you exercise your option and acquire shares of Common Stock, the value of such shares of Common Stock may increase or decrease in value, even below the exercise price&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">no claim or entitlement to compensation or damages shall arise from forfeiture of your option resulting from your Termination of Service (for any reason whatsoever and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where you are employed or otherwise rendering services, or the terms of your employment or other service agreement, if any)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">unless otherwise agreed with the Company, your option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service you may provide as a director of any Parent or Affiliate&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the option and the benefits evidenced by this Agreement do not create any entitlement to have the option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for in connection with any corporate transaction affecting the shares of Common Stock&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">neither the Company, the Employer nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the option or any amounts due to you pursuant to the exercise of the option or subsequent sale of shares of Common Stock acquired upon exercise. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Advice Regarding Option Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the issuance of shares of Common Stock upon exercise of your option or the sale of the shares of Common Stock.  You should consult with your personal tax, legal, and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you would like to participate in the Plan, you will need to review the information provided in this Section 13 and, where applicable, declare consent to the processing and&#47;or transfer of personal data as described below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">EEA+ Controller and Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are based in the European Union, the European Economic Area or the United Kingdom (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA+</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you should note that the Company, with its registered address at 1020 Kifer Road, Sunnyvale, California 94086, United States of America, is the controller responsible for the processing of your personal data in connection with the Agreement and the Plan.  The Company is represented in the EEA+ by Intuitive Surgical SAS, Cit&#233; de la Photonique, b&#226;timent Gienah, 11 avenue de Canteranne, 33600 Pessac, France.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company collects, uses and otherwise processes certain personal data about you, including but not limited to, your name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all options granted under the Plan or other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, which the Company receives from you, the Employer or otherwise in connection with this Agreement or the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the legitimate purposes of implementing, administering and managing the Plan and allocating shares of Common Stock pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are based in the EEA+, the legal basis, where required, for the processing of Data by the Company is the necessity of the Data processing for the Company&#8217;s performance of its obligations under the Plan, and where applicable, the Company&#8217;s legitimate interest of complying with contractual or other statutory obligations to which it is subject. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are based outside of the EEA+, the Company&#8217;s legal basis for the processing of Data is your consent, as further described below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company transfers Data to E*TRADE Financial Services, Inc. and certain of its affiliated companies (the &#8220;Designated Broker&#8221;), an independent service provider based in the United States, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Designated Broker may open an account for you to receive and trade shares of Common Stock acquired under the Plan.  You may be asked to agree on separate terms and data processing practices with the Designated Broker, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company and the Designated Broker are based in the United States, which means that it will be necessary for Data to be transferred to, and processed in, the United States.  You should note that your country may have enacted data privacy laws that are different from the United States.  For example, you understand and acknowledge that the United States is not subject to an unlimited adequacy finding by the European Commission and that your Data may not have an equivalent level of protection as compared to your country of residence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The onward transfer of Data from the Company to the Designated Broker or, as the case may be, a different service provider of the Company is based solely on your consent, as further described below.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If you are based outside of the EEA+, Data will be transferred from your jurisdiction to the Company and onward from the Company to any of its service providers based on your consent, as further described below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  The Company will hold and use the Data only as long as is necessary to implement, administer and manage your participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax, exchange control, securities and labor laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; You may have a number of rights under data privacy laws in your jurisdiction. Depending on where you are based, such rights may include the right to (i) request access to or copies of Data the Company processes, (ii) rectify incorrect Data, (iii) delete Data, (iv) restrict the processing of Data, (v) object to the processing of Data for legitimate interests, (vi) restrict the portability of Data, and&#47;or (vii) lodge complaints with competent authorities in your jurisdiction. To receive additional information regarding these rights or to exercise these rights, you can contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Necessary Disclosure of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand that providing the Company with Data is necessary for the performance of the Agreement and that your refusal to provide Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Participation in the Plan is voluntary and you are providing the consents herein on a voluntary basis.  You understand that you may request to stop the transfer and processing of the Data for purposes of participation in the Plan and that your compensation from or<br>employment relationship with the Employer will not be affected. The only consequence of refusing or withdrawing consent is that the Company would not be able to allow you to participate in the Plan. You understand that the Data will still be processed in relation to your  employment or service relationship and for record-keeping purposes.  For more information on the consequences of refusal to consent or withdrawal of consent, you should contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are based in the EEA+, by accepting your option and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, you explicitly declare your consent to the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S. as described above.  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are based outside of the EEA+, by accepting your option and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, you explicitly declare your consent to the entirety of the Data processing operations described above including, without limitation, the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S.</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is governed by and will be interpreted and enforced under the laws of the State of Delaware without regard to such state&#8217;s conflict of laws rules.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this option grant or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">litigation shall be conducted only in the courts of Santa Clara County, California, or the federal courts for the United States for the Northern District of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Electronic Delivery And Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide to deliver any documents related to your option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that you are sufficiently proficient in English or have consulted with an advisor who is sufficiently proficient in English, so as to allow you to understand the terms and conditions of this Agreement. If you have received this Agreement, or any other document(s) related to your option and&#47;or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control, unless otherwise prescribed by local law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that a waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other participant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Appendix.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provisions in this Agreement, your option shall be subject to any additional terms and conditions for your country set forth in the Appendix attached hereto. Moreover, if you relocate to one of the countries included in the Appendix, the additional terms and conditions for such country, if any, will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to you shall be addressed to you at your last address reflected on the Company&#8217;s records.  By a notice given pursuant to this Section 20, either party may hereafter designate a different address for notices to be given to that party.  Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service or any equivalent non-U.S. postal service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Rights As Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of any shares of Common Stock purchasable upon the exercise of any part of the option unless and until such shares of Common Stock shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan, the Grant Notice and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules, in accordance with applicable laws.  All actions </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taken and all interpretations and determinations made by the Administrator will be final and binding upon participants, the Company and all other interested persons.  To the extent allowable pursuant to applicable law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that you may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States, your country, the broker&#8217;s country and the country or countries in which the shares of Common Stock are listed, which may affect your ability, directly or indirectly, to purchase or sell, or attempt to sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., options), or rights linked to the value of shares of Common Stock, during such times as you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in the applicable jurisdiction(s)).  Local insider trading laws and regulations prohibit the cancellation or amendment of orders you placed before possessing the inside information.  Furthermore, you understand that you may be prohibited from (i) disclosing the inside information to any third party, including fellow employees (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties by sharing with them Company insider information, or otherwise causing third parties to buy or sell Company securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may apply to you under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you should speak to your personal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Foreign Asset&#47;Account Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you reside in a country outside the United States, there may be certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold shares of Common Stock or cash received from participating in the Plan (including from any dividends paid on shares of Common Stock) in a brokerage account or bank outside of your country. You may be required to report such accounts, assets or related transactions to the tax or other authorities in your country.  You may also be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to your country within a certain time after receipt. It is your responsibility to comply with such regulations and you should speak to your personal legal advisor on this matter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Amendments, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the options in any material way without your prior written.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Successors And Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section&#160;8 hereof, this Agreement shall be binding upon you and your heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Limitations Applicable To Section&#160;16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, if you are subject to Section&#160;16 of the Exchange Act, the Plan, the option and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan, this or the Grant Notice, the Plan, this Agreement and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section&#160;409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;Section&#160;409A&#8221;).  The Committee may, in its discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Committee determines are necessary or appropriate to comply with the requirements of Section&#160;409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your option is subject to all the provisions of the Plan and the Severance Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan and the Severance Plan.  In the event of any conflict between the provisions of your option and those of the Plan or the Severance Plan, the provisions of the Plan and the Severance Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All awards will be subject to recoupment by the Company to the extent required to comply with applicable law or any policy of the Company providing for the reimbursement of incentive compensation, whether or not such policy is in place at the time of grant or payment of the award.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Imposition Of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on your option and the shares of Common Stock purchased upon exercise of your option, to the extent the Company determines it is necessary or advisable in order to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By signing the Grant Notice, you are deemed to have read, understood and agreed to all of the provisions in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE AMENDED AND RESTATED INTUITIVE SURGICAL, INC.<br>2010 INCENTIVE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Global Stock Option Agreement (the &#8220;Agreement&#8221;) or the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern the option granted to you under the Plan if you work and&#47;or reside in one of the countries listed below.  This Appendix forms part of the Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you are a citizen or resident of a country other than one in which you are currently residing and&#47;or working, transfer employment and&#47;or residency to another country after the Date of Grant, or are considered a resident of another country for local law purposes, the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to you. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes information regarding exchange control and certain other issues which you should be aware with respect to participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the respective countries as of November&#160;2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time you exercise your option and acquire shares of Common Stock or sell shares of Common Stock acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your personal situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently residing and&#47;or working, transfer employment and&#47;or residency to another country after the Date of Grant, or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">. The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Act&#8221;) applies (subject to the conditions in the Act).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you acquire shares of Common Stock pursuant to the option and offer the shares of Common Stock for sale to a person or entity resident in Australia, such offer may be subject to disclosure requirements under Australian law. You should obtain legal advice as to your disclosure obligations prior to making any such offer. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acceptance of Option. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The timing of taxation of this option depends on whether it is accepted (i) within 60 days of the offer (for taxation at offer) or (ii) more than 60 days after the offer (for taxation at exercise). You should consult your personal tax advisor with respect to this option before taking any action. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A stock exchange tax applies to transactions executed by a Belgian resident through a financial intermediary, such as a bank or broker. If the transaction is conducted through a Belgian financial intermediary, it may withhold the stock exchange tax, but if the transaction is conducted through a non-Belgian financial intermediary, the Belgian resident may need to report and pay the stock exchange tax directly. The stock exchange tax likely will apply when shares of Common Stock acquired under the Plan are sold, including pursuant to a cashless sell-to-cover or cashless sell-all exercise of options.  Belgian residents should consult with a personal tax or financial advisor for additional details on their obligations with respect to the stock exchange tax.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Method of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 3 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As set forth in the Grant Notice, you are prohibited from surrendering shares of Common Stock that you already own or attesting to the ownership of shares of Common Stock to pay the exercise price or any Tax-Related Items in connection with your option.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision replaces Section 1(b) of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of your option, your Termination of Service will be deemed to occur as of the date that is the earlier of (i) the date of your termination, (ii) the date you receive notice of termination, or (iii) the date you are no longer actively providing services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., active service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under Canadian laws or the terms of your employment or service agreement, if any), regardless of the reason for such termination and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where you are employed or providing services or the terms of your employment or service agreement, if any&#59; unless otherwise expressly provided in this Agreement or determined by the Company, (i) your right to vest in the option under the Plan, if any, will terminate as of such date and (ii) the period (if any) during which you may exercise the option after such termination will commence on such date&#59; in the event that the date you are no longer actively providing services cannot be reasonably determined under the terms of this Agreement and the Plan, the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of your option (including whether you may still be considered to be providing services while on a leave of absence).  Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued vesting during a statutory notice period, your right to vest in the options, if any, will terminate effective as of the last date of the minimum statutory notice period, but Participant will not earn or be entitled to pro-rated vesting or exercisability if the vesting date falls after the end of Participant&#8217;s statutory notice period, nor will Participant be entitled to any compensation for lost vesting or exercisability. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions apply to residents of Quebec&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A French translation of the Plan, Grant Notice and the Agreement will be made available to you as soon as reasonably practicable.  You understand that, from time to time, additional information related to the offering of the Plan might be provided in English and such information may not be immediately available in French.  However, upon request, the Company will translate into French documents related to the offering of the Plan as soon as reasonably practicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Une traduction fran&#231;aise du Plan, de l'Avis d'octroi et de la pr&#233;sente Entente sera mise &#224; la disposition de Participant d&#232;s que raisonnablement possible. Participant comprend que, de temps &#224; autre, des informations suppl&#233;mentaires li&#233;es &#224; l'offre du Plan peuvent &#234;tre fournies en anglais et que ces informations peuvent ne pas &#234;tre imm&#233;diatement disponibles en fran&#231;ais. Cependant, sur demande, Intuitive Surgical traduira en fran&#231;ais les documents relatifs &#224; l'offre du Plan d&#232;s que raisonnablement possible.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 13 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or non-professional, involved with the administration of the Plan.  You further authorize the Company, the Employer, any Affiliate, E*TRADE Financial Services, Inc. and any other stock plan service provider as may be selected by the Company from time to time to assist with the Plan, to disclose and discuss the Plan with their advisors.  You acknowledge and agree that your personal information, including any sensitive personal information, may be transferred or disclosed outside of the Province of Quebec, including to the United States.  You also authorize the Company and the Employer to record such information and to keep such information in your employee file. You also acknowledge and authorize the Company, its Affiliates, and other parties involved in the </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">administration of the Plan to use technology for profiling purposes and to make automated decisions that may have an impact on you or the administration of the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The sale of shares of Common Stock acquired under the Plan may not take place in Canada.  This requirement will be satisfied where the shares of Common Stock are sold by the designated broker under the Plan through the facilities of the U.S. stock exchange on which the Common Stock currently is listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., the Nasdaq Global Select Market).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Options Not Tax-Qualified</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The options granted under this Agreement are not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-177 to L. 225-186-1 of the French Commercial Code, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting your option, you confirm having read and understood the documents relating to this grant (the Plan, the Agreement and this Appendix) which were provided in English language.  You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez ainsi avoir lu et compris les documents relatifs &#224; cette attribution (le Plan, le contrat et cette Annexe) qui ont &#233;t&#233; communiqu&#233;s en langue anglaise.  Vous acceptez les termes en connaissance de cause.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree not to sell any shares of Common Stock that are issued to you or your heirs prior to the six-month anniversary of the Date of Grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Warning</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">WARNING&#58; The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the grant. If you have any questions regarding the contents of this Agreement or the Plan, you should obtain independent professional advice. Neither the grant of the options nor the issuance of shares of Common Stock upon exercise constitutes a public offering of securities under Hong Kong law and is available only to eligible employees and other service providers of the </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Company, its Parent or Affiliates. This Agreement, the Plan and other incidental communication materials distributed in connection with the options (i) have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong and (ii), are intended only for the personal use of each eligible employee or other service provider of the Company, its Parent or Affiliates and may not be distributed to any other person.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are a director, shadow director or secretary of an Irish Affiliate and have a 1% or more shareholding interest in the Company, you must notify the Irish Affiliate in writing upon receiving or disposing of an interest in the Company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, options, shares of Common Stock) or upon becoming aware of the event giving rise to the notification requirement, or upon becoming a director, shadow director or secretary if such an interest exists at that time.  This notification requirement also applies with respect to the interests of a spouse or minor child (whose interests will be attributed to the director, shadow director or secretary).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ISRAEL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Israeli Sub-Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The options are also subject to the Sub-Plan for Israeli Participants (the &#34;Sub-Plan&#34;). The terms used herein shall have the meaning ascribed to them in the Plan and the Sub-Plan. In the event of any conflict, whether explicit or implied between the provisions of this Agreement and the Sub-Plan, the provisions set out in the Sub-Plan shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The options are intended to be subject to the Capital Gains Route under Section 102 of the Israeli Income Tax Ordinance &#91;New Version&#93; - 1961 (the &#8220;Ordinance&#8221; and the &#34;Capital Gains Route&#34;), subject to compliance with the requirements under Section 102 of the Ordinance and any rules or regulations thereunder, including the execution of this Agreement and the acknowledgments included below. However, in the event the options do not meet the requirements of Section 102 of the Ordinance, such options and the underlying Shares shall not qualify for the favorable tax treatment under the Capital Gains Route.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company makes no representations or guarantees that the options will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102 of the Ordinance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The options and the Shares issued upon exercise of such options and&#47;or any additional rights, including without limitation any right to receive any dividends or any shares received as a result of an adjustment made under the Plan, that may be granted in connection with the options (the &#8220;Additional Rights&#8221;) shall be issued to or controlled by the Trustee for the benefit of the Participant under the provisions of the Capital Gains Route for at least the period stated in Section 102 of the Ordinance and the Income Tax Rules (Tax Benefits in Share Issuance to Employees) 5763-2003 (the &#8220;Rules&#8221;). In accordance with the requirements of Section 102 of the Ordinance and the Capital Gains Route, the Participant shall not sell nor transfer from the Trustee the Shares or Additional Rights until the end of the required the period of time required under Section 102 of the Ordinance or any shorter period of time determined by the Israeli The Authority (the &#8220;Holding Period&#8221;). Notwithstanding the above, if any such sale or transfer occurs before the end of the required Holding Period, the sanctions under Section 102 of the Ordinance shall apply to and shall be borne by the Participant.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any fees associated with any exercise, sale, transfer or any act in relation to the options shall be borne by the Participant and the Trustee and&#47;or the Company and&#47;or any Subsidiary shall be entitled to withhold or deduct such fees from payments otherwise due to&#47;from the Company or an Subsidiary or the Trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any and all taxes due in relation to the options and the underlying Shares, including, but not limited to, the grant of the options and&#47;or the vesting, exercise, transfer, waiver, or expiration of options and&#47;or underlying Shares, and&#47;or the sale of underlying Shares, shall be borne solely by the Participant, and in the event of death, by the Participant's heirs. The Company, any Subsidiary, the Trustee or anyone on their behalf shall not be required to bear the aforementioned tax, directly or indirectly, nor shall they be required to gross up such tax in the Participant's salary or remuneration. The Company and&#47;or any Subsidiary and&#47;or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Participant hereby agree to indemnify the Company and&#47;or any Subsidiary and&#47;or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to him. The Company and&#47;or any Subsidiary and&#47;or the Trustee, to the extent permitted by law, shall have the right to deduct from any payment otherwise due to the Participant or from proceeds of the sale of the Shares an amount equal to any Taxes required by law to be withheld with respect to the Shares. The Participant will pay to the Company, any subsidiary or the Trustee any amount of taxes that the Company or any Subsidiary or the Trustee may be required to withhold with respect to the Shares that cannot be satisfied by the means previously described. The Company may refuse to deliver the Shares if the Participant fail to comply with his obligations in connection with the taxes as described in this section.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Covenants and Undertakings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Participant must sign a consent letter, which will be provided to the Participant separately, confirming that&#58; (i) The Participant is familiar with and understands the provisions of Section 102 of the Ordinance and any associated rules or regulations in general, and the tax arrangement under the Capital Gains Route in particular, and agrees to comply with such provisions, as amended from time to time&#59; (ii) The Participant agrees that the options and the Shares that may be issued in connection with the options will be held or controlled by a trustee for at least the duration of the Holding Period, as determined in Section 102 of the Ordinance under the Capital Gains Route&#59; (iii) The Participant agrees to the provisions of the trust deed signed between the Company and&#47;or the Subsidiary and the Trustee attached hereto&#59; (iv) The Participant acknowledges that releasing of the Shares from trust, or any sale of the Shares prior to the termination of the Holding Period constitutes a violation of the terms of Section 102 of the Ordinance and agree to bear the relevant sanctions&#59; (v) The Participant authorizes the Company and&#47;or his&#47;her employer to provide the Trustee with any information required for the purpose of administrating the grant of the options, including without limitation information about his&#47;her options, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the Trustee&#59; (vi) The Participant declares that he&#47;she is a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if he&#47;she ceases to be an Israeli resident or if his&#47;her engagement with the Company or any Subsidiary is terminated, the options and underlying Shares shall remain subject to Section 102 of the Ordinance, the trust agreement, the Plan and grant documents&#59; (vii) The Participant acknowledges, understands and agrees that the options are an extraordinary, one-time benefit granted to the Participant, and does not create any contractual or other right to receive a future grant of options.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Security Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company has obtained an exemption from the requirement to file a prospectus in Israel in respect to the offer securities of the Company under the Plan (including </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Israeli Sub-Plan). Copies of the Plan (including the Israeli Sub-Plan) and Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available, free of charge, upon request from the local human resources department.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Grant Notice, the Agreement or the Plan, due to legal restrictions in Italy, you will be required to exercise your option using a same-day sale or cashless sell-all exercise method pursuant to which all shares of Common Stock are sold immediately upon exercise and you receive the sale proceeds less the exercise price, Tax-Related Items and any applicable broker fees or commissions. You will not be entitled to hold any Shares of Common Stock acquired at exercise. The Company reserves the right to provide additional methods of exercise to you depending on the development of local law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Document Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the option, you acknowledge you have received a copy of the Plan, the Grant Notice and the Agreement (including this Appendix) and have reviewed the Plan and the Agreement (including this Appendix) in their entirety and fully accept all provisions thereof. You further acknowledge that you have read and expressly approve the Grant Notice and the following provisions of the Agreement&#58; Section&#160;1&#58; Vesting&#59; Section&#160;3&#58; Method of Payment&#59; Section&#160;5&#58; Securities Law Compliance&#59; Section&#160;6&#58; Term&#59; Section&#160;7&#58; Exercise&#59; Section&#160;8&#58; Transferability&#59; Section&#160;9&#58; Option Not a Service Contract&#59; Section&#160;10&#58; Withholding Obligations&#59; Section&#160;11&#58; Nature of Grant&#59; Section&#160;12&#58; No Advice Regarding Option Grant&#59; Section 13&#58; Data Privacy&#59; Section&#160;14&#58; Governing Law&#47;Venue&#59; Section&#160;15&#58; Electronic Delivery and Participation&#59; Section&#160;25&#58; Amendment, Suspension and Termination&#59; and Section&#160;30&#58; Imposition of Other Requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foreign Asset Tax Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The value of financial assets held outside of Italy (including shares of Common Stock acquired under the Plan) by Italian residents is subject to a foreign asset tax. The taxable amount will be the fair market value of the financial assets assessed at the end of the calendar year.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Entitlement for Claims or Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following section&#160;supplements Section&#160;11 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting your option, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The option grant the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, with registered offices at 1020 Kifer Road, Sunnyvale, CA 94086, is solely responsible for the administration of the Plan, and participation in the Plan and the grant of your option do not, in any way, establish an employment relationship between you and the Company since you participating in the Plan on a wholly commercial basis and the sole employer is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intuitive Surgical, S. De R.L. De C.V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, nor does it establish any rights between you and the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting your option, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety, and fully understand and accept all provisions of the Plan and the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in Section&#160;11 of the Agreement, in which the following is clearly described and established&#58; (i) participation in the Plan does not constitute an acquired right&#59; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis&#59; (iii) participation in the Plan is voluntary&#59; and (iv) the Company, any Affiliate of the Company and the Employer are not responsible for any decrease in the value of the shares of Common Stock acquired upon exercise of your option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and Affiliates of the Company with respect to any claim that may arise under the Plan or the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Spanish Translation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">T&#201;RMINOS Y CONDICIONES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Sin Derecho a Reclamaciones o Contraprestaci&#243;n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  La siguiente secci&#243;n suplementa la Secci&#243;n 11 del Contrato de Opci&#243;n de Acciones&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Modificaci&#243;n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  La aceptaci&#243;n de esta opci&#243;n significa que usted entiende y conviene que cualquier modificaci&#243;n al Plan o al Contrato de Opci&#243;n de Acciones o la terminaci&#243;n de cualquiera de estos no constituye un cambio o detrimento de los t&#233;rminos y condiciones de su trabajo.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Declaraci&#243;n de Directrices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  El otorgamiento de la opci&#243;n por la Compa&#241;&#237;a de conformidad con el Plan es unilateral y discrecional y, por lo tanto, la Compa&#241;&#237;a se reserva el derecho absoluto de modificarlo y discontinuarlo en cualquier momento sin responsabilidad alguna.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">La Compa&#241;&#237;a, con oficinas registradas en 1020 Kifer Road, Sunnyvale, CA 94086, es &#250;nicamente responsable por la administraci&#243;n del Plan, y la participaci&#243;n en el Plan por usted y el otorgamiento de la opci&#243;n a usted no establece, en forma alguna, un relaci&#243;n de trabajo entre usted y la Compa&#241;&#237;a, ya que usted participa en el Plan sobre bases exclusivamente comerciales y el &#250;nico patr&#243;n de usted es </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Intuitive Surgical, S. De R.L. De C.V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, y el Plan tampoco establece derecho alguno entre usted y su Patr&#243;n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Reconocimiento del Documento del Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.  La aceptaci&#243;n de su opci&#243;n significa que usted reconoce haber recibido copias del Plan, haber revisado el Plan y el Contrato de Opci&#243;n de </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Acciones en su totalidad y que usted entiende y acepta todas las disposiciones del Plan y el Contrato de Opci&#243;n de Acciones.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adicionalmente, usted reconoce asimismo que ha le&#237;do y acepta espec&#237;fica y expresamente los t&#233;rminos y condiciones de la Secci&#243;n 11 del Contrato de Opci&#243;n de Acciones en la que claramente se describe y establece lo siguiente&#58; (i) la participaci&#243;n en el Plan no constituye un derecho adquirido&#59; (ii) el Plan y la participaci&#243;n en el Plan se ofrece por la Compa&#241;&#237;a de manera totalmente discrecional&#59; (iii) la participaci&#243;n en el Plan es voluntaria&#59; y (iv) la Compa&#241;&#237;a, cualquier Afiliada de la Compa&#241;&#237;a y el Patr&#243;n no son responsables por la disminuci&#243;n del valor de las Acciones Comunes adquiridas al momento de ejercer su opci&#243;n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Finalmente, en este acto usted declara que no se reserva acci&#243;n o derecho alguno de presentar cualquier reclamaci&#243;n en contra de la Compa&#241;&#237;a por cualquier contraprestaci&#243;n o da&#241;o como resultado de su participaci&#243;n en el Plan y, por lo tanto, otorga un finiquito amplio y bastante al Patr&#243;n, la Compa&#241;&#237;a y las Afiliadas de la Compa&#241;&#237;a en relaci&#243;n con cualquier reclamaci&#243;n que pueda surgir de conformidad con el Plan o el Contrato de Opci&#243;n de Acciones.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that any shares of Common Stock acquired under the Plan will not be offered for sale in Singapore prior to the six-month anniversary of the Date of Grant, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;SFA&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of the option under the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements and is not made with a view to the underlying shares of Common Stock being subsequently offered for sale to any other party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are a director (including an alternate, substitute or shadow director) of a Singapore Affiliate, you must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, options, shares of Common Stock, etc.) in the Company or any Affiliate within two business days of (i) acquiring or disposing of such interest, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, sale of shares of Common Stock), or (iii) becoming a director.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section&#160;11 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the option, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan. You understand that the Company has unilaterally, gratuitously and discretionally decided to grant options under the Plan to individuals who may be employees of the Company or of a Parent or Affiliate throughout the world. This decision is a limited decision that is entered into upon the express assumption and condition that any grant will not bind the Company or any Parent or Affiliate other than as expressly set forth in the Agreement. Consequently, you understand that the options are granted on the assumption and condition that the options and any shares of Common Stock acquired under the Plan are not part of any employment or service contract (either with the Company or with any Parent or Affiliate) and shall not be considered a mandatory benefit or salary for any purpose (including severance compensation) or any other right whatsoever.   Further, you understand and agree that, unless otherwise expressly provided for by the Company or set forth in the Plan or the Agreement, the option will be cancelled without entitlement to any shares of Common Stock underlying the option if you incur a Termination of Service for any reason, including, but not limited to&#58; resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> subject to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">despido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article 40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, or under Article 10.3 of Royal Decree 1382&#47;1985.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, you understand that this grant would not be made to you but for the assumptions and conditions referred to above&#59; thus, you acknowledge and freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the option shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The option grant described in the Agreement does not qualify under Spanish regulations as a security. No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the option. The Agreement has not been, nor will it be, registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and does not constitute a public offering or prospectus.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 10 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 10 of the Agreement, in accepting the option, you authorize the Company and&#47;or the Employer to sell or withhold shares of Common Stock otherwise deliverable to you upon exercise to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Agreement nor any materials relating to the options (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 13 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby acknowledge that you have read and understood the terms regarding the collection, processing and transfer of Data contained in Section 13 of the Agreement and by participating in the Plan, you agree to such terms.  In this regard, upon request of the Company or the Employer, you agree to provide an executed data privacy consent form to the Company or the Employer (or any other agreements or consents that may be required by the Company or the Employer) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such consent or agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The offer of participation in the Plan is available only for employees or service providers of the Company and any Parent or Affiliate.  The offer of participation in the Plan is not a public offer of securities by a Taiwanese company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding Obligations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following provision supplements Section&#160;10 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section 10 of the Agreement, you hereby agree that you are liable for any Tax-Related Items related to your participation in the Plan and hereby covenant to pay such Tax-Related Items, as and when requested by the Company or (if different) the Employer or by HM Revenue &#38; Customs (&#8220;HMRC&#8221;) (or any other tax authority or any other relevant authority).&#160; You also hereby agree to indemnify and keep indemnified the Company and (if different) the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), you understand that the foregoing provision will not apply. Instead, any Tax-Related Items not collected or paid may constitute a benefit to you on which additional income tax and National Insurance Contributions (&#8220;NICs&#8221;) may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Company and&#47;or the Employer (as appropriate) the amount of any employee NICs due on this additional benefit, which can be recovered by any means set out in the Agreement.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112077021.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>q422ex-1010xfy23rsuagreeme.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0104f89d38894f1e9740ac0a0d6f0e69_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC. 2010 INCENTIVE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intuitive Surgical, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to its Amended and Restated 2010 Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants to the holder listed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the number of Restricted Stock Units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth below.  The RSUs are subject to the terms and conditions set forth in this Global Restricted Stock Unit Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Global Restricted Stock Unit Agreement (including any additional terms and conditions for Participant&#8217;s country included in the appendix attached thereto) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Plan, which are incorporated herein by reference.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in the Grant Notice and the Agreement.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Number&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Number of RSUs&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Type of Shares Issuable&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Common Stock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs shall vest as shown in the Vest Schedule on the corporate broker&#8217;s website, subject to the Participant&#8217;s continued service with the Company through each applicable vesting date.</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By Participant&#8217;s signature below, or by indicating acceptance of this award through the Company&#8217;s online acceptance procedure (including online acceptance through a third-party website authorized by the Company), Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and the Grant Notice.  Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing or accepting the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, the Grant Notice or the Agreement. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:33pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARTICIPANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">via Online Electronic Acceptance</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt;text-indent:0.36pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant the number of RSUs set forth in the Grant Notice (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6.7pt"><br>GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan or the Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The RSUs and the shares of Common Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) issued to Participant hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are subject to the terms and conditions set forth in this Agreement (including any additional terms and conditions for Participant&#8217;s country set forth in the appendix attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.04pt"><br>AWARD OF RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Award of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective as of the grant date set forth in the Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company has granted to Participant the number of RSUs set forth in the Grant Notice, upon the terms and conditions set forth in the Grant Notice, the Plan and this Agreement, subject to adjustment as provided in Section 13.2 of the Plan.  Each RSU represents the right to receive one Share or, at the option of the Company, an amount of cash as set forth in Section 2.3(b), in either case, at the times and subject to the conditions set forth herein.  However, unless and until the RSUs have vested, Participant will have no right to the payment of any Shares subject thereto.  Prior to the actual delivery of any Shares, the RSUs will represent an unsecured obligation of the Company, payable only from the general assets of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Vesting of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Subject to Participant&#8217;s continued employment with or service to the Company or an Affiliate on each applicable vesting date and subject to the terms of this Agreement, the RSUs shall vest in such amounts and at such times as are set forth in the Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event Participant incurs a Termination of Service, except as may be otherwise provided by the Administrator or as set forth in a written agreement between Participant and the Company, Participant shall immediately forfeit any and all RSUs granted under this Agreement which have not vested or do not vest on or prior to the date on which such Termination of Service occurs, and Participant&#8217;s rights in any such RSUs which are not so vested shall lapse and expire.  For purposes of the RSUs, a Termination of Service will be deemed to have occurred as of the date Participant is no longer actively providing services to the Company or any Affiliate (regardless of the reason for such Termination of Service and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where Participant is employed or otherwise rendering services, or the terms of Participant&#8217;s employment or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">service agreement, if any).  Participant&#8217;s employment or service relationship will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Participant&#8217;s period of service will not be extended by any contractual notice period or period of &#8220;garden leave&#8221; or similar period mandated under applicable laws in the jurisdiction where Participant is employed or otherwise rendering services, or the terms of Participant&#8217;s employment or other service agreement, if any).  Notwithstanding the forgoing, the Administrator shall have exclusive discretion to determine when a Termination of Service has occurred for purposes of the RSUs (including when Participant is no longer considered to be providing services while on a leave of absence). In the event of Participant&#8217;s leave of absence, vesting of the RSUs shall be governed by the Company&#8217;s leave of absence policies, as may be amended from time to time, and in accordance with applicable laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding 2.2(a) hereof and the Grant Notice, but subject to 2.2(b) hereof, vesting of the RSUs is also subject to acceleration under certain circumstances following a Change of Control (as defined in the Intuitive Surgical, Inc. Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), in accordance with the terms of the Severance Plan, as may be amended from time to time.  The Severance Plan can be found on the Company&#8217;s Infoweb. The terms of the Severance Plan include that the Board has the discretionary authority to amend or terminate the Severance Plan in any respect by resolution adopted by a two-thirds or greater majority of the Board, unless a Change of Control has previously occurred.  Any changes to the terms of the Severance Plan properly approved by the Board shall be binding on the RSUs being granted in the Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Distribution or Payment of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Unless otherwise indicated in this Agreement, Participant&#8217;s RSUs shall be distributed in Shares (either in book-entry form or otherwise) or, at the option of the Company, paid in an amount of cash as set forth in Section 2.3(b), in either case, as soon as administratively practicable following the vesting of the applicable RSU pursuant to Section&#160;2.2, and, in any event, within sixty (60) days following such vesting.  Notwithstanding the foregoing, the Company may delay a distribution or payment in settlement of RSUs if it reasonably determines that such payment or distribution will violate securities laws or any other applicable law, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that such distribution or payment shall be made at the earliest date at which the Company reasonably determines that the making of such distribution or payment will not cause such violation, as required by Treasury Regulation Section 1.409A-2(b)(7)(ii), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no payment or distribution shall be delayed under this Section 2.3(a) if such delay will result in a violation of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that the Company elects to make payment of Participant&#8217;s RSUs in cash, the amount of cash payable with respect to each RSU shall be equal to the Fair Market Value of a Share on the trading day immediately preceding the applicable distribution or payment date set forth in Section&#160;2.3(a).  All distributions made in Shares shall be made by the Company only in the form of whole Shares.  The Company, may, in its sole discretion round any fractional shares up or down to the nearest whole Share or distribute the fractional Shares in cash in an amount equal to the value of such fractional share determined based on the Fair Market Value as of the trading day immediately preceding the date of such distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Restrictions on Issuance &#47; Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision in the Plan or this Agreement, unless there is an available exemption from registration, qualification or other legal requirement applicable to the Shares, the Company shall not be required to issue any Shares to Participant prior to the completion of any registration or qualification of the Shares under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or of any other governmental body, or prior to obtaining any approval or other clearance from any U.S. or non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolutely discretion, deem </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">necessary or advisable. Participant understands that the Company is under no obligation to register or qualify the Shares with the SEC or any state or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares.  Further, Participant agrees that the Company shall have unilateral authority to amend this Agreement without Participant&#8217;s consent, to the extent necessary to comply with securities or other laws applicable to the issuance of Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Regardless of any action the Company and&#47;or the Affiliate employing or otherwise retaining Participant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the participation in the Plan and legally applicable to Participant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains Participant&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  Participant further acknowledges that neither the Company nor the Employer (i) make any representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including but not limited to, the grant, vesting or settlement of the RSUs, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends&#59; or (ii) commit to or are under any obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate Participant&#8217;s liability for Tax-Related Items or achieve any particular tax result.  Further, if Participant is subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Prior to any relevant taxable or tax withholding event, as applicable, Participant agrees to make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items.  In this regard, Participant authorizes the Company and&#47;or the Employer, or their respective agents at their discretion to satisfy their withholding obligations with regard to all Tax-Related Items by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">by requiring payment by cash or check made payable to the Company and&#47;or the Affiliate(s) with respect to which the withholding obligation arises&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">by the deduction of such amount from salary, wages or other compensation payable to Participant&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">with respect to any Tax-Related Items arising in connection with the vesting and settlement of the RSUs, by withholding a net number of vested shares of Stock otherwise issuable pursuant to the RSUs to satisfy the Tax-Related Items&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">by withholding from proceeds of the sale of Shares acquired upon vesting&#47;settlement of the RSUs either through a voluntary sale or through a mandatory sale arranged by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(on Participant&#8217;s behalf pursuant to this authorization, without further consent)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">in any combination of the foregoing, or any other method determined by the Administrator to be in compliance with applicable laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding rates or other withholding rates, including maximum withholding rates in Participant&#8217;s jurisdiction(s), in which case Participant may receive a refund of any over-withheld amount in cash and will have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no entitlement to the Share equivalent.  If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, Participant is deemed to have been issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of the Shares is held back solely for the purpose of paying Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Participant agrees to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Participant&#8217;s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue and&#47;or deliver Shares or proceeds from the sale of Shares, if Participant fails to comply with his or her obligations in connection with the Tax-Related Items. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event any tax withholding obligation arising in connection with the RSUs will be satisfied under Section&#160;2.5(b)(iv), then the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on Participant&#8217;s behalf (either through a voluntary sale or mandatory sale, without further consent) a whole number of Shares from the vested Shares then issuable to Participant pursuant to the RSUs as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the tax withholding obligation for Tax-Related Items and to remit the proceeds of such sale to the Company or the Affiliate with respect to which the withholding obligation arises.  Participant&#8217;s acceptance of this Award constitutes Participant&#8217;s instruction and authorization to the Company and such brokerage firm to complete the transactions described in this Section 2.5(e), including the transactions described in the previous sentence, as applicable.  The Company may refuse to issue any Shares in settlement of the RSUs to Participant until the foregoing tax withholding obligations are satisfied,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that no payment shall be delayed under this Section 2.5(e) if such delay will result in a violation of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accepting this Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the grant of the RSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">all decisions with respect to future RSUs or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the RSUs and the Shares subject to the RSUs, and the income from and value of same are not part of normal or expected compensation for purposes of, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar mandatory payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from Participant&#8217;s Termination of Service (for any reason whatsoever and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where Participant is employed or otherwise rendering services, or the terms of Participant&#8217;s employment or other service agreement, if any)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise agreed with the Company, the RSUs and the Shares acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of any Parent or Affiliate&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the RSUs and the benefits evidenced by this Agreement do not create any entitlement to have the RSUs or any such benefits transferred to, or assumed by another company, nor to be exchanged, cashed out or substituted for in connection with any corporate transaction affecting the Stock of the Company&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">neither the Company, the Employer nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to Participant pursuant to the settlement of the RSUs or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account).  Except as otherwise provided herein, after such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.38pt">                                                     &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                                    </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan, the Grant Notice and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules, in accordance with applicable laws.  All actions taken and all interpretations and determinations made by the Administrator will be final and binding upon Participant, the Company and all other interested persons.  To the extent allowable pursuant to applicable law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">RSUs Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The RSUs shall be subject to the restrictions on transferability set forth in Section 11.3 of the Plan, subject to the Intuitive Surgical, Inc. Equity Domestic Relations Order Policy, effective July 1, 2014, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent permitted under applicable laws, the Administrator may accelerate the vesting of all or a portion of the RSUs in such circumstances as it, in its sole discretion, may determine.  Participant acknowledges that the RSUs and the Shares subject to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan, including Section 13.2 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to Participant shall be addressed to Participant at Participant&#8217;s last address reflected on the Company&#8217;s records.  By a notice given pursuant to this Section 3.4, either party may hereafter designate a different address for notices to be given to that party.  Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service or any equivalent non-U.S. postal service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying Shares.  Participant should consult with his or her own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant would like to participate in the Plan, Participant will need to review the information provided in this Section 3.7 and, where applicable, declare consent to the processing and&#47;or transfer of personal data as described below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">EEA+ Controller and Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is based in the European Union, the European Economic Area or the United Kingdom (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA+</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Participant should note that the Company, with its registered address at 1020 Kifer Road, Sunnyvale, California 94086, United States of America, is the controller responsible for the processing of Participant&#8217;s personal data in connection with the Agreement and the Plan.  The Company is represented in the EEA+ by Intuitive Surgical SAS, Cit&#233; de la Photonique, b&#226;timent Gienah, 11 avenue de Canteranne, 33600 Pessac, France.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company collects, uses and otherwise processes certain personal data about Participant, including but not limited to, Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Stock or directorships held in the Company, details of all RSUs granted under the Plan or other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor, which the Company receives from Participant, the Employer or otherwise in connection with this Agreement or the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the legitimate purposes of implementing, administering and managing the Plan and allocating shares of Stock pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based in the EEA+, the legal basis, where required, for the processing of Data by the Company is the necessity of the Data processing for the Company&#8217;s performance of its obligations under the Plan, and where applicable, the Company&#8217;s legitimate interest of complying with contractual or other statutory obligations to which it is subject. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based outside of the EEA+, the Company&#8217;s legal basis for the processing of Data is Participant&#8217;s consent, as further described below. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company transfers Data to E*TRADE Financial Services, Inc. and certain of its affiliated companies (the &#8220;Designated Broker&#8221;), an independent service provider based in the United States, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Designated Broker may open an account for Participant to receive and trade Shares acquired under the Plan.  Participant may be asked to agree on separate terms and data processing practices with the Designated Broker, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company and the Designated Broker are based in the United States, which means that it will be necessary for Data to be transferred to, and processed in, the United States.  Participant should note that his or her country may have enacted data privacy laws that are different from the United States.  For example, Participant understands and acknowledges that the United States is not subject to an unlimited adequacy finding by the European Commission and that Participant&#8217;s Data may not have an equivalent level of protection as compared to Participant&#8217;s country of residence.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The onward transfer of Data from the Company to the Designated Broker or, as the case may be, a different service provider of the Company is based solely on Participant&#8217;s consent, as further described below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based outside of the EEA+, Data will be transferred from Participant&#8217;s jurisdiction to the Company and onward from the Company to any of its service providers based on Participant&#8217;s consent, as further described below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax, exchange control, securities and labor laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Participant may have a number of rights under data privacy laws in Participant&#8217;s jurisdiction. Depending on where Participant is based, such rights may include the right to (i) request access to or copies of Data the Company processes, (ii) rectify incorrect Data, (iii) delete Data, (iv) restrict the processing of Data, (v) object to the processing of Data for legitimate interests, (vi) restrict the portability of Data, and&#47;or (vii) lodge complaints with competent authorities in Participant&#8217;s jurisdiction. To receive additional information regarding these rights or to exercise these rights, Participant can contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Necessary Disclosure of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Participant understands that providing the Company with Data is necessary for the performance of the Agreement and that Participant&#8217;s refusal to provide Data would make it impossible for the Company to perform its contractual obligations and may affect Participant&#8217;s ability to participate in the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Participation in the Plan is voluntary and Participant is providing the consents herein on a voluntary basis.  Participant understands that he or she may request to stop the transfer and processing of the Data for purposes of participation in the Plan and that Participant&#8217;s compensation from or<br>employment relationship with the Employer will not be affected. The only consequence of refusing or withdrawing consent is that the Company would not be able to allow Participant to participate in the Plan. Participant understands that the Data will still be processed in relation to his or her employment or service relationship and for record-keeping purposes.  For more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information on the consequences of refusal to consent or withdrawal of consent, Participant should contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is based in the EEA+, by accepting the RSUs and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, Participant explicitly declares his or her consent to the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S. as described above.  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based outside of the EEA+, by accepting the RSUs and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, Participant explicitly declares his or her consent to the entirety of the Data processing operations described above including, without limitation, the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S.</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit to and consent the courts of Santa Clara County, California, or the federal courts for the United States for the Northern District of California, and no other courts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Conformity to Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all applicable laws, including, without limitation, the provisions of the U.S. Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the U.S. Securities and Exchange Commission, and any other laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to such applicable law. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Amendment, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">, provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in Section 3.2 and the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the RSUs, the Grant Notice and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Not a Contract of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or in the Plan shall create an employment or service relationship with, or confer upon Participant any right to continue to serve as an employee or other service provider of, the Company or any Affiliate, or shall interfere with or restrict in any way the rights of the Company and its Affiliates, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or an Affiliate and Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan, the Grant Notice and this Agreement (including the Appendix and any other exhibit&#160;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that this Award (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate for this Award either to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participant acknowledges that Participant is sufficiently proficient in English or has consulted with an advisor who is sufficiently proficient in English, so as to allow Participant to understand the terms and conditions of this Agreement.  If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion decide to deliver any documents related to current or future participation in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Agreement Severable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of the Grant Notice or this Agreement is held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the RSUs shall be subject to any additional terms and conditions for Participant&#8217;s country set forth in the Appendix attached hereto.  Moreover, if Participant relocates to one of the countries included in the Appendix, the additional terms and conditions for such country, if any, will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participant acknowledges that he or she may be subject to insider trading restrictions and&#47;or market abuse laws in applicable jurisdictions, including but not limited to the United States, Participant&#8217;s country, the broker&#8217;s country and the country or countries in which the Stock is listed, which may affect Participant&#8217;s ability, directly or indirectly, to purchase or sell, or attempt to sell or otherwise dispose of Shares, rights to Shares (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., RSUs), or rights linked to the value of Shares, during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in the applicable jurisdiction(s)).  Local insider trading laws and regulations prohibit the cancellation or amendment of orders Participant placed before possessing the inside information.  Furthermore, Participant understands that he or she may be prohibited from (i) disclosing the inside information to any third party, including fellow employees (other than on a &#8220;need to know&#8221; basis) and (ii) &#8220;tipping&#8221; third parties by sharing with them Company insider information, or otherwise causing third parties to buy or sell Company securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may apply to Participant under any applicable Company insider trading policy. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak to his or her personal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Foreign Asset&#47;Account Reporting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant resides in a country outside the United States, there may be certain foreign asset and&#47;or account reporting requirements which may affect Participant&#8217;s ability to acquire or hold Shares or cash received from participating in the Plan (including from any dividends paid on Shares) in a brokerage account or bank outside of Participant&#8217;s country. Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in Participant&#8217;s country.  Participant may also be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to Participant&#8217;s country within a certain time after receipt. It is Participant&#8217;s responsibility to comply with such regulations and Participant should speak to his or her personal legal advisor on this matter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All Awards will be subject to recoupment by the Company to the extent required to comply with applicable law or any policy of the Company providing for the reimbursement of incentive compensation, whether or not such policy is in place at the time of grant or payment of the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to applicable law, each of which shall be deemed an original and all of which together shall constitute one instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Deemed Acceptance of Agreement for Participants in the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event Participant works and&#47;or resides in the United States, unless Participant notifies the Company within ten (10) calendar days following receipt of the Grant Notice and this Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Participant declines the Award, Participant will be deemed to have accepted and agreed to the terms and conditions of the Grant Notice, this Agreement and the Plan.  Participant acknowledges receipt of a copy of the Plan and represents that Participant is familiar with the terms and provisions thereof, which are incorporated herein by reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or any other Participant.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">* * * * *</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC. 2010 INCENTIVE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOR PARTICIPANTS OUTSIDE OF THE UNITED STATES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Global Restricted Stock Unit Agreement (the &#8220;Agreement&#8221;) or the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern the Award granted to Participant under the Plan if Participant works and&#47;or resides in one of the countries listed below. This Appendix forms part of the Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is a citizen or resident of a country other than the one in which Participant is currently residing and&#47;or working, transfers employment and&#47;or residency to another country after the Grant Date, or is considered a resident of another country for local law purposes, the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to Participant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Appendix also includes information regarding exchange control and certain other issues which Participant should be award with respect to participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the respective countries as of November 2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Participant not rely on the information in this Appendix as the only source of information relating to the consequences of Participant&#8217;s participation in the Plan because the information may be out of date at the time Participant vests in the RSUs and acquires Shares or sells Shares acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the information is general in nature and may not apply to Participant&#8217;s particular situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant&#8217;s country may apply to his or her personal situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, if Participant is a citizen or resident of a country other than the one in which Participant is currently residing and&#47;or working, transfers employment and&#47;or residency to another country after the Grant Date, or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Participant in the same manner.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRALIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) ) (the &#8220;Act&#8221;) applies (subject to the conditions in the Act).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Control Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exchange control reporting is required for cash transactions exceeding A$10,000 and international fund transfers of any amount.  The Australian bank assisting with the transaction will file the report for Participant.  If there is no Australian bank involved with the transfer, Participant will have to file the report. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The grant of RSUs is being made under Division 1A, Part 7.12 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Corporations Act 2001 (Cth)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Participant offers Shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. Participant should obtain legal advice on applicable disclosure obligations prior to making any such offer.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUSTRIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BELGIUM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Exchange Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A stock exchange tax applies to transactions executed by a Belgian resident through a financial intermediary, such as a bank or broker. If the transaction is conducted through a Belgian financial intermediary, it may withhold the stock exchange tax, but if the transaction is conducted through a non-Belgian financial intermediary, the Belgian resident may need to report and pay the stock exchange tax directly. The stock exchange tax likely will apply when Shares acquired under the Plan are sold.  Belgian residents should consult with a personal tax or financial advisor for additional details on their obligations with respect to the stock exchange tax.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BULGARIA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 2.3 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in the Plan and the Agreement, the RSUs will not be settled in cash or a combination of cash and Shares.  The RSUs will be settled only in Shares. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision replaces Section 2.2(b) of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event Participant incurs a Termination of Service, except as may be otherwise provided by the Administrator or as set forth in a written agreement between Participant and the Company, Participant shall immediately forfeit any and all RSUs granted under this Agreement which have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not vested or do not vest on or prior to the date on which such Termination of Service occurs, and Participant&#8217;s rights in any such RSUs which are not so vested shall lapse and expire.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the RSUs, Participant&#8217;s Termination of Service will be deemed to occur as of the date that is the earlier of (i) the date of Participant&#8217;s termination, (ii) the date Participant receives notice of termination, or (iii) the date Participant is no longer actively providing services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., active service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under Canadian laws or the terms of Participant&#8217;s employment or service agreement, if any), regardless of the reason for such termination and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where Participant is employed or providing services or the terms of his or her employment or service agreement, if any&#59; unless otherwise expressly provided in this Agreement or determined by the Company, Participant&#8217;s right to vest in the RSUs under the Plan, if any, will terminate as of such date&#59; in the event that the date the Participant is no longer actively providing services cannot be reasonably determined under the terms of this Agreement and the Plan, the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of his or her RSUs (including whether Participant may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued vesting during a statutory notice period, Participant&#8217;s right to vest in the RSUs, if any, will terminate effective as of the last date of the minimum statutory notice period, but Participant will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of Participant&#8217;s statutory notice period, nor will Participant be entitled to any compensation for lost vesting. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">The following provisions apply to residents of Quebec&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A French translation of the Plan, Grant Notice and the Agreement will be made available to Participant as soon as reasonably practicable.  Participant understands that, from time to time, additional information related to the offering of the Plan might be provided in English and such information may not be immediately available in French.  However, upon request, the Company will translate into French documents related to the offering of the Plan as soon as reasonably practicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consentement &#224; la Langue Utilis&#233;e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. Une traduction fran&#231;aise du Plan, de l'Avis d'octroi et de la pr&#233;sente Entente sera mise &#224; la disposition de Participant d&#232;s que raisonnablement possible. Participant comprend que, de temps &#224; autre, des informations suppl&#233;mentaires li&#233;es &#224; l'offre du Plan peuvent &#234;tre fournies en anglais et que ces informations peuvent ne pas &#234;tre imm&#233;diatement disponibles en fran&#231;ais. Cependant, sur demande, Intuitive Surgical traduira en fran&#231;ais les documents relatifs &#224; l'offre du Plan d&#232;s que raisonnablement possible</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 3.7 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or non-professional, involved with the administration of the Plan.  Participant further authorizes the Company, the Employer, any Affiliate, E*TRADE Financial Services, Inc. and any other stock plan service provider as may be selected by the Company from time to time to assist with the Plan, to disclose and discuss the Plan with their advisors. Participant acknowledges and agrees that Participant&#8217;s personal information, including sensitive personal information, may be transferred or disclosed outside of the Province of Quebec, including to the United States.  Participant also authorizes the Company and the Employer to record such information and to keep such information in Participant&#8217;s employee file. Participant also acknowledges and authorizes the Company, its Affiliates and other parties involved in the administration of the Plan to use technology for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">profiling purposes and to make automated decisions that may have an impact on Participant or the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The sale of Shares acquired under the Plan may not take place in Canada.  This requirement will be satisfied where the Shares are sold by the designated broker under the Plan through the facilities of the U.S. stock exchange on which the Shares are currently listed (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Nasdaq Global Select Market).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CZECH REPUBLIC</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FINLAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">FRANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RSUs Not Tax-Qualified</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The RSUs granted under this Agreement are not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the RSUs, Participant confirms having read and understood the Plan and Agreement, including all terms and conditions included therein, which were provided in the English language.  Participant accepts the terms of those documents accordingly. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">En acceptant ces &#34;RSUs&#34;, le Participant confirme avoir lu et compris le Plan et Accord de, incluant tous leurs termes et conditions, qui ont &#233;t&#233; transmis en langue anglaise.  Le Participant accepte les dispositions de ces documents en connaissance de cause.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HONG KONG</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following provision supplements Section 2.3 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in the Plan and the Agreement, the RSUs will not be settled in cash or a combination of cash and Shares.  The RSUs will be settled only in Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant agrees not to sell any Shares that are issued to Participant or Participant&#8217;s heirs prior to the six-month anniversary of the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">WARNING&#58; The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Participant is advised to exercise caution in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">relation to the grant. If Participant has any questions regarding the contents of this Agreement or the Plan, Participant should obtain independent professional advice. Neither the grant of the RSUs nor the issuance of Shares upon vesting of the RSUs constitutes a public offering of securities under Hong Kong law and is available only to eligible employees and other service providers of the Company, its Parent or Affiliates. This Agreement, the Plan and other incidental communication materials distributed in connection with the RSUs (i) have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong and (ii), are intended only for the personal use of each eligible employee or other service provider of the Company, its Parent or Affiliates and may not be distributed to any other person.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IRELAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is a director, shadow director or secretary of an Irish Affiliate and has a 1% or more shareholding interest in the Company, he or she must notify the Irish Affiliate in writing upon receiving or disposing of an interest in the Company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, RSUs, Shares) or upon becoming aware of the event giving rise to the notification requirement, or upon becoming a director, shadow director or secretary if such an interest exists at that time.  This notification requirement also applies with respect to the interests of a spouse or minor child (whose interests will be attributed to the director, shadow director or secretary).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ISRAEL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Israeli Sub-Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The RSUs are also subject to the Sub-Plan for Israeli Participants (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sub-Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;). The terms used herein shall have the meaning ascribed to them in the Plan and the Sub-Plan. In the event of any conflict, whether explicit or implied between the provisions of this Agreement and the Sub-Plan, the provisions set out in the Sub-Plan shall prevail. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The RSUs are intended to be subject to the Capital Gains Route under Section 102 of the Israeli Income Tax Ordinance &#91;New Version&#93; - 1961 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ordinance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Gains Route</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;), subject to compliance with the requirements under Section 102 of the Ordinance and any rules or regulations thereunder, including the execution of this Agreement and the acknowledgments included below. However, in the event the RSUs do not meet the requirements of Section 102 of the Ordinance, such RSUs and the underlying Shares shall not qualify for the favorable tax treatment under the Capital Gains Route.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company makes no representations or guarantees that the RSUs will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102 of the Ordinance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The RSUs and the Shares issued upon settlement of such RSUs and&#47;or any additional rights, including without limitation any right to receive any dividends or any shares received as a result of an adjustment made under the Plan, that may be granted in connection with the RSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be issued to or controlled by the Trustee for the benefit of the Participant under the provisions of the Capital Gains Route for at least the period stated in Section 102 of the Ordinance and the Income Tax Rules (Tax Benefits in Share Issuance to Employees) 5763-2003 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). In accordance with the requirements of Section 102 of the Ordinance and the Capital Gains Route, the Participant shall not sell nor transfer from the Trustee the Shares or Additional Rights until the end of the required the period of time required under Section 102 of the Ordinance or any shorter period of time determined by the Israeli The Authority (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holding Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the above, if any such sale or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfer occurs before the end of the required Holding Period, the sanctions under Section 102 of the Ordinance shall apply to and shall be borne by the Participant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any fees associated with any vesting, sale, transfer or any act in relation to the RSUs shall be borne by the Participant and the Trustee and&#47;or the Company and&#47;or any Subsidiary shall be entitled to withhold or deduct such fees from payments otherwise due to&#47;from the Company or a Subsidiary or the Trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any and all taxes due in relation to the RSUs and the underlying Shares, including, but not limited to, the grant of the RSUs and&#47;or the vesting, transfer, waiver, or expiration of RSUs and&#47;or underlying Shares, and&#47;or the sale of underlying Shares, shall be borne solely by the Participant, and in the event of death, by the Participant&#8217;s heirs. The Company, any Subsidiary, the Trustee or anyone on their behalf shall not be required to bear the aforementioned tax, directly or indirectly, nor shall they be required to gross up such tax in the Participant&#8217;s salary or remuneration. The Company and&#47;or any Subsidiary and&#47;or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Participant hereby agree to indemnify the Company and&#47;or any Subsidiary and&#47;or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to him. The Company and&#47;or any Subsidiary and&#47;or the Trustee, to the extent permitted by law, shall have the right to deduct from any payment otherwise due to the Participant or from proceeds of the sale of the Shares an amount equal to any Taxes required by law to be withheld with respect to the Shares. The Participant will pay to the Company, any subsidiary or the Trustee any amount of taxes that the Company or any Subsidiary or the Trustee may be required to withhold with respect to the Shares that cannot be satisfied by the means previously described. The Company may refuse to deliver the Shares if the Participant fail to comply with his obligations in connection with the taxes as described in this section. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Covenants and Undertakings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Participant must sign a consent letter, which will be provided to the Participant separately, confirming that&#58; (i) The Participant is familiar with and understands the provisions of Section 102 of the Ordinance and any associated rules or regulations in general, and the tax arrangement under the Capital Gains Route in particular, and agrees to comply with such provisions, as amended from time to time&#59; (ii) The Participant agrees that the RSUs and the Shares that may be issued in connection with the RSUs will be held or controlled by a trustee for at least the duration of the Holding Period, as determined in Section 102 of the Ordinance under the Capital Gains Route</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant agrees to the provisions of the trust deed signed between the Company and&#47;or the Subsidiary and the Trustee attached hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">The Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledges that releasing of the Shares from trust, or any sale of the Shares prior to the termination of the Holding Period constitutes a violation of the terms of Section 102 of the Ordinance and agree to bear the relevant sanctions&#59; (v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Participant authorizes the Company and&#47;or his&#47;her employer to provide the Trustee with any information required for the purpose of administrating the grant of the RSUs, including without limitation information about his&#47;her RSUs, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the Trustee&#59; (vi) The Participant declares that he&#47;she is a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if he&#47;she ceases to be an Israeli resident or if his&#47;her engagement with the Company or any Subsidiary is terminated, the RSUs and underlying Shares shall remain subject to Section 102 of the Ordinance, the trust agreement, the Plan and grant documents&#59; (vii) The Participant acknowledges, understands and agrees that the RSUs are an extraordinary, one-time benefit granted to the Participant, and does not create any contractual or other right to receive a future grant of RSUs. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Security Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company has obtained an exemption from the requirement to file a prospectus in Israel in respect to the offer of the RSUs. Copies of the Plan and Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available, free of charge, upon request from the local human resources department.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ITALY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the RSUs, Participant acknowledges that he or she has received a copy of the Plan, the Grant Notice, the Agreement (including this Appendix) and has reviewed the Plan and the Agreement (including this Appendix) in their entirety and fully accepts all provisions thereof.  Participant further acknowledges that he or she has read and specifically and expressly approves the Grant Notice and the following provisions of the Agreement&#58;  (i) Section 2.1&#58; Award of RSUs&#59; (ii) Section 2.2&#58; Vesting of RSUs&#59; (iii) Section 2.3&#58; Distribution or Payment of RSUs&#59; (iv) Section 2.4&#58; Restrictions on Issuance &#47; Compliance with Law&#59; (v) Section 2.5&#58; Tax Withholding&#59; (vi) Section 2.6&#58; Nature of Grant&#59; (vii) Section 2.7&#58; Rights as Stockholder&#59; (viii) Section 3.2&#58; RSUs Not Transferable&#59; (ix) Section 3.7&#58; Data Privacy Information and Consent&#59; (x) Section 3.8&#58; Governing Law&#47;Venue&#59; (xi) Section 3.10&#58; Amendment, Suspension and Termination&#59; (xii) Section 3.17&#58; Electronic Delivery and Acceptance&#59; (xiii) Section 3.18&#58; Agreement Severable&#59; (xiv) Section 3.20&#58; Imposition of Other Requirements&#59; (xv) Section 3.21&#58; Insider Trading Restrictions&#47;Market Abuse Laws&#59; and (xvi) Section 3.26&#58; Waiver.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">JAPAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">KOREA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MEXICO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Entitlement for Claims or Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following section supplements Section 2.6 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the Award, Participant understands and agrees that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Policy Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Award the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company, with registered offices at 1020 Kifer Road, Sunnyvale, CA 94086, is solely responsible for the administration of the Plan, and participation in the Plan and the grant of the Award do not, in any way, establish an employment relationship between Participant and the Company since Participant is participating in the Plan on a wholly commercial basis and the sole employer is a Mexican or other Affiliate, nor does it establish any rights between Participant and the Employer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting the Award, Participant acknowledges that he or she has received copies of the Plan, has reviewed the Plan, Grant Notice and the Agreement in their entirety, and fully understand and accept all provisions of the Plan, Grant Notice and the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Participant further acknowledges that he or she has read and specifically and expressly approves the terms and conditions in Section 2.6 of the Agreement, in which the following is clearly described and established&#58; (i) participation in the Plan does not constitute an acquired right&#59; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis&#59; and (iii)&#160;participation in the Plan is voluntary. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Finally, Participant hereby declares that he or she does not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of his or her participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Affiliate with respect to any claim that may arise under the Plan or the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Spanish Translation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Ausencia de derechos de reclamaci&#243;n o compensaci&#243;n&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Estas especificaciones complementan la Secci&#243;n 2.6 del Contrato.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Moficaciones&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Al aceptar el Premio, el Participante reconoce y acepta que cualquier modificaci&#243;n al Plan o al Convenio o la terminaci&#243;n del mismo no significar&#225; una modifiaci&#243;n o detrimento en los t&#233;rminos y condiciones de su relaci&#243;n de trabajo.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Establecimiento de la Pol&#237;tica.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> El Premio que la Empresa est&#225; haciendo por medio del Plan es unilateral y discesional, por tal motivo, la Empresa se reserva el derecho de modificarlo o cancelarlo sin responsabilidad alguna hacia Usted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">La Empresa, con domicilio registrado en 1020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Kifer Road, Sunnyvale, Ca, 94086, es la &#250;nica responsable para la administraci&#243;n de Plan y que su participaci&#243;n en los Plan y adquisici&#243;n de acciones no constituye una relaci&#243;n de trabajo entre la Empresa y el Participante, toda vez que su participaci&#243;n en el Plan es totalmente en base a una relaci&#243;n comercial y que el patr&#243;n del Participante  es una sociedad Mexicana, afiliada o no a la Empresa. El Plan no establece derechos entre el Participante y su patr&#243;n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Reconicimiento de los T&#233;rminos y Condiciones. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Al aceptar el Premio, el Participante reconoce que ha recibido una copia del Plan, que ha revisado el Plan y la Notificaci&#243;n de la Entrega y el Convenio completos y reconoce y aepta todas y cada una de las condicioines del Plan, el Aviso de Entrega y el Convenio.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Aunado a lo anterior, el Participante reconoce que ha le&#237;do y espec&#237;ficamente aprueba los t&#233;rminos y condiciones descritas en el punto 2.6 del Convenio, el cual establece que (i) La participaci&#243;n en el Plan no constituye un derecho adquirido, (ii) El plan y la participaci&#243;n en dicho Plan son ofrecidos por la Empresa en forma totalmente discrecional&#59; y, que (iii) la participaci&#243;n es voluntaria.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Por &#250;ltimo, el Participante declara que no se reserva acci&#243;n legal ni derecho alguno qu&#233; hacer valer en contra de la Empresa por ninguna compensaci&#243;n o da&#241;o derivado de su participaci&#243;n en el Plan&#59; y por tal motivo en este acto otorga a favor de su patr&#243;n, la Empresa y cualquier empresa relacionada, el m&#225;s amplio finiquito que en derecho corresponda en virtud de cualquier reclamaci&#243;n que pudiera surgir con motivo del Plan o el Convenio.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NORWAY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No country-specific provisions apply.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SINGAPORE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participant hereby agrees that any Shares acquired under the Plan will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SFA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of RSUs under the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements and is not made with a view to the underlying Shares being subsequently offered for sale to any other party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director Notification Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is a director (including an alternate, substitute or shadow director) of a Singapore Affiliate, Participant must notify the Singapore Affiliate in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, RSUs, Shares, etc.) in the Company or any Affiliate within two business days of (i) acquiring or disposing of such interest, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, sale of Shares), or (iii) becoming a director.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SPAIN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 2.6 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting the RSUs, Participant consents to participation in the Plan and acknowledges that he or she has received a copy of the Plan. Participant understands that the Company has unilaterally, gratuitously and discretionally decided to grant RSUs under the Plan to individuals who may be employees of the Company or of a Parent or Affiliate throughout the world. This decision is a limited decision that is entered into upon the express assumption and condition that any grant will not bind the Company or any Parent or Affiliate other than as expressly set forth in the Agreement. Consequently, Participant understands that the RSUs are granted on the assumption and condition that the RSUs and any Shares acquired under the Plan are not part of any employment or service contract (either with the Company or with any Parent or Affiliate) and shall not be considered a mandatory benefit or salary for any purpose (including severance compensation) or any other right whatsoever.   Further, Participant understands and agrees that, unless otherwise expressly provided for by the Company or set forth in the Plan or the Agreement, the RSUs will be cancelled without entitlement to any Shares underlying the RSUs if Participant incurs a Termination of Service, for any reason, including, but not limited to&#58; resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> subject to a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">despido improcedente</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relocation under Article 40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, or under Article 10.3 of Royal Decree 1382&#47;1985.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, Participant understands that this grant would not be made to Participant but for the assumptions and conditions referred to above&#59; thus, Participant acknowledges and freely accepts that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the RSUs shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The grant of RSUs described in the Agreement does not qualify under Spanish regulations as a security. No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the RSUs. The Agreement has not been, nor will it be, registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and does not constitute a public offering or prospectus.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 2.5 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 2.5 of the Agreement, in accepting the RSUs, Participant authorizes the Company and&#47;or the Employer to sell or withhold Shares otherwise deliverable to Participant upon vesting to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Agreement nor any materials relating to the RSUs (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FinSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TAIWAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 3.7 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant hereby acknowledges that Participant has read and understood the terms regarding the collection, processing and transfer of Data contained in Section 3.7 of the Agreement and by participating in the Plan, Participant agrees to such terms.  In this regard, upon request of the Company or the Employer, Participant agrees to provide an executed data privacy consent form to the Company or the Employer (or any other agreements or consents that may be required by the Company or the Employer) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in Participant&#8217;s country, either now or in the future.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant understands that Participant will not be able to participate in the Plan if Participant fails to execute any such consent or agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The offer of participation in the Plan is available only for employees or service providers of the Company and any Parent or Affiliate.  The offer of participation in the Plan is not a public offer of securities by a Taiwanese company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This provision supplements Section 2.5 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limitation to Section 2.5 of the Agreement, Participant hereby agrees that he or she is liable for any Tax-Related Items related to his or her participation in the Plan and hereby covenants to pay such Tax-Related Items, as and when requested by the Company or (if different) the Employer or by HM Revenue &#38; Customs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HMRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any other tax authority or any other relevant authority).&#160; Participant also hereby agrees to indemnify and keep indemnified the Company and (if different) the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Participant&#8217;s behalf.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Participant understands that the foregoing provision will not apply. Instead, any Tax-Related Items not collected or paid may constitute a benefit to Participant on which additional income tax and National Insurance Contributions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NICs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may be payable. Participant understands that he or she will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and&#47;or the Employer (as appropriate) the amount of any employee NICs due on this additional benefit, which can be recovered by any means set out in the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US-DOCS&#92;112028384.3&#160;&#160;&#160;&#160;   029884-0030</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>q422ex-1011xfy23psuagreeme.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2a95439f697b464ea53656aa261e0cf7_1"></div><div style="min-height:64.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC. 2010 INCENTIVE AWARD PLAN </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERFORMANCE STOCK UNIT AWARD GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intuitive Surgical, Inc., a Delaware corporation, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to its Amended and Restated 2010 Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants to the holder listed below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an award of performance stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each vested Performance Stock Unit represents the right to receive, in accordance with the Performance Stock Unit Award Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a number of shares of Common Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) based on the Company&#8217;s achievement of certain performance goals over the applicable performance period.  This award of Performance Stock Units is subject to all of the terms and conditions set forth herein and in the Agreement and the Plan, each of which are incorporated herein by reference.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Performance Stock Unit Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Agreement.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Number&#58;</font></div></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Participant&#58;</font></div></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Number of PSUs&#58;</font></div></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Achievement Factor %&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The PSUs shall have the Maximum Achievement Factor % as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The PSUs shall vest as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination of PSUs&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as set forth in the Agreement, if the Participant experiences a Termination of Service, all PSUs that have not become vested on or prior to the date of such Termination of Service will thereupon be automatically forfeited by the Participant without payment of any consideration therefor.  In addition, in the event that the TSR Achievement Factor and&#47;or the Procedures Achievement Factor (each, as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) as of the applicable Determination Date (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) is zero, the PSUs eligible to vest based on the applicable Achievement Factor (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) will thereupon be automatically forfeited by the Participant without payment of any consideration therefor.</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By accepting this Award electronically through the Plan service provider&#8217;s online grant acceptance policy, the Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and this Grant Notice.  The Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Agreement and the Plan.  The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.  In addition, by accepting this Award electronically through the Plan service provider&#8217;s online grant acceptance policy, the Participant also agrees that the Company, in its sole discretion, may satisfy any withholding obligations in accordance with Section 2.6(b) of the Agreement by (i) withholding shares of Common Stock otherwise issuable to the Participant upon vesting of the PSUs, (ii) instructing a broker on the Participant&#8217;s behalf to sell shares of Common Stock otherwise issuable to the Participant upon vesting of the PSUs and submit the proceeds of such sale to the Company, or (iii) using any other method permitted by Section 2.6(b) of the Agreement or the Plan.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10318731_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:14.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTUITIVE SURGICAL, INC.&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PARTICIPANT</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center;text-indent:0.36pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.12pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">via Online Electronic Acceptance</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i2a95439f697b464ea53656aa261e0cf7_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO PERFORMANCE STOCK UNIT AWARD GRANT NOTICE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PERFORMANCE STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Performance Stock Unit Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to which this Performance Stock Unit Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is attached, Intuitive Surgical, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has granted to the Participant the number of performance stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Grant Notice under the Company&#8217;s 2010 Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each Performance Stock Unit represents the right to receive a number of shares of Common Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) based on the Company&#8217;s achievement of certain performance goals.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6.7pt"><br>GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The PSUs are subject to the terms and conditions of the Plan, which are incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.04pt"><br>GRANT OF PERFORMANCE STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Grant of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to the Grant Notice and upon the terms and conditions set forth in the Plan and this Agreement, effective as of the Grant Date set forth in the Grant Notice, the Company hereby grants to the Participant an award of PSUs under the Plan in consideration of the Participant&#8217;s past and&#47;or continued employment with or service to the Company or any Subsidiaries and for other good and valuable consideration. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Unsecured Obligation to PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each PSU constitutes the right to receive a number of Shares upon vesting, as determined in accordance with Section 2.3 and 2.6 below.  Unless and until the PSUs have vested in the manner set forth in Article 2 hereof, the Participant will have no right to receive Common Stock under any such PSUs.  Prior to actual payment of any vested PSUs, such PSUs will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Vesting Schedule&#59; Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Subject to Section 2.5 hereof, the PSUs shall vest and become non-forfeitable with respect to the applicable portion thereof in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Grant Notice and this Section 2.3.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Section 2.3(a), if a Change in Control occurs and Participant has not experienced a Termination of Service prior to the date of the Change in Control, then a number of PSUs equal to the greater of (i) such number of PSUs as would vest based on the TSR Achievement Factor and each Procedures Achievement Factor as determined by the Administrator as of the Change in Control in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and (ii) the Target Number of PSUs (such greater number the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deemed Performance Vested Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be deemed performance vested upon the Change in Control, shall be assumed, substituted, replaced or continued by the surviving corporation or successor (or affiliate thereof) and shall vest on the third anniversary of the Grant Date as long as Participant does not experience a Termination of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Service prior to such anniversary.  Notwithstanding the foregoing, all such assumed, substituted, replaced or continued PSUs shall immediately vest if Participant experiences a Termination of Service within twelve months following the Change in Control due to termination by the Company without Cause or as a result of an Involuntary Termination (each as defined in the Intuitive Surgical, Inc. Severance Plan).  If a Change in Control occurs, Participant has not experienced a Termination of Service prior to the date of the Change in Control and the PSUs are not assumed, substituted, replaced or continued by the surviving corporation or successor (or affiliate thereof) in connection with the Change in Control, then a number of PSUs equal to the Deemed Performance Vested Units shall immediately fully vest upon the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consideration to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In consideration of the grant of the award of PSUs pursuant hereto, the Participant agrees to render faithful and efficient services to the Company or any Subsidiary.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Forfeiture, Termination and Cancellation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt">Subject to Section 2.3(b) and to subsections (b) and (c) below, upon Participant&#8217;s Termination of Service for any or no reason, all Performance Stock Units which have not vested prior to or in connection with such Termination of Service shall thereupon automatically be forfeited, terminated and cancelled as of the applicable date of the Termination of Service without payment of any consideration by the Company, and the Participant, or the Participant&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt">Upon Participant&#8217;s Termination of Service (i) by the Company without Cause after the first anniversary of the Vesting Schedule Commencement Date or (ii) due to Participant&#8217;s death, the following number of PSUs shall accelerate and become immediately vested&#58;  the number of PSUs equal to the product of (A) the Target Number of PSUs and (B) a fraction, the numerator of which is the number of days from the Vesting Schedule Commencement Date until the date of Termination of Service and the denominator of which is 1,096.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt">No portion of the PSUs which has not become vested as of the date on which the Participant incurs a Termination of Service, after giving effect to any acceleration of vesting in connection with such Termination of Service, shall thereafter become vested.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt">Notwithstanding anything herein to the contrary, in the event that the TSR Achievement Factor and&#47;or the Procedures Achievement Factor as of the applicable Determination Date is zero, the PSUs eligible to vest based on the applicable Achievement Factor will thereupon be automatically forfeited by the Participant without payment of any consideration therefor, and the Participant, or the Participant&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Settlement upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">As soon as administratively practicable following the vesting of any Performance Stock Units pursuant to Section 2.3 hereof, but in no event later than March 15 of the calendar year following the year in which the Vesting Date (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) occurs (for the avoidance of doubt, this deadline is intended to comply with the &#8220;short term deferral&#8221; exemption from Section 409A of the Code), the Company shall deliver to the Participant (or any transferee permitted under Section 3.2 hereof) a number of Shares equal to the number of vested PSUs as determined in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, in the event Shares cannot be issued pursuant to Section 11.4 of the Plan, the Shares shall be issued pursuant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the preceding sentence as soon as administratively practicable after the Administrator determines that Shares can again be issued in accordance with such Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">As set forth in Section 11.2 of the Plan, the Company shall have the authority and the right to deduct or withhold, or to require the Participant to remit to the Company, an amount sufficient to satisfy all applicable federal, state, local and foreign income and payroll taxes required by law to be withheld with respect to any taxable event arising in connection with the Performance Stock Units based on the minimum statutory withholding rates applicable to supplemental taxable income.  The Company shall not be obligated to deliver any Shares to the Participant or the Participant&#8217;s legal representative unless and until the Participant or the Participant&#8217;s legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes applicable to the taxable income of the Participant resulting from the grant or vesting of the Performance Stock Units or the issuance of Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Conditions to Delivery of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shares deliverable hereunder may be either previously authorized but unissued Shares, treasury Shares or issued Shares which have then been reacquired by the Company.  Such Shares shall be fully paid and nonassessable.  The Company shall not be required to issue Shares deliverable hereunder prior to fulfillment of the conditions set forth in Section 10.4 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The holder of the PSUs shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the PSUs and any Shares underlying the PSUs and deliverable hereunder unless and until such Shares shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 13.2 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.38pt"><br>OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon the Participant, the Company and all other interested persons.  No member of the Administrator or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the PSUs.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">PSUs Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The PSUs shall be subject to the restrictions on transferability set forth in Section 11.3 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tax Consultation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant represents that the Company has not provided the Participant with any tax advice in connection with the PSUs and that the Participant is not relying on the Company for any tax advice in connection with the PSUs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the limitation on the transferability of the PSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Adjustments Upon Specified Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that the PSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and Section 12.2 of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to the Participant shall be addressed to the Participant at the Participant&#8217;s last address reflected on the Company&#8217;s records.  By a notice given pursuant to this Section 3.6, either party may hereafter designate a different address for notices to be given to that party. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Participant&#8217;s Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Shares issuable hereunder have not been registered under the Securities Act or any applicable state laws on an effective registration statement at the time of such issuance, the Participant shall, if required by the Company, concurrently with such issuance, make such written representations as are deemed necessary or appropriate by the Company and&#47;or its counsel.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any other Applicable Law.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the PSUs are granted, only in such a manner as to conform to Applicable Law.  To the extent permitted by Applicable Law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Amendment, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the PSUs in any material way without the prior written consent of the Participant.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon the Participant and his or her heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, if the Participant is subject to Section 16 of the Exchange Act, then the Plan, the PSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by Applicable Law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Not a Contract of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries or interfere with or restrict in any way with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right of the Company or any of its Subsidiaries, which rights are hereby expressly reserved, to discharge or to terminate for any reason whatsoever, with or without cause, the services of the Participant&#8217;s at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that this Award (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate for this Award either to be exempt from the application of Section 409A or to comply with the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  The Participant shall have only the rights of a general unsecured creditor of the Company and its Subsidiaries with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to PSUs, as and when payable hereunder.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant would like to participate in the Plan, Participant will need to review the information provided in this Section 3.17 and, where applicable, declare consent to the processing and&#47;or transfer of personal data as described below. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt;text-decoration:underline">EEA+ Controller and Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is based in the European Union, the European Economic Area or the United Kingdom (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EEA+</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Participant should note that the Company, with its registered address at 1020 Kifer Road, Sunnyvale, California 94086, United States of America, is the controller responsible for the processing of Participant&#8217;s personal data in connection with the Agreement and the Plan.  The Company is represented in the EEA+ by Intuitive Surgical SAS, Cit&#233; de la Photonique, b&#226;timent Gienah, 11 avenue de Canteranne, 33600 Pessac, France.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company collects, uses and otherwise processes certain personal data about Participant, including but not limited to, Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Stock or directorships held in the Company, details of all PSUs granted under the Plan or other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor, which the Company receives from Participant, the Employer or otherwise in connection with this Agreement or the Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), for the legitimate purposes of implementing, administering and managing the Plan and allocating shares of Stock pursuant to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based in the EEA+, the legal basis, where required, for the processing of Data by the Company is the necessity of the Data processing for the Company&#8217;s performance of its obligations under the Plan, and where applicable, the Company&#8217;s legitimate interest of complying with contractual or other statutory obligations to which it is subject. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If Participant is based outside of the EEA+, the Company&#8217;s legal basis for the processing of Data is Participant&#8217;s consent, as further described below. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company transfers Data to E*TRADE Financial Services, Inc. and certain of its affiliated companies (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), an independent service provider based in the United States, which is assisting the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner.  The Designated Broker may open an account for Participant to receive and trade Shares acquired under the Plan.  Participant may be asked to agree on separate terms and data processing practices with the Designated Broker, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Company and the Designated Broker are based in the United States, which means that it will be necessary for Data to be transferred to, and processed in, the United States.  Participant should note that his or her country may have enacted data privacy laws that are different from the United States.  For example, Participant understands and acknowledges that the United States is not subject to an unlimited adequacy finding by the European Commission and that Participant&#8217;s Data may not have an equivalent level of protection as compared to Participant&#8217;s country of residence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The onward transfer of Data from the Company to the Designated Broker or, as the case may be, a different service provider of the Company is based solely on Participant&#8217;s consent, as further described below.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.7pt">If Participant is based outside of the EEA+, Data will be transferred from Participant&#8217;s jurisdiction to the Company and onward from the Company to any of its service providers based on Participant&#8217;s consent, as further described below. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax, exchange control, securities and labor laws.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Participant may have a number of rights under data privacy laws in Participant&#8217;s jurisdiction. Depending on where Participant is based, such rights may include the right to (i) request access to or copies of Data the Company processes, (ii) rectify incorrect Data, (iii) delete Data, (iv) restrict the processing of Data, (v) object to the processing of Data for legitimate interests, (vi) restrict the portability of Data, and&#47;or (vii) lodge complaints with competent authorities in Participant&#8217;s jurisdiction. To receive additional information regarding these rights or to exercise these rights, Participant can contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.02pt;text-decoration:underline">Necessary Disclosure of Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Participant understands that providing the Company with Data is necessary for the performance of the Agreement and that Participant&#8217;s refusal to provide Data would make it impossible for the Company to perform its contractual obligations and may affect Participant&#8217;s ability to participate in the Plan. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.69pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Participation in the Plan is voluntary and Participant is providing the consents herein on a voluntary basis.  Participant understands that he or she may request to stop the transfer and processing of the Data for purposes of participation in the Plan and that Participant&#8217;s compensation from or employment relationship with the Employer will not be affected. The only consequence of refusing or withdrawing consent is that the Company would not be able to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">allow Participant to participate in the Plan. Participant understands that the Data will still be processed in relation to his or her employment or service relationship and for record-keeping purposes.  For more information on the consequences of refusal to consent or withdrawal of consent, Participant should contact the Company&#8217;s global privacy officer at data.privacy&#64;intusurg.com.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Participant is based in the EEA+, by accepting the PSUs and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, Participant explicitly declares his or her consent to the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S. as described above.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Participant is based outside of the EEA+, by accepting the PSUs and indicating consent by signing the Grant Notice or through the Company&#8217;s online acceptance procedure, Participant explicitly declares his or her consent to the entirety of the Data processing operations described above including, without limitation, the onward transfer of Data by the Company to the Designated Broker or, as the case may be, a different service provider of the Company in the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All awards will be subject to recoupment by the Company to the extent required to comply with applicable law or any policy of the Company providing for the reimbursement of incentive compensation, whether or not such policy is in place at the time of grant or payment of the award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Foreign Asset&#47;Account Reporting Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Participant understands that the Participant&#8217;s country may have certain exchange control and&#47;or foreign asset&#47;account reporting requirements which may affect the Participant&#8217;s ability to hold Shares received from the PSUs in a brokerage or bank account outside of the Participant&#8217;s country. The Participant may be required to report such accounts, assets or transactions to the tax or other authorities in the Participant&#8217;s country. The Participant acknowledges that it is the Participant&#8217;s responsibility to comply with any applicable regulations, and the Participant should speak to the Participant&#8217;s personal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Additional Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Participant acknowledges that for employment law purposes outside the United States, the PSUs and the income from and value of same are not part of normal or expected compensation or salary for any purpose, including but not limited to for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement benefits or similar mandatory payments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-7</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>q422ex-211xsubsidiariesq4o.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i56126adc04cb48b0ac6d6fd9ce14d645_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTUITIVE SURGICAL, INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES (All 100% owned other than Intuitive Surgical-Fosun (HongKong) Co., Ltd. and Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd.)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Subsidiaries of the Registrant</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">State or Other Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Fluorescence Imaging LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Australia Proprietary Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Bulgaria EOOD</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Canada Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Deutschland GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical GK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical HK Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical India Private Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical International B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical International Finance LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Ireland Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Italia s.r.l.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Korea Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Israel Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Medical Device Science &#38; Technology (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Medical Device Taiwan Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Operations, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Optics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Osterreich GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Service Optics Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical S. de R. L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical S.A.S.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Sarl Taiwan Branch</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Spain, S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical SRL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical Turkey Medikal Cihaz Ticaret Limited Serketi</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical-Fosun (HongKong) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intuitive Ventures Fund I, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KindHeart, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orpheus Medical GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Subsidiaries of the Registrant</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">State or Other Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orpheus Medical Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orpheus Medical Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orpheus Medical USA Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, U.S.</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>q422ex-231xauditorconsentq.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i183914da056d4f04b5aa5fe15501b647_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (Nos. 333-266304, 333-258073, 333-240046, 333-232829, 333-221043, 333-211064, 333-203793, 333-189399, 333-184488, 333-180863, 333-175904, 333-173803, 333-166833, 333-164586, 333-159228, 333-152558, 333-143433, 333-135004, 333-127162, 333-116499, 333-99893, 333-65342, and 333-43558) of Intuitive Surgical, Inc. of our report dated February&#160;10, 2023, relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;10, 2023</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>q422ex-311xceocertofsoxsec.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia7565e75d60d432387d9b649c949ad5c_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Certification of Chief Executive Officer</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Gary S. Guthart, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Intuitive Surgical, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58;  February&#160;10, 2023 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.243%"><tr><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">ARY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"> S. G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">UTHART</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Gary S. Guthart, Ph.D.</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>q422ex-312xcfocertofsoxsec.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic10340f52d094fc1acdc102d97f516f8_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Certification of Chief Financial Officer</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Jamie E. Samath, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Intuitive Surgical, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58;  February&#160;10, 2023 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.243%"><tr><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47; JAMIE E. SAMATH</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Jamie E. Samath</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>q422ex-3212xceoandcfocerto.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1660788c025049bd865c1e8a82c9e5c3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Intuitive Surgical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ompany&#8221;) hereby certifies, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:44.57pt">the accompanying annual report on Form 10-K of the Company for the annual period ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:41.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February&#160;10, 2023</font></div><div style="margin-top:3pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.660%"><tr><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">ARY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"> S. G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">UTHART</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Gary S. Guthart, Ph.D.</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Intuitive Surgical, Inc. (the &#8220;Company&#8221;) hereby certifies, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:44.57pt">the accompanying annual report on Form 10-K of the Company for the annual period ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:41.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February&#160;10, 2023</font></div><div style="margin-top:3pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.660%"><tr><td style="width:1.0%"></td><td style="width:17.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:144%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47; JAMIE E. SAMATH</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Jamie E. Samath</font></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:144%">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>isrg-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:isrg="http://www.intuitivesurgical.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.intuitivesurgical.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="isrg-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="isrg-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="isrg-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="isrg-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.intuitivesurgical.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.intuitivesurgical.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.intuitivesurgical.com/role/DescriptionoftheBusiness">
        <link:definition>0000003 - Document - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>0000006 - Statement - Consolidated Statements Of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>0000007 - Statement - Consolidated Statements Of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>0000008 - Statement - Consolidated Statements Of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary Of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.intuitivesurgical.com/role/FinancialInstruments">
        <link:definition>0000011 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails">
        <link:definition>0000012 - Disclosure - Consolidated Financial Statement Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.intuitivesurgical.com/role/Revenue">
        <link:definition>0000013 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.intuitivesurgical.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.intuitivesurgical.com/role/IntangibleAssets">
        <link:definition>0000015 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.intuitivesurgical.com/role/CommitmentsAndContingencies">
        <link:definition>0000016 - Disclosure - Commitments And Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensation">
        <link:definition>0000018 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShare">
        <link:definition>0000020 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.intuitivesurgical.com/role/EmployeeBenefitPlans">
        <link:definition>0000021 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationAndQualifyingAccounts" roleURI="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts">
        <link:definition>0000022 - Disclosure - Valuation And Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Summary Of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0000024 - Disclosure - Summary Of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsTables">
        <link:definition>0000025 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsTables" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables">
        <link:definition>0000026 - Disclosure - Consolidated Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.intuitivesurgical.com/role/RevenueTables">
        <link:definition>0000027 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.intuitivesurgical.com/role/LeasesTables">
        <link:definition>0000028 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000029 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityTables">
        <link:definition>0000030 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesTables">
        <link:definition>0000032 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareTables">
        <link:definition>0000033 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000034 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails">
        <link:definition>0000035 - Disclosure - Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails">
        <link:definition>0000036 - Disclosure - Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails">
        <link:definition>0000037 - Disclosure - Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1">
        <link:definition>0000037 - Disclosure - Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails">
        <link:definition>0000038 - Disclosure - Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails">
        <link:definition>0000040 - Disclosure - Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEquityInvestmentActivityDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails">
        <link:definition>0000041 - Disclosure - Financial Instruments - Summary of Equity Investment Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails" roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails">
        <link:definition>0000044 - Disclosure - Consolidated Financial Statement Details - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsInventoryDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails">
        <link:definition>0000045 - Disclosure - Consolidated Financial Statement Details - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails">
        <link:definition>0000046 - Disclosure - Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails">
        <link:definition>0000047 - Disclosure - Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails">
        <link:definition>0000048 - Disclosure - Consolidated Financial Statement Details - Other Accrued Liabilities&#8212;Short Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails">
        <link:definition>0000049 - Disclosure - Consolidated Financial Statement Details - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails" roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails">
        <link:definition>0000050 - Disclosure - Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenueDisaggregatedbyTypesandGeographyDetails" roleURI="http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails">
        <link:definition>0000051 - Disclosure - Revenue - Revenue Disaggregated by Types and Geography (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails">
        <link:definition>0000052 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails_1" roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails_1">
        <link:definition>0000052 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofContractAssetsandLiabilitiesDetails" roleURI="http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails">
        <link:definition>0000053 - Disclosure - Revenue - Summary of Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSalestypeandOperatingLeaseRevenueDetails" roleURI="http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails">
        <link:definition>0000054 - Disclosure - Revenue - Sales-type and Operating Lease Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseReceivablesDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails">
        <link:definition>0000055 - Disclosure - Leases - Lease Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseReceivablesDetails_1" roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1">
        <link:definition>0000055 - Disclosure - Leases - Lease Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails">
        <link:definition>0000056 - Disclosure - Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>0000057 - Disclosure - Leases - Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails">
        <link:definition>0000058 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000059 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000061 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000061 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails" roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails">
        <link:definition>0000062 - Disclosure - Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>0000064 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
        <link:definition>0000065 - Disclosure - Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000066 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>0000067 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails">
        <link:definition>0000068 - Disclosure - Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails">
        <link:definition>0000069 - Disclosure - Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityOtherComprehensiveIncomeLossDetails" roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails">
        <link:definition>0000070 - Disclosure - Stockholders' Equity - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>0000071 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofRSUandPSUActivityDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails">
        <link:definition>0000072 - Disclosure - Share-Based Compensation - Summary of RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails">
        <link:definition>0000073 - Disclosure - Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails">
        <link:definition>0000074 - Disclosure - Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>0000075 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails" roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails">
        <link:definition>0000076 - Disclosure - Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails">
        <link:definition>0000077 - Disclosure - Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>0000078 - Disclosure - Income Taxes - Schedule Of Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000079 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails">
        <link:definition>0000080 - Disclosure - Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Schedule Of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails" roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails">
        <link:definition>0000082 - Disclosure - Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>0000083 - Disclosure - Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails">
        <link:definition>0000084 - Disclosure - Net Income Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>0000085 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationAndQualifyingAccountsDetails" roleURI="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails">
        <link:definition>0000086 - Disclosure - Valuation And Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="isrg_RangeFourMember" abstract="true" name="RangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_ConsolidatingReportingDomain" abstract="true" name="ConsolidatingReportingDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="isrg_ModerateCreditRatingMember" abstract="true" name="ModerateCreditRatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" abstract="false" name="SalesTypeLeaseNetInvestmentInLeaseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" abstract="false" name="ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_AggregateReductionInCommonStockDuringStockRepurchases" abstract="false" name="AggregateReductionInCommonStockDuringStockRepurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_PerformanceShareUnitsPSUsMember" abstract="true" name="PerformanceShareUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="isrg_NewHireOptionsMember" abstract="true" name="NewHireOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_TradeAccountsReceivableCurrent" abstract="false" name="TradeAccountsReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_OctoberAcceleratedShareRepurchaseProgramMember" abstract="true" name="OctoberAcceleratedShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_EnterpriseWideSoftwareMember" abstract="true" name="EnterpriseWideSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_MaximumPercentageOfPayrollDeductionUnderEspp" abstract="false" name="MaximumPercentageOfPayrollDeductionUnderEspp" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" abstract="false" name="MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_ScheduleofCommonStockRepurchasedTableTextBlock" abstract="false" name="ScheduleofCommonStockRepurchasedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="isrg_SalesTypeLeaseGrossInvestmentInLease" abstract="false" name="SalesTypeLeaseGrossInvestmentInLease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" abstract="false" name="ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="isrg_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="isrg_SalesReturnsAndAllowances" abstract="false" name="SalesReturnsAndAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" abstract="false" name="IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_RangeSixMember" abstract="true" name="RangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_AugustAcceleratedShareRepurchaseProgramMember" abstract="true" name="AugustAcceleratedShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ConsolidatingReportingAxis" abstract="true" name="ConsolidatingReportingAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" abstract="false" name="IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwentyTenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="isrg_AwardedtoAxis" abstract="true" name="AwardedtoAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="isrg_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" abstract="false" name="DepreciationandGainLossonDispositionofPropertyPlantEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_BroncusHoldingCorporationMember" abstract="true" name="BroncusHoldingCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_DomesticAndForeignMember" abstract="true" name="DomesticAndForeignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_InitialGrantOptionsMember" abstract="true" name="InitialGrantOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" abstract="false" name="AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_RangeSevenMember" abstract="true" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SystemsMember" abstract="true" name="SystemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AnnualGrantOptionsMember" abstract="true" name="AnnualGrantOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_CommonStockRepurchaseProgramMember" abstract="true" name="CommonStockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_UnbilledReceivablesAndOtherReceivablesCurrent" abstract="false" name="UnbilledReceivablesAndOtherReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_ComputerAndOfficeEquipment" abstract="false" name="ComputerAndOfficeEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_InstrumentsandAccessoriesMember" abstract="true" name="InstrumentsandAccessoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_VariableLeaseRevenueUsageBasedArrangementsMember" abstract="true" name="VariableLeaseRevenueUsageBasedArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" abstract="false" name="AmountChargedToRetainedEarningsDuringStockRepurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" abstract="false" name="MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_SystemSalesArrangementWarrantyPeriod" abstract="false" name="SystemSalesArrangementWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_IntangibleAndOtherAssetsNetMember" abstract="true" name="IntangibleAndOtherAssetsNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" abstract="false" name="EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_RangeNineMember" abstract="true" name="RangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_LowCreditRatingMember" abstract="true" name="LowCreditRatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_CostOfSalesProductMember" abstract="true" name="CostOfSalesProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AwardedtoDomain" abstract="true" name="AwardedtoDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" abstract="false" name="ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" abstract="false" name="EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_ServiceFeeCredit" abstract="false" name="ServiceFeeCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_FebruaryGrantMember" abstract="true" name="FebruaryGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ScheduleOfAvailableForSaleSecuritiesAxis" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" abstract="false" name="PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_IntangibleAndOtherAssets" abstract="false" name="IntangibleAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_StockRepurchaseProgramincreasedtoauthorizedamount" abstract="false" name="StockRepurchaseProgramincreasedtoauthorizedamount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_TotalRevenueMember" abstract="true" name="TotalRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AccountsReceivableExtendedPayment" abstract="false" name="AccountsReceivableExtendedPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_RangeEightMember" abstract="true" name="RangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_RangeFiveMember" abstract="true" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" abstract="false" name="LessorSalesTypeLeaseLeaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" abstract="false" name="OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="isrg_EquipmentAndFurnitureMember" abstract="true" name="EquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" abstract="false" name="DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_TwoThousandEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SellingGeneralAndAdministrativeMember" abstract="true" name="SellingGeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_CostOfSalesServiceMember" abstract="true" name="CostOfSalesServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_InitialRSUgrantsMember" abstract="true" name="InitialRSUgrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_RexMedicalLPMember" abstract="true" name="RexMedicalLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_PurchasedSoftwareMember" abstract="true" name="PurchasedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_OfferingPeriodEmployeeStockPurchasePlans" abstract="false" name="OfferingPeriodEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_AugustGrantMember" abstract="true" name="AugustGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_NonvestedStockOptionMember" abstract="true" name="NonvestedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" abstract="true" name="AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_HighCreditRatingMember" abstract="true" name="HighCreditRatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" abstract="false" name="CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_RangeTenMember" abstract="true" name="RangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" abstract="false" name="AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="isrg_StockOptionsGrantedInitialVestingPeriod" abstract="false" name="StockOptionsGrantedInitialVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" abstract="false" name="SalesTypeLeaseLeaseReceivableExtendedPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" abstract="false" name="CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" abstract="false" name="OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" abstract="true" name="TwoThousandNonEmployeeDirectorsStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" abstract="false" name="LongLivedAssetsMaintainedInTheUnitedStatesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" abstract="false" name="MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" abstract="true" name="ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="isrg_SalestypeLeaseDeferredSellingProfit" abstract="false" name="SalestypeLeaseDeferredSellingProfit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="isrg_DeferredPurchaseConsiderationPaymentsCurrent" abstract="false" name="DeferredPurchaseConsiderationPaymentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>isrg-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0342e8d7-46ef-45a7-9d35-db6656984a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_542f586b-1945-4f4a-bc44-a22b8b200e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0342e8d7-46ef-45a7-9d35-db6656984a50" xlink:to="loc_us-gaap_LiabilitiesCurrent_542f586b-1945-4f4a-bc44-a22b8b200e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_56e6e560-1be1-4750-a485-507410886413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0342e8d7-46ef-45a7-9d35-db6656984a50" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_56e6e560-1be1-4750-a485-507410886413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30215a8b-d9cf-4e9b-93fb-5b52e0119c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30215a8b-d9cf-4e9b-93fb-5b52e0119c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_13d93bc0-5d61-4b48-ac4f-4ad44e7b44cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_13d93bc0-5d61-4b48-ac4f-4ad44e7b44cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db0876d8-9de3-4257-ae7e-22a66817e82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db0876d8-9de3-4257-ae7e-22a66817e82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_76b13e5f-2c2e-491a-8cf6-d330da93bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:to="loc_us-gaap_InventoryNet_76b13e5f-2c2e-491a-8cf6-d330da93bcc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_985586c1-2e6a-4730-9f78-e0c865402f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_19ade6d1-8b26-4a62-96df-b0763f12a088" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_985586c1-2e6a-4730-9f78-e0c865402f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f9b53f7-36ee-4b95-9279-3177e88ebee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f25b256-1e43-4d38-8bc8-bab196f1fab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f9b53f7-36ee-4b95-9279-3177e88ebee8" xlink:to="loc_us-gaap_StockholdersEquity_0f25b256-1e43-4d38-8bc8-bab196f1fab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_733859ee-32ea-436d-b253-02cebc6a3a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f9b53f7-36ee-4b95-9279-3177e88ebee8" xlink:to="loc_us-gaap_MinorityInterest_733859ee-32ea-436d-b253-02cebc6a3a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85113f56-0531-4371-a976-e19fc3ceb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c65fbb12-a0c2-4d3a-805a-88aab6449c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_85113f56-0531-4371-a976-e19fc3ceb3ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_c65fbb12-a0c2-4d3a-805a-88aab6449c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17a0f71b-facc-4849-8efc-a8f291720f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_85113f56-0531-4371-a976-e19fc3ceb3ab" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17a0f71b-facc-4849-8efc-a8f291720f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_4f5a0638-0232-429a-9be8-02be2a6b96ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_85113f56-0531-4371-a976-e19fc3ceb3ab" xlink:to="loc_us-gaap_DeferredRevenueCurrent_4f5a0638-0232-429a-9be8-02be2a6b96ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a65a0b2c-1fe0-4461-9e19-c4751cbf908e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_85113f56-0531-4371-a976-e19fc3ceb3ab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a65a0b2c-1fe0-4461-9e19-c4751cbf908e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c3f476a8-58a3-479e-9ac4-dab4ca55280f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_us-gaap_AssetsCurrent_c3f476a8-58a3-479e-9ac4-dab4ca55280f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ee6151f-13f7-43ac-8172-824443a41235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0ee6151f-13f7-43ac-8172-824443a41235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a0668481-09be-4ce1-aa93-537b1d3f5a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a0668481-09be-4ce1-aa93-537b1d3f5a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b8e0b804-8938-4293-beba-764fa61e2ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b8e0b804-8938-4293-beba-764fa61e2ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssets_9819a67a-8ca9-4c0a-8707-0e554ef047f1" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_isrg_IntangibleAndOtherAssets_9819a67a-8ca9-4c0a-8707-0e554ef047f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_650c8907-bc98-4538-91ba-279da560514f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99ebc371-3f84-4e04-9763-7dca1e0cf283" xlink:to="loc_us-gaap_Goodwill_650c8907-bc98-4538-91ba-279da560514f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b039ef58-2a37-4559-b7b1-78e8b4ebf6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:to="loc_us-gaap_PreferredStockValue_b039ef58-2a37-4559-b7b1-78e8b4ebf6f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6ca57a6f-f84b-4705-af38-4ada6c29057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:to="loc_us-gaap_CommonStockValue_6ca57a6f-f84b-4705-af38-4ada6c29057b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49bffcfb-e1c6-40e6-a186-9b686681154e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49bffcfb-e1c6-40e6-a186-9b686681154e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50ce6bb8-0fb1-48bf-a2e7-df587fce18b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50ce6bb8-0fb1-48bf-a2e7-df587fce18b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_984791ce-9c33-4281-9aeb-45f5c48232ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e48e9870-e2c9-465c-8489-04b63ac294b9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_984791ce-9c33-4281-9aeb-45f5c48232ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8e6f0fc-25e4-4582-bbdf-e7086bdc9d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_681aea24-2ca3-4e3c-8029-9a15ebb7bee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8e6f0fc-25e4-4582-bbdf-e7086bdc9d7f" xlink:to="loc_us-gaap_Liabilities_681aea24-2ca3-4e3c-8029-9a15ebb7bee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dd5b691e-a622-4336-a62c-8c0458e785f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8e6f0fc-25e4-4582-bbdf-e7086bdc9d7f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dd5b691e-a622-4336-a62c-8c0458e785f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_207b5e77-d85f-4584-89ec-62c16badf825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8e6f0fc-25e4-4582-bbdf-e7086bdc9d7f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_207b5e77-d85f-4584-89ec-62c16badf825" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfIncome"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ca86c13-58b9-4e6e-b815-64d2e1254b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f33cd465-acd6-468c-932a-fd79735e4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ca86c13-58b9-4e6e-b815-64d2e1254b71" xlink:to="loc_us-gaap_GrossProfit_f33cd465-acd6-468c-932a-fd79735e4dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2b059dfb-1868-4812-9474-7b1344f74f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ca86c13-58b9-4e6e-b815-64d2e1254b71" xlink:to="loc_us-gaap_OperatingExpenses_2b059dfb-1868-4812-9474-7b1344f74f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f9f3d45d-0af7-4b99-851e-04aa1939bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b93776a5-420a-4812-bf69-21e2e552238b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f9f3d45d-0af7-4b99-851e-04aa1939bbdb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b93776a5-420a-4812-bf69-21e2e552238b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1482e827-ea68-4e55-bc3d-8ddab7a3107f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f9f3d45d-0af7-4b99-851e-04aa1939bbdb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1482e827-ea68-4e55-bc3d-8ddab7a3107f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_33f25707-505a-4efd-9bba-ea5eacf9c6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2320347b-1d32-4360-960c-50b0eb9c4510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_33f25707-505a-4efd-9bba-ea5eacf9c6aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2320347b-1d32-4360-960c-50b0eb9c4510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_db6b1832-fa57-434f-95c1-3291f0a55d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_33f25707-505a-4efd-9bba-ea5eacf9c6aa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_db6b1832-fa57-434f-95c1-3291f0a55d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1175f858-896d-4da9-83db-4eab85c0f36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_02e4c352-8a23-4ff8-b1d8-66a3d79ed58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1175f858-896d-4da9-83db-4eab85c0f36f" xlink:to="loc_us-gaap_OperatingIncomeLoss_02e4c352-8a23-4ff8-b1d8-66a3d79ed58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9bcc6aa3-312a-4e26-9f6b-600104cfec02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1175f858-896d-4da9-83db-4eab85c0f36f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9bcc6aa3-312a-4e26-9f6b-600104cfec02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2fb4c77b-7d7e-4a71-a780-4689fe5b1d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6fef61cf-fb78-47c9-a4f8-c1844f20ef7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_2fb4c77b-7d7e-4a71-a780-4689fe5b1d23" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6fef61cf-fb78-47c9-a4f8-c1844f20ef7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cf4ad668-c394-417f-8424-aa6c31bb587e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_2fb4c77b-7d7e-4a71-a780-4689fe5b1d23" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cf4ad668-c394-417f-8424-aa6c31bb587e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_596abc3e-cf5d-407c-91e6-0016e7e2c870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_99a697e1-d6be-4985-96d0-7fb8e6ed5942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_596abc3e-cf5d-407c-91e6-0016e7e2c870" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_99a697e1-d6be-4985-96d0-7fb8e6ed5942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d90198ab-4468-4131-8276-1d6861434758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_596abc3e-cf5d-407c-91e6-0016e7e2c870" xlink:to="loc_us-gaap_ProfitLoss_d90198ab-4468-4131-8276-1d6861434758" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8f760011-3fb9-4c10-a76b-2898165a7a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_208c3f98-cff2-4b78-b784-91ef11453cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8f760011-3fb9-4c10-a76b-2898165a7a97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_208c3f98-cff2-4b78-b784-91ef11453cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_3a1f6221-3f4c-46f6-bf93-eadf0abf2b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8f760011-3fb9-4c10-a76b-2898165a7a97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_3a1f6221-3f4c-46f6-bf93-eadf0abf2b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c62f0e9a-2119-449c-9644-422a3d14cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_59048c86-60d8-4738-9537-f2cf5f48cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c62f0e9a-2119-449c-9644-422a3d14cd2e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_59048c86-60d8-4738-9537-f2cf5f48cb14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_a688f766-312b-4f50-a285-1d9f5758ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c62f0e9a-2119-449c-9644-422a3d14cd2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_a688f766-312b-4f50-a285-1d9f5758ec5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b7a3d33c-af08-4b8a-aaa4-c25edaf6aff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91e1a356-ea8c-492c-8c2f-c7952123f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b7a3d33c-af08-4b8a-aaa4-c25edaf6aff5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91e1a356-ea8c-492c-8c2f-c7952123f8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_56c69611-e59f-4176-a927-330c594b249f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b7a3d33c-af08-4b8a-aaa4-c25edaf6aff5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_56c69611-e59f-4176-a927-330c594b249f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3389e47-c1a1-491a-aeec-a97ab3b2f244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f439367d-fd11-4427-9c42-e1ee1583063b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3389e47-c1a1-491a-aeec-a97ab3b2f244" xlink:to="loc_us-gaap_ProfitLoss_f439367d-fd11-4427-9c42-e1ee1583063b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ae70bc5b-a88f-4c1e-9f30-f257c8f4b980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3389e47-c1a1-491a-aeec-a97ab3b2f244" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ae70bc5b-a88f-4c1e-9f30-f257c8f4b980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fede286b-eca8-455f-8fda-2ef4c95db2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_36a727da-4d6d-470b-92c4-3e863ca02b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fede286b-eca8-455f-8fda-2ef4c95db2c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_36a727da-4d6d-470b-92c4-3e863ca02b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_93a0cdc1-fa0d-43ac-a537-866ff71bb386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fede286b-eca8-455f-8fda-2ef4c95db2c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_93a0cdc1-fa0d-43ac-a537-866ff71bb386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_919310b2-996e-4049-916b-288cd56fb7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9267e7b9-0c21-426f-a04c-3686b3e8d3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_919310b2-996e-4049-916b-288cd56fb7a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9267e7b9-0c21-426f-a04c-3686b3e8d3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18abf025-d2c6-445a-8992-5091abbf7425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_919310b2-996e-4049-916b-288cd56fb7a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_18abf025-d2c6-445a-8992-5091abbf7425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_941c2295-a2cf-45eb-9b38-9e2b3e383830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_919310b2-996e-4049-916b-288cd56fb7a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_941c2295-a2cf-45eb-9b38-9e2b3e383830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e0c0f27a-9ba6-4baf-a016-b7896ad2df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_919310b2-996e-4049-916b-288cd56fb7a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e0c0f27a-9ba6-4baf-a016-b7896ad2df8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfCashFlows"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602ef080-fbb2-4d46-913d-0a9bafdea9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e0975d9-a3a0-41f1-8575-ace8f42e682c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602ef080-fbb2-4d46-913d-0a9bafdea9cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e0975d9-a3a0-41f1-8575-ace8f42e682c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e56186e-2bc6-43ed-addb-af657693a856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602ef080-fbb2-4d46-913d-0a9bafdea9cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e56186e-2bc6-43ed-addb-af657693a856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c5c257c-aba0-4747-94ce-da7206d1efa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602ef080-fbb2-4d46-913d-0a9bafdea9cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c5c257c-aba0-4747-94ce-da7206d1efa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b65057d-f2c7-40f4-b912-1c58d7453ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602ef080-fbb2-4d46-913d-0a9bafdea9cd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b65057d-f2c7-40f4-b912-1c58d7453ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d5232c99-2df5-4d0a-909a-557e78863361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d5232c99-2df5-4d0a-909a-557e78863361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1234b5ab-1e5e-4d10-9f48-f5bfec96760b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1234b5ab-1e5e-4d10-9f48-f5bfec96760b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fe2e5012-84db-4bbe-bc17-5cf8469a325c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_fe2e5012-84db-4bbe-bc17-5cf8469a325c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_358083ae-8e5d-42d5-a55e-5dcd83a858a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_358083ae-8e5d-42d5-a55e-5dcd83a858a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1761762c-4403-40fd-8718-c55eac75b615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81c1b561-1b81-452a-8f40-44e3413df039" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1761762c-4403-40fd-8718-c55eac75b615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dfc7171-a634-49b1-8a2f-32c01a7fce40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_aa1ca5ea-cf3b-4ab4-978a-23caeb5652f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dfc7171-a634-49b1-8a2f-32c01a7fce40" xlink:to="loc_us-gaap_ProceedsFromStockPlans_aa1ca5ea-cf3b-4ab4-978a-23caeb5652f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6f2cdfff-aad8-4309-a068-8e5d17212132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dfc7171-a634-49b1-8a2f-32c01a7fce40" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6f2cdfff-aad8-4309-a068-8e5d17212132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7139c0bb-f8ff-4e48-b8b2-0c6d69661639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dfc7171-a634-49b1-8a2f-32c01a7fce40" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7139c0bb-f8ff-4e48-b8b2-0c6d69661639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f403d165-9395-423e-b804-f521ea5a7225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3dfc7171-a634-49b1-8a2f-32c01a7fce40" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f403d165-9395-423e-b804-f521ea5a7225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f96b29ef-04f9-4022-b551-b673138532a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_ProfitLoss_f96b29ef-04f9-4022-b551-b673138532a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_950cc48e-8529-4706-96bd-344c4bc18cc1" xlink:href="isrg-20221231.xsd#isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_950cc48e-8529-4706-96bd-344c4bc18cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_78bbaa65-2a74-4050-ad6d-20025a920e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_78bbaa65-2a74-4050-ad6d-20025a920e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_af14b172-91cc-4178-b905-eae63efe6a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_af14b172-91cc-4178-b905-eae63efe6a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b4615ad4-9476-44c9-b091-98da8c387324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b4615ad4-9476-44c9-b091-98da8c387324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_89980211-6aa1-4ea7-ab0a-a667f648fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_89980211-6aa1-4ea7-ab0a-a667f648fad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_57eee416-4da6-46ab-9c84-b98d78198485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_ShareBasedCompensation_57eee416-4da6-46ab-9c84-b98d78198485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_1d59fde2-e917-4f8f-902d-a4436d43d98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_1d59fde2-e917-4f8f-902d-a4436d43d98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ca28aab2-155a-427c-acbd-d4a07fe295de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ca28aab2-155a-427c-acbd-d4a07fe295de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4752da3d-18e4-46a9-a7f3-69eb0f2c37c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4752da3d-18e4-46a9-a7f3-69eb0f2c37c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be67a132-3348-4948-8402-00977133cc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be67a132-3348-4948-8402-00977133cc2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef8a3367-1639-4106-8594-95439442d246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef8a3367-1639-4106-8594-95439442d246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_524e20e8-80ea-4fb3-a2ff-39f3db079b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_524e20e8-80ea-4fb3-a2ff-39f3db079b8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_0635e6b6-9589-4f84-ae4b-adef50b85822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_0635e6b6-9589-4f84-ae4b-adef50b85822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_23118053-e633-4fe5-9fb8-731186f15d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3b77da3-4b5b-488d-86ab-5ccaa6b4a3f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_23118053-e633-4fe5-9fb8-731186f15d49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_01bac76e-578c-4024-b974-cdf6da228b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_01bac76e-578c-4024-b974-cdf6da228b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_f763b6cd-51cc-458a-bb23-72868300f1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_f763b6cd-51cc-458a-bb23-72868300f1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_282c4604-4205-4f68-8d98-a98ab662f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_282c4604-4205-4f68-8d98-a98ab662f3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_77baa4b7-117a-418a-9042-e7de8af2dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_77baa4b7-117a-418a-9042-e7de8af2dc22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_62abda33-36e9-40b9-b08b-e0bdb35bc5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_62abda33-36e9-40b9-b08b-e0bdb35bc5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_d1dc6f2e-ed2b-4213-8696-6a1e0b7e0ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a0e7a168-1da6-4a6f-b45f-91f6dd43c4a2" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_d1dc6f2e-ed2b-4213-8696-6a1e0b7e0ab7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_5e57bce6-00e7-4b1d-a6fe-1c1f86e17a00" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e5bdfea6-ace4-476d-a15a-7818affb2e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_5e57bce6-00e7-4b1d-a6fe-1c1f86e17a00" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e5bdfea6-ace4-476d-a15a-7818affb2e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38ede15d-082d-418d-96e4-be2b58aa7f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_5e57bce6-00e7-4b1d-a6fe-1c1f86e17a00" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38ede15d-082d-418d-96e4-be2b58aa7f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e490985b-9a30-4ecc-b4fa-3a39a7e39136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_5e57bce6-00e7-4b1d-a6fe-1c1f86e17a00" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e490985b-9a30-4ecc-b4fa-3a39a7e39136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_80340415-3715-4353-8730-86d5fc6fd971" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_5e57bce6-00e7-4b1d-a6fe-1c1f86e17a00" xlink:to="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_80340415-3715-4353-8730-86d5fc6fd971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_3786e2ce-0859-4a58-a78a-a4ff6b0a4cda" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_547283bd-0dce-4ded-b44e-e8ae331cec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_3786e2ce-0859-4a58-a78a-a4ff6b0a4cda" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_547283bd-0dce-4ded-b44e-e8ae331cec2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4a82562b-bfde-4fb9-9735-125fa40b60f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_3786e2ce-0859-4a58-a78a-a4ff6b0a4cda" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4a82562b-bfde-4fb9-9735-125fa40b60f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1fbd0c3-cdec-44e7-a867-5e1da7a041df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdfd8b0-bb14-47a3-b210-3c21c73f3792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1fbd0c3-cdec-44e7-a867-5e1da7a041df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdfd8b0-bb14-47a3-b210-3c21c73f3792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_31af836f-dc4b-463d-abcd-a96e383828a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1fbd0c3-cdec-44e7-a867-5e1da7a041df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_31af836f-dc4b-463d-abcd-a96e383828a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fbae3fef-e3a2-4b41-a87e-4b34dfdeec31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1fbd0c3-cdec-44e7-a867-5e1da7a041df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_fbae3fef-e3a2-4b41-a87e-4b34dfdeec31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_abb5606e-8b96-4bbb-895a-39424f735a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1fbd0c3-cdec-44e7-a867-5e1da7a041df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_abb5606e-8b96-4bbb-895a-39424f735a96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_127b151c-ed40-4457-9716-6c8535f03666" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4760980-7de4-4a73-9f34-02ce10986ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_127b151c-ed40-4457-9716-6c8535f03666" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4760980-7de4-4a73-9f34-02ce10986ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93189b22-8e8d-408d-a160-b1c7cacd9f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_127b151c-ed40-4457-9716-6c8535f03666" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93189b22-8e8d-408d-a160-b1c7cacd9f51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6315d5b2-9cb8-4c15-8758-dd404180d4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_568f9d91-99dc-4f8b-af27-8e9df1849e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6315d5b2-9cb8-4c15-8758-dd404180d4fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_568f9d91-99dc-4f8b-af27-8e9df1849e99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_175760fe-21ca-4824-b356-0f510b613486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6315d5b2-9cb8-4c15-8758-dd404180d4fc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_175760fe-21ca-4824-b356-0f510b613486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57a0d6fb-e7ab-46d8-b7d3-761b486703ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_552f11f6-8377-454b-9355-888dee4af354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57a0d6fb-e7ab-46d8-b7d3-761b486703ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_552f11f6-8377-454b-9355-888dee4af354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3091c3a0-d4c1-4e20-9b6e-fef78d7324ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_57a0d6fb-e7ab-46d8-b7d3-761b486703ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3091c3a0-d4c1-4e20-9b6e-fef78d7324ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52e9c6d3-fa1a-479e-8ec1-88063ddf9394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a25dd580-957b-47b9-8ff3-2bf900e9b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52e9c6d3-fa1a-479e-8ec1-88063ddf9394" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a25dd580-957b-47b9-8ff3-2bf900e9b86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_39fd387a-8b7d-433e-877e-eb280a4174c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52e9c6d3-fa1a-479e-8ec1-88063ddf9394" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_39fd387a-8b7d-433e-877e-eb280a4174c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_eedb1be5-7e92-4172-ad70-9b7a418e5b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c2720dbb-fb3c-48b4-8fbb-5f1e8f684a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_eedb1be5-7e92-4172-ad70-9b7a418e5b38" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c2720dbb-fb3c-48b4-8fbb-5f1e8f684a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a726a35e-e5fd-4aa4-b469-35628c43a593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_eedb1be5-7e92-4172-ad70-9b7a418e5b38" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a726a35e-e5fd-4aa4-b469-35628c43a593" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_038e3e83-6ddc-483c-8fdf-3b8bdec09b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TradeAccountsReceivableCurrent_76bc1ae7-db5d-4046-9437-88f70e354679" xlink:href="isrg-20221231.xsd#isrg_TradeAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_038e3e83-6ddc-483c-8fdf-3b8bdec09b57" xlink:to="loc_isrg_TradeAccountsReceivableCurrent_76bc1ae7-db5d-4046-9437-88f70e354679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_454c9e5a-1162-40a6-ab7c-973ac99ad50d" xlink:href="isrg-20221231.xsd#isrg_UnbilledReceivablesAndOtherReceivablesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_038e3e83-6ddc-483c-8fdf-3b8bdec09b57" xlink:to="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_454c9e5a-1162-40a6-ab7c-973ac99ad50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesReturnsAndAllowances_1fe6dc9a-882e-42e8-a19d-016331d39bfe" xlink:href="isrg-20221231.xsd#isrg_SalesReturnsAndAllowances"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_038e3e83-6ddc-483c-8fdf-3b8bdec09b57" xlink:to="loc_isrg_SalesReturnsAndAllowances_1fe6dc9a-882e-42e8-a19d-016331d39bfe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_796442be-d8b2-4d4d-af66-e9b591d617a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8171866b-d11e-45e2-a5fc-321b65e8814e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_796442be-d8b2-4d4d-af66-e9b591d617a8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8171866b-d11e-45e2-a5fc-321b65e8814e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d753078b-5131-41d1-9ad1-c6abce91dc63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_796442be-d8b2-4d4d-af66-e9b591d617a8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d753078b-5131-41d1-9ad1-c6abce91dc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d035824-bdfb-42ce-a124-d50142fb2fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_796442be-d8b2-4d4d-af66-e9b591d617a8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d035824-bdfb-42ce-a124-d50142fb2fe2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28e06350-03a2-4798-82ed-4729b255186f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_7d1ce9ac-dcc1-4636-a0c6-fdc34216d09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28e06350-03a2-4798-82ed-4729b255186f" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_7d1ce9ac-dcc1-4636-a0c6-fdc34216d09d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_92286bda-fdb2-4ab3-9294-bf3fab779525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28e06350-03a2-4798-82ed-4729b255186f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_92286bda-fdb2-4ab3-9294-bf3fab779525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_92f7ea6f-fdc6-4950-948b-45e85c325516" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28e06350-03a2-4798-82ed-4729b255186f" xlink:to="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_92f7ea6f-fdc6-4950-948b-45e85c325516" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_df316fac-1183-413c-aa42-3b8b2612d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_Land_df316fac-1183-413c-aa42-3b8b2612d494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_bbf60b88-c966-42f4-987f-ff874b911f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_bbf60b88-c966-42f4-987f-ff874b911f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_9d94bbd2-f849-4bbf-a4b7-cdc0d08da243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_9d94bbd2-f849-4bbf-a4b7-cdc0d08da243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_fed5313f-e0a0-4a06-986f-f4b9ef7ed535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_fed5313f-e0a0-4a06-986f-f4b9ef7ed535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ComputerAndOfficeEquipment_8c80c6e6-254b-4006-9e18-89e071604c9a" xlink:href="isrg-20221231.xsd#isrg_ComputerAndOfficeEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_isrg_ComputerAndOfficeEquipment_8c80c6e6-254b-4006-9e18-89e071604c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_2ac8dff4-3074-401b-b0e2-a064d8ae26df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_2ac8dff4-3074-401b-b0e2-a064d8ae26df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_773047de-34ab-4c45-8b37-2dbc87604ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_b1f8b2ad-c24e-4c2d-b28a-0341ad3ef6e2" xlink:to="loc_us-gaap_ConstructionInProgressGross_773047de-34ab-4c45-8b37-2dbc87604ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5244f6df-8e10-4f68-aee1-16c70b8ea576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d8dbbfb4-9dcf-4184-b267-1c0c68213311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5244f6df-8e10-4f68-aee1-16c70b8ea576" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d8dbbfb4-9dcf-4184-b267-1c0c68213311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0defe153-ca98-4f8e-89bc-b88d70ef922c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5244f6df-8e10-4f68-aee1-16c70b8ea576" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0defe153-ca98-4f8e-89bc-b88d70ef922c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e782f01b-58d7-4076-af6b-8b27add30eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e782f01b-58d7-4076-af6b-8b27add30eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_891a99b7-ab9a-4101-a8c5-022fb3e35850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_891a99b7-ab9a-4101-a8c5-022fb3e35850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_5b479660-eab9-449a-ade7-f6349e548168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:to="loc_us-gaap_LitigationReserveCurrent_5b479660-eab9-449a-ade7-f6349e548168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent_e23f1b3a-d5c6-45b5-8c80-30488adae792" xlink:href="isrg-20221231.xsd#isrg_DeferredPurchaseConsiderationPaymentsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:to="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent_e23f1b3a-d5c6-45b5-8c80-30488adae792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_3bc1f78b-4679-4d6b-804c-8fa31ad44970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4776818f-b3e4-437a-88fb-a5ab0bdda592" xlink:to="loc_us-gaap_TaxesPayableCurrent_3bc1f78b-4679-4d6b-804c-8fa31ad44970" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_1b5c912a-b1ad-4270-9d76-fe55fa1aac52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fd8ac165-2bf2-49a9-a8ea-862b825f144c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_1b5c912a-b1ad-4270-9d76-fe55fa1aac52" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_fd8ac165-2bf2-49a9-a8ea-862b825f144c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6c57e73c-0b0a-48f0-bae6-957cd60de59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_1b5c912a-b1ad-4270-9d76-fe55fa1aac52" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6c57e73c-0b0a-48f0-bae6-957cd60de59b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_cbdbb4e6-8222-4e28-bca1-59f59b95a951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_1b5c912a-b1ad-4270-9d76-fe55fa1aac52" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_cbdbb4e6-8222-4e28-bca1-59f59b95a951" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesLeaseReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a00b16b4-1bae-47ca-8bec-f79154f8af47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_79141a41-2592-4d1d-aeef-f4084303c146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a00b16b4-1bae-47ca-8bec-f79154f8af47" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_79141a41-2592-4d1d-aeef-f4084303c146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_02e4c2b2-c373-4ffb-8fa8-2c5ff9a4b595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_a00b16b4-1bae-47ca-8bec-f79154f8af47" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_02e4c2b2-c373-4ffb-8fa8-2c5ff9a4b595" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesLeaseReceivablesDetails_1"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_5444f3e8-03e7-475e-bdb5-b122091bedd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_a7607d73-cfdc-4c4a-978e-e138491f60c6" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseGrossInvestmentInLease"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_5444f3e8-03e7-475e-bdb5-b122091bedd2" xlink:to="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_a7607d73-cfdc-4c4a-978e-e138491f60c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalestypeLeaseDeferredSellingProfit_df5e0095-00b2-4cfc-b8f5-630b710b159b" xlink:href="isrg-20221231.xsd#isrg_SalestypeLeaseDeferredSellingProfit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_5444f3e8-03e7-475e-bdb5-b122091bedd2" xlink:to="loc_isrg_SalestypeLeaseDeferredSellingProfit_df5e0095-00b2-4cfc-b8f5-630b710b159b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_1346f717-f47b-4fda-a8c0-e4e8b0963d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_1346f717-f47b-4fda-a8c0-e4e8b0963d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_3b617e92-f1aa-45d2-852a-e057266e178f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_3b617e92-f1aa-45d2-852a-e057266e178f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_7ae5dc05-b116-4ece-a46e-c5e8b3b6efb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_7ae5dc05-b116-4ece-a46e-c5e8b3b6efb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_6bafa8c6-2847-49dc-ba69-3aa1ba6732a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_6bafa8c6-2847-49dc-ba69-3aa1ba6732a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_ac7e2d45-b4d8-4f57-a946-e8d2150f45b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_ac7e2d45-b4d8-4f57-a946-e8d2150f45b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_98265df7-b64a-4cc5-ac32-f11adb33b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_f082d04b-dfe3-4ad1-a4b4-e4a5e8fb4024" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_98265df7-b64a-4cc5-ac32-f11adb33b33e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_5a2572ec-5d6e-4952-bb94-9b683992ef06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_5a2572ec-5d6e-4952-bb94-9b683992ef06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_1002c08f-4607-42b5-820a-105f4998a641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_1002c08f-4607-42b5-820a-105f4998a641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4a6aafea-5bd6-4e89-addb-11944a038e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4a6aafea-5bd6-4e89-addb-11944a038e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f9d492c6-81bf-41e4-bfb7-60195c12a546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f9d492c6-81bf-41e4-bfb7-60195c12a546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_71d09f5f-cdbe-410c-ba94-2379aad353ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_71d09f5f-cdbe-410c-ba94-2379aad353ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_2ab1bb72-7655-4642-a57f-e59283b79d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7432ed7-5c85-4a4d-835b-27f231508327" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_2ab1bb72-7655-4642-a57f-e59283b79d64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_169fcd80-2643-4d01-8ec3-8fc5e28c95c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a2a1f8a-006c-4b5f-8504-6b8c1cd3bbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_169fcd80-2643-4d01-8ec3-8fc5e28c95c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a2a1f8a-006c-4b5f-8504-6b8c1cd3bbbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d59981f6-5a58-4550-b229-1421af2be085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_169fcd80-2643-4d01-8ec3-8fc5e28c95c5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d59981f6-5a58-4550-b229-1421af2be085" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4baa46c8-28d9-4979-a6e5-7e48b5019c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4baa46c8-28d9-4979-a6e5-7e48b5019c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93a9ba82-07c5-40ce-891e-4f211fe9c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93a9ba82-07c5-40ce-891e-4f211fe9c76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b87f20f6-f965-4d61-9809-e43f428b708c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b87f20f6-f965-4d61-9809-e43f428b708c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d74b8aec-40ef-4bac-8db1-7c9badc2fc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d74b8aec-40ef-4bac-8db1-7c9badc2fc0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_88d246ad-064b-4da9-83e3-a04e0c620437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_88d246ad-064b-4da9-83e3-a04e0c620437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0e76ff7a-7efe-42dc-b697-a05b78419b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8fda622-3c2c-4f1f-a881-b2fff1b814cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0e76ff7a-7efe-42dc-b697-a05b78419b35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aab9185-f875-4bf7-b431-3f8c070a8841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e032a70d-60ba-4117-beb5-9be066837afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aab9185-f875-4bf7-b431-3f8c070a8841" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e032a70d-60ba-4117-beb5-9be066837afb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b72fff81-9065-471d-9826-32edcc2453c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aab9185-f875-4bf7-b431-3f8c070a8841" xlink:to="loc_us-gaap_OperatingLeaseLiability_b72fff81-9065-471d-9826-32edcc2453c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef628faf-7794-46a7-bf32-8cd58d46e18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4d8d557-54ba-49cc-a898-ce6fb0eec4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef628faf-7794-46a7-bf32-8cd58d46e18f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4d8d557-54ba-49cc-a898-ce6fb0eec4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed053712-edc7-44ce-a4d9-dbad8ea35c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef628faf-7794-46a7-bf32-8cd58d46e18f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed053712-edc7-44ce-a4d9-dbad8ea35c8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_237ebcec-4523-4a1d-a73e-10d184aac40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_237ebcec-4523-4a1d-a73e-10d184aac40f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad24ddb6-fb41-4426-baf6-4aca2aaae8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad24ddb6-fb41-4426-baf6-4aca2aaae8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fed716b0-0d40-4a9d-ad49-2c976fde3652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fed716b0-0d40-4a9d-ad49-2c976fde3652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_628c0bb2-a3dd-49b1-afe4-c5c693f02b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_628c0bb2-a3dd-49b1-afe4-c5c693f02b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_661bb78f-bdeb-4838-b790-73246673b631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_661bb78f-bdeb-4838-b790-73246673b631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_71901984-9bf4-498a-b597-9b56cfb1ac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e940418c-35b1-4306-bee3-a1be77bfc992" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_71901984-9bf4-498a-b597-9b56cfb1ac2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_867e8df7-f95d-4986-9055-fcd1e07ef1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_017174b2-5d87-4942-b4df-edf1ded1077f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_867e8df7-f95d-4986-9055-fcd1e07ef1d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_017174b2-5d87-4942-b4df-edf1ded1077f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2c44a5aa-721b-47e0-b878-412a9ffeb411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_867e8df7-f95d-4986-9055-fcd1e07ef1d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2c44a5aa-721b-47e0-b878-412a9ffeb411" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6e77537b-b36c-4fdc-93d5-27fa6c8eac24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca3487db-2d66-4bab-b7c5-7fe2b3c2b909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6e77537b-b36c-4fdc-93d5-27fa6c8eac24" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ca3487db-2d66-4bab-b7c5-7fe2b3c2b909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bb5e2e04-b735-451a-be3c-d0ac22602166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6e77537b-b36c-4fdc-93d5-27fa6c8eac24" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bb5e2e04-b735-451a-be3c-d0ac22602166" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe9724a9-80ad-4d78-9f3a-424f685c26b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6d1c62ed-bd6c-4ed0-826d-7bb1ac5166e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe9724a9-80ad-4d78-9f3a-424f685c26b0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6d1c62ed-bd6c-4ed0-826d-7bb1ac5166e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_deb56371-7ce1-48f6-a9de-053b2e470b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe9724a9-80ad-4d78-9f3a-424f685c26b0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_deb56371-7ce1-48f6-a9de-053b2e470b97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5d60e92c-58e1-4de0-8005-04c10fa8f4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3d12cbb7-0884-48b7-bc52-33e050b06b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5d60e92c-58e1-4de0-8005-04c10fa8f4ce" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3d12cbb7-0884-48b7-bc52-33e050b06b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_01c9bff2-8e3c-40eb-b2be-4a02baa933c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5d60e92c-58e1-4de0-8005-04c10fa8f4ce" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_01c9bff2-8e3c-40eb-b2be-4a02baa933c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f254fb73-324b-4ae2-b68c-5e44a08efae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c280cfe9-462b-458e-b075-b59112dc3efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f254fb73-324b-4ae2-b68c-5e44a08efae4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c280cfe9-462b-458e-b075-b59112dc3efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d5e62416-6a74-483e-99ea-3bcb010c390e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f254fb73-324b-4ae2-b68c-5e44a08efae4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d5e62416-6a74-483e-99ea-3bcb010c390e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cd16d273-a462-4ecd-a31c-4833cef3d054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f254fb73-324b-4ae2-b68c-5e44a08efae4" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cd16d273-a462-4ecd-a31c-4833cef3d054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3f80338-4ff3-43fe-bab0-b6c7dec0d205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_57f61e23-a294-48d7-9984-0ae710916312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3f80338-4ff3-43fe-bab0-b6c7dec0d205" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_57f61e23-a294-48d7-9984-0ae710916312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_69488d1d-b367-4df8-aa97-77d2fe754644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3f80338-4ff3-43fe-bab0-b6c7dec0d205" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_69488d1d-b367-4df8-aa97-77d2fe754644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fd09a348-1731-4077-ac66-65fadd5541ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f3f80338-4ff3-43fe-bab0-b6c7dec0d205" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fd09a348-1731-4077-ac66-65fadd5541ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_3349e757-f73e-4c3d-bae6-1a13c01b7144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_3349e757-f73e-4c3d-bae6-1a13c01b7144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_654fd783-9017-4393-a163-c71555975ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_654fd783-9017-4393-a163-c71555975ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_04f2df32-1288-4fda-be4a-bca85e86cf3a" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_04f2df32-1288-4fda-be4a-bca85e86cf3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_081eedd8-12e8-438c-969e-68a306144bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_081eedd8-12e8-438c-969e-68a306144bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e9d75377-301b-46b5-8c64-56bed9f8a1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e9d75377-301b-46b5-8c64-56bed9f8a1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_7f4f288d-09be-48b9-8d94-75660027dad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_7f4f288d-09be-48b9-8d94-75660027dad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_01b149f0-d726-42e3-a718-eba26fb943db" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_01b149f0-d726-42e3-a718-eba26fb943db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_bc9793d1-fd0f-425d-b942-24b2714cd398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_bc9793d1-fd0f-425d-b942-24b2714cd398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ae047b86-c7fe-4261-8a8b-5c4f4ce0a9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ae047b86-c7fe-4261-8a8b-5c4f4ce0a9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ac9fe219-ed7a-44a1-acbf-5cdcfe10564b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ac9fe219-ed7a-44a1-acbf-5cdcfe10564b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_caacb508-22f3-42d7-96d5-9055958063d0" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6be67136-95e0-44aa-95fe-a46b5217932b" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_caacb508-22f3-42d7-96d5-9055958063d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0a92e057-cf5d-4171-925b-29c9980b9b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_be5c55c1-d242-49d9-b2e1-30b4c7e4869d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0a92e057-cf5d-4171-925b-29c9980b9b0a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_be5c55c1-d242-49d9-b2e1-30b4c7e4869d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_79e8c829-261c-4d9c-848d-9593d54598ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0a92e057-cf5d-4171-925b-29c9980b9b0a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_79e8c829-261c-4d9c-848d-9593d54598ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_91946168-32a9-4396-a23a-409618ae9dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset_48abb856-35b5-45f1-b67a-40a395b7322b" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91946168-32a9-4396-a23a-409618ae9dd8" xlink:to="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset_48abb856-35b5-45f1-b67a-40a395b7322b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3d694ce-75a0-469d-ae38-d68c9bc07211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91946168-32a9-4396-a23a-409618ae9dd8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a3d694ce-75a0-469d-ae38-d68c9bc07211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5a906949-b2ea-4c37-84c1-da83bf97a808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91946168-32a9-4396-a23a-409618ae9dd8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5a906949-b2ea-4c37-84c1-da83bf97a808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1c0608cc-a870-46b9-8505-74aa8a718fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91946168-32a9-4396-a23a-409618ae9dd8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1c0608cc-a870-46b9-8505-74aa8a718fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8f861278-02c1-403b-9069-7b0ecd206394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8f861278-02c1-403b-9069-7b0ecd206394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8cef0f55-c13a-4016-885b-226c53abc7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8cef0f55-c13a-4016-885b-226c53abc7fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4f5a33f8-2c8f-4123-9910-54ff9feafcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4f5a33f8-2c8f-4123-9910-54ff9feafcb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3d8508d7-ac93-4579-86aa-7cdecd7291fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3d8508d7-ac93-4579-86aa-7cdecd7291fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8144a397-0f75-41e2-b28a-42134a49a6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8144a397-0f75-41e2-b28a-42134a49a6aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_549b2501-f3a4-4cbe-9945-d9a729812e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_549b2501-f3a4-4cbe-9945-d9a729812e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9eb04100-2577-4e1b-9e0b-55e90987032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9eb04100-2577-4e1b-9e0b-55e90987032e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability_e04da89e-2d72-415e-a16b-60b2e5c3dcc5" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_16d09a4f-b9a0-4f5f-85ab-0624bb72694d" xlink:to="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability_e04da89e-2d72-415e-a16b-60b2e5c3dcc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9509f6f5-d9dd-4641-a56d-458193808bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_30a588e8-c94f-4381-ae05-faf60717ec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9509f6f5-d9dd-4641-a56d-458193808bb5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_30a588e8-c94f-4381-ae05-faf60717ec0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b272f0ed-51b0-4d6a-9193-6de843010545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_9509f6f5-d9dd-4641-a56d-458193808bb5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b272f0ed-51b0-4d6a-9193-6de843010545" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dcd24f9e-ee0a-481a-945f-c261c87479ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63f767fa-5132-435c-8440-ed4b408aaa67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dcd24f9e-ee0a-481a-945f-c261c87479ae" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63f767fa-5132-435c-8440-ed4b408aaa67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bf80ff05-f808-4328-87e9-cd555427565b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dcd24f9e-ee0a-481a-945f-c261c87479ae" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bf80ff05-f808-4328-87e9-cd555427565b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>isrg-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfIncome"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" id="idbc5f7f8aeb041d79e001ee1296e1e3b_ConsolidatedStatementsOfIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb7a23f1-416b-4a5b-9b55-3f247f59a249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb7a23f1-416b-4a5b-9b55-3f247f59a249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7c5de7d6-9af6-44c6-aceb-1072fda2bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7c5de7d6-9af6-44c6-aceb-1072fda2bd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_581539da-9aea-47bf-ac87-d2235f025634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_GrossProfit_581539da-9aea-47bf-ac87-d2235f025634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_52570404-d11d-4d16-8cd1-6c4e9d73cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_52570404-d11d-4d16-8cd1-6c4e9d73cf38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e149890e-5bb3-46b6-88ec-74b7d5d779a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e149890e-5bb3-46b6-88ec-74b7d5d779a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bc0b3aee-6ba6-447c-9835-96fd76d59b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_OperatingExpenses_bc0b3aee-6ba6-447c-9835-96fd76d59b81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3eaa82e-06a8-4458-b34a-e46142c38e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_OperatingIncomeLoss_f3eaa82e-06a8-4458-b34a-e46142c38e85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_da1d1e57-e31c-48a6-a495-c8274f35005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_da1d1e57-e31c-48a6-a495-c8274f35005c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c66e74b-4248-44f9-b552-92bfa6b4d3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c66e74b-4248-44f9-b552-92bfa6b4d3f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4998ba59-02e9-45b0-a9af-5e02a256ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4998ba59-02e9-45b0-a9af-5e02a256ae2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_513d903f-4937-4138-b6d8-b98ea4c3f57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_ProfitLoss_513d903f-4937-4138-b6d8-b98ea4c3f57f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_82d07432-4644-4bc2-9990-ee2b2b09904c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_82d07432-4644-4bc2-9990-ee2b2b09904c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a467a06-2b03-4623-819c-3043f122c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NetIncomeLoss_8a467a06-2b03-4623-819c-3043f122c45a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4f88726-c7a0-43b5-9d1f-3082e776373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4f88726-c7a0-43b5-9d1f-3082e776373d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5beba847-561c-4009-94a4-f03b849924e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5beba847-561c-4009-94a4-f03b849924e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f72efdf-c523-4568-85b5-2fcf77cda835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f72efdf-c523-4568-85b5-2fcf77cda835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea747d5c-99b5-4edf-a865-f8b21fbca363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea747d5c-99b5-4edf-a865-f8b21fbca363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:to="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f4e9c29c-d45a-4b59-88ee-691115e4f229_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:to="loc_srt_ProductsAndServicesDomain_f4e9c29c-d45a-4b59-88ee-691115e4f229_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:to="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ec10fe14-254a-435a-9e2d-3e1fda57e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:to="loc_us-gaap_ProductMember_ec10fe14-254a-435a-9e2d-3e1fda57e66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6ac758e5-bb30-4d45-af08-ba88983c45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:to="loc_us-gaap_ServiceMember_6ac758e5-bb30-4d45-af08-ba88983c45f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6dd2698c-82bd-4ede-997e-7976ca21f76a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:to="loc_us-gaap_RelatedPartyDomain_6dd2698c-82bd-4ede-997e-7976ca21f76a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:to="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_49dcef50-2b75-42ea-8c27-bec44e7b4866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:to="loc_us-gaap_CorporateJointVentureMember_49dcef50-2b75-42ea-8c27-bec44e7b4866" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" id="i58d630ce1fb0402299f7f3b6bfb24f8e_ConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_858d349c-3881-4d93-bfca-03eb2add768d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_858d349c-3881-4d93-bfca-03eb2add768d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea066e3a-b50e-497a-9aaf-bc49f93f15dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea066e3a-b50e-497a-9aaf-bc49f93f15dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f345b9c2-05b5-42b3-962c-a254cb4dde7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f345b9c2-05b5-42b3-962c-a254cb4dde7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a086129-228a-4443-bb80-f8db642a7a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a086129-228a-4443-bb80-f8db642a7a71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e898bd9b-394b-413d-998c-a251cae05ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e898bd9b-394b-413d-998c-a251cae05ddd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b42a8fa7-fda2-4ccc-80ff-7438e7209a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b42a8fa7-fda2-4ccc-80ff-7438e7209a8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1496eeb0-d838-456b-b5da-ed14e96f6677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1496eeb0-d838-456b-b5da-ed14e96f6677" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cd39fa40-63d0-4900-ac0c-d4cc4b65704a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cd39fa40-63d0-4900-ac0c-d4cc4b65704a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b26210ce-c952-4b92-8d7c-07730ebe02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b26210ce-c952-4b92-8d7c-07730ebe02c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3343896-5cbb-4e0d-907b-79820d5d3a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_NetIncomeLoss_c3343896-5cbb-4e0d-907b-79820d5d3a8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99a0f9a1-d652-495a-beea-f81ae6d37545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99a0f9a1-d652-495a-beea-f81ae6d37545" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45f33159-bc32-4121-92d2-d48ddf1c05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45f33159-bc32-4121-92d2-d48ddf1c05c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6d3daa6-fca1-49e4-a586-9d34205f6ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e9f7a07-488c-40e0-a79f-c80fec241fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:to="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7229a7b6-c65c-434e-b2ea-f870d154c0de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:to="loc_us-gaap_EquityComponentDomain_7229a7b6-c65c-434e-b2ea-f870d154c0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:to="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_007f0d2d-7962-46c1-ac02-f8ca57ead378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_CommonStockMember_007f0d2d-7962-46c1-ac02-f8ca57ead378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_350a413a-3945-42b1-8ffb-3190c2417776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_350a413a-3945-42b1-8ffb-3190c2417776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ae8283db-3ae3-42dd-b404-85c3ce9f42e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_RetainedEarningsMember_ae8283db-3ae3-42dd-b404-85c3ce9f42e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8bb9f9bb-01fe-4bff-abae-93276b012002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8bb9f9bb-01fe-4bff-abae-93276b012002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_f6a32cba-e923-4f65-9a9a-f28d24ed8306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_ParentMember_f6a32cba-e923-4f65-9a9a-f28d24ed8306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7530710a-1536-42fc-b42a-d3ba412d1c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7530710a-1536-42fc-b42a-d3ba412d1c6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_666f5936-ca6e-497b-bd50-13cd0d83d837_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_666f5936-ca6e-497b-bd50-13cd0d83d837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6e6ccbfc-fe07-476d-99c4-068425e2f6d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6e6ccbfc-fe07-476d-99c4-068425e2f6d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ia8af97af34c34d5ca9570dea566748ab_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4be2b53-3e27-4f47-9981-4a1b7eb46d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4be2b53-3e27-4f47-9981-4a1b7eb46d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1e50eaa-8460-4269-ba6c-af7357875521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1e50eaa-8460-4269-ba6c-af7357875521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c172d9d2-3e98-4480-af18-582848905d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c172d9d2-3e98-4480-af18-582848905d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ServiceFeeCredit_4009eef4-d257-4efc-849b-a29979d7c209" xlink:href="isrg-20221231.xsd#isrg_ServiceFeeCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ServiceFeeCredit_4009eef4-d257-4efc-849b-a29979d7c209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_36bc70db-8c2d-49ab-ac97-75a2e46fd641" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseLeaseReceivableExtendedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_36bc70db-8c2d-49ab-ac97-75a2e46fd641" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableExtendedPayment_699fea91-2702-452f-81e0-741959d53595" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableExtendedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_AccountsReceivableExtendedPayment_699fea91-2702-452f-81e0-741959d53595" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_322aa134-5a4e-4baa-b181-b90798e1320a" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_322aa134-5a4e-4baa-b181-b90798e1320a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bd745dee-d0a2-45e5-8a40-ff4358b8e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_RestrictedCash_bd745dee-d0a2-45e5-8a40-ff4358b8e0c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_19b635ff-8875-473d-b444-70da7c71cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_Depreciation_19b635ff-8875-473d-b444-70da7c71cc5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1aac852b-6d6a-43a2-960c-e1a66b5305a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1aac852b-6d6a-43a2-960c-e1a66b5305a0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_119cc58c-9ab9-4e81-bc23-fb186ab7d08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_119cc58c-9ab9-4e81-bc23-fb186ab7d08c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed6c0437-cb08-488b-9334-1dc144ecdd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed6c0437-cb08-488b-9334-1dc144ecdd33" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_950aa826-7d54-4109-b87b-ae3f0ffd24f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_950aa826-7d54-4109-b87b-ae3f0ffd24f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemSalesArrangementWarrantyPeriod_f8355a7d-a6e4-48cb-8fef-d59220e1f9a3" xlink:href="isrg-20221231.xsd#isrg_SystemSalesArrangementWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_SystemSalesArrangementWarrantyPeriod_f8355a7d-a6e4-48cb-8fef-d59220e1f9a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_b3e20aff-6dd4-43e7-89c3-20d66cad2f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_AcquisitionCosts_b3e20aff-6dd4-43e7-89c3-20d66cad2f1f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_b4e9d1ee-113b-4473-8d5f-c29dc40176aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_b4e9d1ee-113b-4473-8d5f-c29dc40176aa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_98ca5206-9646-4176-a012-7437d9979e81" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_98ca5206-9646-4176-a012-7437d9979e81" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_4c618609-cfef-4306-af8e-e8994dbeb9d5" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_4c618609-cfef-4306-af8e-e8994dbeb9d5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_957a834b-8297-4439-ab2a-1b339a9741ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_DerivativeTermOfContract_957a834b-8297-4439-ab2a-1b339a9741ef" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_7205117a-c4bd-478b-9431-1b4e04450c2a" xlink:href="isrg-20221231.xsd#isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_7205117a-c4bd-478b-9431-1b4e04450c2a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_696b101d-799e-4e77-b8b1-755961af8e4b" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_696b101d-799e-4e77-b8b1-755961af8e4b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_87a25fcd-8382-4fe6-a256-374f53f1b221" xlink:href="isrg-20221231.xsd#isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_87a25fcd-8382-4fe6-a256-374f53f1b221" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07d82e99-554d-4e8e-be0c-4985f5906122_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_07d82e99-554d-4e8e-be0c-4985f5906122_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2246d77c-c0b9-4705-bd09-6c058e2a8142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:to="loc_us-gaap_AccountsReceivableMember_2246d77c-c0b9-4705-bd09-6c058e2a8142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TotalRevenueMember_bf735caa-fc81-4d7b-b7cb-7293d7d577a6" xlink:href="isrg-20221231.xsd#isrg_TotalRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:to="loc_isrg_TotalRevenueMember_bf735caa-fc81-4d7b-b7cb-7293d7d577a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_139daeee-606d-4e72-bf88-c403e2ebab87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_139daeee-606d-4e72-bf88-c403e2ebab87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_cbf82f98-583c-45aa-aa57-1496f4d02235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_cbf82f98-583c-45aa-aa57-1496f4d02235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_582bb42b-d1a5-4074-aecf-5deb6d8ad59b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:to="loc_us-gaap_GeographicDistributionDomain_582bb42b-d1a5-4074-aecf-5deb6d8ad59b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:to="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_f5817cdf-553d-48e7-8e39-19bf9972d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_f5817cdf-553d-48e7-8e39-19bf9972d45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_40ec76a6-a98f-459a-a74d-eb0531d15394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_40ec76a6-a98f-459a-a74d-eb0531d15394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18beb4c9-98f1-4231-a19f-ae548dfa4f0a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:to="loc_srt_RangeMember_18beb4c9-98f1-4231-a19f-ae548dfa4f0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:to="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da7d374a-4058-40c2-86d1-2ca3c8beb61d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:to="loc_srt_MinimumMember_da7d374a-4058-40c2-86d1-2ca3c8beb61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8801f9c9-d215-4dd1-b8d3-714ee985a3c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:to="loc_srt_MaximumMember_8801f9c9-d215-4dd1-b8d3-714ee985a3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3d40608a-be3d-4181-afe1-1182deec4953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3d40608a-be3d-4181-afe1-1182deec4953" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" xlink:type="extended" id="i67c938399fc7443f8c6588d739b2e8f3_SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c733c666-34ab-4d8f-98fd-37f1f460f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c733c666-34ab-4d8f-98fd-37f1f460f64b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7078b292-366c-4c5a-83a5-6ff7c1c709d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7078b292-366c-4c5a-83a5-6ff7c1c709d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_11457159-8480-48b6-9ac0-06da0f082cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_BuildingMember_11457159-8480-48b6-9ac0-06da0f082cdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_612332dc-3dc2-4bee-a629-c1bd9b26dddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_BuildingImprovementsMember_612332dc-3dc2-4bee-a629-c1bd9b26dddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquipmentAndFurnitureMember_55d71408-ce1b-4d01-99a8-7da4aa6dfb13" xlink:href="isrg-20221231.xsd#isrg_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_EquipmentAndFurnitureMember_55d71408-ce1b-4d01-99a8-7da4aa6dfb13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_2c9af352-0df3-42e5-b8d4-2f3f6e50e633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_2c9af352-0df3-42e5-b8d4-2f3f6e50e633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4d81f02c-4429-4aa4-8270-3535d2344998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_ComputerEquipmentMember_4d81f02c-4429-4aa4-8270-3535d2344998" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EnterpriseWideSoftwareMember_8ccf78cf-c5bb-4ba5-b576-f818e37aac8d" xlink:href="isrg-20221231.xsd#isrg_EnterpriseWideSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_EnterpriseWideSoftwareMember_8ccf78cf-c5bb-4ba5-b576-f818e37aac8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PurchasedSoftwareMember_319f5957-8957-4c99-8a65-7fae4393b28f" xlink:href="isrg-20221231.xsd#isrg_PurchasedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_PurchasedSoftwareMember_319f5957-8957-4c99-8a65-7fae4393b28f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:to="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_389425bd-f89b-4a8b-a589-3dd6ec4706c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:to="loc_srt_RangeMember_389425bd-f89b-4a8b-a589-3dd6ec4706c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:to="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd9d157b-3540-445c-b1e9-0f764727af82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:to="loc_srt_MaximumMember_cd9d157b-3540-445c-b1e9-0f764727af82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72e16473-67eb-4677-8d5c-7470703fb583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:to="loc_srt_MinimumMember_72e16473-67eb-4677-8d5c-7470703fb583" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="extended" id="if380626f768f4db3a3f5660e1eb9454a_SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_eb40c0fd-2c79-424d-a713-08149acc15ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_eb40c0fd-2c79-424d-a713-08149acc15ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_55aa53c5-3577-4986-a41d-24c7574450ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_55aa53c5-3577-4986-a41d-24c7574450ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_47f29d3b-2874-4fca-bd80-79da361f7310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_47f29d3b-2874-4fca-bd80-79da361f7310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_bad31df8-06eb-468f-95bc-c512a38fcf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_bad31df8-06eb-468f-95bc-c512a38fcf37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_e8659505-de93-4d75-8e0c-bf33686b74af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_e8659505-de93-4d75-8e0c-bf33686b74af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_706d5bae-a948-4161-9451-6d74d0af9662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_706d5bae-a948-4161-9451-6d74d0af9662" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_eaacb5eb-ea41-438e-be98-191f4a1fbdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_eaacb5eb-ea41-438e-be98-191f4a1fbdd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:to="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_c5c02d72-58e3-40b3-979b-9712edc4b099_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_c5c02d72-58e3-40b3-979b-9712edc4b099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_HighCreditRatingMember_2f3eef92-d759-4151-ad63-adab722549ed" xlink:href="isrg-20221231.xsd#isrg_HighCreditRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_HighCreditRatingMember_2f3eef92-d759-4151-ad63-adab722549ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ModerateCreditRatingMember_2456c8cc-cd41-4635-8195-3a6730a27c3e" xlink:href="isrg-20221231.xsd#isrg_ModerateCreditRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_ModerateCreditRatingMember_2456c8cc-cd41-4635-8195-3a6730a27c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LowCreditRatingMember_12a59976-493d-419b-8d40-d66c18655dde" xlink:href="isrg-20221231.xsd#isrg_LowCreditRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_LowCreditRatingMember_12a59976-493d-419b-8d40-d66c18655dde" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended" id="i2fbdeacf82f240a0999b085c47423508_FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e415fd2-ce2f-4608-86a5-0a1c23c3c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e415fd2-ce2f-4608-86a5-0a1c23c3c00c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8b198485-dd9b-43b5-80d5-8d5eae713afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8b198485-dd9b-43b5-80d5-8d5eae713afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb48af25-e2fc-443b-ab10-b2e22dda4347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb48af25-e2fc-443b-ab10-b2e22dda4347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_761d3f28-be9d-4470-a92e-dd301b20d31c" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_761d3f28-be9d-4470-a92e-dd301b20d31c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b4f8c04-ce2f-4a9c-b28c-e2b4c56a36be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b4f8c04-ce2f-4a9c-b28c-e2b4c56a36be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae7bd294-6d35-4d94-a3b4-c4546d5082f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae7bd294-6d35-4d94-a3b4-c4546d5082f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ab6eb3d4-3cfb-49fb-b016-8e9c743994d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ab6eb3d4-3cfb-49fb-b016-8e9c743994d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a1b2d39-f951-4c50-8673-8ba2757d6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a1b2d39-f951-4c50-8673-8ba2757d6fc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_38cb61a4-9db9-4df7-9049-1796fd178857" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_38cb61a4-9db9-4df7-9049-1796fd178857" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d09234cb-853f-4bd1-b088-011bff4189da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d09234cb-853f-4bd1-b088-011bff4189da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_33f33765-99cc-4965-a098-c4fc65ac051c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_33f33765-99cc-4965-a098-c4fc65ac051c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4499fde-2706-49e1-804d-98ce64686a52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4499fde-2706-49e1-804d-98ce64686a52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eafeb8c7-559b-40c4-8014-462b400c6386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eafeb8c7-559b-40c4-8014-462b400c6386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4c7a24e1-e2fc-4ee9-9e34-d172b9ea0f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4c7a24e1-e2fc-4ee9-9e34-d172b9ea0f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4b4655c-0145-4d89-bbf4-9aa1e262219a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4b4655c-0145-4d89-bbf4-9aa1e262219a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6b734511-b7a8-46e2-aac8-ed547e92571c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CashMember_6b734511-b7a8-46e2-aac8-ed547e92571c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_225e0382-b13d-4349-8ff6-87dd72bf19a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_225e0382-b13d-4349-8ff6-87dd72bf19a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_56e2a530-e5fd-4207-b51b-91d25f5a433c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_56e2a530-e5fd-4207-b51b-91d25f5a433c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_af0e8365-b142-48d7-9c7a-e2f83ba2eda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CommercialPaperMember_af0e8365-b142-48d7-9c7a-e2f83ba2eda1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4f253ad1-9439-4747-a6d5-cdf53d12df33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4f253ad1-9439-4747-a6d5-cdf53d12df33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e762214c-e9d7-49b4-ad43-c18f93bde642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e762214c-e9d7-49b4-ad43-c18f93bde642" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalNotesMember_bf4330ec-50c7-48a5-a988-3956f52ef7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_MunicipalNotesMember_bf4330ec-50c7-48a5-a988-3956f52ef7af" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i2f18d6c6e2e14fa0b82b5292aac3bade_FinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_27b399b7-d63d-45e6-8f54-f9e2709b3727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_27b399b7-d63d-45e6-8f54-f9e2709b3727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a57d91a0-8978-42e5-8ec1-758f2a1ccc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a57d91a0-8978-42e5-8ec1-758f2a1ccc42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c0b89ba7-2649-4d45-aec8-df396ff43f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c0b89ba7-2649-4d45-aec8-df396ff43f67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_8bdd1f45-bc20-4558-a1b2-b884087550ed" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_8bdd1f45-bc20-4558-a1b2-b884087550ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1f91a40-40e6-4e0e-97c7-e8c2598627cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c1f91a40-40e6-4e0e-97c7-e8c2598627cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9c02f001-8cd9-4a3f-af09-0d76900b1913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9c02f001-8cd9-4a3f-af09-0d76900b1913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba2185bc-4700-4ef8-92db-8d327df9b833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba2185bc-4700-4ef8-92db-8d327df9b833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_17b1738c-320b-4fe7-a78a-58001114980c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_17b1738c-320b-4fe7-a78a-58001114980c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_BroncusHoldingCorporationMember_38fdf36b-7def-4f50-b3c6-d00794f61b0a" xlink:href="isrg-20221231.xsd#isrg_BroncusHoldingCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:to="loc_isrg_BroncusHoldingCorporationMember_38fdf36b-7def-4f50-b3c6-d00794f61b0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="extended" id="i5633de2da9444fca85dbf64f1b21152f_FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4c48abf3-0648-44e7-bd47-aa7d5c2ec48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4c48abf3-0648-44e7-bd47-aa7d5c2ec48e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b979bb88-a134-4d67-af9e-6ba4cf98f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b979bb88-a134-4d67-af9e-6ba4cf98f0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d1b9dc17-1e3d-4a0b-a444-33d757f0bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d1b9dc17-1e3d-4a0b-a444-33d757f0bf87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a29d4554-c7f0-40b3-baae-4022b63348ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a29d4554-c7f0-40b3-baae-4022b63348ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f4960523-e1c8-4f46-982f-3e289ac3940b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f4960523-e1c8-4f46-982f-3e289ac3940b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fe8d263f-ef7e-49bd-889d-66a9eefaa01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fe8d263f-ef7e-49bd-889d-66a9eefaa01a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:to="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_3542325c-967f-4155-adf2-de5e27f094ec_default" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:to="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_3542325c-967f-4155-adf2-de5e27f094ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:to="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_92f64a0d-295a-43bb-9b7c-cda686dde187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_CommercialPaperMember_92f64a0d-295a-43bb-9b7c-cda686dde187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_00091b53-941d-4830-9f98-174c8bbddf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_00091b53-941d-4830-9f98-174c8bbddf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_723bd64a-5719-4764-aba1-aba1bb88c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_723bd64a-5719-4764-aba1-aba1bb88c8ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3a6781e1-9ed4-442e-820d-56fd1f274eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3a6781e1-9ed4-442e-820d-56fd1f274eb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalNotesMember_a7304359-be0d-4efb-9e78-31dab9d8946e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_MunicipalNotesMember_a7304359-be0d-4efb-9e78-31dab9d8946e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails" xlink:type="extended" id="i0f052ca8e38c472aba13ac0da6970e23_FinancialInstrumentsSummaryofEquityInvestmentActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c25587c5-3db6-4a80-8464-fc61124c9b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c25587c5-3db6-4a80-8464-fc61124c9b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_62a4f026-afd4-473b-9e24-72ebd725564d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_62a4f026-afd4-473b-9e24-72ebd725564d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_299be4f2-6b69-4047-8987-68739b17ffae" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_299be4f2-6b69-4047-8987-68739b17ffae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dace5962-ba77-4dbd-ab25-667021911623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dace5962-ba77-4dbd-ab25-667021911623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_86b5b87b-1664-4167-8940-a50ffe45ccb4" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_86b5b87b-1664-4167-8940-a50ffe45ccb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_393c9893-fd65-449d-8740-c8af136a402a" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_393c9893-fd65-449d-8740-c8af136a402a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_99542bd0-eb16-41f3-9893-d70528200333_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_99542bd0-eb16-41f3-9893-d70528200333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_007e0361-75d6-44da-97f5-de9dffb9cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_007e0361-75d6-44da-97f5-de9dffb9cb73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssetsNetMember_6bf2913b-c23d-4306-94ab-1aa8498a4b27" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssetsNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:to="loc_isrg_IntangibleAndOtherAssetsNetMember_6bf2913b-c23d-4306-94ab-1aa8498a4b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ce45564-a1f1-4793-8cc1-b9fea995cdd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0ce45564-a1f1-4793-8cc1-b9fea995cdd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_81127529-9c0c-48e1-95d8-ffc52bccf847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_81127529-9c0c-48e1-95d8-ffc52bccf847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0596f8b6-fc32-4922-bb80-9dfe4fdd7120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0596f8b6-fc32-4922-bb80-9dfe4fdd7120" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails" xlink:type="extended" id="i5f8c5133fc10435fb6e73d9f54b724a5_FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48510b89-c0ca-4e80-8da1-4e3dd47731ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48510b89-c0ca-4e80-8da1-4e3dd47731ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_34e94e0b-abd0-419f-9780-70a235636fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_34e94e0b-abd0-419f-9780-70a235636fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6e1624ec-16e9-4160-bbd5-e9c5701ff8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6e1624ec-16e9-4160-bbd5-e9c5701ff8b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_119bbe2a-146f-41e4-83c6-3619d4511656_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_119bbe2a-146f-41e4-83c6-3619d4511656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_fc2648dc-0dd0-43e5-87c4-30137d1bdb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_fc2648dc-0dd0-43e5-87c4-30137d1bdb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:to="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_138df6dd-33fa-4c49-a8f2-fbac06a45b89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:to="loc_us-gaap_HedgingDesignationDomain_138df6dd-33fa-4c49-a8f2-fbac06a45b89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:to="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0a7ca05b-dca1-470e-be56-2a9a19de48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:to="loc_us-gaap_NondesignatedMember_0a7ca05b-dca1-470e-be56-2a9a19de48ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails" xlink:type="extended" id="i382bdbd1bcb24815a9ad6c95ef576925_FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9bd0d486-a782-4d43-aa91-ca0913a93985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9bd0d486-a782-4d43-aa91-ca0913a93985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_47f2cb74-3622-435f-9ec0-716c14b55a05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_47f2cb74-3622-435f-9ec0-716c14b55a05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_6bd4e969-50e8-481e-955a-65199adc157c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_6bd4e969-50e8-481e-955a-65199adc157c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6301c4c9-0f99-4b74-a513-fc233d331578_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:to="loc_us-gaap_HedgingDesignationDomain_6301c4c9-0f99-4b74-a513-fc233d331578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:to="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00568d60-d704-433d-b505-532080f5ef68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00568d60-d704-433d-b505-532080f5ef68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f81d101b-52f8-47fc-8de3-78c1ea500548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:to="loc_us-gaap_NondesignatedMember_f81d101b-52f8-47fc-8de3-78c1ea500548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_112d1532-d9fa-400b-a725-4c8c64c9ceaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_112d1532-d9fa-400b-a725-4c8c64c9ceaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_736fc904-f4c9-4373-a8a8-961cb9305716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_736fc904-f4c9-4373-a8a8-961cb9305716" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_1bd8c892-ffef-4e81-9d24-41a0bbe7ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:to="loc_us-gaap_OtherLiabilitiesMember_1bd8c892-ffef-4e81-9d24-41a0bbe7ec1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueRevenueDisaggregatedbyTypesandGeographyDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails" xlink:type="extended" id="iad54e03c3aca4a288ad04c0554497b9b_RevenueRevenueDisaggregatedbyTypesandGeographyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a1f64c4-ee53-467e-a9ce-25c1ad7189b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a1f64c4-ee53-467e-a9ce-25c1ad7189b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:to="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_6ff4f53b-3b06-4d7c-b578-86127e202936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:to="loc_us-gaap_GeographicDistributionDomain_6ff4f53b-3b06-4d7c-b578-86127e202936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:to="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_19b1e482-5c9b-41a0-9c18-2b047d21ee43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_19b1e482-5c9b-41a0-9c18-2b047d21ee43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_fabe231d-cb5a-415b-a217-f08cea99858a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_fabe231d-cb5a-415b-a217-f08cea99858a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:to="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2507549-6818-4f5f-aa73-8a40da8baf0e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:to="loc_srt_ProductsAndServicesDomain_e2507549-6818-4f5f-aa73-8a40da8baf0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:to="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:to="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InstrumentsandAccessoriesMember_6322117a-5b40-4fa4-be9c-295e1f7ded91" xlink:href="isrg-20221231.xsd#isrg_InstrumentsandAccessoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:to="loc_isrg_InstrumentsandAccessoriesMember_6322117a-5b40-4fa4-be9c-295e1f7ded91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemsMember_ce082faa-c6d3-4f23-8678-d7bce63d954e" xlink:href="isrg-20221231.xsd#isrg_SystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:to="loc_isrg_SystemsMember_ce082faa-c6d3-4f23-8678-d7bce63d954e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1db909b5-a4c4-454d-ae6d-9b2873750e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:to="loc_us-gaap_ServiceMember_1db909b5-a4c4-454d-ae6d-9b2873750e3b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails" xlink:type="extended" id="ie6ba4613e98744b69b92ed70f5b2bb00_RevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d06317df-8270-47c4-a254-7e33085422ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d06317df-8270-47c4-a254-7e33085422ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended" id="i3cc39c130b374c79ba6a61d328abdc82_RevenueAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueSalestypeandOperatingLeaseRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails" xlink:type="extended" id="i766987adc342417b888a8de37bc54bb6_RevenueSalestypeandOperatingLeaseRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_2a6a5c34-8a8b-448c-8f0c-772e43ea0152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_2a6a5c34-8a8b-448c-8f0c-772e43ea0152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_6770d076-4d87-41ae-b148-b091632553e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_6770d076-4d87-41ae-b148-b091632553e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_877284ad-ca7d-4a7a-8e16-576320a18f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_877284ad-ca7d-4a7a-8e16-576320a18f00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_1648a7d3-2fed-481d-a3b9-33782c2985d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_1648a7d3-2fed-481d-a3b9-33782c2985d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_a6406040-68dd-451a-ad97-33528d48866f" xlink:href="isrg-20221231.xsd#isrg_VariableLeaseRevenueUsageBasedArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:to="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_a6406040-68dd-451a-ad97-33528d48866f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesLeaseReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="extended" id="ic952a36b676147c5b49b60eb69d12eab_LeasesLeaseReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_c0d30289-a5b7-4ed5-8da6-82b63ccd2306" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseGrossInvestmentInLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_c0d30289-a5b7-4ed5-8da6-82b63ccd2306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalestypeLeaseDeferredSellingProfit_e012594e-52c9-41fb-92cb-d8d4d538830c" xlink:href="isrg-20221231.xsd#isrg_SalestypeLeaseDeferredSellingProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_isrg_SalestypeLeaseDeferredSellingProfit_e012594e-52c9-41fb-92cb-d8d4d538830c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_54f16005-9601-49e6-9e44-7986500d9327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_54f16005-9601-49e6-9e44-7986500d9327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_a0b52546-3861-4d83-bb7d-77fee0982f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_a0b52546-3861-4d83-bb7d-77fee0982f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_93c251fc-2552-45e8-9e2b-57db3a56108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_93c251fc-2552-45e8-9e2b-57db3a56108c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_31ba64d9-953a-47dc-b0bd-258f53126615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_31ba64d9-953a-47dc-b0bd-258f53126615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_c50ad748-d317-45f9-9d6d-ee4e62124ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0f4a1eac-0fd4-4344-aeee-87085d2a9c25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0f4a1eac-0fd4-4344-aeee-87085d2a9c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f6754e01-6350-49f5-9f3f-534823ffb816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f6754e01-6350-49f5-9f3f-534823ffb816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4b7c7a69-2cda-4719-882f-f9d664538ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4b7c7a69-2cda-4719-882f-f9d664538ec7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="ie67da41f937744258bc9b8d78eaf98c6_GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7020ab8b-53d0-4535-a4ec-bdde2213feb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7020ab8b-53d0-4535-a4ec-bdde2213feb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_94419786-614a-4369-b1af-613d1201d8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_94419786-614a-4369-b1af-613d1201d8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a1d8058-aa3e-4cb2-91ab-67eddb33f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a1d8058-aa3e-4cb2-91ab-67eddb33f5e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6773081d-ad15-45f9-9135-113818fdae31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6773081d-ad15-45f9-9135-113818fdae31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fd688302-36a5-48dc-95b3-2cb1eeee7376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fd688302-36a5-48dc-95b3-2cb1eeee7376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_3becb27a-092a-4c1a-8791-5131f266d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_DistributionRightsMember_3becb27a-092a-4c1a-8791-5131f266d7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_53accbb3-9039-4355-95c0-4a95297bd07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_CustomerRelationshipsMember_53accbb3-9039-4355-95c0-4a95297bd07f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i889cc50d770a4db7b04e4f83b182bbe5_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_151586a2-0bd5-4156-b1b1-3a29d980d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_151586a2-0bd5-4156-b1b1-3a29d980d4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_c757957e-18de-4c01-8c12-440fa3651b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_LitigationSettlementExpense_c757957e-18de-4c01-8c12-440fa3651b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_af3dff11-8a78-4e64-89fc-6893887d915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_af3dff11-8a78-4e64-89fc-6893887d915f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:to="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7957e491-1544-4183-ad87-a7c1507f81ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:to="loc_srt_LitigationCaseTypeDomain_7957e491-1544-4183-ad87-a7c1507f81ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:to="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RexMedicalLPMember_f5b73515-ad2a-4283-83dc-cdf5df504b6c" xlink:href="isrg-20221231.xsd#isrg_RexMedicalLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:to="loc_isrg_RexMedicalLPMember_f5b73515-ad2a-4283-83dc-cdf5df504b6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i0b997f064b2e4da79b808817e48b2f4c_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4a3a41e6-6d35-463d-a1d0-ee3b93e009e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4a3a41e6-6d35-463d-a1d0-ee3b93e009e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_cbe8f15a-39c3-4006-8afe-f36f6a79a742" xlink:href="isrg-20221231.xsd#isrg_StockRepurchaseProgramincreasedtoauthorizedamount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_cbe8f15a-39c3-4006-8afe-f36f6a79a742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_13cb98d6-9ba6-470b-9009-1d5ed40bca18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_13cb98d6-9ba6-470b-9009-1d5ed40bca18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_12531d4d-735a-4287-b513-3e878e17b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_12531d4d-735a-4287-b513-3e878e17b4e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_a2466d38-c861-46f8-9a29-6d83e5ed22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_a2466d38-c861-46f8-9a29-6d83e5ed22f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4a9e3470-dbc7-4f4e-a3f5-22b6200905cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4a9e3470-dbc7-4f4e-a3f5-22b6200905cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases_d7adb785-ea54-424b-beb6-a045cac19a68" xlink:href="isrg-20221231.xsd#isrg_AggregateReductionInCommonStockDuringStockRepurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases_d7adb785-ea54-424b-beb6-a045cac19a68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_9725d34a-993f-4ea9-b864-69a676475105" xlink:href="isrg-20221231.xsd#isrg_AmountChargedToRetainedEarningsDuringStockRepurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_9725d34a-993f-4ea9-b864-69a676475105" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_566e6d4c-a248-4c34-b4e2-1a7e24fe2997_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:to="loc_us-gaap_EquityComponentDomain_566e6d4c-a248-4c34-b4e2-1a7e24fe2997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:to="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ea81f68-4e17-4748-8f7d-1419c0e4d7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:to="loc_us-gaap_CommonStockMember_8ea81f68-4e17-4748-8f7d-1419c0e4d7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_419e7bbc-550c-42e7-a44e-a01a05c9eb6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_419e7bbc-550c-42e7-a44e-a01a05c9eb6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember_3055d038-3f4b-46bb-a1e0-bd42174575e3" xlink:href="isrg-20221231.xsd#isrg_AugustAcceleratedShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:to="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember_3055d038-3f4b-46bb-a1e0-bd42174575e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember_036cfe4f-0e87-4438-a341-dc8b44e819fa" xlink:href="isrg-20221231.xsd#isrg_OctoberAcceleratedShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:to="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember_036cfe4f-0e87-4438-a341-dc8b44e819fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails" xlink:type="extended" id="i8178951675bb485996df4874f66f5df8_StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78bce8e8-54e1-49fb-a71e-a02edccd7185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78bce8e8-54e1-49fb-a71e-a02edccd7185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5a97e1ab-eb31-49ad-a7be-ae307710ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5a97e1ab-eb31-49ad-a7be-ae307710ada7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4ad259a2-6278-4ab9-9a97-9f2371a3a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4ad259a2-6278-4ab9-9a97-9f2371a3a70b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b04eacd5-1e56-4c4a-9964-794302ae92f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b04eacd5-1e56-4c4a-9964-794302ae92f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CommonStockRepurchaseProgramMember_e4518070-7127-452f-9ade-aad9981856cb" xlink:href="isrg-20221231.xsd#isrg_CommonStockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:to="loc_isrg_CommonStockRepurchaseProgramMember_e4518070-7127-452f-9ade-aad9981856cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5a3e4b51-f0d4-4a98-8509-d59a534071a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:to="loc_us-gaap_EquityComponentDomain_5a3e4b51-f0d4-4a98-8509-d59a534071a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:to="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4e00581c-8199-416c-b1ac-8c8373d59b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:to="loc_us-gaap_CommonStockMember_4e00581c-8199-416c-b1ac-8c8373d59b97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="extended" id="i2d83b3f0d0be40f9ad1f7e63b4f6528a_StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca5d6289-e3c4-44b1-994d-6b342a16f0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_StockholdersEquity_ca5d6289-e3c4-44b1-994d-6b342a16f0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_94bef6c8-796d-42cd-b53f-f2d92b635542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_94bef6c8-796d-42cd-b53f-f2d92b635542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_32cfaece-c859-4e88-a5c8-b0520222b1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_32cfaece-c859-4e88-a5c8-b0520222b1fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5bcca72-cc17-4661-8de5-4bda410abb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5bcca72-cc17-4661-8de5-4bda410abb0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5285f66a-ab7a-4442-a4dc-e53084346a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:to="loc_us-gaap_EquityComponentDomain_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:to="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_3bde81b0-1759-4a10-99db-a2b755330727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_3bde81b0-1759-4a10-99db-a2b755330727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b2e937f4-7ccc-4f5d-a2a0-2460097469b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b2e937f4-7ccc-4f5d-a2a0-2460097469b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cf949917-a29e-44cb-afde-4e5c7d2a8c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cf949917-a29e-44cb-afde-4e5c7d2a8c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_9e962d39-0d6c-49f1-b4b4-1b358d18b16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_9e962d39-0d6c-49f1-b4b4-1b358d18b16f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5397a3bd-269a-4e6f-a15a-52b7113f3f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5397a3bd-269a-4e6f-a15a-52b7113f3f2d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i6914ac75871548609e79b35e345ba119_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b632dfb-c625-41f6-a109-24bdabe3a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b632dfb-c625-41f6-a109-24bdabe3a466" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0e9a17cf-c46b-41a5-9f26-56b82a2de0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0e9a17cf-c46b-41a5-9f26-56b82a2de0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0bd5a050-cfc1-4795-a6f7-4dcff11e4969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0bd5a050-cfc1-4795-a6f7-4dcff11e4969" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7f0755a-99d2-435a-9ab1-262f6f263338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7f0755a-99d2-435a-9ab1-262f6f263338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockOptionsGrantedInitialVestingPeriod_7d94b5c6-4532-463d-9846-ca230ba64910" xlink:href="isrg-20221231.xsd#isrg_StockOptionsGrantedInitialVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_StockOptionsGrantedInitialVestingPeriod_7d94b5c6-4532-463d-9846-ca230ba64910" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_d42350e4-6bd6-48cf-b72d-013245acad3f" xlink:href="isrg-20221231.xsd#isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_d42350e4-6bd6-48cf-b72d-013245acad3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_3ac7813f-7b36-49b6-ab7e-2c0f3dc04c9a" xlink:href="isrg-20221231.xsd#isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_3ac7813f-7b36-49b6-ab7e-2c0f3dc04c9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_b5cd522c-675b-4e85-a068-c702bb7dd7ba" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_b5cd522c-675b-4e85-a068-c702bb7dd7ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_7c2a2a87-81ed-453c-bda1-6c139e0b5474" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfPayrollDeductionUnderEspp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_7c2a2a87-81ed-453c-bda1-6c139e0b5474" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans_81b84002-6228-4716-a468-cb90b0ed5a39" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans_81b84002-6228-4716-a468-cb90b0ed5a39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_b4a046d7-a4ee-4653-9718-10f2d51bbb54" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_b4a046d7-a4ee-4653-9718-10f2d51bbb54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_1210cf29-b150-438e-8cc5-6d04b78630aa" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_1210cf29-b150-438e-8cc5-6d04b78630aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_60a93c55-0072-436c-bd2b-0574369b9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_60a93c55-0072-436c-bd2b-0574369b9f02" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b972b0e9-9c06-4616-af42-e49917ea28e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b972b0e9-9c06-4616-af42-e49917ea28e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_6cdbd00d-2273-4b6e-a8ce-669518a00813" xlink:href="isrg-20221231.xsd#isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_6cdbd00d-2273-4b6e-a8ce-669518a00813" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0034642d-dadf-4690-83da-6933922481c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0034642d-dadf-4690-83da-6933922481c9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50654782-792d-4de5-8201-46a6ba61e777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50654782-792d-4de5-8201-46a6ba61e777" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_57cd17c9-a75e-489e-aab2-b4669cf1a89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_57cd17c9-a75e-489e-aab2-b4669cf1a89f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7be427b-6ce9-47b3-8172-273d5e62d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7be427b-6ce9-47b3-8172-273d5e62d69d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e58e1f06-e77b-4f6c-84ca-8c1b383a72f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e58e1f06-e77b-4f6c-84ca-8c1b383a72f1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c1079c78-e81d-4854-8e0c-c5ebc189004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c1079c78-e81d-4854-8e0c-c5ebc189004d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82420a2d-cdc8-4616-99e9-c6b81195db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82420a2d-cdc8-4616-99e9-c6b81195db5e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7f66f885-02a1-4153-b237-861f2bf4bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7f66f885-02a1-4153-b237-861f2bf4bac9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5c478c54-fa40-4430-a937-97a5b472004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5c478c54-fa40-4430-a937-97a5b472004d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_256d4c27-e274-4d84-b935-7a952759660a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_256d4c27-e274-4d84-b935-7a952759660a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_57502572-5884-4191-b7bb-e1c9d2804124" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_57502572-5884-4191-b7bb-e1c9d2804124" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_faba57c8-7df3-4f48-80b3-0186e0de988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_faba57c8-7df3-4f48-80b3-0186e0de988c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_04993aea-ad35-4385-96f7-b15b67c820f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_04993aea-ad35-4385-96f7-b15b67c820f8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_edeb7282-d900-489a-a277-0a787e245ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_edeb7282-d900-489a-a277-0a787e245ee4" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9a34e5a-b99c-4788-9cc7-f75faae11862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9a34e5a-b99c-4788-9cc7-f75faae11862" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_551f497c-a501-453b-9979-ce079c22a4aa" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_551f497c-a501-453b-9979-ce079c22a4aa" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_1848c774-3e1c-44a8-a7a1-c79b7e890bb0" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_1848c774-3e1c-44a8-a7a1-c79b7e890bb0" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_83bfec48-336b-46cb-aec7-5cc2e227c2cb" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_83bfec48-336b-46cb-aec7-5cc2e227c2cb" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_abbb5bac-a6d5-4a36-b76d-8879e6160f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_abbb5bac-a6d5-4a36-b76d-8879e6160f48" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_b346ad9d-74ce-4a22-91f7-417d9c273ab9" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_b346ad9d-74ce-4a22-91f7-417d9c273ab9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_3fef3c5a-ae94-4048-8a4c-9de1b3fff364" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_3fef3c5a-ae94-4048-8a4c-9de1b3fff364" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_baffd993-e2cd-408e-b361-deafdfd2c822_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:to="loc_us-gaap_PlanNameDomain_baffd993-e2cd-408e-b361-deafdfd2c822_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:to="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_5264595f-14e9-4ada-a57a-2443177d4dce" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_5264595f-14e9-4ada-a57a-2443177d4dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_b92a058c-4d82-4b66-a0a4-d94102c8a90a" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_b92a058c-4d82-4b66-a0a4-d94102c8a90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_d888f184-40a1-419d-87d6-55a1a8f74813" xlink:href="isrg-20221231.xsd#isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_d888f184-40a1-419d-87d6-55a1a8f74813" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember_4bd26051-d95a-4880-a800-fa2e6bff8c41" xlink:href="isrg-20221231.xsd#isrg_TwoThousandEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember_4bd26051-d95a-4880-a800-fa2e6bff8c41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac0b95e5-b085-4865-bbf9-92483914eaef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac0b95e5-b085-4865-bbf9-92483914eaef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8ad15217-3aca-4d93-ba4a-e661f4bc897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8ad15217-3aca-4d93-ba4a-e661f4bc897f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AnnualGrantOptionsMember_8204acd5-4e4b-4663-8e39-23ac0eb78b69" xlink:href="isrg-20221231.xsd#isrg_AnnualGrantOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_AnnualGrantOptionsMember_8204acd5-4e4b-4663-8e39-23ac0eb78b69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialGrantOptionsMember_8e0f7512-258e-4f3d-b260-8f5f5b0fffb2" xlink:href="isrg-20221231.xsd#isrg_InitialGrantOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_InitialGrantOptionsMember_8e0f7512-258e-4f3d-b260-8f5f5b0fffb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_99400c49-d486-4378-bdf1-20f9aa8a748a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_us-gaap_EmployeeStockMember_99400c49-d486-4378-bdf1-20f9aa8a748a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NonvestedStockOptionMember_e9e18900-2826-4307-8aca-6e5dbed1a058" xlink:href="isrg-20221231.xsd#isrg_NonvestedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_NonvestedStockOptionMember_e9e18900-2826-4307-8aca-6e5dbed1a058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialRSUgrantsMember_73af57cd-6090-401a-8584-703d58b9f961" xlink:href="isrg-20221231.xsd#isrg_InitialRSUgrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_InitialRSUgrantsMember_73af57cd-6090-401a-8584-703d58b9f961" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NewHireOptionsMember_19b065fc-32ae-4996-9e73-413d18402246" xlink:href="isrg-20221231.xsd#isrg_NewHireOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_NewHireOptionsMember_19b065fc-32ae-4996-9e73-413d18402246" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_0dfbeea7-04d7-4b48-96e1-cb485151dded" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_0dfbeea7-04d7-4b48-96e1-cb485151dded" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:to="loc_us-gaap_AwardDateDomain_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:to="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustGrantMember_b34036a9-169e-4c8b-b0f3-61e139904963" xlink:href="isrg-20221231.xsd#isrg_AugustGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:to="loc_isrg_AugustGrantMember_b34036a9-169e-4c8b-b0f3-61e139904963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_FebruaryGrantMember_9afbfe54-9aff-41c9-bcb4-abc7ed6cde88" xlink:href="isrg-20221231.xsd#isrg_FebruaryGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:to="loc_isrg_FebruaryGrantMember_9afbfe54-9aff-41c9-bcb4-abc7ed6cde88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:href="isrg-20221231.xsd#isrg_AwardedtoAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoDomain_d557ada9-e46d-458a-ab79-45428f9846e4_default" xlink:href="isrg-20221231.xsd#isrg_AwardedtoDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:to="loc_isrg_AwardedtoDomain_d557ada9-e46d-458a-ab79-45428f9846e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:href="isrg-20221231.xsd#isrg_AwardedtoDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:to="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EmployeesMember_c93f1711-fb3e-4eb8-9b84-5f73c4b98869" xlink:href="isrg-20221231.xsd#isrg_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:to="loc_isrg_EmployeesMember_c93f1711-fb3e-4eb8-9b84-5f73c4b98869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b80f8f79-5d54-4606-9373-b05f27935de5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:to="loc_srt_DirectorMember_b80f8f79-5d54-4606-9373-b05f27935de5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationSummaryofRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails" xlink:type="extended" id="iebc8c774813640e9ac1b5346b12068b7_ShareBasedCompensationSummaryofRSUandPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe7f8026-0498-47aa-94ab-8d273d9e8fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe7f8026-0498-47aa-94ab-8d273d9e8fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_df9d0790-00f7-4f76-a671-88c5ddc86256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_df9d0790-00f7-4f76-a671-88c5ddc86256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b61b4254-9b98-4c95-a30c-88390277258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b61b4254-9b98-4c95-a30c-88390277258f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_d10ce837-3d98-40a2-9c31-40699d124884" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_d10ce837-3d98-40a2-9c31-40699d124884" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0fb7b27a-4bfd-489e-8ae8-b131765b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0fb7b27a-4bfd-489e-8ae8-b131765b68df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63601455-4796-47db-9c03-7b20360afd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c1cf6ab-935b-4edf-83a5-5192a00acd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c1cf6ab-935b-4edf-83a5-5192a00acd28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9ed4281-01b2-4cb6-873a-d4c164b560a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9ed4281-01b2-4cb6-873a-d4c164b560a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ca657ab-1027-4661-a216-c0f4a8ce680d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ca657ab-1027-4661-a216-c0f4a8ce680d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_f86a53bf-86a2-4c90-9f7d-58bb09f09957" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_f86a53bf-86a2-4c90-9f7d-58bb09f09957" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6572fe1c-dfae-42d8-b368-977a7c754b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6572fe1c-dfae-42d8-b368-977a7c754b8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f7254e6-086e-4989-9eb1-47d736098df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:to="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_08837056-50db-425a-95da-b04493ae96f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_08837056-50db-425a-95da-b04493ae96f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_8d3d772c-185b-4c51-abba-b7aaca052ec8" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_8d3d772c-185b-4c51-abba-b7aaca052ec8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails" xlink:type="extended" id="i7f8676fd1f40444e844a14bef18876c6_ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b19520eb-17d4-4d05-8148-a95249971a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b19520eb-17d4-4d05-8148-a95249971a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_74eb0406-b3d9-46e9-bf83-24f172e6ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_74eb0406-b3d9-46e9-bf83-24f172e6ee98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3368a635-0525-4d1d-9008-6e6151d61a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3368a635-0525-4d1d-9008-6e6151d61a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8f7779d9-8f51-4539-b959-1d47928b5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8f7779d9-8f51-4539-b959-1d47928b5cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6e5dfb5b-2dc8-48a5-95c4-669909af1c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6e5dfb5b-2dc8-48a5-95c4-669909af1c28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ac1505ce-4457-48c2-a05d-b0dcde7fc594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ac1505ce-4457-48c2-a05d-b0dcde7fc594" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ac1384e5-4ed6-4811-b897-835a7f211f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ac1384e5-4ed6-4811-b897-835a7f211f65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b9015581-7e14-453e-91a5-87076953524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b9015581-7e14-453e-91a5-87076953524c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_aef3cf18-25b5-4246-8542-ccbd55abf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_aef3cf18-25b5-4246-8542-ccbd55abf3b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8608e28-e53d-4744-8f69-69c92f39785e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8608e28-e53d-4744-8f69-69c92f39785e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ee14ae83-b6f4-4e2e-a8b0-8fc2cdd2c217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharePrice_ee14ae83-b6f4-4e2e-a8b0-8fc2cdd2c217" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e7590423-00d2-47e1-b851-e263c7fad6a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e7590423-00d2-47e1-b851-e263c7fad6a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeOneMember_ff2d2f83-2a78-4337-8b20-d8c8eb89a6f6" xlink:href="isrg-20221231.xsd#isrg_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeOneMember_ff2d2f83-2a78-4337-8b20-d8c8eb89a6f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTwoMember_13f4e7d4-a4cf-4e9d-8075-20b542c5b756" xlink:href="isrg-20221231.xsd#isrg_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeTwoMember_13f4e7d4-a4cf-4e9d-8075-20b542c5b756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeThreeMember_135cc804-af31-4f70-9cd5-de345b9ec728" xlink:href="isrg-20221231.xsd#isrg_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeThreeMember_135cc804-af31-4f70-9cd5-de345b9ec728" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFourMember_759c6e71-5ca0-4b4f-a2dd-56d64043906b" xlink:href="isrg-20221231.xsd#isrg_RangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeFourMember_759c6e71-5ca0-4b4f-a2dd-56d64043906b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFiveMember_0bfe0068-52b3-4f80-8373-08f98a87df2b" xlink:href="isrg-20221231.xsd#isrg_RangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeFiveMember_0bfe0068-52b3-4f80-8373-08f98a87df2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSixMember_bc49e14d-7a69-40d3-8389-45fa3d035862" xlink:href="isrg-20221231.xsd#isrg_RangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeSixMember_bc49e14d-7a69-40d3-8389-45fa3d035862" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSevenMember_cbe1cb8b-3604-46ae-a91a-6ecf3569b01d" xlink:href="isrg-20221231.xsd#isrg_RangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeSevenMember_cbe1cb8b-3604-46ae-a91a-6ecf3569b01d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeEightMember_73590283-5d5a-4379-85d8-a5fb05c547d6" xlink:href="isrg-20221231.xsd#isrg_RangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeEightMember_73590283-5d5a-4379-85d8-a5fb05c547d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeNineMember_c31bed18-554f-4bc7-8c5e-951c635518d6" xlink:href="isrg-20221231.xsd#isrg_RangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeNineMember_c31bed18-554f-4bc7-8c5e-951c635518d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTenMember_e3d53af1-d6c7-452c-a5a4-ddfa307d74d5" xlink:href="isrg-20221231.xsd#isrg_RangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeTenMember_e3d53af1-d6c7-452c-a5a4-ddfa307d74d5" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i36e202d6d8e547eba1ae825223440d7b_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_afd8ea84-8a19-40a7-8917-38a616700c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_afd8ea84-8a19-40a7-8917-38a616700c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083f0522-a94b-4b47-ae40-b27d6150f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083f0522-a94b-4b47-ae40-b27d6150f84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a33220e3-420f-4002-b318-0562f328dc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a33220e3-420f-4002-b318-0562f328dc8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b68726b4-ba9e-4c50-a969-a53773d246c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b68726b4-ba9e-4c50-a969-a53773d246c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3f84ea39-40b6-42e6-9af7-0add23c2500b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_us-gaap_CostOfSalesMember_3f84ea39-40b6-42e6-9af7-0add23c2500b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SellingGeneralAndAdministrativeMember_2e1b60f2-b945-48d2-b9bb-19d9775befa6" xlink:href="isrg-20221231.xsd#isrg_SellingGeneralAndAdministrativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_isrg_SellingGeneralAndAdministrativeMember_2e1b60f2-b945-48d2-b9bb-19d9775befa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ResearchAndDevelopmentMember_0b08ede4-6f1d-4e6e-95a9-8a63d43974c3" xlink:href="isrg-20221231.xsd#isrg_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_isrg_ResearchAndDevelopmentMember_0b08ede4-6f1d-4e6e-95a9-8a63d43974c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:to="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingDomain_3906d194-8bde-41a3-b34a-9c91e4403f0d_default" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:to="loc_isrg_ConsolidatingReportingDomain_3906d194-8bde-41a3-b34a-9c91e4403f0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:to="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesProductMember_8516b13a-a430-4c65-b11f-f45a542b0e81" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:to="loc_isrg_CostOfSalesProductMember_8516b13a-a430-4c65-b11f-f45a542b0e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesServiceMember_5003f0de-38aa-4fc5-85a7-f1243c958db1" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:to="loc_isrg_CostOfSalesServiceMember_5003f0de-38aa-4fc5-85a7-f1243c958db1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="extended" id="i910557803e644e8488e6a4fbcceea017_ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_abbae062-cca6-4816-b04b-3bb854e35d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_abbae062-cca6-4816-b04b-3bb854e35d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6217072b-eef3-49ed-a332-f4e3670eeee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6217072b-eef3-49ed-a332-f4e3670eeee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c3ee1c96-17ee-49f7-8c58-92b481262b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c3ee1c96-17ee-49f7-8c58-92b481262b0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6678d43b-e328-40e4-bf0c-e83d667c0a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6678d43b-e328-40e4-bf0c-e83d667c0a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b512ad5d-c45e-4005-af43-2328d148a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b512ad5d-c45e-4005-af43-2328d148a61b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:to="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_153c150e-287b-449b-9d2e-c90dc7fd34be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_153c150e-287b-449b-9d2e-c90dc7fd34be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd6707c6-1949-437b-8332-3dd9d5900c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd6707c6-1949-437b-8332-3dd9d5900c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_115b2970-22a8-4c32-8d52-8c5404ac6215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_StockOptionMember_115b2970-22a8-4c32-8d52-8c5404ac6215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_8d9689eb-47a1-4166-b1c7-e647b6d1b862" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_8d9689eb-47a1-4166-b1c7-e647b6d1b862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b5dfaf76-8961-40e1-b0ec-496e5a61db77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_EmployeeStockMember_b5dfaf76-8961-40e1-b0ec-496e5a61db77" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i342b540405e447e69e77d12c94dd8071_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_79df5721-e24e-4d58-9eb5-cbf90a4c778b" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_79df5721-e24e-4d58-9eb5-cbf90a4c778b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3c328ee9-e80c-49c8-9466-d767875e1163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3c328ee9-e80c-49c8-9466-d767875e1163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_b1d7b780-77c1-4a3e-9b9a-3d60c0d5e06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_b1d7b780-77c1-4a3e-9b9a-3d60c0d5e06d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1578c92f-8c00-44ad-a5c5-f89e812d297a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1578c92f-8c00-44ad-a5c5-f89e812d297a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_9c74a3b9-0ce3-4804-84aa-fa9dc365220a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_9c74a3b9-0ce3-4804-84aa-fa9dc365220a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a31ff8f5-a0c4-47f7-88c8-9e07538db66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a31ff8f5-a0c4-47f7-88c8-9e07538db66a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4a55a831-04be-4c73-8e48-e15cf7a1092b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4a55a831-04be-4c73-8e48-e15cf7a1092b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_8af50159-98a3-4838-9f63-57e62bf5d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_8af50159-98a3-4838-9f63-57e62bf5d4da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_db7e7550-c284-47e1-bd68-04f48facd248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_db7e7550-c284-47e1-bd68-04f48facd248" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_dd0555d8-3854-408c-8f84-3b92a9f392a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_dd0555d8-3854-408c-8f84-3b92a9f392a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DomesticAndForeignMember_1f73634b-fe43-43fb-885a-28c3b617a818" xlink:href="isrg-20221231.xsd#isrg_DomesticAndForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:to="loc_isrg_DomesticAndForeignMember_1f73634b-fe43-43fb-885a-28c3b617a818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fd907dc9-ea33-477e-afd6-8be3fd70e9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fd907dc9-ea33-477e-afd6-8be3fd70e9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1c8a2ea2-4700-4998-8978-c7157e2880c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:to="loc_srt_SegmentGeographicalDomain_1c8a2ea2-4700-4998-8978-c7157e2880c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:to="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a262a46b-5cfe-492a-aee1-c30e12ac5183" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:to="loc_stpr_CA_a262a46b-5cfe-492a-aee1-c30e12ac5183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_cec34217-0d26-47bf-bf64-a73fa5bf9d8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_cec34217-0d26-47bf-bf64-a73fa5bf9d8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fde1f3bc-9daa-4078-b55c-6745d06b6994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:to="loc_us-gaap_ResearchMember_fde1f3bc-9daa-4078-b55c-6745d06b6994" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ValuationAndQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails" xlink:type="extended" id="i0916239c4e444dfc970ec7052c0750ec_ValuationAndQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a086644c-9be3-4547-a857-68d7f93bf348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a086644c-9be3-4547-a857-68d7f93bf348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_734bbe10-8862-471c-a391-e557395e2218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_734bbe10-8862-471c-a391-e557395e2218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_860de249-c89f-4595-b047-4b0ef8fdd911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_860de249-c89f-4595-b047-4b0ef8fdd911" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2fd06fb8-b893-47eb-b1d5-8c88c088cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_9cc3973c-400d-49d0-8195-dc6e52f59fb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_9cc3973c-400d-49d0-8195-dc6e52f59fb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_7a2d10f1-e1ac-409d-ba56-344757e45456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_7a2d10f1-e1ac-409d-ba56-344757e45456" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssets_0bb936a2-40be-4e9d-969c-a40fb4d37e8b" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_isrg_IntangibleAndOtherAssets_0bb936a2-40be-4e9d-969c-a40fb4d37e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_Liabilities" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>isrg-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_d602fd7a-9130-468d-9f8b-27819e6e4d4f_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_51f12ede-06e0-4fe1-9845-68229d40e17e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_d76ecd7e-4ac2-4a96-9fae-a1677fe2f325_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes, Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_6737fa84-ab21-4164-91ae-cc5dccf49dd1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d76ac568-ca47-4dab-9baa-d18d381e59a7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_224a506e-8c33-41a2-8f14-303a87c0967a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember_ac436b7c-d120-49d0-a064-9ab285670aab_terseLabel_en-US" xlink:label="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2000 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:href="isrg-20221231.xsd#isrg_TwoThousandEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:to="lab_isrg_TwoThousandEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_967f5d9a-67a8-4747-a28b-af5a0af45b19_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_487c592e-f60e-4001-b07f-e79deba7c5e3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2d055ef1-af3c-4c29-870a-db108b2aeb6e_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_428937e5-9550-48a6-8a7b-87ffc347abed_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_fe266f07-a8f1-49ec-afa1-9e0b45b6341b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EnterpriseWideSoftwareMember_032813b8-0864-48a6-8066-0debdbf90da7_terseLabel_en-US" xlink:label="lab_isrg_EnterpriseWideSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enterprise-wide software</link:label>
    <link:label id="lab_isrg_EnterpriseWideSoftwareMember_label_en-US" xlink:label="lab_isrg_EnterpriseWideSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enterprise Wide Software [Member]</link:label>
    <link:label id="lab_isrg_EnterpriseWideSoftwareMember_documentation_en-US" xlink:label="lab_isrg_EnterpriseWideSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enterprise-Wide Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EnterpriseWideSoftwareMember" xlink:href="isrg-20221231.xsd#isrg_EnterpriseWideSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EnterpriseWideSoftwareMember" xlink:to="lab_isrg_EnterpriseWideSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_069c51f9-bff6-4a09-b09d-761d1ce43dc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3dd4b33b-3382-447c-a5a7-fe968e12979f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9dddca15-eb64-4746-b0e4-8699c50c2b92_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes, State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_4bf67410-aab2-4e0b-baa6-0e82da20a722_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AwardedtoDomain_edc4185a-f99c-4e0c-ab66-7c52d2b3866c_terseLabel_en-US" xlink:label="lab_isrg_AwardedtoDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded to [Domain]</link:label>
    <link:label id="lab_isrg_AwardedtoDomain_label_en-US" xlink:label="lab_isrg_AwardedtoDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded to [Domain]</link:label>
    <link:label id="lab_isrg_AwardedtoDomain_documentation_en-US" xlink:label="lab_isrg_AwardedtoDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Awarded to [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoDomain" xlink:href="isrg-20221231.xsd#isrg_AwardedtoDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AwardedtoDomain" xlink:to="lab_isrg_AwardedtoDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93d22715-6291-4c90-850b-e3299045f718_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options excluded from computation of diluted net income per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AugustGrantMember_83a2a1b3-fe9a-4560-ae93-5d95fd40bfac_terseLabel_en-US" xlink:label="lab_isrg_AugustGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August Grant</link:label>
    <link:label id="lab_isrg_AugustGrantMember_label_en-US" xlink:label="lab_isrg_AugustGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August Grant [Member]</link:label>
    <link:label id="lab_isrg_AugustGrantMember_documentation_en-US" xlink:label="lab_isrg_AugustGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustGrantMember" xlink:href="isrg-20221231.xsd#isrg_AugustGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AugustGrantMember" xlink:to="lab_isrg_AugustGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_07951462-cadf-4022-8fc5-1f640036ac7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reclassification adjustment for gains on securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_42719269-fea0-42f9-8a5f-1e18dc453678_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6daa037f-b039-49b4-94d1-54ee2d9945ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_3bb529b5-3ee7-4574-9fec-ef46b4ac40cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Ranges Of Outstanding And Exercisable Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e5742044-8fcf-4f43-b65a-d4d8a0dc622a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock_6f2c2d4d-9816-4f7a-88b5-32f7581e1c48_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis By Year of Origination and Credit Quality Indicator</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30da3561-3a29-47e9-8b25-f03dce0980bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c318f822-bc6b-42eb-9ac9-a2dd6ca6b6be_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to tax positions taken during the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9051c056-1bb8-468f-ab56-a7dc09e05d8c_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a35baa58-1c7d-47b5-aebd-aa15909766c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_237533fc-304f-4aba-a9db-35b891b9a0ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_19aa21a7-25cf-4fc2-8354-9a518e02e68f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6791c757-3119-4d4a-8b61-e47f29ae2aa9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5349e978-b281-4ba0-a030-ea1753ed58ec_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_aee1f8a7-b218-4cdd-b490-399f9ea730df_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_58e68f11-54c2-4f2d-9f1b-0697fc1fb33a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1bb38f30-a4a7-4702-91fa-34199845fca1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e292ba39-7564-4d8b-aa67-922d98edf5fc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d1de6529-2dc7-400b-b98c-8fb2a91ad17b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_FebruaryGrantMember_b2d4f929-9825-4e1a-81fd-d85c493745eb_terseLabel_en-US" xlink:label="lab_isrg_FebruaryGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February Grant</link:label>
    <link:label id="lab_isrg_FebruaryGrantMember_label_en-US" xlink:label="lab_isrg_FebruaryGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February Grant [Member]</link:label>
    <link:label id="lab_isrg_FebruaryGrantMember_documentation_en-US" xlink:label="lab_isrg_FebruaryGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_FebruaryGrantMember" xlink:href="isrg-20221231.xsd#isrg_FebruaryGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_FebruaryGrantMember" xlink:to="lab_isrg_FebruaryGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_34513270-e997-4cd1-afda-26e10d7d1625_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_ac4b960f-0888-4286-bbef-1f665a2224d2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0b7cdf71-b2b1-473f-a764-9325c885b760_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_17fa2d29-08ad-42f0-8d79-c49417dd8002_terseLabel_en-US" xlink:label="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of each shorter offering period</link:label>
    <link:label id="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Period Offering Divided Into, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Period Offering Divided Into, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:to="lab_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_641a5e76-46d5-4714-9b65-df70f091702f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_295f7fac-0244-454e-af04-abce1acf0141_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to settlements with tax authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9965a25a-d947-4401-be07-04aad2745574_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1057ed79-6bdd-4dcd-939e-ba20d3f55dca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7fca84b6-6e42-4bbc-8969-cdc9b7158d87_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited/expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5443f03d-2d95-4881-bb00-78bc6d24e513_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_IntangibleAndOtherAssets_a9bb7752-d0de-4507-91f1-bcf3d540f15a_terseLabel_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and other assets, net</link:label>
    <link:label id="lab_isrg_IntangibleAndOtherAssets_label_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible And Other Assets</link:label>
    <link:label id="lab_isrg_IntangibleAndOtherAssets_documentation_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges and other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssets" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_IntangibleAndOtherAssets" xlink:to="lab_isrg_IntangibleAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_293740a6-5770-4e01-af76-5c8f6a7926e2_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_01fc14a1-9667-41aa-b0d9-ffe99a930a25_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:to="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_14f2edb7-767e-4ede-9788-47ab2b257492_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ee5ac316-057f-47c5-88e2-617b8ad751fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a02b92d-4852-45d5-b8cd-c9d9a438fa73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_af7e9dec-e446-48f6-b020-5c8435c08812_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_7a548f1b-7083-4b42-b5fc-cb78bc189289_terseLabel_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/Purchases/Others</link:label>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_label_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Sales, Purchases and Other Adjustments</link:label>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_documentation_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Sales, Purchases and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:to="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5c90aed3-6c15-4f08-b32e-dc49f52e8f2a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a092c10a-bd9c-4d02-8235-84cba1b7e51a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_02167e62-08e5-4ec3-b28c-1ebf5fb90f62_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_26146be7-ee0e-461a-8440-5f921136f830_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160; Gains (Losses) on Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_74907dc4-5dce-4873-8bbd-a3eaad175fcf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_847ca8f6-1b11-4cbd-bb20-34c47d5cdf4a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful&#160;Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_26e1d745-8a93-4a02-a535-062521d467fa_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems" xlink:to="lab_us-gaap_CapitalLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25fa61c1-781c-453f-8d92-c4e1d79632a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent_8400d8fb-fe0e-414b-accc-328391f43e1e_terseLabel_en-US" xlink:label="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred and contingent purchase consideration</link:label>
    <link:label id="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent_label_en-US" xlink:label="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Purchase Consideration Payments, Current</link:label>
    <link:label id="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent_documentation_en-US" xlink:label="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Purchase Consideration Payments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:href="isrg-20221231.xsd#isrg_DeferredPurchaseConsiderationPaymentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:to="lab_isrg_DeferredPurchaseConsiderationPaymentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ed19483f-209d-42c5-92cb-383a13db6fb4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdf806eb-f117-40ca-9f87-c62bc00c7c24_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_9d8dc73b-2799-4196-aef5-41bf0bbf81aa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_199994e4-bc92-489d-a958-0abf90393c22_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_a0031402-e9c4-43b4-8a7d-98d5913fb632_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b6bc58d9-688d-4004-91b3-446a346b4d15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_4d03ce2b-82a4-4709-969b-67750e905e56_terseLabel_en-US" xlink:label="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Likelihood of tax benefits being realized upon ultimate settlement</link:label>
    <link:label id="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_label_en-US" xlink:label="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement</link:label>
    <link:label id="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_documentation_en-US" xlink:label="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax examination minimum likelihood of tax benefits being realized upon settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:to="lab_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_87117b83-913a-4d1b-8e01-22e8a6c241f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DomesticAndForeignMember_1463b89a-38dc-4c71-a830-399fbc0a3393_terseLabel_en-US" xlink:label="lab_isrg_DomesticAndForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Foreign</link:label>
    <link:label id="lab_isrg_DomesticAndForeignMember_label_en-US" xlink:label="lab_isrg_DomesticAndForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Foreign [Member]</link:label>
    <link:label id="lab_isrg_DomesticAndForeignMember_documentation_en-US" xlink:label="lab_isrg_DomesticAndForeignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic and Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DomesticAndForeignMember" xlink:href="isrg-20221231.xsd#isrg_DomesticAndForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DomesticAndForeignMember" xlink:to="lab_isrg_DomesticAndForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e8e59629-817b-4901-8044-6e190a55a703_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RexMedicalLPMember_ec30fad1-a1df-4144-a93c-e2f924246d8b_terseLabel_en-US" xlink:label="lab_isrg_RexMedicalLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rex Medical, L.P.</link:label>
    <link:label id="lab_isrg_RexMedicalLPMember_label_en-US" xlink:label="lab_isrg_RexMedicalLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rex Medical, L.P. [Member]</link:label>
    <link:label id="lab_isrg_RexMedicalLPMember_documentation_en-US" xlink:label="lab_isrg_RexMedicalLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rex Medical, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RexMedicalLPMember" xlink:href="isrg-20221231.xsd#isrg_RexMedicalLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RexMedicalLPMember" xlink:to="lab_isrg_RexMedicalLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_e61320fa-1b78-41e0-a7a9-f4cb4459962d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans (net of tax):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_20a4606a-ebc0-41b9-82fd-bba45ab79c4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit for net losses recorded in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_28c6d3ff-31ee-47e6-a340-8f47bcd8cdff_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7d45d613-f391-47b4-a295-0e212670a01c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_f15e9313-d8bc-4a8c-8162-ffd990803eec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8c2f2534-99c3-47d7-89bf-fd2b87443f5d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ca6af2c-1f8f-4b72-9682-5158a6c46d20_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a44731ef-5bb3-459b-84b3-0c7077f35bc7_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaids and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_3862fd68-24c3-43cb-aae5-577058a526b6_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_72d2dc77-c33c-4163-aab9-159e3a6e3860_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_02624670-bcaa-4818-ad73-ce3dcc992117_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_45cc93b3-2d5a-4117-9090-9a99bf6054d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_f9bbe44e-10c7-4b78-b18c-11db0871b7f7_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building/leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_55573486-66bd-4226-b4cd-2a15179d02cf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unrecognized compensation expenses are expected to be recognized, years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_cf9fc70a-a16e-497b-9def-439cff675c23_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f9344b24-b113-4106-af72-c3cd49881f66_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_63572831-7ef0-4651-a347-b2e53b7a8618_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_857efe06-ccaa-4694-a2c6-8ea28ff2c652_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_960fe631-b620-46cb-8e33-8462693079a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_100091f7-3c86-44cf-86ec-86273f2bcf9b_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_81a2687f-e425-454e-944e-e48471578cc9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ee2c8bd5-0d1a-49c0-b5ee-4086393dd881_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, maximum (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_feb84837-fd27-4752-b119-e4b93ae81e23_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type lease revenue</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_9582b1fb-cd82-4e6c-af89-b00ed0005aaa_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2cf0a7e3-ed9f-48b3-baac-b81da22d10ed_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_950fa8dd-93d2-4519-ac9c-8c728b05b25e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e72893eb-1c18-4076-b0d6-33db0f1f1cfd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_00d64c80-46cc-4b8a-b961-8a9c053145a7_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_87862617-213a-4e8e-b3a8-b203791e1f4d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7f9c46ec-7454-4241-b2a3-0704b002a718_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_cc8aae1c-527a-490c-add7-1cd2d7361f08_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b8a3f10b-2fdd-4a33-8cf1-7ea2e0179c59_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f77a2a87-40f0-4d26-92aa-b0df5f0bcbfd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3985bef5-f921-4367-b123-d2f52c5d2546_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7407de0a-8588-4dca-8ce4-c866c1f941a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation not benefited</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_1037a2c2-5138-47d4-aa9e-dc5355df0685_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72d971ec-8981-445f-858b-78dcf32477f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ba2946dc-ef47-4478-a674-c67824277aa8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_66274c57-78a1-4d85-8af8-01e278ac4179_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OUS</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember" xlink:to="lab_us-gaap_GeographicDistributionForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dd8df832-5413-4a35-bc57-1d726792b0ba_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8db961f5-8553-4ccd-a200-1fd987eb2d12_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_335ade7f-ee65-4d7a-ae7d-ac083c3d37c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_55d26c4d-099e-4134-92c6-0e180ed3677f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_335c9247-e65d-45f7-97a2-1d63329cc868_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9b8b9c5c-bb1d-4603-a6b0-4276b78cfa62_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_bd6d7e82-fcf3-4c90-afb4-615068b060d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_88c7317d-d729-47f2-ac19-6d828f4af89f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a5a10296-47d3-4941-8d46-0f594f0d576b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_InitialRSUgrantsMember_adf8250d-6541-4739-a7dd-4154aca0ea81_terseLabel_en-US" xlink:label="lab_isrg_InitialRSUgrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial RSU grants</link:label>
    <link:label id="lab_isrg_InitialRSUgrantsMember_label_en-US" xlink:label="lab_isrg_InitialRSUgrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial RSU grants [Member]</link:label>
    <link:label id="lab_isrg_InitialRSUgrantsMember_documentation_en-US" xlink:label="lab_isrg_InitialRSUgrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial RSU grants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialRSUgrantsMember" xlink:href="isrg-20221231.xsd#isrg_InitialRSUgrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_InitialRSUgrantsMember" xlink:to="lab_isrg_InitialRSUgrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_2961dbca-96dd-426e-adc5-a5eb1102bef2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7ccc5a94-7f4d-49aa-b63b-cf11db0087a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0bb70fba-a913-43b5-a721-879a693af248_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_2125e975-d766-48d7-b47f-2ea3456d2045_terseLabel_en-US" xlink:label="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Receivable, Extended Payment</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_label_en-US" xlink:label="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Receivable, Extended Payment</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_documentation_en-US" xlink:label="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Receivable, Extended Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseLeaseReceivableExtendedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:to="lab_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8fb1667b-e8b6-4661-859f-8c00c398f3f9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e5d3e57a-99d7-4cbe-86bc-56c4dd0d8fae_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK OPTIONS</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1f6b92dd-867c-4515-93bb-a64dc4650484_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_92d2bf89-13f7-4fc2-b01c-3d835b7a6ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_87c64f9c-4915-4a48-8854-9477461c0cd6_terseLabel_en-US" xlink:label="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employees on stockholders to participate in ESPP</link:label>
    <link:label id="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percentage Of Employees On Stockholders To Participate In Employee Stock Purchase Plan</link:label>
    <link:label id="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employees on stockholders to participate in employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:to="lab_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_37094338-cc3e-410d-bc4b-1c3cb4749ce0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d731fd05-1633-45a3-ad28-dfbc9a539a54_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d36bd675-d43f-4a06-9381-45e935a23fb8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_8607ccb5-8056-4df9-a3e1-386f8bc90148_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_fced733b-51ef-432c-9b44-e3ba7bbf57b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6dba3948-514b-406e-93b4-c63093047055_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_9f5deaad-634e-4278-939e-900532249aea_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ba3afd2a-4a4c-47f1-9ba2-08ccdbbf2481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1_b74aeab4-d789-4567-a0be-55817f680ba1_terseLabel_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type leases term</link:label>
    <link:label id="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Sales-type Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:to="lab_us-gaap_LessorSalesTypeLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_09456470-caf0-4497-9ceb-abd599f3dcd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment transfers from inventory to property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_cbee5cd4-ddfb-484b-83d9-9f0d57ecc80b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5a904406-cf67-4b0a-aa2e-41c351a6ea8d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_a5bdca95-545d-45fc-9d4d-d67dc95e41a7_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_13d9a449-2161-4889-8d29-41d864a77d82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e9f01eaa-9c6f-4d7b-9fea-94cc9beb15d2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63deba33-1859-4c3c-b50a-6554a4faf4e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f21f0041-9262-48f8-bbcc-b48da1601b4e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_c6265566-81e8-4169-862b-873ad0dab67b_terseLabel_en-US" xlink:label="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled accounts receivable and other</link:label>
    <link:label id="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_label_en-US" xlink:label="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables and Other Receivables, Current</link:label>
    <link:label id="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_documentation_en-US" xlink:label="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables and Other Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:href="isrg-20221231.xsd#isrg_UnbilledReceivablesAndOtherReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:to="lab_isrg_UnbilledReceivablesAndOtherReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_dbbda357-f3f2-492c-aa2a-6039365a36a3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalCreditAssessmentDomain_0bca25b9-dd40-4f9e-af3f-c8485efa8c5f_terseLabel_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Domain]</link:label>
    <link:label id="lab_us-gaap_InternalCreditAssessmentDomain_label_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain" xlink:to="lab_us-gaap_InternalCreditAssessmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88de8a87-10e6-47f3-84d4-c4f629800234_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_eec9f8d6-3da1-4a3e-ad70-4447a0b743cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through employee stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_b0c61e3e-2b5f-431c-bbce-0357b1f2c3ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4de9a464-e216-472c-b5da-b0f99c499bc3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_4a0a6307-f059-4f7b-9802-ede7ab3795b1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c1b2db02-975e-4563-907a-b6c70b3dfc72_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6c64a3a6-d1c5-440f-bf4d-d0bcfd561726_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_8dc2b77c-8080-4090-9a36-5d3cc95d1976_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment for share repurchases</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_814d878d-2164-4854-90bf-930d2ac8d981_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Financial Statement Details</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_d4de6de6-e8c0-4a41-82fe-1ff73c88cdd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on fair market value on the offering date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_042d399f-08f3-4fb2-a49e-3b1637e468f8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_b857225f-16e0-4d22-97bc-81b88c54bf6c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease Receivable</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_25534cac-ca88-4ec9-92b2-b05a42490c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_c64b51e4-d176-4f6f-bbe6-f770b73360a4_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7e3b82c9-e660-44a8-947a-873dfacbd6df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses less than 12 months, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e1f0be38-49cd-46e2-a552-b4225090d4f8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0ecf501e-4b33-4f2a-983b-f95f33542e84_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_25508e2f-4dfb-4f01-bb5d-fe9d68720f82_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_815bb900-94fc-4a83-8551-2bf3c78deb28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction-related capital expenditures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab19ff8a-8e88-40e0-a285-361bf606c4c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_bc2e9e47-74a6-41ab-9172-39501c40d8db_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_95dc0259-b413-456b-a23a-1375eb37e369_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_e67e2db2-6ab9-4844-b6d3-ed836bc89aa3_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6c8e2fd2-24c5-4ad9-98b9-a1d90b8a8806_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_14538a22-3d50-41ed-beb0-b468d03b63d1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_bce5e8fa-5100-4c41-8d55-74954db2b721_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_261a1e02-469f-4625-9099-9e9c3a64f233_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, weighted-average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_e993e0c4-7764-45de-8ea9-53fb236401bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_740ba5de-5f6f-4c8a-bf24-25ef3f909be5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_b3435a61-bb1d-40a8-920e-648fdcf6ab13_terseLabel_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price Per Share</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9aebd1f0-a0f9-4bb5-82f7-4af3e580c1ac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03baf8b3-653c-4443-a0a8-b23e149f10a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_NonvestedStockOptionMember_cfeca9e3-4a8c-4aa3-8823-17cd2c818b39_terseLabel_en-US" xlink:label="lab_isrg_NonvestedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Stock Option</link:label>
    <link:label id="lab_isrg_NonvestedStockOptionMember_label_en-US" xlink:label="lab_isrg_NonvestedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Stock Option [Member]</link:label>
    <link:label id="lab_isrg_NonvestedStockOptionMember_documentation_en-US" xlink:label="lab_isrg_NonvestedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NonvestedStockOptionMember" xlink:href="isrg-20221231.xsd#isrg_NonvestedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_NonvestedStockOptionMember" xlink:to="lab_isrg_NonvestedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4d90d668-223c-4b60-94bd-5ddb1cfa7cc8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable value, Carrying Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7679e806-2649-4249-94c0-afac34511cb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1425dd27-b085-4393-8faa-1cb9d1bbe45b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balances (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7a39fbd0-ad8b-475a-958c-457c625c4597_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balances (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_762490a2-c462-41bf-a027-cff73a6eded8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Year Two, Originated, Fiscal Year before Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_da373255-aa37-4b4c-a144-4fbe126d6b91_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b5fcafcd-9a03-4423-9d75-68b973c0d790_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_350fe538-fa6d-45b5-bd8a-2e56ff77d862_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2332f84-5227-4b0a-95ac-0358bf2a80ef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2a7f7348-4c52-4f01-a637-44a388fe33e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1fb41cf0-a4d7-4787-a57e-5e8c7bd5427c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b10c6381-0646-4934-9c64-79c2a0129952_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6a4b46ad-10e8-428e-b98e-4a4a50032447_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_b7fa9151-d93e-442f-9642-2bda38673055_terseLabel_en-US" xlink:label="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum hours employed per week</link:label>
    <link:label id="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Hours Employed Per Week To Participate In Employee Stock Purchase Plan</link:label>
    <link:label id="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum hours employed per week to participate in employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:href="isrg-20221231.xsd#isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:to="lab_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_49142a4e-63db-46ee-b0c1-d4b3eb7beed5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_875406ff-36c9-4dd3-a698-04f6e79d7eb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation period</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_29af2456-dae7-4543-bc82-380bc96b24a2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionCosts_859f9b4a-0fdd-4361-86ee-1498cd44f5c1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract acquisition costs</link:label>
    <link:label id="lab_us-gaap_AcquisitionCosts_label_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Costs, Period Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionCosts" xlink:to="lab_us-gaap_AcquisitionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_0ea94fda-d504-4b6f-ac67-50f85045cf9f_terseLabel_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available-For-Sale Securities [Axis]</link:label>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_label_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available-For-Sale Securities [Axis]</link:label>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_documentation_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available-For-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:to="lab_isrg_ScheduleOfAvailableForSaleSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ecd43c1a-555d-4417-b3ff-8e00117bcf58_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1e23915-a253-4098-a736-166613a17381_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_IntangibleAndOtherAssetsNetMember_a42e1abe-8e30-435d-9be5-4f0e3ed26077_terseLabel_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssetsNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and other assets, net</link:label>
    <link:label id="lab_isrg_IntangibleAndOtherAssetsNetMember_label_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssetsNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and Other Assets, Net [Member]</link:label>
    <link:label id="lab_isrg_IntangibleAndOtherAssetsNetMember_documentation_en-US" xlink:label="lab_isrg_IntangibleAndOtherAssetsNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and Other Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssetsNetMember" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssetsNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_IntangibleAndOtherAssetsNetMember" xlink:to="lab_isrg_IntangibleAndOtherAssetsNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_bad3e964-357e-4920-9f73-a10ad1ee2a20_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_ce137e22-248c-4939-afcd-512ab4d8e680_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software Costs for Internal Use</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1c87c150-a08b-4de4-bc2e-02498b8314b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4854f241-8c7a-4b59-999e-0aa7a1091beb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 600.0 shares authorized, $0.001 par value, 350.0 shares and 357.7 shares issued and outstanding as of December 31, 2022, and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_53a93857-5482-417c-87ee-5ff08f9bb68b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_62933a73-982a-4db3-9820-ca78b80192e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_f7536ecc-70c3-42b7-bdef-78ffe10f47f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_eea5f7ee-e9b2-451a-887c-ebd6c5a1047c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capitalized Property Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset_cc94a116-56df-4d7e-b80b-99c7a2131299_negatedTerseLabel_en-US" xlink:label="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:label id="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_isrg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_685dc02a-ca85-4dda-909b-6b15784db58f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82084802-6ed3-46a6-96af-82db8f0a8c67_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b991042a-0c19-4bb3-b27f-7246f3b8e74b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_78db21f4-d3d6-4701-98bf-2c8fb492423d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_47b3efb7-cf51-484e-9424-39d77ff942f9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_758ca978-575e-499f-bc46-cf44ec4680f4_terseLabel_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance change (usd per share)</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:to="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3a4865fb-5098-4302-abd2-83f4b38772f6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_96d7c8e8-ca14-4bc4-8dab-4a95c22e3085_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_11c2ca12-d883-4424-a42b-f8cd6c9b5b64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of shares vested and expected to vest, years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_CostOfSalesProductMember_3058499a-f50c-4960-a2ad-2b002208d566_terseLabel_en-US" xlink:label="lab_isrg_CostOfSalesProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue&#8212;product</link:label>
    <link:label id="lab_isrg_CostOfSalesProductMember_label_en-US" xlink:label="lab_isrg_CostOfSalesProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales Product [Member]</link:label>
    <link:label id="lab_isrg_CostOfSalesProductMember_documentation_en-US" xlink:label="lab_isrg_CostOfSalesProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesProductMember" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_CostOfSalesProductMember" xlink:to="lab_isrg_CostOfSalesProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_12e576e2-a099-4d86-b306-940c001892c8_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intuitive Surgical, Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_63ba116f-c443-4451-82cb-7e68f6ec1e4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c3bf14e6-6b56-493a-833f-7b443bfb508d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bd39007d-09a8-418e-b70d-2e580a4f0ff9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d89df635-8d14-4c2e-bb24-1784c085ec23_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life, intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases_b495bb44-aa56-474f-8a40-8e1a2a800bd4_terseLabel_en-US" xlink:label="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate reduction in common stock and additional paid-in capital during stock repurchases</link:label>
    <link:label id="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases_label_en-US" xlink:label="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Reduction In Common Stock During Stock Repurchases</link:label>
    <link:label id="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases_documentation_en-US" xlink:label="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reduced under Common Stock and Additional Paid-In Capital accounts under the par value of method of accounting for stock repurchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:href="isrg-20221231.xsd#isrg_AggregateReductionInCommonStockDuringStockRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:to="lab_isrg_AggregateReductionInCommonStockDuringStockRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_5733077d-ffa6-44ce-a097-0f5a72b0a394_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e2b0ba2-cc0c-4560-a33b-720160be6e82_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d97d6177-9746-4711-a527-6669ba5b3857_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_a17b3738-7b7f-4a59-93fa-25d63cff16ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities (net of tax):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bc5beec5-6817-45d7-a54b-626f75cd83b6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition activity</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b273e20a-5393-4544-9a53-9273edb0de91_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_b94295aa-ba17-4fb4-aea2-e2bd25207256_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0986677f-98f3-43b9-aedd-9f7aa4a479b4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_97326ff3-524c-47ad-a54c-aab2033adc5f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_65a8eeef-aa73-41ca-9dce-5db7392afb92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c4608cdc-2a4b-424b-a3c0-0e7b28b0b222_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability_7eb859da-e6d9-4230-9f4e-967d19db8ea3_terseLabel_en-US" xlink:label="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_isrg_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cdf1a105-cceb-49e7-af1b-5c7fa03e19b0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State or Other Jurisdiction of Incorporation or Organization</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ResearchAndDevelopmentMember_f43a46df-323b-4fa0-bdc5-256e22ace9a4_terseLabel_en-US" xlink:label="lab_isrg_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_isrg_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_isrg_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_isrg_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_isrg_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ResearchAndDevelopmentMember" xlink:href="isrg-20221231.xsd#isrg_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ResearchAndDevelopmentMember" xlink:to="lab_isrg_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2eec88d2-e990-4582-86c6-0ae775019f8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for leases that were included within operating cash outflows</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_d3302815-7bcc-43f8-b097-5d063d8496c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_209e7764-f17e-46fd-b390-a133433be5ce_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f14b8ee9-8c3f-4192-a935-16fe34f698c2_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_9e423235-7b39-4ee4-ae1f-e0d4d96997ac_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases, average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_649c7d45-ada5-4fef-bc76-477b40f6586a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e814e351-6ae8-43a1-90fa-7cffd7197315_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_716a1339-af38-490e-89c3-210bcd581716_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bc45eeb1-8853-4f78-837d-e90ca6dd93f2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_96473d86-07c7-4e18-94c7-a9e24b1fe68c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_5f636675-d43a-4e9d-8530-998023d96920_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Joint Ventures</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_13f86462-712f-4bdd-9bbd-db0bab75f0c4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment in sales-type leases</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_42f536e8-b2c5-49f9-88b7-e44ffc5614f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_70de7bd9-8038-4821-9cab-0112f083029f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_d2328f03-564d-4a3f-aa77-91bac519a64d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares repurchased (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a5c88f6-61f5-4825-b9da-6ae868482731_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aba090c6-7b67-47b4-954c-8c0d2657053a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4297f788-556a-4475-9d2d-bd646d84758a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_5e577997-faf7-425e-bb6a-ee88bb7d7a48_terseLabel_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based implied volatility (period)</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_label_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Period</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_documentation_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:to="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_167b3567-fd43-4df7-b019-19d5ea7df0cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_afe2d718-498d-4133-8f2c-cb3508125ce1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_ae4a6984-6eae-4b3b-9a95-0c0e82e3596b_terseLabel_en-US" xlink:label="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/Purchases/Others</link:label>
    <link:label id="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_label_en-US" xlink:label="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Sales, Purchases and Other Adjustments</link:label>
    <link:label id="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_documentation_en-US" xlink:label="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Sales, Purchases and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:to="lab_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_04159384-c604-4a8a-a999-8aff561590ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of PSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_b8a6b72c-2a35-4abf-92a8-f38cfdb17aa1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_14d70f1d-d25e-4184-a309-8438404825fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_47febb5d-9287-41d9-9b2d-af8ee00d20cb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_40166018-f38f-4886-b622-7180b5ff0fd0_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionRightsMember_b7970316-29a5-4622-9b2a-0ec6612ab2cc_verboseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution rights and others</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b9ee75dc-9c3e-493f-9e3d-03a1f839ba05_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_158c9bed-df1d-40f0-b83e-63e76c17d698_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Each Class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cbf1822c-b279-4143-af1e-54b6b7452b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross Unrecognized Income Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_59195380-1ade-467c-8fd8-4a29f6835350_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_TotalRevenueMember_9a52a6c1-211a-4c48-b610-eff6c4efd12b_terseLabel_en-US" xlink:label="lab_isrg_TotalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_isrg_TotalRevenueMember_label_en-US" xlink:label="lab_isrg_TotalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue [Member]</link:label>
    <link:label id="lab_isrg_TotalRevenueMember_documentation_en-US" xlink:label="lab_isrg_TotalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TotalRevenueMember" xlink:href="isrg-20221231.xsd#isrg_TotalRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_TotalRevenueMember" xlink:to="lab_isrg_TotalRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_d0cce169-6b83-49e6-8014-188e5a1b40b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_291fb65b-2e89-4137-b2ef-a5c4eead9669_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cadc0bfc-11d4-4d36-bffd-493e62305c00_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on investments, accretion of discounts, and amortization of premiums on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_10f9f0f1-8279-436d-8e38-e9779f082d2a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_61e34861-c33b-446f-93a9-a768a018dd9b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses 12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_51606c85-c613-4dc5-adad-824c3e78a1e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b757930b-ef77-4804-bd05-bf9cb1e1982e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26e8d1b3-2a50-4b32-87cb-99802550ba8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ef24aa60-5789-429f-9746-1daba2e1af12_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_6fee8506-bed6-4489-93a2-d52418258dfc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_92d0958c-cf5f-40f6-9802-5880eff51619_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b25c6159-c2db-481e-8e60-c17dfa385f77_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b16f3e5b-3702-4637-9657-b694a3be8b8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3f3cee59-21b0-4f7a-99fb-5c8c9bf2ba11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_LowCreditRatingMember_cdb64e3a-07ce-44f8-af2b-f3b460eb1bc5_terseLabel_en-US" xlink:label="lab_isrg_LowCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low</link:label>
    <link:label id="lab_isrg_LowCreditRatingMember_label_en-US" xlink:label="lab_isrg_LowCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Credit Rating [Member]</link:label>
    <link:label id="lab_isrg_LowCreditRatingMember_documentation_en-US" xlink:label="lab_isrg_LowCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Credit Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LowCreditRatingMember" xlink:href="isrg-20221231.xsd#isrg_LowCreditRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_LowCreditRatingMember" xlink:to="lab_isrg_LowCreditRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_237e2728-9a1e-4c4f-8dd6-fab0cc286cc2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e63d993-5220-4f49-baf8-1e341d1d0537_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_8d4ac4d7-bb3b-4552-b51e-ff8d6c28d6aa_terseLabel_en-US" xlink:label="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and loss on disposal of property, plant, and equipment, net</link:label>
    <link:label id="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_label_en-US" xlink:label="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label id="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_documentation_en-US" xlink:label="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:href="isrg-20221231.xsd#isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:to="lab_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_77472fd7-7805-42a5-b43f-389e850a6c19_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amounts of outstanding currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_19fb2985-32e1-4ace-9cf3-d882e6a68df1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2022, and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c782fedd-2be7-4888-958a-37af841909c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_84baf5ea-cf70-4928-b7f6-d5165c5341d4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_58cd3364-2624-4e6e-a471-a77a83ba6dfd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_d5508472-5f5b-4c8a-b602-6862144b2327_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge instruments (net of tax):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_044b2ac9-86f8-4b72-b3d6-9f007e599a53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_f8d3c6a2-5a85-43be-b920-bee35da8992a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_4695760d-4d48-43fa-8a51-632fc71ff7e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d61176c0-592b-4fcd-944e-eb3db9b689f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_16aab4ac-5f3b-4bb9-be51-c6355851a890_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_ee7777bd-1e7c-4b60-8d2f-663bc5edfb2a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7a5b0ba6-cd73-44e8-be4b-c8faaa6a4c1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_9246e1fc-00ea-4ccf-b796-d7bdb2f14c67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reclassification adjustment for losses on employee benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_33925414-5514-4a21-bbd7-1fd5f2e5806a_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c7641e14-f2ec-4084-8ec9-7fcd0c352916_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Joint Venture</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SalestypeLeaseDeferredSellingProfit_20e35e07-3abe-414e-9cca-49a8d48bb9fd_negatedLabel_en-US" xlink:label="lab_isrg_SalestypeLeaseDeferredSellingProfit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned income</link:label>
    <link:label id="lab_isrg_SalestypeLeaseDeferredSellingProfit_label_en-US" xlink:label="lab_isrg_SalestypeLeaseDeferredSellingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Deferred Selling Profit</link:label>
    <link:label id="lab_isrg_SalestypeLeaseDeferredSellingProfit_documentation_en-US" xlink:label="lab_isrg_SalestypeLeaseDeferredSellingProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Deferred Selling Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalestypeLeaseDeferredSellingProfit" xlink:href="isrg-20221231.xsd#isrg_SalestypeLeaseDeferredSellingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SalestypeLeaseDeferredSellingProfit" xlink:to="lab_isrg_SalestypeLeaseDeferredSellingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_a32582d0-9c50-422f-a021-d06810ad5cd1_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_c7de103c-0d84-45c4-9a88-7b5ef906afeb_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_fee7e98f-a427-4888-8203-ab56994d0388_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AuditInformationAbstract_9549bde5-5125-444f-8ce3-2ef2a7bb247f_terseLabel_en-US" xlink:label="lab_isrg_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_isrg_AuditInformationAbstract_label_en-US" xlink:label="lab_isrg_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_isrg_AuditInformationAbstract_documentation_en-US" xlink:label="lab_isrg_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AuditInformationAbstract" xlink:href="isrg-20221231.xsd#isrg_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AuditInformationAbstract" xlink:to="lab_isrg_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_81c6af3e-981b-4180-a40e-ace887d6fdb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ac792cf4-1d54-41ec-99a1-9063588f478d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bf49f79b-c96c-4b9a-8234-15d76fc1fa9c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_932c9bd8-6d93-430e-be0c-23964cea8333_terseLabel_en-US" xlink:label="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount charged to retained earnings during stock repurchases</link:label>
    <link:label id="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_label_en-US" xlink:label="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Charged To Retained Earnings During Stock Repurchases</link:label>
    <link:label id="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_documentation_en-US" xlink:label="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount charged to Retained Earnings under the par value of method of accounting for stock repurchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:href="isrg-20221231.xsd#isrg_AmountChargedToRetainedEarningsDuringStockRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:to="lab_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_771082ea-9b2e-468e-8f55-7155bfe8547c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33be0ce1-9a5e-472e-b68e-b448a76dc226_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9130d6e7-e202-4400-8015-c403d02b67b6_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_42bee09e-0686-443d-a6f1-20009787c949_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash, and intellectual property and other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3bd68a24-96d2-4d32-853d-0519d62cc5ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_97704ddf-241b-41ad-9564-c38380db9c14_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_5fb204d5-ac61-4dd0-952f-de0b069eb29e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_52438478-c6d5-4a96-854b-0b1f575dee5a_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_eab28f90-89d7-46e7-a702-6fb8660a2e08_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c0ce2a5c-c81d-4e5b-8725-ec6117b05725_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f6a4ca87-3ce4-48d7-b7ae-07811f31a1cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47492d66-35e0-454f-ac8a-ef453d09f5fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense related to employee stock plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_876b4d88-79e5-4b1c-8e81-bb61fb757878_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_53e01c42-a219-4a1d-b41e-e7466c75a62f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f84b7a24-5458-42a8-931a-45a405cbb911_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_PerformanceShareUnitsPSUsMember_e2b9b361-2154-492a-b09c-e47dfd7aa920_terseLabel_en-US" xlink:label="lab_isrg_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_isrg_PerformanceShareUnitsPSUsMember_label_en-US" xlink:label="lab_isrg_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs) [Member]</link:label>
    <link:label id="lab_isrg_PerformanceShareUnitsPSUsMember_documentation_en-US" xlink:label="lab_isrg_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_PerformanceShareUnitsPSUsMember" xlink:to="lab_isrg_PerformanceShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_bd9db1cc-85bc-4604-b0c6-d29337c7d920_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_257709e8-c534-43cf-b276-802a6737b2f8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_b1f8c86c-397a-4fd6-b2fe-e578e469a8bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4d8e06bb-8dfe-45eb-8125-4215d6de6143_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, options, expiration term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_2d6e4985-03ab-43e0-9913-e0c604a899f3_terseLabel_en-US" xlink:label="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, increased to authorized amount</link:label>
    <link:label id="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_label_en-US" xlink:label="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, increased to authorized amount</link:label>
    <link:label id="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_documentation_en-US" xlink:label="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased to authorized shares repurchase amount for Stock Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:href="isrg-20221231.xsd#isrg_StockRepurchaseProgramincreasedtoauthorizedamount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:to="lab_isrg_StockRepurchaseProgramincreasedtoauthorizedamount" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_InstrumentsandAccessoriesMember_e1967519-b83d-463d-ba43-968538e8a89c_terseLabel_en-US" xlink:label="lab_isrg_InstrumentsandAccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments and accessories</link:label>
    <link:label id="lab_isrg_InstrumentsandAccessoriesMember_label_en-US" xlink:label="lab_isrg_InstrumentsandAccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments and Accessories [Member]</link:label>
    <link:label id="lab_isrg_InstrumentsandAccessoriesMember_documentation_en-US" xlink:label="lab_isrg_InstrumentsandAccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments and Accessories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InstrumentsandAccessoriesMember" xlink:href="isrg-20221231.xsd#isrg_InstrumentsandAccessoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_InstrumentsandAccessoriesMember" xlink:to="lab_isrg_InstrumentsandAccessoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_268fdade-8938-4c80-9227-d266de84a164_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5a4f1b39-d1af-44c4-82cd-485571680cc3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AccountsReceivableExtendedPayment_8f59d9f4-6687-43a3-a4d1-a1c50aa26943_terseLabel_en-US" xlink:label="lab_isrg_AccountsReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Extended Payment</link:label>
    <link:label id="lab_isrg_AccountsReceivableExtendedPayment_label_en-US" xlink:label="lab_isrg_AccountsReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Extended Payment</link:label>
    <link:label id="lab_isrg_AccountsReceivableExtendedPayment_documentation_en-US" xlink:label="lab_isrg_AccountsReceivableExtendedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Extended Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableExtendedPayment" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableExtendedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AccountsReceivableExtendedPayment" xlink:to="lab_isrg_AccountsReceivableExtendedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_eab41268-0aaa-463d-bb8a-183864aa9e9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices, minimum (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_72ac98ec-3da5-4008-b9c8-f1d7d536f31f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8b9c1366-657d-441f-8dbd-819f252fb140_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_f856acbb-f135-4cb1-b1a9-6408694b9afc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains/(losses) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d8c41245-21c9-48ec-b591-08188ce0465a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_979139d4-df7e-49e9-a625-5e9b427767ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of shares vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_1c572d3e-79cc-417d-8d82-d4c5bc4adb50_terseLabel_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance change (shares)</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_label_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_documentation_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:to="lab_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0f19e220-62ba-46e0-a9e6-4d479a53a0f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1cf62d64-f3fd-4fda-85ef-d7ad626365b2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_197f3cd3-92aa-434b-b565-f94debbd32b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock_4e97276b-2d12-4e07-a90a-f38ebc50c404_terseLabel_en-US" xlink:label="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Sales-type Lease, Lease Income</link:label>
    <link:label id="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Sales-type Lease, Lease Income [Table Text Block]</link:label>
    <link:label id="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Sales-type Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:href="isrg-20221231.xsd#isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:to="lab_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d84f8c7e-383e-41e7-baae-972c1e6c387b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I.R.S. Employer Identification No.</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fe42b110-0272-4bcc-a722-d6a3fd51d86c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock reserved for issuance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_56dfe216-6e81-42e3-b4cc-e9a82c5744d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on fair market value on the purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_5e3d7abd-7869-4c05-a589-764f4149a450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Fair Values Of The Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions and Fair Value of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_0e9fb0d1-a535-4047-b349-385d4f4938be_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f73885ca-f986-42e9-8695-e2aa8f43ca78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld related to net share settlement of equity awards (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_ed503b00-f85d-4878-bad0-6778729db36f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax litigation charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_87a75396-b50b-4da0-a82a-cd825aa4e1f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Income Tax Difference From The Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3056aac5-a0ca-4181-840f-07638d286a2f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c0cac72d-17da-4f7e-8b91-f20aa5371ffa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fb55d60c-86b6-4fd3-8f7f-f7c4fb4d86d3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_328ebae6-0b43-46e9-9047-94dd6bec13e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ead2f0c5-7554-4c94-bfb9-4e964b2341b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c8d9c72-d408-4b0d-a758-c6dfcec8e64f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_e6fa709c-9eac-4f92-ab55-8ed3f2cfed84_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e097c778-2b78-4bef-b42e-77c521c4a366_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_002b3851-3a7b-487c-9e9c-028f177db122_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_aae75305-49fe-4f7c-8ae8-2b9ba8a7c2f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available-For-Sale Investments With Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_1898b69f-bf9d-4137-9232-e90418eb2dda_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaids and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_26c64909-ea85-4ab7-9727-d29bc1f0fed8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contributions, per person, per year</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_483f5300-c723-476f-992c-6d3b2f8035a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_61c89670-df15-46fa-b0cc-4e21a8fdbbcd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Net Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_87879e4f-9c5f-4a54-ab38-f0d35c43b524_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_278191f2-ccd3-422f-be78-aa62d0ff24a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at grant date (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_f5e3a60e-43ec-44a5-907c-c9704fce5f8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ce824d70-579c-42c6-8523-496f0bfbd55e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_4f4796ad-212d-4615-983c-11fcafb5f0ad_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_eade6e09-2d2f-4474-bd4a-2e87f2f737e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_84fedcd1-9a03-47ac-8fa8-34395fd24425_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9c349261-bf4d-409b-8bf1-413943dbc355_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation Of Basic And Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f84ff206-7363-4a1a-b8ef-18d21f99aafc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets recognized related to new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5fe49c1f-0b20-4fc7-b096-5b67bc52be25_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_78113867-75f1-4baf-8379-e13702e2055b_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_30ce4322-27c1-4e05-a2be-d10a417a09d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c122799a-ab8f-4151-abba-2ed1d3aa3369_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_a1064d85-f4a0-458d-8db5-8952d1bd03e6_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Year One, Originated, Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e0a9c644-831c-477a-9419-9bd17ce45995_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8c9306c2-468a-4cd5-ba2d-cfbb43d6a923_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_NewHireOptionsMember_6b27776e-3c1d-415a-8032-d81c1ea3c2e6_terseLabel_en-US" xlink:label="lab_isrg_NewHireOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Hire Options</link:label>
    <link:label id="lab_isrg_NewHireOptionsMember_label_en-US" xlink:label="lab_isrg_NewHireOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Hire Options [Member]</link:label>
    <link:label id="lab_isrg_NewHireOptionsMember_documentation_en-US" xlink:label="lab_isrg_NewHireOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Hire Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NewHireOptionsMember" xlink:href="isrg-20221231.xsd#isrg_NewHireOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_NewHireOptionsMember" xlink:to="lab_isrg_NewHireOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c2dc98c4-190a-4eed-af1b-42bfa9c956f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_703ce1c9-534f-4e98-af89-95b3ee743d70_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeTenMember_3ae938e7-1dcb-47eb-b6e5-4fefc74fa282_terseLabel_en-US" xlink:label="lab_isrg_RangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 10</link:label>
    <link:label id="lab_isrg_RangeTenMember_label_en-US" xlink:label="lab_isrg_RangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Ten [Member]</link:label>
    <link:label id="lab_isrg_RangeTenMember_documentation_en-US" xlink:label="lab_isrg_RangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Ten</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTenMember" xlink:href="isrg-20221231.xsd#isrg_RangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeTenMember" xlink:to="lab_isrg_RangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_bc2da0fd-cafd-4dfc-86c6-5f818ec64941_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5fa957d1-d66c-4340-8f34-b612e5c386d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c29a1bbf-a987-49b4-9cdd-b597896de86c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_073d0f02-cb75-4a67-9457-e2352bb23a19_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_50d433d5-aa04-44d9-97cc-d317a959cd60_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_88b39a32-8878-4383-b8ad-acc222a3a593_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal use software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_0baaa3e6-8eac-49e4-aba2-6bf6e8d4d670_totalLabel_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value, Fair Value</link:label>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_label_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Debt Securities, Available-for-sale, Fair Value</link:label>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_documentation_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Debt Securities, Available-for-sale, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:to="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeTwoMember_4b3a26a3-e6c3-4d12-b180-e992c8dbae67_terseLabel_en-US" xlink:label="lab_isrg_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 2</link:label>
    <link:label id="lab_isrg_RangeTwoMember_label_en-US" xlink:label="lab_isrg_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_isrg_RangeTwoMember_documentation_en-US" xlink:label="lab_isrg_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTwoMember" xlink:href="isrg-20221231.xsd#isrg_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeTwoMember" xlink:to="lab_isrg_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_53af5dc7-eaef-4877-b317-b4847e06bd54_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95f06b15-30ba-4b18-bbb7-09edfb848381_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_fe514b1b-3438-4f63-941e-05b02862ea9c_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to expiration of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_BroncusHoldingCorporationMember_385dfc96-fa18-4ff2-87cb-1ec735810f52_terseLabel_en-US" xlink:label="lab_isrg_BroncusHoldingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broncus</link:label>
    <link:label id="lab_isrg_BroncusHoldingCorporationMember_label_en-US" xlink:label="lab_isrg_BroncusHoldingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broncus Holding Corporation [Member]</link:label>
    <link:label id="lab_isrg_BroncusHoldingCorporationMember_documentation_en-US" xlink:label="lab_isrg_BroncusHoldingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broncus Holding Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_BroncusHoldingCorporationMember" xlink:href="isrg-20221231.xsd#isrg_BroncusHoldingCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_BroncusHoldingCorporationMember" xlink:to="lab_isrg_BroncusHoldingCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AwardedtoAxis_b35555ac-dc71-494e-8c64-6a2ecff71cd7_terseLabel_en-US" xlink:label="lab_isrg_AwardedtoAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded to [Axis]</link:label>
    <link:label id="lab_isrg_AwardedtoAxis_label_en-US" xlink:label="lab_isrg_AwardedtoAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded to [Axis]</link:label>
    <link:label id="lab_isrg_AwardedtoAxis_documentation_en-US" xlink:label="lab_isrg_AwardedtoAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded to [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoAxis" xlink:href="isrg-20221231.xsd#isrg_AwardedtoAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AwardedtoAxis" xlink:to="lab_isrg_AwardedtoAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_550d8902-66d0-4518-b6ac-f26906c6d34e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_008ebd7c-6ee0-495c-9306-0ba363f10602_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Intuitive Surgical, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_275ce504-3776-4992-bb58-15b5e0c008a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ServiceFeeCredit_478d570d-e7bc-4bd5-9d70-88641472b3fc_terseLabel_en-US" xlink:label="lab_isrg_ServiceFeeCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Fee Credit</link:label>
    <link:label id="lab_isrg_ServiceFeeCredit_label_en-US" xlink:label="lab_isrg_ServiceFeeCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Fee Credit</link:label>
    <link:label id="lab_isrg_ServiceFeeCredit_documentation_en-US" xlink:label="lab_isrg_ServiceFeeCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Fee Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ServiceFeeCredit" xlink:href="isrg-20221231.xsd#isrg_ServiceFeeCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ServiceFeeCredit" xlink:to="lab_isrg_ServiceFeeCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_31cf15e9-ff8b-427f-bb63-cb7c65d13168_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_af71c26d-3511-47b4-be16-e72af35654d9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in one to five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_8a3cedde-8838-434b-bb9b-9feeceddf0b2_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_6a80d9ab-bb69-4c64-9a46-bac14ee2859c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses deducted in later years for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans_cbeff939-36b4-492b-81b9-96dd298f4bec_terseLabel_en-US" xlink:label="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration for each offering period</link:label>
    <link:label id="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:to="lab_isrg_OfferingPeriodEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8e94e73a-c3a3-4bea-b356-adf8d74417f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_db6d8e4a-4b9d-49c3-9b6c-08fdc3369bab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_df258adf-20a1-4ea3-a2ac-d083237a5e20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d29a7869-5f4e-4d3d-bf65-7291dc96e6ea_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_dafa780b-b4a1-4b32-94ae-112d47b18ff1_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense after income taxes</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_59a82761-7367-43d5-bb6e-ca04248d32e6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_ec0ef0c4-849d-45bc-b508-ae6e411f4fb7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_9fafa191-107e-44df-88c2-bce4cac83c91_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c7552086-e3d7-4fbf-b806-81d538298835_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c4d2e4b9-a721-4da3-be87-295e3250f1cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_082fe53b-a9c1-4cc4-9a84-ec7c0dcdd454_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_83139e32-0b9b-47ce-8298-d3f8af7d3040_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Notional Amounts for Outstanding Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ConsolidatingReportingDomain_51723ecb-c11d-4e7b-bf6f-b9577ef6d392_terseLabel_en-US" xlink:label="lab_isrg_ConsolidatingReportingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Domain]</link:label>
    <link:label id="lab_isrg_ConsolidatingReportingDomain_label_en-US" xlink:label="lab_isrg_ConsolidatingReportingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Domain]</link:label>
    <link:label id="lab_isrg_ConsolidatingReportingDomain_documentation_en-US" xlink:label="lab_isrg_ConsolidatingReportingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingDomain" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ConsolidatingReportingDomain" xlink:to="lab_isrg_ConsolidatingReportingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_a5886ad7-71ba-48ac-9df7-3f0ff208cd98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of the Other Accrued Liabilities&#8212;Short Term Balance Sheet Item</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_282dde81-a74d-4b1b-9450-44dea1f47b55_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_0648f382-287c-4a86-8018-69028d626899_terseLabel_en-US" xlink:label="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease Revenue, Usage-Based Arrangements</link:label>
    <link:label id="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_label_en-US" xlink:label="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease Revenue, Usage-Based Arrangements [Member]</link:label>
    <link:label id="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_documentation_en-US" xlink:label="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease Revenue, Usage-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:href="isrg-20221231.xsd#isrg_VariableLeaseRevenueUsageBasedArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:to="lab_isrg_VariableLeaseRevenueUsageBasedArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ef84126-0b1c-4df5-94c5-010854c25037_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_01afca89-2766-43f1-bde7-65b387d99292_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. tax on foreign earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_288747e3-cfc4-4fa5-bcbd-de0316b0e294_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ecba2dd2-27d8-41b4-bc52-fbecb98c3412_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum rate of employees' contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_9eb92dd4-2989-4f5c-83b7-74f8c5a661d1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7cb2aa0f-1777-4d15-adb8-0b15272db6be_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_7571f931-0264-4814-865d-0b54790ccc1b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Originated, More than Five Years before Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e0e9c248-bef9-4a5c-b0b4-bd00105beb29_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems_cdcdab07-e65c-4792-a600-0f82381573c6_terseLabel_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_isrg_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_2d882718-3c4d-4b0f-bf86-53ccd0c5148c_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents and developed technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_83518716-01c1-4b03-95fe-41100de4154c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of The Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d224bbaa-d2ab-4fc2-aae6-293ca52b41b4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of the Property, Plant and Equipment, Net Balance Sheet Item</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EmployeesMember_45ae7502-377d-441c-b772-a92058a21b94_terseLabel_en-US" xlink:label="lab_isrg_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_isrg_EmployeesMember_label_en-US" xlink:label="lab_isrg_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_isrg_EmployeesMember_documentation_en-US" xlink:label="lab_isrg_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EmployeesMember" xlink:href="isrg-20221231.xsd#isrg_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EmployeesMember" xlink:to="lab_isrg_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_de3ab76b-70ad-4c37-8727-e954c8d9ea4e_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Year Four, Originated, Three Years before Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9c406cec-898d-4bd7-82de-8c118ebe6a02_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation_69691181-9b7f-4aa3-91af-efb0a09ed0f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with operating lease assets - Intuitive System Leasing</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Lessor Asset under Operating Lease, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_5f791d13-4c24-42d4-8d84-aca5d405dae4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05a17c03-b352-4c05-90d8-94bc46d9fd57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a2cff9cc-805f-492a-8e27-374dac30630b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_8bed0ad3-74ff-44c2-b49b-efb8a87ced9b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e0604e97-034b-4aa5-aceb-cb508c966a07_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_517e16d9-61d1-48c9-b1be-4b35389eedf1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_063a88ef-c5fd-4a3d-9c93-c632023012e4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to tax positions taken during a prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bece40f2-1c0b-4482-901a-cfe800efe411_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ec3bf351-0c7a-4237-aa8a-03c1bb257f84_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_5dde2c0e-b7a4-47ca-8063-4dbc9a105043_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_1ae4bda9-0bf4-408d-ad9c-9552ee27201a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6e0e62a1-b0e1-4d2a-b046-bbf63d20c173_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_1b1dbdcd-e556-4776-b114-a8a64ab6de5a_terseLabel_en-US" xlink:label="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2000 Non-Employee Directors' Stock Option Plan</link:label>
    <link:label id="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_label_en-US" xlink:label="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Non Employee Directors Stock Option Plan [Member]</link:label>
    <link:label id="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_documentation_en-US" xlink:label="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Non-Employee Directors' Stock Option Plan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:href="isrg-20221231.xsd#isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:to="lab_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_301e2f53-09f9-4c78-9089-44b53785d187_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_8bacd525-519e-42f2-bbb7-78608e2b5124_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_f53b84c9-0357-4d5e-8324-538c1387a731_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_82edae45-2006-463d-8048-245bbd468184_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_db0d4116-a145-4e79-ac1d-43521188a91b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_b84cca6f-1498-4547-96b9-39c91c0f6c9f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Year Five, Originated, Four Years before Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4fcc671f-ca00-4c4b-ba2b-b0dd8ac78699_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Intuitive Surgical, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a34133c4-3c6e-408a-b887-f269d5fe6dbc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_StockOptionsGrantedInitialVestingPeriod_5c0a6114-7b80-41e3-b095-261c9eacc3d7_terseLabel_en-US" xlink:label="lab_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted initial vesting period, years</link:label>
    <link:label id="lab_isrg_StockOptionsGrantedInitialVestingPeriod_label_en-US" xlink:label="lab_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Granted Initial Vesting Period</link:label>
    <link:label id="lab_isrg_StockOptionsGrantedInitialVestingPeriod_documentation_en-US" xlink:label="lab_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted initial vesting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:href="isrg-20221231.xsd#isrg_StockOptionsGrantedInitialVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:to="lab_isrg_StockOptionsGrantedInitialVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09545ee1-a5d9-40bf-892a-bccfec222785_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_93b993b1-418f-4b4c-8e95-9c2814e81463_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock_04f8be51-7555-4c9b-8564-3a05fcea9bbb_terseLabel_en-US" xlink:label="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock Repurchase Activities</link:label>
    <link:label id="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock_label_en-US" xlink:label="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Repurchased [Table Text Block]</link:label>
    <link:label id="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock_documentation_en-US" xlink:label="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Repurchased [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:href="isrg-20221231.xsd#isrg_ScheduleofCommonStockRepurchasedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:to="lab_isrg_ScheduleofCommonStockRepurchasedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9920b7d0-51e6-4621-827f-84dbaa9ba089_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionDomesticMember_ad2ad08f-bde1-4eb5-b3c2-33c9d2c60089_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomesticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionDomesticMember_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomesticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution, Domestic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomesticMember" xlink:to="lab_us-gaap_GeographicDistributionDomesticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_67e3c659-8dd2-490d-a626-8b636157cd3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b36cb49-ea4b-4793-9954-661406c74a78_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c9b78a86-f0c5-4ea8-bf4e-a62db402f7a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_c380c7f5-c8eb-4eca-a65c-452cb17a126d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_128fc475-95c3-4118-a296-5e294fefe109_terseLabel_en-US" xlink:label="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum months employed per year</link:label>
    <link:label id="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Months Employed Per Year To Participate In Employee Stock Purchase Plan</link:label>
    <link:label id="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum months employed per year to participate in employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:href="isrg-20221231.xsd#isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:to="lab_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeFourMember_36dbc578-8c23-43cc-b28a-70d07c76a7b5_terseLabel_en-US" xlink:label="lab_isrg_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 4</link:label>
    <link:label id="lab_isrg_RangeFourMember_label_en-US" xlink:label="lab_isrg_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label id="lab_isrg_RangeFourMember_documentation_en-US" xlink:label="lab_isrg_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFourMember" xlink:href="isrg-20221231.xsd#isrg_RangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeFourMember" xlink:to="lab_isrg_RangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fe63978b-05cd-4e4d-b98e-0225c9fd28e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ff01c51f-9cb2-4352-9c38-6125badcad43_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bef0fb7f-df9f-4542-ac29-f5ae0aaeb9f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_b74625ae-765b-4ca1-8638-d3dfc30b350e_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Leases</link:label>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_4e64cd1b-d1a1-447f-bd94-efd5196c46b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_8d26f62b-4bdb-4e8b-ab87-dbda8bb3048e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock relating to employee stock plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_5efebd73-8f37-43f5-a870-7e65bcc8ddb4_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_43866dd5-ca08-4129-b03d-a483c5629f85_terseLabel_en-US" xlink:label="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding</link:label>
    <link:label id="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_label_en-US" xlink:label="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding</link:label>
    <link:label id="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_documentation_en-US" xlink:label="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:to="lab_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_21093ab7-c46f-446a-a27a-e6eb3db08577_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_e10f5fa6-47aa-45ca-91d2-18a084bec3c2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_57cc34b1-b5dd-44fa-9035-fdf56aa01309_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2e0c7949-58c2-49cf-90ad-a558af531015_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_d268e12e-3de9-4d7d-aec7-0221efcf8753_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_7a307db6-4dc9-4a90-858f-36c9ba7c1a43_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vesting at the end of one month</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting at the End of One Month</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting at the End of One Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_275c2822-dcc2-4233-8172-b76d991f0d19_terseLabel_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Employment Commencement Incentive Plan</link:label>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_label_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Twenty Zero Nine Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_documentation_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2009 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:to="lab_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_a4e73209-319b-471b-be4c-11631b90595d_terseLabel_en-US" xlink:label="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets, percent</link:label>
    <link:label id="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_label_en-US" xlink:label="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Maintained In The United States Percent</link:label>
    <link:label id="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_documentation_en-US" xlink:label="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets maintained in the United States.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:href="isrg-20221231.xsd#isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:to="lab_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d141cff0-6125-43b8-8d38-2c5f115070c9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in joint venture</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_403358b9-51f6-4b4d-adb6-773585ffde48_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_8ba47f36-41ec-41fd-9db0-e2f17882fdfb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported as:</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Net Investment in Sales Type Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract" xlink:to="lab_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_5a999a09-922b-48ba-81c4-70f32ba55f48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_e9ca7c2f-f729-4442-aacf-3406fcd05c32_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross interest related to unrecognized tax benefits accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ConsolidatingReportingAxis_15eb3036-83d8-494f-8658-a07719eb659c_terseLabel_en-US" xlink:label="lab_isrg_ConsolidatingReportingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Axis]</link:label>
    <link:label id="lab_isrg_ConsolidatingReportingAxis_label_en-US" xlink:label="lab_isrg_ConsolidatingReportingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Axis]</link:label>
    <link:label id="lab_isrg_ConsolidatingReportingAxis_documentation_en-US" xlink:label="lab_isrg_ConsolidatingReportingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidating Reporting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingAxis" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ConsolidatingReportingAxis" xlink:to="lab_isrg_ConsolidatingReportingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_b53b3759-cfaa-4bab-a9fa-d76ae66d9458_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_e9200fc3-7020-4ce5-95f1-3f46276dc84a_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c452a4bb-cc3e-49ea-8fac-09bd1cf13e7a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f16a9111-1190-40ce-8bd5-012c3449f58d_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d6746d0c-05ce-4a4a-9e9b-7acf7298c8bf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_24a43a58-4d19-4455-b053-fe758cf94c4a_terseLabel_en-US" xlink:label="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment in sales-type leases &#8211; short-term</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_label_en-US" xlink:label="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Current</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_documentation_en-US" xlink:label="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:to="lab_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalNotesMember_4bebd509-bc96-4967-a3fa-b82926739fde_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalNotesMember_label_en-US" xlink:label="lab_us-gaap_MunicipalNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalNotesMember" xlink:to="lab_us-gaap_MunicipalNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember_80d655a5-8b42-4da4-9977-9825a107901e_terseLabel_en-US" xlink:label="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August ASR Program</link:label>
    <link:label id="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember_label_en-US" xlink:label="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August Accelerated Share Repurchase Program [Member]</link:label>
    <link:label id="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August Accelerated Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:href="isrg-20221231.xsd#isrg_AugustAcceleratedShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:to="lab_isrg_AugustAcceleratedShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_02ddabf0-6d8c-490f-ae75-609ff6a7fdea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8a06d15b-cf31-43c7-9a08-7d9080184d4a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to tax positions taken during a prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_04dc2000-fff2-4fdc-9939-c3d8e36b6d4d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_42fde426-3fa7-4645-9434-67d58f4bb94e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9e1b3dd6-4db9-4167-9aa1-3b4b4b5ed698_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3c82bec7-0704-4790-a029-cbb683953449_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0f305979-1ca9-4548-9145-c39c0db66bf2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_576c615a-9733-4d84-bb3e-03b6cf6b0303_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6cb6e097-c9e8-407b-8386-cf8629fea26d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_bcd89eb6-3bb1-4465-bee2-1aa6f9aa5a1c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_1815d0e5-5b39-4981-b433-f632e658091f_terseLabel_en-US" xlink:label="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shorter purchase periods that each offering period is divided into</link:label>
    <link:label id="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Number of Purchase Periods Offering Divided Into, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Period, Number of Purchase Periods Offering Divided Into, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:to="lab_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7f648020-a2b9-4e38-b1d1-3ef0998415df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7d697d90-9660-4670-8c90-a054106e87f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses 12 months or greater, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3b0e7309-042c-456e-b0d9-52b88ad11cc9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_c18aeb04-2933-4efa-804d-634414213208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b7acd7b-c065-425f-b1bb-2fe01b6f9835_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_ba670ef9-f5b5-45a5-93a3-2dff4f88ba6d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_HighCreditRatingMember_5f3255fa-4023-408d-86da-f7f91b95431e_terseLabel_en-US" xlink:label="lab_isrg_HighCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High</link:label>
    <link:label id="lab_isrg_HighCreditRatingMember_label_en-US" xlink:label="lab_isrg_HighCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Credit Rating [Member]</link:label>
    <link:label id="lab_isrg_HighCreditRatingMember_documentation_en-US" xlink:label="lab_isrg_HighCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Credit Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_HighCreditRatingMember" xlink:href="isrg-20221231.xsd#isrg_HighCreditRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_HighCreditRatingMember" xlink:to="lab_isrg_HighCreditRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b98068c8-7a95-49be-a0f2-e911f9188b58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_cc2dbb1d-0d65-4113-a67a-a2aeaee49842_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_54ad42e3-b495-4d98-b4a1-5a3c2a25fbfb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intuitive Surgical, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_84bd1854-527d-492a-8477-f2c3c0df89d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_27bf51fa-2ddc-4116-9f60-44e7db894ced_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8889aff6-f121-4e83-8ecd-ee103450dc52_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_6ff4d328-7481-4365-90d0-8ac1cc5e4137_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_773598b2-8537-40ac-a816-c104186a0103_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_3ce03448-8f6f-4b41-8114-d795e757b3ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0195d7b2-f99f-48a7-954a-8f0a6d8d8b81_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale securities and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_c896a951-7198-49d1-966d-ed04d8bb3379_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract acquisition assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ef36ea48-8121-49b6-af60-1fbfe1ca0ddd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_404c5471-37b5-47a2-81a9-d52beebc2049_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_7e6f9e1c-1606-44cb-b742-2478ffd88763_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_74d75149-bed7-4955-bdcd-f987624ff87b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_eb918902-2cfc-4590-83c7-fc01e6f2c293_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_64c1032a-f09a-44f4-927d-33dde3e69b20_totalLabel_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value, Amortized Cost</link:label>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_label_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label id="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_documentation_en-US" xlink:label="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:to="lab_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_9a069819-009a-491a-8979-5ac3047df9cb_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_33d6d264-8111-44eb-8ac8-980590a859ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_48fa3f5b-1aaa-4634-8e21-ad144989d7d6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_21bf857e-5fea-4f0a-bce4-2b7a51383eaf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow and Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26706fca-f452-467c-8178-0cfb00ed23b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SalesTypeLeaseGrossInvestmentInLease_031d1c92-64e7-4930-89ab-75cb82fcc90f_terseLabel_en-US" xlink:label="lab_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease receivables</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseGrossInvestmentInLease_label_en-US" xlink:label="lab_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Gross Investment in Lease</link:label>
    <link:label id="lab_isrg_SalesTypeLeaseGrossInvestmentInLease_documentation_en-US" xlink:label="lab_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Gross Investment in Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseGrossInvestmentInLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:to="lab_isrg_SalesTypeLeaseGrossInvestmentInLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e14a7546-edf4-4eb7-aaa5-ea07c9ec2d70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1e5831d7-e9cd-4cd1-bd72-d50fa23398b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_864d3482-902b-479f-9294-7abb406b5546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_ea313945-5179-4c88-b0a7-b6247f89a9c7_terseLabel_en-US" xlink:label="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of look-back that could cause offering period to reset</link:label>
    <link:label id="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Look-Back That Could Cause Offering Period to Reset, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Look-Back That Could Cause Offering Period to Reset, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:href="isrg-20221231.xsd#isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:to="lab_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d7cce455-62b8-4ca3-a830-5572fef38264_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b132d276-1f82-4459-98f8-9b6a448dcb22_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_b49c670c-5a6f-4426-8a04-d9a34fa15d69_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5cdf027d-0d2f-48cf-90e6-c03248f10878_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred purchase consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d309469e-cccb-4a72-aea3-3a3da555e669_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $22.4 and $20.2 as of December 31, 2022, and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_678b0f15-00a0-445c-8998-5083637b6456_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0a272047-0fe2-453f-92b1-9eaf48daa425_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_a6901136-ecb1-4ba4-8b02-b0143e3120a3_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8baa61c5-4168-4212-a630-27b38a12cefa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_6da8ce2d-abcd-491d-b422-aec62d5083d9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeNineMember_40f52c76-7103-4e73-aa42-6487830f24b5_terseLabel_en-US" xlink:label="lab_isrg_RangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 9</link:label>
    <link:label id="lab_isrg_RangeNineMember_label_en-US" xlink:label="lab_isrg_RangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Nine [Member]</link:label>
    <link:label id="lab_isrg_RangeNineMember_documentation_en-US" xlink:label="lab_isrg_RangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Nine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeNineMember" xlink:href="isrg-20221231.xsd#isrg_RangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeNineMember" xlink:to="lab_isrg_RangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9e1c5fc8-5205-4e91-8462-2ec3af49d877_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_004be1bd-0945-4b3c-b493-478b8486ea05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited/expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_56c2a54c-f675-4ba9-bb5d-b246cbc621fb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9aaafd8f-98b2-4133-b3d7-05ced5343c82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b28aa083-7c1e-4707-9c1e-561f81539052_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed469069-0f67-46ef-94cf-ccdbe6b5192a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d5e243ae-4a83-4a0a-920f-0f97859d0f50_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7c85c945-35b9-4272-8a08-dcbcb3bc4355_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_fa830827-5366-4af2-a040-ace82351bb23_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_372a5531-4d3a-4e51-999c-0cb1ccc962c2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_38aa93b3-4278-41c7-9e09-70adff8735cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9bd0ac65-dbb2-4192-a89b-bbb1dacc3ae7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and other assets, net (Right-of-use assets)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_242bda92-f1e5-421f-867c-f1dc02a14208_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a685ce42-4a7a-4697-8711-6b7cb86172f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)/Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_027a887a-59cc-45e7-8c14-80a5fae48d86_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_a63b1126-86d2-419b-9aa8-abbf92a6c023_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_b2746741-3cf1-40e8-807c-025a0acb25df_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2ae70acf-0aaf-4667-932e-205968bf34c4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_aedafb99-5d1e-4d89-8b29-032064838980_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_60ec9460-fbfe-4e0b-978d-26c19e9c26e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Stock Option Activity Under All Stock Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b3835044-9d64-417a-af5b-056c951350bb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_632bd443-9f21-46ed-b8db-2d7ca278d6df_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cb1596ec-d2d6-4c21-8d3b-62146a56fe8e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3bb9739a-942d-42bd-9a97-e058b520fa38_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_6068e3a1-80ce-4135-b1c2-418f050cda7d_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_c684b240-2189-4897-b012-b0ae2dd757c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_b0f33d95-9e6c-4d69-b749-7c2c39eab4e4_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vesting upon one year of service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon One Year of Service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon One Year of Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6a293edc-b29b-4660-a10f-c865510c61cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bbbf8624-c5a5-45fa-99e9-9d538628403c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0c02ad66-33df-48de-9646-e92f4a85bc0c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0b68d664-5380-4e99-b4f0-8f11b75bb2ed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeOneMember_31d7006e-c3ff-4000-b60f-c7e37c83868c_terseLabel_en-US" xlink:label="lab_isrg_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 1</link:label>
    <link:label id="lab_isrg_RangeOneMember_label_en-US" xlink:label="lab_isrg_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_isrg_RangeOneMember_documentation_en-US" xlink:label="lab_isrg_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeOneMember" xlink:href="isrg-20221231.xsd#isrg_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeOneMember" xlink:to="lab_isrg_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_406bd6ba-62bb-4f83-afd4-cc3f5ffbdf02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_fc720287-d11e-41ef-9c67-322d5b277c05_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_88db406b-cce4-43d4-83b5-be6b860c4a93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1809463f-d69e-4be1-9358-d568c857f9f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_47c59264-74a1-457d-ac91-f6e7d558be01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9748f786-4421-4721-bf93-49f9201e68d9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d8580fef-2f3b-488f-8d73-d79d3d632485_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_841e7188-af43-43fa-b1fc-c404f600f073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised under stock option plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b424c97-9924-4677-a1b8-a92af14627ad_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6fe6eb46-6feb-4420-9a7e-509253c551fa_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing diluted net income per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4cff5958-4bfd-4bf5-acec-158efa73ee94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of the Inventory Balance Sheet Item</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4e6c9e6-7888-4468-9fd6-fe4ae2b280b7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_03e495ba-cdca-4922-b0bf-a095d336cc85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c41d649f-4ead-4b40-a42b-5b18ff209d44_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_f16926c9-4464-4054-a74f-2088e3ef04c7_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vesting per month after six months of service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After Six Months of Service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After Six Months of Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_cd1e6ceb-13da-4fb4-a9e2-2986ce04b8bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets &#8211; Intuitive System Leasing</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59445065-5ee8-4187-b8a5-3c36ce461f45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_c07df305-b6f1-4716-800f-ceeb0339c8e4_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_749e2bfa-7d5d-4da3-91f8-7e4bc65ee4b2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_374ea2bf-7435-4d40-8787-a9fa2e23e148_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5eec3ea7-cb68-423a-8ea8-bcf05d75e312_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2967c0ed-ea77-4ead-8084-91202839849d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income attributable to noncontrolling interest in joint venture</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ffba287d-8f28-456a-ad17-9a3df9e24277_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest in joint venture</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a2a9f2e1-4e71-45ec-9c80-bf08b69e0506_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_b953f08f-3620-4b7a-a23b-58762b421941_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_45f81643-aef5-4027-9c87-e190aff12b73_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AnnualGrantOptionsMember_f7a23b50-8363-4b5e-ae6b-02320caa2a9d_terseLabel_en-US" xlink:label="lab_isrg_AnnualGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Grant Options</link:label>
    <link:label id="lab_isrg_AnnualGrantOptionsMember_label_en-US" xlink:label="lab_isrg_AnnualGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Grant Options [Member]</link:label>
    <link:label id="lab_isrg_AnnualGrantOptionsMember_documentation_en-US" xlink:label="lab_isrg_AnnualGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Grant Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AnnualGrantOptionsMember" xlink:href="isrg-20221231.xsd#isrg_AnnualGrantOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AnnualGrantOptionsMember" xlink:to="lab_isrg_AnnualGrantOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_101d4c95-1784-4db8-a8bc-215169bb0def_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2df972f2-3185-42b4-a795-cf87bf72d0a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on&#160;Hedge Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9589c548-175f-4bbc-9fe3-9b105400d376_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property, plant, and equipment in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9e07b1f2-ceac-43f0-bcb7-91c5acf516b9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses) related to balance sheet re-measurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_fc024e7a-9f87-49ef-80ad-9b10137dfd1f_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="lab_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15ad9ea-3d38-43f9-8a1a-5f441f417eea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_af67c811-df91-4041-9345-223dac89dc1b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_0d4fc4d7-0c79-424a-8103-811177b06487_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table]</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_a411c5ca-869b-4e74-b364-12d1dff06182_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_43d9e942-b0b5-492b-ae05-baa23e2243fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7e351482-66e8-4f39-9583-1eaef58a4d31_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Intuitive Surgical, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_477813bb-e577-4792-8384-7181abd64733_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3703131e-9211-42dd-b8ad-97d86789d718_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from option exercises and employee stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_CommonStockRepurchaseProgramMember_f0e46684-6f1e-4738-8bb2-a95f46bc6e7f_terseLabel_en-US" xlink:label="lab_isrg_CommonStockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Repurchase Program</link:label>
    <link:label id="lab_isrg_CommonStockRepurchaseProgramMember_label_en-US" xlink:label="lab_isrg_CommonStockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_isrg_CommonStockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_isrg_CommonStockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CommonStockRepurchaseProgramMember" xlink:href="isrg-20221231.xsd#isrg_CommonStockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_CommonStockRepurchaseProgramMember" xlink:to="lab_isrg_CommonStockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9dae0563-e767-4191-9e0f-cc44aaee4bf1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_60342fb1-256d-432a-98e7-509c81129480_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0bef0dc6-0019-4525-8c75-37eed0436d7c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_63bbc86d-8847-4ac5-9751-bbebabb08ade_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesTable_d23bdd38-eca9-42e9-9b7d-14dffe67ab0b_terseLabel_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_isrg_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_isrg_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_04cb6829-ca1f-4d13-b030-f5f78617007a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation and other</link:label>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Translation and Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d9cc4f70-abaa-448b-8e7e-f07600d57625_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2e2124c2-d4e3-40ec-8b79-c1db4d6d9856_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0072ed76-e8aa-4124-8354-68f79484a6e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_26d966f4-f6f6-4a3d-8105-36712aeb6566_terseLabel_en-US" xlink:label="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges de-designated (period)</link:label>
    <link:label id="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_label_en-US" xlink:label="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Designation As Cash Flow Hedges, De-Designation, Period</link:label>
    <link:label id="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_documentation_en-US" xlink:label="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Designation As Cash Flow Hedges, De-Designation, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:href="isrg-20221231.xsd#isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:to="lab_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2253a063-7a57-4693-838f-72037c4c3be1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0ac78c3-8b83-491b-9628-f3acd43ff8a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_1b72d018-cf7e-4f12-b789-24dd4d491104_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation-related accruals</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ae9a5371-9e20-4961-8af4-71901d6e8b18_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71f61559-aa1e-4350-857d-7cfb072e2290_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_10d566ba-b4e6-4afc-9336-3abd5516c018_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d22135cd-2e25-4b2c-a05b-93eea46bc18b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_311dbac9-4cfe-40d4-adf3-8e3fb76aabba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Future Amortization Expense Of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_e159948c-7a6b-4d7e-9868-68fdba870898_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_c964ec9d-042e-46c3-9508-027ccba8b760_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vesting per month after one year</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After One Year</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_635bff8a-2f3c-4177-8c33-85b473435160_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e9d9c69a-78a9-442a-a819-91c41cf8b28d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_08a37ab0-ef2d-407c-b9a4-650e011c733e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_d7e1baf2-49d9-4af5-879b-b580b4f7d32e_negatedLabel_en-US" xlink:label="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of unrecognized tax benefits</link:label>
    <link:label id="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:label id="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_documentation_en-US" xlink:label="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cc96c94a-45e2-454c-bab3-fd51a53bf7a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5d120a6-fb60-47ce-903e-dad36e764429_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EquipmentAndFurnitureMember_228b07e9-34c4-4654-8b71-7ea9cbb20ad4_terseLabel_en-US" xlink:label="lab_isrg_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and furniture</link:label>
    <link:label id="lab_isrg_EquipmentAndFurnitureMember_label_en-US" xlink:label="lab_isrg_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:label id="lab_isrg_EquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_isrg_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquipmentAndFurnitureMember" xlink:href="isrg-20221231.xsd#isrg_EquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EquipmentAndFurnitureMember" xlink:to="lab_isrg_EquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ff57cc75-ab78-4075-b203-0d1b3b884205_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_916cb43e-f9ef-4db3-9d5a-2a9a0cdbd92b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income and other taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7de460ff-d3ae-4969-80da-a93b0e74c6ba_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2be4e868-624b-4caf-a2dc-fd5a27d537e0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_afb6b5b0-855e-4d51-a2f3-e647f01d283c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_92b1a084-3a36-45dd-b22a-e941c58d9c9f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_089d330b-4899-4946-9ef0-507c33ead770_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5aae0159-9afa-4456-b851-9c777d1bc66f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_18301c4e-8a94-4c87-b12e-0ebd2c17098a_terseLabel_en-US" xlink:label="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee payroll deduction under the stock plan, maximum</link:label>
    <link:label id="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_label_en-US" xlink:label="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percentage Of Payroll Deduction Under Espp</link:label>
    <link:label id="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_documentation_en-US" xlink:label="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of payroll deduction under ESPP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfPayrollDeductionUnderEspp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:to="lab_isrg_MaximumPercentageOfPayrollDeductionUnderEspp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_136de2c1-22f2-47dc-871a-1f514cff2358_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c9f239d8-8595-4a2e-a1ee-1073e0e07081_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_319f89b1-e2ef-4dbd-9d79-88a492971bee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, tax benefit from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_76f552ac-0d78-404e-bb3b-961c4f11b296_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Gross Lease Receivables</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb51194b-799e-4393-88df-cf8cf4ef6bc2_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a5d9d8ef-eaef-4474-b772-cafe19aa3538_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_PurchasedSoftwareMember_cef0c688-01bc-46dc-920e-07c997f4abd1_terseLabel_en-US" xlink:label="lab_isrg_PurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased software</link:label>
    <link:label id="lab_isrg_PurchasedSoftwareMember_label_en-US" xlink:label="lab_isrg_PurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Software [Member]</link:label>
    <link:label id="lab_isrg_PurchasedSoftwareMember_documentation_en-US" xlink:label="lab_isrg_PurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PurchasedSoftwareMember" xlink:href="isrg-20221231.xsd#isrg_PurchasedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_PurchasedSoftwareMember" xlink:to="lab_isrg_PurchasedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bff0257c-6956-4bde-87b2-82acf4de7325_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6bdd8040-d671-40a7-89d1-73f16d30e0f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_c32b5fa1-b0ce-48c1-b1d2-a2d911cc0687_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_3750cbc9-2292-4fc3-bff7-7fa6394542b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of the Other Long-Term Liabilities Balance Sheet Item</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeSevenMember_18880db4-e208-416d-9c6b-5cb1f450f7ff_terseLabel_en-US" xlink:label="lab_isrg_RangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 7</link:label>
    <link:label id="lab_isrg_RangeSevenMember_label_en-US" xlink:label="lab_isrg_RangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Seven [Member]</link:label>
    <link:label id="lab_isrg_RangeSevenMember_documentation_en-US" xlink:label="lab_isrg_RangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSevenMember" xlink:href="isrg-20221231.xsd#isrg_RangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeSevenMember" xlink:to="lab_isrg_RangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_2c756b66-f5b9-48d9-a713-a914cf7ca3b3_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SellingGeneralAndAdministrativeMember_918c707d-783c-47c3-98fd-a6972df13d90_terseLabel_en-US" xlink:label="lab_isrg_SellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_isrg_SellingGeneralAndAdministrativeMember_label_en-US" xlink:label="lab_isrg_SellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative [Member]</link:label>
    <link:label id="lab_isrg_SellingGeneralAndAdministrativeMember_documentation_en-US" xlink:label="lab_isrg_SellingGeneralAndAdministrativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to selling, general and administrative activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SellingGeneralAndAdministrativeMember" xlink:href="isrg-20221231.xsd#isrg_SellingGeneralAndAdministrativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SellingGeneralAndAdministrativeMember" xlink:to="lab_isrg_SellingGeneralAndAdministrativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_f25be53f-aac2-468a-b91e-f42fc8196df5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_ada574bc-de59-4ade-b9b8-002358de6d73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Other than Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_99763438-d393-4842-9a67-4ccd44a37e6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5aa6507a-af7d-4a74-9005-56c9e75dba44_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through employee stock plans (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5ed6d16a-2106-4a82-ad52-a58974c52a75_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_03f4b09a-efce-4bad-bf0e-eaa2d694f907_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_af8dcd86-6e77-4976-8e52-bc980b0b2c95_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8ca869d6-81ff-40a5-90d6-f57f7c1d1d69_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at Beginning&#160;of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_39f47a5b-6b64-430a-998d-d9232bbc8075_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance&#160;at End&#160;of&#160;Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_14eb179e-13e4-4e33-aa6b-0ae7ef98ee54_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0fbec786-1ce2-46f6-a13c-5a9190ebc3eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5839dd5c-8285-41f5-910d-4254b64836bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_f8311bfc-c904-42bb-8f16-bb2fb8e97335_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized gains (losses) in interest and other income, net</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2e968e9e-08d7-42a3-92db-e22c73bfad48_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalCreditAssessmentAxis_30762a3b-a534-486e-a59a-0978e785870b_terseLabel_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Axis]</link:label>
    <link:label id="lab_us-gaap_InternalCreditAssessmentAxis_label_en-US" xlink:label="lab_us-gaap_InternalCreditAssessmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Credit Assessment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis" xlink:to="lab_us-gaap_InternalCreditAssessmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e3fa2f8e-2b84-4221-a851-4ee6dd51be59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4776508-c154-46b0-8d0c-0f6e8714ad40_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a739b15d-d086-42f4-89cf-77e44f3228c2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_16f7093e-a7bb-45a2-b8c1-6c9fdcb628ba_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0d247082-ed7f-47ce-b6fe-b844834724f4_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_f14b86d4-1d03-4e27-9241-f9c085157758_terseLabel_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax remeasurement due to Swiss Tax Reform</link:label>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_cae95d5b-b0f2-4df1-be7b-5b222330537c_verboseLabel_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax re-measurement</link:label>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_label_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount</link:label>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_documentation_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:to="lab_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_c4557b21-c7ea-4142-9410-5a1b0b14f0e3_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeFiveMember_cedef792-b175-4690-94f3-33366d2b4fd8_terseLabel_en-US" xlink:label="lab_isrg_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 5</link:label>
    <link:label id="lab_isrg_RangeFiveMember_label_en-US" xlink:label="lab_isrg_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label id="lab_isrg_RangeFiveMember_documentation_en-US" xlink:label="lab_isrg_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFiveMember" xlink:href="isrg-20221231.xsd#isrg_RangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeFiveMember" xlink:to="lab_isrg_RangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_191faed9-96d1-4e5c-9fc7-cdbb52c1ca14_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock_3e23ed96-1f9a-4aad-bb8e-e36190045830_terseLabel_en-US" xlink:label="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="isrg-20221231.xsd#isrg_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_isrg_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_c93d0c1b-2d9b-414c-80d1-9e14b40fa277_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes, Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_b1b96bfa-a14a-4c5d-9523-47b54eb0ac82_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_e603c2e1-faca-4703-a02c-b022abbdd66b_terseLabel_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based implied volatility (percent)</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_label_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Percent</link:label>
    <link:label id="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_documentation_en-US" xlink:label="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:to="lab_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3283be7e-c17f-4859-bf5b-528b5b6bb4e4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense before income taxes</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c8357eac-a6f3-4995-a3b9-7222c4afbb21_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c3d327fa-43b6-4c22-b7cf-24b8b18f1366_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e11502cf-9dca-441a-80cb-e96e360e5737_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fd55042-01b4-4090-8040-9b05a2531107_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2bd4cd09-79a2-437c-a13a-f35750b9570e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_bffd2722-e3b1-443c-8e14-ab046ccdeb5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reclassification adjustment for (gains) losses on hedge instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_InitialGrantOptionsMember_29aa264f-f9e3-46cb-866e-64932989a9e8_terseLabel_en-US" xlink:label="lab_isrg_InitialGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Grant Options</link:label>
    <link:label id="lab_isrg_InitialGrantOptionsMember_label_en-US" xlink:label="lab_isrg_InitialGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Grant Options [Member]</link:label>
    <link:label id="lab_isrg_InitialGrantOptionsMember_documentation_en-US" xlink:label="lab_isrg_InitialGrantOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Grant Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialGrantOptionsMember" xlink:href="isrg-20221231.xsd#isrg_InitialGrantOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_InitialGrantOptionsMember" xlink:to="lab_isrg_InitialGrantOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61cab571-ecfa-479d-9e89-b1995d1fda8a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_d97cfff3-9dc5-498b-a7f7-9b2eff948b64_terseLabel_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit related to share-based compensation</link:label>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_label_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Unrecognized Tax Expense (Benefit), Share-Based Payment Arrangement</link:label>
    <link:label id="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Unrecognized Tax Expense (Benefit), Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:to="lab_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f6d3349d-3427-41fd-ab5b-4b7c4f9a07e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares were reserved for future issuance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2112027f-27bd-4043-8d4f-5ccb75790752_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_CostOfSalesServiceMember_7fc69f50-6b9f-4992-8077-6f4635686caa_terseLabel_en-US" xlink:label="lab_isrg_CostOfSalesServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue&#8212;service</link:label>
    <link:label id="lab_isrg_CostOfSalesServiceMember_label_en-US" xlink:label="lab_isrg_CostOfSalesServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales Service [Member]</link:label>
    <link:label id="lab_isrg_CostOfSalesServiceMember_documentation_en-US" xlink:label="lab_isrg_CostOfSalesServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesServiceMember" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_CostOfSalesServiceMember" xlink:to="lab_isrg_CostOfSalesServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_78ad7154-377b-48f0-a5dd-8d369a9e5a40_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_a11fc01a-5c99-4625-a4b3-40cedb1b53ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9846d805-e961-47b0-890d-2dd663257d76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SalesReturnsAndAllowances_b65bd7e0-7f47-4579-8094-cc761a137cd7_negatedTerseLabel_en-US" xlink:label="lab_isrg_SalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns and allowances</link:label>
    <link:label id="lab_isrg_SalesReturnsAndAllowances_label_en-US" xlink:label="lab_isrg_SalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances</link:label>
    <link:label id="lab_isrg_SalesReturnsAndAllowances_documentation_en-US" xlink:label="lab_isrg_SalesReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesReturnsAndAllowances" xlink:href="isrg-20221231.xsd#isrg_SalesReturnsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SalesReturnsAndAllowances" xlink:to="lab_isrg_SalesReturnsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_be877133-bc40-40eb-bb23-69d085fbe4c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SystemSalesArrangementWarrantyPeriod_daba8dc0-a730-446c-940f-371fcd391594_terseLabel_en-US" xlink:label="lab_isrg_SystemSalesArrangementWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System sales arrangement, warranty period</link:label>
    <link:label id="lab_isrg_SystemSalesArrangementWarrantyPeriod_label_en-US" xlink:label="lab_isrg_SystemSalesArrangementWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System Sales Arrangement, Warranty Period</link:label>
    <link:label id="lab_isrg_SystemSalesArrangementWarrantyPeriod_documentation_en-US" xlink:label="lab_isrg_SystemSalesArrangementWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System Sales Arrangement, Warranty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemSalesArrangementWarrantyPeriod" xlink:href="isrg-20221231.xsd#isrg_SystemSalesArrangementWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SystemSalesArrangementWarrantyPeriod" xlink:to="lab_isrg_SystemSalesArrangementWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeSixMember_7f7de367-bb63-47db-96a1-114883ad2bb7_terseLabel_en-US" xlink:label="lab_isrg_RangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 6</link:label>
    <link:label id="lab_isrg_RangeSixMember_label_en-US" xlink:label="lab_isrg_RangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Six [Member]</link:label>
    <link:label id="lab_isrg_RangeSixMember_documentation_en-US" xlink:label="lab_isrg_RangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSixMember" xlink:href="isrg-20221231.xsd#isrg_RangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeSixMember" xlink:to="lab_isrg_RangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a2808bd0-144f-4935-ab9d-a42e699b5b70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2f0bf4a5-8b3f-46bc-8ce0-b08f7668cdc9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aa648773-0ca6-45ad-aaf1-3f265caa4c7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a562a83e-7493-46f9-9f89-74883d0adc8d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b321a3a2-b448-429f-bd33-6aeee867b1fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_f4cb525a-b5ba-43a8-b363-57ef1e1bc875_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_67e89dcc-afb3-4a47-9b6e-61486f28d770_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_b53956fd-66a1-45da-9af6-eb2b4e17c317_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_85e3fd5c-0b9c-40f3-b605-e58b8632e9da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Income Before Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b20575b2-5ca4-48d3-9648-314cda192add_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_aa50369d-ab70-4726-af3f-f4e57e0f1bc8_terseLabel_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vesting upon six months of service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_label_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon Six Months of Service</link:label>
    <link:label id="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_documentation_en-US" xlink:label="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon Six Months of Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:to="lab_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7ea785ad-c897-4a01-8b14-223bba091198_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties related to unrecognized tax benefits accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_01ce6714-ae32-4f45-9279-5d58f9237c9b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c2fc8892-7517-410f-a405-4dbd48a73d3c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_03164dca-c488-4142-9687-84f0b0d2b5a2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5e666601-795d-4ae1-9f7c-597f270a0548_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_4e2bb4c5-cfae-4ecf-bd25-1cf10bb80d47_terseLabel_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Incentive Award Plan</link:label>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_label_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Twenty Ten Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Twenty Ten Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:to="lab_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e76fea47-a506-44f0-9dd0-3ebd177f7f66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeThreeMember_fde69e0a-40a2-4228-a19c-566935df2b3b_terseLabel_en-US" xlink:label="lab_isrg_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 3</link:label>
    <link:label id="lab_isrg_RangeThreeMember_label_en-US" xlink:label="lab_isrg_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_isrg_RangeThreeMember_documentation_en-US" xlink:label="lab_isrg_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeThreeMember" xlink:href="isrg-20221231.xsd#isrg_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeThreeMember" xlink:to="lab_isrg_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dfee6810-dc14-4284-aa39-0a758c269104_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ModerateCreditRatingMember_f19bbfa0-36bc-4f93-8931-73c3e47fcce5_terseLabel_en-US" xlink:label="lab_isrg_ModerateCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderate</link:label>
    <link:label id="lab_isrg_ModerateCreditRatingMember_label_en-US" xlink:label="lab_isrg_ModerateCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderate Credit Rating [Member]</link:label>
    <link:label id="lab_isrg_ModerateCreditRatingMember_documentation_en-US" xlink:label="lab_isrg_ModerateCreditRatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderate Credit Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ModerateCreditRatingMember" xlink:href="isrg-20221231.xsd#isrg_ModerateCreditRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ModerateCreditRatingMember" xlink:to="lab_isrg_ModerateCreditRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_020a2230-87dc-4b6b-bfb2-062899928e71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9b6563b1-8e73-45ac-bef5-883640f4b1a3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a321b69c-d089-40f6-b878-82af54f36584_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_00eb1db1-58ba-48ed-b81d-9ae715461d77_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a17bc29e-4635-4346-b49b-d1089c7d33b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_313c3e71-e2f7-45c6-a936-9a0d713876de_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_4bd80ecb-b9c2-466d-be7b-3f9878819f3f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_c8413e6c-0787-4985-b3b6-fdd76bbd46f7_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_d6ec72dd-bf48-4ec6-afac-db82a1da40ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_07e1c4fc-9807-4076-8357-68a19d0e4c78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fa65a98a-2fe1-4b91-a9e6-8aa4afa95c49_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2c41fb7d-f03f-4e4a-aace-29d73d757560_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_b6864c74-7f32-4d2a-bd8f-99937878b84d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b8d98c46-3078-446a-80ec-776ca41fe385_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b4152a2c-65b1-4326-95c3-9a95ba9191e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_26fe444d-ed3c-4aa8-8ff5-e0c3385fe47d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ebffc5eb-e15b-4a08-81b7-e7b57a3a11c3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_ee68f11a-025b-48b9-a918-c231b8b6a85a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_3e8aa463-0b68-414a-8712-c636e519c055_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember_50d7965c-e775-4fea-9f93-f8e7f543d9bb_terseLabel_en-US" xlink:label="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October ASR Program</link:label>
    <link:label id="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember_label_en-US" xlink:label="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October Accelerated Share Repurchase Program [Member]</link:label>
    <link:label id="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October Accelerated Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:href="isrg-20221231.xsd#isrg_OctoberAcceleratedShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:to="lab_isrg_OctoberAcceleratedShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_3121981f-9a4a-4b17-bf56-cbfcf372b08b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_7f18e24b-697c-4c8c-9f13-e6add7925e04_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_9c1dd5f6-2fe3-466e-95a9-4faf0baf8b0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible and other assets, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1a37e537-9c9c-4682-8527-94f5572a3b44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2319d7cc-a080-4ff0-a80e-694b26d57cf9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Disaggregated by Types and Geography</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e6a93d2e-f1d3-4d0e-aff9-0257a006cbb5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_501fab18-3c4c-49d4-a892-e51c90ed86be_terseLabel_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available-For-Sale Securities [Domain]</link:label>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_label_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale And Held To Maturity Securities [Domain]</link:label>
    <link:label id="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_documentation_en-US" xlink:label="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available For Sale and Held to Maturity Securities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:to="lab_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock_c92f9cae-6738-4196-bd24-66329993022f_terseLabel_en-US" xlink:label="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Sales Returns and Doubtful Accounts</link:label>
    <link:label id="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Sales Returns And Doubtful Accounts Policy [Policy Text Block]</link:label>
    <link:label id="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy for allowance for sales returns and doubtful accounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:href="isrg-20221231.xsd#isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:to="lab_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_0bf6e26c-04f6-43db-be3a-d379519f1190_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease, Year Three, Originated, Two Years before Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_TradeAccountsReceivableCurrent_4d4c3599-ff8e-4c73-866b-580396473c6a_terseLabel_en-US" xlink:label="lab_isrg_TradeAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net</link:label>
    <link:label id="lab_isrg_TradeAccountsReceivableCurrent_label_en-US" xlink:label="lab_isrg_TradeAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable, Current</link:label>
    <link:label id="lab_isrg_TradeAccountsReceivableCurrent_documentation_en-US" xlink:label="lab_isrg_TradeAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TradeAccountsReceivableCurrent" xlink:href="isrg-20221231.xsd#isrg_TradeAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_TradeAccountsReceivableCurrent" xlink:to="lab_isrg_TradeAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b1aaf29-5149-41c2-b744-89347b046190_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: dilutive effect of potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_129d76e3-9267-42d8-85d7-9403b1fdc658_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation And Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6f83fd42-30d2-4643-866c-20f1d2a38d94_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a1af78e1-1e6b-47a1-82ed-76fe0799ccb1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_061aa7c8-b228-4947-a6a9-ae6de86f0c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_68b1b6f1-7323-45b1-8680-01e993f92ddb_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns and allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5cee68b7-77c3-428e-b800-2813929abe2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b440b0de-0d6c-4c8f-9ff8-eb09cfefc11e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_6276b2a8-a727-4c68-815a-4d2c299f9ac0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_RangeEightMember_79156012-23ab-4c6a-8473-32d72bf554f7_terseLabel_en-US" xlink:label="lab_isrg_RangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range 8</link:label>
    <link:label id="lab_isrg_RangeEightMember_label_en-US" xlink:label="lab_isrg_RangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Eight [Member]</link:label>
    <link:label id="lab_isrg_RangeEightMember_documentation_en-US" xlink:label="lab_isrg_RangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeEightMember" xlink:href="isrg-20221231.xsd#isrg_RangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_RangeEightMember" xlink:to="lab_isrg_RangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_b79c841b-6e12-4654-8150-b3e3cd31118b_terseLabel_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value</link:label>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_label_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_documentation_en-US" xlink:label="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:to="lab_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fba0c75b-82da-40a2-9dd1-1bb878ade025_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_88e0c251-a9d7-4643-96d3-3c7da500b4c1_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6077a4fb-9437-4ac2-91a3-78c7600a949b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ComputerAndOfficeEquipment_6c4a4612-53e1-4006-b84c-7b4eb60afbb4_terseLabel_en-US" xlink:label="lab_isrg_ComputerAndOfficeEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_isrg_ComputerAndOfficeEquipment_label_en-US" xlink:label="lab_isrg_ComputerAndOfficeEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Office Equipment</link:label>
    <link:label id="lab_isrg_ComputerAndOfficeEquipment_documentation_en-US" xlink:label="lab_isrg_ComputerAndOfficeEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount as of balance sheet date of long-lived, depreciable asset used in production process to produce goods and services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ComputerAndOfficeEquipment" xlink:href="isrg-20221231.xsd#isrg_ComputerAndOfficeEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ComputerAndOfficeEquipment" xlink:to="lab_isrg_ComputerAndOfficeEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_dc81a894-cdb9-4d44-84a7-b62d9507e5f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_a0ba0fc4-b767-4cb9-9334-bce76a0429fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec10f145-f9e3-4ca6-9701-460c067570ff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_SystemsMember_362a82a6-b3f1-4b8f-97d5-ffae673c2630_terseLabel_en-US" xlink:label="lab_isrg_SystemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems</link:label>
    <link:label id="lab_isrg_SystemsMember_label_en-US" xlink:label="lab_isrg_SystemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems [Member]</link:label>
    <link:label id="lab_isrg_SystemsMember_documentation_en-US" xlink:label="lab_isrg_SystemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemsMember" xlink:href="isrg-20221231.xsd#isrg_SystemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_SystemsMember" xlink:to="lab_isrg_SystemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock_8f83385d-3ed7-49cb-aef8-3a7d6680d017_terseLabel_en-US" xlink:label="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency and Other Hedging Instruments</link:label>
    <link:label id="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency And Other Hedging Instruments Policy [Policy Text Block]</link:label>
    <link:label id="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy on foreign currency remeasurement and retranslation. Accounting policy on hedging instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:href="isrg-20221231.xsd#isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:to="lab_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f9346f45-e748-4e80-a6d2-bd58da624177_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2f8709ed-32eb-4505-b9e2-a064e5b3255f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_f681f480-eede-4396-8aa5-8c1f237789c6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6de3774f-491d-4dcf-a3d5-011ee3c2c8e2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>isrg-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:300c1a24-af9b-4b5a-9e71-8b2ccdfca58c,g:45929c90-2416-4fa5-86d3-46b327406780-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/CoverPage" xlink:type="simple" xlink:href="isrg-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f002fe58-78ea-4763-81ae-0dab1c8f4350" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentType_f002fe58-78ea-4763-81ae-0dab1c8f4350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_85432f46-dee5-4c61-a8c1-8ef2551e2358" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentAnnualReport_85432f46-dee5-4c61-a8c1-8ef2551e2358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a89b1cee-cad5-4381-9f79-ae6e378dee83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentPeriodEndDate_a89b1cee-cad5-4381-9f79-ae6e378dee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d3dc738e-2d6b-4aba-b628-2169667bc23f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentTransitionReport_d3dc738e-2d6b-4aba-b628-2169667bc23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6e6acc47-ea29-4738-bba2-9e3cac20050e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityFileNumber_6e6acc47-ea29-4738-bba2-9e3cac20050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b70aed9e-cd38-4df1-bbfa-b74b301530af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityRegistrantName_b70aed9e-cd38-4df1-bbfa-b74b301530af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a2a1511-7555-453a-b686-4effb51bac0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a2a1511-7555-453a-b686-4effb51bac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c3f5a926-e1d0-4f94-b180-e6936694223a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityTaxIdentificationNumber_c3f5a926-e1d0-4f94-b180-e6936694223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_52a6754e-95c9-4a25-a45d-62b4a2afa320" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityAddressAddressLine1_52a6754e-95c9-4a25-a45d-62b4a2afa320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_36163218-ecda-44aa-884a-2a7b50e94b99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityAddressCityOrTown_36163218-ecda-44aa-884a-2a7b50e94b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fe185297-ef10-4bf2-ab3c-669f0062711a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityAddressStateOrProvince_fe185297-ef10-4bf2-ab3c-669f0062711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_76893520-c0ed-47dd-8ece-5e11a1acbbed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityAddressPostalZipCode_76893520-c0ed-47dd-8ece-5e11a1acbbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a108e481-e30b-4be2-833d-86979150b2f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_CityAreaCode_a108e481-e30b-4be2-833d-86979150b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ecfffe6a-a5bd-458c-8c13-3a9ee9e83985" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_LocalPhoneNumber_ecfffe6a-a5bd-458c-8c13-3a9ee9e83985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_73ba6854-92ca-4380-b27b-4e2b502aedfd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_Security12bTitle_73ba6854-92ca-4380-b27b-4e2b502aedfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d374ca79-926d-4b63-9190-77624641e3d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_TradingSymbol_d374ca79-926d-4b63-9190-77624641e3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e43c733e-1571-430d-81ef-cf98c81d6717" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_SecurityExchangeName_e43c733e-1571-430d-81ef-cf98c81d6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_73945033-de40-4ef5-aaf6-5068dcd001d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_73945033-de40-4ef5-aaf6-5068dcd001d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_53720435-56f9-4c68-b623-ea4db01e7f64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityVoluntaryFilers_53720435-56f9-4c68-b623-ea4db01e7f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_39d9e2c5-26fb-4ca1-85eb-e40a60c5479a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityCurrentReportingStatus_39d9e2c5-26fb-4ca1-85eb-e40a60c5479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_47ed763d-9f3f-4b7a-86ae-94c4506096c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityInteractiveDataCurrent_47ed763d-9f3f-4b7a-86ae-94c4506096c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_37a1ecf5-9f68-455b-b95b-0b785e529b72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityFilerCategory_37a1ecf5-9f68-455b-b95b-0b785e529b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3f073660-f0ec-47fd-999e-60abeeb9de8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntitySmallBusiness_3f073660-f0ec-47fd-999e-60abeeb9de8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a81df6c9-c98c-49f5-8f8a-5a9b493ecdc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityEmergingGrowthCompany_a81df6c9-c98c-49f5-8f8a-5a9b493ecdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b9bb29da-87c0-402a-87fa-4b7c5a8941aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b9bb29da-87c0-402a-87fa-4b7c5a8941aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_27f937a9-1293-40ff-9445-cc200c30edfb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityShellCompany_27f937a9-1293-40ff-9445-cc200c30edfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4283c707-83d0-4062-843c-ea8a959f236d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityPublicFloat_4283c707-83d0-4062-843c-ea8a959f236d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bbee35b7-357b-43b3-bc4a-0fd76637834b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bbee35b7-357b-43b3-bc4a-0fd76637834b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8d98ecce-557e-49cd-900c-e6f1f002e5a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8d98ecce-557e-49cd-900c-e6f1f002e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_68b86573-e841-4a21-a9e6-c5ac6da964b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_EntityCentralIndexKey_68b86573-e841-4a21-a9e6-c5ac6da964b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f92f0e91-6f39-407f-bb9a-1de0cf7afef3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_CurrentFiscalYearEndDate_f92f0e91-6f39-407f-bb9a-1de0cf7afef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cd3c0196-002f-4b9b-a595-3cd2abc005e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentFiscalYearFocus_cd3c0196-002f-4b9b-a595-3cd2abc005e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c5e34b3f-e562-4f15-830f-a08a035dad98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c5e34b3f-e562-4f15-830f-a08a035dad98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c9f78826-0c59-42c4-96f0-980dd2c0d237" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f442e679-20a4-4a5e-a25f-b0902bf8d2c4" xlink:to="loc_dei_AmendmentFlag_c9f78826-0c59-42c4-96f0-980dd2c0d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/AuditInformation" xlink:type="simple" xlink:href="isrg-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AuditInformationAbstract_9bc0d9b3-1f42-4df0-8821-0579784b8e7c" xlink:href="isrg-20221231.xsd#isrg_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_9021f997-8f67-415f-bb34-8c2018fa4b43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AuditInformationAbstract_9bc0d9b3-1f42-4df0-8821-0579784b8e7c" xlink:to="loc_dei_AuditorFirmId_9021f997-8f67-415f-bb34-8c2018fa4b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_ea0681b0-9f6c-48f9-a864-0745bdb7dbe7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AuditInformationAbstract_9bc0d9b3-1f42-4df0-8821-0579784b8e7c" xlink:to="loc_dei_AuditorName_ea0681b0-9f6c-48f9-a864-0745bdb7dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_228d41be-f954-4482-8f8a-664f559f8fdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AuditInformationAbstract_9bc0d9b3-1f42-4df0-8821-0579784b8e7c" xlink:to="loc_dei_AuditorLocation_228d41be-f954-4482-8f8a-664f559f8fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="isrg-20221231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_553e6ba5-89e4-48c5-8bd8-46f3d6b37147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_976f24ae-a168-4e26-8e96-1feb7eeab565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_553e6ba5-89e4-48c5-8bd8-46f3d6b37147" xlink:to="loc_us-gaap_NatureOfOperations_976f24ae-a168-4e26-8e96-1feb7eeab565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_97f1923d-12be-4ef4-8b45-a82ec859116b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97f1923d-12be-4ef4-8b45-a82ec859116b" xlink:to="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d014ab9-f485-4aa7-8032-cf5465ba1391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d014ab9-f485-4aa7-8032-cf5465ba1391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_883380f8-de7b-492f-9ad1-b4c678741197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_883380f8-de7b-492f-9ad1-b4c678741197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_23ae3aeb-db32-44b8-abd0-c98cd5f8c927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_23ae3aeb-db32-44b8-abd0-c98cd5f8c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9da9bcc4-4eac-46a1-9f18-f536335284ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_InventoryNet_9da9bcc4-4eac-46a1-9f18-f536335284ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c18bfcfd-4a32-4afe-b390-b4c03a74b996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c18bfcfd-4a32-4afe-b390-b4c03a74b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_edc4fcd9-0a7f-4c9f-89be-7d6f931c9d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b34ada8d-d297-43da-ba2c-010581e2d9bc" xlink:to="loc_us-gaap_AssetsCurrent_edc4fcd9-0a7f-4c9f-89be-7d6f931c9d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52e885dd-508a-4d08-894b-8f06771f9aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52e885dd-508a-4d08-894b-8f06771f9aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_b5e3e57a-d054-49f1-97da-51b8425d1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_b5e3e57a-d054-49f1-97da-51b8425d1e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c9c46de1-c0bb-4055-a38b-2177be65c975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c9c46de1-c0bb-4055-a38b-2177be65c975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssets_08075955-9af3-4f64-9791-59f629601264" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_isrg_IntangibleAndOtherAssets_08075955-9af3-4f64-9791-59f629601264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2eef817c-16b9-4de7-93cb-ff7168ab86c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_Goodwill_2eef817c-16b9-4de7-93cb-ff7168ab86c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_764ca8f6-9c40-45d3-9507-a0916476c0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6cfd7e6a-7167-4963-af11-2697dd529328" xlink:to="loc_us-gaap_Assets_764ca8f6-9c40-45d3-9507-a0916476c0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97f1923d-12be-4ef4-8b45-a82ec859116b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f3ebbd19-92d4-4c1c-a130-f36cdebb3461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:to="loc_us-gaap_AccountsPayableCurrent_f3ebbd19-92d4-4c1c-a130-f36cdebb3461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20e39dca-0ee1-49cf-ba09-6ca558738c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20e39dca-0ee1-49cf-ba09-6ca558738c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_b26454cd-8051-4975-ae9b-4026c71c6991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:to="loc_us-gaap_DeferredRevenueCurrent_b26454cd-8051-4975-ae9b-4026c71c6991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6365f368-c183-4a7f-86d6-cdee154fb80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6365f368-c183-4a7f-86d6-cdee154fb80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_803650d6-b021-4b85-93db-0689f75725f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4dd651d3-e51c-4c54-b98a-4bc06ff706b7" xlink:to="loc_us-gaap_LiabilitiesCurrent_803650d6-b021-4b85-93db-0689f75725f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_6372eae2-afc1-4720-880b-dadeab1ab313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_6372eae2-afc1-4720-880b-dadeab1ab313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_360b300b-f141-4bf7-a07d-539a6a38456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_Liabilities_360b300b-f141-4bf7-a07d-539a6a38456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d15ffee7-8c5f-43a9-84fc-9694fb085d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d15ffee7-8c5f-43a9-84fc-9694fb085d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4ac2305a-2df0-4dc2-b2c8-5577738d3201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_PreferredStockValue_4ac2305a-2df0-4dc2-b2c8-5577738d3201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_44de4c61-c06b-4684-8847-14ad46d562a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_CommonStockValue_44de4c61-c06b-4684-8847-14ad46d562a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54b834ea-9713-46c1-ad72-c461fcb25944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54b834ea-9713-46c1-ad72-c461fcb25944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28a27671-42b6-4a71-ad15-cd4b490fbb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28a27671-42b6-4a71-ad15-cd4b490fbb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16bf110b-ec51-4154-92ec-2c108911a77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16bf110b-ec51-4154-92ec-2c108911a77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5fb0adc-cfcd-4255-a8ea-e5d28e2f5056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_StockholdersEquity_f5fb0adc-cfcd-4255-a8ea-e5d28e2f5056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_14586af3-901f-4714-aa83-d03ff7ae9724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_MinorityInterest_14586af3-901f-4714-aa83-d03ff7ae9724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34ac7c95-626a-4256-bb9f-f8e2076fc61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ab26e951-5fee-4966-a000-6ba4e217f85b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34ac7c95-626a-4256-bb9f-f8e2076fc61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bef36f4-9d2e-4a36-bf22-2d9ca861ef99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_930289a3-2c77-4346-845c-b5cb91bedbaf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bef36f4-9d2e-4a36-bf22-2d9ca861ef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_913f3fca-a499-4235-bc44-f1439bb1d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_913f3fca-a499-4235-bc44-f1439bb1d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5254365a-f4b3-4cca-b4ca-adbc09f875d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5254365a-f4b3-4cca-b4ca-adbc09f875d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fb693509-972e-4405-b25c-b313f425b705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fb693509-972e-4405-b25c-b313f425b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7999f3a8-b343-4ded-ba9a-ed04424d2a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7999f3a8-b343-4ded-ba9a-ed04424d2a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ff8fa507-9314-450f-bbe4-813fd0587793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ff8fa507-9314-450f-bbe4-813fd0587793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c6c74d22-60b7-463f-a268-ecba7da3d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c6c74d22-60b7-463f-a268-ecba7da3d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b2407254-ace7-4050-829a-dc1c9a773b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b2407254-ace7-4050-829a-dc1c9a773b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b5c5cc02-0a2f-489d-a4a8-945148890763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_CommonStockSharesIssued_b5c5cc02-0a2f-489d-a4a8-945148890763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ace1bfbe-6c0e-458a-8b07-ba1fba2301e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f38327a7-9e9b-40e1-b410-565411768c0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ace1bfbe-6c0e-458a-8b07-ba1fba2301e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfIncome"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_bba940e6-57ca-45c0-959e-7a368a7d9de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bba940e6-57ca-45c0-959e-7a368a7d9de8" xlink:to="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:to="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f4e9c29c-d45a-4b59-88ee-691115e4f229" xlink:to="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ec10fe14-254a-435a-9e2d-3e1fda57e66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:to="loc_us-gaap_ProductMember_ec10fe14-254a-435a-9e2d-3e1fda57e66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6ac758e5-bb30-4d45-af08-ba88983c45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b9b138e0-f479-4827-bd4c-b57e27c89dc9" xlink:to="loc_us-gaap_ServiceMember_6ac758e5-bb30-4d45-af08-ba88983c45f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6dd2698c-82bd-4ede-997e-7976ca21f76a" xlink:to="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_49dcef50-2b75-42ea-8c27-bec44e7b4866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_391d52d2-ee6d-4ad5-b1f7-aa3ca1422292" xlink:to="loc_us-gaap_CorporateJointVentureMember_49dcef50-2b75-42ea-8c27-bec44e7b4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b0f32363-6738-4b99-ae35-d05b8b8d98ef" xlink:to="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb7a23f1-416b-4a5b-9b55-3f247f59a249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_aae84eca-fa3e-414d-a3e9-18aa216b07a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb7a23f1-416b-4a5b-9b55-3f247f59a249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7c5de7d6-9af6-44c6-aceb-1072fda2bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_f15f6759-c5ed-4dee-b616-c5e432c6eda0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7c5de7d6-9af6-44c6-aceb-1072fda2bd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_581539da-9aea-47bf-ac87-d2235f025634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_GrossProfit_581539da-9aea-47bf-ac87-d2235f025634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_52570404-d11d-4d16-8cd1-6c4e9d73cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_52570404-d11d-4d16-8cd1-6c4e9d73cf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e149890e-5bb3-46b6-88ec-74b7d5d779a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e149890e-5bb3-46b6-88ec-74b7d5d779a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bc0b3aee-6ba6-447c-9835-96fd76d59b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_429f0003-c128-4e24-b887-eced22699c7b" xlink:to="loc_us-gaap_OperatingExpenses_bc0b3aee-6ba6-447c-9835-96fd76d59b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3eaa82e-06a8-4458-b34a-e46142c38e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_OperatingIncomeLoss_f3eaa82e-06a8-4458-b34a-e46142c38e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_da1d1e57-e31c-48a6-a495-c8274f35005c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_da1d1e57-e31c-48a6-a495-c8274f35005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c66e74b-4248-44f9-b552-92bfa6b4d3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c66e74b-4248-44f9-b552-92bfa6b4d3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4998ba59-02e9-45b0-a9af-5e02a256ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4998ba59-02e9-45b0-a9af-5e02a256ae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_513d903f-4937-4138-b6d8-b98ea4c3f57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_ProfitLoss_513d903f-4937-4138-b6d8-b98ea4c3f57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_82d07432-4644-4bc2-9990-ee2b2b09904c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_82d07432-4644-4bc2-9990-ee2b2b09904c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a467a06-2b03-4623-819c-3043f122c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_NetIncomeLoss_8a467a06-2b03-4623-819c-3043f122c45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4f88726-c7a0-43b5-9d1f-3082e776373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4f88726-c7a0-43b5-9d1f-3082e776373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5beba847-561c-4009-94a4-f03b849924e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d196e6f4-500a-4afa-b7ea-4e3f190bb511" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5beba847-561c-4009-94a4-f03b849924e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49ca6d40-1f5c-473d-860f-86f3ced1ef8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f72efdf-c523-4568-85b5-2fcf77cda835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f72efdf-c523-4568-85b5-2fcf77cda835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea747d5c-99b5-4edf-a865-f8b21fbca363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_41026251-3334-46cc-9c8f-c2cafd97b0d3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea747d5c-99b5-4edf-a865-f8b21fbca363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4529d0c1-4274-418f-bb5e-0136d693d712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_ProfitLoss_4529d0c1-4274-418f-bb5e-0136d693d712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5856a0e5-e434-4d21-9275-0c45a169fef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5856a0e5-e434-4d21-9275-0c45a169fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c0cc86-71ed-492c-ab7f-454b025c10d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5856a0e5-e434-4d21-9275-0c45a169fef5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c0cc86-71ed-492c-ab7f-454b025c10d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_ed0b63af-01fc-42a5-ac9a-2487c3c4b642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_ed0b63af-01fc-42a5-ac9a-2487c3c4b642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_062a32cd-6ada-4443-8665-976171a7d5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_ed0b63af-01fc-42a5-ac9a-2487c3c4b642" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_062a32cd-6ada-4443-8665-976171a7d5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cfe64475-0052-4b85-b76f-2dcdb7c89fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_ed0b63af-01fc-42a5-ac9a-2487c3c4b642" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_cfe64475-0052-4b85-b76f-2dcdb7c89fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_745512e2-2b41-48e7-89c6-35b5109f6ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_ed0b63af-01fc-42a5-ac9a-2487c3c4b642" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_745512e2-2b41-48e7-89c6-35b5109f6ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_24f22cb3-cec6-447f-a206-c6137da0c3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_24f22cb3-cec6-447f-a206-c6137da0c3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d97b3fc0-bc8a-43d4-bc6b-63bf9804a944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_24f22cb3-cec6-447f-a206-c6137da0c3ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d97b3fc0-bc8a-43d4-bc6b-63bf9804a944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f4f4eeab-60cb-4bdc-9da7-f8e0563934a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_24f22cb3-cec6-447f-a206-c6137da0c3ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f4f4eeab-60cb-4bdc-9da7-f8e0563934a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4b474ee6-2651-468a-b5f8-6990223c6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_24f22cb3-cec6-447f-a206-c6137da0c3ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4b474ee6-2651-468a-b5f8-6990223c6dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_21fd5554-5f05-45c6-9122-c5dec285d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_21fd5554-5f05-45c6-9122-c5dec285d864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_4a84efab-0022-413e-8399-812b1384e7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_21fd5554-5f05-45c6-9122-c5dec285d864" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_4a84efab-0022-413e-8399-812b1384e7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_9660f448-719b-48ca-b2db-2654bddc867c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_21fd5554-5f05-45c6-9122-c5dec285d864" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_9660f448-719b-48ca-b2db-2654bddc867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f7cca7a4-170f-488f-939b-b8526aa9b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_21fd5554-5f05-45c6-9122-c5dec285d864" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f7cca7a4-170f-488f-939b-b8526aa9b9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fa71da84-83f4-4953-bd78-260ea13b9730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fa71da84-83f4-4953-bd78-260ea13b9730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4997f57e-003d-470a-ace0-5289d23ba015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4997f57e-003d-470a-ace0-5289d23ba015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_ea0e1825-884d-43f5-9572-4af6c52479e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_ea0e1825-884d-43f5-9572-4af6c52479e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f32b347-3d18-4869-acf0-1a5c841449f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97f72507-02f2-4435-baf2-7e523fd33cc1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f32b347-3d18-4869-acf0-1a5c841449f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_736651b3-aed5-477f-bc7c-be09dacc36b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_736651b3-aed5-477f-bc7c-be09dacc36b4" xlink:to="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7229a7b6-c65c-434e-b2ea-f870d154c0de" xlink:to="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_007f0d2d-7962-46c1-ac02-f8ca57ead378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_CommonStockMember_007f0d2d-7962-46c1-ac02-f8ca57ead378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_350a413a-3945-42b1-8ffb-3190c2417776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_350a413a-3945-42b1-8ffb-3190c2417776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ae8283db-3ae3-42dd-b404-85c3ce9f42e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_RetainedEarningsMember_ae8283db-3ae3-42dd-b404-85c3ce9f42e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8bb9f9bb-01fe-4bff-abae-93276b012002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8bb9f9bb-01fe-4bff-abae-93276b012002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_f6a32cba-e923-4f65-9a9a-f28d24ed8306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_ParentMember_f6a32cba-e923-4f65-9a9a-f28d24ed8306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7530710a-1536-42fc-b42a-d3ba412d1c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10e184ac-bb11-4de7-98ca-fede8546a1d2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7530710a-1536-42fc-b42a-d3ba412d1c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_666f5936-ca6e-497b-bd50-13cd0d83d837" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6e6ccbfc-fe07-476d-99c4-068425e2f6d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8a2d1840-b6c9-49f2-9c4b-fc60488da322" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6e6ccbfc-fe07-476d-99c4-068425e2f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2a4a57e1-4ada-4382-9eec-d2bf18c9549b" xlink:to="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6d4ce63b-f953-40fb-b57c-e05703133365" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_858d349c-3881-4d93-bfca-03eb2add768d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_858d349c-3881-4d93-bfca-03eb2add768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea066e3a-b50e-497a-9aaf-bc49f93f15dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea066e3a-b50e-497a-9aaf-bc49f93f15dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f345b9c2-05b5-42b3-962c-a254cb4dde7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f345b9c2-05b5-42b3-962c-a254cb4dde7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a086129-228a-4443-bb80-f8db642a7a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0a086129-228a-4443-bb80-f8db642a7a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e898bd9b-394b-413d-998c-a251cae05ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e898bd9b-394b-413d-998c-a251cae05ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b42a8fa7-fda2-4ccc-80ff-7438e7209a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b42a8fa7-fda2-4ccc-80ff-7438e7209a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1496eeb0-d838-456b-b5da-ed14e96f6677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1496eeb0-d838-456b-b5da-ed14e96f6677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cd39fa40-63d0-4900-ac0c-d4cc4b65704a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_cd39fa40-63d0-4900-ac0c-d4cc4b65704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b26210ce-c952-4b92-8d7c-07730ebe02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b26210ce-c952-4b92-8d7c-07730ebe02c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3343896-5cbb-4e0d-907b-79820d5d3a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_NetIncomeLoss_c3343896-5cbb-4e0d-907b-79820d5d3a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99a0f9a1-d652-495a-beea-f81ae6d37545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99a0f9a1-d652-495a-beea-f81ae6d37545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45f33159-bc32-4121-92d2-d48ddf1c05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45f33159-bc32-4121-92d2-d48ddf1c05c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6d3daa6-fca1-49e4-a586-9d34205f6ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a6d3daa6-fca1-49e4-a586-9d34205f6ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e9f7a07-488c-40e0-a79f-c80fec241fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_29852783-2357-4efd-be63-8500bb11dba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e9f7a07-488c-40e0-a79f-c80fec241fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedStatementsOfCashFlows"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_09a4714d-c473-428b-a6d1-81caed0d2376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_09a4714d-c473-428b-a6d1-81caed0d2376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_24f56a31-03b6-480d-a2fe-f2347bea616f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_09a4714d-c473-428b-a6d1-81caed0d2376" xlink:to="loc_us-gaap_ProfitLoss_24f56a31-03b6-480d-a2fe-f2347bea616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_09a4714d-c473-428b-a6d1-81caed0d2376" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_d4ba96e4-5a16-4172-aed7-e54cdfdd48d7" xlink:href="isrg-20221231.xsd#isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment_d4ba96e4-5a16-4172-aed7-e54cdfdd48d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_15d04c70-b826-4b6a-ba80-6f0c016fea4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_15d04c70-b826-4b6a-ba80-6f0c016fea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_1934a6b7-f7b4-470b-b6f9-f1fe916ed3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_1934a6b7-f7b4-470b-b6f9-f1fe916ed3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_80c56b64-a5cb-4984-83ea-3e72ae2c76c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_80c56b64-a5cb-4984-83ea-3e72ae2c76c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3bbb462b-7d49-4023-a5b7-f81805d0720f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3bbb462b-7d49-4023-a5b7-f81805d0720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3f87e8ec-f1eb-496a-8b00-0e3444f0ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_ShareBasedCompensation_3f87e8ec-f1eb-496a-8b00-0e3444f0ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_49e09d8a-13a2-47bb-863e-339bd6125095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_49e09d8a-13a2-47bb-863e-339bd6125095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a0a27927-5944-4d2f-9923-09a25bbb5e71" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ba69e7e-5ac1-4d37-a758-3e278169e9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0ba69e7e-5ac1-4d37-a758-3e278169e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0e7d7213-5a2f-4628-9ea8-c160c096baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0e7d7213-5a2f-4628-9ea8-c160c096baa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c619467-2ac1-47d8-b59d-3ca3decb7ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c619467-2ac1-47d8-b59d-3ca3decb7ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b5b09970-bf13-4a78-8349-4ef21cf98f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b5b09970-bf13-4a78-8349-4ef21cf98f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_60dab8be-8b51-40d2-ae83-74b87aa1230b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_60dab8be-8b51-40d2-ae83-74b87aa1230b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1590016a-1b57-4a84-8bb5-38b2f466fb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1590016a-1b57-4a84-8bb5-38b2f466fb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3c99916f-56d0-42a7-be57-7ec17790c287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c2a83f3-776d-4d78-9021-e7900139685f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3c99916f-56d0-42a7-be57-7ec17790c287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a80f421d-c34f-4824-917d-b2e89ba9dbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_09a4714d-c473-428b-a6d1-81caed0d2376" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a80f421d-c34f-4824-917d-b2e89ba9dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c944f40f-56c7-4b11-a5d6-9f6f7992c9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c944f40f-56c7-4b11-a5d6-9f6f7992c9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_22f67ec1-9f36-4a84-b02d-52bbaf2facdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_22f67ec1-9f36-4a84-b02d-52bbaf2facdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_67b951e4-1873-40ac-b756-1fe59b661f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_67b951e4-1873-40ac-b756-1fe59b661f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_961505a1-bccd-496d-bbb8-fc7a2697859d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_961505a1-bccd-496d-bbb8-fc7a2697859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4acf15ba-efad-4a79-bb6c-b3de3d81e7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4acf15ba-efad-4a79-bb6c-b3de3d81e7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_664644c5-8105-4e65-9b8a-52957b7064b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_83b180c4-7ff7-4e4e-b242-5a6c8719dfae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_664644c5-8105-4e65-9b8a-52957b7064b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c8569e53-9fcd-49d7-9f14-a558ee3f5faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c8569e53-9fcd-49d7-9f14-a558ee3f5faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_552e00c4-2bbf-48d4-b999-19e096709d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_552e00c4-2bbf-48d4-b999-19e096709d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6eab737f-c967-41e6-a35b-0a541c66a9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6eab737f-c967-41e6-a35b-0a541c66a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fcf8d92-1574-4b9e-a0e3-815628e9ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fcf8d92-1574-4b9e-a0e3-815628e9ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa69066b-a023-4799-95ee-f862d5243ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_14948393-bd7d-4960-a395-ccdf1100c12d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa69066b-a023-4799-95ee-f862d5243ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6246e6d-4881-4a66-b30d-766ddd185723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6246e6d-4881-4a66-b30d-766ddd185723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ff47986-350a-469c-b877-0a11dacca101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ff47986-350a-469c-b877-0a11dacca101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f18562f-c573-42cd-b454-fbeacaf85fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f18562f-c573-42cd-b454-fbeacaf85fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca4923ee-3906-4b02-bbb2-79c24b82d9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c686ce1b-3a28-43d2-83cd-c517c59d96be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca4923ee-3906-4b02-bbb2-79c24b82d9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8a8aed6f-cca4-4d01-a0fe-86663085c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_db4c44b4-8ce4-42c0-9a2d-2efde86a2da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a8aed6f-cca4-4d01-a0fe-86663085c90a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_db4c44b4-8ce4-42c0-9a2d-2efde86a2da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstruments" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a602e8ee-aa4e-4d94-88e0-a75746296890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6d632bf7-e154-468e-8cb3-ae26c97d835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a602e8ee-aa4e-4d94-88e0-a75746296890" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6d632bf7-e154-468e-8cb3-ae26c97d835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26657e4f-c184-4808-a7b1-409b63e4d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d7171be4-628c-4009-8a49-d9e0bcd1a281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26657e4f-c184-4808-a7b1-409b63e4d1e0" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d7171be4-628c-4009-8a49-d9e0bcd1a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/Revenue" xlink:type="simple" xlink:href="isrg-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_67b7d691-58b0-461d-a038-7dafbea2da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ce65a81-0a18-488a-9169-6b3d8a3bb3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_67b7d691-58b0-461d-a038-7dafbea2da7f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ce65a81-0a18-488a-9169-6b3d8a3bb3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/Leases" xlink:type="simple" xlink:href="isrg-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d4c9ff2-b6cf-4630-bb67-ef0cab7354d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_09d22d54-3bfa-4524-af14-68f59d9312e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d4c9ff2-b6cf-4630-bb67-ef0cab7354d0" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_09d22d54-3bfa-4524-af14-68f59d9312e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4fd725b-0db8-462d-9492-8b23ff0d252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d4c9ff2-b6cf-4630-bb67-ef0cab7354d0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c4fd725b-0db8-462d-9492-8b23ff0d252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IntangibleAssets" xlink:type="simple" xlink:href="isrg-20221231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcda08ee-39dc-49c6-9071-3a3d40e0ed2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_12faea5e-ba86-4ce9-8569-5214b37e2605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcda08ee-39dc-49c6-9071-3a3d40e0ed2c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_12faea5e-ba86-4ce9-8569-5214b37e2605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="isrg-20221231.xsd#CommitmentsAndContingencies"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bde4a336-49f2-4ab9-87de-9cf231f10022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d8c7042-a6e9-4b21-b6e1-2a9c80af89e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bde4a336-49f2-4ab9-87de-9cf231f10022" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d8c7042-a6e9-4b21-b6e1-2a9c80af89e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquity" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a53753c8-1502-4d81-8e96-368df5a595f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_408d0bc4-7457-44dd-b813-d7955a269055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a53753c8-1502-4d81-8e96-368df5a595f5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_408d0bc4-7457-44dd-b813-d7955a269055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6fc243a7-34c5-4460-89c0-3751d1666a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b989d9ce-96d2-4fe2-989c-d3486459272e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6fc243a7-34c5-4460-89c0-3751d1666a1d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b989d9ce-96d2-4fe2-989c-d3486459272e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxes" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9c436c52-1e30-43a1-a40f-edcd810319fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_43c5ad98-e33d-48f4-b635-7bf0b49f9271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9c436c52-1e30-43a1-a40f-edcd810319fe" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_43c5ad98-e33d-48f4-b635-7bf0b49f9271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="isrg-20221231.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37cec77b-0630-4bc1-8717-5f636c735c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cd59f551-23fe-4780-bdc7-70f7422d46f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37cec77b-0630-4bc1-8717-5f636c735c7a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cd59f551-23fe-4780-bdc7-70f7422d46f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="isrg-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_74b93f91-de32-4eeb-86e2-58e9c0956ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_33b0eb85-4580-49b4-9f1f-244b2e4b90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_74b93f91-de32-4eeb-86e2-58e9c0956ee1" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_33b0eb85-4580-49b4-9f1f-244b2e4b90fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts" xlink:type="simple" xlink:href="isrg-20221231.xsd#ValuationAndQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_40138740-005c-45bf-b27d-931c1c13fad7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5c7ad97a-b3ac-428f-b277-81eac6088fea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_40138740-005c-45bf-b27d-931c1c13fad7" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5c7ad97a-b3ac-428f-b277-81eac6088fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a36fb9c6-d209-44e3-bb1d-4e3db5ad613b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a36fb9c6-d209-44e3-bb1d-4e3db5ad613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_358e0008-4631-4ce0-87c5-521023d4c372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_358e0008-4631-4ce0-87c5-521023d4c372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7c17f8d4-7f1d-49fa-9d22-9b8720e06df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_UseOfEstimates_7c17f8d4-7f1d-49fa-9d22-9b8720e06df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_72975373-23ad-42d1-b4e3-086adf8ca709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_72975373-23ad-42d1-b4e3-086adf8ca709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cc9ca4fb-8d41-4a16-98c9-14b9c5d04c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cc9ca4fb-8d41-4a16-98c9-14b9c5d04c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_f44e3592-51d1-43fb-aa32-007e27e74251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_f44e3592-51d1-43fb-aa32-007e27e74251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_597d613d-8fa7-4843-a975-cc3cb4ef1628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_597d613d-8fa7-4843-a975-cc3cb4ef1628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_a5fcb295-be29-4a61-ab4c-78e8b7aecabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_a5fcb295-be29-4a61-ab4c-78e8b7aecabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019ae739-a746-4c88-bb46-9dccd156f139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_019ae739-a746-4c88-bb46-9dccd156f139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_095d37cd-c4d2-4b8e-956c-f798a337e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_095d37cd-c4d2-4b8e-956c-f798a337e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_80a99c8e-fd24-41d3-b327-f5967e4ce5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_80a99c8e-fd24-41d3-b327-f5967e4ce5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_97c1af1d-ce37-4f6a-8db9-0348e4eedbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_97c1af1d-ce37-4f6a-8db9-0348e4eedbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e723633b-ae8b-4bf4-9baa-94c73bdf7fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e723633b-ae8b-4bf4-9baa-94c73bdf7fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0c0b1b68-5f51-4ac7-8718-85cab3568895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0c0b1b68-5f51-4ac7-8718-85cab3568895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock_08d97d3e-ce60-4907-b7db-5bf2341dcd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_LessorLeasesPolicyTextBlock_08d97d3e-ce60-4907-b7db-5bf2341dcd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c771459e-9e9d-496e-993f-082a78b88483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c771459e-9e9d-496e-993f-082a78b88483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_5a067cb7-53b0-44ce-8aa1-f53a88498002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_5a067cb7-53b0-44ce-8aa1-f53a88498002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock_ebf3010a-f4e9-4966-bc22-e780140fd0e4" xlink:href="isrg-20221231.xsd#isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock_ebf3010a-f4e9-4966-bc22-e780140fd0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c7179e88-25c1-4c1b-819e-8cb5058a141a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c7179e88-25c1-4c1b-819e-8cb5058a141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3e7654d7-8c1a-454d-b1d5-8d6333488d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3e7654d7-8c1a-454d-b1d5-8d6333488d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_56e509dc-8fd1-4290-9b5e-cbd654fdbf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_56e509dc-8fd1-4290-9b5e-cbd654fdbf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock_3ad75c10-4714-4a7e-8cbb-ff10e0cb1d84" xlink:href="isrg-20221231.xsd#isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock_3ad75c10-4714-4a7e-8cbb-ff10e0cb1d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_653631ce-390b-4a81-94a2-8081ca906686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_653631ce-390b-4a81-94a2-8081ca906686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e1f0b9d1-ae20-40a2-83ab-7f7610e9351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e1f0b9d1-ae20-40a2-83ab-7f7610e9351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_41526c60-d9fb-43fa-a97e-5088c576bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_41526c60-d9fb-43fa-a97e-5088c576bdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1dc8f5c2-2276-49b1-9ce9-d52721c8a40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_439a367d-e1d1-4eed-8d46-c6270f6a0c15" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1dc8f5c2-2276-49b1-9ce9-d52721c8a40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2dd0b1fc-e7e1-49e0-be6e-e06d734f94a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e4294002-99bb-4fd6-b2d8-b5a2aa5268b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2dd0b1fc-e7e1-49e0-be6e-e06d734f94a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e4294002-99bb-4fd6-b2d8-b5a2aa5268b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock_7d0a6413-a415-4b79-aba7-bd98454787ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2dd0b1fc-e7e1-49e0-be6e-e06d734f94a5" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock_7d0a6413-a415-4b79-aba7-bd98454787ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a6530b0c-1ced-4b6a-b09d-f33bc8021d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a6530b0c-1ced-4b6a-b09d-f33bc8021d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1bc3ba85-5b43-42bc-9d07-81fb246c4afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1bc3ba85-5b43-42bc-9d07-81fb246c4afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0719e654-9124-4dff-8bab-3940e486fd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_0719e654-9124-4dff-8bab-3940e486fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_7deb329f-27f0-4559-9756-5df16cc9efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_7deb329f-27f0-4559-9756-5df16cc9efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_73ca8dde-dc33-48dc-bcb8-0b58c590829c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_73ca8dde-dc33-48dc-bcb8-0b58c590829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_087c0d6f-7423-467f-b2c6-28304879a502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad0f2660-e9e2-423c-9ad0-ccade0182753" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_087c0d6f-7423-467f-b2c6-28304879a502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_9de4272b-1fd0-4a2a-a882-09bcb2be5b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_9de4272b-1fd0-4a2a-a882-09bcb2be5b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d3adb3cb-bbfa-492b-8ee4-15724571a896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d3adb3cb-bbfa-492b-8ee4-15724571a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_91cb7f37-6c74-40cd-b1d4-cc12a7bf7842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_91cb7f37-6c74-40cd-b1d4-cc12a7bf7842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4cf5d463-f667-482a-bf1f-da0978a7ad09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4cf5d463-f667-482a-bf1f-da0978a7ad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_ddff661b-e987-4efb-9df2-758dd2a87baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_ddff661b-e987-4efb-9df2-758dd2a87baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_89026086-eed9-454b-b01f-9406fd0f0bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_89026086-eed9-454b-b01f-9406fd0f0bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_486a58f3-6828-4053-8755-e96f8478bfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca973b7a-26bc-4180-8f65-9f7af19d9b4b" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_486a58f3-6828-4053-8755-e96f8478bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_215535f1-b258-4574-bec7-ab3065e20a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d0e696d-9c83-440f-bb7b-e0e2758840bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_215535f1-b258-4574-bec7-ab3065e20a75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d0e696d-9c83-440f-bb7b-e0e2758840bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e41c8fc4-8672-4cbf-bc49-f6809519e9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_215535f1-b258-4574-bec7-ab3065e20a75" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e41c8fc4-8672-4cbf-bc49-f6809519e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_b880569e-99ca-4292-90bb-b63617e5deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_215535f1-b258-4574-bec7-ab3065e20a75" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_b880569e-99ca-4292-90bb-b63617e5deb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_cc9deba9-7b03-46aa-8ae7-23fd383795f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_215535f1-b258-4574-bec7-ab3065e20a75" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_cc9deba9-7b03-46aa-8ae7-23fd383795f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock_4e8aa317-eb4c-4882-b405-c2abdc33b2c5" xlink:href="isrg-20221231.xsd#isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock_4e8aa317-eb4c-4882-b405-c2abdc33b2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_1e475d45-2407-4a11-a8a3-11e468184cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_1e475d45-2407-4a11-a8a3-11e468184cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_98215855-32f5-4d26-8ffc-0d43eedc1610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_98215855-32f5-4d26-8ffc-0d43eedc1610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9d129503-d823-4ddb-a666-25cf83d9b125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9d129503-d823-4ddb-a666-25cf83d9b125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AssetsAndLiabilitiesLesseeTableTextBlock_6744945e-f715-47a9-ba8c-b81792eb6d0b" xlink:href="isrg-20221231.xsd#isrg_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_isrg_AssetsAndLiabilitiesLesseeTableTextBlock_6744945e-f715-47a9-ba8c-b81792eb6d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_daf86e9a-c3a5-4362-b06d-bc38816b4814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53879dc9-11df-45b8-a289-d56f2a6d9c36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_daf86e9a-c3a5-4362-b06d-bc38816b4814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ee9660-418f-48d1-8494-6499f37aa295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3b464837-9d73-477b-8d48-f7f5b62c24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ee9660-418f-48d1-8494-6499f37aa295" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3b464837-9d73-477b-8d48-f7f5b62c24fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9afb7416-9f99-4ef7-8dec-649bff1f7175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ee9660-418f-48d1-8494-6499f37aa295" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9afb7416-9f99-4ef7-8dec-649bff1f7175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c04491d9-11f9-4710-86f5-cbf12be862b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ee9660-418f-48d1-8494-6499f37aa295" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c04491d9-11f9-4710-86f5-cbf12be862b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_44a99547-e0d2-4ef1-be9a-a920910e6118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleofCommonStockRepurchasedTableTextBlock_755a07a9-c703-41f5-b9d9-a0d3b4045cd7" xlink:href="isrg-20221231.xsd#isrg_ScheduleofCommonStockRepurchasedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44a99547-e0d2-4ef1-be9a-a920910e6118" xlink:to="loc_isrg_ScheduleofCommonStockRepurchasedTableTextBlock_755a07a9-c703-41f5-b9d9-a0d3b4045cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bbdd5ea2-bc7a-4d2e-8d31-fbf089974314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44a99547-e0d2-4ef1-be9a-a920910e6118" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bbdd5ea2-bc7a-4d2e-8d31-fbf089974314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_f105ef1d-6723-4cd0-93d2-449bd4f5427b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44a99547-e0d2-4ef1-be9a-a920910e6118" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_f105ef1d-6723-4cd0-93d2-449bd4f5427b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bdd92e40-14d6-4d88-9ca2-81ca56219155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bdd92e40-14d6-4d88-9ca2-81ca56219155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_598d7e63-aa8c-4048-b7f9-02a1b24965a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_598d7e63-aa8c-4048-b7f9-02a1b24965a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_8f55446a-834c-4242-9927-fe649c03c257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_8f55446a-834c-4242-9927-fe649c03c257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_2e496025-8960-482b-a091-a3fc46ac9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_2e496025-8960-482b-a091-a3fc46ac9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b04dc5d4-0d5b-4834-9de0-bc4db53e26c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b04dc5d4-0d5b-4834-9de0-bc4db53e26c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_5e0f8802-5233-4955-9c5e-3b3cc828e5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6005c979-c8a2-4014-b889-40d4ad219c0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_5e0f8802-5233-4955-9c5e-3b3cc828e5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_21ff939f-7d26-4e5a-ad8e-8b50679aecca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_21ff939f-7d26-4e5a-ad8e-8b50679aecca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8787cb0d-add9-42af-af1a-40261155625e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8787cb0d-add9-42af-af1a-40261155625e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ae6f4f60-0019-45a7-8bfd-363821f5a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ae6f4f60-0019-45a7-8bfd-363821f5a51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_428bbd00-868e-440b-b2f2-8b4aebe16cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_428bbd00-868e-440b-b2f2-8b4aebe16cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5221f324-aedc-4a8f-afdc-db32a97b1379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea40bf55-67c8-4b60-9d1f-86bd1ecfa08c" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5221f324-aedc-4a8f-afdc-db32a97b1379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="isrg-20221231.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c88a4ccd-1b10-4b9d-a18d-0917643f10de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_39790364-50f8-4564-854b-b7c12b80584c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c88a4ccd-1b10-4b9d-a18d-0917643f10de" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_39790364-50f8-4564-854b-b7c12b80584c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_09a04740-484d-4d29-806f-5d37459485bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_09a04740-484d-4d29-806f-5d37459485bd" xlink:to="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_07d82e99-554d-4e8e-be0c-4985f5906122" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2246d77c-c0b9-4705-bd09-6c058e2a8142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:to="loc_us-gaap_AccountsReceivableMember_2246d77c-c0b9-4705-bd09-6c058e2a8142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TotalRevenueMember_bf735caa-fc81-4d7b-b7cb-7293d7d577a6" xlink:href="isrg-20221231.xsd#isrg_TotalRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06ca7824-5ebe-4325-8d6d-af827e448da2" xlink:to="loc_isrg_TotalRevenueMember_bf735caa-fc81-4d7b-b7cb-7293d7d577a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_139daeee-606d-4e72-bf88-c403e2ebab87" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_cbf82f98-583c-45aa-aa57-1496f4d02235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_65156515-45c2-44e2-95b4-1f925ee7702a" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_cbf82f98-583c-45aa-aa57-1496f4d02235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_582bb42b-d1a5-4074-aecf-5deb6d8ad59b" xlink:to="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_f5817cdf-553d-48e7-8e39-19bf9972d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_f5817cdf-553d-48e7-8e39-19bf9972d45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_40ec76a6-a98f-459a-a74d-eb0531d15394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_983dcd65-b359-4587-adf8-c5b79ac41502" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_40ec76a6-a98f-459a-a74d-eb0531d15394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18beb4c9-98f1-4231-a19f-ae548dfa4f0a" xlink:to="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da7d374a-4058-40c2-86d1-2ca3c8beb61d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:to="loc_srt_MinimumMember_da7d374a-4058-40c2-86d1-2ca3c8beb61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8801f9c9-d215-4dd1-b8d3-714ee985a3c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82e9eedf-bbc3-4445-91c5-7e75ef0b2082" xlink:to="loc_srt_MaximumMember_8801f9c9-d215-4dd1-b8d3-714ee985a3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2c6f1a6-736a-4b97-b9c5-f1511b9a8d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3d40608a-be3d-4181-afe1-1182deec4953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da0e58a5-9d8d-49ae-a6d6-c0bbcdaf99f7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3d40608a-be3d-4181-afe1-1182deec4953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:href="isrg-20221231.xsd#isrg_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesTable_f5eef2b2-8f6e-4303-b6a2-5df5f94d5899" xlink:to="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4be2b53-3e27-4f47-9981-4a1b7eb46d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a4be2b53-3e27-4f47-9981-4a1b7eb46d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1e50eaa-8460-4269-ba6c-af7357875521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a1e50eaa-8460-4269-ba6c-af7357875521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c172d9d2-3e98-4480-af18-582848905d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c172d9d2-3e98-4480-af18-582848905d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ServiceFeeCredit_4009eef4-d257-4efc-849b-a29979d7c209" xlink:href="isrg-20221231.xsd#isrg_ServiceFeeCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ServiceFeeCredit_4009eef4-d257-4efc-849b-a29979d7c209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_36bc70db-8c2d-49ab-ac97-75a2e46fd641" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseLeaseReceivableExtendedPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment_36bc70db-8c2d-49ab-ac97-75a2e46fd641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableExtendedPayment_699fea91-2702-452f-81e0-741959d53595" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableExtendedPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_AccountsReceivableExtendedPayment_699fea91-2702-452f-81e0-741959d53595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_322aa134-5a4e-4baa-b181-b90798e1320a" xlink:href="isrg-20221231.xsd#isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding_322aa134-5a4e-4baa-b181-b90798e1320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bd745dee-d0a2-45e5-8a40-ff4358b8e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_RestrictedCash_bd745dee-d0a2-45e5-8a40-ff4358b8e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_19b635ff-8875-473d-b444-70da7c71cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_Depreciation_19b635ff-8875-473d-b444-70da7c71cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1aac852b-6d6a-43a2-960c-e1a66b5305a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1aac852b-6d6a-43a2-960c-e1a66b5305a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_119cc58c-9ab9-4e81-bc23-fb186ab7d08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_119cc58c-9ab9-4e81-bc23-fb186ab7d08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed6c0437-cb08-488b-9334-1dc144ecdd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed6c0437-cb08-488b-9334-1dc144ecdd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_950aa826-7d54-4109-b87b-ae3f0ffd24f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_950aa826-7d54-4109-b87b-ae3f0ffd24f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemSalesArrangementWarrantyPeriod_f8355a7d-a6e4-48cb-8fef-d59220e1f9a3" xlink:href="isrg-20221231.xsd#isrg_SystemSalesArrangementWarrantyPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_SystemSalesArrangementWarrantyPeriod_f8355a7d-a6e4-48cb-8fef-d59220e1f9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_b3e20aff-6dd4-43e7-89c3-20d66cad2f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_AcquisitionCosts_b3e20aff-6dd4-43e7-89c3-20d66cad2f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_b4e9d1ee-113b-4473-8d5f-c29dc40176aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorSalesTypeLeaseTermOfContract1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_LessorSalesTypeLeaseTermOfContract1_b4e9d1ee-113b-4473-8d5f-c29dc40176aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_98ca5206-9646-4176-a012-7437d9979e81" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod_98ca5206-9646-4176-a012-7437d9979e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_4c618609-cfef-4306-af8e-e8994dbeb9d5" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent_4c618609-cfef-4306-af8e-e8994dbeb9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_957a834b-8297-4439-ab2a-1b339a9741ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_us-gaap_DerivativeTermOfContract_957a834b-8297-4439-ab2a-1b339a9741ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_7205117a-c4bd-478b-9431-1b4e04450c2a" xlink:href="isrg-20221231.xsd#isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod_7205117a-c4bd-478b-9431-1b4e04450c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_696b101d-799e-4e77-b8b1-755961af8e4b" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement_696b101d-799e-4e77-b8b1-755961af8e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_87a25fcd-8382-4fe6-a256-374f53f1b221" xlink:href="isrg-20221231.xsd#isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_SummaryOfSignificantAccountingPoliciesLineItems_a66f073f-e6d7-4c62-be07-77b870a8a7e8" xlink:to="loc_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent_87a25fcd-8382-4fe6-a256-374f53f1b221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7fab7545-494c-499c-a7fc-d6b0c37ee86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7fab7545-494c-499c-a7fc-d6b0c37ee86a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7078b292-366c-4c5a-83a5-6ff7c1c709d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_11457159-8480-48b6-9ac0-06da0f082cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_BuildingMember_11457159-8480-48b6-9ac0-06da0f082cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingImprovementsMember_612332dc-3dc2-4bee-a629-c1bd9b26dddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_BuildingImprovementsMember_612332dc-3dc2-4bee-a629-c1bd9b26dddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquipmentAndFurnitureMember_55d71408-ce1b-4d01-99a8-7da4aa6dfb13" xlink:href="isrg-20221231.xsd#isrg_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_EquipmentAndFurnitureMember_55d71408-ce1b-4d01-99a8-7da4aa6dfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_2c9af352-0df3-42e5-b8d4-2f3f6e50e633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_2c9af352-0df3-42e5-b8d4-2f3f6e50e633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_4d81f02c-4429-4aa4-8270-3535d2344998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_us-gaap_ComputerEquipmentMember_4d81f02c-4429-4aa4-8270-3535d2344998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EnterpriseWideSoftwareMember_8ccf78cf-c5bb-4ba5-b576-f818e37aac8d" xlink:href="isrg-20221231.xsd#isrg_EnterpriseWideSoftwareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_EnterpriseWideSoftwareMember_8ccf78cf-c5bb-4ba5-b576-f818e37aac8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PurchasedSoftwareMember_319f5957-8957-4c99-8a65-7fae4393b28f" xlink:href="isrg-20221231.xsd#isrg_PurchasedSoftwareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_48067a1e-754e-40d7-b63a-84c57307ebb5" xlink:to="loc_isrg_PurchasedSoftwareMember_319f5957-8957-4c99-8a65-7fae4393b28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:to="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_389425bd-f89b-4a8b-a589-3dd6ec4706c1" xlink:to="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd9d157b-3540-445c-b1e9-0f764727af82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:to="loc_srt_MaximumMember_cd9d157b-3540-445c-b1e9-0f764727af82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72e16473-67eb-4677-8d5c-7470703fb583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5d99d0a-4949-4321-b129-8ab82e3d9cd1" xlink:to="loc_srt_MinimumMember_72e16473-67eb-4677-8d5c-7470703fb583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2c5ec3f-1eb1-49dc-b15f-7fb43ceff06e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c733c666-34ab-4d8f-98fd-37f1f460f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c651e19d-a323-4288-8183-ce0904c8257b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c733c666-34ab-4d8f-98fd-37f1f460f64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fd1e019e-f609-4b6a-8d01-951deecf8589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fd1e019e-f609-4b6a-8d01-951deecf8589" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:to="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalCreditAssessmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentAxis_c5c02d72-58e3-40b3-979b-9712edc4b099" xlink:to="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_HighCreditRatingMember_2f3eef92-d759-4151-ad63-adab722549ed" xlink:href="isrg-20221231.xsd#isrg_HighCreditRatingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_HighCreditRatingMember_2f3eef92-d759-4151-ad63-adab722549ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ModerateCreditRatingMember_2456c8cc-cd41-4635-8195-3a6730a27c3e" xlink:href="isrg-20221231.xsd#isrg_ModerateCreditRatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_ModerateCreditRatingMember_2456c8cc-cd41-4635-8195-3a6730a27c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_LowCreditRatingMember_12a59976-493d-419b-8d40-d66c18655dde" xlink:href="isrg-20221231.xsd#isrg_LowCreditRatingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InternalCreditAssessmentDomain_2d2dfb84-0bf7-4d8d-85b3-a74890f58d51" xlink:to="loc_isrg_LowCreditRatingMember_12a59976-493d-419b-8d40-d66c18655dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable_bd083d84-c42d-4dad-b5da-a696447d4975" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_eb40c0fd-2c79-424d-a713-08149acc15ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear_eb40c0fd-2c79-424d-a713-08149acc15ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_55aa53c5-3577-4986-a41d-24c7574450ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear_55aa53c5-3577-4986-a41d-24c7574450ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_47f29d3b-2874-4fca-bd80-79da361f7310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear_47f29d3b-2874-4fca-bd80-79da361f7310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_bad31df8-06eb-468f-95bc-c512a38fcf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear_bad31df8-06eb-468f-95bc-c512a38fcf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_e8659505-de93-4d75-8e0c-bf33686b74af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear_e8659505-de93-4d75-8e0c-bf33686b74af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_706d5bae-a948-4161-9451-6d74d0af9662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear_706d5bae-a948-4161-9451-6d74d0af9662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_eaacb5eb-ea41-438e-be98-191f4a1fbdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems_11fe453b-f777-4043-bb5f-152d0094d027" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_eaacb5eb-ea41-438e-be98-191f4a1fbdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_262dab68-8938-4a80-b26c-0390ff1e23e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_262dab68-8938-4a80-b26c-0390ff1e23e1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b4499fde-2706-49e1-804d-98ce64686a52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eafeb8c7-559b-40c4-8014-462b400c6386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eafeb8c7-559b-40c4-8014-462b400c6386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4c7a24e1-e2fc-4ee9-9e34-d172b9ea0f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f56ca90-a330-4a54-b7d6-98a3604f640e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4c7a24e1-e2fc-4ee9-9e34-d172b9ea0f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4b4655c-0145-4d89-bbf4-9aa1e262219a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6b734511-b7a8-46e2-aac8-ed547e92571c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CashMember_6b734511-b7a8-46e2-aac8-ed547e92571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_225e0382-b13d-4349-8ff6-87dd72bf19a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_225e0382-b13d-4349-8ff6-87dd72bf19a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_56e2a530-e5fd-4207-b51b-91d25f5a433c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_56e2a530-e5fd-4207-b51b-91d25f5a433c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_af0e8365-b142-48d7-9c7a-e2f83ba2eda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CommercialPaperMember_af0e8365-b142-48d7-9c7a-e2f83ba2eda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4f253ad1-9439-4747-a6d5-cdf53d12df33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4f253ad1-9439-4747-a6d5-cdf53d12df33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e762214c-e9d7-49b4-ad43-c18f93bde642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e762214c-e9d7-49b4-ad43-c18f93bde642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalNotesMember_bf4330ec-50c7-48a5-a988-3956f52ef7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalNotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_420d5e7b-13a6-4029-900d-0fa1641aa3da" xlink:to="loc_us-gaap_MunicipalNotesMember_bf4330ec-50c7-48a5-a988-3956f52ef7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_94d5b543-7e76-4857-b248-ec7258c88d51" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e415fd2-ce2f-4608-86a5-0a1c23c3c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e415fd2-ce2f-4608-86a5-0a1c23c3c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8b198485-dd9b-43b5-80d5-8d5eae713afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8b198485-dd9b-43b5-80d5-8d5eae713afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb48af25-e2fc-443b-ab10-b2e22dda4347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb48af25-e2fc-443b-ab10-b2e22dda4347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_761d3f28-be9d-4470-a92e-dd301b20d31c" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost_761d3f28-be9d-4470-a92e-dd301b20d31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b4f8c04-ce2f-4a9c-b28c-e2b4c56a36be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b4f8c04-ce2f-4a9c-b28c-e2b4c56a36be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae7bd294-6d35-4d94-a3b4-c4546d5082f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae7bd294-6d35-4d94-a3b4-c4546d5082f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ab6eb3d4-3cfb-49fb-b016-8e9c743994d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ab6eb3d4-3cfb-49fb-b016-8e9c743994d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a1b2d39-f951-4c50-8673-8ba2757d6fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a1b2d39-f951-4c50-8673-8ba2757d6fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_38cb61a4-9db9-4df7-9049-1796fd178857" xlink:href="isrg-20221231.xsd#isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue_38cb61a4-9db9-4df7-9049-1796fd178857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d09234cb-853f-4bd1-b088-011bff4189da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d09234cb-853f-4bd1-b088-011bff4189da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_33f33765-99cc-4965-a098-c4fc65ac051c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f743a6e-4f8b-43b0-9e53-32705bcd18c1" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_33f33765-99cc-4965-a098-c4fc65ac051c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f2a2c9fb-180f-4bea-9e61-d0f40298773f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a4e5e4a1-1608-4839-ab30-dbd101c0c214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2a2c9fb-180f-4bea-9e61-d0f40298773f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a4e5e4a1-1608-4839-ab30-dbd101c0c214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c01102c6-e1e7-42c8-8856-4592c9849252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a4e5e4a1-1608-4839-ab30-dbd101c0c214" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c01102c6-e1e7-42c8-8856-4592c9849252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b72bd9be-9065-4c13-9caa-2741136de689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a4e5e4a1-1608-4839-ab30-dbd101c0c214" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b72bd9be-9065-4c13-9caa-2741136de689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6dbe0ae5-e0e6-43ac-9ed0-5db36424c35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a4e5e4a1-1608-4839-ab30-dbd101c0c214" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6dbe0ae5-e0e6-43ac-9ed0-5db36424c35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e13bd1d4-27fd-4603-a0f1-205bb1ac55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f2a2c9fb-180f-4bea-9e61-d0f40298773f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e13bd1d4-27fd-4603-a0f1-205bb1ac55d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_365bcc4f-e757-47c6-901c-a64db51fccac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e13bd1d4-27fd-4603-a0f1-205bb1ac55d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_365bcc4f-e757-47c6-901c-a64db51fccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_07255ef8-eaf8-4ce5-8c3f-2345801468b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e13bd1d4-27fd-4603-a0f1-205bb1ac55d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_07255ef8-eaf8-4ce5-8c3f-2345801468b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c406c2da-6f90-4b1d-bf50-8ca38c9a80de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e13bd1d4-27fd-4603-a0f1-205bb1ac55d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c406c2da-6f90-4b1d-bf50-8ca38c9a80de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3edef5a6-b40a-4101-8bd6-c212fdc571a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3edef5a6-b40a-4101-8bd6-c212fdc571a7" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1f91a40-40e6-4e0e-97c7-e8c2598627cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9c02f001-8cd9-4a3f-af09-0d76900b1913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9c02f001-8cd9-4a3f-af09-0d76900b1913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba2185bc-4700-4ef8-92db-8d327df9b833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8712cb02-e1f1-409b-8f68-17fdd6688107" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba2185bc-4700-4ef8-92db-8d327df9b833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17b1738c-320b-4fe7-a78a-58001114980c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_BroncusHoldingCorporationMember_38fdf36b-7def-4f50-b3c6-d00794f61b0a" xlink:href="isrg-20221231.xsd#isrg_BroncusHoldingCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a7eeaaa6-32cc-4d20-883a-cc448bb5ddb2" xlink:to="loc_isrg_BroncusHoldingCorporationMember_38fdf36b-7def-4f50-b3c6-d00794f61b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_edf3a4aa-f24a-4be8-a53b-890239341eb1" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_27b399b7-d63d-45e6-8f54-f9e2709b3727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_27b399b7-d63d-45e6-8f54-f9e2709b3727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_a57d91a0-8978-42e5-8ec1-758f2a1ccc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_a57d91a0-8978-42e5-8ec1-758f2a1ccc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c0b89ba7-2649-4d45-aec8-df396ff43f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c0b89ba7-2649-4d45-aec8-df396ff43f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_8bdd1f45-bc20-4558-a1b2-b884087550ed" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_61726f0c-4ac5-4a0f-a86f-08b07b3474af" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_8bdd1f45-bc20-4558-a1b2-b884087550ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d15a209d-e680-4dec-abfe-b0e7d5c22bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d15a209d-e680-4dec-abfe-b0e7d5c22bc7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:to="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:href="isrg-20221231.xsd#isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleSecuritiesAxis_3542325c-967f-4155-adf2-de5e27f094ec" xlink:to="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_92f64a0d-295a-43bb-9b7c-cda686dde187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_CommercialPaperMember_92f64a0d-295a-43bb-9b7c-cda686dde187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_00091b53-941d-4830-9f98-174c8bbddf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_00091b53-941d-4830-9f98-174c8bbddf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_723bd64a-5719-4764-aba1-aba1bb88c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_723bd64a-5719-4764-aba1-aba1bb88c8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3a6781e1-9ed4-442e-820d-56fd1f274eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3a6781e1-9ed4-442e-820d-56fd1f274eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalNotesMember_a7304359-be0d-4efb-9e78-31dab9d8946e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain_c584c394-1514-416d-a82a-c10423d30d7b" xlink:to="loc_us-gaap_MunicipalNotesMember_a7304359-be0d-4efb-9e78-31dab9d8946e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4973caf5-b08a-455d-9832-b93e19944ee6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4c48abf3-0648-44e7-bd47-aa7d5c2ec48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4c48abf3-0648-44e7-bd47-aa7d5c2ec48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b979bb88-a134-4d67-af9e-6ba4cf98f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b979bb88-a134-4d67-af9e-6ba4cf98f0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d1b9dc17-1e3d-4a0b-a444-33d757f0bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d1b9dc17-1e3d-4a0b-a444-33d757f0bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a29d4554-c7f0-40b3-baae-4022b63348ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a29d4554-c7f0-40b3-baae-4022b63348ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f4960523-e1c8-4f46-982f-3e289ac3940b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f4960523-e1c8-4f46-982f-3e289ac3940b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fe8d263f-ef7e-49bd-889d-66a9eefaa01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_98cf57ac-916c-4f2b-a46b-2090dc8156b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fe8d263f-ef7e-49bd-889d-66a9eefaa01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_27551869-c368-4499-8088-2b95ce6329ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_27551869-c368-4499-8088-2b95ce6329ed" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_99542bd0-eb16-41f3-9893-d70528200333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_007e0361-75d6-44da-97f5-de9dffb9cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_007e0361-75d6-44da-97f5-de9dffb9cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IntangibleAndOtherAssetsNetMember_6bf2913b-c23d-4306-94ab-1aa8498a4b27" xlink:href="isrg-20221231.xsd#isrg_IntangibleAndOtherAssetsNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a46129fc-5dd4-4305-a150-07cc18fc5409" xlink:to="loc_isrg_IntangibleAndOtherAssetsNetMember_6bf2913b-c23d-4306-94ab-1aa8498a4b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ce45564-a1f1-4793-8cc1-b9fea995cdd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_81127529-9c0c-48e1-95d8-ffc52bccf847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_81127529-9c0c-48e1-95d8-ffc52bccf847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0596f8b6-fc32-4922-bb80-9dfe4fdd7120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f31ece6e-49cd-4865-9dda-c8613d4d0d0b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0596f8b6-fc32-4922-bb80-9dfe4fdd7120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_4b66c708-4035-4c4f-83fa-89d3940d1664" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_ed3d023b-cabd-4ae5-a64f-806721798995" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c25587c5-3db6-4a80-8464-fc61124c9b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c25587c5-3db6-4a80-8464-fc61124c9b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_62a4f026-afd4-473b-9e24-72ebd725564d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_62a4f026-afd4-473b-9e24-72ebd725564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_299be4f2-6b69-4047-8987-68739b17ffae" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments_299be4f2-6b69-4047-8987-68739b17ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dace5962-ba77-4dbd-ab25-667021911623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dace5962-ba77-4dbd-ab25-667021911623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_86b5b87b-1664-4167-8940-a50ffe45ccb4" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss_86b5b87b-1664-4167-8940-a50ffe45ccb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_393c9893-fd65-449d-8740-c8af136a402a" xlink:href="isrg-20221231.xsd#isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8d1a9788-6333-458b-a8e3-1cdad9bdcc32" xlink:to="loc_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments_393c9893-fd65-449d-8740-c8af136a402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_973cb8fd-99aa-4d87-a738-a1c1e55f7278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_973cb8fd-99aa-4d87-a738-a1c1e55f7278" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_119bbe2a-146f-41e4-83c6-3619d4511656" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_fc2648dc-0dd0-43e5-87c4-30137d1bdb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a1403b77-149e-4ea0-9754-f69e147a726a" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_fc2648dc-0dd0-43e5-87c4-30137d1bdb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:to="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_138df6dd-33fa-4c49-a8f2-fbac06a45b89" xlink:to="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0a7ca05b-dca1-470e-be56-2a9a19de48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_da029cbb-f5af-41ab-a40a-31bbd70b4c51" xlink:to="loc_us-gaap_NondesignatedMember_0a7ca05b-dca1-470e-be56-2a9a19de48ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eb30173a-a89c-4be0-ada5-37a7b4d9be80" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48510b89-c0ca-4e80-8da1-4e3dd47731ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48510b89-c0ca-4e80-8da1-4e3dd47731ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_34e94e0b-abd0-419f-9780-70a235636fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_34e94e0b-abd0-419f-9780-70a235636fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6e1624ec-16e9-4160-bbd5-e9c5701ff8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1073885a-0a70-4067-a51c-5e760b2b3ec2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6e1624ec-16e9-4160-bbd5-e9c5701ff8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_95315898-a857-4a6b-bd32-809c7a6eab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_95315898-a857-4a6b-bd32-809c7a6eab0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47f2cb74-3622-435f-9ec0-716c14b55a05" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_6bd4e969-50e8-481e-955a-65199adc157c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_53f4d1af-4078-434e-9240-63b4f919b50d" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_6bd4e969-50e8-481e-955a-65199adc157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6301c4c9-0f99-4b74-a513-fc233d331578" xlink:to="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00568d60-d704-433d-b505-532080f5ef68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_00568d60-d704-433d-b505-532080f5ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f81d101b-52f8-47fc-8de3-78c1ea500548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f29c772d-ba98-4937-9e26-764a94874380" xlink:to="loc_us-gaap_NondesignatedMember_f81d101b-52f8-47fc-8de3-78c1ea500548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_112d1532-d9fa-400b-a725-4c8c64c9ceaf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_736fc904-f4c9-4373-a8a8-961cb9305716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_736fc904-f4c9-4373-a8a8-961cb9305716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_1bd8c892-ffef-4e81-9d24-41a0bbe7ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_21abd3d5-b426-41df-adc6-a6b1ebb93638" xlink:to="loc_us-gaap_OtherLiabilitiesMember_1bd8c892-ffef-4e81-9d24-41a0bbe7ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3069be4c-b7bc-44ee-8fef-9a7b44730cca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9bd0d486-a782-4d43-aa91-ca0913a93985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d15cbe1a-4fc9-44fe-bb75-90b8bace86b6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9bd0d486-a782-4d43-aa91-ca0913a93985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ae77ec3b-1a12-44e9-a9a9-588fc9a19ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TradeAccountsReceivableCurrent_4545d189-830b-4726-ab78-20f27b360e77" xlink:href="isrg-20221231.xsd#isrg_TradeAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae77ec3b-1a12-44e9-a9a9-588fc9a19ec1" xlink:to="loc_isrg_TradeAccountsReceivableCurrent_4545d189-830b-4726-ab78-20f27b360e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_245c103f-eca7-44f4-9735-224531efcba2" xlink:href="isrg-20221231.xsd#isrg_UnbilledReceivablesAndOtherReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae77ec3b-1a12-44e9-a9a9-588fc9a19ec1" xlink:to="loc_isrg_UnbilledReceivablesAndOtherReceivablesCurrent_245c103f-eca7-44f4-9735-224531efcba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesReturnsAndAllowances_331fde26-3635-4984-ab6c-0e212ed5b348" xlink:href="isrg-20221231.xsd#isrg_SalesReturnsAndAllowances"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae77ec3b-1a12-44e9-a9a9-588fc9a19ec1" xlink:to="loc_isrg_SalesReturnsAndAllowances_331fde26-3635-4984-ab6c-0e212ed5b348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_92c70c15-57e5-4abb-97ff-b32313d8ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ae77ec3b-1a12-44e9-a9a9-588fc9a19ec1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_92c70c15-57e5-4abb-97ff-b32313d8ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_edba5e9b-1259-4ccf-a806-17338642ae6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_edba5e9b-1259-4ccf-a806-17338642ae6e" xlink:to="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_edb54fb6-bc8e-4e14-9799-6db6cfa21e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_edb54fb6-bc8e-4e14-9799-6db6cfa21e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a87f6294-80e2-48ad-993b-14ac9b63cacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a87f6294-80e2-48ad-993b-14ac9b63cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_aa0d3e56-80d7-4add-9f8d-7f75310b0170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_aa0d3e56-80d7-4add-9f8d-7f75310b0170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4c99a959-e3a0-477d-8842-65b5ecddfefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8d561662-93f5-488b-9ae0-a15b9bd07b85" xlink:to="loc_us-gaap_InventoryNet_4c99a959-e3a0-477d-8842-65b5ecddfefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_582b8ea8-2979-4075-85ab-55a0e11f8eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_2c042889-80ad-4dbb-a2ce-25bec8ca5645" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_582b8ea8-2979-4075-85ab-55a0e11f8eff" xlink:to="loc_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent_2c042889-80ad-4dbb-a2ce-25bec8ca5645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_63492b30-a55f-4f6d-bcb0-f406e6c82aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_582b8ea8-2979-4075-85ab-55a0e11f8eff" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_63492b30-a55f-4f6d-bcb0-f406e6c82aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_d6ddade0-3511-4df9-92c8-978af40a6599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_582b8ea8-2979-4075-85ab-55a0e11f8eff" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_d6ddade0-3511-4df9-92c8-978af40a6599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b5b5b1a6-416f-4440-8255-033aa3459dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_582b8ea8-2979-4075-85ab-55a0e11f8eff" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b5b5b1a6-416f-4440-8255-033aa3459dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72195043-1210-4769-b870-b4899b02f8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72195043-1210-4769-b870-b4899b02f8be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_75b98d55-58c2-4880-9c25-52656dc589b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_Land_75b98d55-58c2-4880-9c25-52656dc589b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_ca0507a1-d765-418e-b3be-7ecf92391693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_ca0507a1-d765-418e-b3be-7ecf92391693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_cbeb78a8-351d-4074-94fa-c9def31bdc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_cbeb78a8-351d-4074-94fa-c9def31bdc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_0f2adc12-e13f-4872-9ac2-3ef67e26643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_0f2adc12-e13f-4872-9ac2-3ef67e26643f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ComputerAndOfficeEquipment_aaaebcc6-fdb5-442c-8ffd-0a9b728f2b35" xlink:href="isrg-20221231.xsd#isrg_ComputerAndOfficeEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_isrg_ComputerAndOfficeEquipment_aaaebcc6-fdb5-442c-8ffd-0a9b728f2b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_3819f2e5-651a-4073-adb8-ba3e7c539685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_3819f2e5-651a-4073-adb8-ba3e7c539685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_6f348dad-0959-49bd-833e-9af857703b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_ConstructionInProgressGross_6f348dad-0959-49bd-833e-9af857703b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d3a17ae5-455d-49c0-9cda-b3ca7a929452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d3a17ae5-455d-49c0-9cda-b3ca7a929452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4c8bc1b-86c5-4d66-be1a-3a3f83ef6464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f4c8bc1b-86c5-4d66-be1a-3a3f83ef6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_85352efb-d71b-4697-b1d8-501591b2b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_85352efb-d71b-4697-b1d8-501591b2b2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation_90f07d66-9dba-4edb-896c-600d5e44e407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_9ac88f20-014f-42f6-b93d-fa72273946c0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation_90f07d66-9dba-4edb-896c-600d5e44e407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_50b2edd3-7ad0-4aa8-b5c2-a0d687324d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_us-gaap_TaxesPayableCurrent_50b2edd3-7ad0-4aa8-b5c2-a0d687324d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7b895753-527d-42c8-a4de-ec0a1df937fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7b895753-527d-42c8-a4de-ec0a1df937fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_0d12b00a-e1a3-4490-8a61-da5ab8814054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_us-gaap_LitigationReserveCurrent_0d12b00a-e1a3-4490-8a61-da5ab8814054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent_c991ef6b-b427-4316-b06c-c4cbc16ef4b3" xlink:href="isrg-20221231.xsd#isrg_DeferredPurchaseConsiderationPaymentsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_isrg_DeferredPurchaseConsiderationPaymentsCurrent_c991ef6b-b427-4316-b06c-c4cbc16ef4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6b209e86-6645-4110-ae6b-2ff5fb468589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6b209e86-6645-4110-ae6b-2ff5fb468589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e38fa973-1b9c-42d6-aac5-24b0c9fc105e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6a592ef5-06c8-4369-800d-97fbbdf03dbe" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e38fa973-1b9c-42d6-aac5-24b0c9fc105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4b880ab-fbaa-42c5-b0e2-7a86b94cbff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_6a3517ee-9abc-48b7-adf4-03e53ec63482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4b880ab-fbaa-42c5-b0e2-7a86b94cbff9" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_6a3517ee-9abc-48b7-adf4-03e53ec63482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_26a88a9c-7283-457a-a1d3-e3d8ae3d5078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4b880ab-fbaa-42c5-b0e2-7a86b94cbff9" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_26a88a9c-7283-457a-a1d3-e3d8ae3d5078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_0d775d72-7db0-4191-83f3-705363f05837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4b880ab-fbaa-42c5-b0e2-7a86b94cbff9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_0d775d72-7db0-4191-83f3-705363f05837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_e17bbe47-e610-4d2c-9ef5-4f391e75f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4b880ab-fbaa-42c5-b0e2-7a86b94cbff9" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_e17bbe47-e610-4d2c-9ef5-4f391e75f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ba605dd-9115-4d71-86ce-6ffa4406de56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_f103a4be-7661-412e-8af0-4304e13b4f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ba605dd-9115-4d71-86ce-6ffa4406de56" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_f103a4be-7661-412e-8af0-4304e13b4f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a75c46c0-8901-452f-a0c5-89936aec9876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_f103a4be-7661-412e-8af0-4304e13b4f57" xlink:to="loc_us-gaap_IncomeTaxesPaid_a75c46c0-8901-452f-a0c5-89936aec9876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_64c801fd-6f6f-4799-ba60-b468b6f32365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_f103a4be-7661-412e-8af0-4304e13b4f57" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_64c801fd-6f6f-4799-ba60-b468b6f32365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_324de561-d32b-4c99-946b-98ea6e4b27e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_64c801fd-6f6f-4799-ba60-b468b6f32365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_324de561-d32b-4c99-946b-98ea6e4b27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_91c14807-4fe6-493a-99c1-6ea7c938d0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_64c801fd-6f6f-4799-ba60-b468b6f32365" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_91c14807-4fe6-493a-99c1-6ea7c938d0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueRevenueDisaggregatedbyTypesandGeographyDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cc763825-1f3f-4a85-8b41-e8de093a746e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cc763825-1f3f-4a85-8b41-e8de093a746e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:to="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_6ff4f53b-3b06-4d7c-b578-86127e202936" xlink:to="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomesticMember_19b1e482-5c9b-41a0-9c18-2b047d21ee43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:to="loc_us-gaap_GeographicDistributionDomesticMember_19b1e482-5c9b-41a0-9c18-2b047d21ee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_fabe231d-cb5a-415b-a217-f08cea99858a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_b963853c-a46f-4d0d-97f9-f8d264d03d94" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_fabe231d-cb5a-415b-a217-f08cea99858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:to="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e2507549-6818-4f5f-aa73-8a40da8baf0e" xlink:to="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:to="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InstrumentsandAccessoriesMember_6322117a-5b40-4fa4-be9c-295e1f7ded91" xlink:href="isrg-20221231.xsd#isrg_InstrumentsandAccessoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:to="loc_isrg_InstrumentsandAccessoriesMember_6322117a-5b40-4fa4-be9c-295e1f7ded91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SystemsMember_ce082faa-c6d3-4f23-8678-d7bce63d954e" xlink:href="isrg-20221231.xsd#isrg_SystemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2cba3f0b-ab42-4b05-aaea-15ee40c79065" xlink:to="loc_isrg_SystemsMember_ce082faa-c6d3-4f23-8678-d7bce63d954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1db909b5-a4c4-454d-ae6d-9b2873750e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99557c45-afb3-478e-8d7e-36edf0ec0db8" xlink:to="loc_us-gaap_ServiceMember_1db909b5-a4c4-454d-ae6d-9b2873750e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_faf3ef26-29a9-483f-bbad-63f26b40fe8e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a1f64c4-ee53-467e-a9ce-25c1ad7189b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cedc45a6-b431-4cf2-84a1-8d16be221d7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a1f64c4-ee53-467e-a9ce-25c1ad7189b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_462ffd60-f12d-4389-89a5-11532759a068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_462ffd60-f12d-4389-89a5-11532759a068" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d06317df-8270-47c4-a254-7e33085422ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d06317df-8270-47c4-a254-7e33085422ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30802bae-db55-4657-805c-e97ae2a118a8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7c71c261-d516-45e1-96b4-fb48c7411b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f5029a4d-466f-43bc-a5ca-d7f0b1e9ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_faff1587-7008-4de8-b273-479b44f0fd36" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57e04093-8ead-4970-93fa-726073fb99b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueSummaryofContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5f8262e-dab9-4d8b-92c1-d60913f86d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b13cce3f-61be-4052-98fa-60c25f02b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5f8262e-dab9-4d8b-92c1-d60913f86d9a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b13cce3f-61be-4052-98fa-60c25f02b6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_49dbd9e6-822e-4e6f-9a6d-e241afaf697b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d5f8262e-dab9-4d8b-92c1-d60913f86d9a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_49dbd9e6-822e-4e6f-9a6d-e241afaf697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#RevenueSalestypeandOperatingLeaseRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_408a8803-3bae-45a3-999f-fe7781df1b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_408a8803-3bae-45a3-999f-fe7781df1b9d" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_2a755fe0-f6f1-4bfc-ab49-30ff1d5a3b56" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_a6406040-68dd-451a-ad97-33528d48866f" xlink:href="isrg-20221231.xsd#isrg_VariableLeaseRevenueUsageBasedArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_57a80dff-9e27-4ee9-b205-2d548a8b5e6a" xlink:to="loc_isrg_VariableLeaseRevenueUsageBasedArrangementsMember_a6406040-68dd-451a-ad97-33528d48866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_79a1b272-5e22-47fb-a5fb-ae9c1fa52d1a" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_2a6a5c34-8a8b-448c-8f0c-772e43ea0152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList_2a6a5c34-8a8b-448c-8f0c-772e43ea0152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_6770d076-4d87-41ae-b148-b091632553e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_6770d076-4d87-41ae-b148-b091632553e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_877284ad-ca7d-4a7a-8e16-576320a18f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_877284ad-ca7d-4a7a-8e16-576320a18f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_1648a7d3-2fed-481d-a3b9-33782c2985d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_b0aed0f3-2773-4a2e-af5d-d796a580ca70" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_1648a7d3-2fed-481d-a3b9-33782c2985d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesLeaseReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19919675-1ef2-4f1e-b12a-25e52e577adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19919675-1ef2-4f1e-b12a-25e52e577adc" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0f4a1eac-0fd4-4344-aeee-87085d2a9c25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f6754e01-6350-49f5-9f3f-534823ffb816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f6754e01-6350-49f5-9f3f-534823ffb816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4b7c7a69-2cda-4719-882f-f9d664538ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_90352313-ccc6-4980-a528-8dd4e1b7a2a2" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4b7c7a69-2cda-4719-882f-f9d664538ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6c5d8f23-7246-4493-a3f6-afbcaf65546d" xlink:to="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_c0d30289-a5b7-4ed5-8da6-82b63ccd2306" xlink:href="isrg-20221231.xsd#isrg_SalesTypeLeaseGrossInvestmentInLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_isrg_SalesTypeLeaseGrossInvestmentInLease_c0d30289-a5b7-4ed5-8da6-82b63ccd2306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SalestypeLeaseDeferredSellingProfit_e012594e-52c9-41fb-92cb-d8d4d538830c" xlink:href="isrg-20221231.xsd#isrg_SalestypeLeaseDeferredSellingProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_isrg_SalestypeLeaseDeferredSellingProfit_e012594e-52c9-41fb-92cb-d8d4d538830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_54f16005-9601-49e6-9e44-7986500d9327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_54f16005-9601-49e6-9e44-7986500d9327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_a0b52546-3861-4d83-bb7d-77fee0982f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss_a0b52546-3861-4d83-bb7d-77fee0982f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_93c251fc-2552-45e8-9e2b-57db3a56108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_93c251fc-2552-45e8-9e2b-57db3a56108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_31ba64d9-953a-47dc-b0bd-258f53126615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_acb3738a-9321-498c-acc4-86392dcbca83" xlink:to="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_31ba64d9-953a-47dc-b0bd-258f53126615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_c50ad748-d317-45f9-9d6d-ee4e62124ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract_31ba64d9-953a-47dc-b0bd-258f53126615" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_c50ad748-d317-45f9-9d6d-ee4e62124ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesLeaseReceivablesDetails_1"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_64da2653-91c7-45db-8de7-dcaad16c5eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_64da2653-91c7-45db-8de7-dcaad16c5eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_7c0c7cbb-f27c-48b6-8720-b2269ff13fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_7c0c7cbb-f27c-48b6-8720-b2269ff13fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_d35120f2-ba12-4ac3-9f0f-20d064b6b53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_d35120f2-ba12-4ac3-9f0f-20d064b6b53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_e131eac9-0161-44ec-a86b-6912045bf321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_e131eac9-0161-44ec-a86b-6912045bf321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_c6c2606d-a68b-4a15-8df8-bf9ed8314f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_c6c2606d-a68b-4a15-8df8-bf9ed8314f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_d9e9647a-8bed-4baa-9f6f-aeab0379aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_d9e9647a-8bed-4baa-9f6f-aeab0379aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_019e82e4-3f9f-4f30-9e81-b487d2d79c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66665f3b-fae1-40b4-a998-ffbc335b5e9c" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_019e82e4-3f9f-4f30-9e81-b487d2d79c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0f219691-c6fb-4366-8d9c-ef84c61646a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0f219691-c6fb-4366-8d9c-ef84c61646a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_ab211256-aa48-443f-8cc2-0ef0059a54de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_ab211256-aa48-443f-8cc2-0ef0059a54de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_28407699-15a8-4af8-9aea-52566fce7dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_28407699-15a8-4af8-9aea-52566fce7dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_54c2db90-d6d4-4c8a-a40d-56a3e68214e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_54c2db90-d6d4-4c8a-a40d-56a3e68214e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_033f451f-c6b8-47a0-9982-bb6de2e1e215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_033f451f-c6b8-47a0-9982-bb6de2e1e215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_e602d002-241c-48ab-99be-b54c5e1da828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_e602d002-241c-48ab-99be-b54c5e1da828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70814e86-a1e6-434a-a4ed-2c2c1f26dea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22283fb0-a4f0-47f0-b73a-78be7d021f51" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_70814e86-a1e6-434a-a4ed-2c2c1f26dea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fd98b099-0391-4857-9415-70ab4de06c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_487b9de7-d287-4b7d-b2ad-3201213e5a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd98b099-0391-4857-9415-70ab4de06c52" xlink:to="loc_us-gaap_OperatingLeaseExpense_487b9de7-d287-4b7d-b2ad-3201213e5a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5fe97093-b660-41dd-9f73-0023ce7aae31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_51024095-9c96-43a9-a06c-c42be0915590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5fe97093-b660-41dd-9f73-0023ce7aae31" xlink:to="loc_us-gaap_OperatingLeasePayments_51024095-9c96-43a9-a06c-c42be0915590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3a2a64ed-e14f-4a1c-8c7a-045fe042c7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5fe97093-b660-41dd-9f73-0023ce7aae31" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3a2a64ed-e14f-4a1c-8c7a-045fe042c7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4525da7-fd79-4ffa-9b27-bc638aa4d734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4525da7-fd79-4ffa-9b27-bc638aa4d734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd809874-45e7-464a-9146-78f22f63a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd809874-45e7-464a-9146-78f22f63a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce4d008b-0af3-41b4-92c8-bd60c16acc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ce4d008b-0af3-41b4-92c8-bd60c16acc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f8a9bd69-3764-438a-9d83-a8ff6fd8e05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiability_f8a9bd69-3764-438a-9d83-a8ff6fd8e05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_880d06af-9bc5-4e43-8b35-f7862ce597d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_880d06af-9bc5-4e43-8b35-f7862ce597d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0655a75d-97eb-468f-a8e7-7bbfc1aff7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0655a75d-97eb-468f-a8e7-7bbfc1aff7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06ef2fe5-85c6-4dcb-98ab-3a440c40b79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06ef2fe5-85c6-4dcb-98ab-3a440c40b79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_093407a2-ddb6-45e6-91f9-ef941a0f1763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_093407a2-ddb6-45e6-91f9-ef941a0f1763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_39cd607f-aad3-4220-8b81-b49a4d1eb2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_39cd607f-aad3-4220-8b81-b49a4d1eb2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_bf318640-9318-4030-a712-af05cc0e6977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_867d0cac-72d8-4ce5-9a03-e01d042d9e34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_bf318640-9318-4030-a712-af05cc0e6977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_83dd40fb-5327-45f7-8f87-ac0dddbdd33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_83dd40fb-5327-45f7-8f87-ac0dddbdd33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4b772020-24ba-4a1d-b236-f49c81aec995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4b772020-24ba-4a1d-b236-f49c81aec995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_34da8779-96c6-4ae9-91d8-aaaa902e98c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_34da8779-96c6-4ae9-91d8-aaaa902e98c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1fbda783-eb74-45b1-82a3-12e88173be16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1fbda783-eb74-45b1-82a3-12e88173be16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f2b57dcb-29dd-4be4-804a-6ff800b18a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f2b57dcb-29dd-4be4-804a-6ff800b18a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_902754eb-244f-4b2f-bc63-d7c2f4b986e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_902754eb-244f-4b2f-bc63-d7c2f4b986e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df669d97-1c28-4355-a443-63ea24484755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df669d97-1c28-4355-a443-63ea24484755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aaba1dd5-49a2-4c2d-8ca5-1e917fef173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aaba1dd5-49a2-4c2d-8ca5-1e917fef173e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d5fbebe3-29c6-4c07-ba4c-3ec081b47e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9abcdc-2b45-463f-8814-293213f653ec" xlink:to="loc_us-gaap_OperatingLeaseLiability_d5fbebe3-29c6-4c07-ba4c-3ec081b47e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="isrg-20221231.xsd#LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56d5de0e-bbae-4a0a-adb9-fb2c711ad594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56d5de0e-bbae-4a0a-adb9-fb2c711ad594" xlink:to="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f1ee9620-d5ec-4336-923c-0d429fc5fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:to="loc_us-gaap_Goodwill_f1ee9620-d5ec-4336-923c-0d429fc5fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_0b2e7607-10d7-47fe-898a-645644bef071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_0b2e7607-10d7-47fe-898a-645644bef071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_0c015ca2-9d41-47b6-809a-7168210c99c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:to="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_0c015ca2-9d41-47b6-809a-7168210c99c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_949e01c5-91d3-4842-9130-5f4c5ceb35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_566a0da4-f16f-40e9-a8d7-4716f1f4739a" xlink:to="loc_us-gaap_Goodwill_949e01c5-91d3-4842-9130-5f4c5ceb35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea3eb13e-75d3-4479-bde7-7e1e0729fe93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ea3eb13e-75d3-4479-bde7-7e1e0729fe93" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6773081d-ad15-45f9-9135-113818fdae31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fd688302-36a5-48dc-95b3-2cb1eeee7376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fd688302-36a5-48dc-95b3-2cb1eeee7376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_3becb27a-092a-4c1a-8791-5131f266d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_DistributionRightsMember_3becb27a-092a-4c1a-8791-5131f266d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_53accbb3-9039-4355-95c0-4a95297bd07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c25e069b-7fd4-4c52-82fb-14b9e3c97f02" xlink:to="loc_us-gaap_CustomerRelationshipsMember_53accbb3-9039-4355-95c0-4a95297bd07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9b3da8b-9dac-499e-81dc-03c91d316edb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7020ab8b-53d0-4535-a4ec-bdde2213feb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7020ab8b-53d0-4535-a4ec-bdde2213feb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_94419786-614a-4369-b1af-613d1201d8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_94419786-614a-4369-b1af-613d1201d8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a1d8058-aa3e-4cb2-91ab-67eddb33f5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_95ae2c98-b600-4976-94ba-14d473e3048e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7a1d8058-aa3e-4cb2-91ab-67eddb33f5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_612d050e-47b7-4c59-b483-fe32a6d8ddcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1f440cea-adaa-4c44-a711-dccc2f9f3915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_612d050e-47b7-4c59-b483-fe32a6d8ddcb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1f440cea-adaa-4c44-a711-dccc2f9f3915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d4c63907-d410-4412-a27a-ab9442da9f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d4c63907-d410-4412-a27a-ab9442da9f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8b691004-f6b9-48a9-841c-1d421e9248cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8b691004-f6b9-48a9-841c-1d421e9248cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_81c1eb84-af33-4de1-b4ae-d7539ca85fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_81c1eb84-af33-4de1-b4ae-d7539ca85fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_809771fd-cfd6-4d3c-8ec0-4472f21450f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_809771fd-cfd6-4d3c-8ec0-4472f21450f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e9a79f0f-bbf3-4cca-8866-af6b0c73d1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e9a79f0f-bbf3-4cca-8866-af6b0c73d1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e98e67cf-8f2e-471a-a1ab-547e364c4abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e98e67cf-8f2e-471a-a1ab-547e364c4abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_610e0919-1d56-4c52-bf61-584aea22b32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1aed3c50-f691-4dd3-85ca-b17ff98ee237" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_610e0919-1d56-4c52-bf61-584aea22b32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd0b45de-0a5d-45db-b73e-68cca584f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd0b45de-0a5d-45db-b73e-68cca584f2f9" xlink:to="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:to="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7957e491-1544-4183-ad87-a7c1507f81ef" xlink:to="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RexMedicalLPMember_f5b73515-ad2a-4283-83dc-cdf5df504b6c" xlink:href="isrg-20221231.xsd#isrg_RexMedicalLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9083f65e-bdfe-4cc3-bf96-1568a0ea9db8" xlink:to="loc_isrg_RexMedicalLPMember_f5b73515-ad2a-4283-83dc-cdf5df504b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_be72b1a0-441a-47ff-8ee5-ae2cc7e23190" xlink:to="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_151586a2-0bd5-4156-b1b1-3a29d980d4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_151586a2-0bd5-4156-b1b1-3a29d980d4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_c757957e-18de-4c01-8c12-440fa3651b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_LitigationSettlementExpense_c757957e-18de-4c01-8c12-440fa3651b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_af3dff11-8a78-4e64-89fc-6893887d915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_31e4f8d2-d191-4dec-bc18-9f4a04fe7223" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_af3dff11-8a78-4e64-89fc-6893887d915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d3e87b0f-7ffc-4a6c-91cd-f4b05f119028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d3e87b0f-7ffc-4a6c-91cd-f4b05f119028" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_566e6d4c-a248-4c34-b4e2-1a7e24fe2997" xlink:to="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ea81f68-4e17-4748-8f7d-1419c0e4d7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e334741c-43c9-4f34-84c2-bd5959930940" xlink:to="loc_us-gaap_CommonStockMember_8ea81f68-4e17-4748-8f7d-1419c0e4d7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_419e7bbc-550c-42e7-a44e-a01a05c9eb6e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember_3055d038-3f4b-46bb-a1e0-bd42174575e3" xlink:href="isrg-20221231.xsd#isrg_AugustAcceleratedShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:to="loc_isrg_AugustAcceleratedShareRepurchaseProgramMember_3055d038-3f4b-46bb-a1e0-bd42174575e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember_036cfe4f-0e87-4438-a341-dc8b44e819fa" xlink:href="isrg-20221231.xsd#isrg_OctoberAcceleratedShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_98998c3a-4afc-4662-98d8-56dd99b688fa" xlink:to="loc_isrg_OctoberAcceleratedShareRepurchaseProgramMember_036cfe4f-0e87-4438-a341-dc8b44e819fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ec73a041-00d8-4e89-899b-2bf70a46d5db" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4a3a41e6-6d35-463d-a1d0-ee3b93e009e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4a3a41e6-6d35-463d-a1d0-ee3b93e009e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_cbe8f15a-39c3-4006-8afe-f36f6a79a742" xlink:href="isrg-20221231.xsd#isrg_StockRepurchaseProgramincreasedtoauthorizedamount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_StockRepurchaseProgramincreasedtoauthorizedamount_cbe8f15a-39c3-4006-8afe-f36f6a79a742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_13cb98d6-9ba6-470b-9009-1d5ed40bca18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_13cb98d6-9ba6-470b-9009-1d5ed40bca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_12531d4d-735a-4287-b513-3e878e17b4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_12531d4d-735a-4287-b513-3e878e17b4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_a2466d38-c861-46f8-9a29-6d83e5ed22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_a2466d38-c861-46f8-9a29-6d83e5ed22f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4a9e3470-dbc7-4f4e-a3f5-22b6200905cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4a9e3470-dbc7-4f4e-a3f5-22b6200905cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases_d7adb785-ea54-424b-beb6-a045cac19a68" xlink:href="isrg-20221231.xsd#isrg_AggregateReductionInCommonStockDuringStockRepurchases"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_AggregateReductionInCommonStockDuringStockRepurchases_d7adb785-ea54-424b-beb6-a045cac19a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_9725d34a-993f-4ea9-b864-69a676475105" xlink:href="isrg-20221231.xsd#isrg_AmountChargedToRetainedEarningsDuringStockRepurchases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_3ce9996c-a9da-48f9-abf9-4a0e608d720c" xlink:to="loc_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases_9725d34a-993f-4ea9-b864-69a676475105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_924e80fc-8a62-4352-8e82-b96deb58970d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_924e80fc-8a62-4352-8e82-b96deb58970d" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_b04eacd5-1e56-4c4a-9964-794302ae92f7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CommonStockRepurchaseProgramMember_e4518070-7127-452f-9ade-aad9981856cb" xlink:href="isrg-20221231.xsd#isrg_CommonStockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8ff70552-ca73-4df1-8735-750ac67c588b" xlink:to="loc_isrg_CommonStockRepurchaseProgramMember_e4518070-7127-452f-9ade-aad9981856cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a3e4b51-f0d4-4a98-8509-d59a534071a9" xlink:to="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4e00581c-8199-416c-b1ac-8c8373d59b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c986d494-44d3-411a-831a-8185053ea0fc" xlink:to="loc_us-gaap_CommonStockMember_4e00581c-8199-416c-b1ac-8c8373d59b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3fd27937-4d99-499f-9205-ca4344312893" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78bce8e8-54e1-49fb-a71e-a02edccd7185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78bce8e8-54e1-49fb-a71e-a02edccd7185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5a97e1ab-eb31-49ad-a7be-ae307710ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5a97e1ab-eb31-49ad-a7be-ae307710ada7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4ad259a2-6278-4ab9-9a97-9f2371a3a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_4cd183ee-07cc-443c-85f3-16d380d77338" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4ad259a2-6278-4ab9-9a97-9f2371a3a70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f527a977-14b6-4821-b725-042fa042a8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f527a977-14b6-4821-b725-042fa042a8c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60f5bcfc-52b9-4ab0-a2df-e7d5b3caef13" xlink:to="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_3bde81b0-1759-4a10-99db-a2b755330727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_3bde81b0-1759-4a10-99db-a2b755330727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b2e937f4-7ccc-4f5d-a2a0-2460097469b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b2e937f4-7ccc-4f5d-a2a0-2460097469b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cf949917-a29e-44cb-afde-4e5c7d2a8c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cf949917-a29e-44cb-afde-4e5c7d2a8c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_9e962d39-0d6c-49f1-b4b4-1b358d18b16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_9e962d39-0d6c-49f1-b4b4-1b358d18b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5397a3bd-269a-4e6f-a15a-52b7113f3f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70d8a74a-a0be-4ada-8cb1-e7bc0c95be07" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5397a3bd-269a-4e6f-a15a-52b7113f3f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0df3d4e2-9a89-4774-a2e2-fd1c152c49b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e70a740-96b7-43cc-862d-423d9bb26eba" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca5d6289-e3c4-44b1-994d-6b342a16f0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_StockholdersEquity_ca5d6289-e3c4-44b1-994d-6b342a16f0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_94bef6c8-796d-42cd-b53f-f2d92b635542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_94bef6c8-796d-42cd-b53f-f2d92b635542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_32cfaece-c859-4e88-a5c8-b0520222b1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_32cfaece-c859-4e88-a5c8-b0520222b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5bcca72-cc17-4661-8de5-4bda410abb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c5bcca72-cc17-4661-8de5-4bda410abb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5285f66a-ab7a-4442-a4dc-e53084346a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_75092f14-3aad-4746-86d9-dade8f8bc4e8" xlink:to="loc_us-gaap_StockholdersEquity_5285f66a-ab7a-4442-a4dc-e53084346a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#StockholdersEquityOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3dc6633f-6871-4f67-ac85-addafdb8cd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_be8bf25a-ba30-4452-ac3b-04dbf377a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3dc6633f-6871-4f67-ac85-addafdb8cd75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_be8bf25a-ba30-4452-ac3b-04dbf377a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6020c3c-47bd-4c28-93f7-e90499589936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6020c3c-47bd-4c28-93f7-e90499589936" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_baffd993-e2cd-408e-b361-deafdfd2c822" xlink:to="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_5264595f-14e9-4ada-a57a-2443177d4dce" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember_5264595f-14e9-4ada-a57a-2443177d4dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_b92a058c-4d82-4b66-a0a4-d94102c8a90a" xlink:href="isrg-20221231.xsd#isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember_b92a058c-4d82-4b66-a0a4-d94102c8a90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_d888f184-40a1-419d-87d6-55a1a8f74813" xlink:href="isrg-20221231.xsd#isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember_d888f184-40a1-419d-87d6-55a1a8f74813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember_4bd26051-d95a-4880-a800-fa2e6bff8c41" xlink:href="isrg-20221231.xsd#isrg_TwoThousandEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b9479339-a753-4de7-b149-b9ee6231837a" xlink:to="loc_isrg_TwoThousandEmployeeStockPurchasePlanMember_4bd26051-d95a-4880-a800-fa2e6bff8c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac0b95e5-b085-4865-bbf9-92483914eaef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8ad15217-3aca-4d93-ba4a-e661f4bc897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8ad15217-3aca-4d93-ba4a-e661f4bc897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AnnualGrantOptionsMember_8204acd5-4e4b-4663-8e39-23ac0eb78b69" xlink:href="isrg-20221231.xsd#isrg_AnnualGrantOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_AnnualGrantOptionsMember_8204acd5-4e4b-4663-8e39-23ac0eb78b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialGrantOptionsMember_8e0f7512-258e-4f3d-b260-8f5f5b0fffb2" xlink:href="isrg-20221231.xsd#isrg_InitialGrantOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_InitialGrantOptionsMember_8e0f7512-258e-4f3d-b260-8f5f5b0fffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_99400c49-d486-4378-bdf1-20f9aa8a748a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_us-gaap_EmployeeStockMember_99400c49-d486-4378-bdf1-20f9aa8a748a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NonvestedStockOptionMember_e9e18900-2826-4307-8aca-6e5dbed1a058" xlink:href="isrg-20221231.xsd#isrg_NonvestedStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_NonvestedStockOptionMember_e9e18900-2826-4307-8aca-6e5dbed1a058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_InitialRSUgrantsMember_73af57cd-6090-401a-8584-703d58b9f961" xlink:href="isrg-20221231.xsd#isrg_InitialRSUgrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_InitialRSUgrantsMember_73af57cd-6090-401a-8584-703d58b9f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_NewHireOptionsMember_19b065fc-32ae-4996-9e73-413d18402246" xlink:href="isrg-20221231.xsd#isrg_NewHireOptionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_NewHireOptionsMember_19b065fc-32ae-4996-9e73-413d18402246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_0dfbeea7-04d7-4b48-96e1-cb485151dded" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dcf7e71-cd64-4b4f-a2ff-eada696953f0" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_0dfbeea7-04d7-4b48-96e1-cb485151dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_04d2ce70-4ed4-4fe2-a552-e3aeef79c07e" xlink:to="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AugustGrantMember_b34036a9-169e-4c8b-b0f3-61e139904963" xlink:href="isrg-20221231.xsd#isrg_AugustGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:to="loc_isrg_AugustGrantMember_b34036a9-169e-4c8b-b0f3-61e139904963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_FebruaryGrantMember_9afbfe54-9aff-41c9-bcb4-abc7ed6cde88" xlink:href="isrg-20221231.xsd#isrg_FebruaryGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_15e9848f-2e89-4dec-986a-22328851382b" xlink:to="loc_isrg_FebruaryGrantMember_9afbfe54-9aff-41c9-bcb4-abc7ed6cde88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:href="isrg-20221231.xsd#isrg_AwardedtoAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:href="isrg-20221231.xsd#isrg_AwardedtoDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AwardedtoAxis_d557ada9-e46d-458a-ab79-45428f9846e4" xlink:to="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EmployeesMember_c93f1711-fb3e-4eb8-9b84-5f73c4b98869" xlink:href="isrg-20221231.xsd#isrg_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:to="loc_isrg_EmployeesMember_c93f1711-fb3e-4eb8-9b84-5f73c4b98869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b80f8f79-5d54-4606-9373-b05f27935de5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_AwardedtoDomain_602955a7-a726-4fb4-89f7-a8eed417fa20" xlink:to="loc_srt_DirectorMember_b80f8f79-5d54-4606-9373-b05f27935de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e480db77-934c-4cc1-84fc-5731cb5105b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b632dfb-c625-41f6-a109-24bdabe3a466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3b632dfb-c625-41f6-a109-24bdabe3a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0e9a17cf-c46b-41a5-9f26-56b82a2de0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0e9a17cf-c46b-41a5-9f26-56b82a2de0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0bd5a050-cfc1-4795-a6f7-4dcff11e4969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0bd5a050-cfc1-4795-a6f7-4dcff11e4969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7f0755a-99d2-435a-9ab1-262f6f263338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7f0755a-99d2-435a-9ab1-262f6f263338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_StockOptionsGrantedInitialVestingPeriod_7d94b5c6-4532-463d-9846-ca230ba64910" xlink:href="isrg-20221231.xsd#isrg_StockOptionsGrantedInitialVestingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_StockOptionsGrantedInitialVestingPeriod_7d94b5c6-4532-463d-9846-ca230ba64910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_d42350e4-6bd6-48cf-b72d-013245acad3f" xlink:href="isrg-20221231.xsd#isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan_d42350e4-6bd6-48cf-b72d-013245acad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_3ac7813f-7b36-49b6-ab7e-2c0f3dc04c9a" xlink:href="isrg-20221231.xsd#isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan_3ac7813f-7b36-49b6-ab7e-2c0f3dc04c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_b5cd522c-675b-4e85-a068-c702bb7dd7ba" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan_b5cd522c-675b-4e85-a068-c702bb7dd7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_7c2a2a87-81ed-453c-bda1-6c139e0b5474" xlink:href="isrg-20221231.xsd#isrg_MaximumPercentageOfPayrollDeductionUnderEspp"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_MaximumPercentageOfPayrollDeductionUnderEspp_7c2a2a87-81ed-453c-bda1-6c139e0b5474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans_81b84002-6228-4716-a468-cb90b0ed5a39" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodEmployeeStockPurchasePlans_81b84002-6228-4716-a468-cb90b0ed5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_b4a046d7-a4ee-4653-9718-10f2d51bbb54" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans_b4a046d7-a4ee-4653-9718-10f2d51bbb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_1210cf29-b150-438e-8cc5-6d04b78630aa" xlink:href="isrg-20221231.xsd#isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans_1210cf29-b150-438e-8cc5-6d04b78630aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_60a93c55-0072-436c-bd2b-0574369b9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_60a93c55-0072-436c-bd2b-0574369b9f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b972b0e9-9c06-4616-af42-e49917ea28e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b972b0e9-9c06-4616-af42-e49917ea28e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_6cdbd00d-2273-4b6e-a8ce-669518a00813" xlink:href="isrg-20221231.xsd#isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans_6cdbd00d-2273-4b6e-a8ce-669518a00813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0034642d-dadf-4690-83da-6933922481c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0034642d-dadf-4690-83da-6933922481c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50654782-792d-4de5-8201-46a6ba61e777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50654782-792d-4de5-8201-46a6ba61e777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_57cd17c9-a75e-489e-aab2-b4669cf1a89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_57cd17c9-a75e-489e-aab2-b4669cf1a89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7be427b-6ce9-47b3-8172-273d5e62d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c7be427b-6ce9-47b3-8172-273d5e62d69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e58e1f06-e77b-4f6c-84ca-8c1b383a72f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e58e1f06-e77b-4f6c-84ca-8c1b383a72f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c1079c78-e81d-4854-8e0c-c5ebc189004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_c1079c78-e81d-4854-8e0c-c5ebc189004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82420a2d-cdc8-4616-99e9-c6b81195db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_82420a2d-cdc8-4616-99e9-c6b81195db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7f66f885-02a1-4153-b237-861f2bf4bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7f66f885-02a1-4153-b237-861f2bf4bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5c478c54-fa40-4430-a937-97a5b472004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5c478c54-fa40-4430-a937-97a5b472004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_256d4c27-e274-4d84-b935-7a952759660a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_256d4c27-e274-4d84-b935-7a952759660a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_57502572-5884-4191-b7bb-e1c9d2804124" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_57502572-5884-4191-b7bb-e1c9d2804124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_faba57c8-7df3-4f48-80b3-0186e0de988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_faba57c8-7df3-4f48-80b3-0186e0de988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_04993aea-ad35-4385-96f7-b15b67c820f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_04993aea-ad35-4385-96f7-b15b67c820f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_edeb7282-d900-489a-a277-0a787e245ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_edeb7282-d900-489a-a277-0a787e245ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9a34e5a-b99c-4788-9cc7-f75faae11862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d9a34e5a-b99c-4788-9cc7-f75faae11862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_551f497c-a501-453b-9979-ce079c22a4aa" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService_551f497c-a501-453b-9979-ce079c22a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_1848c774-3e1c-44a8-a7a1-c79b7e890bb0" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService_1848c774-3e1c-44a8-a7a1-c79b7e890bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_83bfec48-336b-46cb-aec7-5cc2e227c2cb" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth_83bfec48-336b-46cb-aec7-5cc2e227c2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_abbb5bac-a6d5-4a36-b76d-8879e6160f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_abbb5bac-a6d5-4a36-b76d-8879e6160f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_b346ad9d-74ce-4a22-91f7-417d9c273ab9" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear_b346ad9d-74ce-4a22-91f7-417d9c273ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_3fef3c5a-ae94-4048-8a4c-9de1b3fff364" xlink:href="isrg-20221231.xsd#isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99b04c2f-5b49-4bb0-bdde-90c38095ce22" xlink:to="loc_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService_3fef3c5a-ae94-4048-8a4c-9de1b3fff364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationSummaryofRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e7e4031-bf36-45f9-8615-a351195c5840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e7e4031-bf36-45f9-8615-a351195c5840" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:to="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11b2a0bc-b4d7-432d-a00c-959aefe8a9d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_08837056-50db-425a-95da-b04493ae96f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_08837056-50db-425a-95da-b04493ae96f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_8d3d772c-185b-4c51-abba-b7aaca052ec8" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d47e436d-25ee-4802-856d-390a7ea19e30" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_8d3d772c-185b-4c51-abba-b7aaca052ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_761159d7-264f-41e6-bfc8-13cf3c247214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe7f8026-0498-47aa-94ab-8d273d9e8fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe7f8026-0498-47aa-94ab-8d273d9e8fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_df9d0790-00f7-4f76-a671-88c5ddc86256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_df9d0790-00f7-4f76-a671-88c5ddc86256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b61b4254-9b98-4c95-a30c-88390277258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b61b4254-9b98-4c95-a30c-88390277258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_d10ce837-3d98-40a2-9c31-40699d124884" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange_d10ce837-3d98-40a2-9c31-40699d124884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0fb7b27a-4bfd-489e-8ae8-b131765b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0fb7b27a-4bfd-489e-8ae8-b131765b68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63601455-4796-47db-9c03-7b20360afd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2fc54272-d9c2-4880-8520-0a8f6eda6ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_63601455-4796-47db-9c03-7b20360afd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661a1521-cbe8-4e29-9b41-b6ae4965e3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c1cf6ab-935b-4edf-83a5-5192a00acd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c1cf6ab-935b-4edf-83a5-5192a00acd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9ed4281-01b2-4cb6-873a-d4c164b560a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f9ed4281-01b2-4cb6-873a-d4c164b560a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ca657ab-1027-4661-a216-c0f4a8ce680d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3ca657ab-1027-4661-a216-c0f4a8ce680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_f86a53bf-86a2-4c90-9f7d-58bb09f09957" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue_f86a53bf-86a2-4c90-9f7d-58bb09f09957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6572fe1c-dfae-42d8-b368-977a7c754b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6572fe1c-dfae-42d8-b368-977a7c754b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f7254e6-086e-4989-9eb1-47d736098df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_45d72142-14e9-416e-86f7-0c362176404e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f7254e6-086e-4989-9eb1-47d736098df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99680ef5-b935-44e4-bc1a-d112507e9aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99680ef5-b935-44e4-bc1a-d112507e9aa3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aefebcaf-495c-46d3-b3a1-f0850ac9017d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aefebcaf-495c-46d3-b3a1-f0850ac9017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e128aece-eb5e-4985-a5d6-b859e41f5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e128aece-eb5e-4985-a5d6-b859e41f5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52100651-ad04-46d7-910c-fcd3d960124d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_52100651-ad04-46d7-910c-fcd3d960124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fff9ae53-812e-40f0-af03-180f3b204eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fff9ae53-812e-40f0-af03-180f3b204eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f6936ec2-b0fa-46a1-b927-2ee4e05a6dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_447b12e6-2401-4c93-ba73-fbd3d1b67ac9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f6936ec2-b0fa-46a1-b927-2ee4e05a6dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:href="isrg-20221231.xsd#isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99680ef5-b935-44e4-bc1a-d112507e9aa3" xlink:to="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c351466e-3621-40e8-99c1-fc3f02c7d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c351466e-3621-40e8-99c1-fc3f02c7d2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee5012dc-0ede-4b54-83b7-33e9a5bf61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee5012dc-0ede-4b54-83b7-33e9a5bf61a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ea391703-2b42-44d0-9e74-cd07d0bf634c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ea391703-2b42-44d0-9e74-cd07d0bf634c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4f48be1b-f1db-4cc2-a3b4-142d14b8a5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4f48be1b-f1db-4cc2-a3b4-142d14b8a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93f966ae-a510-4d36-8fc7-ba6b3fa0b9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e60d93f3-5f26-4e0d-a7f6-2a8eecdb82b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93f966ae-a510-4d36-8fc7-ba6b3fa0b9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e16b1c39-f8fc-4bdb-ba33-e89e5a5988ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e16b1c39-f8fc-4bdb-ba33-e89e5a5988ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_e7590423-00d2-47e1-b851-e263c7fad6a1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeOneMember_ff2d2f83-2a78-4337-8b20-d8c8eb89a6f6" xlink:href="isrg-20221231.xsd#isrg_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeOneMember_ff2d2f83-2a78-4337-8b20-d8c8eb89a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTwoMember_13f4e7d4-a4cf-4e9d-8075-20b542c5b756" xlink:href="isrg-20221231.xsd#isrg_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeTwoMember_13f4e7d4-a4cf-4e9d-8075-20b542c5b756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeThreeMember_135cc804-af31-4f70-9cd5-de345b9ec728" xlink:href="isrg-20221231.xsd#isrg_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeThreeMember_135cc804-af31-4f70-9cd5-de345b9ec728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFourMember_759c6e71-5ca0-4b4f-a2dd-56d64043906b" xlink:href="isrg-20221231.xsd#isrg_RangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeFourMember_759c6e71-5ca0-4b4f-a2dd-56d64043906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeFiveMember_0bfe0068-52b3-4f80-8373-08f98a87df2b" xlink:href="isrg-20221231.xsd#isrg_RangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeFiveMember_0bfe0068-52b3-4f80-8373-08f98a87df2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSixMember_bc49e14d-7a69-40d3-8389-45fa3d035862" xlink:href="isrg-20221231.xsd#isrg_RangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeSixMember_bc49e14d-7a69-40d3-8389-45fa3d035862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeSevenMember_cbe1cb8b-3604-46ae-a91a-6ecf3569b01d" xlink:href="isrg-20221231.xsd#isrg_RangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeSevenMember_cbe1cb8b-3604-46ae-a91a-6ecf3569b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeEightMember_73590283-5d5a-4379-85d8-a5fb05c547d6" xlink:href="isrg-20221231.xsd#isrg_RangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeEightMember_73590283-5d5a-4379-85d8-a5fb05c547d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeNineMember_c31bed18-554f-4bc7-8c5e-951c635518d6" xlink:href="isrg-20221231.xsd#isrg_RangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeNineMember_c31bed18-554f-4bc7-8c5e-951c635518d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_RangeTenMember_e3d53af1-d6c7-452c-a5a4-ddfa307d74d5" xlink:href="isrg-20221231.xsd#isrg_RangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_8cb3d4d1-a04d-4c0e-9eba-a327169fe5e0" xlink:to="loc_isrg_RangeTenMember_e3d53af1-d6c7-452c-a5a4-ddfa307d74d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d5637ec5-3960-4b74-988b-8f6ea71a1574" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b19520eb-17d4-4d05-8148-a95249971a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b19520eb-17d4-4d05-8148-a95249971a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_74eb0406-b3d9-46e9-bf83-24f172e6ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_74eb0406-b3d9-46e9-bf83-24f172e6ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3368a635-0525-4d1d-9008-6e6151d61a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3368a635-0525-4d1d-9008-6e6151d61a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8f7779d9-8f51-4539-b959-1d47928b5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8f7779d9-8f51-4539-b959-1d47928b5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6e5dfb5b-2dc8-48a5-95c4-669909af1c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6e5dfb5b-2dc8-48a5-95c4-669909af1c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ac1505ce-4457-48c2-a05d-b0dcde7fc594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ac1505ce-4457-48c2-a05d-b0dcde7fc594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ac1384e5-4ed6-4811-b897-835a7f211f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ac1384e5-4ed6-4811-b897-835a7f211f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b9015581-7e14-453e-91a5-87076953524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b9015581-7e14-453e-91a5-87076953524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_aef3cf18-25b5-4246-8542-ccbd55abf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_aef3cf18-25b5-4246-8542-ccbd55abf3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8608e28-e53d-4744-8f69-69c92f39785e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c8608e28-e53d-4744-8f69-69c92f39785e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ee14ae83-b6f4-4e2e-a8b0-8fc2cdd2c217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5818836c-4bbb-47d9-b7eb-68c6b0129b32" xlink:to="loc_us-gaap_SharePrice_ee14ae83-b6f4-4e2e-a8b0-8fc2cdd2c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24c61b14-f2c2-4f6a-8f75-fa23b55a2ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24c61b14-f2c2-4f6a-8f75-fa23b55a2ef5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b68726b4-ba9e-4c50-a969-a53773d246c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3f84ea39-40b6-42e6-9af7-0add23c2500b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_us-gaap_CostOfSalesMember_3f84ea39-40b6-42e6-9af7-0add23c2500b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_SellingGeneralAndAdministrativeMember_2e1b60f2-b945-48d2-b9bb-19d9775befa6" xlink:href="isrg-20221231.xsd#isrg_SellingGeneralAndAdministrativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_isrg_SellingGeneralAndAdministrativeMember_2e1b60f2-b945-48d2-b9bb-19d9775befa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ResearchAndDevelopmentMember_0b08ede4-6f1d-4e6e-95a9-8a63d43974c3" xlink:href="isrg-20221231.xsd#isrg_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45770316-cbf1-49c5-aa4b-a7a2a72dbc5c" xlink:to="loc_isrg_ResearchAndDevelopmentMember_0b08ede4-6f1d-4e6e-95a9-8a63d43974c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:to="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:href="isrg-20221231.xsd#isrg_ConsolidatingReportingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ConsolidatingReportingAxis_3906d194-8bde-41a3-b34a-9c91e4403f0d" xlink:to="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesProductMember_8516b13a-a430-4c65-b11f-f45a542b0e81" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:to="loc_isrg_CostOfSalesProductMember_8516b13a-a430-4c65-b11f-f45a542b0e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_CostOfSalesServiceMember_5003f0de-38aa-4fc5-85a7-f1243c958db1" xlink:href="isrg-20221231.xsd#isrg_CostOfSalesServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_isrg_ConsolidatingReportingDomain_2f8b3fea-2180-4a24-b08a-10dd2bbd78b4" xlink:to="loc_isrg_CostOfSalesServiceMember_5003f0de-38aa-4fc5-85a7-f1243c958db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_953b2350-6848-403a-b58f-8b13517f5d98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_afd8ea84-8a19-40a7-8917-38a616700c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_afd8ea84-8a19-40a7-8917-38a616700c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083f0522-a94b-4b47-ae40-b27d6150f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083f0522-a94b-4b47-ae40-b27d6150f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a33220e3-420f-4002-b318-0562f328dc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_75c48ac8-f243-4f90-ab54-ed1c9b1662ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a33220e3-420f-4002-b318-0562f328dc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5be4d662-b99f-43fd-8248-6277bb2b9d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5be4d662-b99f-43fd-8248-6277bb2b9d0d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:to="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_153c150e-287b-449b-9d2e-c90dc7fd34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd6707c6-1949-437b-8332-3dd9d5900c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd6707c6-1949-437b-8332-3dd9d5900c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_115b2970-22a8-4c32-8d52-8c5404ac6215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_StockOptionMember_115b2970-22a8-4c32-8d52-8c5404ac6215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_PerformanceShareUnitsPSUsMember_8d9689eb-47a1-4166-b1c7-e647b6d1b862" xlink:href="isrg-20221231.xsd#isrg_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_isrg_PerformanceShareUnitsPSUsMember_8d9689eb-47a1-4166-b1c7-e647b6d1b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b5dfaf76-8961-40e1-b0ec-496e5a61db77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af61441d-d7a1-4240-9346-241e31b6bac6" xlink:to="loc_us-gaap_EmployeeStockMember_b5dfaf76-8961-40e1-b0ec-496e5a61db77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_224886e9-98de-47fc-9739-2ab7e06f9c1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_abbae062-cca6-4816-b04b-3bb854e35d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_abbae062-cca6-4816-b04b-3bb854e35d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6217072b-eef3-49ed-a332-f4e3670eeee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6217072b-eef3-49ed-a332-f4e3670eeee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c3ee1c96-17ee-49f7-8c58-92b481262b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c3ee1c96-17ee-49f7-8c58-92b481262b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6678d43b-e328-40e4-bf0c-e83d667c0a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6678d43b-e328-40e4-bf0c-e83d667c0a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b512ad5d-c45e-4005-af43-2328d148a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_89657975-c867-46ee-b432-109d5f0dfc16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b512ad5d-c45e-4005-af43-2328d148a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9ef55ab0-86a4-4ad0-a18a-3dd2c1db5d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_35cb26cc-19c0-4ba6-b434-8704f92be587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ef55ab0-86a4-4ad0-a18a-3dd2c1db5d99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_35cb26cc-19c0-4ba6-b434-8704f92be587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ee12874b-5b99-48f1-beab-29c03a9ba605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ef55ab0-86a4-4ad0-a18a-3dd2c1db5d99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ee12874b-5b99-48f1-beab-29c03a9ba605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ddd9f03c-fd60-467a-b4bf-246300b2c120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ef55ab0-86a4-4ad0-a18a-3dd2c1db5d99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ddd9f03c-fd60-467a-b4bf-246300b2c120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_261fdb31-688d-4f19-8015-5af20a7ee830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_261fdb31-688d-4f19-8015-5af20a7ee830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1134f923-5e72-4230-81b7-8464fdeb3203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1134f923-5e72-4230-81b7-8464fdeb3203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1d1b797d-7519-4f01-bc28-0ff32e5f1b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1d1b797d-7519-4f01-bc28-0ff32e5f1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5506ab5-5ac9-4ad3-979a-c19959ed87b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5506ab5-5ac9-4ad3-979a-c19959ed87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_be280073-340c-47f1-b767-7f014f296041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_be280073-340c-47f1-b767-7f014f296041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d959174b-9a9e-4931-ab30-2a79c366c8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d959174b-9a9e-4931-ab30-2a79c366c8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6b33ff03-a13f-451e-bbbc-35d17dc9eca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6b33ff03-a13f-451e-bbbc-35d17dc9eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a4f30-41d6-4f6a-924e-3d7db32d066f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b54a4f30-41d6-4f6a-924e-3d7db32d066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30a3182b-253c-4296-a1c1-5221f8c6dd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8090ea6f-352b-4035-a851-39db3cbfe5d9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_30a3182b-253c-4296-a1c1-5221f8c6dd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7175785-5e5e-42d3-90b4-8c4b60519bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7175785-5e5e-42d3-90b4-8c4b60519bbc" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_dd0555d8-3854-408c-8f84-3b92a9f392a8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DomesticAndForeignMember_1f73634b-fe43-43fb-885a-28c3b617a818" xlink:href="isrg-20221231.xsd#isrg_DomesticAndForeignMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:to="loc_isrg_DomesticAndForeignMember_1f73634b-fe43-43fb-885a-28c3b617a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fd907dc9-ea33-477e-afd6-8be3fd70e9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f42ea704-11ad-4703-becf-569c9b389c0f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fd907dc9-ea33-477e-afd6-8be3fd70e9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1c8a2ea2-4700-4998-8978-c7157e2880c1" xlink:to="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a262a46b-5cfe-492a-aee1-c30e12ac5183" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6faa45bc-be11-4ddf-af2a-186dff892863" xlink:to="loc_stpr_CA_a262a46b-5cfe-492a-aee1-c30e12ac5183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_cec34217-0d26-47bf-bf64-a73fa5bf9d8d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fde1f3bc-9daa-4078-b55c-6745d06b6994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_029700f4-426a-46b2-bf16-4e97fe257cf6" xlink:to="loc_us-gaap_ResearchMember_fde1f3bc-9daa-4078-b55c-6745d06b6994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1c3c6f87-72b8-4e05-bf56-04b627d2efae" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_79df5721-e24e-4d58-9eb5-cbf90a4c778b" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_79df5721-e24e-4d58-9eb5-cbf90a4c778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3c328ee9-e80c-49c8-9466-d767875e1163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3c328ee9-e80c-49c8-9466-d767875e1163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_b1d7b780-77c1-4a3e-9b9a-3d60c0d5e06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_b1d7b780-77c1-4a3e-9b9a-3d60c0d5e06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1578c92f-8c00-44ad-a5c5-f89e812d297a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1578c92f-8c00-44ad-a5c5-f89e812d297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_9c74a3b9-0ce3-4804-84aa-fa9dc365220a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_9c74a3b9-0ce3-4804-84aa-fa9dc365220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a31ff8f5-a0c4-47f7-88c8-9e07538db66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a31ff8f5-a0c4-47f7-88c8-9e07538db66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4a55a831-04be-4c73-8e48-e15cf7a1092b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4a55a831-04be-4c73-8e48-e15cf7a1092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_8af50159-98a3-4838-9f63-57e62bf5d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_8af50159-98a3-4838-9f63-57e62bf5d4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_db7e7550-c284-47e1-bd68-04f48facd248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_d61cac3a-f38f-487f-859e-2626a4e86638" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_db7e7550-c284-47e1-bd68-04f48facd248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_965378e6-0594-4d56-8f0b-ed1f788e49bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_965378e6-0594-4d56-8f0b-ed1f788e49bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e981a85b-e828-46ee-aa86-a7c88c51dece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e981a85b-e828-46ee-aa86-a7c88c51dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_127b75f5-18f3-425d-ae31-0396d50ddff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_127b75f5-18f3-425d-ae31-0396d50ddff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_490279e2-2379-42fe-b050-ccc7c08dc20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_490279e2-2379-42fe-b050-ccc7c08dc20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9e4bbff6-7f21-43af-ab80-2f234e971303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9e4bbff6-7f21-43af-ab80-2f234e971303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_298e9550-da86-449e-9c4c-8a9378853b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_298e9550-da86-449e-9c4c-8a9378853b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_76c460de-e603-494a-a920-482f92abace5" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement_76c460de-e603-494a-a920-482f92abace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_a57eb677-8afc-4ca1-b53b-ee30c92fc6a1" xlink:href="isrg-20221231.xsd#isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_a57eb677-8afc-4ca1-b53b-ee30c92fc6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c47f584a-93ed-42c3-a259-a36e9c64fd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c47f584a-93ed-42c3-a259-a36e9c64fd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_acf037c0-defd-47c1-a216-08ae8ff7d3e3" xlink:href="isrg-20221231.xsd#isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount_acf037c0-defd-47c1-a216-08ae8ff7d3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f6459535-40f1-4e3c-8125-b192dff989d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f6459535-40f1-4e3c-8125-b192dff989d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12360b3c-0c0f-4f8d-b6b6-36fe582995ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2df0a43-35c8-4dbd-b477-479cbf63503b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12360b3c-0c0f-4f8d-b6b6-36fe582995ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17eb7686-2fe3-4fab-aac5-fe3f61e7f22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17eb7686-2fe3-4fab-aac5-fe3f61e7f22b" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fdf7e8c3-9d14-4b62-81a1-2d8436b22d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fdf7e8c3-9d14-4b62-81a1-2d8436b22d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_260905b1-52ea-43e4-ac31-133179d7fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_260905b1-52ea-43e4-ac31-133179d7fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_3784f107-7260-4b1e-8068-1ddf5550c5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_3784f107-7260-4b1e-8068-1ddf5550c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_355b9c61-6738-4da7-ae27-e8d344a26c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_355b9c61-6738-4da7-ae27-e8d344a26c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_3a5f85d3-0aca-4700-841d-cf7ad6a2ae09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_3a5f85d3-0aca-4700-841d-cf7ad6a2ae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability_9730db9c-c6be-43a8-9d95-09ff1d318a2b" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_isrg_DeferredTaxAssetsOperatingLeaseLiability_9730db9c-c6be-43a8-9d95-09ff1d318a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0741db7e-7b0b-43a0-8ee1-b537bd0db2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0741db7e-7b0b-43a0-8ee1-b537bd0db2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_34702947-e200-426d-8a63-d38c9cf44090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_34702947-e200-426d-8a63-d38c9cf44090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c908d5a5-e124-45ff-8a19-ac3fc1dc4967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c908d5a5-e124-45ff-8a19-ac3fc1dc4967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_863d3719-acaf-4c31-8766-dd517d40416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_863d3719-acaf-4c31-8766-dd517d40416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e2dc96a5-d102-4e60-b1a4-a3a1fec37f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_8e88d71f-80f6-429b-8a47-69d9da4d3091" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e2dc96a5-d102-4e60-b1a4-a3a1fec37f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17eb7686-2fe3-4fab-aac5-fe3f61e7f22b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e40e4ee7-d536-4a9e-9419-507345e98516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e40e4ee7-d536-4a9e-9419-507345e98516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset_1aee5452-c026-4895-8816-4f522e3974fd" xlink:href="isrg-20221231.xsd#isrg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:to="loc_isrg_DeferredTaxLiabilitiesRightOfUseAsset_1aee5452-c026-4895-8816-4f522e3974fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6bd968ab-69e0-43ae-8f4f-a456835843fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6bd968ab-69e0-43ae-8f4f-a456835843fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8534a4cd-92d5-4fce-8206-6741e555f54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8534a4cd-92d5-4fce-8206-6741e555f54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_429b0d9a-422d-4627-ada6-c4acaec10d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4c64e569-0cab-4698-bc42-eaee83ed22bc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_429b0d9a-422d-4627-ada6-c4acaec10d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a25e5ed7-e954-4a87-a2b5-fb3905ff4cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17eb7686-2fe3-4fab-aac5-fe3f61e7f22b" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a25e5ed7-e954-4a87-a2b5-fb3905ff4cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a8d15b59-9b73-42ff-9885-d3dde108906e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a8d15b59-9b73-42ff-9885-d3dde108906e" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_43552867-729a-432b-99a7-3254913832b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_43552867-729a-432b-99a7-3254913832b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f75a371a-8bac-4871-b4b4-291f360f0790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f75a371a-8bac-4871-b4b4-291f360f0790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5346906c-6d5a-479a-8980-49df380a079a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5346906c-6d5a-479a-8980-49df380a079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_65052eb4-c527-429f-969f-979805873d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_65052eb4-c527-429f-969f-979805873d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f2e30884-dda2-4c50-80a8-fa093b446576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f2e30884-dda2-4c50-80a8-fa093b446576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e15601d0-553c-4a99-8525-a7a5cca73894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_e15601d0-553c-4a99-8525-a7a5cca73894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_876ecf78-b68b-46f3-b33c-0f71f9375211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d5bd57b8-f9a3-4cec-8c62-59940ec44670" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_876ecf78-b68b-46f3-b33c-0f71f9375211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58662030-2f0c-4cee-bd5b-fc78e7a10396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_NetIncomeLoss_58662030-2f0c-4cee-bd5b-fc78e7a10396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a13fdfe6-7a8c-47c8-89cb-24218dff49a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a13fdfe6-7a8c-47c8-89cb-24218dff49a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_deb187c2-9f81-4f0f-b4f6-b2be12f2e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_deb187c2-9f81-4f0f-b4f6-b2be12f2e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdf09f3f-dd7c-4278-82c1-e7042b1187d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fdf09f3f-dd7c-4278-82c1-e7042b1187d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2f5b8a79-ba56-472b-9eae-6d3257a231c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_EarningsPerShareBasic_2f5b8a79-ba56-472b-9eae-6d3257a231c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8392ee45-fa23-4c62-9c94-d33dbd6885d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b076c1b-2d5b-49c5-8842-4ef3fb98c1e2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8392ee45-fa23-4c62-9c94-d33dbd6885d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#NetIncomePerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57326679-9da9-427c-adc1-bb07ac4fe5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8647a67-166e-47e6-9040-f3c2b1a98cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57326679-9da9-427c-adc1-bb07ac4fe5e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8647a67-166e-47e6-9040-f3c2b1a98cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ce00d3d5-f5d2-40cc-a81b-f0b99bc22bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_d02ec30c-1a0d-4e60-8992-e5f5ec7ba0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ce00d3d5-f5d2-40cc-a81b-f0b99bc22bcf" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_d02ec30c-1a0d-4e60-8992-e5f5ec7ba0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_7a1909d7-8796-463a-b0bf-baa582bffdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ce00d3d5-f5d2-40cc-a81b-f0b99bc22bcf" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_7a1909d7-8796-463a-b0bf-baa582bffdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_52f1f64f-d223-4c8a-8907-53f8a7a8af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ce00d3d5-f5d2-40cc-a81b-f0b99bc22bcf" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_52f1f64f-d223-4c8a-8907-53f8a7a8af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails" xlink:type="simple" xlink:href="isrg-20221231.xsd#ValuationAndQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_60aac613-ba81-4ca6-81c9-cbb6e2ecd50b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_60aac613-ba81-4ca6-81c9-cbb6e2ecd50b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9cc3973c-400d-49d0-8195-dc6e52f59fb3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_7a2d10f1-e1ac-409d-ba56-344757e45456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_08bd5770-eb34-499c-889b-5bbb53a08a14" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_7a2d10f1-e1ac-409d-ba56-344757e45456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_6ca4f701-c195-48e5-ba12-615e69243f83" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_78523db2-e7d3-4cec-bcf6-2a2f531d08db" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a086644c-9be3-4547-a857-68d7f93bf348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a086644c-9be3-4547-a857-68d7f93bf348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_734bbe10-8862-471c-a391-e557395e2218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_734bbe10-8862-471c-a391-e557395e2218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_860de249-c89f-4595-b047-4b0ef8fdd911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_860de249-c89f-4595-b047-4b0ef8fdd911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2fd06fb8-b893-47eb-b1d5-8c88c088cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ada74e0d-34ca-4870-99d8-a5032e82a867" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2fd06fb8-b893-47eb-b1d5-8c88c088cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>isrg-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 isrg-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !     %$2  0    !          !!9&]B92!);6%G95)E861Y
M 8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'
M!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#
M!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,#/_  !$( QL(1P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<A)=7\'W#V%Y&O=S:W#21RL?02PCZ=* /Z)Z*^9_V!_^"OG[/_\ P4GTM?\
MA5WCW3[W7EB\VY\.:B/L.M6H RV;:3F15[R1&2,?WJ^F* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^2K_@ZZ_:;F_:
M"_X+ ^+=%CN#-I'POTRQ\+685OD#B+[5<G']X7%S(A/4^4OH*_-BO9/^"B/Q
M&E^+O[??QM\432&1M>\=ZU>J2<X1[Z8HH]@I 'L!7C= !76? GX+>(/VCOC1
MX5\ ^%;,WWB3QEJMOH^G0<A7GGD6-2Q_A4%LLW15!)X%<G7ZM?\ !GI^SI:_
M&+_@JO<>+-0MUFM_A?X4O=9M2Z[E6\G:*RCXZ9$=Q<,#V* CGD ']&W_  3Q
M_86\(_\ !.3]DGPG\*?!T$?V30K</J%_Y82;6K]P#<7DO??(XX!)V($0?*B@
M>V444 %%%% !1110!^#/_!XG_P $K;'4/!>G?M3>#M-2WU339K?1?':01X%W
M;N1%9W[X_CC?9;LQR666#H(SG^>FO[K_ -M']GJQ_:R_9(^)/PUU"&.6#QMX
M<OM(3>,B*66%EBE'^TDFQP>Q0&OX4IH7MYFCD5HY(R596&"I'4$4 -HHHH _
MK,_X--/VFYOV@O\ @D+X>T6]N#<:E\+=;OO"DC.V9&@!2[M\_P"RL5TL2]L0
MX[&OTPK\"_\ @QT^(TLVB_M%>$9)&\FWGT+5[9,\!I%OHICCZ1P?E7[Z4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!_!G^T-:36'Q^\<03[O/A\07\<F1@[A<R \?6N/KZ*_X*Y?"27X&?\%0
M/C[X9DB,,=GXZU6>V0C&+:>Y>X@_.&6,_C7SK0 5^X'_  9"ZK:P_M1_'&Q8
MK]MN/"MC/$,_,8X[LJ^!Z9DC_2OP_K]#/^#7K]KNT_9,_P""NW@E-5NEL]#^
M)=K/X)O)7;:J/=&-[7.>/FO(+9,]@Y/L0#^O"BBB@ HHHH **** !F"*2> .
M23VK^!_XF:G;ZW\2/$%Y9[?LEWJ5S-!MZ;&E8KC\"*_M(_X+$_M=VG[#W_!-
M7XN?$":Z6UU*UT&?3=%^;#R:E=K]FM0HZMMEE5R!R$C<] 2/XFZ "BBB@#]U
M?^#'FTE?XU_M!3KN\F/1-'C?TW-/=%?T5J_HGK\,?^#(#X22Z1\ OCSX\>(^
M3X@U_3-!BD(X+65O-.X!_P"W^//X5^YU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR:? <^7P2IF8F5AG!C5BE?H3H'A^P\*:):Z;I=C9Z;IMC&L-M:VL*PP6\:C
M1$4!54#H  !5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  NM4_\ C]'_  \U_:2_Z.#^.'_A=:I_\?H _N,HK^'/_AYK^TE_T<'\</\
MPNM4_P#C]'_#S7]I+_HX/XX?^%UJG_Q^@#^XRBO*?V$M=OO%'[$'P;U/4[RZ
MU'4M1\#:)=7=W=2M-/=2O80,\DCL2S.S$DL222237JU !1110 4444 %%%%
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M0=,UBWCL]-TOQ=J%G9VBFRMF*QQ1RJB L2<*!R2>] ']9M%?PY_\/-?VDO\
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MN4C19@%09P% P  !0!_;Y17\.?\ P\U_:2_Z.#^.'_A=:I_\?H_X>:_M)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OB?_@XQ_Y0I_'[_L"VW_I?:U]L5\3_ /!QC_RA3^/W_8%MO_2^
MUH _C;HHHH *_HF_X,>?^2,?M!_]AK1O_1%W7\[-?T3?\&//_)&/V@_^PUHW
M_HB[H _=:BBB@ HHHH **** "BBB@ HHHH *^1_^"\O_ "AU_:&_[$^Y_FE?
M7%?(_P#P7E_Y0Z_M#?\ 8GW/\TH _B[HHHH **** /8O^"?_ .UYJ_[!O[9G
MP[^+6B^=)<>"]8BN[FWC;:;ZS;,=U;Y_Z:V[RQY[;\]J_N"^'?C_ $CXK_#_
M $/Q1X?O8=2T'Q)I\&J:;=Q'*75M/&LL4B^S(RD?6OX&Z_J,_P"#0/\ ;[_X
M:/\ V!]0^$>M7OG>*/@K=BVM1(^9)]'NB\EL>>3Y4@GAP.%1(1W% 'ZX4444
M %%%% !1110 4444 %?@S_P?'_\ (A?LW_\ 80\0?^B].K]YJ_!G_@^/_P"1
M"_9O_P"PAX@_]%Z=0!_/31110!V'[/?_ "7SP/\ ]C!8?^E$=?WF5_!G^SW_
M ,E\\#_]C!8?^E$=?WF4 %%%% !1110 4444 %?EA_P>%_\ *'Z3_L==)_\
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M_P!C+J/_ *525P] !7ZC?\&@/_*8K3_^Q/U?^45?ES7ZC?\ !H#_ ,IBM/\
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M_P $>/\ E%#^S;_V370/_3?#7TA7S?\ \$>/^44/[-O_ &370/\ TWPU](4
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M%'#_ /(U'_$'/^R'_P _'Q8_\*.'_P"1J_5>B@#\J/\ B#G_ &0_^?CXL?\
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M ).1^(7_ &,NH_\ I5)7#T %?J-_P: _\IBM/_[$_5_Y15^7-?J-_P &@/\
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MD/\ Y^/BQ_X4</\ \C5^J]% 'Y4?\0<_[(?_ #\?%C_PHX?_ )&H_P"(.?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#1>G5^\U?@S_P?'_\ (A?LW_\ 80\0?^B].H _GIHHHH [#]GO_DOG@?\
M[&"P_P#2B.O[S*_@S_9[_P"2^>!_^Q@L/_2B.O[S* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K^#O]IK_ ).1^(7_ &,NH_\ I5)7]XE?P=_M-?\
M)R/Q"_[&74?_ $JDH X>BBB@#]'O^#4#_E-K\./^P5K?_ILN*_K>K^2'_@U
M_P"4VOPX_P"P5K?_ *;+BOZWJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K^='_@^"_P"2^_ /_L7]5_\ 2F"OZ+J_G1_X/@O^2^_ /_L7]5_]*8*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#]GO_DOG@?\ [&"P_P#2B.O[S*_@S_9[_P"2^>!_^Q@L/_2B.O[S* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K^#O]IK_ ).1^(7_ &,NH_\ I5)7
M]XE?P=_M-?\ )R/Q"_[&74?_ $JDH X>BBB@#]'O^#4#_E-K\./^P5K?_ILN
M*_K>K^2'_@U _P"4VOPX_P"P5K?_ *;+BOZWJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K^='_@^"_P"2^_ /_L7]5_\ 2F"OZ+J_G1_X/@O^2^_
M/_L7]5_]*8* /PQHHHH *_M,_P""%G_*'[]G?_L2K+_T$U_%G7]IG_!"S_E#
M]^SO_P!B59?^@F@#ZPHHHH **** "BBB@ HHHH **** /X._VFO^3D?B%_V,
MNH_^E4E</7<?M-?\G(_$+_L9=1_]*I*X>@ K]1O^#0'_ )3%:?\ ]B?J_P#*
M*ORYK]1O^#0'_E,5I_\ V)^K_P HJ /ZMJ*** "BBB@ HHHH **** "BBB@
MK^=G_@^&_P"2T_L^?]@36?\ T?:U_1-7\[/_  ?#?\EI_9\_[ FL_P#H^UH
M_"FBBB@ K^W3_@D5_P HJ?V:_P#LE_AO_P!-EO7\1=?VZ?\ !(K_ )14_LU_
M]DO\-_\ ILMZ /HBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
MAC_X*$_\G]?'#_LH&O?^G&XK^YROX8_^"A/_ "?U\</^R@:]_P"G&XH \?HH
MHH ^[_\ @V7_ .4XWP(_Z^]6_P#3-?U_8;7\>7_!LO\ \IQO@1_U]ZM_Z9K^
MO[#: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_C:_P"#B_\
MY36?'[_L-V__ *06M?V2U_&U_P '%_\ RFL^/W_8;M__ $@M: /BBBBB@#WC
M_@EI_P I./V<_P#LJ'AG_P!.MM7]PE?P]_\ !+3_ )2<?LY_]E0\,_\ IUMJ
M_N$H **** "BBB@ HHHH **** "BBB@ K\(/^#W7]F_^T?AA\$_BY:V^&TG4
M[SPEJ,H7)=;B,75J">P4VUU^,E?N_7P[_P ''?[.'_#2_P#P1R^,EA#;^?J7
MA33H_%MD0,M$VGRK<3$#U-LMPO\ P.@#^.6BBB@ K^J'_@SQ_:'_ .%L_P#!
M*6;P?<3[KSX7^*K[2HXB<LMI<[+Z-OH9;BY4?]<S7\KU?MI_P9-?M#_\(I^U
MK\7/AA<3[+?QIX9M]=MD8\-<:?<>654?WFCOG8^HB]A0!_211110 4444 %%
M%% !1110 5_)G_P=F?M&_P#"]?\ @L)XFT6"X\[3_ACHFG^%X-K?)YGEF\GP
M/[PENWC)ZYBQV%?UAZSK%KX>T>ZU"^GCM;*QA>XN)I#A8HT4LS$^@ )_"OX3
MOVL_CK=?M/?M1?$7XC7GF?:/'7B34-=*OUB%Q</*J>P56"@=@H% 'GM%%% '
M>?LM? V]_:<_:6^'_P .=.\Q;WQUXBL-!B=!DQ&YN$B+_10Y8D\  FO[LO#/
MARR\'>&]/TC3;>.TTW2[:.SM8$^[#%&H1$'L% 'X5_*/_P &E?[-/_"^/^"O
M6@Z_<6_G:;\+=#O_ !--N7]V9B@LX 3_ 'A)=B11ZPD]C7]8U !1110 4444
M %%%% !1110 4444 %?RT_\ !YA_REGT+_LG6F?^EFH5_4M7\M/_  >8?\I9
M]"_[)UIG_I9J% 'Y,T444 ;'P^_Y'W0_^PA!_P"C%K^^2OX&_A]_R/NA_P#8
M0@_]&+7]\E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\3_P#!QC_RA3^/W_8%MO\ TOM:^V*^)_\ @XQ_Y0I_'[_L
M"VW_ *7VM '\;=%%% !7]$W_  8\_P#)&/V@_P#L-:-_Z(NZ_G9K^B;_ (,>
M?^2,?M!_]AK1O_1%W0!^ZU%%% !1110 4444 %%%% !1110 5\C_ /!>7_E#
MK^T-_P!B?<_S2OKBOD?_ (+R_P#*'7]H;_L3[G^:4 ?Q=T444 %?VW?\$>]0
M_M/_ ()1?LVR9SM^&GA^+_OC3H$_]EK^)&O[5O\ @B%>?;O^"1'[.C\?+X$T
MV/@?W80O]* -S_@K%^Q-;_\ !0O_ ()]_$OX6-%"VK:WI;7.A228'D:I;D3V
MC;OX09D5&(_@=QT)K^)34],N-$U*XL[RWFM;RSE:&>&5"DD+J2&5@>00000>
MA%?WZU_(_P#\'1W["?\ PQG_ ,%2O$FM:79_9_"7Q?C/C#32BXCCN97*W\(/
M3<+D/+@?=2YC% 'YQT444 ?U)?\ !H1^WQ_PTG_P3^OOA1K-[YWBCX)W@L[<
M2-F2;1[DO):MSR?+D6XAP.%2.$=Q7ZU5_''_ ,&\G[>W_# '_!4'P+KFI7OV
M/P?XTD_X1'Q(6;;&EK=NBQSMV AN%@E)Z[$<#[U?V.4 %%%% !1110 5^#/_
M  ?'_P#(A?LW_P#80\0?^B].K]YJ_!G_ (/C_P#D0OV;_P#L(>(/_1>G4 ?S
MTT444 =A^SW_ ,E\\#_]C!8?^E$=?WF5_!G^SW_R7SP/_P!C!8?^E$=?WF4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7\'?[37_)R/Q"_[&74?_2J
M2O[Q*_@[_::_Y.1^(7_8RZC_ .E4E '#T444 ?H]_P &H'_*;7X<?]@K6_\
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MQ:_ODH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@_\ 1>G5^\U?@S_P?'_\B%^S?_V$/$'_ *+TZ@#^>FBBB@#L/V>_^2^>!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2<"IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXG_ .#C'_E"G\?O^P+;?^E]
MK7VQ7Q/_ ,'&/_*%/X_?]@6V_P#2^UH _C;HHHH *_HF_P"#'G_DC'[0?_8:
MT;_T1=U_.S7]$W_!CS_R1C]H/_L-:-_Z(NZ /W6HHHH **** "BBB@ HHHH
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MA^SW_P E\\#_ /8P6'_I1'7]YE?P9_L]_P#)?/ __8P6'_I1'7]YE !1110
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MH3_A)_V5_C#\,)Y]TWA#Q);>(+9'/(AO[?RF5?\ 962Q)..AE]Z /VZHHHH
M**** "OY<?\ @\E_:-_X6E_P4ZT7P);W&^R^%_A2UMIHLY\N]O6:[D/MFW>S
M_P"^:_J.S7\//_!3O]H[_AKC_@H7\9/B+'<?:;+Q-XKOIM.DW;LV*2F*T&?:
MWCB'X4 >$T444 >W?\$U_P!FP_M@?M]_"'X:M ;BS\6>*;*UU! ,XL5E$EVV
M/]FW25OPK^XU%$:A5 55&  .E?R\?\&:W[-/_"U?^"EGB#XA75OYEC\*_"T\
MT$NW/E7]\PM8A[9MS>_]\_6OZB* "BBB@ HHHH **** "BBB@ HHHH ****
M"OY:?^#S#_E+/H7_ &3K3/\ TLU"OZEJ_EI_X/,/^4L^A?\ 9.M,_P#2S4*
M/R9HHHH **** "BBB@ HHHH **** "BBB@ HHHH _OTTG_D%6O\ UR3^0JQ5
M?2?^05:_]<D_D*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q/\ \'&/_*%/
MX_?]@6V_]+[6OMBOB?\ X.,?^4*?Q^_[ MM_Z7VM '\;=%%% !7]$W_!CS_R
M1C]H/_L-:-_Z(NZ_G9K^B;_@QY_Y(Q^T'_V&M&_]$7= '[K4444 %%%% !11
M10 4444 %%%% !7R/_P7E_Y0Z_M#?]B?<_S2OKBOD?\ X+R_\H=?VAO^Q/N?
MYI0!_%W1110 5_85_P &R$RS_P#!#;X$LO06VKK^(UO4 ?Y5_'K7]@G_  ;!
M_P#*##X%?]<M;_\ 3[J- 'WQ1110 5'>6D.H6DMO<11S03H8Y(Y%#)(I&"I!
MX((XP:DHH _B=_X+#_L.3?\ !.__ (**_$KX9QV\D.@V6HG4?#KMDB72KK]]
M:X8_>*(WE,?[\+U\RU_1S_P>B_L(_P#"=? GP)^T)HUGNU#P+<CPSXBD1/F;
M3KERUK*Y[+%=%D'J;T>E?SC4 %?H[_P:Y?MY?\,7_P#!47P[HNJ7GV;PA\8(
MQX0U,.V(XKJ5PUA,1TW"Y"Q9/"I<R&OSBJ;3M1N-'U"WN[2::UNK619H9HG*
M21.IRK*PY!! ((Z$4 ?W[45\V_\ !(S]N&W_ ."B'_!/7X;?%#SH9-:U335L
MO$$:8'D:I;?N;H;1]T-(AD4?W)4/>OI*@ K\,?\ @^"@W? /X!2;?N^(-57=
MCIFW@./QQ^E?N=7X>_\ ![Y!N_9D^!<F?N>*-07'KFT0_P!* /YQ:*** .P_
M9[_Y+YX'_P"Q@L/_ $HCK^\ROX,_V>_^2^>!_P#L8+#_ -*(Z_O,H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OX._VFO^3D?B%_V,NH_^E4E?WB5_
M!W^TU_R<C\0O^QEU'_TJDH X>BBB@#]'O^#4#_E-K\./^P5K?_ILN*_K>K^2
M'_@U _Y3:_#C_L%:W_Z;+BOZWJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K^='_@^"_Y+[\ _^Q?U7_TI@K^BZOYT?^#X+_DOOP#_ .Q?U7_TI@H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH/QET>S\KP_\8K#9J#1K\D6KV2I%+G'"^;;FW<=V=)CSS0!^/E%%% '[E?\
M!EO^W=_PA?QJ\??L]:S>;;#QI;GQ3X<C=OE74+9 EW$@[M+;".3V%DWK7]&5
M?PG?L;_M-ZU^QE^U1X!^*?A\L=4\#:U;ZHD0?:+N-&_?6['^[+$9(V_V9#7]
MQ_PC^*6B_''X5>&_&GAN[6_\/^+-+MM8TVY7I/;7$2RQM^*L..U '15^(_\
MP>ZP;OV1O@K)M^[XONEW>F;)CC\<?I7[<5^*O_![=;LW[$GP?F_AC\<2(>.Y
ML)S_ .RF@#^:VBBB@#L/V>_^2^>!_P#L8+#_ -*(Z_O,K^#/]GO_ )+YX'_[
M&"P_]*(Z_O,H **** "BBB@ HHHH **** "BBB@ HHHH **** "OX._VFO\
MDY'XA?\ 8RZC_P"E4E?WB5_!W^TU_P G(_$+_L9=1_\ 2J2@#AZ*** /T>_X
M-0/^4VOPX_[!6M_^FRXK^MZOY(?^#4#_ )3:_#C_ +!6M_\ ILN*_K>H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OYT?^#X+_ )+[\ _^Q?U7_P!*
M8*_HNK^='_@^"_Y+[\ _^Q?U7_TI@H _#&BBB@ K^TS_ ((6?\H?OV=_^Q*L
MO_037\6=?VF?\$+/^4/W[.__ &)5E_Z": /K"BBB@ HHHH **** "BBB@ HH
MHH _@[_::_Y.1^(7_8RZC_Z525P]=Q^TU_R<C\0O^QEU'_TJDKAZ "OU&_X-
M ?\ E,5I_P#V)^K_ ,HJ_+FOU&_X- ?^4Q6G_P#8GZO_ "BH _JVHHHH ***
M* "BBB@ HHHH **** "OYV?^#X;_ )+3^SY_V!-9_P#1]K7]$U?SL_\ !\-_
MR6G]GS_L":S_ .C[6@#\*:*** "O[=/^"17_ "BI_9K_ .R7^&__ $V6]?Q%
MU_;I_P $BO\ E%3^S7_V2_PW_P"FRWH ^B**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K^&/_@H3_R?U\</^R@:]_Z<;BO[G*_AC_X*$_\ )_7Q
MP_[*!KW_ *<;B@#Q^BBB@#[O_P"#9?\ Y3C? C_K[U;_ -,U_7]AM?QY?\&R
M_P#RG&^!'_7WJW_IFOZ_L-H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K^-K_ (.+_P#E-9\?O^PW;_\ I!:U_9+7\;7_  <7_P#*:SX_?]AN
MW_\ 2"UH ^***** />/^"6G_ "DX_9S_ .RH>&?_ $ZVU?W"5_#W_P $M/\
ME)Q^SG_V5#PS_P"G6VK^X2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _ '_@]Y_9O_ .2'_%ZU@_Y_O!^I38^EW9KG_P #C_DU^ -?U]?\'/?[-_\
MPT9_P1L^)S0V_P!HU/P"UKXPLOESY?V24"X;\+.6ZY_I7\@M !1110!_</\
M\$Q/V@O^&J/^">/P7^($D_VB\\2>$-/FOY,YS>I L5T,^TZ2C\*]UK\J?^#/
M7]H#_A:__!)O_A$YIMUU\,?%>H:0D1.66VN-E_&W^Z9+J=1_US-?JM0 4444
M ?S#_P#!YW^T?_PLG_@HIX/^'=M<>98_#/PI&\\>?]3?7\AGEX][>.R/^17X
M]U]$_P#!6S]H_P#X:U_X*7?&SQ]'<?:K+6O%=Y#ITN[=OL;9OLMH?_ >&*OG
M:@ KZ._X)$_LT_\ #7O_  4S^"?P_DM_M5CK'BFUN-2BV[O,L;4F[NQ^-O!*
M*^<:_93_ (,MOV:?^%B?MX_$#XF75OYME\-O"XLK9RO^JOM1EV(P/_7O;W:X
M_P!N@#^FBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^6G_@\P_Y2SZ%
M_P!DZTS_ -+-0K^I:OY:?^#S#_E+/H7_ &3K3/\ TLU"@#\F:*** -CX??\
M(^Z'_P!A"#_T8M?WR5_ W\/O^1]T/_L(0?\ HQ:_ODH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB?_@XQ_Y0I_'[
M_L"VW_I?:U]L5\3_ /!QC_RA3^/W_8%MO_2^UH _C;HHHH *_HF_X,>?^2,?
MM!_]AK1O_1%W7\[-?T3?\&//_)&/V@_^PUHW_HB[H _=:BBB@ HHHH ****
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MA_Z41U_>97\&?[/?_)?/ _\ V,%A_P"E$=?WF4 %%%% !1110 4444 %%%%
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MI./V<_\ LJ'AG_TZVU?W"4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'._%_P"&>F_&KX3>*/!NL)YFD>+=(N]%ODQG=!<PO#(,>ZN:_A"^*'P\U+X1
M?$OQ%X3UB+R=7\+ZG<Z3?1_\\Y[>5HI%_!D(K^]^OX^O^#F7]F__ (9O_P""
MR7Q6CAM_)TSQQ+;^,+(XQYOVV(/<-_X%K=#\* /@BBBB@#]Q_P#@R,^/O]A?
MM%_&KX8S3?N_$OAZS\26T;'@/8W!@DV^[+?(3W(C'I7]&M?QW_\ !M7\?/\
MAG__ (+-_!RYFF\G3_%5Y<>%KM<X\W[=;R0P+_X$FW/OMK^Q"@ KPW_@IE^T
M=_PR/_P3[^,7Q&CG^SWGA?PI?7&GONV_Z:T1BM1GMFX>(?C7N5?DG_P>1?M'
M_P#"J_\ @F'H_@2WGV7WQ2\56MI-%NQYEE9AKR5O?$Z68Q_M4 ?RWDYHHHH
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M#O\ @[XTG^T?^"..JS8S]@\6Z1/TZ9>2/_VI0!_*+1110!V'[/?_ "7SP/\
M]C!8?^E$=?WF5_!G^SW_ ,E\\#_]C!8?^E$=?WF4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7\'?[37_)R/Q"_P"QEU'_ -*I*_O$K^#O]IK_ ).1
M^(7_ &,NH_\ I5)0!P]%%% 'Z/?\&H'_ "FU^''_ &"M;_\ 39<5_6]7\D/_
M  :@?\IM?AQ_V"M;_P#39<5_6]0 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?$__!QC_P H4_C]_P!@6V_]
M+[6OMBOB?_@XQ_Y0I_'[_L"VW_I?:T ?QMT444 %?T3?\&//_)&/V@_^PUHW
M_HB[K^=FOZ)O^#'G_DC'[0?_ &&M&_\ 1%W0!^ZU%%% !1110 4444 %%%%
M!1110 5\C_\ !>7_ )0Z_M#?]B?<_P TKZXKY'_X+R_\H=?VAO\ L3[G^:4
M?Q=T444 %?V"?\&P?_*##X%?]<M;_P#3[J-?Q]U_8)_P;!_\H,/@5_URUO\
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MO//VNOB/'\'?V4/B=XNED\F/PMX3U75WD_N"WLY92?PV5Z'7PG_P<H_'R/\
M9_\ ^",WQCN/.$=]XKLH/"UDF<&=KV>.&91]+8W#?1#0!_'?1110 5^V'_!D
M=X$;4/VS?C)XF\O*Z1X+ATLOC[INKZ*4#\?L9_*OQ/K^C;_@R$^$#:-^SA\=
M/'S0X7Q%XDT_08Y".OV&V>=@/_!@N?P]* /W&HHHH **** "BBB@ HHHH **
M** "OYV?^#X;_DM/[/G_ &!-9_\ 1]K7]$U?SL_\'PW_ "6G]GS_ + FL_\
MH^UH _"FBBB@ K^W3_@D5_RBI_9K_P"R7^&__39;U_$77]NG_!(K_E%3^S7_
M -DO\-_^FRWH ^B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^
M&/\ X*$_\G]?'#_LH&O?^G&XK^YROX8_^"A/_)_7QP_[*!KW_IQN* /'Z***
M /N__@V7_P"4XWP(_P"OO5O_ $S7]?V&U_'E_P &R_\ RG&^!'_7WJW_ *9K
M^O[#: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_C:_X.+_\
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M8?\ *6?0O^R=:9_Z6:A0!^3-%%% &Q\/O^1]T/\ ["$'_HQ:_ODK^!OX??\
M(^Z'_P!A"#_T8M?WR4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/AGX&T7PWHMJEEHWA^P@TVPMT^[!;PQK'&@]E10/PH UJ*** "BBB@ HHHH
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M3PKITK+D-)=RFYN-OHR+:P GKB;W- ']%%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5_+3_P 'F'_*6?0O^R=:9_Z6:A7]2U?RT_\ !YA_REGT
M+_LG6F?^EFH4 ?DS1110!L?#[_D?=#_["$'_ *,6O[Y*_@;^'W_(^Z'_ -A"
M#_T8M?WR4 %%%% !1110 4444 %%%% !1110 4444 %%%% !17%_'_\ :)\#
M_LL?#"\\:?$3Q-I?A'PKI\D45SJ>H2>7;PM*XCC!.#RSLJCW-?/?_#^7]CK_
M *.&^&__ ('G_P")H ^N**^1_P#A_+^QU_T<-\-__ \__$UH>$_^"WG[)?CK
MQ3INB:/\>_A[J&K:Q=Q6-E:PWQ,ES/*X2.-1M^\S, /<T ?5%%><_M-?M=?#
M/]C/P/9^)?BGXTT/P/H.H7RZ9;7VJ3>5#-<M')(L0.#\Q2*1L>B&L7]ES]O_
M ."_[;%YK-O\)_B3X6\>7'AY(I-1BTJZ\U[192XC9E(!PQ1AD<9'TH ]@HHK
MD?CK\?/!G[,GPOU+QK\0/$FD^$?">C^6+S5-2F$-O;F218HP6]6=U4 <DL*
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M=;:O[A*_A[_X):?\I./V<_\ LJ'AG_TZVU?W"4 %%%% !1110 4444 %%%%
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M?_#0GC[_ *'CQA_X.;C_ .+H_P"&A/'W_0\>,/\ P<W'_P 70!_>917\&?\
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M$?@[X5U31M&U_P 9-=+:WFK-(MG#]GM)[MMYC1WY2!@,*?F(Z#)'ZT?LV_\
M!G/\?/@Q^T5X!\8:A\2OA!=:?X3\1Z=K-S#;W&HF:6*WN8YG5-UH!N*H0,D#
M)&2*^+/^#83_ )3G_ K_ *ZZU_Z8M1K^P6@#\>?^#UK_ )1C_#O_ +*A9?\
MIJU6OQ._X(2_\%$9/^":O_!1KP;XTO[Q[?P7KK_\(YXM7)V?V;<NH:9A_P!,
M)%BGXY(A*_Q&OVQ_X/6O^48_P[_[*A9?^FK5:_FAM/ 6L7W@._\ %$-A<2:#
MI=_;:7=WJC]U;W-Q'/)!$Q[,Z6MPP]1$WI0!_?%!/'=0)+$ZR1R*&1U.Y6!Y
M!![@U_.]_P 'F_\ P47_ .$J^(GA']FGPY?;K+PR(_$_BX1/P]Y*A%E:OC_G
MG"[S%3D'[3">J5]9_P#!"?\ X+9^'=6_X(D>)O%/Q&U3SM>_9@THZ;K2/*!<
M:G9I&1I3*3GYYPJVJDY+2PDG[U?S@_&/Q]XZ_;A^.GQ(^)FK0W&L:[JLUWXL
M\03Q ^58PO,JEN3\D*-+%$@Z#=&H["@#]$/^#-O_ )2X:E_V3_5/_2FQK^IZ
MOY8?^#-O_E+AJ7_9/]4_]*;&OZGJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KXG_X.,?^4*?Q^_[ MM_Z7VM?;%?$_P#P
M<8_\H4_C]_V!;;_TOM: /XVZ*** "OZ)O^#'G_DC'[0?_8:T;_T1=U_.S7]$
MW_!CS_R1C]H/_L-:-_Z(NZ /W6HHHH **** "BBB@ HHHH **** "OD?_@O+
M_P H=?VAO^Q/N?YI7UQ7R/\ \%Y?^4.O[0W_ &)]S_-* /XNZ*** "O[!/\
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M %%%% !7\'?[37_)R/Q"_P"QEU'_ -*I*_O$K^#O]IK_ ).1^(7_ &,NH_\
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M[Q<^WEV)_P"!5_030 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5PG[3/[-OA#]K[X%>(OAOX]TV75O
M"'BJ!;;4K2.ZEM6G19$D $D;*Z_,BG*D=*[NB@#\Z/\ B%,_8A_Z);K'_A7Z
MM_\ )%'_ !"F?L0_]$MUC_PK]6_^2*_1>B@#\Z/^(4S]B'_HENL?^%?JW_R1
M7TO^P1_P3 ^#/_!,W0_$FF_!WPS=^&[/Q9/!<ZFD^JW6H>>\*NL9!GD<K@2-
MPN,YYKZ HH **** "BBB@ HHHH **** "BBB@ KC_C[\!_"O[3_P9\1?#_QO
MIK:QX3\66;:?JED+F6V-S"V,KYD3+(N<#E6!]Z["B@#\^/\ B%E_88_Z(O<?
M^%EKO_R91_Q"R_L,?]$7N/\ PLM=_P#DROT'HH _/C_B%E_88_Z(O<?^%EKO
M_P F5]C_ ++?[+O@?]B_X$:#\,_AOHS>'_!?AD3KINGM>3WAMQ-/)<2?O9W>
M1LRS2-\S'&[ P  /0** "BBB@ HHHH **** "BBB@ HHHH \4_;@_P""=WP>
M_P""CO@#2?#'QD\'Q^+M'T+4/[3L(QJ%U82VT_EO&6$MM)')M*N04+;20I()
M52/F/_B%E_88_P"B+W'_ (66N_\ R97Z#T4 ?GQ_Q"R_L,?]$7N/_"RUW_Y,
MH_XA9?V&/^B+W'_A9:[_ /)E?H/10!\"^'?^#83]B/PIX@L=4L/@Y<0WVFW$
M=U;R?\)?KC>7(C!E;!O"#A@#@@BOOJBB@ HHHH **** "BBB@ HHHH ****
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MP'_X*9:[X;U+XQ>$[WQ)>>$X)[;3'@UF\T_R$F9&D!$$B!LF->6SC'%?2U%
M'YT?\0IG[$/_ $2W6/\ PK]6_P#DBC_B%,_8A_Z);K'_ (5^K?\ R17Z+T4
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MV\K1NZ^7-*Z9+1)SC(QUY-?6]%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>isrg-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 isrg-20221231_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\0?^#WG_DUGX'_]E U'_P!(17[?
M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
M?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@#PO\ :P_Y+9\#
M_P#L>Y?_ $F:O=*\+_:P_P"2V? __L>Y?_29J]TH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7X@_\'O/_)K/P/\ ^R@:C_Z0B@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\
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MM)?M'^,%TK0-(0)##$HDN]3NV!\FRM(L@S7$A!"H,  ,S%45F4 A_;9_;8^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<'^T
MU^TS\$?V/?@AK_[17[1'CRT\.>$_#=F;C4=1NFR6/1(8D'S2S2,0B1J"SLP
M&30!#^U/^U/\"_V+O@5K_P"T=^T;X[MO#WA3P[:F6]O)SEY7/$<$,8^:::1L
M*D:Y+,0/4U\/?LE_LL?'3_@JI\>M"_X*<?\ !27P)<^'_ _A^X^V_LY?L]ZJ
M,QZ1$>8]?UB(_++J$B[7CC8$0@J<9"XA_97_ &9OC=_P5V^.N@_\%*/^"BO@
M.[\._"[PY="__9S_ &?-7&5A4\Q>(M:B^[+=R+AHH6RL:D'IS)^E- !1110
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MX"\%_%+P3JWPV^(_A:QUO0-=T^6QUG1]3MUFM[RVE0I)%(C<,K*2"#ZUK44
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7RW_P %/?\ @F]8?MT^!=$\>?"KQL_@'XY?#6\;5OA!\3K%=LVE7PY-K<$
MF6RGP$EB(88.[:V"C_4E% 'R;_P2\_X*0W_[8NB^(?@'^T9X*7P!^T/\*YET
M_P"*_P .YVVXD& FJ6.2?.L+@%71U+!/,52S*T<DGUE7QK_P5#_X)T_$#XZZ
MWX>_;A_8>\1VO@_]I?X60M)X.UR3"6OB>PY:;0-3&0);:8%E0L?W3N2"H9B.
M^_X)J_\ !1;X?_\ !0_X,W?B2V\.77A#XA>$-0.C?%7X9ZQE-1\*ZQ'E9()$
M8!FA9D<Q2X =00=KI(B@'T91110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7X@_\'O/_ ":S\#_^R@:C_P"D(K]OJ_$'_@]Y_P"36?@?_P!E
M U'_ -(10!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^
M3U^_U !1110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_
MR6SX'_\ 8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOPWI%KI^G:?:QVUA86-NL4-M#&H5(HT4!415 4*    !5JBB@ HHHH ****
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MM/U"QN%EAN8)%#QRQNI*NC*0P8$@@@B@"W1110 4444 %%%% !1110 4444
M%%%% !1110 5^(/_  >\_P#)K/P/_P"R@:C_ .D(K]OJ_$'_ (/>?^36?@?_
M -E U'_TA% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC
M_P!/D]?O]0 4444 %%%% !1110 4444 >%_M8?\ );/@?_V/<O\ Z3-7NE>%
M_M8?\EL^!_\ V/<O_I,U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO]#UK39=\-U XR&'<$<AE8!E8%6 (( !TE%%% !1110 4444 %%%% !1110
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MG<G8Q8N<^:[_ *=6]Q;W=NEW:3I+%*@>*6-@RNI&001P01WH ?1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>%=.\"^!/#5AHVBZ191V>E:3I=HD%M9V\:A4BBC0!415  4   5HT %%%%
M!1110 4444 %%%% !116/\0_'WA+X4^ =;^*'C[538:%X<TBYU/6KX6\DOV:
MT@B:6639&K.^U$9L*I8XX!- &Q7(Q?'SX)3_ !I?]G"W^+/AZ3Q]'H;:S-X-
MCU:)M2BT]7CC-R]N&WI'NE0!F !W<9P:^!)/VN_^"EO_  5_<^'_ /@G/X3O
MOV??@3>'9=?M#_$#1C_;_B"V/#-H.EN1Y:,,[;J8C(.5:*1"A^GOV#O^"6O[
M)7_!/;3K[4_@_P"%;S6?&^O9?Q?\4?&5Z=2\1^()F.YWN+R0;@K, QCC"1Y
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5\>_\ !17_ (*EG]FOQII?['7[(?PX_P"%L_M*>,K?/A7X=6$O
M^CZ/"P_Y"FL3*0+.SC!#X9E:0  %%)D7COVW/^"F/QF^)/QRO?\ @FO_ ,$E
M]&T_Q=\:0@3QY\0+U?-\._"VU8E6N+V0!DFO1\WEV@#$.OSJQ4Q-['_P3J_X
M)G?!G_@GIX+U2XT36=0\:?$GQC<?;OB9\6?%#>=K/BB_8[G>21BQB@#$^7 K
M%4')+N6=@#CO^"=/_!+0?LT>,]4_;#_:Y^(__"V?VE/&=OCQ7\1M0B_<:1"P
M_P"07H\3 "SLXP=GRJK2 9(12(E^P:** "BBB@ HHHH **** "BBLWQCXR\)
M?#SPIJ/COQ[XGL-%T31[*2\U75]5NT@MK.WC4L\LLCD*B*H)+$@ "@#2KX4_
M;1_:B_;Z_:)_:9U#_@G-_P $V/!M]X'N]%@MIOBM^T3XP\..VF>&+6XB$L=O
MI,,P"ZE?/&P((S&G3(.Z2*W^QW_P40_::_X*/_M5KXZ_92^%UAH_[*'AA;VR
MU#XD>,=.GCU'X@:B%9$.C0DH8;2&4?-/*IWC<N%<%4^X* /F#]@[_@DO^RQ^
MP?J5]\3M!M=5\=_%?7\R>+?C)\0KTZEXAU:5QB3_ $B3/V>(]/*BV@JJARY7
M=7T_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4DDD
M<,;2RR*J*I+,QP !U)-8FH?$SP!I?C:Q^'%_XML8]>U%'>STDS SR*JER=H^
MZ-H)!.,X.,XKD?BY\ =6^-?BJ&#QC\2M1B\&16J?:/"FF#R/MT^YMQGG4[FB
MQM^0=P3D4 =[I?B/P_K>BKXCT;7+.[T]T9TOK:Y5X6520S!P=I (.3GL:N(Z
M2()(V#*PRK Y!%8MM\-_ ECX%;X96/A:SM] >S>U?2X(MD1A<$.N%Q][)R>I
M)))R:X/P!^SCXC^#OC.SF^%GQ:U.#PAYC?;_  ?K ^V11KM.T6LKG?" VWC)
MR"22>!0!ZO17*>-?C?\ "SX<^*]-\&>.O&-KI5]JT+R6'VW,<4@5@I!E(V*2
M3P&(S751R1S1K+%(K(R@JRG((/0@T +1110 4444 %%%% !1110!\H_\%0?^
M";DO[:/AW0/C5\ _&X^'_P"T%\+IVU'X2_$FU7#6\XR7TZ\P#YUA/DI)&P8+
MO+!6!DCD^B?@U-\6KCX2^&I_CU8Z';>-GT.U/BRW\-3RR:>FH^4OV@6S2@.8
MO,W;=PSC&2>IZ6OFG_@IY\!_VR?BQ\(=$^(W[!/QVOO"GQ.^&VNCQ#H/AV>Z
M"Z-XR"1,DND:DF1OBEC9U1BP5)"&)4XDC /I:BOG?_@FW_P43^&O_!1/X*7'
MC/1-"N_"OCCPM?MHWQ1^&NM934O">LQDK+;3(P#&,LCF.7: ZJ00KI(B?1%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^(/\
MP>\_\FL_ _\ [*!J/_I"*_;ZOQ!_X/>?^36?@?\ ]E U'_TA% 'G_P#P:;?\
MI3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %
M%%% !1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/@?\ ]CW+_P"DS5[I
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>?\ DUGX'_\ 90-1_P#2$5^WU?B#_P 'O/\ R:S\#_\ LH&H_P#I"* //_\
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M<>ZL"/\ "N*^%7[.7A?X+^*KK5OA]XFUNUT6[MV4^%)K\S6,$Q96\Z)7RR'
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MBSXI10O9Z]\4PC%)K'25D :UTYB&22X89<94@_O(0 ?;7[-7[<_[+?[<&O\
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M\L!(I$&!!.W,HY+'<P@ /OJBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_$'_@]Y_Y-9^!__90-1_\ 2$5^WU?B#_P>\_\ )K/P/_[*!J/_ *0B
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
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M7AOPWX=\&^'K'PEX1T&RTK2M,M([73=,TZU2"WM((U"I%'&@"HBJ  J@
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MW [$GH,!\Y]JZ2N*E_9P^ <M[%J*_!SPY#/#*LD4MMI,4+*X.0V4 YR,UVM
M!1110 4444 %%%% !1110 4444 %%%% !7X@_P#![S_R:S\#_P#LH&H_^D(K
M]OJ_$'_@]Y_Y-9^!_P#V4#4?_2$4 >?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#
M_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%% 'A?[6'_);/@?
M_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-7NE !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y?\
MM4_MJ?LI?L1> 6^)?[5WQY\.^"-)VL;9]9O@)[QE&2EM;INFN7 YV1([>U?&
MW_#R7_@I=_P40_XE'_!*/]C-O _@>[^5?V@/VA;62PM)HC_RWTS2$S<78(RT
M<KYC) $B+0!]X_&/XW?!W]GGP%>?%+X[_%'0/!_AS3US>:WXDU6*SMHS@D+O
ME8 L<8"C+,> ":^%M5_X+0_'G]LS4[CP'_P1;_8PU?XI0B9K>;XV?$:&?0/
M]@X.UGC>4)<ZD4(PT42QO@@C<*Z'X.?\$&_@EK'CVS_: _X*2_&;Q1^U-\2K
M9O,@O_B4P7P]I;D@LMAHD9-K!&2/N/YJYY 4U]T:5I6EZ%IEOHNAZ;;V=G:0
MK#:6EI"L<4,:C"HB* %4    8 % 'Y^^&?\ @A_XR_:B\06?Q2_X++_M>^(?
MCSJ=O.MS9_##1))-#\#:3*#E0EC;E'O&3  FE*EQQ(CU]W?#?X9?#CX.^"K#
MX;?"7P%HWACP]I4/E:9H?A_3(K.TM4SG;'#$JH@R2>!U)-;E% !1110 4444
M %%%% !1110 5\H?\%&O^"I7A#]C"_T;]G[X-> +OXJ_M ^.E,?P\^$/A^0&
MXG)R/MU^XXLK%,,S2OC<$?;A4DDC]:_;4D_; '[.>NVG["-GX1?XFWA@M="N
M_&]U)'I^GK+,D<UXRHC^:T,;/*L9&&*8.[_5OYI_P3F_X)>_#']@ZPUGXD^)
M/%]_\2/C3XY87'Q+^,7B@>9J>M3G!,,62?LMFI"A+=#@!$W%BJX /1_V)/#G
M[7_AG]G/1;3]NSXC>&_$WQ,N9;B[UZZ\):1]CL+(32M)'8Q#/[Y8$80B8A2X
M0%@S9=_6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;^_L-*LI=2U2
M]AMK:",O/<7$@1(U R69CP /4T 353O_ !#H&EZE9Z-J6MVEO>:B[)I]K-<*
MLERRJ681J3ER%!)QG %9.B>-=#^*O@6ZU[X3^,K2=+A+BWL-6AC\V.*X3<FX
MJ<;@KC..C#!!P0:Y+X4_LO\ AKP3X@'Q)\>Z[=^,/&<@S+XBUG!\@\_+;1<K
M HR0,<@$@$ XH L?&;X;?&'XHZY:^&M ^)Z>&?"+VN=9DTJ)AJEU)N.8DE/R
MQ1E<?,/FSD$,#QU7PW^&_A'X3>#[7P+X'TYK73K3<8XWF:1F9B69V9B22S$D
M^Y[5NT4 %%%% !1110 45YM\1/VI/AIX(U<^#]#:[\4>)&)6+P]X:A^TSAO^
MFA7Y8P.^XY YP:3X:2_M+^*_%<7B_P"),>C^&-!6)Q%X4M5%U=2EE^5IKCA4
M*G!PG!Z$ \T :/Q7_:&^&_PANX=#UV[NK[6[M UAX>T>U:XO;D$D#;&O0$@X
M+$ X.,XKC_L7[5/QSYU*\C^&/AV7_EWM'%SK-PGN_"6^1Z8=3P0:]A_LG2CJ
MG]N'3+?[;Y A^V>2OF^7DMLWXSMR2<9QDFK% &7X+\*VG@CPM8^$['4KZ\AL
M81$ESJ5R9IY!DG+N?O'FM2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** (-2TW3M8L9=+U?3X+JVG0I/;7,0>.13U#*P(
M(]C6)\4-'^(NL>#Y;'X4>++/1-966-[>ZOK 7$+*IR8F7^$,!M+ $@$X&<$=
M%10!YW\'_B1\8];UVY\"_&;X02:/J%G:^<NNZ7<";2[X!@O[MB=\;G.1&V3A
M221P*\W_ ."E/_!.GX>?\%#_ (-VGAN\\177A'X@^$-0&L_"KXF:-E-1\*ZQ
M'AHYXG4AFB9D02Q9 =5!&UTC=?HRO+/B9^S_ .+M3\8W/Q4^#7Q=U7PUXBN$
MC%W:W,ANM,OMBA562W?(0[0!N7IR0N230!Q__!-?XM_MG_$_]G^;1OV^?@:_
M@_XE>#M<G\/ZUJ=K)$VF^*_LZILUFP"'<L$ZL#AE0!PX4 #:OT'7!^.8_BW-
M\ KJ*X^)>C>#O%SZ:@NO$UIHIU"UTZ4LOF20V\KKYK[=PC#EE\PJ620 QMW:
M@JH4L6('+'J?RH 6BBB@ HHHH **** "BBB@ HHHH **** "OQ!_X/>?^36?
M@?\ ]E U'_TA%?M]7X@_\'O/_)K/P/\ ^R@:C_Z0B@#S_P#X--O^4IG[7?\
MV\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBFS3P6Z"2XF1%+JH9V
M!9B%4<]R2 /4F@!U%%% !1110 4444 >%_M8?\EL^!__ &/<O_I,U>Z5X7^U
MA_R6SX'_ /8]R_\ I,U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<[",D="3@\9JYX,\">#/AWHR>'O _AFRTNS3_EA9P! Q_O,1RS?[1R3ZUK4
M<]\//A3\._A1I T3X>^$;/2X"!YA@CS)*1W>0Y9S[L370T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 (\:2+LD0,,]&&:6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\0?^#WG_DUGX'_]E U'_P!(17[?5^(/_![S_P FL_ __LH&H_\ I"* //\
M_@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "ODC_@
MJG\.?BOX@M?AY\3?AEHVA^.(/"7B&%]?^#&OS1QKXMM9]4TI1-:-*?*2]MY$
MCBC>9?)\O49T9XS(K5];UQGQ;_9[^#WQS?3;CXG^"H-1N=(DW:;?+*\-Q;H9
MH)Y(EEB97$4DEK;F2+.R3R4W [5P ?,VH^-_A]\1?$G[!_Q.^#&I>(D\,ZWX
MFO(]'BUJ\N$N9-/;P#KTD<=Y&[D23J88BS/N;>A(8YR9_C'\(_BG\-_^"C/@
MW]H[QIX9\)_$3P_XPU=_#W@Y4M+VQUSP)<1Z-=W$>PF[DM-1M)7MKMI"8(9H
M7NPX:1(\)]+ZE\!O@YJUYX0OKKX=:8K^ )1)X)6V@\F/0V%NUL#:I'M6'_1W
M>#"@#RG>/[C%2WPG^S_\%/ OCO5OB=X0^&.CZ?X@UR[DNM4U:WLU$TTT@42R
M9_A:38N\K@N5!;) - 'Q%_P3^\;?$.;Q+^R!XQ_M*YN==^+_ ,!_%&O?&EW#
M!]0U%&T6Y^U7*GD2VU[>SVL>?]4ET\0 4*J_H;7,^#O@W\*OA]K]_P"*?!/@
M'2],U#4VD-[=V=JJ.XDF>>11_<5YY))F5<*TLCR$%W9CTU !7E_Q6\*?M9ZO
MXN>\^#_Q7\+Z1HI@0)9:MH3W$PD ^=BX(X)Z"O4** /D+XN^&/VHM)^.7P>;
MXN_$_P -:O')XT(TY=*T1K<PR"$ER^2=P*Y 'K7U+]B\;_\ 0;LO_ 8_XUY'
M^UA_R6SX'_\ 8]R_^DS5[I0!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6
MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C6Q6?XJ\6>%O OAR\\8>-_$NGZ-I&G0-/J&J:K>);VUK$O
M5Y)9"%11W)( H K_ &+QO_T&[+_P&/\ C39;?QE!$T\^OV*(BEG=[? 4#J2<
M\"OAOXB_\%W/"OQ;\97WP/\ ^"3/[-GBC]IWQI:2FWO==\.C^SO!^C2GO=ZU
M< 0MC(8"+<L@!"R UCQ?\$FOVW?V^I5\1_\ !8_]M:ZN_#5PPD/[/GP,GGT7
MPRJ'GR+Z]R+O4EYY5BNUAE)"* .B_:'_ ."YWP(\!_$.;]GG]D6RUC]I+XL+
ME5\#_!K2CJ$-FP.W=?:B,VMI$K9#L&D:,CYT%<A+^Q7_ ,%FO^"C5L+S]OG]
MJ^T_9]^'MYS)\&_@1>[M8N83_P L=1UT@D'&5=+;=%(K=%-?<_[.W[+O[.O[
M)/P]@^%7[,_P7\.^"/#\&#_9WA[3$MUF<#'F2LHW32'O)(6<]R:[R@#Y]_8W
M_P""<'[,O[ 7A1O"?[)WP9\*^%//B":CK$.GM/J>H\YS<WLS///SSM=RH)^4
M <5[5]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_
MXUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\
M!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_
MXUL44 8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\
M!C_C1]B\;_\ 0;LO_ 8_XUL5X;^W9_P4._9K_P"">/PZL/'/Q[UZ_GU'7M13
M3O!_@OPU9?;M<\2WKLJBVL;12&F;+KEB51=R@L"RA@#9_:A_:9^'?[&7P4UG
M]H3]I3XQ:)X7\*:'#ON]0OH3ND<@[((8UR\TSD82) 68]!7P=X*_9S_:\_X+
MN^(=+^/'[<NB:G\-?V8-/OH]0^'GP'NR]MJ7C@(P:'5-?\M@4MSA7CM W/!Z
M 2S?>?QO_8__ &7_ -K[7OAY\2_C_P#!RT\37GP^U5M<\&0Z_#*$L+N6(*7E
MM6(21@ C!9D;8\:L K+FO5Z .:\.^$-7\(Z!9>%/"@T?3-+TVTCM=.TW3]-6
M&"U@C4*D4<:85$50%"J    !5W[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@
M,?\ &C[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_
M !K8HH Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@
M,?\ &C[%XW_Z#=E_X#'_ !K8HH Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_
M !K8KDOBO\<OA;\$K"WO_B5XKBT_[87%E!Y3RS7)7&0B("S8W+DXP-PR1F@#
M5^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&L;X0?&!/C!:7VJV7P_P#$6BV5
MM(BV=QX@T_[,;Y6!)>)222HQU/J*Y?QC^SGX[^)WBB_NOB!^T)XA7P]+<,;'
MPWX>1+!4A[1S3)EYAZYQ]: .O\8:_KG@3PO?^,?$GB*WBL--MFGNY(M.DE94
M49)"H"Q_ 5Y_X ^/'QE^*/BJTM?"7P<UFV\.R.?M?B37[5+$*FT[7BA=B\H+
M8&1VSQ7KOAOP_IOA3P]8^%]&21;/3K2.VM5EF:1A&BA5!9B68X Y))J[0!P7
MB#X):7XK\<Z?\2/$VEZ1?ZQI=L8-/NKNT9Q N[=E4)V[@22&QN&>"*Z7[%XW
M_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8I&DC1E
M5Y%!<X0$_>."<#UX!/X4 9'V+QO_ -!NR_\  8_XU7U6Y\1:%I\NK:WXMTNS
MM($W3W-T@CCC7U9F( 'UK%^+GC#XSZ3?V?ACX.?#2WU2ZOH6>36]5O1%8V&"
M!^\5?GD/(.U<$CIG! YC2OV5)/&.H1>)OVDO'UYXSOHW\R'2>;?2K5O1($QO
M(Z;F^\.JT =?H'B;7?'WA)O%'PX\;:-J4,R3+8W2P,87E0LF#CG:'7!QVY':
MO/9_V8/B=\49X]5_:+^*:ZRBL'7PSI8DM],B(Y (7:TV#T9L'MS7MNF:7IFB
M6$6E:-IT%I:P)L@MK6%8XXU]%50 !["IZ .9\.^#=5\(Z3%H/A8:1IUE ,16
MMEIPBC7Z*N!GW[U>^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[
M%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK
M8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_
M (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E
M_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-
M_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MB
MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MKZ;'J,5J$U2XCEEW'+Q)M&.W%6*** "OQ!_X/>?^36?@?_V4#4?_ $A%?M]7
MX@_\'O/_ ":S\#_^R@:C_P"D(H \_P#^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_
MX--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** /"_P!K#_DMGP/_
M .Q[E_\ 29J]TKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHKRS]J[]MS]DS]ASP&?B3^UA\>_#O@C2RK&U_M>]_TF
M]*C)2VMD#37+C^Y$CM[4 >IURGQG^.GP8_9S\ W?Q3^/?Q4\/^#O#E@/]*UK
MQ)JL5G;H<$A-\K ,YP<(,LQX )KX2_X>-?\ !3O_ (*)#^R?^"5W[&Q^'G@2
M[^5?C[^T-:O90S1'_EMIFCIF>ZR,M'-)F(G =$KJO@Q_P0;^!-[X_M/V@O\
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M 02#G(.>@KT\  8 P!T HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW+,GLW[#/[!7[.'_  3R^"D'P1_9R\(M:6[S?:M?U[49?/U3Q!?L/WE[?7!
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MSJ=MK6L>&M/N[RS!%I=W-FDDL )!.QF!*Y(!X/85?HH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y3XT?';X+?LY>
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ML(^6:5HWP2&#"ON/X+_ CX*_LX^ K7X7? +X4>'O!OAVR'^C:-X:TF*SMU;
M!<I$H#.<<N<LQY))H ^%&_8:_P""O'_!1(?;O^"BG[7T'P,^'UYS+\%?V>+H
MIJ%S"?\ ECJ.O2;G)(RLD=N&AD#'&VOK']CK_@GK^QE^P)X0/@[]DW]G_0?"
M231A-0U2VMS-J6HXYS<WLQ:>?GG#N0"> *]FHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OQ!_P"#WG_DUGX'_P#90-1_](17[?5^(/\ P>\_\FL_ _\ [*!J/_I"
M* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
M0?\ @]Y_Y-9^!_\ V4#4?_2$5^WU?B#_ ,'O/_)K/P/_ .R@:C_Z0B@#S_\
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M 0RQZA=!A=:FP[@L-C [)&4XK[:^$?AK]FS]G;2=&_9B^".C>%?"5GIUH_\
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M,TB+0/"7A^STRQA'[JTL+98HU]]J@#/OWJ_110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7X@_\ ![S_ ,FL_ __ +*!J/\
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M=_P7,^ _A?XDW/[,W["/PUU[]IKXQ1Y1_"'PO99--TI\[=^IZN0;6SC# JS
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_$'_@]Y_P"36?@?_P!E U'_ -(1
M7[?5^(/_  >\_P#)K/P/_P"R@:C_ .D(H \__P"#3;_E*9^UW_V\?^GR>OW^
MK\ ?^#3;_E*9^UW_ -O'_I\GK]_J "ODC_@JG\.?BOX@M?AY\3?AEHVA^.(/
M"7B&%]?^#&OS1QKXMM9]4TI1-:-*?*2]MY$CBC>9?)\O49T9XS(K5];UQGQ;
M_9[^#WQS?3;CXG^"H-1N=(DW:;?+*\-Q;H9H)Y(EEB97$4DEK;F2+.R3R4W
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M_P !C_C7D?[6'_);/@?_ -CW+_Z3-7NE &/]B\;_ /0;LO\ P&/^-'V+QO\
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M$/\ ;F\-:C9Z3^SK^SIX8\8BVD$ESJ'B>*0V[(R9VPB$,Z.&&"2I&.E?3E%
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6
MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%
M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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MX:Y^.'_1C/CO_P "8*]ZHH \%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\
M F"O>J* /!?^&N?CA_T8SX[_ / F"LSQA^W)\5? WAB]\7>)/V+/&5E86$)E
MNKJ[OH4CC7.,LP!P.?0U]&UY1^W/_P FC^/?^P"__H:T <KIW[8_QGU33X-3
MLOV'_'$D-Q"LL4D=W 5=6 ((..00:G_X:Y^.'_1C/CO_ ,"8*]=^%W_),_#O
M_8"M/_1*5NT >"_\-<_'#_HQGQW_ .!,%'_#7/QP_P"C&?'?_@3!7O5% '@O
M_#7/QP_Z,9\=_P#@3!1_PUS\</\ HQGQW_X$P5[U10!X+_PUS\</^C&?'?\
MX$P4?\-<_'#_ *,9\=_^!,%>]44 >"_\-<_'#_HQGQW_ .!,%'_#7/QP_P"C
M&?'?_@3!7O5% '@O_#7/QP_Z,9\=_P#@3!1_PUS\</\ HQGQW_X$P5[U10!X
M+_PUS\</^C&?'?\ X$P4?\-<_'#_ *,9\=_^!,%>]44 >"_\-<_'#_HQGQW_
M .!,%'_#7/QP_P"C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_P#@3!1_PUS\</\
MHQGQW_X$P5[U10!X+_PUS\</^C&?'?\ X$P4?\-<_'#_ *,9\=_^!,%>]44
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M-<_'#_HQGQW_ .!,%>]44 >"_P##7/QP_P"C&?'?_@3!1_PUS\</^C&?'?\
MX$P5[U10!X+_ ,-<_'#_ *,9\=_^!,%'_#7/QP_Z,9\=_P#@3!7O5% '@O\
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MXRS ' Y]#5S3OVQ_C/JFGP:G9?L/^.)(;B%98I([N JZL 00<<@@UU7[<_\
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MVS0Q+<JW7;<J#TH ]EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_&32Z1I-[%:#2=7\))H:W$DMM= ><^K1WCQF2S+[U@D67R3 WVB@#[ HHHH
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M;1)#$R3Q37A4N?+"L ?9U%163W<MG#)?P)%.T2F:)'W*CXY .!D YYP,U+0
M4444 %%%% !1110 4444 %%%% !7X@_\'O/_ ":S\#_^R@:C_P"D(K]OJ_$'
M_@]Y_P"36?@?_P!E U'_ -(10!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!I
MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
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M:>[N9YGGN;J>5R6FGFGEEFDD8EGDD9CR:ZFBB@ HHHH **** "BBB@ HHHH
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MJ&H:[;VPOC+Y82-!(X/FDS1*8_OAI%4@$@5Z90 4444 %%%% !1110 4444
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M,ZHM\I\SFW+NJB8?(68#.2*[9'21!)&X96&58'((]: %HHHH **** "BBB@
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MK/A7QCINKW$3+IVI:7.T-UMG0^7+!\HD248RC#<J,&1?*OA?_P %2O"?Q,^
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MX*=+_P#B*^_J* /@'_AS]^W7_P!)Z?V@/_!3I?\ \11_PY^_;K_Z3T_M ?\
M@ITO_P"(K[^HH ^ ?^'/W[=?_2>G]H#_ ,%.E_\ Q%'_  Y^_;K_ .D]/[0'
M_@ITO_XBOOZB@#YP_8A_8F_:$_97\5:YX@^,_P#P43^)'QJM=5T^.WLM+\<6
M=I%%ILBON,T1@4$LP^4YXQ6O^WU\%/BI\<O"7PZTGX4:!:7UQX9^,_A;Q7JR
MWNI+;*+#3-1BNYUC)!WS,J;44X4D_,Z#D^\44 ?%WAK]C'XZZ1\9_#_C\> M
M'@AL/VN-:^(]]=Q:K$)6T.\\-:CI$8X7+7/FWL;M%G:(XVQ(S;5/!Z+_ ,$_
M?VS_  =\"_ 7P^L/"'@G4-3T']F?QC\)-4QXRFCB22^;2VL]35FLLNC?V?*'
MAP&0RQ?,07*?H;10!\'^,OV#OVI?$>D>/([;PWX7CU#5_AU\)-/TE/\ A)'^
MSW.H^%=:N=2OHFD^S[XXY4G2*&4QDED8NB +N[#QW^Q-\9_BK9_M(W&H66D>
M'M=\>^)_#OBSX5:S!J7VD:9KVCZ1IL=G<2XC1E6/4=-1C@9DMWP0A9D'V!10
M!\=?'7]CO]H>\\1^ _%GAOP3X8^(MC<>"?$'ASXK>#=9\>:AX>MKJXUJYM;R
MZOH)K:&;S;<S0S126LD9W0R1;<F+:WL_QL^#VKZ[\!_#_P $--^"W@GQQX8"
MV^E^-O!?B,^58WVC)9RQM';+/'.ID6=;9HXY3@A"&E0_O!Z]10!\*_"3]@3]
MHSX!6?PYU#X;6EOJ6A?#WX]ZMXD\&_#KQ/XYGF?PSX5OO#-YI":9'J$D4S/Y
M%W=278BPZQPS-"DDAB0N[]DS]CGXN_LVZQX/^('[1W@7PW)H_@3X!:IX?UJ^
MT34Y+^6*Z_MG^TT:%!;K,RB&($F,%Q,%"*^ ]?=%% 'Y)_LY?"WQ)^T_^QMX
MZ_9Z^'>@>$/$'B[Q!^R /A?X4\1^&?BYIVN:7I-G!;S0V=O?_9K>*:WDWZBS
M>;(KLZ6;!45UD:7[ \)?L]_M-Z%\?OB!/K/PE^&_B7PEXT\;V?COPWXH\7:B
M]Q?^%M2CT.STU[(V(MV69T-F1%<Q7$>R*ZDZF,)+]5)%%%GRHU7<Q9MHQD^O
MUIU 'YP:3_P3S_;:/PO\>:%K?@#P1:ZAXN^#WPU\-P6>E>,V-K:ZCX=UG4;F
MY2&%;"&&TLC;7B+!%"H""%%*%GD=?NGX5_$3XB^--?\ &>F>-?A4FA6GA_Q#
M]B\/7]OK7VM=;M?L\4GGD&*(02+([Q/&IE16CP)6;>J=M10!\-?!K]BC]HKP
MEKWPOU3QK\.M&EB\'_M2?$+XD:HD.MPS%=,UR/Q%]B2+<JAKF.36;<NIVJOV
M:1E=CL#8W[.?["_[7?P0@T'PYX@^$'PS\:>&_$'PJL?!?C#PYXLUUI+3P_-I
M^MZM?VU[!#]DD2_MY8=4"R6Y$+^98VXWA?GC^_J* ,;P;JGCK5#JW_"<>$+'
M2/L^M3P:/]AUDWGVVQ7;Y5S)F&/R)'RV81O";1^\;/&S110 4444 %>(?MO?
MLK_&?]JCPKH>@?!C]M;QQ\%;K2M0DN+W5/ ]K;2RZE&R;1#*)P0%4_,,<YKV
M^B@#X!_X<_?MU_\ 2>G]H#_P4Z7_ /$5[?\ L0_L3?M"?LK^*M<\0?&?_@HG
M\2/C5:ZKI\=O9:7XXL[2*+39%?<9HC H)9A\ISQBOH^B@#Y0_:\_X)[?M1?M
M'?&2?XF?"C_@JA\6/A+I$NGP6Z>#_"%A8R64<D8(:8&92VY\Y/;BO,/^'/W[
M=?\ TGI_: _\%.E__$5]_44 >7_LA_ ?XE?LX_!N#X9_%?\ :9\4?%K5XM0G
MN'\8>+X(8[V2.0@K"1" NU,8'?FOF#Q9_P $EOVW?$/BK4]?TO\ X+E?'C2K
M6^U":XMM+M-+TTQ6<;N66%"4R50$*,\X K[OHH ^ ?\ AS]^W7_TGI_: _\
M!3I?_P 17U]\4O@_X[\??LXWWP4\,_'KQ!X8\0W?A^+3X/B)I<43:E;3JJ W
MBJXV>:Q4D@C&7->@44 ? /\ PY^_;K_Z3T_M ?\ @ITO_P"(KV_]B']B;]H3
M]E?Q5KGB#XS_ /!1/XD?&JUU73X[>RTOQQ9VD46FR*^XS1&!02S#Y3GC%?1]
M% 'GOQV\)^,/%.L^ KCPOX8BU*WT?QK'J&MK->1Q".S^Q7=NQ4/_ *Q]UPAV
M< JK?,#@-X'\,OV(/CK^QOXD^+,G[*GB+3]0\(ZYX5BA^#O@[5+@0CP7J,US
M=2W=LCLK*=-269+F"'!,9>6 !8Q'CZ^HH ^3M _8H\?_ +/7[7_PM^-?[.?V
M_4?#5OX N/ _Q-LO%/B97F71XFBGTJ2W&P^=/:W/VG(9E!CO9R&9B <3X4?L
M6?%CPM^UCX2_:[TSX1Z'\.?%7]BWX^.\7@3Q06TGXD74EDR6P%F8XD:=+LBX
M^V3)%*@0P[IUD+I]F44 ?!7@/_@G[^U+XY_X)L_#C_@FU\7M)\*^&]#TP:5;
M_$KQ'8^(I+ZXN[&RU".^:VTZ$6Z+NN&A2%IIG3R4=V6.5MN.Q_:H_8>^,'[4
MGPD^+'B:[U"_\/\ Q*U#4[:\^%,=IXBC:QT^XT:1;GP_/*PCRH2]#W4R@$J;
MJ>-3(NTM]B44 ?(>I^$/C[^RK\6_&_\ P4)MO@#JGC:Z^(7PUT"T^)GPO\!7
ML-WJ]GK&C_:UBGTLW#0QWUN\5[*CQEXY@+>)HXY7D:)=[]BS]F[PCK'[./Q2
MO/$7BVTU2?\ :"\8ZYXG\9QZ%)*D>EOJ=I#9C3X_/CCF22WLK>VB<RQ1R&9)
M&:*/=Y:_3U% 'SW^Q5\/_P!JC]GGX ^"?V4_'_@_PW?)\/=#L?#MGX^L=:;[
M-JVE64:6\%P;,QB6&\>"--\.XQ+)O*S.H56\5TG_ ()[_M''X7>"OAGXI;2;
MK4/A/9^/8=.\4PZOE_&4>MVE];6L4Z,@:#?]LBN;LN2!<6<9C\\-O3[NHH _
M/7X@_P#!.O\ :-\1_"'QGX)T'X<^&X=3UW]C_P ,_##3)WUB)$AUO3Y[^29R
MRH66US>1,D@!<F%LQJ0N6?"WX%2_M4_''XR:)H?AC2+%_"O[:>A>+[WQ>E];
MR7>G_P!EZ'X?N7LT5 7\Z5DDM#SY?E75R2^Y?+D_0VH;73M/L7DDLK"&%IFW
M2M%$%+GU..IY/YT ?!WAG_@G'\>+KX+_  W^%'Q1T'1=8G^$7PH\3>")[ZW\
M57%FWCVWU%+6WB+W$*">R\R&V6YGD)+Q7BQF/S@OFGLOA=^R1^U-X<^*/P?\
M4>/_ !&_BK3_  +\2O$>JRZUXDN[,:\FC7F@R:=9Q7LEK&L5_>)+)AYEP3!'
M&6:253N^Q:* /SJ^''_!.W]KOP1\+?AI\)?'WPG^'_COPY;_  $TKX6>._#%
M]\3-3LK*W_LUY1%JRK#:@7T%RD\@FLW57 AM]LA^?;^B5O%Y%ND .=B!<C/8
M>Y)_4T^B@ HHHH **** //OB-\'?'GC7Q*^N>'_C[XA\.VS0H@TW388FB4@<
MMEAG)[UA?\,X?%?_ *.V\8?^ \'^%>O44 8/PY\):WX*\-+H?B#QS?\ B*Y6
M9W.I:DBK*P)X7"\8':N$U#]GGXI7E_/>6_[57BVWCEF9T@CMX-L8))"C(Z#I
M^%>LT4 >0_\ #.'Q7_Z.V\8?^ \'^%>C:]X;U;5_!4OA>Q\6WEA>26:PKK-N
MJF=' &90#QN./UK8HH \A_X9P^*__1VWC#_P'@_PK1\(? OXC^'/$MGKFK?M
M*>)]6MK:8/-IMY!"(K@8^ZQ49Q]*]-HH Y;XI> /$WCZPM;/PS\4-5\+R6\S
M/+/I4:,TX(QM;>.@ZUQ7_#.'Q7_Z.V\8?^ \'^%>O44 8/PY\):WX*\-+H?B
M#QS?^(KE9G<ZEJ2*LK GA<+Q@=J^</\ @H7^Q]XH_:\CU3PWJ'P)T#6)-.\.
MQR_"/XAZ=XMDT?Q%X.\2L;D/=I=1Q>;;VRXLGW022LY21'MW4+GZMHH _/GX
M\?L!_M__ !:^(VHZO=>//#FI^*?#<WA;6/@=\9KO79;:3PCJ%AIR6^J0SZ6M
MNZRQ7]P;UYEC<"X@O5BD9?LT.WK/$_[*?[37Q,^!OP)\ >)_V>_"?AZ7X>_&
M/3O$OBO2='\=F\6ZM8;>]6]O%N3:VQDN[FZO7G";%SAW>57?8/MJB@#EO#7P
MY\,?!+X8W'@[X _#'0=,AL;>ZN-'\.V873K.>\D+RGS'BB?R_-F8M)-Y;MEV
M<J[9!^8_B3^P)XS^-=YXJ^/T7@;P]X#\<Z[KO@#Q%#X8M-7-S9WFK>%]9DU1
M9[ZXB@16ENED^Q-*L;LD4$+DN0L4?V+10!\<V'[!WQ-TK]JW_AO^.SLY_%MW
M\4[W7+WP=_:"@)H4WA:U\/QVB3D>7]K4V-M>,3^[_>30J[ )*>O\)_L?_$#X
M6_\ !,[Q9^REH<UAJ_C#Q+X;\6/.T5T8K(ZQKUU?WLX65U#"WCN=0D <IO,<
M8.S<=E?2]% 'Q;X8_8)\4>"/&7[)'C7P1\ _!^C7_P (_M!^)E_I1M+>XF\W
MPS>:1B!XXP;H?:+E9SO*?NUS@N=@XWX:?L'_ +8/@KX V'@36O@W\--5\=?#
MW0]#\+Z!X^U;QO>ZI/XIT>QUS3;QYXX+ZUD@T>Y,%AYZ I<(FH")U"QQY?\
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M -IG0_BI9>)M5\5O!>6UC%!:17&F2P+:RYN+=;=HHI$D,<D/EJ3&5(K[@HH
M^&OV?OV(_P!H'P'\*;[X8?&G]GWX?^+=6T#X?WOP_P!(\;:GXYO]3;Q3HEY<
M0"22XL+F-8[*-H(4FN;59'$]Q&%1XT/F#W+]@3X)_%S]FCX17_[//Q)DCU/2
M_"OB"[A\$>+9M1$^H:]H\DK2PS:D JXODWM')(,B8(DIVM(\:>YT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7X@_\'O/_)K/P/\ ^R@:C_Z0BOV^
MK\0?^#WG_DUGX'_]E U'_P!(10!Y_P#\&FW_ "E,_:[_ .WC_P!/D]?O]7X
M_P#!IM_RE,_:[_[>/_3Y/7[_ % !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^(
M/_![S_R:S\#_ /LH&H_^D(K]OJ_$'_@]Y_Y-9^!__90-1_\ 2$4 >?\ _!IM
M_P I3/VN_P#MX_\ 3Y/7[_5_)[_P2[_X+"_#;_@CW_P4#_:*^)'Q(^#NN>,8
M/&.N7^FVUMH=_# ]N\6K3REV,HP00<8%?H)_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_
M$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(
MWG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6
M?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!
M_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16
M/^%'_$;S^RS_ -&/?$#_ ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%
M'_$;S^RS_P!&/?$#_P **Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_
MLL_]&/?$#_PHK'_"@#]OJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T
M8]\0/_"BL?\ "@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_ -&/?$#_
M ,**Q_PH _;ZBOQ!_P"(WG]EG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P *
M*Q_PH _;ZBOQ!_XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"@#]O
MJ*_$'_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\ "@#]OJ_$
M'_@]Y_Y-9^!__90-1_\ 2$4?\1O/[+/_ $8]\0/_  HK'_"O@/\ X+Z?\%]/
MA%_P6$^$7@#X;_#?X ^)/!T_@[Q)=:E<W.N:G;SI<)+;B((HB&001G)H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525189760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 07, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Intuitive Surgical, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">State or Other Jurisdiction of Incorporation or Organization</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">I.R.S. Employer Identification No.</a></td>
<td class="text">77-0416458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1020 Kifer Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">523-2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of Each Class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ISRG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,389,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part III incorporates information by reference to the definitive proxy statement for the Company&#8217;s Annual Meeting of Stockholders to be held on or about April&#160;27, 2023, to be filed within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001035267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525121296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527118784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">DESCRIPTION OF THE BUSINESS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intuitive Surgical, Inc. (&#8220;Intuitive&#8221; or the &#8220;Company&#8221;) develops, manufactures, and markets the da Vinci</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Surgical System and the Ion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> endoluminal system.&#160;The Company&#8217;s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, and a high-performance vision system and use proprietary instruments and accessories.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683526104768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,581.2<span></span>
</td>
<td class="nump">$ 1,290.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">2,536.7<span></span>
</td>
<td class="nump">2,913.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $22.4 and $20.2 as of December 31, 2022, and 2021, respectively</a></td>
<td class="nump">942.1<span></span>
</td>
<td class="nump">782.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">893.2<span></span>
</td>
<td class="nump">587.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">299.8<span></span>
</td>
<td class="nump">271.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,253.0<span></span>
</td>
<td class="nump">5,844.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">2,374.2<span></span>
</td>
<td class="nump">1,876.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">2,623.6<span></span>
</td>
<td class="nump">4,415.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">664.6<span></span>
</td>
<td class="nump">441.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_IntangibleAndOtherAssets', window );">Intangible and other assets, net</a></td>
<td class="nump">710.1<span></span>
</td>
<td class="nump">633.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">348.5<span></span>
</td>
<td class="nump">343.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,974.0<span></span>
</td>
<td class="nump">13,555.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">147.0<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">401.6<span></span>
</td>
<td class="nump">350.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">397.3<span></span>
</td>
<td class="nump">377.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">476.2<span></span>
</td>
<td class="nump">301.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,422.1<span></span>
</td>
<td class="nump">1,149.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">439.3<span></span>
</td>
<td class="nump">453.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,861.4<span></span>
</td>
<td class="nump">1,603.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2022, and 2021</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 600.0 shares authorized, $0.001 par value, 350.0 shares and 357.7 shares issued and outstanding as of December 31, 2022, and 2021, respectively</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">7,703.9<span></span>
</td>
<td class="nump">7,164.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">3,500.1<span></span>
</td>
<td class="nump">4,760.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(162.5)<span></span>
</td>
<td class="num">(24.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Intuitive Surgical, Inc. stockholders&#8217; equity</a></td>
<td class="nump">11,041.9<span></span>
</td>
<td class="nump">11,901.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest in joint venture</a></td>
<td class="nump">70.7<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">11,112.6<span></span>
</td>
<td class="nump">11,951.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,974.0<span></span>
</td>
<td class="nump">$ 13,555.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_IntangibleAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges and other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_IntangibleAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683526126752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000.0<span></span>
</td>
<td class="nump">600,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="nump">357,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="nump">357,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683524916368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 6,222.2<span></span>
</td>
<td class="nump">$ 5,710.1<span></span>
</td>
<td class="nump">$ 4,358.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">2,026.2<span></span>
</td>
<td class="nump">1,751.6<span></span>
</td>
<td class="nump">1,497.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,196.0<span></span>
</td>
<td class="nump">3,958.5<span></span>
</td>
<td class="nump">2,861.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,739.9<span></span>
</td>
<td class="nump">1,466.5<span></span>
</td>
<td class="nump">1,216.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">879.0<span></span>
</td>
<td class="nump">671.0<span></span>
</td>
<td class="nump">595.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,618.9<span></span>
</td>
<td class="nump">2,137.5<span></span>
</td>
<td class="nump">1,811.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,577.1<span></span>
</td>
<td class="nump">1,821.0<span></span>
</td>
<td class="nump">1,049.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">69.3<span></span>
</td>
<td class="nump">157.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">1,606.8<span></span>
</td>
<td class="nump">1,890.3<span></span>
</td>
<td class="nump">1,207.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">262.4<span></span>
</td>
<td class="nump">162.2<span></span>
</td>
<td class="nump">140.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,344.4<span></span>
</td>
<td class="nump">1,728.1<span></span>
</td>
<td class="nump">1,066.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to noncontrolling interest in joint venture</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Intuitive Surgical, Inc.</a></td>
<td class="nump">$ 1,322.3<span></span>
</td>
<td class="nump">$ 1,704.6<span></span>
</td>
<td class="nump">$ 1,060.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share attributable to Intuitive Surgical, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">355.7<span></span>
</td>
<td class="nump">356.1<span></span>
</td>
<td class="nump">351.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">362.0<span></span>
</td>
<td class="nump">365.8<span></span>
</td>
<td class="nump">361.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net income attributable to noncontrolling interest in joint venture</a></td>
<td class="nump">$ 22.1<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,198.0<span></span>
</td>
<td class="nump">4,793.9<span></span>
</td>
<td class="nump">3,634.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">1,700.3<span></span>
</td>
<td class="nump">1,464.1<span></span>
</td>
<td class="nump">1,230.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,024.2<span></span>
</td>
<td class="nump">916.2<span></span>
</td>
<td class="nump">723.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">$ 325.9<span></span>
</td>
<td class="nump">$ 287.5<span></span>
</td>
<td class="nump">$ 266.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527712880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,344.4<span></span>
</td>
<td class="nump">$ 1,728.1<span></span>
</td>
<td class="nump">$ 1,066.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation gains (losses)</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale securities (net of tax):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains (losses)</a></td>
<td class="num">(138.2)<span></span>
</td>
<td class="num">(45.5)<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: Reclassification adjustment for gains on securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(138.2)<span></span>
</td>
<td class="num">(45.5)<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Hedge instruments (net of tax):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Change in unrealized gains (losses)</a></td>
<td class="num">(35.0)<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Less: Reclassification adjustment for (gains) losses on hedge instruments</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans (net of tax):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Change in unrealized gains</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Less: Reclassification adjustment for losses on employee benefit plans</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(140.1)<span></span>
</td>
<td class="num">(49.8)<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">1,204.3<span></span>
</td>
<td class="nump">1,678.3<span></span>
</td>
<td class="nump">1,079.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: comprehensive income attributable to noncontrolling interest</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Intuitive Surgical, Inc.</a></td>
<td class="nump">$ 1,184.0<span></span>
</td>
<td class="nump">$ 1,655.5<span></span>
</td>
<td class="nump">$ 1,073.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527137824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements Of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)/Income</div></th>
<th class="th"><div>Total Intuitive Surgical, Inc. Stockholders&#8217; Equity</div></th>
<th class="th">
<div>Total Intuitive Surgical, Inc. Stockholders&#8217; Equity </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Noncontrolling Interest in Joint Venture</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balances (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">347.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 8,284.7<span></span>
</td>
<td colspan="2" class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 5,756.6<span></span>
</td>
<td class="nump">$ 2,494.5<span></span>
</td>
<td colspan="2" class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="nump">$ 8,263.8<span></span>
</td>
<td colspan="2" class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock through employee stock plans (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock through employee stock plans</a></td>
<td class="nump">308.8<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.8<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards</a></td>
<td class="num">(175.2)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(167.3)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175.2)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to employee stock plans</a></td>
<td class="nump">395.4<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.4<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(134.3)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">126.4<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,060.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">13.0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest in joint venture</a></td>
<td class="nump">6.2<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balances (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">353.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">9,759.1<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">6,444.9<span></span>
</td>
<td class="nump">3,261.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">9,731.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock through employee stock plans (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock through employee stock plans</a></td>
<td class="nump">276.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards</a></td>
<td class="num">(211.6)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(205.0)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211.6)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to employee stock plans</a></td>
<td class="nump">449.2<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449.2<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,704.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,704.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,704.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(49.8)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest in joint venture</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balances (shares) at Dec. 31, 2021</a></td>
<td class="nump">357.7<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">357.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 11,951.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">7,164.0<span></span>
</td>
<td class="nump">4,760.9<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(24.2)<span></span>
</td>
<td class="nump">11,901.1<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock through employee stock plans (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock through employee stock plans</a></td>
<td class="nump">233.8<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233.8<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement of equity awards</a></td>
<td class="num">(194.2)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(186.8)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194.2)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to employee stock plans</a></td>
<td class="nump">524.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(2,607.4)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211.1<span></span>
</td>
<td class="nump">2,396.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,607.4)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,322.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322.3<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(140.1)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(138.3)<span></span>
</td>
<td class="num">(138.3)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest in joint venture</a></td>
<td class="nump">$ 22.1<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balances (shares) at Dec. 31, 2022</a></td>
<td class="nump">350.0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 11,112.6<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 7,703.9<span></span>
</td>
<td class="nump">$ 3,500.1<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (162.5)<span></span>
</td>
<td class="nump">$ 11,041.9<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.7<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Represents the adjustment related to the adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">redit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683520773856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,344.4<span></span>
</td>
<td class="nump">$ 1,728.1<span></span>
</td>
<td class="nump">$ 1,066.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment', window );">Depreciation and loss on disposal of property, plant, and equipment, net</a></td>
<td class="nump">338.0<span></span>
</td>
<td class="nump">282.8<span></span>
</td>
<td class="nump">226.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Loss (gain) on investments, accretion of discounts, and amortization of premiums on investments, net</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="num">(55.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(185.3)<span></span>
</td>
<td class="num">(62.6)<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">513.2<span></span>
</td>
<td class="nump">449.2<span></span>
</td>
<td class="nump">395.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract acquisition assets</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(142.3)<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(546.6)<span></span>
</td>
<td class="num">(256.0)<span></span>
</td>
<td class="num">(170.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="num">(129.2)<span></span>
</td>
<td class="num">(204.9)<span></span>
</td>
<td class="num">(111.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
<td class="num">(32.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="nump">115.1<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">121.7<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,490.8<span></span>
</td>
<td class="nump">2,089.4<span></span>
</td>
<td class="nump">1,484.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(1,399.5)<span></span>
</td>
<td class="num">(6,452.0)<span></span>
</td>
<td class="num">(4,292.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of investments</a></td>
<td class="nump">61.1<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
<td class="nump">800.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">3,254.4<span></span>
</td>
<td class="nump">4,267.8<span></span>
</td>
<td class="nump">2,930.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(532.4)<span></span>
</td>
<td class="num">(339.5)<span></span>
</td>
<td class="num">(341.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash, and intellectual property and other investing activities</a></td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,370.8<span></span>
</td>
<td class="num">(2,461.5)<span></span>
</td>
<td class="num">(940.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock relating to employee stock plans</a></td>
<td class="nump">233.8<span></span>
</td>
<td class="nump">276.5<span></span>
</td>
<td class="nump">308.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(194.2)<span></span>
</td>
<td class="num">(211.6)<span></span>
</td>
<td class="num">(175.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(2,607.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(134.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of deferred purchase consideration</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(85.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(2,572.3)<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="num">(85.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">294.7<span></span>
</td>
<td class="num">(332.5)<span></span>
</td>
<td class="nump">455.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">1,306.0<span></span>
</td>
<td class="nump">1,638.5<span></span>
</td>
<td class="nump">1,182.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">$ 1,600.7<span></span>
</td>
<td class="nump">$ 1,306.0<span></span>
</td>
<td class="nump">$ 1,638.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Gain (Loss) on Disposition of Property Plant Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522364880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of the Company and its wholly and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the results and balances of the Company&#8217;s majority-owned joint venture (&#8220;Joint Venture&#8221;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;). Chindex Medical Limited (&#8220;Chindex&#8221;), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders&#8217; equity. The noncontrolling interest&#8217;s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Split</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued pursuant to the three-for-one stock split (the &#8220;Stock Split&#8221;) of the Company&#8217;s issued and outstanding common stock, par value $0.001 per share, were distributed on October 4, 2021, to stockholders of record as of September 27, 2021. All share and per-share information presented in the Consolidated Financial Statements have been retroactively adjusted to reflect the Stock Split.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management&#8217;s most significant, complex, and subjective judgments include the valuation and recognition of investments, the standalone selling prices used to allocate the contract consideration to the individual performance obligations, the valuation of inventory, the valuation of and assessment of the recoverability of intangible assets and goodwill, the recognition and measurement of current and deferred income taxes, including the measurement of uncertain tax positions, and the estimates for legal contingencies. Actual results could differ materially from these estimates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company&#8217;s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are primarily derived from billings related to revenue arrangements with customers and distributors located throughout the world. The Company performs credit evaluations of its customers&#8217; financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. As of December&#160;31, 2022, and 2021, 60% and 67%, respectively, of accounts receivable were from domestic customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, domestic revenue accounted for 67%, 67%, and 68% of total revenue, respectively, while outside of the U.S. (&#8220;OUS&#8221;) revenue accounted for 33%, 33%, and 32%, respectively, of total revenue for each of the years then ended.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions, including materials shortages and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the Company has experienced increased difficulties in obtaining a sufficient supply of a number of component materials used in its products, such as semiconductor components as well as a range of other materials including, but not limited to, metals and polymers, as global supply has become significantly constrained due to increased demand for certain materials. Additionally, prices of such materials have increased due to the increased demand and supply shortage. With rising interest rates, access to credit may become more difficult, and any insolvency of the Company&#8217;s key suppliers, including sole-source and single-source suppliers, may exacerbate current supply chain challenges. The Company is engaged in activities to seek to mitigate supply disruptions by, for example, increasing its communications with its suppliers and modifying its purchase order coverage and inventory levels. However, the global supply chain shortages will remain a challenge for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such global shortages in important components as well as certain logistics challenges have resulted in, and will continue to cause, inflationary cost pressure in the Company&#8217;s supply chain. To date, the inflationary cost pressure has been more pronounced in the Company&#8217;s logistics costs, but these supply chain challenges have not materially impacted the Company&#8217;s results of operations or ability to deliver products and services to its customers. However, if shortages in important supply chain materials in the semiconductor or other markets or logistics challenges continue, the Company could fail to meet product demand, which could result in deferred or canceled procedures. Additionally, if inflationary pressures in logistics or component costs persist, the Company may not be able to quickly or easily adjust pricing, reduce costs, or implement countermeasures. Additionally, there is uncertainty surrounding the impact of any monetary policy changes taken by the U.S. Federal Reserve and other central banks to address the structural risks associated with inflation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in labor availability globally, including labor shortages and staff burnout and attrition, could also impact the Company&#8217;s ability to hire and retain personnel critical to its manufacturing, logistics, and commercial operations. The Company is also highly dependent on the principal members of its management and scientific staff. The loss of critical members of the Company&#8217;s team, or its inability to attract and retain qualified personnel, could significantly harm its operations, business, and ability to compete.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitals are also experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, rising interest rates make access to credit more expensive, unrealized losses decrease available cash reserves, and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. To the extent macroeconomic conditions remain challenging, it is likely that hospitals&#8217; spend on capital equipment will be adversely impacted. In addition, as competition progresses in various markets, longer selling cycles and pricing pressures are likely to result. As of the date of issuance of these Consolidated Financial Statements, the extent to which these macroeconomic factors may materially adversely affect the Company&#8217;s financial condition, liquidity, or results of operations is uncertain.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to additional risks and uncertainties due to the ongoing COVID-19 pandemic. The extent of the impact on the Company&#8217;s business is highly uncertain and difficult to predict. The Company&#8217;s customers may divert resources to treat COVID-19 patients and defer some elective surgical procedures, both of which may impact the Company&#8217;s customers&#8217; ability to meet their obligations, including to the Company. The severity of the impact of the COVID-19 pandemic on the Company&#8217;s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company&#8217;s customers, all of which are uncertain and cannot be predicted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer Relief Program</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, the Company introduced a series of programs to provide financial relief to customers (the &#8220;Customer Relief Program&#8221;). As part of the Customer Relief Program, the Company provided its customers service fee credits, extended payment terms, and deferred payments related to Intuitive System Leasing arrangements. The Customer Relief Program ended at the end of the third quarter of 2020. There was no similar customer relief program offered in 2021 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service fee credits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As part of the Customer Relief Program, the Company provided service fee credits to customers based on the reduction in the utilization of their systems during the second and third quarters of 2020 relative to a pre-COVID-19 level baseline. The Company reflected the service fee credits as a reduction of service revenue and accounts receivable in the quarter they were earned by its customers. The service fee credit program resulted in an $80&#160;million decrease in service revenue in 2020.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term payment relief</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In response to the COVID-19 pandemic, the Company introduced a payment deferral program to provide financial relief to qualified customers. This relief extended payment terms up to 180 days for qualified and creditworthy customers.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also introduced a lease payment deferral program in which creditworthy customers with active Intuitive system leasing arrangements could elect to defer lease payments up to five months that are payable at the end of the lease by extending the lease term. This program did not result in substantial increases in the rights of the lessor or the obligations of the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lessee, and the Company elected to apply the relief provided by the Financial Accounting Standards Board (&#8220;FASB&#8221;) FAQ on accounting for COVID-19 and market volatility by not applying the lease modification guidance in ASC 842 to the lease arrangements affected by the deferrals and lease extensions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating lease arrangements where the lease term was extended by adding the deferred period to the end of the contract, the Company recalculated the straight-line revenue based on the revised terms, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. For its sales-type lease arrangements impacted, the Company accounted for the deferral in the timing of lease payments as if there were no changes in the lease contract, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. While the short-term payment relief offered did not have a material impact on the results of operations, the Company deferred $15&#160;million of lease billings and extended payment terms associated with $181&#160;million of billings during the program, of which $19&#160;million remained outstanding as of December 31, 2020. All of the trade receivables with extended payment terms have been collected as of December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity from the date of purchase of 90&#160;days or less to be cash equivalents.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, the Company had $19.5 million and $17.9 million, respectively, of restricted cash primarily associated with its insurance programs. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company&#8217;s investments may consist of money market funds, U.S. treasury and U.S. government agency securities, high-quality corporate notes and bonds, commercial paper, non-U.S. government agency securities, and taxable and tax-exempt municipal notes. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest and other income, net, if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to interest and other income, net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at the date of purchase greater than 90 days and remaining maturities as of the reporting period of less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company recognizes equity investments with readily determinable fair values at the quoted market price with changes in value recorded in interest and other income, net. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, municipal notes, and equity investments without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company&#8217;s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the cost basis of the Company&#8217;s inventory does not include any unallocated fixed overhead costs associated with abnormally low utilization of its factories.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant, and Equipment</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater of lease term or 1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise-wide software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of 3 years or life of license</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2022, 2021, and 2020, was $326&#160;million, $280 million, and $221 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Software Costs for Internal Use</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, which are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Once the software is ready for its intended use, amounts capitalized are amortized over an estimated useful life of up to 5 years, generally on a straight-line basis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Implementation Costs in a Cloud Computing Arrangement </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract for which it is the customer in accordance with the requirements for capitalizing costs incurred to develop internal-use software. These capitalized implementation costs are recorded within intangible and other assets, net, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business acquisitions in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires the acquiring entity in a business combination to recognize the assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree using acquisition-date fair values. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets&#8217; useful lives, which range from approximately 3 to 9 years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-lived Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets, which include finite-lived intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue consists of product revenue, resulting from the sale of systems, system components, and instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and the collectability of the contract consideration is probable. The Company&#8217;s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer.&#160;The Company&#8217;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. The Company&#8217;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price. The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations at a point in time. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations in the following manner:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">System sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and accessories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also could occur at the time of delivery, depending on the customer arrangement. The Company generally allows its customers in the normal course of business to return unused products for a limited period of time subsequent to the initial purchase and records an allowance against revenue for estimated returns.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then-fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems can be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. The assigned value of the traded-in units is reported as a component of inventory until resold or otherwise disposed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer&#8217;s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Recognized from the Costs to Obtain a Contract with a Customer</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain sales incentives provided to the Company&#8217;s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial system sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $72.3 million and $71.8 million as of December&#160;31, 2022, and 2021, respectively. The Company did not incur any impairment losses during the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements with certain qualified customers. Leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to 84 months. For these usage-based lease arrangements, the lease fee is generally billed monthly in arrears based on a contractual per-use fee, and usage is generally defined as the number of procedures performed with the system.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company&#8217;s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service. For some lease arrangements, customers are provided with the right to purchase the leased system at some point during and/or at the end of the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. Certain lease arrangements may also include upgrade rights that allow customers to upgrade the leased system to newer technology at some point during the lease term. Generally, these upgrade rights do not specify the terms, including the price or structure of the future upgrade transactions, as those terms are negotiated based on the circumstances at the time of the upgrade, including the then-fair value of the system as well as other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term and is presented as product revenue. Revenue related to lease elements from usage-based arrangements is recognized as the customers utilize the systems and is presented as product revenue.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Leasing Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December&#160;31, 2022. The Company currently does not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company does not have insight into the inputs necessary to calculate the implicit rate of the leases. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s real estate and automobile leases. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company&#8217;s automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. For the years ended December 31, 2022, and 2021, bad debt expense was not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment in sales-type leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company&#8217;s assessment of the current expected lifetime loss on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Lease receivables are considered past due 90 days after invoice.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the credit risk of the net investment in sales-type leases using a number of factors, including, but not limited to, the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Investment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Rating:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, and 2021, credit losses related to the net investment in sales-type leases were not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, procedure coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade and lease receivables as hospital cash flows are impacted by their response to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and are denominated in a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. Additionally, all of the Company&#8217;s investments in corporate debt securities are in securities with high-quality credit ratings, which have historically experienced low rates of default. For the years ended December 31, 2022, and 2021, credit losses related to available-for-sale debt securities were not material.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for sales returns is based on the Company&#8217;s estimates of potential future returns of certain products related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company&#8217;s products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants long-term equity awards under its stock-based compensation plans to certain employees of the Company. These awards include restricted stock units, stock options, and performance stock units. The Company accounts for share-based compensation plans using the fair value recognition and measurement provisions under GAAP. The Company&#8217;s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of restricted stock units (&#8220;RSUs&#8221;) is determined based on the closing quoted price of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock options granted and utilizes the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the date of grant; (2) expected term; (3) expected volatility; and (4) risk-free interest rate.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> year on the Company&#8217;s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company&#8217;s stock and the term of such options. Due to the sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Performance stock units (&#8220;PSUs&#8221;) include predefined performance and market conditions. The fair value of performance stock units with performance conditions is based on the closing quoted price of the Company&#8217;s common stock on the date of the grant and is recognized on a straight-line basis over the requisite service period. The Company estimates the number of awards with performance conditions that will ultimately vest based on the probability of achievement each quarter to determine the amount of compensation expense to recognize each reporting period. The fair value of performance stock units that include a market condition is determined using a Monte Carlo valuation model and is recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of shares to be issued under the Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) is computed using the Black-Scholes-Merton model at the commencement of an offering period in February and August of each year utilizing the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the initial date of the offering period; (2) expected term; (3) expected volatility; and (4) risk-free interest rate. Share-based compensation for the ESPP is expensed straight-line over the two-year offering period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 10. Share-Based Compensation&#8221; for a detailed discussion of the Company&#8217;s stock plans and share-based compensation expense.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Computation of Net Income per Share</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company&#8217;s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company&#8217;s employee stock purchase plan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Other Hedging Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders&#8217; equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company&#8217;s derivative contracts are generally twelve months or shorter.&#160;The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (&#8220;OCI&#8221;) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in the fair value of such derivative instruments also are reflected in current earnings. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Consolidated Financial Statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company includes interest and penalty on unrecognized tax benefits as a component of its income tax expense.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for&#160;Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) as period costs when incurred.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The chief operating decision maker regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. As of both December&#160;31, 2022, and 2021, 84% of long-lived assets were in the United States. Revenue from external customers is attributed to individual countries based on customer location.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company&#8217;s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the Consolidated Financial Statements. The Company expenses legal fees as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company&#8217;s business, financial condition, and results of operations or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2022-03&#8221;), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The Company early adopted ASU 2022-03 as of July 1, 2022, on a prospective basis. There was no impact of the adoption of ASU 2022-03 on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings and Vintage Disclosures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2022-02&#8221;), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses-Measured at Amortized Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company&#8217;s future Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522364880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash and available-for-sale debt securities&#8217; amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,941.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,640.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,619.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,415.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s cash equivalents and available-for-sale debt securities (excluding money market funds) as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities, because certain borrowers have the right to call or prepay certain obligations. Gross realized gains and losses recognized on the sale of investments were immaterial for the years ended December&#160;31, 2022, and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, net unrealized losses on available-for-sale debt securities, net of tax, of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$154.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, were included in accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized&#160;losses&#160;less<br/>than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized losses&#160;12<br/>months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on the Company&#8217;s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of December&#160;31, 2022, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Changes in Fair Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchases / Sales / Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaids and other current assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments with readily determinable value (Level 1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments without readily determinable value (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Recorded in interest and other income, net.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other includes foreign currency translation gains/(losses).</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Broncus Holding Corporation (&#8220;Broncus&#8221;) completed an initial public offering (&#8220;IPO&#8221;) of common shares on the Stock Exchange of Hong Kong. Upon completion of its IPO, the Company&#8217;s preferred shares of Broncus were converted into common shares, which have a readily determinable value (Level 1). The Company was restricted from selling these shares for a period of six months. In 2022, the Company recognized a $21.2 million loss on this investment reflected in changes in fair value for Level 1 equity investments, which was reflected in Interest and other income, net.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a $0.2&#160;million increase in fair value, which was reflected in interest and other income, net, due to changes in observable prices for certain equity investments that lack readily determinable market values (Level 2). There were no decreases in fair value reflected in net income due to impairments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivatives</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the Company&#8217;s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, intercompany balances, and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (&#8220;USD&#8221;). The terms of the Company&#8217;s derivative contracts are generally twelve months or shorter. The derivative assets and liabilities are measured using Level 2 fair value inputs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (&#8220;EUR&#8221;), the British Pound (&#8220;GBP&#8221;), the Japanese Yen (&#8220;JPY&#8221;), the Korean Won (&#8220;KRW&#8221;), and the New Taiwan Dollar (&#8220;TWD&#8221;). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and the Swiss Franc (&#8220;CHF&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive loss in stockholders&#8217; equity and reclassifies the amount into earnings in the same period in which the hedged transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Derivatives Not Designated as Hedging Instruments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, TWD, Indian Rupee (&#8220;INR&#8221;), Mexican Peso (&#8220;MXN&#8221;), Chinese Yuan (&#8220;CNY&#8221;), and Canadian Dollar (&#8220;CAD&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:59.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb">Recognized gains (losses) in interest and other income, net</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) related to balance sheet re-measurement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross fair value recorded in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683613719136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Consolidated Financial Statement Details</a></td>
<td class="text">CONSOLIDATED FINANCIAL STATEMENT DETAILS<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide details of selected consolidated financial statement items (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled accounts receivable and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Inventory</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Prepaids and other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases &#8211; short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaids and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaids and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building/leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets &#8211; Intuitive System Leasing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,845.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Accumulated depreciation associated with operating lease assets &#8211; Intuitive System Leasing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other accrued liabilities &#8211; short-term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction-related capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred and contingent purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities &#8211; short-term</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes &#8211; long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment transfers from inventory to property, plant, and equipment </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property, plant, and equipment in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683531697248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">REVENUE<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by types and geography (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,225.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">OUS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total OUS revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,710.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which revenue has not yet been recognized. A significant portion of these performance obligations relate to service obligations in the Company&#8217;s system sale and lease arrangements that will be satisfied and recognized as revenue in future periods. The transaction price allocated to the remaining performance obligations was $1.86&#160;billion as of December&#160;31, 2022. The remaining performance obligations are expected to be satisfied over the term of the system sale, lease, and service arrangements, which are generally up to 5 years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information summarizes the Company&#8217;s contract assets and liabilities (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company recognized $380&#160;million of revenue that was included in the deferred revenue balance as of December&#160;31, 2021. During the year ended December&#160;31, 2021, the Company recognized $351 million of revenue that was included in the deferred revenue balance as of December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents product revenue from Intuitive System Leasing arrangements (in millions):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">Sales-type lease revenue</span></span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">Operating lease revenue*</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Variable lease revenue relating to usage-based arrangements included within operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527104400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Lessor Information related to Intuitive System Leasing</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-type Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee Information</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $25.7&#160;million, $20.4&#160;million, and $21.0&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. For leases with terms of 12 months or less, the related expense was immaterial for each of the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases that were included within operating cash outflows</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recognized related to new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">Intangible and other assets, net (Right-of-use assets)</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">Other accrued liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">Total lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the future payments related to the Company&#8217;s operating lease liabilities are scheduled as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Lessor Information related to Intuitive System Leasing</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-type Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee Information</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $25.7&#160;million, $20.4&#160;million, and $21.0&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. For leases with terms of 12 months or less, the related expense was immaterial for each of the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases that were included within operating cash outflows</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recognized related to new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">Intangible and other assets, net (Right-of-use assets)</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">Other accrued liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">Total lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the future payments related to the Company&#8217;s operating lease liabilities are scheduled as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527070720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material acquisitions in 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company acquired Orpheus Medical Ltd. and its wholly owned subsidiaries (&#8220;Orpheus Medical&#8221;) to deepen and expand the Company&#8217;s integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical videos.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its annual goodwill impairment test and determined that no impairment existed. As of December&#160;31, 2022, there has been no impairment of goodwill.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.905%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights and others</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $27.8 million, $27.4 million, and $49.8 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense related to intangible assets as of December&#160;31, 2022, is as follows (in&#160;millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, measurement period adjustments to intangible assets, changes in foreign currency exchange rates, impairment of intangible assets, accelerated amortization of intangible assets, and other events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683613647392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments And Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company&#8217;s commitments include an estimated amount of approximately $2.14&#160;billion relating to the Company&#8217;s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures and construction-related activities for which the Company has not received the services, and acquisition and licensing of intellectual property. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its business needs prior to the delivery of goods or performance of services. Additionally, the Company has committed to making certain future milestone payments to third parties as part of licensing, collaboration, and development arrangements. Payments under these arrangements generally become due and payable only upon the achievement of certain specified developmental, regulatory, and/or commercial milestones. For instances in which the achievement of these milestones is neither probable nor reasonably estimable, such contingencies are not included in the estimated amount.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, commercial, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be, and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liability and related charge to earnings are recorded in the Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company&#8217;s business, financial condition, or future results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $28.1&#160;million of pre-tax litigation charges in 2022. During the years ended 2021 and 2020, pre-tax litigation charges were insignificant.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts. The plaintiffs generally allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. Several of the filed cases have trial dates in the next 12 months.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cases raise a variety of allegations including, to varying degrees, that plaintiffs&#8217; injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company&#8217;s part to provide adequate training resources to the healthcare professionals who performed plaintiffs&#8217; surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including, for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. The Company disputes these allegations and is defending against these claims.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimate of the anticipated cost of resolving the pending cases is based on negotiations with attorneys for the claimants.&#160;The final outcome of the pending lawsuits and claims, and others that might arise, is dependent on many variables that are difficult to predict, and the ultimate cost associated with these product liability lawsuits and claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company&#8217;s business, financial condition, or future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, &#8220;Ethicon&#8221;) filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company&#8217;s EndoWrist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stapler instruments infringe several of Ethicon&#8217;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,585,658; 8,479,969; 9,113,874; 8,998,058; 8,991,677; 9,084,601; and 8,616,431. A claim construction hearing occurred on October 1, 2018, and the Court issued a scheduling order on December 28, 2018. On March 20, 2019, the Court granted the Company&#8217;s Motion to Stay pending an Inter Partes Review to be held at the Patent Trademark and Appeals Board to review patentability of six of the seven patents noted above and vacated the trial date. On August 1, 2019, the Court granted the parties&#8217; joint stipulation to modify the stay in light of Ethicon&#8217;s U.S. International Trade Commission (&#8220;USITC&#8221;) complaint against Intuitive involving U.S. Patent Nos. 8,479,969 and 9,113,874, discussed below. There is currently no trial date scheduled for this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2018, Ethicon filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that the Company&#8217;s SureForm 60 Staplers infringe five of Ethicon&#8217;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,884,369; 7,490,749; 8,602,288; 8,602,287; and 9,326,770. The Company filed an answer denying all claims. On March 19, 2019, Ethicon filed a Motion for Leave to File a First Amended </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complaint, removing allegations related to U.S. Patent No. 9,326,770 and adding allegations related to U.S. Patent Nos. 9,844,379 and 8,479,969. On July 17, 2019, the Court entered an order denying the amendment, without prejudice, and granting the parties&#8217; joint stipulation to stay the case in its entirety in light of the USITC investigation involving U.S. Patent Nos. 9,844,369 and 7,490,749, discussed below. There is currently no trial date scheduled for this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2019, Ethicon filed a complaint with the USITC, asserting infringement of U.S. Patent Nos. 9,884,369 (&#8220;&#8217;369&#8221;); 7,490,749 (&#8220;&#8217;749&#8221;); 9,844,379 (&#8220;&#8217;379&#8221;); 9,113,874 (&#8220;&#8217;874&#8221;); and 8,479,969 (&#8220;&#8217;969&#8221;). On June 28, 2019, the USITC voted to institute an investigation (No. 337-TA-1167) with respect to the claims in this complaint. The accused products include the Company&#8217;s EndoWrist 30, EndoWrist 45, SureForm 45, and SureForm 60 Staplers, as well as the stapler reload cartridges. In March 2020, Ethicon dismissed its claims concerning the &#8217;749 patent. The evidentiary hearing took place in February 2021. On March 26, 2021, the U.S. Patent Trial and Appeal Board (&#8220;PTAB&#8221;) issued a Final Written Decision in which it found the claims in the &#8217;379 patent asserted against the Company in this USITC proceeding to be invalid. On June 8, 2021, the Chief Administrative Law Judge issued an Initial Determination concluding that (1) the accused products do not infringe the asserted claims in the &#8217;874 or &#8217;969 patents; (2) the asserted claims in the &#8217;874 and &#8217;969 patents are invalid; (3) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#8217;369 patent; (4) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#8217;379 patent; and (5) the Company was estopped from contending that the asserted claims in the &#8217;379 patent are invalid. Ethicon has not challenged the Initial Determination with regard to the findings that absolve Intuitive of any liability regarding the accused EndoWrist staplers and associated reload cartridges. On October 14, 2021, the USITC issued its Opinion in which it made the following rulings: (1) the USITC absolved Intuitive from any liability regarding the &#8217;874, &#8217;969, and &#8217;369 patents; and (2) the USITC found that, while the SureForm staplers and their associated reload cartridges infringe the asserted claims in the &#8217;379 patent, it has suspended the imposition of any remedial order pending an opinion from the U.S. Court of Appeal for the Federal Circuit of whether the Patent and Trademark Office correctly found the asserted claims in this patent to be invalid. On May 23, 2022, the U.S. Court of Appeal for the Federal Circuit affirmed the earlier PTAB Final Written Decision invalidating the asserted claims in the &#8217;379 patent. A hearing before the U.S. Court of Appeal for the Federal Circuit has been scheduled for March 8, 2023, on Ethicon&#8217;s appeal of the USITC&#8217;s Opinion. An adverse ruling on Ethicon&#8217;s appeal of the USITC&#8217;s Opinion could result in a prohibition on importing the accused SureForm products into the U.S. or necessitating workarounds. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, a jury rendered a verdict against the Company awarding $10&#160;million in damages to Rex Medical, L.P. in a patent infringement lawsuit. The Company intends to appeal the decision and vigorously defend its position. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2019, Restore Robotics LLC and Restore Repair LLC (&#8220;Restore&#8221;) filed a complaint in the Northern District of Florida alleging anti-trust claims against the Company. On May 13, 2019, Restore filed an amended complaint alleging anti-trust claims relating to the da Vinci Surgical System and EndoWrist service, maintenance, and repair processes. On September 16, 2019, the Court partially granted and partially denied the Company&#8217;s Motion to Dismiss the amended complaint.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, the Company filed an answer denying the anti-trust allegations and filed a counterclaim against Restore. The Company filed amended counterclaims after the Court partially granted and partially denied Restore&#8217;s Motion to Dismiss the counterclaim. The amended counterclaims allege that Restore violated the Federal Lanham Act, the Federal Computer Fraud and Abuse Act, and Florida&#8217;s Deceptive and Unfair Trade Practices Act and that Restore is also liable to the Company for Unfair Competition and Tortious Interference with Contract. On January 7, 2020, the Court denied Restore&#8217;s Motion to Dismiss the amended counterclaims.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, the Court granted in part and denied in part the parties&#8217; Motions for Summary Judgment. Shortly thereafter, Restore&#8217;s licensor, Rebotix Repair LLC (&#8220;Rebotix&#8221;) filed a notice in a separate legal action that it had received an email from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) confirming that &#8220;extending the number of uses and modifying [EndoWrist] instrument[s] with a new chip&#8221; constitutes &#8220;remanufacturing&#8221; and required 510(k) clearance, which neither Restore nor Rebotix has obtained. In light of this communication with the FDA, on April 13, 2022, the Company filed a Motion for Reconsideration to the Court&#8217;s Summary Judgment Order, which the Court denied on May 31, 2022. This case was scheduled for trial in February 2023. On January 23, 2023, the parties resolved all of their claims against each other and, on January 27, 2023, the case was dismissed with prejudice. The settlement had an immaterial impact on the Company&#8217;s Consolidated Financial Statements for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the claims asserted in the Restore case, on May 10, 2021, Surgical Instrument Service Company, Inc. (&#8220;SIS&#8221;) filed a complaint in the Northern District of California Court alleging anti-trust claims against the Company relating to </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EndoWrist service, maintenance, and repair processes. The Court granted in part and denied in part the Company&#8217;s Motion to Dismiss, and discovery has commenced. The Company filed an answer denying the anti-trust allegations and filed counterclaims against SIS. The counterclaims allege that SIS violated the Federal Lanham Act, California&#8217;s Unfair Competition Law, and California&#8217;s False Advertising Law and that SIS is also liable to the Company for Unfair Competition and Tortious Interference with Contract. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three class action complaints were filed against the Company in the Northern District of California Court alleging anti-trust allegations relating to the service and repair of certain instruments manufactured by the Company. A complaint by Larkin Community Hospital was filed on May 20, 2021, a complaint by Franciscan Alliance, Inc. and King County Public Hospital District No. 1 was filed on July 6, 2021, and a complaint by Kaleida Health was filed on July 8, 2021. The Court has consolidated the Franciscan Alliance, Inc. and King County Public Hospital District No. 1 and Kaleida Health cases with the Larkin Community Hospital case, which is now captioned on the Larkin docket as &#8220;In Re: da Vinci Surgical Robot Antitrust Litigation.&#8221; A Consolidated Amended Class Action Complaint has been filed on behalf of each plaintiff named in the earlier-filed cases. On January 14, 2022, Kaleida Health voluntarily dismissed itself as a party to this case. On January 18, 2022, the Company filed an answer against the plaintiffs in this matter, and discovery has commenced. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527070720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has authorized an aggregate of $10.0&#160;billion of funding for the Company&#8217;s common stock repurchase program (the &#8220;Repurchase Program&#8221;) since its establishment in March 2009. The most recent authorization occurred in July 2022 when the Board increased the authorized amount available under the Repurchase Program to $3.5&#160;billion, including amounts remaining under previous authorization. As of December&#160;31, 2022, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $1.5 billion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an accelerated share repurchase program (the &#8220;August ASR Program&#8221;) with Goldman, Sachs &amp; Co. (&#8220;Goldman&#8221;) to repurchase $1.0&#160;billion of the Company&#8217;s common stock. The Company made a payment of $1.0&#160;billion to Goldman and received an initial delivery of approximately 3.5&#160;million shares of the Company&#8217;s common stock, which were subsequently retired. In September 2022, the August ASR Program was completed, and an additional 1.1&#160;million shares of common stock were received and retired. In total, 4.6&#160;million shares were repurchased at an average price per share of $217.52. The total cost of the August ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into an accelerated share repurchase program (the &#8220;October ASR Program&#8221;) with Citibank, N.A. (&#8220;Citibank&#8221;) to repurchase $1.0&#160;billion of the Company&#8217;s common stock. The Company made an initial payment of $1.0&#160;billion to Citibank and received an initial delivery of approximately 3.6&#160;million shares of the Company&#8217;s common stock, which were subsequently retired. In December 2022, the October ASR Program was completed, and an additional 0.3&#160;million shares of common stock were received and retired. In total, 3.9&#160;million shares were repurchased at an average price per share of $254.48. The total cost of the October ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock repurchase activities (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of shares repurchased</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the par value method of accounting for its stock repurchases. As a result of share repurchase activities during the years ended December&#160;31, 2022, 2021, and 2020, the Company reduced common stock and additional paid-in capital by an aggregate of $211 million, zero, and $8 million, respectively, and charged $2.396 billion, zero, and $126 million, respectively, to retained earnings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss), Net of Tax, Attributable to Intuitive Surgical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized&#160;<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit for net losses recorded in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications for hedge instruments, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#8217;s Consolidated Financial Statements. The tax impacts for amounts reclassified from accumulated other comprehensive loss relating to hedge instruments, available-for-sale securities, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683613647392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2010 Incentive Award Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2010, the Company&#8217;s stockholders approved the 2010 Incentive Award Plan (&#8220;2010 Plan&#8221;). Under this plan, the Company can issue RSUs, nonqualified stock options (&#8220;NSOs&#8221;), and PSUs to employees, non-employee directors, and consultants. Equity awards granted to employees and non-employee directors include a mix of RSUs, stock options, and, as applicable, PSUs. The 2010 Plan generally permits NSOs to be granted at no less than the fair market value of the common stock on the date of grant. Prior to 2022, NSOs were granted with terms of 10 years from the date of the grant. Beginning in 2022, the Company changed the term of its new NSO grants to 7 years from the date of the grant. The 2010 Plan expires in 2032. In April 2022, the Company&#8217;s shareholders approved an amended and restated 2010 Plan to provide for an increase in the number of shares of common stock reserved for issuance thereunder from&#160;103,350,000&#160;to&#160;110,350,000. As of </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, approximately 27.2 million shares were reserved for future issuance under the 2010 Plan. A maximum of approximately 11.8 million of these shares can be awarded as RSUs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2009 Employment Commencement Incentive Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2009, the Board adopted the 2009 Employment Commencement Incentive Plan (&#8220;New Hire Plan&#8221;). The New Hire Plan provides for the shares to be used exclusively for the grant of RSUs and NSOs to new employees (&#8220;New Hire Options&#8221;), who were not previously employees or non-employee directors of the Company. The Compensation Committee approves all equity awards under the New Hire Plan, which are granted to newly-hired employees once a month on the fifth business day of each month after their hire. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2015, the Board of Directors amended and restated the New Hire Plan to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the New Hire Plan from 10,395,000 to 13,095,000. The New Hire Plan expired in October 2019 and, therefore, there are no shares reserved for future grants under the New Hire Plan. However, awards granted prior to the plan&#8217;s expiration continue to remain outstanding until their original expiration date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted to employees vest in one-fourth increments annually over a four-year period. The RSUs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated RSU grants that vest on the same term as the annual RSU grants. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are paid in cash to the appropriate taxing authorities on behalf of the Company&#8217;s employees.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonqualified Stock Options.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, annual NSO grants were made to employees on February&#160;15 (or the next business day if the date is not a business day) and on August&#160;15 (or the next business day if the date is not a business day). Beginning in 2020, the Company changed the timing of its annual equity award grants to the last trading day of February and on the same date in August or, if that date is not a trading day, the next trading day. The February NSO grants vest 1/8 upon completion of 6 months of service and 1/48&#160;per month thereafter. The August&#160;NSO grants vest 7/48 at the end of one month and 1/48&#160;per month thereafter through a 3.5-year vesting period. NSOs granted to new hires generally vest 1/4 upon completion of one year of service and 1/48&#160;per month thereafter. NSOs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated NSO grants that vest on the same term as the annual NSO grants. Option vesting terms are determined by the Board and, in the future, may vary from past practices.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Stock Units.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company granted PSUs to officers and other key employees, which are designed to provide further incentives for the achievement of the Company&#8217;s long-term objectives. The PSUs are subject to three-year cliff vesting and pre-established, quantitative goals. Whether any PSUs vest, and the amount that does vest, is tied to completion of service over three years and the achievement of three equally-weighted, quantitative metrics that directly align with or help drive the Company&#8217;s strategy and long-term total shareholder return.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2000 Non-Employee Directors&#8217; Stock Option Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2000, the Board of Directors adopted the 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;Directors&#8217; Plan&#8221;). In October 2009, the automatic evergreen increase provisions were eliminated so that no further automatic increases would be made to the number of shares reserved for issuance under the Directors&#8217; Plan. In addition, the common stock authorized for issuance under the Directors&#8217; Plan was reduced to 1,350,000. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years. Prior to 2016, initial stock option grants to new non-employee directors vested over a three-year period with 1/3 of the shares vesting after one year from the date of grant and 1/36 of the shares vesting monthly thereafter. Annual stock option grants vested one year from the date of the grant. Since 2016, new non-employee directors received pro-rated stock option grants that vest on the same term as the annual stock option grants. The Directors&#8217; Plan was terminated in November 2020 and, therefore, there are no shares reserved for future grants under the Directors&#8217; Plan. However, options granted prior to the plan&#8217;s termination continue to remain outstanding until their original expiration date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2000 Employee Stock Purchase Plan.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2000, the Board adopted the ESPP. Employees are generally eligible to participate in the ESPP if they are customarily employed by the Company for more than 20 hours per week and more than 5 months in a calendar year and are not 5% stockholders of the Company. Under the ESPP, eligible employees may select a rate of payroll deduction up to 15% of their eligible compensation subject to certain maximum purchase limitations. The duration for each offering period is 24 months and is divided into four purchase periods of approximately six months in length. Offerings are concurrent. The purchase price of the shares under the offering is the lesser of 85% of the fair market value of the shares on the offering date or 85% of the fair market value of the shares on the purchase date. A two-year look-back feature in the ESPP causes the offering period to reset if the fair value of the Company&#8217;s common stock on the first or last day of the purchase period is less than that on the original offering date. ESPP purchases by employees are settled with newly-issued common stock from the ESPP&#8217;s previously authorized and available pool of shares. In April&#160;2017, the Company&#8217;s stockholders approved an amended and restated ESPP to provide for an increase in the number of shares of common stock reserved for issuance </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from&#160;18,270,945&#160;to&#160;22,770,945. As of December&#160;31, 2022, there were approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December&#160;31, 2022, was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 4.2 million shares of RSUs were expected to vest with an aggregate intrinsic value of $1.12 billion. The aggregate vesting date fair value of RSUs vested was $536 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$578 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $478 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSO activity during 2022 under all of the stock plans was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise&#160;Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised under the Company&#8217;s stock plans determined as of the date of option exercise was $315 million, $613 million, and $598 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Cash received from option exercises and employee stock purchase plans for the years ended December&#160;31, 2022, 2021, and 2020, was $234 million, $276 million, and $309 million, respectively. The income tax benefit from stock options exercised was&#160;$70 million&#160;for the year ended&#160;December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes significant ranges of outstanding and exercisable options as of December&#160;31, 2022 (number of shares and aggregate intrinsic value in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.91-$49.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$51.02-$59.23</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.46-$77.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$77.04-$139.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$143.49-$174.26</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175.53-$182.83</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$182.90-$242.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$243.26-$290.33</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$292.49-$341.16</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$347.42-$347.42</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#8217;s closing stock price of $265.35 as of December&#160;31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, a total of 10.6 million shares of stock options vested and expected to vest had a weighted-average remaining contractual life of 4.7 years, an aggregate intrinsic value of $1.35 billion, and a weighted-average exercise price of $143.06.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 PSU grant metrics are focused on relative total shareholder return (&#8220;TSR&#8221;), year-over-year da Vinci procedure growth for 2023, and two-year compound annual da Vinci procedure growth for 2024. TSR is considered a market condition, and the expense is determined at the grant date. The two procedure growth goals are considered performance conditions, and the expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the two performance conditions. The number of shares earned at the end of the three-year period will vary, based on actual performance, from 0% to 125% of the target number of PSUs granted. PSUs are subject to forfeiture if employment terminates prior to the vesting date. PSUs are not considered issued or outstanding shares of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the fair value for each component of the PSUs individually. The fair value for the component with the TSR metric was determined using Monte Carlo simulation. The fair value per share for the components with the procedure growth metrics is equal to the closing stock price on the grant date.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU activity during 2022 was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 0.1&#160;million shares of PSUs were expected to vest with an aggregate intrinsic value of $18&#160;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, employees purchased approximately 0.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 0.5 million, and 0.5 million shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pproximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$87.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $75.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $71.2 million in employee contributions for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;product</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense after income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans and rights to acquire stock granted under the ESPP. The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted-average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December&#160;31, 2022, 2021, and 2020, were as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$272.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$256.52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$181.89</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK OPTIONS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$73.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$78.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$54.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$299.32</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$57.29</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As share-based compensation expense recognized in the Consolidated Statements of Income during the years ended December&#160;31, 2022, 2021, and 2020, is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $700 million, $121 million, $15 million, and $65 million of total unrecognized compensation expense related to unvested restricted stock units, unvested stock options, unvested performance stock units, and rights granted to acquire common stock under the ESPP, respectively. The unrecognized compensation expense is expected to be recognized over a weighted-average period of 2.3 years for unvested restricted stock units, 2.4 years for unvested stock options, 2.2 years for unvested performance stock units, and 1.5 years for rights granted to acquire common stock under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683526046752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the year ended December&#160;31, 2022, reflected the impact of a change in U.S. tax law effective January 1, 2022, which requires the capitalization and amortization of research and development expenditures incurred after December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was enacted in the United States. The IRA introduces a 15% alternative minimum tax based on the financial statement income of certain large corporations, effective for tax years beginning after December 31, 2022. The IRA also includes a 1% excise tax on the net fair market value of stock repurchases made after December 31, 2022. The Company considered the applicable tax law changes, and there is no impact to the Company&#8217;s tax provision for the twelve months ended December&#160;31, 2022. The Company will continue to evaluate the impact of these tax law changes on future periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2021 income tax expense included a one-time benefit of $66.4&#160;million from re-measurement of its Swiss deferred tax assets resulting from the extension of the economic useful life of certain intangible assets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December&#160;31, 2022, 2021, and 2020, as a result of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in tax resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation not benefited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit related to share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits related to share-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax re-measurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect tax carryforwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses deducted in later years for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $27.4 million of U.S. and foreign federal net operating loss carryforwards, certain of which will expire starting in 2028 if not utilized. Utilization of these net operating loss carryforwards may be subject to certain limitations. The Company does not expect the limitations to result in any permanent loss of these tax benefits. As of December 31, 2022, the Company had $221.9&#160;million in California research and development credit carryforwards, which do not expire.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, the Company had valuation allowances of $168.6 million and $104.6 million, respectively, primarily related to California deferred tax assets, for which the Company does not believe a tax benefit is more likely than not to be realized.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to repatriate earnings from its Swiss subsidiary and joint venture in Hong Kong, as needed, and the U.S. and foreign tax implications of such repatriations are not expected to be significant. The Company will continue to indefinitely reinvest earnings from the rest of its foreign subsidiaries, which are not significant.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December&#160;31, 2022, 2021, and 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to settlements with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 2021, and 2020, gross interest related to unrecognized tax benefits accrued was $21.0 million, $14.9 million, and $11.0 million, respectively. The Company&#8217;s net unrecognized tax benefits and related interest are presented in other long-term liabilities and long-term deferred tax assets on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross unrecognized tax benefits as of December&#160;31, 2022, were $252.6 million, of which $187.4&#160;million, if recognized, would have an impact on the Company&#8217;s effective tax rate.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an increase in the income tax provision of $39.3&#160;million during the year ended December 31, 2020, as a result of a Ninth Circuit Court of Appeals opinion involving an independent third party related to charging foreign subsidiaries for share-based compensation. An additional charge of $13.6&#160;million related to this matter was recorded to income tax expense in 2021, after additional IRS guidance was issued in July 2021. The Company will continue to monitor future IRS actions or other developments regarding this matter and will assess the impact of any such developments on its income tax provision in the quarter that they occur.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files federal, state, and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2016 are closed for the significant jurisdictions. Certain of the Company&#8217;s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company&#8217;s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of&#160;reasonably possible&#160;changes in unrecognized tax benefits that may occur in the next 12 months.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company&#8217;s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company&#8217;s provision for income taxes. If any issues addressed in the Company&#8217;s tax audits are resolved in a manner not consistent with management&#8217;s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683531593296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net income per share&#160;attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in basic calculation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: dilutive effect of potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in diluted calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Intuitive Surgical, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation awards of approximately 3.4 million, 0.8 million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares for the years ended December&#160;31, 2022, 2021, and 2020, respectively, were outstanding but were not included in the computation of diluted net income per share attributable to Intuitive Surgical, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527101840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANSThe Company sponsors various retirement plans for its eligible U.S. and non-U.S. employees. For employees in the U.S., the Company maintains the Intuitive Surgical, Inc. 401(k) Plan (the &#8220;Plan&#8221;). As allowed under Section&#160;401(k) of the Internal Revenue Code, the Plan provides tax-deferred salary contributions for eligible U.S. employees. The Plan allows employees to contribute up to 100% of their annual compensation to the Plan on a pre-tax and/or after-tax basis. Employee contributions are limited to a maximum annual amount as set periodically by the Internal Revenue Code. The Company matches 200% of employee contributions up to $1,500 per calendar year per person.&#160;All matching employer contributions vest immediately.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683531640176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation And Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation And Qualifying Accounts</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance&#160;at<br/>Beginning&#160;of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance&#160;at<br/>End&#160;of&#160;Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales returns and allowances</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2020</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Primarily represents products returned.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683520799824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and include the accounts of the Company and its wholly and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Consolidation and Joint Ventures</a></td>
<td class="text">The Consolidated Financial Statements include the results and balances of the Company&#8217;s majority-owned joint venture (&#8220;Joint Venture&#8221;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;). Chindex Medical Limited (&#8220;Chindex&#8221;), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders&#8217; equity. The noncontrolling interest&#8217;s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management&#8217;s most significant, complex, and subjective judgments include the valuation and recognition of investments, the standalone selling prices used to allocate the contract consideration to the individual performance obligations, the valuation of inventory, the valuation of and assessment of the recoverability of intangible assets and goodwill, the recognition and measurement of current and deferred income taxes, including the measurement of uncertain tax positions, and the estimates for legal contingencies. Actual results could differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company&#8217;s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.</span></div>The Company&#8217;s accounts receivable are primarily derived from billings related to revenue arrangements with customers and distributors located throughout the world. The Company performs credit evaluations of its customers&#8217; financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity from the date of purchase of 90&#160;days or less to be cash equivalents.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, and 2021, the Company had $19.5 million and $17.9 million, respectively, of restricted cash primarily associated with its insurance programs. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Company&#8217;s investments may consist of money market funds, U.S. treasury and U.S. government agency securities, high-quality corporate notes and bonds, commercial paper, non-U.S. government agency securities, and taxable and tax-exempt municipal notes. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest and other income, net, if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to interest and other income, net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at the date of purchase greater than 90 days and remaining maturities as of the reporting period of less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company recognizes equity investments with readily determinable fair values at the quoted market price with changes in value recorded in interest and other income, net. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, municipal notes, and equity investments without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company&#8217;s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. </span></div>Additionally, the cost basis of the Company&#8217;s inventory does not include any unallocated fixed overhead costs associated with abnormally low utilization of its factories.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant, and Equipment</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater of lease term or 1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise-wide software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of 3 years or life of license</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Capitalized Software Costs for Internal Use</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Software Costs for Internal Use</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, which are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Once the software is ready for its intended use, amounts capitalized are amortized over an estimated useful life of up to 5 years, generally on a straight-line basis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Implementation Costs in a Cloud Computing Arrangement </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract for which it is the customer in accordance with the requirements for capitalizing costs incurred to develop internal-use software. These capitalized implementation costs are recorded within intangible and other assets, net, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business acquisitions in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard requires the acquiring entity in a business combination to recognize the assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree using acquisition-date fair values. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets&#8217; useful lives, which range from approximately 3 to 9 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-lived Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets, which include finite-lived intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. </span></div>Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue consists of product revenue, resulting from the sale of systems, system components, and instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and the collectability of the contract consideration is probable. The Company&#8217;s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer.&#160;The Company&#8217;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. The Company&#8217;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price. The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations at a point in time. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations in the following manner:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">System sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Instruments and accessories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also could occur at the time of delivery, depending on the customer arrangement. The Company generally allows its customers in the normal course of business to return unused products for a limited period of time subsequent to the initial purchase and records an allowance against revenue for estimated returns.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then-fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems can be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. The assigned value of the traded-in units is reported as a component of inventory until resold or otherwise disposed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer&#8217;s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Recognized from the Costs to Obtain a Contract with a Customer</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain sales incentives provided to the Company&#8217;s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial system sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $72.3 million and $71.8 million as of December&#160;31, 2022, and 2021, respectively. The Company did not incur any impairment losses during the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Lessor, Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intuitive System Leasing</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements with certain qualified customers. Leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to 84 months. For these usage-based lease arrangements, the lease fee is generally billed monthly in arrears based on a contractual per-use fee, and usage is generally defined as the number of procedures performed with the system.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company&#8217;s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service. For some lease arrangements, customers are provided with the right to purchase the leased system at some point during and/or at the end of the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. Certain lease arrangements may also include upgrade rights that allow customers to upgrade the leased system to newer technology at some point during the lease term. Generally, these upgrade rights do not specify the terms, including the price or structure of the future upgrade transactions, as those terms are negotiated based on the circumstances at the time of the upgrade, including the then-fair value of the system as well as other factors.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term and is presented as product revenue. Revenue related to lease elements from usage-based arrangements is recognized as the customers utilize the systems and is presented as product revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Leasing Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December&#160;31, 2022. The Company currently does not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company does not have insight into the inputs necessary to calculate the implicit rate of the leases. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s real estate and automobile leases. </span></div>Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company&#8217;s automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Loss, Financial Instrument</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. For the years ended December 31, 2022, and 2021, bad debt expense was not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net investment in sales-type leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company&#8217;s assessment of the current expected lifetime loss on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Lease receivables are considered past due 90 days after invoice.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the credit risk of the net investment in sales-type leases using a number of factors, including, but not limited to, the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Investment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Rating:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, and 2021, credit losses related to the net investment in sales-type leases were not material.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, procedure coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade and lease receivables as hospital cash flows are impacted by their response to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and are denominated in a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. Additionally, all of the Company&#8217;s investments in corporate debt securities are in securities with high-quality credit ratings, which have historically experienced low rates of default. For the years ended December 31, 2022, and 2021, credit losses related to available-for-sale debt securities were not material.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock', window );">Allowance for Sales Returns and Doubtful Accounts</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for sales returns is based on the Company&#8217;s estimates of potential future returns of certain products related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company&#8217;s products.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants long-term equity awards under its stock-based compensation plans to certain employees of the Company. These awards include restricted stock units, stock options, and performance stock units. The Company accounts for share-based compensation plans using the fair value recognition and measurement provisions under GAAP. The Company&#8217;s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of restricted stock units (&#8220;RSUs&#8221;) is determined based on the closing quoted price of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock options granted and utilizes the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the date of grant; (2) expected term; (3) expected volatility; and (4) risk-free interest rate.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> year on the Company&#8217;s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company&#8217;s stock and the term of such options. Due to the sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance stock units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Performance stock units (&#8220;PSUs&#8221;) include predefined performance and market conditions. The fair value of performance stock units with performance conditions is based on the closing quoted price of the Company&#8217;s common stock on the date of the grant and is recognized on a straight-line basis over the requisite service period. The Company estimates the number of awards with performance conditions that will ultimately vest based on the probability of achievement each quarter to determine the amount of compensation expense to recognize each reporting period. The fair value of performance stock units that include a market condition is determined using a Monte Carlo valuation model and is recognized on a straight-line basis over the requisite service period. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The fair value of shares to be issued under the Company&#8217;s Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) is computed using the Black-Scholes-Merton model at the commencement of an offering period in February and August of each year utilizing the following inputs: (1) closing quoted price of the Company&#8217;s common stock on the initial date of the offering period; (2) expected term; (3) expected volatility; and (4) risk-free interest rate. Share-based compensation for the ESPP is expensed straight-line over the two-year offering period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 10. Share-Based Compensation&#8221; for a detailed discussion of the Company&#8217;s stock plans and share-based compensation expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Computation of Net Income per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Computation of Net Income per Share</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company&#8217;s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company&#8217;s employee stock purchase plan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock', window );">Foreign Currency and Other Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Other Hedging Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders&#8217; equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company&#8217;s derivative contracts are generally twelve months or shorter.&#160;The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (&#8220;OCI&#8221;) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in the fair value of such derivative instruments also are reflected in current earnings. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Consolidated Financial Statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company includes interest and penalty on unrecognized tax benefits as a component of its income tax expense.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for&#160;Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) as period costs when incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The chief operating decision maker regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. As of both December&#160;31, 2022, and 2021, 84% of long-lived assets were in the United States. Revenue from external customers is attributed to individual countries based on customer location.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal Contingencies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company&#8217;s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the Consolidated Financial Statements. The Company expenses legal fees as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company&#8217;s business, financial condition, and results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2022-03&#8221;), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The Company early adopted ASU 2022-03 as of July 1, 2022, on a prospective basis. There was no impact of the adoption of ASU 2022-03 on the Company&#8217;s Financial Statements in the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings and Vintage Disclosures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2022-02&#8221;), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses-Measured at Amortized Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company&#8217;s future Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policy for allowance for sales returns and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policy on foreign currency remeasurement and retranslation. Accounting policy on hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527123488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives Of The Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater of lease term or 1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise-wide software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of 3 years or life of license</span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building/leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets &#8211; Intuitive System Leasing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,845.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Accumulated depreciation associated with operating lease assets &#8211; Intuitive System Leasing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock', window );">Amortized Cost Basis By Year of Origination and Credit Quality Indicator</a></td>
<td class="text">The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Investment</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Rating:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of credit quality indicator for net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683529012240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Cash and Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s cash and available-for-sale debt securities&#8217; amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,941.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and<br/>Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term<br/>Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>Investments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,942.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,640.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,619.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,415.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of the Company&#8217;s cash equivalents and available-for-sale debt securities (excluding money market funds) as of December&#160;31, 2022 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,359.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule Of Available-For-Sale Investments With Unrealized Losses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized&#160;losses&#160;less<br/>than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized losses&#160;12<br/>months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">Debt Securities, Trading, and Equity Securities, FV-NI</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported as:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Changes in Fair Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchases / Sales / Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaids and other current assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible and other assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments with readily determinable value (Level 1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments without readily determinable value (Level 2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Recorded in interest and other income, net.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other includes foreign currency translation gains/(losses).</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:59.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb">Recognized gains (losses) in interest and other income, net</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains (losses) related to balance sheet re-measurement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Gross Notional Amounts for Outstanding Derivatives</a></td>
<td class="text">Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional amounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross fair value recorded in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683520682432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide details of selected consolidated financial statement items (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled accounts receivable and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Details of the Inventory Balance Sheet Item</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Inventory</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Prepaids and other current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases &#8211; short-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaids and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaids and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Details of the Property, Plant and Equipment, Net Balance Sheet Item</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.156%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater of lease term or 1 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise-wide software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of 3 years or life of license</span></div></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Property, plant, and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building/leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets &#8211; Intuitive System Leasing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,845.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,237.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(968.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Accumulated depreciation associated with operating lease assets &#8211; Intuitive System Leasing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Details of the Other Accrued Liabilities&#8212;Short Term Balance Sheet Item</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other accrued liabilities &#8211; short-term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income and other taxes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction-related capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation-related accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred and contingent purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities &#8211; short-term</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Details of the Other Long-Term Liabilities Balance Sheet Item</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes &#8211; long-term</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental cash flow information (in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment transfers from inventory to property, plant, and equipment </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property, plant, and equipment in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525882528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenue Disaggregated by Types and Geography</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by types and geography (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,225.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">OUS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total OUS revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments and accessories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systems</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,222.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,710.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information summarizes the Company&#8217;s contract assets and liabilities (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock', window );">Sales-type Lease Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents product revenue from Intuitive System Leasing arrangements (in millions):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">Sales-type lease revenue</span></span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">Operating lease revenue*</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Variable lease revenue relating to usage-based arrangements included within operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Operating Lease Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents product revenue from Intuitive System Leasing arrangements (in millions):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">Sales-type lease revenue</span></span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">Operating lease revenue*</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Variable lease revenue relating to usage-based arrangements included within operating lease revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683529009904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock', window );">Lessor, Sales-type Lease, Lease Income</a></td>
<td class="text">Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross lease receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible and other assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment in sales-type leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock', window );">Schedule of Contractual Maturities of Gross Lease Receivables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Operating Lease Payments</a></td>
<td class="text">Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental Cash Flow and Balance Sheet Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases that were included within operating cash outflows</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recognized related to new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">Intangible and other assets, net (Right-of-use assets)</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">Other accrued liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">Total lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the future payments related to the Company&#8217;s operating lease liabilities are scheduled as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Sales-type Lease, Lease Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683529189920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Summary of Changes in Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December&#160;31, 2022, and 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.905%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights and others</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule Of Estimated Future Amortization Expense Of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense related to intangible assets as of December&#160;31, 2022, is as follows (in&#160;millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527004704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleofCommonStockRepurchasedTableTextBlock', window );">Schedule Of Stock Repurchase Activities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock repurchase activities (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of shares repurchased</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized&#160;<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses)<br/>on&#160;Hedge<br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains (Losses)<br/>on<br/>Available-for-Sale Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Gains<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Amounts Recognized in Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit for net losses recorded in other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleofCommonStockRepurchasedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Common Stock Repurchased [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleofCommonStockRepurchasedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683529115920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity for the year ended December&#160;31, 2022, was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary Of Stock Option Activity Under All Stock Plans</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSO activity during 2022 under all of the stock plans was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise&#160;Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary Of Significant Ranges Of Outstanding And Exercisable Options</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes significant ranges of outstanding and exercisable options as of December&#160;31, 2022 (number of shares and aggregate intrinsic value in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value&#160;(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.91-$49.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$51.02-$59.23</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.46-$77.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$77.04-$139.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$143.49-$174.26</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$175.53-$182.83</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$182.90-$242.34</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$243.26-$290.33</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$292.49-$341.16</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$347.42-$347.42</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#8217;s closing stock price of $265.35 as of December&#160;31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Summary of PSU Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU activity during 2022 was as follows (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary Of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;product</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue&#8212;service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense after income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule Of Estimated Fair Values Of The Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions and Fair Value of RSUs</a></td>
<td class="text">The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted-average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December&#160;31, 2022, 2021, and 2020, were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$272.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$256.52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$181.89</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK OPTIONS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$73.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$78.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$54.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$299.32</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$57.29</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683533198896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Income Before Provision For Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule Of Provision For Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Income Tax Difference From The Statutory Rate</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December&#160;31, 2022, 2021, and 2020, as a result of the following (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (reduction) in tax resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation not benefited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit related to share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits related to share-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax re-measurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect tax carryforwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses deducted in later years for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule Of Gross Unrecognized Income Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December&#160;31, 2022, 2021, and 2020, are as follows (in millions):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to tax positions taken during a prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to settlements with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to expiration of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683526984464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation Of Basic And Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net income per share&#160;attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Intuitive Surgical, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in basic calculation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: dilutive effect of potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used in diluted calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Intuitive Surgical, Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521495536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ServiceFeeCredit', window );">Service Fee Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment', window );">Sales-type Lease, Lease Receivable, Extended Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AccountsReceivableExtendedPayment', window );">Accounts Receivable, Extended Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding', window );">Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326.0<span></span>
</td>
<td class="nump">280.0<span></span>
</td>
<td class="nump">$ 221.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SystemSalesArrangementWarrantyPeriod', window );">System sales arrangement, warranty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Capitalized contract acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.3<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod', window );">Market-based implied volatility (period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent', window );">Market-based implied volatility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod', window );">Cash flow hedges de-designated (period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement', window );">Likelihood of tax benefits being realized upon ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent', window );">Long-lived assets, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life, intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeaseTermOfContract1', window );">Sales-type leases term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life, intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeaseTermOfContract1', window );">Sales-type leases term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">84 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Internal use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Geographic Concentration Risk | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=isrg_TotalRevenueMember', window );">Total Revenue | Geographic Concentration Risk | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=isrg_TotalRevenueMember', window );">Total Revenue | Geographic Concentration Risk | OUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AccountsReceivableExtendedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Extended Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AccountsReceivableExtendedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Designation As Cash Flow Hedges, De-Designation, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax examination minimum likelihood of tax benefits being realized upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets maintained in the United States.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SalesTypeLeaseLeaseReceivableExtendedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Lease Receivable, Extended Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SalesTypeLeaseLeaseReceivableExtendedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ServiceFeeCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service Fee Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ServiceFeeCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SystemSalesArrangementWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>System Sales Arrangement, Warranty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SystemSalesArrangementWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorSalesTypeLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorSalesTypeLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=isrg_TotalRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=isrg_TotalRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522775488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EquipmentAndFurnitureMember', window );">Equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Operating lease assets | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember', window );">Operating lease assets | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EnterpriseWideSoftwareMember', window );">Enterprise-wide software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_PurchasedSoftwareMember', window );">Purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EnterpriseWideSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_EnterpriseWideSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_PurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=isrg_PurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521459968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems', window );"><strong>Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear', window );">2022</a></td>
<td class="nump">$ 168.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear', window );">2021</a></td>
<td class="nump">157.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear', window );">2020</a></td>
<td class="nump">79.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear', window );">2019</a></td>
<td class="nump">22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear', window );">2018</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear', window );">Prior</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Subtotal</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">$ 392.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalCreditAssessmentAxis=isrg_HighCreditRatingMember', window );">High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems', window );"><strong>Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear', window );">2022</a></td>
<td class="nump">67.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear', window );">2021</a></td>
<td class="nump">86.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear', window );">2020</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear', window );">2019</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear', window );">2018</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear', window );">Prior</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Subtotal</a></td>
<td class="nump">213.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalCreditAssessmentAxis=isrg_ModerateCreditRatingMember', window );">Moderate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems', window );"><strong>Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear', window );">2022</a></td>
<td class="nump">98.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear', window );">2021</a></td>
<td class="nump">69.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear', window );">2020</a></td>
<td class="nump">34.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear', window );">2019</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear', window );">2018</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear', window );">Prior</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Subtotal</a></td>
<td class="nump">214.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalCreditAssessmentAxis=isrg_LowCreditRatingMember', window );">Low</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems', window );"><strong>Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear', window );">2022</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear', window );">2021</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear', window );">2020</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear', window );">2019</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear', window );">2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear', window );">Prior</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Subtotal</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated more than five years prior to current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated four years prior to current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated in fiscal year prior to current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated three years prior to current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net investment in sales-type lease originated two years prior to current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919232-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=isrg_HighCreditRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=isrg_HighCreditRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=isrg_ModerateCreditRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=isrg_ModerateCreditRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalCreditAssessmentAxis=isrg_LowCreditRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalCreditAssessmentAxis=isrg_LowCreditRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521911216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 1,581.2<span></span>
</td>
<td class="nump">$ 1,290.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">5,359.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost', window );">Total assets measured at fair value, Amortized Cost</a></td>
<td class="nump">6,941.1<span></span>
</td>
<td class="nump">8,640.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(198.5)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">5,160.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue', window );">Total assets measured at fair value, Fair Value</a></td>
<td class="nump">6,741.5<span></span>
</td>
<td class="nump">8,619.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">2,536.7<span></span>
</td>
<td class="nump">2,913.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">2,623.6<span></span>
</td>
<td class="nump">4,415.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">497.2<span></span>
</td>
<td class="nump">572.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">497.2<span></span>
</td>
<td class="nump">572.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,084.0<span></span>
</td>
<td class="nump">713.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">3,799.2<span></span>
</td>
<td class="nump">4,125.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(96.6)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">3,702.6<span></span>
</td>
<td class="nump">4,116.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,100.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">1,076.2<span></span>
</td>
<td class="nump">2,302.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,084.0<span></span>
</td>
<td class="nump">696.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">1,084.0<span></span>
</td>
<td class="nump">696.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">2,715.2<span></span>
</td>
<td class="nump">3,429.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(96.6)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">2,618.6<span></span>
</td>
<td class="nump">3,420.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,100.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">1,076.2<span></span>
</td>
<td class="nump">2,302.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">2,644.7<span></span>
</td>
<td class="nump">3,942.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(101.9)<span></span>
</td>
<td class="num">(15.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">2,541.7<span></span>
</td>
<td class="nump">3,930.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">994.3<span></span>
</td>
<td class="nump">1,812.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">1,547.4<span></span>
</td>
<td class="nump">2,112.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">717.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">717.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">717.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">2,022.0<span></span>
</td>
<td class="nump">2,485.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(76.0)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">1,944.9<span></span>
</td>
<td class="nump">2,476.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">651.8<span></span>
</td>
<td class="nump">886.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">1,293.1<span></span>
</td>
<td class="nump">1,584.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">447.2<span></span>
</td>
<td class="nump">526.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(19.9)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">427.3<span></span>
</td>
<td class="nump">523.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">247.8<span></span>
</td>
<td class="nump">137.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">179.5<span></span>
</td>
<td class="nump">385.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">155.5<span></span>
</td>
<td class="nump">213.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">149.5<span></span>
</td>
<td class="nump">213.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term Investments</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term Investments</a></td>
<td class="nump">$ 74.8<span></span>
</td>
<td class="nump">$ 142.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Debt Securities, Available-for-sale, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521886688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Mature in less than one year</a></td>
<td class="nump">$ 2,586.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Mature in one to five years</a></td>
<td class="nump">2,773.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">5,359.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature in less than one year</a></td>
<td class="nump">2,536.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Mature in one to five years</a></td>
<td class="nump">2,623.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 5,160.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522786944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized investment gains (losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized gains/(losses) on investments</a></td>
<td class="num">(154,200,000)<span></span>
</td>
<td class="num">$ (16,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Loss on investment</a></td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | Broncus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Loss on investment</a></td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss', window );">Changes in fair value</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=isrg_BroncusHoldingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=isrg_BroncusHoldingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522393136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="nump">$ 1,510.4<span></span>
</td>
<td class="nump">$ 4,856.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(49.1)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="nump">3,538.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(149.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">5,048.7<span></span>
</td>
<td class="nump">4,856.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(198.5)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="nump">631.4<span></span>
</td>
<td class="nump">1,687.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(17.6)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="nump">1,221.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(58.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">1,853.3<span></span>
</td>
<td class="nump">1,687.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(76.0)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="nump">731.7<span></span>
</td>
<td class="nump">2,596.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(26.0)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="nump">1,886.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(70.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">2,618.6<span></span>
</td>
<td class="nump">2,596.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(96.6)<span></span>
</td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="nump">102.7<span></span>
</td>
<td class="nump">412.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="nump">324.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(15.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">427.3<span></span>
</td>
<td class="nump">412.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">(19.9)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_MunicipalNotesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses less than 12 months</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="nump">104.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">149.5<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">$ (6.0)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_MunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ScheduleOfAvailableForSaleSecuritiesAxis=us-gaap_MunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683526091616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Equity Investment Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 26.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Changes in Fair Value</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments', window );">Sales/Purchases/Others</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable value, Carrying Value</a></td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss', window );">Changes in fair value</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments', window );">Sales/Purchases/Others</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaids and other current assets | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaids and other current assets | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable value, Carrying Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=isrg_IntangibleAndOtherAssetsNetMember', window );">Intangible and other assets, net | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=isrg_IntangibleAndOtherAssetsNetMember', window );">Intangible and other assets, net | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable value, Carrying Value</a></td>
<td class="nump">$ 59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Sales, Purchases and Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Sales, Purchases and Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=isrg_IntangibleAndOtherAssetsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=isrg_IntangibleAndOtherAssetsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525946576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest and other income, net<span></span>
</td>
<td class="text">Interest and other income, net<span></span>
</td>
<td class="text">Interest and other income, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses) related to balance sheet re-measurement</a></td>
<td class="num">$ (54.2)<span></span>
</td>
<td class="num">$ (16.4)<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Recognized gains (losses) in interest and other income, net</a></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="num">$ (12.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521861104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details) - Forward contracts - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">$ 188.4<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Designated as Hedging Instruments | Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Designated as Hedging Instruments | Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">496.3<span></span>
</td>
<td class="nump">318.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Not Designated as Hedging Instruments | Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Derivatives Not Designated as Hedging Instruments | Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of outstanding currency forward contracts</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683533157504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_TradeAccountsReceivableCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 864.9<span></span>
</td>
<td class="nump">$ 731.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_UnbilledReceivablesAndOtherReceivablesCurrent', window );">Unbilled accounts receivable and other</a></td>
<td class="nump">91.7<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SalesReturnsAndAllowances', window );">Sales returns and allowances</a></td>
<td class="num">(14.5)<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 942.1<span></span>
</td>
<td class="nump">$ 782.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SalesReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Returns and Allowances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SalesReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_TradeAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade Accounts Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_TradeAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_UnbilledReceivablesAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled Receivables and Other Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_UnbilledReceivablesAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683533157760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 382.9<span></span>
</td>
<td class="nump">$ 214.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">159.9<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">350.4<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 893.2<span></span>
</td>
<td class="nump">$ 587.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521447648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent', window );">Net investment in sales-type leases &#8211; short-term</a></td>
<td class="nump">$ 131.2<span></span>
</td>
<td class="nump">$ 110.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investments</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaids and other current assets</a></td>
<td class="nump">164.3<span></span>
</td>
<td class="nump">133.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaids and other current assets</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 271.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Net Investment in Lease, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527139328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant, and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 388.6<span></span>
</td>
<td class="nump">$ 367.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building and building/leasehold improvements</a></td>
<td class="nump">866.5<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">566.4<span></span>
</td>
<td class="nump">497.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross', window );">Operating lease assets &#8211; Intuitive System Leasing</a></td>
<td class="nump">806.4<span></span>
</td>
<td class="nump">616.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ComputerAndOfficeEquipment', window );">Computer and office equipment</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">123.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized software</a></td>
<td class="nump">240.9<span></span>
</td>
<td class="nump">217.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-process</a></td>
<td class="nump">608.6<span></span>
</td>
<td class="nump">209.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant, and equipment</a></td>
<td class="nump">3,612.1<span></span>
</td>
<td class="nump">2,845.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,237.9)<span></span>
</td>
<td class="num">(968.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant, and equipment, net</a></td>
<td class="nump">2,374.2<span></span>
</td>
<td class="nump">1,876.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation', window );">Accumulated depreciation associated with operating lease assets - Intuitive System Leasing</a></td>
<td class="num">$ (285.8)<span></span>
</td>
<td class="num">$ (182.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ComputerAndOfficeEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of balance sheet date of long-lived, depreciable asset used in production process to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ComputerAndOfficeEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123405975&amp;loc=d3e41551-112718<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123422147&amp;loc=d3e41460-112716<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919398-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919398-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123405975&amp;loc=d3e41551-112718<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123422147&amp;loc=d3e41457-112716<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683620471840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Other Accrued Liabilities&#8212;Short Term (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income and other taxes payable</a></td>
<td class="nump">$ 96.1<span></span>
</td>
<td class="nump">$ 54.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Accrued construction-related capital expenditures</a></td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation-related accruals</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_DeferredPurchaseConsiderationPaymentsCurrent', window );">Current portion of deferred and contingent purchase consideration</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">299.0<span></span>
</td>
<td class="nump">209.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current</a></td>
<td class="nump">$ 476.2<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_DeferredPurchaseConsiderationPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Purchase Consideration Payments, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_DeferredPurchaseConsiderationPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683529448304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Income taxes &#8211; long-term</a></td>
<td class="nump">$ 288.0<span></span>
</td>
<td class="nump">$ 316.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue &#8211; long-term</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">110.3<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 439.3<span></span>
</td>
<td class="nump">$ 453.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525911888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 444.2<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="nump">$ 34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Equipment transfers from inventory to property, plant, and equipment</a></td>
<td class="nump">279.2<span></span>
</td>
<td class="nump">302.4<span></span>
</td>
<td class="nump">186.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property, plant, and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 73.4<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 47.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521308992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Revenue Disaggregated by Types and Geography (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 6,222.2<span></span>
</td>
<td class="nump">$ 5,710.1<span></span>
</td>
<td class="nump">$ 4,358.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,198.0<span></span>
</td>
<td class="nump">4,793.9<span></span>
</td>
<td class="nump">3,634.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=isrg_InstrumentsandAccessoriesMember', window );">Instruments and accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,517.9<span></span>
</td>
<td class="nump">3,100.5<span></span>
</td>
<td class="nump">2,455.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=isrg_SystemsMember', window );">Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,680.1<span></span>
</td>
<td class="nump">1,693.4<span></span>
</td>
<td class="nump">1,178.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,024.2<span></span>
</td>
<td class="nump">916.2<span></span>
</td>
<td class="nump">723.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,157.6<span></span>
</td>
<td class="nump">3,853.2<span></span>
</td>
<td class="nump">2,962.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">U.S. | Instruments and accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,507.2<span></span>
</td>
<td class="nump">2,225.1<span></span>
</td>
<td class="nump">1,785.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">U.S. | Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">966.0<span></span>
</td>
<td class="nump">1,024.8<span></span>
</td>
<td class="nump">695.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">U.S. | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">684.4<span></span>
</td>
<td class="nump">603.3<span></span>
</td>
<td class="nump">482.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">OUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,064.6<span></span>
</td>
<td class="nump">1,856.9<span></span>
</td>
<td class="nump">1,395.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">OUS | Instruments and accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,010.7<span></span>
</td>
<td class="nump">875.4<span></span>
</td>
<td class="nump">670.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">OUS | Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">714.1<span></span>
</td>
<td class="nump">668.6<span></span>
</td>
<td class="nump">483.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">OUS | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 339.8<span></span>
</td>
<td class="nump">$ 312.9<span></span>
</td>
<td class="nump">$ 241.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=isrg_InstrumentsandAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=isrg_InstrumentsandAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=isrg_SystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=isrg_SystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683528958256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to remaining performance obligations</a></td>
<td class="nump">$ 1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligations</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522781408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Summary of Contract Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 46.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 438.3<span></span>
</td>
<td class="nump">$ 414.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683520756064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Sales-type and Operating Lease Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList', window );">Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Total revenue<span></span>
</td>
<td class="text">Total revenue<span></span>
</td>
<td class="text">Total revenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncome', window );">Sales-type lease revenue</a></td>
<td class="nump">$ 156.4<span></span>
</td>
<td class="nump">$ 220.3<span></span>
</td>
<td class="nump">$ 154.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList', window );">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Total revenue<span></span>
</td>
<td class="text">Total revenue<span></span>
</td>
<td class="text">Total revenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Operating lease revenue</a></td>
<td class="nump">$ 376.5<span></span>
</td>
<td class="nump">$ 276.9<span></span>
</td>
<td class="nump">$ 176.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=isrg_VariableLeaseRevenueUsageBasedArrangementsMember', window );">Variable Lease Revenue, Usage-Based Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Operating lease revenue</a></td>
<td class="nump">$ 133.0<span></span>
</td>
<td class="nump">$ 78.1<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of comprehensive income that includes operating lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of comprehensive income that includes sales-type lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=isrg_VariableLeaseRevenueUsageBasedArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=isrg_VariableLeaseRevenueUsageBasedArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683524883952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SalesTypeLeaseGrossInvestmentInLease', window );">Gross lease receivables</a></td>
<td class="nump">$ 449.4<span></span>
</td>
<td class="nump">$ 404.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SalestypeLeaseDeferredSellingProfit', window );">Unearned income</a></td>
<td class="num">(14.4)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Subtotal</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">392.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">432.0<span></span>
</td>
<td class="nump">389.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">432.0<span></span>
</td>
<td class="nump">389.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">110.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">110.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Intangible and other assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">300.8<span></span>
</td>
<td class="nump">278.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract', window );"><strong>Reported as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Net investment in sales-type leases</a></td>
<td class="nump">$ 300.8<span></span>
</td>
<td class="nump">$ 278.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SalesTypeLeaseGrossInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Gross Investment in Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SalesTypeLeaseGrossInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SalestypeLeaseDeferredSellingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Deferred Selling Profit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SalestypeLeaseDeferredSellingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683533062864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 137.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears', window );">2024</a></td>
<td class="nump">126.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears', window );">2025</a></td>
<td class="nump">95.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears', window );">2026</a></td>
<td class="nump">60.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears', window );">2027</a></td>
<td class="nump">26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter', window );">2028 and thereafter</a></td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">$ 449.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683533062704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2024</a></td>
<td class="nump">250.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2025</a></td>
<td class="nump">194.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2026</a></td>
<td class="nump">130.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2027</a></td>
<td class="nump">58.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">2028 and thereafter</a></td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">$ 954.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527064144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 25.7<span></span>
</td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521393136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for leases that were included within operating cash outflows</a></td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized related to new lease obligations</a></td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 30.6<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525356608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Intangible and other assets, net (Right-of-use assets)</a></td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">69.6<span></span>
</td>
<td class="nump">66.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="nump">$ 87.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Intangible and other assets, net<span></span>
</td>
<td class="text">Intangible and other assets, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other accrued liabilities<span></span>
</td>
<td class="text">Other accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities<span></span>
</td>
<td class="text">Liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525374800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">21.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">101.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(7.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="nump">$ 87.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525170272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 343.6<span></span>
</td>
<td class="nump">$ 336.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition activity</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Translation and other</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 348.5<span></span>
</td>
<td class="nump">$ 343.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521492928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 242.7<span></span>
</td>
<td class="nump">$ 277.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(192.9)<span></span>
</td>
<td class="num">(206.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">70.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Patents and developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">199.1<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(167.4)<span></span>
</td>
<td class="num">(173.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(19.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(18.1)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683527123488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="nump">$ 27.4<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525394784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 49.8<span></span>
</td>
<td class="nump">$ 70.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522766112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,140.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Pre-tax litigation charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=isrg_RexMedicalLPMember', window );">Rex Medical, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=isrg_RexMedicalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=isrg_RexMedicalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683524975760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AggregateReductionInCommonStockDuringStockRepurchases', window );">Aggregate reduction in common stock and additional paid-in capital during stock repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,000,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases', window );">Amount charged to retained earnings during stock repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,396,000,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (126,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=isrg_AugustAcceleratedShareRepurchaseProgramMember', window );">August ASR Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Initial payment for share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Share repurchases, average price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=isrg_OctoberAcceleratedShareRepurchaseProgramMember', window );">October ASR Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Initial payment for share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Share repurchases, average price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_StockRepurchaseProgramincreasedtoauthorizedamount', window );">Stock repurchase program, increased to authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AggregateReductionInCommonStockDuringStockRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount reduced under Common Stock and Additional Paid-In Capital accounts under the par value of method of accounting for stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AggregateReductionInCommonStockDuringStockRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AmountChargedToRetainedEarningsDuringStockRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to Retained Earnings under the par value of method of accounting for stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AmountChargedToRetainedEarningsDuringStockRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_StockRepurchaseProgramincreasedtoauthorizedamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased to authorized shares repurchase amount for Stock Repurchase Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_StockRepurchaseProgramincreasedtoauthorizedamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=isrg_AugustAcceleratedShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=isrg_AugustAcceleratedShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=isrg_OctoberAcceleratedShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=isrg_OctoberAcceleratedShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521882800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased (in dollars per share)</a></td>
<td class="nump">$ 2,607.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=isrg_CommonStockRepurchaseProgramMember', window );">Common Stock Repurchase Program | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 233.70<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 183.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased (in dollars per share)</a></td>
<td class="nump">$ 2,607.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 134.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=isrg_CommonStockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=isrg_CommonStockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525248496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 11,901.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">11,041.9<span></span>
</td>
<td class="nump">$ 11,901.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Gains (Losses) on&#160;Hedge Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(35.0)<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized&#160; Gains (Losses) on Available-for-Sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(16.0)<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(138.2)<span></span>
</td>
<td class="num">(45.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(138.2)<span></span>
</td>
<td class="num">(45.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(154.2)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Gains (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(24.2)<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(166.1)<span></span>
</td>
<td class="num">(45.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(138.3)<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (162.5)<span></span>
</td>
<td class="num">$ (24.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683532962416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income tax benefit for net losses recorded in other comprehensive income (loss)</a></td>
<td class="nump">$ 39.1<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683517033792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">141 Months Ended</th>
<th class="th" colspan="1">190 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>period </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2009 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised under stock option plans</a></td>
<td class="nump">$ 315.0<span></span>
</td>
<td class="nump">$ 613.0<span></span>
</td>
<td class="nump">$ 598.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from option exercises and employee stock purchase plans</a></td>
<td class="nump">234.0<span></span>
</td>
<td class="nump">276.0<span></span>
</td>
<td class="nump">309.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Employee service share-based compensation, tax benefit from exercise of stock options</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options vested and expected to vest | shares</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of shares vested and expected to vest, years</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of shares vested and expected to vest</a></td>
<td class="nump">$ 1,350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, weighted-average exercise price per share | $ / shares</a></td>
<td class="nump">$ 143.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber', window );">Expected to vest (in shares) | shares</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 1,120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vested in period, aggregate fair value</a></td>
<td class="nump">536.0<span></span>
</td>
<td class="nump">$ 578.0<span></span>
</td>
<td class="nump">$ 478.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unrecognized compensation expenses are expected to be recognized, years</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_AnnualGrantOptionsMember', window );">Annual Grant Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService', window );">Percentage vesting upon six months of service</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService', window );">Percentage vesting per month after six months of service</a></td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_AnnualGrantOptionsMember', window );">Annual Grant Options | August Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth', window );">Percentage vesting at the end of one month</a></td>
<td class="nump">14.5833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_AnnualGrantOptionsMember', window );">Annual Grant Options | February Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService', window );">Percentage vesting upon six months of service</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService', window );">Percentage vesting per month after six months of service</a></td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were reserved for future issuance (shares) | shares</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan, shares issued | shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan, value of shares issued</a></td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">$ 75.9<span></span>
</td>
<td class="nump">$ 71.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unrecognized compensation expenses are expected to be recognized, years</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_NonvestedStockOptionMember', window );">Nonvested Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unrecognized compensation expenses are expected to be recognized, years</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_InitialRSUgrantsMember', window );">Initial RSU grants | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.3333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_NewHireOptionsMember', window );">New Hire Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear', window );">Percentage vesting per month after one year</a></td>
<td class="nump">2.0833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService', window );">Percentage vesting upon one year of service</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber', window );">Expected to vest (in shares) | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unrecognized compensation expenses are expected to be recognized, years</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember', window );">2010 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, options, expiration term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock reserved for issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were reserved for future issuance (shares) | shares</a></td>
<td class="nump">27,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember', window );">2010 Incentive Award Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares were reserved for future issuance (shares) | shares</a></td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember', window );">2010 Incentive Award Plan | Annual Grant Options | August Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based vesting period</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember', window );">2009 Employment Commencement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, options, expiration term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock reserved for issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember', window );">2000 Non-Employee Directors' Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, options, expiration term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock reserved for issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember', window );">2000 Non-Employee Directors' Stock Option Plan | Annual Grant Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember', window );">2000 Non-Employee Directors' Stock Option Plan | Initial Grant Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_StockOptionsGrantedInitialVestingPeriod', window );">Stock options granted initial vesting period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear', window );">Percentage vesting per month after one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7778%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService', window );">Percentage vesting upon one year of service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.3333%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=isrg_TwoThousandEmployeeStockPurchasePlanMember', window );">2000 Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan', window );">Minimum hours employed per week</a></td>
<td class="text">20 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan', window );">Minimum months employed per year</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan', window );">Maximum percentage of employees on stockholders to participate in ESPP</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_MaximumPercentageOfPayrollDeductionUnderEspp', window );">Percentage of employee payroll deduction under the stock plan, maximum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_OfferingPeriodEmployeeStockPurchasePlans', window );">Duration for each offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans', window );">Number of shorter purchase periods that each offering period is divided into | period</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans', window );">Duration of each shorter offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount on fair market value on the offering date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount on fair market value on the purchase date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans', window );">Period of look-back that could cause offering period to reset</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,270,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,770,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employees on stockholders to participate in employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_MaximumPercentageOfPayrollDeductionUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of payroll deduction under ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_MaximumPercentageOfPayrollDeductionUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum hours employed per week to participate in employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum months employed per year to participate in employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_OfferingPeriodEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Period, Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_OfferingPeriodEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Period, Number of Purchase Periods Offering Divided Into, Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Period, Period Offering Divided Into, Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of Look-Back That Could Cause Offering Period to Reset, Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After One Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After Six Months of Service</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon One Year of Service</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon Six Months of Service</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting at the End of One Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_StockOptionsGrantedInitialVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options granted initial vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_StockOptionsGrantedInitialVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AwardedtoAxis=isrg_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AwardedtoAxis=isrg_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_AnnualGrantOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_AnnualGrantOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=isrg_AugustGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=isrg_AugustGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=isrg_FebruaryGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=isrg_FebruaryGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_NonvestedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_NonvestedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_InitialRSUgrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_InitialRSUgrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_AwardedtoAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_AwardedtoAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_NewHireOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_NewHireOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_InitialGrantOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_InitialGrantOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=isrg_TwoThousandEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=isrg_TwoThousandEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521742000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of RSU and PSU Activity (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested beginning balance (shares)</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested ending balance (shares)</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (usd per share)</a></td>
<td class="nump">$ 207.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (usd per share)</a></td>
<td class="nump">272.97<span></span>
</td>
<td class="nump">$ 256.52<span></span>
</td>
<td class="nump">$ 181.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">191.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share)</a></td>
<td class="nump">235.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (usd per share)</a></td>
<td class="nump">$ 241.47<span></span>
</td>
<td class="nump">$ 207.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested beginning balance (shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange', window );">Performance change (shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested ending balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (usd per share)</a></td>
<td class="nump">299.32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue', window );">Performance change (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (usd per share)</a></td>
<td class="nump">$ 299.32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525387760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (shares) | shares</a></td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares) | shares</a></td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited/expired (shares) | shares</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (shares) | shares</a></td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise&#160;Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 125.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (usd per share) | $ / shares</a></td>
<td class="nump">249.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (usd per share) | $ / shares</a></td>
<td class="nump">77.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited/expired (usd per share) | $ / shares</a></td>
<td class="nump">240.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 144.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522517360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 144.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,354.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 121.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,292.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 265.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeOneMember', window );">Exercise Price Range 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">29.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 49.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 45.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 45.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTwoMember', window );">Exercise Price Range 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">51.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 59.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 55.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 55.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeThreeMember', window );">Exercise Price Range 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">59.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 77.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 67.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 67.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFourMember', window );">Exercise Price Range 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">77.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 139.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 108.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 108.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFiveMember', window );">Exercise Price Range 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">143.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 174.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 168.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 168.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSixMember', window );">Exercise Price Range 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">175.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 182.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 179.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 180.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSevenMember', window );">Exercise Price Range 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">182.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 242.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 219.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 224.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeEightMember', window );">Exercise Price Range 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">243.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 290.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 268.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 261.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeNineMember', window );">Exercise Price Range 9</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">292.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 341.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 311.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 330.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTenMember', window );">Exercise Price Range 10</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum (usd per share)</a></td>
<td class="nump">347.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum (usd per share)</a></td>
<td class="nump">$ 347.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number of Shares | shares</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 347.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Number of Shares | shares</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)</a></td>
<td class="nump">$ 347.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=isrg_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521483152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">$ 516.5<span></span>
</td>
<td class="nump">$ 456.8<span></span>
</td>
<td class="nump">$ 398.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefit</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense after income taxes</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">363.1<span></span>
</td>
<td class="nump">317.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Total cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Total cost of revenue | Cost of revenue&#8212;product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">68.9<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Total cost of revenue | Cost of revenue&#8212;service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=isrg_SellingGeneralAndAdministrativeMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">261.1<span></span>
</td>
<td class="nump">231.6<span></span>
</td>
<td class="nump">202.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=isrg_ResearchAndDevelopmentMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before income taxes</a></td>
<td class="nump">$ 164.2<span></span>
</td>
<td class="nump">$ 134.1<span></span>
</td>
<td class="nump">$ 113.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ConsolidatingReportingAxis=isrg_CostOfSalesProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ConsolidatingReportingAxis=isrg_CostOfSalesProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_ConsolidatingReportingAxis=isrg_CostOfSalesServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_ConsolidatingReportingAxis=isrg_CostOfSalesServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=isrg_SellingGeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=isrg_SellingGeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=isrg_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=isrg_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521502192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (usd per share)</a></td>
<td class="nump">$ 272.97<span></span>
</td>
<td class="nump">$ 256.52<span></span>
</td>
<td class="nump">$ 181.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">STOCK OPTIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility (percent)</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value at grant date (usd per share)</a></td>
<td class="nump">$ 73.65<span></span>
</td>
<td class="nump">$ 78.23<span></span>
</td>
<td class="nump">$ 54.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value at grant date (usd per share)</a></td>
<td class="nump">$ 299.32<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility (percent)</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value at grant date (usd per share)</a></td>
<td class="nump">$ 80.61<span></span>
</td>
<td class="nump">$ 89.98<span></span>
</td>
<td class="nump">$ 57.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=isrg_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683524901920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 956.7<span></span>
</td>
<td class="nump">$ 1,298.7<span></span>
</td>
<td class="nump">$ 926.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">650.1<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
<td class="nump">280.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">$ 1,606.8<span></span>
</td>
<td class="nump">$ 1,890.3<span></span>
</td>
<td class="nump">$ 1,207.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525362800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Provision For Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current income taxes, Federal</a></td>
<td class="nump">$ 350.4<span></span>
</td>
<td class="nump">$ 158.8<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current income taxes, State</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current income taxes, Foreign</a></td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">447.7<span></span>
</td>
<td class="nump">226.2<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred income taxes, Federal</a></td>
<td class="num">(188.8)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred income taxes, State</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred income taxes, Foreign</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="num">(43.1)<span></span>
</td>
<td class="nump">32.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(185.3)<span></span>
</td>
<td class="num">(64.0)<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 262.4<span></span>
</td>
<td class="nump">$ 162.2<span></span>
</td>
<td class="nump">$ 140.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525246064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount', window );">Deferred tax remeasurement due to Swiss Tax Reform</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (66.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(168.6)<span></span>
</td>
<td class="num">(104.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Gross interest related to unrecognized tax benefits accrued</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total gross unrecognized tax benefits</a></td>
<td class="nump">252.6<span></span>
</td>
<td class="nump">222.5<span></span>
</td>
<td class="nump">$ 176.3<span></span>
</td>
<td class="nump">$ 96.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Net increase in gross unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties related to unrecognized tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=isrg_DomesticAndForeignMember', window );">Domestic and Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">27.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | CALIFORNIA | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 221.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=isrg_DomesticAndForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=isrg_DomesticAndForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683522362368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">$ 337.4<span></span>
</td>
<td class="nump">$ 397.0<span></span>
</td>
<td class="nump">$ 253.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefits</a></td>
<td class="nump">34.9<span></span>
</td>
<td class="nump">33.1<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(64.2)<span></span>
</td>
<td class="num">(54.3)<span></span>
</td>
<td class="num">(19.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">U.S. tax on foreign earnings</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(41.7)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(37.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation not benefited</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement', window );">Unrecognized tax benefit related to share-based compensation</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(39.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reversal of unrecognized tax benefits</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Excess tax benefits related to share-based compensation</a></td>
<td class="num">(98.7)<span></span>
</td>
<td class="num">(185.8)<span></span>
</td>
<td class="num">(166.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount', window );">Deferred tax re-measurement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(66.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 262.4<span></span>
</td>
<td class="nump">$ 162.2<span></span>
</td>
<td class="nump">$ 140.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Unrecognized Tax Expense (Benefit), Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521751104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Deferred Tax Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 342.8<span></span>
</td>
<td class="nump">$ 369.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenditures</a></td>
<td class="nump">172.5<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development credits</a></td>
<td class="nump">156.7<span></span>
</td>
<td class="nump">98.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="nump">121.3<span></span>
</td>
<td class="nump">110.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Expenses deducted in later years for tax purposes</a></td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Net unrealized losses on available-for-sale securities and other</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">919.3<span></span>
</td>
<td class="nump">651.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(168.6)<span></span>
</td>
<td class="num">(104.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">750.7<span></span>
</td>
<td class="nump">547.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant, and equipment</a></td>
<td class="num">(64.1)<span></span>
</td>
<td class="num">(79.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_isrg_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="num">(9.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">86.2<span></span>
</td>
<td class="nump">106.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 664.5<span></span>
</td>
<td class="nump">$ 440.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_isrg_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">isrg_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>isrg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683520805088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 222.5<span></span>
</td>
<td class="nump">$ 176.3<span></span>
</td>
<td class="nump">$ 96.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken during the current year</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">40.6<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to tax positions taken during a prior year</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to tax positions taken during a prior year</a></td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decreases related to settlements with tax authorities</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Decreases related to expiration of statute of limitations</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 252.6<span></span>
</td>
<td class="nump">$ 222.5<span></span>
</td>
<td class="nump">$ 176.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683532912000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,322.3<span></span>
</td>
<td class="nump">$ 1,704.6<span></span>
</td>
<td class="nump">$ 1,060.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding basic (shares)</a></td>
<td class="nump">355.7<span></span>
</td>
<td class="nump">356.1<span></span>
</td>
<td class="nump">351.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: dilutive effect of potential common shares</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing diluted net income per share (shares)</a></td>
<td class="nump">362.0<span></span>
</td>
<td class="nump">365.8<span></span>
</td>
<td class="nump">361.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (usd per share)</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (usd per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683613576592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Employee stock options excluded from computation of diluted net income per share</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683525960960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum rate of employees' contribution to 401(k) plan</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer match percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Employer matching contributions, per person, per year</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140683521560912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation And Qualifying Accounts (Details) - Sales returns and allowances - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at Beginning&#160;of Year</a></td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">44.4<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(43.0)<span></span>
</td>
<td class="num">(44.1)<span></span>
</td>
<td class="num">(35.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance&#160;at End&#160;of&#160;Year</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>isrg-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:isrg="http://www.intuitivesurgical.com/20221231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="isrg-20221231.xsd" xlink:type="simple"/>
    <context id="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i205ff87813544221905e1bacbc0e834a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib0ed59a4d8384c88a2ad8e007a293a45_I20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb57e4322a5a41099da8c576ba2c235e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a5abb42db044edb933f0bac478561e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3fdd4cfad61458ba3bd1f961574b7c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8e1406152504c24becb2d14ea3aba96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea73322238bf4952ba8f6f56b4843fd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86284f29e88649f98a3081d2acc55f59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie28b90c84ec44021a92cdcdb2c25b28a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b59bb58abc7479d89bc7d2b74d70544_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f52079425724fd694aa42f7b37a71e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46ac86aca2b842e9883ccef967301ae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ae840c0106e4c1996ae436a312416d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a090d2385f44532aa7e60497f976b8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2c801b2cffa477fb54e06f63ca156ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f6e09d2840745a2be9bd85eeaaa8a92_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5043d7c11ba745e8a27d34923ccd110f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c08937764b145139a93a060599d3467_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d7c7907f86d4cce9957516da107670e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdde0a5261214008b1be258b805ec820_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ad839dce5564f57a74be0b40182551f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a4a986595294305b5ea409ad41fcfc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd2ad8e3ddd245609178c33ddcac1011_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4ab8f76e64a46d58941675cc8783c2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c5ce2953a28440b89e7ee68bba323d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8054044227734087aef06647c25d127e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03428188c1ee49ef8ce9c5b683046ed8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb108484a5da4e338d0d4751f13dd73a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16f263d8dd40419bb80418ab7843bf76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecf372d2348047f5953ac29d0036d748_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01169c36a4df47e8985588f97df426ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ae3572c7a714189861826346d019725_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b8c36ddf45540d2be8a68a9375992f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5549eca14af04f2faba84d86c3277878_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdf66fd192a04254983a4b04fde0c089_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff5abbcecdbf42949927127eac25660e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieaf1941ab4cf4eaa9051a8d048ff8396_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d1b51b8c04f48c796dbafa733a218ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <startDate>2021-09-27</startDate>
            <endDate>2021-09-27</endDate>
        </period>
    </context>
    <context id="iecd854fcb4004bbcbf41e8c107112eee_I20210927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="i9a274d8413eb4abe939b46c4859e5585_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i21289ee699604ccda2bbe939f4826b3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e3a2ff2c2da4f4385ae63c2bcc6c672_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie26454d7ae8c44d190970894b06cf238_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ea9298fff88462ca644d8893e65377d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87f6d6fb99c046d289fc7290155d8526_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14855bc25d64407e9c3e34a6c5aa703b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6108e23d4714957986c26ca264b5fe8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">isrg:TotalRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief4c591526ea478bb99b449397dd0039_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if23950580a4342bd9a17e543bc89fa46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27f714fd0e404cf8b81228344910a645_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibac2a4c8f53d40f38da16d18c79f554b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00eade1132384910a1edcc4602cd7f03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i672bca309a9e49d7b8514f35e4e5676e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i212dee94b35b42048df23efbc2d406d9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:EnterpriseWideSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd1fd94d996648b992458725d1c804c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">isrg:PurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia195f6ae1083417ea6ba55e0f754b575_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18ca052badd544ec96dacbdeb71e006a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0af42d049a95445eb385849c884a645d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide0778c030794ba48d3da31c3443b61c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7f29fdc80a74811ae7b3009689d8b76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:HighCreditRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:ModerateCreditRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib606f0cd45974794b541dc9482583db5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InternalCreditAssessmentAxis">isrg:LowCreditRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dba95d10fbc41fc971720e2efa2c528_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46268e7a8003454a8651b908542fda66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id177033e3c704b16966079b0d35b30a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idaaec3561f8241d9906a1ef96fca02df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ce8007a441d425abf12e8e63eb11ef7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564a11c205e348b89bbea004fd0d0881_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7bf33483de84677a014730d8912b575_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id997ca722e2f4788a65a9e8536746348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95fdd74fde53453eba6b56a6ba9600eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i394f7efea4cd4225a8986de3d68e8579_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59583221ff1b4c91878682716a636bb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b36d26e61024eac8645d0f1bb64c21b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2587a04e00144b698e16da96b21f34a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8308ebf06c1c41218705b5b531829bcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id08bf20bd9fe482f996a73a760e92a96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9444962effa548219751ad1adbb4d73f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0705226857e341b09873d9b24560e21a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i357d64746ac9439288fd1ba185b246c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b1b5039fc4342148b973bb59e8d775f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0040bf49a71463b8c92b5c6f4a375af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c67f2127d5141edbb2ca095f39de5ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="isrg:ScheduleOfAvailableForSaleSecuritiesAxis">us-gaap:MunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i702b19a2b8bb41359e443d04869386fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ae9291dcd4e4adf9b84f4736b3bebec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">isrg:IntangibleAndOtherAssetsNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc10b5ae76314ee18fd591fd9b32d6ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5134dae76a5341b9aaabb6667f245625_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">isrg:IntangibleAndOtherAssetsNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71314a12af6b429986b5c9a4271f446a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">isrg:BroncusHoldingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i079b7ef7442a42a7840e702b882a1012_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7280a7103fee4e258e2f35b51eff9ab1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i910cb2fb179a407d8a5c75fc680d2303_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5c8e03657644033b868750e96ab9643_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46df387e6efe4ff08b0f664717fc0831_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21fdc4fc554441f08d904ff171695e33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ided6c6550364405b97c4d34389c5ffff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i964a856360ad4285ade38db2e34a431b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i231b0f91933940b08ff7af08baa651f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf83fed589c5486b9792c680888aeea0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0cbc403979c45828117eb065cab8fa2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i804002ab970d48a5a57bbae1404bf198_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a74a66492084258931e13b5981fa79f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id22a8bae9b2c48eebe8b50b3819f8d70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3edae5cd8cd2410183098ef4010c1892_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i246f937640f04aaca1e106cbdf7b1a32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0cc5eca2d9942c3921b4aba2cde8e4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89b35002f4f84795b5c367b377727c09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf1c067c42d24d09b83f44eb0b71ce2b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ae156a408ef48c79d517473c3535ecd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e0a839f694a4a25a79f064404e8b099_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab0b0eb6066646e28b5f0ecd47f541fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8144e739c7bc4ec28218fb43ce081ed4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3831ecf897f94e55ade9139765dde100_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55328c6d3ad9447fb62f387c720a2058_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1626e0eb7e514e2fb0c7df23826a6fec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8b2f32382954088b7a0390205e6b628_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8304025c63864a2aa1a6a11f46d0864b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6837fa9980f8427899e6791fa305524d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie36d1a1db0674a418d5a7f72e7b54de5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i950b136a19ae40d9b9d11a4c60b1f0a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe17b049a1e34a548921b45ddee7b35f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib380a2c52e2d42409c0b1646842faf2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb5df141ea8e40509cb916df8b2ff26f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c243171572a42cea628d49efffe8709_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieda45a3621c84f1b9aef4071b842c2b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50c746302eaf44e986f9840477b463de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d9c7f30e288439fb419bcf27013ae6f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb59dcfb65644da9a3e23bb2aeea13c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1962e48f84bd458fb0b88daa39518d23_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69bf5f4d5aed4a8b8454b48cd962b54e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b449d3de1df438a8825ceebf4e43693_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:InstrumentsandAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea54ffe275324b9381bef67e6b9ae4a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib46c00d9c67d4ce9b8f5e8bbcc799cad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">isrg:SystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f9ee599e0834c439f28abe74bf98547_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0333e95f85d48cf88145bfeb59afc5d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6107b94bba54498d96a497fbaf65d4cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf73792053ae49508767ca0ac0d77523_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">isrg:VariableLeaseRevenueUsageBasedArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i990140e98ac543b0a1e3275119938c07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22cdd1443bcf48778c9fb236cb3f5a7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic357251bdc6148b78354861f8ff47859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1917b42017a44a168cb0fcb89a52d9bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa0815014e2048d88e0fbadfebe22ea8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88a3a8ceed2f49e880418977490f5d20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f06663da7d74354b3bd5efcad839096_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e20be5b265d48b181f0ff33e8f0c656_D20221019-20221019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">isrg:RexMedicalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-19</startDate>
            <endDate>2022-10-19</endDate>
        </period>
    </context>
    <context id="i454d4ac87d7a4c0cabb826bc3c10cbcd_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i97d83242175d438fb29d5d804eea01f7_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i839d2a9749664c4bab3d1bdaacba0520_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ife86c560869f4c39bf37fbe4692b9019_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:AugustAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id78018ef69be42c396e169846e05b20b_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i5ea6d8fa775a4209b8ce714c8dc3009a_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i6c368f15dd6943a5a4c230f46529d97e_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:OctoberAcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">isrg:CommonStockRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36cb3acbf52841e3bc3c63820c01fa42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c13220ef9824187bfc2e616446c4a3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i181617f6fdb54de7954b15a38947b6bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i473c6bb0442144b58cb06ae162b7e6a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32b37d08e5a44af0beaf8cc7bb58696d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i006259a527c0455b9e5463d5168ec708_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i999a1d9653924dbe965c17ddd3a03def_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b3150d3865845838cf5476e0ce21fc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0051b5c888cd406ea6c081c905d7c0bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70dfa53208644c0c9c0a6ec85264d603_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58f1669e3b2446aca797556ff1d0ccd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94d140b2190d4fc9ae1e1dc1d5ddb6c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15316780633245bbb91889b5d7ee1820_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia17bfdaa573143ba98966885510cdde7_D20100401-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia59158a68bbb4286aa90fa8eb06c7834_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b469324ce32446fb9def5b7b3c5cfbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9145bce4606d4940ad42ef487d849840_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i410198a3903441b68830e22a66897156_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia179814817fd4ff9878baee2be535b17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89170b9133ed4804b600e82c78c15cd5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i409a1f3ac0ee4fcd9e608f4ff5c23e1b_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="idcfae84224074580bb7bb01e54a43b99_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:AwardedtoAxis">isrg:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3241e96d8cae42fd893bed581e6753b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:AugustGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:AmendedAndRestatedTwentyTenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13aa27cc6a90415195d355246bcee08b_I20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-31</instant>
        </period>
    </context>
    <context id="ie8bc21a2592240cda306d477679d44f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i65114e3030914e0a8cb520556e6fff7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialGrantOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9334eee01684436a51c2d0f31644073_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20fe342469174f21b1e6e465beeaa26e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8fa15cbbe464ea8b44d4cc396aa1978_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5c51c4092a524901b1803e5ce38a9526_I20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="i727584465aae4a70bf59561fe029a223_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a94340d69fc401d83c0ba90f1f24db2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66a2672f116a46efa86d9e452117811d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e3066fccc99431ea0149fec8907d401_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65cb93da736742b282702b76ba91dfee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90b8da69b805467d85bab92c30ac5b9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifea0eb37deed46c3a1671bb3033ffa09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i994c9aabae284d2ea354cdf5d3af175d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0740ebe40d864b4da35c3b393f1777dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9ec653142c748c98233a20d2e6fab4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i174231a7f81b42edb1f0569a32f0f3d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic497a710b79f4cfbadc4cbf7577e4244_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">isrg:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib59e1332f83f433bafce8ca9eb07b593_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdc843d98e1341af9834acde67e83d17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32383985adf64f2e954cbe105c317ced_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f463df323b94b2ca79195cb77ae86c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a32dfb6574f44df8ff7344da9391dc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibee7d626dd6442c084221823215a5e3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c2ead6914ce4c29ad6ab0ea4e54ec31_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib8d9f668182e4bce91778830a95c13c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5570cfc269954912b1db7819ee5a7b87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:ConsolidatingReportingAxis">isrg:CostOfSalesServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d1765d5cde54c3a8c9535c06750c11d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7fed7f0046594d5e9b7d0285eebe8dbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fa21ecf135f4e53ae80c53876c575de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c8730f5559847e5a2a128e0dc663cac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i703c917c11ba41f5bc3d9e8c4fa82c6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd22f87fb8ad43d2af45c67cf1ea9e08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie31db10c6d6c45489ada87073252b5c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e05145f69544e49958c2c699ac2e14a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c76b4eb5b2d43bdbd83af671ec30557_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">isrg:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i483a5421245644e8b7c29c4dd81da287_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie37f0a23420d421f959a8c22e7707a05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3634dbe2d578411bbbc75e8831903c17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NonvestedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4cf962b95e84dc7891ff65923990d77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NonvestedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20cd9153845f4947a182196df818b48b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:FebruaryGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic52d8d269cc94237acc26da529069828_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">isrg:AugustGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:AnnualGrantOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:NewHireOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialGrantOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">isrg:TwoThousandNonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2000-03-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i78daf21ac2234a819cab8768cbb59e61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">isrg:InitialRSUgrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="isrg:AwardedtoAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i749d4dedba014c68aa5c7acf3007a4d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">isrg:DomesticAndForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01c4df323b92487582860c45f1709563_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i552384583d88412ebd23eaaff77ee647_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a0a29ffcad84c7ba35a79003fcce055_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id54e38a6bc054a1bb5bcc9ff5b0db69b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i745afcb5136f43d88582feee765c64c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001035267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>isrg:segment</measure>
    </unit>
    <unit id="period">
        <measure>isrg:period</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV8zLTEtMS0xLTE1MDAzNA_5fd8745a-f38d-4644-89c1-f7f947c8159e">0001035267</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV80LTEtMS0xLTE1MDAzNA_3295c6db-1f48-47b9-ae04-c180a0e26dd6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV81LTEtMS0xLTE1MDAzNA_5f1122d7-cdb0-410b-9a55-66440133eded">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV82LTEtMS0xLTE1MDAzNA_b50cbba7-f638-4c64-af03-cff2b0c60ddf">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF80L2ZyYWc6YzBkNmE3NmIxNjJkNDJiNmJmMzkzMDFlOTNiNDM4OGIvdGFibGU6NmU0NzVlNTFiZTRkNDliOWFmOWU2YTViNzJjMjA0MWEvdGFibGVyYW5nZTo2ZTQ3NWU1MWJlNGQ0OWI5YWY5ZTZhNWI3MmMyMDQxYV83LTEtMS0xLTE1MDAzNA_85fd4fe8-d5cc-46e5-8bff-6abf589e2f4a">false</dei:AmendmentFlag>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9">http://fasb.org/us-gaap/2022#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38">http://www.intuitivesurgical.com/20221231#IntangibleAndOtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a">http://www.intuitivesurgical.com/20221231#IntangibleAndOtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37">http://fasb.org/us-gaap/2022#LiabilitiesOtherThanLongtermDebtNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c">http://fasb.org/us-gaap/2022#LiabilitiesOtherThanLongtermDebtNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1">http://fasb.org/us-gaap/2022#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701">http://fasb.org/us-gaap/2022#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService
      contextRef="i20cd9153845f4947a182196df818b48b_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8zLTEtMS0xLTIwMDYzMw_0c3fc56b-485d-4ab2-a444-a28fa13ab863"
      unitRef="number">0.125000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService
      contextRef="i20cd9153845f4947a182196df818b48b_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl80LTEtMS0xLTIwMDYzMw_609169c6-fc23-4587-8660-ef9383058480"
      unitRef="number">0.020833</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService
      contextRef="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl81LTEtMS0xLTIwMDYzMw_a6009330-cc7e-4003-b423-ce1851d40b25"
      unitRef="number">0.125000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService
      contextRef="i21bba285cce1449eb0225d26f28bcc1a_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl82LTEtMS0xLTIwMDYzMw_1136244d-2ddb-4cb1-becd-bdc0d2d85185"
      unitRef="number">0.020833</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth
      contextRef="ic52d8d269cc94237acc26da529069828_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl83LTEtMS0xLTIwMDYzMw_bca98a61-98ed-4709-836f-f6078c937d7a"
      unitRef="number">0.145833</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic52d8d269cc94237acc26da529069828_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl84LTEtMS0xLTIwMDYzMw_423ab172-3605-49bb-acfc-572cef5734c8"
      unitRef="number">0.020833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService
      contextRef="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl85LTEtMS0xLTIwMDYzMw_459f2e7d-799b-4875-90c3-4fc0b8d7d770"
      unitRef="number">0.250000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear
      contextRef="i4f778d566726482e8239f83b562ec8a0_D20220101-20221231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMC0xLTEtMS0yMDA2MzM_d24fb0b4-2cf4-4bf3-bb00-4ba80c29a959"
      unitRef="number">0.020833</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService
      contextRef="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMi0xLTEtMS0yMDA2MzM_76ba640e-2e82-4b23-9564-ae7125616bd3"
      unitRef="number">0.333333</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear
      contextRef="ib25e678c3d1e4a128081a400441d1e87_D20000301-20151231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xMy0xLTEtMS0yMDA2MzM_b30db74b-a7cf-42a7-a68c-5724ab677b11"
      unitRef="number">0.027778</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xNy0xLTEtMS0yMDA2MzM_d6747ed2-2268-409e-b27a-5b6e229bd73e"
      unitRef="number">0.250000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i78daf21ac2234a819cab8768cbb59e61_D20210101-20211231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDExL2ZyYWc6NTkxMmNhYjlmMGZhNDc0MzhmODY3MjA4ZDZiZDhiODYvdGFibGU6MDEzYTE2ODY3OWY4NDI1YzlkMDY0NWVkZjY2YWFkMDIvdGFibGVyYW5nZTowMTNhMTY4Njc5Zjg0MjVjOWQwNjQ1ZWRmNjZhYWQwMl8xOS0xLTEtMS0yMDA2MzM_f359bcbd-4456-43fb-b10e-2769ffc9936a"
      unitRef="number">0.333333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk2_13cd1b3f-d45f-404b-b50d-2fc8cbe74aad">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MWE0MWY3N2RmY2MzNGIxM2FkNTg4MWNhNTc1ZmZlMmIvdGFibGVyYW5nZToxYTQxZjc3ZGZjYzM0YjEzYWQ1ODgxY2E1NzVmZmUyYl8wLTAtMS0xLTE1MDAzNA_5dae84f4-81e0-42d2-8325-2ee40d6f5d48">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY180OTQ3ODAyMzI5MjQ0_9bf61e1e-5015-4c45-8279-93df2cb88a8d">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjMzYTU1YmU5NWM1NDY2Mzk5NGVhZjhjM2U5NjM0YjUvdGFibGVyYW5nZToyMzNhNTViZTk1YzU0NjYzOTk0ZWFmOGMzZTk2MzRiNV8wLTAtMS0xLTE1MDAzNA_7f66bcbc-9d3d-47ac-a048-0c38fea755b7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA1_47af1b48-4813-431b-8c88-0b02045f9731">000-30713</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTEw_f344f141-4d8a-419e-84d6-e94b428d48bf">Intuitive Surgical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6ZmM5MTMwYTdiYjEzNGJlM2JiZTQ3MWI1MDE0ODVhNmQvdGFibGVyYW5nZTpmYzkxMzBhN2JiMTM0YmUzYmJlNDcxYjUwMTQ4NWE2ZF8wLTAtMS0xLTE1MDAzNA_d39f2d39-5e5e-4f1d-95f1-991c3e67b31d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6ZmM5MTMwYTdiYjEzNGJlM2JiZTQ3MWI1MDE0ODVhNmQvdGFibGVyYW5nZTpmYzkxMzBhN2JiMTM0YmUzYmJlNDcxYjUwMTQ4NWE2ZF8wLTItMS0xLTE1MDAzNA_040c1602-b06e-4185-ae15-95b2439e4ef3">77-0416458</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAy_0b0fe70d-d0bd-4a96-8d60-0fc2234e8d2e">1020 Kifer Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDkx_72dd7499-019b-43d4-857d-ecda2a6907ae">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAz_7e2c27f9-724e-4c58-a6cf-9fbdca7c817a">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk3_6d385f5c-7c87-44d5-a82e-183df30d7c18">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDky_6bf77f03-5793-4c76-b8cc-3a16f707bec8">94086</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA2_e88b9330-0fd4-4eff-ab4b-2db89ac64f36">(408)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk4_96d58491-e7ff-415e-9bfb-a0ddc8bd1f05">523-2100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTAtMS0xLTE1MDAzNA_592a4775-eca4-44ff-abfb-b81204859d69">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTEtMS0xLTE1MDAzNA_e746df3d-0f09-4ba0-b210-eed39e2ef36c">ISRG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6NTQ5NWE3MTE0MzFjNDY5ZTgxYmQwNTBiMjUyNjM1OWIvdGFibGVyYW5nZTo1NDk1YTcxMTQzMWM0NjllODFiZDA1MGIyNTI2MzU5Yl8xLTItMS0xLTE1MDAzNA_4df290c8-c0b2-4d6e-8a8c-2964ba6153e3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA3_af650071-7176-43e0-9d56-9ef14c53b5f8">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA0_7ddde211-2f8b-4381-9c79-b007f0e7f960">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTA4_23cfa67e-6bac-44a3-878b-78ba913f8bef">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk0_e8a1ce28-bba4-46d2-9a1a-4400d9797927">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8wLTAtMS0xLTE1MDAzNA_4216c67e-d2fe-463e-b963-fa57d42e175b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8xLTQtMS0xLTE1MDAzNA_9aa86f27-876c-4d42-bc94-c67da4d39f9f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGFibGU6MjcwNDY5NWM0MzVhNDc3YmE3MmFkNTg0ZmEzYzFmMTYvdGFibGVyYW5nZToyNzA0Njk1YzQzNWE0NzdiYTcyYWQ1ODRmYTNjMWYxNl8yLTQtMS0xLTE1MDAzNA_0553ab35-145e-4e1a-b170-d4d8e36fd3e4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk5_3e07f5ca-07dd-496f-9a60-ec6b64bd8e18">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNDk1_be996500-1e09-4181-8c35-ebdb8d4103b6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i205ff87813544221905e1bacbc0e834a_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18yOTAx_e96d6034-da85-442a-acda-740522302ac8"
      unitRef="usd">71400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib0ed59a4d8384c88a2ad8e007a293a45_I20230207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zMjIz_8ea59648-0083-4c9b-befb-fbbd763a2a68"
      unitRef="shares">350389679</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8xL2ZyYWc6MjRmNTRkMGZmYTAxNDI3NjliZjRjMjFjMjQ1MGMyZWMvdGV4dHJlZ2lvbjoyNGY1NGQwZmZhMDE0Mjc2OWJmNGMyMWMyNDUwYzJlY18zNTAw_69f649d4-9021-4e61-810a-3d1a7e166c6b">Part III incorporates information by reference to the definitive proxy statement for the Company&#x2019;s Annual Meeting of Stockholders to be held on or about April&#160;27, 2023, to be filed within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDIvZnJhZzphYWJlMWFhZDA3NGU0NDU3OTMzOTQ1MjFiZTgyYjAwOS90YWJsZTowM2NiMzhjMjUzOTM0ODk4OWUzY2QyZjkwNTZhM2I2Ny90YWJsZXJhbmdlOjAzY2IzOGMyNTM5MzQ4OTg5ZTNjZDJmOTA1NmEzYjY3XzItMi0xLTEtMTUwMDM0_5fa8aebd-0418-4bcd-b261-f7efb7ac69a0">238</dei:AuditorFirmId>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4XzM4NDgyOTA3MDk1OTc_bf79d33b-3ac7-4393-bd8a-06fb2a69f9b8"
      unitRef="usd">1680100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:AuditorName
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4Xzg4MTk_66b7b82a-2106-4e4c-add6-50c62cec70f5">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDUvZnJhZzozNTVhMWYyYjAwYWM0NTRjOWYxMjFjMWNkNjE3OGI1OC90ZXh0cmVnaW9uOjM1NWExZjJiMDBhYzQ1NGM5ZjEyMWMxY2Q2MTc4YjU4Xzg4MjA_256246b9-7891-4035-a6bc-9d922fafb4cb">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzQtMS0xLTEtMTUwMDM0_643b5ec3-01f2-4926-a4a7-3c2191917b3b"
      unitRef="usd">1581200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzQtMy0xLTEtMTUwMDM0_964e2cdb-8dd8-4231-8fc0-14d7b8d6f063"
      unitRef="usd">1290900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzUtMS0xLTEtMTUwMDM0_3e5c9b39-eac3-40e2-aadd-0ba1781aff5a"
      unitRef="usd">2536700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzUtMy0xLTEtMTUwMDM0_7e3885ee-29a8-41f2-9989-e30fe5ec301e"
      unitRef="usd">2913100000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzljMjk3YjVjZTg2NDAzZDk5NGI2M2EwYjJjODAxN2RfNTQ5NzU1ODE0MDA1_537e3aa1-8d56-432b-82de-9300581bfabd"
      unitRef="usd">22400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzljMjk3YjVjZTg2NDAzZDk5NGI2M2EwYjJjODAxN2RfNTQ5NzU1ODE0MDEx_c334ef8a-ceab-4ad3-8ecf-123b1d274bd4"
      unitRef="usd">20200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMS0xLTEtMTUwMDM0_8e313121-698e-4e19-8269-06c99cdb351c"
      unitRef="usd">942100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzYtMy0xLTEtMTUwMDM0_485947cd-860f-451e-a7cb-e073c2a6e5f5"
      unitRef="usd">782700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMS0xLTEtMTUwMDM0_3860936d-1cb1-4384-833c-2d6938cd9a74"
      unitRef="usd">893200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMy0xLTEtMTUwMDM0_3652dc36-52d2-4090-93f7-26528b8cca89"
      unitRef="usd">587100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzctMy0xLTEtMTUwMDM0_addf0141-b03a-4eaf-8740-6fbbb9166f11"
      unitRef="usd">587100000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzgtMS0xLTEtMTUwMDM0_524744bd-d0fd-4519-af4a-0162650682be"
      unitRef="usd">299800000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzgtMy0xLTEtMTUwMDM0_e150eb76-94b6-457a-b550-b6c54ef476e5"
      unitRef="usd">271100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzktMS0xLTEtMTUwMDM0_699cfa6c-2e80-4851-9d6a-08afedf74083"
      unitRef="usd">6253000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzktMy0xLTEtMTUwMDM0_1e7f853b-67cc-4f07-87ee-d852132427e6"
      unitRef="usd">5844900000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEwLTEtMS0xLTE1MDAzNA_7b15a6c4-aa33-4bf8-a329-db22d9846ddc"
      unitRef="usd">2374200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEwLTMtMS0xLTE1MDAzNA_9abb740d-f8ef-481a-91e4-dea275063fcd"
      unitRef="usd">1876400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzExLTEtMS0xLTE1MDAzNA_2906a3c0-29b6-4108-955a-56abb107c327"
      unitRef="usd">2623600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzExLTMtMS0xLTE1MDAzNA_1d7bc8c4-c336-46a8-afe0-86fdb1f0a186"
      unitRef="usd">4415500000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEyLTEtMS0xLTE1MDAzNA_2b84c010-f2f0-4e8d-aa4e-cafa89ca300c"
      unitRef="usd">664600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEyLTMtMS0xLTE1MDAzNA_7c6a6415-1d62-40cd-ae70-7c5511b3c78e"
      unitRef="usd">441400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <isrg:IntangibleAndOtherAssets
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEzLTEtMS0xLTE1MDAzNA_13283c97-9d76-41fd-9616-70f53bf89988"
      unitRef="usd">710100000</isrg:IntangibleAndOtherAssets>
    <isrg:IntangibleAndOtherAssets
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzEzLTMtMS0xLTE1MDAzNA_8a4e9e4e-843d-4b5f-bc35-94ad2179d759"
      unitRef="usd">633200000</isrg:IntangibleAndOtherAssets>
    <us-gaap:Goodwill
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE0LTEtMS0xLTE1MDAzNA_439399c3-618b-42f8-a90f-cb75340f30ff"
      unitRef="usd">348500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE0LTMtMS0xLTE1MDAzNA_5b3ab911-45d5-47d2-a70f-253bf29d5672"
      unitRef="usd">343600000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE1LTEtMS0xLTE1MDAzNA_9d371bde-d4bb-4866-9bbe-ecd88ed7985f"
      unitRef="usd">12974000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE1LTMtMS0xLTE1MDAzNA_8490ddf3-bacb-45bd-aa19-e2b7c085009e"
      unitRef="usd">13555000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE4LTEtMS0xLTE1MDAzNA_53b1d833-ab2e-489f-9d38-7e8e4d66864f"
      unitRef="usd">147000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE4LTMtMS0xLTE1MDAzNA_d9b3596f-648d-4422-abba-2ccf6aa7c32e"
      unitRef="usd">121200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE5LTEtMS0xLTE1MDAzNA_c28b9e81-0480-4690-a3c7-c937436fe4ac"
      unitRef="usd">401600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzE5LTMtMS0xLTE1MDAzNA_8832486d-4298-416b-bcb9-025faa2f574c"
      unitRef="usd">350100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIwLTEtMS0xLTE1MDAzNA_590cf096-93ed-4df0-a449-d5650189aec7"
      unitRef="usd">397300000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIwLTMtMS0xLTE1MDAzNA_3dcbcdf3-79fe-4468-8f3f-33afd5b4f25d"
      unitRef="usd">377200000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIxLTEtMS0xLTE1MDAzNA_f7f53990-9f7e-4356-a4be-7257ec2207e4"
      unitRef="usd">476200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIxLTMtMS0xLTE1MDAzNA_f22370ef-56be-4516-8f0b-c825ed7d19ab"
      unitRef="usd">301300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIyLTEtMS0xLTE1MDAzNA_50fb12a0-63d9-4166-b4e4-fc54e884a991"
      unitRef="usd">1422100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIyLTMtMS0xLTE1MDAzNA_f06927a3-84fb-4283-8a8b-3f0dfd99de72"
      unitRef="usd">1149800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIzLTEtMS0xLTE1MDAzNA_bfb4f65c-6f3c-407a-b827-37719718b5f2"
      unitRef="usd">439300000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzIzLTMtMS0xLTE1MDAzNA_2cca96a0-b326-42d8-93aa-c3ba6aac1f20"
      unitRef="usd">453700000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI0LTEtMS0xLTE1MDAzNA_9b1699ee-f25e-4c71-8a5a-290bd4937f87"
      unitRef="usd">1861400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI0LTMtMS0xLTE1MDAzNA_f6f44908-724a-4c37-8e83-714363e7602f"
      unitRef="usd">1603500000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI1LTEtMS0xLTE1MDAzNA_c1f85c7c-58de-43e4-937c-cb593c7248b0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI1LTMtMS0xLTE1MDAzNA_804b7f63-6b30-4f7f-91ab-e57a0d85037a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzA_7dfafc80-b4c3-475e-b897-87b6b4ce5535"
      unitRef="shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzA_e7c57feb-3e26-4183-b822-5880ea4c5412"
      unitRef="shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzc_789e8d29-60f4-4ef1-b07a-3bcbb37b6e05"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyNzc_8ab57b40-6b81-4c5b-98b4-d76c5f034c95"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_07ac1355-9ec6-45cb-84f7-45c2a64bb471"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_0b16cebd-f01d-4763-b1e7-a76d03e0e4a2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_2224cd64-d0b2-4900-b46a-978d7f1165a5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmUxYTkxMWIyMGM2NjQ2NjFiZTRjYTdiYWEzZDhlMTgxXzQzOTgwNDY1MTEyODc_b6c7f64f-1747-4697-a76b-824f9b831c61"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTEtMS0xLTE1MDAzNA_c6b534db-4b8a-476e-9630-acadb632e20c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI3LTMtMS0xLTE1MDAzNA_7f13d2f0-c628-4705-8baa-7fa3d5c5aa4a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA4NQ_8dda9d1c-27dc-41ed-85d8-c567b784e7f4"
      unitRef="shares">600000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA4NQ_c97d6899-41ff-4394-818e-8ad90215a549"
      unitRef="shares">600000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA5NA_59f61142-26eb-431e-9095-a3583dbd0d0a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzU0OTc1NTgxNDA5NA_d0d887bb-ac54-41ef-8dc1-73a08151b395"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODM_371725e1-554d-4a0f-a3c1-71b45b09d9fa"
      unitRef="shares">350000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODM_c33b686b-bc07-4cf4-bcad-cf8b8d2c20dd"
      unitRef="shares">350000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODc_5a0b2a5c-b82f-46d3-89b7-4d1a1b2ea9b3"
      unitRef="shares">357700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjA2ZDA0NmNlZDVjOTRiMjlhNGMwYzk0NzcwODcyYmVmXzQzOTgwNDY1MTEzODc_ca69dd3b-970e-40f4-9330-ae0301ddc41b"
      unitRef="shares">357700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTEtMS0xLTE1MDAzNA_66762e78-e148-423f-9316-030420fbcf59"
      unitRef="usd">400000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI4LTMtMS0xLTE1MDAzNA_808e0db6-9a26-4949-8a48-470e854b9d5e"
      unitRef="usd">400000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI5LTEtMS0xLTE1MDAzNA_4f94f633-eb95-41b6-886b-846b9425a83d"
      unitRef="usd">7703900000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzI5LTMtMS0xLTE1MDAzNA_68931001-ead2-4aae-8a57-ad50473e467f"
      unitRef="usd">7164000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMwLTEtMS0xLTE1MDAzNA_9e8ec45f-1479-43e9-9210-cee057a8e314"
      unitRef="usd">3500100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMwLTMtMS0xLTE1MDAzNA_4bdc4d9b-ec9a-418c-a8ff-28e3526851f3"
      unitRef="usd">4760900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMxLTEtMS0xLTE1MDAzNA_7bb5fbd3-d5d5-438b-8021-6a61b87bb195"
      unitRef="usd">-162500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMxLTMtMS0xLTE1MDAzNA_9b9aa056-1d07-408e-8d48-a29d4375834d"
      unitRef="usd">-24200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMyLTEtMS0xLTE1MDAzNA_ecf35b68-b219-428b-bc03-af5c3d1cbfc2"
      unitRef="usd">11041900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMyLTMtMS0xLTE1MDAzNA_1d8cc6d1-64bd-40c8-a629-4eb2ffebbf35"
      unitRef="usd">11901100000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMzLTEtMS0xLTE1MDAzNA_04c32df9-0456-412c-b992-88b8cf3bc532"
      unitRef="usd">70700000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzMzLTMtMS0xLTE1MDAzNA_0d0ee1c5-c9fa-4361-92dc-3aeebb4c0491"
      unitRef="usd">50400000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM0LTEtMS0xLTE1MDAzNA_c22dffa9-8859-4852-9dfb-92ab77c51b4b"
      unitRef="usd">11112600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM0LTMtMS0xLTE1MDAzNA_a4d7b1e3-f2da-4ef6-823d-078b289398ba"
      unitRef="usd">11951500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM1LTEtMS0xLTE1MDAzNA_3f5222c4-c76a-4f72-8217-1781c5a49084"
      unitRef="usd">12974000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMDgvZnJhZzo5MjIzMGRiODg4OTU0ODFhOTRjMDU1NDg0MmI5NWU0OC90YWJsZTozZWY4NmE2MzQ3M2I0MmJmODAyZWFkODdjZGExNGQxYi90YWJsZXJhbmdlOjNlZjg2YTYzNDczYjQyYmY4MDJlYWQ4N2NkYTE0ZDFiXzM1LTMtMS0xLTE1MDAzNA_d1c41a9d-3b72-454b-a708-c8d4c7457f88"
      unitRef="usd">13555000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtMS0xLTEtMTUwMDM0_9e9e3a8a-f50b-49be-8d59-5986fd7d593e"
      unitRef="usd">5198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtMy0xLTEtMTUwMDM0_227c20e9-1f04-4f2e-901a-99e0faf2c0fc"
      unitRef="usd">4793900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzMtNS0xLTEtMTUwMDM0_17ccb50e-fa19-45e4-a7bc-78fe48e8783e"
      unitRef="usd">3634600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtMS0xLTEtMTUwMDM0_f15e0215-d394-4000-bfd4-abe733044f02"
      unitRef="usd">1024200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtMy0xLTEtMTUwMDM0_9b1b3ea9-f8f7-4610-be46-c1e1bb018f15"
      unitRef="usd">916200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzQtNS0xLTEtMTUwMDM0_892e8c5a-27c7-475a-8895-a0daa694de0c"
      unitRef="usd">723800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtMS0xLTEtMTUwMDM0_7655ced4-e5db-47bf-8633-6a249b9d4892"
      unitRef="usd">6222200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtMy0xLTEtMTUwMDM0_8bab8ad0-eb83-418a-a2a4-572aef862c19"
      unitRef="usd">5710100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzUtNS0xLTEtMTUwMDM0_4772a152-1877-442b-b9f8-077a3450209e"
      unitRef="usd">4358400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib0492080e94f4f7b8621cf28a25fb8a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctMS0xLTEtMTUwMDM0_701771b3-e58a-41be-b4b2-1c168f904fb0"
      unitRef="usd">1700300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2d018f4ebaf64e22bd8a5fc06849752a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctMy0xLTEtMTUwMDM0_543f5654-9277-4c04-9793-dbb688535f86"
      unitRef="usd">1464100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i63665deddf0a4f459d8a35d6237f6fd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzctNS0xLTEtMTUwMDM0_21c81804-f291-418e-bd3c-98add2c30578"
      unitRef="usd">1230300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtMS0xLTEtMTUwMDM0_ad4fed1e-edba-48cd-81ba-0b0a7516c0aa"
      unitRef="usd">325900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtMy0xLTEtMTUwMDM0_80fc069d-1965-427f-821a-8b253553240e"
      unitRef="usd">287500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzgtNS0xLTEtMTUwMDM0_e5f07190-d997-4a98-94e2-350289b7b828"
      unitRef="usd">266900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktMS0xLTEtMTUwMDM0_efcb8841-61d7-4499-957f-3b861ce11823"
      unitRef="usd">2026200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktMy0xLTEtMTUwMDM0_61ac86d4-b07d-47b7-9275-caac6582b0f9"
      unitRef="usd">1751600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzktNS0xLTEtMTUwMDM0_c6526c7b-3fef-468f-b4b3-c9911428ae8d"
      unitRef="usd">1497200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTEtMS0xLTE1MDAzNA_d1bf4e72-05cf-4e79-9843-7450d81f0733"
      unitRef="usd">4196000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTMtMS0xLTE1MDAzNA_36667086-4b16-4f07-8376-ae7a1c7e1949"
      unitRef="usd">3958500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEwLTUtMS0xLTE1MDAzNA_0af32090-0e42-4003-8c7f-be162ff18550"
      unitRef="usd">2861200000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTEtMS0xLTE1MDAzNA_73e68223-27a8-45ae-90c8-bfb3d51256d4"
      unitRef="usd">1739900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTMtMS0xLTE1MDAzNA_84a09df8-d74c-46d7-8207-6043fb552e77"
      unitRef="usd">1466500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEyLTUtMS0xLTE1MDAzNA_1f119c61-0320-4f65-8850-c0042cae3a66"
      unitRef="usd">1216300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTEtMS0xLTE1MDAzNA_d56af6d3-5953-4c5a-9488-255483a36b10"
      unitRef="usd">879000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTMtMS0xLTE1MDAzNA_f6d7d0e6-ccd5-4e89-a7ee-f18e580796a4"
      unitRef="usd">671000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzEzLTUtMS0xLTE1MDAzNA_f28c6b4d-2905-4af6-a53d-4b37cf41842d"
      unitRef="usd">595100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTEtMS0xLTE1MDAzNA_5e82df7c-f321-4395-8f28-be6ee61e00ef"
      unitRef="usd">2618900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTMtMS0xLTE1MDAzNA_159c576b-d3a9-45f2-91b7-d5c56b5990bc"
      unitRef="usd">2137500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE0LTUtMS0xLTE1MDAzNA_a93807ec-a913-4274-9491-f30ae4bf3485"
      unitRef="usd">1811400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTEtMS0xLTE1MDAzNA_69b7a43c-b769-44ea-a6c0-f94d81b3f253"
      unitRef="usd">1577100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTMtMS0xLTE1MDAzNA_e5872caa-cd67-418a-8782-f936b50939b9"
      unitRef="usd">1821000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE1LTUtMS0xLTE1MDAzNA_a97e6353-741b-471f-8685-00adc53b44a4"
      unitRef="usd">1049800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTEtMS0xLTE1MDAzNA_54e3dea5-c4fd-45d1-8df4-c9144683e027"
      unitRef="usd">29700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTMtMS0xLTE1MDAzNA_56178df5-580b-450a-b54f-1c4861f83531"
      unitRef="usd">69300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE2LTUtMS0xLTE1MDAzNA_59caac93-3eb4-4f30-bdfa-0686de19ca03"
      unitRef="usd">157200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTEtMS0xLTE1MDAzNA_c5607227-60ba-4282-a4df-4187b07aa27c"
      unitRef="usd">1606800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTMtMS0xLTE1MDAzNA_69db53e9-b675-4d3a-b7ab-27d04536cc81"
      unitRef="usd">1890300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE3LTUtMS0xLTE1MDAzNA_4490df86-074d-48de-985b-82a4b71cdcec"
      unitRef="usd">1207000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTEtMS0xLTE1MDAzNA_4e120866-97e7-4ffa-a67a-6bf42d5cf00b"
      unitRef="usd">262400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTMtMS0xLTE1MDAzNA_240bf1d0-8fac-4ae2-bd40-433a82367af7"
      unitRef="usd">162200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE4LTUtMS0xLTE1MDAzNA_ccf6c9ae-b378-4178-8112-719d5866c0b6"
      unitRef="usd">140200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTEtMS0xLTE1MDAzNA_9e002019-582f-4706-8aba-388f1f3aa1a0"
      unitRef="usd">1344400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTMtMS0xLTE1MDAzNA_6a595b57-7d9f-4438-9d53-ee370a5db7e6"
      unitRef="usd">1728100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzE5LTUtMS0xLTE1MDAzNA_81d247c2-6dbb-45e1-bbab-57ecd9a5d0de"
      unitRef="usd">1066800000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id3fdd4cfad61458ba3bd1f961574b7c4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTEtMS0xLTE1MDAzNA_0289b190-d9a4-4582-b866-24ac4e503def"
      unitRef="usd">22100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic8e1406152504c24becb2d14ea3aba96_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTMtMS0xLTE1MDAzNA_fdd1ad5e-0dbf-41de-b790-b2554dbe0a04"
      unitRef="usd">23500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iea73322238bf4952ba8f6f56b4843fd8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIwLTUtMS0xLTE1MDAzNA_7f49251c-a806-4aca-ab70-925895173495"
      unitRef="usd">6200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTEtMS0xLTE1MDAzNA_07a1fe66-4ae4-41a3-9936-4fe7cb052638"
      unitRef="usd">1322300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTMtMS0xLTE1MDAzNA_4be92bc6-bb88-4ea1-805e-b36c7be3a093"
      unitRef="usd">1704600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIxLTUtMS0xLTE1MDAzNA_b9411dcf-af09-43c7-814d-65a2937f0846"
      unitRef="usd">1060600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTEtMS0xLTE1MDAzNA_4e3efbb9-6cbe-4e8a-a467-024272ef5491"
      unitRef="usdPerShare">3.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTMtMS0xLTE1MDAzNA_1dfddc96-6bd0-479d-8b3e-3244cefd7e98"
      unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzIzLTUtMS0xLTE1MDAzNA_db98fcc4-1fbf-47e5-9f58-58305e2f674e"
      unitRef="usdPerShare">3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTEtMS0xLTE1MDAzNA_996e6097-4b8f-47ca-b549-b9549e64f1d3"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTMtMS0xLTE1MDAzNA_da505f47-04b5-46d2-81fb-09fb3f6def80"
      unitRef="usdPerShare">4.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI0LTUtMS0xLTE1MDAzNA_989706a0-c354-42e9-88d8-6a9031a4ce2b"
      unitRef="usdPerShare">2.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTEtMS0xLTE1MDAzNA_fc02180a-7b8f-4697-8a56-1eda28408b65"
      unitRef="shares">355700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTMtMS0xLTE1MDAzNA_a75b91a8-e4f6-4efe-a3d9-52a0f253cd8e"
      unitRef="shares">356100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI2LTUtMS0xLTE1MDAzNA_8167bffc-78dc-4892-b280-9ced69980008"
      unitRef="shares">351100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTEtMS0xLTE1MDAzNA_584332e7-fc11-4538-a62c-cdb978097e79"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTMtMS0xLTE1MDAzNA_dc33f3e0-e33e-45f1-af15-4cd5111983b0"
      unitRef="shares">365800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTEvZnJhZzowNzBmZTMyMTA1OTc0OWM0OGYyMzU4NDdiYmI3ZmJjMi90YWJsZTo1ZTk1NDkxMmZiNTM0NzdhYjZiMDg0YWE3YWEzNmNlMC90YWJsZXJhbmdlOjVlOTU0OTEyZmI1MzQ3N2FiNmIwODRhYTdhYTM2Y2UwXzI3LTUtMS0xLTE1MDAzNA_17a42421-661e-48d7-9d84-511389322a99"
      unitRef="shares">361000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItMS0xLTEtMTUwMDM0_9e002019-582f-4706-8aba-388f1f3aa1a0"
      unitRef="usd">1344400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItMy0xLTEtMTUwMDM0_6a595b57-7d9f-4438-9d53-ee370a5db7e6"
      unitRef="usd">1728100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzItNS0xLTEtMTUwMDM0_81d247c2-6dbb-45e1-bbab-57ecd9a5d0de"
      unitRef="usd">1066800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtMS0xLTEtMTUwMDM0_e56d5ef5-b8ba-4d70-a99b-5477c3e5dd8e"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtMy0xLTEtMTUwMDM0_e8ceb305-cc32-4e0f-a12f-8e54bb2d4e8b"
      unitRef="usd">-13300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzQtNS0xLTEtMTUwMDM0_2890a8e6-5eb3-4fbf-864a-1bd78ddf9035"
      unitRef="usd">5200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtMS0xLTEtMTUwMDM0_916da407-fa8c-4642-a7bd-43aa752e6a57"
      unitRef="usd">-138200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtMy0xLTEtMTUwMDM0_d8c7a2f8-4e48-43fd-8295-34f199eeaa6e"
      unitRef="usd">-45500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzYtNS0xLTEtMTUwMDM0_229f16d0-f529-417d-a4f2-a2866b8cbd34"
      unitRef="usd">13800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctMS0xLTEtMTUwMDM0_8ee3c73e-8069-4cec-837e-fdcb03867ba3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctMy0xLTEtMTUwMDM0_bde8ea6d-9bb6-4b2e-b7ba-06ea9644cbc9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzctNS0xLTEtMTUwMDM0_f3c7ac68-537a-4a5f-95d7-612be8d19a18"
      unitRef="usd">4700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtMS0xLTEtMTUwMDM0_e93bfdfe-2878-4f42-b5c6-3da6e7029802"
      unitRef="usd">-138200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtMy0xLTEtMTUwMDM0_4611fa6c-5a73-4186-b925-3b79aadc1cef"
      unitRef="usd">-45500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzgtNS0xLTEtMTUwMDM0_5b6bd3a5-a7db-413f-81a1-d833d7137fa5"
      unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTEtMS0xLTE1MDAzNA_eb1a66c1-1636-437f-81f9-b3c91eae61fa"
      unitRef="usd">-35000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTMtMS0xLTE1MDAzNA_e2615d75-2e4a-44c0-b6a1-80a059f608c8"
      unitRef="usd">12300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEwLTUtMS0xLTE1MDAzNA_9dcbb88b-0621-4dff-9346-84a6f25584b2"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTEtMS0xLTE1MDAzNA_9f6c29b5-d79e-4497-9726-7e7f39dc6eba"
      unitRef="usd">-27600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTMtMS0xLTE1MDAzNA_7327aa39-354d-4690-b729-14e495be4d71"
      unitRef="usd">4900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzExLTUtMS0xLTE1MDAzNA_0d9a6aec-b8fe-4a2c-b0e2-5670e733b76e"
      unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTEtMS0xLTE1MDAzNA_5310e191-191e-4691-9543-af163246dbaf"
      unitRef="usd">-7400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTMtMS0xLTE1MDAzNA_2b70b316-f38c-4401-9504-12058ce96322"
      unitRef="usd">7400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzEyLTUtMS0xLTE1MDAzNA_ff477435-6e75-4266-b07b-c2acb0e595c9"
      unitRef="usd">-3600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTEtMS0xLTE1MDAzNA_73fdb280-1b1d-43c1-bc66-95f393eb7eb7"
      unitRef="usd">-5800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTMtMS0xLTE1MDAzNA_6e0be272-8059-4942-930d-ac5ffddc44f5"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE0LTUtMS0xLTE1MDAzNA_8fa6dc52-35b4-4280-82ba-2de47ddf4493"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTEtMS0xLTE1MDAzNA_cc7ac09f-4aa8-42db-9583-ac83813ed444"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTMtMS0xLTE1MDAzNA_359cf55d-8b19-49b4-8b1c-f8c0d9ebd987"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE1LTUtMS0xLTE1MDAzNA_0e3f720e-1bd3-4136-8919-954320a4824d"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTEtMS0xLTE1MDAzNA_ee086e90-1330-4e1d-bbdf-b504e19a763b"
      unitRef="usd">-6000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTMtMS0xLTE1MDAzNA_ed2d1e5c-fb76-40ee-b189-6d918be3cc7d"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE2LTUtMS0xLTE1MDAzNA_f44b1893-839f-4ae2-a6fb-49bb3e110f01"
      unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTEtMS0xLTE1MDAzNA_84d41f31-bd4e-4450-93dc-1fb97e2492fb"
      unitRef="usd">-140100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTMtMS0xLTE1MDAzNA_bc4b750a-0246-406e-ae59-9df58a8eba55"
      unitRef="usd">-49800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE3LTUtMS0xLTE1MDAzNA_30b55ff9-4bed-4dec-86d2-67211cd06646"
      unitRef="usd">13000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTEtMS0xLTE5MjE0Ng_57ebb485-4d41-471e-bc01-3ae132e1a78e"
      unitRef="usd">1204300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTMtMS0xLTE5MjE0Nw_db39543c-bd2d-422e-8410-7213292e1c48"
      unitRef="usd">1678300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTUtMS0xLTE5MjE1Ng_e8df8af4-1a65-4e87-b62b-f2327833f5f6"
      unitRef="usd">1079800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTEtMS0xLTE5MjE2NQ_1e90f05f-5789-4cee-94bc-bd41f5692ecb"
      unitRef="usd">20300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTMtMS0xLTE5MjE3Mg_9ba9e43b-d51e-4b77-8bcd-8576a47f52d7"
      unitRef="usd">22800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE5LTUtMS0xLTE5MjE3OQ_f8b6427f-c6d4-469f-bdb4-b2b80453a0a0"
      unitRef="usd">6700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTEtMS0xLTE1MDAzNA_f46b61a2-ec17-4bcc-897d-0f0c76510240"
      unitRef="usd">1184000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTMtMS0xLTE1MDAzNA_62794673-6141-4c2b-b51c-828a338b6508"
      unitRef="usd">1655500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTQvZnJhZzphZDU5Nzk4ZWY3ZjA0ZTlkOGM1ZTQ4YzQwYTgyYTE3NS90YWJsZTo0YzkwOGY0NjY1YWU0ZTJkYjJjNmZhYzY4ODJjNDZmZS90YWJsZXJhbmdlOjRjOTA4ZjQ2NjVhZTRlMmRiMmM2ZmFjNjg4MmM0NmZlXzE4LTUtMS0xLTE1MDAzNA_afa4332e-ac6e-4812-bd6f-5d881bdc622b"
      unitRef="usd">1073100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i86284f29e88649f98a3081d2acc55f59_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMS0xLTEtMTUwMDM0_746a87fe-59ca-4230-8603-24a78cbb09d6"
      unitRef="shares">347900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86284f29e88649f98a3081d2acc55f59_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMy0xLTEtMTUwMDM0_7f699a9f-3acc-41f9-8446-4312490201c4"
      unitRef="usd">300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie28b90c84ec44021a92cdcdb2c25b28a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItNS0xLTEtMTUwMDM0_138be367-b00c-4763-9f46-711aff3fd429"
      unitRef="usd">5756600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b59bb58abc7479d89bc7d2b74d70544_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItNy0xLTEtMTUwMDM0_a4d190fe-92b0-4074-8168-5b7c36a9173c"
      unitRef="usd">2494500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f52079425724fd694aa42f7b37a71e5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItOS0xLTEtMTUwMDM0_0e271428-1a47-4385-88b9-6ed4625c4b7d"
      unitRef="usd">12400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46ac86aca2b842e9883ccef967301ae5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTEtMS0xLTE1MDAzNA_5622fcd2-1491-4458-8680-24fc1df44eaf"
      unitRef="usd">8263800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ae840c0106e4c1996ae436a312416d9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTMtMS0xLTE1MDAzNA_33bf26fb-3855-4744-8d80-16cb464c145d"
      unitRef="usd">20900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzItMTUtMS0xLTE1MDAzNA_b480c6c5-c66d-4cb2-b9fb-39f2d8a39e6d"
      unitRef="usd">8284700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2c801b2cffa477fb54e06f63ca156ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3"
      unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f6e09d2840745a2be9bd85eeaaa8a92_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d"
      unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5043d7c11ba745e8a27d34923ccd110f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4"
      unitRef="usd">-100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMS0xLTEtMTUwMDM0_9c21bb62-e8c8-4232-a8fd-01aa27f812e4"
      unitRef="shares">6800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMy0xLTEtMTY0Mzk1_af3beef7-1839-4b01-a165-e8ae08240b48"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtNS0xLTEtMTUwMDM0_ec6bb413-fbf8-43f0-9772-d7a01ef25ab8"
      unitRef="usd">308700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMTEtMS0xLTE1MDAzNA_e10e9d9d-20e1-45cf-a376-2156a0824cfb"
      unitRef="usd">308800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzQtMTUtMS0xLTE1MDAzNA_735c83ef-e773-43e6-b42b-5df4418e1559"
      unitRef="usd">308800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMS0xLTEtMTUwMDM0_d66b1567-3037-4f29-a147-a20282df31f4"
      unitRef="shares">900000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtNS0xLTEtMTUwMDM0_ae797397-a82f-4d3c-a1a3-a04bac04cd41"
      unitRef="usd">7900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtNy0xLTEtMTUwMDM0_77200ff5-6afb-4a2d-b8e7-0284b28bfe54"
      unitRef="usd">167300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMTEtMS0xLTE1MDAzNA_70f4f6bf-70df-44e6-a264-b0c42a16ceb6"
      unitRef="usd">175200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzUtMTUtMS0xLTE1MDAzNA_125ca316-ff14-4ec9-bc7e-99c28efe69f8"
      unitRef="usd">175200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtNS0xLTEtMTUwMDM0_ea9417dc-ea9a-48e5-9c1f-b479c212f144"
      unitRef="usd">395400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtMTEtMS0xLTE1MDAzNA_03f03da7-68e7-49e6-95d9-1536841fd4af"
      unitRef="usd">395400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzYtMTUtMS0xLTE1MDAzNA_5d085da5-0b6f-4ff2-87eb-842b953a165f"
      unitRef="usd">395400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i0987b5cf48ab478cad75f2eb6a9e01c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMS0xLTEtMTUwMDM0_9468ccfa-c5df-46d4-866b-91a696222604"
      unitRef="shares">700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib6059c5c960d4e549fe28e54b48c1110_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctNS0xLTEtMTUwMDM0_fcfd7646-3cf3-4fa5-a921-bf376406a16e"
      unitRef="usd">-7900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctNy0xLTEtMTUwMDM0_5afb02d8-760a-46ff-80d7-63a94ea02122"
      unitRef="usd">-126400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMTEtMS0xLTE1MDAzNA_d9f40e3c-8595-4d07-b8ee-eca8fefdedcb"
      unitRef="usd">134300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzctMTUtMS0xLTE1MDAzNA_78d4d4f6-8b2b-412b-b674-f277a1dcdd16"
      unitRef="usd">134300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0cb98cae2e664d35a09a7e480a4d0029_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtNy0xLTEtMTUwMDM0_61b55b27-3301-4152-94c3-eb7415274e23"
      unitRef="usd">1060600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtMTEtMS0xLTE1MDAzNA_bec60047-2b8d-4ae1-a014-8d526f3e419f"
      unitRef="usd">1060600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzgtMTUtMS0xLTE1MDAzNA_89aa1228-da49-446e-8fd3-43ee951a8df8"
      unitRef="usd">1060600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c08937764b145139a93a060599d3467_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktOS0xLTEtMTUwMDM0_171a5c63-0c8d-489d-acbb-f45a80948060"
      unitRef="usd">12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb193c7a61994110bec6a7c2209424f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTEtMS0xLTE1MDAzNA_e671439a-a86b-4c34-8de4-fb5b2ab56cdc"
      unitRef="usd">12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTMtMS0xLTE1MDAzNA_c920a636-e9a2-414e-b837-dbedaf0d995b"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzktMTUtMS0xLTE1MDAzNA_93d999c3-99ea-4e0c-acc9-fa068c543c82"
      unitRef="usd">13000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i05f1edae0568469c89f9d30766528e9e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzExLTEzLTEtMS0xNTAwMzQ_abc0d722-1bb1-4f20-a352-1744da50ef18"
      unitRef="usd">6200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzExLTE1LTEtMS0xNTAwMzQ_23306aa0-3a78-4384-86ae-47b6ceac5322"
      unitRef="usd">6200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4d7c7907f86d4cce9957516da107670e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTEtMS0xLTE1MDAzNA_c95af0ee-2ca6-4f16-88a1-5a3d4b34e0c2"
      unitRef="shares">353100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d7c7907f86d4cce9957516da107670e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTMtMS0xLTE1MDAzNA_420514ea-8a95-44c2-a17d-0db6d8310ed0"
      unitRef="usd">400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdde0a5261214008b1be258b805ec820_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTUtMS0xLTE1MDAzNA_2ddd6e58-8484-493d-818b-9cd654605ed9"
      unitRef="usd">6444900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ad839dce5564f57a74be0b40182551f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTctMS0xLTE1MDAzNA_3d6b2174-9507-4d61-8d64-4660daa5b736"
      unitRef="usd">3261300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTktMS0xLTE1MDAzNA_86466a72-93b7-4d9d-a449-014068385925"
      unitRef="usd">24900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a4a986595294305b5ea409ad41fcfc9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTExLTEtMS0xNTAwMzQ_2a710673-d64f-46df-97ec-a11fbeef0e33"
      unitRef="usd">9731500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd2ad8e3ddd245609178c33ddcac1011_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTEzLTEtMS0xNTAwMzQ_6f723e1d-7d6e-4738-8736-ad99a14d3f54"
      unitRef="usd">27600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzEyLTE1LTEtMS0xNTAwMzQ_58e7e3fc-7c07-48b4-a5a2-06d4eb1a09f8"
      unitRef="usd">9759100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTEtMS0xLTE1MDAzNA_d9942d93-951e-4c82-9959-c02536057f99"
      unitRef="shares">5400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTUtMS0xLTE1MDAzNA_351460c3-ffc3-4f6e-b20f-0596812ee942"
      unitRef="usd">276500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTExLTEtMS0xNTAwMzQ_e494160e-184b-4177-9026-4b9b568d3d0a"
      unitRef="usd">276500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE0LTE1LTEtMS0xNTAwMzQ_ec7ed3a1-ab88-43aa-8ae0-1200d1135e5d"
      unitRef="usd">276500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i6e12effc86454cbcb13cbb1f82d0dfed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTEtMS0xLTE1MDAzNA_4c700a00-6035-46c4-80b8-ba42354779d4"
      unitRef="shares">800000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTUtMS0xLTE1MDAzNA_7aa7dba3-39f1-479a-a1d8-fce838dab6b0"
      unitRef="usd">6600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTctMS0xLTE1MDAzNA_8dc20b50-858a-40a9-b91d-7863c5715758"
      unitRef="usd">205000000.0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTExLTEtMS0xNTAwMzQ_e010746f-fb44-46f3-a97f-e5d480faa41a"
      unitRef="usd">211600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE1LTE1LTEtMS0xNTAwMzQ_7e78d8e7-558d-49c1-8cd5-d3b35e98dff1"
      unitRef="usd">211600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb9dc1838ed844ea8824f3064842fcbd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTUtMS0xLTE1MDAzNA_5ff6cdc2-5b6b-4329-8d29-137649e165b8"
      unitRef="usd">449200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTExLTEtMS0xNTAwMzQ_7aa19049-e776-4bb5-8f72-ff2179790062"
      unitRef="usd">449200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE2LTE1LTEtMS0xNTAwMzQ_4545a87b-fcac-4d61-9758-81eb13f7dffd"
      unitRef="usd">449200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i34708ad123b448028097c7b4bff09fa7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTctMS0xLTE1MDAzNA_9ee39f62-8c1b-4ac6-9ac3-90993e7d590d"
      unitRef="usd">1704600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTExLTEtMS0xNTAwMzQ_f5e71b57-ccca-4954-a499-0cd486229f36"
      unitRef="usd">1704600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE4LTE1LTEtMS0xNTAwMzQ_4f9a23f0-b919-48bb-b7ae-1c31e2ba3049"
      unitRef="usd">1704600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTktMS0xLTE1MDAzNA_6dac4637-82cb-4f15-837d-486e630b9737"
      unitRef="usd">-49100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic40adb87eff94aa68dde286fc09fd1ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTExLTEtMS0xNTAwMzQ_96a66ac2-a9a1-409e-91f1-25b3da57022a"
      unitRef="usd">-49100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTEzLTEtMS0xNTAwMzQ_c4b1b68f-e194-4cc4-be75-97ce59c77f23"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzE5LTE1LTEtMS0xNTAwMzQ_74596d05-6921-4b39-b6b9-98b43e32aef3"
      unitRef="usd">-49800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0de47d0330fc42fdb3255d4c8cdac6e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIxLTEzLTEtMS0xNTAwMzQ_701abab4-a8ff-494b-a995-d6e40d71a9ad"
      unitRef="usd">23500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIxLTE1LTEtMS0xNTAwMzQ_ed4e7d37-235b-4d3c-a6a2-db2896f4cb86"
      unitRef="usd">23500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c5ce2953a28440b89e7ee68bba323d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTEtMS0xLTE1MDAzNA_a828b1a8-0cc5-426c-bd1a-e56492fbdc85"
      unitRef="shares">357700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c5ce2953a28440b89e7ee68bba323d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTMtMS0xLTE1MDAzNA_fe5ce8b2-727b-44e7-9c53-cbcb438211c3"
      unitRef="usd">400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8054044227734087aef06647c25d127e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTUtMS0xLTE1MDAzNA_67604fcb-291a-4f10-9a51-8cc586270269"
      unitRef="usd">7164000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03428188c1ee49ef8ce9c5b683046ed8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTctMS0xLTE1MDAzNA_696544f2-2f8b-4c62-8d93-a88a93e4c6f7"
      unitRef="usd">4760900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTktMS0xLTE1MDAzNA_88240cd7-0816-4b13-883b-70e9a86e747d"
      unitRef="usd">-24200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16f263d8dd40419bb80418ab7843bf76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTExLTEtMS0xNTAwMzQ_27931f16-950d-459a-93f6-e6c20365c44f"
      unitRef="usd">11901100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecf372d2348047f5953ac29d0036d748_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTEzLTEtMS0xNTAwMzQ_9ba863d1-6ea6-4c64-ad9e-68de02d60c39"
      unitRef="usd">50400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzIyLTE1LTEtMS0xNTAwMzQ_6fcd0b69-1411-4295-bd18-6b8c8ad9ba84"
      unitRef="usd">11951500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTEtMS0xLTE1MDAzNA_63ef1823-ce89-49f5-898e-7c55fa8111ff"
      unitRef="shares">4200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTUtMS0xLTE1MDAzNA_eb7a4a63-bd92-42a6-b06d-1f14477b5f46"
      unitRef="usd">233800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTExLTEtMS0xNTAwMzQ_ddac22fd-7de1-4876-bd2c-0c007787e191"
      unitRef="usd">233800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI0LTE1LTEtMS0xNTAwMzQ_83e0aa09-dd86-45ae-8fd6-7544b71db7c0"
      unitRef="usd">233800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTEtMS0xLTE1MDAzNA_f4b43073-dcce-4f88-909b-cbe40936d35a"
      unitRef="shares">700000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTUtMS0xLTE1MDAzNA_efae2cbe-5275-4a1c-acaa-9124165aba64"
      unitRef="usd">7400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTctMS0xLTE1MDAzNA_faa660d3-f9ab-4ffe-8490-41c5de2dcd6d"
      unitRef="usd">186800000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTExLTEtMS0xNTAwMzQ_424076f2-0028-498a-b054-9e58bdeb23da"
      unitRef="usd">194200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI1LTE1LTEtMS0xNTAwMzQ_88c11096-b773-49de-8521-5683333db975"
      unitRef="usd">194200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTUtMS0xLTE1MDAzNA_0bc36431-3bf7-46ee-8152-96660168209e"
      unitRef="usd">524600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTExLTEtMS0xNTAwMzQ_83ce37ac-bdd9-4717-8674-e37317bc6452"
      unitRef="usd">524600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI2LTE1LTEtMS0xNTAwMzQ_29793f47-53bc-42bd-b24c-e53f22c658fa"
      unitRef="usd">524600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i01169c36a4df47e8985588f97df426ff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTEtMS0xLTE1MDAzNA_de9b58db-5caa-4c8d-a534-611368609510"
      unitRef="shares">11200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i1ae3572c7a714189861826346d019725_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTUtMS0xLTE1MDAzNA_15efe486-1193-4790-84d8-0375f22602dc"
      unitRef="usd">-211100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTctMS0xLTE1MDAzNA_4043947d-657c-46e1-956b-95e262170ad5"
      unitRef="usd">-2396300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTExLTEtMS0xNTAwMzQ_8bdefd7e-d3c6-42e0-9dfa-93d4045027e0"
      unitRef="usd">2607400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI3LTE1LTEtMS0xNTAwMzQ_1cd48e2a-8501-44aa-8c5e-706969cb4cb2"
      unitRef="usd">2607400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="i639e5e71313a4d6e864cd96308f95920_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTctMS0xLTE1MDAzNA_46ba181b-268c-4620-a24b-75fba4a144ef"
      unitRef="usd">1322300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTExLTEtMS0xNTAwMzQ_a1b06559-0016-43cc-b8e9-ac245f83a743"
      unitRef="usd">1322300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI4LTE1LTEtMS0xNTAwMzQ_850ce3c8-ef71-4e81-933f-9215201d8ca2"
      unitRef="usd">1322300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTktMS0xLTE1MDAzNA_a208308d-8b8d-424d-b246-fd0326a69b87"
      unitRef="usd">-138300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fcb778330b541d49b4b7a3b743e307f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTExLTEtMS0xNTAwMzQ_7be52eb4-2007-4d2d-b3e0-90c7daf26a14"
      unitRef="usd">-138300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTEzLTEtMS0xNTAwMzQ_7fb3fafc-a8ef-4b60-b591-321aff0890a0"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzI5LTE1LTEtMS0xNTAwMzQ_9cbfc619-6281-4768-b107-7b9c196953b0"
      unitRef="usd">-140100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1e5736a0a0a845709d2ebfda5ca1053a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMwLTEzLTEtMS0xNTAwMzQ_14c9f101-5074-4e14-bd0c-903fc1dddd2f"
      unitRef="usd">22100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMwLTE1LTEtMS0xNTAwMzQ_042364ff-393f-42c1-9b5c-2e0ece01ea0f"
      unitRef="usd">22100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTEtMS0xLTE1MDAzNA_21b081f8-0f85-454f-9e9f-babcdafe5787"
      unitRef="shares">350000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTMtMS0xLTE1MDAzNA_f115d8ff-b30c-4212-971c-07764d95d7d9"
      unitRef="usd">400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5549eca14af04f2faba84d86c3277878_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTUtMS0xLTE1MDAzNA_5a40f5e6-36bb-4787-a34b-cdbf0041af64"
      unitRef="usd">7703900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdf66fd192a04254983a4b04fde0c089_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTctMS0xLTE1MDAzNA_3c418c63-8d7b-44c6-85b0-8bb8e1e598ae"
      unitRef="usd">3500100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff5abbcecdbf42949927127eac25660e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTktMS0xLTE1MDAzNA_4ce516ce-ca18-4d72-8674-4947e197fcbf"
      unitRef="usd">-162500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieaf1941ab4cf4eaa9051a8d048ff8396_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTExLTEtMS0xNTAwMzQ_514df5b7-479e-433b-9d40-94330de00e12"
      unitRef="usd">11041900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d1b51b8c04f48c796dbafa733a218ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTEzLTEtMS0xNTAwMzQ_e8689100-634b-4c64-a2d6-f229b5ad254b"
      unitRef="usd">70700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMxLTE1LTEtMS0xNTAwMzQ_012f94f7-85cb-4c0f-a134-9da5d261cc2f"
      unitRef="usd">11112600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtMS0xLTEtMTUwMDM0_80542779-be0c-4c4e-aa8d-41029d8d29e3"
      unitRef="usd">1344400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtMy0xLTEtMTUwMDM0_dac94ad2-3124-4e59-92e2-5f76540a50c6"
      unitRef="usd">1728100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMtNS0xLTEtMTUwMDM0_37b7876b-34a6-4da7-8e4a-d481142b26bc"
      unitRef="usd">1066800000</us-gaap:ProfitLoss>
    <isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtMS0xLTEtMTUwMDM0_e14831fa-bdff-4f8a-be7b-a602bfdb6e1a"
      unitRef="usd">338000000.0</isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment>
    <isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtMy0xLTEtMTUwMDM0_e75b23fa-83cc-479e-9d82-513fbfec5c5f"
      unitRef="usd">282800000</isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment>
    <isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzUtNS0xLTEtMTUwMDM0_4d2f164c-1329-492e-85cb-49f9d287d245"
      unitRef="usd">226400000</isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtMS0xLTEtMTUwMDM0_f5061c7f-1573-4a48-bb06-635691ba32c2"
      unitRef="usd">27800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtMy0xLTEtMTUwMDM0_401b0309-fad0-46ae-8305-078e5262fa7d"
      unitRef="usd">27400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzYtNS0xLTEtMTUwMDM0_7ad1b847-fd28-4bd9-ba5f-75580ef4008c"
      unitRef="usd">49800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMS0xLTEtMTk1ODk5_4058dcf7-15ff-489d-b0f1-2b4f2edaf51b"
      unitRef="usd">3800000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMy0xLTEtMTk1OTEw_a7cc135e-af9e-4aa2-b723-d62b2a11122e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctNS0xLTEtMTk1OTIx_22bd60bd-ef4a-4f18-ae4d-dd4200cfc6ce"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMS0xLTEtMTUwMDM0_7d81e88a-b481-4a37-9cf5-ef24167034fe"
      unitRef="usd">-49000000.0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctMy0xLTEtMTUwMDM0_c080b36e-3fd5-4ad9-a72b-2b15ec0fec13"
      unitRef="usd">-10600000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzctNS0xLTEtMTUwMDM0_fd5503a5-2ff3-4db0-bad5-2ae68e40b78b"
      unitRef="usd">55100000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtMS0xLTEtMTUwMDM0_2d20f6e0-5644-46a5-b7aa-7d0be9c698f0"
      unitRef="usd">185300000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtMy0xLTEtMTUwMDM0_8c5c760a-e4e7-47bf-9dc7-1fd249ba7416"
      unitRef="usd">62600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzgtNS0xLTEtMTUwMDM0_381ffc75-76d7-4a22-9513-faea771dc0c1"
      unitRef="usd">-57600000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktMS0xLTEtMTUwMDM0_3cdc4ef2-7e7d-4f98-8617-e6e7cfc63ecf"
      unitRef="usd">513200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktMy0xLTEtMTUwMDM0_339667a2-5dc1-426c-98a0-c9f7917057b0"
      unitRef="usd">449200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzktNS0xLTEtMTUwMDM0_dd79a5f1-2e15-488c-879c-e6f77ad34b3e"
      unitRef="usd">395400000</us-gaap:ShareBasedCompensation>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTEtMS0xLTE1MDAzNA_50df3d59-279b-40d3-b8e2-56d22407ae52"
      unitRef="usd">26600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTMtMS0xLTE1MDAzNA_85dce361-10cf-4dc1-b6ed-02f44bd2f9ae"
      unitRef="usd">22000000.0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEwLTUtMS0xLTE1MDAzNA_5753b6f6-e024-4312-aae0-0455f65e6b92"
      unitRef="usd">17100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTEtMS0xLTE1MDAzNA_b61259be-efa7-475b-9cf7-af1a2d4601f7"
      unitRef="usd">159300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTMtMS0xLTE1MDAzNA_571181e0-8f32-4d79-b718-d6fd00a7a3f3"
      unitRef="usd">142300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEyLTUtMS0xLTE1MDAzNA_ee46a415-2441-447d-aa9a-982199cda2db"
      unitRef="usd">-5700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTEtMS0xLTE1MDAzNA_12d9e6b7-ea91-4036-8748-6443285decea"
      unitRef="usd">546600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTMtMS0xLTE1MDAzNA_95c33e98-378a-4241-8086-54b6dfdd801c"
      unitRef="usd">256000000.0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzEzLTUtMS0xLTE1MDAzNA_e0860824-efd0-4ebd-b0cf-29bb7f35b3c2"
      unitRef="usd">170100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTEtMS0xLTE1MDAzNA_a359b6fe-016a-4077-a891-34794d350798"
      unitRef="usd">129200000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTMtMS0xLTE1MDAzNA_691499f2-07f7-4c37-9e18-f097c833dcc8"
      unitRef="usd">204900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE0LTUtMS0xLTE1MDAzNA_2936ed61-f531-42c9-8ebd-cb32b174d133"
      unitRef="usd">111800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTEtMS0xLTE1MDAzNA_a8a18ac9-c83a-44b3-87dc-70e2ebeaec8f"
      unitRef="usd">21300000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTMtMS0xLTE1MDAzNA_aedd583b-fb5a-4cfb-85e1-79abba49c54e"
      unitRef="usd">36000000.0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE1LTUtMS0xLTE1MDAzNA_526c741c-b5fe-4095-bad8-4f0d183ac9f5"
      unitRef="usd">-32300000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTEtMS0xLTE1MDAzNA_1ae3d763-bb80-4d0a-99b9-74630d15e1ba"
      unitRef="usd">51500000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTMtMS0xLTE1MDAzNA_83ba632d-4c92-4481-8f1c-13bf7a250a1e"
      unitRef="usd">115100000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE2LTUtMS0xLTE1MDAzNA_23033637-7f3f-4617-9999-d88b9e47e91c"
      unitRef="usd">-16600000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTEtMS0xLTE1MDAzNA_228516a0-b565-4f79-b08a-b145fae12149"
      unitRef="usd">21500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTMtMS0xLTE1MDAzNA_74dcaad2-0d15-46ab-9e45-9341736075e8"
      unitRef="usd">32600000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE3LTUtMS0xLTE1MDAzNA_92bc3ba6-f972-4f78-9ba3-996163155713"
      unitRef="usd">15000000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTEtMS0xLTE1MDAzNA_11973df1-4a0b-4ec7-943b-cf1ea3808b84"
      unitRef="usd">121700000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTMtMS0xLTE1MDAzNA_e2740b4f-214f-4a2a-8ff2-0c5804183b22"
      unitRef="usd">51400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE4LTUtMS0xLTE1MDAzNA_b8229b0b-186c-4e39-b824-72b5c8336886"
      unitRef="usd">36900000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTEtMS0xLTE1MDAzNA_1401d4ba-fd94-45c1-ad29-c763c9a40637"
      unitRef="usd">1490800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTMtMS0xLTE1MDAzNA_d5899b34-b373-4338-ba04-ba0564664ed9"
      unitRef="usd">2089400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzE5LTUtMS0xLTE1MDAzNA_70ad9bb8-67ca-4940-ba3d-0c83981304e1"
      unitRef="usd">1484800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTEtMS0xLTE1MDAzNA_fde7d5d3-a0e3-4600-a73d-b07807b0a150"
      unitRef="usd">1399500000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTMtMS0xLTE1MDAzNA_b352ccbc-a7ef-41cb-9887-faed82bba964"
      unitRef="usd">6452000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIxLTUtMS0xLTE1MDAzNA_d53b53db-61a9-49f1-b19f-6af04c8ef955"
      unitRef="usd">4292900000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTEtMS0xLTE1MDAzNA_0674d8a4-e423-45be-8e5e-b4b3dde432cd"
      unitRef="usd">61100000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTMtMS0xLTE1MDAzNA_7163d831-468b-46cd-b95b-d89c1830de44"
      unitRef="usd">84900000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIyLTUtMS0xLTE1MDAzNA_363ed874-629b-436d-9d14-b47df8eafb24"
      unitRef="usd">800700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTEtMS0xLTE1MDAzNA_6b3c0e1b-f7e0-42f7-9aea-07dbb0c96eab"
      unitRef="usd">3254400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTMtMS0xLTE1MDAzNA_629fe9ac-df88-4c62-aaee-64c20bd5ece3"
      unitRef="usd">4267800000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzIzLTUtMS0xLTE1MDAzNA_c929f5de-4091-46a8-b392-38ae0bc96e6c"
      unitRef="usd">2930800000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTEtMS0xLTE1MDAzNA_440ac132-660b-4182-9db6-550720027490"
      unitRef="usd">532400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTMtMS0xLTE1MDAzNA_9914874f-2ff0-4a14-ac50-7f22a4b415af"
      unitRef="usd">339500000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI0LTUtMS0xLTE1MDAzNA_59cb16ad-8b9f-4cbc-990f-45a9780e128f"
      unitRef="usd">341500000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTEtMS0xLTE1MDAzNA_d04eff56-cceb-49a3-b97c-bd25a358e984"
      unitRef="usd">12800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTMtMS0xLTE1MDAzNA_6b6f0353-e78e-4a4f-bbef-ab9198b94d46"
      unitRef="usd">22700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI1LTUtMS0xLTE1MDAzNA_d55298ff-097f-4c55-bd71-9804f291caf4"
      unitRef="usd">37700000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTEtMS0xLTE1MDAzNA_b968fb7f-3e74-4cf4-bbf4-5cccfe8a11fd"
      unitRef="usd">1370800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTMtMS0xLTE1MDAzNA_a2559416-08c0-4dea-bd3e-c3c4890dbbdf"
      unitRef="usd">-2461500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI2LTUtMS0xLTE1MDAzNA_022ca980-0fdf-48dc-b3cd-4803f996b1e9"
      unitRef="usd">-940600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTEtMS0xLTE1MDAzNA_0257178b-de61-4495-b11a-ce999f6df80b"
      unitRef="usd">233800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTMtMS0xLTE1MDAzNA_bb0858d6-4fe3-4391-a2bf-3ce671ed316c"
      unitRef="usd">276500000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI4LTUtMS0xLTE1MDAzNA_1c63352f-bae9-431f-bbd1-0e6a48585293"
      unitRef="usd">308800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTEtMS0xLTE1MDAzNA_6617c12b-fbbf-47e9-adb5-9062636c16ea"
      unitRef="usd">194200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTMtMS0xLTE1MDAzNA_e2cdf1b5-9063-488a-b307-811715c13366"
      unitRef="usd">211600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzI5LTUtMS0xLTE1MDAzNA_c9164dbe-d83b-4012-9748-3451e0dd7ae5"
      unitRef="usd">175200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTEtMS0xLTE1MDAzNA_c87146a2-bbe6-40f9-94e9-d81c2b2b9d1f"
      unitRef="usd">2607400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTMtMS0xLTE1MDAzNA_08b2c246-be88-4690-9653-8f48224f69b2"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMwLTUtMS0xLTE1MDAzNA_6dc30719-82f3-48fb-a2ec-d5fbb576661b"
      unitRef="usd">134300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTEtMS0xLTE1MDAzNA_92094aac-7cb0-40a2-9c8b-bf10c0564c7b"
      unitRef="usd">4500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTMtMS0xLTE1MDAzNA_91b7c347-5a40-46a0-8c67-e54d8423ca1f"
      unitRef="usd">21900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMyLTUtMS0xLTE1MDAzNA_600e7755-a670-4640-9a34-c82399f585e7"
      unitRef="usd">85000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTEtMS0xLTE1MDAzNA_b12fd948-b546-4d41-b6b3-df796e305df7"
      unitRef="usd">-2572300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTMtMS0xLTE1MDAzNA_08461c7f-d121-495a-a07e-65f0effb93b8"
      unitRef="usd">43000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzMzLTUtMS0xLTE1MDAzNA_cacd7bf7-ddf4-4e8c-917a-54e793f3a4db"
      unitRef="usd">-85700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTEtMS0xLTE1MDAzNA_d2a65d67-b85e-4e4b-9b5b-4cf35c70e414"
      unitRef="usd">5400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTMtMS0xLTE1MDAzNA_44630733-2f17-4ae2-a4c7-52f646105ba4"
      unitRef="usd">-3400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM0LTUtMS0xLTE1MDAzNA_f6702c4f-c4bc-4648-87eb-94bc778e6cf0"
      unitRef="usd">-2600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTEtMS0xLTE1MDAzNA_bbc581b3-b036-4c76-8417-4844d5f2be49"
      unitRef="usd">294700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTMtMS0xLTE1MDAzNA_0624f7a7-b6fc-4fd4-a7c0-eecd2d41c32b"
      unitRef="usd">-332500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM1LTUtMS0xLTE1MDAzNA_a712066d-6189-437b-820c-e1307eb6ec33"
      unitRef="usd">455900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTEtMS0xLTE1MDAzNA_56650930-8dfa-40fc-bb71-2b22d47914a9"
      unitRef="usd">1306000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTMtMS0xLTE1MDAzNA_cc4e7a06-6d34-414e-bdfb-8759b6236fe0"
      unitRef="usd">1638500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM2LTUtMS0xLTE1MDAzNA_366a57c6-6718-4c7f-b4a5-696b09c90e43"
      unitRef="usd">1182600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTEtMS0xLTE1MDAzNA_1c2d42c8-1c4d-43e2-b68a-48349d011fab"
      unitRef="usd">1600700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTMtMS0xLTE1MDAzNA_56c85709-4f07-4b9f-95dd-baa5620cfccd"
      unitRef="usd">1306000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjAvZnJhZzphODcwNTBmNjI1ZWY0Mjc2OWIyNWUwNTBhYWM3OGYwZS90YWJsZTo0M2E1MjM0ODZkNDI0MDU2YjJkNGE5OTljN2FhNTFmZi90YWJsZXJhbmdlOjQzYTUyMzQ4NmQ0MjQwNTZiMmQ0YTk5OWM3YWE1MWZmXzM3LTUtMS0xLTE1MDAzNA_3b15a38f-3e81-4c93-9ed0-aa2b3eeab77e"
      unitRef="usd">1638500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjYvZnJhZzpmYjgyY2UxYzI1NjE0YTc1YmQwYThjNWViMGU5NzQ2Ny90ZXh0cmVnaW9uOmZiODJjZTFjMjU2MTRhNzViZDBhOGM1ZWIwZTk3NDY3XzUwMw_806ba099-f232-4aae-982c-f2c70433c10a">DESCRIPTION OF THE BUSINESS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intuitive Surgical, Inc. (&#x201c;Intuitive&#x201d; or the &#x201c;Company&#x201d;) develops, manufactures, and markets the da Vinci&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Surgical System and the Ion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; endoluminal system.&#160;The Company&#x2019;s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, and a high-performance vision system and use proprietary instruments and accessories.&lt;/span&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjEx_a031e126-ffde-46a9-aaeb-4e713633921f">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include the accounts of the Company and its wholly and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the results and balances of the Company&#x2019;s majority-owned joint venture (&#x201c;Joint Venture&#x201d;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#x201c;Fosun Pharma&#x201d;). Chindex Medical Limited (&#x201c;Chindex&#x201d;), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders&#x2019; equity. The noncontrolling interest&#x2019;s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued pursuant to the three-for-one stock split (the &#x201c;Stock Split&#x201d;) of the Company&#x2019;s issued and outstanding common stock, par value $0.001 per share, were distributed on October 4, 2021, to stockholders of record as of September 27, 2021. All share and per-share information presented in the Consolidated Financial Statements have been retroactively adjusted to reflect the Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management&#x2019;s most significant, complex, and subjective judgments include the valuation and recognition of investments, the standalone selling prices used to allocate the contract consideration to the individual performance obligations, the valuation of inventory, the valuation of and assessment of the recoverability of intangible assets and goodwill, the recognition and measurement of current and deferred income taxes, including the measurement of uncertain tax positions, and the estimates for legal contingencies. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company&#x2019;s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable are primarily derived from billings related to revenue arrangements with customers and distributors located throughout the world. The Company performs credit evaluations of its customers&#x2019; financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. As of December&#160;31, 2022, and 2021, 60% and 67%, respectively, of accounts receivable were from domestic customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021, and 2020, domestic revenue accounted for 67%, 67%, and 68% of total revenue, respectively, while outside of the U.S. (&#x201c;OUS&#x201d;) revenue accounted for 33%, 33%, and 32%, respectively, of total revenue for each of the years then ended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future results of operations and liquidity could be materially adversely affected by macroeconomic factors contributing to delays in payments of outstanding receivables, supply chain disruptions, including materials shortages and inflationary pressure, uncertain or reduced demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In particular, the Company has experienced increased difficulties in obtaining a sufficient supply of a number of component materials used in its products, such as semiconductor components as well as a range of other materials including, but not limited to, metals and polymers, as global supply has become significantly constrained due to increased demand for certain materials. Additionally, prices of such materials have increased due to the increased demand and supply shortage. With rising interest rates, access to credit may become more difficult, and any insolvency of the Company&#x2019;s key suppliers, including sole-source and single-source suppliers, may exacerbate current supply chain challenges. The Company is engaged in activities to seek to mitigate supply disruptions by, for example, increasing its communications with its suppliers and modifying its purchase order coverage and inventory levels. However, the global supply chain shortages will remain a challenge for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Such global shortages in important components as well as certain logistics challenges have resulted in, and will continue to cause, inflationary cost pressure in the Company&#x2019;s supply chain. To date, the inflationary cost pressure has been more pronounced in the Company&#x2019;s logistics costs, but these supply chain challenges have not materially impacted the Company&#x2019;s results of operations or ability to deliver products and services to its customers. However, if shortages in important supply chain materials in the semiconductor or other markets or logistics challenges continue, the Company could fail to meet product demand, which could result in deferred or canceled procedures. Additionally, if inflationary pressures in logistics or component costs persist, the Company may not be able to quickly or easily adjust pricing, reduce costs, or implement countermeasures. Additionally, there is uncertainty surrounding the impact of any monetary policy changes taken by the U.S. Federal Reserve and other central banks to address the structural risks associated with inflation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in labor availability globally, including labor shortages and staff burnout and attrition, could also impact the Company&#x2019;s ability to hire and retain personnel critical to its manufacturing, logistics, and commercial operations. The Company is also highly dependent on the principal members of its management and scientific staff. The loss of critical members of the Company&#x2019;s team, or its inability to attract and retain qualified personnel, could significantly harm its operations, business, and ability to compete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hospitals are also experiencing staffing shortages and supply chain issues that could affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs, rising interest rates make access to credit more expensive, unrealized losses decrease available cash reserves, and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. To the extent macroeconomic conditions remain challenging, it is likely that hospitals&#x2019; spend on capital equipment will be adversely impacted. In addition, as competition progresses in various markets, longer selling cycles and pricing pressures are likely to result. As of the date of issuance of these Consolidated Financial Statements, the extent to which these macroeconomic factors may materially adversely affect the Company&#x2019;s financial condition, liquidity, or results of operations is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to additional risks and uncertainties due to the ongoing COVID-19 pandemic. The extent of the impact on the Company&#x2019;s business is highly uncertain and difficult to predict. The Company&#x2019;s customers may divert resources to treat COVID-19 patients and defer some elective surgical procedures, both of which may impact the Company&#x2019;s customers&#x2019; ability to meet their obligations, including to the Company. The severity of the impact of the COVID-19 pandemic on the Company&#x2019;s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company&#x2019;s customers, all of which are uncertain and cannot be predicted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Customer Relief Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020, the Company introduced a series of programs to provide financial relief to customers (the &#x201c;Customer Relief Program&#x201d;). As part of the Customer Relief Program, the Company provided its customers service fee credits, extended payment terms, and deferred payments related to Intuitive System Leasing arrangements. The Customer Relief Program ended at the end of the third quarter of 2020. There was no similar customer relief program offered in 2021 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service fee credits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As part of the Customer Relief Program, the Company provided service fee credits to customers based on the reduction in the utilization of their systems during the second and third quarters of 2020 relative to a pre-COVID-19 level baseline. The Company reflected the service fee credits as a reduction of service revenue and accounts receivable in the quarter they were earned by its customers. The service fee credit program resulted in an $80&#160;million decrease in service revenue in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term payment relief&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In response to the COVID-19 pandemic, the Company introduced a payment deferral program to provide financial relief to qualified customers. This relief extended payment terms up to 180 days for qualified and creditworthy customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also introduced a lease payment deferral program in which creditworthy customers with active Intuitive system leasing arrangements could elect to defer lease payments up to five months that are payable at the end of the lease by extending the lease term. This program did not result in substantial increases in the rights of the lessor or the obligations of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lessee, and the Company elected to apply the relief provided by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) FAQ on accounting for COVID-19 and market volatility by not applying the lease modification guidance in ASC 842 to the lease arrangements affected by the deferrals and lease extensions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating lease arrangements where the lease term was extended by adding the deferred period to the end of the contract, the Company recalculated the straight-line revenue based on the revised terms, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. For its sales-type lease arrangements impacted, the Company accounted for the deferral in the timing of lease payments as if there were no changes in the lease contract, consistent with the treatment accepted by the FASB FAQ on accounting for COVID-19. While the short-term payment relief offered did not have a material impact on the results of operations, the Company deferred $15&#160;million of lease billings and extended payment terms associated with $181&#160;million of billings during the program, of which $19&#160;million remained outstanding as of December 31, 2020. All of the trade receivables with extended payment terms have been collected as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity from the date of purchase of 90&#160;days or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, and 2021, the Company had $19.5 million and $17.9 million, respectively, of restricted cash primarily associated with its insurance programs. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale debt securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company&#x2019;s investments may consist of money market funds, U.S. treasury and U.S. government agency securities, high-quality corporate notes and bonds, commercial paper, non-U.S. government agency securities, and taxable and tax-exempt municipal notes. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest and other income, net, if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to interest and other income, net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at the date of purchase greater than 90 days and remaining maturities as of the reporting period of less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company recognizes equity investments with readily determinable fair values at the quoted market price with changes in value recorded in interest and other income, net. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, municipal notes, and equity investments without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company&#x2019;s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the cost basis of the Company&#x2019;s inventory does not include any unallocated fixed overhead costs associated with abnormally low utilization of its factories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater of lease term or 1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enterprise-wide software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of 3 years or life of license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2022, 2021, and 2020, was $326&#160;million, $280 million, and $221 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized Software Costs for Internal Use&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, which are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Once the software is ready for its intended use, amounts capitalized are amortized over an estimated useful life of up to 5 years, generally on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Implementation Costs in a Cloud Computing Arrangement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract for which it is the customer in accordance with the requirements for capitalizing costs incurred to develop internal-use software. These capitalized implementation costs are recorded within intangible and other assets, net, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business acquisitions in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires the acquiring entity in a business combination to recognize the assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree using acquisition-date fair values. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets&#x2019; useful lives, which range from approximately 3 to 9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets, which include finite-lived intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue consists of product revenue, resulting from the sale of systems, system components, and instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and the collectability of the contract consideration is probable. The Company&#x2019;s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer.&#160;The Company&#x2019;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. The Company&#x2019;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price. The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations at a point in time. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;System sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company&#x2019;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Instruments and accessories.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also could occur at the time of delivery, depending on the customer arrangement. The Company generally allows its customers in the normal course of business to return unused products for a limited period of time subsequent to the initial purchase and records an allowance against revenue for estimated returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then-fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems can be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. The assigned value of the traded-in units is reported as a component of inventory until resold or otherwise disposed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer&#x2019;s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Recognized from the Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that certain sales incentives provided to the Company&#x2019;s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial system sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $72.3 million and $71.8 million as of December&#160;31, 2022, and 2021, respectively. The Company did not incur any impairment losses during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intuitive System Leasing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements with certain qualified customers. Leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to 84 months. For these usage-based lease arrangements, the lease fee is generally billed monthly in arrears based on a contractual per-use fee, and usage is generally defined as the number of procedures performed with the system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company&#x2019;s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service. For some lease arrangements, customers are provided with the right to purchase the leased system at some point during and/or at the end of the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. Certain lease arrangements may also include upgrade rights that allow customers to upgrade the leased system to newer technology at some point during the lease term. Generally, these upgrade rights do not specify the terms, including the price or structure of the future upgrade transactions, as those terms are negotiated based on the circumstances at the time of the upgrade, including the then-fair value of the system as well as other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term and is presented as product revenue. Revenue related to lease elements from usage-based arrangements is recognized as the customers utilize the systems and is presented as product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Leasing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December&#160;31, 2022. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company does not have insight into the inputs necessary to calculate the implicit rate of the leases. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s real estate and automobile leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company&#x2019;s automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. For the years ended December 31, 2022, and 2021, bad debt expense was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net investment in sales-type leases.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company&#x2019;s assessment of the current expected lifetime loss on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. Lease receivables are considered past due 90 days after invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the credit risk of the net investment in sales-type leases using a number of factors, including, but not limited to, the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit Rating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Moderate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2022, and 2021, credit losses related to the net investment in sales-type leases were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, procedure coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade and lease receivables as hospital cash flows are impacted by their response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale debt securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and are denominated in a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. Additionally, all of the Company&#x2019;s investments in corporate debt securities are in securities with high-quality credit ratings, which have historically experienced low rates of default. For the years ended December 31, 2022, and 2021, credit losses related to available-for-sale debt securities were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for sales returns is based on the Company&#x2019;s estimates of potential future returns of certain products related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company&#x2019;s products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants long-term equity awards under its stock-based compensation plans to certain employees of the Company. These awards include restricted stock units, stock options, and performance stock units. The Company accounts for share-based compensation plans using the fair value recognition and measurement provisions under GAAP. The Company&#x2019;s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The fair value of restricted stock units (&#x201c;RSUs&#x201d;) is determined based on the closing quoted price of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock options granted and utilizes the following inputs: (1) closing quoted price of the Company&#x2019;s common stock on the date of grant; (2) expected term; (3) expected volatility; and (4) risk-free interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; year on the Company&#x2019;s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company&#x2019;s stock and the term of such options. Due to the sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance stock units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Performance stock units (&#x201c;PSUs&#x201d;) include predefined performance and market conditions. The fair value of performance stock units with performance conditions is based on the closing quoted price of the Company&#x2019;s common stock on the date of the grant and is recognized on a straight-line basis over the requisite service period. The Company estimates the number of awards with performance conditions that will ultimately vest based on the probability of achievement each quarter to determine the amount of compensation expense to recognize each reporting period. The fair value of performance stock units that include a market condition is determined using a Monte Carlo valuation model and is recognized on a straight-line basis over the requisite service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The fair value of shares to be issued under the Company&#x2019;s Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) is computed using the Black-Scholes-Merton model at the commencement of an offering period in February and August of each year utilizing the following inputs: (1) closing quoted price of the Company&#x2019;s common stock on the initial date of the offering period; (2) expected term; (3) expected volatility; and (4) risk-free interest rate. Share-based compensation for the ESPP is expensed straight-line over the two-year offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 10. Share-Based Compensation&#x201d; for a detailed discussion of the Company&#x2019;s stock plans and share-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Computation of Net Income per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company&#x2019;s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company&#x2019;s employee stock purchase plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency and Other Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders&#x2019; equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company&#x2019;s derivative contracts are generally twelve months or shorter.&#160;The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (&#x201c;OCI&#x201d;) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in the fair value of such derivative instruments also are reflected in current earnings. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Consolidated Financial Statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company includes interest and penalty on unrecognized tax benefits as a component of its income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for&#160;Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) as period costs when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one segment. The chief operating decision maker regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. As of both December&#160;31, 2022, and 2021, 84% of long-lived assets were in the United States. Revenue from external customers is attributed to individual countries based on customer location.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company&#x2019;s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the Consolidated Financial Statements. The Company expenses legal fees as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company&#x2019;s business, financial condition, and results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-08&#x201d;), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company&#x2019;s Financial Statements in the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASU No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2022-03&#x201d;), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The Company early adopted ASU 2022-03 as of July 1, 2022, on a prospective basis. There was no impact of the adoption of ASU 2022-03 on the Company&#x2019;s Financial Statements in the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Troubled Debt Restructurings and Vintage Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASU No. 2022-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2022-02&#x201d;), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses-Measured at Amortized Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company&#x2019;s future Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDc3_7870f756-5298-4706-8c90-265058833aea">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include the accounts of the Company and its wholly and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTA1_5107a601-d9ce-423f-9053-8226cd6422d0">The Consolidated Financial Statements include the results and balances of the Company&#x2019;s majority-owned joint venture (&#x201c;Joint Venture&#x201d;) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#x201c;Fosun Pharma&#x201d;). Chindex Medical Limited (&#x201c;Chindex&#x201d;), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders&#x2019; equity. The noncontrolling interest&#x2019;s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2022, 2021, and 2020.</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjQ4NjU_ca2ae150-d9ab-413b-8177-4e5705f2086a"
      unitRef="number">3</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iecd854fcb4004bbcbf41e8c107112eee_I20210927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjQ4NTg_c902a585-19e8-4dee-b7e9-7363a534281d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:UseOfEstimates
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTYx_779cb9aa-264c-4ee9-a00f-468bfe152072">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management&#x2019;s most significant, complex, and subjective judgments include the valuation and recognition of investments, the standalone selling prices used to allocate the contract consideration to the individual performance obligations, the valuation of inventory, the valuation of and assessment of the recoverability of intangible assets and goodwill, the recognition and measurement of current and deferred income taxes, including the measurement of uncertain tax positions, and the estimates for legal contingencies. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjA3_4b9a845e-1179-4187-b83f-0756f7d9b8e5">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company&#x2019;s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s accounts receivable are primarily derived from billings related to revenue arrangements with customers and distributors located throughout the world. The Company performs credit evaluations of its customers&#x2019; financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9a274d8413eb4abe939b46c4859e5585_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MjI_2483d917-1837-40bf-b47a-2a0049dc36a1"
      unitRef="number">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21289ee699604ccda2bbe939f4826b3c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0Mjk_3aec60a9-8daa-47e8-a3db-c80868fa5abd"
      unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9e3a2ff2c2da4f4385ae63c2bcc6c672_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MzI_d30ebb15-1ee3-4c83-81c3-3285678a4b69"
      unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie26454d7ae8c44d190970894b06cf238_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0MzU_ed15fde3-4be3-4bde-8a80-71056747f6b3"
      unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ea9298fff88462ca644d8893e65377d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0Mzg_c7854e68-a8ad-4ea5-9f4b-c7efc2ace227"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i87f6d6fb99c046d289fc7290155d8526_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTM_40635487-e11b-4186-946f-78f29ebbb908"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14855bc25d64407e9c3e34a6c5aa703b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTY_807f783d-d189-4931-8105-640be6c5c5a1"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id6108e23d4714957986c26ca264b5fe8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NTk_e8ee04de-b7ed-4978-b5ed-8c3c64718f93"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <isrg:ServiceFeeCredit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzkwMTk_9fbc62ad-b02a-407c-bb59-55e551d6b84c"
      unitRef="usd">80000000</isrg:ServiceFeeCredit>
    <isrg:SalesTypeLeaseLeaseReceivableExtendedPayment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNjU4_4c2254c8-0a6f-4e7d-a104-ce265f79a475"
      unitRef="usd">15000000</isrg:SalesTypeLeaseLeaseReceivableExtendedPayment>
    <isrg:AccountsReceivableExtendedPayment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNzIy_0405a803-e631-42ba-8bfc-1604bbb1c6bd"
      unitRef="usd">181000000</isrg:AccountsReceivableExtendedPayment>
    <isrg:AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzEwNzY2_96589ce1-30d6-4c67-aec0-75ba9c0948f1"
      unitRef="usd">19000000</isrg:AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDgz_85b86815-1b58-449b-9877-d05aa5c768f5">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity from the date of purchase of 90&#160;days or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, and 2021, the Company had $19.5 million and $17.9 million, respectively, of restricted cash primarily associated with its insurance programs. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0NzQ_18258391-1eb1-4526-9d1f-2b8530e71d1d"
      unitRef="usd">19500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE2NDkyNjc1MTE1NTI_ef4f4612-ebb0-4658-83cb-dad1dcf29bac"
      unitRef="usd">17900000</us-gaap:RestrictedCash>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjEy_31e7af8c-8ad3-4501-89f9-e10f74140ff3">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale debt securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Company&#x2019;s investments may consist of money market funds, U.S. treasury and U.S. government agency securities, high-quality corporate notes and bonds, commercial paper, non-U.S. government agency securities, and taxable and tax-exempt municipal notes. The Company has designated all investments as available-for-sale and, therefore, the investments are subject to periodic impairment under the available-for-sale debt security impairment model. Available-for-sale debt securities in an unrealized loss position are written down to fair value through a charge to interest and other income, net, if the Company intends to sell the security or it is more likely than not the Company will be required to sell the security before recovery of its amortized cost basis. The Company evaluates the remaining securities to determine what amount of the excess, if any, is caused by expected credit losses. A decline in fair value attributable to expected credit losses is recorded to interest and other income, net, while any portion of the loss related to non-credit factors is recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of the securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at the date of purchase greater than 90 days and remaining maturities as of the reporting period of less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity investments.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company recognizes equity investments with readily determinable fair values at the quoted market price with changes in value recorded in interest and other income, net. The Company generally recognizes equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIy_de163e98-ef3c-4c0e-9ca0-a9905ad27097">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, municipal notes, and equity investments without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjE2_5f38d6c1-72f5-4d3e-850d-9024f0feea2d">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company&#x2019;s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. &lt;/span&gt;&lt;/div&gt;Additionally, the cost basis of the Company&#x2019;s inventory does not include any unallocated fixed overhead costs associated with abnormally low utilization of its factories.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIz_10ded282-70d7-430f-97f5-e5fd77b4a8a6">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant, and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater of lease term or 1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enterprise-wide software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of 3 years or life of license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc0_495bfa69-a730-4ebf-8145-1707bf777ac1">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater of lease term or 1 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enterprise-wide software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of 3 years or life of license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building/leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets &#x2013; Intuitive System Leasing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,237.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*Accumulated depreciation associated with operating lease assets &#x2013; Intuitive System Leasing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ief4c591526ea478bb99b449397dd0039_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzEtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NzNkMjQ2NTExNGMwNDljYTkyYWExOWM2MTdiYmZiZjNfMTA_ed9fba4d-bdca-41a5-9826-fc2084c48b12">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if23950580a4342bd9a17e543bc89fa46_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzItMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MDc0N2FhNDQ3NmI4NGVhOWFlNzVlMTUyOWMxYjZjYmJfMTA_41a8fe8a-8779-4a3b-96d0-326d3d1b1291">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i27f714fd0e404cf8b81228344910a645_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzQtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MjY1ZGZmYzFmYzg0NDhjMmE0YTQ0ZGFjNzg5MjVlN2NfNA_51ff2024-98f6-426c-8272-57a08cfdf46b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibac2a4c8f53d40f38da16d18c79f554b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzUtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NWUyNjQ2YzQxMGE1NDhhMGFlZmE2Y2M2YjYxNTEzNjNfMjk_46cc85af-8524-416f-8104-ea405a9d598f">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i00eade1132384910a1edcc4602cd7f03_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzUtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246NWUyNjQ2YzQxMGE1NDhhMGFlZmE2Y2M2YjYxNTEzNjNfMzU_6ff3c7f3-eeec-4ae3-911b-10f74158e32d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i672bca309a9e49d7b8514f35e4e5676e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzYtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246MWUwZTdiNDc5ZjQ4NGI4OGIyOGIzNWZlMzE0ZjFiMTJfNA_ffd21252-d2cf-42d3-89d4-90aec17c64d2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i212dee94b35b42048df23efbc2d406d9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzctMS0xLTEtMTUwMDM0L3RleHRyZWdpb246ZmRlZDY1MGM5MDZkNGUyMGJkOGJlNDZlMzMzYzc0MmNfNA_c9550aca-fbd3-4b07-b034-65c0aca02516">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibd1fd94d996648b992458725d1c804c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZToxMDZiMWQzOGY2ODU0MzI3YjNjMmM3M2ZlOGY1YzI2Mi90YWJsZXJhbmdlOjEwNmIxZDM4ZjY4NTQzMjdiM2MyYzczZmU4ZjVjMjYyXzgtMS0xLTEtMTUwMDM0L3RleHRyZWdpb246ZjgyNDFmN2IzZThkNDdiODg0M2NiNmFhMzM2Yjg2ZThfMTQ_7121821c-eeaf-4d2e-85f4-91ca1205b6dc">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0ODc_77832287-f169-42e3-83c1-34b87f429212"
      unitRef="usd">326000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0OTA_a5afd404-b2af-45d4-842a-e117835a8da5"
      unitRef="usd">280000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk0OTM_e50167f2-f7e8-4d58-beef-cb9ad2195339"
      unitRef="usd">221000000</us-gaap:Depreciation>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTcx_3c481019-8596-46cd-a4be-169570d10e03">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized Software Costs for Internal Use&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, which are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Once the software is ready for its intended use, amounts capitalized are amortized over an estimated useful life of up to 5 years, generally on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Implementation Costs in a Cloud Computing Arrangement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract for which it is the customer in accordance with the requirements for capitalizing costs incurred to develop internal-use software. These capitalized implementation costs are recorded within intangible and other assets, net, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia195f6ae1083417ea6ba55e0f754b575_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE2MjY1_d9d8a291-76c9-4f4b-9edb-87f3ec5fd592">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc1_0ccc0ce5-6f61-46ec-b8be-8d86ed5f7f64">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for business acquisitions in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard requires the acquiring entity in a business combination to recognize the assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree using acquisition-date fair values. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjE3_9d0f3fcb-71d9-4151-9d7e-a08f978f81f5">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets&#x2019; useful lives, which range from approximately 3 to 9 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4MTUz_d96b2ceb-bd44-4143-819a-6ec0061c5faa"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i18ca052badd544ec96dacbdeb71e006a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4NTgw_679d353b-37fa-4a9a-9bdc-9ab96b2c71ce">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzE4NTg2_29588960-7008-4494-a1f3-4a311bee4aef">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTc2_30d69c8e-a799-430f-9189-62506d31449e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets, which include finite-lived intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. &lt;/span&gt;&lt;/div&gt;Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTU1_97add4b2-c5dd-40f6-8ba9-526444926ac1">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue consists of product revenue, resulting from the sale of systems, system components, and instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and the collectability of the contract consideration is probable. The Company&#x2019;s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer.&#160;The Company&#x2019;s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. The Company&#x2019;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price. The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations at a point in time. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;System sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company&#x2019;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Instruments and accessories.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also could occur at the time of delivery, depending on the customer arrangement. The Company generally allows its customers in the normal course of business to return unused products for a limited period of time subsequent to the initial purchase and records an allowance against revenue for estimated returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then-fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems can be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. The assigned value of the traded-in units is reported as a component of inventory until resold or otherwise disposed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer&#x2019;s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Recognized from the Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that certain sales incentives provided to the Company&#x2019;s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial system sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $72.3 million and $71.8 million as of December&#160;31, 2022, and 2021, respectively. The Company did not incur any impairment losses during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDg3_26936ab5-c01f-43a5-94b7-f9338253f97d">The Company&#x2019;s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price.</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <isrg:SystemSalesArrangementWarrantyPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMDQ_17167ee9-20b7-4ef1-bc71-25422767b147">P1Y</isrg:SystemSalesArrangementWarrantyPeriod>
    <us-gaap:AcquisitionCosts
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1MDk_441929c6-5fd6-49f7-b0de-ed1e3f2b4f1d"
      unitRef="usd">72300000</us-gaap:AcquisitionCosts>
    <us-gaap:AcquisitionCosts
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1MTI_88781998-b768-4729-b8fa-13811057f544"
      unitRef="usd">71800000</us-gaap:AcquisitionCosts>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTE5_1e31887a-1d09-4da7-a673-2844f6d86654">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intuitive System Leasing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements with certain qualified customers. Leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to 84 months. For these usage-based lease arrangements, the lease fee is generally billed monthly in arrears based on a contractual per-use fee, and usage is generally defined as the number of procedures performed with the system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company&#x2019;s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service. For some lease arrangements, customers are provided with the right to purchase the leased system at some point during and/or at the end of the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. Certain lease arrangements may also include upgrade rights that allow customers to upgrade the leased system to newer technology at some point during the lease term. Generally, these upgrade rights do not specify the terms, including the price or structure of the future upgrade transactions, as those terms are negotiated based on the circumstances at the time of the upgrade, including the then-fair value of the system as well as other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term and is presented as product revenue. Revenue related to lease elements from usage-based arrangements is recognized as the customers utilize the systems and is presented as product revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1
      contextRef="i0af42d049a95445eb385849c884a645d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2MjEw_6aee562a-5de9-4957-99e7-cdb0ed9199a9">P24M</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1
      contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2MjE2_f821315f-eac0-42b1-90f8-8423756f0ed4">P84M</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1
      contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzI2NDIy_7839768c-3a4f-4a6a-8be8-9c0c44c70c1a">P84M</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTU3_f9a58b38-a346-44ef-beb3-35b4ab352b78">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Leasing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December&#160;31, 2022. The Company currently does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company does not have insight into the inputs necessary to calculate the implicit rate of the leases. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s real estate and automobile leases. &lt;/span&gt;&lt;/div&gt;Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company&#x2019;s automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTQ0_ff625690-fa20-4070-8fcc-6b6dde7a1a55">&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. For the years ended December 31, 2022, and 2021, bad debt expense was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net investment in sales-type leases.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company enters into sales-type leases with certain qualified customers to purchase its systems. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. The allowance for loan loss is based on the Company&#x2019;s assessment of the current expected lifetime loss on lease receivables. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, age of the lease receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. Lease receivables are considered past due 90 days after invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the credit risk of the net investment in sales-type leases using a number of factors, including, but not limited to, the following: size of operations; profitability, liquidity, and debt ratios; payment history; and past due amounts. The Company also uses credit scores obtained from external providers as a key indicator for the purposes of determining credit quality. The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit Rating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Moderate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2022, and 2021, credit losses related to the net investment in sales-type leases were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, procedure coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade and lease receivables as hospital cash flows are impacted by their response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Available-for-sale debt securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company regularly reviews the securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. The Company segments its portfolio based on the underlying risk profiles of the securities and has a zero-loss expectation for U.S. treasury and U.S. government agency securities. The basis for this assumption is that these securities have consistently high credit ratings by rating agencies, have a long history with no credit losses, are explicitly guaranteed by a sovereign entity, which can print its own currency, and are denominated in a currency that is routinely held by central banks, used in international commerce, and commonly viewed as a reserve currency. Additionally, all of the Company&#x2019;s investments in corporate debt securities are in securities with high-quality credit ratings, which have historically experienced low rates of default. For the years ended December 31, 2022, and 2021, credit losses related to available-for-sale debt securities were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1
      contextRef="i0af42d049a95445eb385849c884a645d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzU0OTc1NTg3OTA1MQ_6aee562a-5de9-4957-99e7-cdb0ed9199a9">P24M</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:LessorSalesTypeLeaseTermOfContract1
      contextRef="ide0778c030794ba48d3da31c3443b61c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzU0OTc1NTg3OTA1NQ_f821315f-eac0-42b1-90f8-8423756f0ed4">P84M</us-gaap:LessorSalesTypeLeaseTermOfContract1>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTI5_9bb324ab-6cf8-45cd-8553-024d9b3b5c04">The following table summarizes the amortized cost basis by year of origination and by credit quality for the net investment in sales-type leases as of December 31, 2022 (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Credit Rating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Moderate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMS0xLTEtMTUwMDM0_4053a75a-e5cf-4c94-9f98-310e06caa3e0"
      unitRef="usd">67300000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMy0xLTEtMTUwMDM0_ca9e0202-287f-4d43-a3af-81c8ccecea44"
      unitRef="usd">86700000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItNS0xLTEtMTUwMDM0_d98ad3fa-914b-4422-a2e3-5a5be39ff82b"
      unitRef="usd">42600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItNy0xLTEtMTUwMDM0_42a66b8c-b3d8-44ea-8544-288c46a8306d"
      unitRef="usd">14500000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItOS0xLTEtMTUwMDM0_1bee2c1e-7d43-4d03-a859-b59d7a7b94cc"
      unitRef="usd">2200000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMTItMS0xLTE1MDAzNA_66a0a052-7e5c-487a-bd56-64dca62e99a6"
      unitRef="usd">400000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="ie7f29fdc80a74811ae7b3009689d8b76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzItMTQtMS0xLTE1MDAzNA_a79b330c-a361-4844-8e49-af3c360b0b83"
      unitRef="usd">213700000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMS0xLTEtMTUwMDM0_89defa71-1123-4c9b-8bae-cf4c69bdb1d6"
      unitRef="usd">98400000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMy0xLTEtMTUwMDM0_6e4eb352-ff78-45d4-a628-4c54986b13fb"
      unitRef="usd">69600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtNS0xLTEtMTUwMDM0_24fed6b8-b7c9-42f0-b04f-fccc204fc495"
      unitRef="usd">34100000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtNy0xLTEtMTUwMDM0_15f584c8-1ebf-4bcd-9f6f-d02df89d4502"
      unitRef="usd">7700000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtOS0xLTEtMTUwMDM0_4d46ba94-4270-4ea2-a8f3-7ffda90a7efb"
      unitRef="usd">4100000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMTItMS0xLTE1MDAzNA_4afb66d2-e6e7-4b45-8172-f8dd34b0d50c"
      unitRef="usd">300000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="ie616cac6654a4f82b3a5dcfcd7278c81_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzMtMTQtMS0xLTE1MDAzNA_ee3f8f10-d8f6-4cfd-9d16-122c7791f9f7"
      unitRef="usd">214200000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMS0xLTEtMTUwMDM0_00a0fee4-0fa9-421d-abef-3909eae199fc"
      unitRef="usd">2600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMy0xLTEtMTUwMDM0_6b66e7a0-110a-4b27-9918-30e50d4a771f"
      unitRef="usd">1600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtNS0xLTEtMTUwMDM0_c6dc6d7f-eaf7-4943-a0fb-504fe0f9f2b3"
      unitRef="usd">2900000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtNy0xLTEtMTUwMDM0_634c9c66-e739-410b-9dda-677183039136"
      unitRef="usd">0</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtOS0xLTEtMTUwMDM0_2e2b9d2e-4225-4ab2-a4ba-ec93a019969d"
      unitRef="usd">0</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMTItMS0xLTE1MDAzNA_5922161b-25ff-4a09-bedd-29767edacfba"
      unitRef="usd">0</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="ib606f0cd45974794b541dc9482583db5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzQtMTQtMS0xLTE1MDAzNA_6518ee15-73a5-47b0-bbbf-25a739d59576"
      unitRef="usd">7100000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMS0xLTEtMTUwMDM0_385cc3ae-5256-437b-a581-9ed9e3970aec"
      unitRef="usd">168300000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMy0xLTEtMTUwMDM0_4d9174d4-6ea5-4942-bdc9-c88d6cea205e"
      unitRef="usd">157900000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtNS0xLTEtMTUwMDM0_60efd4c6-d31e-4f9e-a62d-78deb8167b5c"
      unitRef="usd">79600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtNy0xLTEtMTUwMDM0_85247086-c12c-41ed-bb65-9b749147241f"
      unitRef="usd">22200000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtOS0xLTEtMTUwMDM0_f8435cd7-f3e6-4f44-85ac-ad0dec4a75e6"
      unitRef="usd">6300000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMTItMS0xLTE1MDAzNA_0ed07132-724e-493b-a819-0c33a3c5550e"
      unitRef="usd">700000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90YWJsZTo5OTRmZDcxNDRiMjI0ZGYxODJiZGJjZmQwYmE5YzhhOS90YWJsZXJhbmdlOjk5NGZkNzE0NGIyMjRkZjE4MmJkYmNmZDBiYTljOGE5XzUtMTQtMS0xLTE1MDAzNA_f2241d24-d32f-477a-9ce6-90efe5f0e593"
      unitRef="usd">435000000.0</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <isrg:AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTIw_64c2a6cc-32be-4869-a42d-7e07ffb738b4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for sales returns is based on the Company&#x2019;s estimates of potential future returns of certain products related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company&#x2019;s products.&lt;/span&gt;&lt;/div&gt;</isrg:AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NDkw_e8921ca8-f555-499e-af24-7842410713f9">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants long-term equity awards under its stock-based compensation plans to certain employees of the Company. These awards include restricted stock units, stock options, and performance stock units. The Company accounts for share-based compensation plans using the fair value recognition and measurement provisions under GAAP. The Company&#x2019;s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The fair value of restricted stock units (&#x201c;RSUs&#x201d;) is determined based on the closing quoted price of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock options granted and utilizes the following inputs: (1) closing quoted price of the Company&#x2019;s common stock on the date of grant; (2) expected term; (3) expected volatility; and (4) risk-free interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; year on the Company&#x2019;s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company&#x2019;s stock and the term of such options. Due to the sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance stock units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Performance stock units (&#x201c;PSUs&#x201d;) include predefined performance and market conditions. The fair value of performance stock units with performance conditions is based on the closing quoted price of the Company&#x2019;s common stock on the date of the grant and is recognized on a straight-line basis over the requisite service period. The Company estimates the number of awards with performance conditions that will ultimately vest based on the probability of achievement each quarter to determine the amount of compensation expense to recognize each reporting period. The fair value of performance stock units that include a market condition is determined using a Monte Carlo valuation model and is recognized on a straight-line basis over the requisite service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The fair value of shares to be issued under the Company&#x2019;s Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) is computed using the Black-Scholes-Merton model at the commencement of an offering period in February and August of each year utilizing the following inputs: (1) closing quoted price of the Company&#x2019;s common stock on the initial date of the offering period; (2) expected term; (3) expected volatility; and (4) risk-free interest rate. Share-based compensation for the ESPP is expensed straight-line over the two-year offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 10. Share-Based Compensation&#x201d; for a detailed discussion of the Company&#x2019;s stock plans and share-based compensation expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjY1MTU_7c9e27c0-a100-480c-8fb0-6c634e4f95d8">P1Y</isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod>
    <isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzM2Mzg2_741cbba5-7f8e-4071-92d6-9eab3e6e7d7d"
      unitRef="number">1</isrg:ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NjAz_8ed2fc93-7675-482e-80bc-4a99c4714fa4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Computation of Net Income per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company&#x2019;s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company&#x2019;s employee stock purchase plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTM5_3db45bc0-f681-429f-9460-4195ac14ee41">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <isrg:ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTgx_dcd74038-a3b8-4d14-bf7f-13c3c6fec7ee">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency and Other Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders&#x2019; equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company&#x2019;s derivative contracts are generally twelve months or shorter.&#160;The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by the re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (&#x201c;OCI&#x201d;) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in the fair value of such derivative instruments also are reflected in current earnings. Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.&lt;/span&gt;&lt;/div&gt;</isrg:ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock>
    <us-gaap:DerivativeTermOfContract
      contextRef="ifdd322b2511f4583a8a69bfc27375fbe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMTI_85f617de-3b2a-4333-83c4-9613701ca70c">P12M</us-gaap:DerivativeTermOfContract>
    <isrg:DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ5NDc4MDI0MjYzMzA_21c899a8-8488-49d8-b4f9-60528e53e1dd">P2M</isrg:DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTE2_4caac9e1-6155-4ecb-b98e-afe3e9d5adfd">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Consolidated Financial Statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company includes interest and penalty on unrecognized tax benefits as a component of its income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for&#160;Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) as period costs when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <isrg:IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQyMjIx_ec719470-15b5-45fa-a4c9-f4dfff7fe8f6"
      unitRef="number">0.50</isrg:IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTEw_35599d0f-7d8b-44af-861a-4fb842f711fe">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one segment. The chief operating decision maker regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. As of both December&#160;31, 2022, and 2021, 84% of long-lived assets were in the United States. Revenue from external customers is attributed to individual countries based on customer location.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQyNjkz_eceb446c-55f4-4043-8dcc-c7e34b3d107f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <isrg:LongLivedAssetsMaintainedInTheUnitedStatesPercent
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzYwNDczMTM5OTk1NTk_3be796f3-447d-4c58-8518-f6a37ff16ffb"
      unitRef="number">0.84</isrg:LongLivedAssetsMaintainedInTheUnitedStatesPercent>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTY2_d1616c4b-515b-4b10-93da-444cdbabb3d4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company&#x2019;s Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the Consolidated Financial Statements. The Company expenses legal fees as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company&#x2019;s business, financial condition, and results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMjkvZnJhZzphMTIyZDFiNWMwZjU0MmFiODc1YzhkMzk4NDQ2NmYyMy90ZXh0cmVnaW9uOmExMjJkMWI1YzBmNTQyYWI4NzVjOGQzOTg0NDY2ZjIzXzQ2NTg5_e28ea984-58eb-45f6-b9b9-7546d2099d96">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-08&#x201d;), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company early adopted ASU 2021-08 as of January 1, 2022, on a prospective basis. The impact of the adoption of ASU 2021-08 had an immaterial impact on the Company&#x2019;s Financial Statements in the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASU No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2022-03&#x201d;), which applies to all equity securities measured at fair value that are subject to contractual sale restrictions. This change prohibits entities from taking into account contractual restrictions on the sale of equity securities when estimating fair value and introduces required disclosures for such transactions. The Company early adopted ASU 2022-03 as of July 1, 2022, on a prospective basis. There was no impact of the adoption of ASU 2022-03 on the Company&#x2019;s Financial Statements in the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Troubled Debt Restructurings and Vintage Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the FASB issued ASU No. 2022-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2022-02&#x201d;), which eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. Additionally, the standard requires disclosure of current-period gross write-offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic ASC 326-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses-Measured at Amortized Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard will become effective for the Company beginning January 1, 2023, and should be applied prospectively. The adoption of ASU 2022-02 is not expected to have a material impact on the Company&#x2019;s future Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MDg_dae7b941-1d8c-44ec-a219-5c4b876a7192">FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s cash and available-for-sale debt securities&#x2019; amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,644.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,941.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,741.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,116.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,640.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s cash equivalents and available-for-sale debt securities (excluding money market funds) as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mature in less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mature in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities, because certain borrowers have the right to call or prepay certain obligations. Gross realized gains and losses recognized on the sale of investments were immaterial for the years ended December&#160;31, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, and 2021, net unrealized losses on available-for-sale debt securities, net of tax, of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$154.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, were included in accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;losses&#160;less&lt;br/&gt;than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized losses&#160;12&lt;br/&gt;months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,853.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,048.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses on the Company&#x2019;s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of December&#160;31, 2022, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Changes in Fair Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Purchases / Sales / Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible and other assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments with readily determinable value (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable value (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Recorded in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other includes foreign currency translation gains/(losses).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, Broncus Holding Corporation (&#x201c;Broncus&#x201d;) completed an initial public offering (&#x201c;IPO&#x201d;) of common shares on the Stock Exchange of Hong Kong. Upon completion of its IPO, the Company&#x2019;s preferred shares of Broncus were converted into common shares, which have a readily determinable value (Level 1). The Company was restricted from selling these shares for a period of six months. In 2022, the Company recognized a $21.2 million loss on this investment reflected in changes in fair value for Level 1 equity investments, which was reflected in Interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized a $0.2&#160;million increase in fair value, which was reflected in interest and other income, net, due to changes in observable prices for certain equity investments that lack readily determinable market values (Level 2). There were no decreases in fair value reflected in net income due to impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The objective of the Company&#x2019;s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, intercompany balances, and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (&#x201c;USD&#x201d;). The terms of the Company&#x2019;s derivative contracts are generally twelve months or shorter. The derivative assets and liabilities are measured using Level 2 fair value inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flow Hedges.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (&#x201c;EUR&#x201d;), the British Pound (&#x201c;GBP&#x201d;), the Japanese Yen (&#x201c;JPY&#x201d;), the Korean Won (&#x201c;KRW&#x201d;), and the New Taiwan Dollar (&#x201c;TWD&#x201d;). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and the Swiss Franc (&#x201c;CHF&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive loss in stockholders&#x2019; equity and reclassifies the amount into earnings in the same period in which the hedged transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Derivatives Not Designated as Hedging Instruments.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, TWD, Indian Rupee (&#x201c;INR&#x201d;), Mexican Peso (&#x201c;MXN&#x201d;), Chinese Yuan (&#x201c;CNY&#x201d;), and Canadian Dollar (&#x201c;CAD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb"&gt;Recognized gains (losses) in interest and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses) related to balance sheet re-measurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross fair value recorded in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MjA_1d470285-93e6-4fe4-bc3e-b24ea7cda8d6">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s cash and available-for-sale debt securities&#x2019; amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit loss, and fair value by significant investment category reported as cash and cash equivalents, short-term investments, or long-term investments as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,644.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,941.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,741.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and&lt;br/&gt;Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,116.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,476.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,942.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,640.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtMS0xLTEtMTUwMDM0_3b14c7fe-25e1-4d5f-98be-a6d7d95fc06c"
      unitRef="usd">497200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtOS0xLTEtMTUwMDM0_6a60e3cc-a494-4f1c-a9e6-296ebea0b3c7"
      unitRef="usd">497200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5dba95d10fbc41fc971720e2efa2c528_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzMtMTEtMS0xLTE1MDAzNA_24ccfdc5-6910-411f-98b0-b9b7bdcfe93f"
      unitRef="usd">497200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i46268e7a8003454a8651b908542fda66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMS0xLTEtMTUwMDM0_82c5699b-645b-40b1-85f4-806a1d7c19c8"
      unitRef="usd">1084000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i46268e7a8003454a8651b908542fda66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtOS0xLTEtMTUwMDM0_3a022b3a-86eb-4d6e-aa83-e2ca192239f9"
      unitRef="usd">1084000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i46268e7a8003454a8651b908542fda66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTEtMS0xLTE1MDAzNA_f03b8ea1-a09b-47a4-9a9f-7bad12623721"
      unitRef="usd">1084000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i46268e7a8003454a8651b908542fda66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTMtMS0xLTE1MDAzNA_b7241464-4630-4eae-9d99-4862dc09fd5b"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i46268e7a8003454a8651b908542fda66_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzUtMTUtMS0xLTE1MDAzNA_dbcd8d5b-cb12-46ad-a24a-2caa012d869d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMS0xLTEtMTUwMDM0_8961267d-d11f-4875-90be-ef9d7d59e9e5"
      unitRef="usd">2715200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMy0xLTEtMTUwMDM0_332c79eb-056a-442a-95fb-b1a8ae4c0be4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtNS0xLTEtMTUwMDM0_9afa850e-e78a-4dfe-924f-d2a4cca76eb2"
      unitRef="usd">96600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtNy0xLTEtMTUwMDM0_4cf7f145-ef6d-40b3-ad7f-65df163a1a28"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtOS0xLTEtMTUwMDM0_497272c0-fd7d-48cd-9d75-f83f62d2a123"
      unitRef="usd">2618600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTEtMS0xLTE1MDAzNA_d71106d7-6bd4-488d-bd51-cd15963ec70e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTMtMS0xLTE1MDAzNA_dfa43fe3-5353-4892-85fa-587e189d02b3"
      unitRef="usd">1542400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="id177033e3c704b16966079b0d35b30a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzYtMTUtMS0xLTE1MDAzNA_9ad29d34-6270-4357-a2a5-d179df4b74c7"
      unitRef="usd">1076200000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMS0xLTEtMTUwMDM0_875087db-ef9e-4bca-8d1f-8b90bc2b08cd"
      unitRef="usd">3799200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMy0xLTEtMTUwMDM0_24e9669e-be67-4c0e-a30a-60c46ed19354"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctNS0xLTEtMTUwMDM0_aa6adadc-5c5a-47a2-83f7-f92cf5456366"
      unitRef="usd">96600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctNy0xLTEtMTUwMDM0_7a537eaf-e7c1-4dbe-8d83-1d39ad677559"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctOS0xLTEtMTUwMDM0_cc4ec8cf-d869-4445-85a1-eb3e73f31381"
      unitRef="usd">3702600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTEtMS0xLTE1MDAzNA_b7a26339-e484-4179-a85c-67e82c32ffec"
      unitRef="usd">1084000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTMtMS0xLTE1MDAzNA_c8f3ad0e-f458-4575-b1a3-a4824e2ddbc4"
      unitRef="usd">1542400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzctMTUtMS0xLTE1MDAzNA_27620c14-203a-4f66-87f8-dd8a7cb13002"
      unitRef="usd">1076200000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMS0xLTEtMTUwMDM0_856b3aea-36b0-47c1-97e6-248f7d7f8cf3"
      unitRef="usd">20000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMy0xLTEtMTUwMDM0_1c2bfea3-46e3-4283-b939-a18a442a0091"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktNS0xLTEtMTUwMDM0_96b0ee6d-1c44-4aa9-ac0d-a8674d71a772"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktNy0xLTEtMTUwMDM0_214ad963-a6ff-4eb5-b93b-cf657f6bda88"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktOS0xLTEtMTUwMDM0_f05444ec-5384-4bec-aa92-989fe7e6f912"
      unitRef="usd">20000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTEtMS0xLTE1MDAzNA_63eb1f37-fdba-41b6-ae67-83c5b8c91eb5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTMtMS0xLTE1MDAzNA_d6303de6-9a03-4cc1-b58a-c9f06d084019"
      unitRef="usd">20000000.0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i6ce8007a441d425abf12e8e63eb11ef7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzktMTUtMS0xLTE1MDAzNA_d41a82b5-3fd5-42e5-9ac9-b7b02e4e8e84"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTEtMS0xLTE1MDAzNA_dacaf44e-a23c-40e2-b744-c02593769ad4"
      unitRef="usd">2022000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTMtMS0xLTE1MDAzNA_e9910c37-0915-4d0d-af6a-e58906ae3f8f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTUtMS0xLTE1MDAzNA_0d11bf5b-9df5-4766-9ed5-d1afcb67bf5b"
      unitRef="usd">76000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTctMS0xLTE1MDAzNA_c903eb3a-f1f7-499c-8d30-00d1e4e791d8"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTktMS0xLTE1MDAzNA_b64c1a37-b0a1-4036-909c-a5c2b501cf67"
      unitRef="usd">1944900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTExLTEtMS0xNTAwMzQ_8ff8fa9d-fa68-4c48-b513-3940e5097791"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTEzLTEtMS0xNTAwMzQ_29c6dafa-9ed5-4e24-92ee-3f2562977be2"
      unitRef="usd">651800000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iec42cb1c1b7c476caf4d5c05b1e9e72e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEwLTE1LTEtMS0xNTAwMzQ_c51e3aad-f4b7-498c-b9fd-afcea4a6d056"
      unitRef="usd">1293100000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTEtMS0xLTE1MDAzNA_14e9c407-8c5b-4237-b3cd-c70869c524f7"
      unitRef="usd">447200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTMtMS0xLTE1MDAzNA_20bd1c33-a14f-47fc-90a8-b0bd12f9ba33"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTUtMS0xLTE1MDAzNA_1ef1cbcc-c220-466c-bda6-ecb3558bdd57"
      unitRef="usd">19900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTctMS0xLTE1MDAzNA_5ea748b7-d2b7-492b-a670-b2f42ba103a4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTktMS0xLTE1MDAzNA_33ec3ee6-64f0-40ca-b486-2393c8cf9e04"
      unitRef="usd">427300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTExLTEtMS0xNTAwMzQ_0c081252-4057-487d-8ec9-ba36721f611c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTEzLTEtMS0xNTAwMzQ_8cd324dd-f171-4b45-aea9-5eb1da04ead1"
      unitRef="usd">247800000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i564a11c205e348b89bbea004fd0d0881_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzExLTE1LTEtMS0xNTAwMzQ_81ccfece-f90c-44f2-a58b-3f9af2aeba37"
      unitRef="usd">179500000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTEtMS0xLTE1MDAzNA_893c698f-424b-4f8f-b175-fd0fe9d105dd"
      unitRef="usd">155500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTMtMS0xLTE1MDAzNA_3c960dce-9b51-40ac-895a-8cd68ddda289"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTUtMS0xLTE1MDAzNA_e8a8b48d-5db5-465e-b416-929213d9e4fd"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTctMS0xLTE1MDAzNA_8766e85f-61dc-4a4f-8717-1673224dca73"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTktMS0xLTE1MDAzNA_ba49f4f5-c2d9-42f5-8089-57c0f6a7f6d1"
      unitRef="usd">149500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTExLTEtMS0xNTAwMzQ_d337662c-774c-4146-af0e-1f363351074e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTEzLTEtMS0xNTAwMzQ_92914f8a-3ae9-4ad9-ae9d-172da88be777"
      unitRef="usd">74700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i3cc9ebd3e1ca453a885fef88d7310ed7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzEzLTE1LTEtMS0xNTAwMzQ_34d0bf4b-81c8-4278-be31-29940f57f4c8"
      unitRef="usd">74800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTEtMS0xLTE1MDAzNA_b6430abf-e0a4-4c69-92f9-11f29c952e5e"
      unitRef="usd">2644700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTMtMS0xLTE1MDAzNA_e86f5c79-e1e6-4d12-8e5e-ec6d9a16c7f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTUtMS0xLTE1MDAzNA_dcc8410c-c7eb-4b8b-b966-cdc30993f765"
      unitRef="usd">101900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTctMS0xLTE1MDAzNA_e25019f4-8598-4dc3-997d-61049e845615"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTktMS0xLTE1MDAzNA_1dbb8a30-9e33-4afe-b5f1-ddb6bb2fb4bf"
      unitRef="usd">2541700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTExLTEtMS0xNTAwMzQ_8d1b99af-941d-4bc8-a59c-a13c44b7360f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTEzLTEtMS0xNTAwMzQ_565ff203-3305-4262-a3b0-cf6bff0e1d19"
      unitRef="usd">994300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE0LTE1LTEtMS0xNTAwMzQ_de7b28f0-7752-452e-a012-e677c2668029"
      unitRef="usd">1547400000</us-gaap:MarketableSecuritiesNoncurrent>
    <isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTEtMS0xLTE1MDAzNA_f9dd326e-e483-4cb6-bdf8-a1c8b0308a87"
      unitRef="usd">6941100000</isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTMtMS0xLTE1MDAzNA_cdcb3be5-8872-4abf-9fe5-53785b1ce7c8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTUtMS0xLTE1MDAzNA_02967932-db81-4316-bd7b-d4a68b131287"
      unitRef="usd">198500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTctMS0xLTE1MDAzNA_f12beae0-013b-490f-8f04-7e3ebf43883d"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTktMS0xLTE1MDAzNA_dca71708-3ecd-40d0-a1a6-da927074f8ba"
      unitRef="usd">6741500000</isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTExLTEtMS0xNTAwMzQ_8bf8e2e9-791e-4e1f-93ca-75ced003a1a7"
      unitRef="usd">1581200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTEzLTEtMS0xNTAwMzQ_016ad47e-f2ae-4f7f-bb5a-0d1e7f8a1c8a"
      unitRef="usd">2536700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpkMWVhYjM5NmY4Mjg0YWU4ODQ0MDhmN2E2NWJiYTEwNC90YWJsZXJhbmdlOmQxZWFiMzk2ZjgyODRhZTg4NDQwOGY3YTY1YmJhMTA0XzE4LTE1LTEtMS0xNTAwMzQ_88e8336d-ca94-4789-9cbe-546d9b6193db"
      unitRef="usd">2623600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if7bf33483de84677a014730d8912b575_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtMS0xLTEtMTUwMDM0_b4577ee4-9491-49a8-8b34-d7856d26b883"
      unitRef="usd">572300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7bf33483de84677a014730d8912b575_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtOS0xLTEtMTUwMDM0_e0f0e227-8943-4704-971e-a231e1840d93"
      unitRef="usd">572300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if7bf33483de84677a014730d8912b575_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzMtMTEtMS0xLTE1MDAzNA_cba85637-e838-475b-900b-09d97d0dd823"
      unitRef="usd">572300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id997ca722e2f4788a65a9e8536746348_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMS0xLTEtMTUwMDM0_67d4ec66-707a-44e2-a016-d0dd1f8a188f"
      unitRef="usd">696600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id997ca722e2f4788a65a9e8536746348_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtOS0xLTEtMTUwMDM0_a22fbc27-5f29-4963-a5dd-c6166ad78868"
      unitRef="usd">696600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id997ca722e2f4788a65a9e8536746348_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTEtMS0xLTE1MDAzNA_7d1824cd-4604-4817-bd0e-78e9f1753c55"
      unitRef="usd">696600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id997ca722e2f4788a65a9e8536746348_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTMtMS0xLTE1MDAzNA_b7e59b3f-5895-4f79-b3eb-ef2959add87d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="id997ca722e2f4788a65a9e8536746348_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzUtMTUtMS0xLTE1MDAzNA_96a1632e-8f10-4bba-9569-a5f4810836ad"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMS0xLTEtMTUwMDM0_5082a9d5-91b0-47af-b96c-05bd4a305c10"
      unitRef="usd">3429100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMy0xLTEtMTUwMDM0_af986b6a-541a-404a-bb5b-bbbd80b8290a"
      unitRef="usd">6300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtNS0xLTEtMTUwMDM0_3fcccdca-b088-4d14-9aa2-11c631ccd4dc"
      unitRef="usd">15400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtNy0xLTEtMTUwMDM0_f8fcc3df-8600-43be-9b59-85d091a8cda8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtOS0xLTEtMTUwMDM0_14c36501-f2f6-4701-a122-6965cd1ff806"
      unitRef="usd">3420000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTEtMS0xLTE1MDAzNA_875048a0-5f67-413a-a09a-8dc6a2841776"
      unitRef="usd">17000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTMtMS0xLTE1MDAzNA_955bc79d-c0c3-4544-b9e3-3748c2ccd6f9"
      unitRef="usd">1100300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i95fdd74fde53453eba6b56a6ba9600eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzYtMTUtMS0xLTE1MDAzNA_08422426-c399-4edc-a9a6-dae1596fd852"
      unitRef="usd">2302700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMS0xLTEtMTUwMDM0_e2fcd450-01b0-45b4-ae5a-be7dad66b060"
      unitRef="usd">4125700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMy0xLTEtMTUwMDM0_fc19f3d4-b7b3-4395-858f-b42afbf45ae7"
      unitRef="usd">6300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctNS0xLTEtMTUwMDM0_fe1b1068-4ff1-4a25-ab75-fed985d38d44"
      unitRef="usd">15400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctNy0xLTEtMTY4NTUz_9a602735-2f6c-4933-81de-6861d1b64997"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctOS0xLTEtMTUwMDM0_f6177320-51b0-436f-ac47-1919013a91c0"
      unitRef="usd">4116600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTEtMS0xLTE1MDAzNA_9785ae91-4e4f-4687-a60c-d8ea137b113d"
      unitRef="usd">713600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTMtMS0xLTE1MDAzNA_707e8cb9-b6f8-4f71-8b6a-0de99cc9934a"
      unitRef="usd">1100300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzctMTUtMS0xLTE1MDAzNA_d22504e3-9920-43eb-ad3f-abd6f21e230c"
      unitRef="usd">2302700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMS0xLTEtMTUwMDM0_5925e52e-0dd4-48fe-a3b8-4f8895545204"
      unitRef="usd">717700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMy0xLTEtMTUwMDM0_6bef1a4e-26a0-4865-89d6-2db99a6bc64f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktNS0xLTEtMTUwMDM0_ec8da079-4f5b-4743-b969-bae59eca2d0c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktNy0xLTEtMTUwMDM0_01873727-a704-4493-b981-2563b80328fb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktOS0xLTEtMTUwMDM0_bdaa5c6b-30d9-4fce-828b-733a73fc8f9f"
      unitRef="usd">717700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTEtMS0xLTE1MDAzNA_74c3b3a6-1e22-45fc-8684-cffdf0b6f013"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTMtMS0xLTE1MDAzNA_162bf471-4cab-45d0-b760-0571d69d9821"
      unitRef="usd">717700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i59583221ff1b4c91878682716a636bb3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzktMTUtMS0xLTE1MDAzNA_b6ee0b6c-b094-4276-8808-b1eaf64e5d15"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTEtMS0xLTE1MDAzNA_cea72d1c-5750-406d-b985-1f224da9f54a"
      unitRef="usd">2485600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTMtMS0xLTE1MDAzNA_35f238bf-f692-415d-a6f7-e61f67dd7fd2"
      unitRef="usd">2700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTUtMS0xLTE1MDAzNA_5bc607b5-be4a-4a80-aca5-be85b599b60e"
      unitRef="usd">11900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTctMS0xLTE1MDAzNA_a21837a7-5545-4de6-99e9-27b022263a51"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTktMS0xLTE1MDAzNA_a7b9159c-9225-46cf-8d93-893513319295"
      unitRef="usd">2476400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTExLTEtMS0xNTAwMzQ_93a4e024-f3ac-40fb-a863-e7a7a0ec838d"
      unitRef="usd">5000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTEzLTEtMS0xNTAwMzQ_809dabdf-3b1b-43a7-806b-4ff004953938"
      unitRef="usd">886700000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8b36d26e61024eac8645d0f1bb64c21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEwLTE1LTEtMS0xNTAwMzQ_745d6786-39ef-4ebc-b10c-70cae4671b11"
      unitRef="usd">1584700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTEtMS0xLTE1MDAzNA_5713f5a6-6dd6-4808-8dd2-60b9910b52a0"
      unitRef="usd">526100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTMtMS0xLTE1MDAzNA_17df62e4-ffd1-4950-bb9c-2c15a698f5da"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTUtMS0xLTE1MDAzNA_4fd1983d-b866-4b8e-a9c4-cc776f9331f5"
      unitRef="usd">2900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTctMS0xLTE1MDAzNA_ad62765d-5ef1-47fa-b834-fc17a050a4b5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTktMS0xLTE1MDAzNA_52768a2d-903f-48ba-84ce-7489d9f8f4d2"
      unitRef="usd">523400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTExLTEtMS0xNTAwMzQ_5ddb93e4-3f10-4a20-8dc2-0abf0f71c91c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTEzLTEtMS0xNTAwMzQ_ffeb0fd5-6a8a-4104-9fb4-0c7cb070e9b8"
      unitRef="usd">137800000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2587a04e00144b698e16da96b21f34a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzExLTE1LTEtMS0xNTAwMzQ_ea52b99d-518a-4d72-81e9-cb9091ad1db6"
      unitRef="usd">385600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTEtMS0xLTE1MDAzNA_274eccf0-fed7-4d85-8354-6d558eed08e5"
      unitRef="usd">213400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTMtMS0xLTE1MDAzNA_945a912a-fde2-498e-8cf6-7df68a25e3cc"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTUtMS0xLTE1MDAzNA_6cff5f5d-a826-4aa0-a794-12d58840079c"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTctMS0xLTE1MDAzNA_62bb05be-41ef-4712-97a0-e65e154ed454"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTktMS0xLTE1MDAzNA_880083fc-8674-46a7-86f0-adb31ae3654f"
      unitRef="usd">213100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTExLTEtMS0xNTAwMzQ_ca7ebcad-02b6-4f6c-bf22-f1354ee5d5fe"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTEzLTEtMS0xNTAwMzQ_3171e9fc-4827-4c02-a26d-ad6edba11ead"
      unitRef="usd">70600000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8308ebf06c1c41218705b5b531829bcc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzEzLTE1LTEtMS0xNTAwMzQ_6b935e4c-d4cb-4003-ad15-a2533bd46b49"
      unitRef="usd">142500000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTEtMS0xLTE1MDAzNA_7318f580-ad7c-48c4-be1f-7b661e3b083b"
      unitRef="usd">3942800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTMtMS0xLTE1MDAzNA_1f98316b-6485-4d7c-a690-dceae2f73035"
      unitRef="usd">3600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTUtMS0xLTE1MDAzNA_bc5a5ace-99b8-49e8-9d5b-dff005c0230f"
      unitRef="usd">15800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTctMS0xLTE2ODU5OQ_8d30da34-7720-4030-923b-f7d0b88ae413"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTktMS0xLTE1MDAzNA_7579b938-166e-4eff-8433-2e7ff9e6ce62"
      unitRef="usd">3930600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTExLTEtMS0xNTAwMzQ_a4dcdd00-19b0-4e07-b937-2ce6db90a0f0"
      unitRef="usd">5000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTEzLTEtMS0xNTAwMzQ_21959f4e-7bf4-4fe1-a942-0c8e362b737f"
      unitRef="usd">1812800000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE0LTE1LTEtMS0xNTAwMzQ_f1647066-adf6-4f16-9931-84af733280b7"
      unitRef="usd">2112800000</us-gaap:MarketableSecuritiesNoncurrent>
    <isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTEtMS0xLTE1MDAzNA_fae4db4d-9483-4fa2-8ac4-f73f39b9291e"
      unitRef="usd">8640800000</isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTMtMS0xLTE1MDAzNA_941403b1-1049-45e5-be65-f1edd7dbd587"
      unitRef="usd">9900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTUtMS0xLTE1MDAzNA_b8bc9b58-5edc-4e99-81a6-e6b2f56c86b0"
      unitRef="usd">31200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTctMS0xLTE2ODYyNA_83f50db8-95ca-434b-9f4c-26b4aac4a17b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTktMS0xLTE1MDAzNA_8fa6b3c4-8335-4cbf-8ca7-fe705ccc6514"
      unitRef="usd">8619500000</isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTExLTEtMS0xNTAwMzQ_30ff124f-a588-4a74-a062-f0c25db5be16"
      unitRef="usd">1290900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTEzLTEtMS0xNTAwMzQ_daff1109-c49f-4227-b23d-0a4014977229"
      unitRef="usd">2913100000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTplM2M2OWZhZTMwYWM0OWUxOTg5ODJhZjQwM2E1NzRiNy90YWJsZXJhbmdlOmUzYzY5ZmFlMzBhYzQ5ZTE5ODk4MmFmNDAzYTU3NGI3XzE4LTE1LTEtMS0xNTAwMzQ_dc56f5c0-438b-44fd-8c01-133e2b70a06b"
      unitRef="usd">4415500000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYzOTE_98a4f8b0-28ed-486f-9fc1-292c990734d1">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s cash equivalents and available-for-sale debt securities (excluding money market funds) as of December&#160;31, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mature in less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,536.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mature in one to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,359.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzEtMS0xLTEtMTUwMDM0_86cb73a8-6008-44a2-9134-048183977d09"
      unitRef="usd">2586600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzEtMy0xLTEtMTUwMDM0_2ef7c8ec-d71b-421a-a3fd-033ff3536017"
      unitRef="usd">2536700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzItMS0xLTEtMTUwMDM0_3f27f439-ecf6-4a93-80f9-137dabb3e133"
      unitRef="usd">2773300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzItMy0xLTEtMTUwMDM0_0e584d7b-a4f0-428b-b778-2b141bb1c9cf"
      unitRef="usd">2623600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzMtMS0xLTEtMTUwMDM0_ee79a124-0220-48d4-a39e-bd8d325ad835"
      unitRef="usd">5359900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpiNGUyNmE0YTE2YTc0NWE5OWIxNTJmZmU0MjQ0MzQ0Ni90YWJsZXJhbmdlOmI0ZTI2YTRhMTZhNzQ1YTk5YjE1MmZmZTQyNDQzNDQ2XzMtMy0xLTEtMTUwMDM0_326ea012-e1b3-42fc-9caf-363005f188c2"
      unitRef="usd">5160300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NTkxOTQ_4eb3d1bc-0e3b-4f66-a2c9-5b450be8c970"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NjgyNDc_7e312d6c-7c7b-4047-bbb3-fd5ceae10fb4"
      unitRef="usd">-154200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYwNDczMTM5NjgyMzU_24f8a585-3521-4afb-8d5e-899086ae5f54"
      unitRef="usd">-16000000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MTk_aeb52a80-0c7c-43c9-bbfe-707ae1f62815">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;losses&#160;less&lt;br/&gt;than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized losses&#160;12&lt;br/&gt;months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,853.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,048.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMS0xLTEtMTY5MjQ4_9fb42b93-ea60-4a49-8907-05592082bd8d"
      unitRef="usd">731700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMy0xLTEtMTY5MjQ4_2c6a4b19-f8ef-4e80-bf94-aa4ae0a07b56"
      unitRef="usd">26000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItNS0xLTEtMTY5MjQ4_b090c6aa-191d-4797-a481-43d9b35cc4cd"
      unitRef="usd">1886900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItNy0xLTEtMTY5MjQ4_d0af0ecd-d100-4d74-92f1-af5acdd4ddac"
      unitRef="usd">70600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItOS0xLTEtMTY5MjQ4_7acfda41-af74-40e0-a744-06cdf8bfe928"
      unitRef="usd">2618600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9444962effa548219751ad1adbb4d73f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzItMTEtMS0xLTE2OTI0OA_882394b6-7f95-4584-a2bd-b4f686ab89cb"
      unitRef="usd">96600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMS0xLTEtMTUwMDM0_b887d226-10f8-45c7-97f2-5812f238103f"
      unitRef="usd">631400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMy0xLTEtMTUwMDM0_c643cdb1-fc05-4875-ab7c-4e3950e3c12c"
      unitRef="usd">17600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtNS0xLTEtMTUwMDM0_17eb76e8-e712-4651-9e0c-ec9d2ffbab3a"
      unitRef="usd">1221900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtNy0xLTEtMTUwMDM0_6e8cd9fd-8516-4165-80b2-ea3203bce566"
      unitRef="usd">58400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtOS0xLTEtMTUwMDM0_91cf2799-dd13-4ea7-950e-abc7a0fc6f67"
      unitRef="usd">1853300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1d9885531f254ed48c9cb4b3b9e2b23e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzMtMTEtMS0xLTE1MDAzNA_8b156b3a-f316-4aae-afbb-610140fde778"
      unitRef="usd">76000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMS0xLTEtMTUwMDM0_cd8c5721-3302-4619-bdf4-f1b56912578f"
      unitRef="usd">102700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMy0xLTEtMTUwMDM0_bac97a55-7c6f-47c9-8db9-8f74e3de4671"
      unitRef="usd">4400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtNS0xLTEtMTUwMDM0_9d622a6a-a9c0-4833-a098-3e929426e17e"
      unitRef="usd">324600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtNy0xLTEtMTUwMDM0_a619e105-a00f-44d6-b47d-62d5e45787b9"
      unitRef="usd">15500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtOS0xLTEtMTUwMDM0_2352eead-f291-44ff-9807-0e1d4104e374"
      unitRef="usd">427300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i94a6bc08f8644e9eb1d911d27af8b5b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzUtMTEtMS0xLTE1MDAzNA_d3a611fb-1385-49b4-94c0-8611f68fc924"
      unitRef="usd">19900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMS0xLTEtMTUwMDM0_be93491e-a583-4016-81d9-6fd47161f7dc"
      unitRef="usd">44600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMy0xLTEtMTUwMDM0_a33c0099-0a9a-447d-89f5-9e0d038d80eb"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtNS0xLTEtMTUwMDM0_621a8d00-5477-4f36-8e1f-8f3585d3a7e2"
      unitRef="usd">104900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtNy0xLTEtMTUwMDM0_48c0f4cc-7794-419b-90ce-55bc711cc513"
      unitRef="usd">4900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtOS0xLTEtMTUwMDM0_4d64c05c-44c1-42bf-928a-fe25d8f302d7"
      unitRef="usd">149500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0705226857e341b09873d9b24560e21a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzYtMTEtMS0xLTE1MDAzNA_869f6662-2600-4b75-8bf3-b23c9415303c"
      unitRef="usd">6000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMS0xLTEtMTUwMDM0_207217ce-a5eb-4bea-ae44-44262cf9a3cc"
      unitRef="usd">1510400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMy0xLTEtMTUwMDM0_aacddd23-971f-46ad-8d64-6bedffe1f7d6"
      unitRef="usd">49100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctNS0xLTEtMTUwMDM0_2e574b6a-b977-4ded-b49a-db880d0472f5"
      unitRef="usd">3538300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctNy0xLTEtMTUwMDM0_5f7b3275-8c14-48b4-bdd3-dad2a64306af"
      unitRef="usd">149400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctOS0xLTEtMTUwMDM0_424735d6-d7db-4d12-a81a-eea680b09c0f"
      unitRef="usd">5048700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzctMTEtMS0xLTE1MDAzNA_864f13a4-a5f3-402c-9510-a3e05b2db1e1"
      unitRef="usd">198500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTEtMS0xLTE2OTI2Ng_88e94007-3c7d-4a74-8c8f-98d312a66795"
      unitRef="usd">2596300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTMtMS0xLTE2OTI2Ng_fbeee95a-fc93-4b1e-a59e-88fa620fe64d"
      unitRef="usd">15400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTUtMS0xLTE2OTI2Ng_0c56414f-e1f3-4834-bd5e-a759a3656d18"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTctMS0xLTE2OTI2Ng_a600db84-206a-444c-af5a-0e57be27f2ab"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTktMS0xLTE2OTI2Ng_307537e6-fb2d-4118-b07f-a81e5d4d85bc"
      unitRef="usd">2596300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i357d64746ac9439288fd1ba185b246c0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTExLTEtMS0xNjkyNjY_86c113ad-6961-4c7a-92bd-e00e7bfa75bc"
      unitRef="usd">15400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTEtMS0xLTE2OTY5NA_c74e91ba-cf9c-4828-89a9-013304c700a9"
      unitRef="usd">4000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTMtMS0xLTE2OTczNw_2afc9053-8d79-45b1-9ad5-fdc0747029b3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTUtMS0xLTE2OTc3OQ_71cd3a16-3d34-4964-988e-854cd7ecf29b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTctMS0xLTE2OTgyMQ_fd998b91-8f8b-4551-b741-d813f2fe2a69"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTktMS0xLTE2OTg2OA_71ae1076-17e4-48ee-985a-445b7f43cb51"
      unitRef="usd">4000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i2b1b5039fc4342148b973bb59e8d775f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzExLTExLTEtMS0xNjk5MzA_6b31093d-38e6-4d9d-aff5-b5dab12996ff"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTEtMS0xLTE1MDAzNA_961107dc-7b57-4e35-82e2-84ba1a200130"
      unitRef="usd">1687900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTMtMS0xLTE1MDAzNA_3096cbb3-6a82-4c6c-ba7f-9412c33f0704"
      unitRef="usd">11900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTUtMS0xLTE1MDAzNA_8ac8951d-073e-4b67-917f-a9458b3f1e80"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTctMS0xLTE1MDAzNA_45409aed-8e47-41e1-b668-a7a9c2a56221"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTktMS0xLTE1MDAzNA_92e30303-2991-457f-bb27-43ff93e60043"
      unitRef="usd">1687900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic0040bf49a71463b8c92b5c6f4a375af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEwLTExLTEtMS0xNTAwMzQ_91df5d7c-99b4-45de-88ad-dbb7da73180c"
      unitRef="usd">11900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTEtMS0xLTE1MDAzNA_05624c3a-e6c2-4d52-89ce-7301ab44bb82"
      unitRef="usd">412500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTMtMS0xLTE1MDAzNA_3f6558b0-7b8d-4c21-90e0-57526803162f"
      unitRef="usd">2900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTUtMS0xLTE1MDAzNA_31adb959-be0d-461e-93e3-6b88aa977be8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTctMS0xLTE1MDAzNA_a55eaf0c-b002-47b3-9dff-1a194b45824e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTktMS0xLTE1MDAzNA_f680c572-31f4-47af-b393-558232056dee"
      unitRef="usd">412500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9c67f2127d5141edbb2ca095f39de5ad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEyLTExLTEtMS0xNTAwMzQ_a88387f5-2944-4bea-93e3-136332e78612"
      unitRef="usd">2900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTEtMS0xLTE1MDAzNA_6725b5ca-1895-4528-a4bd-0f0fe5c228a3"
      unitRef="usd">156000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTMtMS0xLTE1MDAzNA_bea19c0a-5be8-4f25-8141-b544a01d5c3b"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTUtMS0xLTE1MDAzNA_5e8cc14b-5673-4771-b670-ef95f8f82da9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTctMS0xLTE1MDAzNA_2e3f495e-d425-463d-8281-7051d91ae44e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTktMS0xLTE1MDAzNA_8599a4ae-36ec-4380-91b9-f9c0c2c38786"
      unitRef="usd">156000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ideeca8acd2b04ca5b7bd83df64f2ecff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzEzLTExLTEtMS0xNTAwMzQ_fe3fdbc1-96ac-40ca-8701-2dd935c07b53"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTEtMS0xLTE1MDAzNA_eab88ebc-f3bd-4c8c-9dc9-7e3b7816faa6"
      unitRef="usd">4856700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTMtMS0xLTE1MDAzNA_3014432d-b16c-4247-a939-46fdb7c8e105"
      unitRef="usd">31200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTUtMS0xLTE1MDAzNA_bdc2c5d8-2c02-401c-830b-b8e72f8fef71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTctMS0xLTE1MDAzNA_59d38597-66fb-4b62-ae15-08bc17a25098"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTktMS0xLTE1MDAzNA_f6fc34d1-cd19-49cd-a11a-474a52a5908f"
      unitRef="usd">4856700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMjYyNzY0MDQ4Zjc0ZGI0YTQyY2M5Yjk3ZjI2NmUzNy90YWJsZXJhbmdlOjMyNjI3NjQwNDhmNzRkYjRhNDJjYzliOTdmMjY2ZTM3XzE0LTExLTEtMS0xNTAwMzQ_ebf71dbe-83d6-4bca-b796-f6c9ecf87721"
      unitRef="usd">31200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzYzOTQ_6f4865ed-e87f-457d-ab03-044d203ae6fb">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Changes in Fair Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Purchases / Sales / Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible and other assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments with readily determinable value (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable value (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; Recorded in interest and other income, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other includes foreign currency translation gains/(losses).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i394f7efea4cd4225a8986de3d68e8579_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMS0xLTEtMTUwMDM0_072b22d7-11de-4063-bdb2-2f1b343ab5db"
      unitRef="usd">26900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMy0xLTEtMTUwMDM0_4196c251-3806-4264-965c-0c08a74dfe90"
      unitRef="usd">-21200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <isrg:EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments
      contextRef="id75e79d7fde24733a4fa5acd52a211ce_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItNS0xLTEtMTUwMDM0_db1fed9d-5fae-4fc7-9455-3a32512e3dcc"
      unitRef="usd">-1400000</isrg:EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idaaec3561f8241d9906a1ef96fca02df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItNy0xLTEtMTUwMDM0_393d07a7-f31c-45e8-ade2-ad3e49617c97"
      unitRef="usd">4300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i702b19a2b8bb41359e443d04869386fd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItOS0xLTEtMTUwMDM0_c7c07d90-22ff-451f-8f09-33d2ba30e7c8"
      unitRef="usd">4300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7ae9291dcd4e4adf9b84f4736b3bebec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzItMTEtMS0xLTE1MDAzNA_3b79ecd2-cfd1-4490-8771-fb1a52f20886"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id08bf20bd9fe482f996a73a760e92a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMS0xLTEtMTUwMDM0_e4645773-c105-4fc2-b416-f3aa4471f3df"
      unitRef="usd">15600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss
      contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMy0xLTEtMTUwMDM0_e707de29-d493-4b4b-9a51-b394ce282577"
      unitRef="usd">200000</isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss>
    <isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments
      contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtNS0xLTEtMTUwMDM0_c7f1025b-5abd-44f4-bb2a-9bdc68e8568b"
      unitRef="usd">43300000</isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i6bdc674bc94b46d8a24d45cb1975aa99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtNy0xLTEtMTUwMDM0_2fe394af-be09-40f5-837c-6ff5a8e77ad9"
      unitRef="usd">59100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="icc10b5ae76314ee18fd591fd9b32d6ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtOS0xLTEtMTUwMDM0_13242378-3699-4179-b4e4-d004fa0a862b"
      unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5134dae76a5341b9aaabb6667f245625_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTozMTRhYTc3YmE2ZmE0YzEyOTc0MDgwZTMxYWNjNTYxMy90YWJsZXJhbmdlOjMxNGFhNzdiYTZmYTRjMTI5NzQwODBlMzFhY2M1NjEzXzMtMTEtMS0xLTE1MDAzNA_a61fbc90-4393-4111-af0c-fac3e66c0709"
      unitRef="usd">59100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i71314a12af6b429986b5c9a4271f446a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzM4NDgyOTA3MTg3MjU_e1e0f3b7-5109-4dab-99d8-0e1852c23064"
      unitRef="usd">-21200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss
      contextRef="ib8c23b4bd43a4c15a7e41e6d885acdf9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzM4NDgyOTA3MTg5ODA_c78e4085-0288-4506-8231-c57424ea67d6"
      unitRef="usd">200000</isrg:EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MTI_7ac69aec-8af6-4db1-bb22-873dbcf5fd61">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_36dab90d-c583-4376-9d08-dc502afb9832"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_b8fcc648-6d28-49c0-be29-3454447f9231"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMC0xLTEtMTUwMDM0_bb8257d5-b0d0-49c4-ad22-8006454ac2fb"&gt;Recognized gains (losses) in interest and other income, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses) related to balance sheet re-measurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i079b7ef7442a42a7840e702b882a1012_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMS0xLTEtMTUwMDM0_a5db0764-bcfe-4195-adb0-4df0bacf9016"
      unitRef="usd">26900000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7280a7103fee4e258e2f35b51eff9ab1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItMy0xLTEtMTUwMDM0_0dca9176-c84a-4a75-b771-daa62c37e932"
      unitRef="usd">15500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i910cb2fb179a407d8a5c75fc680d2303_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzItNS0xLTEtMTUwMDM0_d9165c82-3635-4c46-9c4a-5c46eb1f2116"
      unitRef="usd">-12300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtMS0xLTEtMTUwMDM0_01ab912b-dc93-4b25-91c1-e6aee0187d01"
      unitRef="usd">-54200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtMy0xLTEtMTUwMDM0_0f63ea55-562a-406b-9f9c-3f741954ec34"
      unitRef="usd">-16400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTpjMmE1YzRjYjYyYzY0YmEyYmQ5ZTMwZjQ4NjkxNDgxZC90YWJsZXJhbmdlOmMyYTVjNGNiNjJjNjRiYTJiZDllMzBmNDg2OTE0ODFkXzMtNS0xLTEtMTUwMDM0_297da13f-6b30-4c80-9c17-8e800cd1068d"
      unitRef="usd">10900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90ZXh0cmVnaW9uOjMyNjJjMzQwZTQwNTRmODA4Nzc3NDdmYjA1YzQ4ZTNkXzY0MjM_2b5eab2a-81db-475e-b096-93f8dc06aa90">Total gross notional amounts (in USD) for outstanding derivatives and the aggregate gross fair value at the end of each period were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.220%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notional amounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross fair value recorded in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib5c8e03657644033b868750e96ab9643_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtMS0xLTEtMTUwMDM0_5859f889-3e14-4362-a5a2-c4f603292c99"
      unitRef="usd">188400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i46df387e6efe4ff08b0f664717fc0831_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtMy0xLTEtMTUwMDM0_298c4435-3b73-48ea-8a53-98076a7536c1"
      unitRef="usd">181200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i21fdc4fc554441f08d904ff171695e33_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtNS0xLTEtMTUwMDM0_369e1d6c-0600-4fea-be13-5e95ada6af63"
      unitRef="usd">496300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ided6c6550364405b97c4d34389c5ffff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzMtNy0xLTEtMTUwMDM0_1b1df814-de72-4a46-b777-bcc9ba03cc36"
      unitRef="usd">318800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i964a856360ad4285ade38db2e34a431b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtMS0xLTEtMTUwMDM0_08b03b05-3b58-4abd-9841-9a0bf0cbea73"
      unitRef="usd">1800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i231b0f91933940b08ff7af08baa651f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtMy0xLTEtMTUwMDM0_d01b4ad3-a17e-4812-8a87-7c62d003e4aa"
      unitRef="usd">5700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idf83fed589c5486b9792c680888aeea0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtNS0xLTEtMTUwMDM0_6e74df07-4c4c-4177-a6bb-be5853bb2d7a"
      unitRef="usd">4300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia0cbc403979c45828117eb065cab8fa2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzUtNy0xLTEtMTUwMDM0_d1c32cc6-de9b-4719-9aa4-ab28e2f4d972"
      unitRef="usd">6900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i804002ab970d48a5a57bbae1404bf198_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtMS0xLTEtMTUwMDM0_68058710-ef43-4042-9c34-71ae50dc859b"
      unitRef="usd">5300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6a74a66492084258931e13b5981fa79f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtMy0xLTEtMTUwMDM0_dea11e45-c974-40ab-a8dc-2b3f8920a692"
      unitRef="usd">500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id22a8bae9b2c48eebe8b50b3819f8d70_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtNS0xLTEtMTUwMDM0_9a1b9163-2605-4c20-b7c4-66410f0778af"
      unitRef="usd">4200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3edae5cd8cd2410183098ef4010c1892_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzUvZnJhZzozMjYyYzM0MGU0MDU0ZjgwODc3NzQ3ZmIwNWM0OGUzZC90YWJsZTo5NmQ0Mzc1YzljOGI0YTFjOWI4N2Y3MDA1ZTkwZDc2OC90YWJsZXJhbmdlOjk2ZDQzNzVjOWM4YjRhMWM5Yjg3ZjcwMDVlOTBkNzY4XzYtNy0xLTEtMTUwMDM0_79f2febe-9aae-477f-aa55-9fd793f99fe1"
      unitRef="usd">800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5NQ_132483e7-cbeb-4005-b07d-252d92f4f815">CONSOLIDATED FINANCIAL STATEMENT DETAILS&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide details of selected consolidated financial statement items (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled accounts receivable and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building/leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets &#x2013; Intuitive System Leasing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,845.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,237.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(968.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,876.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*Accumulated depreciation associated with operating lease assets &#x2013; Intuitive System Leasing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Other accrued liabilities &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income and other taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction-related capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred and contingent purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental cash flow information (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended&#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment transfers from inventory to property, plant, and equipment &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of property, plant, and equipment in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzQ5NDc4MDIzMjU0NzY_081a68f9-8733-44a6-8226-9f456c49ce5d">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide details of selected consolidated financial statement items (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled accounts receivable and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <isrg:TradeAccountsReceivableCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzMtMS0xLTEtMTg4MDE3_fafe9027-65e8-43a0-bdd2-3ac8a7d62235"
      unitRef="usd">864900000</isrg:TradeAccountsReceivableCurrent>
    <isrg:TradeAccountsReceivableCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzMtMy0xLTEtMTg4MDMx_ecdfb4a9-658a-4393-8990-7588574e20e6"
      unitRef="usd">731000000.0</isrg:TradeAccountsReceivableCurrent>
    <isrg:UnbilledReceivablesAndOtherReceivablesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzYtMS0xLTEtMjAwNTQw_2a5943b7-4bea-4568-8978-17ad05bb3e85"
      unitRef="usd">91700000</isrg:UnbilledReceivablesAndOtherReceivablesCurrent>
    <isrg:UnbilledReceivablesAndOtherReceivablesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzYtMy0xLTEtMjAwNTQ2_4e850eec-e879-435f-92a6-ba3cef83aee7"
      unitRef="usd">64800000</isrg:UnbilledReceivablesAndOtherReceivablesCurrent>
    <isrg:SalesReturnsAndAllowances
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMS0xLTEtMTk5NjUz_7aafae6f-5139-4d59-b8ca-39c155cc806d"
      unitRef="usd">14500000</isrg:SalesReturnsAndAllowances>
    <isrg:SalesReturnsAndAllowances
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMy0xLTEtMTk5NjUz_86201808-f143-4d53-96f3-4d8e1704f906"
      unitRef="usd">13100000</isrg:SalesReturnsAndAllowances>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMS0xLTEtMTk5NDk3_728f1436-7b72-4bb9-8309-dd7ae94caf39"
      unitRef="usd">942100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo2ZDZmYjEyMGViNTc0NDY4OGFhNzIxNzE5OTNlN2Y2My90YWJsZXJhbmdlOjZkNmZiMTIwZWI1NzQ0Njg4YWE3MjE3MTk5M2U3ZjYzXzgtMy0xLTEtMTk5NDk4_b9c4b52e-e6be-43fd-aeeb-5a6edea73184"
      unitRef="usd">782700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5MA_4118ea90-e5be-49be-8d64-a15930aeb562">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzMtMS0xLTEtMTUwMDM0_f201327b-b755-4f93-b62c-572325923890"
      unitRef="usd">382900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzMtMy0xLTEtMTUwMDM0_a218998a-e6ab-4259-9e7f-95694edbf43b"
      unitRef="usd">214600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzQtMS0xLTEtMTUwMDM0_b4346cfc-425a-41a0-8666-2f486938b62e"
      unitRef="usd">159900000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzQtMy0xLTEtMTUwMDM0_b2b53bb6-ca0c-4eff-b678-bbdc676ad804"
      unitRef="usd">96400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzUtMS0xLTEtMTUwMDM0_0ab0a979-be23-48df-8f67-89c00928f490"
      unitRef="usd">350400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzUtMy0xLTEtMTUwMDM0_8e105e44-744a-4c70-817e-9219138ed827"
      unitRef="usd">276100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMS0xLTEtMTUwMDM0_3860936d-1cb1-4384-833c-2d6938cd9a74"
      unitRef="usd">893200000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMy0xLTEtMTUwMDM0_3652dc36-52d2-4090-93f7-26528b8cca89"
      unitRef="usd">587100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTpkNDI1YmVjYmZjZjE0ODk4OTg2Y2NmYWM1MTYxYWMxZS90YWJsZXJhbmdlOmQ0MjViZWNiZmNmMTQ4OTg5ODZjY2ZhYzUxNjFhYzFlXzYtMy0xLTEtMTUwMDM0_addf0141-b03a-4eaf-8740-6fbbb9166f11"
      unitRef="usd">587100000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI5MQ_39a6088f-ad6e-4174-86c3-eed843c5dadd">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzMtMS0xLTEtMjAwMDgw_422401d0-08d1-49e2-8708-86e5147b8541"
      unitRef="usd">131200000</isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent>
    <isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzMtMy0xLTEtMjAwMDgw_327a0efe-3129-4824-96ae-39da25e0b8c5"
      unitRef="usd">110300000</isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzQtMS0xLTEtMTUwMDM0_b33e7a1e-914d-4b3b-999e-1243d6cddbf5"
      unitRef="usd">4300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzQtMy0xLTEtMTUwMDM0_85b06ed6-6e41-4d89-bccb-27fa0d772a07"
      unitRef="usd">26900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzYtMS0xLTEtMTUwMDM0_6b8f9d82-22cf-4e79-b82e-f0aa657b7ef8"
      unitRef="usd">164300000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzYtMy0xLTEtMTUwMDM0_06738238-6f71-4f30-baeb-b1254fc5a37c"
      unitRef="usd">133900000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzctMS0xLTEtMTUwMDM0_53a03294-9ae7-448a-8e39-9b7f4fd425e6"
      unitRef="usd">299800000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZGY3ZGRkMDNkMGQ0NjNhYTZlY2EyNTRiZDhkNGRjOS90YWJsZXJhbmdlOjRkZjdkZGQwM2QwZDQ2M2FhNmVjYTI1NGJkOGQ0ZGM5XzctMy0xLTEtMTUwMDM0_3f7a36a4-5247-4e04-930b-64f1077c2fdf"
      unitRef="usd">271100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Land
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzMtMS0xLTEtMTUwMDM0_1a271571-c54e-4eab-bfd2-925b0cac9b98"
      unitRef="usd">388600000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzMtMy0xLTEtMTUwMDM0_db7138ea-6e60-4beb-a6db-063f119c85ef"
      unitRef="usd">367800000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzQtMS0xLTEtMTUwMDM0_5bd573e9-3e83-4d8d-9469-b4eee1e78a1a"
      unitRef="usd">866500000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzQtMy0xLTEtMTUwMDM0_4af9cd8d-bbe1-4460-bf02-986523da9b21"
      unitRef="usd">812500000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzUtMS0xLTEtMTUwMDM0_caba2ca3-a76b-4bd6-bf45-e041a58802e8"
      unitRef="usd">566400000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzUtMy0xLTEtMTUwMDM0_e8014aa4-8821-489d-a4c6-9fd6ca14913b"
      unitRef="usd">497600000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzYtMS0xLTEtMTUwMDM0_376ea8ea-2b39-45a2-b248-8eaaeabd7c3c"
      unitRef="usd">806400000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzYtMy0xLTEtMTUwMDM0_ed0ca1c5-f75f-447d-8d17-6a4dccc36136"
      unitRef="usd">616100000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <isrg:ComputerAndOfficeEquipment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzctMS0xLTEtMTUwMDM0_c6738176-ba22-49ea-85fb-f897bfc060c7"
      unitRef="usd">134700000</isrg:ComputerAndOfficeEquipment>
    <isrg:ComputerAndOfficeEquipment
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzctMy0xLTEtMTUwMDM0_7bad37c2-d4c1-424b-af87-67b7adcf5380"
      unitRef="usd">123700000</isrg:ComputerAndOfficeEquipment>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzgtMS0xLTEtMTUwMDM0_9e02eb8b-05d8-41f7-afb2-83eb88d72adc"
      unitRef="usd">240900000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzgtMy0xLTEtMTUwMDM0_a5fc29e8-55f2-4abf-bef5-b719fcf90dc1"
      unitRef="usd">217600000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzktMS0xLTEtMTUwMDM0_19273857-b566-4aa8-a75c-ebaf42079528"
      unitRef="usd">608600000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzktMy0xLTEtMTUwMDM0_34df97db-59a9-4af9-a4c4-26acfa57d0c3"
      unitRef="usd">209700000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEwLTEtMS0xLTE1MDAzNA_bff5b258-f856-41c4-bde4-16c7e5f7cfc3"
      unitRef="usd">3612100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEwLTMtMS0xLTE1MDAzNA_f57de2df-fec7-4aed-abd7-a62df77ae22d"
      unitRef="usd">2845000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzExLTEtMS0xLTE1MDAzNA_b0582b16-9488-45aa-b4f1-ac8591e57846"
      unitRef="usd">1237900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzExLTMtMS0xLTE1MDAzNA_9c72e732-f215-4ed3-ad39-6b5383a40acd"
      unitRef="usd">968600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEyLTEtMS0xLTE1MDAzNA_7b15a6c4-aa33-4bf8-a329-db22d9846ddc"
      unitRef="usd">2374200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzEyLTMtMS0xLTE1MDAzNA_9abb740d-f8ef-481a-91e4-dea275063fcd"
      unitRef="usd">1876400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzE0LTEtMS0xLTE1MDAzNA_2643f9ef-ed09-4895-a7ab-45369c74ca44"
      unitRef="usd">285800000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTowNzc4YTc3NTRiNWU0YzU0OWYxOTIyZGQyNGZkMGU2OS90YWJsZXJhbmdlOjA3NzhhNzc1NGI1ZTRjNTQ5ZjE5MjJkZDI0ZmQwZTY5XzE0LTMtMS0xLTE1MDAzNA_66856a09-7c55-4dc1-8059-56ca27937507"
      unitRef="usd">182100000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI4MQ_ed49d9fa-e678-4c43-b3ba-60aadd5aa0ba">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Other accrued liabilities &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income and other taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction-related capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred and contingent purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities &#x2013; short-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:TaxesPayableCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzMtMS0xLTEtMTUwMDM0_0ed14567-8229-4ee0-9346-9542706f6c21"
      unitRef="usd">96100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzMtMy0xLTEtMTUwMDM0_c3e05edd-dc9c-4d45-b4a9-4d99689766be"
      unitRef="usd">54100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMS0xLTEtMjAwMTIy_888e12de-d772-45f9-8de2-64cd9c4cdfd8"
      unitRef="usd">50300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMy0xLTEtMjAwMTIy_90a1351e-165f-4c2a-85e8-c10d04156df7"
      unitRef="usd">23100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMS0xLTEtMTUwMDM0_92a91ccf-74fb-4d5c-9757-f1cd58142fe8"
      unitRef="usd">23000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzQtMy0xLTEtMTUwMDM0_9660e4e7-2bed-4e72-976d-3cab7946a162"
      unitRef="usd">2400000</us-gaap:LitigationReserveCurrent>
    <isrg:DeferredPurchaseConsiderationPaymentsCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzUtMS0xLTEtMTUwMDM0_0ed6d646-f963-41c3-be2b-986111804310"
      unitRef="usd">7800000</isrg:DeferredPurchaseConsiderationPaymentsCurrent>
    <isrg:DeferredPurchaseConsiderationPaymentsCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzUtMy0xLTEtMTUwMDM0_876b7af0-ad6a-47ff-ba64-c56594d3f1c4"
      unitRef="usd">12000000.0</isrg:DeferredPurchaseConsiderationPaymentsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzctMS0xLTEtMTUwMDM0_62ad7cdf-8ab0-428d-bccf-73588483480f"
      unitRef="usd">299000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzctMy0xLTEtMTUwMDM0_b90cab4d-d4a7-46bb-a2c6-d349c47266bd"
      unitRef="usd">209700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzgtMS0xLTEtMTUwMDM0_f7f53990-9f7e-4356-a4be-7257ec2207e4"
      unitRef="usd">476200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo0ZDMxZWQzZTEzZDI0ZDJhODgxM2MxZGI2ZWFhNDE5YS90YWJsZXJhbmdlOjRkMzFlZDNlMTNkMjRkMmE4ODEzYzFkYjZlYWE0MTlhXzgtMy0xLTEtMTUwMDM0_f22370ef-56be-4516-8f0b-c825ed7d19ab"
      unitRef="usd">301300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzI4Nw_772c8716-f703-4848-80d4-7045d6e3ed60">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzMtMS0xLTEtMTUwMDM0_902b0078-c4df-47ad-9ef1-edb216027b3c"
      unitRef="usd">288000000.0</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzMtMy0xLTEtMTUwMDM0_8ee9095f-deb6-4ecc-84c9-bc97ada03e52"
      unitRef="usd">316600000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzQtMS0xLTEtMTUwMDM0_55d80ce8-c65e-410f-9117-1afd172ccf40"
      unitRef="usd">41000000.0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzQtMy0xLTEtMTUwMDM0_2959e074-10a7-4e99-921d-bb7725a6c77f"
      unitRef="usd">36800000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzUtMS0xLTEtMTUwMDM0_bc5ab1fd-ca66-4cfa-bd7f-e6bebb68b0c8"
      unitRef="usd">110300000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzUtMy0xLTEtMTUwMDM0_bc1e2cea-91ca-4523-9252-e8230b18ec82"
      unitRef="usd">100300000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzYtMS0xLTEtMTUwMDM0_bfb4f65c-6f3c-407a-b827-37719718b5f2"
      unitRef="usd">439300000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTphNzRiNzk1MWQ5NDk0MWQ5OTU4YzllMmFkMzQ2MTc5OS90YWJsZXJhbmdlOmE3NGI3OTUxZDk0OTQxZDk5NThjOWUyYWQzNDYxNzk5XzYtMy0xLTEtMTUwMDM0_2cca96a0-b326-42d8-93aa-c3ba6aac1f20"
      unitRef="usd">453700000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90ZXh0cmVnaW9uOjRjMGUwMTM3NTA3YzQ0YzJiYzhmZjk4MmU2ZGYyOTg0XzMwMA_f279c91c-72e8-481b-82cf-b45e4f515713">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides supplemental cash flow information (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended&#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment transfers from inventory to property, plant, and equipment &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of property, plant, and equipment in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItMS0xLTEtMTUwMDM0_11f23f96-9dbc-489f-8d51-ffa3d0f81074"
      unitRef="usd">444200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItMy0xLTEtMTUwMDM0_661681a8-1651-43a3-8c40-80e51df79c64"
      unitRef="usd">180000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzItNS0xLTEtMTUwMDM0_17cef421-b4dd-41a5-a04a-862954877483"
      unitRef="usd">34400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtMS0xLTEtMTUwMDM0_0ad3c017-696d-4922-8e13-ffb643bf5ce1"
      unitRef="usd">279200000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtMy0xLTEtMTUwMDM0_f5fe9d88-18c5-45f7-ad01-febb9826829d"
      unitRef="usd">302400000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzQtNS0xLTEtMTUwMDM0_2d7ce8b3-6d89-4335-aa53-50df16d6771a"
      unitRef="usd">186500000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtMS0xLTEtMTUwMDM0_cf281295-502f-425c-8ee8-3137807d678c"
      unitRef="usd">73400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtMy0xLTEtMTUwMDM0_140918be-5bbd-48ce-a095-b36720d4659b"
      unitRef="usd">32100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMzgvZnJhZzo0YzBlMDEzNzUwN2M0NGMyYmM4ZmY5ODJlNmRmMjk4NC90YWJsZTo4M2RhMDM3MWVhODg0OTllOWMzYjBmYTNkZmQ5MTRjNy90YWJsZXJhbmdlOjgzZGEwMzcxZWE4ODQ5OWU5YzNiMGZhM2RmZDkxNGM3XzUtNS0xLTEtMTUwMDM0_e591779f-90f4-478b-9321-e05c0655a58d"
      unitRef="usd">47300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTQ_f32ab9a6-118f-4310-95f0-3f32a0cf5a07">REVENUE&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue disaggregated by types and geography (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,225.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,962.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;OUS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total OUS revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,395.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,455.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,222.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,710.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which revenue has not yet been recognized. A significant portion of these performance obligations relate to service obligations in the Company&#x2019;s system sale and lease arrangements that will be satisfied and recognized as revenue in future periods. The transaction price allocated to the remaining performance obligations was $1.86&#160;billion as of December&#160;31, 2022. The remaining performance obligations are expected to be satisfied over the term of the system sale, lease, and service arrangements, which are generally up to 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information summarizes the Company&#x2019;s contract assets and liabilities (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company recognized $380&#160;million of revenue that was included in the deferred revenue balance as of December&#160;31, 2021. During the year ended December&#160;31, 2021, the Company recognized $351 million of revenue that was included in the deferred revenue balance as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intuitive System Leasing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents product revenue from Intuitive System Leasing arrangements (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9"&gt;Operating lease revenue*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*Variable lease revenue relating to usage-based arrangements included within operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTU_9e725566-cd92-468b-ac42-a60cbe1f4f64">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue disaggregated by types and geography (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,225.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,962.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;OUS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total OUS revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,395.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Instruments and accessories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,455.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,222.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,710.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i246f937640f04aaca1e106cbdf7b1a32_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItNS0xLTEtMTUwMDM0_a59150c2-472e-4634-8e04-154e1bcddb6e"
      unitRef="usd">2507200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0cc5eca2d9942c3921b4aba2cde8e4f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItNy0xLTEtMTUwMDM0_ba44b71e-fe67-4f74-b538-441cfd2dfd7d"
      unitRef="usd">2225100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b35002f4f84795b5c367b377727c09_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzItOS0xLTEtMTUwMDM0_9fc65b32-2bfd-4994-a3f4-496584619254"
      unitRef="usd">1785100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf1c067c42d24d09b83f44eb0b71ce2b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtNS0xLTEtMTUwMDM0_7b0581fb-0cd4-4563-bd51-6c63b0887fee"
      unitRef="usd">966000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ae156a408ef48c79d517473c3535ecd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtNy0xLTEtMTUwMDM0_e4dc9885-b206-46b7-b547-924c05fa12d3"
      unitRef="usd">1024800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e0a839f694a4a25a79f064404e8b099_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzMtOS0xLTEtMTUwMDM0_a91527a3-1c12-4bbc-a6c0-34369fb84b1c"
      unitRef="usd">695000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0b0eb6066646e28b5f0ecd47f541fd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtNS0xLTEtMTUwMDM0_3851b3c6-f239-4146-9d6f-ff57a26a5d73"
      unitRef="usd">684400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8144e739c7bc4ec28218fb43ce081ed4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtNy0xLTEtMTUwMDM0_716b2f8b-a867-464c-9b1b-87facbcc2f6f"
      unitRef="usd">603300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3831ecf897f94e55ade9139765dde100_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzQtOS0xLTEtMTUwMDM0_d8a0d7a9-762f-410d-8e5a-454b6e4a8e6f"
      unitRef="usd">482600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55328c6d3ad9447fb62f387c720a2058_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtNS0xLTEtMTUwMDM0_a70c00b1-6a32-4186-b6bc-f082c5f6a336"
      unitRef="usd">4157600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1626e0eb7e514e2fb0c7df23826a6fec_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtNy0xLTEtMTUwMDM0_1f7ea0e1-33e9-4681-b6bc-59fb5533e6cc"
      unitRef="usd">3853200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8b2f32382954088b7a0390205e6b628_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzUtOS0xLTEtMTUwMDM0_c6c967b7-4bd6-4715-96ac-38168eb0bebd"
      unitRef="usd">2962700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8304025c63864a2aa1a6a11f46d0864b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtNS0xLTEtMTUwMDM0_c5489ccc-09a2-4c32-b297-d04621b2f6a9"
      unitRef="usd">1010700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6837fa9980f8427899e6791fa305524d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtNy0xLTEtMTUwMDM0_4253c141-f413-4e49-9567-595ce9e8054c"
      unitRef="usd">875400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36d1a1db0674a418d5a7f72e7b54de5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzgtOS0xLTEtMTUwMDM0_72bfe070-d344-4d50-8ad4-ffa8e809cc0e"
      unitRef="usd">670600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i950b136a19ae40d9b9d11a4c60b1f0a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktNS0xLTEtMTUwMDM0_4b3c73b4-dcf7-494a-9698-c1370cb25a00"
      unitRef="usd">714100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe17b049a1e34a548921b45ddee7b35f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktNy0xLTEtMTUwMDM0_b8f6e5e8-0f15-4b5b-adf7-2aeb14fc398b"
      unitRef="usd">668600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib380a2c52e2d42409c0b1646842faf2a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzktOS0xLTEtMTUwMDM0_7373c4c5-72cc-4c56-9051-9cbb40f347ef"
      unitRef="usd">483900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb5df141ea8e40509cb916df8b2ff26f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTUtMS0xLTE1MDAzNA_3976bc4c-5c9a-4588-9516-33b8595f3950"
      unitRef="usd">339800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c243171572a42cea628d49efffe8709_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTctMS0xLTE1MDAzNA_e0de00f9-3f89-4d05-956c-9ea3972ffcc8"
      unitRef="usd">312900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieda45a3621c84f1b9aef4071b842c2b2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzEwLTktMS0xLTE1MDAzNA_3eac7fc6-160f-46b7-8a36-2e40fe81d8bf"
      unitRef="usd">241200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50c746302eaf44e986f9840477b463de_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTUtMS0xLTE1MDAzNA_1bc00665-f0d8-4b93-a9d4-71d46b8bdc51"
      unitRef="usd">2064600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d9c7f30e288439fb419bcf27013ae6f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTctMS0xLTE1MDAzNA_ac7b6b67-b6ec-4302-8feb-e1458e5d3ae6"
      unitRef="usd">1856900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb59dcfb65644da9a3e23bb2aeea13c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzExLTktMS0xLTE1MDAzNA_cb74f3bd-ede1-40b6-adb8-d4e0fc72c626"
      unitRef="usd">1395700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1962e48f84bd458fb0b88daa39518d23_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTUtMS0xLTE1MDAzNA_c0d5677a-513a-406d-92ed-47bb720776b9"
      unitRef="usd">3517900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69bf5f4d5aed4a8b8454b48cd962b54e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTctMS0xLTE1MDAzNA_f6b888c8-7f73-4a91-869e-51c75471cf53"
      unitRef="usd">3100500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b449d3de1df438a8825ceebf4e43693_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE0LTktMS0xLTE1MDAzNA_d5e6059c-282b-409e-9508-01601755b53d"
      unitRef="usd">2455700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i459fd0e8d62c483898e85528b96a9207_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTUtMS0xLTE1MDAzNA_bf79d33b-3ac7-4393-bd8a-06fb2a69f9b8"
      unitRef="usd">1680100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea54ffe275324b9381bef67e6b9ae4a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTctMS0xLTE1MDAzNA_1e49f5ee-7341-4b8b-9ad7-8cc986dc1592"
      unitRef="usd">1693400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib46c00d9c67d4ce9b8f5e8bbcc799cad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE1LTktMS0xLTE1MDAzNA_b62cc9d0-430c-49f5-b703-d069759c2354"
      unitRef="usd">1178900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia561aaed8cc1473b90ab99377b3b4c10_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTUtMS0xLTE1MDAzNA_f15e0215-d394-4000-bfd4-abe733044f02"
      unitRef="usd">1024200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e1da611cfe4104814ee856685b5bfc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTctMS0xLTE1MDAzNA_9b1b3ea9-f8f7-4610-be46-c1e1bb018f15"
      unitRef="usd">916200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57e39edb5f7a463ca701f3bfdfcbe0ea_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE2LTktMS0xLTE1MDAzNA_892e8c5a-27c7-475a-8895-a0daa694de0c"
      unitRef="usd">723800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTUtMS0xLTE1MDAzNA_7655ced4-e5db-47bf-8633-6a249b9d4892"
      unitRef="usd">6222200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTctMS0xLTE1MDAzNA_8bab8ad0-eb83-418a-a2a4-572aef862c19"
      unitRef="usd">5710100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTpjMTgwYTE1ZDIyNTA0ZmNlOWMzMmExN2E3MzEwYWQ0NS90YWJsZXJhbmdlOmMxODBhMTVkMjI1MDRmY2U5YzMyYTE3YTczMTBhZDQ1XzE3LTktMS0xLTE1MDAzNA_4772a152-1877-442b-b9f8-077a3450209e"
      unitRef="usd">4358400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2f9ee599e0834c439f28abe74bf98547_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ4OTE_248bce0d-9559-4c2f-9137-cdb8034f98e8"
      unitRef="usd">1860000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i2f9ee599e0834c439f28abe74bf98547_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2Xzc3MQ_e8ddb442-2df7-440f-86a1-7a7970851cd1">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTY_49ce3ee3-056f-4153-bb8a-89127641813f">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information summarizes the Company&#x2019;s contract assets and liabilities (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzItMS0xLTEtMTUwMDM0_514dd2e0-f0b8-4796-849e-58699334db57"
      unitRef="usd">45000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzItMy0xLTEtMTUwMDM0_5ee32f33-b388-493b-b727-0667d8d75eb5"
      unitRef="usd">46900000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzMtMS0xLTEtMTUwMDM0_1eb04e6a-c7d9-4912-9705-a44ad8b7c879"
      unitRef="usd">438300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZToyYWZiYzU1ZTRlODk0Y2NiODBmODg0MmY4ZGFiMTc5Yy90YWJsZXJhbmdlOjJhZmJjNTVlNGU4OTRjY2I4MGY4ODQyZjhkYWIxNzljXzMtMy0xLTEtMTUwMDM0_0350438d-fde9-4373-8440-30c05565a363"
      unitRef="usd">414000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ5MTA_17199cd2-2ba0-4b10-a493-e69c72c57a19"
      unitRef="usd">380000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzYwNDczMTM5NTQ5MTM_376884ee-ad08-4b17-8d27-299bbeae0e80"
      unitRef="usd">351000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMTc_7edbbf0b-4689-4385-b3dd-b46d473d11ab">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents product revenue from Intuitive System Leasing arrangements (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9"&gt;Operating lease revenue*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*Variable lease revenue relating to usage-based arrangements included within operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90ZXh0cmVnaW9uOjgzMjRjYzA2NGYxYjRhOGViODcwOThlNWFmYzhkYTg2XzIxMjA_4af30d2b-ea02-4e54-b181-467b56013da8">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents product revenue from Intuitive System Leasing arrangements (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_62925ded-43b8-479c-b7e0-e207d0158198"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_bb8078c6-240c-44a7-9552-00a29f345c16"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMC0xLTEtMTUwMDM0_c4d8213d-efd2-49f1-9e38-bffe0c846f45"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_1a197999-d676-4158-8b74-25aa715896ea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_73e1d760-a659-4d30-ab0c-4638267fe124"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMC0xLTEtMTUwMDM0_c30e72e2-1071-4ff5-a0eb-ccbc4bf82ea9"&gt;Operating lease revenue*&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*Variable lease revenue relating to usage-based arrangements included within operating lease revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItMi0xLTEtMTUwMDM0_acdb6fef-49db-4261-9f1f-998ae70d4b5f"
      unitRef="usd">156400000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItNC0xLTEtMTUwMDM0_2ab1b46f-e1b1-488e-b0ad-13d1d2a0f41f"
      unitRef="usd">220300000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzItNi0xLTEtMTUwMDM0_3fccc052-ccce-4612-bc95-41a147ea77cd"
      unitRef="usd">154400000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtMi0xLTEtMTUwMDM0_0e94606d-acc4-4415-b373-e8e2bcf4514d"
      unitRef="usd">376500000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtNC0xLTEtMTUwMDM0_2dc54ef3-6311-4d57-b1d0-f38b69adcd09"
      unitRef="usd">276900000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzMtNi0xLTEtMTUwMDM0_c1f0891d-3b94-487b-b681-907945b5f950"
      unitRef="usd">176700000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="ie0333e95f85d48cf88145bfeb59afc5d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtMi0xLTEtMTcxOTM5_46922741-beda-4715-8467-c4406f224e53"
      unitRef="usd">133000000.0</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i6107b94bba54498d96a497fbaf65d4cf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtNC0xLTEtMTcxOTQ2_69c26a7c-145c-4e45-90a3-e10b649347df"
      unitRef="usd">78100000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="ibf73792053ae49508767ca0ac0d77523_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDEvZnJhZzo4MzI0Y2MwNjRmMWI0YThlYjg3MDk4ZTVhZmM4ZGE4Ni90YWJsZTo5NDBiZDFjYTFhZTM0ZWQxODVjOTAyMTA3NWY4OWYwNi90YWJsZXJhbmdlOjk0MGJkMWNhMWFlMzRlZDE4NWM5MDIxMDc1Zjg5ZjA2XzUtNi0xLTEtMTcxOTUz_2512cf0b-4e7d-47a0-aca4-cafe6da925ae"
      unitRef="usd">27500000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzU_f4427358-142b-4371-9a59-28af13327e87">LEASES&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Lessor Information related to Intuitive System Leasing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales-type Leases.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for credit loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible and other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Leases.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lessee Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $25.7&#160;million, $20.4&#160;million, and $21.0&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. For leases with terms of 12 months or less, the related expense was immaterial for each of the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for leases that were included within operating cash outflows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recognized related to new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a"&gt;Intangible and other assets, net (Right-of-use assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0"&gt;Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the future payments related to the Company&#x2019;s operating lease liabilities are scheduled as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODQ_85c19d28-e0f2-4bc0-a000-a48095dc551a">LEASES&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Lessor Information related to Intuitive System Leasing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales-type Leases.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for credit loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible and other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Leases.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lessee Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $25.7&#160;million, $20.4&#160;million, and $21.0&#160;million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. For leases with terms of 12 months or less, the related expense was immaterial for each of the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for leases that were included within operating cash outflows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recognized related to new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a"&gt;Intangible and other assets, net (Right-of-use assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0"&gt;Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the future payments related to the Company&#x2019;s operating lease liabilities are scheduled as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <isrg:LessorSalesTypeLeaseLeaseIncomeTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0OTA_81c8cbe9-a532-4576-ade7-0193d0c51ea8">Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for credit loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaids and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible and other assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment in sales-type leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</isrg:LessorSalesTypeLeaseLeaseIncomeTableTextBlock>
    <isrg:SalesTypeLeaseGrossInvestmentInLease
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzItMS0xLTEtMTUwMDM0_2972a212-c64e-43af-adf7-2c842a444345"
      unitRef="usd">449400000</isrg:SalesTypeLeaseGrossInvestmentInLease>
    <isrg:SalesTypeLeaseGrossInvestmentInLease
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzItMy0xLTEtMTUwMDM0_7297d37e-57c3-4f33-8a09-da3472b7bd81"
      unitRef="usd">404000000.0</isrg:SalesTypeLeaseGrossInvestmentInLease>
    <isrg:SalestypeLeaseDeferredSellingProfit
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzMtMS0xLTEtMTUwMDM0_937c6d9b-b1f8-4c2f-8031-3f1db7f207f8"
      unitRef="usd">14400000</isrg:SalestypeLeaseDeferredSellingProfit>
    <isrg:SalestypeLeaseDeferredSellingProfit
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzMtMy0xLTEtMTUwMDM0_801a0023-d9dc-435b-95e6-2b6879a974c2"
      unitRef="usd">11400000</isrg:SalestypeLeaseDeferredSellingProfit>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzQtMS0xLTEtMTUwMDM0_ac929fd0-8d97-424e-a5d9-d26dd80f88cf"
      unitRef="usd">435000000.0</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzQtMy0xLTEtMTUwMDM0_a734a633-2b6c-408a-b0e0-ae11bed6c507"
      unitRef="usd">392600000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzUtMS0xLTEtMTUwMDM0_436b5c3d-d88e-4921-adc1-38897d1657df"
      unitRef="usd">3000000.0</us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss>
    <us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzUtMy0xLTEtMTUwMDM0_f4ef94a1-cb21-462b-aa06-8d778952b732"
      unitRef="usd">3600000</us-gaap:SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzYtMS0xLTEtMTUwMDM0_a6b24d5d-6a85-434d-bcbc-4607be425439"
      unitRef="usd">432000000.0</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzYtMy0xLTEtMTUwMDM0_da64e772-21dc-4a8e-a10a-4505a286b0d2"
      unitRef="usd">389000000.0</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i990140e98ac543b0a1e3275119938c07_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzgtMS0xLTEtMTUwMDM0_dbffea85-ef0b-44ff-b2b4-ea3c92d76a3a"
      unitRef="usd">131200000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i22cdd1443bcf48778c9fb236cb3f5a7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzgtMy0xLTEtMTUwMDM0_ccc80feb-fe38-46b2-8858-765d9dbf5a06"
      unitRef="usd">110300000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="ic357251bdc6148b78354861f8ff47859_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzktMS0xLTEtMTUwMDM0_2afd5665-4f77-421b-ad6b-72a1ed4e419e"
      unitRef="usd">300800000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i1917b42017a44a168cb0fcb89a52d9bf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzktMy0xLTEtMTUwMDM0_e952291a-f905-4ad8-81a2-a96637000982"
      unitRef="usd">278700000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzEwLTEtMS0xLTE1MDAzNA_c6de5fcd-fbc5-4576-8aac-56f14bd4f3e1"
      unitRef="usd">432000000.0</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTplY2Y3MTM2YzNlMmM0OGIyOGQ3NzIwYzg4YjNmZjkxYi90YWJsZXJhbmdlOmVjZjcxMzZjM2UyYzQ4YjI4ZDc3MjBjODhiM2ZmOTFiXzEwLTMtMS0xLTE1MDAzNA_e6472363-b68c-4a1f-a07f-7a248adfb875"
      unitRef="usd">389000000.0</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0Nzc_486f29a2-8119-43ad-bbb3-605e2b5f476e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of gross lease receivables as of December&#160;31, 2022, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzEtMS0xLTEtMTUwMDM0_f3ff5c69-8d5f-4ef1-8f9f-193d1a210ffb"
      unitRef="usd">137500000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzItMS0xLTEtMTUwMDM0_765cf328-3a4b-4f5b-af17-0c1ff0baf1e2"
      unitRef="usd">126300000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzMtMS0xLTEtMTUwMDM0_7786c4d9-3b42-491d-acda-834e067eb839"
      unitRef="usd">95500000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzQtMS0xLTEtMTUwMDM0_2ab93d9d-c971-4457-9483-c2c3cc1a1292"
      unitRef="usd">60300000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzUtMS0xLTEtMTUwMDM0_8a887cbb-92f6-4251-a221-5262c1d208b6"
      unitRef="usd">26500000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzYtMS0xLTEtMTUwMDM0_e99b7b15-d150-4d68-b77e-10dcecfcaa61"
      unitRef="usd">3300000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTo0MzI5YjNkNzgxZWE0Mzc0ODIxMTUwYTIyMDRmZTQyYS90YWJsZXJhbmdlOjQzMjliM2Q3ODFlYTQzNzQ4MjExNTBhMjIwNGZlNDJhXzctMS0xLTEtMTUwMDM0_5eca383c-8049-4c71-b1c5-1baa491a6c89"
      unitRef="usd">449400000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODA_292ba069-8147-4d3a-80cc-4429dfc64d31">Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December&#160;31, 2022, are as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzEtMS0xLTEtMTUwMDM0_36b4b67a-59f6-4f66-8d78-4b42a5ff620b"
      unitRef="usd">300000000.0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzItMS0xLTEtMTUwMDM0_5c41abf2-c7fa-4244-a039-c1c1f8d8f1ea"
      unitRef="usd">250500000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzMtMS0xLTEtMTUwMDM0_9ba8a401-0186-4496-a3d8-22d54fedef35"
      unitRef="usd">194400000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzQtMS0xLTEtMTUwMDM0_fe4bf054-b780-4fcf-a356-ffcd3d1ebff1"
      unitRef="usd">130200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzUtMS0xLTEtMTUwMDM0_e6dfa401-23fe-4d8d-9d3c-89d5fdd1eb4e"
      unitRef="usd">58700000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzYtMS0xLTEtMTUwMDM0_cd1d448e-7aa4-46cd-8c2d-0514ac5a21b8"
      unitRef="usd">20200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTozMTIwNzRhNTg3ODk0OTY4YTJkYTFhMGFkZWJmODkyZC90YWJsZXJhbmdlOjMxMjA3NGE1ODc4OTQ5NjhhMmRhMWEwYWRlYmY4OTJkXzctMS0xLTEtMTUwMDM0_5d1b556e-c563-40a9-9669-62116614bc7e"
      unitRef="usd">954000000.0</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjM_a8c9c997-9b76-4a49-acc0-142c65a70443"
      unitRef="usd">25700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjY_7dc9524f-b3aa-44f0-a039-103fe9992706"
      unitRef="usd">20400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzYwNDczMTM5NTQyNjk_56fa2c13-d516-4713-a3e0-7902d39ca4d1"
      unitRef="usd">21000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0ODE_51c1eb8b-88c8-422a-8d8e-a689d0f53ad1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information for the years ended December&#160;31, 2022, 2021, and 2020 related to operating leases was as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for leases that were included within operating cash outflows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recognized related to new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItMS0xLTEtMTUwMDM0_aedfdce2-363e-40f1-a6ad-82e540ec415a"
      unitRef="usd">33800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItMy0xLTEtMTUwMDM0_eee7c97d-9401-4273-8fdb-319dd2246f15"
      unitRef="usd">23200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzItNS0xLTEtMTUwMDM0_8ac4f730-12db-4ab3-8f18-ceefc225093b"
      unitRef="usd">11000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtMS0xLTEtMTUwMDM0_efa3a6c1-9dce-417c-ad6c-4e453f2e028e"
      unitRef="usd">34000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtMy0xLTEtMTUwMDM0_0ce4f84b-6159-4117-9d4c-5f7f62b28cf2"
      unitRef="usd">30600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjOGVhNGQ3ODI1ZTU0ODgyOTg4NTQxMTBlZjRkNWU1ZC90YWJsZXJhbmdlOmM4ZWE0ZDc4MjVlNTQ4ODI5ODg1NDExMGVmNGQ1ZTVkXzMtNS0xLTEtMTUwMDM0_9bd773e2-45b0-4a4f-9049-dff32bcfed06"
      unitRef="usd">9600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <isrg:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzA_064090b2-3668-4f5e-8a85-4f474161786d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information, as of December&#160;31, 2022, and 2021, related to operating leases was as follows (in millions, except lease term and discount rate):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_355a5f43-2b31-41c9-9cbc-182e767f8b38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMC0xLTEtMTUwMDM0_4885b332-0077-4f55-859e-ea1d5030f51a"&gt;Intangible and other assets, net (Right-of-use assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2abbcbb5-49d9-4c1f-850f-5c76c68bc398"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMC0xLTEtMTUwMDM0_2ea01751-79a0-46c9-b24d-d64a4107f9b0"&gt;Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_3d532950-c119-4b4a-9e97-6016243eec37"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMC0xLTEtMTUwMDM0_59ee5b14-39a4-48d6-a8d0-a1085064d07c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_b07bdcd6-4408-4444-aae7-2f74bf0476e1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMC0xLTEtMTUwMDM0_c4416eb4-72a4-4a10-a4c8-8f711fe15701"&gt;Total lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</isrg:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMS0xLTEtMTUwMDM0_e860ac68-515f-413b-bde6-b870d3b24948"
      unitRef="usd">82200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzItMy0xLTEtMTUwMDM0_ddb76383-192c-4dd7-a023-8b7d7f4ac5fb"
      unitRef="usd">74400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMS0xLTEtMTUwMDM0_2d5ad1a1-d7fe-4c35-8313-dbd1140191e4"
      unitRef="usd">24200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzQtMy0xLTEtMTUwMDM0_8d91d3af-9a75-4d0c-87ec-a58dbc82ce44"
      unitRef="usd">20400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMS0xLTEtMTUwMDM0_3d2a6b3f-dc4d-41f0-b359-4f8465a9974d"
      unitRef="usd">69600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzUtMy0xLTEtMTUwMDM0_7b3bef69-5ccd-41a9-b87a-9747b9964663"
      unitRef="usd">66600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMS0xLTEtMTUwMDM0_bffd96c6-3432-4d4f-a3ea-8a90ea4972b2"
      unitRef="usd">93800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzYtMy0xLTEtMTUwMDM0_28395a5a-7535-4c74-a87f-ab4f356a5c00"
      unitRef="usd">87000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzgtMS0xLTEtMTUwMDM0_65b719ec-0d68-4afd-bee5-39bdf84a5af5">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzgtMy0xLTEtMTUwMDM0_1d877332-3c8d-4f7e-9e10-097560e3025b">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzktMS0xLTEtMTUwMDM0_881eab94-c70d-4d11-80fb-fe56793da4ea"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjY2E4NmIyYTg4ZDA0NmY1YTc2NjIzOGFkMTRhZDU1YS90YWJsZXJhbmdlOmNjYTg2YjJhODhkMDQ2ZjVhNzY2MjM4YWQxNGFkNTVhXzktMy0xLTEtMTUwMDM0_942518bf-19a8-4026-8518-14621cdc06f0"
      unitRef="number">0.025</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90ZXh0cmVnaW9uOmQ5OWY0NmIyOWMyNzQzZTBhNzQ3Mzk4M2IxNWU2NGU4XzE0NzQ_a9103bf7-97f4-421e-aeb3-4633a82e552b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the future payments related to the Company&#x2019;s operating lease liabilities are scheduled as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzEtMS0xLTEtMTUwMDM0_5b6cdea3-8258-4236-95e2-1f9c3ac5e691"
      unitRef="usd">26000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzItMS0xLTEtMTUwMDM0_f5f5afde-7038-4dbd-a242-ad3e5d325f53"
      unitRef="usd">21700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzMtMS0xLTEtMTUwMDM0_34802449-3a52-496a-8795-2d4ecc2b235a"
      unitRef="usd">19500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzQtMS0xLTEtMTUwMDM0_db8658b8-693f-465c-bbe7-59f741f73334"
      unitRef="usd">16600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzUtMS0xLTEtMTUwMDM0_81863d43-dae6-47ed-a40e-7be12880b88a"
      unitRef="usd">8300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzYtMS0xLTEtMTUwMDM0_21332c79-dacb-4f1c-b374-938958fe08df"
      unitRef="usd">8900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzctMS0xLTEtMTUwMDM0_23e5ecc2-7e09-4c1e-a2d6-70bdec83dad0"
      unitRef="usd">101000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzgtMS0xLTEtMTUwMDM0_5af04ff2-5d19-4206-bd8b-b6742debfc70"
      unitRef="usd">7200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDQvZnJhZzpkOTlmNDZiMjljMjc0M2UwYTc0NzM5ODNiMTVlNjRlOC90YWJsZTpjYTNkNDRhMDliNWQ0MWZkYjg0YTUxZTJiMzNlNmY5Yy90YWJsZXJhbmdlOmNhM2Q0NGEwOWI1ZDQxZmRiODRhNTFlMmIzM2U2ZjljXzktMS0xLTEtMTUwMDM0_3af68577-4424-4c0e-b06a-21d77d560fe9"
      unitRef="usd">93800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU5MDU_3ba873bb-cc38-4ce6-ad35-f7e4887e0bcb">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material acquisitions in 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company acquired Orpheus Medical Ltd. and its wholly owned subsidiaries (&#x201c;Orpheus Medical&#x201d;) to deepen and expand the Company&#x2019;s integrated informatics platform. Orpheus Medical provides hospitals with information technology connectivity, as well as expertise in processing and archiving surgical videos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed its annual goodwill impairment test and determined that no impairment existed. As of December&#160;31, 2022, there has been no impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets was $27.8 million, $27.4 million, and $49.8 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense related to intangible assets as of December&#160;31, 2022, is as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, measurement period adjustments to intangible assets, changes in foreign currency exchange rates, impairment of intangible assets, accelerated amortization of intangible assets, and other events.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU5MDI_90e46f6f-2a04-4b4c-a063-b637f728757b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzEtMi0xLTEtMTUwMDM0_ab1b30da-3e04-425c-8a85-4f6f4c5980af"
      unitRef="usd">336700000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzItMi0xLTEtMTUwMDM0_3520a4fc-04e1-4e2a-913a-e61d500ec6c8"
      unitRef="usd">8000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzMtMi0xLTEtMTUwMDM0_caa5ea9c-008c-454c-aa58-606e24059b58"
      unitRef="usd">-1100000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzQtMi0xLTEtMTUwMDM0_39ac3c16-3eaf-4ab4-a6f3-560c92afe123"
      unitRef="usd">343600000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzUtMi0xLTEtMTUwMDM0_0bb5f347-4ce1-4158-b59e-f4f41d3e0ea7"
      unitRef="usd">6500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzYtMi0xLTEtMTUwMDM0_0a4e0ab8-74c4-4da7-a5df-ec826d2b85e4"
      unitRef="usd">-1600000</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo4NTljMTlhMzgyMGQ0YWNiYjM4YjZlMDFiNmZlNTRmYi90YWJsZXJhbmdlOjg1OWMxOWEzODIwZDRhY2JiMzhiNmUwMWI2ZmU1NGZiXzctMi0xLTEtMTUwMDM0_f30ac57b-03c8-4581-ae8d-257e60ddc5e3"
      unitRef="usd">348500000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU4OTc_90e3acc2-319f-4a79-a469-4ca9834183e0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December&#160;31, 2022, and 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMi0xLTEtMTUwMDM0_2e064eb6-a274-46ca-b083-b68ec6cfc573"
      unitRef="usd">199100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItNC0xLTEtMTUwMDM0_2d5c06a4-9a74-4184-8206-f37a5a2dadbf"
      unitRef="usd">167400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa0815014e2048d88e0fbadfebe22ea8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItNi0xLTEtMTUwMDM0_b550ba97-ac30-4615-ad0b-d75a534bcac2"
      unitRef="usd">31700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItOC0xLTEtMTUwMDM0_33473b2a-c799-4d5d-ae83-6a0bf896748c"
      unitRef="usd">219300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMTAtMS0xLTE1MDAzNA_bf2a1eff-727a-44d7-a5b6-77100946c3d9"
      unitRef="usd">173200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a7e1fb02d8f4e56bd53a3d839fb7385_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzItMTItMS0xLTE1MDAzNA_b09ea1d3-ae4e-41a0-974c-40b837b1d667"
      unitRef="usd">46100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMi0xLTEtMTUwMDM0_8a661b77-294d-4be0-85a5-19f1cc840abf"
      unitRef="usd">11000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtNC0xLTEtMTUwMDM0_1cb71db7-3a59-4bf5-8b5e-8a879fcbe0f0"
      unitRef="usd">7400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa721e4b680944b9a1bbb5f5ba708d0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtNi0xLTEtMTUwMDM0_8ee901d9-b4cc-4178-b2f7-3f6d23179908"
      unitRef="usd">3600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtOC0xLTEtMTUwMDM0_1d59687e-122d-40a7-b1d7-a4d089d44e36"
      unitRef="usd">26300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMTAtMS0xLTE1MDAzNA_5a7a23c3-4dbf-47e6-b564-b7fc09d8bd7f"
      unitRef="usd">19400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i88a3a8ceed2f49e880418977490f5d20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzMtMTItMS0xLTE1MDAzNA_e2e220bb-d93e-4d0d-9a1d-79ec7e412a1c"
      unitRef="usd">6900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMi0xLTEtMTUwMDM0_e1fd5e2b-60b5-4e5d-aa09-2d5847b74647"
      unitRef="usd">32600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtNC0xLTEtMTUwMDM0_dee7af3e-85f7-46a9-8779-d18f824ed9c1"
      unitRef="usd">18100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1f06663da7d74354b3bd5efcad839096_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtNi0xLTEtMTUwMDM0_30f9a535-712c-477f-a0f8-bede1c61cc81"
      unitRef="usd">14500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtOC0xLTEtMTUwMDM0_99327ce4-d92a-4d98-9e87-81ab6fc896b2"
      unitRef="usd">31800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMTAtMS0xLTE1MDAzNA_ccafbc4e-8b98-413a-96e5-950297e04405"
      unitRef="usd">14300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2f6a7b8ae0b647c0a5b7ed4602836a70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzQtMTItMS0xLTE1MDAzNA_d84546bf-ad87-439c-94d3-da1878daaac8"
      unitRef="usd">17500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMi0xLTEtMTUwMDM0_e8ae5895-858b-4c27-a4ca-e4b520875244"
      unitRef="usd">242700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtNC0xLTEtMTUwMDM0_0e113013-9d41-4087-8e90-94f5c8d9c026"
      unitRef="usd">192900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtNi0xLTEtMTUwMDM0_8dbc63d6-d20c-4108-812f-2169d26f11a8"
      unitRef="usd">49800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtOC0xLTEtMTUwMDM0_de900ab5-f17a-4a65-8998-dc9e1d30616e"
      unitRef="usd">277400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMTAtMS0xLTE1MDAzNA_4e54c1bf-a9c6-400b-90fb-6e7e9ebe8778"
      unitRef="usd">206900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZTo1Y2RiYzFmYWU2ZTM0NWE5YjY4MWY3NmI4MDgzY2U5ZS90YWJsZXJhbmdlOjVjZGJjMWZhZTZlMzQ1YTliNjgxZjc2YjgwODNjZTllXzUtMTItMS0xLTE1MDAzNA_e45f0e27-430b-4b6c-bce7-c32aac342e6c"
      unitRef="usd">70500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMTk_19331248-dd81-4380-9b62-0fbd115ec46b"
      unitRef="usd">27800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMjI_6a8756f2-ae66-442b-b7ca-cec8d1cab3cd"
      unitRef="usd">27400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzYwNDczMTM5NjMzMjU_a73ebff2-c4e2-4362-a6fa-8ebd97aaf852"
      unitRef="usd">49800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90ZXh0cmVnaW9uOmQzNWIyMmMxMGNhMzQyMzlhMzgxNmRjNGJhZGQ3NzI4XzU4OTI_02099bd6-afe0-4628-92e2-63534e637396">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense related to intangible assets as of December&#160;31, 2022, is as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzEtMS0xLTEtMTUwMDM0_5a0f2f89-d597-48dc-a526-68d94254f039"
      unitRef="usd">19200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzItMS0xLTEtMTUwMDM0_a9203f4b-e03d-459d-aed4-61f5c0347f9c"
      unitRef="usd">15000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzMtMS0xLTEtMTUwMDM0_f20593fa-2a30-424a-8961-f9cccabbbc5c"
      unitRef="usd">10300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzQtMS0xLTEtMTUwMDM0_90805827-3043-4229-a9d8-4a2b2de95327"
      unitRef="usd">3400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzUtMS0xLTEtMTUwMDM0_13eb7628-d2f7-4e97-b889-ce02ed67fcf6"
      unitRef="usd">1000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzYtMS0xLTEtMTUwMDM0_ea9937b1-c42b-497d-aef2-0a9f33292072"
      unitRef="usd">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNDcvZnJhZzpkMzViMjJjMTBjYTM0MjM5YTM4MTZkYzRiYWRkNzcyOC90YWJsZToxYmJkZmUxNWI5NWI0ZmNmOTZiZjMwMjIyMGQ4ODY2YS90YWJsZXJhbmdlOjFiYmRmZTE1Yjk1YjRmY2Y5NmJmMzAyMjIwZDg4NjZhXzctMS0xLTEtMTUwMDM0_a6c34b89-1125-45e0-b9b1-c95c42f9080c"
      unitRef="usd">49800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzEzODA3_28466580-2030-488f-af0d-11ba11dd7ca0">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company&#x2019;s commitments include an estimated amount of approximately $2.14&#160;billion relating to the Company&#x2019;s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures and construction-related activities for which the Company has not received the services, and acquisition and licensing of intellectual property. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;its business needs prior to the delivery of goods or performance of services. Additionally, the Company has committed to making certain future milestone payments to third parties as part of licensing, collaboration, and development arrangements. Payments under these arrangements generally become due and payable only upon the achievement of certain specified developmental, regulatory, and/or commercial milestones. For instances in which the achievement of these milestones is neither probable nor reasonably estimable, such contingencies are not included in the estimated amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, commercial, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be, and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A liability and related charge to earnings are recorded in the Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company&#x2019;s business, financial condition, or future results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $28.1&#160;million of pre-tax litigation charges in 2022. During the years ended 2021 and 2020, pre-tax litigation charges were insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts. The plaintiffs generally allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. Several of the filed cases have trial dates in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cases raise a variety of allegations including, to varying degrees, that plaintiffs&#x2019; injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company&#x2019;s part to provide adequate training resources to the healthcare professionals who performed plaintiffs&#x2019; surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including, for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. The Company disputes these allegations and is defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimate of the anticipated cost of resolving the pending cases is based on negotiations with attorneys for the claimants.&#160;The final outcome of the pending lawsuits and claims, and others that might arise, is dependent on many variables that are difficult to predict, and the ultimate cost associated with these product liability lawsuits and claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company&#x2019;s business, financial condition, or future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, &#x201c;Ethicon&#x201d;) filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company&#x2019;s EndoWrist&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stapler instruments infringe several of Ethicon&#x2019;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,585,658; 8,479,969; 9,113,874; 8,998,058; 8,991,677; 9,084,601; and 8,616,431. A claim construction hearing occurred on October 1, 2018, and the Court issued a scheduling order on December 28, 2018. On March 20, 2019, the Court granted the Company&#x2019;s Motion to Stay pending an Inter Partes Review to be held at the Patent Trademark and Appeals Board to review patentability of six of the seven patents noted above and vacated the trial date. On August 1, 2019, the Court granted the parties&#x2019; joint stipulation to modify the stay in light of Ethicon&#x2019;s U.S. International Trade Commission (&#x201c;USITC&#x201d;) complaint against Intuitive involving U.S. Patent Nos. 8,479,969 and 9,113,874, discussed below. There is currently no trial date scheduled for this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 27, 2018, Ethicon filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that the Company&#x2019;s SureForm 60 Staplers infringe five of Ethicon&#x2019;s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,884,369; 7,490,749; 8,602,288; 8,602,287; and 9,326,770. The Company filed an answer denying all claims. On March 19, 2019, Ethicon filed a Motion for Leave to File a First Amended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Complaint, removing allegations related to U.S. Patent No. 9,326,770 and adding allegations related to U.S. Patent Nos. 9,844,379 and 8,479,969. On July 17, 2019, the Court entered an order denying the amendment, without prejudice, and granting the parties&#x2019; joint stipulation to stay the case in its entirety in light of the USITC investigation involving U.S. Patent Nos. 9,844,369 and 7,490,749, discussed below. There is currently no trial date scheduled for this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 30, 2019, Ethicon filed a complaint with the USITC, asserting infringement of U.S. Patent Nos. 9,884,369 (&#x201c;&#x2019;369&#x201d;); 7,490,749 (&#x201c;&#x2019;749&#x201d;); 9,844,379 (&#x201c;&#x2019;379&#x201d;); 9,113,874 (&#x201c;&#x2019;874&#x201d;); and 8,479,969 (&#x201c;&#x2019;969&#x201d;). On June 28, 2019, the USITC voted to institute an investigation (No. 337-TA-1167) with respect to the claims in this complaint. The accused products include the Company&#x2019;s EndoWrist 30, EndoWrist 45, SureForm 45, and SureForm 60 Staplers, as well as the stapler reload cartridges. In March 2020, Ethicon dismissed its claims concerning the &#x2019;749 patent. The evidentiary hearing took place in February 2021. On March 26, 2021, the U.S. Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) issued a Final Written Decision in which it found the claims in the &#x2019;379 patent asserted against the Company in this USITC proceeding to be invalid. On June 8, 2021, the Chief Administrative Law Judge issued an Initial Determination concluding that (1) the accused products do not infringe the asserted claims in the &#x2019;874 or &#x2019;969 patents; (2) the asserted claims in the &#x2019;874 and &#x2019;969 patents are invalid; (3) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#x2019;369 patent; (4) the accused SureForm staplers and associated reload cartridges infringe two claims of the &#x2019;379 patent; and (5) the Company was estopped from contending that the asserted claims in the &#x2019;379 patent are invalid. Ethicon has not challenged the Initial Determination with regard to the findings that absolve Intuitive of any liability regarding the accused EndoWrist staplers and associated reload cartridges. On October 14, 2021, the USITC issued its Opinion in which it made the following rulings: (1) the USITC absolved Intuitive from any liability regarding the &#x2019;874, &#x2019;969, and &#x2019;369 patents; and (2) the USITC found that, while the SureForm staplers and their associated reload cartridges infringe the asserted claims in the &#x2019;379 patent, it has suspended the imposition of any remedial order pending an opinion from the U.S. Court of Appeal for the Federal Circuit of whether the Patent and Trademark Office correctly found the asserted claims in this patent to be invalid. On May 23, 2022, the U.S. Court of Appeal for the Federal Circuit affirmed the earlier PTAB Final Written Decision invalidating the asserted claims in the &#x2019;379 patent. A hearing before the U.S. Court of Appeal for the Federal Circuit has been scheduled for March 8, 2023, on Ethicon&#x2019;s appeal of the USITC&#x2019;s Opinion. An adverse ruling on Ethicon&#x2019;s appeal of the USITC&#x2019;s Opinion could result in a prohibition on importing the accused SureForm products into the U.S. or necessitating workarounds. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 19, 2022, a jury rendered a verdict against the Company awarding $10&#160;million in damages to Rex Medical, L.P. in a patent infringement lawsuit. The Company intends to appeal the decision and vigorously defend its position. Based on currently available information, the Company does not believe that any losses arising from this matter would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2019, Restore Robotics LLC and Restore Repair LLC (&#x201c;Restore&#x201d;) filed a complaint in the Northern District of Florida alleging anti-trust claims against the Company. On May 13, 2019, Restore filed an amended complaint alleging anti-trust claims relating to the da Vinci Surgical System and EndoWrist service, maintenance, and repair processes. On September 16, 2019, the Court partially granted and partially denied the Company&#x2019;s Motion to Dismiss the amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2019, the Company filed an answer denying the anti-trust allegations and filed a counterclaim against Restore. The Company filed amended counterclaims after the Court partially granted and partially denied Restore&#x2019;s Motion to Dismiss the counterclaim. The amended counterclaims allege that Restore violated the Federal Lanham Act, the Federal Computer Fraud and Abuse Act, and Florida&#x2019;s Deceptive and Unfair Trade Practices Act and that Restore is also liable to the Company for Unfair Competition and Tortious Interference with Contract. On January 7, 2020, the Court denied Restore&#x2019;s Motion to Dismiss the amended counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 11, 2022, the Court granted in part and denied in part the parties&#x2019; Motions for Summary Judgment. Shortly thereafter, Restore&#x2019;s licensor, Rebotix Repair LLC (&#x201c;Rebotix&#x201d;) filed a notice in a separate legal action that it had received an email from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) confirming that &#x201c;extending the number of uses and modifying [EndoWrist] instrument[s] with a new chip&#x201d; constitutes &#x201c;remanufacturing&#x201d; and required 510(k) clearance, which neither Restore nor Rebotix has obtained. In light of this communication with the FDA, on April 13, 2022, the Company filed a Motion for Reconsideration to the Court&#x2019;s Summary Judgment Order, which the Court denied on May 31, 2022. This case was scheduled for trial in February 2023. On January 23, 2023, the parties resolved all of their claims against each other and, on January 27, 2023, the case was dismissed with prejudice. The settlement had an immaterial impact on the Company&#x2019;s Consolidated Financial Statements for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the claims asserted in the Restore case, on May 10, 2021, Surgical Instrument Service Company, Inc. (&#x201c;SIS&#x201d;) filed a complaint in the Northern District of California Court alleging anti-trust claims against the Company relating to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EndoWrist service, maintenance, and repair processes. The Court granted in part and denied in part the Company&#x2019;s Motion to Dismiss, and discovery has commenced. The Company filed an answer denying the anti-trust allegations and filed counterclaims against SIS. The counterclaims allege that SIS violated the Federal Lanham Act, California&#x2019;s Unfair Competition Law, and California&#x2019;s False Advertising Law and that SIS is also liable to the Company for Unfair Competition and Tortious Interference with Contract. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three class action complaints were filed against the Company in the Northern District of California Court alleging anti-trust allegations relating to the service and repair of certain instruments manufactured by the Company. A complaint by Larkin Community Hospital was filed on May 20, 2021, a complaint by Franciscan Alliance, Inc. and King County Public Hospital District No. 1 was filed on July 6, 2021, and a complaint by Kaleida Health was filed on July 8, 2021. The Court has consolidated the Franciscan Alliance, Inc. and King County Public Hospital District No. 1 and Kaleida Health cases with the Larkin Community Hospital case, which is now captioned on the Larkin docket as &#x201c;In Re: da Vinci Surgical Robot Antitrust Litigation.&#x201d; A Consolidated Amended Class Action Complaint has been filed on behalf of each plaintiff named in the earlier-filed cases. On January 14, 2022, Kaleida Health voluntarily dismissed itself as a party to this case. On January 18, 2022, the Company filed an answer against the plaintiffs in this matter, and discovery has commenced. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from this matter.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzYwNDczMTM5NjY1ODM_1228c7f6-0f0f-4737-a31b-6a6793356ad0"
      unitRef="usd">2140000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzE2NDkyNjc0NjY2NjE_8eb3e7ca-05a4-4933-9d15-981d07852ae9"
      unitRef="usd">28100000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i9e20be5b265d48b181f0ff33e8f0c656_D20221019-20221019"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTAvZnJhZzo0MGNhMTI2YTRjYWM0ZmE3YjhiOTQ4ZTI0YWVkNjhlNS90ZXh0cmVnaW9uOjQwY2ExMjZhNGNhYzRmYTdiOGI5NDhlMjRhZWQ2OGU1XzE2NDkyNjc0NjA4Mjg_d7090fcb-7a8e-4e21-b55a-f548ca21da0a"
      unitRef="usd">10000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMzU_7ab064d8-519f-4409-94f6-6b5a26cecd40">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2022, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) has authorized an aggregate of $10.0&#160;billion of funding for the Company&#x2019;s common stock repurchase program (the &#x201c;Repurchase Program&#x201d;) since its establishment in March 2009. The most recent authorization occurred in July 2022 when the Board increased the authorized amount available under the Repurchase Program to $3.5&#160;billion, including amounts remaining under previous authorization. As of December&#160;31, 2022, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $1.5 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into an accelerated share repurchase program (the &#x201c;August ASR Program&#x201d;) with Goldman, Sachs &amp;amp; Co. (&#x201c;Goldman&#x201d;) to repurchase $1.0&#160;billion of the Company&#x2019;s common stock. The Company made a payment of $1.0&#160;billion to Goldman and received an initial delivery of approximately 3.5&#160;million shares of the Company&#x2019;s common stock, which were subsequently retired. In September 2022, the August ASR Program was completed, and an additional 1.1&#160;million shares of common stock were received and retired. In total, 4.6&#160;million shares were repurchased at an average price per share of $217.52. The total cost of the August ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company entered into an accelerated share repurchase program (the &#x201c;October ASR Program&#x201d;) with Citibank, N.A. (&#x201c;Citibank&#x201d;) to repurchase $1.0&#160;billion of the Company&#x2019;s common stock. The Company made an initial payment of $1.0&#160;billion to Citibank and received an initial delivery of approximately 3.6&#160;million shares of the Company&#x2019;s common stock, which were subsequently retired. In December 2022, the October ASR Program was completed, and an additional 0.3&#160;million shares of common stock were received and retired. In total, 3.9&#160;million shares were repurchased at an average price per share of $254.48. The total cost of the October ASR Program was reflected as a reduction to equity in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock repurchase activities (in millions, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the par value method of accounting for its stock repurchases. As a result of share repurchase activities during the years ended December&#160;31, 2022, 2021, and 2020, the Company reduced common stock and additional paid-in capital by an aggregate of $211 million, zero, and $8 million, respectively, and charged $2.396 billion, zero, and $126 million, respectively, to retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss), Net of Tax, Attributable to Intuitive Surgical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses)&lt;br/&gt;on&#160;Hedge&lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;&lt;br/&gt;Gains (Losses)&lt;br/&gt;on&lt;br/&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Gains&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses)&lt;br/&gt;on&#160;Hedge&lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains (Losses)&lt;br/&gt;on&lt;br/&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Gains&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit for net losses recorded in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications for hedge instruments, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#x2019;s Consolidated Financial Statements. The tax impacts for amounts reclassified from accumulated other comprehensive loss relating to hedge instruments, available-for-sale securities, foreign currency translation gains (losses), and employee benefit plans in 2022 and 2021 were not material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i7b8c36ddf45540d2be8a68a9375992f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMTY_5b349df9-ee41-4be9-8340-e390242214a3"
      unitRef="usd">10000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <isrg:StockRepurchaseProgramincreasedtoauthorizedamount
      contextRef="i454d4ac87d7a4c0cabb826bc3c10cbcd_I20220701"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMjA_f7aa35f7-60c5-4a18-89bb-32aab05aa350"
      unitRef="usd">3500000000</isrg:StockRepurchaseProgramincreasedtoauthorizedamount>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzYwNDczMTM5NTQwMzc_12fbb739-f5fc-4269-a4fa-f504189c0e0a"
      unitRef="usd">1500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i97d83242175d438fb29d5d804eea01f7_I20220831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzU4OA_79b6653c-2a36-4a11-8727-73d9ef1a70bb"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="i97d83242175d438fb29d5d804eea01f7_I20220831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY0MA_79666088-ec6c-49d0-a661-5908d4da0507"
      unitRef="usd">-1000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i839d2a9749664c4bab3d1bdaacba0520_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzYxNA_8a7175a6-d522-435b-ae90-27960a24533d"
      unitRef="shares">3500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ife86c560869f4c39bf37fbe4692b9019_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY5MQ_3c3b0c0e-bb65-4e58-b0d6-a23b4abc61ec"
      unitRef="shares">1100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzY2Ng_69f39c50-0281-41d7-af64-a4ef50dfff8e"
      unitRef="shares">4600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="i5d77ef89b7a243f5bc08bd4abdcfe6cf_D20220801-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxNzcxMg_a1baee87-dba0-4b76-a2b8-f11fe0a02049"
      unitRef="usdPerShare">217.52</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="id78018ef69be42c396e169846e05b20b_I20221031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODI1NQ_32c4a19e-b3f4-4f0f-8229-cdecc9dc7c2a"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="id78018ef69be42c396e169846e05b20b_I20221031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODMzMA_5cdf96c5-9cc2-472d-8f7c-9eba164ce594"
      unitRef="usd">-1000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5ea6d8fa775a4209b8ce714c8dc3009a_D20221001-20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODM4MA_fa56a119-e57a-4d81-8b1f-7773677d7425"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i6c368f15dd6943a5a4c230f46529d97e_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODg4MQ_8baae79c-3bfa-4027-b2d8-a433e08bd589"
      unitRef="shares">300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODkwOQ_6c5c32dd-93fb-4bee-a93e-785c2d74d7e2"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="ic407a9d41014478ab4e1abacdf59b190_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgxODkzMg_c04e70e7-8188-4b59-b70c-6aa544f85b4e"
      unitRef="usdPerShare">254.48</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <isrg:ScheduleofCommonStockRepurchasedTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMjI_d0ffde0b-8af3-4ace-afaf-673019c46011">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock repurchase activities (in millions, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</isrg:ScheduleofCommonStockRepurchasedTableTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItMS0xLTEtMTUwMDM0_05d2964d-5f9f-4988-91a3-a51bf838d7de"
      unitRef="shares">11200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItMy0xLTEtMTUwMDM0_f99ed2ea-42a2-4c8d-9ab8-5cbc62405571"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzItNS0xLTEtMTUwMDM0_61295feb-6458-43e4-8e50-86b339fb1b19"
      unitRef="shares">700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtMS0xLTEtMTUwMDM0_9128ce74-488d-4c01-a8bb-ec7431d8e6d4"
      unitRef="usdPerShare">233.70</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtMy0xLTEtMTUwMDM0_2b563c8c-951b-4f51-a2b9-b9aa3947de55"
      unitRef="usdPerShare">0</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzMtNS0xLTEtMTUwMDM0_a7ea38d2-eba6-4159-9700-e45ea0e1e03c"
      unitRef="usdPerShare">183.84</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtMS0xLTEtMTUwMDM0_6b5479e6-5bfb-4300-a3eb-96d1574f589a"
      unitRef="usd">2607400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i4a3e88557b764ea185d253d09daf281d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtMy0xLTEtMTUwMDM0_755ce8ae-a6c3-4633-af04-b5ec4749760f"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="icaaeb92733a8458ca0650e9fd0fae56a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo1OTA1MGM4ZmQwZTg0ZDgzYTFmMGM1MDk3NGUyMGRlYS90YWJsZXJhbmdlOjU5MDUwYzhmZDBlODRkODNhMWYwYzUwOTc0ZTIwZGVhXzQtNS0xLTEtMTUwMDM0_29f5220b-9a1c-4e2a-ba51-f15c9d7bafff"
      unitRef="usd">134300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <isrg:AggregateReductionInCommonStockDuringStockRepurchases
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjg5Mg_66736c4b-4b32-4ea4-b2c1-87373137a68e"
      unitRef="usd">-211000000</isrg:AggregateReductionInCommonStockDuringStockRepurchases>
    <isrg:AggregateReductionInCommonStockDuringStockRepurchases
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkwMA_b04764e4-d090-43e8-8d4c-30a477bfafb7"
      unitRef="usd">0</isrg:AggregateReductionInCommonStockDuringStockRepurchases>
    <isrg:AggregateReductionInCommonStockDuringStockRepurchases
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkwNw_8ae3f034-9f2a-4ddc-9146-e69638a32161"
      unitRef="usd">-8000000</isrg:AggregateReductionInCommonStockDuringStockRepurchases>
    <isrg:AmountChargedToRetainedEarningsDuringStockRepurchases
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkxNA_a8465360-540f-4d43-bdb5-de3787627e20"
      unitRef="usd">-2396000000</isrg:AmountChargedToRetainedEarningsDuringStockRepurchases>
    <isrg:AmountChargedToRetainedEarningsDuringStockRepurchases
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkyMQ_546460ce-da7e-465a-9c3a-a58c1c08e2c0"
      unitRef="usd">0</isrg:AmountChargedToRetainedEarningsDuringStockRepurchases>
    <isrg:AmountChargedToRetainedEarningsDuringStockRepurchases
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzU0OTc1NTgyMjkyOQ_8c59a29c-9010-41fc-87c4-943426d817a3"
      unitRef="usd">-126000000</isrg:AmountChargedToRetainedEarningsDuringStockRepurchases>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzEyMjQ_69e208a7-d0a2-4212-a283-49bd61c67c6a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income (loss), net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses)&lt;br/&gt;on&#160;Hedge&lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;&lt;br/&gt;Gains (Losses)&lt;br/&gt;on&lt;br/&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Gains&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses)&lt;br/&gt;on&#160;Hedge&lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains (Losses)&lt;br/&gt;on&lt;br/&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Gains&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current-period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i36cb3acbf52841e3bc3c63820c01fa42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItMS0xLTEtMTUwMDM0_e06213a5-b18f-479b-90a7-1407a3e25bb9"
      unitRef="usd">4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c13220ef9824187bfc2e616446c4a3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItMy0xLTEtMTUwMDM0_afc4e2cc-c0b0-4f28-b0c9-f5f18be7124c"
      unitRef="usd">-16000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i181617f6fdb54de7954b15a38947b6bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItNS0xLTEtMTUwMDM0_7d006f06-651f-4722-9f5e-395d08bc432e"
      unitRef="usd">-7900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i473c6bb0442144b58cb06ae162b7e6a4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItNy0xLTEtMTUwMDM0_f5bfb8c9-9ed7-4a72-a820-01333ae10304"
      unitRef="usd">-4800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzItOS0xLTEtMTUwMDM0_9251b21d-2e23-45aa-aad3-e3799f68055b"
      unitRef="usd">-24200000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtMS0xLTEtMTUwMDM0_f7d0d707-dc1a-45b4-8bad-786f2bdb90eb"
      unitRef="usd">-35000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtMy0xLTEtMTUwMDM0_6977ffed-1121-4ac2-9051-2860a1eb1c5f"
      unitRef="usd">-138200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtNS0xLTEtMTUwMDM0_71c96262-1b5a-427a-a600-724e833db164"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtNy0xLTEtMTUwMDM0_ddfd6f9f-bcec-4b9e-9aac-c741a21c8f60"
      unitRef="usd">5800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzMtOS0xLTEtMTUwMDM0_0f2ede49-576c-4fdc-907b-0f58835df6dd"
      unitRef="usd">-166100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtMS0xLTEtMTUwMDM0_d92ee3a0-6526-4b97-bf4a-fa2d22b8b657"
      unitRef="usd">-27600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtMy0xLTEtMTUwMDM0_0ddec7ee-4c87-49fc-9836-813304367805"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtNS0xLTEtMTUwMDM0_a0897811-e9f7-4529-bf1f-1178475e8479"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtNy0xLTEtMTUwMDM0_186b15d9-9ec4-4de8-bad4-35973b80cb6d"
      unitRef="usd">-200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzQtOS0xLTEtMTUwMDM0_9d0d1be3-11f0-4654-942d-5234968ac56d"
      unitRef="usd">-27800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie10bc8221edd4502b2fafd0e1dbfa61a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtMS0xLTEtMTUwMDM0_5f3316d3-071d-43af-b7af-9569ca4091d6"
      unitRef="usd">-7400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if62e887b16c64a99b20fa3d1725777a1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtMy0xLTEtMTUwMDM0_6ef1aec9-7cdf-4f44-9c81-b6d4b359bf26"
      unitRef="usd">-138200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1f76f52001e74dbd95fb282c39b00b19_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtNS0xLTEtMTUwMDM0_20499aba-f121-4967-8b8b-ddcb17388f4d"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a7cc7f1a2a146b490d7b4b76c4c07db_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtNy0xLTEtMTUwMDM0_1a7e4c5f-f762-478e-8f0f-25539cc3ace7"
      unitRef="usd">6000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iefe47c0d9ded4edaabb31152465a70d5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzUtOS0xLTEtMTUwMDM0_8cffa60e-6afc-4308-a2e3-2f35e179a241"
      unitRef="usd">-138300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i32b37d08e5a44af0beaf8cc7bb58696d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtMS0xLTEtMTUwMDM0_cc4dd2c2-e1b8-4b2b-8d6b-925eaa238ad3"
      unitRef="usd">-2900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i006259a527c0455b9e5463d5168ec708_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtMy0xLTEtMTUwMDM0_0d7d30bf-aa2d-41b2-a697-0f221c1af7c1"
      unitRef="usd">-154200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i999a1d9653924dbe965c17ddd3a03def_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtNS0xLTEtMTUwMDM0_9097d568-9a18-416b-b40b-75a8f9e55a59"
      unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b3150d3865845838cf5476e0ce21fc6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtNy0xLTEtMTUwMDM0_bf7a961a-2109-4ad1-9e28-f10e422c512d"
      unitRef="usd">1200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff5abbcecdbf42949927127eac25660e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzYtOS0xLTEtMTUwMDM0_3e109c8e-adf4-40af-87cf-a3af462983df"
      unitRef="usd">-162500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0051b5c888cd406ea6c081c905d7c0bd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTEtMS0xLTE1MDAzNA_504eafbd-7bf3-4b4e-9f51-f274e84e7375"
      unitRef="usd">-2900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70dfa53208644c0c9c0a6ec85264d603_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTMtMS0xLTE1MDAzNA_f12b6ca2-866e-47aa-a6a7-9165629aeb24"
      unitRef="usd">29500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58f1669e3b2446aca797556ff1d0ccd1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTUtMS0xLTE1MDAzNA_600fa397-f73f-4b18-83dd-a57ec540bf5c"
      unitRef="usd">4700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i94d140b2190d4fc9ae1e1dc1d5ddb6c1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTctMS0xLTE1MDAzNA_3c3d914c-1c7c-4489-affd-cb19d8ce2e32"
      unitRef="usd">-6400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15dc573b60ee43619a9a8ca70d7bd3c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEwLTktMS0xLTE1MDAzNA_12ba2995-bce8-4a92-b3a7-3659ee630539"
      unitRef="usd">24900000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTEtMS0xLTE1MDAzNA_542644f6-88c0-4940-825e-f1d1b1849627"
      unitRef="usd">12300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTMtMS0xLTE1MDAzNA_b24f6da7-5fb3-468b-95c2-0970758da3cb"
      unitRef="usd">-45500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTUtMS0xLTE1MDAzNA_beeb8938-415f-4f42-914c-22c7c955cd27"
      unitRef="usd">-12600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTctMS0xLTE1MDAzNA_027781e3-001a-4390-a542-93d4819b8e07"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzExLTktMS0xLTE1MDAzNA_981e746f-8a9d-4478-9a36-c584783bda94"
      unitRef="usd">-45700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTEtMS0xLTE1MDAzNA_fcf28a9e-2a86-4fda-a8b0-c3f2c332e712"
      unitRef="usd">4900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTMtMS0xLTE1MDAzNA_4ee1806a-84ca-48d3-8286-bab94e8aac94"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTUtMS0xLTE1MDAzNA_fce704b0-52a7-40d1-bc4f-6bcb6a8db897"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTctMS0xLTE1MDAzNA_c2a8f54d-d146-40e2-ba15-3778359c1fe1"
      unitRef="usd">-1500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEyLTktMS0xLTE1MDAzNA_d332db38-93e5-4f8d-8deb-2faaf2b02bbc"
      unitRef="usd">3400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7d3dbb70dd9e46b4b28d0346e3598228_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTEtMS0xLTE1MDAzNA_ae172be8-5655-42ca-9162-30168a0d3c96"
      unitRef="usd">7400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i15316780633245bbb91889b5d7ee1820_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTMtMS0xLTE1MDAzNA_6aad0182-b6e3-45d9-94b7-05ae8cfc85f5"
      unitRef="usd">-45500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibe370d312e724909a71b9dd34f59efbb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTUtMS0xLTE1MDAzNA_93438aed-b62e-4bb9-b9cf-90489358b975"
      unitRef="usd">-12600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icc53262ec7ac4ac680cb668dce37ebd4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTctMS0xLTE1MDAzNA_4f56e9ad-8be7-40de-9832-a778d13fb160"
      unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic7116e00b9a44951818b4ce9307192f2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzEzLTktMS0xLTE1MDAzNA_ddaf3ab9-678a-4751-b51a-7f69798d90bc"
      unitRef="usd">-49100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i36cb3acbf52841e3bc3c63820c01fa42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTEtMS0xLTE1MDAzNA_f060a254-d647-4f38-ac40-bc9db22d8b9d"
      unitRef="usd">4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c13220ef9824187bfc2e616446c4a3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTMtMS0xLTE1MDAzNA_c06c1ba2-d8bb-4c67-a488-8bf52855913f"
      unitRef="usd">-16000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i181617f6fdb54de7954b15a38947b6bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTUtMS0xLTE1MDAzNA_58f424a7-69ef-407d-b525-955a7fd7656e"
      unitRef="usd">-7900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i473c6bb0442144b58cb06ae162b7e6a4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTctMS0xLTE1MDAzNA_e3dac752-2103-4cbf-9a06-0cbd7e9ed0e0"
      unitRef="usd">-4800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb108484a5da4e338d0d4751f13dd73a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTo0ZDQxZTQ1MzY1YTc0OGU2YjFmYThkMWUzNzBhOGNlMi90YWJsZXJhbmdlOjRkNDFlNDUzNjVhNzQ4ZTZiMWZhOGQxZTM3MGE4Y2UyXzE0LTktMS0xLTE1MDAzNA_07013b22-562b-4eb5-90d0-eb4eb2052425"
      unitRef="usd">-24200000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90ZXh0cmVnaW9uOmQyMmJhMDc5ZGFiYjRiNTA4MTFlNmUxNTk2ZDE0NDY1XzQ5NDc4MDIzMzM5Nzg_0addc9e8-7ace-4851-900d-dd6ddb0c9098">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax impacts for amounts recognized in other comprehensive income before reclassifications were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit for net losses recorded in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTplZjc3MmU3ZGE2Mzk0OTQ1YmY2MDFlZWMzY2E4Yzc3ZC90YWJsZXJhbmdlOmVmNzcyZTdkYTYzOTQ5NDViZjYwMWVlYzNjYThjNzdkXzMtMS0xLTEtMTk2MTgz_833e3d9c-46cf-4f2d-900a-e5e38b56c0b4"
      unitRef="usd">39100000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTMvZnJhZzpkMjJiYTA3OWRhYmI0YjUwODExZTZlMTU5NmQxNDQ2NS90YWJsZTplZjc3MmU3ZGE2Mzk0OTQ1YmY2MDFlZWMzY2E4Yzc3ZC90YWJsZXJhbmdlOmVmNzcyZTdkYTYzOTQ5NDViZjYwMWVlYzNjYThjNzdkXzMtMy0xLTEtMjAwNjA5_1f8d6395-09eb-47b8-a562-fb3fb8f6cb86"
      unitRef="usd">14900000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MzQ_e3014888-8b90-4227-a10a-942338a9555d">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2010 Incentive Award Plan.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2010, the Company&#x2019;s stockholders approved the 2010 Incentive Award Plan (&#x201c;2010 Plan&#x201d;). Under this plan, the Company can issue RSUs, nonqualified stock options (&#x201c;NSOs&#x201d;), and PSUs to employees, non-employee directors, and consultants. Equity awards granted to employees and non-employee directors include a mix of RSUs, stock options, and, as applicable, PSUs. The 2010 Plan generally permits NSOs to be granted at no less than the fair market value of the common stock on the date of grant. Prior to 2022, NSOs were granted with terms of 10 years from the date of the grant. Beginning in 2022, the Company changed the term of its new NSO grants to 7 years from the date of the grant. The 2010 Plan expires in 2032. In April 2022, the Company&#x2019;s shareholders approved an amended and restated 2010 Plan to provide for an increase in the number of shares of common stock reserved for issuance thereunder from&#160;103,350,000&#160;to&#160;110,350,000. As of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, approximately 27.2 million shares were reserved for future issuance under the 2010 Plan. A maximum of approximately 11.8 million of these shares can be awarded as RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2009 Employment Commencement Incentive Plan.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2009, the Board adopted the 2009 Employment Commencement Incentive Plan (&#x201c;New Hire Plan&#x201d;). The New Hire Plan provides for the shares to be used exclusively for the grant of RSUs and NSOs to new employees (&#x201c;New Hire Options&#x201d;), who were not previously employees or non-employee directors of the Company. The Compensation Committee approves all equity awards under the New Hire Plan, which are granted to newly-hired employees once a month on the fifth business day of each month after their hire. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2015, the Board of Directors amended and restated the New Hire Plan to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the New Hire Plan from 10,395,000 to 13,095,000. The New Hire Plan expired in October 2019 and, therefore, there are no shares reserved for future grants under the New Hire Plan. However, awards granted prior to the plan&#x2019;s expiration continue to remain outstanding until their original expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSUs granted to employees vest in one-fourth increments annually over a four-year period. The RSUs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated RSU grants that vest on the same term as the annual RSU grants. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are paid in cash to the appropriate taxing authorities on behalf of the Company&#x2019;s employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonqualified Stock Options.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, annual NSO grants were made to employees on February&#160;15 (or the next business day if the date is not a business day) and on August&#160;15 (or the next business day if the date is not a business day). Beginning in 2020, the Company changed the timing of its annual equity award grants to the last trading day of February and on the same date in August or, if that date is not a trading day, the next trading day. The February NSO grants vest 1/8 upon completion of 6 months of service and 1/48&#160;per month thereafter. The August&#160;NSO grants vest 7/48 at the end of one month and 1/48&#160;per month thereafter through a 3.5-year vesting period. NSOs granted to new hires generally vest 1/4 upon completion of one year of service and 1/48&#160;per month thereafter. NSOs granted to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated NSO grants that vest on the same term as the annual NSO grants. Option vesting terms are determined by the Board and, in the future, may vary from past practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Stock Units.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2022, the Company granted PSUs to officers and other key employees, which are designed to provide further incentives for the achievement of the Company&#x2019;s long-term objectives. The PSUs are subject to three-year cliff vesting and pre-established, quantitative goals. Whether any PSUs vest, and the amount that does vest, is tied to completion of service over three years and the achievement of three equally-weighted, quantitative metrics that directly align with or help drive the Company&#x2019;s strategy and long-term total shareholder return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2000 Non-Employee Directors&#x2019; Stock Option Plan.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2000, the Board of Directors adopted the 2000 Non-Employee Directors&#x2019; Stock Option Plan (the &#x201c;Directors&#x2019; Plan&#x201d;). In October 2009, the automatic evergreen increase provisions were eliminated so that no further automatic increases would be made to the number of shares reserved for issuance under the Directors&#x2019; Plan. In addition, the common stock authorized for issuance under the Directors&#x2019; Plan was reduced to 1,350,000. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years. Prior to 2016, initial stock option grants to new non-employee directors vested over a three-year period with 1/3 of the shares vesting after one year from the date of grant and 1/36 of the shares vesting monthly thereafter. Annual stock option grants vested one year from the date of the grant. Since 2016, new non-employee directors received pro-rated stock option grants that vest on the same term as the annual stock option grants. The Directors&#x2019; Plan was terminated in November 2020 and, therefore, there are no shares reserved for future grants under the Directors&#x2019; Plan. However, options granted prior to the plan&#x2019;s termination continue to remain outstanding until their original expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2000 Employee Stock Purchase Plan.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2000, the Board adopted the ESPP. Employees are generally eligible to participate in the ESPP if they are customarily employed by the Company for more than 20 hours per week and more than 5 months in a calendar year and are not 5% stockholders of the Company. Under the ESPP, eligible employees may select a rate of payroll deduction up to 15% of their eligible compensation subject to certain maximum purchase limitations. The duration for each offering period is 24 months and is divided into four purchase periods of approximately six months in length. Offerings are concurrent. The purchase price of the shares under the offering is the lesser of 85% of the fair market value of the shares on the offering date or 85% of the fair market value of the shares on the purchase date. A two-year look-back feature in the ESPP causes the offering period to reset if the fair value of the Company&#x2019;s common stock on the first or last day of the purchase period is less than that on the original offering date. ESPP purchases by employees are settled with newly-issued common stock from the ESPP&#x2019;s previously authorized and available pool of shares. In April&#160;2017, the Company&#x2019;s stockholders approved an amended and restated ESPP to provide for an increase in the number of shares of common stock reserved for issuance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from&#160;18,270,945&#160;to&#160;22,770,945. As of December&#160;31, 2022, there were approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity for the year ended December&#160;31, 2022, was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, 4.2 million shares of RSUs were expected to vest with an aggregate intrinsic value of $1.12 billion. The aggregate vesting date fair value of RSUs vested was $536 million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$578 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $478 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NSO activity during 2022 under all of the stock plans was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&#160;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised under the Company&#x2019;s stock plans determined as of the date of option exercise was $315 million, $613 million, and $598 million during the years ended December&#160;31, 2022, 2021, and 2020, respectively. Cash received from option exercises and employee stock purchase plans for the years ended December&#160;31, 2022, 2021, and 2020, was $234 million, $276 million, and $309 million, respectively. The income tax benefit from stock options exercised was&#160;$70 million&#160;for the year ended&#160;December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes significant ranges of outstanding and exercisable options as of December&#160;31, 2022 (number of shares and aggregate intrinsic value in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$29.91-$49.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$51.02-$59.23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$59.46-$77.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$77.04-$139.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$143.49-$174.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175.53-$182.83&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$182.90-$242.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$243.26-$290.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$292.49-$341.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$347.42-$347.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#x2019;s closing stock price of $265.35 as of December&#160;31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, a total of 10.6 million shares of stock options vested and expected to vest had a weighted-average remaining contractual life of 4.7 years, an aggregate intrinsic value of $1.35 billion, and a weighted-average exercise price of $143.06.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 PSU grant metrics are focused on relative total shareholder return (&#x201c;TSR&#x201d;), year-over-year da Vinci procedure growth for 2023, and two-year compound annual da Vinci procedure growth for 2024. TSR is considered a market condition, and the expense is determined at the grant date. The two procedure growth goals are considered performance conditions, and the expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the two performance conditions. The number of shares earned at the end of the three-year period will vary, based on actual performance, from 0% to 125% of the target number of PSUs granted. PSUs are subject to forfeiture if employment terminates prior to the vesting date. PSUs are not considered issued or outstanding shares of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the fair value for each component of the PSUs individually. The fair value for the component with the TSR metric was determined using Monte Carlo simulation. The fair value per share for the components with the procedure growth metrics is equal to the closing stock price on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU activity during 2022 was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, 0.1&#160;million shares of PSUs were expected to vest with an aggregate intrinsic value of $18&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ESPP, employees purchased approximately 0.4 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 0.5 million, and 0.5 million shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pproximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$87.9 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $75.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $71.2 million in employee contributions for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&#x2014;product&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&#x2014;service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense after income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option pricing model is used to estimate the fair value of stock options granted under the Company&#x2019;s share-based compensation plans and rights to acquire stock granted under the ESPP. The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted-average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December&#160;31, 2022, 2021, and 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$272.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$256.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$181.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;STOCK OPTIONS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$73.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$78.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$54.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$299.32&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$80.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$89.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$57.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As share-based compensation expense recognized in the Consolidated Statements of Income during the years ended December&#160;31, 2022, 2021, and 2020, is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $700 million, $121 million, $15 million, and $65 million of total unrecognized compensation expense related to unvested restricted stock units, unvested stock options, unvested performance stock units, and rights granted to acquire common stock under the ESPP, respectively. The unrecognized compensation expense is expected to be recognized over a weighted-average period of 2.3 years for unvested restricted stock units, 2.4 years for unvested stock options, 2.2 years for unvested performance stock units, and 1.5 years for rights granted to acquire common stock under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia17bfdaa573143ba98966885510cdde7_D20100401-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ2Ng_28a3c058-3a48-42c3-a592-b4f5794cf1cb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia59158a68bbb4286aa90fa8eb06c7834_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTkyMjg_ee11ad39-91df-430a-acee-6704715dfeb9">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3b469324ce32446fb9def5b7b3c5cfbb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzcyMA_03000bd8-d9a9-4a5c-b76d-f3f5dc020fd2"
      unitRef="shares">103350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9145bce4606d4940ad42ef487d849840_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzcyNg_6bc01d0e-d1ab-4bfb-9531-6302ffcf24f0"
      unitRef="shares">110350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i410198a3903441b68830e22a66897156_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzc1NA_83491837-d5ff-4b40-a76a-88674c8e9b3b"
      unitRef="shares">27200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia179814817fd4ff9878baee2be535b17_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzgzMg_1e107ec9-e21b-4030-8392-52ca84aa3a7d"
      unitRef="shares">11800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i89170b9133ed4804b600e82c78c15cd5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE1Njg_3dd8aa96-91a7-421d-b68d-c938f530199a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i409a1f3ac0ee4fcd9e608f4ff5c23e1b_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE4MDI_35c56342-b4e8-43bb-99d6-b76f1c3bb967"
      unitRef="shares">10395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idcfae84224074580bb7bb01e54a43b99_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE4MDg_e7994367-5b0e-461f-abe2-74c0deba0965"
      unitRef="shares">13095000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib6a82f13c87242d19b461196170e58ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTM_30b7230f-6590-475d-943c-4478ae797bf2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3241e96d8cae42fd893bed581e6753b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzI3MjA_589a2c75-1f54-47ee-8b3e-f2096e8a987c">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i13aa27cc6a90415195d355246bcee08b_I20091031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzM0MTk_a0ce42ff-6a86-4c6d-9ad0-bef79e882432"
      unitRef="shares">1350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie8bc21a2592240cda306d477679d44f7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc5MDA_9d441ef2-978c-44b7-acfa-0a98e43a8304">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <isrg:StockOptionsGrantedInitialVestingPeriod
      contextRef="i65114e3030914e0a8cb520556e6fff7b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTU_d2871d26-c067-46e1-b718-a80d1ef03834">P3Y</isrg:StockOptionsGrantedInitialVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id9334eee01684436a51c2d0f31644073_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzM4MzI_a9a3b1e4-0856-4d9a-9609-5969b8793a6a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <isrg:MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1MTM_95b74ad3-7d8f-40bb-8523-8c0ef788ba5a">PT20H</isrg:MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan>
    <isrg:MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1NDU_c908d568-aefe-4fc6-839f-277280363f5a">P5M</isrg:MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan>
    <isrg:MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ1ODY_892c017b-2deb-48df-a34c-141127ba6688"
      unitRef="number">0.05</isrg:MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan>
    <isrg:MaximumPercentageOfPayrollDeductionUnderEspp
      contextRef="i20fe342469174f21b1e6e465beeaa26e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ2OTg_40128523-47f2-4d1f-a0e2-e040d38f39b0"
      unitRef="number">0.15</isrg:MaximumPercentageOfPayrollDeductionUnderEspp>
    <isrg:OfferingPeriodEmployeeStockPurchasePlans
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4MjI_5b68a130-83b9-4ce9-987e-fa7dea1cf4c2">P24M</isrg:OfferingPeriodEmployeeStockPurchasePlans>
    <isrg:OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4NTI_ae9147de-6dc5-4715-a917-1451fd6a2c76"
      unitRef="period">4</isrg:OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans>
    <isrg:OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ4ODk_413c01fb-9d9d-4500-a0d6-e50412fa7bd0">P6M</isrg:OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5OTg_80309d6c-a9ed-4bb1-a6f1-66689753820a"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzUwNjQ_5ffc88c3-3287-47b6-a7aa-534355f4cae7"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <isrg:PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans
      contextRef="if5b31dbdfc4745718d4ba4ed0d603282_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTc4OTQ_0233b01e-41d3-41a0-86ce-de1c9d6c20f2">P2Y</isrg:PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if8fa15cbbe464ea8b44d4cc396aa1978_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzU2NjI_0dcd9310-8ffb-433e-a0d4-5e7300ef4b09"
      unitRef="shares">18270945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5c51c4092a524901b1803e5ce38a9526_I20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzU2Njg_796c61fa-d4a9-4877-8eae-4c6947e277d7"
      unitRef="shares">22770945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i727584465aae4a70bf59561fe029a223_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA2ODM_8f8c9404-f6d1-401f-ae34-e03761d0fdbc"
      unitRef="shares">2400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTY4MzQ_404bbd6a-5537-4a78-9a4a-a066677b9850">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity for the year ended December&#160;31, 2022, was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a94340d69fc401d83c0ba90f1f24db2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzEtMS0xLTEtMTg4OTE1_3b8b39c6-e821-427c-b830-43ce969a657f"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9a94340d69fc401d83c0ba90f1f24db2_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzEtMy0xLTEtMTg4OTE1_b1e6d855-2e78-426a-b02f-e1803730bc0c"
      unitRef="usdPerShare">207.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzItMS0xLTEtMTg4OTE1_32ddf5d2-5367-4e84-aed0-5b0722a0a3a6"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzItMy0xLTEtMTg4OTE1_5def3130-a471-4ecd-8c3a-a3994a57d462"
      unitRef="usdPerShare">272.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzMtMS0xLTEtMTg4OTE1_d453b132-7517-456c-a0f5-81c3d610f241"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzMtMy0xLTEtMTg4OTE1_2ead39e6-9ae2-4788-8434-2437b64361ab"
      unitRef="usdPerShare">191.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzQtMS0xLTEtMTg4OTE1_ecbcf094-0556-4d27-b041-78a10843a065"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzQtMy0xLTEtMTg4OTE1_9d04726a-e995-41c2-a7ba-506163539e13"
      unitRef="usdPerShare">235.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzUtMS0xLTEtMjAwNjU1_4127d7e3-d164-41a7-a574-baf07ea45bb4"
      unitRef="shares">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo0OTBjYjMzMjJjZDg0ZGQ1OTM5ZWNkOGY1MzJlZjNhNS90YWJsZXJhbmdlOjQ5MGNiMzMyMmNkODRkZDU5MzllY2Q4ZjUzMmVmM2E1XzUtMy0xLTEtMTg4OTE1_a94611a1-cc78-4ee9-a343-4711512ac9e3"
      unitRef="usdPerShare">241.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE3MjY_be34a7d9-a91d-43a2-b461-e1d9e5274108"
      unitRef="shares">4200000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4MDQ_5afdf288-3985-4966-a891-cb41f0428429"
      unitRef="usd">1120000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4NjY_afbdb5d7-9a2e-4e54-ad4b-b5927b52f48d"
      unitRef="usd">536000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i65cb93da736742b282702b76ba91dfee_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4NzE_2e08ee85-d757-4efe-bbb1-c87786b59cbf"
      unitRef="usd">578000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzYwNDczMTM5NzE4ODA_3b7dea65-623e-4208-8222-c202dcdc6cb9"
      unitRef="usd">478000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1Mjg_510bbf69-c514-417d-a4bd-aa397a1ea926">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NSO activity during 2022 under all of the stock plans was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&#160;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzItMS0xLTEtMTUwMDM0_db703442-34bb-43f5-a919-8deb1e65272c"
      unitRef="shares">11700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzItMy0xLTEtMTUwMDM0_c11ca4d7-f560-4d2d-82d8-7b9361db77da"
      unitRef="usdPerShare">125.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzMtMS0xLTEtMTUwMDM0_9f80395e-ca0a-4029-81ae-128f8c44b683"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzMtMy0xLTEtMTUwMDM0_1c7f09d0-e125-4201-a447-79fb6e3f2039"
      unitRef="usdPerShare">249.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzQtMS0xLTEtMTUwMDM0_8028f469-d333-4f73-b7ac-7e34b6e95124"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzQtMy0xLTEtMTUwMDM0_ec20ca55-17c4-45f8-b1ce-83f14862607f"
      unitRef="usdPerShare">77.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzUtMS0xLTEtMTUwMDM0_65704896-ad8c-4a82-9e63-46b95a683afc"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzUtMy0xLTEtMTUwMDM0_5e8abcb6-ef7d-4b15-81b4-b99154b89f07"
      unitRef="usdPerShare">240.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzYtMS0xLTEtMTUwMDM0_c8391a0b-d2b5-4748-ac4d-2565ce818126"
      unitRef="shares">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiZjBlMTMwZjhlM2Q0NjViYThkNTg4ZTYzNzZlYmQ1OS90YWJsZXJhbmdlOmJmMGUxMzBmOGUzZDQ2NWJhOGQ1ODhlNjM3NmViZDU5XzYtMy0xLTEtMTUwMDM0_adcfd2f8-6020-4e17-a62f-5b07cdc24e1a"
      unitRef="usdPerShare">144.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3Mjk_bd01c5da-9653-4e3f-8729-b9831654a514"
      unitRef="usd">315000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3MzM_48c7cf99-2b53-4af8-9578-bd788b0f8b08"
      unitRef="usd">613000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3MzY_3e6a5605-eb45-489d-bc5e-d524315868ae"
      unitRef="usd">598000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTI_779766bb-af88-43a3-91e1-34ec9155daf3"
      unitRef="usd">234000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTU_45a8c540-1f5d-4d4c-b08d-47f452a24587"
      unitRef="usd">276000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3NTg_ebc3466d-95fc-4e94-90e0-1115a80fd55c"
      unitRef="usd">309000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3Nzg_c51d1e74-2ffd-407c-a6b3-b5339fd3cd3b"
      unitRef="usd">70000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1Mzg_5ef90c72-e474-4d0d-bc6f-a3e35c3e1aa5">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes significant ranges of outstanding and exercisable options as of December&#160;31, 2022 (number of shares and aggregate intrinsic value in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of&lt;br/&gt;Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$29.91-$49.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$51.02-$59.23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$59.46-$77.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$77.04-$139.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$143.49-$174.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$175.53-$182.83&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$182.90-$242.34&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$243.26-$290.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$292.49-$341.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$347.42-$347.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#x2019;s closing stock price of $265.35 as of December&#160;31, 2022, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMC0xLTEtMTUwMDM0L3RleHRyZWdpb246ZWJiOTNkMmYxYTk4NDBjNTllMTA2OGZjNmZjZTUyOGJfNDM5ODA0NjUxMTExMw_08a6d7e0-aeae-45da-8aac-a9c8d0b89de4"
      unitRef="usdPerShare">29.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMC0xLTEtMTUwMDM0L3RleHRyZWdpb246ZWJiOTNkMmYxYTk4NDBjNTllMTA2OGZjNmZjZTUyOGJfNDM5ODA0NjUxMTExOQ_3b401969-470f-4082-86bb-7deb73b55c61"
      unitRef="usdPerShare">49.34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMi0xLTEtMTUwMDM0_5361ad04-1881-48bc-b4ee-0f5a705752ed"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i914fd8f0cac2495f9d8d84a4b7659f16_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItNC0xLTEtMTUwMDM0_636dad09-7239-4d34-bf62-5586de123d8f">P0Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItNi0xLTEtMTUwMDM0_707784af-fa3e-4d0d-83de-d5551581d7d9"
      unitRef="usdPerShare">45.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMTAtMS0xLTE1MDAzNA_815a85c3-aa63-45fd-b3fb-c18262a3eec8"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i90b8da69b805467d85bab92c30ac5b9c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzItMTQtMS0xLTE1MDAzNA_f3fd005f-fc60-46ab-82d6-b42dbe232363"
      unitRef="usdPerShare">45.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NGNjZDgyMzBlMmIwNGQ3ZGEyZmEwOGVkZTY2Mzk5NjJfNDM5ODA0NjUxMTExMw_02c08c84-697c-41d9-80bc-98691020193c"
      unitRef="usdPerShare">51.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NGNjZDgyMzBlMmIwNGQ3ZGEyZmEwOGVkZTY2Mzk5NjJfNDM5ODA0NjUxMTExNw_6a156de6-2f00-4675-991c-7ac78c96480a"
      unitRef="usdPerShare">59.23</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMi0xLTEtMTUwMDM0_6938ff36-c6b7-4ce1-9c39-caf11bf22e5f"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5ca567eccd6741a0ba287fe7ac1ecf61_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtNC0xLTEtMTUwMDM0_7bfc7a2e-3e38-4af7-98b8-f46151a499e8">P2Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtNi0xLTEtMTUwMDM0_f720454c-af8c-4b36-81b5-cdff9c46fd2b"
      unitRef="usdPerShare">55.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMTAtMS0xLTE1MDAzNA_daa77748-74ba-4014-8661-6eb56106d4f1"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i062e12a2983e44c2a74b0c1e2dc1d924_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzMtMTQtMS0xLTE1MDAzNA_b830e7ed-fa0d-4395-85fd-b6a802907fad"
      unitRef="usdPerShare">55.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NmRiNDgzNjkzZGU0NDM4NTk1MDA5Yjk5MDgzOTRiMzBfNDM5ODA0NjUxMTExMw_f1d6fe9c-3c01-4625-b728-2c51e7c81f71"
      unitRef="usdPerShare">59.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NmRiNDgzNjkzZGU0NDM4NTk1MDA5Yjk5MDgzOTRiMzBfNDM5ODA0NjUxMTExNw_85e6a667-6ba4-4e59-b0b9-87ee7de8577c"
      unitRef="usdPerShare">77.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMi0xLTEtMTUwMDM0_20156992-4200-4836-ab29-c8a3ccb872a0"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i27f02ef68ae6436da46f7d9282b7015b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtNC0xLTEtMTUwMDM0_db8e2a7b-67e6-40cd-982c-0ed8af0914f4">P2Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtNi0xLTEtMTUwMDM0_a96d3062-e11b-47b7-bc0d-83784181b3db"
      unitRef="usdPerShare">67.23</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMTAtMS0xLTE1MDAzNA_d9b8c0d3-3d0e-42e4-a15f-2470d28fbf6a"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ifea0eb37deed46c3a1671bb3033ffa09_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzQtMTQtMS0xLTE1MDAzNA_5b2b42f4-4641-4606-a5ba-8ed3c010eed1"
      unitRef="usdPerShare">67.23</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MGQ4Mjg0OGI1N2RmNDNmZDk5ZWM1N2ZhZGIwYjJlNGNfNDM5ODA0NjUxMTExMw_7c596a29-aee6-450c-9d8a-087a535c03a7"
      unitRef="usdPerShare">77.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MGQ4Mjg0OGI1N2RmNDNmZDk5ZWM1N2ZhZGIwYjJlNGNfNDM5ODA0NjUxMTExNw_2ba3c153-308e-4ac2-86de-2d4c1ccef88f"
      unitRef="usdPerShare">139.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMi0xLTEtMTUwMDM0_eb207e2a-6e89-4ce7-ab56-d4c1d1469110"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i41f6760a51224b2b94510042ae3342ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtNC0xLTEtMTUwMDM0_c7ea2174-4c35-4bff-88fe-d7b8f3414cf5">P4Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtNi0xLTEtMTUwMDM0_bf43f0d4-ed47-4b89-8da6-bcac1b0ea3de"
      unitRef="usdPerShare">108.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMTAtMS0xLTE1MDAzNA_763715d0-384b-4370-a860-50956f4c2df7"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i994c9aabae284d2ea354cdf5d3af175d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzUtMTQtMS0xLTE1MDAzNA_2e5bff75-5ca7-4f55-a46e-e0066d8bdaa4"
      unitRef="usdPerShare">108.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NzZlOGE4YzdjODYwNGY3MDk2ZGUwYmNmOWFiMWFlZTFfNDM5ODA0NjUxMTExMw_1d4b2f21-4df5-4678-b272-c2cda0fc09dd"
      unitRef="usdPerShare">143.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246NzZlOGE4YzdjODYwNGY3MDk2ZGUwYmNmOWFiMWFlZTFfNDM5ODA0NjUxMTExNw_6344051f-2f27-49c6-bde3-6a9b8fc72ceb"
      unitRef="usdPerShare">174.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMi0xLTEtMTUwMDM0_d8466897-34eb-48fb-a2e6-1cd063136e07"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i22b073c4ee2649a18ed75c1ad6162b8a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtNC0xLTEtMTUwMDM0_fb92f01a-db39-4f40-8997-a47d93108554">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtNi0xLTEtMTUwMDM0_64ec62ed-90b9-4daf-831c-39d6219f5fff"
      unitRef="usdPerShare">168.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMTAtMS0xLTE1MDAzNA_971158f1-e7d7-4d03-bb72-a3104921c373"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iaac61cf5e16b49a4b9fffc34707d27a2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzYtMTQtMS0xLTE1MDAzNA_71ff49d3-019e-443a-8334-a4c5e82130b4"
      unitRef="usdPerShare">168.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzkxNDU3MmUxZmEyNGZlMmJjY2Q0ZmQ4NGUzYjZlOTFfNDM5ODA0NjUxMTExMw_dd31020a-2a56-4a27-8631-1d72839ead27"
      unitRef="usdPerShare">175.53</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMC0xLTEtMTUwMDM0L3RleHRyZWdpb246MzkxNDU3MmUxZmEyNGZlMmJjY2Q0ZmQ4NGUzYjZlOTFfNDM5ODA0NjUxMTExNw_efb5b20d-4be5-4643-817e-fa298f7fe752"
      unitRef="usdPerShare">182.83</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMi0xLTEtMTUwMDM0_1da4bc61-4600-4c57-8c4a-32fba0dd0612"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iee5869d7a84a44438b742cb5f2a1c901_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctNC0xLTEtMTUwMDM0_47da6d27-5e87-4ce1-839b-6fbb6e8dd6e3">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctNi0xLTEtMTUwMDM0_b33e2d98-6cac-46a3-93bd-cd09dec057fb"
      unitRef="usdPerShare">179.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMTAtMS0xLTE1MDAzNA_25c8d7d1-01ac-4025-87f9-32e97b809efd"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i0740ebe40d864b4da35c3b393f1777dc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzctMTQtMS0xLTE1MDAzNA_40fd96dd-daa0-4338-8e41-185c05abd503"
      unitRef="usdPerShare">180.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YTc2MGYxNDk2NTUyNDVmNWExNjdkMmNmYzIwYjY2MWRfNDM5ODA0NjUxMTExMw_15645b2c-50fd-4640-a83d-d8af28197a19"
      unitRef="usdPerShare">182.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YTc2MGYxNDk2NTUyNDVmNWExNjdkMmNmYzIwYjY2MWRfNDM5ODA0NjUxMTExNw_94f1a643-7ce6-4182-a7f6-275ff31485d9"
      unitRef="usdPerShare">242.34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMi0xLTEtMTUwMDM0_b8763fd7-8e17-47a3-a0de-08b1d7af1728"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibe73022342d24f4184ada47fd2826ad0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtNC0xLTEtMTUwMDM0_1f3ef1f5-1586-4763-96f3-bff22429f6bd">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtNi0xLTEtMTUwMDM0_5ba72ed1-5ac5-46aa-bf72-a5f708248df2"
      unitRef="usdPerShare">219.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMTAtMS0xLTE1MDAzNA_1f190d74-9cca-4437-8ef3-e2479bc9f7a0"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="if9ec653142c748c98233a20d2e6fab4d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzgtMTQtMS0xLTE1MDAzNA_08980b2e-b972-470d-8963-6c318907d82c"
      unitRef="usdPerShare">224.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YzFlY2Q2YzRiMjcxNDNmZTlmZWI1YjY5Zjg5Nzk2MTdfNDM5ODA0NjUxMTExMw_f2aaa464-7b9a-487c-93ec-05948dff71ea"
      unitRef="usdPerShare">243.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMC0xLTEtMTUwMDM0L3RleHRyZWdpb246YzFlY2Q2YzRiMjcxNDNmZTlmZWI1YjY5Zjg5Nzk2MTdfNDM5ODA0NjUxMTExNw_8fb10c7e-f11f-4e3e-9434-7abfeaadced4"
      unitRef="usdPerShare">290.33</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMi0xLTEtMTUwMDM0_147586a4-8a44-4289-9a70-1bb1ba81c7c8"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iadf56d8ed33c4dc1b8dab015fc6fcdc8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktNC0xLTEtMTUwMDM0_d29534ed-15d0-4a07-a6a8-93a7aaf88249">P7Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktNi0xLTEtMTUwMDM0_c8d6ebba-cd38-46a2-9c47-6ee559b19300"
      unitRef="usdPerShare">268.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMTAtMS0xLTE1MDAzNA_4ba19a2d-b7da-4dd9-8464-7765dc4ccc28"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i174231a7f81b42edb1f0569a32f0f3d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzktMTQtMS0xLTE1MDAzNA_8994f023-9607-469f-ae04-d72fdbab823e"
      unitRef="usdPerShare">261.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmZkMmI2MGY4OGMzNTQzMzU4Y2Q3MjZlNWRjOWQzOGUzXzQzOTgwNDY1MTExMTM_82d4dc5d-1a3e-4aac-b500-f1c3f069ce52"
      unitRef="usdPerShare">292.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOmZkMmI2MGY4OGMzNTQzMzU4Y2Q3MjZlNWRjOWQzOGUzXzQzOTgwNDY1MTExMTc_a9df7283-3374-48c2-8aaf-9f9294e70630"
      unitRef="usdPerShare">341.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTItMS0xLTE1MDAzNA_a14e8972-002f-4ba2-bedd-f65288000347"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0aa65ea27d834208aefdce2fe0e52c30_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTQtMS0xLTE1MDAzNA_3310c8de-7d15-4066-af95-b627ae91fbd2">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTYtMS0xLTE1MDAzNA_051feae8-5225-4c97-9755-9c410672fe59"
      unitRef="usdPerShare">311.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTEwLTEtMS0xNTAwMzQ_9e8c965a-9276-4450-869c-f700c9f2451c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ifcca1a9790a442a7bcd5e9f18ce4df43_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEwLTE0LTEtMS0xNTAwMzQ_91c6724a-01ba-42a7-88d1-5656f447521f"
      unitRef="usdPerShare">330.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjc1Yjk4M2EyYTBjOTQ3MzhiNDVhZGYxMjQwN2YwMGRjXzQzOTgwNDY1MTExMTM_367a2701-6447-4c2f-a2b5-8119034458b7"
      unitRef="usdPerShare">347.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTAtMS0xLTE1MDAzNC90ZXh0cmVnaW9uOjc1Yjk4M2EyYTBjOTQ3MzhiNDVhZGYxMjQwN2YwMGRjXzQzOTgwNDY1MTExMTc_0b722dc3-db66-409a-9a6e-803efc858a83"
      unitRef="usdPerShare">347.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTItMS0xLTE1MDAzNA_c0451e79-d656-4f3c-bbac-d1eee619c51c"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i6e01120c5efd4a7e86a4130c86cafb45_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTQtMS0xLTE1MDAzNA_b31795e1-9f6d-4029-a26a-2c82dfa428a2">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTYtMS0xLTE1MDAzNA_21c1d23d-818e-45b4-b616-3c9a9a2423a4"
      unitRef="usdPerShare">347.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTEwLTEtMS0xNTAwMzQ_e293f77e-fb77-4136-bab6-f02f3fb8b3f8"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic497a710b79f4cfbadc4cbf7577e4244_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzExLTE0LTEtMS0xNTAwMzQ_2e9a1f9b-d91a-4031-8b22-8e906133bd8e"
      unitRef="usdPerShare">347.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTItMS0xLTE1MDAzNA_9437593d-0585-4768-9712-bc7678b9652c"
      unitRef="shares">10800000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTQtMS0xLTE1MDAzNA_180c8ba4-110f-4c2a-9d30-772e3fa193d8">P4Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTYtMS0xLTE1MDAzNA_cd3f6e05-6650-47e8-9024-ca786030399e"
      unitRef="usdPerShare">144.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTgtMS0xLTE1MDAzNA_b0a3d9d0-452d-4335-82dd-3e0d505d3389"
      unitRef="usd">1354000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTEwLTEtMS0xNTAwMzQ_956a0feb-c948-422b-9e4a-9ccc1d69b66d"
      unitRef="shares">8800000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTEyLTEtMS0xNTAwMzQ_6b365d5c-7016-4f7f-bf31-68cbf44bd249">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTE0LTEtMS0xNTAwMzQ_9045919e-a1f2-4f78-ac54-51b03716cbc5"
      unitRef="usdPerShare">121.60</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZToxNzEyN2QyOTkwYmI0OWIwYWJiZjU3NjJjNGIwZWU3Zi90YWJsZXJhbmdlOjE3MTI3ZDI5OTBiYjQ5YjBhYmJmNTc2MmM0YjBlZTdmXzEyLTE2LTEtMS0xNTAwMzQ_18e03467-5a17-4f00-9666-60ee6d39144a"
      unitRef="usd">1292000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA3ODY_41a05be9-d7ef-484c-9b1d-d4355907e347"
      unitRef="usdPerShare">265.35</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MDU_9c9f1654-22d7-488c-b9a6-cfab9b71dae0"
      unitRef="shares">10600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MDg_a8bc0fda-5142-4f4f-8cdb-ad801b0273d8">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MTE_4ceb76ac-7450-4ee7-a787-3bcacd392f92"
      unitRef="usd">1350000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA4MTQ_7d79a3b2-46af-4ab1-ba29-362adee04b8c"
      unitRef="usdPerShare">143.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQ5NDc4MDIzNTY4MzU_115847d5-d836-4cc7-b8e9-b982a392105d">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PSU activity during 2022 was as follows (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib59e1332f83f433bafce8ca9eb07b593_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzEtMS0xLTEtMjAwNjc0_d707414a-020c-4a79-b434-f11a7c64d3ae"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib59e1332f83f433bafce8ca9eb07b593_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzEtMy0xLTEtMjAwNjc0_8a2880e5-c98a-476a-b09a-e0f1bb736050"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzItMS0xLTEtMjAwNjU4_8249ef7c-3147-417e-9b98-bfa89f2d545a"
      unitRef="shares">100000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzItMy0xLTEtMTk0NjQz_08a05a53-9883-4c5a-8a35-7958789a823f"
      unitRef="usdPerShare">299.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzMtMS0xLTEtMjAwNjc0_30263517-a8b9-48a0-a4fd-e7f5e4549050"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzMtMy0xLTEtMjAwNjc0_fb5c90f3-ec84-435b-9c37-0951a8f7f5ea"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzQtMS0xLTEtMjAwNjc0_bc1ea200-31b1-41f5-b62d-6fee4c877d82"
      unitRef="shares">0</isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange>
    <isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzQtMy0xLTEtMjAwNjc0_7b78ae42-d6f7-4398-9d69-4b2ac989c3d2"
      unitRef="usdPerShare">0</isrg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzUtMS0xLTEtMjAwNjc0_425f3ca0-b5f6-4643-968d-1b6f90ea475c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzUtMy0xLTEtMjAwNjc0_287b84d5-77e0-4de5-97b9-629f8db20a05"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzYtMS0xLTEtMjAwNjc0_5c8e1e6e-4b81-490f-ada5-383f7fd164ee"
      unitRef="shares">100000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4YWM4MDc0ZmJjMjQ0Yjk1ODUzNDg5MmViYjlhNGIxMy90YWJsZXJhbmdlOjhhYzgwNzRmYmMyNDRiOTU4NTM0ODkyZWJiOWE0YjEzXzYtMy0xLTEtMjAwNjc0_6e571f6c-ff3b-4977-9b29-bc3f14a2cced"
      unitRef="usdPerShare">299.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyODg3Njc_38e6af60-c677-484b-ac3a-167722cbe712"
      unitRef="shares">100000</isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyODg3NTk_188b8b65-b690-4669-b28a-2a74b5523968"
      unitRef="usd">18000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MTA_51c108bc-b61b-4904-b181-39910f2b3a2e"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MTU_79421da5-b730-4447-88a5-980070375422"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5MjQ_ee706baa-3096-4e7d-8af7-1a676784c9cf"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5Nzg_6eec5012-deb1-4ec9-b788-c65bff7d0618"
      unitRef="usd">87900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5ODM_0dbad8e9-4a14-4281-92b8-098e68635b5d"
      unitRef="usd">75900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NTk5OTI_da7c6401-ea02-417e-b17d-6311a59de2dc"
      unitRef="usd">71200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MzE_abb33784-8882-421d-8d28-65ec55f0247f">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&#x2014;product&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&#x2014;service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense after income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f463df323b94b2ca79195cb77ae86c6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItMS0xLTEtMTUwMDM0_b0a9ff90-4f73-4d04-914d-64507966d2f9"
      unitRef="usd">67600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a32dfb6574f44df8ff7344da9391dc0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItMy0xLTEtMTUwMDM0_eb7a1c71-e4cb-485c-8b8b-4b300d1745dd"
      unitRef="usd">68900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibee7d626dd6442c084221823215a5e3d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzItNS0xLTEtMTUwMDM0_1584d1bb-33d7-4e1a-8e2b-2445fd27d322"
      unitRef="usd">58900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c2ead6914ce4c29ad6ab0ea4e54ec31_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtMS0xLTEtMTUwMDM0_57897346-d0a6-42d5-9b8c-3d184e5fa3e2"
      unitRef="usd">23600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8d9f668182e4bce91778830a95c13c2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtMy0xLTEtMTUwMDM0_26fb3c1f-9de4-4b2b-a0d2-1fe5ef95d744"
      unitRef="usd">22200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5570cfc269954912b1db7819ee5a7b87_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzMtNS0xLTEtMTUwMDM0_05c0c696-5ce9-42e7-ba1b-4a297130500e"
      unitRef="usd">24000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d1765d5cde54c3a8c9535c06750c11d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtMS0xLTEtMTUwMDM0_6f6864f9-6eb1-4a16-ac56-0dea6ea576c2"
      unitRef="usd">91200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7fed7f0046594d5e9b7d0285eebe8dbd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtMy0xLTEtMTUwMDM0_63426451-d774-4b35-9ee7-f827c8148990"
      unitRef="usd">91100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fa21ecf135f4e53ae80c53876c575de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzQtNS0xLTEtMTUwMDM0_b32c36cd-dd3e-4d90-87ab-93d8bdb9909d"
      unitRef="usd">82900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c8730f5559847e5a2a128e0dc663cac_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtMS0xLTEtMTUwMDM0_84acc132-b6ec-463b-8e79-09ff0a2e75a8"
      unitRef="usd">261100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i703c917c11ba41f5bc3d9e8c4fa82c6e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtMy0xLTEtMTUwMDM0_4ba616cf-1409-4c0f-83b0-b1785faa376b"
      unitRef="usd">231600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd22f87fb8ad43d2af45c67cf1ea9e08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzUtNS0xLTEtMTUwMDM0_bd4bc45d-99d9-4506-92c1-f00ad89015a6"
      unitRef="usd">202200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie31db10c6d6c45489ada87073252b5c5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtMS0xLTEtMTUwMDM0_6d91e827-642d-4244-a3b4-4e1da9d6ace4"
      unitRef="usd">164200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e05145f69544e49958c2c699ac2e14a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtMy0xLTEtMTUwMDM0_20c205c7-4b7b-42d1-b490-c2098e338c37"
      unitRef="usd">134100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c76b4eb5b2d43bdbd83af671ec30557_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzYtNS0xLTEtMTUwMDM0_791dc971-d078-4e7c-a28e-db9c071a3d93"
      unitRef="usd">113600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctMS0xLTEtMTUwMDM0_ec69d94b-9aa6-4472-948e-23d748ac2cc6"
      unitRef="usd">516500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctMy0xLTEtMTUwMDM0_9a4ecb84-d912-4d7f-8de8-9b3e2df6d9c2"
      unitRef="usd">456800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzctNS0xLTEtMTUwMDM0_6fe90eee-d968-42b8-b37b-266a48b3e02c"
      unitRef="usd">398700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtMS0xLTEtMTUwMDM0_a064ef68-914d-46e0-b9e0-0e83c2224df5"
      unitRef="usd">101700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtMy0xLTEtMTUwMDM0_5073d03a-3c73-4a20-9a35-267c83b4539f"
      unitRef="usd">93700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzgtNS0xLTEtMTUwMDM0_61a168cc-ae04-4b77-8dc2-9183922c8d1e"
      unitRef="usd">81400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktMS0xLTEtMTUwMDM0_c35edcb4-6c5c-4309-aeda-d47effc3716a"
      unitRef="usd">414800000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktMy0xLTEtMTUwMDM0_a8a001e6-a51b-418d-b8c5-07a2d5ff9fad"
      unitRef="usd">363100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTpiMGZlODg4YmZjNjY0NjhiYmUyNzlmNjQ3YWZiMjg4My90YWJsZXJhbmdlOmIwZmU4ODhiZmM2NjQ2OGJiZTI3OWY2NDdhZmIyODgzXzktNS0xLTEtMTUwMDM0_6d17f5aa-7bd9-402f-a68e-79af54b662a4"
      unitRef="usd">317300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4Xzk1MTk_41ab0611-25a3-4852-b6eb-f872f351530c">The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted-average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December&#160;31, 2022, 2021, and 2020, were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$272.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$256.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$181.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;STOCK OPTIONS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$73.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$78.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$54.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$299.32&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$80.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$89.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$57.29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMS0xLTEtMTkyMjM4_d8444615-e8c4-4b1b-8858-9783f7946c38"
      unitRef="usdPerShare">272.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i65cb93da736742b282702b76ba91dfee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMy0xLTEtMTkyMjM4_d2ae5399-1345-475c-a23a-b284d07d2451"
      unitRef="usdPerShare">256.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9b4e383bccd54b57bef6b6a9af63dc12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtNS0xLTEtMTkyMjM4_53551a18-9364-4045-8204-553842034213"
      unitRef="usdPerShare">181.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItMS0xLTEtMTUwMDM0_99614939-b62f-4d42-9e0d-1ac4dec540e3"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItMy0xLTEtMTUwMDM0_0cb52698-5d18-4582-8676-acea5776379a"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzItNS0xLTEtMTUwMDM0_276839cc-ccd6-4bf0-8b48-6d91d1bb3828"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMS0xLTEtMTUwMDM0_b0de6eab-d322-40cd-b8bb-794748cbf169">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtMy0xLTEtMTUwMDM0_7f29bc9b-9ece-4c99-9422-72df9453a8f6">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzMtNS0xLTEtMTUwMDM0_1b7c666f-51f9-412a-a85a-17ad91183401">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtMS0xLTEtMTUwMDM0_ea0402ee-4e34-4f69-bb84-62cb26e54bf4"
      unitRef="number">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtMy0xLTEtMTUwMDM0_a1c4090f-ccf6-472c-a7d6-42d78a1e9eb0"
      unitRef="number">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzQtNS0xLTEtMTUwMDM0_a4359e54-9aac-4ed7-bae0-20b62d504140"
      unitRef="number">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i06aed63fafe34e248d1237896e642e3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtMS0xLTEtMTUwMDM0_8f668f6c-92bc-4e90-b038-efb9fb322231"
      unitRef="usdPerShare">73.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2c28d614ad1a4e898026e685f6891660_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtMy0xLTEtMTUwMDM0_d33be621-9d6e-45f0-a36c-6b8fe4de4cdf"
      unitRef="usdPerShare">78.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idef7cb16c9cb4efdac4cbb23f8da7104_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzUtNS0xLTEtMTUwMDM0_54178ea7-89fe-4746-a1e2-1ad0e9bb2122"
      unitRef="usdPerShare">54.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTEtMS0xLTE5MjI0OA_7f4066a5-6963-44e9-bc90-112ea7516f67"
      unitRef="usdPerShare">299.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i483a5421245644e8b7c29c4dd81da287_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTMtMS0xLTIwMDY4Mw_4210d565-f411-4d48-967a-072304e6cbbe"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie37f0a23420d421f959a8c22e7707a05_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTUtMS0xLTIwMDY4Mw_f021f00d-9016-4d1c-b45a-923d0b6fac19"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctMS0xLTEtMTUwMDM0_4984b390-28f0-46d4-8473-56410c07eb72"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctMy0xLTEtMTUwMDM0_be016512-76c0-461e-ab6f-7110f0e02535"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzctNS0xLTEtMTUwMDM0_857b7530-e995-42de-aace-48131bbb627b"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtMS0xLTEtMTUwMDM0_953b52a2-2b91-47b7-a46a-717cfdfe751e">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtMy0xLTEtMTUwMDM0_843a47b9-5e40-47d3-9963-451df84d43f7">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzgtNS0xLTEtMTUwMDM0_bfd60ec3-28c2-4dd4-88ec-e0cb0b60e96b">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktMS0xLTEtMTUwMDM0_12c3083a-b7b3-4d0a-801f-8aea4210a4c8"
      unitRef="number">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktMy0xLTEtMTUwMDM0_cf8d309c-a978-498d-be89-465d04e92f98"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzktNS0xLTEtMTUwMDM0_9caf335d-81c7-43f1-a4ef-be8c6c9e3045"
      unitRef="number">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTEtMS0xLTE1MDAzNA_405480ee-75e7-4b40-a6f8-ebc4bb1ff428"
      unitRef="usdPerShare">80.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i32383985adf64f2e954cbe105c317ced_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTMtMS0xLTE1MDAzNA_a1fff7dd-2a08-4212-941c-a4708812b889"
      unitRef="usdPerShare">89.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4b4619ff7e354813992eca0e4db507b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90YWJsZTo4ZDc3MzYzYWI4YzU0NmMzODg3MDYwYjk5YjQxNGFmMy90YWJsZXJhbmdlOjhkNzczNjNhYjhjNTQ2YzM4ODcwNjBiOTliNDE0YWYzXzEwLTUtMS0xLTE1MDAzNA_a835587e-885d-459c-8c77-4c1f31c9c7e7"
      unitRef="usdPerShare">57.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2e3066fccc99431ea0149fec8907d401_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MTg_fb261116-b580-42f7-bf3f-916d5fbda18b"
      unitRef="usd">700000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i3634dbe2d578411bbbc75e8831903c17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxNDU_91438b2c-76ef-4b53-8341-cee1c02c98c7"
      unitRef="usd">121000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifdc843d98e1341af9834acde67e83d17_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxMDY_1da1268c-0ffe-4a8e-a327-ca21c4e4479a"
      unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i727584465aae4a70bf59561fe029a223_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MjE_2c29357a-123a-4251-88b4-1b07a9a5e417"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i66a2672f116a46efa86d9e452117811d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzE2NDkyNjc0NjA5NjU_afc87fc2-44f1-4507-b6e7-92b2466d20ec">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib4cf962b95e84dc7891ff65923990d77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5MDU_91c310de-ced5-4000-b1be-defa1c865039">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icedfbca7878743f8b63e8c8f7731a1b8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzIxOTkwMjMyNzUxNTM_b99e481e-dded-445a-9ff8-0430d8e991ba">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i61144b0a10d944fcb11c154b41e3c09b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNTYvZnJhZzo5MmQ0YmNjMmE3ZWM0OThhOWFkZGEwNDExZmZiNzBmOC90ZXh0cmVnaW9uOjkyZDRiY2MyYTdlYzQ5OGE5YWRkYTA0MTFmZmI3MGY4XzQzOTgwNDY1MjA5Mjc_6b42614a-8a28-4e97-8d0e-4acf060b272d">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzQ_e3ecaeba-2de7-4e15-8588-a07fda890cb4">INCOME TAXES&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the year ended December&#160;31, 2022, reflected the impact of a change in U.S. tax law effective January 1, 2022, which requires the capitalization and amortization of research and development expenditures incurred after December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 (the &#x201c;IRA&#x201d;) was enacted in the United States. The IRA introduces a 15% alternative minimum tax based on the financial statement income of certain large corporations, effective for tax years beginning after December 31, 2022. The IRA also includes a 1% excise tax on the net fair market value of stock repurchases made after December 31, 2022. The Company considered the applicable tax law changes, and there is no impact to the Company&#x2019;s tax provision for the twelve months ended December&#160;31, 2022. The Company will continue to evaluate the impact of these tax law changes on future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2021 income tax expense included a one-time benefit of $66.4&#160;million from re-measurement of its Swiss deferred tax assets resulting from the extension of the economic useful life of certain intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December&#160;31, 2022, 2021, and 2020, as a result of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (reduction) in tax resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation not benefited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefit related to share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reversal of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits related to share-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax re-measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect tax carryforwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses deducted in later years for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized losses on available-for-sale securities and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $27.4 million of U.S. and foreign federal net operating loss carryforwards, certain of which will expire starting in 2028 if not utilized. Utilization of these net operating loss carryforwards may be subject to certain limitations. The Company does not expect the limitations to result in any permanent loss of these tax benefits. As of December 31, 2022, the Company had $221.9&#160;million in California research and development credit carryforwards, which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, and 2021, the Company had valuation allowances of $168.6 million and $104.6 million, respectively, primarily related to California deferred tax assets, for which the Company does not believe a tax benefit is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to repatriate earnings from its Swiss subsidiary and joint venture in Hong Kong, as needed, and the U.S. and foreign tax implications of such repatriations are not expected to be significant. The Company will continue to indefinitely reinvest earnings from the rest of its foreign subsidiaries, which are not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December&#160;31, 2022, 2021, and 2020, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to tax positions taken during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to tax positions taken during a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to tax positions taken during a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to expiration of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, 2021, and 2020, gross interest related to unrecognized tax benefits accrued was $21.0 million, $14.9 million, and $11.0 million, respectively. The Company&#x2019;s net unrecognized tax benefits and related interest are presented in other long-term liabilities and long-term deferred tax assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross unrecognized tax benefits as of December&#160;31, 2022, were $252.6 million, of which $187.4&#160;million, if recognized, would have an impact on the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded an increase in the income tax provision of $39.3&#160;million during the year ended December 31, 2020, as a result of a Ninth Circuit Court of Appeals opinion involving an independent third party related to charging foreign subsidiaries for share-based compensation. An additional charge of $13.6&#160;million related to this matter was recorded to income tax expense in 2021, after additional IRS guidance was issued in July 2021. The Company will continue to monitor future IRS actions or other developments regarding this matter and will assess the impact of any such developments on its income tax provision in the quarter that they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files federal, state, and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2016 are closed for the significant jurisdictions. Certain of the Company&#x2019;s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company&#x2019;s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of&#160;reasonably possible&#160;changes in unrecognized tax benefits that may occur in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company&#x2019;s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company&#x2019;s provision for income taxes. If any issues addressed in the Company&#x2019;s tax audits are resolved in a manner not consistent with management&#x2019;s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1Njg_bee3fe9e-ebd2-4c54-9818-cfcd147b4554">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItMS0xLTEtMTUwMDM0_1b68f68b-7fa5-46ff-8c42-6c8c60dd6915"
      unitRef="usd">956700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItMy0xLTEtMTUwMDM0_0c935ea0-a4fe-4b7d-8802-546d4065cdec"
      unitRef="usd">1298700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzItNS0xLTEtMTUwMDM0_824a6ce0-3ea7-49c9-96e8-88a55a173a8c"
      unitRef="usd">926800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtMS0xLTEtMTUwMDM0_b170dd2c-63f3-4ffa-ab36-d51b24e31b4c"
      unitRef="usd">650100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtMy0xLTEtMTUwMDM0_077e30ae-9517-4e4d-842d-51f4294dc697"
      unitRef="usd">591600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzMtNS0xLTEtMTUwMDM0_bbef1469-75e0-407b-8934-7bec4ae3c9ed"
      unitRef="usd">280200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtMS0xLTEtMTUwMDM0_04486abb-9de6-4388-ba17-a6e1348ba12b"
      unitRef="usd">1606800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtMy0xLTEtMTUwMDM0_f07fc8a3-b06d-43ca-9b16-ee31a5336a1b"
      unitRef="usd">1890300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpiZWUyMmE5YWNiNWM0MDRiYmE0NWFiNmM3YmVmNjJkNy90YWJsZXJhbmdlOmJlZTIyYTlhY2I1YzQwNGJiYTQ1YWI2YzdiZWY2MmQ3XzQtNS0xLTEtMTUwMDM0_fbecd462-17d5-40ce-8140-19994f1485ab"
      unitRef="usd">1207000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzY_53ab56f3-3c3e-4702-b24a-98d861fd9288">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the years ended December&#160;31, 2022, 2021, and 2020, consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtMS0xLTEtMTUwMDM0_d974997a-bb80-4d9d-acf9-bb007142da2a"
      unitRef="usd">350400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtMy0xLTEtMTUwMDM0_598a3130-1d1b-4240-9ab6-d9678935818f"
      unitRef="usd">158800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzMtNS0xLTEtMTUwMDM0_de3d19ac-f6be-4e5d-82ee-b10c27add452"
      unitRef="usd">34200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtMS0xLTEtMTUwMDM0_202fb54b-30c2-45ce-b9d1-d21dcdfb0be9"
      unitRef="usd">49200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtMy0xLTEtMTUwMDM0_a5bdee64-eb2f-4bcf-a3e2-4d66fa7f6f52"
      unitRef="usd">17300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzQtNS0xLTEtMTUwMDM0_741dcfa9-6e1f-4066-8314-9a421d65cd7f"
      unitRef="usd">21500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtMS0xLTEtMTUwMDM0_fc03542e-241a-4e93-8935-bf9b2405ab5b"
      unitRef="usd">48100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtMy0xLTEtMTUwMDM0_f3fb40a8-2fc8-4f2c-abb2-20f8e2a6f478"
      unitRef="usd">50100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzUtNS0xLTEtMTUwMDM0_a8ae5ccc-02c3-483a-93e5-5977ce714bfd"
      unitRef="usd">26900000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtMS0xLTEtMTUwMDM0_1f175032-c114-46c8-9a1e-738d83e5fe4a"
      unitRef="usd">447700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtMy0xLTEtMTUwMDM0_ae5fce93-90ff-4fa9-908e-bcfca073a8b3"
      unitRef="usd">226200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzYtNS0xLTEtMTUwMDM0_0f30833b-17e1-4712-95bd-3f8fc21c2c9d"
      unitRef="usd">82600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtMS0xLTEtMTUwMDM0_37c4d01f-cbdd-4af8-9d46-5b026b2b81bb"
      unitRef="usd">-188800000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtMy0xLTEtMTUwMDM0_04065928-8997-4f89-9873-f00109cfe204"
      unitRef="usd">-21400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzgtNS0xLTEtMTUwMDM0_ee851f0a-32e1-4ded-8013-eda6c8b78770"
      unitRef="usd">23800000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktMS0xLTEtMTUwMDM0_6de0288a-8bc7-471e-841f-019cffbb7c13"
      unitRef="usd">-16400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktMy0xLTEtMTUwMDM0_495323f4-e31b-486b-866a-ecf9565300fb"
      unitRef="usd">500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzktNS0xLTEtMTUwMDM0_9f47aa15-56fa-43e3-9c4e-45276eba9a37"
      unitRef="usd">1600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTEtMS0xLTE1MDAzNA_6bff05c5-6638-4e9f-ade8-db30356c2072"
      unitRef="usd">19900000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTMtMS0xLTE1MDAzNA_a4d56ce3-084c-40a6-80c5-c47134d42cae"
      unitRef="usd">-43100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEwLTUtMS0xLTE1MDAzNA_6167fc7c-2690-4aa3-8a7d-64eabe89cb63"
      unitRef="usd">32200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTEtMS0xLTE1MDAzNA_4be2284d-b936-4259-b9d9-06eda9186dd3"
      unitRef="usd">-185300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTMtMS0xLTE1MDAzNA_f160a3c2-f8dc-4810-87f4-ee9694d1dc2e"
      unitRef="usd">-64000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzExLTUtMS0xLTE1MDAzNA_517c597e-4ed3-4d39-8b2a-20913bf46aef"
      unitRef="usd">57600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTEtMS0xLTE1MDAzNA_1b69a2dc-42e4-437f-b4a3-edc38e42379c"
      unitRef="usd">262400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTMtMS0xLTE1MDAzNA_68a5b860-c401-4541-999e-012aeaaf6f86"
      unitRef="usd">162200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo0ODkwMGYxZjE0Yzc0MTE1ODYyYzEyMTVkZWNiNGJmZS90YWJsZXJhbmdlOjQ4OTAwZjFmMTRjNzQxMTU4NjJjMTIxNWRlY2I0YmZlXzEyLTUtMS0xLTE1MDAzNA_893c299d-647b-4879-bbe8-bc11f02241a9"
      unitRef="usd">140200000</us-gaap:IncomeTaxExpenseBenefit>
    <isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM4NDgyOTA3MDYyMjI_040c89e2-dcc7-4e28-9274-69862f168f38"
      unitRef="usd">-66400000</isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1OTU_cca47592-a68a-423b-89a3-dff2b28b6506">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December&#160;31, 2022, 2021, and 2020, as a result of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (reduction) in tax resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation not benefited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefit related to share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reversal of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits related to share-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax re-measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItMS0xLTEtMTUwMDM0_6a5c3a2e-b492-4493-9e98-afc68fb8b125"
      unitRef="usd">337400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItMy0xLTEtMTUwMDM0_0aace0c6-15b0-482e-9932-ea81a4fbcc29"
      unitRef="usd">397000000.0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzItNS0xLTEtMTUwMDM0_1d597fcc-bfdf-4c4a-ace7-8eff251af7b0"
      unitRef="usd">253500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtMS0xLTEtMTUwMDM0_36e5c1e1-846b-4bef-a94c-91ea513b32f0"
      unitRef="usd">34900000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtMy0xLTEtMTUwMDM0_f42c7f0c-1c0a-41a3-9fc2-18a4c9d5bd7d"
      unitRef="usd">33100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzQtNS0xLTEtMTUwMDM0_d457428c-2190-48c9-a048-75632ab39556"
      unitRef="usd">23100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtMS0xLTEtMTUwMDM0_8b5158f6-982d-4f1c-84b4-6b957c7e0b37"
      unitRef="usd">-64200000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtMy0xLTEtMTUwMDM0_f7689700-aee3-4eee-8771-1c4e6dd7fddf"
      unitRef="usd">-54300000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzUtNS0xLTEtMTUwMDM0_62619dac-44c0-482e-8140-341c156cd2b6"
      unitRef="usd">-19300000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtMS0xLTEtMTUwMDM0_43b6e20f-015b-4bd5-a203-679080fbe265"
      unitRef="usd">75400000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtMy0xLTEtMTUwMDM0_df979993-77ca-47c1-b6ea-1fe86d18f26b"
      unitRef="usd">40100000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzYtNS0xLTEtMTUwMDM0_53932dd4-d817-4967-9fab-7da8b5b48a6b"
      unitRef="usd">29300000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctMS0xLTEtMTUwMDM0_2f6d2af6-edfe-42c0-b90c-e97bc0f65189"
      unitRef="usd">41700000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctMy0xLTEtMTUwMDM0_2a51c82f-1118-43b5-a5bc-0145afd9c5b9"
      unitRef="usd">30700000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzctNS0xLTEtMTUwMDM0_00142887-cc3b-4507-a0bb-c669c6d17d11"
      unitRef="usd">37100000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtMS0xLTEtMTUwMDM0_327db923-7162-4fa8-a32f-4d1a8db71f5c"
      unitRef="usd">24100000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtMy0xLTEtMTUwMDM0_d2e4a92d-2027-4ec4-9201-7ea6c6956031"
      unitRef="usd">17800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzgtNS0xLTEtMTUwMDM0_d9e6d350-58e3-40e1-ab64-e1fdef2ea7a9"
      unitRef="usd">14300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktMS0xLTEtMTUwMDM0_c66aa5eb-b7b9-4f45-a0b1-0f7780803319"
      unitRef="usd">-3300000</isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement>
    <isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktMy0xLTEtMTUwMDM0_1135498e-81f8-4131-b023-865390686da0"
      unitRef="usd">-13600000</isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement>
    <isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzktNS0xLTEtMTUwMDM0_1ba75176-7eb6-4845-b3ee-345d9c94016f"
      unitRef="usd">-39300000</isrg:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement>
    <isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTEtMS0xLTE1MDAzNA_884589be-0a4a-4709-82f7-914814821d88"
      unitRef="usd">11100000</isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTMtMS0xLTE1MDAzNA_1dc2ce05-a8e8-4957-b8f0-9f51ece96426"
      unitRef="usd">3000000.0</isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEwLTUtMS0xLTE1MDAzNA_7f635892-193e-4232-8cc5-61ea746164aa"
      unitRef="usd">4000000.0</isrg:IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTEtMS0xLTE1MDAzNA_a3a46116-f453-456b-b9c9-746e4d237d45"
      unitRef="usd">-98700000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTMtMS0xLTE1MDAzNA_19eaa03c-8b7c-4a84-8777-c16ec0651af5"
      unitRef="usd">-185800000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzExLTUtMS0xLTE1MDAzNA_4efdf000-225d-4b3f-9381-82f533c514f7"
      unitRef="usd">-166200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTEtMS0xLTE1MDAzNA_866c6f32-c980-4435-86f8-18f73a46f51c"
      unitRef="usd">0</isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount>
    <isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTMtMS0xLTE1MDAzNA_57bd8c16-3554-4771-8a4d-4f043547e6c4"
      unitRef="usd">-66400000</isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount>
    <isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEyLTUtMS0xLTE1MDAzNA_f780d5c0-ec5c-433c-a2b4-df50496380e7"
      unitRef="usd">0</isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTEtMS0xLTE1MDAzNA_be53a5d9-5898-488f-9241-32928d7cad5f"
      unitRef="usd">3000000.0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTMtMS0xLTE1MDAzNA_a10a5982-b9c0-4bdf-9e07-9a8eeb5f112f"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzEzLTUtMS0xLTE1MDAzNA_477ff11b-75b1-46d7-8dc3-476766e9af9f"
      unitRef="usd">7300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTEtMS0xLTE1MDAzNA_9a40a20a-80f5-4af8-b62d-55eef4c75a80"
      unitRef="usd">262400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTMtMS0xLTE1MDAzNA_495b7499-1226-40e1-95c5-c2198b7b6994"
      unitRef="usd">162200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTpmMzI5YjhhZjdmMWY0ZDZmOWZhODc3MzZiMjkyMjAwOC90YWJsZXJhbmdlOmYzMjliOGFmN2YxZjRkNmY5ZmE4NzczNmIyOTIyMDA4XzE0LTUtMS0xLTE1MDAzNA_2d23999a-1123-45f2-8a1e-5782e71801b6"
      unitRef="usd">140200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1NzE_571239d7-7f30-4ae5-bf74-f2b45c36c00a">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect tax carryforwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses deducted in later years for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized losses on available-for-sale securities and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMS0xLTEtMTk3NDc3_c060d86f-64c6-477a-9a49-240490c928b7"
      unitRef="usd">342800000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMy0xLTEtMTk3NDc3_ac488ddd-6d8e-4136-88f0-91e236801b64"
      unitRef="usd">369100000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMS0xLTEtMTk3NTA1_866c2a4c-4c25-4e4c-843d-54a92bfac103"
      unitRef="usd">172500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMy0xLTEtMTk3NTA1_96bf57b5-4ca1-4704-a5d4-7838bafbd5ea"
      unitRef="usd">4800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMS0xLTEtMTUwMDM0_b7061e8a-300c-4a47-8b04-35faa62f48af"
      unitRef="usd">156700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzMtMy0xLTEtMTUwMDM0_67d26442-f896-40fe-91d0-e6584d92d6d3"
      unitRef="usd">98500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMS0xLTEtMTUwMDM0_ee3b9358-f39f-4637-8cfe-de4bfff0bea5"
      unitRef="usd">121300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzQtMy0xLTEtMTUwMDM0_82767df8-f900-4c62-bded-71d59f72ead7"
      unitRef="usd">110900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzUtMS0xLTEtMTUwMDM0_fd40f4a2-3b73-47ee-bcf7-859b4978440e"
      unitRef="usd">57500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzUtMy0xLTEtMTUwMDM0_45cea204-75b0-4513-bae7-f8e382c4e749"
      unitRef="usd">38400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <isrg:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzgtMS0xLTEtMTUwMDM0_9eda91b8-f5f0-4e35-9624-87f9645317b1"
      unitRef="usd">16600000</isrg:DeferredTaxAssetsOperatingLeaseLiability>
    <isrg:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzgtMy0xLTEtMTUwMDM0_eba64c00-1e4b-410b-b17a-72c936424831"
      unitRef="usd">15200000</isrg:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzktMS0xLTEtMTk1MDEy_a517d6b6-3288-48a3-8bca-33a811205d84"
      unitRef="usd">6400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzktMy0xLTEtMTk1MDUw_ec2ad3e5-42a2-4bc6-950b-17fe6baf3022"
      unitRef="usd">9700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTEtMS0xLTE5NzkwMg_75b31ee1-386b-4585-bd3e-82e130e32f81"
      unitRef="usd">45500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTMtMS0xLTE5NzkwMg_b524d2db-02c4-4af3-b54c-a516a6d32f44"
      unitRef="usd">5300000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEwLTEtMS0xLTE1MDAzNA_6681f7ca-b7e3-4cd4-afd2-7609ce746073"
      unitRef="usd">919300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEwLTMtMS0xLTE1MDAzNA_79fcd2f7-8ee0-422d-b851-988e9b85f320"
      unitRef="usd">651900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTEtMS0xLTE1MDAzNA_0672df2d-8022-49f3-9ab5-4d3b196de5aa"
      unitRef="usd">168600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzExLTMtMS0xLTE1MDAzNA_c7200490-dc66-4bba-ba7d-b5ba803f5783"
      unitRef="usd">104600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEyLTEtMS0xLTE1MDAzNA_09267fed-eba0-4e8f-b09c-ef9e9ef29334"
      unitRef="usd">750700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzEyLTMtMS0xLTE1MDAzNA_7fbb8416-88f8-4020-9e5e-528973c39462"
      unitRef="usd">547300000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE0LTEtMS0xLTE1MDAzNA_4a925c93-44bc-4e31-b113-f79b52f3f8a1"
      unitRef="usd">64100000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE0LTMtMS0xLTE1MDAzNA_146b8172-f713-4ce9-a42f-bf54a89a69a4"
      unitRef="usd">79400000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <isrg:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE1LTEtMS0xLTE1MDAzNA_2b2d8c7d-2992-4f63-8469-7d2306a3011f"
      unitRef="usd">11800000</isrg:DeferredTaxLiabilitiesRightOfUseAsset>
    <isrg:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE1LTMtMS0xLTE1MDAzNA_33988a37-0dbf-4f1a-a781-c280f2f1ab4b"
      unitRef="usd">12300000</isrg:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE2LTEtMS0xLTE1MDAzNA_57a85cdb-8ae3-401a-a403-2dd905e66506"
      unitRef="usd">9300000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE2LTMtMS0xLTE1MDAzNA_3da06853-0418-4c0c-83e0-5e5670c99ebc"
      unitRef="usd">9700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE3LTEtMS0xLTE1MDAzNA_93cdb5e6-412e-4ddd-bd16-2af998cf5e4d"
      unitRef="usd">1000000.0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE3LTMtMS0xLTE1MDAzNA_4cc161b7-7c5e-45a5-8ad5-f71d4951caaa"
      unitRef="usd">5100000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE4LTEtMS0xLTE1MDAzNA_56eb3d69-d895-4fc7-901f-f586d55b02d8"
      unitRef="usd">86200000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE4LTMtMS0xLTE1MDAzNA_c0c71cb3-c9a9-4c65-b2e0-6faeade7de18"
      unitRef="usd">106500000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE5LTEtMS0xLTE1MDAzNA_8bb47f07-a432-40f5-aba0-a13f12bc0038"
      unitRef="usd">664500000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo4MzIzOTBkMWM0ZDg0ZWFhYWFjZWNlNmFjNzgzODExYy90YWJsZXJhbmdlOjgzMjM5MGQxYzRkODRlYWFhYWNlY2U2YWM3ODM4MTFjXzE5LTMtMS0xLTE1MDAzNA_6e4158fb-25e6-415c-82a5-73584f76bba5"
      unitRef="usd">440800000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i749d4dedba014c68aa5c7acf3007a4d0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzE2MjMz_6ee028c5-b505-4296-8443-a305045d93ae"
      unitRef="usd">27400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i01c4df323b92487582860c45f1709563_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzE2MjM3_72fa53dc-c00a-4521-9563-dcbf07bd7a92"
      unitRef="usd">221900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTQ4OA_0672df2d-8022-49f3-9ab5-4d3b196de5aa"
      unitRef="usd">168600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTQ5MQ_c7200490-dc66-4bba-ba7d-b5ba803f5783"
      unitRef="usd">104600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU1OTI_64099933-4b9b-4517-b028-ab59676bcbdb">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December&#160;31, 2022, 2021, and 2020, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to tax positions taken during the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to tax positions taken during a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to tax positions taken during a prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to settlements with tax authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to expiration of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItMS0xLTEtMTUwMDM0_65b2e7a0-2cc5-4a38-8ce2-d0490c3148a5"
      unitRef="usd">222500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItMy0xLTEtMTUwMDM0_f1a5c65e-4f47-45bb-9d87-ee74e06fd8d3"
      unitRef="usd">176300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3a090d2385f44532aa7e60497f976b8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzItNS0xLTEtMTUwMDM0_67e28780-b26e-44c0-b1c5-ec0b36f84ee2"
      unitRef="usd">96700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtMS0xLTEtMTUwMDM0_9ad624c4-6871-4cfb-bb24-bc78912237cd"
      unitRef="usd">49500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtMy0xLTEtMTUwMDM0_03914d35-43b2-459b-8051-36f416943934"
      unitRef="usd">40600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzMtNS0xLTEtMTUwMDM0_caa32803-2a45-43bd-89f1-d9d09ed7af8d"
      unitRef="usd">40100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtMS0xLTEtMTUwMDM0_5c48069f-64c8-47c1-9c70-7386173a3b5f"
      unitRef="usd">4900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtMy0xLTEtMTUwMDM0_b61f2798-9290-486b-aed9-f3bda8c20bc7"
      unitRef="usd">11200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzQtNS0xLTEtMTUwMDM0_c4987ebb-7db9-46cf-927f-c670c1c2ec97"
      unitRef="usd">46100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtMS0xLTEtMTUwMDM0_ab162f86-e145-4e80-9da5-1169e7cc4e89"
      unitRef="usd">16500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtMy0xLTEtMTUwMDM0_b1ca3c70-31a4-46bc-b596-d51aa76b4c89"
      unitRef="usd">1300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzUtNS0xLTEtMTUwMDM0_2a060db7-f781-4a83-b56d-20d33acfa691"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtMS0xLTEtMTUwMDM0_fea92d7e-f80c-417a-b033-afd91f82ef6a"
      unitRef="usd">1200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtMy0xLTEtMTUwMDM0_5ce7410b-b873-4621-9452-619118fdc208"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzYtNS0xLTEtMTUwMDM0_6ac3dc8b-dce8-45bb-bae2-f847dff7d485"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctMS0xLTEtMTUwMDM0_88523332-8c55-49a1-8d33-629864bc5db6"
      unitRef="usd">6600000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctMy0xLTEtMTUwMDM0_fddc5b42-3ccf-4a18-9836-bca010813683"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzctNS0xLTEtMTUwMDM0_aaf5fb10-c446-45dd-8f8d-0408b91059fe"
      unitRef="usd">6100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtMS0xLTEtMTUwMDM0_8efdf962-3b05-4f45-ad2f-940cf4ba71e8"
      unitRef="usd">252600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtMy0xLTEtMTUwMDM0_87eef1b9-43b1-4de1-82af-e486209d2842"
      unitRef="usd">222500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90YWJsZTo1MDJiYzY5ZGYzMWU0ODM1YTQ0NjY4YzU1Mzg0OTVkZi90YWJsZXJhbmdlOjUwMmJjNjlkZjMxZTQ4MzVhNDQ2NjhjNTUzODQ5NWRmXzgtNS0xLTEtMTUwMDM0_b28e1940-0253-429a-8a01-edbc5fcd95a8"
      unitRef="usd">176300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTczNA_ffefd8d3-a261-4d0e-b8cd-6b10b4f7c164"
      unitRef="usd">21000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTczNw_415b1401-e065-4a03-a5f1-543f570b2bd4"
      unitRef="usd">14900000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="if4ab8f76e64a46d58941675cc8783c2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTc0MA_2d4bff63-7405-4c3c-81fc-b47d09854173"
      unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzU0OTc1NTgxOTc1Nw_05c28c05-3125-49b0-ac72-d37d8f22441d"
      unitRef="usd">252600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="idb57e4322a5a41099da8c576ba2c235e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzI3NDg3NzkwODQzODI_052de69e-f245-48d0-8ec4-3c2d8516a343"
      unitRef="usd">187400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM2ODA_ce58aa70-e743-4c9a-b82e-a48771e2d909"
      unitRef="usd">39300000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5a5abb42db044edb933f0bac478561e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjIvZnJhZzpiNzUyM2JmNzQxYjE0YmI2YTUzYmExYmY5NjEzNDgwYS90ZXh0cmVnaW9uOmI3NTIzYmY3NDFiMTRiYjZhNTNiYTFiZjk2MTM0ODBhXzM3NDg_708e9d39-b279-4354-be33-5fb9a7aaa689"
      unitRef="usd">13600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU4NQ_93fc6bde-4795-44c3-ab59-8836eb828897">NET INCOME PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net income per share&#160;attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Intuitive Surgical, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding used in basic calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: dilutive effect of potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding used in diluted calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Intuitive Surgical, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation awards of approximately 3.4 million, 0.8 million, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares for the years ended December&#160;31, 2022, 2021, and 2020, respectively, were outstanding but were not included in the computation of diluted net income per share attributable to Intuitive Surgical, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU4Mg_493ecb20-5a80-4bea-b777-c150925194c6">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net income per share&#160;attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Intuitive Surgical, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding used in basic calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: dilutive effect of potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding used in diluted calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Intuitive Surgical, Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtMS0xLTEtMTUwMDM0_fd92bffa-51c2-447b-9aee-629aa77101a3"
      unitRef="usd">1322300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtMy0xLTEtMTUwMDM0_3b559059-2e88-4655-92c9-35a4af570fa4"
      unitRef="usd">1704600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzMtNS0xLTEtMTUwMDM0_8fe8ec60-3473-4a5e-bba9-e68a403c3a44"
      unitRef="usd">1060600000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtMS0xLTEtMTUwMDM0_fc02180a-7b8f-4697-8a56-1eda28408b65"
      unitRef="shares">355700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtMy0xLTEtMTUwMDM0_a75b91a8-e4f6-4efe-a3d9-52a0f253cd8e"
      unitRef="shares">356100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzUtNS0xLTEtMTUwMDM0_8167bffc-78dc-4892-b280-9ced69980008"
      unitRef="shares">351100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtMS0xLTEtMTUwMDM0_5d4ef6c6-976c-4f9d-aefb-2dc1d8b3c4a7"
      unitRef="shares">6300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtMy0xLTEtMTUwMDM0_f8847d75-2a10-46dd-bb1a-ed12db7714a8"
      unitRef="shares">9700000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzYtNS0xLTEtMTUwMDM0_419a75ed-5745-40fb-ad7b-68722e75cb1a"
      unitRef="shares">9900000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctMS0xLTEtMTUwMDM0_74edf9cd-33d4-44dc-88b4-33eb8a2f9144"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctMy0xLTEtMTUwMDM0_9ba1188c-fa1e-49d0-b634-35b605fa849f"
      unitRef="shares">365800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzctNS0xLTEtMTUwMDM0_dd147251-e152-425e-b0ba-a837937eb260"
      unitRef="shares">361000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktMS0xLTEtMTUwMDM0_3adc52a8-e740-400d-9343-a29fef098dc2"
      unitRef="usdPerShare">3.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktMy0xLTEtMTUwMDM0_f51d5be3-7c08-4c0d-a81d-a265f160406b"
      unitRef="usdPerShare">4.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzktNS0xLTEtMTUwMDM0_8e68c3a9-d925-48a6-be5f-88818f0d7289"
      unitRef="usdPerShare">3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTEtMS0xLTE1MDAzNA_bab5c7e4-1d5b-4a68-acc5-4b69a1d80f42"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTMtMS0xLTE1MDAzNA_3df8a433-151e-40c5-9753-2b8ba9df881b"
      unitRef="usdPerShare">4.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90YWJsZTo3ZDYxNTM1ZGM0OTg0Y2RiOGNjODI0MTJjZjBmYzY0OC90YWJsZXJhbmdlOjdkNjE1MzVkYzQ5ODRjZGI4Y2M4MjQxMmNmMGZjNjQ4XzEwLTUtMS0xLTE1MDAzNA_5fe83b8c-fdce-4cd2-9619-251dd1665d92"
      unitRef="usdPerShare">2.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ3OA_df56beff-9712-4d9d-8027-370e78373ba9"
      unitRef="shares">3400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i884794fecf5c4c6d8fa6045cf8b81695_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ4MQ_537a6f50-5018-4e9e-94d6-34fe9eb838d1"
      unitRef="shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i15614cbe6d8745ffb2269854b7985e0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjUvZnJhZzpjOTdjOGFmMDUxODQ0ZjU4YmMxYjhjMjAzMzg3NmI0ZS90ZXh0cmVnaW9uOmM5N2M4YWYwNTE4NDRmNThiYzFiOGMyMDMzODc2YjRlXzU0OTc1NTgxNDQ4NA_3659b44f-5c3a-4807-83f9-80c320b3be4e"
      unitRef="shares">1900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzc1NA_8131a1b8-5ba8-4308-a6b8-4acbdcacad7b">EMPLOYEE BENEFIT PLANSThe Company sponsors various retirement plans for its eligible U.S. and non-U.S. employees. For employees in the U.S., the Company maintains the Intuitive Surgical, Inc. 401(k) Plan (the &#x201c;Plan&#x201d;). As allowed under Section&#160;401(k) of the Internal Revenue Code, the Plan provides tax-deferred salary contributions for eligible U.S. employees. The Plan allows employees to contribute up to 100% of their annual compensation to the Plan on a pre-tax and/or after-tax basis. Employee contributions are limited to a maximum annual amount as set periodically by the Internal Revenue Code. The Company matches 200% of employee contributions up to $1,500 per calendar year per person.&#160;All matching employer contributions vest immediately.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzQyMw_52b5450d-f390-4870-9901-7cf190d0cb64"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzYzMw_8c0e4c64-f0cb-4c11-9287-5099d6fb88cf"
      unitRef="number">2</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNjgvZnJhZzo2NDJmMmMwZWQ5ODc0YmRhODZmY2Q4ZDRmMmQ4NzFjZS90ZXh0cmVnaW9uOjY0MmYyYzBlZDk4NzRiZGE4NmZjZDhkNGYyZDg3MWNlXzY2OA_f6afe341-1140-456c-82fa-d243af559f7d"
      unitRef="usd">1500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90ZXh0cmVnaW9uOjA1NGJiYjRjYjQyNTQxZDBiNjczM2QxMTc2ZTdkZTEwXzQ4_0703574d-3613-49b8-be90-b7f6b7241a24">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance&#160;at&lt;br/&gt;Beginning&#160;of&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance&#160;at&lt;br/&gt;End&#160;of&#160;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales returns and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Primarily represents products returned.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItMS0xLTEtMTUwMDM0_ec8b51c4-2cae-4b9d-8b0e-59127dee2526"
      unitRef="usd">13100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItMy0xLTEtMTUwMDM0_65ef812c-db85-48c5-b6f8-1ab8e6d1318b"
      unitRef="usd">44400000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i7b93e60ae1a84c5b89753efadac0555c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItNS0xLTEtMTUwMDM0_ead13879-2f9a-4d33-b232-19c94edaf165"
      unitRef="usd">43000000.0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i552384583d88412ebd23eaaff77ee647_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzItNy0xLTEtMTUwMDM0_ce27f16c-9169-4f81-bb18-bda2b759228f"
      unitRef="usd">14500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7a0a29ffcad84c7ba35a79003fcce055_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtMS0xLTEtMTUwMDM0_3f4ab0ce-3a67-473d-8df3-5e08786cd239"
      unitRef="usd">15500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtMy0xLTEtMTUwMDM0_890f01d4-e587-4c34-acd6-f94f9503b193"
      unitRef="usd">41700000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icbf4188c30b14c03a53ce6ddf762aab1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtNS0xLTEtMTUwMDM0_e7b25174-9d05-44af-870c-eedcc9e234b0"
      unitRef="usd">44100000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i13598596c8ae43da85a2f7f5bd4d8d95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzMtNy0xLTEtMTUwMDM0_2d1d63a3-82b6-4e2e-820a-19e50ef17420"
      unitRef="usd">13100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id54e38a6bc054a1bb5bcc9ff5b0db69b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtMS0xLTEtMTUwMDM0_9fd3c72d-1cd2-496e-bc9b-f761194b51be"
      unitRef="usd">11700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i745afcb5136f43d88582feee765c64c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtMy0xLTEtMTUwMDM0_075ae097-296b-4060-8210-910eb06336b0"
      unitRef="usd">39700000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i745afcb5136f43d88582feee765c64c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtNS0xLTEtMTUwMDM0_6808c178-cbee-4060-8f8b-583d9ee90796"
      unitRef="usd">35900000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7a0a29ffcad84c7ba35a79003fcce055_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yNzcvZnJhZzowNTRiYmI0Y2I0MjU0MWQwYjY3MzNkMTE3NmU3ZGUxMC90YWJsZTo3MDM2NDIyNjdmN2E0YjY0YjRkZjU1ZjdlNzRjODkxNS90YWJsZXJhbmdlOjcwMzY0MjI2N2Y3YTRiNjRiNGRmNTVmN2U3NGM4OTE1XzQtNy0xLTEtMTUwMDM0_a3491d52-2e2a-4968-a288-7f2fdd8ddc34"
      unitRef="usd">15500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Represents the adjustment related to the adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, C</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">redit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtNy0xLTEtMTY0NjY3_148df6c2-ade5-4bb3-bf9b-fd04f4b4cef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTEtMS0xLTIwMDQwNA_30e24862-20e9-4391-ab1a-b3fbecbeb48d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzMtMTUtMS0xLTIwMDQwNg_b46af5fe-5ab7-41fb-b93b-4bca9a4da0d4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAyNWRlMWVlYzMyMDQ0ZjVhMzBjNTg3MjU2OWYwZThkL3NlYzowMjVkZTFlZWMzMjA0NGY1YTMwYzU4NzI1NjlmMGU4ZF8yMTcvZnJhZzo3Y2QyNzAzMzA4MWM0YjcxOTZjZTAxOTYyNWQ5MWRjYy90YWJsZTphZTVkZTAwYmZlOGU0MjJlOTRlYWM1YTQ5MTcyY2I1Mi90YWJsZXJhbmdlOmFlNWRlMDBiZmU4ZTQyMmU5NGVhYzVhNDkxNzJjYjUyXzM0LTAtMS0xLTE1MDAzNA_e0208da5-2a3c-4bda-866c-052e26f41198"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MN+I):VP,;4K*DEB-U'5)ZOH44D]D1=6," WL$<?:KFC6F28RI2J-1/.4KVB
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MVSFL@5=9 \^<U$_'#T]HE(94,HY&4A*PZ=FBY$.$5UIJ9KU#.WWFL,;0SF$
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M"8T&]^8"I>\8WM"B<E6Z%]K4O)N6ILF"M YF_R"$/AGV@*YM9W\!4$L#!!0
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M&\#O=P+T5'>A7[3T+]8V_P-02P,$%     @ :(E*5G(GB_@V P  '@L  !@
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M@L>5*B]C9<?(K+C/K*3!VU'13/ ""\H&X/Q:2O/4L5>D^DH<_@%02P,$%
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ML:]^[GBRYD4)T/]OA%#/!^4%3F_'+?X&4$L#!!0    ( &B)2E9S(X"P404
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M[(_R<W:<^VWG30/]G#SH-F^5>,9ZG9OI2+)QJ_I/D"%])%F()(M:'0R%#)F
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M1:U%E[+6=7TC],BXTKM+JH1G%!(7SS&4*M2#'I(!_*6= 3"<1_NX",'YL\5
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ME3,*VJNJU 8"WD,X1@_EL7-@L-/NL)M$NL9@Z8G26J,EAO)XA\VGU)<Q$$A
M;[F27!@I=*P]2UI+WN4W(B[_'P[_.Y58B19'];JZ BK=E/C-0TPV<#XGXZH4
M:X%_'IQ_&XQ/P%#H*T!N/J*YA]FY!^=/S^U*80UC_G?J@P3_]P'(K;[$<;Q+
M.PSSR?+[&??]J;/5YH6S%5:&Z C@L;,/^PQ"(^K$+N?@>&LG#_WP.G;R) 9(
MV[\\.?<2#G*L:WO,Q*Y@B;9<EQBS2I-.;&(*<7TLVZRR'\0Z4J,4IVP6;M1;
M-,>$:]=2Q,#@?D'K0EIU17;X81X9 I][</[]/-!HHG+?QDT)HMBJ,LK?4F80
M8E/2LQIT)&#3"JCVI(6/7"1JG"P+;Q/)VIX6V]MLTUMXCO\^RVIG(C.3'GG%
MW>/@44%,2S7I2*Q+S7%1'RVJ)I":A>TNF@[G+<$QRC9]1IA#/ZB-6O5U :!1
MRAQ5"""&^^^Y^W_02G0P^\Z(Q4[)4:)F!NY7HE*0))06#2UNTLB[?(=%FKJI
M3[]@ S+P^6VNZ(2?3]VMV^ZZV/C$VPUZQW/,$F)BDYO'Z+9 Q <ZX6.T4E6&
MU##6#+6P9M[";K28\V&3!U$Y:KVRI2-0>P*WC-U-MH-]"SP 5\V_@-+BJ0\R
MHJ&OD2#<PZ.@<"AW28Y>;,^3MBHND[9K*=5+2C9R*_=7$K?.Q#)9+QV4F522
M :L23?&1R'QB)HI2N#'K69.QL,MH9E/:K8KI]19$".TL/6CA((?E.SH]53H7
M>"DF);]T@SDO=F@KS1D&D^0=HR9&?V-/#C!U5X;6_-LEY?9+*CO-\%14N"W8
M"=ZQPD[ZNH""&#B1!P.$,HBG4LZB[[2F-OT^7TK /G-&R'VDX:8HBI\1(2'F
M9:8P"084-ME)4ZEV*[[YTV_%'1/5EMP;D);;A[CR-^PH&5R"(J/<,3H^33 F
M,_'_?,#I\)5R$,^C2J<"4%E(*8B=XJWK-DV!&EJX?@WT%!^7,:<+H,RD#=4D
M$_:H=V/UBR]7I$J:#$ODL]CTJJ'4R)ZNT5LC70'BH9:5:U-3JX30AYOF*4G/
M+C=Y2U2[1(M><Y<:G7I9@=V1$-9;K\Z@YTN/D8![QRY86YC8Y#7=D$D_2_0U
MW?5QHZ<4HKS@IE,66.[EB-V_[!].OXS5U/O>'^9PJ"7]G^[? :B37,VH%UEZ
M8*-[SQKBRSDT!3;>SKL;; KQBR9Z[5]R!))=^%OOC;6**G&'5360>7Y"C\1>
M/\47Z$PV"\P?T>I\?G-T:@5"$V&OZVGXQ#H JP=84C<=VZ&_6K4*]G13F;0%
MS80G^(U0^DN\"I"ZR=J-P.U!44L?\8PT*YYZ2$,OY:M8A?<;MJQ+_YNV;+G0
M>H(HB>A09]-G[R@3>9ZX@M,]]G)D2A&;$_>40>)E+F#C72\*,WK/9 <H[N;.
MQ8$?=X?31_C"WX_Z>H2\@1]W)S:/"C,=9RC&-WB/G*(RBN"X#>Z0%#J%V?S
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MGQ=F8$5ECQ^B7F_* *$14[.WG,J:X#5\DM+(][/:?%B[I6M$5)E@NE(5@6>
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M</7CR>7YL\N+DT?P9GS\Y8L=T/P7JK>CFEW!JV?S[[\]88]%?^F:'2Z)WWD
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M4'1W>UY"D8U0AQ!NNR^L_%V12)0N'#"XMTIE1,SJ0448MFE+JO)K'95:Z8Z
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MH,U/LOB$%, 5P_S>$'^'<2>BJI'@EI3-E4H-"WL>)H-^#..UCW)M _@,PTZ
ML3?HX_\.I]!3)9>IV8 HJ;2F+')C!**]082DUM@ZMP4SA-PG^UP*E@DPL&'O
MWPT"W__,S$)I^PF!Y<Q'5@+F^UXG9!<_*FF?-[08%F$ZB!'7K;-9ONF&'Y.(
M'X:0J6-]6P:(#H=(-<:^OP\#[*G:/K=9F?'"MIU" 9]+\K7.\17-4:8&R!#&
MN ^]9Y7,4FH:^OG0?'0=)@N5I4SFU$8-,0WBN--C S_ \YHG"_0PTO3*%.O%
ME.5HV(>16_@$JH-VIW 5TPKJ26$!*G90-GTVZ#=VA56T>N"1CMBGHABKO*R0
MCAJBV4PF8L.:'T:H5C\(\1SS4@)4^1/%9=3,+KD6+(@\H!WXY ZQE]65V[LW
MJS/V")' &T+)+UH91QU[X&1A._:I6X+V(.JA<:^@Y8AHH,JKS%%**I!:4 J9
M^H@>; =AOS-$-PYCV#I<I__MK"'Q[; ?N3;PVX,^(?-QERE"6-$[YI?2+ICZ
MCQDX8!^"0:\S.*0W'[T-"ME1>G7U@UET!:N9Y" QZ-S>4I,B4?DFF5G^1%3-
MGQW)'1!'$ OUHH[C5:<SV<R;%G7829UM)IYPF$PE*!!Z>M2J* :?7<&%.7\E
MX5PDML("CP7 <=ST6@G_F@T9IR^!R=2Y",.$G5M2Z61!")(SV%5TC3>U$$K!
MVX,"]:_75%>==O5O$#M@$7).V0\]']'MS4*FBGDMMJFU ;V&>F7B92DJ#)3@
MD05T7 P+#01:@(DKL44DHNTJC!'\/KLU<_H>/3<CW[X:@89#K,38HW:>5F69
M.>*!X)B;!;O$WH9@ZFL#H;]EVU_M^@9W@@WYA.1G)"\WY/^VO?\NN&Z.EKM@
MQL-[C2?Q-_D<-2TZ\&HH(]37JQ *E*)SH]Y#5IS;'#[HBVX3#HLCM]W47(.#
M8&&0$,-F6N4;NZ-5;]$4[1G#IG2HW,D[(O!1@B5&KDK^#2VR>#DVK/K4'36V
MU"^=9)RAL#Y,1'TD=-NYL[MQO<B%GKM+E&'.3'W36,^N[VFC^GKRLKR^Y%US
M/9<X_F1B!E&OT^^UF*XO3O6'5:6[K#PHBZN/>UW@KBDT+<#_F5)V]4$&UK?7
MT[\ 4$L#!!0    ( &B)2E:0&,)ZE08  ,$0   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;+5876_;.!;]*X0G&.P.5%D?MJ1TD@!IVL4.,+,-DFD7
MB\4^T!)M$2.+&I**Z_WU>RXIVU*3NGG9%XNBR'O//?>#E[[:*?V'J86P[,NV
M:<WUK+:V>SN?F[(66VY"U8D67]9*;[G%J][,3:<%K]RF;3-/HBB;;[EL9S=7
M;NY>WURIWC:R%?>:F7Z[Y7K_3C1J=SV+9X>)![FI+4W,;ZXZOA&/PG[J[C7>
MYD<IE=R*UDC5,BW6U[/;^.V[!:UW"SY+L3.C,2-+5DK]02^_5->SB ")1I26
M)' \GL2=:!H2!!A_#C)G1Y6T<3P^2/^;LQVVK+@1=ZKYIZQL?3TK9JP2:]XW
M]D'M_BX&>Y8DKU2-<;]LY]<N\ADK>V/5=M@,!%O9^B?_,O PVE!$W]B0#!L2
MA]LK<BC?<\MOKK3:,4VK(8T&SE2W&^!D2TYYM!I?)?;9FP?Q)-I>7,TMA-'4
MO!PVOO,;DV]LC!/VFVIM;=B'MA+55, <*(Y0D@.4=\E9B>]%&;(T#E@2)<D9
M>>G1M-3)2\^;QM9:;=D=L&J$ .BU-;MSQ K-_GV[,F[^/R\QX.4O7I9/Z?+6
M=+P4US/D@Q'Z2<QN?OPASJ*?SZ!?'-$OSDD_YYBS&U^&]?#A\X=_?/K ?J_!
MAVJ0BK+=,,M7C6!N56L-<LP35DG#-QLM-MR*BJWVS.X[81AO*[81:J-Y5^_9
M7V2+>&P:I);YZUOV+\'U$ H,CA3;%=@E9WX*'T/G4?J)Z2=BO[0@O=\ZI225
MEZ4P1FD)+1<L"991'B9NE"3+,,8H#O*"1H][8\76L,LL"R/,1LDB+%AVN<3;
M(TR5$,2R8A$N6!:E8<H611)F['=E>>.A'(R\8(L@7N;X>,'2H%BF@\;++ ES
M]O'3XW=00G<<8>4%*_(EU%VP+(\@[8 PCQ? FV4%YA9%&EZ>\*7I)4"G<8+)
M9!%#L<='2D_PDB#*%@Y>#'@9UM(HA:GYL/X\P#18QKG;E09Q%(5+)W.QI/T'
MD'&0%1%@XGF9PH@XB/-B#-4SG+#+.,-OGJ0 [I6?@&;P4N+86P9Y'#E_+8)T
M64#@@Z"#@6+M7FAWA+2E8!]7C41P4>BXB$0&MH;[,MUI*&8<(5JZ\+,*J@Y"
MNI$0-1*B18/%AA;SK>H=(6,)G5957PXTF8-Q$,5VM2SKHS$U-ZQ5ENUQ&JZ$
MH&.G5)M6_E=4(;ME1F*\EB5O+>N4=GC5FMD:"?0=;(1B4#SYBBS"=I2G;<?;
M_8\_%$F<_VR8<0YBAB,_"7,C</(PKD'41GB/VYI3-6L:(,5"*\U:PEI:?4+-
M^"FMH6K=VUX[J%)5)GP-^83N^P[80<]%'!896_F:0(I!S:044!7P.K\OD .F
M^-+A[/8P)C:J)T@D8%;H[>"!,66!YRL8NWM"7C#XG;1L1"LT3-ZSOB--2W@?
MM2P\'1FWQH@A=GZ5' 9*2RDVK:6R]1T2V>X['/!O7G1N>1#,3X*;D>"O2NLS
M#GTEO?M*"I*.JB >5"O>B[706E3C>I<6*(AXHC)%#OT #-B?E,L("3GE<#8:
MU^V ;!^ASJ^PD]K"JF^$"UU:3X2;";LAN^?[H2Q-"*Z (XV(Y"QB%=\;?S:3
M^(IR!)X<H(3/S*-DI85#[!Y.+0!$T!+;D*_%,.M%RC4X$!19*V%WE,X^F#TA
M/G]<?ARS96*Q2URTC,Q8>(@WJL50>!9\H@R1YS.\^F8L3Y.3=APBH$<A/1!+
ML7RL!U,ZGSGS=60<:^(A!0YJD:\UF/%I,WQ;"^'=17@@J._>P#FM#4;^^[/G
M&C Q@G[>MCW-!J23\%"M4$:<ZFO-G\@P5T@';JB.4N3!J:J4CK7J:^.D&:D<
M.>?EK!_@>R;"25A7LG+5'#BHBNXG]5MBC=1$,&L40LR0VUW\OS;PX)=>.\_A
M*]4,)IZW/Y2OP;@*C"VZ2(OHD.EDT+/0E&W9]"1S"(MG7*UXX\+MY6H;OQ9B
M? ;B,OY_0HQ"M#&VER[1?%O"?D7Q)M!GF]7A2#^E!%62;XJ:G)RO;5V_ZEH?
MJ="]H5YX.(Y/I35&?T8M8 )[4O=.'>A'A Q2'^HGZW^BEBS/?$.6#XT=GCG[
MZ3-2UYDY5> K$7&@6(_>7+SQA6IBU=$1=,.!A>IE[:0L3=U!@58O=A@ Y:4;
MRWQTK<2!L'&79TH0-%C^AGF</=[/;_VU]+3<7^Y_XWHC40H;L<96],W+&=/^
MPNQ?K.K<)76E+$X?-ZP%KX2F!?B^5LH>7DC!\5^+F_\!4$L#!!0    ( &B)
M2E8N5F C2P8  /,:   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;.U9
M76_;-A3]*X2;%@G@R)+\G28!DC3="K1KT+0KBF$/M$3;0BE1):DXWJ_?N:3L
M*(OMHL$>_6*)$N_EN>=^&CI=*/W=S(6P[#Z7A3EKS:TM3SH=D\Q%SDV@2E'@
MS53IG%LL]:QC2BUXZH1RV8G#<-#)>5:TSD_=LQM]?JHJ*[-"W&AFJCSG>GDI
MI%J<M:+6ZL&G;#:W]*!S?EKRF;@5]DMYH['JK+6D62X*DZF":3$]:UU$)Y=]
MVN\V_)F)A6G<,[)DHM1W6KQ+SUHA 1)2))8T<%SNQ)60DA0!QH]:9VM]) DV
M[U?:WSK;8<N$&W&EY-<LM?.SUJC%4C'EE;2?U.)W4=OC "9*&O?+%GYOA,U)
M9:S*:V$@R+/"7_E]S4-#8!1N$8AK@=CA]@<YE&^XY>>G6BV8IMW01C?.5"<-
M<%E!3KFU&F\SR-GS]P(FF=..A2YZTDEJN4LO%V^1BV+V015V;MAUD8KTL8(.
M0*R1Q"LDE_%.C6]$$K!NU&9Q&,<[]'77EG6=ONY.R]A?%Q-C-9S_]R8CO8K>
M9A64$">FY(DX:R'BC=!WHG7^ZD4T"%_O -A; ^SMTKZ#^IURFU&]O[ZXO;YE
M[X4Q2K-WA4]7GSF26Y$RJ_#85AEE ;M=&BMR1A"R8L9NN13FV"Y+P3RJP%\A
MG(CLCD_PVBNBW=!D'@2DV\BUYL5,(%VMP4(P!ZV@@X'!S@6[4H51,DL=F$LN
M>9$ !P4N! R;*HD"8=AA5B#.I01T<W3"$!4BGPB]C@SZB=AO6AE3']W$>,!Z
MO7'0HVO8"T+VI1!<%S@P*Q*5"W88]8+>$2X176ZKB5662];K]K&Y.XZ# ;L@
M' X<.&2)%FEFF:3C#KM!>$2_@R/V!^IE5MP)8\EDW#ZAQ('IQM![P+JC,:Z?
M1*DT6<_-";O1HN19"ML+4 2"<%:E-2GCQA I!RSJ1D%,UR@,NN0]4)S!SH:,
MW]MF!?!TPS 8L7@X"H;/P@</N4RIP B"I]*(%6Q34S;;0C=W;Y_XJ.TB8+M3
MWV8FP1G?X!MVD:L* "'6=18/@SXM>BR*!S :MWTV[ON' S8(_;,APUOW;.3(
M("X$GUH"@1V?G5=7P?"Q%-I'[BJX/[MXS$M>+%^]&,71\#4,6>_R=D)7[D-Y
M)@J\DG*)-Z#!SCG8%'>B8$M8 '5O*Y EJ#QG>977\B5?^FQH)"#E0:&*XX3B
M2THBD5%,4)Z"R/]  &^+>9;,F;A/9)5BG<!#>$T>W:2^,NBCQ]2DTD<)>?3_
M.XIB+?2.BONA=T6?16.DE_=4U V#V+NJ3P&YR54Q;5GY:MRGA*4")L2C M9P
M%J.*H@W"&=8^88OR%:HE0]2#$AA7H7VJ20:WM=W9B= 6@PH3/ZJL)&J"1G!X
MMXE[S#NX+L#*0=P'\IJ/-I8AK%LO2>%!' %T_<@!(!>[L !6-,9-G%,%\^*X
M"]O ;$KAIA.Y1#!!26W0(K/S.@[A/;3<W+=<M\/ )CILY?\F\ P3%N0R<$&8
M!$<00<,O8PM0(LM2NBB"KH2;.9LB4." !_\\R^IFV#YQ))FP/2B_N7.N-Y_C
MVX,[X8K04HUU"&O52%[+%HA Z@B45*EC&2<\H'!F8H"=NM,1ZUV4U0,6=^MB
M3*6<AKUC-3VNJ/?Y>HW"J&9%]@]4-HPK,)CZR%(3F<T<94YISU?>$"T'P8_?
M1U1/Z@;I)_,&W>T=N>RYC=K/);=-E4:4ME$!G=(49< E/S2)[4WYIPWJ< -M
M1[!^%#MFAU0\/GJI)-$5#) 91_KZ/@0/]-P^EX9^GU3%[-CA;.X<$)V# 7Y\
M<?'F/-8U]DX=#>&&KVYV%^DQOP-9,\HI^C_SN!>P'JJ<C_%>,*[OGD@^H@J]
M*&0O60S!E^QBF]LH=Z:^@VSK&3_K54W3J*+3?[>TDF[4^/7:CM:Z*NV1K]Q4
MV5<M.")>75T?^5[\I*R/0$^3^+5541C5)?X$):JLK!O,((*"S0Z'07Q4R^VR
MKW;=C@&\OQ[ ^\\<P'?*[0?P_0"^'\#W _A^ -\/X/L!?#^ [P?P_0"^'\#=
M -YI?(C(A9ZYSRW4-6&<_R:Q?KK^HG/A/V0\;/>?@SYP/<L*FGFF$ V#(69R
M[3^Q^(55I?NL,5$63<;=S@5/A:8->#]5RJX6=,#Z.]?YOU!+ P04    " !H
MB4I6O*8QQ,D%  #0#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R=
M5VUOVS80_BN$%Q0I8,B6[-C.*^ D;1<@38,F6S$,^T!+9XNK1*HD%<?]]7N.
MLATG<9)M7VR^W!V?NWON2!W-C?WN<B(O[LM"N^-6[GUUT.FX-*=2NLA4I+$S
M-;:4'E,[Z[C*DLR"4EETDFYWT"FETJV3H[!V;4^.3.T+I>G:"E>7I;2+4RK,
M_+@5MU8+7]4L][S0.3FJY(QNR/]675O,.FLKF2I).V6TL#0];HWC@],^RP>!
MWQ7-W<98L"<38[[SY"([;G49$!64>K8@\7='9U04; @P?BQMMM9'LN+F>&7]
M8_ =ODRDHS-3?%.9SX];HY;(:"KKPG\U\U]IZ<\>VTM-X<*OF#>R>[V62&OG
M3;E4!H)2Z>9?WB_CL*$PZKZ@D"P5DH"[.2B@/)=>GAQ9,Q>6I6&-!\'5H UP
M2G-2;KS%KH*>/[G07NJ9FA0DQLZ1=T<=#[.\V4F7)DX;$\D+)N)$?#;:YTY\
MT!EECPUT@&<-*EF!.DU>M7A.:21Z<5LDW21YQ5YO[60OV.N]8.^3,=E<%860
M.A///!;GRJ6%<;4E\>=XXKP%5?[:%H?FE/[V4[A\#EPE4SINH3X<V3MJG;S[
M)1YT#U_QH;_VH?^:]3=\V(;V#7M?OIQ_N[B\%..K<W%Q=3N^^G1Q>OE!C&]N
M/MS>B''ZHU9.<>4X<9L38C/G'VW /D]622#9E%$Z9"O PR". %)\I(FM4>N\
MTFT+GY,X,V4E]:)1MI2)+[;*J7;B,V4JA=5+GT7!BD)JYKDIBH4P<PU)5T^<
MRI2TBIS8???+*$FZAT_4PVI\^%YX@^(D]*Y@B^XK_ML P(+Q\)"!>YI9^(03
M==/E5.I$54C/L^@9P,J:.Y4!0FY<I;PL %/Y_$$;S<93FFM3F-E"I$9K;D%W
MRB_:0D*8.(N.,9'URA''#D93<D[I6< K;9I# S/0<A:.Y3.-B\2:",B*F"(\
M9LYR7C(;FMZJ?@(=^YKFH F%Y(2IM'81CBA-K;TP4S%;6=N%3(D!)_/]@1@W
M$J>RD#HEA@MAU"65$[*KVNR*'='K#:+A)EV:1@MGQ2CJBELKM2N:H+!C!CBL
MV(VC^/T;QF/1Z_>BP7;3@VCO9=.#MTPGC+L_8AL;C$SQ7U#@ 9@GM:X1]75\
M%(24Q77DD5SGPXD9I"V:,C&SI.?BV!"C>^5@+4*);@41Z@$EE0/DA$#4Q^H;
MR8FV-*U_DWTX9#1LA?-GUKC ]I4AR8; R#2MR[H(!0!>@)$_0TS;P46-=\%3
M'5R#(;KNI?"VUUW@*:V>9^)YVC\%H&<KKBZ9.-Z .=Z *:X Z'^H7&-9ASQS
M'N_P.JDXC0]UNR/B_?THQO]N/!A&_?=,FAA<WQ%)O!_UPL:P%R6\T1] $O>(
MMVI2AS,L/P?< S&=B&/4PVZPQ+Q.!K"Q"TN8#Z)]<18N>P3"4D-JEZO*B5X"
MV=UXQ 43]T%98!AAH1_UL#!D#AOTH&=)<HRSGP2\."6)]@/.?2AC8P@8O)%T
M!\W&L M+CX+$[4FC.04X'!JSY8PY&+"3#&%TF>1VF/8?IAR G7#L<@FLM8&>
M"Y*("O&;81N%F MK(N'RP)5:A3Y*Q2(*]$<9JC)@F]:>;V_YG_&_2& 5]IH"
M<T]9_!$/!H3\#SBPXAJT>H$R4<+COHCWD&V,]D3<1:(Q&B#M?1X,1=SLC<3R
M4L)S>HI6(KK@09/.9:K833PF4EP]X#6[E#ZMT[6C#%FO@X*VDWKN8$VO#WYN
M52OE0F1J.L7Q4VO*C:BN-+.:.'HRRT(7WD*V1T^!MBA)\FLJM#'<<<K 5O8W
M^%V&DMN6B?;F706&X#6M\?ZUEG2Z -9F5_ ]#=G';7*+,30U//SMLZ;VDOCZ
M^D G ,1HVX.ML_'*1IW.PK>$0Y=%D)H']WIU_;DR;E[I#^+-M\YGB4L=CZ:"
MIE#M1L.]5M,P5A-OJO!FGQB/IA"&.3ZYR+( ]J?&^-6$#UA_Q)W\ U!+ P04
M    " !HB4I6CUA"K%H5  #R/P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6S-6VES&SF2_2L(3<>$'5&F1$K6T3XB9-G:UHZOL-0S'SKZ U@%DK"+
M!4X=HK2_?E]F B@41<ER1^].?[%%LG#D]?)E O5R[>IOS<*85MTLRZIYM;-H
MV]7/N[M-OC!+W8S<RE3X9>;JI6[QL9[O-JO:Z(('+<O=R=[>X>Y2VVKG]4O^
M[G/]^J7KVM)6YG.MFFZYU/7M&U.Z]:N=\4[XXHN=+UKZ8O?URY6>FTO3_KKZ
M7./3;IREL$M3-=95JC:S5SNGXY_?'-#S_, _K5DWR=^*))DZ]XT^7!2O=O9H
M0Z8T>4LS:/QW;<Y,6=)$V,:__9P[<4D:F/X=9C]GV2'+5#?FS)7_LD6[>+5S
MO*,*,]-=V7YQZU^,E^<YS9>[LN%_U5J>?3[947G7M&[I!V,'2UO)__K&ZR$9
M<+QWSX")'S#A?<M"O,NWNM6O7]9NK6IZ&K/1'RPJC\;F;$5&N6QK_&HQKGU]
MYI9+VT++;:-.JT*=N:JUU=Q4N37-R]T62]"#N[F?[HU,-[EGNO%$?< ,BT:]
MJPI3#"?8Q=[B!B=A@V\F#\[XUN0CM3_.U&1O,GE@OOTH\#[/M_\(@?6FP.JM
M;?+2-5UMU&^GTZ:MX36_;U.#+'*P?1&*I)^;E<[-JQV$2F/J:[/S^N]_&Q_N
MO7A A(,HPL%#L_^XS;XSW:</'RZN/KS[>'6I3C^^56>?/EY=?/RO=Q_/+MY=
MJL%BC7(S!8N8Y=34T2J9:A>&'ESIZO;O?SN>C(]>-"I/!MHJ+[O"0.'*-*U%
M,)E"Z:7KJI9FU*M5[6[XZ_)6_309C0_4U):E!'ZI23K5NJW+$#RI55?G"\2F
M<G5A:C%L#JV0^3I=*C<M[5P3##281&/1/.]J;(NGQ"!; 9$PI*MIDIF:=@VT
MU#29WSIM(!5H;=M%7 'Q6'4S6JH.BS?=:E5:^@3<5.N%S1?I[A4VJRK70KK<
M )4*_G'N7 &! )EP&)L;K)ZN23/E>F5;"&1N('9A:<4H+;RU8ZA[QCHC#1/D
MV98<^P>VT:].$^O\WYUMK$ H/I?X"9 ,?4!-MH+%"&!)R;#ARM3M[4B=ENW"
M=?/%/<9!<-%V+3YA25-A;[G1T]+( F:N2[C!U%:D=G&NUM3+1L'%3<T_XA_$
M3"H*&W+%VX2GY+K*39E!,$IC15<:+TWQ%9BJ+-19&PA6&]$M 7NA,)9^"<97
ME3$PR*JV4)YWO\*44!1\!=)'>T%L3H]8D[X/"H0BBH(U1WO.[FA>C$N&PN1+
M_8V=#!I$*E6SCFP+Q"\1,*XR:J5O9:N\$5L7^*9FTV(F^I-6CL8ASRE+/74U
M>[T(7YAK).$530,CU!J0P5..U.<P>0?4KFFC,%?Z2*+ZJ<&^H8A.S(5]L>E<
MA=^ZE9.0TOG"8C5>"OL*4C4KD]N9-8.]:+;3O(//NOJ6M[I+K@[MF#JW\*RH
M!6P5N1ANU[2D; *6Q*LW%A4I^K'*DD41N) 0OCKE;5>8#F2F@8VF$$#0:4KN
MTG2YA'B?'<AS*5P\G!4!0#8Q;;215<YKMU1XQ+#Q\/_0%RS)<>W*:YE1JVM=
M6].RC^6EMDN$8JG730?G)$"ZIO4\G(EE(4X.7\6*S0 P&P.8$P"@"3)ZL !(
MP%$T -:VM]GV&,X2]=,CR(BD\*S'O,(VJZXEE##+5>G8?V0SCC4,?2!H8; S
M;_MHD2"*X!;+QYHM$*NUG8H29EW-TQ0&@TLX'>)]I"Y:-B),L')-8\F D!(I
MMK#8TIJ0G7&@:]E'>R>0S0"V2YI+]IF: 'A!L\X[#3E;8R1+T"] $%=VC"M^
M-/D+@0K!1:^E\K;W(X]74!QR6TM@!2CH=<ZK!XP&--9S%L/HNF(+DC* R 27
MT<7@4-B'+7C,.=)5Q9%QV>*+/CTP=FXX[7IA9 KP&HZ!!'MC& 1]^)P,=7A!
MAX&!Q4?JBIYK&@ D1YHEEWMFKG79\>9(.0C%G"8B-X0_65?P"C8!6BA%Z6O8
MEM>WE=07C%5]RJ4M65@HYX"NS-RU-OA]8]JV%-F!'UU)JH-A"X)>QD*OBZYJ
M*!/TGIFLQ=\",DA_*_%3'SDL18[-CM1'/$#.6 H?8(E[]V,_B3 ?<#LLWF#B
M)[T\@SU_[8JY_U,>GYF0=&6CP4509 #5C4SWE$0J"R20:YB!/!OZQ6 (;HB\
MF-G,D+JJK6RIYS6SZ$/P!]E^1KG,"P"W1UW#?(\0090NMH^P50%<R(M^FAR/
MQ@2T3-@P @'YK-4W\/B 4][-&;"),H[46P"3M_ M/+\!#R!WQX]C5@'^V,L>
MFFD-#R9DLO,**04>"]C][.'M?0RU]_W JR'D\N:K%KY=Z25!-P)/5%UH<FL"
MXJICHLM,IP"5*CQ&#C&T1[09D@V'+"&XZQK54'RR/#-34 )ECMEZ3:X ?@B2
MV6R#VIBY=RQHYY:,HM5,0[^W:BG,F]/TFJ(/P#R'\*6D@(+Y( \%9)7V?SRE
M*[3Z)\QEU65X_/*V 7!XKMJ0XY,*TLP#JS?LTK;Z"EL)SZ3@5 UA*\4&W*@P
M&DR8=2<NPP2(4B?M#$1II"XI?HB$,QI['?%P<>*6_9>0K0EH5YF;5J&67'(M
M*<J2$;6V1$W2C;+"/+F/H991$..A6W*RPLQKCBW63*]U'Q:]A"("MC>CC WB
MNG)UB,"\C=M[2)U$76: -0JB>X*0V1KG+0>7@C0%J"CY"3*K ! E';!FTP3:
MN3 :G#JGS(!1,T0PPPVANPOTD_#\CFAB!6L&2@S)=</58G30_H65AJW!]0HI
MC4T0<FF;VG!U6[7>S5:NQ0>R9FV;;TUX<@K?GED!DX?4A_CM P+".4XST-60
M$>F.9"##YQOY(N,D:&XT& DQ.'C6($YC\DDM2P 2#)Q1CD&I:)CKS&K=P>.G
MG.]I051=-=4%G,N65. 5:LTTF2A6AK#DZL)46'?1$R).O+1SRN'@[-U0TL:8
M;YSON:X@"<0NQ0,AN!32PB&XZBI+K2WH=:GG9@.E T\+I#X)%I^2!?/([?1<
M$[7VCPHU&\P673C0@6!2TD!N5\)HD*;H>V9.UP'D5WX-\<"4":1I70IKL#57
M5^962 V-YKWH*@ G):]R@^;%%;;PRR2K>GA<4K<.3 MHDHD2:#A7#EZ[Y'+$
M3?P 9JBPE\T)Y'K6V7-)?"\Z807 =1W2*RF$91*=/I [$C:\U%1FQ=S.P8>T
M3NF*-E.E5,T+[[-9;QBIW?.Z(Y20#L%_CC;$A@!9P)"^=<J6A4V)/D39GJQ6
M"+G<-!$YO,P4+,CZE-W,C6W:YDX]U7D:[GJ%"$!YVB8A"8I%%2ZSQ4>NQTB)
M!:B*H[J9 "\E&9\J]=\=RO7]/>J-C8\R]0[/0U?J_?NS_L.[JG#/+B5#9NJB
MRD?B1^'W7R_I>?6$JGC#C6MJ() ])GLO_$/\:?SBJ<^HFHH120 <-BO9&]@N
M$2VIBI, 3V@<?_QU=#FB]J=@YAFQE!A]\6ON_L%C$0P^GX0E,U^'KW7#_0\)
M[70=1YJ!*X\G03,"<\V=_!/=CK3T+X1H2W4.(%TJ_[H+3461#.M%@I&HQJ?:
M5CH<0;&249JA6C"0Q??F_.@PX"1[?OP\.WQ^_$(=9P=')]G)X<D+?#L>[V?'
M1P?T[<G)<;8G#YR<C+/#HR-Z8._X(#O<&[]@>QYGA^/#[&!_3 4@1_>@4T=Y
MG6DP]R-K4=JGO'5$\KB[.CY.BU4RBFV:CLWM.UL\G#IK-#;V9B?',GI$'OE!
MUS#-1%SR)$LFFW.Y6VS5_@<7NFG0_FV$5\#/!<;4T%9->>6+N:;#%SPV)9Y2
M^A@Q09M7-4C$4M??6([3U<H0(KUQNF:&4<MP,50 1>*0]B9$(=FW"J:DZI_$
MG[IK ;EKG>L@0D\E6>[3;D[Y>/RPW+Z/%AC35T<1!-1844?*:V#I@,#29&Q(
M&0B:DC/(%I]C5V(55=I7A:P#::4S<U-/?"C_>GEQ=18#N0_@$*B8II/D+ATB
M,L =5XW^R?J(+IHQ9>L:2K.^?W(5X#<I?ERBM>!3Q( Y]FWC>R>I/B='P3-#
M5 4$:@QEA?\H$'T?50"[AD[TU.%>P)4$3&:D[#\928X!"?L$'T?9P<E>=G1P
M0IAQN#?))L?'_9]'+[P!]R>'V='1WI#(>1U3SZ)9<V>LXN*&&BF!JL58)V\7
MG]\TD8]JTNA[P^674^>66D#XKX9)3I=2B9_UT%Z;I;OV:T7V&+H3&#\4>=1+
MX'ONQ:/'BKH.H*ZC$P^@WK='DEHI@1S=C6>J06I1CV!AT(YD<4@D=)RH&&@C
MD;>O*!ERWPID.(A,]1%XP"#0^H**/)<8'-4^-54I*3JP2U.4#QNW#\6SUX"/
MY^@S?W(\OPG\NQ][3S_N7FZUU-_,D,FE=<%6CF5\5[2B1C]2.RF B^U!H]9[
M\FV@45O\N _X0*]%S9D/3)KX\:$9 =E;'5\%5$ZB=O,I?-4_U?OMYEQ'@Z<\
M.F\^A:_ZIP:>O_GD2;^W4>2;/M_[H!"'NW8^Q@AJ;=MQ5;#AAD\H7O?WCYY=
MG3X;CP^/GHHZP>-75 _X]H.O2QBAN8/L=>^;P2 OC723J;CICWL?YG1DV_[3
MP?.L1V;Z0#K8!M5D8+4VU#YN0D)F;@A0<9HZ2S4"H.!"^*+G/L1^@@\ACB@1
M4ZL.N_7"X8?<U%5 @=[$'OI%5D,=&^IQH%0/Y*UU[ANU7G)&@G,S1=&%GZF5
MF=*O0SXM'V=]EHL,B2NQR(X\.0IF_WQU^B92A,C^SKD$ANX0,,S[;".PXHFX
MI:S9>>:8VB^*1J[J<[.$#,U[7UZ&U<6I^J,F3_G@3[JT1>^*QZF<9PMK9NJT
M6-J*<K=F+O->K_$H3!3%(4YIN7/TUM#9B:U\L]<E9P'(YT_&3_U1WX;+%<Z?
MS/DTWOI#"I9JJ_@4@T"G/JA"BG^AGDR>/G(",MK=&;A9X/6"V?:'>XY.W03R
MP5FR[Q?<<>1$K+4+F_&YI0<LOSH6//C_6/"H7Y"F>_+\Z<!KJ!"D@U=XM&^G
MTK&4KR$B-WM8PZF'UHFGA3@.UQ?R!9&+:NX)_797\K@V]W6'M*(K.3.5IL.4
M^E4FX=R.$U72K)'AD5=X_?8@]F@%<[3$0N]@@ Q"%B0P")\^K1 [&Z&]U!Y>
M9XYN0G#/6([ ?HXQ(A-YJ8I$++;&0X+U#IXEWIVEWKZ?Q@O;?Y*N&J!'2V.@
ME,UN=T3\8NO'NN,/^ R?U9&+-%VS$D[KSQ.=O\_B[4N70 IR&*&.2:'KO.H#
M0Q'8%LJ)P1ZN0W5R[H]XSFR=0]7TQ'IAN-.>U,,D<E\3?Z*.(I4OX& Y<; >
MM+?*:4,EL@5]B3!-]M,[63^T78VM\"D"_8C41O>7%"6?^W,-KZTC<WZL9:@9
M$I+GU& _YL=W2X:=&FQG2'$EUTH*@BJHU;91R&F9-Z7F\3<?:MA?%3NCM6^Q
M_*&9?-?5'XWQF2)2UL).O0-6[(YUNPDI,5(23N5!B[4$22M#G4K;BOKI[JNN
MR7>:/TKM"V<$3E%<T#T:%>] "''?Y.NQEL#B)&32L1["VTEP2:V^=C7%6R77
M#[2"BOGJQC;>0=4]!^)/X[UXN@P5^F,."H OYD9]H#8\W5)Y/_H\\BK>TG'P
M??;-(VS*2#R5-R:?3P4'Y_:2G3OHM:$F/!^4,"8'"/E+Z/JLORDU[$3W5#26
MS%\H)R/>OKBI:VW><)N9Y(P_F)4&''/WV1-0_],#_68?Z!\=GRM6@S[->>F
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M$>NC9*RFN?,E4OZ(?0?)=@/'\=*QM_<.E\?AMQ#\UG#J^P)\^0:T[LQ5324
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M&PVS]!\R\ ]20:Z-]?4-K$3X(2TFTL-<W8(C-VN**=N?:U^1,)A6<1#DTL.
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M4@BBI0%XOC0HWOB#%FC^W?3\/U!+ P04    " !HB4I6G>L0M,X#  #;"
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M+W=O<FMS:&5E=',O<VAE970R,2YX;6R556UOVS@,_BN$=S=L0&L[3KHKVB1
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MEM(^-@2 5TV;@^HP3JM?-@)!GKDK,P3X,:!*8\D73Q,5-C@PIBQDH8 +<(0
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ME:.O""/CR4_F+S+ X.BZEJ44: 3 2S&59DD&EYSQE9C?P1D+S&S7%6"-7H6
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MTMVRU"94*&3*8C@P#<BP:\D>\W *,532-;.,?1-IR[46Q!XG%M//GF<[P9X
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M?\%Q'?[5..2X7V4_PDJM%+B^<,NU;["X3577K+F0XR:"7E[R#0KD_O Y=5/
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MA&AH_=W@WR?PUJ^49 73/GY*BSE_A!VD_Y(\>4:K6?,Z'M-O9[S.!X]69Y&
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MN\>C@19UL1\ +LY>HFIZ=-JV3+9<M/^061;F+LG:\79+V*7^:5X:=NVEAI3
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MAU$O@_Y[V6U^1PX'^'5AVE5C<:,O$5):_GL'-B"#8X:0U\NS!XNI-2@EK\^
MDO\CZ^P1,JZF3\B(C4IDH,=JVE28S-:914YID8A-6(SM\4WUKK59#*('ZNGL
M)P3L.>0;JD?!@F=/DRW;LQ0?T."T'=:.V+_.9[AV(A<1;URQ[]?/BD)+9I0S
M.I3HA%0S1B6 <F&4;U%\!]I!."OM=,7="*?6;E&W4Q -_Z<3BA=P;P2+)^7;
MKW75;0H:9=,RPE&#9U*D$*Z_84X0'/)/!I9 ,N\HW><N-+,>[ZK6+.,F:4)
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M \P8G/5N?W3_KB\SO="'%33ST+:[.80AI*DG?+@9AH0BPA4A_6Q.^LX,,;,
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M #M8;;YWF9LRW_(WIGE>EOF&+]=H,4J3 ,:7>5[6-S1!\]'QYK]02P,$%
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M0]'$,YTB@=IPT,>'YF5<[/?_+$U'$S8+(_Q^X=D*!$+E?,[824J%-YE/H>2
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MN\U)+R)M%X&9<6)*FK&S'E#?,'W/>N<OGD63\&6'@6EC8-HE'0PT1ND!N:,
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M&?W;0,,'Z/M2:[=9L('M_Y?I'U!+ P04    " !HB4I6!GAH2!,(  !%%@
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M=?4"ZLY:>>L.^MCTK55O\K([C7=MK3[-5;OV^EU>9N4RSPKPOFS:>JO.4-N
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M/U15^_5%]],=^Y]JN?X34$L#!!0    ( &B)2E:=V<]5M@(  'D'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+6546^;,!#'OXK%JJF3UI! @:0C
M2&FS:GVH5C5K]^R0(U@U=FJ;I-VGW]FD*%-(-$W="]CX[G^_.Y]-NI'J29<
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M&%8<AJT</L 6. DOFM;7:OG<X.L(K$9R5)$<O>XQ'76I5$=@-:7&E5+C]G#
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M)"P56_X:K,,H X<PWE-3-8ZW\(I;Y-/080X]Z#ID-C[4\]3-2.#YSJ0R:V1
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M[ARPR*#:1<8=>FQM-(56);IE4^!E+S1Y?DVIV1!:54U4JHF.7&R,[=21L?G
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MZW1QN @]#!3?YG>)CUPIGN2/&R Q"!.@YU><JZ>!N9XLKZ,7_P-02P,$%
M  @ :(E*5NEI%PZ^ @  1 <  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&ULK55=3]LP%/TK5H8FD*#YZA<LC02MT'A@JNC8'J8]N,EM8^'8F>VV\.]W
MG80HT+1BTEX2V[GGY)SKZ^MH)]63S@ ,><ZYT!,G,Z:X<EV=9)!3W9,%"/RR
MDBJG!J=J[>I" 4U+4,[=P/.&;DZ9<.*H7)NK.)(;PYF N2)ZD^=4O=P E[N)
MXSNO"P]LG1F[X,910=>P /-8S!7.W(8E93D(S:0@"E83Y]J_F@YM?!GP@\%.
MM\;$.EE*^60G=^G$\:P@X) 8RT#QM84I<&Z)4,:?FM-I?FF![?$K^VWI';TL
MJ8:IY#]9:K*),W9("BNZX>9![KY"[6=@^1+)=?DDNSK6<TBRT4;F-1@5Y$Q4
M;_I<YZ$%\/L' $$-"#X*"&M 6!JME)6V9M30.%)R1Y2-1C8[*'-3HM$-$W87
M%T;A5X8X$T^ET)*SE!I(R2T35"2,<K(PN(";9<@,#&5<DPMRG21R(XPF#Y
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M(U V =^OI#1O$]OONNLM^P=02P,$%     @ :(E*5OS;P&#* @  < <  !D
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M)7TWT2&)IE=I!HK7]O1><*5[ 7N[TNT=" /0STO.U6Y@7M UC.G_4$L#!!0
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M9^SUU&6((Z[GC0.SO'#'8F)K)8OGHKS[QAJLF<?>?5 T!H6FLT84:^1$BFJ
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M@P?"&.C]&>=J.S$'%"UC^!M02P,$%     @ :(E*5K+>W&Y7 @  Q04  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULK51=;],P%/TK5V%"FP3-9\<H
M::2N%1H2DZ95@P?$@YO<--8<.]AN,_X]MI.&=NO&'GB)O^XY/N<Z]Z:MD/>J
M0M3P4#.NIEZE=3/Q?9576!,U$@UR<U(*61-MEG+MJT8B*1RH9GX4!.=^32CW
MLM3MW<@L%1O-*,<;"6I3UT3^OD0FVJD7>KN-6[JNM-WPL[0A:URBOFMNI%GY
M TM!:^2*"@X2RZDW"R?SQ,:[@&\46[4W!^MD)<2]77PIIEY@!2'#7%L&8H8M
MSI$Q2V1D_.HYO>%*"]R?[]@_.^_&RXHHG OVG1:ZFGH7'A18D@W3MZ*]PM[/
MV/+E@BGWA;:/#3S(-TJ+N@<;!37EW4@>^CSL <+D&4#4 Z+7 N(>$#NCG3)G
M:T$TR5(I6I VVK#9B<N-0QLWE-M77&II3JG!Z>P6M\@W".]AV;TCB!+F@FMI
M$@PSI5 K(+R KY2L**.:HH+3!6I"F3HSL+OE DY/SN $*(=KRIAY')7ZVFBS
M-_AYK^.RTQ$]HV.!^0CB\!U$010=@<]?#P\/X;[)R)"6:$A+Y/CB?Z2EE*+^
MFXZ6Z@KF[E%0PH_92KG]G\?L=OS)<7Y;FQ/5D!RGGBD^A7*+7O;V37@>?#IF
M_C^1':0B'E(1O\2>#>Z)^QF.>>T(+AR!;1O;+!FG_G;?01<RW@\Y'WT<@@Z4
M)8.RY$5E"RQ12BQ,-W&O=4Q:\O3>^&(4/U*7/#40)H_$^7M%9AO<-9%KRA4P
M+ TJ&'TPE\BN:70++1I7=RNAS0_CII7ILRAM@#DOA="[A2WEH7-G?P!02P,$
M%     @ :(E*5HJSJ[B  P  SPT  !D   !X;"]W;W)K<VAE971S+W-H965T
M-30N>&ULO5?;;MLX$/T50ELL6B"Q;KYF;0&QU:(!&FP0-^U#T0=&&MM")5)+
MTG;Z]QU2LBHYLNMMW?K!(JDY1S.'PR$YWG+Q1:X %'G*4B8GUDJI_,JV9;2"
MC,H.SX'AFP47&578%4M;Y@)H;$!9:GN.T[<SFC K&)NQ.Q&,^5JE"8,[0>0Z
MRZCX.H64;R>6:^T&[I/E2ND!.QCG= ES4 _YG<">7;'$209,)IP1 8N)=>U>
MA:ZC <;B0P);66L3'<HCYU]TYR:>6([V"%*(E*:@^-C #-)4,Z$?_Y6D5O5-
M#:RW=^QO3/ 8S".5,./IQR16JXDUM$@,"[I.U3W?OH4RH)[FBW@JS3_9EK:.
M1:*U5#PKP>A!EK#B29]*(6H MW\ X)4 ;Q_0/0#P2X!_*J!; KI&F2(4HT-(
M%0W&@F^)T-;(IAM&3(/&\!.FYWVN!+Y-$*>">]@ 6P.Y)'.:@KQ47W,@E,7D
MWQP$50E;DG> NI*=X<L0%$U2^0HA#_.0O'SQBKP@"2.W29KB3,JQK= OS6Y'
MI0_3P@?O@ ^N1VXY4RM)7K,8XB:!C0%547F[J*;>4<80H@[QW0OB.9[7XM#L
M=+C; @]/ASM'HO&K.?(-GW^0;P%"0%S-P;40E"T!EY\BG]ZA-;E1D,G/;=(7
MU-UV:EU5KF1.(YA86#8DB U8P=]_N7WGGS;9SDD6GHFL(6FWDK1[C#THDOV]
M3G:3WA=EEM^PB&?8FRNJ"GWYHAPD7) 9S]"9E2Y[FYTQ^?3Z2>F1QQ0P@=>9
M63><M<[&<:_><T53K*9FEMOT_S5X^-/PAL:]2N/>"1J;@I(:<0][-BV8>H9)
M;U6;P.WU.]VQO:F'_]S*\YR.W[0*V[BZ-:Y&,/TJF/[18/;*X9_*E^-._3!?
M?@T>_C2\(?&@DGAPHL0_3)?!LRGV!_U.;R]=GEMY:#7:2Y?G5BY:#=K395C%
M,CP:RP<J$JHGN+%Y7I 'B8>IRRF.Q?4JWKII'OW"_ZW<YR0+ST364'94*3OZ
M?9OAZ)R2GI,L/!-90U+7^7X(=,ZU]$JF87V]^'LE>%8:U1?58-AQ1O7?WC)L
M@7B#VI(N(K-K)UTLG$MS8Y DXFNFBN-A-5K=2J[-67QO?*IO*^8$_9VFN.K<
M4K%,F$0E%DCI= ;HDBAN#T5'\=R<IQ^YPM.Y::[PQ@5"&^#[!>=JU]$?J.YP
MP3=02P,$%     @ :(E*5A>MV=#6 P  Y!$  !D   !X;"]W;W)K<VAE971S
M+W-H965T-34N>&ULM5AMCYLX$/XK%E>=6JD+&!*2["61MEG=W4KM:;6K[7TX
MW0<')HE5P)SM).V_/QM87H)#=UOR);%AYO$S+\P,S(^,?Q$[ (F^)G$J%M9.
MRNS:<42X@X0(FV60JCL;QA,BU99O'9%Q(%&NE,2.Y[J!DQ":6LMY?NV>+^=L
M+V.:PCU'8I\DA'_[ #$[+BQL/5]XH-N=U!><Y3PC6W@$^93=<[5S*I2()I *
MRE+$8;.P;O#U"L^T0B[QF<)1--9(F[)F[(O>W$4+R]6,((90:@BB_@ZP@CC6
M2(K'?R6H59VI%9OK9_3?<^.5,6LB8,7BOVDD=PMK:J$(-F0?RP=V_!-*@\8:
M+V2QR'_1L9 -U(GA7DB6E,IJG]"T^"=?2T<T%/#HC()7*G@O5?!+!3\WM&"6
MFW5+)%G..3LBKJ45FE[DOLFUE34TU6%\E%S=I4I/+C^"\H% 5RA?H <(@1[(
M.E;7WMZ")#06[]3=I\=;]/;-._0&T11]HG&L0B#FCE0,-(X3EJ=]*$[SSIQV
M"Z&-?/P>>:[G&=17+U?';75'V5T9[U7&>SF>?P9O13(J25S8'J$;(4 *],]'
M)8;N)"3B7Y.)!>;(C*D?NVN1D1 6EGJN!/ #6,M??\&!^YO)X(' 6N;[E?E^
M'_KR#\Z$0'$>>%X'WF1S 33.@71E."Q'HYD]FCN'IC&%U+0IY=8R+8ZCBN.H
ME^-3"H2G*C@T#5D")FX%P*1QZA4>=;B9I+!]AMVX8C?N9?>X7TNF,LA$J] ,
MFL[PQR>DQAU2_LRS S.IH"(5])*ZB55M)FD(2%5Y%'*(J$2Q"K6)9=!A>>6?
MD RZGO//<9Q4'">]'/]2#8JF!Q!2M02]1(*HU+N2WS(H,M+(=F+PJ7="MROC
M3V=FMM.*[;2W3CQ QKA424C$M8G6=,B*,!!8R]!99>CL$F&9O2 L79FS8<%N
MW;S<7K[W'#)"(X%(&B$F=Z#R?<^YYD[R8FYL4;V8KPW74&AM#S3:-[Y "RM!
MAW+!0&AM%]1-'/<VR1]-VA*U6=>PC^W3O#6)8=?VSZ1NW7NQ_U,U!??V[E>'
M:""TMK%U$\?]7?Q'0]1MVL80&<1Z0E0W=]S?W>]22=(M53-1H[X4=>4]2D$:
M*?="OCIL Z&U'5 /$CBX1''I'4]>[8*!T-HNJ.<4?)%!I41M37:N:T]/,[<K
MYDVF]N1,YM;S"OZY@04/.K$,A=8VMIY9\$6&EA)U_+T0=<5,(7(:K^#Z^\<G
MPK<TU6]7&Z7GVA,%P(M/"L5&LBQ_*U\SJ=[Q\^4.2 1<"ZC[&\;D\T:_Z%<?
M=I;_ U!+ P04    " !HB4I6;38"=H4"  #*!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6R%E5]OFS 4Q;^*Q:JIE;9 ($#2$:2VT?Y(JU0UZ_8P
M[<$AEV#58&:;I/OVNS8490M)7H*-?<_O'!,NR4[(9U4 :/)2\DK-G4+K^MIU
M559 2=5(U%#A2BYD235.Y<95M02ZMD4E=WW/B]R2LLI)$WOO0::):#1G%3Q(
MHIJRI/+/+7"QFSMCY_7&(]L4VMQPTZ2F&UB"?JH?),[<7F7-2J@4$Q61D,^=
MF_'U[<SLMQN^,]BIO3$Q259"/)O)E_7<\8PAX)!IHT#QLH4[X-P(H8W?G:;3
M(TWA_OA5_:/-CEE65,&=X#_86A=S9^J0->2TX?I1[#Y#ER<T>IG@ROZ27;?7
M<TC6*"W*KA@=E*QJK_2E.X>] M\_4N!W!;[UW8*LRP75-$VDV!%I=J.:&=BH
MMAK-L<H\E*66N,JP3J=? 2,I\IXL\7&O&PY$Y.1.5%KB>364DWNJ&\DTPTVX
M\DD*I8@M(H^0 =O2%<>ERP5HRKBZ(A>$5>2><8YGKA)7HT=#<K/.SVWKQS_B
M9P'9B 3C=\3W?)\\+1?D\N+J7QD7(_8Y_3ZG;W6#TSE_WJR4C?9KR%HK,1F6
M,*_'M:II!G,'__\*Y!:<].V;<>1].&$PZ T&I]13S!L,>6JK0EMEWK!M.@[B
M49BXVP'8I(=-SL$F0["V*MZ'^=$H&(:%/2P\!PN'8.$!;!8>"Q;UK.@<*QIB
M10>LR#N6*^Y9\3E6/,2*#UAXAD=R37O6]!QK2FBU)KH [+VY!CF$GAZ@@V,I
M9SUY=I+\36C*AUBS@S_F9#(;3?ZCN7NMR73Y>RHWK%*$0XYUWBA& =EVSG:B
M16V[U4IH['UV6.#'!J39@.NY$/IU8AI@__E*_P)02P,$%     @ :(E*5G'#
MXH9Y @  L@8  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULA95A;YLP
M$(;_BL6JJ94V(! "Z0A2VVCJI%6+VG7[,.V#DQS!JL',OB3MOY]M4I0M;O(%
M?+;O?>[%<.1;(9]4!8#DN>:-FG@58GL9!&I104V5+UIH]$HI9$U1AW(5J%8"
M7=JDF@=1&(Z"FK+&*W([-Y-%+M;(60,S2=2ZKJE\N08NMA-OX+U.W+-5A68B
M*/*6KN !\+&=21T%O<J2U= H)AHBH9QX5X/+Z['9;S?\8+!5>V-BG,R%>#+!
ME^7$"TU!P&&!1H'JVP9N@',CI,OXL]/T>J1)W!^_JG^VWK67.55P(_A/ML1J
MXF4>64))UQSOQ?86=GX2H[<07-DKV79[T\@CB[5"4>^2=04U:[H[?=X]A[V$
MZ*V$:)<0V;H[D*UR2I$6N11;(LUNK68&UJK-UL6QQAS* TJ]RG0>%E]!6U+D
M([FCN)8,F0Y$2;ZU("FR9D7L!C*C+_HD4)'S*2!E7%V0,\(:<L<XUP]7Y0'J
M8HQDL-B!KSMP] 9X"@N?Q(,/) JCB#P^3,GYV<6_,H'VTAN*>D.1U8V/&_IU
M-5<H]9G_=I7620S=$N8[N%0M7<#$TR^Z KD!KWC_;C */QTI,.X+C(^I%]IO
M[*JIR\ILEOF4-D4<AGFP<:"&/6IX"C5TH;JL= \5):&?N&%)#TM.P1(7+#F
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M3 ?6WAE\9[#2&VMBE<RD?+*;FWSL!38@X) 9RT#QM80I<&Z),(S?+:?7N;3
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MG$F#W=<M2QRHH*P!?I]+:=8;ZZ ;T<D_4$L#!!0    ( &B)2E9XON(NLP,
M +X-   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+57VV[C-A#]%4)=
M% E@Z^Y;:AM(G%TT0+8-UDWW8=$'6AK;Q%*D2E)V\O<E*44K)XJ<+%P]V+K,
M')USAN10TST7W^460*&'C#(Y<[9*Y1>>)Y,M9%BZ/ >FGZRYR+#2EV+CR5P
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M5=0"UP-4_X(Q^=S095-5)B?_ %!+ P04    " !HB4I6U0=MF,\"  "O!P
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M&8#W9T+HYX;9RJN36_074$L#!!0    ( &B)2E:,]0J6V0(  $\)   9
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MM88Q<&Z%,(R_I:93+6D==]M;]>\Y.[*\4 UCR7^QV"0C9^"0&.9TQ<VCS'Y
MR=.U>I'D.G^2K+3U'!*MM)%IZ8P1I$P4;[HI]V''P>\<< A*A^"]0^^ 0[MT
M:.>@160YUH0:&@Z5S(BRUJAF&_G>Y-Y(PX3]BD]&X2Q#/Q..99HR@Y_%:$)%
M3,92&"86("(&FER1FSAF=K\I)W>B^&GL[I]/P%#&]06:/#]-R/G9!3DC3) I
MXQP-]- U&)U=PXW*2,9%),&!2/R 3''Q1)-O(H9X7\!%K(HMV++=!HV*#Y%I
M$?_+)0F\(*@+J-E] E&+M/TZ][UPVM56MW.]]@&]>ZGUN_W]?8\VY,Y JO_4
M!'A;"';J!6V"7^LEC6#D8 9K4&MPPL^?_)[WM8[V1&)[[)V*O=.D'CZ8!!2)
MWGZV.MI&B6-I"[%!+F:/LG48^!UOZ*YK*+H51;>18J;@RM -X9@2BR(1HH2J
M!=3B-&H=BU.(=7=Q!BV_'J=7X?0:<1YA0Z80LXCR2W+?FK7J*!HECJ4XD=@>
M;;^B[9\Z_?JG9#^1V![[H&(?-'[I"4VQ).,)GU'UX6PM6 <?\L5_RY:"H'&-
M8PG<G9J5 N:0+>4:CXB5,$7YJD:KV\)-7B3=-_/BJC'%%&1"$PYS=/5:?4P3
M593OHF/D,J^ +])@/<V;"=YX0%D#G)]+:;8=NT!UAPK_ U!+ P04    " !H
MB4I633".C&P'  "430  &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6RU
MG%MSHS8<Q;^*QNVTNS.)#?B>)IY)PIWN-+/IM@^=/A"CV,QR\8*<;/KI*RXQ
MQL:RV9SDP0&L\Y.$=9"0_G#Y'"=?TR6EC'P/@RB]ZBP96UWT>NE\24,W[<8K
M&O%O'N,D=!G?31:]=)50U\M%8=!3)&G4"UT_ZLPN\V-WR>PR7K/ C^A=0M)U
M&+K)RPT-XN>KCMQY/?#97RQ9=J WNURY"WI/V9?57<+W>AN*YX<T2OTX(@E]
MO.I<RQ>.TL\$>8J_?/J<;FV3K"H/<?PUV[&\JXZ4E8@&=,XRA,O_/=%;&@09
MB9?C6PGM;/+,A-O;KW0]KSROS(.;TMLX^-OWV/*J,^D0CSZZZX!]CI]-6E9H
MF/'F<9#FG^2Y3"MUR'R=LC@LQ;P$H1\5_]WOY8G8$LBC P*E%"B[@N$!0;\4
M]'<%@P."02D8G)K#L!0,3Q6,2L'HU$J/2\'X5,&D%$Q.K?2T%$Q/%<C2ZR\G
MG5IM>?-C%XVN:"5Y$U-=YLXND_B9)%EZSLLV\G::ZWG+\J/,4O<LX=_Z7,=F
M]RR>?UW&@4>3]%>B?5O[[(6<DVO/\[,F[P;$B@KC9@;XH%+F^D'ZD2?Y<J^2
M#S]_)#^3'DF7;D)3XD?D2^2S]&SKP"<_"+@TO>PQ7MPLT]Z\+-I-433E0-%D
M\BF.V#(E6N11KT&OB_7*,;TAUO>/Z<TCY1<5H,=_I\V/I;S^6#>*D*C2>9?T
MY3.B2(K24*!;L?R/.1/*5;'\GJZX7#HHU\3RZ_5"F+O^MMR-MYTZ\VURZW2Y
MW""W3Y=+#7)'++?709=(C86O-</^YIK1SWG] [SB*G%&;@,W34G\2/[DG7FZ
M3EY(?C4A__S.!<1B-$S_;;)]01\TT[,QQ$6Z<N?TJL,'"2E-GFAG]LM/\DCZ
MK:G)(V$J$J8A83H29B!A)A)F(6$V$N: 8#7##3:&&XCH12?-!["K=3)?\O$C
M627Q(G'#,WXL&S;[T8*X:[:,$_\_ZA$WC-<1:W)>D<TDSR8;;#_-Y*%4_EWV
MGK9])2Q16U\A81H2IB-AQNFGUSP]J84LHHV$.2!8S1/#C2>&0D]<+Q8)7;B,
M<@]XZ^+^C \WYW$8\JTT=XP;<3-4(]F5ZWOG61IWY3.^[ZV3S#GICKL:AZK"
MPK3MLY P%0G3D# ="3.0,+. C;;<=Z[(<J/[AGM&W4EA[Z<XGS2A'% 5:G89
M;>PR$MLE[Q,(;^#)@G<1+.8-GM_*17R;NDG6@Z2M_"#,K:T?D# 5"=.0,!T)
M,Y P<]3@A_YTU&B(T5%#[*<XEY5&F .J1<T2XXTEQF)+K!?KE)'K^\_DKAA/
M-35T(:-M0T?"5"1,0\)T),Q PDPDS$+";"3, <%JMIIL;#5YU]F!"=)P2)B*
MA&E(F(Z$&4B8B8192)B-A#D@6,UPTXWAIC\X.W#2G( 0WM9O2)B*A&G3_1MN
MJ?F&6T?F:R!A)A)F(6$V$N: 8#4WR5*U(B8)_61%/O/SZ8*7D/)[IL<X*=:S
MCMT3B;EMK02EJ5":5M+J0_Q#=H)F;4!I)I1F06DVE.:@:'53;2TSR^).JE@0
MKASDD0]^5*X3?VQTDQ#8VDU(FEK2QMN]25>NMWNM(5&_.]PUQWZB07=43V1
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M@KCI/@S[P$AGBP@EJB1E-\!^?$E*D65'5F) W1=;I.YY[NXAC^)--HP_B01
MHN\IS<342J3,KVQ;1 FD6 Q8#IEZLV0\Q5(-^<H6.0<<&U!*;<]QAG:*26;-
M)F;NCL\FK)"49'#'D2C2%//G&Z!L,[5<ZV7BGJP2J2?LV23'*UB ?,CON!K9
M-4M,4L@$81GBL)Q:U^Y5Z'H:8"R^$MB(QC/2J3PR]J0'G^*IY>B(@$(D-056
M?VN8 Z6:2<7QK2*U:I\:V'Q^8?]HDE?)/&(!<T;_)K%,IM;80C$L<4'E/=O\
M"55"%YHO8E287[2I;!T+1860+*W *H*49.4__EX)T0"XPP, KP)X^X#@ ,"O
M /Y[ 4$%"(PR92I&AQ!+/)MPMD%<6RLV_6#$-&B5/LGTNB\D5V^)PLG90K+H
M*6$T!BY^0Q^^%40^H]_10NVON*" _EHB8X+N(2]XE"B)T;5>*R()"'0:@L2$
MBC.%>5B$Z/3D#)T@&XD$<_6:9.@A(U*<-R:^)*P0.(O5Y(D>WQ)*U0X0$UNJ
M?'14=E3%?E/&[AV(W?70+<MD(M"'+(9XE\!60M1J>"]JW'B=C"%$ ^2[Y\AS
M/*\EH/G[X6X+/'P_W.G(QJ_7UC=\_@&^<C7/T9QB(1!;HB_J9! %?ZZ6])_/
M"H ^24C%OVWJE^Q!.[L^D*Y$CB.86NK$$<#78,U^_<4=.G^T*=<G6=@3V8ZJ
M0:UJT,4^^XII 5K-:DOSNC!B=*KV<\PHQ5R@''AI<M:F;>GCPOC09_-ZY@V=
MT2"8V.NF:IVA'*O::Y^N'PS\VN6.'!>U'!>=<LQ9FJKSV^RHMD0[T<=NHC[)
MPI[(=E0;UJH-?VII#OM4M4^RL">R'55'M:JCSKVX:*_(LE!;R[#D&S9+PE57
MIKTJ[/1ZK$"O78X:#G?R'M=YC]]=@\T/]1UG*XY3]!]ZJTH[^8_=3WV2A3V1
M[>AZ6>MZ^5.K]+)/5?LD"WLBVU'5=;9W3J?G.JT(WRK4%K,]D[#%Y&#]N8U;
MM-N9T?4:N&J34,Y)!-M/_Q$7@LJ!#F][)?#]P6@_Q=)NW)5B"Y4[]@?CX$":
MWC9-[W^X^U1.WKS\5':=J;ZF:KO3V(T&*06^,HVF0!$K,EEV!_5LW<Q>FQ9N
M;_Y&-[FF\=K2E!WR+>8KD@E$8:DHG<%(Q<3+IK,<2):;-NR12=74F<=$->K
MM8%ZOV1,O@RT@[KUG_T 4$L#!!0    ( &B)2E8X@VDJ/08  %\C   9
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MLO5M_LG\XR"9S?+7KM_=9?DQ%GNZFU3'\[$\'NW,\:B:$BP7V?-:,1;3>-H
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M:CZJ!:@64IH8. =E.E4:.)_S1,E#H\B7+]OIV&TI3GGS^<O7]6^-D2'UVG9
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MH9J/:@&JA90F!HI6!XKVRG=_>^A*N*BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M:.@/L>)+UV"YB1:5;6I>A<86R;YNL"D%:3;@^DH(?9@8 TV;F_X+4$L#!!0
M   ( &B)2E8C[2]O- D  #Y*   9    >&PO=V]R:W-H965T<R]S:&5E=#<T
M+GAM;,V<;6_;.!+'OPKA*PY=("N+#Q*I7F(@:7=Q"VQW@P;=?;&X%XK-V$)M
M*R?)27NX#W^4)7OD-4E+E'SKOFC\(''^'(WGQR%%7;^FV9=\(66!OJZ6Z_QF
MM"B*YW?C<3Y=R%6<>^FS7*MOGM)L%1?J;38?Y\^9C&?;DU;+,?']<+R*D_5H
M<KW][#Z;7*>;8IFLY7V&\LUJ%6??[N0R?;T9X='N@T_)?%&4'XPGU\_Q7#[(
MXO/S?:;>C?>MS)*57.=)ND:9?+H9W>)W=]@GY1G;0WY+Y&O>>(W*OCRFZ9?R
MS4^SFY%?2I)+.2W*-F+UYT6^E\MEV902\N^ZU='>:'EB\_6N]1^WO5>]>8QS
M^3Y=_I[,BL7-2(S03#[%FV7Q*7W]IZQ[%)3M3=-EOOT?O=;'^B,TW>1%NJI/
M5@I6R;KZ&W^M/=$X@9E.(/4)6T>,*T-;E1_B(IY<9^DKRLJC56OEBVU7MV<K
M<<FZO"P/1::^3=1YQ>1A$6?R^SO5KQEZGZ[4U<[CK;N^1[]NBKR(U[-D/4?J
M#_KAJ\RF21X_+B7Z];D\*$>?XO5<YNCM!UG$R3+_#KU!8Y27;>8H6://ZZ3(
MKQH??$R6R_+$*W5@X^WUN%!]*16-I[7NNTHW,>C&!'U,U\4B1S^L9W)VV,!8
M.6'O";+SQ!VQMOA!3CU$\14B/B'H\\,']/;-07^J/Q9+=.]SNK5$K3Y_//+Y
M%7JH+-UNBD6:)?]1WV]4[S+T4*33+[73T?TR+AU87PZ)[K-D*JLK@?[X6=E"
M/Q5RE?]+Y]1*&-,+*U/ N_PYGLJ;D?J-YS)[D:/)W_^&0_\?EFZS?;>9K?7)
M+F8:<76%?MFL'E4'TZ==W_^K]7.EOFJ?;]LO\\W+!/N>N!Z_:%0%>U5!=U6_
M;W_,ROVW+S)3V0E]DF6**W\)[U7492J7;.(E^CEYDCJ==HL,?9-QEB.!5E4$
MJUB>Q=]LD17N.Q,.T)D_1<Y]&6"ES]';33Y#S^KM]A)\I^M:91_[S6O F">X
M_BKPO7#>7?CM?)[)>5RH@%8^3Q0*INBW>+F1*DC>Z,15-D13&PV87IG8*Q.M
ME#6R7\>H%4=1*SSA-_]AO<1H+S'J+K%G"-LM[D*8M ]A[ .1_ &ZTR>(:P&'
M44RP%^JO V[ %'>7WCF,:R,'<4PB8A!'0!RQBJO<LW67UBHY=@H) X\&!L.
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M:AL'B,&,>BPRW/8 ! R<"=B>*X%FT1!SYA%#214 ]@([]OISI39PF#0,8[L
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M.\"N)U1.F.1=:Q4.B.1#(+)/!N2:65*"(],6 PXXY.UPZ(X4?CQ)ZION5^:
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MC%5J+P]0WS^E:;%[4QK8/S)J\C]02P,$%     @ :(E*5N'S P^^!   ZQL
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M^LWW.,*"Z94E?+4?ZN.:^V9P+F[@US]G2K+RO+#=]+[')?Z "BKHFURB,:;
M!%-=NLI?PW83^F:GZ&N]G=^<&=HPY#<GAIY-/P]097M1N^TU:A2+OFK[T,"U
M>\UBT,;YMM_\!TD7U^V?:I-G[9R<%">$K=6).P=+NDM%?AI:MI:G^A-UEMUH
MG\*K(#^;KVCRGPJ^8K:.4@YBLI*4KMV7VP/+3]_S&T&WZCSZD0I!$W6Y(3@D
M+ N0SU>4BI>;K(/R-Y#Q_U!+ P04    " !HB4I6L4+!0-8"   P"   &0
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ME@9'A%M6.)-!60.\+Z4T^XTEZ*=\]AM02P,$%     @ :(E*5F 7_>T2 P
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( &B)2E:'#+R$[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( &B)2E:97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ :(E*
M5LP,T&;E!P  A2\  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( &B)2E;=Y[FK/@(  ,(%   8
M      " @2@0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" !HB4I6:)!?!C #  "\!@  &               @(&<$@  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ :(E*5D;.^'VM!@  9!L  !@
M             ("! A8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( &B)2E9R)XOX-@,  !X+   8              " @>4<  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !HB4I6T=7L$?$&   I
M)P  &               @(%1(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ :(E*5G,C@+!1!0  )!@  !@              ("!>"<
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &B)2E80^L][
M) \  #F.   8              " @?\L  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " !HB4I6LIF2<X@(  #,)@  &
M@(%9/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ :(E*
M5C.M\V,#*0  '(8  !D              ("!%T4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " !HB4I6MNY#6IX.   "*@  &0
M        @(%1;@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( &B)2E:*>&B\(@8  ,D.   9              " @29]  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ :(E*5I 8PGJ5!@  P1
M !D              ("!?X,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " !HB4I6+E9@(TL&  #S&@  &0              @(%+B@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &B)2E:\IC'$
MR04  - -   9              " @<V0  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ :(E*5H]80JQ:%0  \C\  !D
M ("!S98  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !H
MB4I6!.P#,><'   D&   &0              @(%>K   >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &B)2E: ($=E"A0  *L_   9
M          " @7RT  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#
M%     @ :(E*5J1.MJ*3#0  Z20  !D              ("!O<@  'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !HB4I6G>L0M,X#  #;
M"   &0              @(&'U@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;%!+ 0(4 Q0    ( &B)2E9<3BW"> ,  )P'   9              " @8S:
M  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ :(E*5JA\
M&'>; @  ^@4  !D              ("!.]X  'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"% ,4    " !HB4I6T5C)E!<S  "NM0  &0
M    @($-X0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M &B)2E;R[UV1. 4  /@+   9              " @5L4 0!X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ :(E*5CJ(CB67"0  @!P  !D
M             ("!RAD! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " !HB4I6A,2.RH,'   9%0  &0              @(&8(P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &B)2E9/>RTYA 0
M ,X,   9              " @5(K 0!X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ :(E*5OTSR++N!0  Y1   !D              ("!
M#3 ! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !HB4I6
MIG.8>R4$  #?"@  &0              @($R-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &B)2E:X3B+5LP0  ,L,   9
M      " @8XZ 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ :(E*5@9X:$@3"   118  !D              ("!>#\! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !HB4I60Q-259P'   '%0
M&0              @('"1P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( &B)2E;CAF@8.P,  &,'   9              " @95/ 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ :(E*5M6^9)'2
M"   &$$  !D              ("!!U,! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " !HB4I6D"(U\K$#  !)$P  &0
M@($07 $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( &B)
M2E:S]:3M"04  *(?   9              " @?A? 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ :(E*5NL!RDQ["0  MD4  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( &B)2E9B9NGXR@,  ,P,   9
M  " @?^  0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M:(E*5F4:;1?[ P  FA8  !D              ("! (4! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " !HB4I6Z6D7#KX"  !$!P  &0
M            @($RB0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( &B)2E:%\CW:C (  .H&   9              " @2>, 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ :(E*5OS;P&#* @
M< <  !D              ("!ZHX! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " !HB4I6AN>G>^$#  !D#   &0              @('K
MD0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( &B)2E;0
MU\T,00,   4)   9              " @0.6 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ :(E*5D?P+]O* @  <P<  !D
M     ("!>YD! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B)2E:*LZNX@ ,  ,\-   9              "
M@3"L 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ :(E*
M5A>MV=#6 P  Y!$  !D              ("!YZ\! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " !HB4I6;38"=H4"  #*!@  &0
M        @('TLP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( &B)2E9QP^*&>0(  +(&   9              " @;"V 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ :(E*5JR%Y39P @  A08
M !D              ("!8+D! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " !HB4I6P-C5EMT"  "N!P  &0              @($'O $
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &B)2E9XON(N
MLP,  +X-   9              " @1N_ 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ :(E*5KS'8%(/ P  ,@L  !D
M ("!!<,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !H
MB4I6U0=MF,\"  "O!P  &0              @(%+Q@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( &B)2E;Z5,\AZ0,  &P2   9
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M970V-RYX;6Q02P$"% ,4    " !HB4I60U1=I:T#   &$   &0
M    @('\W0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M &B)2E8X@VDJ/08  %\C   9              " @>#A 0!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ :(E*5M>3M66) @  ]@4  !D
M             ("!5.@! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    " !HB4I6C<B/^;H9   #J $ &0              @($4ZP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &B)2E;TB\:1304
M /\B   9              " @04% @!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ :(E*5I:1]3Y7 P  \@H  !D              ("!
MB0H" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " !HB4I6
M(^TO;S0)   ^2@  &0              @($7#@( >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( &B)2E;A\P,/O@0  .L;   9
M      " @8(7 @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ :(E*5JD?]$#5!   #QD  !D              ("!=QP" 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " !HB4I6L4+!0-8"   P"
M&0              @(&#(0( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( &B)2E;X+>+9I0,  #L-   9              " @9 D @!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ :(E*5BN$O@#M
M!   :AD  !D              ("!;"@" 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    " !HB4I6RD#'8X<$   2$   &0
M@(&0+0( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( &B)
M2E8 O>#TF@0   X1   9              " @4XR @!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ :(E*5DV.+$N@ P  ,@P  !D
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M=#@V+GAM;%!+ 0(4 Q0    ( &B)2E9^&AF-4 ,  + 5   -
M  "  :%' @!X;"]S='EL97,N>&UL4$L! A0#%     @ :(E*5I>*NQS
M$P(   L              ( !'$L" %]R96QS+RYR96QS4$L! A0#%     @
M:(E*5I/J$X<K!@  PC@   \              ( !!4P" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( &B)2E92-<:CB@(  +DR   :              "
M 5U2 @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &B)
M2E:#T:P!+@(  $0Q   3              "  1]5 @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !> %X R1D  'Y7 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>303</ContextCount>
  <ElementCount>516</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Document - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements Of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements Of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements Of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements Of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements Of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements Of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Consolidated Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails</Role>
      <ShortName>Consolidated Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments And Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments And Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Valuation And Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts</Role>
      <ShortName>Valuation And Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary Of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary Of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary Of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Consolidated Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables</Role>
      <ShortName>Consolidated Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/Revenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/ShareBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/NetIncomePerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails</Role>
      <ShortName>Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Financial Instruments - Summary of Equity Investment Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails</Role>
      <ShortName>Financial Instruments - Summary of Equity Investment Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails</Role>
      <ShortName>Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails</Role>
      <ShortName>Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Consolidated Financial Statement Details - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Consolidated Financial Statement Details - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails</Role>
      <ShortName>Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Consolidated Financial Statement Details - Other Accrued Liabilities???Short Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Other Accrued Liabilities???Short Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Consolidated Financial Statement Details - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails</Role>
      <ShortName>Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Revenue - Revenue Disaggregated by Types and Geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails</Role>
      <ShortName>Revenue - Revenue Disaggregated by Types and Geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Revenue - Summary of Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue - Summary of Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Revenue - Sales-type and Operating Lease Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails</Role>
      <ShortName>Revenue - Sales-type and Operating Lease Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Leases - Lease Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails</Role>
      <ShortName>Leases - Lease Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails</Role>
      <ShortName>Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Leases - Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails</Role>
      <ShortName>Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Stockholders' Equity - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Stockholders' Equity - Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Share-Based Compensation - Summary of RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails</Role>
      <ShortName>Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails</Role>
      <ShortName>Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Income Taxes - Schedule Of Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule Of Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Schedule Of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule Of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Net Income Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails</Role>
      <ShortName>Net Income Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="isrg-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Valuation And Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails</Role>
      <ShortName>Valuation And Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear, isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService, isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService, isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService, isrg:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  isrg-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="isrg-20221231.htm">isrg-20221231.htm</File>
    <File>isrg-20221231.xsd</File>
    <File>isrg-20221231_cal.xml</File>
    <File>isrg-20221231_def.xml</File>
    <File>isrg-20221231_lab.xml</File>
    <File>isrg-20221231_pre.xml</File>
    <File>q422ex-1010xfy23rsuagreeme.htm</File>
    <File>q422ex-1011xfy23psuagreeme.htm</File>
    <File>q422ex-109xfy23optionagree.htm</File>
    <File>q422ex-211xsubsidiariesq4o.htm</File>
    <File>q422ex-231xauditorconsentq.htm</File>
    <File>q422ex-311xceocertofsoxsec.htm</File>
    <File>q422ex-312xcfocertofsoxsec.htm</File>
    <File>q422ex-3212xceoandcfocerto.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>isrg-20221231_g1.jpg</File>
    <File>isrg-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1451">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "isrg-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 1451,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 303,
   "dts": {
    "calculationLink": {
     "local": [
      "isrg-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "isrg-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "isrg-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "isrg-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "isrg-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "isrg-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 779,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 20,
    "http://www.intuitivesurgical.com/20221231": 9,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 34
   },
   "keyCustom": 55,
   "keyStandard": 461,
   "memberCustom": 44,
   "memberStandard": 55,
   "nsprefix": "isrg",
   "nsuri": "http://www.intuitivesurgical.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.intuitivesurgical.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary Of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary Of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Consolidated Financial Statement Details",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails",
     "shortName": "Consolidated Financial Statement Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.intuitivesurgical.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.intuitivesurgical.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.intuitivesurgical.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments And Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.intuitivesurgical.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments And Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.intuitivesurgical.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.intuitivesurgical.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.intuitivesurgical.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Valuation And Qualifying Accounts",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts",
     "shortName": "Valuation And Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary Of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary Of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary Of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary Of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Consolidated Financial Statement Details (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables",
     "shortName": "Consolidated Financial Statement Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.intuitivesurgical.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "isrg:LessorSalesTypeLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.intuitivesurgical.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "isrg:LessorSalesTypeLeaseLeaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000003 - Document - Description of the Business",
     "menuCat": "Cover",
     "order": "3",
     "role": "http://www.intuitivesurgical.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "isrg:ScheduleofCommonStockRepurchasedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "isrg:ScheduleofCommonStockRepurchasedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.intuitivesurgical.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary Of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i99b0a36f203b4b46a1d2d5bdbef3d587_D20210927-20210927",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ief4c591526ea478bb99b449397dd0039_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails",
     "shortName": "Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ief4c591526ea478bb99b449397dd0039_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails",
     "shortName": "Summary Of Significant Accounting Policies - Amortized Cost by Credit Quality (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
     "shortName": "Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "isrg:CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails",
     "shortName": "Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
     "shortName": "Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Financial Instruments - Summary of Equity Investment Activity (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails",
     "shortName": "Financial Instruments - Summary of Equity Investment Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idaaec3561f8241d9906a1ef96fca02df_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
     "shortName": "Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ib5c8e03657644033b868750e96ab9643_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails",
     "shortName": "Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ib5c8e03657644033b868750e96ab9643_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:TradeAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Consolidated Financial Statement Details - Accounts Receivable, Net (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails",
     "shortName": "Consolidated Financial Statement Details - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:TradeAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Consolidated Financial Statement Details - Inventory (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails",
     "shortName": "Consolidated Financial Statement Details - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails",
     "shortName": "Consolidated Financial Statement Details (Details) - Prepaids and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:SalesTypeLeaseNetInvestmentInLeaseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails",
     "shortName": "Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Consolidated Financial Statement Details - Other Accrued Liabilities\u2014Short Term (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails",
     "shortName": "Consolidated Financial Statement Details - Other Accrued Liabilities\u2014Short Term (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Consolidated Financial Statement Details - Other Long-Term Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails",
     "shortName": "Consolidated Financial Statement Details - Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails",
     "shortName": "Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Revenue - Revenue Disaggregated by Types and Geography (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails",
     "shortName": "Revenue - Revenue Disaggregated by Types and Geography (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i1962e48f84bd458fb0b88daa39518d23_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Revenue - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Revenue - Summary of Contract Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue - Summary of Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Revenue - Sales-type and Operating Lease Revenue (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails",
     "shortName": "Revenue - Sales-type and Operating Lease Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:SalesTypeLeaseGrossInvestmentInLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Leases - Lease Receivables (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails",
     "shortName": "Leases - Lease Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:SalesTypeLeaseGrossInvestmentInLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails",
     "shortName": "Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Leases - Maturities of Operating Lease Payments (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails",
     "shortName": "Leases - Maturities of Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements Of Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements Of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "isrg:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "isrg:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i5a5abb42db044edb933f0bac478561e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "if4ab8f76e64a46d58941675cc8783c2e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "isrg:AggregateReductionInCommonStockDuringStockRepurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails",
     "shortName": "Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "isrg:ScheduleofCommonStockRepurchasedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie8146221033447d29f3e4f18dc7a409d_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i5a5abb42db044edb933f0bac478561e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails",
     "shortName": "Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i0051b5c888cd406ea6c081c905d7c0bd_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements Of Comprehensive Income",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Consolidated Statements Of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Stockholders' Equity - Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails",
     "shortName": "Stockholders' Equity - Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i9a94340d69fc401d83c0ba90f1f24db2_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Share-Based Compensation - Summary of RSU and PSU Activity (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails",
     "shortName": "Share-Based Compensation - Summary of RSU and PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i66a2672f116a46efa86d9e452117811d_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i5a5abb42db044edb933f0bac478561e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails",
     "shortName": "Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i5a5abb42db044edb933f0bac478561e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails",
     "shortName": "Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i66a2672f116a46efa86d9e452117811d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i06aed63fafe34e248d1237896e642e3f_D20220101-20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Income Taxes - Schedule Of Provision For Income Taxes (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule Of Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "isrg:EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i86284f29e88649f98a3081d2acc55f59_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements Of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements Of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i86284f29e88649f98a3081d2acc55f59_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Schedule Of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule Of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "idb57e4322a5a41099da8c576ba2c235e_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i5a5abb42db044edb933f0bac478561e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Net Income Per Share - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails",
     "shortName": "Net Income Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "i13598596c8ae43da85a2f7f5bd4d8d95_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Valuation And Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails",
     "shortName": "Valuation And Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "id54e38a6bc054a1bb5bcc9ff5b0db69b_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements Of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements Of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "isrg-20221231.htm",
      "contextRef": "ie02b97b1b58d44ad88d0eced00283529_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "isrg:DepreciationandGainLossonDispositionofPropertyPlantEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 102,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "State or Other Jurisdiction of Incorporation or Organization"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "I.R.S. Employer Identification No."
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of Each Class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "isrg_AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding",
        "label": "Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding",
        "terseLabel": "Accounts Receivable, Deferred Lease Billing and Extended Payments, Outstanding"
       }
      }
     },
     "localname": "AccountsReceivableDeferredLeaseBillingAndExtendedPaymentsOutstanding",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_AccountsReceivableExtendedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Extended Payment",
        "label": "Accounts Receivable, Extended Payment",
        "terseLabel": "Accounts Receivable, Extended Payment"
       }
      }
     },
     "localname": "AccountsReceivableExtendedPayment",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_AggregateReductionInCommonStockDuringStockRepurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount reduced under Common Stock and Additional Paid-In Capital accounts under the par value of method of accounting for stock repurchases.",
        "label": "Aggregate Reduction In Common Stock During Stock Repurchases",
        "terseLabel": "Aggregate reduction in common stock and additional paid-in capital during stock repurchases"
       }
      }
     },
     "localname": "AggregateReductionInCommonStockDuringStockRepurchases",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy for allowance for sales returns and doubtful accounts.",
        "label": "Allowance For Sales Returns And Doubtful Accounts Policy [Policy Text Block]",
        "terseLabel": "Allowance for Sales Returns and Doubtful Accounts"
       }
      }
     },
     "localname": "AllowanceForSalesReturnsAndDoubtfulAccountsPolicyPolicyTextBlock",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "isrg_AmendedAndRestatedTwentyTenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated Twenty Ten Stock Incentive Plan [Member]",
        "label": "Amended And Restated Twenty Ten Stock Incentive Plan [Member]",
        "terseLabel": "2010 Incentive Award Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwentyTenStockIncentivePlanMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated 2009 Stock Incentive Plan [Member]",
        "label": "Amended And Restated Twenty Zero Nine Stock Incentive Plan [Member]",
        "terseLabel": "2009 Employment Commencement Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestatedTwentyZeroNineStockIncentivePlanMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_AmountChargedToRetainedEarningsDuringStockRepurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to Retained Earnings under the par value of method of accounting for stock repurchases.",
        "label": "Amount Charged To Retained Earnings During Stock Repurchases",
        "terseLabel": "Amount charged to retained earnings during stock repurchases"
       }
      }
     },
     "localname": "AmountChargedToRetainedEarningsDuringStockRepurchases",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_AnnualGrantOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Grant Options [Member]",
        "label": "Annual Grant Options [Member]",
        "terseLabel": "Annual Grant Options"
       }
      }
     },
     "localname": "AnnualGrantOptionsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "isrg_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "xbrltype": "stringItemType"
    },
    "isrg_AugustAcceleratedShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August Accelerated Share Repurchase Program",
        "label": "August Accelerated Share Repurchase Program [Member]",
        "terseLabel": "August ASR Program"
       }
      }
     },
     "localname": "AugustAcceleratedShareRepurchaseProgramMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_AugustGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August Grant [Member]",
        "label": "August Grant [Member]",
        "terseLabel": "August Grant"
       }
      }
     },
     "localname": "AugustGrantMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_AwardedtoAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awarded to [Axis]",
        "label": "Awarded to [Axis]",
        "terseLabel": "Awarded to [Axis]"
       }
      }
     },
     "localname": "AwardedtoAxis",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_AwardedtoDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Awarded to [Axis]",
        "label": "Awarded to [Domain]",
        "terseLabel": "Awarded to [Domain]"
       }
      }
     },
     "localname": "AwardedtoDomain",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_BroncusHoldingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broncus Holding Corporation",
        "label": "Broncus Holding Corporation [Member]",
        "terseLabel": "Broncus"
       }
      }
     },
     "localname": "BroncusHoldingCorporationMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost",
        "label": "Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Total assets measured at fair value, Amortized Cost"
       }
      }
     },
     "localname": "CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Debt Securities, Available-for-sale, Fair Value",
        "label": "Cash and Cash Equivalents and Debt Securities, Available-for-sale, Fair Value",
        "totalLabel": "Total assets measured at fair value, Fair Value"
       }
      }
     },
     "localname": "CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_CommonStockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Repurchase Program",
        "label": "Common Stock Repurchase Program [Member]",
        "terseLabel": "Common Stock Repurchase Program"
       }
      }
     },
     "localname": "CommonStockRepurchaseProgramMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_ComputerAndOfficeEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of balance sheet date of long-lived, depreciable asset used in production process to produce goods and services.",
        "label": "Computer And Office Equipment",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipment",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_ConsolidatingReportingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidating Reporting [Axis]",
        "label": "Consolidating Reporting [Axis]",
        "terseLabel": "Consolidating Reporting [Axis]"
       }
      }
     },
     "localname": "ConsolidatingReportingAxis",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_ConsolidatingReportingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidating Reporting [Domain]",
        "label": "Consolidating Reporting [Domain]",
        "terseLabel": "Consolidating Reporting [Domain]"
       }
      }
     },
     "localname": "ConsolidatingReportingDomain",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_CostOfSalesProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Sales Product [Member]",
        "label": "Cost Of Sales Product [Member]",
        "terseLabel": "Cost of revenue\u2014product"
       }
      }
     },
     "localname": "CostOfSalesProductMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_CostOfSalesServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Sales Service [Member]",
        "label": "Cost Of Sales Service [Member]",
        "terseLabel": "Cost of revenue\u2014service"
       }
      }
     },
     "localname": "CostOfSalesServiceMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_DeferredPurchaseConsiderationPaymentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Purchase Consideration Payments, Current",
        "label": "Deferred Purchase Consideration Payments, Current",
        "terseLabel": "Current portion of deferred and contingent purchase consideration"
       }
      }
     },
     "localname": "DeferredPurchaseConsiderationPaymentsCurrent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Right-Of-Use Asset",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_DepreciationandGainLossonDispositionofPropertyPlantEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation and Gain (Loss) on Disposition of Property Plant Equipment",
        "label": "Depreciation and Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Depreciation and loss on disposal of property, plant, and equipment, net"
       }
      }
     },
     "localname": "DepreciationandGainLossonDispositionofPropertyPlantEquipment",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instrument, Designation As Cash Flow Hedges, De-Designation, Period",
        "label": "Derivative Instrument, Designation As Cash Flow Hedges, De-Designation, Period",
        "terseLabel": "Cash flow hedges de-designated (period)"
       }
      }
     },
     "localname": "DerivativeInstrumentDesignationAsCashFlowHedgesDeDesignationPeriod",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_DomesticAndForeignMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic and Foreign",
        "label": "Domestic and Foreign [Member]",
        "terseLabel": "Domestic and Foreign"
       }
      }
     },
     "localname": "DomesticAndForeignMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Tax Reform, Amount",
        "terseLabel": "Deferred tax remeasurement due to Swiss Tax Reform",
        "verboseLabel": "Deferred tax re-measurement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignTaxReformAmount",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Expense (Benefit), Share-Based Payment Arrangement",
        "label": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Expense (Benefit), Share-Based Payment Arrangement",
        "terseLabel": "Unrecognized tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxExpenseBenefitShareBasedPaymentArrangement",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_EnterpriseWideSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enterprise-Wide Software [Member]",
        "label": "Enterprise Wide Software [Member]",
        "terseLabel": "Enterprise-wide software"
       }
      }
     },
     "localname": "EnterpriseWideSoftwareMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_EquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment and Furniture [Member]",
        "label": "Equipment And Furniture [Member]",
        "terseLabel": "Equipment and furniture"
       }
      }
     },
     "localname": "EquipmentAndFurnitureMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Sales, Purchases and Other Adjustments",
        "label": "Equity Securities, FV-NI, Sales, Purchases and Other Adjustments",
        "terseLabel": "Sales/Purchases/Others"
       }
      }
     },
     "localname": "EquitySecuritiesFVNISalesPurchasesAndOtherAdjustments",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Sales, Purchases and Other Adjustments",
        "label": "Equity Securities without Readily Determinable Fair Value, Sales, Purchases and Other Adjustments",
        "terseLabel": "Sales/Purchases/Others"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueSalesPurchasesAndOtherAdjustments",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)",
        "label": "Equity Securities without Readily Determinable Fair Value, Unrealized Gain (Loss)",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUnrealizedGainLoss",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_FebruaryGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February Grant [Member]",
        "label": "February Grant [Member]",
        "terseLabel": "February Grant"
       }
      }
     },
     "localname": "FebruaryGrantMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy on foreign currency remeasurement and retranslation. Accounting policy on hedging instruments.",
        "label": "Foreign Currency And Other Hedging Instruments Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency and Other Hedging Instruments"
       }
      }
     },
     "localname": "ForeignCurrencyAndOtherHedgingInstrumentsPolicyPolicyTextBlock",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "isrg_HighCreditRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High Credit Rating",
        "label": "High Credit Rating [Member]",
        "terseLabel": "High"
       }
      }
     },
     "localname": "HighCreditRatingMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination minimum likelihood of tax benefits being realized upon settlement.",
        "label": "Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement",
        "terseLabel": "Likelihood of tax benefits being realized upon ultimate settlement"
       }
      }
     },
     "localname": "IncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations",
        "label": "Income Tax Reconciliation Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations",
        "negatedLabel": "Reversal of unrecognized tax benefits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationUnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_InitialGrantOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Grant Options [Member]",
        "label": "Initial Grant Options [Member]",
        "terseLabel": "Initial Grant Options"
       }
      }
     },
     "localname": "InitialGrantOptionsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_InitialRSUgrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial RSU grants [Member]",
        "label": "Initial RSU grants [Member]",
        "terseLabel": "Initial RSU grants"
       }
      }
     },
     "localname": "InitialRSUgrantsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_InstrumentsandAccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments and Accessories [Member]",
        "label": "Instruments and Accessories [Member]",
        "terseLabel": "Instruments and accessories"
       }
      }
     },
     "localname": "InstrumentsandAccessoriesMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_IntangibleAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges and other non-current assets.",
        "label": "Intangible And Other Assets",
        "terseLabel": "Intangible and other assets, net"
       }
      }
     },
     "localname": "IntangibleAndOtherAssets",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_IntangibleAndOtherAssetsNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible and Other Assets, Net",
        "label": "Intangible and Other Assets, Net [Member]",
        "terseLabel": "Intangible and other assets, net"
       }
      }
     },
     "localname": "IntangibleAndOtherAssetsNetMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_LessorSalesTypeLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Sales-type Lease, Lease Income",
        "label": "Lessor, Sales-type Lease, Lease Income [Table Text Block]",
        "terseLabel": "Lessor, Sales-type Lease, Lease Income"
       }
      }
     },
     "localname": "LessorSalesTypeLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "isrg_LongLivedAssetsMaintainedInTheUnitedStatesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets maintained in the United States.",
        "label": "Long Lived Assets Maintained In The United States Percent",
        "terseLabel": "Long-lived assets, percent"
       }
      }
     },
     "localname": "LongLivedAssetsMaintainedInTheUnitedStatesPercent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_LowCreditRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Low Credit Rating",
        "label": "Low Credit Rating [Member]",
        "terseLabel": "Low"
       }
      }
     },
     "localname": "LowCreditRatingMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employees on stockholders to participate in employee stock purchase plan.",
        "label": "Maximum Percentage Of Employees On Stockholders To Participate In Employee Stock Purchase Plan",
        "terseLabel": "Maximum percentage of employees on stockholders to participate in ESPP"
       }
      }
     },
     "localname": "MaximumPercentageOfEmployeesOnStockholdersToParticipateInEmployeeStockPurchasePlan",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_MaximumPercentageOfPayrollDeductionUnderEspp": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of payroll deduction under ESPP.",
        "label": "Maximum Percentage Of Payroll Deduction Under Espp",
        "terseLabel": "Percentage of employee payroll deduction under the stock plan, maximum"
       }
      }
     },
     "localname": "MaximumPercentageOfPayrollDeductionUnderEspp",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum hours employed per week to participate in employee stock purchase plan.",
        "label": "Minimum Hours Employed Per Week To Participate In Employee Stock Purchase Plan",
        "terseLabel": "Minimum hours employed per week"
       }
      }
     },
     "localname": "MinimumHoursEmployedPerWeekToParticipateInEmployeeStockPurchasePlan",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum months employed per year to participate in employee stock purchase plan.",
        "label": "Minimum Months Employed Per Year To Participate In Employee Stock Purchase Plan",
        "terseLabel": "Minimum months employed per year"
       }
      }
     },
     "localname": "MinimumMonthsEmployedPerYearToParticipateInEmployeeStockPurchasePlan",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_ModerateCreditRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Moderate Credit Rating",
        "label": "Moderate Credit Rating [Member]",
        "terseLabel": "Moderate"
       }
      }
     },
     "localname": "ModerateCreditRatingMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_NewHireOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Hire Options [Member]",
        "label": "New Hire Options [Member]",
        "terseLabel": "New Hire Options"
       }
      }
     },
     "localname": "NewHireOptionsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_NonvestedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonvested Stock Option [Member]",
        "label": "Nonvested Stock Option [Member]",
        "terseLabel": "Nonvested Stock Option"
       }
      }
     },
     "localname": "NonvestedStockOptionMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_OctoberAcceleratedShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October Accelerated Share Repurchase Program",
        "label": "October Accelerated Share Repurchase Program [Member]",
        "terseLabel": "October ASR Program"
       }
      }
     },
     "localname": "OctoberAcceleratedShareRepurchaseProgramMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_OfferingPeriodEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Period, Employee Stock Purchase Plans",
        "label": "Offering Period, Employee Stock Purchase Plans",
        "terseLabel": "Duration for each offering period"
       }
      }
     },
     "localname": "OfferingPeriodEmployeeStockPurchasePlans",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Period, Number of Purchase Periods Offering Divided Into, Employee Stock Purchase Plans",
        "label": "Offering Period, Number of Purchase Periods Offering Divided Into, Employee Stock Purchase Plans",
        "terseLabel": "Number of shorter purchase periods that each offering period is divided into"
       }
      }
     },
     "localname": "OfferingPeriodNumberofPurchasePeriodsOfferingDividedIntoEmployeeStockPurchasePlans",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "isrg_OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Period, Period Offering Divided Into, Employee Stock Purchase Plans",
        "label": "Offering Period, Period Offering Divided Into, Employee Stock Purchase Plans",
        "terseLabel": "Duration of each shorter offering period"
       }
      }
     },
     "localname": "OfferingPeriodPeriodOfferingDividedIntoEmployeeStockPurchasePlans",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_PerformanceShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSUs)",
        "label": "Performance Share Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of Look-Back That Could Cause Offering Period to Reset, Employee Stock Purchase Plans",
        "label": "Period of Look-Back That Could Cause Offering Period to Reset, Employee Stock Purchase Plans",
        "terseLabel": "Period of look-back that could cause offering period to reset"
       }
      }
     },
     "localname": "PeriodofLookBackThatCouldCauseOfferingPeriodtoResetEmployeeStockPurchasePlans",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_PurchasedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased Software [Member]",
        "label": "Purchased Software [Member]",
        "terseLabel": "Purchased software"
       }
      }
     },
     "localname": "PurchasedSoftwareMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Eight",
        "label": "Range Eight [Member]",
        "terseLabel": "Exercise Price Range 8"
       }
      }
     },
     "localname": "RangeEightMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Five [Member]",
        "label": "Range Five [Member]",
        "terseLabel": "Exercise Price Range 5"
       }
      }
     },
     "localname": "RangeFiveMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Four [Member]",
        "label": "Range Four [Member]",
        "terseLabel": "Exercise Price Range 4"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Nine",
        "label": "Range Nine [Member]",
        "terseLabel": "Exercise Price Range 9"
       }
      }
     },
     "localname": "RangeNineMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]",
        "terseLabel": "Exercise Price Range 1"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Seven",
        "label": "Range Seven [Member]",
        "terseLabel": "Exercise Price Range 7"
       }
      }
     },
     "localname": "RangeSevenMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Six",
        "label": "Range Six [Member]",
        "terseLabel": "Exercise Price Range 6"
       }
      }
     },
     "localname": "RangeSixMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Ten",
        "label": "Range Ten [Member]",
        "terseLabel": "Exercise Price Range 10"
       }
      }
     },
     "localname": "RangeTenMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three [Member]",
        "label": "Range Three [Member]",
        "terseLabel": "Exercise Price Range 3"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]",
        "terseLabel": "Exercise Price Range 2"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_RexMedicalLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rex Medical, L.P.",
        "label": "Rex Medical, L.P. [Member]",
        "terseLabel": "Rex Medical, L.P."
       }
      }
     },
     "localname": "RexMedicalLPMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_SalesReturnsAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Returns and Allowances",
        "label": "Sales Returns and Allowances",
        "negatedTerseLabel": "Sales returns and allowances"
       }
      }
     },
     "localname": "SalesReturnsAndAllowances",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_SalesTypeLeaseGrossInvestmentInLease": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Gross Investment in Lease",
        "label": "Sales-type Lease, Gross Investment in Lease",
        "terseLabel": "Gross lease receivables"
       }
      }
     },
     "localname": "SalesTypeLeaseGrossInvestmentInLease",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_SalesTypeLeaseLeaseReceivableExtendedPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Lease Receivable, Extended Payment",
        "label": "Sales-type Lease, Lease Receivable, Extended Payment",
        "terseLabel": "Sales-type Lease, Lease Receivable, Extended Payment"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseReceivableExtendedPayment",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_SalesTypeLeaseNetInvestmentInLeaseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Net Investment in Lease, Current",
        "label": "Sales-type Lease, Net Investment in Lease, Current",
        "terseLabel": "Net investment in sales-type leases \u2013 short-term"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseCurrent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_SalestypeLeaseDeferredSellingProfit": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Deferred Selling Profit",
        "label": "Sales-type Lease, Deferred Selling Profit",
        "negatedLabel": "Unearned income"
       }
      }
     },
     "localname": "SalestypeLeaseDeferredSellingProfit",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available For Sale and Held to Maturity Securities [Domain]",
        "label": "Schedule Of Available For Sale And Held To Maturity Securities [Domain]",
        "terseLabel": "Schedule Of Available-For-Sale Securities [Domain]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleAndHeldToMaturitySecuritiesDomain",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_ScheduleOfAvailableForSaleSecuritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Available-For-Sale Securities",
        "label": "Schedule Of Available-For-Sale Securities [Axis]",
        "terseLabel": "Schedule Of Available-For-Sale Securities [Axis]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAxis",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_ScheduleofCommonStockRepurchasedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Common Stock Repurchased [Table Text Block]",
        "label": "Schedule of Common Stock Repurchased [Table Text Block]",
        "terseLabel": "Schedule Of Stock Repurchase Activities"
       }
      }
     },
     "localname": "ScheduleofCommonStockRepurchasedTableTextBlock",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "isrg_SellingGeneralAndAdministrativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs related to selling, general and administrative activities.",
        "label": "Selling General And Administrative [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_ServiceFeeCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Fee Credit",
        "label": "Service Fee Credit",
        "terseLabel": "Service Fee Credit"
       }
      }
     },
     "localname": "ServiceFeeCredit",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change",
        "terseLabel": "Performance change (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChange",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Performance Change, Weighted Average Grant Date Fair Value",
        "terseLabel": "Performance change (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceChangeWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "isrg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Percent",
        "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Percent",
        "terseLabel": "Market-based implied volatility (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPercent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Period",
        "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Market-based Implied Volatility, Period",
        "terseLabel": "Market-based implied volatility (period)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsMarketbasedImpliedVolatilityPeriod",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After One Year",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After One Year",
        "terseLabel": "Percentage vesting per month after one year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterOneYear",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After Six Months of Service",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Per Month After Six Months of Service",
        "terseLabel": "Percentage vesting per month after six months of service"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingPerMonthAfterSixMonthsofService",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon One Year of Service",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon One Year of Service",
        "terseLabel": "Percentage vesting upon one year of service"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponOneYearofService",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon Six Months of Service",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting Upon Six Months of Service",
        "terseLabel": "Percentage vesting upon six months of service"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingUponSixMonthsofService",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting at the End of One Month",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting at the End of One Month",
        "terseLabel": "Percentage vesting at the end of one month"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsPercentageVestingattheEndofOneMonth",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "isrg_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "isrg_StockOptionsGrantedInitialVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options granted initial vesting period.",
        "label": "Stock Options Granted Initial Vesting Period",
        "terseLabel": "Stock options granted initial vesting period, years"
       }
      }
     },
     "localname": "StockOptionsGrantedInitialVestingPeriod",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_StockRepurchaseProgramincreasedtoauthorizedamount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased to authorized shares repurchase amount for Stock Repurchase Program",
        "label": "Stock Repurchase Program, increased to authorized amount",
        "terseLabel": "Stock repurchase program, increased to authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramincreasedtoauthorizedamount",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "isrg_SystemSalesArrangementWarrantyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "System Sales Arrangement, Warranty Period",
        "label": "System Sales Arrangement, Warranty Period",
        "terseLabel": "System sales arrangement, warranty period"
       }
      }
     },
     "localname": "SystemSalesArrangementWarrantyPeriod",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "isrg_SystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Systems [Member]",
        "label": "Systems [Member]",
        "terseLabel": "Systems"
       }
      }
     },
     "localname": "SystemsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_TotalRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Revenue [Member]",
        "label": "Total Revenue [Member]",
        "terseLabel": "Total Revenue"
       }
      }
     },
     "localname": "TotalRevenueMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_TradeAccountsReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Accounts Receivable, Current",
        "label": "Trade Accounts Receivable, Current",
        "terseLabel": "Trade accounts receivable, net"
       }
      }
     },
     "localname": "TradeAccountsReceivableCurrent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_TwoThousandEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Employee Stock Purchase Plan",
        "label": "Two Thousand Employee Stock Purchase Plan [Member]",
        "terseLabel": "2000 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_TwoThousandNonEmployeeDirectorsStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Non-Employee Directors' Stock Option Plan [member]",
        "label": "Two Thousand Non Employee Directors Stock Option Plan [Member]",
        "terseLabel": "2000 Non-Employee Directors' Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandNonEmployeeDirectorsStockOptionPlanMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "isrg_UnbilledReceivablesAndOtherReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled Receivables and Other Receivables, Current",
        "label": "Unbilled Receivables and Other Receivables, Current",
        "terseLabel": "Unbilled accounts receivable and other"
       }
      }
     },
     "localname": "UnbilledReceivablesAndOtherReceivablesCurrent",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "isrg_VariableLeaseRevenueUsageBasedArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Lease Revenue, Usage-Based Arrangements",
        "label": "Variable Lease Revenue, Usage-Based Arrangements [Member]",
        "terseLabel": "Variable Lease Revenue, Usage-Based Arrangements"
       }
      }
     },
     "localname": "VariableLeaseRevenueUsageBasedArrangementsMember",
     "nsuri": "http://www.intuitivesurgical.com/20221231",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r220",
      "r281",
      "r286",
      "r292",
      "r355",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r568",
      "r569",
      "r570",
      "r571",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r220",
      "r281",
      "r286",
      "r292",
      "r355",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r568",
      "r569",
      "r570",
      "r571",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r220",
      "r281",
      "r286",
      "r292",
      "r355",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r568",
      "r569",
      "r570",
      "r571",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r472",
      "r646",
      "r682",
      "r705",
      "r706",
      "r760",
      "r771",
      "r782",
      "r846",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r472",
      "r646",
      "r682",
      "r705",
      "r706",
      "r760",
      "r771",
      "r782",
      "r846",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r333",
      "r648",
      "r761",
      "r780",
      "r841",
      "r842",
      "r848",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r333",
      "r648",
      "r761",
      "r780",
      "r841",
      "r842",
      "r848",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r463",
      "r472",
      "r502",
      "r503",
      "r504",
      "r622",
      "r646",
      "r682",
      "r705",
      "r706",
      "r760",
      "r771",
      "r782",
      "r837",
      "r846",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r463",
      "r472",
      "r502",
      "r503",
      "r504",
      "r622",
      "r646",
      "r682",
      "r705",
      "r706",
      "r760",
      "r771",
      "r782",
      "r837",
      "r846",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Valuation And Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r334",
      "r335",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r725",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r762",
      "r781",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r690",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r725",
      "r726",
      "r762",
      "r781",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "terseLabel": "Share repurchases, average price per share (in dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "terseLabel": "Initial payment for share repurchases"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $22.4 and $20.2 as of December 31, 2022, and 2021, respectively",
        "totalLabel": "Total accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Loss (gain) on investments, accretion of discounts, and amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r1",
      "r192",
      "r205"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Income taxes \u2013 long-term"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r29",
      "r34",
      "r168",
      "r799",
      "r800",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r102",
      "r228"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r28",
      "r34",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Gains (Losses) on\u00a0Hedge Instruments"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r243",
      "r253",
      "r254",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized\u00a0 Gains (Losses) on Available-for-Sale Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r233",
      "r675",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r252",
      "r253",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r31",
      "r34",
      "r168",
      "r613",
      "r683",
      "r684",
      "r799",
      "r800",
      "r801",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)/Income",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r27",
      "r34",
      "r168",
      "r253",
      "r254",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Gains (Losses)"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Capitalized contract acquisition costs"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Consolidated Financial Statement Details"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r811",
      "r812",
      "r813",
      "r893"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld related to net share settlement of equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r140",
      "r141",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense related to employee stock plans"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense before income taxes"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Share-based compensation expense after income taxes"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Sales returns and allowances"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r234",
      "r339",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r53",
      "r89",
      "r94"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Employee stock options excluded from computation of diluted net income per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/NetIncomePerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r191",
      "r204",
      "r231",
      "r267",
      "r318",
      "r327",
      "r331",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r555",
      "r562",
      "r577",
      "r779",
      "r844",
      "r845",
      "r903"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r223",
      "r237",
      "r267",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r555",
      "r562",
      "r577",
      "r779",
      "r844",
      "r845",
      "r903"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r342",
      "r377"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Mature in one to five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r77",
      "r345",
      "r673"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Mature in one to five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Mature in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r77",
      "r344",
      "r672"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Mature in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r74",
      "r341",
      "r377",
      "r664"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfCashEquivalentsAndAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails",
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r174",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails",
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingImprovementsMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building Improvements [Member]",
        "terseLabel": "Building improvements"
       }
      }
     },
     "localname": "BuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Building and building/leasehold improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Accrued construction-related capital expenditures"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property, plant, and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capital Leased Assets [Line Items]",
        "terseLabel": "Capital Leased Assets [Line Items]"
       }
      }
     },
     "localname": "CapitalLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Net Investment in Sales Type Leases [Abstract]",
        "terseLabel": "Reported as:"
       }
      }
     },
     "localname": "CapitalLeasesNetInvestmentInSalesTypeLeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r919"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract acquisition assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r226",
      "r736"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "isrg_CashandCashEquivalentsandDebtSecuritiesAvailableforsaleFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r55",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r187"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r197",
      "r211"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r403",
      "r404",
      "r692",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares were reserved for future issuance (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r811",
      "r812",
      "r893"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balances (shares)",
        "periodStartLabel": "Beginning balances (shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, 600.0 shares authorized, $0.001 par value, 350.0 shares and 357.7 shares issued and outstanding as of December 31, 2022, and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r123",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r36",
      "r248",
      "r250",
      "r257",
      "r667",
      "r678"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Intuitive Surgical, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r164",
      "r171",
      "r248",
      "r250",
      "r256",
      "r666",
      "r677"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r185",
      "r186",
      "r336",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r185",
      "r186",
      "r336",
      "r689",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r185",
      "r186",
      "r336",
      "r691",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r202",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r185",
      "r186",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r185",
      "r186",
      "r336",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Joint Ventures"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction-in-process"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r436",
      "r438",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r436",
      "r437",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSummaryofContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r768",
      "r770",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Joint venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).",
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateNoteSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r41",
      "r648"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Cost of revenue:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Credit Loss, Financial Instrument"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r805",
      "r883",
      "r885"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current income taxes, Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r805",
      "r883"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current income taxes, Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r155",
      "r539",
      "r547",
      "r805"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r805",
      "r883",
      "r885"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current income taxes, State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r343",
      "r377",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "negatedTerseLabel": "Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r350",
      "r384",
      "r755"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Unrealized losses 12 months or greater, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r350",
      "r384"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized losses 12 months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r350",
      "r384",
      "r755"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Unrealized losses less than 12 months, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r350",
      "r384"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Unrealized losses less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Cash and Available-For-Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r348",
      "r381",
      "r755"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r349",
      "r382"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r805",
      "r884",
      "r885"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r155",
      "r805",
      "r884"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r53",
      "r155",
      "r540",
      "r546",
      "r547",
      "r805"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r193",
      "r203",
      "r534"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r796"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue \u2013 long-term"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r805",
      "r884",
      "r885"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r881"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r881"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Net unrealized losses on available-for-sale securities and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r150",
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other",
        "terseLabel": "Expenses deducted in later years for tax purposes"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r152",
      "r882"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant, and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Employer matching contributions, per person, per year"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum rate of employees' contribution to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r53",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r891"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Recognized gains (losses) in interest and other income, net"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r179",
      "r180",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amounts of outstanding currency forward contracts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative, term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r458",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenue Disaggregated by Types and Geography"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r476",
      "r507",
      "r508",
      "r510",
      "r516",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "verboseLabel": "Distribution rights and others"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share attributable to Intuitive Surgical, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r258",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r295",
      "r297",
      "r298",
      "r299",
      "r303",
      "r571",
      "r572",
      "r668",
      "r679",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (usd per share)",
        "verboseLabel": "Basic net income per share (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r258",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r295",
      "r297",
      "r298",
      "r299",
      "r303",
      "r571",
      "r572",
      "r668",
      "r679",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (usd per share)",
        "verboseLabel": "Diluted net income per share (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Computation of Net Income per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r876",
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Excess tax benefits related to share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unrecognized compensation expenses are expected to be recognized, years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Employee service share-based compensation, tax benefit from exercise of stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r111",
      "r220",
      "r252",
      "r253",
      "r254",
      "r278",
      "r279",
      "r280",
      "r283",
      "r289",
      "r291",
      "r307",
      "r355",
      "r435",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r570",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r613",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r232",
      "r576",
      "r738"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r680",
      "r821"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Loss on investment",
        "terseLabel": "Changes in Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable value, Carrying Value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r419",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r574",
      "r619",
      "r620",
      "r621",
      "r758",
      "r759",
      "r768",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r419",
      "r464",
      "r469",
      "r574",
      "r619",
      "r768",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r419",
      "r464",
      "r469",
      "r574",
      "r620",
      "r758",
      "r759",
      "r768",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r419",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r619",
      "r620",
      "r621",
      "r758",
      "r759",
      "r768",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r346",
      "r347",
      "r361",
      "r364",
      "r365",
      "r366",
      "r371",
      "r383",
      "r385",
      "r388",
      "r420",
      "r433",
      "r566",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r755",
      "r818",
      "r819",
      "r820",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life, intangible asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r230",
      "r397"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r93",
      "r650"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r90",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r93",
      "r649"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains (losses) related to balance sheet re-measurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Forward contracts",
        "verboseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r561",
      "r802"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedTerseLabel": "Gain on sale of business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r669",
      "r670",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]",
        "terseLabel": "Geographic Distribution [Axis]"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [
      "r669",
      "r670",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]",
        "terseLabel": "Geographic Distribution [Domain]"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicDistributionDomesticMember": {
     "auth_ref": [
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic.",
        "label": "Geographic Distribution, Domestic [Member]",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "GeographicDistributionDomesticMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "auth_ref": [
      "r669",
      "r670",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as foreign.",
        "label": "Geographic Distribution, Foreign [Member]",
        "terseLabel": "OUS"
       }
      }
     },
     "localname": "GeographicDistributionForeignMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r229",
      "r393",
      "r663",
      "r756",
      "r779",
      "r826",
      "r833"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r394",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisition activity"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r157",
      "r834"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Translation and Purchase Accounting Adjustments",
        "terseLabel": "Translation and other"
       }
      }
     },
     "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofSummaryofChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r40",
      "r267",
      "r318",
      "r326",
      "r330",
      "r332",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r577",
      "r749",
      "r844"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r173",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r268",
      "r548"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r38",
      "r190",
      "r198",
      "r213",
      "r318",
      "r326",
      "r330",
      "r332",
      "r670",
      "r749"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r268",
      "r548"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Holiday [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r524",
      "r532",
      "r538",
      "r544",
      "r549",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r270",
      "r290",
      "r291",
      "r317",
      "r522",
      "r545",
      "r550",
      "r681"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r251",
      "r518",
      "r519",
      "r532",
      "r533",
      "r537",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation not benefited"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "U.S. tax on foreign earnings"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfIncomeTaxDifferenceFromStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r50",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effects of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalCreditAssessmentAxis": {
     "auth_ref": [
      "r71",
      "r565",
      "r753",
      "r754",
      "r757",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by entity-defined rating.",
        "label": "Internal Credit Assessment [Axis]",
        "terseLabel": "Internal Credit Assessment [Axis]"
       }
      }
     },
     "localname": "InternalCreditAssessmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalCreditAssessmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity defined credit risk rating.",
        "label": "Internal Credit Assessment [Domain]",
        "terseLabel": "Internal Credit Assessment [Domain]"
       }
      }
     },
     "localname": "InternalCreditAssessmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software Costs for Internal Use"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r87",
      "r739"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r236",
      "r737",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r225",
      "r235",
      "r305",
      "r389",
      "r390",
      "r391",
      "r647",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r87",
      "r741"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r87",
      "r740"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r353",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r794"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow and Balance Sheet Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Lessee, Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r602",
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor, Leases [Policy Text Block]",
        "terseLabel": "Lessor, Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorSalesTypeLeaseTermOfContract1": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's sales-type lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Sales-type Lease, Term of Contract",
        "terseLabel": "Sales-type leases term"
       }
      }
     },
     "localname": "LessorSalesTypeLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r267",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r556",
      "r562",
      "r563",
      "r577",
      "r748",
      "r844",
      "r903",
      "r904"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r196",
      "r209",
      "r779",
      "r804",
      "r822",
      "r894"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r224",
      "r267",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r556",
      "r562",
      "r563",
      "r577",
      "r779",
      "r844",
      "r903",
      "r904"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.",
        "label": "Liabilities, Other than Long-Term Debt, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r21",
      "r838"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Litigation-related accruals"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Pre-tax litigation charges"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r405",
      "r406",
      "r407",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r838",
      "r839",
      "r840"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Long-term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r25",
      "r195",
      "r208",
      "r267",
      "r354",
      "r410",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r577"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest in joint venture"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Notes [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r308",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r51",
      "r54"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r39",
      "r54",
      "r199",
      "r212",
      "r222",
      "r246",
      "r249",
      "r254",
      "r267",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r296",
      "r318",
      "r326",
      "r330",
      "r332",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r572",
      "r577",
      "r749",
      "r844"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income attributable to Intuitive Surgical, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r166",
      "r170",
      "r246",
      "r249",
      "r290",
      "r291",
      "r801"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: net income attributable to noncontrolling interest in joint venture",
        "verboseLabel": "Net income attributable to noncontrolling interest in joint venture"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r162",
      "r435",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest in Joint Venture"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsDerivativeInstrumentsUsedtoHedgeagainstBalanceSheetForeignCurrencyExposuresDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r318",
      "r326",
      "r330",
      "r332",
      "r749"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r897"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of comprehensive income that includes operating lease income.",
        "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncome": {
     "auth_ref": [
      "r306",
      "r601",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income",
        "terseLabel": "Operating lease revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r306",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Operating Lease Revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r593",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for leases that were included within operating cash outflows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r590"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Intangible and other assets, net (Right-of-use assets)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r598",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r597",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.",
        "label": "Other Capitalized Property Plant and Equipment [Member]",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]",
        "terseLabel": "Available-for-sale securities (net of tax):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans (net of tax):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Hedge instruments (net of tax):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r239",
      "r240",
      "r242"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r34",
      "r37",
      "r253",
      "r583",
      "r585",
      "r589",
      "r799"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Change in unrealized gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Less: Reclassification adjustment for (gains) losses on hedge instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r111",
      "r247",
      "r250",
      "r255",
      "r583",
      "r588",
      "r589",
      "r665",
      "r676",
      "r799",
      "r800"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r247",
      "r250"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Less: comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r247",
      "r250"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Change in unrealized gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r32",
      "r35",
      "r86",
      "r245"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: Reclassification adjustment for gains on securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r35",
      "r245",
      "r470"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax",
        "negatedTerseLabel": "Less: Reclassification adjustment for losses on employee benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r164",
      "r165",
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "terseLabel": "Income tax benefit for net losses recorded in other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Details of the Other Accrued Liabilities\u2014Short Term Balance Sheet Item"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Other Liabilities, Current"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r174",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental non-cash investing and financing activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Intangible and other assets, net"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Details of the Other Long-Term Liabilities Balance Sheet Item"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r797",
      "r825"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaids and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Intuitive Surgical, Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of deferred purchase consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Acquisition of businesses, net of cash, and intellectual property and other investing activities"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r261",
      "r886",
      "r887",
      "r888"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchase of property, plant, and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2022, and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaids and other current assets",
        "totalLabel": "Total prepaids and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsDetailsPrepaidsandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaids and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsGrossNotionalAmountsforOutstandingDerivativesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails",
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r46",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Cash received from option exercises and employee stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r259",
      "r260"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r44",
      "r73",
      "r259"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock relating to employee stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r222",
      "r246",
      "r249",
      "r263",
      "r267",
      "r282",
      "r290",
      "r291",
      "r318",
      "r326",
      "r330",
      "r332",
      "r354",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r554",
      "r558",
      "r559",
      "r572",
      "r577",
      "r670",
      "r749",
      "r776",
      "r777",
      "r801",
      "r844"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r101",
      "r227"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Gross property, plant, and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r103",
      "r210",
      "r674",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Total property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant, and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Estimated Useful Lives Of The Assets",
        "verboseLabel": "Details of the Property, Plant and Equipment, Net Balance Sheet Item"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "terseLabel": "Equipment transfers from inventory to property, plant, and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful\u00a0Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation": {
     "auth_ref": [
      "r217",
      "r218",
      "r400",
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.",
        "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, Accumulated Depreciation",
        "negatedTerseLabel": "Accumulated depreciation associated with operating lease assets - Intuitive System Leasing"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross": {
     "auth_ref": [
      "r216",
      "r218",
      "r399",
      "r605"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.",
        "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation",
        "terseLabel": "Operating lease assets \u2013 Intuitive System Leasing"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsPropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r2",
      "r194",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Other commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized investment gains (losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r34",
      "r37",
      "r253",
      "r583",
      "r587",
      "r589",
      "r799"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r471",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r471",
      "r614",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r143",
      "r215",
      "r911"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r793",
      "r803",
      "r912",
      "r914"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r112",
      "r207",
      "r686",
      "r688",
      "r779"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r220",
      "r278",
      "r279",
      "r280",
      "r283",
      "r289",
      "r291",
      "r355",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r570",
      "r683",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r315",
      "r316",
      "r325",
      "r328",
      "r329",
      "r333",
      "r334",
      "r336",
      "r457",
      "r458",
      "r648"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r462",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r448",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Performance obligation period"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price allocated to remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r596",
      "r778"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets recognized related to new lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Gross Lease Receivables"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesScheduleofContractualMaturitiesofGrossLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of comprehensive income that includes sales-type lease income.",
        "label": "Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Sales-Type Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "SalesTypeLeaseIncomeComprehensiveIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseIncome": {
     "auth_ref": [
      "r306",
      "r601",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.",
        "label": "Sales-type Lease, Lease Income",
        "terseLabel": "Sales-type lease revenue"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueSalestypeandOperatingLeaseRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r306",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from sales-type lease.",
        "label": "Sales-type Lease, Lease Income [Table Text Block]",
        "terseLabel": "Sales-type Lease Receivable"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseReceivable": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.",
        "label": "Sales-type Lease, Lease Receivable",
        "terseLabel": "Net investment in sales-type leases"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLease": {
     "auth_ref": [
      "r340",
      "r365",
      "r610",
      "r823"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease.",
        "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails",
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss": {
     "auth_ref": [
      "r359",
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on net investment in sales-type lease.",
        "label": "Sales-type Lease, Net Investment in Lease, Allowance for Credit Loss",
        "negatedTerseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]",
        "terseLabel": "Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Line Items]"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about credit quality indicator for net investment in sales-type lease.",
        "label": "Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table]",
        "terseLabel": "Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table]"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of credit quality indicator for net investment in sales-type lease.",
        "label": "Sales-type Lease, Net Investment in Lease, Credit Quality Indicator [Table Text Block]",
        "terseLabel": "Amortized Cost Basis By Year of Origination and Credit Quality Indicator"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseCreditQualityIndicatorTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated more than five years prior to current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Originated, More than Five Years before Current Fiscal Year",
        "terseLabel": "Prior"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedFiveOrMoreYearsBeforeLatestFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated four years prior to current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Year Five, Originated, Four Years before Current Fiscal Year",
        "terseLabel": "2018"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedFourYearsBeforeLatestFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated in current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Year One, Originated, Current Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedInCurrentFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated in fiscal year prior to current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Year Two, Originated, Fiscal Year before Current Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedInFiscalYearBeforeLatestFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated three years prior to current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Year Four, Originated, Three Years before Current Fiscal Year",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedThreeYearsBeforeLatestFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net investment in sales-type lease originated two years prior to current fiscal year.",
        "label": "Sales-type Lease, Net Investment in Lease, Year Three, Originated, Two Years before Current Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseOriginatedTwoYearsBeforeLatestFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAmortizedCostbyCreditQualityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r34",
      "r895",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss), Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r78",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalLeasedAsssetsTable": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Capital Leased Assets [Table]",
        "terseLabel": "Schedule of Capital Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalLeasedAsssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/LeasesLeaseReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary Of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule Of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation Of Basic And Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Income Tax Difference From The Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r90",
      "r92",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r90",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r756",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule Of Income Before Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Details of the Inventory Balance Sheet Item"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "terseLabel": "Gross Notional Amounts for Outstanding Derivatives"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r178",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r473",
      "r475",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary Of Significant Ranges Of Outstanding And Exercisable Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r125",
      "r130",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary Of Stock Option Activity Under All Stock Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryofEquityInvestmentActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule Of Available-For-Sale Investments With Unrealized Losses"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r775",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule Of Gross Unrecognized Income Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule Of Estimated Future Amortization Expense Of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service",
        "verboseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/RevenueRevenueDisaggregatedbyTypesandGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discount on fair market value on the offering date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount on fair market value on the purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value at grant date (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested ending balance (shares)",
        "periodStartLabel": "Unvested beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested ending balance (usd per share)",
        "periodStartLabel": "Unvested beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vested in period, aggregate fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Volatility (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares of common stock reserved for issuance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised under stock option plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options forfeited/expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value at grant date (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule Of Estimated Fair Values Of The Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions and Fair Value of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (usd per share)",
        "periodStartLabel": "Beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of shares vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, weighted-average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails",
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryofRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited/expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r480",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Summary of PSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Prices, minimum (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options Exercisable, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options Outstanding, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Prices, maximum (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based compensation, options, expiration term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life of shares vested and expected to vest, years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationOutstandingandExercisableOptionsRangesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld related to net share settlement of equity awards (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r62",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Internal use software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r111",
      "r220",
      "r252",
      "r253",
      "r254",
      "r278",
      "r279",
      "r280",
      "r283",
      "r289",
      "r291",
      "r307",
      "r355",
      "r435",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r570",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r613",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r307",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock through employee stock plans (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationSummaryOfStockOptionActivityUnderAllStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan, value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r112",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock through employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "STOCK OPTIONS"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ShareBasedCompensationScheduleOfEstimatedFairValueOfOptionUsingBlackScholesOptionPricingModelWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Repurchase and retirement of common stock (shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedLabel": "Repurchase and retirement of common stock",
        "terseLabel": "Value of shares repurchased (in dollars per share)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r72",
      "r779",
      "r804",
      "r822",
      "r894"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Intuitive Surgical, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/StockholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeNetofTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r162",
      "r163",
      "r169",
      "r220",
      "r221",
      "r253",
      "r278",
      "r279",
      "r280",
      "r283",
      "r289",
      "r355",
      "r435",
      "r512",
      "r513",
      "r514",
      "r542",
      "r543",
      "r570",
      "r583",
      "r584",
      "r589",
      "r613",
      "r684",
      "r685",
      "r804",
      "r822",
      "r894"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedBalanceSheets",
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r119",
      "r266",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income and other taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedFinancialStatementDetailsOtherAccruedLiabilitiesShortTermDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Patents and developed technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI"
       }
      }
     },
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r346",
      "r347",
      "r420",
      "r433",
      "r566",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r818",
      "r819",
      "r820",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/StockholdersEquityScheduleOfStockRepurchaseActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r746",
      "r768",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r671",
      "r768",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. government agencies"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r746",
      "r768",
      "r770",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsScheduleOfAvailableForSaleInvestmentsWithUnrealizedLossesDetails",
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Net unrealized gains/(losses) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r517",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decreases related to tax positions taken during a prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Decreases related to settlements with tax authorities"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties related to unrecognized tax benefits accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to tax positions taken during the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to tax positions taken during a prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r878"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Gross interest related to unrecognized tax benefits accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Net increase in gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Decreases related to expiration of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesScheduleOfGrossUnrecognizedIncomeTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r309",
      "r310",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r271",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance\u00a0at End\u00a0of\u00a0Year",
        "periodStartLabel": "Balance\u00a0at Beginning\u00a0of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ValuationAndQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r814"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Add: dilutive effect of potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r294",
      "r299"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted-average shares used in computing diluted net income per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r293",
      "r299"
     ],
     "calculation": {
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted-average shares outstanding basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.intuitivesurgical.com/role/ConsolidatedStatementsOfIncome",
      "http://www.intuitivesurgical.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41457-112716",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41460-112716",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919232-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888252",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953659-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(4)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)(i)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)(ii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "1402",
   "Subsection": "Instruction 5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(4)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921842-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r783": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r784": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r785": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r786": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r787": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r788": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r789": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r791": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r792": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001035267-23-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001035267-23-000019-xbrl.zip
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MY=?,C9V=]+JI.VE35;QKN=NO^3VU:NYX-'GX?#3,IVFR/;IR =?/NMQ1E^[
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MLZ)3#EH#L0R7U@-HBT8FE471=:&U<+KA=+I38V3%IF*BECGFDH#]5B=]AHA
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M%.MJ*8._MS8<91K]XU[5R0\^$_S7OXR'IR-6A9=?CX@%4E5CN?OVUU_XCZL
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M"0_8J@==/'^X?>_-,$ZPJ('O;=^__CCX0Q^H8:A'!_WQ& .A>]&H?ZB&"C3
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M4Q6_-UY1*_B&5K4X;>*K&+V(BRS2:+U2Q=@"F;_YK->?8,%(9NTL>=V*6$3
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M4;^R)9IT'RB&I3'_DF<IZ-X9&*)7"AMM%MFDY'\U<U]SC2PA<6B<0I<6*<%
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MJV2IBH^"NFT?!K4G-0DD0HSK:4Y1R8E67 61UK7/]9G35;@!^)Q^F'LUM^I
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MH/@ZU[.'H?,9'=%%-O<2<W!?=-*\Q%[#DS!W5BF&L*6I)#.#V'044VOP:-^
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MN7=SC!:[HDR&E'!THR=@#O,70>@-_2/6.V+5CQN&+>A<28_6(&"2UA4<V/;
MEFS;)*KWW0W)U!9!V%15_$]3Q/ .BQ@V71/;6H;'H8K_6:L@8<^.<S .4DKF
M(M8_@/42$X[,0[V).B1@*"B$K(\8:&DQ2NXD;-UQG-KJ953;6T[7N!LX;3Q>
M6B_#)D!QNPA^ NXIZ)D_U56_6,"600H+@=$@]"**QU62L5KEQNUF$Y%/F6B/
MH@3W&A4@4:MJ?'V"Z_FD.&6N*N*+,V1!DWC*EK"8M ;_W%2"<JR 8UZ!JGWF
MZEA$0PGDQ^1KZ<UID;))GY@6X*]Y7(H)'\5A:=:A9@=CR96Q@K%#PE;PJKX2
M0L@IJ$%<0;4 :SC#;%N"$%SG+(+:OLSBR'MGN]9X2!!8SK.P"4/L$@]%-44D
M<6$.(4+41\PX'L540#[S?%/#FFZX:_'\7V!- [D05SRV%,GZ8!FN/_#L*;8R
MR?R*A3NNR"DB!AY*1!9<6Y S-S7[33F>S/DR_10\B[?T%C)@I$7,I0MT-.!9
MEJ732C^7]!I=7%]OTO[P/)BHD,"0^!^#NUZ[RH3V]19WY7TVI-'T:[-@CM7N
M;?SIJ1QQ-W8E6V6@"L:&N30NV#("U4+:2^A4KK( .V!@*P)=O&!CXMGPN4DR
M-AADGHV>-P&!$J+S@W*O^+<. 2P435)O4O,V=6K(O7,=S\=53A0XI>&M8D(/
MXF\B2J>66ZP9Q,6L*GH>8PEG^%%=(/K6!)8H.D>L(LV\F]7/_G-[;4_"F2^$
M%[9!>M7H;J/*TO28MV8>&>4APPQQO]F.B%YK<"SI1#BRE/#*TKKR'1X#MNA>
M!A--6C'JTJVK#__O;C+6YYY90BUYK>L=['=SKX6?N,Z$)-A5I.!?*ZZ'X_PQ
M-2Y>1RG*Q 5O,S;(^$HX_#!2);$\4R!7W_JFQ8D@6VL*\+_;R'GXEN3/72&D
M#FR34/>=/F!20(\KBSV@EMN?OU^Y/P]O;J/?;B@QW7!E1 69MH8TV4>U"9L6
M>/DY-MC(\H\@'^'G^F*/YA"VU OGQ%V\&5S:%Q:BA:97L#] 4]&O];8*GWKC
MX*&U+@;2DIMQ + 4]B1EP0RPO%D]7N.$9[8/>Z1=$SON21,.[M42)EFA$XG6
M4%\MTR+&;[&1,_&NS_K6((6PI C71'R(9#2W1&);P1'9HZ]UJ#%(S;MO>]@+
M1H/1B.(@,_(>244Q&[FQCO=[NSL[Z^?55V0[O=V];;]\H1<,>]L'!_C1<06F
MN,8/1ML[^,%1@17!^)[;NX?F1SG6Z(EE#9.61+1L6-*(;09X'>RNECQDE==J
MAVS3&W+?/M$/8=:'O8/]W1[(:VM@$AZ)R5*4 :YXQMI=CWZ5PO5(T&H'9FJ)
M\(.E5GG N*#V&7XR 9]KM^.1W1T(#Z4MR=W\KK[:SFKG(?D<<=X>#>FNEG!^
M>S3 SV5+Y9J@@25#5&T9SF_<B$H:7'WT7\?FH5D!G4B]N1Q[(#-^>RBZF2D9
M.OUP;BN&[&QV*+(:BFRT'D5V!UZEG1\ZZ%D'/7O<+_#9T+/'R@IVKA*)=+PR
MS>7.&53P5$[%.]KB_,+4J/.IO.%-Y&<F]E(CWS(H!N[^&A3TVD1Y(XTLB[HM
MR"9@\$S;ZHUS).[O!>\1TC1%0-@)S#'8%C_GL%>$KHNP<,<*,4K&BE08*ZK2
M$L-KSWO!JQG8!KW@OQ3,32\XIY#MO\!P5MCX*4(K\T+%5\2;&A'G*^RT_ZK
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M$N_M(!EQR??^6>=PU6?6OS^B=78H'80HL;/#D<7)I \JH%_,=,*M ;.4IIP
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ML!![7VJ N2K$*&\4D+M2RX XKCEMY]Z_%D-"?S8N*X\]2M)3S-5,[ *@@XF
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M( 8"GTL/\]NM7?VW\L>J"F?L: K%L_^^.$^EK.D7=)D[)A;V/*MX?U?FH$F
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M)%V#-/YT@*1H@R;R1_:4V? 12./(W"R*!&6F/9?!B/+;!XLT]JE>DK]] ^X
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M[XJA4R(F&S@W=EMC&<!G4*]S$2,5NJW<K&44 <L)> K'5G#YTXTY9ES;QBI
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MI23IY<8T%2O\AF(4T!0P+=[0[84_3XF":=;YYC0(,Q[,8,6_!*E"O6Y=9^>
MS7=N:3!C,I5&GR@+?N-;G>LHP#VD+K\;RW1,P4[L$_R$-[<MD6"NIF<RW.:N
M)>%2DG:(29+4'YY&0GAGA/7ZK**AH9AKFEK;(D]BJ.-%UP=.$DDEZUX&WFCU
MM<6B,L69--79X&REX0,Q"24:OBWX&I'%I?%!;81'6RKEBCTFDJG+8D\9-=Q'
ME#"45W#Q*WE@S10'7CK]8>;V1Q?(16]].;(3)%^UYB=;Y"4S9#$WG6%S)<>:
M;I_X6.Q>-@("YY8S (WCMG@"BR1@D>^>FLJ><!^/[0$>8U/9<.439<OSR;OC
M\<GA!&7,B]-WD]'XY&AT<7SRAOYY01^@OUQ\.#M[=SPYO^"_C5\=OSN^_#LJ
MOV?TY[?C"_K.Y6A\>#@YNQR_HJ^=G1\?3NC#],77KX\/CR<GEW*-OZ/T:874
MBVQT-CZ_I/_@JH>G[\].3^B3L>QZ_I[KJNY^[R>32[KZZ=&'P\O1T>0]OGA\
M0C>Z/'X_H:O3+TXFYRBU_G1\^9;^\NK#T9O)Y6YX(!?UC1'NQ*.\'4A+0J?]
M9KK<]!/MC8=X> *<-<>H=&K8*3N/QRQ.LN0$=G]CD&L$35N.S8_/.)3"W]B?
M;N%77'/K.,TD8JX]9*#M<'9Y<>6RU#O,:W:2K3%BM.06+G! W!0:$M\Q \3&
M&LOS&*RZ9^+(0;/U&FL%?14)!CN/')\H4W'!MEG?2JH74%L*+T0OT5[1@-_5
M]J/#$)*K#^:=DRSQ2#K.N:NW)7ENJ3SZ6WH_Q4%T>E$GTO[;GTKO,_14=FV4
M Z(C)*1%+AW'3M1G%:BO<UH)':%W60*K4'%!44YS$Z:DBM&#ZZE=Y+-(0C+/
M;X3WE#MYUHX?FP/QAE53DMRU=+\*V>XOZ[+1LHV ## )4;Y95)1S=EVC>]W9
M=[XLYJ]X!SNPD42B$!_?IY>.[3_*H^VD2BS,TCZ@F# 5I5!H9-(G.?ICN@0F
M/D2\AAT@+8U=.OM(D"7U;%$\L=NUTK %K4[.0H6"'#^&]HC);/0>1%XK79PF
MH?->W>=28X6V):4SELP.4[E,U_.K(HDHMF4K8_CZ;Y^M3%(LW?G'K@Q:Q)92
MDVV*_AADT&)Y([/Y=%?0S(:$GR-&I= BY\2C$$VRN;!EZ6IPN&# ,@1CPD7<
M8 KED!E72;,:4SO2W%W1*M^TJ^)&2)\;-5T)K&8SQ;M<Y3-!4+"AZB(6.;^!
M4XF3\;Z,EVFD[^7:XV[0?>X&>N0#\J; !D[K4EM"\Q8H$J'*JQM74QD(V:-*
M\*\H3 N^*DD$( T%^= VQ-F*AI3N9RXE0YW)BO%IC[YN*!CS4"M*P$@Z:F&'
MXG _*6;&D!I,G3'?$0M/[@QP3^7"?3\9+2--@AH35*Y:-30L]2JS-5O6Z\#<
MJ96R*\Y^LT5Q[;D.3!K91YD0K4 8?U.O"JL=TYJ*!5[ZZLLW$;AC^9"Y=D<F
M%O"N(.NT5,90Y=W&UG R"C4K%?,&I-]<2=8B)B?B.0S'+..Y*GX%4+5(T'&.
M#<Z:=$-?471V!&I#:V03RN6),\;U-69WD@JA>E!!ZI[3)O;VK=B()R(;BY^J
ME=_ 0@#*UI1S2[I@08WELTCLU61?X@WY;(\#KDF5+AR,"TY%P3AS'BN.5_Y>
MSN)2[#R#W&U/$D-Q/YCGDVS1N@D$3%('C?E]UF@+#M%GI)#N.U;I-P#E/488
M[MF'5^^.#T=O)^-WEV]'A^?'%Q1#4B@W.3NF4(_^<D2_H6#S@K&TEV\ISIR<
M(^8\!@#W-7YS3)]^_7IRB*!2HL@^:A?_XL\\@7;1)&@(T[!V8&/KD '5=H*.
MVW>[GI(3:4QO,R2$M92U7G&BCM=C<5LR.C(+.$FCVJ<-R;4(,G.\#R-*V&?&
M[6+J5-8@OY&31>*/AHS&7=G0=9X9(O,Y5^GG7$\-*$V<5-?Y/!O,VE^SPD;$
MTG;\QC@O6<\B=; MW&@O[DALJ<0A7;5IUKZ#X[CEB(;C4Z5((--H%M$P6=:B
MD:G9,<-@N 5?,F8#+(C2H2?&7SH=%@ZMT\6M]%$F@M?S272F# BAR$,@DB%(
M!GE-P4MP@$XA<\P51&&%EUADF0\^G"_"N'!9^F&T2*_!CT=E2#%N,#1E[+I3
M:3=76;1O5Z'T%819[*"I&SOKI0B'>P E*+SS[(K0?.D60%$=!28^T,,M^)$Y
M;((/)N6$I1+IX5D:K@./^"PQ5T^1@I@8_J9]+_E2)GS;R&M89?Q71J.L>+&%
MJB=J($Q0')^.5GG864*58=ACGG_#W;I, E<P).2U;PI%?/!H!N2ZU"[UH-;Q
M0<N&'-SK?+G 5]!"GYE7'!9(L@;FQ0PFD$,9BY\U<]0#0/]4M,@::7= UED#
M%G3("F"_T6;'3GKG\7*A3N,IYNY2+NTX%\E>[("P.[9V2FY<T9K56G'PQ1@C
M9;XN-,QF-M8>QHG\\<8 \@,S&X-JOZ7Z"$]\?=UR5F4 RLNI#&DXIS_/\]'?
MT-\^7!K652^P5NF0#WSA=.J3]5G/S5_6$.#EP=?//B9R]]BQ\3:TUG!QQ=@@
MD4>.-JZ'K 0$"6:!.$>R,LYD\-1UD(3XFOEMK$ASQ^$*#C)4YG,FSPC=9:^/
MQMS=5DO;2?@"?QY*'Y%-A[\3/KA>79O!H(\*[P[Z(^1]XPG#V$",C-9WQ*)B
M1UMSF*U#@4V0[7!:]:*#().Y&[[+^ &%/W,<>@;!FX, P7&QEC^E&?%9&MML
M/^O1Y/!'' PB. *%1[1W,H%D-\  02<[A:QRLNL>ZJ3XV,3%7W53#?:9L@EX
M\B3EIFY!'L\YB4"M9I^>,QJF#]BSSEEF(PN3=TV?X]%=1R@LS85W1]#50^?*
MJG#HJO:Z0%I^#Z(BK'Q$%_Z*]^IRL??+&MMJ!5L-JRE='\EYD1+=DFF<_R+\
M<=9V4H7BAW?@7%I(N[\"HY5/\,1I%QROD7"@\RL0;9BUA/=6LOY3?-"Y- #'
MJ=>2A\N]=I7(Y 1B;451IDMS*F)XS70'P%M7-9SSY"OUI0!@Q=R*/"7T)\0!
M8XQU8K&O:5J%GCTQYFR@;NH[N:U4<;H 8Q/19.>*MAC0!'/GM=;</2=?NV6Z
M7=VLXKB'OJ<^\)$'%L_<)]R$QTW\Z0DW\82;>&P/\!AQ$\/[SWMKL5<R;4 5
M(%C.Z/K@B0_@)*5/6=M;4+3CL#M&OI_*7 3_?&OFHM/<&LJ]2=&371#A9("1
ML#.##TOIW4SD)_]!66.)2Y7 TI,V<)XI&VJ\C7UB_1IV(KXSU#OJ&VEP"W^'
MC6?X9[XM.J+@B[  +:1;\<8+N-!WZR6JSZY#Q965S'N2X@%/3>9D,:6I:1Z:
MQ>[H$DGWNU.G,.WD;JN.SD'M)4.-(HP#TGQ1F.C'3!\7(:O,O7U2.@RE9<&)
M,7D!9KQVVG#7]C R#!5^XX\6^=5Z5V*('LO( #=(#W4_N!<'2XJQ-R#=@%8R
MD&2 "1/S@A\"RN:N%R'*TU>ZK)/27,B^P.E"VX?D?/K?J4/BUS$*N#TV6V./
M+$/<&7ORIIM.;Y\^\ /9,PN0XGIF]Q@YW(#<*!:YE#%\H&LX=J&SB^$*YL>P
M*0P.8.)GRS9&Z)!C1>=J%T-&6C%.(3P;;@9$FPZB0C2EDQ/-HUV6OZS+.6]?
M^U7L9G.&!B4?L=VA2B3:MU DLQ46"HF:[ [+(_24S-3^=1KN>AU]:K6=DIRE
M--O"E9)SC"&8W@"7\/:0&QWQ:E1=F#N?S40EMG:P&J6Y-)B04+;:;6#%J2]W
MR#3_ T4/.FI*T!X;331+I$SK92Y!4C9Z7\[G9+,G((X^I[=2TB2B/GNQJ>8-
M'[X74%B&G@K"[.&/Z%YX>W!R8-=U9<K?.IE=)=4; S/TYJ#/2*+FQ&P,659+
M\TDC G?]<L(F;:1J2WJ_>1/0!J$';]BNH]URR>?['"PO=SQFQ_X4"UG;.%/2
M-.=0=E-CZW_99LH_J,[[TV0T/@>H^-5?4(6]/!V].[X\?C.6BNOQR=\F%_:C
M8H-/+]].SD?O)F_&[X#^/9Q,CHY/WO1)J!09C (Q_73XX>+R]/WDW'X\?7\V
MN3P&&YU<]<WIWR;G)^\!3CZ?O/E EZ(_C2[?CB\_LW8\6#$^.J9/7@*)/'XS
MP<454G4Q&E]>TH_\(=P^X)NM!+T;)E$Z8V/$(A AV+KISR8(J)UH2]I3&@H5
M.$65/6.9ES?JC.2H+$LU*@C7*UBKY/(H5,G:Y,BA(U9S>W:R0M=D'0 BZL;X
MNT*>58 84H, +BT)YUA5A1.C-#@T;<XTH1CH^DN+#9:"Y@G0L=N<F\637_-A
MW<Z:<BI)Q1-XVM^;Y:((N:V7Y9Q3CH/TRS(P^>X9Z/./CVG?T%^%=_'[W5A(
MQRFA0F+L!:+0*D;!9_4%KP"#+!,OJVGH3=E?#'Y8K(0E6]>?HY-"+GK5H"]4
M_@;>*,TPR[J1PM7-381)VSE*3ID CN;T=6#2DS3VMD$YIJ(IIUUI)UP!<+ 2
MH+XXEM![T/)G-HI*VRU@OH6J]0JR6$&RL0=;XCEFW/IYW6B$\A7[WOGJN@=0
M",L_XI>85%%<%;X=0//B]O)VRAM9_U]92X)^AI:S@4.#]/QTPRR4=)_K35O2
M8F<] XO,I=88&A]"G<\(N,G#03%6$,M^%NZO:YU'G4+'V-*?<4;CH8K*>%4-
M'!!-Z, '9XQKT1+"B4-WRVJFJ-DSZ!S&2(W0PZ_:H>5B.D<*OV6:IZ!=H-(A
M 8NH7GX4K.C?"Q7%XHIV.5<Y]<YU_"0@)TM>.6W=Q>!'T#RX=18""N _1)+3
M$6T0]#DJ>?R)/<*9/4(V^NFZX,&-T3BO8=MQE>M/&<P>./?PD CVS@(,O.&?
M32_ED =W+D0Q[T6/>2P< :I'G7P;$V-?L7CZJ+ P5#]&O[F1&;0KX[_296"D
M]DP/T&59=< &7EPAYV.DHS2<@=?9\?E"$;QC9CYE!="U#E('&$FFBJ\_JG"A
MF+. :BB9VDC.CA#Y,J3G5DMO0E!AQZ:&V;MQC, LD.LPB\U3[0-F((;+?>=D
M!JT>Y@90')&AX4( S7C? *T5#TC[E,+1!8(,!@WPDK))MX%8LHCKH&5,]FT=
ML-7E<J1B5:6"N?1X+#KD>2'9D@*D9?QT DU3\H2!L2E)@$)3F1HOH-9Y@=VI
MZJ?V'35N\2]K!L>GFX/F(_7#W,1:EN0>SMX4%7OU;Z*X*,;/VPDVP U3'_6<
M#>02SX"D&JV45>9\+FN^ 5AF3V@3'9$8%__O0DFVDS>7YBOO8LC*D =_YE'K
MJ]721'9^7L^O])_R\441!+PU(22S@Y.T:G4>G^N0$"%J,O8FJ'Z,()!:!;*7
M^\)ZX5"!1JXNY'QZ2]<W((&G2->M?ZC Q*@GE^3O?^9T,A]0R[)8>/OCDH7_
MW!"7UW%,5/!:#*%$+!CST0SYJ$"[(=W]JK$N3YPR/,L6>I0Q]*O)X?C#Q83C
MQ_?C\[].+B\XJ'Y[_.8M!:D6ZU(LFL4XF#Y)?WI[>DI?],V[G>C8>H LF@8(
M^F)R_C?NZ3T]YZN<G%K#[^C\]-7IY?'AWOCBXOCB<D)A,T7GAQ:I'WTX!V#[
MI[?'AV\UK!9 -?IVS^G/]!'Z[]\F)Q^D\_C=Z<6%= GCJ487%"9/=N,D.J]I
MF.5LCR)(,KS<10M8GK;MY5M=6]X:W>^21U#-KNMV5M_"?19S-CJ&'GPU1QZV
MA)LB0$5A>+*>J=(W#<)+X-M[%7GF/"0C*C%$3/+=AGT%1]GX$H>KFC3F)\2&
M1VQ\_X38>$)L/+8'V!W$AA8<G#]ER+60^[DK!HT=^Z)P2"HSV,P6>R>^&%F]
M]\=TP,V;-><JFOR6"[E-/B^U6=6NZ=V_8%[I4U=5S11/4FM?H:G1+MW:2< X
M8O">H1NO&\H$) FP&VCA=NIUG7R4]@I*K:^7OE!'CAGZI"3%WM(:%9W+<'[,
MQ,43X+.IFGS4_L7PM*V00$6< 3CL-7=''B_/-J@?UJ&/<9@+ .QY1:>F7,/J
M%Y)#6%=2&,56H[E1O'@@=>"HFT\U/O-:X5&C?\E[Z+]P3"*/?%I4!4(>H63]
MBFMX[6HO/A /OW<P]\]"'XG1B"SDXU&XE!<W2'*FRS\JXTH$(ELK_%>B 7]@
MNTDW,9?D(KW>RVFZ["6*M:ZK@ /R+L-NN&!1)T?E>!<ZL=I+S91?LR+)!S/$
M*5#O:YU3:NW,VRHM.OPS JN&ET'66QA:!;ZY70/WW%LNUE*BL;'RL!V&VRI]
MM#0DQTQL:%Y:E,52$")RWRT^&5_F)I\S+)[344X;5N4N>C2B[#>YNX28-Z.@
M;L4Q*',G<K"?:<.Y22&%F?OS:-P"OM1VM!-_!%D^W2"W$;^YF;[]<73X_CPZ
MPN]6<_K<7^KK"C"D_\IO;L-//X[>\_>:ND2J+^@K\N]U,MK>'T3.=G2[G/V(
M?AUNG^'\HHSH=+FA%]7YVD5^TZ[IB29!#A<?V,\P.OHK68,Y#.=/M.#R>O2F
MJ=>W.K;EZ*RF*Q8QC2D/A.]<7>?EZ'TYDR9U?(&&/'K&7W\>KK\OXIR7Y8HV
MC5V4E2=/ T^ +!2)[-=3( DE%QG;6YB,@"L1#$RSR1%C&1(XRXVTV0<96K>Z
M C[ OLO)0V$!L$U3-PK8,::6R'TB:U<A-LI,[UAI0<M<"JIG#A860\;I5<.V
MD\P:YWZCH91Z8?&9QTZ/[_"^R^AKX1$=:T!(,;PQTXRX/A?;563&0%?[SV-0
M'DB(#"@ A%2C$&LW]5V13"#GH#5N"HD<9_1C L]->39B$)"LBM4U^H)Y@1FW
M0L")[,;YT $$ELU\CXO! 2VF_:LFCVWMK$&]8E7_DY5(^8I_!C*FG'W& _V!
M^JWD<V]+:&#_;DE5R#HWF0!VDPM7HM7EM^:.+"%SJ!D*R^TKK>O^=B80_K"P
MG ]TUP9*,WN%PG=+)Z =R>P K&.JW=9"Z+OR4A]<"[NQY+]12-A'NZ#K%6N(
M<'KFP<5F#\C<*F!YX7RSK3E0H*E(< X)Z/^)&DC>8:TT/=[CSW[(AU6J8(>%
M&  Z9=)H9%"PI E>TNVW!B[VM2BNN;%QK5%1%3^Y2T\7@%WA>:54IU+7W58V
M<4F$.SF0XC!"%T6)UF/#M#I>MI%&JE>9^]R#07-XU>;A%]DY/W!?.3X>91+Z
M^'6"NAH=G6I>^.WQY&^2S7T_/CZYI/^S=*Z21)X<3K+13Y/13\?OWO%W7M''
MP1QY>3IZ,SD!R\:$&3XL,WPR.9Q<7(S/F0425)*GYY<[")ZZ? #A$"@EDB(_
MZFRAG8+AR+E40Y8;[ER^SS=*?XZM*ITE_0!U/+LNB[LH4R*>!&]W"U SZS4.
MC.EAF=_F&U3'DRK\9\3% C.AP2MA\DU!#L:\,]I>DH.VZZQ9LZ^D>U_W(6_6
MM']1J7=R?CH^*8*3I.YC''3F#@;VZ[BT%FB2DOR$$G"%CSDO+- 4KJZC.%2D
MZ'1][*FA^0D)AR4/LY,8""H'0[,>_YK,/K?H<OXBB"?UT:G]S(L\$2JP;:N^
MX*+W9I,O0+Y/6]#W1V>=9 :SV1LQ@0?R))=85^R?WW..!&T$0A^V*AQ\R;I6
MHSX"F?"&YURR(FB0:(3_0XO:G+PH?T&ORFA"KT%9'7$/\8VY0Z-[-J:Y%SWP
MNPWTF4_;L)N"B) ?EZE4.RD<GD(Z&2)8N-,3D&#"9D#ZU,+[W@YH^-ET)BG(
MZP(P0*LGM26S04X+K5T+KYC\K03(!WVXFVZJL$-#T7E$E%VYD1>]+O5M)\%D
MM]*E1Z]C5M"LSAU>08F$Z#^A;\RM"$>R$)O,?6L"][Z4-U/ /=G/T"MT]T/F
M0(/<DCUBE#?/NG(CN*9BLCVT%^A3]-!<>HHW+^[J)5M$YN-PWW']%[MQZ/P4
MJ 1MPS7%8,HP1_N,0+24 Q$E=Q#X2]^/)_6A_0<Y//XB9P>8F4T ))JR&C &
M^Z-739W/!^V$,J>V$3@H*,_.+?<-%>:L5L@&*Y6.@*>4X#3A> 6/:L&FIXPW
MVA9Q(]<_1US,E%0#3P\T'V_ZMH.?":>$H\H<;)]ZK'[AV].+L^/+\3M!)7PX
M,>?N]!5[@X> WH_?B(]X/CE^_^K#^06CY4>O3\\=<F $]^Y-!]Q/UT^_<WPQ
M.CYQ7.-T([X#NY"'IQ?"WJ9XA_[UZ(YTR7?'[VG$(OR,01^_/SN]F!R-7OW=
M=0I<@"4=5QV_/_U =XK/>3BFQWH[/J>'PB,<3L[Y21,0Q(2Q$Z_\A 1OUU.E
MC]_1D^^THWL<^98\^UCD^9["_EC_7@C]HO,26"Y]I<0:"X:.!2.8TVPQG;3R
MKW)NE&I.F2T&OMK^A RUQYTM\TH<SCAV16,I#:[;[Y]U;HD!'7+3>D\JO=4+
M/UX_RM0O9(0<,S_)\ 2Y%^J*G^D89EM41X>\W?9SW-TTT=;7U9-#",[*J+TN
M%SIMK#-L=A9X.\6[UNM5Y[=QQ$\H%(]"^>$)A?*$0GEL#[ [*!17B^M5OP;H
MNC[=8BJ%-LV X"NG'RZB-"LW]@J#N\FX%30+94H?E02J"1-T>G)9.!S/G3WF
M?:SA/+L 2;OVDY)V_\ #:-M?_1;Y<3[D[W*.83W]U=1($C9P[RF6]H_)F5LW
M*('XS(<(&Q7WB#+ZLGLN<X],)PKU.3(IM!I?7W)S9LSH>PE^ @;&]UL,JA_K
M=%^J\(":#B;W8CEM>KX@TWP+I>[6E\\\%/H.3(LA=[&VJ60FK+*.-54DT3GW
M)O 5A1<D;=MUVV'B9*7VXBY?ZA <?COTE"MW!OX<NCC;8KDT#A465&>^=?RN
MG\B3#*.-Q_AO9ZLHUHX0^+-[GPZ5V(6&\S8^_[OBJFQ-;Y5N>L:-"_3Z-J.W
M4BM^;[7BL=:*)Z%6C"W^*M2*8TOH85(K/H_H^=-0+/Z2]B7'*A>]6CRO>+3)
M>MB=>N\AK>1<0"MOUS2S: J[*V6"W0N\*&;K!K,SGI/C4W*&DJWTC0*R.NR2
M#(AAJWN?ZD0C 3F[9M6B0-[)+*6!HU7<;\/Q!%<]BEXD6@GU B2P(& ..3XN
M%#2TG6X1X;"8"WG2#814E I[*Y^4!RULX94:#!ETU\H,WLH,IN; 5EGZ$9WX
MO/2_'#V#HT_;18R=_ X^ %[5<V:LX5,!D+JU$OU*)Q#+N-L;H?/O!F9'=)TP
MA?_,E^)1?KF<Z)MZ[;&&MW%A.<N8)^O)9<ZA2]#&\J>,_;'F@Y(ZX>&IU 2/
M)DS5SQS_)X?(ITS.P>G_^O3\/2O2T3=>O9N\CZF3M^._<=;D?'(X?O<NO>KX
MY"@;C:$Z)PTFH)(XA'S<D5 SC-^-/IS0I2<7D\F)9(6478)%\,X^2/*'[X-D
MS.3\<R?[FW]I&^<=Q(XS:)H\<MR[=N%N5E:4U.YCZY63^S  A4<N>BI:.7Q7
M@"]@4P9Y*L"*(AER<&R$TCYQ86C3!*[7FP+,:9*[$/D@U5]1=',46KM=]7YG
M.!) ,-ERWBM5A>OE-ZO(:KQ-4XO^7?'K-7G-*T?MY'!1]]=%Y5RTQKC)(UQ3
MD)PBY!,OT6&=17]D!F8(^)>APY[[\&*:N&R5-U@C MQSSPYR.=8'R9ML=%VY
M6B"P*Z:/"\@S:_WC_$TV"JP H!G@ZHY8R(ZSE[BIF+'J&OZH0L'=I"((7(E_
M%>?7D4OA*A2PJF/,$T)6&BEU+NPI?P;- YQ54/Q5S!JT$A3D3=&PA6VO1>=]
M?_3*:E-=)429:5F?TT*4D$4ZB8M"4@OX=2A7EGE=(VQ+)!V-JU 5D.B%%962
M[UKWKKYZSDU9-;\#1^(4E_6G R];"F.@I-*@]"0+@V=?WD:[BO((H."B:6[(
MC&A3/TA+%'$>]_.83A^.Y7J3XGHK^WO6Z<!)!1(ABZ3:].0ST Z?@/PVMZ#1
M\6$7#4>=*^;&SW1I9-O6AB%SDH!:)QG[:-OW=+,W!@CK8I6Q.6IP$OSY"VS_
M+79!=;6W+!:K/[_\]M.GP=X?>!QP1/#=CW\<+C"=KH-O]U]B+ASIG[Y'V\'M
MCT^OXG=]%>C?EWH[Y_.?IO\/V FC(8C2TYOXG=^$)V(0X*:BW9_>Q._\)D3#
MUY)O@9'HZ3W\ON^APQ<5FE[$:T6C;&P)(Y?:=X795Q&=S)O\'FF7@ (34P=:
M78 @/>6XAD/AY\ 8+ HY0<L'#FGR*RY/&\4QZQRCFU7D=)Z6S>^[;-P+4.K$
MIS?P^[X!'U,J[W4#EC[H[&R$?.A'^M479!>?WLIO9TZ[K%Z[45PY9(:LKG2H
MYB^V)GVZ]<O?@V+J,2;5?YHHG=*KA$KYXOC-R?'KX\/QR64V^G "6.3Y1%B5
M(@]32*6/ \>Q,1P#]C@&O_')DSSN:T?0I_HDD74M=)+$>G\HGVMVD(O>RAWA
MB^[[PM.;P/ZE:/T)SC\=A+:?8()N*IHO_K3H>M:J@":2'XU)($3PA>,Y-$0@
MG0*>4\_1^^4KNXEPB K*3W+-@N79".%@2OUGA)9QLO@>-/ ;-,@K\\;F5I*C
M-FO9"$T,U[^LP242AM/),G=$3ATJT5<RP[NQMQ>Z0@9>%E?&-;TN@N=^5/NC
MLZ:X*=<WK>K5H\7/AAZOIO0,X9!-Q=LJK5F.-O2(RAPKI1@&6H90/]BJ-J:'
MRV9&-^?X'^ZOD8?TAA 1KF$E^,XA6Q#V._<]C^N45;HLTHG&$#4-P<!/(6-L
MN.%TN8PI]GLL#X&_,N2_;E8N>I9;LO:N]((H PU_5AEHM-D2RZE!<XK;$W-H
M]P!^TX(1%5LS7^7MJJEO*08QTDE^US-MYAEXV5;^8,B_TD??<A=F)$R@5;JN
M(@U-: X=.'[2ROAO?OS\.T)4O_GZ":+Z!%%]; _P&"&J6\$:Y%J^ T?H7R=_
M!QSCXO3D9/(.OE[:RS.^O#R'JR@]/(SH$*&.\!T1WAB_.GYW?/EWZ<H!RZCV
M?9/C"@V,R9' ,(Y/#L\G8_)2P0SZ;OP*333<NO. &(<YJ__NGJJ(;HBHC<$]
MF8Q!:\0-<$>W$)$JI!TMZMX&=F&P3G/#"AP7L$(M%@.JNU$!(*A-23>,WC43
MW:YFE0UH)N<K(<P0O(DZ"H;"B,@.C^D0;S?0#145O9,"Y.2CL5S,FM;E>OB)
MJ]4LGBVD_56Q#(W-,\@8S7J]XWT5"#A[0Q<J6X&4@A)ON"MPX"'CUX<<J2OT
M'RM?![<^LT0#:_*%&M# Z-C=BU<6WSKBT;KZN8$ABF8N84'KB#VHITHF$<LL
M"(NWJWKV41A7HA<*HL ]/ 1<7ZR<N]AV'OW1@-=CE.)<+U6;XK9V%]^5Q3U0
M1(R#P&ODKO"[?+DNQ%.D>6/9EZOEQI2KEM 3!G*1UCT4SFCF2R'(?D]^(GR^
M*/)>,5*8/J4?=B+J0@W%[B=\1-:9RNS]28^U>ZR>1)]H8,I5RVHA*%]@V%VG
M,,WZ3AB:UTO:_.M(L"VK-$&4#^FARL?::PH(F%R<C0TL#/G,3072.>Y^L/<G
MBX+;%\S#3@W)==D4PQNLN\$3C%4VDKYZLB1AQQM@R!-L7<9N- Z4UU$<,]46
M2S8IF:_ELF#P=P=)4ZWI+L ("6*\[4K%:NS* >K#NF59.M?TL6BD>,/+"=!^
M+!GY(_,22 *M:>%>6KP+?6B9RG4E.N)LTC405J"_0.3UVQG+SMR5-;1M0UW&
M-KNPX= L,(['29,SJ;1VC].OR"YM,J.N9T59M_7$;#FZU!C)"=\<[T5)6V=Q
MSV5"3:!O"H T#KGN2H3D[N&XYX'?'$.%9!UQA8*7=;VE%10H.2@\A1Q!5U[>
M8O98GW03F*P566(&M'!J]4-'CK:$4TCYX$DZ]-6.E$L0>K"1>D5;834RNR=)
M'K.,1L#?53G5HG@_INTHGH8H>#?<K7BZ"*E(()J1MT+FB[R5NUQED+LV2G^Y
MS'_5DY7FBC45F;MO+DTF-T4ABD5"#!#6VU53WZ^N,V7V,U1LD WN.ES&?,/W
MP4>OR+>KV3"![2*N648[EKS%I.%XN@Q""NO P,OTQ)6\4,;^)8H6G%2)@,]I
MP2L/Z-<NNTT>[31?J9RN5W73<<JX68'E;[8\;&CWL6LOR"# NRVKJKY3DP F
M!I%DE@:[13T3]KCBUV*V5K,1-6K)0F/V6&HRC/%C5=^3.;UBT:JJ11\0+A9_
MW=*#,E'$>[>7H^WC]!$& 8PN"RO#2Q?8[Q8S;U[&_\_>FRZW<63;PJ]2<6_<
M&W($J+;L'DZ?CN^+@$A00IO3 4"I??X5@0)9+0"%4P609C_]S;6GW%DH4%*W
M95ML_+%%$J@AAYU[6'NM#W#!XMDB#<^>ZU& M@(FI:%Q@&WI9PK[@HWL8R,]
M$I$#1Q[382E[HCBE@BJJ&A-VFGTZ.,+_O AXPL)6"B34,[!US+:?U$2S6F;V
M2>.XD1:R)I+*?)55GXL!A#'?#;*KZ]=GP^,05J.F,Z"PNW]\?$U4$N"SN-"?
M>HB"CP>CBS;O!3ZFRA_]BQ]-G .2'+MT;10UM]HM=O0\3@8<PI_HQ\)OSO%!
M3A$D8A_/)/*>D"L5E;K"V<]]A%B2:(Y<H$_*2,C!1X4U2V43I2Q@OX(<)&3I
M\^GC3M5TATXMT0YY2A@O;!RJHC:;3-/&9&=I0^^RX@L+6^R-E.+(E,P:W94X
M[949YV)'WBSI3HO<TD0Z#;HP^AS7(\"-V8O6Q2G#E4X9;AJ5X5(6^-K+X5EJ
MGXC"=K"3.W5E=O_39HB9*</%-(<IP^4:$W,]A[DN6N4IWP'8(?S6T7P1:T9)
MH_<>K<INL^S5C)@"&0)8%;4EL*<9KRV?,D:D.=.1NN? '"UPOI3SN96+@J.,
MIA;M5D:Q)R<",>)<*3@4 <5?S@QA$).&FI<PJ7KJSJ9BWO$PEM9GU_'&I X=
M]::^2FO]?I -_G8U& T'L*!GE\$"PQ*^ZX^&E$0][A-YD!#^'/]X'/['M6%\
M;!Q,*=K6D#L=MLOQL9#/0E"G9\'<7@M]D7PZ)D(E]?EL3&ZPF0O5)C>*1G*=
MIX_3A6UV[; OH36\NMW</?:,JHY:=[1!'WLF_SO5%%EUO'3,!5C!=I?(4!3Y
MR& DH<]QGU-/25.LRBK)K?J.ZIY>,1?B[=M\5?Y#0TBY#VS=+1C@Q0Z[>)01
MC)RV6X/"GX4O4C-$HX,6'I$*21N-6MD)3Q!^4\ZX)EVKH=ZP_H:U_JALBKTQ
M1>3RM=@@!$@H$* \[()XZ,=4HV=]8HH"H-Z%;'+!60FAA-:Q5T4W%J5323?A
M<1,^.!Y;G<6;;7#.-T1-0,E,!5ZPS>MEPY,+&6:6\ 6I.:>K<+@&"[Z!B]M$
M3F,8OEHZ[,1BBCZTSMJZ>I#H %>,GT%2!,E,O@$_YMY#77,.=%"O\7;_,+Y*
M(I5RI['K3E87X$!!;C=O.4.1?UMB$.G0]#FC%O(LYCQ<*I(W&-N:L!'CUMH
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M-B%Z1HY##H"X:B&02E3F-*$@Q*8"W%?_62Y;- X1F5PZ>.@LV$IE6^F=B97
MB(\@X&TILI:D6C]%>R\7>2Q+;'1\=F,B>/_7E5L.*V??RC%7F>C/Q(Y;_74%
M2'V8ON!\YT0_!@3,AKQ ZI1FBIT>^$Z61&A%&0]OMX$LV(#J[+$R-C9RPI\'
MY.A]6QYA#\1!_YZT!4G$2M+OU"50%\S!>\=]!M@T:%2FH$=9=%FXUY(0=^4:
MH[MY $$37<EPR3AU>YRLMTW?"W.V7H3WWH"(;4ET<%"O,,"[S%>;S<>629AR
M722IC5&*'9? +"!I(-!<10(856^O72<LEC=AXJN"^PY@66I@$X&'F2IW*7_#
M[F;HX4X&)!TOT?*FZF/^8)@XJ6/<$OP2M8H/PEZQU,ZH^%*,4-ZA2Z"D.N5>
M><T:W!)DH)JSC<!0?7SPAW!+%6HHR7,OJUKS'M(I$<UC6AW;_2Y1)WG"$ZZW
M$J[4NC(8]0C-;DWYQPYR$(S*,EB&]V8U:/7CC!4QO%9X?4+HVSQ1/8&2T3U7
MV&-][7R3IT_>R3K1HM?4]HT[!>I2,KR= Z>.@MV)CY1,C0EAZYSJB]$DI$!+
M:I17%'$^W5GC9-R(^0L/5Q:UTJNB)U-[3VRC)#LTC+=^>7?_,_ESI*<4<E>V
MI3/9'7XC* &-K1/N_3GB2:;<IF[3>\/UMP:8@&9",<[@"6FG>9F-,>-=]U.L
MO62\PRQL%@007E6&RX5.X;1($+@M#G&/RPQS"B;.@B2K4^$1P>[0\M-)>YE=
MF?=B7(<;*)S4=24L!CQ<GEZ7:#VEC(DLTG8325^Q[D4 Q3C-HNZ6[9KPCWDY
M*Y2DMQ%YFY=9WW-#M&PG;SS5=(SM3)]BNW0)1\O\ ,JQEE8+NKTZU5K,9GB9
M'%NV^DM=JT7SA>3#?BNG=,+T'W8<(Q8M,G4,5/E2V%W"WP8(:AZS,R DZJVP
M3DE?$ZM%&7[%@>/RL"^FE+9>UR7SODHN&^<9B&A4YDCM9+E#M6>/R&!SJ>=J
M 3XLCN*#4.1P)-SY*K1]R&K+-J=-:^=O,,E5IF1A'GUNUM,]*QP+XN&+1/MM
MVEO> AXF8&)B[<6:6OY(W"R$J=2@B0;'*0S.)B$"LH,76+%(1>0[%P2(9#U]
M+0&C%-%MC%]3:TYJPDF#($A_Y=CP$24)2&:'69MZ2)K@;#2%QZIUTDK;LW0X
M@HRN?'2;_I\Z^DKO#0JA3%['PO]#52_^1=CY;V=W+Q;5 ]4 /%Z%FG5GVR7W
M Z_"="KZ=%'<EHWLI9O'%C1"!^CZ![$0/V34BX[UR_J^*#"IN._@6OS*C?#4
MN_-G6MGT!O<WA,1T>;X3^<R;U$N(0(W!-3<-#Z[)5+_Z2WB(B5WWV%VW;]=]
M@2]*$FUR;#FT[$')])AVZ;YL1!T#WE%XU[_FJRT$'5YY2#>5(ZB_*"PU<N*Q
MC<YS^Q@_7[A/V.4%MQ(!_DU=0DP@.%>N[QD=U[."UN7+[&WU4-P+]977YGA=
M%S^5FYZ.ZKE\[X2_EXVB^:/@2IR*$C8=[Q]IES!QU#T'=GRX<GZZ:6<VU3:L
M'GJZ,C@.]2?<TZY-;*%&WAUN47T0YS*%-M["B)&J7CH N-(;</&%%RY9QT_"
MQ$8HQ9)X+T'(SL+^0)\6K3Y[O?#@[@UC6VIX5B+&N*N ?@[7%KIH]YCS$$J6
M$7M"N]NOPJ=&Y+:B4FQ5H\OI97:YROZZ7179=W_4!@%<XOSMJ.\8@GG%JY%$
MRNC5MV%O%Q_8TUJ(L$"5M&2Y@T]X6%O#R2_[TCU<$]>%TI#C')59>2BHCZX,
M!H[6JO!K,:<;-<:Z95_BO<*'PCM]3X<2G2DF^T*K(#)_A:_IIW__TD9-M&&"
MJ0E#RD+>^)'(+@GQO*H>/.J9B-CU:",=8W;-P?!GMD[HR/Q'C7J$*4JXZ[80
MZ#0\[/;@T4[2("@/@QCV,[)\S"]P/* ?/O+\<@V4>*%H4T)L8X,.+#W*B4%-
MD=G*UF*+4CT0NS>3'X!U9X74!+8#,9OCFK3"OO^65MCWSI38E]G-B>8AS%-U
MNPIGB5D'F-9D$+N&L+<C&:";WYD2E5W*L15I$,$++YO8!)/F\_*GU@M*0!8;
M^' 'Z,1PD!P^_*BN#WK6J\4L,W$-?I'$@+1,,=GXF:0._ E$K!@"22+J CK6
MO'4+2S'W# R.O#N.AX^(!=\9PJ_[(HP&_SG)^EA[$V>08U9!A"$$ G"DHAR^
M'TJ?ED.2R*DM9ROTDN@[^K@@E5@LFNR%);-:KMPWK/G5W@76>$ U)D2E<;W.
M:"=LFR231/:WA9QD>R?G+T<+>&JR,G(6$YD!7&%9HH6Q2,*40R$*)L,IIUK2
M1#(UCO@D?!\]%=+8I<ND)"J.]F8+8QTB#P0-Y",M)!Z^QY>V-4: UXJ]7SD7
MY0*)D86G:,E/R_HT- :K2I-X<@+2>Q/I]2*?T@IIC;68]HN*B$I7V1 3']D6
MZ,48<-5JW=E=\DWA.^DX4J98IJA!/&*G/5KO=7GY+XB#7H&+O<=F_2Z?2:7C
M,<G>?ERAFX6A,JO#M-1N8R'$BBA*8&&Q0$+2=%-8;Z@=Z"W>@1:7*_5?4[/Q
MO]I.^EOQZW>X'RC"G1<SHJ!P'CO<,:+@5WLA,3=]GOUQ"ML2^GYR<:6S#)Z(
M,#+$B)W6:-8'WSSR7Z>H:;$3[IQNV? 7_=.)*UM#/&5EQ>\5,?2,27?EZ#QX
M7-/JZ#A?Y;.\XTK7X_-C=Z5(FB/>.KP+]L&_[6#'>&J$G*O<$QH!>%WEK#"M
M%N1U^2@,][($/67")!&@E4'*]4JJ4#_&Z:TYQUI<"7DT#GY_<E8QN$;.U8*P
MY.D/$"T/T?K^ -$Z0+2^MA=X/A2BSI223Z'5$3Y=8I',LZ,_U04I";FD"4_4
MU(*73;&Y%:K,1/KVG6"*!UMT0?>R?E/F_JK.)7VBWN92B=0HNS>+6$DGOU$/
M6!63>W%_G5+LGC?[K(+L+UE/3:<ZSFU,%/\S6=[GX>>):L&2J/MS%JC(" 7.
M*1]=@:*+4L/1A9>]4@HD\AMFD$VKV_("3H5(HUR6W=4L;_QJ(B'5ZN8IK6+X
M:<OD=]0-BYH&N.QFE UH47@\BZECQAU,2231(]8WQZTCA2$T3?5L+EWAHY.?
MSP00W=Z0S?W 0A [FI^.]NC)4.US*'Q^SF+HK\?2 X[9X<7Q]2@[NQQ#A+X_
M'E\>#_N3P4GV?CAYFX4_C087QS^F2DL@J\57+RXGT+,G5:?)938@CMKA._#5
MOAV<O!D0N<_@;U>7X^O1X'FLZ\M.AN,VX5P%>T&F6N!R;:KIIWL"A=AQ79=+
M4M1V6,K/O)#D-QK.\C.7C^N,<C+@;=/I[!L?5,1IV[*,G-P!M+18"1%YAWWT
MYK-M6MM5T(:I)EMO=>0?3MX#V6.L&XI"F3Z$W\\!.&Z*[B(SWXLSUY_1GBF:
MJ5W8E3JG@BQAT87(#;/%PJ#$]LB$.)N:!&MLN'8&-+C%\I2][F]\W@"3N5QX
M!2_.TY%A4V+/3QAMSA*SDK7(US.=W5;6%CD_P@'<]J<ZO,6837-7"0?RMB:!
MZ,(:FW>FYZZ8":NE,=Y'8DTZ#S1IH1E)+NW9.#(#5O<A[G$!SQCV\KZ 7&RQ
M7$NM4[%6WKERIW/X=XW*Z-[)<%A4C-S?M[-;7S'W'7@4]$!-IA%&><:R5M3=
MMUV1E"97),@N!:]M@1K([5VDB-2.3ZJJZW(0]3 "OP"O3FO]CG2*A6@VVM#/
MV?%LA,M%3!5K'4XS52W#2;6D$('Q]D5>.CQJ=@44&O_JKWF8<8SMCX4DYWX(
M#Q06P7M-UF&6)WGY$'YW(KM88Z7Q0QF\FE,P<!J4CNN@-3TBR@7TPNUQX?U&
M@C]8C*(4T62K HX50WW=UUQ]1JV=F#$"HM)AT%XNYE)%UTFB+]KD9&VW*R)\
M(;,)H@(A*O[8.=:.R/;:=+89NZ[;?AQ;-BZL/#.$VMV?^B^S_]I2XTINT=U_
M$?\W_WQ2-M-%Q7%:_P;UN7,N4HS"4M:2#I'LQ:!_%KZS;1I7Q-:0.UKT^,KA
M.E^E2TG*RM?CR>7Y8,0*!E#I'$$.^?JT'QS(T8!DD7]W.<JN+_K7D[>7H^%_
MA]]-W@Y')T=7_1&I?HXGH^LHBP YYN"6CH8#4P!M2S"W5);I:RH:'9S1X?E5
M7\031H.KZPFYL<_#DO<3(N]6;*QG=]D8[_?,;'FB;/>$? Q\/ CCD%4M1.J.
MT@]%=TV,4Q.Q=X=I)^MY ?#!TS(UOR,QD_T?$6F3*#N=%&3E A)T;L.Q4:/
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M@L3_6Z\@JTN8 W/J",B9UFHCTLD)(G13K.FP_5 4ZXZ+=27%I'5,@+)AZ#>
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MX-TG)'>L&4RDP$$X0Z)A05%K6F"Z8]F^/7>E"+Q1[5J,@P4S3OSR9EN'=Z1
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M\0Y4"6W8PW\<8 \'V,/7]@+/F"KA,_T,N'^@$]0,6G248YMN3$);TPL'G]H
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MKG?<OS7?U@MBK;)"&19;<"$7U6.A/O>F6L>_.^W;9Q&IC(MU7I/<=$_:MM<
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M-L&'L9;;H<4INQ3:G4#ZV&JT%2CY<5F9;  $H[+,_PX3[;ZC'W,%C/:6"&_
M*659:*W:H9#.I*]FQ\=3[P*L0B=PA,".AE22&[A??-+U"43"&$5K3<$2I68U
M:@5LB8\:48R=C= =,T4?QWQ ][LKUVO.SE'=$#5#Y,%L71)V*UWZ;7Q*6[G>
MN53,+2/P@G@9F6)!6JVV7+2A3P)>H'/.!8NT!BED1#=NG*'R B =I]VJ+??U
MRI81\D\'7'N@',\'KI65]T7KP _?NYQN*@ DPHG_YUYVE;/NZ)N<1V.P""NW
M5BP?T]1FA?Q2ZCLF&'114>IGY3<A\^_W,CHSNA\>E8_[2J"^<+:QP<Q*AT,>
M7A+1(='I%GQQJE\!N2J^^B-EF^S".%H9N6:,.E)EH3T545^P[^*ORAFB3W@3
M5MP'P--V,1D.,ZC(E!1&^"D+G<Q6M'7[1TX1.(04D35R1S@5$.(Q=Y?(GU*I
M1Z#18&6"HLPBGDGQ(0D3QA=I;R!-J]G.3=N2!.A%ZVQ#!H96%^M@TC]IW]V)
M ACJB(]*!0I_+S9I4?Y4M ?I!%@BTQ@697"9-J[P1OQ-#$9N#;X,'4/ND)V.
MKQJYD<2PLG,"$'D%\4%&'Q6+^5%)J,N9)1WQ.$#[2[=PK SB)"=4LHJTU![N
M(R)G I40.R4UO)8,Y2:->[KC,"@V4HG3A!Q:^ O^:Q-.>^F2=D:J&S\D))JN
MUAF.D]7&S#]?T<5\,>[AS+3>NF4@GX?OO=-IXOQIP7HR*+TU4=A%/#1N$?ED
M>QPW\A87Q:W$GDF[9$SCI\+'7NQ8P]3=8%FHT!R*P0=/6GY 8TI=%*N["K[K
M+9K'(P@S1+/,(0I?3)C>K/K WBPMYJ@D8M4ILJFL39P_-)Q\B+5[[#OVDS<P
MWPR/S5<&YN,!J>I]X]%UZOL5:.'VS;8.BT@]TX;1S\NBV*@,C%Z]"F?8K8:_
MQQ&ADLP"4:JU4R_>!<YH7YJG8?:^U^%=[IP8 N%.#HJ(<PS6*XS5S;:+1LN,
MB4I=XT%ODN7:3.OPU94PH]Z)/Y3(*UISR8X>30.%^+MJ08<4.3+ ^$B,.4AA
M,F-*I/!SOZ$"%4W$B\'XS3?A@1'34Z',*.O<)"@RB+"O.IOR-,FC.ME(*0CY
M@"O%!>^35[-B;$IR79&LC&+CC87O)THJF)J<M C;7K'0)ZP+[L9M(Z63A50E
M8YJ\V]>)2* 4->G+(K_,N(+ANT$VZ?\M&R&)_='V_2^$.OAM,_2]W\G8;/*?
MBMT4#*^FOP?#T<RTU2$/$838!BK8AB X_TD$\_C[826G7Q&SX&Z74##SN2&X
M24]6C%[RF"6*B1<0 T0D=2(Y&^DGG>.A"H'J\)'^7TVL-S\G#^"!Z/TS6(BP
M?M)58A -)I;ATYHTB9>EN" WT&&O5=D":W9VT'7XY><-<<#"/ +&GX;98C /
M'^<0V S[2OL;M$F.?V^].X?)^X6IOU)I9E.85L<.H/0:$2C-4P@M)0WLTJB'
M*?N%"0U73I/;(GMD!F9<A4)R 'D)3-EZ6X/X/W$M'\)6*XZJ^9R"M7PJN&V0
M> 5G_$8ASDZ1G.A\JAE!M5@F4<13>"_3)1I1WSVLAE]S R<H<#1,AC4P!3D!
MU7K##W>$C7O4>"[\9J:URR?F[M\2=?;] 75V0)U];2_P+PL='HSRSVJ4F[L0
MM!S=6#HPG-8TOP<IL5_WK P'G^:#.9\>;/<:S8/J_5)*T#YFR4K^NNA=(/=*
MS$<%42"A0TT@^*LIBD7/I/KPOLU2JVHTA)%P'"(8R3BR\X^GCB0/A$8OEJ="
MLV,^=:5'R=0 K(>;24:5)D=O_!"Y&=H,#)S<=:DE+]C]9"+H(XP/_[[TLN\'
MV34ZML83 @6/>]EY_X=!]M?KDS?H;P\_ \O;O[HZ^Y%85_O#B^Q\,'E[>4)9
MV9/!9# Z'UZ J!59UYAKU>PJOD[?Z8]9-P6M9%>CRS>C :."$Z[5K \5E4'Z
M1*V'T=MS<KA'%^C,Y3+Q;/AK?SP.%R>*W/"!IQY 0,WO^J,?G\=F!X!I66SN
M*D ^P3>TE$[HL(7_OIW=<MW@H0!D@OK$U]*R2P5=9P2U*[NC+I+NGCU@8,*4
M?OQ)B#Z5!>5*01H5O22S[.BX!>(:(9]60(0&QE+Q;P)TB^GC\+U"6+]*P/"4
M<8#8A;:-:UNB\MK''CHI[#G4EWN([A*?4&97-2QD(MR'$7P>"S"<-@3<^8>M
M0\IF:-Z7:HC;\#I34_K+<'EA7I,J  6WC^LB>S%%U:^6)ON;8A7>^!L/E>M6
MR=)B)S'?D#@V7#BKBC(3,J\#T8Z-DYW.M8(??OYU^C*[!!3&;DM.RR</#//I
M=;RZ>41/O;F'QK"6Z<<VM+%F$-0*=1UY\):FW;QU@@^ZA_5?61/)JW_J7.NG
M<C04Y%.EHVK\Q&NUFT8#[HQ9#(9(._\3*'3*K2VK6:[83D..\QXG[I$BC'%9
MH8N?'B3V<6@6[IX0-E:5K^K.;R=9PW3B@R$I@JNCF"J/R14CV"+DY(0^&4)F
MU3(4A.O=Y+V[,TU?9G9Z!'G&]8G\39'XT5QVH_#+V?_WOSX>5?\QA-6?8E+E
M-YMJ_9]__NUX;$]E:9C*:#0X"^X/'*U+<8W>7(??7(X@9?=N.+HDK8"OT5<]
MOCP/;BA>C3B:5 ;A]'(T&+ZYT!<ESV\8G+^,/C_X&YR]8T("J#]XVA^>78\&
M&*'3ZS-XMG1E<?Z4'.IZC ^,PZ6'I\/C?G >!Q?A7L<#UEHX?D9X@=>%<.$G
M_0$U8WR+6OG?U"CA7%DI=4#"BU(UFR.Q"?LP*N1AM@7@Y]5B43T<RO2_@EB0
MLHJV98.$G-'DV?]K/.H9/QW-9^.09X*GYWD46"':'YN-,@ZAJS$<;-5T2Y"N
MB)?EL\F6D:K7^6--T-B;%D^9M%DX\)O0^!T$OK[@DEGD-\7"8ST/=<)?!:7A
M-Z=D,+'^[\H;;@#-;R%SCFZ$14,IMV79(,+EOH;@X;(]ELR<S6I%1P :ASES
M&E4\PE^V*Z&PI^0>#<ZW?ZGF\R/Z.OW\ZB^("0XKXA=>$1'Q3(8<4::+'& I
M4^+5;&1_=/NX9>$U->*M_(>B6",&R,L%==F!Y)4"O1 YP]S?QOYE>Y+&%J,R
MKT;V%7Y(S3?#J2OGR<<B/XLT@U;2)<^N"+4;A(_F0,?6Z'XIF='H[]OZD977
M%O,M:Y=S(CIG&79JGJ"T\*+\@*R,^$#^ZD]?O 1GMG6_U>C$/RS[7W;9Y[.P
M4I%VV$:B\K B:\G_,UD?=>W0CU*H4*9H] UC9,%CS$AK^B;;0.[U<8E.#=J)
MLYTZO)K$0++EQ(45:R[-]K*IFNWM;<%[(&OR97$H&OY:\$:U?$@<RF*)K4=+
MD<EH^;H=IG#7=(5+A5!)>JLI#^,7H]P&"/V50_OGW% 7B1ZXPPT!TXST7\IJ
M885,NM/IR7$_IJU1;-NYR+/)'N]0#YB> KO_"#8E8WA?E(L%]^<\VI20#*>
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M,%YE0PSI#9AI2-4I!':4)B143AW>2. 9,Q^ITI>)4"VLUC*ODSH<2;2N.9-
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M -X1YHCPQJ)@F43DKVF9D3;T8[AQP[^\*43Z@\#=Y ?D=<V=&M9CN-U,@:;
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MG0@X*Z"?X$#2;M/6)G';YJYL_HM2T\_CXD.)C)Q.:T70*K72<K7=F=R"^9X
M@:L'-%C& ZR29O1-//9B7B$A0FH;[A*^"CR@"CN1Y$[7,KK.B!BJ*$W)H" :
ME<[2?T?;&JYJ>?^ "7:"#W0;:G@W5$" &Z,EBBJKKTR;6(="]@&O8JL0)R@-
M2ZYI*>EF(UZ"HOS(-L4MPP9]X;'ONM.G,+V@E[A?EPCZW #+DCM$4@4'-1A,
M2(O<<D7'M0G#+HDV55)R$*!N4/'\.0OH9@5P+&A+R%GQW6E"*SCHKL?%/7#
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MII0$;D$ZF(R]TUEI.L_5FW&2*D.OR .]IIR";RO <+;\R'B!>K>4RW4P0M1
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MYKGQ5,*3E;L305@6 *;G/?0L.8IM+[QDC<$,.9"N,L&TA?FD*)WWN^ *TZ[
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M1Z)KF&..3B?&ESG?XM8$RSWBY+U*]U>NWK2%J_@46U-D&[_HV#$9#XJBXNK
M1?M$'20U+U@HRQ4RFXJ0FIBU8R6BU2SD;F<P,$WHN25P11G<6P'G\NM\Z];7
M#\0=[:XK[NAM_Q21H 'BCQ Y>GEV,7BJRO_HZO+JHA]@2)M15-QIS,3,?^V?
MG'T(!OV#JPN&Q_9.>R=_#"X'VK/=]!:#1="_]?]QWC^X)-2JN3'<]F+X8OC!
MP6]P]\!=@TK_D=I\]X?6YH<<2B7M$E48*X+_K:5"E'-+K/!"HQR)Y924(P/'
M24F"'48-+[6+![4<3#2Q(RU8R*^P)*M^@Q#-S@F])096;?I:!J//H>)^2K?G
MQJQ?TIU&L6%U1%G<2A:-WL(9.NOS+F;H:F2BH#"874\60HPZ6HRR)<-.Z6:,
M_D? "Q4/1H2Z(=8(RIW'2DF :IAH^9.<>YE4<V1%2;GDFX9EZ&?XT3C/QG.Y
MNU,H<VDC&C!-.EC%HC7?8M<;D@<!U9O<*%GJ0@CK>^-IY?.J8@YC%%6UA?;8
M]#(3AX*(PJU]S5$#-\]-_3?05U*X#^_'/<P)7/G!SKRRZVA=O&-D_/*(@SF+
MJ#OS5I:,ZU_V7NA1E7.Y]1T/)E%GOGSS_7#1_MIT7W3V<"U<XJM"+G8?(CB:
MI,F-LN;)"=1SRQ896'%O-GOT]?9(2ZC<E@(.N%M:"FRVX"MN@7+!(?!'*8VE
MG1M\!!?4=+/^7W/]TWS,I3'<)3.I&*%GV,68)XYWR2%!9G+B9EQJLU-?<:<H
MUIM.=1,<W)K"[I;#;72:R$:Q_?V83'C&OT<*D,VF?;U-0SPPHU@V!^5;6E[X
M#,88\8DA!F*#>+=' D-.,-9,\'(4O_%BSEQK33_8;-I7WC2JQI;R">L.:6L,
M03DZ572;T_2-KIWENR:T2+_0N5O(DZ4,W22B7*KPMBW[R!AVIL0C&'K#J$HW
MF_AU3U>S5:BA6>=4L1"J;C;AVYVD5;4X4A[&1%S<SL4DV!T^4H62;O;L&^Z9
MR839_HAWU8V]P5U\1!9ALSU?8C4P+XL)C))IYS/KK4=>V>&+II8'/&.#.#%6
M+E-N6 9M!*YP<0RWVXF5+UCN9@EPP\^(ZI!:6#%IH&4*G$0UD1';[\(KE+I\
M:4Q:1SM,,FXC)E%YRXLC7)),-AYEBZJN;),89'$5"%7%M$M<)B P#8<^&K.[
M!.!0#D+NN@/?6'!JQO2<<:N0GCK(PTVWO>L-@E_[_=.0" 0^')^<!"?'OR'X
MPR6]^;4?!K^?(;?"R9JDY2YM)F6U5#01?N,,F_HY56R8"M(_>M5PW$Z)^LB2
MQ'>"([?ULG1JVMG>V6;)C&)<'W@%EN\R6G35H+C.%+O 8N8*O_+SSJN=SJMM
M=DP#/#+XQ^[.3F?O]1M]UP8U[Z+F=S>H^0UJ_JE-X(M0\^WJ^#N=/U!\W3"@
M=FM+RFSWY5[GQ4Y#F>WLO.[L;K]ARA"K/7=6/V2[L[VD$5_O=K9?<B;<Q6TB
MT,UJ<6I/A^GO(?=9Q )AGP%LD__^FKE5#\4;#;%:?^[ -@R/P,9__8J[<!.!
MXV.:P;1;Z92@,/#!ZWD:;X 'WR"LH %4@V<?PD9(9SUD#(6WKR+,V.S-5]P;
ME]UOAM YI#1TV)^FMJ)CLQ%?<R-&$VQL;A27(D6T<^4F9OUM]T#9A ,D*I]2
MHU7*(Q"L'1NNTBV#Y8,2R-ELS+?9F&A$=#*;,_&-EAXD/B^FZ2C0/2 Z,*IZ
MR306=4.-(C%ML-F*;^9DN##.-EPA 4,86PA;E^8;6,ZWW"M;O;E9YJ^XS%CE
M'C%-0'2=..T:M:46I5?TOT(LMBBEZU661/B\S?9\3;QS@>< 4Y*6UFUS87_=
M-:\F2)8GM3HPHDE4VJH=+R?C]=V17G)@T<H#,,]?;I+ZWR(XHBFRV;R$J[HR
MG5K6(X-_Q-GS59.TB7,F<;L6WN8HP'!>4E.5]'(Y%R?QV^J 5_3[09O(M 42
M@H<IT[A=WMV[6QD\#,F<F82.PSM67@J5N733JN9T?#T))BGF^DDI$NFE4Y<=
M&K[NNZ3")\ 9)GDR9N)-OP62DRM8#SGR"BUY=DI.RK63IE#3R7XKL:"S)5R(
M:KX2>NPPG%O!WX!3,Y\FCF^#<I)6SA\HTQYYS""V8+UNI.J; !#N[6MH0#!%
M$.5*T"S9FV",<JK-B16GS1U;$7R%9"E%+B20U*38A+L=7(M2MB*O(T[3OLNI
M]Z0O+(^NP2)D?ND>1*3FH66WDHTPUR3)W98XEF=H:8D]@((I%9:*X.8ZRFQ2
M_] YO-O,<*GUINZC]?Q2^NTNV@%[D-K>WCSP3Q)1<_"N=XIDKMB1X_BT=XI4
M)\A@<G9U2D7TI@\4E='WCHZP6P=SF)R?75SV#TV9_=F1UMZ?G:X+TZL$.QKQ
M)M,IV.GM[2D/GZZ"NZ8EL9=ZXK8Y-<@H-5DTQ=?$JX$=;;/%T@\[-"\W\%46
M7KJ1VC:4"^5.+V?(XV%09ZM_2%/0#G]F>/2')A#H0*(_=)+AG/OK(:U#RB1!
M*)K!V=&#2:GB;$="BMFL._<7RU[IYA[GA]_"3YE_E_M6NTP!G\WP\?+1#!_=
MG::5^_(!F+$M_-+WZL*#;=BZOW;^XW]U7VZ_6?Z_5Z=PE,].?H<S#:?^Z(C)
MCTXOOXP1Y$<YRZ=%*^;Q@?*Q_U>1CYV5XB%LX<?]]9"''NG$PP1TX# I>8J[
MW5!P.:!@D(N24J&?*.\#:FJGL\W?@^%DJ-JJ?\V1@V.<))2\AFDP_WZWNP/:
M5MSM3 S/P3S/%Z 6P>PX@!4!JRQ/(XI4P2.0/*505C:P,'(D!Z%FGC&^HR:>
M+&S.'I78DH6J) S-4JA$_:$I)$?/7?O"H<]C&?&5D]!0IKB5LW]6:\P?99//
M;+."5<O/&VT9^FQ35&)C)TX_:Y 2M8RVYJ/82FAJ]4)_,9'7'!8J2?@_6D@S
MG0VR5K0O<GN[VR$LT4I)>[F]+&CG""BKD1W[ "9)DO,V*6#3(J*GI"Y &?6-
M\-_U:N^.=U$K0A$=;UZW\%T473/))?%#IQ9=>*1CL<LI=@4M\MER3PFS,U)<
M(COS'HP.\"O2D/]5A'A80")!=&B(J\29A]:;#Y$:- P&X('_.RDS N3Y3]"&
M&;:1IGL(B>;G8 *V":/__U[ =X/?0<S1H:15K5QA8B=NU;%MR(NM6W?.(;[P
M;8(>W,*J)62]IQULO.J.Z1-[W7">9C&V\' )=$03$).<;7VLFXW<K=J%R?Z&
M>( &H\E__*^=%R_?H)]WE((:+69@W@5OI\-W-.[CJHP2IOQL#M<5>2MACN_J
MC P=ZS1.J<7:63F;)"!(W ,Y:] NF1>IO/D[V5@M6Q#-!_XAVN\OB3=_L1IO
M_G ;ZO6.L:$V(/4-2/W'G, 74[L_?0]@=Z4'<-)_RUV##OK]P^/3M^OA"& M
M59I3D%2Z'N.]Q.U:[DD2;;3#PP_7SMXV.N%U$KS6*#4<-+@!TYBBV4<FWC.H
MX0_3Y@G\'J+AR<(Y]LX]/@Z#8Q@=3**0$DV.6#%5,:S0#!<)?H%N72K=WL?P
M[[PU_?+ JW/OKQ)^>+%2^;P_/NT'@]Y1__*/X/!X<'!R-KBZ6)-8!!P+;4H!
M]^?&^/2,S[T_Q?A\O3$^U_IZ^<L;GZ3P5S.0?Z,SW*[:L>4"7)V?>_WM=_\J
MU]]>)UAY__4N?NM?!D=GF'I]>SRXO.B=7@I-^8!2-6>G0?^_KXXO_PBQ_T7O
MDO(X9P>_O3L[.>Q?!.][EY?]BP%3)1P/!E?PM_.KBX-W/6R0<78D/W88TM?B
M;NUE&6/?N$M\4F[Q?[DF/S* XOF(.1-*D(5&<E89#H@K=YPI(@';K"1;\*0M
M;-O(8)0*+O+:\*-SYTX*,LUKTX>Z"10Z&]4%5NQB:?'3Q!&P )+ K87<G"W!
MN2IN-!YCW!V=QM.HBJ-_!6^S8HA>2T)"\9Y!(G0#,)AF,1T664"HP^TWQX.+
MMQWZ=_>AX-<?>YDXC7:4#,MY5"Y85;VB+-JN-K>]Q?_3W=WF=9P468Q]4:@V
M'6[,N U*$V(']0GWIJ5GT/EM4)10=Z[2J75W('#%;2XO60N4SN'Q[\>'_=/#
M]5#)'Z131(Y-<XB/*"H9SS:+4F$GC:I) -/#MH)QI4@:'^F%K=886$)\-362
MQI%ZYB25%NYQ.W?3W]X$^;FZ]1/,OW+HH&S3B69B 2$K^)PH$+R=_H1?B"WT
M])4T"@/77(V\IO;(E(2;8<'ZT^1D<CNJ7%V^.[LX_A^P/-!.02.C=WK0#ZY.
MT0 1^P)NBO/^Z8!P8L'Y2>]T/83ZG!-/59)P@*B[TPE^&C"2<A&<D3Z:I#.R
M\26U]JO55_PYB>1[V\L0__-"T)X#JSSA*T31_Y-<,Q*9.C8AJ5Z>(R_?!4>F
M0-J.P-0)NMM;O]%I<$T?^'^,0,".'2GWWC8?F@9YPP5/:F>[^RQ^CN^YX'IQ
M_-9@Z[<G*;@7_8/^Z64PZ)VP_8OX)S2L^Q=H.:^7%;P"_?3C;])7<52^_WZ@
M_<B]YY@EL)I/$8/P;[PGVB#_4IFS,%ER 20$<.G!^6R',3UBPV$9>#@F8%B"
M9ME"DO!H5B6_Z#_>(.(\BQ:_I#E-BG[TQG\<1LAN$+(QBC*1(5IU_EB"9_O[
MG==[NQ@_JTOX_V-]L836.A1:^UL=+W^V^[JS]^K5RH^W.]V5G]WUV&ZW\W+W
M\QY[]V=[NSM_\<&^Z.R]?/E4!KO7>?WZ82O[-Y)<EEXX'WC4_O.GW9]L=)FB
M3[_LS#X%75^E8D"J>43X=/S9ZNCU?4J68MA':87%'>?$:VJ4ALS_<5/C.../
M-+G+HHXR5HRG<ZLDB_'_&99_^Z\!&>?TSPNC;A^S!MNX C^MSW+UN(2:5N0<
M2UT$_0N>&?\-+AU:M+_P&I%(!:<:>' $219+Y8C_L\?R168ZUF$$YU3KE2WH
MSSUA<XB#<Z[K^PLO;,\"4H-#-#E*7J(I%J[HN>7_==?[<A+5],7WX*/_D1#I
ML]D#^N#*Q.-DD8-GW>?>0M^CS8?1Z.-U"<.(MV0M1J,D&8_?/%+-U\6,<X;?
MW.ZD!=8X<Q?]/?T/M1<;^::F3.W<OQAB-E(&9E8'A.X(=%;N2FT'+>M%]/'?
M1AP?N%R[X<O=O?#%JQ<L9\V3^:<M!WY*R_+PY;CCR-\KJTVU\76W]=M9.P_<
MU9^_VCX^8O^^Q\1W]EYT7KQ<;UG>J*N-NMJHJ[505]W.#ZBKOL="\"H,N>KP
MRZS6,?U_3\QJ/2UN*+S)9JOYK]WM+[9;6Y;CB>AZ@O[LO'GD 6G?_J^JS!NO
M?+ R?^C6/&%]W3;%C=1]"ZG;*(<GL4T;Y?"4E,/C[;4_1^*>N$GV) .)FG%F
MD\S\UY\72GR"6G=G_W6XW7WU>3[+$_*OUUGKMDWQ!Y<Z#.J]?O)"M]$-3V*;
M-KKA*>F&;F?ONTC<$[?(OC!(UDB]2_W9]\ :.F@%:3OX$-S@E\?3) !KZ=N#
MN)@CO%!GNWZ9E_W=W?#%?O?S'* _;[TV#OO&8?^Z^> ?+TJTT4P;S?1P(?G<
M9Y 5\3<"O/^H)13MM0;/NL^#08H$\.^)AG!G>WN?*MJ8K#W"BCLN,%C=G"%X
MAM@Y*6*U0%E%TTE%Z_-.0/6@+&JKN%6QP.'7(N+*S\.T3*BE0_ ,_RYOH(_U
MH3S$>3TIL$""1WM]72;7B!*,"!J(3YK/@KK@=_W<W5:J5K$'^3^(]*\QPRK$
M']].TM&$6=Z+"GLRCZC^2EXJI5)*D)WFP=_GR ?+5+&3)'?F! N-K/T)-]YR
MA\TCC6ZB-*-2"R[>PE\N+ZB=RJZ:\#(3ZE(! YPRZ>CR8UN+#VT]LC.BEM=&
M]V]?6@4_@U\1>..Y^ZEQ 4/(BUJXTG,LNTRE"C.^L^[Q+\EX\W(UX\V&O&9#
M7O-C3N"+F1-_F))#XK (SOL71V<7[ZE^^>U%[_S=4ZD#I2?^DH+/GXX>5(D(
M"AVT]&R"FAV5M-S!%755I08/VAA%;F3J/),D4U#V\MUQFB5Z7W-W([QJ!OT#
MJE>$^P"T,)? #Q)N_=U]K6S/_4_29*,WJD/3B^PVQ<O+MHW)TFBHW+UZF46U
M/DZXDR?8BQ2G,$QT@!XGGTO&AXP!!7$-P."I:A_&<YS7\Y0,H<$<-A5,TA#^
M-NHX]^? -L?IC<CPZ**!C3=G-*6HBNT^.(UB+/"$-: &A*2GZ2%XZ1%#():#
M8-$UV!78EH=>37];:"\C9P:X;ADLU3R2EB3PK6H.=@O/8#THV]&:8'&LL&]/
M48(P<8TL-1U"8P97<#2?SMD$ .G ^)9#+H*,#/,R;V.-@$?5MTCOTV;==%^Q
M'*UL"J""O?1R?>$X>)8^YY_5EB'F  :.5D@"LA0GGT+XDONMP7]$T]F;\V!O
M>SMXER#QR0CI3N2[."#X_JH?T+>H#R^SS8 ,(LE16L32IHK7$CN938GL&@3G
M)JEJXA> \8*I#+;R-J[5JB5)EY>1^T2MFIX[QO8)M<^"*/)EH-Q&9LL?K"$$
M8>*,?+$^(L_"G5*WKVJ")._"5\+[QR< 5W%(O@5LA-,_#M0)<_N/P Y/J5U5
MQ/Q43O,WKQ78RE?('9"#+%05L^+# J6C2%13"!^71'9:"^<*DV*ACAM%5<V[
M/RO0#D!B"VFUUFA#]G!2GC:C_-M6JK]^U=E[]5F5ZONO._O;JS_^<VJ)OV41
MW_T&U+9P@9WW+HX'9Z?(UG!P]?[JI'=Y_'L_N#R[[)T$%_W+JXO3H/?^[/1M
M<'QZ>76,'X;!:6]PV/MOXH<Y&QQ?PE^,$NGW3B[?'?0N^O#]P_X_F,/.4R#X
MY^6DS\IP39M8I=/KH"I'__E36I776ZCRNSN[W?_O>J?SS]GU3\A(M>JCAK.Z
MO3W[]#F2]A)_B [<-Z=B>-'=^QP!W\&C\7F5_7?6X,.-])F/O8\P8.]K#'9G
M9W<SV*\RV(T8?+W!OOXS+Z;5T?8?[A+;?] =YB(:'P,F^#/2#X])J?S8JX@.
MQ /H#+YL)39++4O]>K/4WVJI]S=+_8V6>F=[L]3?:JF[FZ7^5DN]\_UJ1KX'
M"F558/WKE;:O&;ALW4K[*>K\XU7W;V@J-K+\:%G>[79V=M=#EC_K$M\(^E]$
MT%_N=K8_L])L(^@;07\R@KZS\Z+SN;5Z&T'?"/K3$?3]O<[N#TBRM1'TC:#_
MN8+>?=WI_J@V^C>M3_T>J]\$BGU12=V:';2G5S7X6;&;'Z]J<"-T3TGH]E]U
MND^_4G4C<T])YKJ[.YW7GUDWNQ&ZC=!]GM#M[W1>/#;VL!&ZC=!]D7NTN]?I
M/I8J:"-T&Z'[(DVW][KS\CL*W=J#+NXJ+/LBTK,U.SI/D-?M"^ 33P@AL1&Z
M'VENW>T7G9?[&Z';"-VW%+J=%YV=[T-BN1&ZOZS0[;[NO-@(W4;HOJG0O>IV
M]C<VW4;HOBVD;Z_S^CL*W=JGOI=83C:Y[R<=L]KDOC="]\USWWN=ESL;F=O(
MW#?UN_<ZKS9"MQ&Z;RIT+UYW7F_2D!NA^[: BVYG[[%531NAVPC=E^6^7W9>
M?T>A^X)F!AXW^G_]GV'YM_]:9F],X__\Z7[:Z/T7/SWH[?(70N#O( V\UUAI
M]WYRSRW\TE??ZG8ZZ>/+_OO@Y2.82K^]2-(X_^]%?]"_^+U_^/\V;/S.LNR]
M\I>CR6?^0$E_921]0^&_H?#_,2?PQ13^3U]/O^KPG;S\?]_W3GMO^^_[IY?4
M7/W5FT%P>#PXN!H,CL].B8\6OG#RQ^!X@*2W1\>GO=.#X]Y)<'!V>GA\J=\!
M'7MU<DE?.3OO7_3P@\'G7I^@ !YV?_XPK17.P"BY29/;M:#M/ILE\,YY>9V4
M"VG(P[SELS*)"U#;44X$]E,\5_H]8ONO@GG%?82BC/H-)3?T&5P%VA5A6,2+
M3O"NN,6/F%0[@[5!WO]16J5($UXF_YJGV(\(>RP4[F"P U&=!'49S:<1LG//
M0"_@J88'+69H%&8XXFJ>47L'&$=6Y/#+8%)4,^H<(2V/<+0EZ!4:7HV+%SH-
MCIK?'L%4*B9XQX./?XLR>'?*#ZKFXW%"32C57L"AP3JE4QI0FM]$%36AXFE0
M'X4R"=[#D8(E,QV..L$13I@I[\L$6SV,HAB'AM^<1+@R\7R$O.1+"X M(.!E
MQ2T.HTJR9(1](?B%V-(!OCHT;.74PPDL\.M)4.$0@UE1PB- R4ZX_T3>W)..
M&<(0FPS /9W Q**XF-6R3R.PRG%!*J'!P@9;,-0Y[,9ZD-D?1L'ON!Z&Z"L8
M+*HZF59!DC.M-2XVRB^L-0PYD78 PR1/QFE-;3AP$5$TL,&%V;G;21'<%O,L
M=AJ$T$5W7011,,4>&TT)PMV>5[C52*\_KR,6R3 H"UC+=,2R"N)WC=^ID]$D
MAU6Z%D% "8/?)3P..9=9.DWY.312D# CZ-X1Q*TN\AMDP:</84H=6A*:.@\J
M"N(5BX7/PI8EV)<,ERRA]B4P&.R' :L(,E7#S^$-8$4G :I4?N#N81A,8#?
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MM?FT5JO"],AKPFN%H?2;E I*U+6AC\F[')*PBF?I)2AA#V^BT0BV1?)?RD>
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M[:5LB%:%D6KUG0]<N?O<C-E$"@+6TTO]FT*!!>)T6<<?^YVN.)AA-"_/G<R
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MK5DN1'=)H2>?T[2BP.][VY)!7-_*UMA_\7PT+HVC@F&"?\QX1OHI8<<P8RR
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M21A9"A=FV3>-5'W/2EA9EB>K5:]^ST6"YD@MJ/,@KT36?-?6&,H0>0D1=F
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MT<!:ZT]EKG=WM"Q*R>PKXXV+%FSAWRR3=@46LM</1@S(RP)Q!GF*8>)9E&+
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MQS[]OK %W@=8[T<U_>)=.\T16A^=!!>)\O/"*]Y%_X9O8-'[@"OV1XF-'']
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M%QCVHA5\*,0\94F#L\3C5EB4Z8 DQ#/5)$[DITN&E;'L4TSJ%E25^)9^*_6
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MKOW0093P[@4FO$#GY2SQ.*24R;LQAEOR2C?S,.BCAH82E5!&"@,E^^D )V:
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M=P):5^4=WW$[2JMH8 $E')@_UW#:[T'>X2_4/E.YS:B5JE MUU5KF"#QKU
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M1P4-GRD[W]*-HIK%NYT7DAOVVG?F\9VF>[B@ ![_>6YFA>94L,<J;CVPT)(
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MLB28%(:!.=V*,,3_7<0^6NW"F@#NQ +.QH$)TTI6D<#+.8-1<,P\D7\QBYW
M"#,B/FMG,"GUD(UIMPL;,X&;'  9^];4UC^=D@X3YC[120+[X_$&X$7 V4K*
M UI8 @.4O_#FP*T+ X$R&*3OEA-X26-,\A">QWD!GX*!O/!5P]X;'C.; ^>=
M%&;8=/X1P\!R?-QLW'[8":9W9C*XZ7Z0)OD2V39L:)Z:']Y]^/WZ_94[@L4
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MB&#R^42:O6$\!D(=YXDO&*\=I$3.1"SY="H21L@E<3XCASRL<@)'BD.H"6"
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M9JLK9+\H952O%W-C&\XXSVA"8; (>.\;SE1XIDSZ-(\F7%Y=1O,**R]R@IG
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MO[/@!/PJ#_(BN">[@=2QW/N?;']X_:H]CA(4TI[*ED>3#8_F4\6@%YQH4_Q
MVQX[_.![';58T#Y-CV\]TOA56?W]T[/ST5ASK3VJD(\)TU>P.OVB%HDB14+0
M^K6F^O/A%;,N,_.K#%(/YL?13HS!CGC":[ZQ6(%3N@9_#33K"X"\,$+#8Z/U
M6:-,*B!]3-A9T&L6WSQ27_W,_>$TSR2.TIZW7*JEJD<4Q[XO&W8G5*>$DSB^
MALOW% @8^-,G3KEPN+KN>WSB8,PF5V5NE<DT4]\59/"*"[Z6.-$87?2!!YVS
MHMO6<%C//8J_[Q3M@NH^Y?K#XO?4;2I].84)G<++6ZQ>]#%5)5?^F<'=;-S8
M1SZ\GM#'TU5]?757#OV!4)&*+TS+H^:HCI\>'8.%-;;Y2G[XLS,7$2\4#(ZJ
M7*5R(=RX%BEZ?.;]<6IZ'>) %@[ZBM'%5,.RIJ<?<OC":L]0N4U(+B=$"^,M
M*,WI2M_K1G?;:.'=&<?"X'^/Q]:O8T3A1J_@LM:/SL]\5'"TC4.H5U*-U4=;
M^/D+IM-2+RUB3PM"P8$K8!R;"$71_?-88C>,WMW^^2C<?-5!!_5S.'17'O!X
MM/_O7 4G98#_*B4I]%N87$N=FB1<,R_33!S N3(+ CY3;XGRKR[6RWR=F",[
M7MPH#.$H%!5@5133 U+Q6S6N)3V(RSD3TICR8PRF6#0*3)YHYG-OS\O#6YV@
MF']5CW],"A;'\EXA_E,#[&MY$A>04CRF/_&!G)F+EZ;0R1Z5F^%US+GHG!8G
M,)(P7+@RF6-2(:\:O?-8=1.<YG$#RXZ1L8BQ>&<1X2GZ[%6W8R@N7=2B8[WH
MAGG<[]I8NCSH?"ORVI4ILW1JY=LQ;C9YI=/STA< 8'W<&*FJ-*UW7RJI%,?7
M=H@Z3L95IL86E]-$!)T:],HI78]Y\JHC742JQU6IG:FZV3%KRSC 5]PC)9G"
M'&=Z-&!"_DB-F2%ZN<<8;8L2@GJLK= )H[NWKH4$I\58+>A$HM.YW+@09CX?
M%CIG4?M]&9LK^N&/YWK>&[IN<?,-7)EE%*[2LB)@/(=IOAK5^-H+U=O]&DU\
M7" _]?+^#H&Y,ENJ[) WRW/CQK03M4A;F4T+0HUV1<U5?;K\4)F]5B9#>X6C
MUZ]6OF0.GWPJEL44/?_J!0HQG>2R.&'E3*O]K>U:=:5.[K5J_&6)\-7[O#Z5
M_U263@>UKSZ7F./M]\C_/#$";L8*^]2NEBM(S!>E'=8Z_$P=L=E5#&I />UA
M80"IT-ZJ'KAQL0NW1UT'NS*%;RS_$T=(B YM3&B6%QWN0IN(]V4 YYJ^/)-C
M-U$0R_3'LKFO*:M+QAA4T<H6GP\HURU[_EH/I='%>>3&&56% 31RI=I51(S&
M0%%9+4%W*57&*VZ%8'N%%E)1 0N-C6/0;! S7H85,DW-X2R$K\QH+F4PQN,K
MG3EFNH?E]T W<#'P/PP75:$*5U,M73=5Y+?><;9*)J^'KN>"QAM1A@KW:,AD
M"\IB;16B,CK1/J<3+"9NV^NFEM>[,ZTOH@)8+R^L2?;YI*=A[-E590/=@<Z<
MWYC.'.%5XC/_L+N]VVHWMK:W]S^VVGNM-XUW'_9;_N?MW:9_X>!90-Z=6,0K
MTNX2FL97QG7Z+=Z5,7R*,+Q>J3&1J0D/=F@6-\,;/NCW^L$&+4LIIXD-)T77
M$TX/6^&KLF7[M+ILVE+Z:C0HBWK-W.SN?)&!:G1UH/HFZ"/74G@[A;=7>P)W
M#F_/WIU3))_\&LTT0'C38U56MG>;C6RK9'F;__/]QRU_[;:WVGM_[S:V6CL-
M_XNWU;]W]@ZVW^X??/RP>]#8^FO_8[O1W/KPO[OMQH>]@_^]T\W\:'6F9<S_
M0^4T;A:%C!\ZPZ_/0M5H1Z=QI] MQL[G6G5IV:1@TONUC&!$=\#@FZL2?D/B
MY7&G.V8DK%+QNAUO9=G@C:GW+/4&1K_J-^<O]U#06GUYF55>EL,GLM";DX46
MUEO-N19+?\O$]#+ /4_45S8V'IM#98U&E>LXJI?ZE7&V<< C)D+&N$]EW9:D
ME#&67A%-3*A3HL9V'9*<.)/B (>GA0R#H] M<;IWS.18J)^'P\-PSKR6^;T*
M9,,-4;50W\LG*3Z#HF5+9UC:I>7>3S$MSI+=^ILGB-=TP7$MG:<QS7I8$ [&
MUL.A;_"$+5#5N8DJNL!0EE+U @ZUUZ.2M6ZK<7QY%E:OZ!!S5<+0S,3T90.S
MLI#\K-^)_(\3([88<^43'C^F2*0=/W*^^#,VCH^DB[76)L-)B&1JX?^!\(1:
M:9I.Z6=[&#V])0/K^:@3UK/N69X8U77:R>@X"3G$Y;[5UB+L\==GXBC[. [>
M39:A.+C#!:=Q%&6JB"F7R6,%:V'YD?5X8@M"@3$5[P3,.Z6O9^ZKULO4WU%
M^L:W?C"*NN4G\L[W"7E]Q)NIKRQ)#J;)$TLSMH9F5?"SI(DLVWF%^44O8:=
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M+HDP5JJ,AC;LY.YQZ^1_75WA7)86D(3S+L(Y>^L3SK UA /_%P842@@DR3.
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M$$.(EV>NO V2.P@$SZU&.51(\+5-NDX1VV K),_/WG>RXW(WB)T^U?>4%?)
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M>Z,[IL).#H['T5'B/K2/52^PDH>=V'%Z5*?130!U$X!:1$^E<TUSS@S@.3&
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M@BKA@.0$ F64U9Q@AZ%9VXS!#/SG"N5%IJ3F%<T?2O)[G_([%Y#UJABQ.(?
M<"R\_$(&A%8*9+DBEAFF%%6K*+\/&@M>P;!AR$[H]VX7,UR:#[081 KR+$$V
MZ2]UY9,M_'G'S_74/W?G[Q,_[D[SI'O<>A/F_16V?I@+KQ/[[_C[]#\__!S:
M!OGU^][:V:*M]U^$M4I:9 #.K $4>0@5S I@&,]T)JC+<OHPYE@Z1T_Y'!F9
M62YD**[/<T")I$ @X8!05GK0\-!"0^=V"!>T/UC]:&'M(*:(SNH?2!9I)G..
M$,4 <^>M$(*\ 0(E XHP0:RVT$+UN)'"=*B>W*'RIT:(3&MOQC(:;LL<"&L0
MR(B" C&DR2VCA(_C[YR[7Z><G>F"?<2C-^74_+&_T_Q",I1AYA!@C%I %<P#
MK[X_>TA3IJ&T,O\9H#WL0:H"?^D,K=09,H1H+B*[.\P -3GU/REO"^=""^OW
M'%I;\+S?1$OKV4?*:$C'[BD<._.%*:@]Q)B0/NB- VX)$%+[ VB10AH[)35Y
MK+ARN@.?T$$RBDMKB08R@P[0D /H]QT"Y2"!R%I#4:"<9-D"KH6E1^[6&_[3
M9\X_[)OK7MXACO<B^-[O0=4H@P!)1F\HHW/!.LXSCETF@$-4 (I)[L4*<>"%
MBF*8:Y,S&<R:95$$/%$6@.<MH/=PH28!O9V +BB/% Y:S8%4H1)#4@F$HC$N
MYP2C6EKF5DU 7TXCABT_X+#8JMLX4QT+.KV&46>=D>HFHL)[;V@]7OMW?NGW
M>MO%PM= *+&-+!&<%C5\I+FD.2<$."T9\!HX!R+X& 3E6E+,E"!V;3-;SR#9
MD"N4*I!2?594@T@R_= R/:=P<.$-  @1<,IB0)4*D5R6 649I!EQE&=YD&G$
MZ=W[V:]>^L\34#H^N)'RO[0-IP8]/_0[T1H^;UQ:EJY1+?ENN>);QIR?GL>V
MM#LN[YA.HG)?(BXU%S6/E$XX0UD.$,UD(#.20&($@4<0R#(E'$%T;9.L,[B$
M5K7)6[&Z,KTL72/)]$/+])RN0;4UU$H-G)$JT$P8H$2> ^REF6$N&,K)VB9=
MSSB\N_V0'!RW<7!,A*+1CVT93/_T;.".76_8^>8:W?[PI?5D^.U!](^AGZ?_
M:<Y FNQ')'C?KN_&7L]OCGOKMZ3E1OMY6WU/('4SD%K4EC+3FN7:$F"995[Q
M$!H(?\$ KCC2(24,A<POQ!>QX<QQ=B;OQE,4X]NK'$F,'TF,YW0-J:52D'&
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M"[_NM$[W+O9W/AP?MOUSVDU\B#]>_.?'.(HX:K8_7C1WFO"+=-(1)13(&=2
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M-X/^<-@X&_3SSNU2H&Y"CO@\L6SI5D[<DW=Q2Q)X+0^\=B\6M"&T2.?491A
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MW;@'#H'';=VR/)*4!'0O ^B6GNZ<@.Z>@.YR!NBX8I)IEH',2@]TE @@+2/
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MO4LYXZ8-NGC%I$U91TY\ G2,0Q D9!=(3E1F&62$+$J=X7Q3\A\KLMN*[$K
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MT'/G@;/W6M,D2':^#'K+Z#U*1XED427@*2:=-K:9U6V935$A74VI>R.FI>8
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M U)P AJI=95WUYEWYQJ#B2B9C5H0FPSRKHR:6!4HL2%88*"<];"Q+385752
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M<Z)29$1R'8FSGI+HLG',4&4".NQ2NHK7^XS7E2<!*EY7@M<Y&S\EX[PJ!<#
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MU#MEP'_=X0+=&]V0@C)(#)RC!R@9=2YY&Q6J!<\C%VIJ"MYT]JWJAA7J!K'
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M;E!/:292VY"1(CDU_-Y$85#D!0SG0K\7)DRQJ:=QE"ED\08OG(#19<>L0*A
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M+^%_4Y+O%A< E6DAI,FP>=-69Z^I+FJJ+]"_GST]H](A7D2CKCXI5QC"U K
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M(,ZJC"I/=.I03YJW@J\?1"O0D7L"1]?EA2"W"A.1KJ4\5UT'9I@P)<V*'<T
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MP;QNAJVJQ*L3W:E 5Q&UDD<-Y"#)LZ7C'-TT' E7J@KI :HZQ5 =B8(Q6'A
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M3-B$(S[#2J+=Q00$@PUT,$8&@Y398KEB]1)6PM\ ;:1&=?B-MK4@'O2.S=/
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M<5J6XC"'+_RNP?<[MK-XKXGBX[2<?"!F,O[)BT+_@G?N?3V6/';3('9L-\Q
M>PES9K. IW8>B#S/XUPF>?3L9;BJ)G34P!MQ6'4-:9C/?(J8H<N/-/]&D/<]
M"PUC[>F[4V"Q(RQ*4EW@&^3O$07A);H#RHGV417DXR<>CM]<G::^68Q/?D6!
ML@"8B8(45MMA73@O6ANJZ?E&2DP++#5H 6L$*HD%G,!%Z@5!2 )L=MKTO*-Z
M,@SE5+(OGE<UKU/ZP%LU)&.OS2MX5U[8J$L*$QLQ/IRW>^^.6B\.J\TN5*J
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M>I/GP%'!OD:A:O69[X.^#PR/1?_3:G@TONS_R:K?7G;]V?>+2$\"&&]1IR=
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M:*L9*&92/;/3P(L0*J$OND9^BR?*Z?D30%H!NT>/\%;\Y9:0/6522%V$=*%
M,5Z XCH!FF*!5K@8FY(MJ9:R6ZHR=@W5BR[B<M^P;D5<YH/UE(&A0S3,!@TA
M*P2%C@%&K/]T.FCO@V%Y;8/S==^:M*P.I.\!T<UW?J_ CI/ 1L&=M&BAAKF"
M2MF ]]F#L($)(8Q$S5N;E@;PUJ9ER9']<0K9-GBN?00O!"';Q (N>0G.2\VE
MY%YXW=G8ULPHOM:0W9#=BJ/<S>G8Y],3LJWM9Y\VO_[ZSDM4F18+BL0(BI4
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M/.4-T0]?3C=/^;WB>MI3GHRP1B?0N78RL@4)X9*D=^2TWIJA"DL98]\ OJ0
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M::&X6/W%?;Z+!^^[HY[>+]@?CJ>L=SIG"QV07G?Z&F.:<1!3#X9!KO,9:F3
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M.GI4PO*BE,';+U?PD)N%_7C][TVU]>+]E]?;S^3F>/SO,L^LR&!!\^HW3!C
M^^2 9>ZTB$(RHZXH2W!:"'O<:Z+#57]T(9"9MD_9&[>4(&,WGA="++40XGA+
MURUYLJMGE-L^A<9XAU^XV:N;6,XKRIS;BP#BO8<D-6S^$#8U7?<N6I<5<QJ8
M< Z49@8<+1!$;950&8U-YEM!A:?X/.TL=!E[5X+KV\=23WJ)<%N%V#F@!X'V
M^)^=I.H:"XU%31RW7IA51K_KY;.')(%GBCN"Z<=\-![FZ#S7H1-[)$T[D7HP
MJ/MTW#%I@E0NO0T-^63XIP/O$Z;ZPW$OHWDK^-\2,71WO'[;C5].3J">GYY
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M7.SI)O3\0R$RUZ+GDZUX&M&_?1Y0=TK7?\\U8&$;/S>BOA%1SRC,SS@&ST6
M%+OJW4*#YY%#-I@SX\XFQM<VM)JK-V\K0M=XZ:YXR3EEO2HY%M(UHDFNH&%*
MQ^*"X\;K:]C%C9?NGI>F3.5B9$:M01M!IC(S 7SQ$62Q]5Q0Y2@5*9!FKH;!
MC9<:+]W1<1W7AJL8:OZQ5;J4((3Q3JM@Z<_,RC6LV<9&=\5&4^:L\#8AEP5,
MD(S,6<?(G.467':,Q<29<8G8B,WOF%AT5<QO5U:I_Z[;M']PW$6/7PK2/=GJ
M2JS;&C\[7:_N))9R#(4+7SP)NF7G7\% 5OGQT=5?F8H%NJ=H:L[$Y:#EBW_N
MGE48/<3W&<(PXT?H$J2>XMXG_#):^^ERE'/_ "8F<?+]KWS+4FZEB!^]Y'@7
MI5J,L5OSI[3[\G!<7?!ON"Q#Z>T.*V_^OSX3.F6>2=X+IE31*%G4S@IM?&'9
MI7=V;:-+>JB),\\KY1X<C?[V$V[,6L>)[3YF0\4"2Z%DRXI3S*+C)6K-5>9:
M<2WQ>[D!)[^IYT]+GRI0LY+HQ7'O+-6MYI==D3UP.!S\V4\TL0=GN<NG&=07
M4^G^)&COY_7>G274;)V\P[CJ\^AU>7U\-#K"@\J8Y^>XIYDQHY82\V'SG0@Z
M8^W6XW@*H*PF_F+>@)?%I<@,HF=CE87 D=.S6J-$NA(="J9%SDIF%B095+1(
MA?LL;+:3*33;@R/:6"3/1J/I?58S0][\_N*OW88;G"_8I9RYTWQ)?/]^F+O2
M!>.[74B1/\F#RP==':>,<?<TY?-[N2B3LN_:N2G?!?C:%<SRW0F\AQ07R^R/
MI+@HNZZDO(U$#,%_+'/F>UDC;;"K-5AQ]<<_D(]S9;"Z7\TDEXOYT-_-A;Y&
MQ/]CF*=KY8W_2);0H\J$N)12%88_M62<1<[D=;)SVF2U;7>KV^[!YS9M35@C
M3Z^SD>:*-[G.#KMIE%P;Y&H,<D'Q0MVAKUUF6/TR6:>FA?\\$G=6T-%E)HVV
M1BDF97#&6<VR-QB\4?*ZO=XNA%U>.M1[("ZK@=[:_Y5M?HU\Y^O>A]?_>,5V
MMG_Y\/J/5VI+T%N\>,;?;G_\]/9%%*\G758?/HJW+W[]NO7U/W3]IMKY\-ON
MYA^;>N?#>_GV0_RT^>(_>Z^W__YQZ^N.FAG8HYWVQ3D/,G,%2AH!J%% 5,4P
M*;R(WJ]M<.=F>-!;C\G&.\O).\JD(IW-)I>L2F$NL&*,LMR6R)SD'>_<*-FE
M\<Y\O#/5C=N[J)34((.5H%Q&<*@E>,>L0:NEB;SRSJRR^HUW&N\L)^\(7A))
MSJAK)0%.O),\(_[AMH849MGTG;OFG:D0'6E\YLE$8(8Q4(5X)V0N06>O,:'!
M8N3:AO)F1LI)XYW&.\O).RG3EC9:DZE%=I8.WD:5I)+.1UU?N^D[=\T[D_H.
M#SP51R96RE: 0F5J3J^%$*,/R&2,TJQM2.[6W1+QSH,_\?W'9-S(\+S[\%RG
MO\MR+-GN<8U[/)J3V'\/\R'VT\6:W^-:OD<G);_;R>PCT1B\4>BTD89A4L*1
M[INE2T%D2;))\M LE3O5&-[,2+ETX?]G[UV;VDJ2K>&_HF">]\29$RZF[A>?
M"2)H@QUTM$3;EML#7XBZ@D!('$DTEU__9FT)#)*PN0B01'UH3 MI:^^JRE69
M62M78N9PSI (#1Z#"\AH3I"QV"7L7;0*(A4R5_Y"B5,*ZOPT/P+(@I,AAC&3
M^?0Z)65S>M9:*4CB)4YY:=09CU,")H[;P) E*B*N"47::H64ES1@S"*W=F5-
MK*J".@5U%@1U(/!F*0:1LR%<2V>4H5D?2&MM8[2X^#HOC#H365D9519O5%D"
MR"-.E$)6.H=<%%HPYVA0@#J\Y&0+ZBP,ZECPT3W'#-#&<Z&I)K"C.BR%MTXG
M2XNO\]*H,^'K$,^H]Q*%:'*Q&S$07%F.K*-9)I,'H^C*V@QD9.<O(SO_J:IA
MISSK?>\TWNJ1^U#=MV4&T&F/N#0 JC%<@EIPUW#@V@HKE',V$HZY2\3HXK:]
M*(#N3*:HP(<66A&,8N(,P;Q09#SC2!$;!0Y>"^-RL/ADM^TG(#:G4K0%=>;I
MV1Z .M(J;J7DAF+-*<2,C$3"G#":)*M,.4I_<=29<-NB)21R@;Q1'%#'.F1U
M\(@ZEC1,FY4&W#8\,W7L@CH%=9X]146IU>#<&$<]US&ZJ)W CFEBD@ZJI*A>
M&G4F4E3&$F>(9(A*G*6J*49.>8Y@JR X8:6T33E%]62Z<D&=@CHOA#HL!G#4
M?= ^4%C%1#-L-/CRF&!/8"LMOLY+H\ZXKP,.)TVP&^3$5$1<J81LECLU*2C#
MDC$IDNSK/)D$,$/4N2TH."$=^$-B<%)2L%HDOY1RHTRO/%21B="[))F>UT8G
M:NTK_9K&=G.SQE>'<S3Y\YDETM9ACH=F^K'5L1W?LNVM3NKVCJN9V&CU?;OJ
MZCX_8FC[5]:+=RY_:]<W-L&BOITU:!T^5[_8.:[SW>,=L;WQ>[MQ_.6X?GC$
M&Q-B:%\.X7IG]6:=-9KK;.?R,USK]];.Y<'Q+KR_?OR-[G[:N=AN[N/_7&Z)
MQN<]PBC7+"KD77009^#<O5 %1 4-AB:>=&Z%?5L+3>!@3)3>.8A0# 4;E9J&
MZ)0T3-&8QK70/FPWOF[_L;6QWMS<J'W<:JPW/FRM_U'[VH07ZIN-9FUCL[F^
M]<?7G\N23545^_6MW+YUYW4@ANKHM>6$**.I%)S"4A,Q1"RO=Y;G5^Y;][[2
M7X#=)/;_Z(*AK7?":*UV]K_ =6&[F2NUOI=>H)]%8\/S^L86W-LW#-O''M;$
M2IT,THHQ!%,@D:94PD[!A?3<^"C"^.K[.7K.MT+E4+XOJS15.\T/&<H0![;5
M[F?9OWYL1Y\UG6"I5H(,E<!3N@(]N&UX(<L[U5KP[Z04X'VE_UY#H$\+]AB!
M/D57I:'/H<PFF7H6&;EGNEDS2QFY18AYICN$UP^UL$)N-U2+BD;;+[O5%VVL
M1P[<TDIA37OBGXE_7SEGN51JY(?=[L!=%)YF7%<T#ZMD^I[2[%GPN.P]5T2A
MNBUI'C$XH2)GE%H!H2,V)ECMA9+.4D^9B+\ZO6CU>_OOJ[5T!2X_8KQAYY)Y
M2B4^+M8;I1+I[@;\]7#SHO[IKU:CZ7%C8X=O?_IX -]SWKC<%-O-1KM!=VC]
M8CR5N'O4.-YMU9M;9[O?X9X@/FP<[O.=[YOP3/!?\TC4Z3>V>[AS>5OI:1_B
MQ$VVEVR*!E.%I(@:<68Q<B%0Q"P$_"I("C.ULJ8EGRN^6V'9%NCY&?0(@!SG
M. T.<QZ#,XPE#&/ E1:21/VK(XP"/<\ /1<WH:=^OA=]2(Y; ]"C+4"/84@;
M@Y$26@O%(\51KJPI!D'['$'/+[RWJUP.W&S\.5J]U#N7[887*8J:#F3?.J[5
M;F=1^4D7^4<-_IV1$WW84$S=N!8:W6?B6%Y-P@]@S\<)%;_\QDL%[!\#]C=(
MP8?K9XWFY[,]F"O#F5.(NPA@+Z0&L%<:$64#%LZQJ,'/-.3I):3SQY0IECM3
MOZQ8[K-:[L4MRZ5['"P3Q^A1U,J FR82,M1*Y"SS,6EF8^Y%!0'BW+%-ECG'
M]M7FT\U>')SV.D/A'IM//FW'3]9"W0M_[AORSA_^/*3!]TQ<AVKLOPR''I!G
M_7K@"]@\"&SV;Z2CCD3C\-OEGK(VV2@3$H0!V 1AD-/>(F8\$<)[C67NE<NG
MT/@7N7-WL=#9N@C%0F=FH1=C%JIS#TJ--4HD5_>%K,XM4_Y-1Z(P3R:3P@A;
M)?-AH6^F-'K80/7)IVZWCS5']",& Q"ZISD_D1_D[D//I4Z9SW)HYANP7]"C
MNJ8?3R3:&W%0@K@9^%4;1VQ/49WQ6B+ELM"P<P;EL@X4@K+1<&\3,RMKAM,I
ML/VX*&X65C+G%4X%(PM&OHA/6S#RN3W;C2.^YXSG3M"(HG01<98"LC$Z)*R,
M(>NJ$LU7UI2F,\M1OR9&WJ['NJZ^NEE-\@MR^_!9<T_0!W'B7ZI<9*OS-YA%
MMW<Q,I#FVZX-V1+U]3U.B([68!1%7N(&?N@@.;)$&(9M=$+2B7*04L10BACF
MVSTI10REB*$4,90BAJ<6,5R[#*5JX>U5+7RQ9[5C"];9@NBK%"F\$:;PK-*7
MU] !RZA^M8H@.M].7R(\Q=]+<_1T<M38V"([QW\=[D"4L7NXB;<A>(88 T+R
MQO'.]SJI-W?.X=_SW:]C 7J62SG\J[7[O=':/6X<UYN?\^?@>R DI[L'<*_G
MC<./\._']M2NU E"/T:50TX)@7@R##E)/1**,BH,9=K@E34& 7JI52@(M"@(
M-*OD8$&@V2/0N/"2I40;HRV*TCK$ 720B2HA(Z3)<Y<X<^!2$[XJYPB!ELBC
MGVYMW[N](]3JH)->U\?^X_AO;X)_.W-O)X_\5N?/X;@7L'D\V'R>='<<9USZ
MY#/.6,2)Q4A+*1%-7$O#-/@^$+,289[N[A3._/S:[,S]@V*SL[/9<0?!49<[
M$TGD+0;#A=4)(8K2R+G@I9(V:,Q7UHQ<Y7-DLDN?VOG8ZK3Z!S'4]KO=\-;H
M\:_I'EP-_*<\[@5J'@\UTSK!6H>M40:Y2!GB.B2DDU1(&X^QH3KQ*ALB\-.Q
M9OZR(<5FG\T]*#8[.YL==P]T)%A$SI'B'%QZK\"ESQU5#26&,!V#IFIEC2KY
M=!KF_.4/%H5"W[KK%/!)=*Z?,KH**_2A [0T^#USGPL@NP#U@X!Z2@\SIB4V
M3 9$O".(,\V19LPC&G+FQ0=C%<1QVK"9=?:8G6T4UOR<H$!AS<^79UN0\1'(
M..[",BEH\$PB^(<BC@U&AB6%*+RNG?;>:E.F>>&G&1 E8<()<IA!I!)M0EIQ
MC&1R+G>\DHF0E36AU91(9>FJ(\:[;-RGS&'.JR,JN9Q19<1ZOQ\'_5(?\7F/
M&2NQU@G9("/B1(';)SU#$2)SSKP(L+1*?42IC[@/R[Y4';P)\GRI.BA5!T^K
M.OBS%T]L*_1_2'_6_'!CKMEJ9R[5"&^O&@&"F"H1W1\,.U'!#61-(S2X.(FU
M=K1]^*K_^H>&P.A_:_V#;F^ P,*/R]'V\PN_-6$&_L@3 %.T=3U#6YWJM24K
MQL?@'[/=3U^.ZAN-H_JG7%#?.-AI[K9WZ.9%H_FEM;MQ<-3X].5P>SS^//QR
MM'L8CG8_?3ZKT\]GNQN?:9U^/&CD6+8)]_CI]Z-MN-[NI[JXQ?4_7(?X<_]L
MCU/*,0D881T(XB92B#^Q!G<\"L*5TX*3+#-%GIZ +:?;\VNVLU.#*V;['&9[
M,6:VC"J+8XJ($6H0UY0C(RW\+^ M%1$[ %TP6X)7V1R9[1(YG],M;O/_3EN#
MBQL.1>'(/_N!['#,OT;PY5N#5NQ__+O1*@#S(("91HIG+"I+(C*$!\0=<\@8
M$Q&AG 7I0W ) (8_'5X*)7Y^37161T;%1&=AHA,D-^&PC$$B&3G)NK &.>\=
MHBI9')2B%F>2FYRKLI6E3RA4!SZUDT?GFMY\*#(KOZ":B%'.;_/\)'9*^/$X
MZ)E"VY).)Q,T193ZA'C,['A-(TK86BF44S%I"#_D#/R#DC687U.=E7]03'5V
MICKN)6"IF*9,(YD4> F)8>1L=,@1*GCRPC+E<X*/S968QQNCPC_872CDST+^
MG"MOZS9Z7_4)&S*>"I8_!LO]I-LEF,6,&HZ,C0IQKBW2D1EDG$H\!4Y%[N1*
M,W5I";B!CSO<?O2M%GY]@=BY]I(+Q#X#Q$[0[I.R3%J.!.4 L1$#V#+LD.2)
M8*4\32'ERE&R% T\[D&_SJ_FY=SJG-HAZ_SIA.R1)7&ZJC(7]Z3;;U5DK5YL
MPW?\'4<4W)&EW?C@Z(OPCX]8!T-R.KC[(Q/TO)<'#)KOB6!V>SQN_CSH_:!W
M[D?D>M$>(9O@;M_;]IF]Z*_\Z_:XPZ"/#>+X\]_YE"D]YBGU/1[R9^2[?]MY
MN97:02_#\C]:F(H028R>40#F!)$P]D(K*J1)..JPIR \JSCGW53[D!&].L^U
M:]/F<<Q*ANCKO [$4!V]!N>:**.I%)PJ1T0,,?=ONT>9PK3+DNBYD0&SQ%40
MFL4DG8"7F8+[IH4K_\:Y\HO@5)9> DLZ<TM*HR_U!Z7^X*GU!]T3N,N+=S78
M=#N#=U6R-_[?:>LD,\6F=@\M%0C+3QCX Y9!:8/P1D3(9Y5NSXMF69(]9XU+
MSW>:GN7$3N/[-[C&-PSW<[[=W+K8_?3YHO%I]PB^BTXF>]99X_+@ #Y/&I^V
MR&[S"SS/9[%[N"GJA[\?[6YLX=WCS_!<.V)JHP-BJ2)"$>0%C[GXWB&7 D6&
M"H>]]<89G1L=Z+F2&2^-#@K&O$2^N6#,8S!F/*$<G,J*@Q;)*#'B+CID97 (
M2Y8(,5Z+F !CI'KZF=W\\2_FU^OZ[;35SG=:.>%N]#__J@H^#[KM4&L=G_2Z
M?\=2P_$B[LS5;/37.V'KQLA_ZG7[RR*'^E(8-*680[@@%(L&L:A99HH'9+@T
MR/$8(XE*6V)7UK24JV*.J.*EG&-.'8-BK3.UUG&/@=MD?+91YR)!G(/;X!*&
MJ$1+05FPQE$"UDKH7%GKTN=IZM8?P(N]B]MYNU+(\=S.P?7  ]QL7@U[P9J'
M8\V4Y@;>YMFP#%F8%XA.@@2LX0)%S(D56F,:]<J:D#-HI#)_&9!BJK/V#(JI
MSLY4Q]V"J#'AUG*D-06W0)N +/<2F12DMX0;DGLB<J/F*EFYS(F$BM>U?1+S
M45]G?Z@6-:K7N-:,VNH,3EN9TU;[>M$?Q.-:UD&!=Y><PO-7) R/6[^>NL/H
M!\WN=F_];]MJ9Y+3QV[O>MXJ89J"40_'J&ER_DI&FY.=U#&#N+ 4.<HU@I=L
MM"XHSSR$+GB^^K*51,.<NA/%A)_?A"?<C(#!F_ ")242XEP%I -12%H>O/=,
M$B97UB290>NDDGVXO_5]Z!Z?G YB;U@AFE++QY*#>"$YRJNQSR4WU<A?AS8%
M;AX$-U-*&GTN3R=*(I@1FO4G+=(B.92T42YY++%7N3R=KZHYBFI* F+./(9B
MIS.VTW&W0#D;F/(4!>X)XI0[9),&MT Y98-/@FD,=DK97-GI,F<?AFZ!/6D-
MX"8N(PQH-PW.;"^6U,)SIQ9NC/H5YGP=#7Z)0AX.-_N3;H&)F$:G'<(B:,1)
M4@ WCB+-X%4=% 7,65FC',^5N%U)),R96U ,]KD,=J*/F4B>FJB1$ G\>.L2
M<C$)Y!0QR2>#@R=@L&0&IQ,E;?"0M$&G/^B=5N.,6AUTTNOZV"_JD\_O(MP8
M^*W.G[WN?@_&O8#-P\'F:$K=AJ&*::&0$U("V%B-K!(>16<3IU@90?7*FL1+
M6;=1;'7FWD&QU=G9ZH2@#@_)J."0,-:@S&W,M 6.J+0^6:$"]BS7"9N2.'A)
M,ZM6=^WDIR7)3TDDW+N$??E@:=8$AC_SU$PA5*5N[]@.X O/!^\[I\<H=*O*
M\WR] EL/@JW-LPJRAFX&J6^L7S;6]UQ*PE&A48+=!'$"F.5"Y(A(KZ)(RJ<,
M7.R=)'366F#W$GY8E S%&T:"6?,@"A*\!!+4QY$@@9<2:4@H1:_ A8D!92X3
MLA)>5,I&2@.X,.\T%ZMX49!@Z5,??X /_[ZV[OWI\6G;#F( $SOI@554PBS_
M\\92(/_]"@[,C;'?N#'T\'L[YE\ R=:/NS!&E]7K=Z)< ;@9 MSY-%<'"TT=
MD<APK3-MTR+'$T'6:V%(%$ISN;)&WE&FIIRW_+,D4Y;!ZF?EK,S.ZHMA/]"P
M)SP7XQ6-BE&4*!$(9I4A&YA!T@FFF>78>O!<C)R6*'T5LWYS?3\>+ GWO.'6
M FOZ//CYYQNZYRGAU(C%!YLE5%],\<&R*+25GB-K&4/<)8TLHP8%!]&E 0<L
M5(R7=TSQI[=B7[!T4\&\@GDOG5HKF#=SS)MT3V$*%<<!)1T3XII8!.$FAR&V
M5(FLD);=4_).J]D5#+Y48NWJ1JX6N*@0;=9AZSVN<>.!QYJ+W'SBIWS#*]WE
MTI_1_L]=R<M<9-[-O\/K9ZW!0:T[FR+T)Y--%W\K7:#=\C52N@^JR+TC$U1V
MSH?MG'A*M$ E9\G IAD#-ED,1""KK$-<,&F\XMYR#M&"%E-41>^?V)D_:GQ!
MJ&5%J%?1#"@(-2N$FO#MI81YLP!.R@N!>/ $:2P,$M*#<V\8^/>YL%=/(\^\
M"D)-],*[W?5NHHG=(WO?W='EZT?CO=MF$3%U1CGBA Z<VZ!UP-$#ZF.JF:!F
M;R-OW)A@@G[LX%.ZJX\:1/[1LJ[5!E\P]JO69DWXHM_:77^TH M]]S\'V!__
MU;'?S>GVX9=#N-Y9O5F'!;_.=BX_P[5^;^U<'ASOPOOKQ]_H[J>=B^WF/O[/
MY1:O?]Z+@9M@DD51*HVXYPPYYBR2V,**$M8" JW4(J#!"0SHH'<:2V^UTEMM
M[GV*TEMMVLR]M<9;I6-9Z5CVM(YEE>=0L][#QA=J[1^^PW5FJ7_0[0T03.%Q
M:5WV]EJ7;75\]S@.):FJI3*PYW#U$WN1O9W2U.R--!R:57*QF5?/G\/%LW0-
M[3?JY[O?/U_N-C<OJ^AYX_>#[8W]\SJ%US]MT=WO'P\:&YMB9TI#^_HEW.-&
MHUUO-H[J^?^/-_DV?/_.Y<>CG</=]L[W35QOM@^F]CC#,1 NI$*:4H-XC!@9
MQB4RN1$UEDGZW$W S$#.;_[8G05QEA1Q9I4L+(@S \09K_CU+&(10T#!&X]X
MX (YGFM_@S%2&R6E ]]2\+E"G"7R\J=;U_K(B_<W%4%Z<7BX[(?Z.+5X?A([
MH34X[<72]>P%NI[UX3;Z_0_=8]?J5-'7ARKGO \XE$4)6B$.@[*KM.U% :G'
M@-2-EFB'ZV?UYM;%GM8Z$AHB"DI1Q$4R2(=(D>0^& \_4LB-3_ JFR.YHJ(O
M-J=^1+'DE[/DBS%+-M@2)DA$1&;!<D^S@G#4R!,<,"="AJ16UBA[BWKEKVJ'
M?[0&K7U[R\^H4HE@0V^L^/8U&L1?#_Z7"'?]=PEOGNHY7$N34FN(]PDIGAP$
M-<(CHX1"B?@@-.$TY99I@#=/E@*8OX1*L=.9-UDO=CICO^#:3J7$D4>%J(L!
MP2\4[%0&Q+QURG!IB:1@IW/5V'#ILQ"CU5T[R07@8&'=!-:1(KP8JF,D?^TU
MUTY.>_X@D]G]3?^Y9"6>M=7)QF@R_AP-_JW8Y4][4?5Y+A#U&(B:TGT5QR"#
MY!(E(UF6&&/(1>IRIV="B,:<$;RRIJ9PN$L.8FGL=B:M3XK=/J?=CKL6&E!5
MV821#=(BKE)"SDJ.O)#"\, @%."Y&<K,U, 6*.7P>K[%G6REDFUX[FQ#-?2C
M$Z8;%/,".(\!G"E=TB2U0?F0D+8.(TYU0*Y*03"A-=>,:YP@EC&F)!V6V5QG
ME70HYCI;<QWW#YS!WCH>4.!6(2Z=0P"H$@7&#4P6E=*%I=4\7Q3MK>X3R,WW
MY J/ZGS&! WN9A(O-2%MED.S-(@^4P>L0/D3H7Q*([JDDF#&8&22BH@S(9'E
M+B)%8>(\I1BF;V6-*SEK4:XG&<B<5^D7>"SP^/(.;X''I\/CN*>;*&4*QX2$
M!%#D@DBD88:0UU3$H (QUJVL,4QFQJ-[37B<D CX4;6_\ (!C6['%XV <8V
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M.#>!A4A"XDQ;K:F X,8E'G./+U9RBHL'7A,YQ2"BQ,)X1#5UX'D!;AF!-<*
M2D0)X02K-!6YF$%.<4Y91O,>2I?2Z1= .RY,"CCJ(*GGFFFCHQ:":F>D-1""
ME#ASP=".3(DS75*PHS&'F/4*<69RMVEM$9;)42M-,D[G$Q2I<:FM7F9KCU;P
ME")5@M%,K]+$Q215E)DL#9%:"<P6S]HG C,2N4DB1J08)X@[[9"Q02'MO=$R
M>"(,K:S=L*=+5A5KGU]K=UQZC(/Q4@7N(X \+ OMG/?*&&]#B606S]HG(AD'
MCILW 6>.F$?9\I%3F*& I5$0X5 F>+9VHG2ISB[5V4L,=U9(8FT,L,\1KI@S
MV#ICF%*..>X)+J',@L$=G1+*)"(B>*8"!68X@C6#D4N!(^NB8@QSGG#EW&#*
MYZH\K%C[C*V=XDB"E83X%#G!7!,>HQ92:N&$2R_4 :P8] ,->B):R2VJ6;0&
M)9U5WR0!@XY<(D\B<0X3#1:_LF:(+.:\S.8L5&0F!B>2LEPR;Q4FB0&T)^\B
MCD4H:C[->2(<T89&[85%5.54HX+?M#8"61RLE8:'B/W*FJ)LKJ15WF#Q]NL7
M;@\'X3T,5RUT3UT[#JG.I8#GJ4.S-)L">/K.*' 0A Z<VZ!UP-''@#'53%!3
M(KH%VS'8E(A.22%@3CF*(KA,?4Q(2\:0M)1G)><L +NR)M]12F?=Y_5)9K88
M=9 %9 O(_J+!EN;*\!1]$IY[&72R$G/ADW::2"/*F>#B@>Q$E*V===H&C*+3
M#'&B+;+4<I2E[V+2DGIB5M;$.T5FQP H(%M MH#LB%0J).'>18!7Q45*CE)I
MM.!.P<^(4SF*73R0G<A]< 5H2@1%1"N%.*<..9,TPDI9Q@7,JXDK:_P=$WIF
MQ(O7!-DJ:_*O@86ONVX_/'RHQBFLP9:O6B9?/<*Q[>VW.E=W*L'"1J_DNY.W
MX>\0EG$K73R?75=7?-\:P-?YGU<ATVSI7^*Q;75@O&I_QEYE11T?:]L.;K:J
M2_YQLEN-PD^?>O(QAR^U.B%VX MUM0.],)Y53]D\B#5 DDY_A&<G,(6Q9MOM
MKK>#&&J#;JUW/1 G-P:B^V,@X!UM>',_O]D>PX+-=; WKW#2ZX93/ZJ.[8\.
MQC,RU<X.6O[@*B]5.[#]6J<[J%W$0<W%V($_^.Y^!QXGK-;6:WT8OU:"I=D9
MU$ZZO>I^NZDV.(C]^(M[RW<Q^N);?VUU\L=K'[K',/87__4/38GZWWZM7]&0
M:WU Q^J>V]'"5]@>#-1^'!;Z#@[LH';6:K?A3N&-@U8_M>!I\[M_W'7-]J\?
M#KXJG0Y.>]6MMKJAOUJ[Q^#GN_OU!)S!]_R_AQRD)1.C,"9BS;C/@E)4Y]-4
M[E+>H=3>UM3<BKQC1[HVE1N6\L-0[K<'F07=@W;_<X#]\5\=^]V<;A_NP_=\
M.=RY7*?P7><[AU\.MC_]U=K>\&?;<(W&]X_'.Y<'1SO-??J?RYVSQD;>7^JB
MT?S,MYN;>Y1KYR,.R AA$/<T(4.80CXXC1E/F:B]LD96]5U"> [68YYZ6 Y@
M&!O1QV,7>\._,?*NEF=UN.Q^O:8LK-1X?A+]:"7>6N9=V"2JM3F(O>.1$=ZT
MFG=#DWEWT^)OV<^[D>GG;]F/G=B#57]1.SW)W_3O6QO*XU?N(];JYNB! 6/A
M+=OI:_7$PS'^LS);<FLY ^SZ]^&T=Q%M[\TM8,_JG_>B#L&!WX-H;O7#.<ZI
M/$N0LLHHK 7Q,&1K8MQ+J.41ZZ\^:0^=&U?ARANO9<][M,W]T;)@C:W!31&(
MZB%_LK@?E?N^O<JG!0;57:UWPM4M732S^]:$K_T-=IJC-[=NM\[KS9T];GQD
M,3*$A4R($\&0<]HB;0A5DA--6%JI1=B>3F!\![U3\.,7V<M+7? KSC+BMSI#
M!,L[1?_T&!X$+M6?Z@CYJY5M?ZSL]H^57?MO\&J.AYM._Y_OGVK-55AQ'?X,
MXQ@8HK8]Z<?W5[_\;VCU3]KVXGVK4SUH]:'_O?T-XF0BC*F^</CG_SUKA<%!
M#NA7\3"H'QT#C[YY].?5ZD]C0=GP;XJO*J7N_#->)7?^[6>7)7A5&/&HR_[\
M;X+=_:5/NEE]K\O^XJC]ETP9,_'6*>DS#S86>R^3+#+WT+%:6;OROVK@>MV*
M\9\Z'C>RFW<%^U/B_?D>K+RAW8>8<)\'?FL#1QZRNF8E$0=#]THYV ^W-Z69
MZ3R^K2S]/9Y_:5+QP0D5.:/4"LL)-B98[862SM)<+!/OR'=,9.#O]*X;<; D
MV?3NQ<[WW19<E^PVO[2W-X[@\PUPI'\[WM[8Q_7C'7C_QU:]Z<7.Q5@V_1"^
M\_AW>(:_V@VXE^TF..1TB]<_[?#MC<\7NX?@@'_?.F]<M@_!";_*I/]H.2D(
M#X%&C!)V&G%E)-(\J\MH:0QC/,_BRAH7J_BY%5\7\TBR(-K;030!2.8<I\%A
MSF-P8!]@-=9SI84D45>(=@_B1D&T62+:>$=L$2.CB3'DF 9$,\PAIZA"6$H5
M=% B.@&(]@)R_C,]_WMZ">=<X\]&3+'7B^$NOG21 5M24'U.-_$Z^5I0]4&H
M6I_T$TF$32]*B[P*!E"54&04%LA6.7.GO%8&4)7I539']29%@[" SVMY= 5\
M'@T^XRX=9@(#M 240@3P88I!D,HQ8MAC(61N1LL ? A_>I0ZZV*W)]"VYOMH
M:W1J56MU_NY6U*+6H%_SH[7?KSG;SY2%(=6GHDAT]L$.#F(X;<>* Y3?GVD+
M_5L<A=7:G_9B).M_BZ803F.-X4Q5D+@6[$6_EGK=X^KR(9.-NNGJ5E9K8\G*
MBO64WS@B =5.>K&?<\HALW_R41Q<OQ='KPXOV4K@C\;,SW!Q<)9Y44-6T)!7
M-"0B542C:]K1K2>N&%"MO_/!FNT$V^YVX-<X'(4AXVC$WQA2I<*=C)#;+*?\
MB:OCP5/;OA[8S BY)E;='LYQQ_J>@W%-+KLBDEQ];;]V=@ C,R2?C/Z68AQ.
M5[X?N-#I"8+)Z0S>W9B__SNU/;A-^ V^WW8ZI_G5=_D[\_UDTE6W'W\0U0[L
MW_G!*D;::&PR(2VO/)C4KF]5HQ;&'Z[5O_&5-R9G.G=F=/O#D1A>_&I9!XCA
M,BT.[B/3T2YN$>%:\)Y6+P]PK=W-Q-\\[=7ZO^_">QH)8UYP8..T5ZT^>,),
M+:E%N*-P!P7JW<VS[IM3\Q .W5,+%2?(=#_=N*_92U?WNMS,[AFQZD2]N;Y'
M%#'&!XJHLQAQ1S!$"H:A*$WN)":4S74P3-^U7X_X#=E2)S"WU<F<>U@Y([R;
M  %GVQ6._H211P 8[[]XR4P6[U,+P,KB?9'%6]]C2L)<Q8ALP+D],E%(!ZH0
M-<:Y:"..&L/B%9,%7+7G7K=X;./(-Y 760OVT^H.;FXE(ZSF=%5E<LY)M]^J
MFGM=.2<_.#G_WVV:U6CSP3\^8EV_VSX=W/V1B>/Z5]J2"!9C(W3CY\%U*\ 3
MNQ^1ZT5[A&R"NWUOVV?@4Z[\Z_9>#!OQV""./_^=3YG28YY2W^,A?]:L[=]V
M7FZE=M#+J/>/%J8B1!*C9S3+AD&PAKW0B@II4A;$WE,04%0D-%CT&=*RW_KO
M?]FU:?,XMMQ'6.4$Y\H*[)GBL/UKYB./V$O',3/Z$1S"N6&Y;G4&IZTJD!BJ
MM-?^B+8/V]9+TENWP7N%T>[LY^^.U8^MCH?-IE!:FWY/Q>!<P@YQJ7-N0@OD
M6 C(<1FX8H$0ZR8HK<\[85]S5-V\.(EEPL8G['!]C]O$<* .18LIXE%PY(@F
M,'_*"8D)"U8O)P=Y2/4=Q:#]JPJQ'XF!G$^Y"W!N%V(]BH)L%IZ"+.DJ%H^C
M(/_\;TSSQ2$VEYO%JX 3+\+"?L!;B5A,QO9.+DJJ;=Z*OI^3O?VZC:478DKN
MRPM_\# \E#"^_.-,RCB_R#CCUZ#KO^XQ^,TOS36SJ'6.#EH!?-+W"^?TCXZ@
M16/CM];NQL?#G>;'@]UF'>]^_WR^O?'7X79S_:+>7&>-[SL\W]_U9ZZ/H(]P
M_=/O1_7OC8/Z]X_M^N67]NX&7/M[7=0W(##8\&3W<%_L'J[3BE7X8>P(6E*3
M\Q@!(KPA3]HCIR)&D6(5,!&:&%W&?+9C[IS&2GN)*,\M-[A5N4B?(HPM-8EQ
MX8DL8S[;,?<\: HQ,(HIT-SFA" 3F48NI8B]YC)QL;)691C0X.(DCF0ZQEF;
M4_^9!W;^4G.U'O;P2\/BFKE\[9T)M(4_)GMQ?&F-X8OUP<D4$T!+5J&E$O E
MD82,T38J'+@3:66-"#EKY:ZE$$ L>/86\&SF2K$%SV:%9XUQ?XE:V'? *T*1
M.(*XUA$Y; ,"%XH$:G'B!/ ,=I^G\^(+GA4\FY^G?DU1UH)G,\.S<?^,)>\]
MAB ;_HFY311%SAN!.+&$JVB5\B'[9WQ!_+.W4#M9,B"/MH#Z9 8$%KI1QA@4
MI))9HTPC[11'5%BKX/^,C+:,^6S'7+%(@I(869E%. .#WUS.^4FFJ50I$LK+
MF,]VS#W#4=%($<$*/->4<O.PZ #XG><N:1JM65F[)G_=3O3]S^PR?:7V\FW6
M7LX\:W<G3[%XA0_%BG&O$$?#)98!6>\YXK I(I>K,*..U/G$LXK0RAI3<E7,
M40%F0:""0"^:9RL(-"L$FLRS!2]X3 Q)1L!;"4(A1P)&B6DGC0T^8/!6J)J!
MK$]!H() BYH9*P@T,P0:]X$\25@;$A!S!GP@K1QR4A-D,&PBPHED!%Y9(X!
M:HX0:)3_&BL)9!6\/#\G>8G>^D*4P>-6".WXB]K"9X6O__G+]EI51<:MB'\D
M:9'+2+JUTWY5/UDI7MPJ#+FN<3UK#0Y:G5IW>OI@K+3O!0^>EGFKG/:(2[-5
M1LP8BT8D+0+7X*-K JB;HA/&)B]"21>\TE;Y[4:ZP)]O-^MBCTM#J>($N1@L
MXHH(I+E4R'..9:*41\%@JV1L9JK""W3T71!HGI[M 0@D"5;@^CEG!>=&!R,M
M-RHYFR1 DD\E7?!J"/0C79 1Z#/=D\93:95'L$EXQ",7X*=;AB+!3G+#N II
M94WIF35A+@!4 .BY <@EQ92A6# ;.42;6DGE+;8>!Z4$925;\'H =,L%^G:Y
M1P6AOI*%B"J "V0QLMYRY&V*,EA#A8TY7_GT Y,9 M ]%"NG_?^D %&U9GXI
M_$)Y/M2_AP+>C0;&A+ZP8,M/Y5D:V\W-FEP=SMCDSV?6^?@C=QR/MXVX/S_R
M'I]'EGMRM-UL'S<V=EOUP_9A_=#C.OUVMM/TN'%9%]L;C58]"\,>?FEO?QB3
M]SC^+. ><.-XZV+[>_VB<?GY<K?YVP'\R^J71[Q.M\X;W[_1+"K[G\M-N-ZW
MO<0Y54QHV/FIRUJQ!!DK#*+:)H@XJ(I:#7$5EFP,ZUD/#4:=*@L. V.:!TZ,
M<9P[X5QB%J(7]L+Z+6,SNIWR1'=[&ZV^;W?[I[TYDG!Y^3G>WOB\IX4G)E"-
M(DX4<><!7,'0D>4:&Q&\$,1.S'$2V'()CKF)W!)E'.$I6JH$X=;ZB;:3?VRN
M?]W\^FO\&]-AFE2G^O7B&K_1&(T7L-ECP4/05GKMX<$B?$QHZ5;N^IY?/N#M
M[Q&22+ )+#V3G(%CP1*!&S1@*)8DY7ZA>C,/$EF5 S4TCMK6C0:;5Z*Z@^Z=
M>C9W:M:\JIC/G8\^7=[G1AGF$"I6:[6K!WL-N:%GPL56O[?_?CC-BR)M]0JX
MV%S?TP2@PD6#K&" BT))9$-4"!/# CA?)&9IJ]LP$(C2-#)-N.1<.F63(T%C
M[ID)D=$)[;(_1GE\'UM_YS'OWSH8Z(\7!M\Z'<@2T3_DID=2V1^ZG8KS75GL
M;R,)S*\'L6I]VQ_)5TU*3OT,AQ^N]C==5_!70_/2TE7&K&K!'M4\EZY*0V>O
MA$16)7L.02Q8O\]SLZ8TSRW-<TOSW+E2/5KZYKF?>MU^__H$_'KG+$UTG^OY
MER;E^]3N:)7K?-MIKA;C5N?OV!]DKVRK4[TZ1QG?Q_G.PXSO27N'PMTVZW3G
MLM&N']?Q]B?PGS]]9O ]\'W[?.>P<;Q[>'2^,Y[Q/?[K</?0G]<O=P_A>RYV
M+C_#>[?X[H:'9_KM<'OCH%6GN\?;S8^MJ9UTJ5'4PE0@+WE$G-D$SG=2B'K-
MJ>6<LZR<P[EY_LK)615/OG8Q>,&U9<6UIS9>*[CV;+@VWGQ- ; %IB(2RC/$
M<V==;;%!P3*NJ%,N: *XAF?0?&W)&NJ^GL/YK1-MKU.U&LG)L3O#%/JP9YZ*
MO_.'0__]*@[6X J(KCJN?1WV>_NSUTVM>>KKO0@X-*4#K6'*RV <<B1IQ#U-
M2&-&$$LD.)4H5DFOK)%IPA3_7.#:GV*KS^ T%%N=K:V.^PP:$XLQ92B8X"$6
M$@X9$26B3FIEK%%@OF"K9%YL=489J*')F7GV#+Z>ND%W8-N/<@EF$J_-'P:]
M0K?ZVZ%+(PY*X/(T$/H\Z3!8;ZA) 2,=C$*<\HBL"!"X4!F"QDEKGW++>K$X
M@<N,$C+%V%^T.WPQ]MD;^[C'817C5C*670SP.+"VR.&(D8V$N!BD%UBMK#%#
M5^6B&/O29RG6,[.CHGOD/MD>W/#6L*%VR5?,@0-R/3L?N[T/U=S\ 5-3D.I!
M2/5MTBWA3#KA64 ABP5S0PFRP1/$M#8J$"FJTJ1II9$EC;$4)OQR;D4QX=F8
M\+BSD7A,AEN"O*.Y<2AUR%HL(=!02AM!G6(TF_"DJU&R&\]JAF $M=:U%>1&
MZ^.$U$*Z*8?3K^-C53^^7+._"@H_"(5WIN1WI*,\B("DU0)QQ@-RWF718*Q<
MY%1P9G)^A[ZY_$[!M()I+^)T%DQ[(J:->Y;!2AZ5HHB2?'!F(4*T!%O$!1:6
M:NEPR)ZE-HN#:=,5Z,1/%.B>M47S7%]CZ9GP7^))MY<+O6S__7/TA9R+:RQ]
MXO;/7CRQK="OV4ZH=0<'L5?SI[U>#KELOQ\']P^RBH#M8KL5QF#"<33:>G"W
M';8DLEQQ3HQAVF-50J67=ROV)T.ED-OWYB@I5I(T/"7DJ.,H6N8-#4I:9K,@
M'UFE<Z1=6]2S"_C\#'PH]2$0#KCC$]=*:6^2HTQZQY*PRI>8YE7 9SRF\=YK
MG*)#*3<2Y])1I+702$D1#""3L%AF,N ,6F3.7])\?IVXK<[ =O9;6;_@AQLW
M=-_>U3IQ\!2&X *>X#T =SP3B@KB@I>$:Z<T$UQ+DG1*.9UBBM/S\KAS-*4@
MTZ8@I!2()Y7Y?\0A&Z1#BH*7&GCDQ,25-8;QJIXC#;Y7H/@MM[420Y3C%!-E
M.;=$:N]P\DX;*V@P+A4OX56L==Q+B$90:HA%R6 P61LTTL129(V43,%J,IIF
MP4S]]/8:LU;,?'JJYXT=K8\&891Z'BD@,1B&T#W-_LC5T[S9<ZK9#]#2P'DY
MG)\_.-\\JZ!\Z("1^L;Z96-]S\L01?(!)>?%4(Q.6^N1D(EP%WABD<SH>'[F
MYC+G&:L"G 4X"P-@28"S/@Z<47)%F62YO5SF )"$+%8)*4NYMB$YK<2,. !S
M YRWE><G-.6OY96?477[>EVO=\)&JQ?]X&.K8SO^6H=[;*G7[>"TUQI<O'GE
MV<:EW^-:)FH@7-.$F"Q^%9!SCB&)1:1.)*YDG%!1OZ_F_W35UA>49?ZIZ/$'
M>$<VOU/;KAT/UT0+KMY-M?WILG]9U1;^>B6V.3191M[5\LI\5XGD_D3W]MXZ
MM[\<P 62K]5RE<AG4H35LU2$?55OZC[RF\,[@_V]VZNP]3WL!K&7W[6R]K&5
M-^_:3K2]>W!S%DIS=/T8MKW;1QI+?\ #<,)*M4-A!K]T0N6>_M.?]J)2A6]V
M?QN]&D,#[JIY%MM_QSK<XL&RE*IU<?UR2T#(<-2XW#_?_;X)_^_Q=NXCU<R?
MW8+[_7*\V_Q\L?-UO _59[BW-H0,G]GVQL?V3O/S)?AAO'ZX>=X GZQ^N'76
M^+3;;FS\?@"^V.0A6&(I"2\-TD$DQ&,B2">34.X(0"PE."67F3^S:T15ZN)G
M -S\C97 +RA>-<^ZV5LJ./4PG)JBGJRD\(E1C9CE#O$D'+*)*(0]23E-E4C,
MBF%4%I+0"T.1*$2@A8"B@UZ,!8P>#D93I$:5TM+S8!!SG")N2$#6!XLTXQ%+
M%9W.E:5&S%_SSB5WBV1QBQ8!BSYV3WL%BAX.15-$#*EU$*D96,M&$<2Y4,AP
MS9"GGGE/+*$&_")9N-,O#46JN$4+ 47PHT#1PZ%HBG"9MEHK[QPR-$G$J2#(
MPC0B027U)%"LG033D,4K>F$HTE4!1Z[?B#8-XMV'-\5)FB-D:E[/5X&F!T'3
M%"F@:(Q3C@@4B,"(!ZF14RHB@H.//GEK)<F";$OH)"T =;PY37#^GL<(A>/X
M @-4\/T9\+V@^H-0W4^BNHC>,LT\TI@;Q#T$P(YX@8BSEAMBI=?F63HJS@T1
MLF)YC;<Z?S#KZT4X<M45W[< Z5O^'JRY[9/8&W:-'QK4:JUV-5FO0>)K5HWH
MC^&;+_[K'YH2];_]6O?Z%H<4/O#4CH<][/=C!_[4;E_ 7_I]\+SS#<>_8Z=V
MD4/-U=HS4U7_@&_M]JZ'L!K!:1!4**HCBNKVQOH>-=19G)D0A"OP$9D%7/$>
M<4Y-2%["*V2XG;0ZIS&L#V",X._),DM@QA*G,%="*,$$BXH[IWP8I[1^/(4!
MC[7C5J=U?'H\6C<GHYFI]6+;9NVK03<':S58(,AG=>9VNZ)A9F6LO+]UT_C2
MZ]?^^^R@Y0]J\=RW3P/\__ V]W,EWK3+G_;M?D0./AI@P?8LO+-ZSS^?QCT=
M Z+'<E&'6_I-AO=P1?YRM%^!L,J)>"QA%8MG(:R:^UVV$%8+877QLNJ%L%H(
MJR\5Y-W7BUI64NIEO0D!V.67@WPOVQM'>+NYPW>:OQ_M-#\>U#]]/-K]_OLQ
MO'ZQ^V$\L*N?P[VQQJ=-LKWA^7;SLV@<'AS4C[\<U+]OGNW ,^\<[\#KOQ]-
M):4RZ;B3RB)A\DE"DE7K!(VX@VU?I"0I=D-EED53N5WJ<X9"2IT;3%HVXND+
M8=$4XJGPG%B7*/(JV=PEDB.+F4&>>))TT(E$"ZM?X*<?:\[?X<%<PTTAGLX/
MW"P=N?2% &=:'WMGM>68($PT.#_<2&19T(C2('B*(28F5M:(F=;(OO H"KOT
M30#.TC%(7PAOIC!(4^0N8<&14QI#L.43X(V0*"4?6"#1I41R!2">*^WOM^#@
M% KI_.#-LM%$7PAOIM!$HPRI\F\H2Q'QH ,R(1_BFR!2R(##X\J:6$H=S[F&
MFT(3G5?T63XJZ O!SQ0JJ \D<*XC4M9RQ*4/2'L:$!:$6R\L)4YG<UA&;Z=P
M0=_V*6#A@KXBB!?H?A!T3^-[!N*$D!%Y(1GBV!IDI#1(4D*D)-QY%7/9-9_U
ML>#<\#WO$+Z<\OK$*S?X5R.+X71599K32;??JI@S%4$,ENJ(W32RJ!L?'(T#
M_O$1Z^"13P=W?V2"1/-**HP$R]M\M)L_#ZZ[CYY4O#APMHY0Y6^]M^TS>]%?
M^==M ENK@\8&<?SY[WS*E![SE/H>#_DS)M2_[;S<2NV@E^'W'RU,18@D1L\H
MYCP)R[ 76E$A3<)1AST%WD!%Y^NF6A;1S(#Z[W_9M6GS.)4O&%.,Q@N7%!8\
M!)T)X9YK#!$F%UJZNWB&0A*I;<+2,\D94X8EHGDP5%M+DG*_DB:=*J7YTK3J
M"=I8909YLXJQMM5)W=YQ]<@/8&G.K\;J#7IVK4*9?JW5&70G>;+PV#6P[G8M
M]@=V$-_5["D\7=>UVK'_KHI_/:"Q;75J\?].6R=Y$U^M;8\1O>/Y2>S OV>V
M7_M_#_ X'L7L_IGK<=OIV!S>UDIM.+?PA>>#]YW38Q2ZE2WFRRR\$_)XEO?.
M66/#@_-2%XWFYXO&87T/_#WCC5'(."41M]P@ZSU&A%,OA54 2RP?[=^9B1IQ
MG]\]:!5HS97A*?HD//<RZ&0EYL(G[3211E2K@%RM@GL(KI=5\(15L+.G@C>"
M\H0<LS;W/L5#@@?!+$5C#%6Y_2#%=QZW7J^"#!\/60D$-AKN780UH+A(R5$J
MC1;<*?@9<:I6 KY:";BLA&=="4=[0B:(_0A#01#  P6_618Q4@;3P(RW/!!8
M">3.\&*T$JI=)E=P5-4^L"&%&.XLJ<@V/EPZ>8[?P>[4/XD^N^'MB]7:1[C2
M:.LZ:PT.1C5&X! 16CNNV*:UZAU]V+WR-U[5>-S<HEK',/NPK\*NEV\L6G^0
MK_"X&UQ]HL+X;5_AN<N@8. ^=/N#4M^TL;DGB"?1:8>T]AIQ2BW204=DI38!
M)\$LK.YQ"?[7<.:^GIZ<M*MZ)%BQWO8/:JG=/0.'[MIG?8*!W:R"FO .L[7\
M4EK_94N,2"8Y#Z/*A]882?@D5<]18\35X[3V?_XWINXGM;_<-\ON>]DIYP!7
MBPXP-3[G.^]9.W9GSU$B%K/HJF( U#9OP4T-D.8>Q66+,C7W.-.^,^?YL]/N
M^9O,O#O<8^(>/@PW1Z*,<QYG4L;Y1<89+PX0S8J@]ZJGC1^R<WIB8;FD'W':
MX, .:F>Q%\%CK:KQ0Q6Z@2_YP]^LO-KNZ2 [MO=OB_NK6K4W=)+]JX=?FE/J
M9\X97QU4+WP>:-27\7#[TU\'C4]94&B+[#:_0>2[?['=W.>-YN?S>O.W]N[A
MER.(C,G$X?1QG6?QHMT-S^%^V_!^#M> []DGC8W-\_JGOX[ANG#-OZ;7B=D8
M4O"1(B991!PG I&U#4C3*#A,&2?"KJPQMJJ?NV3U13O5CJ'VO3O5%BQ[>UCV
MS"<?!<L>BV47XQ3M&)4W*B"3>=J<*H9T"@XQ8D*@E,L$$?P:94_G2!8L*U@V
M/T\]/V=W!<L>B66-255RSY-B&!$*",:MRUA&-,K+UE,JL&&YP=W=AWJ+@&5S
M$M0O4NS^)?^.N@F=]K.F73]6"GF^N]^!BX2;QT0=^,(A\:?KX+ZK$ZB[@O;E
M0?KEA.V9A]/5,MI.W_IQ/:^A;9?)8S%L=3;/_4'65?PXS@W_HV5=J]T:7!1L
M?Q"V3Y%*B%D.4GJ"#$3>B!/ED0W2(QZY8(G"9&N +O9@/OCS ?4O?,L"'_,-
M'S./8 M\O"!\C(>YV$>>-'=($F$ /H@"(.$>B:22I(YJGVB6F5N5!3X*?,QC
MT%C@X^7@8R*R-"XHQ2)%7#B<Z>,)F=R((*3$J/,)O$JYLF;F!SWF)$I\J=MX
MR^\L4_#J[RQ3\.KO+%/PZN\L4_#J[RQ3\.KO+%/PZN^<$%*XU:EF?HN96OW>
M_OLJNNNO=\)5^-;*+>9R*?>;+VUJ7*[O8<FQP2YSKZ1&/(F(M-4"?N.*$TF4
MEA.MF%Z_M,G9=N[N5.L?Q#BX6=[T[E==F(:U3.3=8XN9WN5&41%BRQ^-RZJ+
M@MWXW%:F!E>*"UCQI-AS53P)_KAF3;\H(M*/^^0O;_;>8_#:@/R$2A6SF#5$
MRU\W] !)I/F>JOM6",VJ0&69!NX^)3]SLK:7HA3EUI?"13QJG:.#5@ ']?W"
M^8-7J?T=NLFS'[C3W.>[&_!=Q_F[/&T<;EUN?_IX5&]^.=C=^$8F.@L?-P[A
M,W3G\/>#[8V#(W@NFI^K<;E#ZX=UOO/]\WD#/M]H_G50$6 _C#>@$L**Q!FB
MCA'$B3?(>.<1T30JJ9)V3)<QG^V8<ZV%8XPBC)7*3KQ 6IB(HB5!8(:3('9E
M;0M<Y\Y^*SNDV6/M9KGB$7WK7:T#?O1_3R%V_?,:C&[_4XB]A=C[7+*@MX]=
MQPYJE^;P]<708H+ZI26V'J)]040"A&8.N1 E<EKAP!SEA@-":UI*% J2O5$D
M Q?&.L=I<)CS&)QA+&$8':ZTD"3J"LD>7&55D.R)2#;.0@O!*<DT0\10CW@(
M"EE,&=).!96R)GUR*VMJ=NV^WD"!PM5;1J8C*I"\+\:.Z?;/2%IB3#QZ)I>?
MGULLH7P)Y>< 7C]/AI44]D#OG$#<!(.X)PG"2IR0\$J"_^@\,R64G_681XN)
M$@0I8W'NL6(0>.0!!<G_?_;>A*FM9-D6_BL*[OM>=$=0G)H'^WZ.H(WMZW,;
M\("/#W[QPE'3!F$-7 W&^->_K-I; Y+ " L0L#NB,4A[J"%SU<JLK,QD4ZG"
M.+SQ8K^TW;WO#6-HM"8[F[]GK3\!)OLX^>KM6-[C@.>7PUXO=FK"NK1VSYK>
M- @;B"4(Z&D$1&4":9:RYKI ",?$D,@W7E"^,M/[ 1G8-?BL4]_NW5BNP>=W
MP6?66M;!D,!L@8Q5P.D"]D@KH&M6Z."\ICYR?F6V]O4!G[6UF6Y6N[*VF1ZF
MDGU:L/T9!*-&8.0) 9O)<8M,- I)3"3E+-7L4?68KW;,A8E1.,(1,ZDNI0X2
M61TPL@2#O2H!Z90?V4RM;N<(Y:B]:UM-8\6OB[?>KIFQU^WX>K&_F4[,6AHL
M4"L=*U#P/"!."HP<2T>U"\VEL,8H'C9>R*6/6-YJK=95^W"?O,+>,C6O%?;F
M"CO+SI5C+A;2(.%]4EAKTH8\L ?%E3-&<BD9**Q\  J[MNS\-TL[US3]86K;
MX3QE=%BYX($H<HXU_. <61L5HH7BKL!<R4CJ,5_MF'O.B8R.(T4330=VCBSW
M&NE"$5)$(A0F517SZG3-RC8VZN"=)Q2\<\M62DUUE@6"6=O$%44PTDO$8)80
M#[Q(Q0(MTM;@:+E1U-&-%Z;.]UYCV%/%L%LVW&H,6Q;#9LTUJIE)DX248 )Q
MKX! :@5 YGC!A+3"8[SQ0JLZ-W(=>KBV37Q@AOI:+VF?\Q\Q( NMLD>IGG#;
M-COCK (Y5<"-BKG]>C#6=JE;F-%C&7Y^U6HV&O'M<L _C,8[?WD HTTNU.].
M]ONS,.REPK?UJG>-5>]HGKE+X10QT2,<4K806P3D8A2(&1<*S6%""['Q@F^)
MV30Q9;GA58C_C5#SL:G0,O2P5J%[5:%9XDB"5BJ=U65>!\0+%9&)!"-LE) X
M,DR%2RID;JQ":[NJ/\#@F+E5_4*>GSI2H,2CSC"E95F)&XXM!5@[U6Q\@,EX
M%WM^>B<2T1JBK@%1W^97>:U)M,YPY!4&B J$((T+AXHHI#(L6!Y3/<;?-VU7
MLQ-Y'ZKP__U.6>8Z;N$:\'$S#U@-'W</'[,,QW JB'8%(L:"D8"I1!H^0(1+
M2GSP6!9XXP6=& DU?-P[C;MV=L\[2]XY4N R5^<E?NQ=.QCVX-\ZE>?/]U^M
M(9BY0B&C"HXX)1'9Z!CBDC&;:BD+ZM8BE>?VE2DZ!\>Q40QA7F/CM"KE.)VL
M,WW]LMN&9I__[__0E*CG_=D$GM-Q PT+S^G[XQB&+7C )5D][RMAIS%;6K";
MY.O4<HM(>ALI,"73CR<%YKW:F-?)^%>V# A,MY<3V#Z#]2WVTE4;+UXW$Q=I
M'(+=?XWUXD&E.=QN)]ZU;JO@FLO3-<D%P"B[C$,]A1B")Q8JL*IPIRN)UJBH
M\LXP[L&;#\YBZWO<A68<]Q]/+,'!WK>]G0_'NSNMYM[G]WCW\Y=OAR='^/#@
MTX\O!_]L[O[<:X$1)0[/YPRFXUWZ'MKVZFS_\UOR9>?]CR_M#\U]>-8>M'VW
M_?8GO!^,J-8)<+5Y?XMPTH=H&=)4@,%$F41&1(I(83RS7D1I"*BU7-KA\OA#
M!A[UEC+H+;^1B_FZ)^IKW%L"]Q(-.SCKUG"W%-PMR#]9B$+8(D2D, .X"RX@
M2SE%-K H J/P-0/A)UNJ/H?^*-FIN :HU=BU<NPZ[L58H]=2Z+6@<#KC&I9E
M;A"S@B)NI$5:&8%HX-%[ZF#Z[,8+8I9U;S]ZD'HLE$S6E&R=8.UU=]BK46TI
M5%N0F"PX+85V&DG#"L2E\,BYJ) PA>*D4(PQ#JBV@M/'3X63/8KP)U!759.U
M^T"UYO>:JRV':@N2H&BB)0N<H6"C1%RE.#Z.P?!TD5"ML=,:N)K>8C55>Y14
M3>="-RGO4[3%(%Z^BU8SMSO&N.TT'370W0CH%IRHIH0QZI4!H/,.\8( ?6.*
M(\.T$;J(6(<B 9VIV=MJV=O#R!TSG5-C%%-S'2R\^6YQ#89+@&&-?TOAGU^
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M5H.9%VC!3=0:<Z*-4MS@0@2*ZSV;>U+7N3T;$H216D5$* 5FC*U"8.HK9'G
MV@3.(Y,;+ZC\_2V;6E_7F!G?@<+6S'A%QNW\9H2PRE+F&>+!%8BK*)$3DB.G
M"H]-T"ZH9-Z:FAP_)/U=+_6MR?%-5'7.RQYII!0[AX)A$?05!P2F3$#*1*\B
M)]02G]*MFC5:;I_"X:N7PSZ\//8:96GC;J=_W#R]F?^\SA1]3=0B!992LF!5
M4)P)[I@+(A;>INU!;&3M/[\7W%J0]CZ2 F:&.B2Q$XC'%-EEL4$T",V54UQR
M!48]_7VK?H59HFM]7;65< <*6UL)JU'A.?]YB%'9 CB'%H5"7%J#M%(&!:(+
M37D,QA.P$?2ZE-^IM??AK;:UC7 #19TK,8,+8P432!'JP9A7!;*XT,C%$(F7
M:;\Z*2I?JXH,M;:N6%MI(:URVD;L@%MY;(53,7"9,JK"-[4'_;[T=<Z#;@RC
MRD<.%CVU8-$;C4S4"FEBG2R\-M*59[ETK:\/3%^7X<9WH+ U-UZ1>3OO0??>
M%LYS8,<.])>G<KM&1H&,P-2HB#G'(B^Z\]M@-3M>6_U=+_6MV?%-5'7.@QXT
M%UPZ8,4!5EG.C$>&!X:")5KI8*U-Y;&)6BM^O*)0]/QNM=:5R[H#VYK+GGXK
M@>B_NN_*,AWXJDH=C_TXTNH'Z-&L ZNJ[U/;72M="184KHRP6 MM!-)".\0]
M34%+WJ+(G:!8*T$YWWA!.?W])!HKUY=[#IRHD;-&SM5;P'< G;4%O!HPG=L=
MPI$0A@E#)G"".$[^JV@P,.M">!V,QU2F"#*Z(#!EZ1"R&D=K''UB.+I>,%I[
M(FX F7,'78+SD@6) L7IH O62!-:($JD"506A%B]\8*;W_?[U[!9PV8-F[^
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M:2"PRG/O(LB!@@6F<)1*HP5W"GY&7&1IP"-IP+4TW(TT?/IJ%8NN &GP/%+
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M\=GW@VXR^7(8&-'3;OLDGLU^?Y@%OPJ\R+>GP(]T[RB2K$%U>?=6 W1SU_9
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M+KV3LS9G8%:X@?N44>%^HBMK5+@%5)B+L(Q@PT9OD/*A0+S@0'F\)@C,&N[
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M56<XA"^-G!4PUFZW$:]XK"]Q]LK4Y*%U_'[#3CARZ_?KGJ%]N"I,CC$#MFT
M$ [WQU[BU$GP#P=3=Y1=S<&>Y0%'"_>LKZLH;[ZTTV_D&S;'LW/EF7;8J+PU
ML>\[H-/'_8ZO)^N.#NSK/=?5NNW;O_/(*[]BOFOVV__P$1Y\DS-1&Z*P,X2Q
M&+C&W$D,)))ZI3T1/HCB3'P19R(\?V^7 :6VUDAD2.YM24DN Z\#\H;I)!CP
M2F.O=U2_FFWASC$Z,0FL(/L;%_@QUVLY P2+\%[:"__,5?_E\4D__U:IW50
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MU:Z*$M^$[DDX1H(+R7/%!>QJ@3O+8\!!8D8UO8&\5@RC50=+_[MWTA^,WC
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MC,K)UP6@T&R4-5+#DLI%NIQ2"#BR1,XZB1*FB26G'4O5T=>"0>7H:V& J\,
M2X3UR;%V)L)*H[$D&8>"(1;L3D:0=I0B'0V6A#$7="R4[Z%G7T-G<-RU9WG2
MXLV/+5>6*Y?CRB+2Y<H5N[*(=+ERQ:XL(EVN7+$KBTB7*U?LR@651JH=;.:N
MF;@OX8+:Z@UM]S$G@5VO'V(?U6;^>P8O'7HGKAL;X[$OXK#:K0\970#S^#[/
M^Z#7[83JP]6/M 0G5.2,4BLL)]B88+472CI+/64BEA2T5^W].YN3@F8X4\*P
M@+#0(C>QUL@H0I'S2BKMC!2YH1C!EV?^'WFX8D'Z]PK/9;S^]+6(J3/*$2=T
MX-P&K0../@:,J6:"FI*^]G:09"9]C6CLM;,<$8)3/A)AD0D,(Z5H9,D2 !F]
MMLZ;JA0/*<=#'QV\?!A5*>EKJP5",^EK/K D(Q9(2H&!SD2@,YARY*W2$C/,
MC '+C'#>U"M8/.0E;9_7#YB+FIW7B[7/:@Y^Z/<S:!X"!?[Y[/*2W^U9_M.'
M4]L/(Q2=P-7/0.,Z1X.._\MV3^+50B=')X<H](9H-)1B'=X;3O=FCB1@RX+)
M7;@$#8@S)I"F(2 6<1!8!,:T 3A]Q\2C>U"LIGE8'%*KZY JJ;\+@)PY!9:$
MM#A%A[SA&G%*'3*1@S'IO2=!&B=ER,>@BD.J.*2>S"$U2T[<->1D @7NZ'PB
MQ?GT:-0XFT8-Z9@407BD,,E'J55"+C&"I/8N<>Y"U324+ZAI:/$^%>_3LGF?
M2NK\DZ/.;'$RS(4A)B)+$LVHHY'U@B-!'&:*2.^\ /N(DJ9<P>)DQ=U4W$W+
MZFY:#*.[ZFXBQ=^T8$"ETX!*=,2,2X6$)0H %6-DI)1(XAAE8(8 R\\.)VH>
M?11I.<R_*CWLIV$6MO51A:WJ1_67B\'70X"!=^WQ(+X?__+O<<)9YZC2O.I+
M_SZT_;W.T?B-Q/%LBE@>8?WQOT\[8;C_GI@FYSRKZRA3;?3@T:?-2I.G9K3^
MS.BFP==_C)OD'U=>==@?7S"""59M*=?L2%?6YIK9GSV,-3.=X_M=G1D),S.Z
M"<K;R7NBK^XQ!R>#82>=U7_J  L[&KY'^:)%8ZF^#4IIGN%_DG^-A?O9GWYU
MHG135K.PM1\;=F^O'_?L,#8Z8[!L_)W1LM&/Q\!C8=(&C2%<.,SI@0WX$XCI
MC^F+WS4J-&[ #I&OS<!MC\ZJ*MKJWX.&[_8&\'1X96#!< \@L(U>:CRDCN(B
MJ7O%I%\]D;Y::/#[V<[&'YUMVCK;W@HPAB]B\]-'L?WMC^_;6Q]P:^O7PYW#
MSRRWB+M2:/#@ ]O<V-[EQ&+AHD%!Q82XYAX91P(*G EAL(I53RDJ19/-%C5K
MV$%>U8WH8_:PUGC.R+M&7I%WC=/]CM]OG/9.NJ&Q;_^.#1?C$4B9CYV_073<
M624ZO6H3;^SWN@ = [@P-&RW"_*&X%-TV#N*9]/7Q)%A%/(-.OW1QX/1<(;[
M%O8$$/#F5"'$*3_"C3AS"ZH\!:C<3M J5/EPXYS;D=K")<ODN;][[/"O.,@6
M\%'X^.,X>OAUJY?_-!%2K-WYJTWM%J3BO+7Q===XDX@$(Y?2 !1-:X^<L1+Y
M9)UQB@0;<94Q.MOCL0'RV\VR4XM,EJH:T<<:]W>U6@U8&%#*>KU  *L_UYK<
M.!WY-)"MG1J@_R,O:R5_(S=KH]M)<4)HE]5Y?+MTOE6?\N(D=F_7:N=Q"A8)
MPK.7AB>D?7 (EAP3AZFZ+C.QD2=P "AX= /-N8V'O"Y@G#!^/XQ?^2%)%^:M
MR]W6QUWNHU/2>J1REQ@>HT)6:868\]:#,4N3H8"4<ZF0JY'R786%<V!OS%F6
MAPP_Z29]DRN[$/ +F?NRJX(RECF .6F!@%M'$"RF04Q2&V+$W.E\GH.S)I[=
MGZ<8[CT9[=,1V.J.[SM 1#O^"J55<RDM"'L%44>@&%7<I/$55&'PJ)=;%KJ>
M3>ZLDXW?__S:V ,%&S8.(\"S!W.E'P&:_<G(CN['+JCAWV/#NZ)<M<4#'PU/
M^D>-?V;[FN)_;_WY1_4;^?>_WE5;'NJ!FJ'\&Q@^C;\Z1[X#.-,#;G0"S]CK
M]TZ'^WD7R"-A-40-3WOU%SP@0':SP5^/,A.[]0:\V8 !-#J##$V##HPO,\ &
M+,KW.,Q_"YWA!1)F"R\SPR- /OA&B$,@/S!)\(UA]6$])96YULAS!>.:??)>
M#W"LFJ^)1QY/2,W%4P=S'PLV9_9,A:M."_AV]+8BL!/W&MNMU=?L8! '^2O1
MPI_Z\;C7'V;J"M=W>E.W@U$["]M 9WB6X1V^T(E_YXN'X]>:.^#ZM8\JHZ8B
MV#75AJ69F*4([U29MG"G_7Z,]=*-1G$*6P]PF_[9A%-F1*NOO%?J]PX;^!^9
MH!,J_G%Q0] F6+C+$8"D#NIUB:%9_RM/_>#$'0#8YZ_#/5/L#/,*=5(C'AYW
M>]4>T:A7%Q9SD/<YD!>X.#\C&P1Y*NIUOKCE46\XN:*=P> D#Q]&<;F33-@>
M$YZFQR'?,H'#Z(4:L"7ZDVXU=95PVDY_1%BSWE7R5ZGJ49[GT614$PFOT?F[
M$V"YNV>U,$U]-U]Y^=73#BA4_E-6XAJ*&J?VBFJ>5+Z[5B8>C5]LO]MK##J'
M>6P@KS-/ !&KEVCV68/+A\VH]!@$0<WB_V91'4G*7,_AT3147%W]9[ 99\C2
MQ)XUBO]G?O3UJ+:(/\#^_#< P5;FY5LPFI^[\#IOC^Z(]H8'D^[S.3R;M\Z_
M[A(B-%=!H*"91-Q[A9R.!CFCJ06&3;   RP"03R&)1CV3_*Y_%>JW7G'MR-!
M:(#L9[&NJ$!6-_B_U.MV>Z>#QC\[1V-'"VQ?\8>/Q\,)M;*'L#T/!_]Z_UBR
M]\PA*HR;N(XTW3=&)7734'.G&-5];DM84Y"'W?;FSP2[6T#MOH.E]#YQNNN"
M<O?L#/>BV0?S0\+W>ZE[I,0^X$7,U'O,6#2UR+O^3^M/$OR[V_/K+>D>\WB'
M].0ER4*^VP2,_0]HY("H%N1312 VLE/PUTQ@*O=8 W;R1C5?5Z9K065@EKP/
MXYBO@.%0G6F=BN@U1H$E<DM+L;N?FIG-RG@3YV*<,)$P1I-FB3/F;/)1>VNB
MPPH^JYOCDB=T(G_\WQ-@(9^/!D"I\A\'F\"H^UO[]FCDTFOW1J(P+[RV>BW)
M^?:W%A!3CW<.?SMH'<#W#[Z3S8VOY^V-/;C?7YWM@^Y^^]/G'ZVSZ:2I_?WM
M\[W3]OD?A]N'K;,VD.'-+1C?%CQW \CQM]\ZF]\^POT^GO_/^<?Q ;TAO,]I
M^\#CW:"PXB3WQZ78(VX5D%_..$J$6.4E#\S&1?<CO[/RO8X$U0>"R-*QG8>F
MH-[A_5\I>%X?^7@8@BXN\G%W )T*?52D(W..3#GF!.3F8.MKC8L\.[:>36&K
MME1K' 7R1MM<',LBEWNG1IR(<XI)+/"KP]9G[0C^$FCPJ78U7VNME)Y*:YT4
MO.8L& T@R(E-1C-N?8A21<T"4;=E(70&_;W;LU_<-=DO\\%O> E^XSCPL(H#
MCREDH8KW@+//4U3Q*]_5E)N8E$>,Y*;E1$5DG-'():M-HD%P87-3);)Z73X>
MK?"OF.R]C69&,227JSS!_SA+VDD&?$XGI1BQQ.FY@9D7(7;5]C3XG",^G=Y=
MV%T!N[N W9B[;7W'[8,OY[M86RRL8,AHS1#WPB)MF4#*") 18S5E:6V=&M-D
MR]35Z%G]A"^AVW6NUX/(V5U/S[\B0)O?\/)Q6/:<;KYZ-<=@5KQ\"T&SUJR7
MCV$JF2 *6>T,XH!MR/(44%1)1"ZX>0)+]!4Y\E:9OKV)@AJOA[Y=1;Q'..<*
M$-X%"*==<LD);W!B*'K-$6?"(>.90M@(8D%>  [M,@+ARGO=)I.N_7Y6L^*
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M+Y5-K,42%4]8/GC%4G57]94?;Q.EXO:%</OI'"...&DLS5H<C1QQIA)RW.9
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M(JT4 8N"@T(95 HA9P_DB\@27(%Z&4&] /.A O63@GK&GI!4$A.L1YS[<5B
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M!?"[ 'S679&<TYP4R3DUXIAB9**(2%!M%//,<$G7U@5?7#GJ!P?XRTK2?^F
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MPZ0"^*(!/FVA"!\5)]@AIQ4#"R6G'^6"(DD,(3H%3[%>6\<5P%<5X$]KHE0
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MN\+!E)&;MT)RZHIS49KOQ8(QL5]+K "IC]JV#T)0XBR6#-YN'<5VZZ 'DEN
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M$E:$.Z-R<,MYC[N5@ZNH'U$.+JS$M[QJLLS:@<JL[5 5/B&7)>/M.MKYDG&
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MN/I&C%NDO9%.X[;6N<;,. "\1O.V1;Y][S2[U\TZ8E^7].YJ/?+8:?QHM'J
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ME]GXK>S=W;V\.^W$-WD;MQFN2,RWR6)-2%<A64[_>^^NUNEM(LRF?S<GC'^
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M<V%2O6T7X?"4M25X6PES2W#OE2/&ZA1#,S'LP./U$C>:4=?"G@N45L ><Y'
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M\H:XX^D%L72M)LA!_P7+;([?<OIP\>(+D9O6?SP-\Z\O:=46=X1+.+>Z..W
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MB3>@#,I,;TJCPU:]G<;'Y26C0WL38I((J6C2.,PF\!P-D&HP:%$D9UL[^%<
M-)W-5K>NW@?C+7+(ICXA\T[7DF ,;(D.#5E97C6W:W8%N>-1VN\FV)\P-TR4
M7H75A^F2/>/>A5B?RM,AS24')ZP!GHTSG)QJJUO72+O+=#FMU=N.!'NN[FD3
M(&[)O6R9#7';QQ\E->+!>;7*D[@G@?5-_0:1>OTB\,ULL9SC<CSO,*Y597T?
MOGB:__-BL5R_#E_EO+IBJQ=3WZK5>]C$&6EE<FV$\XX;'6QH7G&HIZDT*;?2
M#M;*KGV+:1(6BW$9K_J+?/_Y][1CP5R2Q9,14XH 58U9^K^J!T+A7&F9XL!%
ML/5<A^3A#&%'W5IU9N@<;%O@Z([9W@VZ.I)/7S][N?5Z_#J;TSS_'L;3*]G^
M,O!B2+60G%0B+Z08B,5+P) +"[&(*)K'>D\YX2$90X]M[PV+C2US\J_/]AN@
M9$1AZ ,(SFDIE2<+U2ARLH4(,G.5LF@=T+@'3H\SW2OS6'NF7'(&#,LU]E1?
MYVMIH0@RZ O]*#;OQM1X"D-2Q:UX>,L#AY-)_2A:<C.;7281C*O'I*F7&>0X
MEMJ@2#A-/J,OFOQ%3+IU+G+C*0PJPMD7=T\I]J-P]^FG,)Y4R*01WX7+Y:IN
M4>PU.RU+F2 41CLON@ A! 5):,RAF%!*ZR<]K;#WM89_3.<8)N/_QOQOLTD]
MR38VQ>OI)3CS\8)^])R^I*,.Y^-9_O[<E2,/4ANR,1R9'+Y[W24*).MUC;@4
M%\R1UO30N0Q)F9V$\]N>'D<ES4 <Q?5:ORZ7"N)MIJ--,MZ0PX#:EWJ!9"!X
M84%*EK1742C?.B6JM\D,2BT.>A<<ES?'<-?V,F>CE,ZCLI!XX*LF30$QU2+)
M(<HHBE"/RHDYZ**J*.FEL1E*)K$J1<+T20E CLBUD\PT;\:PVT75 )RQWEEV
MSU77+O(YJN\U"FA93#I"( N[!IT0?)$,:E)R<D5%[UIG +0J['*L>-^0.-5<
MID=A6VV\^NMD]OG?,'_ C='VM-!ZW%!DT^XI0\&,HO:PQA1J_4A=P)5,KB@6
ME;S.4:3661HM\1]]+>^X*ZD(N_BL"5986C^5:V(IL0/(]E4@T1F9 A.1'?.V
M8(\I#$G'G(SINQP&?=/D=.?&G?"]#"SEQ*$$EE<%XT,-<#IC2FV#$Z4[5DA@
M9_"/QOT9-L&;<..X!ICG7G(6!7AO$!13'CSO;OU<RMH4<B&/F4!QC(04\DV)
MQ]-5UX_T]?T\3!<A;3A3OYI<\VJ_KY8P%FWTP)(@VTF8 H&I!-(0Q>B<RC(?
MTUS=?R:/1:'MQ=-=]O&1R#"\6P'N0BQ,:,BB5HM5M8&?]P(T(X\@QF)5\T)?
M_=P*##<;HW?R]B;P8;IE7O$DA-<01*HERY ,Q%COD5'0?I.._G?,T_<PM^RT
M%>I.2MM>!7\4ZAZ29X4LL2)L[8(8:!_&4-4&-S5GT)N012[NF-<FS;*&'ZRA
M?3JOH7=&'XL/)WZ'L-ZWBZ:O#[Y]Z''>'-P^AT8O#>JGU__7NIR?2"'3D&^1
MN#!.!*/^@!AR]1N7?G-U6TRDFF-8X'-<_?M;C/?%E_0Q3#_@6YK,BU(P+4>&
MD1O+'(,28^W$K S16=;B1\2EDC'XE%M?0AUUA@T>Z%4(;^:S3V.2[B]?_UC4
MEE[?"B \)4O_TZJPLT+FK<X> OGJH'CAX+2M]1#1%270.-$ZM6M[=$-RUP;,
M\5N>_/4A_I:O86_#]W)*)]HU? ZUX8Z4EHC5>I>8(>0<(12CK?$R.-TZNK@]
MNB$Y9(^?GH>*OV]Z_CJ>AFFZBD\GG>KU'H18MX]5%KQ*"#E8P4SF6)J'$;='
M-R3'Z_'3\U#Q-Z/G:HJOR^5IOYX>M, C&XUFNF9*B&3)02@*HN<">-(N6Z4E
M-N=Q#],84G.C1T3X4Q/J)'8%3SR2;@$>'0>E10"R=V@/*Y2*%JXPV;I%Y;YV
MQ1XI:N%KY_:]GSU-)),YWM;@>92UD")Y#^1J:Z(,(U><^0!:6[3.&2E-ZY+Y
M6P$;6AV./BAU(VFMN<1:%N9(B+DKQK3*;;T[_/X<XW+$A511AP@<-1)*SL 7
MY:#H2.>,-]8T3WO9%>.0#/=C,:Q/,?9"MM_"<HWGS1S/UQND-AT*D\GB/OBC
M4JN6,](V3M4Z?C$BQ,0MZ%2<,CY(T?RY6A/@0S+83T#+XPB\'5>OG]DTEWQ1
MEP773;VE=LS)@$!N; 8ELH:@:3/IG+*KOJL+K8V,!T$-ZO+B5-KU($GU1Z!?
M+A;C:2TLOKJYZ8SLU4_RB%M#_XA$$V:R&M09G.4.DJX%JZV.AK?.6]@%WXXM
M07],6K62WRDB63359'DML&BD N4CKR61"Y#!R7BHS7%5#S4)]XID'6C#UCYR
MW:7D* 2>:KUW2$62V@A1@;<N@) I(+%"B](ZN'P[DB'=<_3$F7OMT?U$TOP@
M?HM=X]_WL_?A2^W[\''UWK7:&Q\#;>] *U%OPG&ZZ%9R9(I(N90"(=3B#I)Y
M",RX3HMP*[C@LO6#B7VQ#BK5^5@<.X9<F[.08+W%\XMY^DBXNFJ!WUK=6RY]
M8C%"<01.(;ECT44!+)ELO#'<-(]:/8QJ1Z_EAV)6(UFUYA#!^M::=UE30F@M
MYNNTDE6+UJ^WK0@9/C)SH\%+7WN!R=I@CRER^07'H(,5S7-C#P+\&'R9GIAW
M! GW;87>EHY 2M_:7#N,1TWJWSFRDDV(Y,BG$$Q403;OZKUO-LIA+\>]B<)C
M ::*)V] "(A:<XC&2BZ=EJ)]9&"0+\=[XL9]C\)W6/J#MT#-!QP]Q_,YIG&W
M'&&:-YF_L^GS\>)\MAC7[\\*0:1)+[]6.WA9K]*Z-GPCKUE*RB$X+7Q]'6B
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M]<W#J Z.MS\XPNOY^,-X6FV"E^N"I,M?QPL2[?_#,!\Q'D.R!D';VCV(B1H
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MF?37A'!MZ)0NSBZZV[&_SV>+Q??.V_4]P&IG=J7S=<P%Z50(J::46$-+PG4
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MUEHK8;71K0VS/:$.Z8;IY.1K+-DME?CZ^_6/2&[4W_[T_P%02P,$%     @
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M2FLCK0^]"L_?;8LIFMGPZ>^N$\4>=UMJ1":@$[(Y:DY"X;4QP1J*BS5@GR+
M+@^N7ROQ^V@*\[J,RT%_^FHT_(P_*O7B1;2LYV4 'I0@ C@N-$M3+N$4XY4%
M T'J)-I713R.L;M]M3E5GKZ*7%%=;=LGO/?CT_',]9D7["['-?0\ T7!>V*E
MINBQ:D>"UY'X;(0RUBC%:P>,-X!UQ"2JK90F6<5A1%-A/NWQ0W_R)P(KW_!G
MP'J1&9Y<XLAI5T8X6HJPF"7*<BNMHRJYVK6TC^$Y:J944D/%T,)<"/,[2V\
M7HTAE>&.E#J +$GB\VK.B,QU@7CNG'')1$[=9N?OO4\^0NWN+\&*"8(Y&#^
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MJ4MRJ[:=O1FRPS=XJ\J*47/M-,@174/[#7S)65W<R65=XUU4N6P"ME$-[U9
M#U/2VT+CZTC53%T'YYC)2D?O*/%"4"*]DB2@LXF@O=!49BUI[1C],^#6$Y7
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M/4UN2I%=U=# <%V-<5&JM4R;X3]##SV1&)1'B"H0SYDAF=I8FE];96M?+]@
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M(_/$&L>(8H)EKG4RL78IR3HLQTV3*AIHT15QT4#O PQFP8G)>?]R"4T)'V-
MECHJ')%"*21M1.?%.\6="8F:7)D<C\ Y;G[4TL/:<$";S,VKT<5%?[J<[%<Z
M,_:'9S",?9C4'M:UZZ-JYFNJ+/=>JL9:%Z.BR1CJ90HF4 DR6Q&8Y2& ZNWZ
MT/TVAE)H?N=9-Z$,P0K Q$EBKI2?E[AX&;7NLO149C"<UXX0KD>S=X'#U3B>
MX\E](^7KWHV_X9\75Q<G%Z.KX73^\RFD'E-,6>TYH2&I,D%<D\ "(\)SEYRE
M2>;:):=;@^Q^LZS$EP?E#DW5T\#4>H=RGG?Y_ C3Z3Q2MBC6Z$6CC%,&"+.I
MQ'4I(S8R3J2DV0NM6!"R]HNS'L[1<*26R!N85W=7_/6UO_!GN&W_Y?'STS_]
MX IZ/HN4,T-<WE@B04MB78Y$6R>L-<DQ5=O*>AK5\7"CK@(:9%L>+'P1I\5E
M!>;1RI.LE.OD3"R (B6+$ V@5>1JGS*KD7251>F$ #N)]]!YDC( ^&:/>U7N
M!98 V&Q?DR@0IB2Z&\P*XDO+2F\B4^@26 8;;1SX\;?8@5_=,&/UDP^5Y:BA
MRE$UD58\+1ZBN=5/91-,VV0FME+WH3I9U=#/6E7O*=RN%.^H%5DK("'E8KI$
M04)V&J%JZREX=VNR]XM1^)H$0%?ZWD:FM3M+?8 OOT$J 85W[Y=A816,0'\%
M5U6"?QS79T6*)*:L\']4!KU9LXZ'G]WM?/HZ A_5DU;'_9X^3D?QS_/1 )\T
M^>6_\+>^U@Y_;?F$FE&O?19W+]A%@RMA4"T#!YF\<<%2:QF^Y#;P+&-ORV?M
M9WK/'S +XY[F3V/PN/:O,P2W;,\(SCD="5(526>S(QX93-#R!$UM,OQ^/YV]
M[? -8.U=XE4^[0-<+J(K[\>CL[&_.+F:GH_&96K./*C">M(++QEHHI,H<TA$
M(IXE2@!$< (H=>!JUW=M!JU[#[4V6QY4>3702?4.5"LQ]H=Q/+LW.QWY:[A^
M!K<7 ]C,E"?"X=XO*=7H9^-1D(7.&C< ;R3?Z(C;^M''PY .1-^B9=5*P-?A
MVQMBW_S.DN),Q.!LTJ3,)$67C@;BD->$)05)TA ]JSWM:G>TQ\.SCC77()AV
M$B,,2H]]2!_/_1AN $YN8L/O_=?RG]/QK&W'Y;3'N!(LR430O)P9EH8$Q001
M8(T%9H*L?LKM!/3XF-9>7RWZ7]U]/=+)$%^$:7\,Z?75>#[SK3^:KV?2\UQJ
M/*@MB;->73I;XCQW>'A; ?A.<#1[VVYEC^([/DHUTTZ#GEF/T/]-'SV>]^-^
MA/>^GQ#T[!?0^',@<%LE*41#9)90FI$HPGG0'#=:JF+M"Q=;@SP^3K754\6F
M63-+\>3L; QG"/8#I*O94,FWPY(?'PUG(IF_!O=>DTDO&9^"L8J 5Q(W51E(
M@*")IU)%'YGSVFYDJ._T^./A3$<J>$@:O1]IYF442-XS2)]&'TJ 90CI%S\N
M)M]D#6)GN$I">N*<R$2"=R18+8E&J$9+HQA5FY%FE\<?&VF:J^ A:<S>!:0K
M9#'/RT$T IG+"*6IY-6M(]:Y0'C(I=1-)U7];N!:,%TEL5L?1'6D?>B$]HVI
MACODK%IG+K;1Q>5H6.H<9\D?I37H)%%.7.**RHQ.-.PY8=X EQFX<]6;$C\&
MZ%!I[THZ?V FUY)]@]#1/4S+R2(;@&IT1V\EH,/<Q*NHN%$KJ7=&"1!H9$L6
MB12E*W\N<WQEY"0DY10>B-3)VE52'5+AB=MR73-A&V&WN*IR8S\O$L(6O&59
MEZVO-/\M;8!M-HDPR5RD().IWD7L 8B#V:#[*.>^5;&79!L44=]SLI>IL$)K
M!  FA$B4HKA8#H9X6;QKRCPZU0[]I=J-H=:C.3*3H([46W0D68ELP?Q-L#4R
M"Q[#=2#KH)(.-Z+&'@IHD6]\#*/#M\#&TK_>9\2H-2?.XANB=$KX?FAK<^T1
MC]V3XRE[X0#<V$;NM0ON3J[.KB;3];';!=+E15RJ5*+"$I%E0*0A$,^ X@$J
M.3-2F0=]K]:%LK9Y;/?F0SUUC3J1=>T2EM,X'2&&3:%2H6,&F0D%BY:01-!>
MX/F:H@WXAECF[F\<:VBQW7./A1<-I=UQD]J'E8DW79?N!65/(GX$?LQ>$S_W
M>E[;\L]=%W[_YC,SUBFFC0I!6G12=,K2&IFU+@6]=D4QZ!9/;E\:*F-B5@ 0
M:F(L9(W$JBP(*QGE<J%;B-I52MV7ACZ>/S<V1+" &P$ZBJ7%.&[DAA6[@4.*
M,1EF:X\0>?G5#=OP9J_JAFVTT\"+O[/\DXB209@GG_$8.(-7H\GT.EFNO#-0
M&EQ"$ 6G3X@3/6$/@AK#J$^^=AQG4VS'QZ F6FE?/KJ&Z?,KO-(GKISG1/-R
MA=<'1QRB)RYS89@7WM#J;4@WAW=\'&JEFP:AH_6A,I$3-TZ@F8DF;.F$F8DK
M@^JC+\-;!./651\*_A+RT_L0HXZTGTU^>GW I'3I\3$IPD!I(N.L_D*72;]2
M4.[!\5P].?V"PM!;:7OS,/0V4N\ZPK@)MN]AZ"UUN$VH<1<%=$T2F[.A93QO
M]$;@RY$9L48H8A3U49NHK*UNJ+R@,'0S;FPC]]IAZ%O9U75A+Y"*66HH,8R7
M*;8<MTN?T-3VN'U:]-+T_:KN-4'&IY_US *+6REFU$ZJ+9+8CY=G> $R*$8R
M+<TBO;-H95%'$MK*2DB*IG']F[4OJKIM+QNBFNP;N"1KZJPV /7-5[=MH[C-
MJMMVD'IGU6W169VD0UPRX>;(2F]@4?[ O8LJ 9[F1KT'GG]U6W4F;"/L3JK;
M)%"J+$/OFY7]C^E8QD3AE]$*(W"AH7K]\[.M;MM*.4]6MVTCV8,WDKDA_BC?
MFB@VG_J*/QO#>7FC/L/;(7X*_ [34?[DOU3-/.Z)H6TVLJ: [F4H>;(B"-QB
M: !),UJ/+!O0(LBL%;=^189R3S1[WR=]ZH&EB=ZM6!\8ZHVDQ.E@2NDHO@2:
M)R*Y2"X$KB'4+HO:%N/>=VQ/7[T]F<Z;[Q>[\M/HO2_#<5'RIT7R'T:#P9O1
MN'0$[:'7@2XFDT2@CU#*7C6*(^&I@FZ#S39$";4SNEO ZWXS;LJG!Y=L&RFJ
MB6MW_[7O1:^21I>$@(CEF J,."<3T4%([IG.--2_K70?Q0$8TDIIJS).NTN\
M@<'VV OQ,^11B7G$XMSV<W\^X'NR%$K/R0!91TN,T^7EB(D$)3+)/#D>M%#J
M?E.D.N//=X-[O*SJ2H<-@@CW@;U!(6ZP7;^:3X:?)VBOUR)XS!XBD&B5*[<&
M+/$*EQ:H*D3B@55W-&OB/UZ"'DS+#=KF//:R+3&^+V.247$K1-N+*L3H#2<Q
MECM)6C-B$R@B0QEU3WT(M+:MNB?DX^5EE[ILT'=GA36![IS*6GOB@_%H34A.
MO$R1@!+42B&UE]4OB#QAOS7S_^;Q=9JR2.5&J/-H1$EC)/$<O\R)1:9XE"[4
M[DRU#;ZN2F*Z]7%:*>C9E,P\&K75-..+GR-1/)2&%X'BBE(F8)(*(GK(K';)
MU;-,>K6CP59YL&W4T5G28Q-0WWH>;"O%;93]V$7JG5'"T&1QQ\6SF>+[)7WR
MQ$9T]\&$2*-3 6CMV,I+R8/59\(VPF[ @%M;(QJ2OR*BLA,6O^<U3/IGP]F>
M.?[?5W[0SU_[P[-7?G+^9C#ZZQ^0SN!FJ"J:L QEP4SQ=#S#P]JE@*()1BDA
MJ.&U"5,#]W/)MFU%@?463C?Z:Q#>O;N&/X9C0+3_7:; ?H;); CA<ET+O(&#
M$R9+8F(IF<XJ(51/"9>:4H>>E0NUV]!LB_'XN%59+VWWLD]C/YS,1_N>I/^\
MFJ-=H(S92>?0#_;<H4AD1*+G,JT05#2)>QM%@_;3&R [,L[4TD&;ON5+E*^+
MF"']#$/\R_3] #$_0.O H<<I'*%)QW*QCY$@@R0L"&43LX'IVC,CMT-X9,RI
MK9,&T=4-7,KK<>+.>#QA"=?.EWF7F?@R)0(M2,.8R"+SU(X\CX,[,MY4U,3:
M*&BC.J12M/USN=M7X"/VQ;99>:C5]D^I6DNTYR+O50MIQZ2/1EG#E+2:.C .
M7WX04@7/F.OM\+P*=U$>/G",!^'9S*?\^>O-KRS&+,QFX]Y$.QV:2#+R3%20
M:(J'4+JTX,'H:!26.A6!UTY5[X^ZRAV>\#2"<!_!+U\N^^/9+\]S;^C):('^
M>"!1\S*-/&M\Q:E#"S0D?*[P4NL6XJL!_D!71;KCZ\HK1)VKO57_Q%WD^/M5
M4=!IGC>0N!GTTZ/@/#,QDRAUP 5Y52YP:Z)TL-SS!#15C]S77L2WR>>#T:!M
MD?PK?]F?^L$<X0>8P/@SI#>C\9NKZ=48WDXF5WX8H4=#4IXJ2F*.C$CC%/$Z
MESM%L<Q\!^ET;=]Z:Y#?'"_;JK%5_]%=Y#7[XY\PF5XWQ6"];#(U2I6KK8D3
M6498.8^^!=<\:WR91/VV437Q?W-L/9CR*T8);B9(GE[.RAA_1?33$CE%W?G!
M'9 ]DYP,*FHBE>#S :/.2DVBYX(&KZ5C]"G/;IL'?C.,:J:%BB52,XR_H08N
MKB[^,;H:3WY!1W[T%<IHJW\!_#DKX9KV8__23^'M</%3F*WJ_?(:]L />TER
MH2A(HD/"15@T&H+AB5 FN%0^^B3R1BRJ .;;8EC7VJL]OVR!_[?1<'I^>P'_
M%_QXXP4('XUE(A,3!"[ E3%:P0#AD6:1(DK6;=:WM0::;Y)_W>FO]BRTW_R7
ML@"$'%$L_@Q.\Q+HY'1XNVQSX^7@3IX4YY&4;J>E]AH-6*HMB8;R$$Q*YOY%
MNW5TK([M&R/G875;<0+;NN6@P% 9@]?+R8-_#/$YOTPN+WOF_V_O2WO<.I;V
MON=7O,CWNK?W!0@"R++U1H&OY6C)1?*%Z*5:(CPB#9(CR_GUJ28Y.SG<^AQR
M1!JV/,,9G5/+4]U5W;4DBM&#L^ XYNI7)!):X& 2EQY9U,JJ?4&X]JUG#Z\V
M^G@*''=8&_12\*Y5XUIP3P>.1Z<8J_T;A:/0F]-"K"JZHV>1(<7EC[,3UC5
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M>K%\D)QA#H4#U#*32I0"5XP'XY,717KK=#_'?2VXN1C*Z8#EJ1GX)F8P%]<
M:=,+Z"1$4U2MET (+C(B)XF4LTB"=]*(?_[V"\SV5\:*>\;#;]TW%#]L):>?
M_GXJJ45%1-9&6DP:I#>,1&45>.=BA3X&6^MV;-\E4(=Q=-RZJ..B]G2@<BH%
M5(T%,4^.1ZL]4T("8UF0BK"&^YH#"B.3+2&;T#K=NP,V3K68JT^0MCLO:@*6
M4T]36:9<;\-2KV5B![%SG"JQHT.MRZ/2 W#R0DS I2BSRAP"4Q0K)(:U<C]
MD,)RXPMJ[*?2[ 2AOZ'0[!R0OPL\6H\U7=R!CW!9QE**R&*>%QFL R6E!1<%
M@^R2P^A\,.71?)TUY40/G_O"H\1]]#1N(^36]60+W^>O\9(4+HO"FAX>5"H4
MKOH,CEE-"HU:B:2C?3Q/Z3E]WS[WHN]]A=R)?7\DU>$M,3HEQXB84F=-%,O
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M,AHBYP6*TD$K$1DZOJ5R5[^AOZV\L0;&K<77VDN_1]1R%UL21:%!12C6J]
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M^N8;_P:27C@:NA!\0U.?3F:#V\:E_XGCSY/PYY>:#[+(:$XN$,NB\LI >>_
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M]).%4/$^FOO BK[:7,%CDXT62_UF&U]\BE9^/H]B!F*"XMW$2EPQ UG'X'U
M='QE[='37.5LG[GJ ^@63\]GNJ5UL6RM&X'[B\>I!4+H&!'91*Y04VI/)U?J
M7Y[4OZI[>K83L7@<=_B\VO@9SY,?+73P9KJ:/1^#" D7=+["S7A,9H)/ '.P
M',T60E><.MM-QIWM\]LHLSPT^S=\2A'7N^^^_J9=_LVYFO@.:M*?+=>?].?2
M!!F3*15"$ILY-NAL,N] @\D"_\?>B>G.RAF<VJ!;EU\U^53?R@BIVKYWR&JI
MM'FW[&H=R%X(!<<"#=M?J A^+B^4H2@%F']2\]IKB].XPJI1MFL8Z[ES.F,A
M0=?S9J%=R8(%QS*7YP[7@%&LP97= 3[@9ZI_7"^CK+4L3ADY>]OG!<>9O#'I
MX>R0.Y[1K.=?5:4"*-KKM6\&F_OK#]SGNP9L%A3";O,]V79E!:>]/,L<:EAV
M=W/JTXN7;G1T&]YJ6S%#YG%#IO+QXR9VIA**N_]**J@^^^'>8HU%+QL-G'8(
M(8M/62W1[%I>-6M@4,]E[UW_+YOGJFJ835<@OJ9QS(40LI%X@/,\\0FZ5O!T
MQ9=&@X,[')H#S*)T.^S/[4ZI"!FO&Q5,XE8>7?'RV!M,H<X4S_ +S;=.0NBE
M.1LJR"D'/=[L2O6..>"7<^89;_SDFU!+S9N6=MOV2/^R?4'P\C%8E\;QMD/G
M2:62BC0(]21Y],"GY_J%4DAP7W56WNLSFOY+OVX30H<NC_",CMX[VGWYGIW4
MNX.$5$>=;M^-VMYZ7\/9'2SE[8F1(8NO;MNR;)Z\V5O-=,C*7-%6["?]CR-)
M."+_8!(B6Q*;E)=.='2_8!+AKB<0=)5>#OTH?2/_5I[&M*>I1RY"GLA[8&T-
MP$YW&]*0Y;D#Z>G^'RV?IZ.XA,P>9[F/7Y8<J-QU@'U@5[#[VY%CQC<.[EUR
M]!"I&RYF"*'<SXQ,OW[\$W3Q!Q^'MC)8[7E'ZV@%<FN^6M/1SU'K-4Z0IQ_B
MO#T^;X18DPXI[C:'E%YS.EDQUTQ6^5?7E!8J<+!L-EG>PZ:KU3W6^GIN;HQ>
MTPQ%C]K*;IU>*J))1A6HE0R.G4_4'O<-NF06'?+W[83G($EN,V_::YY^L3E_
MAO<A\>S5$)0IOXK2V\>3  LY'J .?GH$K"27$F7R-5V?5"W>$1N5?3(AD.AP
M&/4S6NQ]XL&-B!S#Q?WF\VRE1K9\CX0IC!R+RDTK9/N&))$SK*[$#W)S_*F'
MHCKV).=M\=:*)8P[*16D->2;"2%)9]*G"R;13<J%*Y#Y:3O3*)F.GF_"MU?6
M[<R1IMR7P1*TXW%L&J\"S$&3U$!\$1?C^Q0U1:S8T@$;C\O6/'>7W$2T#E\E
MA/26Q+8\,*6--2_D4>_T\?EG9R\\('8W5%HS6&>8@,DZ@:'R$"E>-:<C@RO.
M=(YY@FY"7LML:GCC]#+]>00[J?<M]_J2[-(S.?MDKI=-A'P=D1>?.)N0C08R
M]3Q9KI'9/G+(;:O"#ZA9?'O5T92>\1>_>NM^BPS/]PZ[Z_*+F>1+;8C:LQ&3
M _XY^-6A@(N(M1_?$!G9YTE61 DO^:Z75SQ?_"XV-.J)3NNQ8;K'NSS)TX=/
M0K(S#-'FIE12&2/;]2KA\% KK0A60E</&A*G]]81)Y9W2?3/;=N4J8#.V?QQ
M*Z/_K9LX_VG":R%T60C-&?6)I,@&&'7JSVK7&P]##R:V>:IY 3P5S6M2T,TP
M8D<EO9&!M!/"?]+_,,)VT)A]U%9OGU993%:<W:Z\,63M30YM9P8G^]<#$^)7
M"S^=/B5@G3JS:$[#A%6WSLB1@MN8C"97C1A!RV54,!2M%][,'IK?9_?4LE9A
M*$G[<?,RZ**8LY&IA"]E&DG6/X07A=2QB!!RX!W#_W:%0WHA.=GLK5W<>65#
M7?B*V8G,L_NGQTF<]IT$8%CR JDVFJ9*8SX=U]!MT&OTA*]@B@6-7E;/NQRK
M6G6TD9Z;\\M+Q9OC->-,I4:]A-!TKN!*OB;X_45P*T"+DUS\P8)G+?/9Y!'<
M=?F^ ^VD7/F7@O&WG4&6S9?D U+B+[K\S3]+,>FHAA:X-#VCP5@EF=30,:M^
M#V-?_?'<NH!S-RPN^7E_,7<E(=@ZADO>JBJ7Z%G!:RC?DFAOA%";!>]"AN 9
M[1CY&D'.5_IH-$[=_S1_NW7GHF4N5Z*76? MEU9*99AZ(GMB57+O/;[IL%YS
MR4'[7U+GFRE"K=H)081G=,2@GG?_/B\86/]FY*)YP2LCM9B2=F]^R:TU.<?<
MQ*SR H30RPPG7:LV^<X,:KT,*BN$0N:;:%JMC>";^V^S5*_*I6S^-'#;6/*F
M3\*OG3WS\'=)DW]ZR/M)__TDQ7'E;W&P/LSE5\K;Y-'#RE2X53=#7AUZB\,[
M=/9U4Q&=F!)+DB1<;&MB@AS??GU5"]*W/ZY%ND(O^?7%JX1U+M<QPY%T2(E_
M"9C?YMZ<%U@#/.^$/;7-VUCGJ/$6PJJHC2^IEWKN:0IT.!AM"X'91&T=K.?M
M!)J;Y[_$T#$Q\P.VI)7.O%_EE/-T4UWDP)DX$\^W>K<WA=SN-R5098"^_X4D
M?PFW9,ZRW)2&X)%[J6U]\&QCL_.NN?TQ%^Z^^^#5DY%XY!4J31W0Q&3G\)U:
M2:4,CC4Q@B*_](VCTXXF,XIU'>F$<>S=5D%L@W9OF\O=0Y?>;O\\.IW,]O[^
M[01?F%EYWY+821R0V# X?+3.P)]1?\;FK-WH 6IW'&TFS'R+NWRK!P\5&B-<
MMHG-54/!&K/PS>OT7'P,!L4 ED)&$+M!W^\PZ2?]SR)8G\ YC^N_9U0\A&CS
MPK@FC0U)9.[%4JZE+NND^N[Z$H=WM"NT9O+KHSW$FX:"$+BXDL#9=8W&3"!R
MK,D*S=UK]2YV#H6]A$OL6*\ZK>N=JF16OLHZ=+K"\]R-Y>2"Y:4]Q,HJ=I#,
M?9N&%0;WD17IQV-;>QO-H^<FG+ZUM??TLV?KI\M+:]XPWP*F\@O,,<4ANKLB
M039N*[BC.Y"=OKD1=YTDF1U.+X\]L_*@?G#0M=2R_./+7LAZJ4;MJ0E*6LT(
M:.*$\5>2&DC&@DC26C>:/*:.A/-+,-T/+B-ZSP?(LY*'RI?/>Y:QCO7XY/ZP
MZ7:C-T'@*P0Q)1N3PQK4-.ZSZ%&G#Z+SD4O9AV_;_IKI[[,OX'3/^JJLVAG+
M3I[3AW:4,2'2F]T'3:2YO"M<H](#K4VA8^E:96J;>H=R:?4^FGDY#P/W;*\Z
MH,%LS(84H]@&NF7+4ZJTXI78E&P&JNC'].M?R&K)QH4SYACKL99&K5E\(:#I
MB->N[J.$UYGDL\,\_E73M[4Z$SW KWP"&4&]LZ[@M?&FM(!5B)9[6L FA)BB
MT]I[(;'TZAA]=HG_JH>7(QS/S3/P>#>L/[/XX.,%<V'.V5Q4F6@C*#39:(\N
M0LX\??Z(0V5%=M:<27&T?,,HNU!1K[[K\LD/1<^XVTI#5^\L>OE2#;WW'0,5
M9H)1E\+%QCX$9B*#8TN?CDA:'4SB1%'6-04X;@C)D5O>_BEQ<^G@O5^?R%PT
M8(Y*!A&28,1H(V_G?9XIN'8KNORCH>Q>S^=(3AU*?*JSHG%$OZWV\LK>N7JD
M]^KB;U?%/=097![5V+A1W8T5NHX5JC1CGMNC_8HS(8@)K2M*_;-K3#_ISR!J
M%QF;=1VHC^$AK)22%4FOL)G6HTN;8:)%S&]2:*OD4^4\AEVZ<A><?/'.KT;%
M%'=/ ]K:+MAEA^>.,_4OPQZXD+B%'*FH42N"@K]-^=I(EY3F0^3H8\;!TEWS
M[75T4F=>?UIM!GT $,$\D 7<21882]5_!)NAQW7VY/L/H7LY/DYO=,!;<Z[F
MJA]IT7&YF'5DXY6YI;\L+O+>*<^MY 1^=X]G:7+8&O]29D="4YP\U_5:@([_
M%V6*1<.WC)M7>Z*OW>$Z,:X2F(\H^'S'Q.RH-&Y-IV3RD9H7;>U(S>[819O6
M9I4=Y5#Q"4%+"@KO[\F/9K/=O5<L/3)LI:E\7G784NN636I*B@@BI*EMN^G'
MECO06%+2R)Z<G-R7"Q[7J_3*HC8_792RY-ZO0=#<Q9=,9WT8W<B8TW?N@O=]
M5]\4CPV7>[P\/;WF6!F^>UZ\Q\!\>N8:>0BZM5U)X \<23Z!L]U-"#'O"J&,
MX2JVI^,9K@][0=A>[L['L\YVR01$&MJ?/"#??RAXB]7B7W4?K1I10=5# !3Z
M6L5?:!+#[>Q,NCTGP"9VH5%HON')1TTE;J68B>N\D O5I/T]D-;Z&U@?[T+0
MOT<Y/^E_%JTD::'ZG&\5U+#)W"O&3H]Z2(LY'07>C;&A]U+:TLNSOUA_<E*5
MOX@_(J:Z0 TC$9C/A!#'=;" -7_+7BZM/_-D*Q9>_GPI9VGR.67LK:^.RYF%
MLAMFU;VK62 NUG4T'+OF%H]CAK']2FAS I2X!>.A 8=9 YXE'8L^,FKRZ@T]
ME^D.#MROZ[PA22P[8V\HJ,<:&"^^E>#;/$O2'J-VB!_+9UY+1>*"P!U5#KWO
M- K-2]ANEF.1#4U?"0/+OM?3Z$)HMO>@OHDZTE=)F^F]=''BDZ^;_':%U'M8
M=8'W @\90O!J1;N!7#(PH[?4B%;?A@@6,9(H-_:KV01^?_W0V<;#@QGI1?A[
MSQUW 4BA#;M;>N_WQI8$S K5&)CUZ.F.4FS:B7VD+#&DRYR$!,P'G\$;+O-^
M=)\M5<E7]]]'7EM?VJ'F'FOV67>D]A$I:>FD'0/_4A]5:^,OPJK]HM]$?@LQ
MQ(4[=*7.S(TSS%?AA/;"=9KV _:N\;>T-)N>FQ)B&8C6.#K;J)..*N:5R[<"
M@9B/U88N':8:6Z>$9GX8Q4ZV#=H?;KE8*7]^DWS3Z&. ?LZ!:9S&Y@ 7L6(/
MO;RUM)2KV:D2,^(?SFO6>W[]W<JJY*(S79P=]WZ]9^\J:7CD[N2<>']2:4GL
MDN?W$YM;>MYX7?>4RTY_IC-3F9M2M-5<;+]I-P3MK_[3RSD_Z2?]I)_TDW[2
M_QPJ)(#<9@+=W(0IP<4+2.O\0THFOV:P"B[N_*CW);,A*Z]*=TA/E>&XS*WK
M>MJCY=NK;Q9K%D"!E\SA63!GA-AJA47A.L,P%8=D(81_C&EX\BWANF+TI! J
MZ=LGA#I'Q005NXFE%-2XB7=+"#T.04#6=*4Q50A5]HTG8S/;!(^Q1:0Z@C2V
MX7. *?=;I+'OJ<3>R9WG3ON'.;[^I%'GK'ZK;^[#YO@C3[<?<A7_&$1PZYYZ
M(0?!0C[[EQ[@2*&S/3L;L^-[8Z,BGKD7*KZ*_3A9TC7PW.N04FGE(OGJT@9Y
M-_%>#QWDJ! *NXP&"J$$%A>D+K)Z%D*(O%L(X68@?"%D7MHIA2D[ /"F$8\;
M/!V.J0HA%HN A[M?!?P"EE<#/MG9 )>6D$R$4-U)I!BL*QH I,H4<?Z#!)HT
MS*23D>7$:X6KD#"V5A'MFK-^4\#N]-4X9?_CXXX-B85O_!L6J^0D'+SWZQ4A
M9'%77F/-QJ/II*$IJM5*2*00DGH8 '._%5'$,?I+?WQ%QPK.B=B[O#>YD8_Z
M5-3..%V.*OWE1DD?S?MK17_GJ<J]IOA< SM.Y12K 5*:PQW'(L(J<*AN-A[;
M9(K_W*6$;D.E!332QE["O !UGU-<*OLS;Z0O9U6-8MS*AKF+]YX,2I4\(6\Q
M70W[G/*[C!S]!"!A>J$HT[5!9R=8^Q5A.ERM$%\ZLM.@!AZ0P^VE['HS?,_U
M<]P)76H6\YBKU+0@PHX4*HL^A;[ I>]A=_W)=80H/.+D04%)0817U3K(&2"K
M6.PC<?0D/(_ >?.)@ CP/^@?D-/J<&P>D--76E:,8!Z^$H>NR+;!"!93J%^W
M./]Z BV,@)RG#BP! I#BE@(=2-\+=* .<,U0\(36S<36P2S?IS!W$L(ZM?^_
MGG U?%CO'+\<GR%57&"S-_]-@Z^>15'KDD_M[0WI!N-["B[/'-[>;[4F<[;5
M;,O%MYW3_VX[DH2B'=,/U3#C[T-M!0^Q=0'RV0C,U:PLE,AI&-VTR_%M_B:V
M;,'JC;F.5S=G14P/GQ>T7>*EZ=(@0H#;O\I4V!DOVN"DUD=0$%4K\&*^# 6/
MUKB"YQYQ\IFO"AI\U9/?O,F_DUI3I7LY+V/0_I:;>$_U5"FI#O)$D  SG]"R
M#MSDFR*]'^L[OU6D.3H2Y7OE2V>:&#5\7+?;^YC,TX03HC._3+%#?O^<C)IZ
M5%"U-+Y[P%&D1PA)$#,^!'AQ7=FNU\^NY3Q/75^?35<D>BB'FBMXP<O=#QJM
MV#5K]1I3?/W^OV/SW]A-134L^7O178*'A2M0V5S ;O7*.(G<3P:!#E9OT4W4
M]IYKYZH,7VR[8;8H;+EJD..ZJK%X7,?3?U4QB<W)Z&QZ^8;D* +SGA#*[,A.
M][";K,A("UC'$72-"<9*/Q_JH"]]*%ZE^W*][N [*^4CEHMOG3'5X/[HU2:$
M$'!KZU$[KDVQ#:+91,[?PF3,1D)*' 3/DQ\_48N+2+$^?%ZF\-&T5P>/N/C.
M?!(L]F4V3E%L4NP_(?IT_\@&"#YUQX[S[4=;(OR>"\!CNBBAZX70[]64/(7@
M/TB-S_W_?,*BO4C:^0>?^@]A,\A\DSZ'KXDIGAMJTSGC6_(*:86O+D:D5<55
M*)]WN5GE>NZ(Y?'%MRR7%@;%3PO7_AWI3*P6X1%2!V6>") 0 2"!2X!UF^CZ
M^YC5&T;X]X^VZY>W7GGX,.&^SG&=>;NK4X(RM&2D%L>!B1RO^^<XQ\T30M.;
MP7A7L0\:HG$C J;5C9&C**K97EH'$#*K;V.;#EW-8V];A]G29.];YHN]5MEM
MV[/_[J7ILZ47-/',IS+,:AK'D2Z%Y)4S.#NHD39,@H)_1$GA"@X6A"VLS]:3
MW1U;,JGY2\_YY8MOO*0-+0RUKPX9F2$=CWOZ+\?#0&!/DN^!)&PQ72+XY1B@
MQ+*Y2E$J7.1?6DHRJ<^6D^J/6\C5^YKH*5$5]+EX4:7Q]80M2UY6J,HQ"C77
M'37%-UR9TMD 4JI%?T'N)Z&*B!6;/-=3KJO'9/;'%6-I7VO7%GO)OE](YZ=X
M(HE<'U3)D7>'ZQ.>O<G!ADR<J\O8FQ<]$)_-?9XX4W[NO-?;ZXZ+V;J*F19!
M8J;XMJY_4B-U8(ZW5B4%8)@<5U2)RFH,8>,BB:K90S.04RM0J^<'G9'*W:]S
M7@4W*@_?LN\X\CSR+*^ZNBA8->J"W9CE5,(:<0$.R!-K(:@4BHD89^ TIXBF
M1%KLKV]^N\C!M[[9S61I0;V7P_&\P@,W*F>&)[[=+Y%Q2_&"#(3=_I<CU__5
M<."_;,(WB<BBL $!MY-M@RI=9)J$L/4C*2J& MP^KE.^RIMSB9URFWL_#J]6
M7[9XS\[=#9,K%]&>/_UO3XQTV#"RKA*S3>;RL:(<QB31DWC"KDP(<4Z1T4<V
MG>."2UZTT<+&($+D&Q%VP*[1F)64"4U\%EX0FN4C4/ CUKZ'MS(X1^GH37(K
M#BMU,,*NYL7CVCVF@AX3>$RV1@AI^PH>T?IM7F/NQ$-V;\%@SL2)+=0!.2%T
M)) ^L@/"5OPE]>'I(UI":.!\&E9,RW$MI44XZ#]<4AD\=O7YH%>G5]+D^\SY
MGPKAGO2\&HV+/G0/C%DX'Q%"VQ$J1PAMX5J$#1UNR,+/=N=XQ'I]MECFZV7L
MJ;M'/U-S&=X!D^R;O [@O*D0\J$A;D*H&6^+6*0[3W1H(SKG]-*WDN]IU0U&
M5)TX_V5BSPQ6$6OWPOGE$.G5;G-%Z-^3'9..XO%":)%*/T,('<;)P]T%&VCG
MTSBN& X8\$U9GH\0>A%VE3#J_- 43[<&]C@_K']<""T9*1)"O)7V<,]67\%7
M.XXK?Y,0J@K@$ 37E?&3N^?#Y^_\_4!=8:B&"F >Z396Z02X8O:*VC")O@!K
M (&C"_<1;NY[(H2ZC13%T-3?SW(*$A/4PL6;X"_%)E)P"^$#/-KNXUSL# +<
M]#$A='LZ,E\('0.#"*%ZWX*+$G^W&T()!9&FF$,<)I* -VFF/15"/3N5!"IV
M(R ME"J&JP(1*2!++$T():ZTE6)%BIP0[$[A;*9/;!GO'P+O[8_!@CV13.K
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MP#F3/* NA&:"5&JZ)_+XR^= RE[NAVS.E9AU(R9-*_F;L;4WVT\-]!#?RL%
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M._F;D3X6+SF/OZ4(6U#XP5MVILI%Q[#+N1_ZW_:;48<6T6[9(!OJ1>GW%7&
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M+=\V,1ESQ: ;=3QF6K.U-2#MU"KQAC:]$B%4U"V.='W__MXP;"97\$@(L4X
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M%O:E>0*17++[9@TI\8Q0>?'O6U@ : HN0N6:$BE5&9^,30O5\ZM*5+.U.\H
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MTE=RP?EU8FVN@W>&N]+8DYJ/]BZFW:6]SW"=IFI_+4^,2*'*M[\WU_>"^1Y
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M((F?1NN+!KE#<OLV&OD-5DQ@-A,FS,**J)-=P+_UC.^.QQ7^944CE-8^GB?
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M^OSJU1,$Y%V"^?WAVOGA^0J#0)GC8#T0GF?:QNET1@EFAP?;CHI#$?XW"QR
M++U DZVS!R-T,5SYO2W43%0[*_A)_>V!/U0,@$O 'U,7?G*H_>=@ +5T[X^4
M&G..?Z(=2 +G*1< E8$?4Q=^\J4_)". QBWS%19("4".W^/4G:[P\GSD )>S
M$_VW>-0_W$M"-G_]T0T;X8[-U]+FAV()^M?G?RJ5B*]J$/@A'\%FX,.?ZPF,
M<"V%\S[33O29]. $<L<44IY4CY **4-)\\4-&H3HEM_?<);,-*/,&EN-MJ%V
MAUH%SITIIC TY@L;- @U_CR2_F.! .'SP(\Y"P>$2/S=,P/"\BB;WU@+2? P
MA$O%R!W*5\XR2M^[><,&#7]YBO!]A>:) U!&$ZC1%&@[%3ELBYJD*I0$S^WR
M,,))\9=D L>TL)HUKQM%W:#SGBI@SKN(,KZ"&D:=+VCPE]M)8:(&U;Y+Q%K*
MM1Y5YMG<5)=81O>Z">.R?:X79;:4;A.[G)6$+"]3#3!H+I,(L/@CBI!"J)Q+
M^7CK"@Z>2NVQCC"&984I$X%4$@7:D<@O]@\E?L].L(Z1!U7VL:J+D"W/MM<E
ML]M#/NLAB[,;8%5!&M_7 %[\R^#J2=1V0@&AEA*J9<FAKH NU5<G-.;1#*,K
M@BW+1HM?6YU74HSGRK6Q^"DA+7  ^O$@^O$?8(472405*];1@;KK.6W;IP*[
MB<I;-)%%R1<FBJAY(ABU*I"602CPA;<!L.1$GTRUVR#'</ ZO/&*UZ.R,>IP
MMD1$LVO16<6U4-L+FWXRK&C,00%R)8H*@T\-(8N*R<XS-9HK[3HMI4?]$ZQ/
M4=83 _8G..+&#@A-]NS_#F3G4%P2LA-$_>L1=#WLZQ4<[&<OA=40);M'MKZU
M$6NU_OW9]<!@M[._@VU[$3OU[/17SV-6.?J[W E>MV[<];=S&,''*H7@!3 7
M-SJ &[W!60%O@EQBTR_X:5:RY9Q[/L8Y**NQ;^ I6V-))0>$<OY>)L)"*>"_
M0RE@NPHLCWI,U2T0R@&.HZ8</Z(#7_G+L/_?:E?ZJ+"B#M_=5DYQPTL!5III
M_I0W.LX99']Z(Z5>(_;2L/RM&/NWSZ5'=VYZH^7U =SJS1V!3T/&]Y$&G!!\
MF$:0M(N<$(>J]KYH+%3=^8;H)6F\1BC?TS&DG<:FT$O8Q=QD[_KV&?9=5ELE
M#[-BHUS=U<*LZ WNNI[V\=&O8[QQGQ,,XS2?O&P02FD0;XKEIPG?!RO$P+,D
MR,\4EM2D4V.(FO@.1C2^'I&8D)3V_ 2ZVUZ5B@,XAU7BO4@65PEJ8,7 )=\N
MD!:79$">&F1A+9*'DRVF47_\E:X):4FR40=UW9ES"&JBX?/\\RV@1$=N\?W:
ML<F<QT[7WH8;.A?TH&"K*4F$WRPCI$R;/(:#E&*R=+786.EAR>GAQ#B ^]@(
M]U;]?\O)_$/^R;P2ED3 V NY-^@<P#Z6D>9A&&ISZI3!9 0;_<D.%\[#Y,>S
MQ;NB]0A!BM5U&JEU/(R)" 96^(-N*B'">[S95$BI;G2\"J<9XBD90BYY 3X$
MI;]Q;X(5SU-5"3)@A6290+?:;/#J=>.OR7N(F=WEIO2!/N8];/&/(#C8)RH)
M@X@#[CL2^MB1K.G(&2>6XH.JH;/I.9N*\&N@$&0%%>>1E#'6VVEW;<;VVY2R
M"U)(,EH<F(ZJ)SFW@,H\=EEWM1+3YVG=,">6:QQH;_-5!99]>+\(Q::+3[?F
MK/1=IDGO>72^#G=1_ITP]6[:U#WLR&\+9P;_7F<&W^>23(0,!]G$2>]Z=,O+
M9*/6M8\A.B$T<GAL..\Z2K][WY<!8:W4>TGP%*JOJ)JX8B$W$J1$K#:_5\PQ
M><1D?ZFO8>^1[6"[!Y2$LFO29U303=>/1S]</)E&J>9,! .R!NO[+/7.-9<J
M9=M^M4Y?G6[AJ;_O+GOVILU,-%U3RM:OK_*E2V'&>PWML=\^J779FIK_%B^8
M%KBIO(VI0NC$PLMM4,NI38#YEQVIA,L1\8SZ*@DW&;']Q]]DE R/VI?UL3T[
M#'U=7V&N^!+>M\&*9(XQ:F2O</P"=D)$HM>7#G@G\_[WW,+#_IG[;9M)A'6=
MC?E(-[BO$#Z,[NDSH!L%.@U"FWKKK%:9 IUG!EB6M?&G5'?8JF_6;2]_-]K8
ME0:69PH.\"DA'EW:8,7 #P"S%60>Y6&N(MB$WC']2U#<:H^#NU^8%C15$?:1
MAG**!O Y0H?4.%:4+[V(6"HW":1OX3[%;PZP?EG<ZTDCB5?<ZRBAO-7P7EI:
MZPST'#O3;76/_-EF.O8GM$ =8/J'P0_)J#E[YIT!#KO<)S07SO.J$>X6/]/G
M3 ">AXF=06U7[C7<W%8/3C^%1J3/P*27..XU?M^52$+O_$6G_PJ9KR*04O0C
M9S?"U79_GXT?F#AET&6^TL$&H?%Y&<D\K;(I.3^FZ&% F3^R#(+!BEQP,@1[
ME?#M'=\%C*<1ZKK!DV3F&1Q\KXIFPSW/YWR<S :AWO^?>?2!%4/D7!!>0UY=
M*LK9[=9Z69N'66U/$H,B?K6*]Y9W4O=02QU3SW12#'Y]J6WZ H%?P' 2'?]K
MD/8 8.[OO4$02RN.<;C$V:\?%N:0*V:773R1?:YN/.SBY.\\S'F;;_>PC+,1
M<>RWGKJ3'I?#G8J?%U]0R#-[>$)7:/$QQ5V+3H8<;!"Z%_B67&!2S%%&/@4N
MAI+IK6I/_>3M"EO5FWQ:GD^FBS7D(?WALJM\;=91'U&A'8<9BI$<$[#B%7X=
M:R9T?/%,&&Q4)L<23\8+U1,O@&Z.CD,^[[?M5(A #JJQB6Q[;AZ5G@G0FHB=
M6G3QQ]YLDD2 Y/-/22VK\Y6&M;Y:)_J,W7K3L=GW(*OR0;7^<E5!5AS?3E3]
M$ 17@[2XJ3Q,?YD?#JD5Q7)58ZBE;W\2P_QS67\\ES&/ZU<5#./'&Z<OSQL!
MSYKE5SP<  9TJ>+ Z$I^J.49@YH]\M=?S20CV#"F/0%>S4V%C0O&/GU+\;!4
MCPG](FJ.@0/?@INX[92W &3@05?SXV&0I6KN%&-95Z9F]'3W(1O!\:K-OKJ_
MXAS7-Q/"41).^8YKOZ&&>,E5^(A5.(YI&@V8VNJ9TX@RISNU- (G?F_LC3'$
M=H$IX$8=#M_K[$8:'R^ALM[15[>43VG<RV7YW%ERV>2#NU\[#U.4H(3:XZ%-
M?S;\I5/LEQ )5]';L8?A&_GPUAM298]DB[?O+4YPST=;<UC7YGY;)<@\3ZI#
M\3'JEB$EO=J=I.VF5Q@EJ@;J3G<J4BBN,;*WKZA'5UU9WB#$ZOT.CHMP3"??
MJ_('N/F!V_R2W[T=5A0-L] DO3Q+>7 ;6S?J.DFIGD.BJ;375M>6I05^Q*TV
M"&B@!Q@S+(%=,;OUN:$=@R<!YLD7L*&JX(S< E[X]\,++\!H'D;D(@\3@YI-
MV(%VQ<'7';^MD:B]L['8Y]2+J_3 G7".1R;*^:]2PP,7-P?*H#O^./-C'K;C
M&U%\1$;.>90P]=9/V:V?4'$[HHY2 M#ZT6^G(K(41'3M]\I&E7VLZ'Y^9://
M+)5XP^4Y$1;E[.5ARCWH^B@5Y]_$KH%L!RM1;+YH@$4-=DU^_Y*I$KTA3KE^
M+LOBG9M3E&./VSBIC_#>,K #K(@#Y:W" '3AHPA8IV0G_&9F2MGS<"NL!MEG
M'>;R:+,"5VKN@-#$S!B9Q=#L\&7_"J6PY*Q1^' -5SD74[CJ;)S%XH(XD]2!
ME*-&X\=LF(]\?=6YS;<^*'W0_N@49[KS3OO=.*OS5I>0?( V2NG$P"M0=+ =
MRC(/)6Z88IB\R(!.2!^>\MR6W!'$=CO3OV<485#CYE"[D>UV2;WWAG>6H6YE
MCT76V.Z+1<6A6Q.33$\^N7<I84V@M@#W&.H TH!\*UBU%U(.3&1X1()JAZ#'
M#%$>9GF)/F,745Y450I=4>,LL[(FR1[J 8^//(R355 "^5G=*(4Y2"\D)7C"
MHO229=A+XAL\+E^,[I_1>/O>ZGQUVX.?\/!W5K#B*70ON3901U/<R7.VF3;?
MU.=Y]8!0/S^%6AZ'I?9?:>#W<!%"HNR0635(_H=#@9\WUOCODOGNY/ 8BYBG
M10%JV(J_3\A\70>^SG;,>X/'10%.]KRS^N<D?[6O$3^<#QCA:OX -C]"BC;6
MS'S1!VV!F9H_IV>_IL *?P3VI<"*0Z4',]U]0!=F6,UM_-9//AN4(MR[KX\J
MY:I=5#Z7-I[.$H''*"-=B/@'+OIP]"S4O"7IX0T^G4$:&91@/4O&*EN9;>89
M9M*&N[<./0E6"\4GI'Z#TQL$3J1PMB.?.DGERW ,W5O"29XXANNUG%+U)_9I
M)[?EUW@1-V!E8[[T2-<[E)1_K?^]\?O8_C>0^O<\#-,6Z&!8=3Y"EGJPFBIT
MF3HM[/MTBZPNX=WC6B=LKUX^$]*=41P5J#-=HW0O5B17[.F670H21KCR]2NG
M3>&5)+91,ANE,\$WX&.0(]NEJ$G;T,=]^J2-P/2[J..V-R\I[-I\VJMVX%1[
MQ&Q/D,A</2)\A7.N#C5Y<^B;D@*T6$B:-]M*]$/ 14 B[XS)2T_:I',LUUK:
MB:R8*S*[+0*#(&GQ+M$.LK;'G(\I!!L:ZU,W46FM9$CM(7FL@J/<"2NQ?#*S
M6?;T]5$^)ZU4)@J[9;>N?O5I,-$OM-UYY/RZ\Q<TA$:R_Q0]A] -_!7%%'?U
M,ZA,"FU)HL\SW01<;>J:&_)KUWM?]I#:/E2QK"_>8"Q!JR$*H2/M0"$I!#S5
MVT&M(4@%^&=JD.G4I1V%[Y\K?2RY-5[C*:Q\-LE6Y(&FSZFX)6:(*N!)[*RO
M[BTV'3O<!T8J:MQ<3:Q-NM53NFD@+>\:YJ:]B17^^):G7AK^7:OJ=]S#JO]1
M(".)^E?N70(;7==@'7ACS$COZ!PY.NT%Z\K@JJG%H^_9'Z!.]6Q0%<Q#[5-W
M%G]0*D%XF2'4DA64>N?8#2]=ES.1KQPGH-P/^JC.O.X=O4\9OUQ^0K@)+PO)
M&S-[(D\GV.F%C:YI.J/>-%Y!%/-0<#.,E\)6!NG,6]XS3VD"^&O+/#V3@@"1
M/_(DYJM+ "6\YVV;%(0/_RE F"]Q !G\?O=W\#54S;@!YU"W<94"#M<R@@P"
M^6DB):C2_U"9 "H2?FR:]/-6+_-U0@*="N>K8L! #_C?[C=O44(\C-J$^3HG
M_?2,%[D,T&9('56CJ;K06I9/:R_0*6U3)M'\2'#\]^,.G1OQR!4Z#Q-D0RL$
MC_<RO;\W&^5?:;#H'*M[X!6U4T<S3(^-UR@X\&+-'I78<QUC1:U?Z%2:#AS5
M(,#OP9[7BXZ1O@^L<"];7I#O;XU7C>-4%2MMG\(W.6^KI$++U\!9-+OIB?9'
MC#98%>C"T8$8L;*]$% KM__9Q%U,PDSLW@[VIG3<F0:A,2*,$V!U>=>5$T*M
MIZZT-,-6H/2E_BK/T^VP1MVL#K24D$%F^DS4AK .(Z(;&9ZKG:=.09?IW2I5
MC;2!(P5+N$%SAE."X\)CA#L7,38=9";QT??$ =3)+;X"J=VW)+*C]?:TAD7H
MB.4X'BOH]Z@1!UY.UDCY#064[VRK]>8\1BV@*?(!Z"+(!6H%G'A9S.T-FXZT
M$AG^]*Q?._%\<G)T652D!T8E9\,,BDJD?IJX_]]_1.$%XG@8-[(@\@XGIFG@
MSI*L[B1<"U![]$;*1C_UODHB470O8WO%=H/\9YDS.E.],)#(UD>_*Y2?NG-U
MD(>Y<0^;H\K/]Z?#U+PVKH)>%0AC =C2S<\*$?7GK(>^UNB?O9$&7X8N9Y[N
MK/ELK6N=VRNY_OWD<[.^@\436EL$/S<(M4C9W$6:"(5M54![?3D[<#WTJ,\2
M6SXG?C_@I7,A^[%>O%B;ND+<9B,:7+,N-F\H- ]TKD>U@T8=R_-_V@6K0+?H
M1,7C?O[K;AV,W/MRZD2CLX:2RR&!*JE3L;6FGX(,@R/48J&OK*D*<KY*)=>B
MEKK<P#P=,JV\!"1HZECN/;7LU8LXXX@M]BTI+48*<95!^B-J%3R,RP2T$35\
M7 X!W@TNA;=">72L'!2WTURSRZI)(^K69N&WE U;\ <<!'@8/YO2A<.=_]SA
MSO<"<# "5G\$#59V)MS(ZJC*=->O>5JD5Y2O,31^,E[$7%Y\Y&VUQ) 'A**L
MX%BD3HXTNICC!9M!%IE+DX"E'BN,'UFISE*T9[?JW!TL.M%C]GM?FO3J+$X4
MI9P,&9JRL1SCL"IRIY9Q_FQV/;RV3,6O#=H_.[KAS"5<0?5[\-4O<R(8)-#M
M_]K _[FU$7R/4(F##*:0I;V:$098&K7S<%41W@F17THGRJRZ17YFOM9#/J%N
ME7FJF6V,N=YR\4A"_3+P$D$!$?$CLDG0#@91P*]J/\F:61=9T%&0O;<%FCH5
M+U+4!&_6BC_U-G?1R:N$FF)XI1*RM(E1#ZWG8<9"&)JA^ TQ'LGROGIEN);W
MEQW;M.M<)C5LBD9_B4D;-XLI#5J*F>67/8@/LL]PTP/<.>M@(G.FVBJL<Z M
M+,">'GG?V]%?8.C<'I,1/[]N"Z6T7YX^+0]>!EI3F284:#N13H!78BM?$D._
MO7NE5XZ32[OA6,IL^8P<EZL.NJ"1HD3N53O?8[[A2/_RD3)'<)W.^H>?BV0.
MUB^*VZ.MH1QCUIYE4MZ_W'1-R$=C# A*V4QJ<5"F6=$(%A)'O3)LAV;*5)H0
M-3^7#[]ZM?M]E"E]?EUHE47UQ1<?,8+O_5=Z5;8-^:)SRG>H;6PO%5*9H%^R
M^?.#-]8WZ$ ZBV[.A7^)^86Z>XQTV A7(F73-T:%%2D<C<*7!50L@E=^/G#8
MY)/M+C;0N6=6I ]9P\^#!84N=MG*5U*7X#=X' [RV9!]V3%#3;'#K8=&>HUZ
MM7A_O3$2NKO5N5<#)1S\NAC%D=/U(D,-H=+#6N,ES0.">,L"T3L;;O(PW@+E
M_?1=2K,T[F,J;8K0*<GX</U#6!4@[*="-\PN7TL4*2IYLFNXR#Q>G8>9R'*$
M; 82QP0X>P.,N$^0M9_]\AFF40'&?42)X]'95[)Z7KT/OZ-LDARC%.5$7[[X
M1/D!H3: >1P+:=A$@;0<'F8EK:"XN)3YJ!(G=EP[59'9MU?LUIM@ZMG233ZO
MJC:N45V_UGI3>H+O+=H<?RNJ=5!/:K9?J"4S#Q(Z'U7R,"(!HJ<)1]H>=?M>
M8B44-XXVA!CV5U^,T=E1M_CW)V+YF6MPV52FBPTLF4%<"1]AN8ZI,]26.&A5
MLLSIE*7:CZMGFM9PG-]*UH_?.R6LM";YL>D1':Y4VUWD=>^S-A2;_4;N*$8-
MC6B A"L;6 ;I65G(>[9/:<@G)/@+EV][IV008X3)+\9XG8C^.Z<#"PDV_Z($
MF^])-J0Q 29HQ;V/7^375&Z72QBERKO9\/MO^JQ[>95^@72ROXT9V4<4&L%A
M#5R_=_+,]K849_,[>;9N?. 38PS+FL%JG"%*7R(BKL^]"]#OH  ACRJK#7G"
MT7HU=A%^1:^O7H_W%DY@_"9T[\5EE.<&'1"J*D#GWI>'*5096\W =@[VH9"F
M3 E*0SE'5\^F%_;)5"7?!%E'LW*'ZKN+C15N'5_,GZO6-ECN#D>;AZG"@Q6*
M!K@GQ^VYY"-0\N->OZ*A;7"7\DU[^ZFA5G;N\S%.U8C'K#Y3,T0'&X[H-L([
MTXW:[(I>75F2XBS\57O*+*^6&KD%%PVB<YL_6-$-L'TA41H9,[P=><?<?]WY
M7N<IGR]JQU:LW/YMK0#L)IC[4PHS\ C!;D%W0/X0@;V_H)Z[N5EM+F&>5U4%
M)UU0H[R,]*>+M>+A7Y0*SLJ:6Q^^N:M?#N6L]/L&5WB8/751 /,"RA1K&H1F
M[AB#2T!F0RJ>A[G?5XN#=CSG81A#/$SH-=8,%ZN(?E'%!Y1RRQCA>IQ7\GL5
M5^WVXR!AI%4@[0LZPY%IB)QD7>^T@1_J7H7T<+ #!O2_;<-TY7.)OHDY10.4
M888DDQ -$N1FA0,;6'U86.$SR+HHP/URD%!!AK552-0A/U88(GX6@%X"_^4A
MHJRN0BQ0UZ\>U8#@$J2>[=NCP3(<2ZF+S(X[IM*B$K?#9EF5VM9%E^60NN^Y
M_H(# *1N.BK#($(;";!D7PU!&%Z;Y6:G6$(Y,3RSI<<#NZG3I&C&:S\]RFPB
M+M.H,M5LN)6Z&'0C0-JB?76C TS1.MSR0F(X#R,\<9$B  7R,-4V">Q$N:O/
M4^4MW#64S:KLGDPX1UU]?C5NF]$7ZN/33!#:1(339/C-8IX1&$2N-@J=624<
M@<":LK7HL,,"VQ0EH)UTA\,FC84\C*S.I\Z>TQ_6=52Q+YN/=_E'KYXU6R6V
M<39\:)OI5U/^Y=5++L !T%:.L9]0K5Q8->6:C!UX#39]Y*&WI>OSZ0WNOQ6_
MB'$]TNVVA)%I]$90V2D"RD>6H8;V]B LPL/DO&Q#?B^40RK<!%F#"-8.?=T1
MWLG7>6<>)B/;FBI)I5VC,@_* K0D]!=E"?0)88W!,CE46"E5_7@*:JTU[F>@
MZ[Q/^=BCOKBU:K )]0Q(^T:9-0&JJ)Q-TH2YTRT>L_<+F-)Y5VCH!TOM.>6U
M(>1A;Y>[K^\3P)MXP4MA<I>DXOMACW-5S;_VW!;@LG89^!Y0SM-_HQ ANWK_
MP$G_18JTMJE7_)HV='F-T9V\";I!QW4\JDKL>EJZ38D%1%ZSJNK9>\W6K@P8
MO*LQM7*'T-B6U,<$6_2_H[B55A2XNH5*NZ&X@655[7GX8QO599GJ\,M/!O>.
MG_9QEY4[O'''[*!(T9/]%A9+529LID)8I+H>?>[S0/T ,^A.UAZOIQXOG[8%
M;F8M8@D.'*N<VI30#]],LY RTU_6F#FJ*CB]!Q%#E^'V\],$MM4W*^[&/,K(
M)6H"#M(B(H?HC\$.H 68SJBE/O[K0[2%E.[_F-+]_YZLEDJ[3WBFF,CQ1VI
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M,<9PNYN!@E$EN>LMUXJ:9HFRI]0+8M\49-T\4/1I=]S2HTI? .AZ(GL5#_-
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M8+!%9C.&'C4&5BCH; _L2ET1FS!(TRW$-[6^L_LT(3#GKZ>.0C,I =@1)<(
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MLB +LB +LB +LB +LB +LB +LB +LB +LB +LB +\B\6'*_C_P!02P,$%
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MO[& '75D!'. NX0%/-@>8\("F$*&+.!6&68"2Z6P@/(7GS<V\0"6,!+^XV#
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MF+5 O++Z)G^.XRFC]![I?7/3S%9OXZ;-H!%TX;-OV 9,N%[D8.U"@=Y[W)/
M0E@6PF]M$D$RZM2^3+"^N4!CF'QB 76970Z^'4S9UKIGNKK)GN\GO;R.-X?"
M _A.^' FV^VX7"[PU:+6X?MS<4<V*W%'G@3F./RKEQD4QDYNZ#)O&EPNC4:M
MGF !*G70"&>>8P%+>F[-OU7]O[](?%NDB_LR^37)J4R^,7+D3._<[N$UM,,"
M3'0N79.(ZPKE.I3;E!H1I7BRH2G=<J?WFWR_%MNTG<2\$AM@4SB%GH('55@
MUR-&FAR64(<0,5/UIMM2'E>:S&=@ZPQ3IH;7UWAU![GRT^/:YY>(9;>>#N8.
M#W#8T;K.;X;0M)FC"$[\Z<$8IASC 38@4Z8#%WVTFVJQ@&Q-2DIOMN-\,:Y>
M<J:?TJ0Q8%X(VU^<H@;\1\M_#5K^K!6.3A80 ONA7<#! E8NYT \*??Y<*LN
M]0D+R)J"FNA[AEV_6S7[']?FGU_(F: :DBX.)^30Q4H(9\$:BE/8]U!?EQ9O
MO?9\KB&QUV-HMRJ[6*'T!_LE3YWR?P<JBK]_?]L52&+R*T'S!@8:0&SQ$Z@)
M[\Y,SL[)W;AF\'FH%&T"7BY2SW&EG,+MD-34=+^EMZUNQP_#Z[%)@J^2F>J0
MQ$<6$!>-]A\UVW6,!70@L82RC<A++&"5B^0E!DLR,>+@NX!+V-P7=_3@R&@V
MJC[TW(ZGG%D>8QY-]LIO(8%]>$(!7-;$F_(8"6K8T"4XIX-9@-SW&26I>!-I
M@1_-;IW/Y;ZZ':X]<O!>[:,#&QRJ6LN/HFR_7IG=SX7QPPSC^9G;H:<((P)#
MPYG\$C2U:&.:%^,>^OS#5/RT+E$RE2^2_/SE]6I2W@Z1SHK/Y]F)D6GD>YXS
MZW-%HUI:!EY\Z\^/#,C>\[KCJ7DO)+FK3^LTKY^_R>[KM@ID\T)!5 )*PDP.
M?18,+T:C0)L%6?B6Z(#N2Z?=-G<TE+W^:!X5OOV+V]%U0GP<KT*,N<1;MP]O
M:GQ).- H:F&]3>=MM8$0DJH(YI 4IL?SV$V^HF4F=!YPK(JHO<3Z(96 ?L28
MGB":YKJXOF8Q<0$I'AB)V4%^4Q-2L=2<_BC*$U/D>Z:VZSQGBOQ>WP@5;VE;
MG_;KYIR.7,UJQ3'\_Y%"-V<!\7/8]^,8R+!.[1_%KE]U6_V.48#&<0WQ-03Q
M$RJ%P8A-"S6.01;P.XQ5D7G^ (V_:\;D=R#3_",L_L=4^:<7G!BC#1$>'@LG
M'YZ/B<+*F>T)/CK@EW<:K4N\HFXRB^S.?7#?O'S*8F^V6WB'E%8W$,@.!]5@
MJRR ;/33S&\/3V,!6[^$X7#A.CF'R5'Q]7[?(E#BP;5GN1+N*VDK9W3[$:X>
MJUF!#>+)2-0DQT)!]WR&$I,?,HQ<=DT->'"D<JH>"S.3MU'-*Z5K#"N_\-KG
MO]<-[Q\^_^X*P5[-I&8G]%H1>)\"R/W+8O9U07)0E!-7'O3$@1+\=>PF,:"3
MP R[2ZZRNWD[T<#$[J'Q]5-/E<YE.?N0\5?^CWOB1F:BN0CXE.-\8VVR:!MR
M0T9384@SNM'X3>;#F4?C&]G#17;;;\@FNAXQYQG'&[0)1J_USI/W8Z=A!QG7
M,69@+@MP9=QHVQX2&D[V(IGAS@PW=:4?/J7+ GBIY7I79HQ4TL2>=:9]V7>@
M3'=D<P$1B)S:($!&Y"C9MQM1M]:'X_2,3NT\KCXR/>@^C)/Z<$.8O_G)CY(;
M6S4?I%@J%==>=Y8!5F[?'C7>J9 6!^,\,O%Q?N4HS1R-@E0]RARZI$H7/4_]
M2GD^]XR V-+OP\AA&H8(Q59ZJ;.9&#RT[RQ=!RHM^MA=)DMDBP\RE O94]3^
M\8+?@B5L%/PP*(AE 51' SA#48)V!96,(%\>I.<.MK, FII,)O-Z"@"Y.5!_
MAGGD+LV;!<ST,0M4<?/+=+8_2!7X\S9@ HQ'B/>-:!@+J/F"8NP(WCA(QD]W
M,>T#?CY>_@,+&#Z%N_ ?4^.?6C3[?J9=S*028'2Q!2IFE 4$9DY+=8>'E$WO
MG@DR=LCB"__^VKSCZVDM8K\>4I&3K=U1>K)2<R>01/W":#%CQW:88  4'0O^
MJ!YH'!IHO,0=6ZZ0XT3A+E4PLR[P%SZO-2PR4EP1<++R0>9=O ]V$KDPORI+
M^3+"Y&^"$.(TM!UU39<#%C_/*_VJ.:KSM<YA-XTNT>!:G1&M[C#+OH$.5S7L
M"?ADU,+:JA>%V<7D;_DI129Y14^KW6WC0TO<?=4(%[PPQ>N7Z^S#V5P?HVFG
MJ1:8O$VS4@7_21L0=[+Z-^4B8K6&)H7F9> 1 :'GJ4&,(K1^>+W#\5TJU1]:
M.%N'PQWAVS>'CXE)=!\Z5]VO4+O3+_+HUT&Z6 %U"%RCF="C64"2%83S0ZVV
M.FTJ2ZY(1,=:2@[0%T*Q,4]51)T72S_,N35WNWW;\-0YP:PKC..0!>;:"F'C
M,EH-NJ?2(4>0X+V0?G"MBZDRI'O3#8R@<%BK&"#X/N\Z4?B\\<;!)L%*^9WM
MQAF5'7+[33=3P (F7P+T##X0MY I%X(E'\:":H?O!1$'IY'$YW<N]UWE74%?
M*<G,EL,Z['%<)L",#3A\WZ\B\]4PD[^0]4]#U0 +.#T_HT> K8C1$)\1]3FK
M\ 6NX7HA179+P8/*+:-?)N$[!H:UX@VZKVZIV D(OG*1N+M?D=&(#<V,09"1
M4+1 <V.4X /Q$MB 3].1BC4UC4XJ7VHN$7X8&IYY+_U862'!*08(.%GQJ.O]
MVF0X516$!BT \]8X@"YQGLF?1T0]B<YX[8F,80'L7]Q?^),7D.>D=76<8D27
MO\9DO!D0/*#+_WE;Y%MF]WQ-0=_:#)X:.XP@5$+.TKF I_'VE;*;1BO0'Z*4
MM.Q\MMIST@:RDY-LAM5JO.]KX_GX;=W<%QH9(G]Q &#94#13CB<[?(;-E+<W
MJV::241/T3DH+XG5"\'SO&:J[H^GZJN(+QJ>*HAIWP+YM [L[)AM>.($\=8.
M703A@1$+:-1))<%CL/4!<3GM\'I$Y[,<)(@C?XF<N<;-'IR]5_7-DZ=<WG+V
MG-\D['?7G[/[?AL= J'$$L+8!?I^\',U>)E*9"2UVH1 SFT:1?335HUO>+$S
MNTWUR8>RMP:[KJLTWI%TUL)>^&*K(9T,T#12?@PR^:J@1TB"V-]B=+THDGVX
ML'>T)4GJJ@%'"=H%#'CD;P#G_RSRP2_N@(]TT2F;7?8Q<N8\(0^2\=;_&!7]
M T0QVOZ K0$760!=)I0%J!]B/(:<]0(+0-Z<6/N. : !*YO_>FMP>HTYAUC_
M88IA ;]KYG\LN9> &%$#;C6(#*<J@ (XS#"J/BE#X2U:M]!K[6D>,^AQF8E-
M:+C\>?VO1@,W<,K?VSEC>+&GX3,<!/B*.IGG&.,!"PB"R_04@^&6J5G Y51:
M(L] ?6.JPNNSBK(N/,]47#R2>N=K<E:N4+Y!U(VV_Q.>[ (#-7CB'@Q5KT<9
MP>L&(9!@[&>B=P\E!WX/M38$'"H'V/<(XI]U9DEDZ\?!)S>HAT#(1G+M!AE%
MT+MR@DA;/D^!!9F99#3- @*04]^._"@BOV[9XCO^W;V_>_I^H6;E$T;_]!EI
MIY,,N7_7TL#B(:"5HIXT]<'9Z:?JH=D/38\._0N3)T BT<'$"UQH7^[=IYMR
MB=WG1=F[2G*XR)8K^:?#!K:?<]U>8(7I*&A"MJ^!:E$KJZ5,B"-R1*AGSY&L
MZR;6A<P/7$I*^KZG74KFRGMOWUQ#4]!?X_-M?]6IJF_EU&^,G#:(EW28(@+S
MCC+Y(04YE\C.FZ_</E73#J)%1\S<6X/*K.U"3P[LZ@S.7O9^P;$[O2\[R/4,
M;"A8$V(Z_OCI)$+.ZETRO M?G[E"67 W6../SN\_%K1QG4QILE.X:]RC'R8M
M;_C!P];@DSC@9/7WE3]:V\"'5U%XF# (23<]0#C4!PXGR,6([)>'X,Y]#SMP
M%!&"IT'N?>3]=QH#!1GAH"9ZJ1X5"C>:,AEF2!1^],^;82-B&Y+HV8,_?:3I
M2ZB-U\>7CDO1W+$O3O]LP/<=?O/0V)=;?W?O_[GE#+9^8E6/;$,U!15QS"%4
MO4VFMLE>(D)HZEZZC5/SZ6Q3T:W7T<.OE;9<DXE[\PJ0UF>#K2)I1^D"C-0V
M+L@(UT>MRBZTA,.BCW8UEGG-O'ASW,W$AG-79F[0@],:UL^TNF%'43#,"VQM
M7Q\2U"COJQ9@\I^%(*)"5AE,HL.(M,Q&YAM4W5REGOP-D8^F6/=D>NVRJ,Y$
MAB&G!?]]/QU%QFT6<"H\?9[L%I[1#*.+ES#Y-0G[\,)T'?*'MWC&?0A7KX_Y
MGSCZZOCV\6):[6S_T\"BTX^"S9=>%93J_ZTCP?;C!NT@71-,A>;V'D81Q/_4
MW%:*")]7PZFAE#=E.E"<C+_JJ:4RT[FA8]&4<N&.#7])]2N!A&F]SM"0\"'L
MW[>>T5#A[A[<*+9TJ?26D6'3SGHWPPF1I SWR2W] ]'^"M?-"?&HG,V>S!0\
M878^<QALL:@?-4!,)I%0R?$AGA=XO[T@AQQKO@ZK/U"BS;AADL:AP *<7^WZ
MMNIU'38:K%&6\/A3OMK;%;H#,>_DA--(A*S[EWJ&12_1/_$CG[C)N=[E@\V[
MKW?$*L3Q5EWX[P&TLP52;0BT#BC3?!)M/O[%MWD\+%M(\]"(?E4J;:;X5*+D
MA:;&##M/_2P25Y1 PZ&AN'.?MG+4%;?F],PWN:WD$!Q0G9=T4\T,EAK#%Z(O
M_&@U.C?^[?FC)<R,EJ=70EI7*#7GA^*W.81!K/,[<XD6'',$ST'7H_39,^XU
MA,L\H935!>N<UO<*U5D^=U)3B3O+O3BPZ,>)&S5*#SL7MRHIR*U*](("U'AP
M+V5?CY29$%DWH_J[D,6TYK4#=H(53;O,SX269\_9..8X]>SY^B#:8]Q(XY%S
M;?S4_TQW+-&'>0NOY^E8FPHA?,13-A86,[70!D1=P4F#N9JJ^391Y6U<CKN'
M;5=<1 VX9J=<S$]R 98T:^90 1<+\,/'08YPE8]F'OWU91=&E#QVX]E8A/T$
MT<8J71P]/+!BH1PLL*^V,LY6@FRS\IJVEQX(>;D!^IFW"$(QGNR(8)L#SQ.:
M$L.YBVC[,(.; ]B^"?I7RHYG4II:7Q[H[S1TD8C]P!=$9.29 >B3D.@4.N0M
MEE (;TJ*U6TU(G-T;G0Y,@K,V$/4$\?O8RM_DU0RSGOKU>BL%)56=XR9"P#M
M6SD*_SX&4(N^3-#EHA\A'ZXFSY 0"8\BGG-XCWRH&;]PY?#LJ:;6QMO\=N+)
M[W;79O&:-51; 1@?]%;*?#J>  7L]?*W:0KT*Q0#9C5-"7U@?'J>T-1]Y3BQ
M-#Q)YOXK%%-D]? I6F.8_5;5\PG2[R*O'4*5#PPLRVW=8FW.$Z>9SBA"!,Q#
M<4$#LB-S"W,0+]\J$D32Y8LN1X:8^AYL164?V*.QW/4QXX#/XRQUP8R4 7/'
M$,+:9#DU#L1#QJZ<4;R.!)475S\L7'Y^OAVC>+V#IDL_/2[+X=QXA#TZY$A.
M@OTG-N>$#,ZJ&FNC [?8-NW^&X2\*"5LAS.=CS O9D7>Z&E$B1JP (!N39Y[
M)C?1Q0*2)8T/35P*+5MUL[6_)V2A2*NJ*-\Q?>+4![\[2Q^*(P+M<(^#:JVV
M536ZC\7XM.\<5'@/;X_!\@-@%"E@U8" O8;E0+.1850<:$!"\GXVVT'>2$([
M4/9US4F#_M7+.\WU=<//R]_@F)[J%_78T9!A:.=NQ_54HT<Y<#*BN2]&?]:2
MNM $WJ.IT&W!A++HE(V>\TLL0,YD7Z7A$Z9<2ZV#C'OQ<\F-S]1 '=]L.0.?
M_&[<_:);UWR_R2.J/Q7"!M<F50E-/:9*WHP;K?"'H-?1D0A8+(JCU8XXG[(A
M%3E<;%7YDI$9V)CO&Z-J)#:%C"ZUYT[A+5,]_;:.&3-D!4A =%H"[X=+Q&]M
M/<;4IUCC2:F7FV(5=RV9*>5.RU7L%.[>,_AP[7B1%8!.H$11/<&+Y*2%G([/
MF8(A^2I/0VUZ$]5[JW"OSXDKJ_2V+W[8N^W&Z%G4$1;0"7N '7R]QN1JN C_
MO0WC1M 5-FWH]#DH2O6"O "OV0T6@##"@Y)C-5: [Y^*P\GQ2_!OWRZS@-A0
M+_%?DK\D?TG^DOPG2TJ\0@>"0V0<-1)T>TP/ V<6[L&$P*-=GI?G/E\:+]?I
M#RTZOMBR2UFC&&)"E85UP/Z=&./H;X2HE2%RYG%PE3)!V@Z&=&*DGX2\#O$8
M#9_RC=O5#@CF1)X447+TGKWM+.D#6UQ<H= ,T(>AT&0>[3/$ L)T9VPZ<O&)
MV%/S0BB(?L3,<QHT;0\7MWTF F9ZI65)2Q_V:=Q[I'IN]^N(\X2"#GPJG'P<
MD79)=;6 =B):UXD\N%)'-+5%T85!S4<V'UXO!(UL1XB$G+T0R+LW;O*#AU?K
MZ=6(S0AQ)W/1+L'@Y!0)$6OVV+=LDX[<%J"4M15OCE0,6PS7B \_"C1?S_SQ
MXSD+:&^L3E'C@#.W7%%B8L*Q9.T*%G 5;LL""N[-TP6")XMC=K$ (L\P8O'C
M!@M@G\[\)?F/2U:]1)S&38I1+S):$ &,$.IYD%8\APJ<KN73#B,VST24'E<P
M<_C^Z"I<(_K.!R_.+1[NN_74J<UJ'-]P3+Y9&I+N [)1?N )60CR483$L4&*
M[J&ZRYGQ\^*E3Z.KS=0"=RV&))X\^] B7NR 7>2TEY9Y%A*/^).NM08P^:'.
M<E)!""E<4B",!?"W],G<GD^BVQ>C=N#(GTG<:0>#,6+C)[O,+X=NOQTF[6QR
M(B9"SB7.^(<N70RB\V(45)^\\3B$-HB,DQWS#$>Z"NH+NB[OW,CD%9D$:39P
M+6-F[IFBL7;Y"\'<?2^F"TP<8Z[$_BDP1['_BLG33ONW0L_Y5V#:_ F<77O$
MV3+_QTA*K,\:"VF,>GJUIA5=>_78_=N7X)Y?"\5_-R.-I=B3<KIP<2CA!EQJ
M@23=OQR\W&4F-_*^;?Q[]1&"%5=>LV!="[R?[84RP*?@R(F5PNC0]4 ^\LMC
MX$M*3N\T-LE$F_C<S'XUW&M,]2NA/I9'J^^A,H$+J-O%7YC%1E\ K<A5I'*Z
MU#R)F4GS8([);QFE[Z(I@_;.4O/<S"W+E#OE8%*$]'93K$?J\_*C7#4#S??O
M%T7F%0BV;:,[LH#X6*9.$+:^:566&'JT"UXS?]7@Q$5R%1'S4,S\/,7XZXY]
M!L]=E?J?\-S1SA3EN'E;RX]A5E=7/[*Z_<F3A@Q>A73?.%Y'#>N4G1+["0
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MX<J. 4U37?N1T&S9R_;1H\IG;60 R.NH.4+678/Q%[GT^X)&H]4AF@:F?5[
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M%PTEGY-G9MJ>@'O)7D35E>_D10?0BFQ$;$LG(@0#R3\\PY(*EY9"0]DW%+<
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M'IOQ#,2+U'-L5\[>6$F9T5'8+Z]Y_1'A@)3@D9WXL -^NQ[>E3A6,5<Y!6P
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M""$,WW1WF];8\2N'US@<WEZ8;*5]'E=E\[UV\3WE*?%\[_D>: B%L8'A8NA
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M< N,"$M;EIAF1I,Q8O-?M@]D7=6G8VJ"HNUW-1<UV7A=KOH3P&.E^=X&Q.V
M] >R2&F48QR(X 9R?Q%+UA?K@#2BX_K-P)C]Z"RS0U9""]_PDKU';5]&%-W9
MW3QU+]566]9W\&(R8]B<;Q'6Z$(98VBQ/\KO@/IAW.P/L#V?::90L/[M<:9#
M[5?G7V)?-R,UK3(OXY^)?93LT]#3MCO"IZQ[S($AQ>[9 36J,R481 1'$U!^
M*! ':]S6Y&^7IG;4P#Q/+%?5>IE(!Y>-O+8M(#G>2W EGA8$D=HW%W[18P$M
MA@9BWP22!SF&$FW""P*.??0_83R31%Q^[LOU(2VU[ 7__!&3>LWWM@<Z_@'
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M_!^>[D9J--%$L$-8I;66EH&1K\;T%NV*>Y*^7 T)!''9.(ZC8?OX-21S>0^
M(=VM1Z5@90I[,==]&%<*S5-_A_*$X,#W3I>TB@Q_Z\"U;0*G4"'QQ]BF2!U
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M0=R\??UG&[_2U233MX<4ERV+PS?ZYRS_%XL:Y\G;=*B9]YV0]2O^/_ZT%5,
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M_>-WEI<6<"],,@[$K#BQ!F)6"OPN]38UF-Z6B?*>.L?E!:.Y]Z*;RS&DU4X
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M7&N?1=53<)\/MGS/7NZ 4CE*VB6"4,UQ(6[VU1X[6V1M-O\JID3XQ.?X2<A
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MXO#+V\; +;%$'<YM^2EE\*-8\MN?NQ-,OI65!6M$MW>VV3S.B;95JY.Z&%L
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MHU93J_C@'#XHX=CF,N;OI7+]!]W^OVQ2ZE *UQJWO:FK4G))>!VDV7\X-Z[
M7.G).,^S_TWO+S!FK"?08/!"#1U*%49S7-O S1RV M4LM>QV=->^Z4F>,(+/
MD+#/9OF9B%Q]_Q,I"!=UIE0K?9[5\224\^,]BM"K(987J%L]"Y"AL=Q\QPK
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M3@2FL:6?#4IULTS%!\*L4QT[J8+DM&*U0)6Y>F?[TF[HE9 6F*%B*9!%5V&
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M7-C!=_3S7G\T$(#)@&QZ08W9H.Y'ZK,H2?0;7<HZ,Z8:MGG:F0Q":#/TQX;
MOXY@Y-@@_!DQ=-]%Q@TVJ$2:BF-Q]WAN6?QI\3_= CE'A"^,$7WN;D4KG9R%
M>6E+SG]<S4V8M4U8MH_W)-JWIUCN*!C-N''JU\S8/SQ+W/"?G3YO+!OT#SU8
M_>-?UL__:?+_8),+BWS,#M8!Y/$)E1F&.ET:T?5K7O9-X-6\$?OX<>_TYC:1
M\\ANBN71K=IGJ[V<IQ2R01LGMX+I\EL8YD$]+O#?PP+_?]Q"//VO3J[9B?!_
M2N)BMO=O;'O_+9J,YL!;,/T<9<AZ,F!-S+0.SU]E&!^YZ>D4_[V/BU-.G&C7
M^LAS%/^9J>[SCS$ROQNV<<\.PH'(R:7HKX.U845@'C8HH14@L$&6NB0L@S\V
M\Q^#W>+S/TW^%YH\Z;A,OXETHA@F:",]B'8?&@:=G27V/@ZJJ5E_>HITD:31
MO4\H6O#B)/8Z.HVCPUWEWG0P0#P5M-_U2K;QJ]UM+[GWAKQ6F'6BA[)!;TJ
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M^_!TO)];P#'S%@]6?\8];XBL5V\HS>>Q",\JI>_LA3?@R(9/D2C@#K2!DDO
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MYG'\L2<TC_;K7[LM<3(;5 =>LZ6?0 VS#LV:'*=B6+M5J4HDIYK*\J%@[U*
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M7IPM<C"#@#A\]I]=??#_O.?>C!;C6L;*=:B2P&*KT!VO*-@$Q:GJ3;3,T/.
M /W/(7QKK(&(H %S-J@J>I;OUHW=E<ANO.$=A@XS"7J,-<A2!AI4URJ(FC![
M2D8KX<)3P!A//H<_82+Y?#0T7/-3O;'ZP<ESKME+?#?.>'^)X4FSRJSEQ*/[
MC> /)4-L4,,L&4UI(<'7EFE,JSYG%N@5!=:_H"T&//;T'B?ZED\\:Y$%%YA6
MC\W?E'X@M>ZS_W$2KRC!:LV5ZM6+:\J\BPWHU"7()U*6!^ ?6DBD#D]NZO%
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MER^14#*_;P]M!L=V@3X@1-T 0\JD$W6V[Q/8G-)UAT1V']QN>\8Z.+X6/FI
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M-=&XOED^:#)MB/6Z5,O=G3"7U.@3V/[>#7DR'U__04I^!5KMKD"G7P6*!6A
M\,=)_5'VQ%P]!!B5W_H#M,N"%[1T6=34.L[B8T%H,2_J0I@@'RFB-)5!!DFN
MS!R$!5.V#@DA%@%%"4UC%%*7P\HS_4WMM%([6;BO&*IC&-N:0=Z0&]PR:@$;
M/(SJ#!:>8ZF.]?8B 55G5#\6577NL1Y'D^\6M2@?2T5&?R^X^+J4M5J<1'M<
M$\11'L8TAT&>HM:P"M(4!EQ03B4.N%U0U=F>IN9IVL@*_U#"@JJ5UN%4["2P
M%N>,ON :F"XV8@(M)^@$[7.0>!(RAZ-#7]"-=%BX];(Y0NAV2&@#R\ECP9,-
MC'<0:*/'LZ,_JP=\W)7[N]"I)@2__J8^O1-OBXHM5XOZB]KM*5-07]6;!2EF
M22@QI%*F$)% _11@#K,TY"$3*.;,*9K=58"I,6TG,22-R("W,@.EUD47["P&
MP\YV&Q+B@=EY[SI>)SUHQ0>=_$ K< 5:%8:ZJ6</WB 7^"RZ?\%[??;@G+[N
MY]!./]*[YKS02R*9WY""?UB\(8^%VLV]63X\+!=FGSN+.4<TCBF,XSR""&5J
MYYF0#$J!TUR$$<ZP4RZ"\UU.C=@V$H-')3(L%H U0KN1F@78=C3F%\*!B6L+
M/2VM=HRU\EZ!1N(FFLH?4=G#XXF:+#H<E8SL =BE'X<G+[IV_%59XN)ZP77R
MJOG^E5C,.6<D3*"@>K>:H5295@+!/,7*Y@I81''4X_+QZ5ZG1CN'KR ;'7I=
M0#Z#N1WU>$=R8/;I0#0"FR!](_)(EY+M8/)[-?E,GR]Q0=D.AB/7E"T?[AOA
MV5YN%)4FO!FB,LU0&$!"J#)V1$ A)22%@<@C3J* 9%'D%DBPT\/T8@D^;-&+
ML6]<8SR?(VA'(Q>@,C!A;&X>*SAN3L'1(Z+SH-+>@CF?MSYR'.=!U?9#. ]_
MK8>WVYR\"EXOV\ ]P1D*\X1 J4P$/7/5-H6F*<Q8$O&(QGF:,FL']T[C4[,,
M6O% O70,F3R(G(4'^P(\AMY=>(7"P3-] 20C.:,[/(!<EF ;I^OO1>7+$WT$
MAI/.Y]UGQO,W'Y'VF8OYV'=Z.E@6=<&+^:HNOHFO@JU*<]+W[CN;KU0G[Y5X
M.N1DU;P+G^4[4BZ*Q5UU(TH3:W#]H/T],QSS*,K4?BB-< B13E^<)\HV$7&$
M<8 2F86YDP_&AU138\7UY2R3-P$LUT%3C59-4FFVT0LL)3 @J+\MQ'J?]2C*
M)K>"HW/'RT!;^G_&'KZA27Q+'[!1"+Q[-G1OG@]=IY5V=#>Q65>@T<RC)\DG
MT+Z<35YD&M<?Y1/&/9>5U\;[6**KNU55_UR21=T><.<QB4A(8^TC)Q EJ=I/
M"AS#A.-$<A1021QLT=WFI\:[C8# 2.AB>^W!9F.(7@+&T"RVA4.?F(E]0%S,
MT4N &<D@=0/(T0X]IO]I2W3OJ1%MT6,2/[=&CWZK9Y1#?2]*38BEN!>+2G%F
MLR?_N*RJ+X+-2545LF@J2ESS_U1]ZQ=#L^CUYS<?WB_+KV0N/LL-T7X2]6>I
M=O2S(,-)B-((,L(E1 IKF$N6P%"F2&&3$I:)V5Y^_O-']D,);#5![*H7^)PD
M'T55_07L:@;(6C6SG;M3.Y,*J,^KM5Z. 1:#O0=V)NS+#NM((1M:1_!,R2ZQ
MX2NMYX]7^^-\O37.VNC5VIH1U_IJLW>C<7/U7'VDM/88Y3'TP/@*!QE,SG'C
M1H:&>R_ 9/ .>UX6T\;X%_'8Y? H=6;\A^YJ?92%.$JQ,JA) %$D,<Q)(F$H
MPIPSE,1IYN3_.-79U,QK(RO8" M::7O>EC^)LQUW^T)O8/KM#YS[S2P+1'S=
MP3K5U;BWK2R4WKM79?-,/P+1AI,0.^GRV\L53^U]O>KM2EQ+-6O_0Y#RO>*^
M6<H)">),0AK$&"),$<2(AS!!0D0<8Y0(JZWZ15),C7+42Y>;6 F]5@BB174C
MF7YC8<<^@R,\,"TU\NL[H[OU-3HEKO0I#17F]/D*&/B!5@1H3?R1UD5 >F*S
M?C*,2G,7P;3+?Y<UUM.R8O>"KXS1IMG77&#>ON?<7&J]7M7WR[+X;\%_7:BV
MM^ZXZG1JU>NG[J;K35DP\45?C+X5W^O7<Q,C3&D289K 6(@,HB13+"H%@T*B
ME"+"4,"<6'1XD:=&N5]7#P^D? *?U0ZON%L8$]R$\BNA*_WI5EID<*U3$3:Z
M$:JVA>U=9$=#</C7PM*<G-1@CV&4[B81V.09Z%();#() *-/\R* WV[->&O%
M@-',IPT[VC#XLH2'%WA<>WJT =BSRL?KN=\2IO,WUT]:I.5"S9(NY$NM,U&
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M^/=^QLE-N7P49?VD:SC4UPNNW>>/NNU?*R%7\X^%%+,<98SH<)N0AB%$3$U
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M,%>V(D18V8=Y@!!,18@#DB0D"YRJ?9WH:VI4V.X%U[*"3ECG,\2CZ%J?'OK
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MOB_FXM/*+#0YUW>EI5JVDT3-.\8X)$IZ&$J.\TS0B(=6)XB'&I_:U&MC/+6
MH)'0-09V"[CS,_ 2.(8^@K-'HD>$Z[[*%X2U;C4V<BSKOAK[ :P'OG-!L-C'
M@M!B;F+D6SLPCA/"A<X,+M)$V=<9@41D:HZR((]9S..,N1=+VNMF:A.UB0PB
MC)4KP<%\(VZ/@*U]3.ULZ\N1&G@.-R!M23B _7P:!)_!2_N=C!^#=%31@Z%$
MQ[_=CP%N2T&J5?ED0E*OF=K7E^O"EOIL>AU G20\2AGB,,!80&4N(XAU ;5
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M<V;WT?.9B[M7 _U,T%\KG4RKJHL'4HMJEDL:IFE&H<BI6@+25-F:"98P9T'
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M! S8S86%>K?*J8GOM7$+S^(LP"B.<\A8K%-Q!AQ2AB@,6<PHRA!F(NA5?_=
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MZIPI&^J+J!3+LOOK!7\KOHGYTE3@T4>A02XB78504L5_00@I33B4 O,TSZ)
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M^)!!'.[H1A:V:FY5;FI]5%.<$448HC!20D"4YC'$9O<2(X*Y0$AEW"OV]W"
ML1'#._I8KNBL_(>MJS2WE?8 W0FM?UCY]AU\!JH;*UP"5<]<T!+-EB"JK+6B
M3;_ !8E>@B 0 3Q[_*"?_4O*'7[L+U[7I80U_R;%>B9OU-5W6LYL/O5B:=(.
M=JG7-O(PDI0@)2@4681,*0D%*<\+F$4*ZY]D7!&GP$^O4<=&!ANYP8T"6\FA
M%AT:V=MU"WP"0/TFPL'YW@>\/1/(&)#U*:K< \)#%49V13I4+6-/J$[7(W9]
MV( UA3WUVZ\+['MSUZ(6U>I&F32!ZFHNOLCE]Y++ZLMB)J92&VTICRG,LDS;
M<R@N($N5@EA&41P7C*O,*__VY:'&1N9U/*@QWXS79%GOP7V3_%_$U<VD"X-6
MS]S\KH'(BFG3'3:" B-IR/3^<V@$2^Y_<:"!4_O/*?P\L?_L'5TW>GKU6<],
MW-5[^;B4O&S<3X\SV92"O'I8+%?E/^S/7TP&F-)8)BF),TB3+(4H(AC2(LUA
MG.=YG-*X2''L%UT62C2G3VK0$+1/LJK^%;3T Z*EH.^F,M $NFY&!YR4H3:Q
MNWEHZV0\[(U6EOW:>DW 03K89#\?+.36-RS@P;;,@<0:>*L=%LSG6_3 S^^P
MM;_66XDZG4X_\6;U32[KZ+]?Y:HI<4I1(F-]HS;VT@BB5!N I@^>R;"2J11)
M'A5.>55NPXW-_ML);#_9A1$9T":<=2X=0Q0<H7;8M0<%L&>J/,#.2KL-!38E
M43K4XCT/HL<&/2B8 ^W,SX$::$/N#,W)G?CYIPRW!7?6:&_O[7Y7-XOZTZ*J
MWBWFIM6IG'.]D?]4SN7U2CY44T9%*DF.8&KR+A%)(DA4D4(:1U3$4B8TB7PV
MW2\/-3;2-9*"/5'![T988*7U/&<]@;";$1L&MYZYMBMDWA;F>30"V8PG!AK4
M"CRO\*%=YW!'U]1W_?7-Z>QK);\LU.H/NI2WBUG)GZ9<QFDADP0FR!3B)"F!
MMJA0%B>4(8%ECKVXXL61QD85[9/7C:3UX2)0BR78Z &^^J=POX2U&VL$0;!_
M VV+SA8]O46U<H+?FS_OY(\5>*L_B;\'I)&S\ 3+[GYIG('SN\^H^SS#^]P-
MG3UXIOYU]5ER67XW1PF-V1QS7/ X,[W[3%%?(1%D/)$P2A#!#*<Q\@M5?6F@
ML1'(1DZP$]3;I78<46<7V<4X]>_R.H0H8"<05R#"N:*.#S.T:^FDLD=<1:>O
MO[B.O2V./T4X0RI!,<2\H!"QC$!"B&8!2@N][R QDZQC[7H[P-B^_OUZ]7D4
M_1QMJM;3]>K;8FD,BPGX?_KG46P2P#9-/M*L?:G>B.M-VL_%Y@=E5:VU06(]
M1JWB][0R)V3O]1R:N0-I/ 'F_:R]P:9J[P3HNQ^E[3P_\VPB^FPN70\7N\]0
M[T>*[9KA30N/:PMM+]7"]_0/7R&\?OQK507?4^Y$)?#]ZP+5E_CK4F^)MGW)
MLY22%&<%S! VU;P+#G$A)<R4BK BC.78BV1.#S<VRMD61C#5I6I/\K]>6%)B
M'UZW[SX<:#VSP-%"$E;8H"W5_7#IJX#$_F"O6SOBJ.)GRT8<OZN[>5+6G;>N
MYF+/I5)OALS6U.Y,IWE"TI06*20XT8:+8/9O$>2TT+N7*":)]&ZZXS;TV/CE
MD[S7._H]B?T-"4?4W4V,\%@.8'PT0EOS;$_L87PD_K@%-%H<!Q[<G/$#Y)BA
MX_F$P&62?Y6K[4JMBBS-)>>PB'@*4<(*R(14L,!*R3A2J%!>:3(N@XZ-KG:1
M,8^[R!BYJY3L?,;NA;P;<87&LV?*.E-SVIZX]V Q^:#4=\7D]I#C*)E\! 3G
MFLG'[NU&1_;DNG56\N*0C>]22IHILR>3A.DM6A93B+'>ITDF<I[1.$*F^J\[
M,WF./S:2NM'"4K-4@)EII])LV_QXR7<*W"BJ1V![9JLZ<J5]?K>1_1A]]>!P
M[@A=( KS'7U0-NL(S2&Q=7U,ASC&UC[T4TE9.;-9,9_+^V^K&_6UDG9S.N6<
M(!K'.<QRH?0NL9!0;PX9)(07-(E34\UX$W9^YQC2Z#2RTW>W'U5^-P"O62GA
M0L&U)ZEY8'Z:QP)#^ HNJ9;$$U #>J.@.5&W8@?'TR.^,3BN \4X!L'7+][1
M"ZJ3,8]N3QHN[M%+L[W81[\[.[KX:/7-_-\L!=_I3-HS3FWREEQ3H/F%7B;V
M?]"Z<IKC3/ HH9!3T_=9" I)1!C,69P5& F68=6A[_,E,OE\3L-U7#-"3@#7
M_[5[ZT;6>K.]W*IB+Y@ MFW/ME#@Z52GR1ZF%"<11CA*8"Y%"E%.<TARJB!.
M!,,JHICG_LVEAYW0_AO!>4VG-*?0PT^DHV]XJ*GIVUULH3;_!1_:,[*3'=27
MF"DZ^&'[CH#>XQ#(AG(H7R3+L#[F$+ ]<SL'>>@EKI_%P^-2?I/SJOPNZ^XQ
M)DKYXV(IR_MYW5R8/]TMZ;RBO,D]L_^:U27@Q?^LZX:ROTJ]]FN#8,H(B2.D
ME]Z(QP0BQE+(DD+!(D&Y2AF6!?(ZQ.]'S+$YDMY]T_^RU:-5K1/@C5)@M=,#
MW--R7H$W,ZV[K%[NJ#3D?/NXHUYS%H?Q6K4U!$TWK#=&R9\FH-$3;!0%+4TM
M_;=T!3ME:P>]*<U)?X1V<O4U(4%]8<&%? 6765] '_>L]3;:)9T9K0@:GOIP
M=:VW$8WW?#&OZH[CV^YE<B/KM,"");%"4*0BAZB(8D@P4S#A6#%$$I2DPK]Y
M8Q=1QK9B-&)UZ3_8:2;<>'X8?'OF\CW>!N:3!CM-P$X5O2$VNH!=UT/CBCHW
M,1W;'5Z":=".B)T$>86FB9< =KROXD5/[)@&O/.OU;R]"U5 !4NE8@7D*HLA
MPDA"@A($4R**0BG]=T6\TH!?'&ILU->(!V8[B3TC94_ ZL9S8<#JF<?V/.0;
MT/J(]#B/1JC<WY<'&C;W]ZS"SW)_S]_1I0"K22MY2RLIC,VG#;[:@%LNS6ZR
M[JZ]N^26/ID?7?U!E_:$=?5T/=<BV(.;RAJ.=WH7>F.KQ5>M<O+UWO1OTOCW
MI;CZKBGO7OY5#[%Z3U?R(RV7=5Y)D6%.28%A5F2F+@%1D'&4:WY"2.J_X$@A
M]R*O(])L;/S7;N7 :\?!FW55]Z2RB4:.GH'1 >U4GG9$\HZ(ZZW.T"H-VL"
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M".?\J*]P7N,,Q?'#&??;N]&3M;'9>3.<'9KAC;']FZR,93T76RY=F!_=[,H
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M+W<NQ8C@/"\*!0E6V@Q/&=&L+@0DJJ 44500YE5JRFOTL7'W1GCK#3P,OJW
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M)TH* 1,F37HLQI!DF,*TH JCF$2$IWZ<<V[(\5'09O=<6_R;]'(K]06UT1W
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M#'(*$:%8(,P846+CECA-)JY#=G :]$PI7^>:L.=;KZM'$687A$^S1U#4!CK
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MQA)4*.<^=2^-,C8ZM7*"EJ N)>@\0'5PEX6 JF\3JV>4/'QA(= :R 'V#+5
MCJYS$)ST;KUX\W NK7/R[_FQSEY\:=KEQC5V1W]<595<55=SL2D74VIJWD^*
MPS'7&\E40H)C!E&,(VV=1A+J-P#C0N1*,#^;M)L<8Z/1C1HF]W'KY34%/6M5
MNJ8[^LV-HTG9/^)]&Y4;L!='P;;%5%MZ#)1TV G-X&F#?E*\4N)?)ZA>3MWK
M]KANO/G7Q4+\4<YFGQ>SV<>ZP>&4\H(D7"$8BPQI3I0<$D)C2*(\S3!6J,!>
MG0J.C#$VOMN("'XW0H)&2L^-\S$LW3CL0H1ZYB=?<+Q)YX3Z@0CEV B#DL4)
M%0^)X-2EW3[RIO+%+5VNGNZ6=%YI>\M4$7K[U/Z-=1TSA8@J"(.<Y";1EE"(
MDU1302:*7/%84<)]OGWWH<=&"8U\P K8R2GO ;L;3?0#9L_LX86C-W7X0Q*(
M43P&'I1H_ $YY)\.3^CBMK*-:=]]H\M[;>DL/LL5-2DM'^AR7L[OJ_?KI?[#
MEDC[+!_UN_C-5&B>DC3AA D,<T%2B%*]4V,RXC!)28ZXI#A-G>JK=Q=A;#15
M*P%XK84)YUXV>@#9* *$U:3N6JM_O=7%Q]73:;I<O&5]3T+?KK0:_T8!<+<
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MHB379A9B,&*QRHI,2)G1Z7>Y9(N!P6V/.0B\UWW ZV9X!8*L9W;=20EV8DY
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M4&KG9I=SU[[FW>,H=@2S.>#I[-'B)K5>DX.)!E89DP*G%:O_ :QJ@4]F>YZ
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M']-(Q40F203SA)D05AE!2F0.D4 %H5E*(^75L;LO0<=FZM2S:A*H#@]XP.:
MQ\_#T-L,NSD0QC!O/9LT-^^N)^"]9*N]M*VK[[2<F3T,U!\L_$+-GKYUVM1H
MW3YUF@ F];42[#JK30!5^JTS@5KAMOU]3TF@77UO8@ZZ:>\;[,,]>>_C79+
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M8G#7A[L$K^3D\(;H97>&_Z,N:!YZNY2/M!1-SMR[]7*IQYG&F&"6$[V?4$1
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M/'1).5](CI23\WY$-^;ZA9HP';E\NIH+4]KST9AX?UTNJFJ*%"I(3@5,XD1
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M??,5QYKT\NXS/=Q]KO_X0U0ZX>VKWG36U1CUX1IY%#,D,!1Y0@!+2 (4Z1-
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M9K&:/U"NXQ<1!82B''#*":(T"2&RFD2<;F9JY-!9V61!%%6U)JHW]7X1:R1
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ML]7"SUT_,*=16[M8+>N!X&M1_:5KU'PHGTFQF#$6<THC#G3U" "C* %J34<
MB8D@0D",8&R5Q7B^K:E1PIZI@;8UT,8&?S;F&@[W)B";D84CZ#SSQ6#4[#,4
M+^/A*B>QIZ5QLQ ONWR4=VAPR\"#,QW(^E3.U1V53FE<_9BED' 8BP10J&</
M'"/U-Q*!E"0L)G$JJ:0V^8+'35B1Q A9?P^Z#7U4K(S3^6;?ULO'@I%Y+1O]
M<U#M.%#7$,S_(Q"U(Y:G9L=8(TAYA%((TCCG:J86$X!@G@,9LX2%7"+,\:Q)
M./FV(LO5&(@?-N</]W?BL5@L].J+$O4+ZQ+-QWC&.95II%;U,>=,CW09P%)'
M#$*1<XHP9(*W>'Y<&"IQN4"S:\SCOF0MC^ ,2,-3W*N@\7UXNV/<OP6->6?V
M#QT>X)Y%Q-6Y[7$#XQ[7GG7PZ)3V_)7#QJJ-'M:NNFVC;39#"&$B909D%$<
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M[;KC)\O_2BQ'X,(^*R9#B 90V;"BR>,&9O_K[3&]G=_F+>0BDUC-]D"4A1F
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M&<0:L>%)2'U(N,Y).MG6VZ0H];E]-F.I]R;[P(,O:N;R6&^WO5?3>IT_WA;
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M6.L4(< 9932A#":IU:'RV9:F1N^?%ZH5-537V2UE/1\M:GL'9#Z?A]>,:IV
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M;=4/LO'SWRWE>GR\!V:D_M:]ZYGQ#SIVXV"@/-R/K]:_UGX&]SM]^Y/V5;T
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MQY-&SFTP+^OFY>.RV*Q+PZPHV\]__T&7=8CJK_H1FUU\ZE&(4/G+=_J=W;E
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M?XX>5E9 >VM793=:C\#$+_H+^V%&^[92&_VPIK(9ERK@:9;!(&0<HE1P2*)
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M*&$RB16DE$<0I1F%C(02*A0IGH4D%<HI&,A^Z*DQ>W6^MC"GET98L-AKXF9
M.Z!/!4TP8AP*F>@M#!52H\\R& 2F-IJ0J<!.6YB!T!^M0>KJ%>; ;JLR#+)#
M>]/W0L_JT_F-EKMU1&]$G[4.E?WM.-P!\[2O<!AXU-V#.R#'>X0>3WB=V--?
M]86;XF-=FGA."$YC%&=0F*18E*$($IIBB#@7"-$8R]2IP(U?\2:W#M51I@]&
M2FV]_5)6N2G^,FX\Z=$46I[GO-K$#+U=\1@Y6BEI<F\K-<N>-L:%^F&U5K+L
MMNZA+]VP4S*1L-$CX?Y4L:+G@?4=('IAE)[+@JF@\[$HME*\VZZK6O7ZJ:4
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M Y7*#(=(;_@#EPV_JP#_"S;^SIC;+21#(CGXT>-!?/(,['2!:K6&1IL9V&D
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M3&$M.P:]-J"3B;<;=D"*+&N&+?92ER$F14ON,OD,_T=-CVZ\>!5^._[S">K
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MF+>7'%9?]6$>V\"L:]3X=Y _/FT-R3;E&QRS,'I-B1V%#@?S2/D:I?PSL-,
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M) XACGDL$5:<2ZLJ<5?&F1I%-9(ZF!P=(%J88GZ@&9AV&B%!)26HQ.QCGW6
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M.:=6N_VV".Y-C.IG8][!M]W#M[9 /R$:E=>1E:G%CO;@9ZB#CQK\S;$JU,W
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M7RXW6\1;OS0K,E\L+__ES >8==^=))A.ND]^%5;KI8_K29:2@S8.N?*22*^
M>*XR"=11'K)-/,K;,BCTKY"!3D4KB'\]67S_&3_XYR*7\D4GH$XX=Y;;"&D_
MNB]WY%?\W4FFE&=0EA@+GDBC!;', Z')!Q9MED+1@\B^N=IMJF\J]]4R_K18
M)EBB2;E<SB_C'47?AO/V-WX^\TO\(!*_36?I\E\7VU)#5^M%!<EMU(+D_N4G
MY#K#<@GIPT8K#S+7<;9&0PO=;];0^*OY_-S//L/98KF>6"4%SU*3!*"(C)H1
M;R,:4LA<*09<*%M%\S=7[84 WCX"]I9D(TCX!,OI(KV;I[=X)D^\=0A9 !)]
M0@:$9<1E%(X'#<)89,N**E"XM6PO+(CVL;"_+!L!P]>EGZ^F1?!;0">1HA$6
M/82DT<?RP9.@N26<::>U"9&+7.=0V%FY%R1D^Y X2*(CH^+=?#U=7_PRG<%O
MYZ<!EA,-VL<H#0'/'1YTPI(0/$>W6T0?<7E%X2 T[*[8"P6J710<),$FM/\9
M3J9%"//U;_X4)L%0#\FA34M(NDR9(?T9(6QD$)0I0?UA]N"^57NA0+>.@@,D
MV002WF-LOT03U@G^"\H?WBS.Y^OEQ9M%@HGSW#/%&#%*X6&G1#%K%N-MR#DH
M%GRL8AH>):(73DSK.*DGYR9@\]7_>)]0?-,\W:0MMI8PBJR\XYH 2Y3(["0)
MS%("V@FMG>1<^ J >6#Y7E"QK4.EAFR; ,FKE% %J^U_/DSGP":*>VV4!.)4
MQ*,2Q4*\5(EH'O O/GO!#\M'/+AT+W"XUL%QJ$Q; L8;_/+C\NOBS_E$:*8%
M9Y9 3)Y(Z3VQ5GK"O0GH/#D9G*L'B^N%^V6LZ M!Q9X";0D3W='X<?EIN?@^
MG4>89&!6<8>N=69H]$+FQ <1"1J\3*GFAK$:!\K]J_=#1\,)S6JB;0DBGQ:K
MM9_]G^E9YSH9;9U0G!)TD1+&7BD1"Q&( B2?^1@"I'H N;5V/W@TG.VL)-:1
MP5&LWJLE^(YNSZ@%:1D!0<OU(7!BA4#BM3..*1IX/BSK?7.U?@!H.,6YM^A&
M5GFY+)U]^K:87V9@(.:<07OB54"X*AN)C4P0X1V  RN<50>I?7?%?JIO.)5Y
MD A'5O\7B.=+A"[CX>MT/4-K)8+75DGB>/0E*4])X 9!#!R]'>XAY<,.@=T5
M^ZF_X1SF02(<6?U?E[Z4HWRY. V+V20)(Z-'"6!HC+@-6A#''"7&:"ZU9"#2
M81'EK>7Z*;[AM.7^PFMDT[_[$;_Y^0ET^5:0(AHA@#!E&**6XG'%().8G8V6
M)6V8J;+Q;Z[:#P,-IR0/%F43X<#?83;['W,,=K^ 7^$YEMZO5N=XD!GAI*)"
MD 22EA2J(MYG3135-L5$*4N'8>+1Y?N!H_DD9 WA-H&2_UC,SE$!R^Z^;KF:
M*&$XE4(1I;,KQ1RVW-0* EZF0!F8K ^KX[IWV7ZH:#[[>(@PFT##F_-ED=?F
MUKX<@ZB$\]5$N.2 1T6XSNCR1,^(51 (8MQK&I4TKD:6Z?[5^]5,-9^#K"#:
M)B#R?HZ?AN*8?H>W?NVW;$VD@60TAL,NBXR>DO$8&'L@3D8TB)HZ'0^KH7IL
M]7X0:3X164&T34"DLWYO_!I.%LN+B3">8?"LD'RT?U*I0(+#/V@PB'3%73"\
M C)N+=H/$,VG'O<79!,X^'+J9[/7YZOI'%9HZ3(U0FM*,H5(I,D(:.> :(K_
M%H)+8$,%'-Q:M!\.&LY 'BK()G#P[A26)WCD_6VY^'/][<WB],S/+R8>@Z:L
MHR,1 R@B'0+;9NN)\BY()R"F6.-.\][%^^&BX?1D+<&.C(_W,2]?G:<I_L:K
M]1I6&QW\,O,GD^!"X"[A66<B1E*4EZ^R+^=?5-XZR?QA/N?#:_=#1\/9RTIB
M;<)X?/F&H?8EM+G)#H]!1QAW JG/&;T@J4@L5:114$BYRAER8\U^8&@XHWF@
M&)L P:?S,)O&7V8+C^XPMR(::H@5I<Z+:DZL%!&#:NN=<ID+7>-&^\:2_2#0
M<$+S,"$V@0"$[FFI#%W$/[Y\0[&M/IZORRO1DJR?!/1[A J&"%6N9$00)$3I
M"<T8.&EAK) US,)C-/3#2/-YS6IB;N1MS^JZL!C2ZXO/A1*81_@*/]:O\9?_
MF-CD+,12NJ$,H+<4T9M&(TA 9U;>. *>B@=AIS<I_2#4<!)T&*&W87Z0K:6?
MO9\G^/$_X&*B;;!:&4' 2E9J2AGQ#C1!'RKJY)V6@=6P.+>7[?=DL/U4Z '"
M'+N8:I.3^V6ZBG[VO\$O+]\]9L<Q''>,Z"P<'J@&A1&<)RP!C=GX#/FP_.=#
M*_?#1,.YSRHB;>2XN6;B%_S.:A*3B)0Y3<IC>8RQ7"!>.45$3-R'2*F"P^Y:
M'UBX'R@:SG_6$&A3F-B\DMXRH0 ])9$)*/2[968*W7":B:?64Z&2Q].Q(BIN
M+-T/%PWG0^L(=61DO$(.4L=%R<A$EXVU'"$=%9HY9)PXG2EQEB84 TU<'&8C
M;BW7#P$-9S[W%UXUK?_+SW>$]P&_<7 #H2YE]WZ>%\O3[D-O$]ZOC]"=SZC;
M3NAQ$@_L*E2XF>RN< 48A^8].8PY69:\O!VF!#7/"%7&&2N#!1.?DLZC*QRT
MI3?9UE^FR]/W:8((9MDY0VS6ADA68!V$)#9RRFSV,LC#G,%;RXW35JB>LF[M
M[KWE.+9-WQ"^*17T5%L6:+FHC43:[(BW6A)JI HIF!0.]/IN+#9.1Z%!E?]L
M&;:A^@_;#G43SFV2+ #)3N'))BW?W+]I+;-2+MN<#DM0[RPX3B.A02&PERR;
M/]_?PBHNIV?E\Q9Y_0VNJA3V..<?_*RZYWT_D@\\]\]7Y,3[L\FK&$O3A^G\
MY--B-HU36%WA22D!.I0NE@X0!S;B5R%9(G4620=AF'S,I&:_"IW2MTMM-A;,
MUJO+[USOL*>IV==87'[R;WY]OH2/^>,9;!I>K";.Z,RE1Q^8E=H>0(_6 H:Y
M+$,P #XH_=@#K7WXNTO%.(Y$9>U?6I-*PF[>J+Q!CE!>J<NU^UGIF_KE&\!Z
M+ZOR\(?5[DK:B^A*=J5[V5U"QH_YE^D<%YOZV:?%ID'9]8EE,G-<),(X'C<2
M,KJ902KT.CA$JQQC^K$[Q'UV8!^Z#K4UKU8K%.L5ESKF9,HK1L.*1^VT(#XS
M1KAV)B7%G>"/I9[VLJ.W*!C7QE1'PJZU.4#<(WJQMZG?)N2OF,"(RR=O$TFE
M&X(4R9/@>2244649</3SXB"8V2%DY./I ,W>"Y)#Q-P 5M[XU;=7\U3^\^X_
MSZ??_:S<_+Y:O_'+Y04>XO_A9^<P,8DRZ8,C65I%I/<8RU/!2<Q*:A4\$^ZQ
M>])]L-.+L!:P=!  %D-KHP&(_>J7?\#:AQEL7V2B3WCY*,):(2S-EB0HM2B.
M9^)\8B3(J(TUDC%7.R!XA)QQLC##P:F6Y!L T3:L6'V&"+@OD*7?8'W)"Q<>
M\'^!I(#;0,I@B0^)=I73264;'1\HK+R7GG$R.</!J)KL&\#1^_EWI'JQO$ 6
M)BYY9#MB+ H^8ACJ2Y=K9DE60@NAN)7P6.//?7!S<_UQ^D0/AY.]9=L +CXM
MX<Q/T[L?9S!? 9[!']??8'E+1I/(;,CH,.*16Z#N,Y @'"TFDPIO2K,Y71DN
M/<@:I\_T<"BJK8D&P'6;>$A1YI@<H=YD(J/+Q#H,44W2V0D67>*//8DY.! ;
MIR7U@,?3WM+='QJ+M9]5LCN+,UBN+S[-?)G'D8K;?U92&\6&*@[6JI2(HM83
MF:A%7F0@-E-M#,O.0^V0_3%Z6G"/JT3NU83>@&VYS\?_;3&/V^T0% A0QI-$
MR\T;'L$$Y>.)8L%*KA(#\U@CD%H!UC5%+3C'54!44? -P.CM=ME2\W\*7_V/
MC:3*AH@N2IV D4@#1HI4*>*%#80S8P)H%9VI?:GU,#4M^,Q5X%-)X"-"IRL=
M>(_2GY],<1?<]M0FU%*C')+N?!9$9BU):;!)E,N:.TT9W^U ]$"=UT,KM.#W
M'H2$>O)KP'[\;;%(?TYGLPD'R):92)@.#H]/,,2)&$C.*!KK@WV\@\P^UN)R
M[18<VRJV82]A-@""+72-EM';K G:,4JD2H(X10WQU#$MC2[UO(,$..,,41GL
M:NE9@FP@EODP]6$ZZQPA-&;=Z]-OBQD*?54<[/7%]=6LH-PZ+PB/ID1[4A,K
M521!Q>!8@!0>G<2T#T#ZTC9NC#/XQ?8@*FK \MS@:S>U(%/2BN'6 <4BD1&]
M\>!*9!<BU6A(J0ZU+P<>IF;<"\MAM/\PQ Y110.@NKSW^.0O2IAWF6'* D)(
MK'033AC9163%,T%)%CHF*)7MNO9E^/V4- .F@_3\P&73 4)O #KO3L]FBPN
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MHE35[H[T(#&-O-&J@YHZ(F_@0+I&_66^<SH_1Z:VVZ)<)4->+.%JLC>LWOU
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M>O)F8S++_-R<(:XW;Q4^YE=I<=9IIP2F6NNL'+(2O49[Z4P@(2E*F(B)XJ[
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M3E"9MS86&OZX."^-$^?ITQ).I^>GJ_?S[[!5Q<32J'30)3E;YKVZ;NP$>"+
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M@H=L"##T,*6VN*5B$,0#U]&99(6J?0':D[1Q35$UK.P:HR$4T[PUNCGLZ$H
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MR[HT'NI:]EP^TIEX!HJ"]\3*TKR.ZS++4T<TZT8H8XU2O':OVQYD-5_$5 >
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MA^2#,"D-AIO'U(S;I?94&#I2"V/'.V[%0B)Z?;T@=_IZL6W@IW6R7#$',?,
M*C$.WJ,#FU AFE0"WZW:ZX5%QGFX/S1(FHJV@R/GW>I37KS"+]/538#O6;EM
MYX)%CT5J 2P5"4ID79LV*A!%%E.;8)CF5=-[DCA.6X!3'4Y#ZJL#.-:$\S5]
MW$,V5'*\,$'VI*+CEC:2 B<L ZFE3D(J<J-=8]@]0\HX+0-.!:\6\A_]XIO1
M!WU93)?YW].4M\WRMDUG8RS6Q5+;UH?Z]I?V@[8&BN,N2UN?3Z7=;KX75AFG
M&\!IKKY6PAT;)>^O%_%3K4IYP(/DOFBO:RUM;; 2/3D/:#38@EE)+X-P92>
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MF=E&UO6[Q27.IO]STWSREJJZ:V;I_3U&[TT$OZ7SKI@[IX Z>X*XT.1@QE@
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M'5&E##DRY*EX:4OK\L##J1TW9SP^5$^DYPX0_9;NM<LU)YM7=%L^6.(B,(9
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M6!X8K[%*E2.@,P&,)YDH'8H4K3N -F5@W-AS9Z ^3*T_"J;ICQOFHXG",),
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M<TO#H>3AI76L!CKPZK8L3 K/V1O!(.D<R5&0!KR0$5A2PI>H2[2M4Y?;M?N
MR\%*? 84>TGT8"30M3F=IP\K7*R:XN$B_K_K*1'Q,]W0L\OWZU4F+(AL#9E@
MG*V%43(X[Q",TD:ID NSK=,Z+]$S;OYP*-P<+?F.3I6/"YPMKVY4,DOOKQ?Q
M$UEW%W'M'1)W%^F_KF]&Z"XG+#*N(SF&/BE.+-9Q:LPCD.B<X"QZ'UL[50>0
M.6[6<"C,#:6GCJ X\<IGQJ.NJ4X)RBGB@$L&NJBH8PY2Q]85N'M=<(,E^P:[
MX/:1Z)$7W"^S= +_?"?7YY%-.;#_]]QZ(WA].[$^BJ^74>; 90:K*Q25]1!J
MCS6;>6:6S*WL6S\3.:FOM]7!NLAWNLIO:XO*A\M^7 ^&#S[(A"[0^8QD=GI/
MI@)/9';*6/<I-SDUGXRU,W5]F/KM,?5HHM P^NK@/GV!GY^^_H;_-5^\NL+E
M\N*?Z7)BK)6,F"&/FNM:85GKC*0&SJ7CKJ0!6M;M0=ZX6!P*(?/3J*MO)-XQ
M]CM^SC_/ZW/T210Z,^,#V+)NG*\%.%$"<!5\)E':PEJ71>Q)XKB(' PJNT/R
M:+UU ,N/.7Z:S:_FEU]_(A_J,8OY<\B+24G&.<D$2(,D0$?;V>L@0<3 ,_W/
M2MNZ1'$GPKJ%X/'0F ^MIP[ 1V;,:C$-UU5AZ\?F6SYDR#&(VD_1"R1)<01G
M/0?-96UF;I*-K5L!/$?+N&&[4T*LB38.1M5?>1'FC7#UZGJYFG_.BS_R391H
M^6GZ9<N,EAACH#WAF?0W)49>1P8*O1;>AL2:9PY>(&?< -TIT=5*)QT<6R^(
M[>UTEM^L\N?EQ&O,(GH'P3#BQ%L#OKZ?X2HI*[-DRK6N\MJ%KG&/L_'=B,,4
MU#?H?EW,E\N)98)A</6!8")^M*RUDSE"2"F+6M&4PPG=US5-W9IG!Z)@=YCM
MKY(N+LX7.+J(\?KS]56M5KSX/%^LIO^S5N3$*\6]=08,5U@'K'H(' M]*Q,7
MC"?7? +D_E1V:\0-#L06:CNVNO7C*0[!W_-J8I'H9KH^#929[)-04SP8P-B<
M4I"RZ-PZKOXR1=V:=X/C;E]U=#^3ZH644^M!58<N=;(<V\E'6NV7"C%<)*99
MKNE^6]T4.MN4DU"R%&CH9$NQ=4[II.FU^P?YNT=IS@DOM<E>KI6!6-UUI6KC
M' XIQBB*+](WGTCZ,D7GE$;;!SL/C\.&>NG^<< .&?AWY9?E:OJY6@"OKU=5
MR/?DLYDO]EA,PQ8H'$?3R8L8&HIPE).88TXR:@;%U'ET*<G:$13)U+2E>)>S
MD*V=@Y.>Q"\9WH\U]:BG3U+12,\L),7)]E*UNUF-LV(@\UPD]$6<TG?Z/L7G
M=)+O@[U]'*K&>NT[M/0$M]NV0"Z07!E3)-_@ZUAC#ZX...9)"9Z]4*YYCN8@
M0ONHN^X-LX=H\3RANNXAY'CD.3BRN(J4)-A<&Y]BAF2U]!&=+K'UZZH#2>VC
M9+M+N.ZMR;,$[+KMD&/>6EX2Q))J W49P>6:$5-6%,&59N6$D:P7*.VC6+Q'
MN.ZMQ_-$:^T-DSU:7UB!$.IPIT@R=<X8VJ(FL&AEXGC"6K47*!VWE537:-U7
MCV>'UF_;&662H+&Q@"NB!GLX6><U-JUKCP:CHL+0NNOO$>2.VWNJ5]P>KM&^
MP5MS)X:S.N7:DR&NS4VI32B&@W9D[* 008K63^,;I+(&:T;5!03WU4OW.:U7
M\\^?IS</)7&67LW7KR?S+$YS\YS6H4NU#;DV8;A1)/4>+1</:'D"TC&QH'3*
MP% GH*\"!"LS&$>W-(&OB-+ZO?%>!![=2FV^7'ZSQ*8*+%L1.*Z#:%A?DM/Q
MGK.&FK..EO8Q]ZV')#Y-R;B1S^&P\JA7VO%Z&/%R72Y6D[>TC2_7FGE57X77
M]Q_6:YL5705<*P6*URFBJ?;.MY%K9HOC>:>:7_KX>PBB[^[0\_3*(X\M:*#+
M>3/!=@6+C_0O-D7-GKG:[2U#2*56J41)-[HWQ))QR#+Z%'9Z:;\7..[6'P<B
M+?3Y+#0.%.Z( *GVRN2/_,]O.56#X>W[[7L:30>GYK0W4GWY($@>3J8(,15-
M_V<JF/@]R^>9S^Y%[X<J:]Y.<AUX8X^.RK>W!7*29U5<$I#XVIFH];N1._!%
M(5.%#E/1.A3[/#4C#R%I=Z$T%GP'$-KVH;FSU6X'2_]&?WZ^_GS36/;F[U<Y
M33CM#V=0  NUS2QM,_)0 P>)PB?O6%*EM7&[-Y&=63 'HF-^2E5U@,6[(_Y#
M7JVNUA/W-D&S2;1Z?<T#=ZF>\HR#BUS0YF4%I=$\R-:IT!?(Z>Q :X.O5N+O
M 4G?2.CKS_@9+_/RHK9ERND_\.HZ3[#(5 HG/M Z4-DH<+Y$<C>]=,XFSW7S
M,7+?I6KD>4D#X:JM,KHO,OVPFL?__C2_(F4M?_E_]%M?6X<E]URA;33R&/8:
M!2$WRVXC1TEF9P,K0#9<!(4F@N<Q05&!:4*59Z)UU[EO*3CZY7=]L?RN?%QD
M)'E_74OXQDC-T4K:8!P8J\-LL_.T,7P $8IEJ&I?W=:/ IXE9ERCZ@B=/WK4
MW43<'5QSMW.);X1#AM^7^6P=;JUA$6U,-DE%0*'J(&2I(*@L@"-Y-W1F"^];
MU^F^2-#(P>@V2G_8@ZR9!CJ TP,>-O&5+*6RM;A2R>A!%6+"J2B 7 JOO9?,
MJ];^WI.$C-Q*K)VBYZVEW@%TJL])?D/=5)M0FLOH>#%U0_':\Y3DXHI-P!7W
MD665;&Q]^CPBHH<;ZRC%/KRXCI)R%V_U/WPBV?V1OVQB&>\7\\L%?EYO(B(Y
MVQ B:,U(/"+;.D8K S*.3$>?@VG=>^1Y:L;U\ >ZK-K(OH/CYFE.M@D!$HB+
ML@Y]KJ:A,0*\(V%IDQ*)RCA76A<AO43/R/=6(YWO!*4#%#!V^NSB^O)ZN;J(
M,5_5X4@Y/<W9MJ<8TSHQZ4"2GT&<A0#(,Z/#6PENE;:/6C4\DUG;:]D>$72(
MJN<GD?O8B'H75W.B>5?6F#2Q9%6 D4,+2A&3*%5]7^T"[4;'_</3ZAE([;?N
MR!VU!L'4@)+OX,[;F)-/6 ;WPK0Q>^\-^2$^D?Q<\8"!_E#(LF$N6<%:UX?O
M0-:X4>UA;*G6VN@ 8&OJ'YL*UZM/\\7T?]:=F*YG*SY1*%'Q;, DN1Y!F>@P
M3@QREL'+S)C/K8LZ=R2M"W^O'20>Q9K:ZV?LR_)IGJ:S6,67TVJ.M^SAS8#;
M&+(K7"-('R4HQ@PX+!F*-,6@]6B5V.F^W'OI<:_,H=!U C5T>[;=UD_<;:*[
MW]EN)RYC(/O#@ ]H0%D6P-,>JD\I<E(L1.2MLTN'4SON53O."=A<BQW@]7D;
M=GE7G+&90?]N\4>.>?IE->%"2YY4 BOUNGS10M!<0LV5N<QM4,UOYH,('??Y
M]= H'5YW'0#TP59,%S/:=*N',Q77_"\G*,B+2^1?16<X623%@4?AR4!Q,M/^
M$Z*T+M[:A[YQWU>?^-!LIZD.4/C"5GL]G>'5^\4TYO<X3<3D^A?(./99TO$/
M*41R^DN-=\JB08A@:@M8IIMW6=R;R''?38]X/#;0V=@.S<7EY6+=/_B/G*YC
MU=F;V;VTW<V6>[ EEY-D,07K-&34B@Y_%2#D8 "9TA$C]VC<3D[-0<N/^TAZ
M4,=F>'6,#KB;FF_:*)<Y?9S_4<ON9CG]@HMJ$B^?X=!;H9-4"-[+ BJCA^",
M D.L6:.LYDSO!KA#EM\)<.X\ 3>X.LZP_O6N,>@#SB]H2_Y%'Y./::!ZU'I#
MU\8>ROHPE;)>J.Q8B>#0B#JR1H#+3D#P)N6@G;>L=??#4U7*RI*$]9+L@^1]
MG;Q2P NF(:*22DDN7//IM.=1*;N/SG>OE-U'W!TX"B^4001&YVU,&GA>]T99
MG\)T]EJO)!.8O2C-RV2/*SL:H49V+W7O7G:TC^R[1=$F;>U*L4S3[HIH:XO'
MPL%9J<%JAM'8J)UK/A/Z',N.]M+Y/F5'^RA@;*O]G@_R7'E"5IH[1EZOY8+V
MG1:TY3"1ZXNT!1UWVCR,5#QCHG]_K1ZQ<HA2Y\-)N(?3Y^42=)19!<VAL#KE
M$+T#IYF'I#UJJ9CEV#XK?^QKCQ$*:(^ZR9IIH ,X/5V>'KTS27FB7R7:;[Q.
M397U#]H.3,N,9$G^KW_ML8^B=WKML8_4.X#.XW<(*C.F'2<G@]==Q4VL@]GH
MV^BDE228T/RMV5F\]MA+L=]][;&/E#N R2Z!-A43=S)G8#;&6H1)W.@B@=<L
M%$O62CG,V]VSK%@\YO)JK8T. +97:M.Z$+/+#K3*G&170AUD59\[B)QB3):V
M9.])Z%%K%_<"QS%)Z'TTU0$*OQ'7121)$@T7?^4%7N97\^7J-H^IT=M<FSOG
M("M?F(BO0'QER:SE#!.VOB1WI:W_VL9CT#>(ACI WFZ[ZJ;%BL(DR#X58$1M
ML8+!D[/K+?@B)!FL$BUK'I[:G;S^ZQ:'/_WVU],9I@+O7*EYN3?E^=WJ4U[4
MOUOD3WFVI ][,Z-/R;_GU;Q\Q'^:I@>/I&'HE&%+$0V31BQ:6,*D!:Z" >4$
MAV"%!J9$0?H#76P].:5M&G$'L=:N53=&-TM%IMK-P:,CH]M:!2CHVY)XY%I$
MY4/KZL5]Z.O!<#P(&4\4A@VCE"YNZI<"2H85'6*)H$4=9X>!$3.I0+9)!QDQ
M%]XZ=]UQIY[A<+!7.'<?I72 L*?C3Y8EAU8A^4YDQI)M@>!BX,1$B"QZ'3)K
M[7*<73AW+T7O%,[=1^H=0.?>AB-CXE?BH.ZOUR3&G_-R>CE;[\3%_[W&JVGY
M2N;J*UQ^>GTU__M?.5WFY?:)?DC9<9(=M[I*D3/P/I'G+H+56I+_U'PJ< NZ
M>[@]CX+/\Y?H:739'7[_G)$#=U5?@;V9D<&];I2\E<.&OR"RE[8H(%>.?+FB
MR<T7R$ HPYBWROC0NJ79OC1V$9 9#)>-==07!C\N<+:\NM%5^J_K&^XV7,7B
ME??<$B^>1*@B;:I2.RIG'6VJYK$<X(7>#I1U$8 9!F^M]-$7RG[.I1:6_Y1G
M],7J_17Q^(@[G[T127I@R<0:2*]3AX,"'J1VB;O 3>L>U_M1V,5#T&%0UUH_
M?:'O.<=LPYB6WB)9$2",Q]K/NP#69@%D85O.99%%M*XSWYFX+EY[#H.YAEKI
MHEGDCI& >T'Z;!G)D<Q5$VSML!G!T0X#)63R(0B30^O6?_O2.*YA=[+8RJ"J
MZ^$L?/?JS<5JM9B&ZU45UL?Y^[4"R+A]5Z/Q?\ROKE[/%W7(P<1JYD7A"B1B
MJDU:#;&6/"0D-ZNX$%5N7>.R!WEG$>P[$"</03F0TCK X^,TTB2B3D;0SLTR
MU@(TND^\5PE,D$H@F18LM.___I"*D=$UE,*?2O >+OV#\?/EIFQFA8M5$Q2]
MM 5_RF5>Z_1C39-/RS2NM;C<BG+B5<C%1 ?6F[H=8X*@90$R*KP(1FK]L#'7
MT7 [@MR1K^$3X?)4^NS@ 'S(2 UY[G"YO+I>5,'?5&#<\BY%+)ACANAJ #0[
M!ZA)%('I"D(1>/,J^);TCQO,.16X1]/X_FCW-VB?K5M1I,&/ZBU7[^>+M=*?
M4,8DZA C6@$QULD!QG!P*6M0(:'B#$-@K5VE(TD>-UC4PY'=6J^'']OS%5X-
M9;=JX70Q!@&#1;*<E !4*4+6DCDEE4'5O'__87;K8%&B$>W6?:1_I-WZR^S^
M47BZ&L27MEC30L-=%AJZFG!O9H<I&90I&B/)?#3.<E#%6$"Z:@%3PI*"B\FV
M?GW1MF3PY7#92T<RGX3L0A$:(:"L\Z8U[:DH S"50I'6HC2M:Z^/(+>'DHB#
M<+//5=I29?V78=?'#3_5RO,J#1+%)AG:>"KI_JLT/OR.9+/1R??S=!FOYD1>
M?E?N$_)'7OLE]<')<DUJJ*1N&L$N[R9;&B98E)&N\D#W>10.O"P6LF?*>^V\
MEZ;Q87$<Q4>;@'<MLIY6X&*!L\MU_=[RIZ]WO[.A8SU(>#/003F6@K4D,$7R
M(PL8G*J%?5;R&&H3M=!:=,V('_?4/2%F']F@HZB_@XA5K0GX'3_GFZXX6$HB
M,4&N@3;%7(8@R7=+F:ZYDD1THG7T]/[Z(]?GC@.!>2-]=(2E33U!\,IZ*3V@
MU;5K3K80N/(0?,Z&[FLG;6L7^EL*QL73X9I\!A('B'7L#E,7G]>VS/JIX7*U
MKH/[FT3W]6.^:2E!IC!]2W94Y7%;("*,TEX7X"K[FS(4U!9!U-X"UB:5XG>M
MP$,7[P,QARAZ?D*I]XJJ_R\OYK]/9_E9)H,7R+2C,SDY 2J8VDT9%22O.*,]
MB/YAN'E/:'V/@G$3?D/CJZG\QP;9Q[_G'S_-KY<X2[_/9[^0[SG_FO//TT6.
M]*^6:Q[??:FJN\=@<LX5[A2=\,A!<9_ V61 :^3HBE7NX1NZ9P!VR.KC)MQ:
M@6MPN7<$K"UW:Z;>;]L#WK&E0A*&:3(3?!W'XAP#=(Q!09%-*,5%Q?>%TW?6
M'#>_-0"(6LJX QO[QLV@7UZ;E1A9\#IK",QI(M[05[5#O!?*24]7.>;FM?7W
M"1AY@&L7'MOA&ND 3H<+[H[M67JP;46*Q6;+(29#1W)0!5"4 IFL2N.-U[*T
M?MDV!!\C5PT>#JNG^A6/J>,.<%X-U<4TUG$_]1[X<S9=+?_X\.?F#G"8N!;<
M@L2(M:V=A( *(1O#BPK1>=OZ&'V1H Y:(8^*ET<U5JV4-[;M=S&;7>/5KR3)
MU8T-NWUHZ@13ZW[D*J]GRQL)+I/A(X@IEH-UP?B=++WG5NA@U'H/D&JGA;&A
M](9VP?1I+C(K5G,!0KL,JL@$@4Q<<$47'5@I)>PVG/C9)<;U-/L"4QL]='!%
M?N,H;=^&>L58)(\KD<D!2EH'H7:_%ZQXQ/I:T+4.X3]!QK@^:3=P:Z6HL4^N
MW^?K=@N;V_QFSVR'(?C,G2?O6SA1V6 67+W53=8IY,1K]'"GH^OY-<:MJ>P&
M3"TU,3:@-D<PF827]13>GK]68M$V)C#,,U"L=CS73H%E,FD7?/%FM^C9TY\_
M[H#4OH#40 -C@^CW_/>_IHO\[17.?6!&EPA28*ZMS@WX;&L/?9FX4X04978[
MCY[X]'$GGO8%H*.E/S9\WN?%NJYO%O-::FLG]?V'/[>\L%1"SFAK[::MDG'@
M329!T5>::YYJR=\N2/K.0N-.->T+5"UUTH&!OA;1S[BZB0@2S2)F2\=JKO-?
M2A: =415EIASL3XRFQN;YM\0,+(/V$_H_R"-] 2GS3;C.GNG7 &1:Z.-E"-X
M9Q"$D,+1?I!.-!]*_RT)'03<#U/F<[ X0+)CWV,7UY?7R]4ZFK$MVI"*28,>
MN*G=R:(+$%B18'CFTM?:6K-;3<.CC^Y$WX=H:=Y,9&,K_'4.BVM<?+U/O\<2
M2M8*Z(M"YE;T$.A2! S1YF1BRFXW-_R)#Q^YYT$KI1\KMK'5OA9$3JOY^K1+
M6ENRICQD5=LL:+=^>4D"T4JX0A(R6>VVQ^]_[,AQNU%-A".%W T\-OO$,.&U
M)E,9___VOJS'C21)\WU_Q6+?;<;O U@LH%))O5I4E;0ZNC%/A)\2MU*DAH=:
MFE^_YB3SOH*D1X23U0UT5B9),>SXS-W,W-Q,EW101E0;F_%/DW!_I#H[1O8#
MR)A;_K'*>5#'!TAJ;"U?9I(O Z)@>:::4LB>E_:C'@,B;P3(K'D0WAK3\13R
MSA>WH.5#U#.O)*L1];Q<K":7Q9.7WHDAV: +"S+B7B444;BP:5ZZC.0RV$_&
MU.D6-'[U#2<?_[IV\.\_=9QMOQH$CA1C ^'>LYO@8WO@;U==[ZSU1 2607J!
M*Z/W!'R,"2P)W! K0ZI^/>QXJD<^[VDB3S&P[EM!NW^>8W^7XU<_ODT7FP]O
M>S--N%><Q>PA*";1J<\*'"466.EEXQ-W0E6_SEN+^,;KR"JC[B'0#PZ!5K!_
MB-S_6)>-;;=4+5^L5U_FBS(>84*2=52'#$$HCP)PLDP"5""5-\RQF$BL/AJJ
M-A.-%\ -8 NC0:(!F[@QQORE^S9=N8LM1^\1!HOO*;Z>+UZO5^M%>K-<KLN!
MT83X*!V1!$+&K59H*\&I7(9>AYPI3<+>C86.QOS>1#9>A]<OIOM5:0.8/5B^
MFQ]_3\O5U517.LDZ$XU13YFAQ$#P\IOS%)AB6:'A\OHC[FO2WW@)8*.K][%
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M;:1;E:QN4#_+@[_QU'O*V\&=\JGO;GI1BGE?SQ>;P],)TBJ48+',R<MHX):
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M<E+$@(HRC84J7-%*^QH2N&*XI@DBFND?WX\(3C2[<S)'&;W!\:S=W>[BFYA
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M'C(M'=\#!K..>P%4L$B%-PZCV/9L<2\>QTD:_F6LL3^\G8(]5O+;47]6*9?
M24I 1*[ Y*#!.^5Y=L3;Y,XX*JR>ACP3ZQL!72=<0WI#'/AS)X(R"& GKO=%
MK/5K1_=[[! UHT<(HHU:T425IX%;R(A3C)]PJ_".<TC&)NFD-:;Z:67;(QBW
MY]LOUJLO\\7TOU+<5/[>..[>%/_^\O.6V6^TO!V$$:7B.@4)W"I< #PZP"A#
M#Z51E=.E-8X>>B[C<1R==.WH/NC>=UCC@$!IUCT[6 :;\7!)2TL$XT!(Q(A1
M)UJ*GB@DIGC0V47EABF-.XJ-MJ=)#HG23C[7<) Y;:NY+X#=R# 3/(\B4G!$
M1(SK2"K7E!P&=TQ397.2:9C+=D>QT6+U]8#0K&<J57 R=JN*#=UO9VDWO"YG
M%EDV'$,[;4!PKL%X1B":8)(WUJFLGHL@'OC>D\5<'1W/ZPB\":Q\_.=\1SKE
M620=!3@1,HAD(QBB)8+!2\&"]/KNI)>GL'+UO2U6O8^)E<,$W@964.WIBG@9
M@B%(?"YMZ[,F8$.4$!,7TML4]-WNE$^BY?J;6RP?'Q4O!PJ]"<2\GJ\7.]IQ
M4P\J:0HRN.( BPR.Q0A2Q7*CG5NB?'? 7']QB_758^+E0)&W 9?I]TNH$Y\3
M(<J 9)XCU$NG<J[1)S39&F=TS&P?N%Q]<8LEQJ/"Y3"1-P&7#],?.])]$#91
M9%\[94&0R)%T@[_)['@D7!K%NJ/EZGM;[$LR)E@.$W@;6$G?TVQ'?/")!F\\
M<+6Y755.F2QUH%+(7"KK"8U[H.7ZFSOA1?^%\'*@T)M S*MR.GFYDW)I"<.P
M3D;I,*S3%HR,!IS,GL@@A8Y[Q$8WOKD38LQ?!S&'"KT)Q/PQO<H#!$Y]BA3W
M4EG&N/N@P02)HI T*"XE-?L YOJ+.^'%_G7P<J#(FX#+QZNU,?$HN<L4HD*J
MA60!0>X$Q(B[*=%1BRB[H^7C7ML1)7\=M!PF\7,[_OCM:L2,--08KLJ!KO>E
M/9L%KY,'98+"_9A9SX>YV',L)R,G&<_RZ+ 6<,[.?.;_3(N=/+Y.5Q-/K60$
MF:<EERLBD6"H0#<%7Q;6HH)D[29Q??)S1F<[!^*U5Q,Z CSG9DB?OGV[)0LM
MDB>"*, MWF*$F%!)FZ,TD:EF2:5DAQEX58>?,SKX:M"0C@'/N1G2MK7#VWRC
MAG97-3OA7!F'T0\0R22N+S2")<2 2HI*&A5U8IB[H]59.Z-SP@;-JQ*D6K$T
M7TDL]\5QYQ+#^U3"5'S[Y7RVJ9Q=NXN/:?&534S66EM4J,F28L3)4;566J!1
M:,N,EZ&?_CSCLWY&)[05+75\O>P%R;^<)=_Z)[^DS]-9D>$O[J+,P*$3E63,
M7GI@,1@0QDFP,@A0REIB7::AG^FLC?!_1L?HIVC3%<'9BF'7N5/X!I>XZ6PY
M#=M)%"Y0261(((34*(AR=9?(")[$$)/.0=KJEXCZ8N:,BA'Z='B'ADVS]G.D
MYW__"F81"S<BR3+&6:%8:"G,MQH,ETYG1FE6\A2"R?NLG5'A1L/!Y)&0:L72
M[NWR]Y<<_\B2<T,"';UT.O&64(FZ!)VH*%YZ DMQ1S>::&4EEZR?UD/#LGE&
MA3!].I3M0*U9:SQ0:_<7IZ=\;EI&<O"0J0$F/2Y?3"@P4C (P4<IG2]]IUL.
M /?D]XP*CQH,^/H$7[.&>M!:=MM3IY-@%#&)&4B21U2A$*4NPH*RP;+,K39R
MF+1J#6[.J6"KN5WP&.2T8D.7K3JI<,EP\"KC-IU8 F<\*0V26(B1!49U'YC?
MHV7R7ZY 9'_-5,/4P%-/'WSUU8_R:ZH_Y+3+TP:9:;HWVVVTI4*/75&/WGQ&
M\('(RB$8M83L&/?H*K"4:^=L6FE+]0IA-_^9TH>T^([&^4BZ\&+SE?C;V_P^
MA?GG65D_META-Y1N:S Q^/&,2X(+@C @"'?@I<E@/.62ZBQC_=JD/A@YZ294
M^V#Y\2948\&B 1_BS0Q7N?0!%;[QG7[;L;CINN*5T4QY =[9!"(@4\ZB.^0D
MUYI'##%"[:ZZ3Y#32B^HT< R[T=S[8)P=\%#2*T)IPJ"SQ2$#1*<$QZ<=LQI
M%GV0M;.=3Q(T+A"KJ;T;G [000. *B;V-G]P%VFYN]W#LQ&EBSH:F5<@RO M
MZ[(&XM 'YX%)0GQE$-TCHDG@'*+@>4UICWWQ[D.ZP-<__RW-TL)=O)C%%_'K
M=#8M#L;JNA,"2]0KDAEX*R0($\MO&!=2&ZW6TJ=\M\/\8_/ NCQNW$+Q^DCI
M2=!C0^<]Z@6?_@5Y^35]3Q?S;T5>5[TSB$DQ"5"91@S\5;EWZBR42MDHN-4B
M\$Z(>>HIXY8\]P24:F(=&Q\OY[/E_&(:42JSS^_3M_FB_++9JDNGG4BM0%>O
MS-:AKHQO%PYLL#0)] 0SZ=9PXO%GM'(#<FR'N:8JVD34SN!8-I[GY(!10T X
MAHX@,0XHP5W7^ZB-%T=@:DSOMZH.G\?% 0(='QE73MB[Q3RNP^6":61IU(V&
MX@1')H*2X"G-D(5T4C!/DJ$=4?'P$YI#Q"':F]<694-XV"V\.R;0]R[6D( ;
MYT!DW):-=!HR98('*TWT>^/AUA-&'-_7.QX.%V4#47&=C?CZA$S+((P+!C*R
MB^Q; JX,"4R1!NNI4JSZ_:7*+(Q\8[ 9%ZD%A#1@(#O.4GSR:&_B<C3)&70V
M'"TI#K1X8ZDNJX"B2A,22.W9"MTH&S?!-"IXYKUKL@%\=I+P1_?CES1+>;IZ
MC2IZB&MB<->2C(&S&(X++S2X) AXIJ.BDF0CXACK]K.4CQO1MH3O$9#0 /Z[
M6?4?";TUY'WB.&>,))0M(QFMFS ,"JD!(A7+G)D83!YEG;ZD<%SWHR4\]ZC9
MPW$[7[F+\8JJKIW#Y6KZM<CFM9LN-I6*;_.VANW3LESQO'#A3_PT?M5R5]JV
MF 9\X_=Y3!=WBH9?+)?KK]LZR/J%64-1/$AQURCB;Z- 3/HD(IHK>&O1NGB.
M8!C&$HII[3WS-M[-39]-@=BS%T@?G22\#;X8RLF43D/6E#RDS@&LYA:8\SH1
ME6V@U6O/:Q%_TH5@^V!VWVF$_:B_!7]J0SE^>)-#IY*72\X)F-'H# KKP4:6
M(%@2@\Z1"U\;N[<(:*7 :U 0W/6##M9( W Z7'#7;,]B*<S_PWV];._KLJ)"
MT A1.UKN-1&P7"A@@B9.O?*N>A%B'WR,"^XC8+5OAX6^==P SM\GW'2FH40K
MY3[)I]ETM7S_X=/EO+>H--%! ;7"EA[U'@R&*\!CM%%:0H*M75[_)$$M=F\=
M$B_SOI1W,!(Q%O#S6FON]8VFRXE@5'IF-0'&G $1D'H3)2N=[P41*!E&J[?D
MN$M$BXU.1\3<<4H:^R3Y75KD^>)KZ2.UD=K&9-Y]^'19[&FB5<:F<D>N2(8J
M!9X&#4D)[56DONNDI6<>U&)[SQ% 55TG#>RH5ZG(8BB7\Z1DS"YK!<8J9(&4
MF;\D!1!6)>D4C5[7OM+Z !DM=JH<<24[5E%M[)F'=@F[SG4CJU);+2$8I4MO
MZ01>X").";H)F<0<Z.!1R;-4MU(0.F: /;#N&UA;#^;XU7^NIZN?;V;H+Z\W
M6GF[^I(6'[^XV:Z3PM_P*U;+-[/M:="=5/?FS5_=*EVES2?.>X?Z*3U)W*:S
M%VY*1'C@WALI$I>1#M-Y? 3F&X_"*J.^EM&-"L%3MMTKCF^<.+V?+O]\O4BE
MZTE"_*W>HV0F&&A@P,L\I)0Y;MDI0CE<A8S"P% XX?^::8?:E:G&H\]&;:T7
MR+1B0X?T"WI((*40H>2.MLWQ D^)!JN :E21L'DS7]" 91Z7%J:8)ZX/X^F%
MF\;#ZP&L9GR0M&(NM=:/.QORW^<7^&T7N*5O%Q*E310<%Q+.2J5R$N S"9 ,
MC_A>(([6KJ,=CKO&$P<GM G5 ]%I9Q\.='F]I,Q%&2$(F4JMG 27!0=6ZN2H
M*)7.M3L?#,QBBY,GVC>U >#4?#^[[07VC^Y'6EZGI[8O_I+RO/3PFW^?+O%Q
MK^>+&Q\^HG;RV$?6+7ZL*H!*U8M7C[DN";LJ\[(IEV:V!(QR H2+!!PUKIS/
MLD"CE]'63B$]04Z=OD>_S9?+;8'^;#6=K3<37M)BH]7E5@DW!8^_+%?3,.$R
M>*9" &I#&0'L5%DS1&G,+3+ZEDF:VL<C1Y#;0NN;XQ'U<,^D_O770%AP *NX
M8N!N,BL=4)G1PH/TUH(PF8)/S@-#QKFSR#FI79!P.+4M=-YI JB':.\T<?KJ
M!PH8-3N=N<7/C4/VQQS?G:V0M(OM)*!-\FL28[29\  YEJGK2CLT69^!"<4)
M\:@%1L8'<E=V6F@=U 32>]%_\[>.'O3\!G)WQW=Q&W-K#;$D.96!2^;+G7T,
MJHRDP&WT//B<$/*GX]:^7"_*$O ZQ=+H#1^QN[ZWNXPZ88IFY(N",B:"R-2"
M(52"=)D1IU,RO/8Z^@Q)[;JG^R#C7E_&BGIH8&O?L;-I-_=B%G_#?_  4Y3R
MXC]SD$DS$(SC-D*]!B.4R#%YS@CO!UQ/$]:N8UD!8A5UT@[0=A[P ^Q$)-[J
M"%J6KA&9H$L<F &2,V=)9GRW]D6I9TAJUY>KL7[5T$,[L+J2UAUNDI1$.5^6
MWV"+U\O!:NL@4&NE3=%H7SNA\S1%XYY@]0RJ&EJHYN,?<=-[]]C='O\85SXQ
M0XCFP 4)I6(2+44K#1IM1F1F%1&U3UJ[43;NT4U?&.M!*PVL7Y=<W=KL'^,M
MHK70DC:RFU;T%KU,YW'?9T[;P)4*)M<ND-Z'OG$G9_>-N^H::@A].V_@,:Z4
MYSQGPL%1GD%(FL!['Z!4=NH8; JN]B[:C;)QYTGWOM+5TTI#6'MTX9;"B5Q:
MP-(RHKI,';),).!1H\A8)$K5;BSU#$GCSDKN&UTU]-" L_88&YPX3@U*ATF.
M?@!N_&@G@8)DC&835(RF]B2Q8V#4VTC?OF!40^ZGE,]_$>.T?&_9^S>W1,L?
M=7+X3WYU;WG[[@P-D*L/FFJI#4:(J11 L1(A$B_ !.$5D=3BQG8ZN?JKK]X>
ME7U.L_!S>\N.!AY4-AB.,&] )"+!9ZF ()M,1Y9R]>[.CQ+3;GY^'S0\NBX=
M)?L&_*4K1G;C=E<_-WUF8B12RFB &REPS38!3#8"N+?,V<SQ9V_[VBU*&H'/
M<6I^##R'R[Q)Y.PNJ6?!DM-$ *6NC.+&V,&GD$&66=R>&QM(;1?[,5H:0<\1
M>GX6.@<(?>RN))>%="]FE\'G96N5K+GBPD-.I0TMSQZ,D0Z8"=PKJIVAYCF/
MY\DGM(:'0Y0WKRW)!M:26UFO_[->3)=Q&F[TW,G1DI)L@.0XLJ-U I<Q;C0^
M\1PU2;;Z=O0,28V<"== 4A]*&!%3R\5J<C77[F]I_GGAOGTI\<FV@5XP#D7$
MBFP("&L-&*L-H#,H=6+&D-#I. 6?<@-%^-<U@IXDH!'<5/%GZDEZ;+BDSW=9
MV-F3RLX)Z0-:$:4@8LR(>>: &A5S-I89U:DDY3FX/$; .!M61<7.:TMY3*BL
MOBTF+U],'%/,">5!AER.7Y!2EQ*%P$FBS 5)S5.@6*;P;Y_GW_^]?-T6%.6W
M&X#8/F9$U==1U/QPJ37@DI1%$I\Z7;UTB\7//%]L6G,5_(<4N&!4 XE,H1'X
MC$NE$N TST[Z;*.IW6/]46(:J1ZJ&A[7D7RK$+K1S8V4-I(D8PS(E ,T#8;L
M4&0L69T3DSI4/VA_AJ1QXZ-*BN\"IP.UT "H+B<L7SGEB6:.*[*-98XAP7W8
M2QE :2$C45Y96[L)T&T*&H3,H<J]WV[X4$DW@).'UN;?KJZM1T6#"]Q!YB:#
M,#J#D38![M'*B624XKWE=Q\BJ)&"Q7[2O$=K8.R$W:N<4RA'?5<LE?X=9:;4
M+$POIAL]79?ZOB^WM+Z^^#I?SU83;6.6FE%(Y71?Q-(])WE9!LM;XD30VMQI
M8?%(2N]P&AI)^AV/@OGP*FE@(=M=_YM]+C<#;R[SRPD/G)F4+"13JC!M0$Z$
M4A"UTD9+C%&Z1>=[K&*/4]->9N<XF%66?P-(>MB_W!J%IU%[;0AH'3"R=3R!
M];9<7%4DD"@34<,$==V7K$'#NCI8JJ6!!L!T6>!6DO#+95HM2X^=J[F+_RSM
MW2=4:A,L0P&%DBD3+H*304(V-AG*(CJGM9L,=B"K/5^K#KAJ:V1_D-DMR&;I
M<YE[5@5FGV:+J]&=UT-AEY<7V]_.;M9:A;!8ISBQ0:/Y> LDE#F;A@@P F.6
M[&P,7$G&JO>V/(#,1NZ/5(=AWQIK8.U[A,6)XS1GDR4X$D2Y%:/!F.(4)*(E
M-]$K-1#P&KDD,A2X]I)\NP#Z^,6M_C%?7\0W7[^YL+J*<7;1S40X*9WAM(3?
M&+D$S<$D82!1&;)VE%A6NQ_B890V<F-D*/C5U%N[Z-RV643A+I);IE_3]K\3
MX[(D5):1%JZLW1RM+BL.4B?%?)91Q($6O8<);.1^R5!8K*"E=B%X)<UW:>8N
M5E/T(&;QTK.X=":BUTE+22 P4_:",M0G*H/&EX7)+D0F:N=VCR"WD7LKP[F!
ME35XRHU:-W7YN%F@ID(J3;]*T<D:+6/3'[J?3JW=GCE8J]8#1## 19G(8B9.
M<. 2G4@1?00OM$8HVN!QV92$UW:TAK@H<SL]_LC=LA>779>N-'$KQ3ZQ2G)M
MD@(BK2CI<P4F$P\ITJP-^C76]R:;&@PT<AQR).H>/6P;7,<-> N/,/]P+X&T
MG"1KJ#,2^3&E\7YI6NZ<4>!TP*A1TIA";_?#NI'8R&'*,""MHJ=V87BWP<!F
M8]OM>:NINYA0IKV660(U92H1DQ%<*M$BMRI*$F/.O;50W(_41LYEAH%E5;VU
M"\_WZ9M;+;:_O\T[IE^YQ0S#@>5$6,*T30P8UQ9YS D\*9YY"#H0$P,CO5T9
MWH/.1LYTA@%F/8VUB\JKD]+E91G:Q";A?<X*=&84!'<9G#<$6&:\U+-17KT]
M9F?B&CG,&09_1^JFB7/%1UC[8UXBRW583?U%VOG,#X^I>3E?KB;,FF1+HB(6
MMT0(F\ &$< XB_ZSD=R+@2"Y'^&-' \- ]<>=7H*A8EW$G&W \'[\Y6NIR]-
MM I"D9@@*5*F90H'SC("PK!LF?,NI#O3+XZH73R8S$;.FBIAN3&UC@WP1TSZ
MD>3R^ZV9E^FO:;F^* GMDE+\S7U;IK?YQ;=O%]-0RIJW60]\Z;?IU^D6*\N)
MDSIYA>HQ+@<0P5'PL@SG2YR4DIF@'.V$]N%H;N1HJR;T&U5X$SY+EV7AX8WM
MU8^0ELMKP>U*#H/061JT?\M3Q% A<'!,6G!<)1M*@W-2^P)6;1X:.3ZK[,F,
MJNFQU_PC2OM=R(1CE LQY=+^(5!DDRH@QB63LXX\\6H>RS&W+<BI(')(C30Q
MX_:1#>CMZDM:O(C_;[U<%2=J.<E*2"NY!$$R1KR)8X1 F01/+2N)/V/[FWOS
M-&G=$'@N)UQ'*::E_-?="1&,*^*1>!)(!I$-BDIY!5SE) VS5O9W1G7(A*'3
M/8PZ0O"GU%KUNO+BWD6!VI4FCSY@@+*2;LP-4$-",;K0RBA@N=2T9^?!N7+5
M(O&L:-*952_6[;&&Y)Y8_[:8+Y?7/8Z3,5'3#(9D5?H1>XRJA :%BVUT(G)B
M^YK2\3!%[59Y[(.+9Z_X'*Z%!K:^^]S,Y_&?TXN+;4F@FWTN&=OM6Y,<LTX&
MXQ8;J8!R_1RW=0S9632"*\]8%+7]K7WH&Q=O-7'Q+.0J*:E% +Z9O5O,2P!]
M>;"%3/Z:OJ>+^;=-ZI0I8HGTI<]Z<B!X$N "IT YI]I&G3%0ZAN$S] X;N70
MD$"LJ:P6P?CQH<O"RPG71F1*2DN.,LK7TX325 9HC%E*28)TM3O>="1MW.J@
M(:%7036-(N[RM5U0=#.UB.9UF7=_XOB42^EM4!24YB4D<QI<8AJ2B5P(QU00
MO2^1%?@8MZ!H8"P/JO23!OXFVS3A3F8C(P?B@MNV 36"1BB7^:)RS"72NR^Z
M'\GCUB<U">?]53GVP<@]7J];TY0[?K]-G9]>3%<_)U9S$M$@(:ARWY0[@PZY
ME4!LSC1R:MS=U,-C?>0[/G'<>J(>X-6?O%M<_IYH<40T6H/7";0GOK"&]E&Z
MUGK)M8_(-<NR[Z7NR)Y3O=7^#+FL55)1D^C;+L2X]C*+XDFL=*9A*J*T%(?(
M3; A"X'!7.] Z[Q5]E94,RBF]A9\B_#9"&@2+#%1.@F),@%"9A21H[9$_#G0
M&(15?0U/O4W)N 4I@R8"]Q9\ X,LNS3),HI'KC<\N RBY(R,+FW]HJ0Z"B)H
M]5YXM=J6]5=8,B2RCM1)$\5Z]YCZ(ZTFB<5@%1I+I(2!2(J ITZ XX[F%+C.
MU:^P/$3'R!4B0T)I7ZFWM41=AABE3<:E>$10(DE5>J4Y=/>4->"#8)!<2H:G
MR%CU(9Y/4]3N7>5*1ZW':J$MK^D&-^\6<PPK5C_?7;C9ZL4LOOK/]71[=I($
M22(E#5%RM$%7+L$(7'TET5S(9(VDM2N#]R2QF0/7H]'1"7AU5#7JSG@WIW*#
MN_?3SU]6;_.GY?8@>4)13E)(!H&4>1?&2C"FC"W(DK'$K1;YC@?V? +K\<<U
M<V1:"TH]2?I8]'SL>3E[HC+A7J6"\M$J@Q)5-I&2-$E@LLC@A%2&2R,P>AED
M@=N#Z&;.5X=9\OI29VOAP0V6MQD9([EP(D2P+$JTQ(#,,*+*I!6:I)19BA[C
MS[OD-',2.@SJ]E=!4WBZ<H=OL#0I,12)UF$PQ2)*B6EPT2D( J/I%"B)K*\^
M[ _1T\QA9%^(.EH);46AVS7V!B\EJ'9,)IFBAF3+%&]GD!WF,;;RW!*9LPBY
M]XK?VR2UVYRH:LGO$7HXS>L*F^S0S0O 5Y^Z/,JO?7^A^Q,'N-!P(/L#W'!P
M)E+I2T]AKTO_JYS!&B,A\A@3)<82U=L5I?HW'.Y<*\N/7#E_]2-<K.-T]GE[
MP;'T6T;IE]9+'^>O?KBOT]GFX^_3:KV8+=_/+RY>;P]J)U'Z*+4WD&UIP1Q2
M !,4 VDMAO!!"*5KGW#VS5.[MRSVP>;]P8<-(:&!Y.%C0Q<$EY(95<I=BUO#
MF0=KG0;.I+"4&WRA-J"/&7?1&P[;PDO'B1G[*.]@#'[;-*/_L'*+5<]MX3==
M[F]W 7FY7A3M;1OBXZ??S9?3;>>/K*7CFCHPWH72UYR"%UX LS1S13+1U6M-
MZE ^;J;R%''>)S3:79H?YOH=<KMX@&?),<PE*H"*LM3 XGI@K"$@;,S<$(<\
M#S8O:P^ZQXWWSL<8:L"B75.XG(#2C6<EB60)[3U(IDOM ;J-JOS0R+DTFD>1
MAS&%O>@>-T=[BJ;0'RQ.S10^I-7J8M,9</F/Z>H+?KZH:+WZ,E]L$Y>9)4Z,
M$1"C8RA]20"M'Y7AB.4>A2]U[5J J@R,FVX^'^.H"I0F#DWZZ"J8J%2$1@)2
M\E#*,2P8R20X[60(3G-C:U_/':NS9&\7>D[19@8#3<N6,S%:I9"U :],.3W+
M'#POO92RIMER+1FM?2IT3$JHMZM!IXC@O91W9$KHU2P.<)ST1UIM<\0HU\WM
MY7(5=+W:Z>07MYR&TC-B>H$&&>]]^(A3I3H/KGNXU(,P*ITQ78ZNN'S6];FI
M)UH%ZH$AW#'N#*4X3902[LRSMR;0Q"JO)H_1<NR">270<G]O(HU2C/ R'X&4
MUL,I@2\LYJ!-*@-AN:WM4M\B8-Q\>15]WUW4#A=P P';/U(IRTSQQ?>T<)_3
M'^NO/BW>YHUTEF_7J^7*S<HVL;'2B:,\QYP4:&="Z:EJP-B 4A.,FIBSL*YV
M^X&]"!PW2]T+NOI34!--;Q]D;[<5W./QNMGJ)"9/C0X,;#841"89O,@*//.)
M,HP'T748 HG/DSINLG@X3%966KMKXV.,EAYTQ*+T($:-QL?0GS4L4$B:".8I
MLAYK[ZU[DCANMG;(];&*DAHHAKPKL^TRS[+TQFD+WDF%RWPY0D\N@8J<2>TP
M& BU!XT_2,BX"<Y>\'2\P)O85^^RL;.'B>&6I20D9"0:W5,,W&VP B+GL4PZ
M+QV)>D;.CI1Q$WV#8.<0H5=$SV#)C1<Q;HZKR@S=,H%A\ZB:28PG']!SLJ([
M<WTG):3F3"E<A&QT9;XF[E\NXM;E$;(NB)QDJNWS]I64>#%;36.Q#M3!AQ36
MVW.<;5(RQ4VAS,T<T3TR=K-EC!+:*0U4J82K,L8]E@@"F0?<RAT::ZCM<%4A
MO-$DR#[XNKOT#:_0:@%"7\OD*USJYC_3Y7B'<G]Z67NEW/L9=1?+XUBLM%[>
MZ;+X/JVFB\UA\0/%V2$1$GG$G5A&W--)0(@;W.PS\=;Z4*Y8U:ZRV8.\"C>G
MRKG-R_ELM9CZ=7EB4<GO[L?TZ_KKB]EL[2YNOEG,[U*%^&O8Q.B$I<!) .I(
MW+8L,=8R2#++%+1WI'J*KP+9XZZH?2'P@1M9@^JW@1S,(RSON%K\[E:HF]GG
M6^]O.7V;-V].M*.6V*C!:(NAF^(.//$9(SDG#?,YQ]A#U_+CB!XWCSTRG'O2
M;;M@[F2_.P])LDRS$ADBVX22II3&$@V29^.T,R[+'KI''$GUN"GP4UB=#]!N
M\_[O=2^]6?R_R/LT_RS' 2%L"DZ.<'J[?7%=3_< 9HYT;Y>+U>3IIUZA5A'G
M@J(<U[URKA*< D.#A>"]2KC=1TDZ#?S"1]Y8$/"OZ\6@.S6'+I+//^':7C^6
M>K:)"DYD32@$:B4(DR0*@#)05"9EF4"CZ93+/(KM.T2-XXCVA)7+%:Y?U32P
M,=]O^[G<[!3+M,#%X"-^RXL?T^7$AL"M+G62I/C.-J+O7/B+025<NJ7-OG;R
MO!MEK:+N*%C,>]=1\\C[=?[536<38DK)I2:0/!?(DPU@C/4@O?>2.V(<K1W"
M=*%KW*"[#SSL!;D#E-, X*Y8>3U?;"=)E;*UWU,Y-L=XBD5:AA<G6NZ@8FBU
M/?#D0FBIDY!"5D^H/T%/RP [1/MW<^:U5#$BK/;9 ]#U3F]6Z>MRHHUD/'H&
M2<==#3D&5@J80XOD-!(3^W=8'R!LG+S+,/MH_YIJ8'7[??Y]$]J_F3UMO3<O
M-+CHM$BX.7!1!C$9-&9KHP$G"6?),&>J#W X@,SV7;P#03,?5H,-@/1IQGYQ
M%YNY [AW*"5$ .M+ZS8I-#@C-2@3=;;<9RYJUWAU(FS<3;EW>.SE AZBJV9:
MVCS-VLLO;O$YQ8_S,F:QM/W>CK2;:"Z\3Q2]:*,8"$T#.&[139%2<RL38W18
M6#Y"Z+A'*&W!M(8NFU\W?[VZ!CLQBL3$A(5@;$9S1!_)$[1)X4G*)L=HJ]\%
M[4K;N$<A;<'R0(TU<0VYV[[ <B0J>P/>6%[JF3QX&B688$P@^/\HA@7B/GMX
M;_< VD+A(;H:Y@[R[HWRP[ME^E__[?\#4$L#!!0    ( &B)2E8L12K&L&8
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M=;UA_Z]I]CH;TC*GM>OV0M]%8B*$"*3H(FR/*Y6DI&;TC9ZSOT%1)K"GQ1M
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M=R;LSS%L4C%&4%Q:[\11B!A6=@Z[M>RN80#)0Y2?W LOQ[P>5HT(\3W'^ S
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M.[2:4\\"]<H@"F.?-EAYN1QG59$K[O/*'5^W&=RBI!TU/U+Z2UO W,HEIK9
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MC,S%:A7;"',E[M;$(BH44FY# 6<#97*4Z87CU:<XK!.\9SE-="RI$+RA>91
M>8W! AX==1- $X;PU,TQ&!PSQ9;5!#M-)2Z#^G%X/FPB<?.@IZM[K&,=$*:J
MGN4+DZ$+H6Q"-MA^/55EK/YIZ.3.R;Z,N)GQ%U>3]A4P^W^/#W^)SHX_?/SY
MW<EAS[7,(\S9-(,\.7TW.OT<CM+'M?G3UN9L='IXW/.=]&"8([M?A/+ 8#]A
MA=;.?]4P)#R)>V!TW([=- @PK$TBF \8R/^D-V 'D[:1U/10\B2G/X6(#0P*
M;(S'@<RZ*&NTC[%;NI8:L'?#:'__V<[>JQ<[>_B%]_<S1F\'5^[L[>X\>V4O
MQ#^?[QK#0U(HA\BJ5M H#G.,W&*%V)P&?T^AW3W+&_Z\E#8<!E_0PLQ11\<$
M-R]X2MQ'1W'+#DGNY;F#;]#G'N+?A8%4NH)25;!2,;,C))EIE7&-EFV(J=$V
MM9?*++;:)N"KE$VT"8;>7 1?.9JS_LK09]JVQYF\.RT8)68.GK[&M:1_#*)4
M=ZTI9GKSI(C2&I,QE"*BA >OI:Z$$B["G4?KQ%N^QFL0_TXECB7_UBSH %1*
M$N62_3EX7?'_<#1QGE":)N5<GR2"<!7?Z8Z%U)Q[<7FP$A-7DR ?0_2-60:W
M*:E=5LPMW[\X6]K3D__M\=FOH]/_TU=Q?334PN7ZY?WIV^CO\)^>+]ACN6 O
MTI:/Y8(]*1?L^7RO\$BD)X&TPCX/@H\;W05_SL.[9R7:*)%98,QPNI8BO3FQ
M(-.6D- I=_<B7K"R;C<1"'G$;-H2T\5E6$=4)C<[<Q@8BGZ&&K!4A6UKYTA:
M[Z>,/R8LOME!U:\H_>^CL].3T[=T^I':QN/"@(8IGF%L?\[<\;&@$9UYE>AK
M5[M4Z,LZ5032EI1]19K^EQR.I+_G"+-NDC C^H)WH+[!J$-)OH1!#SRFWVWZ
M_7EK+A[3[P\[_?Z9NYBEG^MR*D.CV*+YFV$T#[8JP:K)%W1]*JJNK1]45#F(
MU6J"/FR#BA!0BEFVV>J', -)-9-\J.5ZM(9G)H_!H]DTXY9CFQ#AIG[$_XWK
MIDZDM?489BQ ?'M]+3A*:S42L: 396GI =+)1$6=!"N=N$H?'8",FA@VF\$-
M\$DP43)Y#JED6@F%=K>UR:4E2#:AT@V%W>+G\SJ3HSA"6$61J)3"-&"%CHD$
M+.&@C#8$J0*(DQ*J[8;F7A1ZH0K^&0?G:*XM3K$K;.WUK%>F;A+>G1BDZM)4
M31('U9W6@$ >KIC*^]XOIO*/#QH:5O .I*NO#(Z6:RJ"8_%U".>"YU*98VLA
MJ7]JYS+>>16#AA)C':R&U!P)&HU&],#"+2=GQY^9L^R/77C_+=LC8J4#<?1?
MI4<&;E<GL5C&/,#JTCB_MA]P#3#&*L1[ CUX4F#.P6XVVFMT=D5[_X;7SW-$
MW>"Y@+2"5%^(V\0KBK3[=T:;O<0J1U@S*A^<,E*G^1!L[H$J".XFU4=("4#Z
MJS Q<59F"%[K?E[?(#AZ>+EA" ZGM_@,IWZ,-+=C;-]$H:IK[@KEE4E?\J07
MZ V(-9/Y<NX!M 8=-[RKI"52K.TOIKY)L+62,K7:,!4&%K9J" ):%I;.+EY%
M<W?F/H] CNAL*K#L%FG59PF83UO7E#1SUYJXF:K\8X409G=ZOX>&;3HY/QL=
MO[N7ZOJD+!28(-A!80?-O,V3K'/3,.R*A<+;:+Q@ADDVE1F[I\]+T\KAX.GK
MS;W*.EGIPT33]&SS='O-<=<VPUW9"S<(V)NW ^_.9Y>0Q@J8:(:SH1I8O@1#
M2$#4'W/44[%E,R.3V64&5U-%F(<.FC]!XC1L6B<CM<+#;PB>!KI5_4W[K[>S
M!,N[<8LJV+.^5Q:R[),APDV9H[?@C9?P='38V.,RN:^]7=LLP>QNKX7+>XP&
MD#OXP_>O]E[C*_P&'@S\$/X^>!WM1'NOGN\%W5SZJ03LBVQ6"[!?;+91CY5F
MA^!L7G\.?/&FKJ&)"U4P+U*KFT2'G#NA-C6)19TR29%$K:5$!;0SW22HIR,*
M'&1;MY4HG2K2%:[Q:"S.2AI(6VZ#!BF0;&TAK9MK7;7?C"C35K_6P..>,\/A
MI5WB&T@$C54R/L3'('(=PA5(!-%/@ IPJ$,7JNF0COO:Y_K"<]>P6HFHBOSR
M73H)B^BR5H3M-"G#,#ON3^&JZ6NRO8'P4GR1.CTND*V(^"^F*V\@749=:/)V
M";^?V49<DXL"AJ WJG3\D]88/KQW)%=,OB9#&>9B= 4[SW3RI$):Q[+"/)&^
M4D$%AF93FLR3RA33+AW!D_ 1"I0#0Y/(Z")W+GE,<DW,71RXJ:R$)U2,ZSGG
MI@>V<Y)7(VV*\<;:(IC7QI![?]R/W&R?T6SWX-C?=IW<'=8 7?Z<>JVEKLQ=
M9-\JY+'.]#2QN9$6PT^GX=YM_%%('BG*D/5+0N1(9XB46KSJMQZ89"HZ$_&,
MSLXM_.?//,[2(GK I)3,#;SJL<F;;$?/7CP_V-G?W3VX!Z)$[]<'\2$/KYF@
M^5S;P#%6M(5CT)(N9R,0;(;R<<)*(!P,GK1Z^A%S(\T="*):):E/[>:-/?9E
M$;]"3@?[W1TL.:L+\Z+21?-.;?9'X^N@AA]9?$+_I?$7B7!_H!?LAUAV\22J
M<7ZE#0\AGXI<E?O(H^ !.5X\ CG^8D".M7-M=2LSC<.YCW2C*U5FJ M8>V,5
M!OLL=U":K-XM0235G!D399P7F3;:TF^EVG./HGMF1T@:1)"-DJKJ*D.0A-I)
M8"0#TE #=\(9RWU"\<PFIH8LX5NGRYZWYI3TW (_4]CP%L[K<9E0\S+W")_$
MU/90(VIC),1C'4OO2"?S0BW%(*@,5W)<HQU&C[&'MWD^(36\I\KP9-1]7_25
MS;0W#,".1EYSCPJ'0XNP2II6!FL\7Y'I=XG5&YU%$H?!"OQ40]:LG+O6QM<J
MH2!47G#W 8OA;_Z^8TB-NQO2C8XK&[L$3F?D_&QOEH$TC [S&+%6U6S0<7F(
MQF9OW6;ZPUTT"/8@;[(\TZX=WEC#&*>>P3OV;5,,K2M!*:%*QIT%$X5?8<-"
MTQ>0Z=3-7TQ'S'>$7RZ;M[PL\A*!;$+A#OZ3R>]T41ZK5+8E/+W.="'=PB_N
MI$,:2V7F@<?F^C&2@-KZ3".:'4'5!EP+J>(''$3E)?3"J,TPAX%HR,.P'T9=
M(!3P#;//(9BC[8A@*!:!Q1AFQ7$AL'">&>S&%T\ (4FD%>4\ FF=$[V\ND2G
MB'4WL_!YVQC#=DC3PL$^:]U*(T8+'D F<PW>3[7D0')( =<.^ SLC1-M:"[=
M&F1Z@MC):NDK?]JV\#<E#NE#C1\&0[+#E_.  T#XHV3^QZ1G8,9&72LJ=+GF
MV":)7"R0B$$SK6FC67)@M8;6/*E:4I"+U[DH<FPU;P,=1O5X'BA&O:BI?*0Q
M-FM >'0DN%W((Y74F9G!3MB&*66Z: R) KK4,C0/D4:\"BO.4Z_I/8V;1F7#
MROZ9'*Y$XRX2LO.5BMW,JU^"'^3Z!C@Z(U&QF'\N*5F;Y'5)[00D$QU*##Z^
MT-.:D3DQU_T%8=)VO&JJDM1F;[@7++/\>^U(5X0>16.4;CBVU4/)U][3Q+(7
M*CD$KSDC5 6JFX^H;"OJ5+YA.Z8I]H2>PW0X5?\1DT*4:MC]A>4/$,22I1#H
MV,\E H^) 'Q@2N(Y?J"X_)+ RLU'PW+32\*&<!CED.B\&0R]4P[0\PPZTX$@
M:Y<:#]YT8 TU8NHH"N3ENCU#AG<@,LH)W+,8!%2BX88@[>U>P:?=:%.?<FL1
MZF74G"J?J+1E9/K*0!2)A*77A?[-LI*B; 6O%9B6+G0=Q)GC.B3O:SJOM*]M
ME.ZV./3:B=YDV2.OQB8W*S6FVFCEYR;??M46R%?D2$A>L>%83.JL 8;JL(T$
MUN391N'!7E5J,A-H5Y5O;AW6!9$W+:3KQK:57&U0>M>-K*<3UI#XQ[EKZ82
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MD97"A4.L+RNG1@P O2&%_]Y[C:H $<5Q+B[/6J&3]6T8RG1!B;MC@L3<55Z
M6E',QF_O:H^]06@9.)]0RV=\H(,XQ8JF<,YF/3*Y+-"@G(*I [^HV /03O G
M><'&44R2>I4451WC -PS6A$2O,6BCN$[L %JD#9B9C$O9MV&_&Y*\B^7@-S?
M?4Q ]BL!V5-$Z^GQQ2_'9]CL]/PSM/TCXOA/6Y_W9[^//J?4[W%I_JRE.3\Y
M?3OZ\/[LN*]FTE\##^X5 F%J]ASI;:@0RE9O$7)NPS"+5=RO'N+6$'U.@B81
M-OOG=UHRF6G,?!*?#R;AP:I4"\Q6!G0^97*S,X<1(IPKPW*G4OH0NSK%(\*
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MY*C>GJ_[=.A6<?=;XIF>4J<W)00CG8P,PL!%%U@+KQD,^H=-E&S]!)NL4'_
M4V2_BNSO/T7VO]M!M[X8"68&(4_CWE)RR9I"N')4^3EHEO=HE.V*1@(QP?+C
MZI2W\":RA37)?,^XZ9/;TLO('-:JLAPFM=]D4KZ<LR7?8/V!)$50?6.MV>H+
M$,#DXLLMNCE;;QA7^*N,<]D0D?05P8#7P+[QW,RR$A>NM)%,C'X84';T4%9V
MZUBB-8GY7V#R@7&79*%(3"45K$M*1:DS]N.!,9IG:-2*+U*9H9'YFH@;W?J
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MM!;57(K/+;TFF]7)V/%<X>0UD -8L<4=,44ZS<H>3M..*DPWK([0YON=KW'
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M(LNC-,^N-::;T:2 (Y>%!^50L*YE$^6! @3_F<SG29K@W78*?0V6")=%\U/
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MLWH931#[%04-IE $]WMW7D-R@,-DA:#P65S!:>$:_$;X(S!<3.2C/7%Q_6R
M/0,LAOJG@SCD9$"V@<$-8V;E'0+MU6JY-<T;/,)5H20*NV#VB.P/7-*3!6.-
MJ65_LQF@:\ [:LN@)3D=PI#F6&7LJ&A"CCL#T/5 0#EOOL@1TO1:!H4S[BR<
MZ![S3MS.N<)BXY#Z@BT'E]#HB@QV[JSGDF@:4-L92C2=*XHV?I#2M VGH\\H
M/Z"750/<U(I(C'SB&_H_BWS:TCC\P30.AHJYC+"1&.SE$ENF&?>,*D&:[D_9
M8'Z&79^1X(UL8L0!4Q 34RX9H^+S0;=]@XHT/$)7GE,5\@"C/UYLLP56Y)I#
M0C^//"<=US6?@?W*N&C\,\XU0TP$$=+LGF&-<=O^P9C+\YJT% V!SAM^/+>O
ML*E&D*HTT77P/8:A\$"2#SSSTW!I%^"?H'2E*TO&H<KJ.0G4\'Q"#-+%>D:$
M@.W$LZRV#^TL&VT_IK9-8".FT@#[/*=E'*!!?H^5"]K!*H3U*_&?F-1\M4UJ
M;I.:3T'Q#(^"H\G!(%2.:W,-#+EPP&L#XQ!LD]!0@B&+(6GR;A5U_Z&>1QA5
MDT)K,DN6J9I)$E9GQ'-)-@L%%/W$RW,Z?^;#$8,7X_VC#<F!X8?+\F+!-JO^
MC(:+CL.,6Z.UULA2AKK>GZ-HIM)9+2QO-';3,F:$]A!5''(BT5$OC0@^D&%O
M(#"&P/!!HE4TO746M*P3R!T83C=YFB M"7PRBJ9Y5E-D%IMX[=G.;MCZ&3XT
MPDR9ILKP)6-9C4[G. /6UO9ZUKGDFWGF<Y+ZZ^%(O>^"BXULA71-8-LK]VNX
M;G6& 15"W)D,'"?.,"UI@Y-+$+AD9NEVA$3B>;' W0QGE8UMG<P?5JQI (:@
MOPKJ\@L6.(M%NV1.8),M&@^36*+?/:=U38:SKB_&K][*NF(PLY-CA,XP/JC6
M<M*[LVE-42-&U:Q04*2_(2 2':&BX8X"^N<D!_\:DARP[0+;;9:J9$$F1)C0
M#0P)7#FU(( /(Z>PNEOL%# RYCKA:$D8F.-,5(@2ZF/9;5#H!M59S[>A\G,2
M[T_#$6]S?-7-QL"T K%+\=GLP :,>!/[5:4%CUBK?22"W$A+CL1 9W$R> Y#
M5479W]B6T#&HXR,\CF4QQ-$]$Z%+AR-TYFQM"5U?#^IIBQ !G9H N^EH,XQP
M6>='4Z7'S&2D@LX0IMS#I3@:RIULK9"4@R0+3W)7->61$6#-"P$,RGI!CT11
M%*"G7\Z3<W=R;J@2CP@[A+JTYC+6>@KB4]65D#OVE.3,<G!9"ZI6Q2%('9KB
MHG*!O71O3EOV\DS$>S$8\3YX8TR&=B57 [Z;B32Q>+@:05N6C24&EKB=\$WP
MU,SU]:&EGZ=8A,0:<:JK.ZT%YD:=<2+J@)O-5G9C_)A1<=9E19BXDSRED@2$
MN*".9.$)[=:V_#-.I_1HK!OPW-[N2B+<CZSO"B@^GDL3E8,!]1-E>$D>36(Z
M,2]LS:#P(0P!;^(CJ83^P%$U$;8 JU>Y@QA6MH#UG%'UJZ*7&M%^2YI$7Y_,
MK\$<H%8ML1*;W$S!^KR9-6_O[_ZSGE1';O.@;DG_I,J,O$YC,HD0QN806TR,
MIE)O/MCF"F>DS(MF<:C)\C)BS[RPCII5O(8BV4V>'#U>,;#YP;;5M2_&K[=I
MQ&T:\2F<30/J%4QGTXFJ%+:TOE6S3=--G7%,\([4;YI\TFO4Y<BC=M,F'WF;
MZ#MQ@+'\4HJ^ N<'CBG+0G6$.G<DT1>_/@_4=8I.LK2T,UJ7(,!ER:K95<>)
MDT*H>'-"Q#BK0=\FBB_^KA;6G^(6="_6L""9K\U<P;KE',+XFA,&\,LO_GYZ
M.OE_F6D*3'()YUUXW ZWF^X7>^8*E*>J=&[Z:5WD2PVF 7@6QAFWGYV"<.:+
M9!9-0 <;&T=<D'_ [,3Y(MJ9X1M3B6:Z,KPG&URX>Q9ID\L0DJ&("6A;<X2^
M)EF$&)\P#40QAA;'!09=X-J#_<-]6 )4"1>Y @5S66?9"LN21M$Q=AG-BRQ1
MT=L7^V]>C1I>(^B0R0+>8*9&QJ*>.<FU;"KBNS:4DBVX"+103VV!B]48_Y6,
MRI8W8%E0/+G$#35==;#T19>32WC)I/K+EX='1^] _44IG"XW>95GR2^8:YG"
M-X>OWB%:&1[]7:(S=3.*#@XB=:N1J@M^<8Q1R0)[KX^BHZ-7^_O11V37GXVB
M;PD5\.1*BWITZ( 0SIQ37[<_R4PX%G4BT< ?2[ !!^2[BK8K1Q&".QA[[<=
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M-WLN,:@!U:S?KYW.[0%WDI2S-"^E9O6C@2)L.G$[)EWE158HQN&J 5H!;),
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M)?KV[/S]Y/QDNS9#7)N+R?GQZ9,\P1'8^QQPO1^D=>HYG-R(Q_SO&D:%I_$
M#!'3UM40_G6VYN34=47%)*:1U2_T$FQ6TUXR15^8Z,CI3Z'' CL"'!GNX..7
M;T@X#\RS<71X^'+OX/5K_-C\]>;5WH&Q(B2)@;8"IB7AWM@MB+K'2&^MIQF
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M4'N9>9M$<+!G_W].5/9G13T#-RF2!!OXHS?%(ZVYGR<7YV?GW_'0KIANJS*
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M6L"JR4<]MR^U6&4*;QL;?<[Q.QJID?P";K7R0G?T ;:"]/8(BV4I]2T@OQ3
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ML_P9FN4KS$O!?VZJ1?KW_Q]02P,$%     @ :(E*5IFD3;(?!@  .UH  !X
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M+HU<@M<!;J839][0R^QXRBA&)U*D9JS56"Y0G\ZH67*YQ/5*45_([@:? I<
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M<OAB]VUTI]&.=Q[X]&=L81%6.0_PW/H'4$L#!!0    ( &B)2E8E.N1'@0,
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M-R2=/ A"]Y[V_+#%0/W(<3H_ON/['>VYWKV^ZY-[G\Z0!DY+HZ,.3Q2%'<S
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M'"7=Z# Y_E<$)QLP#WU</M7R966DTMI0TOR];B?+3R=*Y,->U&S^M;)JQ^T
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MYTV:%R@6Z'5;8#5BKJMX%M>Q<B=[NW*MG5NY5]QAO; XHRF[3\U$2S&0U;"
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MQ<]"S(8P2:^E06(V2WQM4J586@X'/.;"/[+UIZ-&C"F9LWCI/QVS.<W@'5W
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M1?\-;'A:63NJ-5]Q3;=^)];HPUH]_/D<U'>:Y\LM:;O$;(]P[.$.L@%0K88
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M,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ :(E*5BQ%*L:P9@  U[@" !X
M             ( !L'P) '$T,C)E>"TQ,#$P>&9Y,C-R<W5A9W)E96UE+FAT
M;5!+ 0(4 Q0    ( &B)2E9[XF.Q]2D  #TF 0 >              "  9SC
M"0!Q-#(R97@M,3 Q,7AF>3(S<'-U86=R965M92YH=&U02P$"% ,4    " !H
MB4I6'_ 3QUYD  #.D0( '@              @ '-#0H <30R,F5X+3$P.7AF
M>3(S;W!T:6]N86=R964N:'1M4$L! A0#%     @ :(E*5IFD3;(?!@  .UH
M !X              ( !9W(* '$T,C)E>"TR,3%X<W5B<VED:6%R:65S<31O
M+FAT;5!+ 0(4 Q0    ( &B)2E8E.N1'@0,  "@)   >              "
M <)X"@!Q-#(R97@M,C,Q>&%U9&ET;W)C;VYS96YT<2YH=&U02P$"% ,4
M" !HB4I6A]NM"#H(    *P  '@              @ %_? H <30R,F5X+3,Q
M,7AC96]C97)T;V9S;WAS96,N:'1M4$L! A0#%     @ :(E*5M:/S= Z"
M9"D  !X              ( !]80* '$T,C)E>"TS,3)X8V9O8V5R=&]F<V]X
M<V5C+FAT;5!+ 0(4 Q0    ( &B)2E8L*;V:?@4  $(E   >
M  "  6N-"@!Q-#(R97@M,S(Q,GAC96]A;F1C9F]C97)T;RYH=&U02P4&
/ !  $ !N!   )9,*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
